,assay_id,doi,year,volume,issue,assay_description,compound_smiles,compound_name,value,unit,relation,log_value,classification_label,scaffold_smiles
0,2246941,10.1021/acs.jmedchem.1c02132,,,,Inhibition of CYP3A4 (unknown origin) incubated for 10 mins in presence of NADPH by LC-MS/MS analysis,CC(=O)Nc1cc(-c2cc(F)c(OC[C@@H](N)CC(C)C)c(Cl)c2)ccn1,(S)-N-(4-(4-((2-amino-4-methylpentyl)oxy)-3-chloro-5-fluorophenyl)pyridin-2-yl)acetamide,0.8,uM,=,-0.0969100130080563,0,c1ccc(-c2ccncc2)cc1
1,1685713,10.1016/j.bmc.2017.04.033,,,,Inhibition of recombinant CYP3A4 (unknown origin),C[C@@H](c1ccc(-c2ccccn2)cc1)N1CC[C@](CCCO)(c2ccccc2)OC1=O,"(R)-6-(3-hydroxypropyl)-6-phenyl-3-((S)-1-(4-(pyridin-2-yl)phenyl)ethyl)-1,3-oxazinan-2-one",23.0,uM,=,1.3617278360175928,1,O=C1OC(c2ccccc2)CCN1Cc1ccc(-c2ccccn2)cc1
2,51898,10.1016/s0960-894x(98)00653-2,,,,Antiviral activity as inhibition of human liver microsomal Cytochrome P450 3A4,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1,"((1R,2R,4R)-1-Benzyl-2-hydroxy-4-{(R)-2-[3-(2-isopropyl-1lambda*4*-[1,3]thiazin-5-ylmethyl)-3-methyl-ureido]-3-methyl-butyrylamino}-5-phenyl-pentyl)-carbamic acid thiazol-5-ylmethyl ester",0.25,uM,=,-0.6020599913279624,0,O=C(CNC(=O)NCc1cscn1)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
3,542857,10.1021/jm801313t,,,,Inhibition of human recombinant CYP3A4,CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cncn6)(c6ccc(F)cc6F)C5)cc4)CC3)cc2)c1=O,Posaconazole,0.35,uM,=,-0.4559319556497244,0,O=c1[nH]ncn1-c1ccc(N2CCN(c3ccc(OC[C@@H]4CO[C@@](Cn5cncn5)(c5ccccc5)C4)cc3)CC2)cc1
4,51927,10.1021/jm034111v,,,,Inhibition of recombinant human Cytochrome P450 3A4 using BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 30 minutes,C[C@H](NC(=O)/C=C/c1ccc(F)cc1)c1ccc(F)c(N2CCOCC2)c1,(E)-N-[1-((S)-4-Fluoro-3-morpholin-4-yl-phenyl)-ethyl]-3-(4-fluoro-phenyl)-acrylamide,19.0,uM,=,1.2787536009528289,1,O=C(/C=C/c1ccccc1)NCc1cccc(N2CCOCC2)c1
5,305432,10.1016/j.bmcl.2005.01.044,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,CC(C(c1ccc2cc(OCc3cccc(C(N)=O)c3)ccc2c1)n1ccnc1)N(C)C,3-[6-(2-Dimethylamino-1-imidazol-1-yl-propyl)-naphthalen-2-yloxymethyl]-benzamide,0.481,uM,=,-0.3178549236261682,0,c1ccc(COc2ccc3cc(Cn4ccnc4)ccc3c2)cc1
6,2134185,10.1021/acs.jmedchem.1c00855,,,,Inhibition of recombinant human CYP3A4 expressed in Escherichia coli using VG as probe substrate incubated for 15 to 60 mins by fluorometric assay,COCCNc1nc2cnc3cc(-c4c(C)noc4C)c(OC)cc3c2n1Cc1ccccn1,"7-(3,5-Dimethylisoxazol-4-yl)-8-methoxy-N-(2-methoxyethyl)-1-(pyridine-2-ylmethyl)-1H-imidazo[4,5-c]quinoline-2-amine",15.8,uM,=,1.1986570869544226,1,c1ccc(Cn2cnc3cnc4cc(-c5cnoc5)ccc4c32)nc1
7,830184,10.1016/j.bmcl.2012.05.118,,,,Inhibition of CYP3A4,O=C1Nc2ccccc2C2(CCN(C(=O)N[C@H](Cc3csc4ccccc34)C(=O)N3CCC(N4CCCCC4)CC3)CC2)N1,"(R)-N-(1-(1,4'-bipiperidin-1'-yl)-3-(benzo[b]thiophen-3-yl)-1-oxopropan-2-yl)-2'-oxo-2',3'-dihydro-1'H-spiro[piperidine-4,4'-quinazoline]-1-carboxamide",0.1,uM,=,-1.0,0,O=C1Nc2ccccc2C2(CCN(C(=O)N[C@H](Cc3csc4ccccc34)C(=O)N3CCC(N4CCCCC4)CC3)CC2)N1
8,464738,10.1016/j.bmcl.2008.01.126,,,,Inhibition of CYP3A4 in presence of 7-benzyloxy-4-trifluoromethyl coumarin substrate,Cc1oc(-c2ccccc2)nc1CCOc1cccc(C[C@H]2C(=O)N(c3ccc(C(C)(C)C)cc3)[C@H]2C(=O)O)c1,"(2R,3R)-3-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-(4-tert-butylphenyl)-4-oxoazetidine-2-carboxylic acid",20.0,uM,=,1.3010299956639813,1,O=C1[C@H](Cc2cccc(OCCc3coc(-c4ccccc4)n3)c2)CN1c1ccccc1
9,874946,10.1021/jm301039c,,,,Inhibition of CYP3A4 preincubated with substrate,CN1C(=N)N[C@@]2(c3cc(-c4cccc(C#N)c4)cs3)CN(c3ncc(F)cn3)C[C@H]2C1=O,"3-(5-((4aR,7aR)-6-(5-Fluoropyrimidin-2-yl)-2-imino-3-methyl-4-oxooctahydro-1H-pyrrolo[3,4-d]pyrimidin-7a-yl)thiophen-3-yl)benzonitrile",1.9,uM,=,0.2787536009528289,1,N=C1NC(=O)[C@@H]2CN(c3ncccn3)C[C@]2(c2cc(-c3ccccc3)cs2)N1
10,767875,10.1021/jm200758k,,,,Inhibition of CYP3A4,COc1ccccc1-c1ccc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nn12,"[7-(2-Methoxy-phenyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl]-[4-(4-methyl-piperazin-1-yl)-phenyl]amine",9.4,uM,=,0.9731278535996988,1,c1ccc(-c2ccc3cnc(Nc4ccc(N5CCNCC5)cc4)nn23)cc1
11,1487309,10.1124/dmd.111.043505,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis,Cl.Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1,Paroxetine.HCl,24.1,uM,=,1.3820170425748683,1,c1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1
12,1527962,,,,,"Inhibition Assay (Testosterone Hydroxylase): To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.",c1cncc(-n2ccnc2)c1,3-Imidazol-1-yl-pyridine,109.0,uM,=,2.037426497940624,1,c1cncc(-n2ccnc2)c1
13,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)CCCNCCC(C)=O)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, D-72",2.78,uM,=,0.4440447959180762,1,O=C1[C@H](Cc2ccccc2)N2C(=O)CNN(C(=O)NCc3ccccc3)[C@H]2CN1Cc1cccc2c(-c3ccccc3)c[nH]c12
14,1367425,10.1021/jm5003606,,,,Inhibition of recombinant CYP3A4 (unknown origin) by LC/MS/MS analysis,CCc1nc2cc(Cl)ccn2c1C(=O)NCc1ccc(N2CCC(c3ccc(F)cc3)CC2)cc1,"7-Chloro-2-ethyl-N-{4-[4-(4-fluorophenyl)piperidin-1-yl]benzyl}-imidazo[1,2-a]pyridine-3-carboxamide",2.07,uM,=,0.3159703454569177,1,O=C(NCc1ccc(N2CCC(c3ccccc3)CC2)cc1)c1cnc2ccccn12
15,1772941,10.1016/j.ejmech.2018.01.002,,,,Inhibition of human supersome CYP3A4 using testosterone as substrate assessed as testosterone 6beta-hydroxylation after 30 mins by HPLC-UV detection,O=S(=O)(c1cncc2ccccc12)N1CCC[C@H]1CCN1CCN(c2cccc3sccc23)CC1,(S)-4-((2-(2-(4-(Benzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)pyrrolidin-1-yl)sulfonyl)isoquinoline,10.0,uM,=,1.0,1,O=S(=O)(c1cncc2ccccc12)N1CCC[C@H]1CCN1CCN(c2cccc3sccc23)CC1
16,828928,10.1016/j.bmcl.2012.06.022,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(NCCCn3ccnc3)oc2c1,"thiazol-5-ylmethyl(2S,3R)-4-(2-(3-(1H-imidazol-1-yl)propylamino)-N-isobutylbenzo[d]oxazole-6-carboxamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate",0.031,uM,=,-1.5086383061657274,0,O=C(N[C@H](CCNC(=O)c1ccc2nc(NCCCn3ccnc3)oc2c1)Cc1ccccc1)OCc1cncs1
17,1465541,10.1016/j.bmcl.2015.01.051,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(C6CN(CCO)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O,"(1S,4R,5R,6R,8R,10S,11R,12S,13R,16R,18S,21R)-8-[(1S)-1-ethoxy-2-hydroxy-2-methylpropyl]-18-{[(2S)-4-[1-(2-hydroxyethyl)azetidin-3-yl]morpholin-2-yl]oxy}-4,6,12,17,17-pentamethyl-9-oxahexacyclo[11.9.0.0^{1,21}.0^{4,12}.0^{5,10}.0^{16,21}]docosan-11-ol",4.9,uM,=,0.6901960800285137,1,C1CO[C@@H]2CC3C(CC[C@@]45C[C@@]46CC[C@H](O[C@H]4CN(C7CNC7)CCO4)C[C@@H]6CC[C@@H]35)[C@H]2C1
18,1364172,10.1021/ml500019s,,,,Inhibition of CYP3A4 (unknown origin) co-incubated with enzyme,C=CC[C@H]1N(C(=O)c2cnccc2C(F)(F)F)CCC[C@@]1(Oc1ccc(C(F)(F)F)cc1)C(=O)N1CCN(c2ccccc2OCCOC)CC1.Cl,"((2R,3S)-2-allyl-1-(4-(trifluoromethyl)nicotinoyl)-3-(4-(trifluoromethyl)phenoxy)piperidin-3-yl)(4-(2-(2-methoxyethoxy)phenyl)piperazin-1-yl)methanone hydrochloride",2.1,uM,=,0.3222192947339193,1,O=C(c1cccnc1)N1CCC[C@@](Oc2ccccc2)(C(=O)N2CCN(c3ccccc3)CC2)C1
19,2076129,10.1021/acsmedchemlett.0c00387,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate measured after 5 to 20 mins in presence of NADPH by LC-MS/MS analysis,Cc1cc(-c2cnc3[nH]cc(-c4ccncc4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,"2-[(1S)-1-Cyclopropylethyl]-7-methyl-5-[3-(pyridin-4-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-2,3-dihydro-1H-isoindol-1-one",0.3,uM,=,-0.5228787452803376,0,O=C1c2ccc(-c3cnc4[nH]cc(-c5ccncc5)c4c3)cc2CN1CC1CC1
20,555225,10.1016/j.bmcl.2008.05.058,,,,Inhibition of CYP3A4,CC(=O)Nc1ccc(-c2ccc(C(CN3CCOCC3)N(C)C(=O)CN3C(=O)COc4cc(C)c(C)cc43)cc2)cc1,"N-[1-(4'-Acetylamino-biphenyl-4-yl)-2-morpholin-4-yl-ethyl]-2-(6,7-dimethyl-3-oxo-2,3-dihydro-benzo[1,4]oxazin-4-yl)-N-methyl-acetamide",6.4,uM,=,0.8061799739838872,1,O=C(CN1C(=O)COc2ccccc21)NC(CN1CCOCC1)c1ccc(-c2ccccc2)cc1
21,1859914,10.1021/acsmedchemlett.9b00114,,,,Inhibition of CYP3A4 (unknown origin),O[C@H](C[C@H]1c2c(F)cccc2-c2cncn21)[C@H]1CC[C@H](O)CC1,NAVOXIMOD,2.8,uM,=,0.4471580313422192,1,c1ccc2c(c1)-c1cncn1[C@H]2CCC1CCCCC1
22,1291572,10.1016/j.bmcl.2013.12.058,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N(C)[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1,"Thiazol-5-ylmethyl(2R,5R)-5-((S)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-N,3-dimethylbutanamido)-1,6-diphenylhexan-2-ylcarbamate",0.41,uM,=,-0.3872161432802645,0,O=C(CNC(=O)NCc1cscn1)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
23,304712,10.1021/jm048978k,,,,In vitro inhibitory concentration against Cytochrome P450 3A4,CC(C)S(=O)(=O)n1c(N)nc2ccc(-c3[nH]cnc3-c3ccc(F)cc3)cc21.CS(=O)(=O)O.CS(=O)(=O)O,6-[5-(4-Fluoro-phenyl)-3H-imidazol-4-yl]-1-(propane-2-sulfonyl)-1H-benzoimidazol-2-ylamine; Bismesylate salt,0.8,uM,=,-0.0969100130080563,0,c1ccc(-c2nc[nH]c2-c2ccc3nc[nH]c3c2)cc1
24,676065,10.1016/j.bmcl.2010.09.028,,,,Inhibition of CYP3A4 after 30 mins,CC(C)(CO)N1CCN(C(=O)OC2([C@H]3C[C@@H](O)C[C@@H](C4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)CC1,"1-((2R,4S,6S)-1-(4-chlorophenylsulfonyl)-6-cyclopropyl-4-hydroxypiperidin-2-yl)cyclopropyl 4-(1-hydroxy-2-methylpropan-2-yl)piperazine-1-carboxylate",19.5,uM,=,1.290034611362518,1,O=C(OC1([C@H]2CCC[C@@H](C3CC3)N2S(=O)(=O)c2ccccc2)CC1)N1CCNCC1
25,1466989,10.1021/jm501719e,,,,Inhibition of human CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)coumarin as substrate assessed as formation of 7-hydroxy-4-trifluoromethylcoumarin incubated for 2 mins prior to NADPH addition by fluorimetric assay,Cl.c1cncc(CCCNCCc2ccnc(-n3ccnc3)n2)c1,N-2-[2-(1H-Imidazol-1-yl)pyrimidin-4-yl]ethyl-3-(pyridin-3-yl)-propan-1-amine Trihydrochloride,70.0,uM,=,1.845098040014257,1,c1cncc(CCCNCCc2ccnc(-n3ccnc3)n2)c1
26,563097,10.1016/j.bmc.2009.03.001,,,,Inhibition of CYP3A4 in human liver microsome assessed as 1'-hydroxymidazolam formation by competitive inhibition assay,Cc1ccn(-c2ccc(C(=O)N3CCC(F)(F)/C(=C\C(=O)NCc4ccccn4)c4ccccc43)c(Cl)c2)n1,"2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}-N-(pyridin-2-ylmethyl)acetamide",11.0,uM,=,1.0413926851582251,1,O=C(/C=C1\CCCN(C(=O)c2ccc(-n3cccn3)cc2)c2ccccc21)NCc1ccccn1
27,1689562,10.1021/acs.jmedchem.7b00598,,,,Inhibition of CYP3A4 (unknown origin),N#Cc1cc(S(=O)(=O)Nc2ncns2)ccc1Oc1ccc(Cl)cc1-c1ccnc(N)c1,"4-(2-(2-aminopyridin-4-yl)-4-chlorophenoxy)-3-cyano-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide",0.205,uM,=,-0.6882461389442457,0,O=S(=O)(Nc1ncns1)c1ccc(Oc2ccccc2-c2ccncc2)cc1
28,489969,10.1021/jm800566m,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein substrate,Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1Cc1ccccc1,3-[(4-{Methyl[3-methyl-2-(benzyl)-2H-indazol-6-yl]amino}-2-pyrimidinyl)amino]benzenesulfonamide,74.0,uM,=,1.869231719730976,1,c1ccc(Cn2cc3ccc(Nc4ccnc(Nc5ccccc5)n4)cc3n2)cc1
29,1629312,10.1016/j.bmcl.2016.11.020,,,,Inhibition of CYP3A4 (unknown origin),Cc1cc(Nc2cc(C)c(C#N)c(N[C@@H](C)CCCC(C)(C)O)n2)n[nH]1,(S)-2-(6-hydroxy-6-methylheptan-2-ylamino)-4-methyl-6-(5-methyl-1H-pyrazol-3-ylamino)nicotinonitrile,9.3,uM,=,0.9684829485539352,1,c1ccc(Nc2cc[nH]n2)nc1
30,1924430,10.1021/acsmedchemlett.5b00485,,,,Inhibition of CYP3A4 (unknown origin) preincubated for 10 mins followed by addition of BFC as substrate measured after 10 mins in presence of NADP by fluorescence analysis,Cc1cc(-c2cnn3c(NCCN4CCOCC4)cc(Oc4cccc(F)c4)nc23)ccc1C(=O)NC1CC1,"N-cyclopropyl-4-(5-(3-fluorophenoxy)-7-((2-morpholinoethyl)amino)pyrazolo[1,5-a]pyrimidin-3-yl)-2-methylbenzamide",0.78,uM,=,-0.1079053973095195,0,O=C(NC1CC1)c1ccc(-c2cnn3c(NCCN4CCOCC4)cc(Oc4ccccc4)nc23)cc1
31,979641,10.1016/j.bmcl.2013.07.029,,,,Inhibition of CYP3A4 in human liver microsomes in presence of NADPH,C[C@@H]1CN(c2cccnc2C#N)CCN1C(=O)C12CC3CC(CC(C3)C1)C2,3-[(R)-4-(Adamantane-1-carbonyl)-3-methyl-piperazin-1-yl]-pyridine-2-carbonitrile,7.0,uM,=,0.8450980400142568,1,O=C(N1CCN(c2cccnc2)CC1)C12CC3CC(CC(C3)C1)C2
32,1446329,10.1021/ml500387y,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2c(C)cncc2[nH]1)C(F)(F)F,"1,1,1-trifluoro-4-(5-fluoro-2-methylphenyl)-4-methyl-2-((4-methyl-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)pentan-2-ol",2.0,uM,=,0.3010299956639812,1,c1ccc(CCCCc2cc3ccncc3[nH]2)cc1
33,2188376,10.1021/acs.jmedchem.2c01170,,,,Inhibition of CYP3A4 in human liver Microsome using midazolam as substrate in presence of NADPH by LC-MS/MS analysis,CCCC(CCC)c1nc2c(Nc3ccc(I)cc3)nc3ccccc3c2[nH]1,"2-(heptan-4-yl)-N-(4-iodophenyl)-1H-imidazo[4,5-c]quinolin-4-amine",61.6,uM,=,1.7895807121644254,1,c1ccc(Nc2nc3ccccc3c3[nH]cnc23)cc1
34,2157126,10.1021/acsmedchemlett.1c00445,,,,Time dependent inhibition of human CYP3A4 using testosterone as substrate by fluorescence plate reader analysis,C[C@@]1(c2cc(NC(=O)c3ccc(C#N)cn3)ccc2F)Cn2c(C#N)cnc2C(N)=N1,"(R)-N-(3-(8-amino-3-cyano-6-methyl-5,6-dihydroimidazo[1,2-a]pyrazin-6-yl)-4-fluorophenyl)-5-cyanopicolinamide",0.27,uM,=,-0.5686362358410126,0,O=C(Nc1cccc(C2Cn3ccnc3C=N2)c1)c1ccccn1
35,2070445,10.1021/acs.jmedchem.9b02101,,,,Inhibition of recombinant human CYP3A4,COc1cc(F)c([C@@H]2CNC(=O)[C@H]2NC(=O)Nc2ccc(Cl)s2)c(F)c1,"1-(5-Chlorothiophen-2-yl)-3-[(3S,4R)-4-(2,6-difluoro-4-methoxyphenyl)-2-oxopyrrolidin-3-yl]urea",5.6,uM,=,0.7481880270062004,1,O=C(Nc1cccs1)N[C@@H]1C(=O)NC[C@H]1c1ccccc1
36,804824,10.1016/j.bmcl.2011.12.080,,,,Reversible inhibition of CYP3A4,COc1cc(C)c2nc3[nH]nc(C)c3c(C(O)c3ccncc3)c2c1,"(+)-(6-methoxy-3,8-dimethyl-1H-pyrazolo[3,4-b]quinolin-4-yl)(pyridin-4-yl)methanol",2.9,uM,=,0.4623979978989561,1,c1ccc2c(Cc3ccncc3)c3cn[nH]c3nc2c1
37,2160656,10.1021/acs.jmedchem.1c01875,,,,Time dependent inhibition of recombinant human CYP3A4 using midazolam as substrate preincubated for 30 mins in presence of NADPH generating system followed by substrate addition incubated for 30 mins by LC-MS/MS analysi,C[C@]12CCC(=O)C[C@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](c3ccc(=O)oc3)CC[C@]12O,"5-(14-Hydroxy-10,13-dimethyl-3-oxo-hexadecahydro-cyclopenta[a]phenanthren-17-yl)-pyran-2-one",0.09,uM,=,-1.0457574905606752,0,O=C1CCC2[C@H](CC[C@H]3C4CC[C@H](c5ccc(=O)oc5)C4CC[C@H]23)C1
38,1923418,10.1021/acsmedchemlett.6b00056,,,,Inhibition of human CYP3A4 expressed in supersomes assessed as testosterone 6beta-hydroxylation after 15 mins by HPLC analysis,COc1ccc2c(c1)c(C1=CCNCC1)cn2S(=O)(=O)c1ccc2cccnc2c1,"7-{[5-Methoxy-3-(1,2,3,6-tetrahydropyridin-4yl)-1H-indol-1-yl]sulfonyl}quinoline",20.0,uM,=,1.3010299956639813,1,O=S(=O)(c1ccc2cccnc2c1)n1cc(C2=CCNCC2)c2ccccc21
39,1744980,10.1016/j.bmcl.2017.09.046,,,,Inhibition of human CYP3A4 expressed in Escherichia coli co-expressing CYP-reductase using diethoxyfluorescein as substrate measured after 10 mins by fluorescence assay,CCc1cccc(-c2c(Cl)cccc2C(O)(CCCNC(=O)OC)[C@@H]2CCCN(C(=O)CCCNC)C2)c1,methyl 4-(6-chloro-3'-ethylbiphenyl-2-yl)-4-hydroxy-4-((R)-1-(4-(methylamino)butanoyl)piperidin-3-yl)butylcarbamate,0.14,uM,=,-0.8538719643217619,0,c1ccc(-c2ccccc2C[C@@H]2CCCNC2)cc1
40,463856,10.1016/j.bmcl.2008.01.100,,,,Inhibition of CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as a substrate,CC(C)(N)C(=O)N[C@H](COCc1ccccc1)c1nnnn1[C@H](CC#N)COc1ccccc1O,2-amino-N-((S)-2-(benzyloxy)-1-(1-((R)-1-cyano-3-(2-hydroxyphenoxy)propan-2-yl)-1H-tetrazol-5-yl)ethyl)-2-methylpropanamide,9.8,uM,=,0.9912260756924948,1,c1ccc(COCCc2nnnn2CCOc2ccccc2)cc1
41,52065,10.1021/jm0310129,,,,Inhibitory activity against cytochrome P450 3A4,O=[N+]([O-])c1cccc2[nH]c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)ncnc3c12,"4-{4-[2-(3,4-Difluoro-phenyl)-ethyl]-piperazin-1-yl}-9-nitro-5H-pyrimido[5,4-b]indole",6.62,uM,=,0.8208579894396999,1,c1ccc(CCN2CCN(c3ncnc4c3[nH]c3ccccc34)CC2)cc1
42,1465541,10.1016/j.bmcl.2015.01.051,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(C6CN(C(C)C)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O,SPI-1865,37.0,uM,=,1.568201724066995,1,C1CO[C@@H]2CC3C(CC[C@@]45C[C@@]46CC[C@H](O[C@H]4CN(C7CNC7)CCO4)C[C@@H]6CC[C@@H]35)[C@H]2C1
43,1499751,10.1021/acs.jmedchem.5b00424,,,,Inhibition of CYP3A4 (unknown origin),COc1cccc(CC(=O)Nc2cc(-c3ccnc(F)c3)cs2)c1,N-(4-(2-fluoropyridin-4-yl)thiophen-2-yl)-2-(3-methoxyphenyl)acetamide,3.8,uM,=,0.5797835966168101,1,O=C(Cc1ccccc1)Nc1cc(-c2ccncc2)cs1
44,52064,10.1016/s0960-894x(03)00058-1,,,,Inhibitory activity against CYP450 3A4 isozyme,CCc1cn(CC(=O)N(CCN(CC)CC)Cc2ccc(-c3ccc(Cl)cc3)cc2)c(SCc2ccc(F)cc2)nc1=O,N-(4'-Chloro-biphenyl-4-ylmethyl)-N-(2-diethylamino-ethyl)-2-[5-ethyl-2-(4-fluoro-benzylsulfanyl)-4-oxo-4H-pyrimidin-1-yl]-acetamide,7.0,uM,=,0.8450980400142568,1,O=C(Cn1ccc(=O)nc1SCc1ccccc1)NCc1ccc(-c2ccccc2)cc1
45,1512779,10.1016/j.bmcl.2015.07.038,,,,Time dependent inhibition of CYP3A4 in human liver microsomes assessed as reduction in testosterone 6beta-hydroxylation incubated for 60 mins in presence of NADPH generating system by LC-MS/MS method,COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C,"Methoxy-acetic acid (1S,2S)-2-(2-{[3-(1H-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)-6-fluoro-1-isopropyl-1,2,3,4-tetrahydro-naphthalen-2-yl ester",140.0,uM,=,2.146128035678238,1,c1ccc2c(c1)CCC(CCNCCCc1nc3ccccc3[nH]1)C2
46,481543,10.1021/np0400104,,,,Inhibition of human CYP3A4,CC(C)CC(=O)c1c(O)cc(O)cc1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O,"2-beta-D-glucopyranosyloxy-4,6-dihydroxyisovalerophenone",120.0,uM,=,2.0791812460476247,1,c1ccc(O[C@H]2CCCCO2)cc1
47,1475768,10.1021/jm5017413,,,,Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system,CC(C)c1nc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)[C@@H]3C)co1,"(R)-(3-(2-Isopropyloxazol-4-yl)-8-methyl-5,6-dihydro-[1,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(thiophen-2-yl)phenyl)-methanone",43.0,uM,=,1.6334684555795866,1,O=C(c1ccc(-c2cccs2)cc1)N1CCn2c(nnc2-c2cocn2)C1
48,1534761,,,,,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",COc1ncccc1CNc1ccc(Cc2c[nH]c3ncc(C)cc23)c(F)n1,"US9096593, P-2052",5.0,uM,=,0.6989700043360189,1,c1cncc(CNc2ccc(Cc3c[nH]c4ncccc34)cn2)c1
49,1336778,10.1021/jm401911v,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,CC(C)(C)S(=O)(=O)C[C@H](C1CC1)N1C(=O)[C@@](C)(CS(N)(=O)=O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1,"((3S,5R,6S)-1-((S)-2-(tert-Butylsulfonyl)-1-cyclopropylethyl)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-3-methyl-2-oxopiperidin-3-yl)-methanesulfonamide",0.5,uM,=,-0.3010299956639812,0,O=C1CC[C@H](c2ccccc2)[C@@H](c2ccccc2)N1CC1CC1
50,990449,10.1016/j.bmcl.2013.09.001,,,,Inhibition of CYP3A4 in human liver microsomes in presence of NADPH,Cc1cccc(NC(=O)c2cc(Cl)cc(Oc3cncc(F)c3)c2)n1,3-chloro-5-(5-fluoropyridin-3-yloxy)-N-(6-methylpyridin-2-yl)benzamide,0.7,uM,=,-0.1549019599857432,0,O=C(Nc1ccccn1)c1cccc(Oc2cccnc2)c1
51,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1ccc(-n2cccn2)cc1C[C@@H]1COCCN1C(=O)c1cccc(C)c1-n1nccn1,"US9150566, 190",26.0,uM,=,1.414973347970818,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2cccn2)c1
52,802673,10.1016/j.bmcl.2011.12.125,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,O=C(Nc1ccc(Cl)cc1)Nc1ccc(-c2ccnc3[nH]cnc23)cc1,"1-(4-(3H-imidazo[4,5-b]pyridin-7-yl)phenyl)-3-(4-chlorophenyl)urea",0.31,uM,=,-0.5086383061657274,0,O=C(Nc1ccccc1)Nc1ccc(-c2ccnc3[nH]cnc23)cc1
53,455108,10.1016/j.bmcl.2006.12.043,,,,Inhibition of CYP3A4,NC(C(=O)N1CCC(Nc2ccc3[nH]ncc3c2)CC1)c1cccc(Cl)c1,1-(4-(1H-indazol-5-ylamino)piperidin-1-yl)-2-amino-2-(3-chlorophenyl)ethanone,0.17,uM,=,-0.7695510786217261,0,O=C(Cc1ccccc1)N1CCC(Nc2ccc3[nH]ncc3c2)CC1
54,487712,10.1016/j.bmcl.2008.05.104,,,,Inhibition of CYP3A4,COC(=O)N1CCN(C2CCN(c3cc(C)c4nc(-c5c(NC[C@@H](O)c6cccc(Cl)c6)cc[nH]c5=O)[nH]c4c3)CC2)CC1,"(S)-methyl 4-(1-(2-(4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-2-oxo-1,2-dihydropyridin-3-yl)-7-methyl-3H-benzo[d]imidazol-5-yl)piperidin-4-yl)piperazine-1-carboxylate",0.0035,uM,=,-2.4559319556497243,0,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(N3CCC(N4CCNCC4)CC3)cc2[nH]1
55,487712,10.1016/j.bmcl.2008.05.104,,,,Inhibition of CYP3A4,Cc1cc(N2CCC(N3CCN(C(=O)N4CCOCC4)CC3)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,(S)-4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-3-(4-methyl-6-(4-(4-(morpholine-4-carbonyl)piperazin-1-yl)piperidin-1-yl)-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one,0.019,uM,=,-1.7212463990471711,0,O=C(N1CCOCC1)N1CCN(C2CCN(c3ccc4nc(-c5c(NCCc6ccccc6)cc[nH]c5=O)[nH]c4c3)CC2)CC1
56,1640556,,,,,"null: Microsomal preparation: One lobe of fresh pig liver is obtained (e.g., at about the time of slaughter from a food-processing company) and immediately placed in ice cold 15 mM KH2PO4/250 mM sucrose (pH 7.4) and kept on ice during transportation. A 10 g sample of liver is minced and homogenized in 30 mL of homogenization buffer (15 mM KH2PO4/250 mM sucrose) using a Tekmar homoginizer or equivalent by pulsing 3 times with 20 second pulses. This procedure is repeated for a total of 8x10 g samples of pig liver. The remaining pig liver may be stored at -80 C. The homogenates from the 8 samples are pooled and centrifuged at 13,000xg for 20 minutes at 4 C. to remove crude debris. The supernatant is further centrifuged at 100,000xg for 70 minutes at 4° C. The microsomal pellets are re-suspended into 50 mL of 150 mM KH2PO4/1 mM DTT (pH 7.4) and 1 mL aliquots are stored at -80 C.100-150 ug of pig liver microsomal protein in 150 mM KH2PO4 is incubated at 37° C.",c1ccc(Cn2ccnc2)cc1,1-Benzyl-1H-imidazole,77.5,uM,=,1.8893017025063104,1,c1ccc(Cn2ccnc2)cc1
57,651640,10.1016/j.bmcl.2010.07.009,,,,Inhibition of CYP3A4,c1ccc(Cn2nnnc2C(c2ccc(-n3cncn3)cc2)N2CCCN(C3CCC3)CC2)cc1,"1-((4-(1H-1,2,4-triazol-1-yl)phenyl)(1-benzyl-1H-tetrazol-5-yl)methyl)-4-cyclobutyl-1,4-diazepane",29.0,uM,=,1.462397997898956,1,c1ccc(Cn2nnnc2C(c2ccc(-n3cncn3)cc2)N2CCCN(C3CCC3)CC2)cc1
58,813216,10.1016/j.bmcl.2012.01.125,,,,Inhibition of CYP3A4,COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n(Cc3ccccn3)c12,"7-(3,5-dimethylisoxazol-4-yl)-8-methoxy-1-(pyridin-2-ylmethyl)-1H-imidazo[4,5-c]quinolin-2(3H)-one",12.9,uM,=,1.110589710299249,1,O=c1[nH]c2cnc3cc(-c4cnoc4)ccc3c2n1Cc1ccccn1
59,342118,10.1021/jm051106d,,,,Inhibitory activity against CYP3A4,COC[C@@H](O)COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C,"(R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)-3-methoxypropan-2-ol",1.0,uM,=,0.0,0,c1cc2c(Oc3ccc4[nH]ccc4c3)ncnn2c1
60,2071175,10.1021/acs.jmedchem.0c00500,,,,Inhibition of CYP3A4 in human liver microsomes after 20 mins by LC-MS/MS analysis,CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,SID144204227,0.069,uM,=,-1.1611509092627446,0,c1ccc([C@@]2(Cn3ccnc3)OC[C@H](COc3ccc(N4CCNCC4)cc3)O2)cc1
61,990449,10.1016/j.bmcl.2013.09.001,,,,Inhibition of CYP3A4 in human liver microsomes in presence of NADPH,Cc1csc(NC(=O)c2cc(F)cc(Oc3cncnc3)c2)n1,3-fluoro-N-(4-methylthiazol-2-yl)-5-(pyrimidin-5-yloxy)benzamide,22.3,uM,=,1.3483048630481609,1,O=C(Nc1nccs1)c1cccc(Oc2cncnc2)c1
62,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)Nc6cccc(C(N)=O)c6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, D-15",15.97,uM,=,1.203304916138483,1,O=C(Nc1ccccc1)c1ccc(-c2c[nH]c3c(CN4C[C@@H]5N(C(=O)NCc6ccccc6)NCC(=O)N5[C@@H](Cc5ccccc5)C4=O)cccc23)cc1
63,2254484,10.1021/acs.jmedchem.2c00527,,,,Inhibition of CYP3A4 in human liver microsomes at 0.01 to 30 uM using phenacetin as substrate in presence of NADPH by UPLC-MS/MS analysis,CC(C)NC[C@@H](C(=O)N1CCN(c2ncnc3c2[C@H](C)CC(=O)N3)[C@H]2C[C@H]21)c1ccc(Cl)cc1,"(R)-4-((lR,6S)-5-((S)-2-(4-chlorophenyl)-3-(isopropylamino)propionyl)-2,5-diazabicyclo[4.1.0]heptan-2-yl)-5-methyl-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one",15.2,uM,=,1.1818435879447726,1,O=C1CCc2c(ncnc2N2CCN(C(=O)Cc3ccccc3)[C@@H]3C[C@@H]32)N1
64,1765748,10.1021/acs.jmedchem.8b00913,,,,Inhibition of CYP3A4 (unknown origin),COc1cncc(NC(C(=O)c2c[nH]c3ccccc23)c2ccccc2)c1,1-(1H-indol-3-yl)-2-(5-methoxypyridin-3-ylamino)-2-phenylethanone,0.05,uM,=,-1.3010299956639813,0,O=C(c1c[nH]c2ccccc12)C(Nc1cccnc1)c1ccccc1
65,1288280,10.1016/j.bmcl.2013.12.057,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,Cc1nc(CN(C)C(=O)N[C@H](C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1,"Thiazol-5-ylmethyl(2R,5R)-5-((S)-3-methyl-2-(3-methyl-3-((2-methylthiazol-4-yl)methyl)ureido)butanamido)-1,6-diphenylhexan-2-ylcarbamate",0.1,uM,=,-1.0,0,O=C(CNC(=O)NCc1cscn1)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
66,979124,10.1021/jm400484p,,,,Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes,COc1ccc2ccc(-c3cccnc3)c(Cl)c2c1,3-(1-Chloro-7-methoxy-naphthalen-2-yl)-pyridine,3.56,uM,=,0.5514499979728752,1,c1cncc(-c2ccc3ccccc3c2)c1
67,1662668,10.1021/acs.jmedchem.6b01850,,,,Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated with enzyme in presence of NADPH followed by substrate addition,COc1cc(-c2cccc(C(F)(F)F)c2)ccc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3ccon3)ccc21,"US9212182, 323::US9212182, 324",45.0,uM,=,1.6532125137753435,1,O=c1ccc2cc(S(=O)(=O)Nc3ccon3)ccc2n1-c1ccc(-c2ccccc2)cc1
68,1528565,,,,,"Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",CC(C)c1nc(CN(C)C(=O)N2CCC[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,"US8987313, 39",0.26,uM,=,-0.585026652029182,0,O=C(N[C@H](CC[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)NCc1cscn1)Cc1ccccc1)OCc1cncs1
69,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",COc1ccc(C[C@@H]2COCCN2C(=O)c2ccccc2-n2nccn2)cc1-c1cnccn1,"US9150566, 6",26.0,uM,=,1.414973347970818,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2cnccn2)c1
70,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1ccc(-n2nccn2)cc1C[C@@H]1COCCN1C(=O)c1ccccc1-n1nccn1,"US9150566, 121",18.0,uM,=,1.255272505103306,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
71,859942,10.1021/jm300122u,,,,Inhibition of human CYP3A4 using testosterone as substrate after 45 mins,O=C([C@H](Cc1ccc(Br)cc1)NC(=O)C1(c2ccc(Cl)cc2Cl)CC1)N1CCC(O)CC1,"N-[(1S)-1-[(4-Bromophenyl)methyl]-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]-1-(2,4-dichlorophenyl)-cyclopropanecarboxamide",1.3,uM,=,0.1139433523068367,1,O=C([C@H](Cc1ccccc1)NC(=O)C1(c2ccccc2)CC1)N1CCCCC1
72,1772538,10.1016/j.bmcl.2018.05.055,,,,Inhibition of CYP3A4 (unknown origin),CC(=O)N[C@@H](C)/C=C/c1ccc(Oc2ccc3nc(C(C)C)sc3c2C(F)(F)F)nc1,"(S,E)-N-(4-(6-((2-isopropyl-7-(trifluoromethyl)benzothiazol-6-yl)oxy)pyridin-3-yl)but-3-en-2-yl)acetamide",17.0,uM,=,1.230448921378274,1,c1ccc(Oc2ccc3ncsc3c2)nc1
73,2125132,10.1021/acsmedchemlett.1c00540,,,,Inhibition of human CYP3A4 using testosterone as a substrate by LC/MS/MS analysis,Cc1cn(-c2ccnc(N[C@@H]3CCN(C(=O)c4nccs4)C3)n2)c(-c2ccccc2)n1,(R)-(3-(4-(4-methyl-2-phenyl-1H-imidazol-1-yl)pyrimidin-2-ylamino)pyrrolidin-1-yl)(thiazol-2-yl)methanone,0.94,uM,=,-0.0268721464003013,0,O=C(c1nccs1)N1CC[C@@H](Nc2nccc(-n3ccnc3-c3ccccc3)n2)C1
74,993439,10.6019/CHEMBL2448688,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,O=C(C1CC1)N(Cc1cccnc1)c1cccc(-c2nc3ccccc3s2)c1,,1.4,uM,=,0.1461280356782379,1,O=C(C1CC1)N(Cc1cccnc1)c1cccc(-c2nc3ccccc3s2)c1
75,1489010,10.1124/dmd.111.042739,,,,Inhibition of CYP3A4 (unknown origin),CC[C@@H](C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O,"Cis2-((R)-sec-Butyl)-4-[4-(4-{4-[(2S,4R)-2-(2,4-dichloro-phenyl)-2-[1,2,4]triazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-phenyl]-2,4-dihydro-[1,2,4]triazol-3-one",0.004,uM,=,-2.397940008672037,0,O=c1[nH]ncn1-c1ccc(N2CCN(c3ccc(OC[C@@H]4CO[C@@](Cn5cncn5)(c5ccccc5)O4)cc3)CC2)cc1
76,1785637,,,,,Inhibition of CYP3A4 (unknown origin),O=S(=O)(C1CC1)N1CCN(c2ccc(/C=C/c3cc(F)cc(-c4ccncc4)c3)cc2)CC1,(E)-1-(cyclopropylsulfonyl)-4-(4-(3-fluoro-5-(pyridin-4-yl)styryl)phenyl)piperazine,0.636,uM,=,-0.1965428843515861,0,O=S(=O)(C1CC1)N1CCN(c2ccc(/C=C/c3cccc(-c4ccncc4)c3)cc2)CC1
77,1741066,10.1021/acs.jmedchem.8b00450,,,,Inhibition of human CYP3A4,c1cnc2c(c1)CCC[C@@H]2N(CC1CCCCC1)C[C@H]1Cc2c(cccc2N2CCNCC2)CN1,"(S)-N-(cyclohexylmethyl)-N-(((R)-5-(piperazin-1-yl)-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)-5,6,7,8-tetrahydroquinolin-8-amine",1.78,uM,=,0.250420002308894,1,c1cnc2c(c1)CCC[C@@H]2N(CC1CCCCC1)C[C@H]1Cc2c(cccc2N2CCNCC2)CN1
78,1465595,10.1016/j.bmcl.2015.02.039,,,,Inhibition of CYP3A4 (unknown origin) using DBF fluorometric substrate,COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2NC(=O)OCC2CCCCC2)C(C)C)ccc1OC,"cyclohexylmethyl (3S,4S)-4-((N-isopropyl-4-methoxy-3-(3-methoxypropoxy)benzamido)methyl)pyrrolidin-3-ylcarbamate",3.4,uM,=,0.5314789170422551,1,O=C(N[C@@H]1CNC[C@H]1CNC(=O)c1ccccc1)OCC1CCCCC1
79,827974,10.1016/j.bmcl.2012.05.087,,,,Inhibition of CYP3A4 using testosterone as substrate,COc1ccc(C(C)=O)cc1CSc1nc2cc(F)ccc2n1CC(=O)O,2-(2-(5-acetyl-2-methoxybenzylthio)-5-fluoro-1H-benzo[d]imidazol-1-yl)acetic acid,15.0,uM,=,1.1760912590556811,1,c1ccc(CSc2nc3ccccc3[nH]2)cc1
80,1696494,10.1016/j.bmcl.2017.08.068,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as substrate,NC(=O)c1cc(Cl)c2c(Cl)c(C3CC3)n([C@H]3CCCNC3)c2n1,"(S)-3,4-dichloro-2-cyclopropyl-1-(piperidin-3-yl)-1H-pyrrolo[2,3-b]pyridine-6-carboxamide",21.0,uM,=,1.3222192947339193,1,c1cnc2c(c1)cc(C1CC1)n2[C@H]1CCCNC1
81,1528565,,,,,"Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",CC(C)c1nc(CN(C)C(=O)N2CS(=O)(=O)C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,"US8987313, 18",0.26,uM,=,-0.585026652029182,0,O=C(N[C@H](CC[C@H](Cc1ccccc1)NC(=O)[C@@H]1CS(=O)(=O)CN1C(=O)NCc1cscn1)Cc1ccccc1)OCc1cncs1
82,1829871,10.1021/acsmedchemlett.8b00308,,,,Inhibition of CYP3A4 (unknown origin),Nc1cc(OCc2cc(-c3cccc(F)c3)ccc2Cl)c2nn[nH]c2n1,"7-((4-Chloro-3'-fluorobiphenyl-3-yl)methoxy)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-amine",0.06,uM,=,-1.2218487496163564,0,c1ccc(-c2cccc(COc3ccnc4[nH]nnc34)c2)cc1
83,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",O=C(c1ccccc1-n1nccn1)N1CCC[C@H]1Cc1cccc(-n2nccn2)c1,"US9150566, Ref. 1",5.5,uM,=,0.7403626894942439,1,O=C(c1ccccc1-n1nccn1)N1CCC[C@H]1Cc1cccc(-n2nccn2)c1
84,873423,10.1021/jm3006788,,,,Inhibition of CYP3A4,Cc1ccc(-c2c(C3CCCC3)c3ccc(C(=O)NC4(C(=O)Nc5ccc(/C=C/C(=O)O)cc5)CCC4)cc3n2C)nc1,(E)-3-(4-(1-(3-cyclopentyl-1-methyl-2-(5-methylpyridin-2-yl)-1H-indole-6-carboxamido)cyclobutanecarboxamido)phenyl)acrylic acid,5.8,uM,=,0.7634279935629373,1,O=C(NC1(C(=O)Nc2ccccc2)CCC1)c1ccc2c(C3CCCC3)c(-c3ccccn3)[nH]c2c1
85,774749,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Cc1cc(C(C#N)c2ccc(Cl)cc2)c(Cl)cc1NC(=O)c1cc(I)cc(I)c1O,"N-{5-Chloro-4-[(4-chloro-phenyl)-cyano-methyl]-2-methyl-phenyl}-2-hydroxy-3,5-diiodo-benzamide",5.0,uM,=,0.6989700043360189,1,O=C(Nc1ccc(Cc2ccccc2)cc1)c1ccccc1
86,1659464,10.1021/acs.jmedchem.6b01662,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate in presence of NADPH by LC-MS/MS analysis,COc1ccc2c(c1)c(CN1CCN(C)CC1)cn2S(=O)(=O)c1ccccc1Br.CS(=O)(=O)O.O,1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole Dimesylate Monohydrate,2.64,uM,=,0.421603926869831,1,O=S(=O)(c1ccccc1)n1cc(CN2CCNCC2)c2ccccc21
87,449485,10.1016/j.bmcl.2007.07.097,,,,Inhibition of microsomal CYP3A4,CCN(CC)CCN[C@@H](CC(C)C)c1cc(F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1,"1-((R)-3-(2,4-dichlorophenyl)-1-(4-(2-((S)-1-(2-(diethylamino)ethylamino)-3-methylbutyl)-4-fluorophenyl)piperazin-1-yl)-1-oxopropan-2-yl)pyrrolidin-2-one",37.0,uM,=,1.568201724066995,1,O=C([C@@H](Cc1ccccc1)N1CCCC1=O)N1CCN(c2ccccc2)CC1
88,856843,10.1021/jm300356u,,,,Inhibition of human recombinant CYP3A4 using DEF as substrate preincubated for 5 to 10 mins before substrate addition,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H]3[C@H]2O/C(=N/c2ccc(OC)cc2)N3C)[C@](C)(OC)C[C@@H](C)C(=O)N[C@H](C)[C@@H](O)[C@]1(C)O,"(2R,3S,4R,5R,10R,11R,12S,13S,14R)-2-ethyl-3,4-dihydroxy-13-((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yloxy)-10-methoxy-11-((3aR,4S,6R,7aS)-2-(4-methoxyphenylimino)-1,6-dimethylhexahydro-1H-pyrano[4,3-d]oxazol-4-yloxy)-3,5,8,10,12,14-hexamethyl-1-oxa-6-azacyclopentadecane-7,15-dione",0.7,uM,=,-0.1549019599857432,0,O=C1CCC[C@H](O[C@@H]2OCC[C@@H]3N/C(=N\c4ccccc4)O[C@@H]23)C[C@H](O[C@H]2CCCCO2)CC(=O)OCCCCN1
89,550965,10.1021/np030556a,,,,Inhibition of human CYP3A4 by radiometric assay,C/C1=C\[C@H](O)C[C@]2(C)O[C@@H]2CC(C)(C)/C=C/C1=O,"(2R,3R,5R)-2,3-epoxy-6,9-humuladien-5-ol-8-one",42.6,uM,=,1.6294095991027189,1,O=C1C=CCCC2O[C@@H]2CC/C=C/1
90,1467195,10.1021/jm5005336,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay,COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5[C@H](C)CN(C)C[C@@H]5C)cc4)n[nH]c3c1)C(=O)N2,"(1R,2S)-5'-Methoxy-2-(3-((E)-4-(((2R,6S)-2,4,6-trimethylpiperazin-1-yl)methyl)styryl)-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-one",10.0,uM,=,1.0,1,O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccc(CN4CCNCC4)cc3)n[nH]c2c1
91,539794,10.1021/jm8005405,,,,Inhibition of CYP3A4 in human liver microsomes,Cc1ccc2c(NC3CC3)noc2c1-c1ccc2c(NC(C)C)nncc2c1,6-(3-(cyclopropylamino)-6-methylbenzo[d]isoxazol-7-yl)-N-isopropylphthalazin-1-amine,5.6,uM,=,0.7481880270062004,1,c1cc(-c2ccc3cnncc3c2)c2onc(NC3CC3)c2c1
92,619264,10.1016/j.bmcl.2009.07.002,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,Cc1cccc(C)c1COc1cccn2c(C)c(C)nc12,"8-(2,6-dimethylbenzyloxy)-2,3-dimethylimidazo[1,2-a]pyridine",5.5,uM,=,0.7403626894942439,1,c1ccc(COc2cccn3ccnc23)cc1
93,804824,10.1016/j.bmcl.2011.12.080,,,,Reversible inhibition of CYP3A4,Cc1cc(Cl)cc2c(C(O)c3ccccn3)c3c(C)n[nH]c3nc12,"rac-(6-chloro-3,8-dimethyl-1H-pyrazolo[3,4-b]quinolin-4-yl)(pyridin-2-yl)methanol",1.8,uM,=,0.255272505103306,1,c1ccc(Cc2c3ccccc3nc3[nH]ncc23)nc1
94,774749,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Clc1ccc(CO/N=C(\Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1,"1-(2,4-Dichloro-phenyl)-2-imidazol-1-yl-ethanone O-(2,4-dichloro-benzyl)-oxime",0.09,uM,=,-1.0457574905606752,0,c1ccc(CO/N=C(\Cn2ccnc2)c2ccccc2)cc1
95,993439,10.6019/CHEMBL2448688,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,CN1CCC(NCC(O)COc2ccc3cc(Br)ccc3c2)CC1,,44.4,uM,=,1.64738297011462,1,c1ccc2cc(OCCCNC3CCNCC3)ccc2c1
96,519907,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,Cc1cccc(C)c1COc1cc(-n2ccccc2=O)cn2c(C)c(C)nc12,"1-(8-(2,6-dimethylbenzyloxy)-2,3-dimethylimidazo[1,2-a]pyridin-6-yl)pyridin-2(1H)-one",9.2,uM,=,0.9637878273455552,1,O=c1ccccn1-c1cc(OCc2ccccc2)c2nccn2c1
97,642991,10.1021/jm1000248,,,,Inhibition of CYP3A4,Cc1cc2nc(NCCCO)n(CC(=O)c3cc(C(C)(C)C)c(O)c(C(C)(C)C)c3)c2cc1C,"2-(2-(3-Hydroxypropylamino)-5,6-dimethyl-1H-benzo[d]-imidazol-1-yl)-1-(3,5-di-tert-butyl-4-hydroxyphenyl)ethanone",3.0,uM,=,0.4771212547196624,1,O=C(Cn1cnc2ccccc21)c1ccccc1
98,1367425,10.1021/jm5003606,,,,Inhibition of recombinant CYP3A4 (unknown origin) by LC/MS/MS analysis,CCc1nc2ccc(Cl)cn2c1C(=O)NCc1ccc(N2CCN(c3ccc(F)cc3)CC2)cc1,"6-Chloro-2-ethyl-N-{4-[4-(4-fluorophenyl)piperazin-1-yl]benzyl}-imidazo[1,2-a]pyridine-3-carboxamide",0.49,uM,=,-0.3098039199714864,0,O=C(NCc1ccc(N2CCN(c3ccccc3)CC2)cc1)c1cnc2ccccn12
99,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCCCOC)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, F-10",2.01,uM,=,0.3031960574204888,1,O=C1[C@H](Cc2ccccc2)N2C(=O)CNN(C(=O)NCc3ccccc3)[C@H]2CN1Cc1cccc2cc[nH]c12
100,988938,10.1021/jm401094t,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of dextromethorphan metabolism by HPLC/MS analysis,Nc1ncc(-c2cnc3[nH]cc(-c4ccc5[nH]ccc5c4)c3c2)cn1,"5-(3-(1H-Indol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrimidin-2-amine",21.8,uM,=,1.3384564936046048,1,c1ncc(-c2cnc3[nH]cc(-c4ccc5[nH]ccc5c4)c3c2)cn1
101,876026,10.1021/jm3011838,,,,Inhibition of CYP3A4 in human liver microsomes in presence of NADPH by LC-MS/MS method,Nc1ccccc1NC(=O)/C=C/c1ccc([C@H]2CN(CCO)C[C@@H]2C(=O)Nc2ccc(Cl)cc2)cc1,"rac-(trans-3,4)-4-{4-[(E)-2-(2-Amino-phenylcarbamoyl)-vinyl]-phenyl}-1-(2-hydroxy-ethyl)-pyrrolidine-3-carboxylic acid(4-chloro-phenyl)-amide",2.0,uM,=,0.3010299956639812,1,O=C(/C=C/c1ccc([C@H]2CNC[C@@H]2C(=O)Nc2ccccc2)cc1)Nc1ccccc1
102,821298,10.1021/jm201454n,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis,Cc1cnc2nc1-c1ccnc(c1)OCC/C=C/COCc1cc(ccc1OCCN1CCCC1)N2,"3-Methyl-11-(2-(pyrrolidin-1-yl)ethoxy)-14,20-dioxa-5,7,22,26-tetraaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2-(26),3,5,8(27),9,11,16,21,23-decaene",0.97,uM,=,-0.0132282657337551,0,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2ccnc(c2)OCC/1
103,802673,10.1016/j.bmcl.2011.12.125,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,COc1ccc(NC(=O)Nc2ccc(-c3ccnc4[nH]cnc34)cc2)cc1,"1-(4-(3H-imidazo[4,5-b]pyridin-7-yl)phenyl)-3-(4-methoxyphenyl)urea",0.2,uM,=,-0.6989700043360187,0,O=C(Nc1ccccc1)Nc1ccc(-c2ccnc3[nH]cnc23)cc1
104,2134958,10.1021/acs.jmedchem.1c00224,,,,Inhibition of CYP3A4 (unknown origin),O=S(=O)(c1cccc(F)c1)n1ccc2c(N3CCNCC3)nc3ccccc3c21,"1-((3-Fluorophenyl)sulfonyl)-4-(piperazin-1-yl)-1H-pyrrolo[3,2-c]quinoline",57.0,uM,=,1.7558748556724917,1,O=S(=O)(c1ccccc1)n1ccc2c(N3CCNCC3)nc3ccccc3c21
105,342118,10.1021/jm051106d,,,,Inhibitory activity against CYP3A4,Cc1cc2c(F)c(Oc3ncnn4cc(OCCCS(C)(=O)=O)c(C)c34)ccc2[nH]1,"4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methyl-6-(3-(methylsulfonyl)propoxy)pyrrolo[2,1-f][1,2,4]triazine",17.0,uM,=,1.230448921378274,1,c1cc2c(Oc3ccc4[nH]ccc4c3)ncnn2c1
106,2152998,10.1021/acs.jmedchem.1c00635,,,,Inhibition of CYP3A4 in human liver microsomes using ketoconazole as substrate incubated for 5 mins in presence of NADPH by LC-MS/MS analysis,CCc1cccc(CC)c1NC(=O)c1ccn(-c2nc(Nc3ccc(N4CCC(C(=O)N5CCN(C)CC5)CC4)cc3OC)nc3[nH]ccc23)c1,"N-(2,6-diethylphenyl)-1-[2-[2-methoxy-4-[4-(4-methylpiperazine-1-carbonyl)-1-piperidyl]anilino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]pyrrole-3-carboxamide",3.1,uM,=,0.4913616938342727,1,O=C(Nc1ccccc1)c1ccn(-c2nc(Nc3ccc(N4CCC(C(=O)N5CCNCC5)CC4)cc3)nc3[nH]ccc23)c1
107,2024795,10.1021/acs.jmedchem.0c01741,,,,Inhibition of CYP3A4 in in human liver microsomes at incubated for 10 mins in presence of CYP3A4 substrate/NADP+ by fluorescence based assay,COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC,"2-(3,4-Dimethoxy-phenyl)-5-{[2-(3,4-dimethoxy-phenyl)-ethyl]-methyl-amino}-2-isopropyl-pentanenitrile",21.33,uM,=,1.3289908554494287,1,c1ccc(CCCCNCCc2ccccc2)cc1
108,436456,10.1021/jm061195+,,,,Inhibition of human CYP3A4,O=C(NCC1CCCCC1)c1cnc(Nc2cccc(Cl)c2)nc1C(F)(F)F,2-(3-chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(cyclohexylmethyl)amide,82.0,uM,=,1.9138138523837167,1,O=C(NCC1CCCCC1)c1cnc(Nc2ccccc2)nc1
109,1301273,10.6019/CHEMBL3137386,,,,DNDI: CYP Inhibition,CS(=O)(=O)c1ccc(N2CCN(C(=O)C(c3ccc(Cl)cc3)c3cccnc3)CC2)cc1,2-(4-Chlorophenyl)-2-(pyridin-3-yl)-1-(4-[4-(methylsulfonyl)phenyl]piperazin-1-yl)ethanone,19.0,uM,=,1.2787536009528289,1,O=C(C(c1ccccc1)c1cccnc1)N1CCN(c2ccccc2)CC1
110,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN6CCCC6C5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, E-43",6.6,uM,=,0.8195439355418687,1,O=C(c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12)N1CCN2CCCC2C1
111,1460909,10.1021/jm501326k,,,,Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase/human b5 reductase using 7-benzyloxyquinoline substrate,CCOC(=O)c1[nH]cc2c1NC1=C(C(=O)CCC1)C2c1ccc(Sc2nc3c(N)cccc3[nH]2)o1,"(+/-)-Ethyl 9-[5-[(4-amino-1H-benzimidazol-2-yl)sulfanyl]-2-furyl]-8-oxo-2,4,5,6,7,9-hexahydropyrrolo[3,4-b]quinoline-3-carboxylate",0.08,uM,=,-1.0969100130080565,0,O=C1CCCC2=C1C(c1ccc(Sc3nc4ccccc4[nH]3)o1)c1c[nH]cc1N2
112,552281,10.1016/j.bmcl.2008.04.036,,,,Inhibition of CYP3A4,COc1cccc(-c2cn(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](NCCCC(=O)O)c3ccccc3)c2=O)c1F,"(R)-4-(2-(3-(2-fluoro-6-(trifluoromethyl)benzyl)-5-(2-fluoro-3-methoxyphenyl)-2,6-dioxo-2,3-dihydropyrimidin-1(6H)-yl)-1-phenylethylamino)butanoic acid",36.0,uM,=,1.5563025007672873,1,O=c1c(-c2ccccc2)cn(Cc2ccccc2)c(=O)n1CCc1ccccc1
113,611723,10.1021/jm9014263,,,,Inhibition of human CYP3A4 using BQ substrate by fluorescence assay,COc1ccc(C(=O)NCc2cccc(C(=O)NCCc3ccncc3)c2)cc1OC,"3,4-Dimethoxy-N-[3-(2-pyridin-4-yl-ethylcarbamoyl)-benzyl]-benzamide",21.0,uM,=,1.3222192947339193,1,O=C(NCCc1ccncc1)c1cccc(CNC(=O)c2ccccc2)c1
114,862399,10.1021/jm300601d,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis,Cn1ccnc1C(=O)N1CCC(c2ccc(C(=O)NC(=N)N)cc2C(F)(F)F)CC1,N-{4-[1-(1-Methyl-1H-imidazole-2-carbonyl)-piperidin-4-yl]-3-trifluoromethyl-benzoyl}-guanidine,26.0,uM,=,1.414973347970818,1,O=C(c1ncc[nH]1)N1CCC(c2ccccc2)CC1
115,305432,10.1016/j.bmcl.2005.01.044,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,COC(=O)c1cccc(COc2ccc3cc(C(C(C)N(C)C)n4ccnc4)ccc3c2)c1,3-[6-(2-Dimethylamino-1-imidazol-1-yl-propyl)-naphthalen-2-yloxymethyl]-benzoic acid methyl ester,0.21,uM,=,-0.6777807052660807,0,c1ccc(COc2ccc3cc(Cn4ccnc4)ccc3c2)cc1
116,657984,10.1021/jm100482n,,,,Inhibition of CYP3A4 in human liver microsomes measured immediately,CNC(=O)c1ncn2c1COc1c(CCN3CCN(c4cccc5nc(C)ccc45)CC3)cccc1-2,"N-methyl-6-(2-(4-(2-methylquinolin-5-yl)piperazin-1-yl)ethyl)-4H-benzo[b]imidazo[1,5-d][1,4]oxazine-3-carboxamide",21.0,uM,=,1.3222192947339193,1,c1cc(CCN2CCN(c3cccc4ncccc34)CC2)c2c(c1)-n1cncc1CO2
117,873423,10.1021/jm3006788,,,,Inhibition of CYP3A4,Cn1c(-c2cccc(N)n2)c(C2CCCC2)c2ccc(C(=O)NC3(C(=O)Nc4ccc(/C=C/C(=O)O)cc4)CCC3)cc21,(E)-3-(4-(1-(2-(6-aminopyridin-2-yl)-3-cyclopentyl-1-methyl-1H-indole-6-carboxamido)cyclobutanecarboxamido)phenyl)acrylic acid,7.0,uM,=,0.8450980400142568,1,O=C(NC1(C(=O)Nc2ccccc2)CCC1)c1ccc2c(C3CCCC3)c(-c3ccccn3)[nH]c2c1
118,44705,10.1016/s0960-894x(02)00473-0,,,,Inhibition of cytochrome P450 3A4,Cn1cc(Cc2cn(CC(=O)N(CCN3CCCCC3)Cc3ccc(-c4ccc(C(F)(F)F)cc4)cc3)c(SCc3ccc(F)cc3)nc2=O)cn1,2-[2-(4-Fluoro-benzylsulfanyl)-5-(1-methyl-1H-pyrazol-4-ylmethyl)-4-oxo-4H-pyrimidin-1-yl]-N-(2-piperidin-1-yl-ethyl)-N-(4'-trifluoromethyl-biphenyl-4-ylmethyl)-acetamide,10.0,uM,=,1.0,1,O=C(Cn1cc(Cc2cn[nH]c2)c(=O)nc1SCc1ccccc1)N(CCN1CCCCC1)Cc1ccc(-c2ccccc2)cc1
119,874112,10.1021/jm300118s,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis,COCC(=O)N[C@@H](Cc1cccc(-c2ncco2)c1)[C@H](O)CN[C@H]1CC2(CCC2)Oc2ncc(CC(C)(C)C)cc21,"N-((2S,3R)-3-Hydroxy-4-((S)-6'-neopentyl-3',4'-dihydrospiro-[cyclobutane-1,2'-pyrano[2,3-b]pyridine]-4'-ylamino)-1-(3-(oxazol-2-yl)phenyl)butan-2-yl)-2-methoxyacetamide",0.1,uM,=,-1.0,0,c1cc(CCCCN[C@H]2CC3(CCC3)Oc3ncccc32)cc(-c2ncco2)c1
120,802673,10.1016/j.bmcl.2011.12.125,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,O=C(Nc1ccc(-c2ccnc3[nH]cnc23)cc1)Nc1cccc(C(=O)N2CCCCC2)c1,"1-(4-(3H-imidazo[4,5-b]pyridin-7-yl)phenyl)-3-(3-(piperidine-1-carbonyl)phenyl)urea",0.079,uM,=,-1.1023729087095586,0,O=C(Nc1ccc(-c2ccnc3[nH]cnc23)cc1)Nc1cccc(C(=O)N2CCCCC2)c1
121,487712,10.1016/j.bmcl.2008.05.104,,,,Inhibition of CYP3A4,Cc1cc(N2CCC(N3CCCC3)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,(S)-4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-3-(4-methyl-6-(4-(pyrrolidin-1-yl)piperidin-1-yl)-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one,0.0045,uM,=,-2.3467874862246565,0,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(N3CCC(N4CCCC4)CC3)cc2[nH]1
122,1491687,10.1124/dmd.112.045708,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate addition by LC-MS/MS analysis in presence of NADPH,CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1,"(R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide",22.0,uM,=,1.3424226808222062,1,O=C(Cc1ccccc1)N(Cc1cccnc1)Cc1nc2ncccc2c(=O)n1-c1ccccc1
123,1778315,10.1016/j.bmcl.2018.06.040,,,,Inhibition of CYP3A4 (unknown origin),CC(C)NS(=O)(=O)c1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1,"N-(4-(1H-pyrrolo[2,3-b]pyridin-3-yl)thiazol-2-yl)-2-(3-(N-isopropylsulfamoyl)phenyl)acetamide",2.6,uM,=,0.414973347970818,1,O=C(Cc1ccccc1)Nc1nc(-c2c[nH]c3ncccc23)cs1
124,44705,10.1016/s0960-894x(02)00473-0,,,,Inhibition of cytochrome P450 3A4,CN(C)CCN(Cc1ccc(-c2ccc(Cl)cc2)cc1)C(=O)Cn1cc(Cc2cnn(C)c2)c(=O)nc1SCc1ccc(F)cc1,N-(4'-Chloro-biphenyl-4-ylmethyl)-N-(2-dimethylamino-ethyl)-2-[2-(4-fluoro-benzylsulfanyl)-5-(1-methyl-1H-pyrazol-4-ylmethyl)-4-oxo-4H-pyrimidin-1-yl]-acetamide,8.0,uM,=,0.9030899869919436,1,O=C(Cn1cc(Cc2cn[nH]c2)c(=O)nc1SCc1ccccc1)NCc1ccc(-c2ccccc2)cc1
125,355280,10.1016/j.bmcl.2006.02.020,,,,Inhibition of CYP3A4,C[C@H]([C@@H](c1ccc2cc(OCC3(C(=O)O)CCCCC3)ccc2c1)n1ccnc1)N(C)C,"1-((6-((1R,2R)-2-(dimethylamino)-1-(1H-imidazol-1-yl)propyl)naphthalen-2-yloxy)methyl)cyclohexanecarboxylic acid",8.0,uM,=,0.9030899869919436,1,c1cn(Cc2ccc3cc(OCC4CCCCC4)ccc3c2)cn1
126,1736154,10.1021/acs.jmedchem.8b00300,,,,Inhibition of CYP3A4 in in human liver microsomes in presence of NADPH regeneration mixture using luciferin IPA-OH substrate by P450-Glo assay,CCCS(=O)(=O)NCCOc1ccc2c(c1)C(C1(c3ccc(Cl)cc3)CCC1)NCC2,"US8653100, 4",0.62,uM,=,-0.2076083105017461,0,c1ccc(C2(C3NCCc4ccccc43)CCC2)cc1
127,1283600,10.1021/jm401610c,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone,O=C([C@H](c1ccc(Cl)cc1)c1cccnc1)N1CCN(c2ccc(C(F)(F)F)cc2)CC1,(R)-2-(4-Chlorophenyl)-1-{4-[4-(trifluoromethyl)phenyl]piperazin-1-yl}-2-(pyridin-3-yl)ethanone,17.0,uM,=,1.230448921378274,1,O=C([C@H](c1ccccc1)c1cccnc1)N1CCN(c2ccccc2)CC1
128,1301328,10.6019/CHEMBL3137440,,,,DNDI: CYP Inhibition,FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(Cc3cccc(C(F)(F)F)c3)CC2)cc1,,18.0,uM,=,1.255272505103306,1,c1ccc(CN2CCC(N(c3ccccc3)c3cccnc3)CC2)cc1
129,469873,10.1016/j.bmcl.2008.01.012,,,,Inhibition of human CYP3A4,CC(C)c1c(-c2nnc(NCCCN(C)C)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12,"N-cyclopropyl-5-(6-(5-(3-(dimethylamino)propylamino)-1,3,4-oxadiazol-2-yl)-5-isopropylpyrrolo[1,2-f][1,2,4]triazin-4-ylamino)-2,4-difluorobenzamide",29.0,uM,=,1.462397997898956,1,O=C(NC1CC1)c1cccc(Nc2ncnn3cc(-c4nnco4)cc23)c1
130,991614,10.1021/jm4008906,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,CCN(CC)C(=O)[C@@H](C)N1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O,"(R)-2-((S)-3-(Aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-diethylpropanamide",9.6,uM,=,0.9822712330395684,1,O=C1NCc2nccc(-c3ccccc3)c21
131,719028,10.1021/ml100249e,,,,Inhibition of CYP3A4 in human liver microsomes,O=C(Nc1cnc(-c2ccncc2F)c(-c2cnco2)n1)C1CC1,"N-[5-(3-Fluoropyridin-4-yl)-6-(1,3-oxazol-5-yl)pyrazin-2-yl]cyclopropane-carboxamide",5.0,uM,=,0.6989700043360189,1,O=C(Nc1cnc(-c2ccncc2)c(-c2cnco2)n1)C1CC1
132,1923841,10.1021/acs.jmedchem.6b00280,,,,Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase and human b5 reductase assessed as reduction in 7-Hydroxyquinoline production using 7-benzyloxyquinoline as substrate and NADPH incubated for 15 mins by fluorimetry,O=C(NCCN1CCOCC1)Nc1nc2ccc(Sc3nnc4ccc(Oc5ccccc5)nn34)cc2s1,"1-(2-morpholinoethyl)-3-(6-(6-phenoxy-[1,2,4]triazolo[4,3-b]pyridazin-3-ylthio)benzo[d]thiazol-2-yl)urea",7.9,uM,=,0.8976270912904415,1,O=C(NCCN1CCOCC1)Nc1nc2ccc(Sc3nnc4ccc(Oc5ccccc5)nn34)cc2s1
133,742805,10.1016/j.bmc.2011.02.009,,,,Inhibition of human CYP3A4 after 30 mins,CC(C)C(O)(c1cccc(-c2ccc(Cl)cc2)c1)c1c[nH]cn1,"rac-1-(4'-Chloro[1,1'-biphenyl]-3-yl)-1-(1H-imidazol-4-yl)-2-methyl-1-propanol",2.4,uM,=,0.380211241711606,1,c1ccc(-c2cccc(Cc3c[nH]cn3)c2)cc1
134,1739974,10.1016/j.ejmech.2018.05.051,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis,O=C1Nc2ccc(C(=O)N[C@H](CO)c3ccccc3)cc2/C1=C(\c1ccccc1)c1ncc[nH]1,(3Z)-3-((1H-imidazole-2-yl)(phenyl)methylene)-N-((1S)-2-hydroxy-1-phenylethyl)-2-oxoindoline-5-carboxamide,3.03,uM,=,0.481442628502305,1,O=C1Nc2ccc(C(=O)NCc3ccccc3)cc2/C1=C(\c1ccccc1)c1ncc[nH]1
135,1910981,10.1021/acs.jmedchem.8b01464,,,,Inhibition of human CYP3A4 in presence of NADPH by luciferase reporter gene assay,Clc1ccc(-c2cc(C(c3ccc(Cl)cc3)n3ccnc3)c[nH]2)cc1,1-[(4-Chlorophenyl)[5-(4-chlorophenyl)-1H-pyrrol-3-yl]-methyl]-1H-imidazole,1.4,uM,=,0.1461280356782379,1,c1ccc(-c2cc(C(c3ccccc3)n3ccnc3)c[nH]2)cc1
136,469873,10.1016/j.bmcl.2008.01.012,,,,Inhibition of human CYP3A4,CC(C)c1c(-c2nnc(N3CCC(N)CC3)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12,"5-(6-(5-(4-aminopiperidin-1-yl)-1,3,4-oxadiazol-2-yl)-5-isopropylpyrrolo[1,2-f][1,2,4]triazin-4-ylamino)-N-cyclopropyl-2,4-difluorobenzamide",0.3,uM,=,-0.5228787452803376,0,O=C(NC1CC1)c1cccc(Nc2ncnn3cc(-c4nnc(N5CCCCC5)o4)cc23)c1
137,583357,10.1021/jm900945d,,,,Inhibition of CYP3A4,CC(C)(C)Sc1c(CC(C)(C)C(=O)O)n(Cc2ccc(-c3nccs3)cc2)c2ccc(OCc3ccccn3)cc12,"3-(3-(tert-butylthio)-5-(pyridin-2-ylmethoxy)-1-(4-(thiazol-2-yl)benzyl)-1H-indol-2-yl)-2,2-dimethylpropanoic acid",0.0014,uM,=,-2.853871964321762,0,c1ccc(COc2ccc3c(ccn3Cc3ccc(-c4nccs4)cc3)c2)nc1
138,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCC(C(=O)N(C)CCN(C)C)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, E-54",4.97,uM,=,0.6963563887333322,1,O=C(c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12)N1CCCCC1
139,490336,10.1016/j.bmcl.2008.06.073,,,,Inhibition of CYP3A4 in pooled human liver microsome using midazolam substrate,CC(C)c1onc(-c2c(Cl)cccc2Cl)c1COc1ccc(-c2ccc3c(C(=O)O)cccc3c2)cc1,"6-(4-((3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl)methoxy)phenyl)-1-naphthoic acid",7.2,uM,=,0.8573324964312685,1,c1ccc(-c2nocc2COc2ccc(-c3ccc4ccccc4c3)cc2)cc1
140,984301,10.1021/jm401266k,,,,Reversible inhibition of CYP3A4 in human liver microsomes assessed as inhibition of midazolam turnover preincubated for 3 mins followed by midazolam and NADPH addition measured after 5 mins by HPLC-MS/MS analysis,COc1c(CCc2ccc(NS(C)(=O)=O)cc2)cc(-c2ccc[nH]c2=O)cc1C(C)(C)C,N-[4-[2-[3-tert-Butyl-2-methoxy-5-(2-oxo-1H-pyridin-3yl)-phenyl]ethyl]phenyl]methanesulfonamide,0.34,uM,=,-0.4685210829577448,0,O=c1[nH]cccc1-c1cccc(CCc2ccccc2)c1
141,1465541,10.1016/j.bmcl.2015.01.051,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(CC6CN(CCOC)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O,"(1S,4R,5R,6R,8R,10S,11R,12S,13R,16R,18S,21R)-8-[(1S)-1-ethoxy-2-hydroxy-2-methylpropyl]-18-{[(2S)-4-{[1-(2-methoxyethyl)azetidin-3-yl]methyl}morpholin-2-yl]oxy}-4,6,12,17,17-pentamethyl-9-oxahexacyclo[11.9.0.0^{1,21}.0^{4,12}.0^{5,10}.0^{16,21}]docosan-11-ol",22.0,uM,=,1.3424226808222062,1,C1CO[C@@H]2CC3C(CC[C@@]45C[C@@]46CC[C@H](O[C@H]4CN(CC7CNC7)CCO4)C[C@@H]6CC[C@@H]35)[C@H]2C1
142,1277670,10.1016/j.bmcl.2013.10.052,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,CC[C@@H](Cn1cc(C#N)c2ccccc21)NS(=O)(=O)c1c(N)cc(Cl)cc1Cl,"(S)-2-amino-4,6-dichloro-N-(1-(3-cyano-1H-indol-1-yl)butan-2-yl)benzenesulfonamide",5.8,uM,=,0.7634279935629373,1,O=S(=O)(NCCn1ccc2ccccc21)c1ccccc1
143,519907,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,Cc1nc2c(N[C@@H]3CCc4ccccc43)cc(-n3cncn3)cn2c1C,"(R)-N-(2,3-dihydro-1H-inden-1-yl)-2,3-dimethyl-6-(1H-1,2,4-triazol-1-yl)imidazo[1,2-a]pyridin-8-amine",5.1,uM,=,0.7075701760979364,1,c1ccc2c(c1)CC[C@H]2Nc1cc(-n2cncn2)cn2ccnc12
144,1460909,10.1021/jm501326k,,,,Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase/human b5 reductase using 7-benzyloxyquinoline substrate,CCOC(=O)c1[nH]cc2c1NC1=C(C(=O)CCC1)C2c1ccc(Sc2nc3cc(F)ccc3[nH]2)o1,"(+/-)-9-[5-(5-Fluoro-1H-benzimidazol-2-ylsulfanyl)-furan-2-yl]-8-oxo-4,5,6,7,8,9-hexahydro-2Hpyrrolo[3,4-b]quinoline-3-carboxylic acid ethyl ester",12.0,uM,=,1.0791812460476249,1,O=C1CCCC2=C1C(c1ccc(Sc3nc4ccccc4[nH]3)o1)c1c[nH]cc1N2
145,643713,10.1016/j.bmcl.2010.06.009,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader,C[C@@H](Oc1cc(-n2cnc3cc(-c4cnn(CCN5CCOCC5)c4)ccc32)sc1C(N)=O)c1ccccc1Cl,(R)-3-(1-(2-chlorophenyl)ethoxy)-5-(5-(1-(2-morpholinoethyl)-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)thiophene-2-carboxamide,2.1,uM,=,0.3222192947339193,1,c1ccc(COc2csc(-n3cnc4cc(-c5cnn(CCN6CCOCC6)c5)ccc43)c2)cc1
146,1744980,10.1016/j.bmcl.2017.09.046,,,,Inhibition of human CYP3A4 expressed in Escherichia coli co-expressing CYP-reductase using diethoxyfluorescein as substrate measured after 10 mins by fluorescence assay,CCc1cccc(-c2c(Cl)cccc2C(O)(CCCNC(=O)OC)[C@@H]2CCCN(C(=O)[C@@H]3CC[C@H](NC)C3)C2)c1,"methyl 4-(6-chloro-3'-ethylbiphenyl-2-yl)-4-hydroxy-4-((R)-1-((1R,3S)-3-(methylamino)cyclopentanecarbonyl)piperidin-3-yl)butylcarbamate",0.049,uM,=,-1.3098039199714864,0,O=C(C1CCCC1)N1CCC[C@@H](Cc2ccccc2-c2ccccc2)C1
147,834929,10.1016/j.bmcl.2012.07.020,,,,Inhibition of CYP3A4,O=c1ccc(-c2nc3cc(S(=O)(=O)C(F)(F)F)ccc3[nH]2)cn1-c1ccccc1,1-phenyl-5-(5-(trifluoromethylsulfonyl)-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one,5.1,uM,=,0.7075701760979364,1,O=c1ccc(-c2nc3ccccc3[nH]2)cn1-c1ccccc1
148,2061612,10.1016/j.bmcl.2015.11.049,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,Cc1cc(Nc2nc(Nc3ccccc3S(=O)(=O)C(C)C)c3cn[nH]c3n2)c(OC(C)C)cc1C1CCN(C)CC1,"N6-(2-isopropoxy-5-methyl-4-(1-methylpiperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine",3.3,uM,=,0.5185139398778875,1,c1ccc(Nc2nc(Nc3ccc(C4CCNCC4)cc3)nc3[nH]ncc23)cc1
149,519908,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,Cc1cccc(C)c1CNc1cc(-n2ccccc2=O)cn2c(C)c(C)nc12,"1-(8-(2,6-dimethylbenzylamino)-2,3-dimethylimidazo[1,2-a]pyridin-6-yl)pyridin-2(1H)-one",48.0,uM,=,1.6812412373755872,1,O=c1ccccn1-c1cc(NCc2ccccc2)c2nccn2c1
150,1523285,10.1016/j.bmcl.2015.06.066,,,,Inhibition of CYP3A4 (unknown origin),CCCCC(C(=O)COc1c(F)c(F)cc(F)c1F)n1cc([C@@](C)(NCc2ccn3nccc3n2)C2CCCC2)nn1,"3-(4-((S)-1-cyclopentyl-1-(pyrazolo[1,5-a]pyrimidin-5-ylmethylamino)ethyl)-1H-1,2,3-triazol-1-yl)-1-(2,3,5,6-tetrafluorophenoxy)heptan-2-one",0.263,uM,=,-0.5800442515102421,0,O=C(COc1ccccc1)Cn1cc(C(NCc2ccn3nccc3n2)C2CCCC2)nn1
151,2103815,10.1016/j.bmcl.2021.128010,,,,Time dependent inhibition of CYP3A4 (unknown origin) measured at 30 mins,Nc1cc(Cc2ccn(Cc3cccc(C4CCNCC4)c3)n2)c2nn[nH]c2n1,"7-((1-(3-(piperidin-4-yl)benzyl)-1H-pyrazol-3-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-amine",3.3,uM,=,0.5185139398778875,1,c1cc(Cn2ccc(Cc3ccnc4[nH]nnc34)n2)cc(C2CCNCC2)c1
152,596864,10.1021/jm9005912,,,,Inhibition of human CYP3A4 using dibenzylfluorescein as substrate,Cc1cn(Cc2ccc(Cl)cc2Cl)c2c(/C=C/C(=O)NS(=O)(=O)c3cc(Cl)c(Cl)s3)cc(F)cc12,"3-(1-(2,4-dichlorobenzyl)-5-fluoro-3-methyl-1H-indol-7-yl)-N-(4,5-dichlorothiophen-2-ylsulfonyl)acrylamide",7.6,uM,=,0.8808135922807914,1,O=C(/C=C/c1cccc2ccn(Cc3ccccc3)c12)NS(=O)(=O)c1cccs1
153,1528904,,,,,"Homogenous Time-Resolved Fluorescence Assay (HTRF): The standard assay conditions for the in vitro HTRF assay consisted of a 50 ul total reaction volume in black 384-well Costar polypropylene plates in 1PBS buffer pH 7.4, 1 mM DTT, 0.1% BSA, 2.5 nM GST-hMDM2 (aa 1-188), 5 nM biotinylated-p53 (aa 1-83), 1.8 nM SA-XLent (Cisbio; Bedford, Mass.), 0.6 nM anti-GST cryptate monoclonal antibody (Cisbio; Bedford, Mass.) and 200 mM KF. Amino acid residues 1-188 of human MDM2 were expressed as an amino-terminal glutathione S-transferase (GST) fusion protein (GST-hMDM2) in Escherichia coli. Residues 1-83 of human p53 were expressed as an amino-terminal AviTag-TrxA-6His fusion protein (biotinylated p53) in E. coli. Each protein was purified from cell paste by affinity chromatography.Specifically, 10 uL of GST-hMDM2 was incubated with 10 ul of diluted compound (various concentrations, serially diluted) in 10% DMSO for 20 minutes at room temperature. 20 uL of biotinylated-p53 was added to the GST-hMDM2+compound mixture.",CC(C)(C)S(=O)(=O)C[C@H](C1CC1)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)c(F)c1,"2-((3R,5R,6S)-1-((S)-2-(tert-Butylsulfonyl)-1-cyclopropylethyl)-6-(4-chloro-3-fluorophenyl)-5-(3-chlorophenyl)-3-methyl-2-oxopiperidin-3-yl)acetic Acid",0.000102,uM,=,-3.9913998282380825,0,O=C1CC[C@H](c2ccccc2)[C@@H](c2ccccc2)N1CC1CC1
154,1291572,10.1016/j.bmcl.2013.12.058,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1,Desoxy-ritonavir,0.13,uM,=,-0.8860566476931633,0,O=C(CNC(=O)NCc1cscn1)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
155,1291572,10.1016/j.bmcl.2013.12.058,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@H](CC[C@H](Cc2ccccc2)N(C)C(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1,"Thiazol-5-ylmethyl(2R,5R)-5-((S)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-3-methylbutanamido)-1,6-diphenylhexan-2-yl(methyl)carbamate",0.71,uM,=,-0.1487416512809247,0,O=C(CNC(=O)NCc1cscn1)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
156,1459303,10.1016/j.bmc.2014.06.027,,,,Inhibition of CYP3A4 in supersomes (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate after 30 mins,CCc1ccccc1C(C(=O)Nc1ccc2[nH]nc(-c3cccc(S(N)(=O)=O)c3)c2c1)N(C)C,(+/-)-2-(Dimethylamino)-2-(2-ethylphenyl)-N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)acetamide,0.7,uM,=,-0.1549019599857432,0,O=C(Cc1ccccc1)Nc1ccc2[nH]nc(-c3ccccc3)c2c1
157,550965,10.1021/np030556a,,,,Inhibition of human CYP3A4 by radiometric assay,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,"1-(4-{4-[2-(2,4-Dichloro-phenyl)-2-imidazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-ethanone (ketoconazole)",0.245,uM,=,-0.6108339156354675,0,c1ccc(C2(Cn3ccnc3)OCC(COc3ccc(N4CCNCC4)cc3)O2)cc1
158,1613496,10.1021/acs.jmedchem.6b00972,,,,Inhibition of human CYP3A4 expressed in microsomes using 7BQ as substrate after 10 mins by P450 cypex assay,Cc1ncoc1-c1nnc(SCCCN2CC[C@@]3(C[C@H]3c3ccc(F)cc3)C2)n1C,"(1S,3R)-1-(4-Fluorophenyl)-5-(3-{[4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-5-azaspiro-[2.4]heptane",3.4,uM,=,0.5314789170422551,1,c1ccc([C@@H]2C[C@@]23CCN(CCCSc2nnc(-c4cnco4)[nH]2)C3)cc1
159,617698,10.1016/j.bmcl.2010.01.087,,,,Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay,Cc1cc(N2CCC(NC(=O)C3CC3)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,"(S)-N-(1-(2-(4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-2-oxo-1,2-dihydropyridin-3-yl)-7-methyl-3H-benzo[d]imidazol-5-yl)piperidin-4-yl)cyclopropanecarboxamide",0.7,uM,=,-0.1549019599857432,0,O=C(NC1CCN(c2ccc3nc(-c4c(NCCc5ccccc5)cc[nH]c4=O)[nH]c3c2)CC1)C1CC1
160,2064945,10.1016/j.ejmech.2017.12.079,,,,Inhibition of human liver microsome CYP3A4 using dextromethorphan as substrate incubated for 5 mins followed by NADPH addition and further incubated for 10 mins in shaking water bath by LC-MS/MS analysis,C=CC(=O)N1CCC(Cn2cc(-c3ccc4c(c3)OCO4)c3c(N)ncnc32)CC1,"1-(4-((4-Amino-5-(benzo[d][1,3]dioxol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl)piperidin-1-yl)prop-2-en-1-one",3.19,uM,=,0.5037906830571811,1,c1ncc2c(-c3ccc4c(c3)OCO4)cn(CC3CCNCC3)c2n1
161,321462,10.1016/j.bmcl.2005.06.056,,,,Inhibition against Cytochrome P450 3A4 prepared from baculovirus-infected insect cells using resorufin benzyl ether,NC(=O)Cn1c(=O)c(CCO)c(-c2cc(Cl)ccc2O)c2cc(C(F)(F)F)ccc21,2-[4-(5-Chloro-2-hydroxy-phenyl)-3-(2-hydroxy-ethyl)-2-oxo-6-trifluoromethyl-2H-quinolin-1-yl]-acetamide,50.0,uM,=,1.6989700043360187,1,O=c1cc(-c2ccccc2)c2ccccc2[nH]1
162,51911,10.1016/s0960-894x(03)00474-8,,,,Inhibition of human liver microsome Cytochrome P450 3A4,CC(C)(c1ncc(-c2cnccc2Cl)o1)N1CCN(C[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3OC[C@H]2O)[C@H](C(=O)NCC(F)(F)F)C1,"(S)-4-{1-[5-(4-Chloro-pyridin-3-yl)-oxazol-2-yl]-1-methyl-ethyl}-1-[(S)-2-hydroxy-4-((R)-(S)-3-hydroxy-3,4,4a,8a-tetrahydro-2H-chromen-4-ylcarbamoyl)-5-phenyl-pentyl]-piperazine-2-carboxylic acid (2,2,2-trifluoro-ethyl)-amide",0.04,uM,=,-1.3979400086720375,0,O=C(N[C@@H]1CCOc2ccccc21)[C@@H](CCCN1CCN(Cc2ncc(-c3cccnc3)o2)CC1)Cc1ccccc1
163,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2C(CN(Cc3cccc4c(C(=O)Nc5ccc(CCO)cc5)cn(C)c34)C(=O)[C@@H]2Cc2ccc(O)cc2)N1C(=O)NCc1ccccc1,"US8940739, G-10",7.4,uM,=,0.8692317197309762,1,O=C(Nc1ccccc1)c1c[nH]c2c(CN3CC4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12
164,1660136,10.1021/acs.jmedchem.6b01918,,,,Inhibition of human CYP3A4 assessed as inhibition of dealkylation,N[C@H]1CC[C@@](CCOc2cc(F)c(S(=O)(=O)Nc3ncns3)cc2F)(c2ccccc2)CC1,"trans-4-(2-((1S,4S)-4-amino-1-phenylcyclohexyl)ethoxy)-2,5-difluoro-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide",0.68,uM,=,-0.1674910872937636,0,O=S(=O)(Nc1ncns1)c1ccc(OCCC2(c3ccccc3)CCCCC2)cc1
165,1581635,10.1021/acs.jmedchem.5b01146,,,,Inhibition of C-terminal four-histidine tagged human CYP3A4delta3 to 24 residues expressed in Escherichia coli assessed as 7-benzyloxy-4-(trifluoromethyl)coumarin O-debenzylation pretreated 2 mins followed by NADPH addition by fluorometric method in presence of rat cytochrome P450 reductase,CC(C)(C)OC(=O)N[C@H](CSCCC(=O)NCc1cccnc1)Cc1c[nH]c2ccccc12,(S)-tert-butyl 1-(1H-indol-3-yl)-3-(3-oxo-3-(pyridin-3-ylmethylamino)propylthio)propan-2-ylcarbamate,0.21,uM,=,-0.6777807052660807,0,O=C(CCSCCCc1c[nH]c2ccccc12)NCc1cccnc1
166,632105,10.1016/j.bmcl.2010.03.057,,,,Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin,Cc1cc(N2CCN(CC#N)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,"(S)-2-(4-(2-(4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-2-oxo-1,2-dihydropyridin-3-yl)-4-methyl-1H-benzo[d]imidazol-6-yl)piperazin-1-yl)acetonitrile",1.4,uM,=,0.1461280356782379,1,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(N3CCNCC3)cc2[nH]1
167,600767,10.1016/j.bmcl.2009.07.127,,,,Inhibition of human CYP3A4,COC(=O)c1cccc(NC(=O)COc2ccc(C34CC5CC(CC(C(=O)N6CCN(Cc7ccc(C(F)(F)F)cc7)CC6)(C5)C3)C4)cc2)c1,"3-[2-(4-{3-[4-(4-Methoxy-benzyl)-3,6-dihydro-2H-piperazine-1-carbonyl]-adamantan-1-yl}-phenoxy)-acetylamino]-benzoic acid methyl ester",2.03,uM,=,0.3074960379132129,1,O=C(COc1ccc(C23CC4CC(CC(C(=O)N5CCN(Cc6ccccc6)CC5)(C4)C2)C3)cc1)Nc1ccccc1
168,546182,10.1016/j.bmcl.2009.03.165,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,CCNc1cc(C(=O)N[C@@H](Cc2ccccc2)[C@H](O)CNCc2cccc(C(F)(F)F)c2)c(F)c(N2CCCC2=O)c1,"5-(ethylamino)-2-fluoro-N-((2S,3R)-3-hydroxy-1-phenyl-4-(3-(trifluoromethyl)benzylamino)butan-2-yl)-3-(2-oxopyrrolidin-1-yl)benzamide",6.3,uM,=,0.7993405494535817,1,O=C(N[C@H](CCNCc1ccccc1)Cc1ccccc1)c1cccc(N2CCCC2=O)c1
169,828928,10.1016/j.bmcl.2012.06.022,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,CN(C)CCN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N3CCCC3)oc2c1,"thiazol-5-ylmethyl(2S,3R)-4-(N-(2-(dimethylamino)ethyl)-2-(pyrrolidin-1-yl)benzo[d]oxazole-6-carboxamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate",0.23,uM,=,-0.6382721639824072,0,O=C(N[C@H](CCNC(=O)c1ccc2nc(N3CCCC3)oc2c1)Cc1ccccc1)OCc1cncs1
170,51930,10.1016/s0960-894x(01)00614-x,,,,Inhibition of recombinant human Cytochrome P450 3A4,Nn1nnc2ccccc21,"1H-1,2,3-benzotriazol-1-amine",0.45,uM,=,-0.3467874862246563,0,c1ccc2[nH]nnc2c1
171,535882,10.1016/j.bmcl.2008.08.010,,,,"Inhibition of human CYP3A4 by microtiter plate assays using N-N,diethyl-formamide as substrate",O=S(=O)(c1cccc(Cl)c1)n1cc(Cl)c2cc3c(cc21)CCNCC3,"3-chloro-1-(3-chlorophenylsulfonyl)-1,5,6,7,8,9-hexahydroazepino[4,5-f]indole",12.0,uM,=,1.0791812460476249,1,O=S(=O)(c1ccccc1)n1ccc2cc3c(cc21)CCNCC3
172,1528565,,,,,"Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",CC(C)c1nc(CN(C)C(=O)N2CS(=O)(=O)C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,"US8987313, 18",0.16,uM,=,-0.7958800173440752,0,O=C(N[C@H](CC[C@H](Cc1ccccc1)NC(=O)[C@@H]1CS(=O)(=O)CN1C(=O)NCc1cscn1)Cc1ccccc1)OCc1cncs1
173,1446329,10.1021/ml500387y,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2cc(N)ncc2[nH]1)C(F)(F)F,"2-((5-amino-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)-1,1,1-trifluoro-4-(5-fluoro-2-methylphenyl)-4-methylpentan-2-ol",0.5,uM,=,-0.3010299956639812,0,c1ccc(CCCCc2cc3ccncc3[nH]2)cc1
174,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",C[C@@H]1CN(C(=O)c2ccc(Cl)cc2-n2nccn2)[C@H](Cc2cccc(-n3nccn3)c2)CO1,"US9150566, 185",20.0,uM,=,1.3010299956639813,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
175,1924472,10.1021/acsmedchemlett.6b00038,,,,Inhibition of CYP3A4 (unknown origin),COc1ccc2nc(NC(=O)Cc3ccc(-c4ccncc4)cc3)sc2c1,N-(6-methoxybenzo[d]thiazol-2-yl)-2-(4-(pyridin-4-yl)phenyl)acetamide,0.8,uM,=,-0.0969100130080563,0,O=C(Cc1ccc(-c2ccncc2)cc1)Nc1nc2ccccc2s1
176,1685713,10.1016/j.bmc.2017.04.033,,,,Inhibition of recombinant CYP3A4 (unknown origin),COc1ccc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)cn1,"(S)-6-(2-hydroxy-2-methylpropyl)-3-((S)-1-(4-(6-methoxypyridin-3-yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one",11.6,uM,=,1.0644579892269186,1,O=C1OC(c2ccccc2)CCN1Cc1ccc(-c2cccnc2)cc1
177,550965,10.1021/np030556a,,,,Inhibition of human CYP3A4 by radiometric assay,C/C1=C\CC(C)(C)/C=C/C(=O)/C(C)=C/CC1,zerumbone,21.8,uM,=,1.3384564936046048,1,O=C1/C=C/CCC=CCC/C=C/1
178,2286942,10.1021/acs.jmedchem.1c01215,,,,Inhibition of CYP3A4 (unknown origin),COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(B3C=CC=CN3)cc2)CC1,"4-(1,2-azaborinin-2(1H)-yl)-N-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butyl)benzamide",11.0,uM,=,1.0413926851582251,1,O=C(NCCCCN1CCN(c2ccccc2)CC1)c1ccc(B2C=CC=CN2)cc1
179,455108,10.1016/j.bmcl.2006.12.043,,,,Inhibition of CYP3A4,NC(C(=O)N1CCN(c2ccc3[nH]ncc3c2)CC1)c1ccc(Br)cc1,1-(4-(1H-indazol-5-yl)piperazin-1-yl)-2-amino-2-(4-bromophenyl)ethanone,0.41,uM,=,-0.3872161432802645,0,O=C(Cc1ccccc1)N1CCN(c2ccc3[nH]ncc3c2)CC1
180,2205638,10.1016/j.bmc.2022.116917,,,,Inhibition of CYP3A4 in human liver microsomes preincubated for 10 mins followed by NADPH addition and measured after 5 mins by LC-MS/MS analysis,COc1ccc(S(=O)(=O)n2cc(C(F)F)c3ccc(Cl)cc32)cc1N1CCNCC1,6-chloro-3-(difluoromethyl)-1-((4-methoxy-3-(piperazin-1-yl)phenyl)sulfonyl)-1H-indole,4.02,uM,=,0.60422605308447,1,O=S(=O)(c1cccc(N2CCNCC2)c1)n1ccc2ccccc21
181,619265,10.1016/j.bmcl.2009.07.002,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate,Cc1cccc(C)c1CNc1nc(-c2ccccc2)cc2c(C)c(C)[nH]c12,"N-(2,6-dimethylbenzyl)-2,3-dimethyl-5-phenyl-1H-pyrrolo[2,3-c]pyridin-7-amine",6.6,uM,=,0.8195439355418687,1,c1ccc(CNc2nc(-c3ccccc3)cc3cc[nH]c23)cc1
182,1979602,10.1021/acs.jmedchem.0c00369,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,C[C@@H]1COCCN1c1cc(-c2ccnn2C)c2ccnc(-c3ccn[nH]3)c2n1,"2-[(3R)-3-Methylmorpholin-4-yl]-4-(1-methyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridine",7.0,uM,=,0.8450980400142568,1,c1cc(-c2cc(N3CCOCC3)nc3c(-c4ccn[nH]4)nccc23)[nH]n1
183,1574682,10.1021/acs.jmedchem.5b01995,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone and midazolam as substrate preincubated for 30 mins followed substrate addition by LC-MS/MS analysis,COc1nc(N2C[C@H]3C(=O)N(C)C(N)=N[C@@]3(c3c(F)cc(F)c(F)c3F)C2)nc(C)c1F,"US8541427, 29",30.0,uM,=,1.4771212547196624,1,O=C1NC=N[C@@]2(c3ccccc3)CN(c3ncccn3)C[C@@H]12
184,52069,10.1021/jm021012t,,,,Inhibition of human cytochrome P450 3A4,CN/C(=N\CCSCc1nc[nH]c1C)NC#N,N''-cyano-N-methyl-N'-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]thio}ethyl)guanidine,15.0,uM,=,1.1760912590556811,1,c1c[nH]cn1
185,716717,10.1016/j.bmcl.2010.12.109,,,,Inhibition of CYP3A4,CCCCN1C(=O)[C@H](CC2CCCCC2)NC(=O)C12CCN(Cc1ccc(Oc3ccc(C(=O)O)cc3)cc1)CC2.Cl,"4-(4-{[(3S)-1-Butyl-3-(cyclohexylmethyl)-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl]methyl}phenoxy)benzoic acid hydrochloride",24.9,uM,=,1.3961993470957363,1,O=C1NC2(CCN(Cc3ccc(Oc4ccccc4)cc3)CC2)C(=O)N[C@H]1CC1CCCCC1
186,1640556,,,,,"null: Microsomal preparation: One lobe of fresh pig liver is obtained (e.g., at about the time of slaughter from a food-processing company) and immediately placed in ice cold 15 mM KH2PO4/250 mM sucrose (pH 7.4) and kept on ice during transportation. A 10 g sample of liver is minced and homogenized in 30 mL of homogenization buffer (15 mM KH2PO4/250 mM sucrose) using a Tekmar homoginizer or equivalent by pulsing 3 times with 20 second pulses. This procedure is repeated for a total of 8x10 g samples of pig liver. The remaining pig liver may be stored at -80 C. The homogenates from the 8 samples are pooled and centrifuged at 13,000xg for 20 minutes at 4 C. to remove crude debris. The supernatant is further centrifuged at 100,000xg for 70 minutes at 4° C. The microsomal pellets are re-suspended into 50 mL of 150 mM KH2PO4/1 mM DTT (pH 7.4) and 1 mL aliquots are stored at -80 C.100-150 ug of pig liver microsomal protein in 150 mM KH2PO4 is incubated at 37° C.",CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,"1-(4-{4-[2-(2,4-Dichloro-phenyl)-2-imidazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-ethanone (ketoconazole)",8.8,uM,=,0.9444826721501688,1,c1ccc(C2(Cn3ccnc3)OCC(COc3ccc(N4CCNCC4)cc3)O2)cc1
187,1703499,10.1021/acs.jmedchem.7b00408,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 15 mins by LC-MS/MS analysis,C[C@@H]1c2nnn(-c3cnccn3)c2CCN1C(=O)c1cccc(C(F)(F)F)c1Cl,"US9464084, 74",2.3,uM,=,0.3617278360175928,1,O=C(c1ccccc1)N1CCc2c(nnn2-c2cnccn2)C1
188,1668433,10.1016/j.bmcl.2017.04.014,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate pretreated for 10 mins followed by substrate addition measured after 10 mins in presence of NADPH by LC-MS/MS method,C=CC(=O)Nc1cccc(C)c1Nc1ncc(OCc2c(F)c(OC)cc(OC)c2F)cn1,"N-(2-((5-((2,6-difluoro-3,5-dimethoxybenzyl)oxy)pyrimidin-2-yl)amino)-3-methylphenyl)acrylamide",6.9,uM,=,0.8388490907372553,1,c1ccc(COc2cnc(Nc3ccccc3)nc2)cc1
189,1446329,10.1021/ml500387y,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,CC(C)(CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F)c1ccc(F)cc1,"1,1,1-trifluoro-4-(4-fluorophenyl)-4-methyl-2-((5-morpholino-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)pentan-2-ol",0.1,uM,=,-1.0,0,c1ccc(CCCCc2cc3cc(N4CCOCC4)ncc3[nH]2)cc1
190,2103815,10.1016/j.bmcl.2021.128010,,,,Time dependent inhibition of CYP3A4 (unknown origin) measured at 30 mins,Nc1cc(Cc2ccn(-c3ccccc3)n2)c2nn[nH]c2n1,"7-((1-phenyl-1H-pyrazol-3-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-amine",0.21,uM,=,-0.6777807052660807,0,c1ccc(-n2ccc(Cc3ccnc4[nH]nnc34)n2)cc1
191,1488507,10.1124/dmd.112.045708,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis in presence of NADPH,COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1,"Acetic acid (2S,3S)-5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester",8.1,uM,=,0.9084850188786496,1,O=C1C[C@H](c2ccccc2)Sc2ccccc2N1
192,1778315,10.1016/j.bmcl.2018.06.040,,,,Inhibition of CYP3A4 (unknown origin),COc1cccc(CC(=O)Nc2nc(-c3ccnc(N)c3)cs2)c1,N-(4-(2-Aminopyridin-4-yl)thiazol-2-yl)-2-(3-methoxyphenyl)-acetamide,26.0,uM,=,1.414973347970818,1,O=C(Cc1ccccc1)Nc1nc(-c2ccncc2)cs1
193,959421,10.1021/jm4000038,,,,Inhibition of CYP3A4 (unknown origin),CC1(C)OC(=O)N([C@H]2CC[C@H](n3c(=O)[nH]c4cc(C#N)c(F)cc43)CC2)[C@H]1c1ccccc1,"trans-1-(4-((S)-5,5-Dimethyl-2-oxo-4-phenyloxazolidin-3-yl)cyclohexyl)-6-fluoro-2-oxo-2,3-dihydro-1Hbenzo[d]imidazole-5-carbonitrile",7.6,uM,=,0.8808135922807914,1,O=C1OC[C@H](c2ccccc2)N1[C@H]1CC[C@H](n2c(=O)[nH]c3ccccc32)CC1
194,857201,10.1021/jm200900q,,,,Inhibition of CYP3A4,N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(C(=O)Cc4ccccn4)CC3)cc2C2=CCCCC2)n1,4-Cyano-1H-imidazole-2-carboxylic Acid{2-Cyclohex-1-enyl-4-[1-(2-pyridin-2-yl-acetyl)-piperidin-4-yl]-phenyl}-amide,1.5,uM,=,0.1760912590556812,1,O=C(Nc1ccc(C2CCN(C(=O)Cc3ccccn3)CC2)cc1C1=CCCCC1)c1ncc[nH]1
195,536049,10.1016/j.bmcl.2008.08.010,,,,Inhibition of human CYP3A4 by microtiter plate assays using PPR substrate,O=S(=O)(c1ccsc1)n1ccc2cc3c(cc21)CCNCC3,"1-(thiophen-3-ylsulfonyl)-1,5,6,7,8,9-hexahydroazepino[4,5-f]indole",22.0,uM,=,1.3424226808222062,1,O=S(=O)(c1ccsc1)n1ccc2cc3c(cc21)CCNCC3
196,1629312,10.1016/j.bmcl.2016.11.020,,,,Inhibition of CYP3A4 (unknown origin),Cc1cc(Nc2cc(C)c(C#N)c(NCCOc3ccccc3Cl)n2)n[nH]1,2-(2-(2-chlorophenoxy)ethylamino)-4-methyl-6-(5-methyl-1H-pyrazol-3-ylamino)nicotinonitrile,1.2,uM,=,0.0791812460476248,1,c1ccc(OCCNc2cccc(Nc3cc[nH]n3)n2)cc1
197,755387,10.1021/jm101177s,,,,Inhibition of CYP3A4,O=C(NO)c1cnc(N2C[C@@H]3[C@H](C2)[C@H]3NCc2ccc3cc(F)ccc3n2)nc1,exo-2-(6-{[(6-Fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide,10.0,uM,=,1.0,1,c1cnc(N2C[C@@H]3[C@H](C2)[C@H]3NCc2ccc3ccccc3n2)nc1
198,632105,10.1016/j.bmcl.2010.03.057,,,,Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin,Cc1cc(N2CCN(C(=O)CCCF)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,(S)-4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-3-(6-(4-(4-fluorobutanoyl)piperazin-1-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one,0.8,uM,=,-0.0969100130080563,0,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(N3CCNCC3)cc2[nH]1
199,1791587,10.1016/j.ejmech.2018.08.006,,,,Inhibition of CYP3A4 (unknown origin) using luciferin-IPA as substrate preincubated for 10 mins followed by NADPH regeneration system addition and measured after 10 to 30 mins by Promega P450-GloScreening assay,OCC1CCCC(c2ccc(O)cc2)CC1,Rac-4-(4-Hydroxyphenyl)cycloheptanemethanol,33.0,uM,=,1.5185139398778875,1,c1ccc(C2CCCCCC2)cc1
200,948527,10.1016/j.bmcl.2012.12.040,,,,Inhibition of CYP3A4 (unknown origin),O=C(O)c1cccc(OCC2CCN(c3ccc(NC(=O)c4cccc(Oc5ccccc5)c4)cn3)CC2)c1,3-((1-(5-(3-phenoxybenzamido)pyridin-2-yl)piperidin-4-yl)methoxy)benzoic acid,5.0,uM,=,0.6989700043360189,1,O=C(Nc1ccc(N2CCC(COc3ccccc3)CC2)nc1)c1cccc(Oc2ccccc2)c1
201,945618,10.1016/j.bmc.2012.11.058,,,,Inhibition of CYP3A4 (unknown origin),O=S(=O)(Nc1cc(Cl)c(Oc2cnc3ccccc3c2)c(Cl)c1)c1ccc(Cl)cc1Cl,"2,4-Dichloro-N-(3,5-dichloro-4-(quinolin-3-yloxy)phenyl)benzenesulfonamide",25.0,uM,=,1.3979400086720375,1,O=S(=O)(Nc1ccc(Oc2cnc3ccccc3c2)cc1)c1ccccc1
202,1933089,10.1021/acs.jmedchem.6b00028,,,,Inhibition of human CYP3A4 expressed in Escherichia coli pre-incubated for 5 mins before regenerating cofactor solution addition using Diethoxyfluorescein/7-Benzyloxyquinoline as substrate by fluorescence assay,Cc1cc(-c2nc(-c3cccnc3)cc(N3CCC(N4CCOCC4)CC3)n2)cc(C)n1,"4-(1-(2-(2,6-Dimethylpyridin-4-yl)-6-(pyridin-3-yl)pyrimidin-4-yl)piperidin-4-yl)morpholine",40.0,uM,=,1.6020599913279625,1,c1cncc(-c2cc(N3CCC(N4CCOCC4)CC3)nc(-c3ccncc3)n2)c1
203,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",C[C@@H]1CN(C(=O)c2cccc(Cl)c2-n2nccn2)[C@H](Cc2cc(-c3ncccn3)ccc2F)CO1,"US9150566, 154",24.0,uM,=,1.380211241711606,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2ncccn2)c1
204,1625607,10.1016/j.bmcl.2016.10.016,,,,Inhibition of human Cyp3A4 using testosterone as substrate by LC-MS/MS analysis,CS(=O)(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,"1-(4-{[(2S,4R)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)-4-methanesulfonylpiperazine",0.158,uM,=,-0.8013429130455774,0,c1ccc([C@]2(Cn3ccnc3)OC[C@@H](COc3ccc(N4CCNCC4)cc3)O2)cc1
205,438600,10.1016/j.bmcl.2007.03.048,,,,Inhibition of CYP3A4 in microsomes,Cc1cc(C(=O)NC2CC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,"2-(4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-2-oxo-1,2-dihydropyridin-3-yl)-N-cyclopropyl-7-methyl-3H-benzo[d]imidazole-5-carboxamide",10.0,uM,=,1.0,1,O=C(NC1CC1)c1ccc2nc(-c3c(NCCc4ccccc4)cc[nH]c3=O)[nH]c2c1
206,990449,10.1016/j.bmcl.2013.09.001,,,,Inhibition of CYP3A4 in human liver microsomes in presence of NADPH,O=C(Nc1cccc(Cl)n1)c1cc(Cl)cc(Oc2cncnc2)c1,3-chloro-N-(6-chloropyridin-2-yl)-5-(pyrimidin-5-yloxy)benzamide,1.9,uM,=,0.2787536009528289,1,O=C(Nc1ccccn1)c1cccc(Oc2cncnc2)c1
207,1741066,10.1021/acs.jmedchem.8b00450,,,,Inhibition of human CYP3A4,CN(C[C@H]1Cc2c(cccc2N2CCN(c3ncccn3)CC2)CN1)[C@H]1CCCc2cccnc21,"(S)-N-methyl-N-(((R)-5-(4-(pyrimidin-2-yl)piperazin-1-yl)-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)-5,6,7,8-tetrahydroquinolin-8-amine",3.35,uM,=,0.5250448070368452,1,c1cnc(N2CCN(c3cccc4c3C[C@H](CN[C@H]3CCCc5cccnc53)NC4)CC2)nc1
208,305432,10.1016/j.bmcl.2005.01.044,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,COC(=O)c1ccc(COc2ccc3cc(C(C(C)N(C)C)n4ccnc4)ccc3c2)cc1,4-[6-(2-Dimethylamino-1-imidazol-1-yl-propyl)-naphthalen-2-yloxymethyl]-benzoic acid methyl ester,0.04,uM,=,-1.3979400086720375,0,c1ccc(COc2ccc3cc(Cn4ccnc4)ccc3c2)cc1
209,2133633,10.1021/acs.jmedchem.1c00679,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins in presence of NADPH by LCMS/MS analysis,O=C(NC[C@H]1[C@H]2C[C@H](Oc3ccnc4ccc(F)cc34)C[C@@H]12)c1ccc(Cl)cc1,"4-chloro-N-(((1R,3r,5S,6r)-3-(6-fluoroquinolin-4-yloxy)bicyclo[3.1.0]hexan-6-yl)methyl)benzamide",2.1,uM,=,0.3222192947339193,1,O=C(NC[C@H]1[C@H]2C[C@H](Oc3ccnc4ccccc34)C[C@@H]12)c1ccccc1
210,1488504,10.1124/dmd.112.045708,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 90 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis,COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1,"Acetic acid (2S,3S)-5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester",110.0,uM,=,2.041392685158225,1,O=C1C[C@H](c2ccccc2)Sc2ccccc2N1
211,2133633,10.1021/acs.jmedchem.1c00679,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins in presence of NADPH by LCMS/MS analysis,CCC(NC(=O)c1ccc(Cl)cc1)[C@@H]1[C@@H]2C[C@@H](Oc3ccnc4ccc(F)cc34)C[C@@H]21,"4-chloro-N-(1-((1R,3r,5S,6r)-3-(6-fluoroquinolin-4-yloxy)bicyclo[3.1.0]hexan-6-yl)propyl)benzamide",1.4,uM,=,0.1461280356782379,1,O=C(NC[C@H]1[C@H]2C[C@H](Oc3ccnc4ccccc34)C[C@@H]12)c1ccccc1
212,1778315,10.1016/j.bmcl.2018.06.040,,,,Inhibition of CYP3A4 (unknown origin),CS(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1,"N-(4-(1H-pyrrolo[2,3-b]pyridin-3-yl)thiazol-2-yl)-2-(3-(methylsulfonamido)phenyl)acetamide",8.3,uM,=,0.919078092376074,1,O=C(Cc1ccccc1)Nc1nc(-c2c[nH]c3ncccc23)cs1
213,881490,10.1016/j.bmc.2012.05.076,,,,Inhibition of CYP3A4 in human liver microsomes,COC(=O)C(C)(C)C(c1ccc(Nc2ccccc2)cc1)n1cncn1,"methyl-2,2-dimethyl-3-(4-(phenylamino)phenyl)-3-(1H-1,2,4-triazol-1-yl)propanoate",0.2,uM,=,-0.6989700043360187,0,c1ccc(Nc2ccc(Cn3cncn3)cc2)cc1
214,519908,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,Cc1cccc(C)c1CNc1cc(-n2cc(C(N)=O)ccc2=O)cn2c(C)c(C)nc12,"1-(8-(2,6-dimethylbenzylamino)-2,3-dimethylimidazo[1,2-a]pyridin-6-yl)-6-oxo-1,6-dihydropyridine-3-carboxamide",14.0,uM,=,1.146128035678238,1,O=c1ccccn1-c1cc(NCc2ccccc2)c2nccn2c1
215,1655303,10.1021/acsmedchemlett.6b00491,,,,Inhibition of CYP3A4 using in human liver microsomes using midazolam as substrate after 5 to 15 mins,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,"1-(4-{4-[2-(2,4-Dichloro-phenyl)-2-imidazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-ethanone (ketoconazole)",0.018,uM,=,-1.744727494896694,0,c1ccc(C2(Cn3ccnc3)OCC(COc3ccc(N4CCNCC4)cc3)O2)cc1
216,1446063,10.1016/j.bmcl.2014.11.046,,,,Inhibition of human recombinant CYP3A4 expressed in insect cell microsomes preincubated for 10 mins by fluorescence assay,COc1cc2c(cc1OC)C(=O)C(CC1CCN(Cc3ccccc3)CC1)C2,"2-(1-Benzyl-piperidin-4-ylmethyl)-5,6-dimethoxy-indan-1-one",54.68,uM,=,1.7378285058957847,1,O=C1c2ccccc2CC1CC1CCN(Cc2ccccc2)CC1
217,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCC(OC)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, E-52",3.3,uM,=,0.5185139398778875,1,O=C(c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12)N1CCCCC1
218,1294868,10.1021/jm401840s,,,,Inhibition of CYP3A4 (unknown origin),C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,"tert-butyl(S)-1-((2S,4R)-2-((1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-vinylcyclopropylcarbamoyl)-4-(6-methoxyisoquinolin-1-yloxy)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-ylcarbamate",2.0,uM,=,0.3010299956639812,1,O=C(NC1(C(=O)NS(=O)(=O)C2CC2)CC1)[C@@H]1C[C@@H](Oc2nccc3ccccc23)CN1
219,741043,10.1016/j.bmcl.2011.02.067,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH,CCNC(=O)NCCCOc1cc(CCCOC)cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1,"(3R,4S)-N-cyclopropyl-4-(4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)phenyl)-N-(3-(3-(3-ethylureido)propoxy)-5-(3-methoxypropyl)benzyl)piperidine-3-carboxamide",2.4,uM,=,0.380211241711606,1,O=C([C@H]1CNCC[C@@H]1c1ccc(OCCOc2ccccc2)cc1)N(Cc1ccccc1)C1CC1
220,2116571,10.1021/acsmedchemlett.1c00198,,,,Inhibition of CYP3A4 (unknown origin) expressed in baculovirus infected insect supersomes preincubated for 15 mins followed by addition of NADPH regenerating system by fluorescence based analysis,O=C(O)c1cc(F)c2nc(N3CCC4(C=C(c5c(-c6c(Cl)cncc6Cl)noc5C5CC5)C4)CC3)sc2c1,"2-(2-(5-cyclopropyl-3-(3,5-dichloropyridin-4-yl)isoxazol-4-yl)-7-azaspiro[3.5]non-1-en-7-yl)-4-fluorobenzo[d]thiazole-6-carboxylic acid",1.8,uM,=,0.255272505103306,1,C1=C(c2c(-c3ccncc3)noc2C2CC2)CC12CCN(c1nc3ccccc3s1)CC2
221,1661010,10.1016/j.bmcl.2017.02.047,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 10 mins followed by NADPH addition measured after 10 mins,CCCCCCC[C@H](O)CC(=O)CCc1ccc(O)c(OC)c1,8-Gingerol,8.1,uM,=,0.9084850188786496,1,c1ccccc1
222,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCC(NC(=O)CCO)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, E-57",7.65,uM,=,0.8836614351536176,1,O=C(c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12)N1CCCCC1
223,1528565,,,,,"Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",CC(C)c1nc(CN(C)C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H](CC[C@@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,"US8987313, 11",0.3,uM,=,-0.5228787452803376,0,O=C(N[C@@H](CC[C@@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)NCc1cscn1)Cc1ccccc1)OCc1cncs1
224,774749,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C,"(3S,4aS,8aS)-2-[(2R,3R)-2-Hydroxy-3-(3-hydroxy-2-methyl-benzoylamino)-4-phenylsulfanyl-butyl]-decahydro-isoquinoline-3-carboxylic acid tert-butylamide",2.0,uM,=,0.3010299956639812,1,O=C(N[C@H](CCN1CC[C@@H]2CCCC[C@@H]2C1)CSc1ccccc1)c1ccccc1
225,1568322,10.1021/acs.jmedchem.5b01716,,,,Inhibition of CYP3A4 (unknown origin) in presence of NADPH,COCCOc1cnc2ccc([C@H](C)n3nnc4ccn(-c5cc(C)ns5)c(=O)c43)cc2c1,"(S)-3-(1-(3-(2-methoxyethoxy)quinolin-6-yl)ethyl)-5-(3-methylisothiazol-5-yl)-3H-[1,2,3]triazolo[4,5-c]pyridin-4(5H)-one",21.0,uM,=,1.3222192947339193,1,O=c1c2c(ccn1-c1ccns1)nnn2Cc1ccc2ncccc2c1
226,2068645,10.1021/acs.jmedchem.0c01279,,,,Inhibition of CYP3A4 (unknown origin),C[C@H]1C[C@@H](c2ccncc2NC(=O)c2nc(-c3c(F)cccc3F)ncc2N)C[C@@H](O)[C@]1(C)O,"5-Amino-2-(2,6-difluorophenyl)-N-(4-((1R,3R,4R,5S)-3,4-dihydroxy-4,5-dimethylcyclohexyl)pyridin-3-yl)pyrimidine-4-carboxamide",26.0,uM,=,1.414973347970818,1,O=C(Nc1cnccc1C1CCCCC1)c1ccnc(-c2ccccc2)n1
227,1459303,10.1016/j.bmc.2014.06.027,,,,Inhibition of CYP3A4 in supersomes (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate after 30 mins,CCc1cccc(CC)c1NC(=O)Nc1ccc2[nH]nc(-c3cccc(S(N)(=O)=O)c3)c2c1,"3-(5-(3-(2,6-Diethylphenyl)ureido)-1H-indazol-3-yl)benzenesulfonamide",1.0,uM,=,0.0,0,O=C(Nc1ccccc1)Nc1ccc2[nH]nc(-c3ccccc3)c2c1
228,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",COc1cc(C(=O)N2CCOC[C@H]2Cc2cc(-n3nccn3)ccc2F)c(-n2nccn2)cc1Cl,"US9150566, 139",13.0,uM,=,1.1139433523068367,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
229,1331790,10.1039/C2MD20340E,,,,Inhibition of CYP3A4 (unknown origin),Cc1ccccc1-c1nc2ccc(-c3ccc(Cl)cc3)cc2c(=O)n1C[C@H]1CCCN(C(C)C)C1,(S)-6-(4-chlorophenyl)-3-((1-isopropylpiperidin-3-yl)methyl)-2-o-tolylquinazolin-4(3H)-one,0.68,uM,=,-0.1674910872937636,0,O=c1c2cc(-c3ccccc3)ccc2nc(-c2ccccc2)n1C[C@H]1CCCNC1
230,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2C(CN(Cc3cccc4c(C(=O)Nc5ccc(N6CCN(C)CC6)nc5)cn(C)c34)C(=O)[C@@H]2Cc2ccc(O)cc2)N1C(=O)NCc1ccccc1,"US8940739, G-41",7.6,uM,=,0.8808135922807914,1,O=C(Nc1ccc(N2CCNCC2)nc1)c1c[nH]c2c(CN3CC4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12
231,603292,10.1016/j.bmcl.2009.10.136,,,,Inhibition of human liver CYP3A4,O=C(N[C@@H](Cc1c[nH]c2ccc(O)cc12)c1cscn1)c1ccc2c(c1)nc(-c1ccoc1)n2C1CCCCC1,1-cyclohexyl-2-(furan-3-yl)-N-((S)-2-(5-hydroxy-1H-indol-3-yl)-1-(thiazol-4-yl)ethyl)-1H-benzo[d]imidazole-5-carboxamide,0.4,uM,=,-0.3979400086720376,0,O=C(N[C@@H](Cc1c[nH]c2ccccc12)c1cscn1)c1ccc2c(c1)nc(-c1ccoc1)n2C1CCCCC1
232,1587034,10.1021/acs.jmedchem.6b00203,,,,Inhibition of CYP3A4 (unknown origin),CNCC(=O)N1CCC(n2nc(C)c(Nc3ncc(Cl)c(-c4cnn5ccccc45)n3)c2C)CC1,"1-[4-(4-{[5-Chloro-4-(pyrazolo[1,5-a]pyridin-3-yl)-2-pyrimidinyl]amino}-3,5-dimethyl-1H-pyrazol-1-yl)-1-piperidinyl]-2-(methylamino)ethanone",3.8,uM,=,0.5797835966168101,1,c1ccn2ncc(-c3ccnc(Nc4cnn(C5CCNCC5)c4)n3)c2c1
233,813040,10.1021/jm201533b,,,,Inhibition of human CYP3A4 using testosterone as substrate by LC/MS/MS analysis,O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)[C@@H]1C[C@@H](Cc2ccc(F)cc2)CN1C(=O)Cn1cncn1,"(2S,4R)-1-(2-(1H-1,2,4-Triazol-1-yl)acetyl)-4-(4-fluorobenzyl)-N-(4-(4-fluorophenoxy)phenyl)pyrrolidine-2-carboxamide",12.605,uM,=,1.1005428500124648,1,O=C(Nc1ccc(Oc2ccccc2)cc1)[C@@H]1C[C@@H](Cc2ccccc2)CN1C(=O)Cn1cncn1
234,2023287,10.1016/j.bmcl.2020.127636,,,,Inhibition of CYP3A4 (unknown origin),COc1ccccc1C1c2c(C(C)(C)C)n[nH]c2C(=O)N1c1ccc(-c2noc(C)n2)cc1,"3-tert-butyl-4-(2-methoxyphenyl)-5-(4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)-4,5-dihydropyrrolo[3,4-c]pyrazol-6(1H)-one",13.0,uM,=,1.1139433523068367,1,O=C1c2[nH]ncc2C(c2ccccc2)N1c1ccc(-c2ncon2)cc1
235,1911030,10.1021/acs.jmedchem.8b01226,,,,Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins,COc1cccc(C(=O)N2CCC(=CC#Cc3cccc(C)n3)CC2)c1,(3-Methoxyphenyl){4-[3-(6-methylpyridin-2-yl)prop-2-yn-1-ylidene]piperidin-1-yl}methanone,4.6,uM,=,0.6627578316815741,1,O=C(c1ccccc1)N1CCC(=CC#Cc2ccccn2)CC1
236,740075,10.1016/j.bmcl.2011.02.033,,,,Inhibition of CYP3A4,CC[C@H](NC(=O)c1c(O)c(-c2ccccc2)nc2ccccc12)c1ccccc1,3-Hydroxy-2-phenyl-quinoline-4-carboxylic acid ((S)-1-phenyl-propyl)-amide,4.0,uM,=,0.6020599913279624,1,O=C(NCc1ccccc1)c1cc(-c2ccccc2)nc2ccccc12
237,1685713,10.1016/j.bmc.2017.04.033,,,,Inhibition of recombinant CYP3A4 (unknown origin),C[C@@H](c1ccc(-c2ccncc2)cc1)N1CC[C@](CCCO)(c2ccccc2)OC1=O,"(R)-6-(3-hydroxypropyl)-6-phenyl-3-((S)-1-(4-(pyridin-4-yl)phenyl)ethyl)-1,3-oxazinan-2-one",1.8,uM,=,0.255272505103306,1,O=C1OC(c2ccccc2)CCN1Cc1ccc(-c2ccncc2)cc1
238,448320,10.1016/j.bmc.2007.05.069,,,,Inhibition of CYP3A4,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNS(C)(=O)=O)C(=O)C(C)(c1cc(F)cc(F)c1)O2,"N-(2-(6-(2,4-diamino-6-ethylpyrimidin-5-yl)-2-(3,5-difluorophenyl)-2-methyl-3-oxo-2,3-dihydrobenzo[b][1,4]oxazin-4-yl)ethyl)methanesulfonamide",2.18,uM,=,0.3384564936046048,1,O=C1Nc2cc(-c3cncnc3)ccc2OC1c1ccccc1
239,526157,10.1021/np0401765,,,,Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation,OC[C@H](Cc1ccc2c(c1)OCO2)[C@H](CO)Cc1ccc2c(c1)OCO2,dihydrocubebin,9.5,uM,=,0.9777236052888478,1,c1cc2c(cc1CCCCc1ccc3c(c1)OCO3)OCO2
240,2048449,10.1016/j.bmc.2020.115734,,,,Inhibition of recombinant CYP3A4 (unknown origin) by fluorescence-based assay,COc1nc(-c2csc(Nc3c4c(nn3CCO)CCCC4)n2)ccc1-n1cnc(C)c1,"2-(3-((4-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)thiazol-2-yl)amino)-4,5,6,7-tetrahydro-2H-indazol-2-yl)ethanol",30.0,uM,=,1.4771212547196624,1,c1cn(-c2ccc(-c3csc(Nc4[nH]nc5c4CCCC5)n3)nc2)cn1
241,802673,10.1016/j.bmcl.2011.12.125,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,CC(C)NC(=O)c1cccc(NC(=O)Nc2ccc(-c3ncnc4c3ccn4C)cc2)c1,"N-isopropyl-3-(3-(4-(7-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)ureido)benzamide",2.9,uM,=,0.4623979978989561,1,O=C(Nc1ccccc1)Nc1ccc(-c2ncnc3[nH]ccc23)cc1
242,2135244,10.1021/acs.jmedchem.1c01452,,,,Inhibition of human recombinant CYP3A4 by fluorescence assay,COc1cc2ncnc(-c3c(-c4ccccc4)n(Cc4ccccc4Br)c4ccccc34)c2cc1OCCCN1CCOCC1,4-(3-((4-(1-(2-Bromobenzyl)-2-phenyl1H-indol-3-yl)-7-methoxyquinazolin-6-yl)oxy)propyl)morpholine,4.1,uM,=,0.6127838567197355,1,c1ccc(Cn2c(-c3ccccc3)c(-c3ncnc4ccc(OCCCN5CCOCC5)cc34)c3ccccc32)cc1
243,1352242,10.1021/jm4010835,,,,Inhibition of CYP3A4 in human liver microsomes,CCn1nc2c(-c3ccc(Cl)cc3)c(-c3ccncc3)c(=O)n(Cc3ccc(C(F)(F)F)nc3C)n2c1=O,"8-(4-Chlorophenyl)-2-ethyl-5-((2-methyl-6-(trifluoromethyl)-pyridin-3-yl)methyl)-7-(pyridin-4-yl)-[1,2,4]triazolo[4,3-b]-pyridazine-3,6(2H,5H)-dione",9.1,uM,=,0.9590413923210936,1,O=c1c(-c2ccncc2)c(-c2ccccc2)c2n[nH]c(=O)n2n1Cc1cccnc1
244,801015,10.1016/j.bmcl.2011.11.067,,,,Inhibition of CYP3A4,CCn1c(=O)c(-c2cc(C(=O)NC3CC3)cc(F)c2C)cc2nnc(-c3c(F)cccc3Cl)n21,"3-(3-(2-chloro-6-fluorophenyl)-5-ethyl-6-oxo-5,6-dihydro-[1,2,4]triazolo[4,3-b]pyridazin-7-yl)-N-cyclopropyl-5-fluoro-4-methylbenzamide",11.8,uM,=,1.0718820073061257,1,O=C(NC1CC1)c1cccc(-c2cc3nnc(-c4ccccc4)n3[nH]c2=O)c1
245,774749,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O,idebenone,7.0,uM,=,0.8450980400142568,1,O=C1C=CC(=O)C=C1
246,519907,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,Cc1cccc(C)c1CNc1cc(-n2ncccc2=O)cn2c(C)c(C)nc12,"2-(8-(2,6-dimethylbenzylamino)-2,3-dimethylimidazo[1,2-a]pyridin-6-yl)pyridazin-3(2H)-one",7.2,uM,=,0.8573324964312685,1,O=c1cccnn1-c1cc(NCc2ccccc2)c2nccn2c1
247,2273354,10.1021/acs.jmedchem.8b01971,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 10 mins followed by NADPH addition and measured after 15 mins by LC-MS/MS analysis,Cc1ccc(CS(=O)(=O)NC(=O)C2(C)CCN(c3nc4c(cc3C#N)C(=O)OC4)CC2)cc1,"1-(3-Cyano-5-oxo-5,7-dihydrofuro[3,4-b]pyridin-2-yl)-4-methyl-N-((4-methylbenzyl)sulfonyl)piperidine-4-carboxamide",1.11,uM,=,0.0453229787866574,1,O=C1OCc2nc(N3CCC(C(=O)NS(=O)(=O)Cc4ccccc4)CC3)ccc21
248,630896,10.1016/j.bmcl.2010.03.017,,,,Inhibition of CYP3A4,CCOC(=O)[C@H](C)NP(=O)(COc1cc(C)c(C)c2c1-c1ncsc1C2)N[C@@H](C)C(=O)OCC,"(2S,2'S)-diethyl 2,2'-(((6,7-dimethyl-8H-indeno[1,2-d]thiazol-4-yloxy)methyl)phosphoryl)bis(azanediyl)dipropanoate",0.58,uM,=,-0.2365720064370627,0,c1ccc2c(c1)Cc1scnc1-2
249,1335568,10.1021/jm401731q,,,,Inhibition of CYP3A4 (unknown origin),CN1CCN(c2cc(N3CCC[C@@H](C(=O)NCCc4ccc(C#N)nc4)C3)nc(C(F)(F)F)n2)CC1,(R)-N-(2-(6-Cyanopyridin-3-yl)ethyl)-1-(6-(4-methylpiperazin-1-yl)-2-(trifluoromethyl)pyrimidin-4-yl)piperidine-3-carboxamide,10.0,uM,=,1.0,1,O=C(NCCc1cccnc1)[C@@H]1CCCN(c2cc(N3CCNCC3)ncn2)C1
250,1899431,10.1016/j.bmcl.2019.01.035,,,,Inhibition of CYP3A4 (unknown origin),O=C(Nc1ccncc1)c1cn(Cc2ccc(Cl)c(Cl)c2)c(=O)c2cnn(C3CCNCC3)c12,"5-(3,4-dichlorobenzyl)-4-oxo-1-(piperidin-4-yl)-N-(pyridin-4-yl)-4,5-dihydro-1H-pyrazolo[4,3-c]pyridine-7-carboxamide",7.0,uM,=,0.8450980400142568,1,O=C(Nc1ccncc1)c1cn(Cc2ccccc2)c(=O)c2cnn(C3CCNCC3)c12
251,982382,10.1016/j.bmcl.2013.07.071,,,,Inhibition of CYP3A4 (unknown origin),COC[C@@H](Oc1cc(C[C@@H]2C[S@@+]([O-])C[C@H](N[C@H](C)c3cccc(C(C)(C)C)c3)[C@H]2O)cc(F)c1N)C(F)(F)F,"(1R,3S,4S,5R)-3-[4-Amino-3-fluoro-5-((R)-2,2,2-trifluoro-1-methoxymethyl-ethoxy)-benzyl]-5-[(R)-1-(3-tert-butyl-phenyl)-ethylamino]-1-oxo-tetrahydro-thiopyran-4-ol",0.1,uM,=,-1.0,0,c1ccc(CN[C@H]2C[SH+]C[C@@H](Cc3ccccc3)C2)cc1
252,44705,10.1016/s0960-894x(02)00473-0,,,,Inhibition of cytochrome P450 3A4,CN(C)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(=O)Cn1cc(Cc2cnn(C)c2)c(=O)nc1SCc1ccc(F)cc1,N-(2-Dimethylamino-ethyl)-2-[2-(4-fluoro-benzylsulfanyl)-5-(1-methyl-1H-pyrazol-4-ylmethyl)-4-oxo-4H-pyrimidin-1-yl]-N-(4'-trifluoromethyl-biphenyl-4-ylmethyl)-acetamide,30.0,uM,=,1.4771212547196624,1,O=C(Cn1cc(Cc2cn[nH]c2)c(=O)nc1SCc1ccccc1)NCc1ccc(-c2ccccc2)cc1
253,355280,10.1016/j.bmcl.2006.02.020,,,,Inhibition of CYP3A4,CC(C)N(C)[C@H](C)[C@@H](c1ccc2cc(OCC3(C(=O)O)CCCC3)ccc2c1)n1ccnc1,"1-((6-((1R,2R)-1-(1H-imidazol-1-yl)-2-(isopropyl(methyl)amino)propyl)naphthalen-2-yloxy)methyl)cyclopentanecarboxylic acid",0.8,uM,=,-0.0969100130080563,0,c1cn(Cc2ccc3cc(OCC4CCCC4)ccc3c2)cn1
254,1744980,10.1016/j.bmcl.2017.09.046,,,,Inhibition of human CYP3A4 expressed in Escherichia coli co-expressing CYP-reductase using diethoxyfluorescein as substrate measured after 10 mins by fluorescence assay,CCc1cccc(-c2c(F)cccc2C(O)(CCCNC(=O)OC)[C@@H]2CCCN(C(=O)CC(O)CN)C2)c1,methyl 4-((3R)-1-(4-amino-3-hydroxybutanoyl)piperidin-3-yl)-4-(3'-ethyl-6-fluorobiphenyl-2-yl)-4-hydroxybutylcarbamate,0.44,uM,=,-0.3565473235138126,0,c1ccc(-c2ccccc2C[C@@H]2CCCNC2)cc1
255,1467195,10.1021/jm5005336,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay,COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5CCOCC5)cc4)n[nH]c3c1)C(=O)N2,"(1R*,2S*)-(E)-5'-Methoxy-2-(3-(4-(morpholinomethyl)styryl)-1H-indazol-6-yl)spiro [cyclopropane-1,3'-indolin]-2'-one",2.4,uM,=,0.380211241711606,1,O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccc(CN4CCOCC4)cc3)n[nH]c2c1
256,1289241,10.1016/j.bmcl.2013.12.088,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,Fc1cc(OC(F)(F)C(F)F)cc([C@@](Cc2ccccc2)(Nc2nc3cc(F)cc(F)c3[nH]2)c2ccc(Cl)cn2)c1,"(R)-N-(1-(5-chloropyridin-2-yl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-5,7-difluoro-1H-benzo[d]imidazol-2-amine",24.0,uM,=,1.380211241711606,1,c1ccc(C[C@@](Nc2nc3ccccc3[nH]2)(c2ccccc2)c2ccccn2)cc1
257,519908,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,Cc1cccc(C)c1CNc1cc(-c2ccco2)cn2c(C)c(C)nc12,"N-(2,6-dimethylbenzyl)-6-(furan-2-yl)-2,3-dimethylimidazo[1,2-a]pyridin-8-amine",1.5,uM,=,0.1760912590556812,1,c1ccc(CNc2cc(-c3ccco3)cn3ccnc23)cc1
258,1474044,10.1021/jm501740a,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,O=C(N[C@@H](c1ccccn1)C1CC1)c1ccc2[nH]nc(-c3ccc(N4[C@H]5CC[C@H]4CC(O)C5)cc3)c2c1,N-((R)-Cyclopropyl(pyridin-2-yl)methyl)-3-(4-((endo)-3-hydroxy-8-azabicyclo[3.2.1]octan-8-yl)phenyl)-1H-indazole-5-carboxamide,1.3,uM,=,0.1139433523068367,1,O=C(N[C@@H](c1ccccn1)C1CC1)c1ccc2[nH]nc(-c3ccc(N4[C@@H]5CCC[C@@H]4CC5)cc3)c2c1
259,1534761,,,,,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",COc1ncccc1CNc1ccc(Cc2c[nH]c3ncccc23)c(F)n1,"US9096593, P-2045",5.0,uM,=,0.6989700043360189,1,c1cncc(CNc2ccc(Cc3c[nH]c4ncccc34)cn2)c1
260,2073864,10.1016/j.bmcl.2020.127428,,,,Inhibition of CYP3A4 (unknown origin),Nc1nc(-n2cc(C(=O)O)c(=O)c3cc(F)c([C@H]4C[C@@H](O)C4)c(Cl)c32)c(F)cc1F,"(1s,3s)-1-(6-amino-3,5-difluoro-2-pyridyl)-8-chloro-6-fluoro-7-(3-hydroxycyclobutyl)-4-oxo-quinoline-3-carboxylic acid",24.8,uM,=,1.3944516808262164,1,O=c1ccn(-c2ccccn2)c2cc(C3CCC3)ccc12
261,342118,10.1021/jm051106d,,,,Inhibitory activity against CYP3A4,Cc1cc2c(F)c(Oc3ncnn4cc(OCCCN5CCCC5)c(C)c34)ccc2[nH]1,"4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methyl-6-(3-(pyrrolidin-1-yl)propoxy)pyrrolo[2,1-f][1,2,4]triazine",3.4,uM,=,0.5314789170422551,1,c1nc(Oc2ccc3[nH]ccc3c2)c2cc(OCCCN3CCCC3)cn2n1
262,443559,10.1016/j.bmc.2007.03.014,,,,Inhibition of human CYP3A4 expressed in insect microsome using 7-benzyloxy-4-trifluoromethylcoumarin substrate after 30 mins,COc1ccc(CN2CCN(c3ccc(NC(=O)c4ccccc4NC(=O)c4cnc5ccccc5c4)cc3)CC2)cc1OC,"N-(2-(4-(4-(3,4-dimethoxybenzyl)piperazin-1-yl)phenylcarbamoyl)phenyl)quinoline-3-carboxamide",20.2,uM,=,1.305351369446624,1,O=C(Nc1ccccc1C(=O)Nc1ccc(N2CCN(Cc3ccccc3)CC2)cc1)c1cnc2ccccc2c1
263,2017934,10.1021/acs.jmedchem.0c00834,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis,Cc1c(-c2ccccc2)nc2ccc(Br)cc2c1C(=O)NCC(CCCC(=O)O)c1ccccc1Cl,(+)-6-{[(6-Bromo-3-methyl-2-phenylquinolin-4-yl)carbonyl]amino}-5-(2-chlorophenyl)hexanoic acid,13.0,uM,=,1.1139433523068367,1,O=C(NCCc1ccccc1)c1cc(-c2ccccc2)nc2ccccc12
264,51916,10.1016/j.bmcl.2003.11.005,,,,Inhibition of cytochrome P450 3A4,c1cncc(CCCOc2ccc(-n3ccnc3)cc2)c1,3-[3-(4-Imidazol-1-yl-phenoxy)-propyl]-pyridine,0.417,uM,=,-0.3798639450262425,0,c1cncc(CCCOc2ccc(-n3ccnc3)cc2)c1
265,1924430,10.1021/acsmedchemlett.5b00485,,,,Inhibition of CYP3A4 (unknown origin) preincubated for 10 mins followed by addition of BFC as substrate measured after 10 mins in presence of NADP by fluorescence analysis,Cc1cc(-c2cnn3c(NC[C@H]4C[C@@](C)(O)C4)cc(Oc4cccnc4)nc23)ccc1C(=O)NC1CC1,"N-cyclopropyl-4-(7-((cis-3-hydroxy-3-methylcyclobutyl)methylamino)-5-(pyridin-3-yloxy)pyrazolo[1,5-a]pyrimidin-3-yl)-2-methylbenzamide",0.51,uM,=,-0.2924298239020636,0,O=C(NC1CC1)c1ccc(-c2cnn3c(NCC4CCC4)cc(Oc4cccnc4)nc23)cc1
266,1910067,10.1016/j.ejmech.2018.12.025,,,,Inhibition of CYP3A4 in liver microsomes (unknown origin) using ketoconazole as substrate preincubated for 5 mins followed by NADPH addition and measured after 15 mins by LC-MS/MS analysis,Cc1cc(NC(=O)Nc2cc(C(C)(C)C)nn2-c2ccccc2)ccc1-c1cnc(NC2CC2)c2nccn12,"1-(3-(tert-Butyl)-1-phenyl-1H-pyrazol-5-yl)-3-(4-(8-(cyclopropylamino)imidazo[1,2-a]pyrazin-5-yl)-3-methylphenyl)urea",3.52,uM,=,0.5465426634781311,1,O=C(Nc1ccc(-c2cnc(NC3CC3)c3nccn23)cc1)Nc1ccnn1-c1ccccc1
267,1865168,10.1021/acsmedchemlett.9b00186,,,,Inhibition of human recombinant CYP3A4 using testosterone as substrate,COCc1nnc(N2C[C@@H]3C[C@]3(c3ccc(F)cc3Cl)C2)n1-c1ccc(OC)nc1,"(1S,5R)-1-(2-chloro-4-fluorophenyl)-3-(5-(methoxymethyl)-4-(6-methoxypyridin-3-yl)-4H-1,2,4-triazol-3-yl)-3-azabicyclo[3.1.0]hexane",20.0,uM,=,1.3010299956639813,1,c1ccc([C@]23C[C@H]2CN(c2nncn2-c2cccnc2)C3)cc1
268,1581635,10.1021/acs.jmedchem.5b01146,,,,Inhibition of C-terminal four-histidine tagged human CYP3A4delta3 to 24 residues expressed in Escherichia coli assessed as 7-benzyloxy-4-(trifluoromethyl)coumarin O-debenzylation pretreated 2 mins followed by NADPH addition by fluorometric method in presence of rat cytochrome P450 reductase,CC(C)(C)OC(=O)N[C@H](CSCCC(=O)NCc1cccnc1)CC1CCCCC1,(S)-tert-butyl 1-cyclohexyl-3-(3-oxo-3-(pyridin-3-ylmethylamino)propylthio)propan-2-ylcarbamate,30.0,uM,=,1.4771212547196624,1,O=C(CCSCCCC1CCCCC1)NCc1cccnc1
269,2104174,10.1021/acs.jmedchem.1c00173,,,,Inhibition of CYP3A4 (unknown origin) by UPLC-MS analysis,Cc1c(C2(c3ccc(C(F)(F)F)nc3)CC2)c[nH]c1C(=O)NC(C)c1c[nH]cn1,N-(1-(1H-imidazol-4-yl)ethyl)-3-methyl-4-(1-(6-(trifluoromethyl)pyridin-3-yl)cyclopropyl)-1H-pyrrole-2-carboxamide,1.7,uM,=,0.2304489213782739,1,O=C(NCc1c[nH]cn1)c1cc(C2(c3cccnc3)CC2)c[nH]1
270,1972830,10.1021/acsmedchemlett.9b00612,,,,Inhibition of human recombinant CYP3A4 expressed in insect cell microsomes in presence of NADPH by fluorescence assay,Cc1ccc(C(=O)Nc2ccc(CN3Cc4ccc(O)cc4C3)c(Cl)c2)cc1C#Cc1cnc2cccnn12,"N-(3-chloro-4-((5-hydroxyisoindolin-2-yl)methyl)phenyl)-3-(imidazo [1,2-b]pyridazin-3-ylethynyl)-4-methylbenzamide",4.61,uM,=,0.6637009253896482,1,O=C(Nc1ccc(CN2Cc3ccccc3C2)cc1)c1cccc(C#Cc2cnc3cccnn23)c1
271,1614026,10.1016/j.bmcl.2016.09.043,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 1'-hydroxymidazolam metabolite formation using midazolam as substrate incubated for 10 mins by HPLC-MS method,Cn1c(NCCc2ccc(OC(F)(F)F)cc2)nc2cc(Cl)ccc2c1=O,7-Chloro-3-methyl-2-[2-(4-trifluoromethoxy-phenyl)-ethylamino]-3H-quinazolin-4-one,4.0,uM,=,0.6020599913279624,1,O=c1[nH]c(NCCc2ccccc2)nc2ccccc12
272,945618,10.1016/j.bmc.2012.11.058,,,,Inhibition of CYP3A4 (unknown origin),O=S(=O)(Nc1cc(Cl)c(Oc2cnc3ccccc3c2)c(Cl)c1)c1ccc(C(F)(F)F)cc1Cl,"2-chloro-N-(3,5-dichloro-4-(quinolin-3-yloxy)phenyl)-4-(trifluoromethyl)benzenesulfonamide",2.3,uM,=,0.3617278360175928,1,O=S(=O)(Nc1ccc(Oc2cnc3ccccc3c2)cc1)c1ccccc1
273,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN6CCN(CC)CC6C5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, E-50",5.04,uM,=,0.7024305364455253,1,O=C(c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12)N1CCN2CCNCC2C1
274,469873,10.1016/j.bmcl.2008.01.012,,,,Inhibition of human CYP3A4,CC(C)c1c(-c2nnc(N3CCN(C)CC3)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12,"N-cyclopropyl-2,4-difluoro-5-(5-isopropyl-6-(5-(4-methylpiperazin-1-yl)-1,3,4-oxadiazol-2-yl)pyrrolo[1,2-f][1,2,4]triazin-4-ylamino)benzamide",0.2,uM,=,-0.6989700043360187,0,O=C(NC1CC1)c1cccc(Nc2ncnn3cc(-c4nnc(N5CCNCC5)o4)cc23)c1
275,1488508,10.1124/dmd.112.045708,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 90 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis in presence of NADPH,CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1,"(R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide",2.7,uM,=,0.4313637641589873,1,O=C(Cc1ccccc1)N(Cc1cccnc1)Cc1nc2ncccc2c(=O)n1-c1ccccc1
276,1517864,10.1016/j.bmc.2015.08.019,,,,Inhibition of CYP3A4 (unknown origin) incubated for 45 mins using NADPH by fluorescence assay,Clc1cccc(C(c2ccc3[nH]cnc3c2)n2ccnc2)c1,5-[(3-Chloro-phenyl)-imidazol-1-yl-methyl]-1H-benzoimidazole,0.69,uM,=,-0.1611509092627447,0,c1ccc(C(c2ccc3[nH]cnc3c2)n2ccnc2)cc1
277,2125914,10.1021/acs.jmedchem.0c02008,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate,C[C@@H](C[C@@]1(C2CC2)NC(=O)NC1=O)C(=O)N1CCN(c2ccc(F)c(F)c2)[C@@H](C)C1,"(S)-5-cyclopropyl-5-((S)-3-((S)-4-(3,4-difluorophenyl)-3-methylpiperazin-1-yl)-2-methyl3-oxopropyl)imidazolidine-2,4-dione",1.5,uM,=,0.1760912590556812,1,O=C1NC(=O)[C@](CCC(=O)N2CCN(c3ccccc3)CC2)(C2CC2)N1
278,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN6CCN(C=O)CC6C5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, E-48",12.1,uM,=,1.08278537031645,1,O=C(c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12)N1CCN2CCNCC2C1
279,802673,10.1016/j.bmcl.2011.12.125,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,O=C(NCc1ccc(F)cc1)Nc1ccc(-c2ccnc3[nH]cnc23)cc1,"1-(4-(3H-imidazo[4,5-b]pyridin-7-yl)phenyl)-3-(4-fluorobenzyl)urea",0.28,uM,=,-0.5528419686577808,0,O=C(NCc1ccccc1)Nc1ccc(-c2ccnc3[nH]cnc23)cc1
280,859942,10.1021/jm300122u,,,,Inhibition of human CYP3A4 using testosterone as substrate after 45 mins,NC1CCCC(NC(=O)[C@H](Cc2ccc(Cl)cc2Cl)NC(=O)C2(c3ccc(Cl)cc3Cl)CC2)C1,"N-(3-Aminocyclohexyl)-2,4-dichloro-N-alpha-{[1-(2,4-dichlorophenyl)cyclopropyl]carbonyl}-L-phenylalaninamide",0.42,uM,=,-0.3767507096020995,0,O=C(NC1CCCCC1)[C@H](Cc1ccccc1)NC(=O)C1(c2ccccc2)CC1
281,630896,10.1016/j.bmcl.2010.03.017,,,,Inhibition of CYP3A4,Cc1cc(OC[P@@]2(=O)OCC[C@@H](c3ccncc3)O2)c2c(c1C)Cc1scnc1-2,"6,7-Dimethyl-4-(2-oxo-4-pyridin-4-yl-2lambda*5*-[1,3,2]dioxaphosphinan-2-ylmethoxy)-8H-indeno[1,2-d]thiazole",2.2,uM,=,0.3424226808222063,1,O=[P@]1(COc2cccc3c2-c2ncsc2C3)OCC[C@@H](c2ccncc2)O1
282,1829871,10.1021/acsmedchemlett.8b00308,,,,Inhibition of CYP3A4 (unknown origin),Cc1nn(-c2ccccc2)nc1COc1cc(N)nc2[nH]nnc12,"7-((5-Methyl-2-phenyl-2H-1,2,3-triazol-4-yl)methoxy)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-amine",0.37,uM,=,-0.431798275933005,0,c1ccc(-n2ncc(COc3ccnc4[nH]nnc34)n2)cc1
283,52065,10.1021/jm0310129,,,,Inhibitory activity against cytochrome P450 3A4,CNc1nccc2c1c1ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c1n2C,"(4-{4-[2-(3,4-Difluoro-phenyl)-ethyl]-piperazin-1-yl}-5-methyl-5H-pyrido[3',4':4,5]pyrrolo[3,2-d]pyrimidin-9-yl)-methyl-amine",53.81,uM,=,1.730862992046494,1,c1ccc(CCN2CCN(c3ncnc4c3[nH]c3ccncc34)CC2)cc1
284,746947,10.1021/jm200128m,,,,Inhibition of human CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,Nc1nc2c(c(-c3c(Cl)cc(Cl)cc3OCCn3cccn3)n1)CN(C(=O)NCC(F)(F)F)C2,"2-Amino-4-[2,4-dichloro-6-(2-pyrazol-1-ylethoxy)phenyl]-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carboxylic Acid(2,2,2-Trifluoroethyl)amide",1.9,uM,=,0.2787536009528289,1,c1ccc(-c2ncnc3c2CNC3)c(OCCn2cccn2)c1
285,619264,10.1016/j.bmcl.2009.07.002,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,Cc1cccc(C)c1CNc1cc(C(=O)NCCO)cn2c(C)c(C)nc12,"8-(2,6-dimethylbenzylamino)-N-(2-hydroxyethyl)-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxamide",9.0,uM,=,0.9542425094393248,1,c1ccc(CNc2cccn3ccnc23)cc1
286,595557,10.1016/j.bmcl.2009.10.084,,,,Inhibition of CYP3A4 using BFC as a substrate,Cc1cc2cc(N/C(=N\C(=O)c3ccc(Cl)nc3)N[C@H]3CCCCN(CC(=O)N4CCCC4)C3=O)ccc2o1,(S)-6-chloro-N-((2-methylbenzofuran-5-ylamino)(2-oxo-1-(2-oxo-2-(pyrrolidin-1-yl)ethyl)azepan-3-ylamino)methylene)nicotinamide,8.0,uM,=,0.9030899869919436,1,O=C(/N=C(\Nc1ccc2occc2c1)N[C@H]1CCCCN(CC(=O)N2CCCC2)C1=O)c1cccnc1
287,1499751,10.1021/acs.jmedchem.5b00424,,,,Inhibition of CYP3A4 (unknown origin),CNc1cc(-c2csc(NC(=O)Cc3cccc(OC)c3)n2)ccn1,2-(3-methoxyphenyl)-N-(4-(2-(methylamino)pyridin-4-yl)thiazol-2-yl)acetamide,11.4,uM,=,1.0569048513364727,1,O=C(Cc1ccccc1)Nc1nc(-c2ccncc2)cs1
288,1467195,10.1021/jm5005336,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay,COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5C[C@@H](C)O[C@@H](C)C5)cc4)n[nH]c3c1)C(=O)N2C,"(1R,2S)-2-(3-((E)-(4-cis-2,6-Dimethylmorpholino)methyl)styryl)-1H-indazol-6-yl)-5'-methoxy-1'-methylspiro[cyclopropane-1,3'-indolin]-2'-one",10.0,uM,=,1.0,1,O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccc(CN4CCOCC4)cc3)n[nH]c2c1
289,1528565,,,,,"Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",CC(C)c1nc(CN(C)C(=O)N2C[C@@H](N)C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,"US8987313, 29",0.19,uM,=,-0.721246399047171,0,O=C(N[C@H](CC[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)NCc1cscn1)Cc1ccccc1)OCc1cncs1
290,1487309,10.1124/dmd.111.043505,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis,COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1,[1-(4-Fluoro-benzyl)-1H-benzoimidazol-2-yl]-{1-[2-(4-methoxy-phenyl)-ethyl]-piperidin-4-yl}-amine,10.6,uM,=,1.0253058652647702,1,c1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccccc3)CC2)cc1
291,856843,10.1021/jm300356u,,,,Inhibition of human recombinant CYP3A4 using DEF as substrate preincubated for 5 to 10 mins before substrate addition,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H]3[C@H]2O/C(=N\CCCSC)N3C)[C@](C)(OC)C[C@@H](C)C(=O)N[C@H](C)[C@@H](O)[C@]1(C)O,"(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-11-((3aR,4S,6R,7aS)-1,6-dimethyl-2-(3-(methylthio)propylimino)hexahydro-1H-pyrano[4,3-d]oxazol-4-yloxy)-2-ethyl-3,4-dihydroxy-13-((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yloxy)-10-methoxy-3,5,8,10,12,14-hexamethyl-1-oxa-6-azacyclopentadecane-7,15-dione",1.33,uM,=,0.1238516409670858,1,N=C1N[C@H]2CCO[C@@H](O[C@H]3CCCC(=O)NCCCCOC(=O)C[C@@H](O[C@H]4CCCCO4)C3)[C@@H]2O1
292,859942,10.1021/jm300122u,,,,Inhibition of human CYP3A4 using testosterone as substrate after 45 mins,CN1CCN(C(=O)[C@H](Cc2ccc(Cl)cc2Cl)NC(=O)C2(c3ccc(Cl)cc3Cl)CC2)CC1,"1-(2,4-Dichlorophenyl)-N-[(1S)-1-[(2,4-dichlorophenyl)-methyl]-2-(4-methylpiperazin-1-yl)-2-oxoethyl]-cyclopropanecarboxamide",1.03,uM,=,0.0128372247051722,1,O=C([C@H](Cc1ccccc1)NC(=O)C1(c2ccccc2)CC1)N1CCNCC1
293,762002,10.1016/j.bmc.2011.05.022,,,,Inhibition of CYP3A4,CCCCN1C(=O)C(C(C)C)NC(=O)C12CCN(Cc1ccc(Oc3ccccc3)cc1)CC2.Cl,"1-butyl-3-isopropyl-9-(4-phenoxybenzyl)-1,4,9-triazaspiro[5.5]undecane-2,5-dione hydrochloride",9.3,uM,=,0.9684829485539352,1,O=C1CNC(=O)C2(CCN(Cc3ccc(Oc4ccccc4)cc3)CC2)N1
294,519908,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,Cc1cccc(C)c1CNc1cc(-n2ncccc2=O)cn2c(C)c(C)nc12,"2-(8-(2,6-dimethylbenzylamino)-2,3-dimethylimidazo[1,2-a]pyridin-6-yl)pyridazin-3(2H)-one",8.5,uM,=,0.9294189257142929,1,O=c1cccnn1-c1cc(NCc2ccccc2)c2nccn2c1
295,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1ccc(C(=O)N2CCOC[C@H]2Cc2cccc(-n3nccn3)c2)c(-n2nccn2)c1C,"US9150566, 92",44.0,uM,=,1.6434526764861874,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
296,1475768,10.1021/jm5017413,,,,Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system,CC(C)c1nc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)[C@@H]3C)cs1,"(R)-(3-(2-Isopropylthiazol-4-yl)-8-methyl-5,6-dihydro-[1,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(thiophen-2-yl)phenyl)-methanone",35.0,uM,=,1.5440680443502757,1,O=C(c1ccc(-c2cccs2)cc1)N1CCn2c(nnc2-c2cscn2)C1
297,2068401,10.1016/j.bmcl.2020.127676,,,,Inhibition of CYP3A4 (unknown origin),CN[C@@H](C)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)Nc1cc2c(NC[C@H]3CC[C@H](CNc4ncnc5cc(OC)c(NC(=O)[C@@H]6CCCN6C(=O)[C@@H](NC(=O)[C@H](C)NC)C6CCCCC6)cc45)CC3)ncnc2cc1OC)C1CCCCC1,"(S,S,2S,2'S)-N,N'-(4,4'-(1r,4r)-cyclohexane-1,4-diylbis(methylene)bis(azanediyl)bis(7-methoxyquinazoline-6,4-diyl))bis(1-((S)-2-cyclohexyl-2-((S)-2-(methylamino)propanamido)acetyl)pyrrolidine-2-carboxamide)",0.66,uM,=,-0.1804560644581313,0,O=C(Nc1ccc2ncnc(NC[C@H]3CC[C@H](CNc4ncnc5ccc(NC(=O)[C@@H]6CCCN6C(=O)CC6CCCCC6)cc45)CC3)c2c1)[C@@H]1CCCN1C(=O)CC1CCCCC1
298,461436,10.1016/j.bmcl.2007.10.092,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,O=S(=O)(c1ccc(Cl)cc1)N1[C@H](C2CC2)CCC[C@@H]1C1(Cc2noc(CN3CCCC3)n2)CC1,"(2S,6R)-1-(4-chlorophenylsulfonyl)-2-cyclopropyl-6-(1-((5-(pyrrolidin-1-ylmethyl)-1,2,4-oxadiazol-3-yl)methyl)cyclopropyl)piperidine",1.2,uM,=,0.0791812460476248,1,O=S(=O)(c1ccccc1)N1[C@H](C2CC2)CCC[C@@H]1C1(Cc2noc(CN3CCCC3)n2)CC1
299,2048449,10.1016/j.bmc.2020.115734,,,,Inhibition of recombinant CYP3A4 (unknown origin) by fluorescence-based assay,COc1nc(-c2csc(Nc3c4c(nn3C3CCC3)CCCC4)n2)ccc1-n1cnc(C)c1,"N-(2-cyclobutyl-4,5,6,7-tetrahydro-2H-indazol-3-yl)-4-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)thiazol-2-amine",0.59,uM,=,-0.2291479883578558,0,c1cn(-c2ccc(-c3csc(Nc4c5c(nn4C4CCC4)CCCC5)n3)nc2)cn1
300,1527876,,,,,Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,C[C@@H](c1ccc(-c2ccn(C)c(=O)c2)cc1)N1CC[C@](CC(C)(C)C#N)(c2ccccc2)OC1=O,"US8575157, 50",14.0,uM,=,1.146128035678238,1,O=C1OC(c2ccccc2)CCN1Cc1ccc(-c2cc[nH]c(=O)c2)cc1
301,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C#N)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, H-2",9.33,uM,=,0.9698816437465,1,O=C1[C@H](Cc2ccccc2)N2C(=O)CNN(C(=O)NCc3ccccc3)[C@H]2CN1Cc1cccc2c(-c3ccccc3)c[nH]c12
302,1485439,10.1124/dmd.111.042739,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrates after 5 mins by LC/MS analysis in presence of NADPH,CC[C@H](C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O,"trans-2-((S)-sec-Butyl)-4-[4-(4-{4-[(2R,4R)-2-(2,4-dichloro-phenyl)-2-[1,2,4]triazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-phenyl]-2,4-dihydro-[1,2,4]triazol-3-one",0.02,uM,=,-1.6989700043360187,0,O=c1[nH]ncn1-c1ccc(N2CCN(c3ccc(OC[C@@H]4CO[C@](Cn5cncn5)(c5ccccc5)O4)cc3)CC2)cc1
303,1619192,10.1016/j.bmcl.2016.08.071,,,,Inhibition of CYP3A4 (unknown origin),S=c1[nH]nc(-c2c(N3CCCCC3)nc3ccc(Cl)cc3c2-c2ccccc2)o1,"5-(6-chloro-4-phenyl-2-(piperidin-1-yl)quinolin-3-yl)-1,3,4-oxadiazole-2(3H)-thione",15.0,uM,=,1.1760912590556811,1,S=c1[nH]nc(-c2c(N3CCCCC3)nc3ccccc3c2-c2ccccc2)o1
304,1291572,10.1016/j.bmcl.2013.12.058,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@H](CCNNC(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1,"(6S,9S)-thiazol-5-ylmethyl 6-benzyl-9-isopropyl-13-(2-isopropylthiazol-4-yl)-12-methyl-8,11-dioxo-2,3,7,10,12-pentaazatridecan-1-oate",0.63,uM,=,-0.2006594505464183,0,O=C(CNC(=O)NCc1cscn1)N[C@H](CCNNC(=O)OCc1cncs1)Cc1ccccc1
305,604207,10.1016/j.bmcl.2009.11.088,,,,Inhibition of CYP3A4,NC[C@H]1CC[C@]2(CC1)OOC1(O2)C2CC3CC(C2)CC1C3,"dispiro[adamantane-2,2'-[1,3,5]trioxolane-4',1''-cyclohexane]-4''-ylmethanamine",9.7,uM,=,0.9867717342662448,1,C1CCC2(CC1)OOC1(O2)C2CC3CC(C2)CC1C3
306,536049,10.1016/j.bmcl.2008.08.010,,,,Inhibition of human CYP3A4 by microtiter plate assays using PPR substrate,O=S(=O)(c1ccccc1)n1cc(Cl)c2cc3c(cc21)CCNCC3,"3-chloro-1-(phenylsulfonyl)-1,5,6,7,8,9-hexahydroazepino[4,5-f]indole",19.0,uM,=,1.2787536009528289,1,O=S(=O)(c1ccccc1)n1ccc2cc3c(cc21)CCNCC3
307,2062192,10.1016/j.bmcl.2016.04.018,,,,Inhibition of human liver microsomes CYP3A4 using testosterone as substrate by MUX-MS/MS analysis,Cc1cc(-c2ccc3c(c2)-c2nnc(Cc4cccc(Cl)c4)n2CCO3)ccn1,"3-(3-chlorobenzyl)-10-(2-methylpyridin-4-yl)-5,6-dihydrobenzo[f][1,2,4]triazolo[4,3-d][1,4]oxazepine",1.06,uM,=,0.0253058652647702,1,c1ccc(Cc2nnc3n2CCOc2ccc(-c4ccncc4)cc2-3)cc1
308,479364,10.1016/j.bmcl.2008.05.027,,,,Inhibition of CYP3A4,N#CCN(CC(=O)N1CCCC(c2ccccc2)C1CN1CCOCC1)c1ccc(Cl)c(Cl)c1,"rac-2-((3,4-dichlorophenyl)(2-(2-(morpholinomethyl)-3-phenylpiperidin-1-yl)-2-oxoethyl)amino)acetonitrile",0.49,uM,=,-0.3098039199714864,0,O=C(CNc1ccccc1)N1CCCC(c2ccccc2)C1CN1CCOCC1
309,1291572,10.1016/j.bmcl.2013.12.058,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CCN(Cc2ccccc2)C(=O)OCc2cncs2)Cc2ccccc2)cs1,Thiazol-5-ylmethyl benzyl((S)-3-((S)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-4-morpholinobutanamido)-4-phenylbutyl)carbamate,0.34,uM,=,-0.4685210829577448,0,O=C(NCc1cscn1)N[C@@H](CCN1CCOCC1)C(=O)N[C@H](CCN(Cc1ccccc1)C(=O)OCc1cncs1)Cc1ccccc1
310,1587034,10.1021/acs.jmedchem.6b00203,,,,Inhibition of CYP3A4 (unknown origin),Cc1nn(C2CCN(C(=O)[C@@H](C)O)CC2)c(C)c1Nc1ncc(Cl)c(-c2cnn3ccccc23)n1,"(2R)-1-[4-(4-{[5-chloro-4-(pyrazolo[1,5-a]pyridin-3-yl)-2-pyrimidinyl]amino}-3,5-dimethyl-1H-pyrazol-1-yl)-1-piperidinyl]-2-hydroxy-1-propanone",21.0,uM,=,1.3222192947339193,1,c1ccn2ncc(-c3ccnc(Nc4cnn(C5CCNCC5)c4)n3)c2c1
311,349088,10.1016/j.bmcl.2006.01.084,,,,Inhibition of CYP3A4 using BFC fluorogenic substrate,COCCCN1CCCc2ccc(OC[C@H]3CNCC(=O)N3c3ccc(OCCCOCc4ccccc4OC)cc3)cc21,"(R)-1-(4-(3-(2-methoxybenzyloxy)propoxy)phenyl)-6-((1-(3-methoxypropyl)-1,2,3,4-tetrahydroquinolin-7-yloxy)methyl)piperazin-2-one",0.012,uM,=,-1.9208187539523751,0,O=C1CNC[C@H](COc2ccc3c(c2)NCCC3)N1c1ccc(OCCCOCc2ccccc2)cc1
312,1685713,10.1016/j.bmc.2017.04.033,,,,Inhibition of recombinant CYP3A4 (unknown origin),C[C@@H](c1ccc(-c2ccc(=O)n(C)c2)cc1)N1CC[C@](CCCO)(c2ccccc2)OC1=O,"US8575157, 30",10.5,uM,=,1.021189299069938,1,O=C1OC(c2ccccc2)CCN1Cc1ccc(-c2ccc(=O)[nH]c2)cc1
313,438600,10.1016/j.bmcl.2007.03.048,,,,Inhibition of CYP3A4 in microsomes,Cc1cccc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-3-(4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one,0.71,uM,=,-0.1487416512809247,0,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccccc2[nH]1
314,1614025,10.1016/j.bmcl.2016.09.043,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 6-beta-hydroxytestosterone metabolite formation using testosterone as substrate incubated for 30 mins by HPLC-MS method,Cn1c(NCCc2ccc(-c3ccc(F)cc3)cc2)nc2cc(N)ccc2c1=O,7-amino-2-{[2-(4'-fluorobiphenyl-4-yl)ethyl]amino}-3-methylquinazolin-4(3H)-one,30.0,uM,=,1.4771212547196624,1,O=c1[nH]c(NCCc2ccc(-c3ccccc3)cc2)nc2ccccc12
315,1447575,10.1016/j.bmcl.2014.05.068,,,,Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method,N#Cc1ccc(-c2ccc(C(F)(F)C(O)(Cn3cnnn3)c3ccc(F)cc3F)nc2)cc1,"4-(6-(2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(1H-tetrazol-1-yl)propyl)pyridin-3-yl)benzonitrile",16.0,uM,=,1.2041199826559248,1,c1ccc(-c2ccc(CC(Cn3cnnn3)c3ccccc3)nc2)cc1
316,988989,10.1021/jm400732v,,,,Inhibition of CYP3A4 (unknown origin),CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)c2cnccn2)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O.Cl,"(S)-N-((S)-1-((6-Bromo-2-methoxynaphthalen-1-yl)methyl)-2-oxo-5-(pyrazine-2-carbonyl)-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-yl)-2-(methylamino)propanamide hydrochloride",1.6,uM,=,0.2041199826559248,1,O=C1CCN(C(=O)c2cnccn2)c2ccccc2N1Cc1cccc2ccccc12
317,455108,10.1016/j.bmcl.2006.12.043,,,,Inhibition of CYP3A4,O=C(C(O)c1ccc(Br)cc1)N1CCN(c2ccc3[nH]ncc3c2)CC1,1-(4-(1H-indazol-5-yl)piperazin-1-yl)-2-(4-bromophenyl)-2-hydroxyethanone,4.0,uM,=,0.6020599913279624,1,O=C(Cc1ccccc1)N1CCN(c2ccc3[nH]ncc3c2)CC1
318,1301328,10.6019/CHEMBL3137440,,,,DNDI: CYP Inhibition,FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ccc(C(F)(F)F)nc3)CC2)cc1,N-4-Trifluoromethylphenyl-N-{1-[6-(trifluoromethyl)pyridin-3-yl]piperidin-4-yl}pyridin-3-amine,16.0,uM,=,1.2041199826559248,1,c1ccc(N(c2cccnc2)C2CCN(c3cccnc3)CC2)cc1
319,857201,10.1021/jm200900q,,,,Inhibition of CYP3A4,N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(c4ccccn4)CC3)cc2C2=CCCCC2)n1,"4-Cyano-1H-imidazole-2-carboxylic Acid[2-Cyclohex-1-enyl-4-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-phenyl]-amide",1.7,uM,=,0.2304489213782739,1,O=C(Nc1ccc(C2CCN(c3ccccn3)CC2)cc1C1=CCCCC1)c1ncc[nH]1
320,982382,10.1016/j.bmcl.2013.07.071,,,,Inhibition of CYP3A4 (unknown origin),COC[C@@H](Oc1cc(C[C@@H]2C[S@@+]([O-])C[C@H](NCc3cc(CC(C)(C)C)on3)[C@H]2O)cc(F)c1N)C(F)(F)F,"(1R,3S,4S,5R)-3-[4-Amino-3-fluoro-5-((R)-2,2,2-trifluoro-1-methoxymethyl-ethoxy)-benzyl]-5-{[5-(2,2-dimethyl-propyl)-isoxazol-3-ylmethyl]-amino}-1-oxo-tetrahydro-thiopyran-4-ol",1.1,uM,=,0.041392685158225,1,c1ccc(C[C@@H]2C[SH+]C[C@H](NCc3ccon3)C2)cc1
321,535882,10.1016/j.bmcl.2008.08.010,,,,"Inhibition of human CYP3A4 by microtiter plate assays using N-N,diethyl-formamide as substrate",COc1cccc(S(=O)(=O)n2ccc3cc4c(cc32)CCNCC4)c1,"1-(3-methoxyphenylsulfonyl)-1,5,6,7,8,9-hexahydroazepino[4,5-f]indole",17.0,uM,=,1.230448921378274,1,O=S(=O)(c1ccccc1)n1ccc2cc3c(cc21)CCNCC3
322,1528565,,,,,"Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",CC(C)c1nc(CN(C)C(=O)N2C[C@@H](O)C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,"US8987313, 8",0.17,uM,=,-0.7695510786217261,0,O=C(N[C@H](CC[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)NCc1cscn1)Cc1ccccc1)OCc1cncs1
323,349088,10.1016/j.bmcl.2006.01.084,,,,Inhibition of CYP3A4 using BFC fluorogenic substrate,COc1ccccc1COCCCOc1ccc(N2C(=O)CNC[C@@H]2COc2ccc3c(c2)N(CCN2CCCC2=O)CCC3)cc1,"(R)-1-(4-(3-(2-methoxybenzyloxy)propoxy)phenyl)-6-((1-(2-(2-oxopyrrolidin-1-yl)ethyl)-1,2,3,4-tetrahydroquinolin-7-yloxy)methyl)piperazin-2-one",0.042,uM,=,-1.3767507096020994,0,O=C1CCCN1CCN1CCCc2ccc(OC[C@H]3CNCC(=O)N3c3ccc(OCCCOCc4ccccc4)cc3)cc21
324,973938,10.1021/jm400634n,,,,Inhibition of CYP3A4 (unknown origin) using vivid red as substrate,Nc1ccccc1NC(=O)c1ccc(CNC2=N[C@@H](c3ccccc3)CS2)cc1,"N-(2-Aminophenyl)-4-({[(4S)-4-phenyl-4,5-dihydro-1,3-thiazol-2-yl]amino}methyl)benzamide",25.0,uM,=,1.3979400086720375,1,O=C(Nc1ccccc1)c1ccc(CNC2=N[C@@H](c3ccccc3)CS2)cc1
325,449485,10.1016/j.bmcl.2007.07.097,,,,Inhibition of microsomal CYP3A4,CC(C)C[C@H](NC(=O)CCCN)c1cc(F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1,"4-amino-N-((S)-1-(2-(4-((R)-3-(2,4-dichlorophenyl)-2-(2-oxopyrrolidin-1-yl)propanoyl)piperazin-1-yl)-5-fluorophenyl)-3-methylbutyl)butanamide",15.0,uM,=,1.1760912590556811,1,O=C([C@@H](Cc1ccccc1)N1CCCC1=O)N1CCN(c2ccccc2)CC1
326,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cc(F)cc(-n2nccn2)c1,"US9150566, 145",22.0,uM,=,1.3424226808222062,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
327,659957,10.1021/jm100643t,,,,Inhibition of CYP3A4,CC(C)(C)c1ccc(SCC(c2c[nH]cn2)C2CCNCC2)cc1,4-(2-(4-tert-Butylphenylthio)-1-(1H-imidazol-4-yl)ethyl)piperidine,6.5,uM,=,0.8129133566428556,1,c1ccc(SCC(c2c[nH]cn2)C2CCNCC2)cc1
328,1750153,10.1016/j.bmcl.2017.12.040,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins with substrate followed by NADPH addition measured after 15 mins by LC/MS/MS analysis,O=c1n(-c2ccc(C(F)(F)C(O)(Cn3cnnn3)c3ccc(F)cc3F)nc2)cnn1C1CCCCC1,"2-cyclohexyl-4-(6-(2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(1H-tetrazol-1-yl)propyl)pyridin-3-yl)-2,4-dihydro-3H-1,2,4-triazol-3-one",50.0,uM,=,1.6989700043360187,1,O=c1n(-c2ccc(CC(Cn3cnnn3)c3ccccc3)nc2)cnn1C1CCCCC1
329,1301328,10.6019/CHEMBL3137440,,,,DNDI: CYP Inhibition,N#Cc1ccccc1N1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1,2-(4-(pyridin-3-yl(4-(trifluoromethyl)phenyl)amino)piperidin-1-yl)benzonitrile,5.2,uM,=,0.7160033436347992,1,c1ccc(N2CCC(N(c3ccccc3)c3cccnc3)CC2)cc1
330,2109894,10.1016/j.bmc.2021.116138,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate incubated for 5 mins followed by NADPH addition and measured after 5 mins by LC/MS/MS analysis,C=C[C@]1(C)C[C@@H](OC(=O)CSCCN(CC)CC)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O,"(2-diethylamino-ethylsulfanyl)-acetic acid (2R,3S,4S,6R,7R,8R,14S)-3-hydroxy-2,4,7,14-tetramethyl-9-oxo-4-vinyl-tricyclo[5.4.3.1,8]tetradec-6-yl ester",1.6,uM,=,0.2041199826559248,1,O=C1CC[C@]23CCCCCC(CCC2)[C@H]13
331,421699,10.1016/j.bmcl.2006.11.065,,,,Inhibition of CYP3A4,O=C(NC1CCN(Cc2ccc3c(c2)OCO3)CC1)c1cc(=O)c2ccc(F)cc2o1,"N-[1-(1,3-benzodioxol-5-ylmethyl)piperidin-4-yl]-7-fluoro-4-oxo-4H-chromene-2-carboxamide",23.5,uM,=,1.3710678622717365,1,O=C(NC1CCN(Cc2ccc3c(c2)OCO3)CC1)c1cc(=O)c2ccccc2o1
332,1291572,10.1016/j.bmcl.2013.12.058,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)NC(Cc2ccccc2)CN(Cc2ccccc2)C(=O)OCc2cncs2)cs1,thiazol-5-ylmethyl benzyl(2-((S)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-4-morpholinobutanamido)-3-phenylpropyl)carbamate,0.46,uM,=,-0.3372421683184259,0,O=C(NCc1cscn1)N[C@@H](CCN1CCOCC1)C(=O)NC(Cc1ccccc1)CN(Cc1ccccc1)C(=O)OCc1cncs1
333,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)N6CCN(S(C)(=O)=O)CC6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, D-90",6.96,uM,=,0.8426092396105621,1,O=C(c1ccc(-c2c[nH]c3c(CN4C[C@@H]5N(C(=O)NCc6ccccc6)NCC(=O)N5[C@@H](Cc5ccccc5)C4=O)cccc23)cn1)N1CCNCC1
334,536049,10.1016/j.bmcl.2008.08.010,,,,Inhibition of human CYP3A4 by microtiter plate assays using PPR substrate,O=S(=O)(c1cccc(Cl)c1)n1ccc2cc3c(cc21)CCNCC3,"1-(3-chlorophenylsulfonyl)-1,5,6,7,8,9-hexahydroazepino[4,5-f]indole",7.0,uM,=,0.8450980400142568,1,O=S(=O)(c1ccccc1)n1ccc2cc3c(cc21)CCNCC3
335,699809,10.1016/j.bmcl.2010.11.015,,,,Inhibition of CYP3A4,CN([C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1)S(=O)(=O)c1ccc(F)cc1,"(R)-2-(7-(4-fluoro-N-methylphenylsulfonamido)-6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl)acetic acid",34.0,uM,=,1.5314789170422551,1,O=S(=O)(N[C@@H]1CCc2cc3ccccc3n2C1)c1ccccc1
336,825128,10.1016/j.bmcl.2012.03.070,,,,Inhibition of human CYP3A4 in liver microsomes,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,"1-(4-{4-[2-(2,4-Dichloro-phenyl)-2-imidazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-ethanone (ketoconazole)",0.07,uM,=,-1.154901959985743,0,c1ccc(C2(Cn3ccnc3)OCC(COc3ccc(N4CCNCC4)cc3)O2)cc1
337,1491688,10.1124/dmd.112.045708,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 90 mins followed by substrate addition by LC-MS/MS analysis in presence of NADPH,COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1,"Acetic acid (2S,3S)-5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester",19.0,uM,=,1.2787536009528289,1,O=C1C[C@H](c2ccccc2)Sc2ccccc2N1
338,2156515,10.1021/acs.jmedchem.1c01272,,,,Inhibition of CYP3A4 in human liver microsomes using IPA as substrate preincubated for 10 mins followed by NADPH generating system addition and measured after 20 mins,COc1cc2c(cc1OC)CN(CCc1ccc(-n3nnc(-c4cc(OC)c(OC)cc4NC(=O)c4cc(=O)c5cc(-n6ccnc6)ccc5o4)n3)cc1)CC2,"N-(2-(2-(4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl)-6-(1H-imidazol-1-yl)-4-oxo-4H-chromene-2-carboxamide",3.341,uM,=,0.5238764756381313,1,O=C(Nc1ccccc1-c1nnn(-c2ccc(CCN3CCc4ccccc4C3)cc2)n1)c1cc(=O)c2cc(-n3ccnc3)ccc2o1
339,860549,10.1021/jm3003747,,,,Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins,CC(C)(C(N)=O)N1CCN(Cc2cc3nc(-c4c(F)cc(F)c5[nH]ccc45)nc(N4CCOCC4)c3s2)CC1,"2-(4-((2-(5,7-Difluoro-1H-indol-4-yl)-4-morpholinothieno-[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-methylpropanamide",0.6,uM,=,-0.2218487496163563,0,c1cc(-c2nc(N3CCOCC3)c3sc(CN4CCNCC4)cc3n2)c2cc[nH]c2c1
340,1467195,10.1021/jm5005336,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay,CN(C)Cc1ccc(/C=C/c2n[nH]c3cc([C@@H]4C[C@@]45C(=O)Nc4ccccc45)ccc23)cc1,"(1R*,2S*)-(E)-2-(3-(4-((Dimethylamino)methyl)styryl)-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-one",5.0,uM,=,0.6989700043360189,1,O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccccc3)n[nH]c2c1
341,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N(C)CCO)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, F-3",2.51,uM,=,0.3996737214810381,1,O=C1[C@H](Cc2ccccc2)N2C(=O)CNN(C(=O)NCc3ccccc3)[C@H]2CN1Cc1cccc2cc[nH]c12
342,1462160,10.1016/j.bmcl.2014.12.026,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,CCCn1cc(S(=O)(=O)c2ccc(CNC(=O)c3cc4ccncc4o3)cc2)cn1,"N-(4-(1-propyl-1H-pyrazol-4-ylsulfonyl)benzyl)furo[2,3-c]pyridine-2-carboxamide",5.7,uM,=,0.7558748556724915,1,O=C(NCc1ccc(S(=O)(=O)c2cn[nH]c2)cc1)c1cc2ccncc2o1
343,1614026,10.1016/j.bmcl.2016.09.043,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 1'-hydroxymidazolam metabolite formation using midazolam as substrate incubated for 10 mins by HPLC-MS method,COc1ccc(-c2ccc(CCNc3nc4cc(Cl)ccc4c(=O)n3C)cc2)cc1,7-Chloro-2-[2-(4'-methoxy-biphenyl-4-yl)-ethylamino]-3-methyl-3H-quinazolin-4-one,8.0,uM,=,0.9030899869919436,1,O=c1[nH]c(NCCc2ccc(-c3ccccc3)cc2)nc2ccccc12
344,776115,10.1016/j.bmcl.2011.09.074,,,,Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin,COc1ccccc1N1Cc2c(nc(C)c(CN)c2-c2ccc(Cl)cc2Cl)C1=O,"rac-3-(aminomethyl)-4-(2,4-dichlorophenyl)-6-(2-methoxyphenyl)-2-methyl-5H-pyrrolo[3,4-b]pyridin-7(6H)-one",1.5,uM,=,0.1760912590556812,1,O=C1c2nccc(-c3ccccc3)c2CN1c1ccccc1
345,2221809,10.1016/j.bmcl.2022.128625,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as substrate in presence of NADPH,CCC[C@H]1N(C(=O)c2cnccc2C)CCC[C@@]1(Oc1csc(C(F)(F)F)c1)C(=O)N1CCN(c2ccccc2OCCO)CC1,"(4-(2-(2-hydroxyethoxy)phenyl)piperazin-1-yl)((2R,3S)-1-(4-methylnicotinoyl)-2-propyl-3-(5-(trifluoromethyl)thiophen-3-yloxy)piperidin-3-yl)methanone",6.9,uM,=,0.8388490907372553,1,O=C(c1cccnc1)N1CCC[C@@](Oc2ccsc2)(C(=O)N2CCN(c3ccccc3)CC2)C1
346,1688648,10.1021/acs.jmedchem.7b00410,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 8 mins by LC/MS/MS analysis,Cc1cc(Oc2cncc(F)c2)cc(C(=O)Nc2ccc(F)cn2)n1,N-(5-fluoropyridin-2-yl)-4-(5-fluoropyridin-3-yloxy)-6-methylpicolinamide,4.3,uM,=,0.6334684555795865,1,O=C(Nc1ccccn1)c1cc(Oc2cccnc2)ccn1
347,766553,10.1016/j.bmcl.2011.06.102,,,,Inhibition of CYP3A4,CN(C)[C@H]1CC[C@@H](c2ccc(OCCCN3CCCCC3)cc2)CC1,"cis-N,N-dimethyl-4-(4-(3-(piperidin-1-yl)propoxy)phenyl)cyclohexanamine",50.0,uM,=,1.6989700043360187,1,c1cc(C2CCCCC2)ccc1OCCCN1CCCCC1
348,536049,10.1016/j.bmcl.2008.08.010,,,,Inhibition of human CYP3A4 by microtiter plate assays using PPR substrate,Cn1cc(S(=O)(=O)c2ccccc2)c2cc3c(cc21)CCNCC3,"1-methyl-3-(phenylsulfonyl)-1,5,6,7,8,9-hexahydroazepino[4,5-f]indole",13.0,uM,=,1.1139433523068367,1,O=S(=O)(c1ccccc1)c1c[nH]c2cc3c(cc12)CCNCC3
349,716789,10.1016/j.bmcl.2010.12.123,,,,Inhibition of CYP3A4,O=C(O)c1ccc(NC(=O)[C@H](C2CCCCC2)n2c(-c3ccc(Cl)cc3)nc3cc(F)c(F)cc32)c(F)c1,"(S)-4-(2-(2-(4-chlorophenyl)-5,6-difluoro-1H-benzo[d]imidazol-1-yl)-2-cyclohexylacetamido)-3-fluorobenzoic acid",39.0,uM,=,1.591064607026499,1,O=C(Nc1ccccc1)[C@H](C1CCCCC1)n1c(-c2ccccc2)nc2ccccc21
350,1651046,10.1021/acs.jmedchem.5b00507,,,,Inhibition of CYP3A4 (unknown origin),Cc1nccn1-c1ccc(OCC(=O)Nc2ccc(-c3ccccc3)cc2)cc1,N-(Biphenyl-4-yl)-2-(4-(2-methyl-1H-imidazol-1-yl)-phenoxy)acetamide,5.2,uM,=,0.7160033436347992,1,O=C(COc1ccc(-n2ccnc2)cc1)Nc1ccc(-c2ccccc2)cc1
351,718215,10.1021/jm1008659,,,,Inhibition of recombinant CYP3A4 after 30 mins,Cc1ccccc1C(=O)Nc1ccc(C(=O)Nc2nccs2)cc1,2-methyl-N-(4-(thiazol-2-ylcarbamoyl)phenyl)benzamide,1.4,uM,=,0.1461280356782379,1,O=C(Nc1ccc(C(=O)Nc2nccs2)cc1)c1ccccc1
352,1586157,10.1016/j.bmcl.2016.06.021,,,,Inhibition of CYP3A4 (unknown origin),Cc1cc(-c2cnn3c(NCC4CCOCC4)nc(NC4CCCC4)nc23)ccc1C(=O)NC1CC1,"4-(2-(Cyclopentylamino)-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)pyrazolo[1,5-a][1,3,5]triazin-8-yl)-N-cyclopropyl-2-methylbenzamide",19.0,uM,=,1.2787536009528289,1,O=C(NC1CC1)c1ccc(-c2cnn3c(NCC4CCOCC4)nc(NC4CCCC4)nc23)cc1
353,2120729,10.1021/acs.jmedchem.1c00104,,,,Inhibition of recombinant human CYP3A4,CN1CCN(c2ccc(Nc3ncc(Cl)c(Nc4cccc(C(F)(F)F)c4)n3)nc2)CC1,"5-chloro-N2-[5-(4-methylpiperazin-1-yl)-2-pyridyl]-N4-[3-(trifluoromethyl)phenyl]pyrimidine-2,4-diamine",7.13,uM,=,0.8530895298518656,1,c1ccc(Nc2ccnc(Nc3ccc(N4CCNCC4)cn3)n2)cc1
354,993439,10.6019/CHEMBL2448688,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,O=C(C1CC1)N(Cc1cccnc1)c1cc(F)cc(-c2nc3ccccc3s2)c1,,1.11,uM,=,0.0453229787866574,1,O=C(C1CC1)N(Cc1cccnc1)c1cccc(-c2nc3ccccc3s2)c1
355,1919651,,,,,"Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase",CN(C)Cc1ccc(-c2cccnc2)s1,Dimethyl-(5-pyridin-3-yl-thiophen-2-ylmethyl)-amine,219.0,uM,=,2.3404441148401185,1,c1cncc(-c2cccs2)c1
356,683838,10.1016/j.ejmech.2010.07.044,,,,Inhibition of CYP3A4,Fc1cccc2c1CCC1(CCN(c3ccc(-c4nnc(Cc5cccnc5)o4)nn3)CC1)O2,"5-Fluoro-1'-{6-[5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol-2-yl]pyridazin-3-yl}-3,4-dihydrospiro[chromene-2,4'-piperidine]",1.6,uM,=,0.2041199826559248,1,c1cncc(Cc2nnc(-c3ccc(N4CCC5(CCc6ccccc6O5)CC4)nn3)o2)c1
357,537847,10.1021/jm800888q,,,,Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,COC1CCc2cc(-c3cccnc3)ccc2C1,"3-(6-Methoxy-5,6,7,8-tetrahydronaphthalen-2-yl)pyridine",12.2,uM,=,1.0863598306747482,1,c1cncc(-c2ccc3c(c2)CCCC3)c1
358,820357,10.1021/jm300138g,,,,Inhibition of CYP3A4,CCN[C@H]1CC[C@@H](c2c[nH]c3ccc(NC(=N)c4cccs4)cc32)CC1.Cl,cis-N-(3-(4-(ethylamino)cyclohexyl)-1H-indol-5-yl)thiophene-2-carboximidamide hydrochloride,23.1,uM,=,1.3636119798921444,1,N=C(Nc1ccc2[nH]cc(C3CCCCC3)c2c1)c1cccs1
359,438600,10.1016/j.bmcl.2007.03.048,,,,Inhibition of CYP3A4 in microsomes,Cc1cc(-n2ccnc2)cc2[nH]c(-c3c(N[C@H](CO)Cc4ccccc4)cc[nH]c3=O)nc12,3-(6-(1H-imidazol-1-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)-4-((S)-1-hydroxy-3-phenylpropan-2-ylamino)pyridin-2(1H)-one,0.06,uM,=,-1.2218487496163564,0,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(-n3ccnc3)cc2[nH]1
360,543015,10.1016/j.bmcl.2008.12.114,,,,Inhibition of CYP3A4,C[C@@H]1CN(CC2(c3ccncc3)CC2)CCN1S(=O)(=O)c1ccc(C(C)(O)C(F)(F)F)cc1,"1,1,1-trifluoro-2-(4-((R)-2-methyl-4-((1-(pyridin-4-yl)cyclopropyl)methyl)piperazin-1-ylsulfonyl)phenyl)propan-2-ol",0.44,uM,=,-0.3565473235138126,0,O=S(=O)(c1ccccc1)N1CCN(CC2(c3ccncc3)CC2)CC1
361,450508,10.1021/jm070806a,,,,Inhibition of CYP3A4,CNCCN[C@H](c1cc(C)ccc1N1CCN(C(=O)[C@H](C)Cc2ccc(Cl)cc2F)CC1)C(C)C,1-{2-[(1S)-(methylaminoethyl)amino-2-methylpropyl]-4-methylphenyl}-4-[(2R)-methyl-3-(2-fluoro-4-chlorophenyl)propionyl]piperazine,9.0,uM,=,0.9542425094393248,1,O=C(CCc1ccccc1)N1CCN(c2ccccc2)CC1
362,2294674,10.1016/j.bmcl.2023.129205,,,,Inhibition of CYP3A4 (unknown origin),Cc1cccc(-c2[nH]c(NCc3cccc(Cl)c3F)nc2-c2ccc3[nH]ncc3c2)n1,N-(3-chloro-2-fluorobenzyl)-4-(1H-indazol-5-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-amine,8.0,uM,=,0.9030899869919436,1,c1ccc(CNc2nc(-c3ccc4[nH]ncc4c3)c(-c3ccccn3)[nH]2)cc1
363,1534761,,,,,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",COc1ncc(F)cc1CNc1ccc(Cc2c[nH]c3ncc(C)cc23)c(F)n1,PLX-5622,5.0,uM,=,0.6989700043360189,1,c1cncc(CNc2ccc(Cc3c[nH]c4ncccc34)cn2)c1
364,434960,10.1021/jm0700924,,,,Inhibition of CYP3A4,Clc1ccc(C2(c3ccc(-c4ncnc5[nH]cnc45)cc3)CCNCC2)cc1,6-(4-(4-(4-chlorophenyl)piperidin-4-yl)phenyl)-9H-purine,10.0,uM,=,1.0,1,c1ccc(C2(c3ccc(-c4ncnc5[nH]cnc45)cc3)CCNCC2)cc1
365,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1ccc(C(=O)N2CCOC[C@H]2Cc2cc(-n3nccn3)ccc2Cl)c(-n2nccn2)c1,"US9150566, 120",19.0,uM,=,1.2787536009528289,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
366,1640557,,,,,"null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.",Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1,1-[(2-Chloro-phenyl)-diphenyl-methyl]-1H-imidazole,0.3,uM,=,-0.5228787452803376,0,c1ccc(C(c2ccccc2)(c2ccccc2)n2ccnc2)cc1
367,52069,10.1021/jm021012t,,,,Inhibition of human cytochrome P450 3A4,Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C,"(3S,4aS,8aS)-2-[(2R,3R)-2-Hydroxy-3-(3-hydroxy-2-methyl-benzoylamino)-4-phenylsulfanyl-butyl]-decahydro-isoquinoline-3-carboxylic acid tert-butylamide",0.55,uM,=,-0.2596373105057561,0,O=C(N[C@H](CCN1CC[C@@H]2CCCC[C@@H]2C1)CSc1ccccc1)c1ccccc1
368,1923489,10.1021/acs.jmedchem.6b00708,,,,Inhibition of CYP3A4 (unknown origin),Cc1cc(-c2n[nH]c3cc(NC(=O)N[C@H](C)c4ccccc4)ncc23)ccn1,"(R)-1-(3-(2-methylpyridin-4-yl)-1H-pyrazolo[4,3-c]pyridin-6-yl)-3-(1-phenylethyl)urea",3.9,uM,=,0.5910646070264992,1,O=C(NCc1ccccc1)Nc1cc2[nH]nc(-c3ccncc3)c2cn1
369,1464796,10.1016/j.bmcl.2015.01.005,,,,Inhibition of recombinant human CYP3A4,Cn1c(N2CCO[C@@H]3CCC[C@H]32)nc(-c2ccncc2F)cc1=O,"6-(3-fluoropyridin-4-yl)-2-((4aR,7aR)-hexahydrocyclopenta[b][1,4]oxazin-4(4aH)-yl)-3-methylpyrimidin-4(3H)-one",445.0,uM,=,2.6483600109809315,1,O=c1cc(-c2ccncc2)nc(N2CCO[C@@H]3CCC[C@H]32)[nH]1
370,1618865,10.1021/acs.jmedchem.6b00624,,,,Inhibition of CYP3A4 in pooled human hepatic microsomes using testosterone substrate in presence of NADPH,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,"1-(4-{4-[2-(2,4-Dichloro-phenyl)-2-imidazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-ethanone (ketoconazole)",0.0285,uM,=,-1.5451551399914898,0,c1ccc(C2(Cn3ccnc3)OCC(COc3ccc(N4CCNCC4)cc3)O2)cc1
371,1797910,10.1021/acs.jmedchem.8b01326,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate/NADPH addition measured after 10 mins by LC-MS/MS analysis,COc1nc(N2C[C@H]3C(=O)N(C)C(=N)N[C@@]3(c3cc(-c4cccc(C#N)c4)cs3)C2)nc(C)c1F,"3-(5-((4aR,7aR)-6-(5-Fluoro-4-methoxy-6-methylpyrimidin-2-yl)-2-imino-3-methyl-4-oxooctahydro-7aH-pyrrolo[3,4-d]pyrimidin-7a-yl)thiophen-3-yl)benzonitrile",11.0,uM,=,1.0413926851582251,1,N=C1NC(=O)[C@@H]2CN(c3ncccn3)C[C@]2(c2cc(-c3ccccc3)cs2)N1
372,1587034,10.1021/acs.jmedchem.6b00203,,,,Inhibition of CYP3A4 (unknown origin),Cc1nn(C2CCN(C(=O)[C@@H](C)N)CC2)c(C)c1Nc1ncc(Cl)c(-c2cnn3ccccc23)n1,"(2R)-2-Amino-1-[4-(4-{[5-chloro-4-(pyrazolo[1,5-a]pyridin-3-yl)-2-pyrimidinyl]amino}-3,5-dimethyl-1H-pyrazol-1-yl)-1-piperidinyl]-1-propanone",1.0,uM,=,0.0,0,c1ccn2ncc(-c3ccnc(Nc4cnn(C5CCNCC5)c4)n3)c2c1
373,1984166,10.1016/j.bmc.2020.115349,,,,Inhibition of human full length CYP3A4 assessed using 7-benzyloxy-4 (trifluoromethyl)coumarin as substrate preincubated for 2 mins followed by substrate addition and measured for 2 mins by fluorometric analysis,CC(C)(C)OC(=O)NC(CSC(Cc1cccc2ccccc12)C(=O)NCc1cccnc1)Cc1cccc2ccccc12,Rac-tert-butyl N-[1-(1-naphthylmethyl)-2-[1-(1-naphthylmethyl)-2-oxo-2-(3-pyridylmethylamino)ethyl]sulfanyl-ethyl]carbamate,0.244,uM,=,-0.6126101736612706,0,O=C(NCc1cccnc1)C(Cc1cccc2ccccc12)SCCCc1cccc2ccccc12
374,803862,10.1016/j.bmcl.2011.11.054,,,,Inhibition of CYP3A4,CC(C)=CCn1c(N2CCC[C@H](N)C2)c(C#N)c2ncn(Cc3nccc4ccccc34)c(=O)c21,"(S)-6-(3-aminopiperidin-1-yl)-3-(isoquinolin-1-ylmethyl)-5-(3-methylbut-2-enyl)-4-oxo-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidine-7-carbonitrile",1.7,uM,=,0.2304489213782739,1,O=c1c2[nH]c(N3CCCCC3)cc2ncn1Cc1nccc2ccccc12
375,2221809,10.1016/j.bmcl.2022.128625,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as substrate in presence of NADPH,CCC[C@H]1N(C(=O)c2c(C(F)(F)F)ccnc2OCCO)CCC[C@@]1(Oc1csc(C(F)(F)F)c1)C(=O)N1CCN(c2ccccc2OCCO)CC1,"((2R,3S)-1-(2-(2-hydroxyethoxy)-4-(trifluoromethyl)nicotinoyl)-2-propyl-3-(5-(trifluoromethyl)thiophen-3-yloxy)piperidin-3-yl)(4-(2-(2-hydroxyethoxy)phenyl)piperazin-1-yl)methanone",50.0,uM,=,1.6989700043360187,1,O=C(c1cccnc1)N1CCC[C@@](Oc2ccsc2)(C(=O)N2CCN(c3ccccc3)CC2)C1
376,2156515,10.1021/acs.jmedchem.1c01272,,,,Inhibition of CYP3A4 in human liver microsomes using IPA as substrate preincubated for 10 mins followed by NADPH generating system addition and measured after 20 mins,COc1cc2c(cc1OC)CN(CCc1ccc(-n3nnc(-c4cc(OC)c(OC)cc4NC(=O)c4ccc(-n5ccnc5)cc4)n3)cc1)CC2,"N-(2-(2-(4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl)-4-(1H-imidazol-1-yl)benzamide",0.516,uM,=,-0.2873502983727886,0,O=C(Nc1ccccc1-c1nnn(-c2ccc(CCN3CCc4ccccc4C3)cc2)n1)c1ccc(-n2ccnc2)cc1
377,828928,10.1016/j.bmcl.2012.06.022,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,C#CCNc1nc2ccc(C(=O)N(CC#C)C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1,"Thiazol-5-ylmethyl(2S,3R)-4-(2-(ethynylamino)-N-(prop-2-ynyl)benzo[d]oxazole-6-carboxamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate",0.038,uM,=,-1.42021640338319,0,O=C(N[C@H](CCNC(=O)c1ccc2ncoc2c1)Cc1ccccc1)OCc1cncs1
378,1276541,10.1016/j.bmcl.2013.09.041,,,,Inhibition of CYP3A4 (unknown origin) after 5 mins,Cc1cc(-c2ccc(NS(=O)(=O)c3cc(Cl)cc(Cl)c3)cc2)ccn1,"3,5-dichloro-N-(4-(2-methylpyridin-4-yl)phenyl)benzenesulfonamide",4.7,uM,=,0.6720978579357175,1,O=S(=O)(Nc1ccc(-c2ccncc2)cc1)c1ccccc1
379,1362864,10.1016/j.bmcl.2014.04.049,,,,Inhibition of CYP3A4 (unknown origin),CC1(C)[C@@H]2CC[C@@]1(C)c1c2c(=O)n(-c2ccccc2)n1Cc1ccccc1,"(4S,7R)-1-Benzyl-7,8,8-trimethyl-2-phenyl-1,2,4,5,6,7-hexahydro-4,7-methano-indazol-3-one",7.7,uM,=,0.8864907251724818,1,O=c1c2c(n(Cc3ccccc3)n1-c1ccccc1)C1CC[C@H]2C1
380,612188,10.1016/j.bmcl.2009.12.071,,,,Inhibition of CYP3A4,Cn1cnc(C(=O)N(Cc2ccc(F)c(C(F)(F)F)c2)[C@@H]2C[C@H]3CNC[C@H]3C2)c1,(endo)-N-(4-fluoro-3-(trifluoromethyl)benzyl)-1-methyl-N-(octahydrocyclopenta[c]pyrrol-5-yl)-1H-imidazole-4-carboxamide,8.2,uM,=,0.9138138523837168,1,O=C(c1c[nH]cn1)N(Cc1ccccc1)[C@@H]1C[C@H]2CNC[C@H]2C1
381,2241412,10.1016/j.ejmech.2021.113981,,,,Inhibition of CYP3A4 in human liver microsomes assessed as reduction in 6-beta-hydroxy-testosterone formation using testosterone as substrate preincubated for 20 mins in absence of NADPH followed by incubation with substrate for 10 mins by LC-MS/MS analysis,O[C@@H](c1cc(C(F)(F)F)nc2c(C(F)(F)F)cccc12)[C@H]1CCCCN1,"(S)-(2,8-bis(trifluoromethyl)quinolin-4-yl)((R)-piperidin-2-yl)methanol",19.0,uM,=,1.2787536009528289,1,c1ccc2c(C[C@H]3CCCCN3)ccnc2c1
382,1640557,,,,,"null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.",CCCCOCCOCCOCc1cc2c(cc1CCC)OCO2,SID17389754,3.0,uM,=,0.4771212547196624,1,c1ccc2c(c1)OCO2
383,2135244,10.1021/acs.jmedchem.1c01452,,,,Inhibition of human recombinant CYP3A4 by fluorescence assay,COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC,"2-(3,4-Dimethoxy-phenyl)-5-{[2-(3,4-dimethoxy-phenyl)-ethyl]-methyl-amino}-2-isopropyl-pentanenitrile",5.7,uM,=,0.7558748556724915,1,c1ccc(CCCCNCCc2ccccc2)cc1
384,657984,10.1021/jm100482n,,,,Inhibition of CYP3A4 in human liver microsomes measured immediately,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(N)=O)ncn4-5)CC3)cccc2n1,"6-(2-(4-(2-methylquinolin-5-yl)piperazin-1-yl)ethyl)-4H-benzo[b]imidazo[1,5-d][1,4]oxazine-3-carboxamide",100.0,uM,=,2.0,1,c1cc(CCN2CCN(c3cccc4ncccc34)CC2)c2c(c1)-n1cncc1CO2
385,619265,10.1016/j.bmcl.2009.07.002,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate,Cc1cccc(C)c1CNc1nc(N2CCCC2=O)cc2c(C)c(C)[nH]c12,"1-(7-(2,6-dimethylbenzylamino)-2,3-dimethyl-1H-pyrrolo[2,3-c]pyridin-5-yl)pyrrolidin-2-one",1.8,uM,=,0.255272505103306,1,O=C1CCCN1c1cc2cc[nH]c2c(NCc2ccccc2)n1
386,1475768,10.1021/jm5017413,,,,Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system,Cc1nc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)[C@@H]3C)cs1,"(R)-(8-Methyl-3-(2-methylthiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(thiophen-2-yl)-phenyl)methanone",50.0,uM,=,1.6989700043360187,1,O=C(c1ccc(-c2cccs2)cc1)N1CCn2c(nnc2-c2cscn2)C1
387,2017934,10.1021/acs.jmedchem.0c00834,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis,Cc1c(N2CCCCC2)nc2ccc(Br)cc2c1C(=O)NCC(CCC(=O)O)c1c(F)ccc(F)c1Cl,"(+)-5-({[6-Bromo-3-methyl-2-(piperidin-1-yl)quinolin-4-yl]carbonyl}amino)-4-(2-chloro-3,6-difluorophenyl)pentanoic acid",12.0,uM,=,1.0791812460476249,1,O=C(NCCc1ccccc1)c1cc(N2CCCCC2)nc2ccccc12
388,350785,10.1016/j.bmcl.2006.02.004,,,,Inhibition of human recombinant CYP3A4,CCCc1ccc(C(=O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)-1-(4-propylphenyl)butan-1-one,7.9,uM,=,0.8976270912904415,1,O=C(CCCN1CCC(C(c2ccccc2)c2ccccc2)CC1)c1ccccc1
389,509824,10.1021/jm800546t,,,,Inhibition of recombinant CYP3A4 expressed in insect microsomes after 45 mins in presence of BZR substrate,O=C(N[C@H](Cc1csc2ccccc12)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1,"(R)-N-(1-(1,4'-bipiperidin-1'-yl)-3-(benzo[b]thiophen-3-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide",0.87,uM,=,-0.0604807473813814,0,O=C(N[C@H](Cc1csc2ccccc12)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
390,305744,10.1021/jm049696n,,,,Inhibitory concentration value against human cytochrome P-450 3A4,Cc1ccsc1-c1cccnc1,3-(3-Methyl-thiophen-2-yl)-pyridine,6.0,uM,=,0.7781512503836436,1,c1cncc(-c2cccs2)c1
391,1541293,10.1016/j.bmc.2015.11.017,,,,Inhibition of human recombinant CYP3A4 by fluorescence assay,COCCN1CCN(C(=O)c2nc3cc(C(F)(F)F)cc([N+](=O)[O-])c3s2)CC1,4-(2-Methoxyethyl)piperazin-1-yl)(7-nitro-5-(trifluoromethyl)benzo[d]thiazol-2-yl)methanone,19.5,uM,=,1.290034611362518,1,O=C(c1nc2ccccc2s1)N1CCNCC1
392,1475768,10.1021/jm5017413,,,,Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system,Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)[C@@H]3C)n1,"(R)-(8-Methyl-3-(3-methyl-1,2,4-thiadiazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(thiophen-2-yl)phenyl)-methanone",80.0,uM,=,1.9030899869919435,1,O=C(c1ccc(-c2cccs2)cc1)N1CCn2c(nnc2-c2ncns2)C1
393,859942,10.1021/jm300122u,,,,Inhibition of human CYP3A4 using testosterone as substrate after 45 mins,NC1C[C@H]2CC[C@@H](C1)N2C(=O)[C@H](Cc1ccc(Br)cc1)NC(=O)C1(c2ccc(OC(F)(F)F)cc2)CC1,"N-((2S)-1-((1R,5S)-3-amino-8-azabicyclo[3.2.1]octan-8-yl)-3-(4-bromophenyl)-1-oxopropan-2-yl)-1-(4-(trifluoromethoxy)phenyl)cyclopropanecarboxamide",2.9,uM,=,0.4623979978989561,1,O=C([C@H](Cc1ccccc1)NC(=O)C1(c2ccccc2)CC1)N1[C@@H]2CCC[C@H]1CC2
394,619265,10.1016/j.bmcl.2009.07.002,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate,Cc1cccc(C)c1CNc1nccn2c(C)c(C)cc12,"N-(2,6-dimethylbenzyl)-6,7-dimethylpyrrolo[1,2-a]pyrazin-1-amine",1.6,uM,=,0.2041199826559248,1,c1ccc(CNc2nccn3cccc23)cc1
395,2062192,10.1016/j.bmcl.2016.04.018,,,,Inhibition of human liver microsomes CYP3A4 using testosterone as substrate by MUX-MS/MS analysis,Cc1cc(-c2ccc3c(c2)-c2nnc(Nc4cccc(Cl)c4)n2CCO3)ccn1,"N-(3-chlorophenyl)-10-(2-methylpyridin-4-yl)-5,6-dihydrobenzo[f][1,2,4]triazolo[4,3-d][1,4]oxazepin-3-amine",11.8,uM,=,1.0718820073061257,1,c1ccc(Nc2nnc3n2CCOc2ccc(-c4ccncc4)cc2-3)cc1
396,1488448,10.1124/dmd.110.035071,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam substrate by HPLC-MS/MS method,CC(=O)N1CCN([C@H]2CCN(C(=O)N(C)[C@H](C)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)[C@@H](c3ccc(F)cc3C)C2)CC1O,"(2R,4S)-4-(4-acetyl-3-hydroxypiperazin-1-yl)-N-((R)-1-(3,5-bis(trifluoromethyl)phenyl)ethyl)-2-(4-fluoro-2-methylphenyl)-N-methylpiperidine-1-carboxamide",8.22,uM,=,0.9148718175400504,1,O=C(NCc1ccccc1)N1CC[C@H](N2CCNCC2)C[C@@H]1c1ccccc1
397,1499751,10.1021/acs.jmedchem.5b00424,,,,Inhibition of CYP3A4 (unknown origin),COc1cccc(CC(=O)Nc2nc(-c3ccncc3)cs2)c1,2-(3-methoxyphenyl)-N-(4-(pyridin-4-yl)thiazol-2-yl)acetamide,0.75,uM,=,-0.1249387366082999,0,O=C(Cc1ccccc1)Nc1nc(-c2ccncc2)cs1
398,1301328,10.6019/CHEMBL3137440,,,,DNDI: CYP Inhibition,CCC(C(C)O)N1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1,,17.0,uM,=,1.230448921378274,1,c1ccc(N(c2cccnc2)C2CCNCC2)cc1
399,567194,10.1021/jm8012757,,,,Inhibition of human CYP3A4 using PPR substrate,CCNCc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O,4-(7-Chloro-quinolin-4-ylamino)-2-ethylaminomethyl-phenol,100.0,uM,=,2.0,1,c1ccc(Nc2ccnc3ccccc23)cc1
400,1747252,10.1021/acs.jmedchem.7b01236,,,,Inhibition of human CYP3A4 using testosterone as substrate preincubated for 30 mins,Cc1cc(CC(=O)Nc2ccn(Cc3ccc(C#N)cn3)n2)ccc1OC(F)(F)F,N-(1-((5-Cyanopyridin-2-yl)methyl)-1H-pyrazol-3-yl)-2-(3-methyl-4-(trifluoromethoxy)-phenyl)acetamide,17.0,uM,=,1.230448921378274,1,O=C(Cc1ccccc1)Nc1ccn(Cc2ccccn2)n1
401,1698217,10.1021/acs.jmedchem.7b01870,,,,Inhibition of CYP3A4 in human liver microsomes using DBF as substrate by fluorescence assay,N#CC1(NC(=O)[C@H](Cc2ccc(OC(F)(F)F)c(Cl)c2)NC(=O)c2cnn(-c3cccnc3)n2)CC1,N-(1-Cyanocyclopropyl)-3-chloro-4-O-(trifluoromethyl)-Nalpha-[(2-(pyridin-3-yl)-2H-triazol-4-ylcarbonyl]-L-tyrosinamide,8.0,uM,=,0.9030899869919436,1,O=C(N[C@@H](Cc1ccccc1)C(=O)NC1CC1)c1cnn(-c2cccnc2)n1
402,1466989,10.1021/jm501719e,,,,Inhibition of human CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)coumarin as substrate assessed as formation of 7-hydroxy-4-trifluoromethylcoumarin incubated for 2 mins prior to NADPH addition by fluorimetric assay,Cl.Fc1cccc(CCCNCCc2ccnc(-n3ccnc3)n2)c1,N-2-[2-(1H-Imidazol-1-yl)pyrimidin-4-yl]ethyl-3-(3-fluorophenyl)-propan-1-amine Dihydrochloride,2.5,uM,=,0.3979400086720376,1,c1ccc(CCCNCCc2ccnc(-n3ccnc3)n2)cc1
403,2246941,10.1021/acs.jmedchem.1c02132,,,,Inhibition of CYP3A4 (unknown origin) incubated for 10 mins in presence of NADPH by LC-MS/MS analysis,COC(=O)Nc1cc(-c2ccc(OC[C@@](C)(N)CC(C)C)c(C3CC3)c2)ccn1,"(S)-methyl 4-(4-(2-amino-2,4-dimethylpentyloxy)-3-cyclopropylphenyl)pyridin-2-ylcarbamate",16.3,uM,=,1.212187604403958,1,c1cc(-c2ccncc2)cc(C2CC2)c1
404,1988423,10.1021/acsmedchemlett.0c00239,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by NADPH addition and measured after 10 mins by LC-MS/MS analysis,CNC(=O)[C@H](C)Cn1cnc2ccc(-c3cnc(OC)c(NS(=O)(=O)c4ccc(F)cc4Cl)c3)cc2c1=O,"(R)-3-(6-(5-(2-chloro-4-fluorophenylsulfonamido)-6-methoxypyridin-3-yl)-4-oxoquinazolin-3(4H)-yl)-N,2-dimethylpropanamide",23.3,uM,=,1.3673559210260189,1,O=c1[nH]cnc2ccc(-c3cncc(NS(=O)(=O)c4ccccc4)c3)cc12
405,499144,10.1016/j.bmc.2009.03.041,,,,Inhibition of CYP3A4,NC(=O)C(Nc1c(Nc2ccncc2)c(=O)c1=O)c1ccccc1,"2-{[3,4-Dioxo-2-(pyridin-4-ylamino)cyclobut-1-en-1-yl]amino}-2-phenylacetamide",8.6,uM,=,0.9344984512435676,1,O=c1c(NCc2ccccc2)c(Nc2ccncc2)c1=O
406,625944,10.1016/j.bmcl.2010.02.080,,,,Inhibition of CYP3A4 preincubated for 30 mins,O=S(=O)(c1ccc(Cl)cc1)C12CCC(O)CC1COc1c(F)ccc(F)c12,"rac-10a-(4-chlorophenylsulfonyl)-1,4-difluoro-6a,7,8,9,10,10a-hexahydro-6H-benzo[c]chromen-8-ol",9.1,uM,=,0.9590413923210936,1,O=S(=O)(c1ccccc1)C12CCCCC1COc1ccccc12
407,759505,10.1016/j.bmcl.2011.06.015,,,,Inhibition of CYP3A4,Nc1ccccc1NC(=O)c1ccc(CNc2nccc(-c3cccnc3)n2)cc1,N-(2-aminophenyl)-4-((4-(pyridin-3-yl)pyrimidin-2-ylamino)methyl)benzamide,0.57,uM,=,-0.2441251443275086,0,O=C(Nc1ccccc1)c1ccc(CNc2nccc(-c3cccnc3)n2)cc1
408,1640556,,,,,"null: Microsomal preparation: One lobe of fresh pig liver is obtained (e.g., at about the time of slaughter from a food-processing company) and immediately placed in ice cold 15 mM KH2PO4/250 mM sucrose (pH 7.4) and kept on ice during transportation. A 10 g sample of liver is minced and homogenized in 30 mL of homogenization buffer (15 mM KH2PO4/250 mM sucrose) using a Tekmar homoginizer or equivalent by pulsing 3 times with 20 second pulses. This procedure is repeated for a total of 8x10 g samples of pig liver. The remaining pig liver may be stored at -80 C. The homogenates from the 8 samples are pooled and centrifuged at 13,000xg for 20 minutes at 4 C. to remove crude debris. The supernatant is further centrifuged at 100,000xg for 70 minutes at 4° C. The microsomal pellets are re-suspended into 50 mL of 150 mM KH2PO4/1 mM DTT (pH 7.4) and 1 mL aliquots are stored at -80 C.100-150 ug of pig liver microsomal protein in 150 mM KH2PO4 is incubated at 37° C.",CC(C)(C)C(=O)C(Oc1ccc(Cl)cc1)n1ccnc1,SID29217911,47.5,uM,=,1.6766936096248666,1,c1ccc(OCn2ccnc2)cc1
409,471117,10.1016/j.bmc.2007.10.061,,,,Inhibition of CYP3A4,Nc1nccn2c1c(-c1ccc3ccc(-c4ccccc4)nc3c1)nc2[C@H]1C[C@H](CN2CCC2)C1,"trans-3-(3-azetidin-1-ylmethylcyclobutyl)-1-(2-phenylquinolin-7-yl)-imidazo[1,5-a]pyrazin-8-ylamine",17.0,uM,=,1.230448921378274,1,c1ccc(-c2ccc3ccc(-c4nc([C@H]5C[C@H](CN6CCC6)C5)n5ccncc45)cc3n2)cc1
410,595557,10.1016/j.bmcl.2009.10.084,,,,Inhibition of CYP3A4 using BFC as a substrate,Cc1ccc(C(=O)/N=C(\Nc2ccc3oc(C)cc3c2)N[C@H]2CCCCN(CC(=O)N3CCCC3)C2=O)cn1,(S)-6-methyl-N-((2-methylbenzofuran-5-ylamino)(2-oxo-1-(2-oxo-2-(pyrrolidin-1-yl)ethyl)azepan-3-ylamino)methylene)nicotinamide,7.0,uM,=,0.8450980400142568,1,O=C(/N=C(\Nc1ccc2occc2c1)N[C@H]1CCCCN(CC(=O)N2CCCC2)C1=O)c1cccnc1
411,464748,10.1016/j.bmcl.2008.01.126,,,,Inhibition of CYP3A4 in presence of 7-benzyloxyresorufin substrate,COc1ccc(N2C(=O)[C@@H](Cc3ccc(OCCc4nc(-c5ccccc5)oc4C)cc3)[C@H]2C(=O)O)cc1,"(2S,3S)-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-(4-methoxyphenyl)-4-oxoazetidine-2-carboxylic acid",26.0,uM,=,1.414973347970818,1,O=C1[C@@H](Cc2ccc(OCCc3coc(-c4ccccc4)n3)cc2)CN1c1ccccc1
412,552281,10.1016/j.bmcl.2008.04.036,,,,Inhibition of CYP3A4,COc1cccc(-c2cn(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](N)c3ccccc3)c2=O)c1F,"3-((R)-2-Amino-2-phenyl-ethyl)-5-(2-fluoro-3-methoxy-phenyl)-1-(2-fluoro-6-trifluoromethyl-benzyl)-1H-pyrimidine-2,4-dione",0.1,uM,=,-1.0,0,O=c1c(-c2ccccc2)cn(Cc2ccccc2)c(=O)n1CCc1ccccc1
413,1469227,10.1021/jm501436m,,,,Inhibition of CYP3A4 (unknown origin),NC(=O)C1CCN(c2c(Cl)cncc2Cl)CC1,"1-(3,5-dichloro-4-pyridyl)piperidine-4-carboxamide",7.0,uM,=,0.8450980400142568,1,c1cc(N2CCCCC2)ccn1
414,355280,10.1016/j.bmcl.2006.02.020,,,,Inhibition of CYP3A4,CCN(CC)[C@H](C)[C@@H](c1ccc2cc(OCC3(C(=O)O)CCCC3)ccc2c1)n1ccnc1,"1-((6-((1R,2R)-2-(diethylamino)-1-(1H-imidazol-1-yl)propyl)naphthalen-2-yloxy)methyl)cyclopentanecarboxylic acid",1.01,uM,=,0.0043213737826425,1,c1cn(Cc2ccc3cc(OCC4CCCC4)ccc3c2)cn1
415,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",O=C(c1cccc(Cl)c1-n1nccn1)N1CCOC[C@H]1Cc1cc(-c2ncon2)ccc1F,"US9150566, 180",36.0,uM,=,1.5563025007672873,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2ncon2)c1
416,1920115,10.1016/j.ejmech.2018.11.045,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by substrate addition measured after 10 mins in presence of NADPH by LC-MS/MS analysis,Cc1csc2c1c(=O)n(CCc1ccccc1)c(=O)n2CC1CCCO1,"5-methyl-3-phenethyl-1-((tetrahydrofuran-2-yl)methyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione",16.0,uM,=,1.2041199826559248,1,O=c1c2ccsc2n(CC2CCCO2)c(=O)n1CCc1ccccc1
417,1465541,10.1016/j.bmcl.2015.01.051,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(CC6CN(C7CCC7)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O,"(1S,4R,5R,6R,8R,10S,11R,12S,13R,16R,18S,21R)-18-{[(2S)-4-[(1-cyclobutylazetidin-3-yl)methyl]morpholin-2-yl]oxy}-8-[(1S)-1-ethoxy-2-hydroxy-2-methylpropyl]-4,6,12,17,17-pentamethyl-9-oxahexacyclo[11.9.0.0^{1,21}.0^{4,12}.0^{5,10}.0^{16,21}]docosan-11-ol",13.0,uM,=,1.1139433523068367,1,C1CC(N2CC(CN3CCO[C@@H](O[C@H]4CC[C@]56C[C@]57CCC5C(C[C@H]8OCCC[C@H]58)[C@@H]7CC[C@H]6C4)C3)C2)C1
418,51903,10.1021/jm020557k,,,,Concentration required to inhibit cytochrome P450 3A4.,CCCCOc1ccc(-c2cc[nH]c2)cc1,3-(4-Butoxy-phenyl)-1H-pyrrole,7.52,uM,=,0.8762178405916422,1,c1ccc(-c2cc[nH]c2)cc1
419,51916,10.1016/j.bmcl.2003.11.005,,,,Inhibition of cytochrome P450 3A4,c1cc(CCCOc2ccc(-n3ccnc3)cc2)ccn1,4-[3-(4-Imidazol-1-yl-phenoxy)-propyl]-pyridine,0.344,uM,=,-0.4634415574284699,0,c1cc(CCCOc2ccc(-n3ccnc3)cc2)ccn1
420,834929,10.1016/j.bmcl.2012.07.020,,,,Inhibition of CYP3A4,CCCS(=O)(=O)c1ccc2[nH]c(-c3ccc(-c4ccccc4)cc3)nc2c1,2-(biphenyl-4-yl)-5-(propylsulfonyl)-1H-benzo[d]imidazole,2.9,uM,=,0.4623979978989561,1,c1ccc(-c2ccc(-c3nc4ccccc4[nH]3)cc2)cc1
421,1625607,10.1016/j.bmcl.2016.10.016,,,,Inhibition of human Cyp3A4 using testosterone as substrate by LC-MS/MS analysis,CS(=O)(=O)CS(=O)(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,"1-(4-{[(2S,4R)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)-4-methanesulfonylmethanesulfonylpiperazine",0.151,uM,=,-0.8210230527068306,0,c1ccc([C@]2(Cn3ccnc3)OC[C@@H](COc3ccc(N4CCNCC4)cc3)O2)cc1
422,51918,10.1016/j.bmcl.2003.08.027,,,,Inhibition of Cytochrome P450 3A4 with midazolam (4-OH),CCOC(=O)CCCn1c(=O)nc2n(CCCCOC(=O)C[C@@H]3CC4C5CC[C@H](O)C5CCC4[C@@]4(C)CCC(=O)C=C34)c3ccccc3cc-2c1=O,"4-(10-{4-[2-((6S,10R,17S)-17-Hydroxy-10-methyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-6-yl)-acetoxy]-butyl}-2,4-dioxo-4,10-dihydro-2H-pyrimido[4,5-b]quinolin-3-yl)-butyric acid ethyl ester",1.0,uM,=,0.0,0,O=C1C=C2C(CC1)C1CCC3CCCC3C1C[C@H]2CC(=O)OCCCCn1c2nc(=O)[nH]c(=O)c-2cc2ccccc21
423,1623139,10.1021/acsmedchemlett.6b00314,,,,Inhibition of CYP3A4 (unknown origin),Cc1nccn1-c1ccc(-c2cn(CC(=O)Nc3cccc(Cl)c3Cl)nn2)cc1,"N-(2,3-dichlorophenyl)-2-(4-(4-(2-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)acetamide",15.0,uM,=,1.1760912590556811,1,O=C(Cn1cc(-c2ccc(-n3ccnc3)cc2)nn1)Nc1ccccc1
424,595638,10.1016/j.bmcl.2009.09.096,,,,Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH,COc1ccc2c(OCc3nnc4ccc(-c5cc(F)c(F)c(F)c5)nn34)ccnc2c1,"7-methoxy-4-((6-(3,4,5-trifluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy)quinoline",2.0,uM,=,0.3010299956639812,1,c1ccc(-c2ccc3nnc(COc4ccnc5ccccc45)n3n2)cc1
425,2204356,10.1016/j.bmc.2022.116894,,,,Inhibition of CYP3A4 (unknown origin) using BOMCC as a substrate,O=C(NCCNc1cc(-c2cn(-c3ccccc3)nc2-c2cccc(O)c2)ccn1)Nc1cccc(C(F)(F)F)c1,1-(2-((4-(3-(3-Hydroxyphenyl)-1-phenyl-1H-pyrazol-4-yl)pyridin-2-yl)amino)ethyl)-3-(3-(trifluoromethyl)phenyl)urea,20.52,uM,=,1.3121773564397787,1,O=C(NCCNc1cc(-c2cn(-c3ccccc3)nc2-c2ccccc2)ccn1)Nc1ccccc1
426,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",COc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cc(-n3nccn3)ccc2F)c1,"US9150566, 131",35.0,uM,=,1.5440680443502757,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
427,1587699,10.1021/acs.jmedchem.5b01891,,,,Inhibition of recombinant human CYP3A4 by P450-Glo luminescence assay,COc1cccc(-c2nc(OC)c3ccccc3n2)c1,4-Methoxy-2-(3-methoxyphenyl)quinazoline,12.86,uM,=,1.1092409685882032,1,c1ccc(-c2ncc3ccccc3n2)cc1
428,443644,10.1016/j.bmc.2007.03.047,,,,Inhibition of human recombinant CYP3A4,C/C(=C\COc1ccc2ccc(=O)oc2c1)C/C=C/C(C)C,"(E)-3-(3,7-dimethylocta-2,6-dienyl)-4-hydroxy-2H-chromen-2-one",42.93,uM,=,1.632760888479439,1,O=c1ccc2ccccc2o1
429,961188,10.1016/j.bmc.2013.03.069,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis,O=c1[nH]c2cc(Br)ccc2c2[nH]c(-c3ccccc3Cl)nc12,"7-bromo-2-(2-chlorophenyl)-1H-imidazo[4,5-c]quinolin-4(5H)-one",24.0,uM,=,1.380211241711606,1,O=c1[nH]c2ccccc2c2[nH]c(-c3ccccc3)nc12
430,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)NCCc6ccccc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, D-75",10.5,uM,=,1.021189299069938,1,O=C(NCCc1ccccc1)Nc1ccc(-c2c[nH]c3c(CN4C[C@@H]5N(C(=O)NCc6ccccc6)NCC(=O)N5[C@@H](Cc5ccccc5)C4=O)cccc23)cc1
431,519907,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,Cc1nc2c(NCc3ccccc3)cc(-n3ccccc3=O)cn2c1C,"1-(8-(benzylamino)-2,3-dimethylimidazo[1,2-a]pyridin-6-yl)pyridin-2(1H)-one",19.0,uM,=,1.2787536009528289,1,O=c1ccccn1-c1cc(NCc2ccccc2)c2nccn2c1
432,1859912,10.1021/acsmedchemlett.9b00114,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 10 mins in presence of NADPH by UHPLC-MS/MS analysis,Cn1cc(-c2ccc(N3CCC(C4c5c(F)cccc5-c5cncn54)CC3)c(F)c2)cn1,"6-fluoro-5-(1-(2-fluoro-4-(1-methyl-1H-pyrazol-4-yl)phenyl)piperidin-4-yl)-5H-imidazo[5,1-a]isoindole",0.35,uM,=,-0.4559319556497244,0,c1ccc2c(c1)-c1cncn1C2C1CCN(c2ccc(-c3cn[nH]c3)cc2)CC1
433,1362983,10.1021/ml400492t,,,,Inhibition of CYP3A4 in human liver microsomes assessed as midazolam conversion to 1'-hydroxy midazolam preincubated for 10 mins followed by NADPH addition measured after 15 mins by LC-MS/MS analysis,Fc1ccc2c(c1)c1c(n2CCCOc2ccc(Cl)cc2)CCNC1,"5-(3-(4-chlorophenoxy)propyl)-8-fluoro-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole",25.0,uM,=,1.3979400086720375,1,c1ccc(OCCCn2c3c(c4ccccc42)CNCC3)cc1
434,1785637,,,,,Inhibition of CYP3A4 (unknown origin),CCOC(=O)CNC(=O)N1CCN(c2ccc(/C=C/c3cc(Cl)cc(Cn4ccnc4)c3)cc2)CC1,ethyl 2-(4-(4-(3-((1H-imidazol-1-yl)methyl)-5-chlorostyryl)phenyl)piperazine-1-carboxamido)acetate,1.67,uM,=,0.2227164711475832,1,C(=C/c1cccc(Cn2ccnc2)c1)\c1ccc(N2CCNCC2)cc1
435,741723,10.1021/jm1013874,,,,Inhibition of CYP3A4,O=c1c2ccccc2c(Cc2ccc(Cl)cc2)nn1C[C@H]1CCCN1CCCCc1ccc(OCCCN2CCCCCC2)cc1,4-[(4-Chlorophenyl)methyl]-2-({(2R)-1-[4-(4-{[3-(hexahydro-1H-azepin-1-yl)propyl]oxy}phenyl)butyl]-2-pyrrolidinyl}methyl)-1(2H)-phthalazinone,0.3,uM,=,-0.5228787452803376,0,O=c1c2ccccc2c(Cc2ccccc2)nn1C[C@H]1CCCN1CCCCc1ccc(OCCCN2CCCCCC2)cc1
436,2246941,10.1021/acs.jmedchem.1c02132,,,,Inhibition of CYP3A4 (unknown origin) incubated for 10 mins in presence of NADPH by LC-MS/MS analysis,CC(=O)Nc1cc(-c2ccc(OC[C@@H](N)CC(C)C)c(OC(F)(F)F)c2)ccn1,(S)-N-(4-(4-((2-amino-4-methylpentyl)oxy)-3-(trifluoromethoxy)phenyl)pyridin-2-yl)acetamide,0.23,uM,=,-0.6382721639824072,0,c1ccc(-c2ccncc2)cc1
437,969015,10.1016/j.bmcl.2013.04.012,,,,Inhibition of CYP3A4 (unknown origin) expressed in baculovirus-infected insect cell microsomes assessed as benzoylresorufin conversion to resorufin metabolites after 45 mins by fluorescence assay,Cc1cc(C[C@@H](NC(=O)N2CCC(c3cc4ccccc4[nH]c3=O)CC2)C(=O)N2CCN(C3CCN(C)CC3)CC2)cc2cn[nH]c12,"(R)-N-(3-(7-methyl-1H-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)piperazin-1-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide",24.0,uM,=,1.380211241711606,1,O=C(N[C@H](Cc1ccc2[nH]ncc2c1)C(=O)N1CCN(C2CCNCC2)CC1)N1CCC(c2cc3ccccc3[nH]c2=O)CC1
438,1487665,10.1124/dmd.112.045302,,,,Reversible inhibition of testosterone 6beta-hydroxylase activity of human recombinant CYP3A4 in presence of human P450 oxidoreductase and b5,Cc1ccc(-c2c(-c3nn(C)c4ncnc(N5CC[C@H](N6CCCCC6)C5)c34)cnn2C)cc1,"1-methyl-3-[1-methyl-5-(4-methylphenyl)-1H-pyrazol-4-yl]-4-[(3S)-3-piperidin-1-ylpyrrolidin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine",0.69,uM,=,-0.1611509092627447,0,c1ccc(-c2[nH]ncc2-c2n[nH]c3ncnc(N4CC[C@H](N5CCCCC5)C4)c23)cc1
439,675407,10.1016/j.bmcl.2010.08.142,,,,Inhibition of CYP3A4,NC(=O)[C@]12CC3CC(C1)[C@@H](OC(=O)N1CC[C@@H](Nc4ncccc4C(F)(F)F)C1)C(C3)C2,(R)-3-(3-Trifluoromethyl-pyridin-2-ylamino)-pyrrolidine-1-carboxylic acid 5-carbamoyl-adamantan-2-yl ester,3.3,uM,=,0.5185139398778875,1,O=C(OC1C2CC3CC(C2)CC1C3)N1CC[C@@H](Nc2ccccn2)C1
440,489969,10.1021/jm800566m,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein substrate,Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1C.Cl.Cl,"3-({4-[(2,3-Dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl}amino)benzenesulfonamide",16.0,uM,=,1.2041199826559248,1,c1ccc(Nc2nccc(Nc3ccc4c[nH]nc4c3)n2)cc1
441,834169,10.1021/jm2013248,,,,Inhibition of human recombinant CYP3A4 coexpressed in Escherichia coli,O=C(NCc1ccncc1)c1nc(CS(=O)(=O)c2ccccc2)no1,"3-(phenylsulfonylmethyl)-N-(pyridin-4-ylmethyl)-1,2,4-oxadiazole-5-carboxamide",14.6,uM,=,1.1643528557844371,1,O=C(NCc1ccncc1)c1nc(CS(=O)(=O)c2ccccc2)no1
442,1641039,,,,,"Inhibition Assay: Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 uM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 Î¼M. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:CH3CN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO: CH3CN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v. Pooled human liver microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 5 mg/mL suspension.",OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(F)nc2)cn1,"US9221791, 31",33.0,uM,=,1.5185139398778875,1,c1ccc(C(Cc2ccc(-c3cccnc3)cn2)Cn2cnnn2)cc1
443,51898,10.1016/s0960-894x(98)00653-2,,,,Antiviral activity as inhibition of human liver microsomal Cytochrome P450 3A4,CCc1ncc(COC(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)[C@H](O)CN2CCN(Cc3ccc(OC)c(OC)c3)C[C@H]2C(=O)NC(C)(C)C)C(C)C)s1,"((S)-1-{(1S,2R)-1-Benzyl-3-[(S)-2-tert-butylcarbamoyl-4-(3,4-dimethoxy-benzyl)-piperazin-1-yl]-2-hydroxy-propylcarbamoyl}-2-methyl-propyl)-carbamic acid 2-ethyl-thiazol-5-ylmethyl ester",35.0,uM,=,1.5440680443502757,1,O=C(CNC(=O)OCc1cncs1)N[C@H](CCN1CCN(Cc2ccccc2)CC1)Cc1ccccc1
444,2158479,10.1021/acs.jmedchem.1c00926,,,,Inhibition of CYP3A4 (unknown origin),Cn1cc(Nc2nccc(-c3ccc4c(c3)CCCC[C@H]4NC(=O)c3noc(C(C)(C)C)n3)n2)cn1,"(R)-5-tert-butyl-N-(2-(2-(1-methyl-1H-pyrazol-4-ylamino)pyrimidin-4-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-5-yl)-1,2,4-oxadiazole-3-carboxamide",3.8,uM,=,0.5797835966168101,1,O=C(N[C@@H]1CCCCc2cc(-c3ccnc(Nc4cn[nH]c4)n3)ccc21)c1ncon1
445,1474044,10.1021/jm501740a,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,O=C(N[C@@H](c1ccccn1)C1CC1)c1ccc2[nH]nc(-c3ccc(N4[C@H]5CC[C@H]4CC(O)C5)cc3)c2c1,N-((R)-Cyclopropyl(pyridin-2-yl)methyl)-3-(4-((endo)-3-hydroxy-8-azabicyclo[3.2.1]octan-8-yl)phenyl)-1H-indazole-5-carboxamide,1.4,uM,=,0.1461280356782379,1,O=C(N[C@@H](c1ccccn1)C1CC1)c1ccc2[nH]nc(-c3ccc(N4[C@@H]5CCC[C@@H]4CC5)cc3)c2c1
446,827973,10.1016/j.bmcl.2012.05.087,,,,Inhibition of CYP3A4 using midazolam as substrate,CCCCNC(=O)c1ccc(OC)c(CSc2nc3cc(F)ccc3n2CC(=O)O)c1,2-(2-(5-(butylcarbamoyl)-2-methoxybenzylthio)-5-fluoro-1H-benzo[d]imidazol-1-yl)acetic acid,4.0,uM,=,0.6020599913279624,1,c1ccc(CSc2nc3ccccc3[nH]2)cc1
447,519908,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,Cc1cccc(C)c1CNc1cc(N2CCCCC2=O)cn2c(C)c(C)nc12,"1-(8-(2,6-dimethylbenzylamino)-2,3-dimethylimidazo[1,2-a]pyridin-6-yl)piperidin-2-one",22.0,uM,=,1.3424226808222062,1,O=C1CCCCN1c1cc(NCc2ccccc2)c2nccn2c1
448,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cc(-n3nccn3)ccc2F)c1,"US9150566, 56",33.0,uM,=,1.5185139398778875,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
449,696217,10.1016/j.bmcl.2010.09.125,,,,Inhibition of CYP3A4,Cc1cc2c(cc1C(F)(F)F)NC(=O)CC(c1cccc(-c3ccncc3)c1)=N2,"7-methyl-4-(3-(pyridin-4-yl)phenyl)-8-(trifluoromethyl)-1H-benzo[b][1,4]diazepin-2(3H)-one",0.2,uM,=,-0.6989700043360187,0,O=C1CC(c2cccc(-c3ccncc3)c2)=Nc2ccccc2N1
450,535882,10.1016/j.bmcl.2008.08.010,,,,"Inhibition of human CYP3A4 by microtiter plate assays using N-N,diethyl-formamide as substrate",CN1CCc2cc3ccn(S(=O)(=O)c4cccc(Cl)c4)c3cc2CC1,"1-(3-chlorophenylsulfonyl)-7-methyl-1,5,6,7,8,9-hexahydroazepino[4,5-f]indole",15.0,uM,=,1.1760912590556811,1,O=S(=O)(c1ccccc1)n1ccc2cc3c(cc21)CCNCC3
451,949159,10.1016/j.bmcl.2013.01.011,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,Cc1cc(C[C@@H](NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)c(Cl)c2cn[nH]c12,"(R)-N-(1-(1,4'-bipiperidin-1'-yl)-3-(4-chloro-7-methyl-1H-indazol-5-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide",3.5,uM,=,0.5440680443502757,1,O=C(N[C@H](Cc1ccc2[nH]ncc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
452,1911030,10.1021/acs.jmedchem.8b01226,,,,Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins,Cc1cccc(C#CC=C2CCN(C(=O)OCCc3ccccc3)CC2)n1,2-Phenylethyl 4-[3-(6-Methylpyridin-2-yl)prop-2-yn-1-ylidene]-piperidine-1-carboxylate,3.7,uM,=,0.568201724066995,1,O=C(OCCc1ccccc1)N1CCC(=CC#Cc2ccccn2)CC1
453,51898,10.1016/s0960-894x(98)00653-2,,,,Antiviral activity as inhibition of human liver microsomal Cytochrome P450 3A4,CC(C)c1nc(COC(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)[C@H](O)CN2CCN(Cc3ccc4c(c3)OCO4)C[C@H]2C(=O)NC(C)(C)C)C(C)C)cs1,"{(S)-1-[(1S,2R)-3-((S)-4-Benzo[1,3]dioxol-5-ylmethyl-2-tert-butylcarbamoyl-piperazin-1-yl)-1-benzyl-2-hydroxy-propylcarbamoyl]-2-methyl-propyl}-carbamic acid 2-isopropyl-thiazol-4-ylmethyl ester",9.6,uM,=,0.9822712330395684,1,O=C(CNC(=O)OCc1cscn1)N[C@H](CCN1CCN(Cc2ccc3c(c2)OCO3)CC1)Cc1ccccc1
454,423507,10.1021/jm060995h,,,,Inhibition of CYP3A4,Cc1n[nH]c(C)c1Cc1sc2c(c1C(=O)N1C[C@H](O)CO1)c(=O)n(C)c(=O)n2CC(C)C,"(S)-6-[(3,5-dimethyl-1H-pyrazol-4-yl)methyl]-5-{[4-hydroxyisoxazolidin-2-yl]carbonyl}-1-isobutyl-3-methylthieno[2,3-d]pyrimidine-2,4(1H,3H)-dione",100.0,uM,=,2.0,1,O=C(c1c(Cc2cn[nH]c2)sc2[nH]c(=O)[nH]c(=O)c12)N1CCCO1
455,473932,10.1021/jm701121y,,,,Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay,Clc1ccc(OC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1,"1-(2-(2,4-dichlorophenoxy)-2-(2,4-dichlorophenyl)ethyl)-1H-imidazole",0.06,uM,=,-1.2218487496163564,0,c1ccc(OC(Cn2ccnc2)c2ccccc2)cc1
456,1301328,10.6019/CHEMBL3137440,,,,DNDI: CYP Inhibition,FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ccc(C(F)(F)F)cn3)CC2)cc1,N-[4-(Trifluoromethyl)phenyl]-N-(1-[5-(trifluoromethyl)pyridin-2-yl]piperidin-4-yl)pyridin-3-amine,12.1,uM,=,1.08278537031645,1,c1ccc(N(c2cccnc2)C2CCN(c3ccccn3)CC2)cc1
457,1986465,10.1021/acs.jmedchem.9b01451,,,,Inhibition of CYP3A4 (unknown origin),CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2c(C)ccc3ccccc23)c2ccc(C#N)cc2N(C(C)=O)[C@H]1C,"CHEMBL2436226::US9422331, 32",16.0,uM,=,1.2041199826559248,1,O=C1CCNc2ccccc2N1Cc1cccc2ccccc12
458,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",O=C(c1ccc(C(F)(F)F)cc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2ncon2)c1,"US9150566, 87",15.0,uM,=,1.1760912590556811,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2ncon2)c1
459,2023287,10.1016/j.bmcl.2020.127636,,,,Inhibition of CYP3A4 (unknown origin),CCOC(=O)c1ccc(N2C(=O)c3n[nH]c(C(C)(C)C)c3C2c2ccccc2OC)cc1,"US8575197, II-057",5.0,uM,=,0.6989700043360189,1,O=C1c2n[nH]cc2C(c2ccccc2)N1c1ccccc1
460,449485,10.1016/j.bmcl.2007.07.097,,,,Inhibition of microsomal CYP3A4,CNCCC(=O)N[C@@H](CC(C)C)c1cc(C)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1,"N-((S)-1-(2-(4-((R)-3-(2,4-dichlorophenyl)-2-(2-oxopyrrolidin-1-yl)propanoyl)piperazin-1-yl)-5-methylphenyl)-3-methylbutyl)-3-(methylamino)propanamide",3.4,uM,=,0.5314789170422551,1,O=C([C@@H](Cc1ccccc1)N1CCCC1=O)N1CCN(c2ccccc2)CC1
461,1971879,10.1021/acs.jmedchem.9b00790,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 2 min in presence of NADPH by LC-MS/MS analysis,Cl.c1cncc(OC[C@H]2NC[C@@H]3C[C@@H]32)c1,"(1S,2S,5R)-2-(pyridin-3-yloxymethyl)-3-aza-bicyclo[3.1.0]hexane hydrochloride",21.1,uM,=,1.3242824552976926,1,c1cncc(OC[C@H]2NC[C@@H]3C[C@@H]32)c1
462,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N(C)CC5(CO)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, F-9",2.53,uM,=,0.4031205211758178,1,O=C(NCC1CC1)c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12
463,673952,10.1016/j.bmcl.2010.08.086,,,,Inhibition of CYP3A4 using midazolam as substrate,Cc1cc(Cl)c(OCCOc2ccc([C@H]3CCNC[C@@H]3C(=O)N(Cc3cc(CCNC(=O)CC(F)(F)F)ccc3Cl)C3CC3)cc2)c(Cl)c1,"(3R,4S)-N-(2-chloro-5-(2-(3,3,3-trifluoropropanamido)ethyl)benzyl)-N-cyclopropyl-4-(4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)phenyl)piperidine-3-carboxamide",2.8,uM,=,0.4471580313422192,1,O=C([C@H]1CNCC[C@@H]1c1ccc(OCCOc2ccccc2)cc1)N(Cc1ccccc1)C1CC1
464,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N(CCO)CCNCCO)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, F-20",2.89,uM,=,0.4608978427565479,1,O=C1[C@H](Cc2ccccc2)N2C(=O)CNN(C(=O)NCc3ccccc3)[C@H]2CN1Cc1cccc2cc[nH]c12
465,559939,10.1016/j.bmcl.2008.10.072,,,,Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate,C[C@@H]1CN(Cc2ccc(-c3ccccc3C(=O)N3CCC(Oc4ccc(F)cc4)CC3)cc2)C[C@H](C)N1,"[4'-((3R,5S)-3,5-Dimethyl-piperazin-1-ylmethyl)-biphenyl-2-yl]-[4-(4-fluoro-phenoxy)-piperidin-1-yl]-methanone",14.0,uM,=,1.146128035678238,1,O=C(c1ccccc1-c1ccc(CN2CCNCC2)cc1)N1CCC(Oc2ccccc2)CC1
466,1785637,,,,,Inhibition of CYP3A4 (unknown origin),CCS(=O)(=O)N1CCN(c2ccc(/C=C/c3cc(F)cc(-c4ccncc4)c3)cc2)CC1,(E)-1-(ethylsulfonyl)-4-(4-(3-fluoro-5-(pyridin-4-yl)styryl)phenyl)piperazine,0.243,uM,=,-0.6143937264016879,0,C(=C/c1cccc(-c2ccncc2)c1)\c1ccc(N2CCNCC2)cc1
467,1288280,10.1016/j.bmcl.2013.12.057,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,CC(C)[C@H](NC(=O)N(C)Cc1cscn1)C(=O)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1,"Thiazol-5-ylmethyl(2R,5R)-5-((S)-3-methyl-2-(3-methyl-3-(thiazol-4-ylmethyl)ureido)butanamido)-1,6-diphenylhexan-2-ylcarbamate",0.14,uM,=,-0.8538719643217619,0,O=C(CNC(=O)NCc1cscn1)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
468,2205592,10.1016/j.ejmech.2022.114569,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate and measured by LC-MS/MS analysis,CCC#CCOc1ccc2cc(C(c3ccc(F)cc3)n3cncn3)oc2c1,"1-((4-fluorophenyl)(6-(pent-2-yn-1-yloxy)benzofuran-2-yl)methyl)-1H-1,2,4-triazole",21.0,uM,=,1.3222192947339193,1,c1ccc(C(c2cc3ccccc3o2)n2cncn2)cc1
469,455108,10.1016/j.bmcl.2006.12.043,,,,Inhibition of CYP3A4,CC(C)[C@@H](O)C(=O)N1CCN(c2ccc3[nH]ncc3c2)CC1,(R)-1-(4-(1H-indazol-5-yl)piperazin-1-yl)-2-hydroxy-3-methylbutan-1-one,10.0,uM,=,1.0,1,c1cc2[nH]ncc2cc1N1CCNCC1
470,52065,10.1021/jm0310129,,,,Inhibitory activity against cytochrome P450 3A4,CCOC(=O)Cn1c2ccc([N+](=O)[O-])cc2c2ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21,"(4-{4-[2-(3,4-Difluoro-phenyl)-ethyl]-piperazin-1-yl}-8-nitro-pyrimido[5,4-b]indol-5-yl)-acetic acid ethyl ester",15.0,uM,=,1.1760912590556811,1,c1ccc(CCN2CCN(c3ncnc4c3[nH]c3ccccc34)CC2)cc1
471,982382,10.1016/j.bmcl.2013.07.071,,,,Inhibition of CYP3A4 (unknown origin),COC[C@@H](Oc1cc(C[C@@H]2C[S@@+]([O-])C[C@H](NCc3cccc(C(C)(C)O)c3)[C@H]2O)cc(F)c1N)C(F)(F)F,"(1R,3S,4S,5R)-3-[4-Amino-3-fluoro-5-((R)-2,2,2-trifluoro-1-methoxymethyl-ethoxy)-benzyl]-5-[3-(1-hydroxy-1-methyl-ethyl)-benzylamino]-1-oxo-tetrahydro-thiopyran-4-ol",2.4,uM,=,0.380211241711606,1,c1ccc(CN[C@H]2C[SH+]C[C@@H](Cc3ccccc3)C2)cc1
472,52065,10.1021/jm0310129,,,,Inhibitory activity against cytochrome P450 3A4,O=[N+]([O-])c1ccc2[nH]c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)ncnc3c2c1,"4-{4-[2-(3,4-Difluoro-phenyl)-ethyl]-piperazin-1-yl}-8-nitro-5H-pyrimido[5,4-b]indole",12.58,uM,=,1.09968064110925,1,c1ccc(CCN2CCN(c3ncnc4c3[nH]c3ccccc34)CC2)cc1
473,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",COc1ccc(C[C@@H]2COCCN2C(=O)c2ccc(C)cc2-n2nccn2)cc1-c1ncon1,"US9150566, 60",41.0,uM,=,1.6127838567197357,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2ncon2)c1
474,1613496,10.1021/acs.jmedchem.6b00972,,,,Inhibition of human CYP3A4 expressed in microsomes using 7BQ as substrate after 10 mins by P450 cypex assay,Cc1ncoc1-c1nnc(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)n1C,"(rac)-(1R,3S/1S,3R)-5-(3-{[4-Methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}propyl)-1-[4-(trifluoromethyl)phenyl]-5-azaspiro[2.4]heptane",0.3,uM,=,-0.5228787452803376,0,c1ccc([C@H]2C[C@]23CCN(CCCSc2nnc(-c4cnco4)[nH]2)C3)cc1
475,717286,10.1021/np100665j,,,,Inhibition of CYP3A4 after 30 mins by fluorometric assay,COc1cc(C[C@H]2CO[C@H](c3ccc(O)c(OC)c3)[C@H]2CO)ccc1O,(+/-)-lariciresinol,25.6,uM,=,1.4082399653118496,1,c1ccc(C[C@H]2CO[C@H](c3ccccc3)C2)cc1
476,859942,10.1021/jm300122u,,,,Inhibition of human CYP3A4 using testosterone as substrate after 45 mins,CN1CCN(C(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)C2(c3ccc(Cl)cc3Cl)CC2)CC1,"1-(2,4-Dichlorophenyl)-N-[(2S)-3-(1H-indol-3-yl)-1-(4-methylpiperazin-1-yl)-1-oxopropan-2-yl]cyclopropanecarboxamide",10.0,uM,=,1.0,1,O=C([C@H](Cc1c[nH]c2ccccc12)NC(=O)C1(c2ccccc2)CC1)N1CCNCC1
477,1527876,,,,,Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,C[C@@H](c1ccc(-c2cc[nH]c(=O)c2)cc1)N1CC[C@](CC(C)(C)C#N)(c2ccccc2)OC1=O,"US8575157, 14",25.0,uM,=,1.3979400086720375,1,O=C1OC(c2ccccc2)CCN1Cc1ccc(-c2cc[nH]c(=O)c2)cc1
478,612188,10.1016/j.bmcl.2009.12.071,,,,Inhibition of CYP3A4,Cn1cnc(C(=O)N(Cc2cccc(OC(F)(F)F)c2)[C@@H]2C[C@@H]3CN(CCC(F)(F)F)C[C@@H]3C2)c1,"(exo)-1-methyl-N-(3-(trifluoromethoxy)benzyl)-N-(2-(3,3,3-trifluoropropyl)octahydrocyclopenta[c]pyrrol-5-yl)-1H-imidazole-4-carboxamide",8.7,uM,=,0.9395192526186184,1,O=C(c1c[nH]cn1)N(Cc1ccccc1)[C@H]1C[C@H]2CNC[C@H]2C1
479,1911030,10.1021/acs.jmedchem.8b01226,,,,Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins,Cc1cccc(C#CC=C2CCN(S(=O)(=O)c3cccc(Br)c3)CC2)n1,2-(3-{1-[(3-Bromophenyl)sulfonyl]piperidin-4-ylidene}prop-1-yn-1-yl)-6-methylpyridine,3.3,uM,=,0.5185139398778875,1,O=S(=O)(c1ccccc1)N1CCC(=CC#Cc2ccccn2)CC1
480,1629312,10.1016/j.bmcl.2016.11.020,,,,Inhibition of CYP3A4 (unknown origin),Cc1ccc(OCCNc2nc(Nc3cc(C)[nH]n3)cc(C)c2C#N)c(C)n1,"2-(2-(2,6-dimethylpyridin-3-yloxy)ethylamino)-4-methyl-6-(5-methyl-1H-pyrazol-3-ylamino)nicotinonitrile",1.7,uM,=,0.2304489213782739,1,c1cncc(OCCNc2cccc(Nc3cc[nH]n3)n2)c1
481,1736291,10.1021/acs.jmedchem.8b00743,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,CN(C)c1ccc([C@H]2C[C@@]3(C)[C@@H](CC[C@@]3(O)C#CC(C)(C)C)[C@@H]3CCC4=CC(=O)CCC4=C32)cc1,"(8S,11R,13S,14S,17S)-11-(4-(Dimethylamino)phenyl)-17-(3,3-dimethylbut-1-yn-1-yl)-17-hydroxy-13-methyl-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]-phenanthren-3-one",2.9,uM,=,0.4623979978989561,1,O=C1C=C2CC[C@@H]3C(=C2CC1)[C@@H](c1ccccc1)CC1CCC[C@H]13
482,1667894,10.1016/j.bmcl.2017.03.043,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins in presence of NADPH by LC-MS/MS analysis,O=S(=O)(Nc1nc(Cl)cs1)c1cc(Cl)c(NC[C@H]2NCCC=C2c2ccc(F)cc2)cc1F,"(S)-5-chloro-N-(4-chlorothiazol-2-yl)-2-fluoro-4-((3-(4-fluorophenyl)-1,2,5,6-tetrahydropyridin-2-yl)methylamino)benzenesulfonamide",40.1,uM,=,1.6031443726201824,1,O=S(=O)(Nc1nccs1)c1ccc(NC[C@H]2NCCC=C2c2ccccc2)cc1
483,51902,10.1016/s0960-894x(02)00026-4,,,,Inhibition of cytochrome P450 3A4 enzyme; Range 1-2 uM,Cc1cc(C)cc(-c2[nH]c3ccc(C(C)(C)C(=O)N4C5CCC4CC5)cc3c2[C@H](C)CNCCc2cccc3cnccc23)c1,"1-(7-Aza-bicyclo[2.2.1]hept-7-yl)-2-{2-(3,5-dimethyl-phenyl)-3-[(S)-2-(2-isoquinolin-5-yl-ethylamino)-1-methyl-ethyl]-1H-indol-5-yl}-2-methyl-propan-1-one",1.0,uM,=,0.0,0,O=C(Cc1ccc2[nH]c(-c3ccccc3)c(CCNCCc3cccc4cnccc34)c2c1)N1C2CCC1CC2
484,537847,10.1021/jm800888q,,,,Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,"1-(4-{4-[2-(2,4-Dichloro-phenyl)-2-imidazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-ethanone (ketoconazole)",57.0,uM,=,1.7558748556724917,1,c1ccc(C2(Cn3ccnc3)OCC(COc3ccc(N4CCNCC4)cc3)O2)cc1
485,495153,10.1021/jm8006454,,,,Inhibition of CYP3A4,COc1cccc(-c2c(C)n(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](N)c3ccccc3)c2=O)c1F,"(R)-1-(2-fluoro-6-(trifluoromethyl)benzyl)-3-(2-amino-2-phenylethyl)-5-(2-fluoro-3-methoxyphenyl)-6-methylpyrimidine-2,4(1H,3H)-dione",0.23,uM,=,-0.6382721639824072,0,O=c1c(-c2ccccc2)cn(Cc2ccccc2)c(=O)n1CCc1ccccc1
486,1911030,10.1021/acs.jmedchem.8b01226,,,,Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins,Cc1cccc(C(=O)N2CCC(=CC#Cc3cccc(C)n3)CC2)c1,(3-Methylphenyl){4-[3-(6-methylpyridin-2-yl)prop-2-yn-1-ylidene]piperidin-1-yl}methanone,6.1,uM,=,0.785329835010767,1,O=C(c1ccccc1)N1CCC(=CC#Cc2ccccn2)CC1
487,1561108,10.1021/acsmedchemlett.5b00253,,,,Inhibition of human CYP3A4,CCn1c(CCC(=O)Nc2ccc(C)cc2C)nnc1CCC1CCCCC1,"3-(5-(2-Cyclohexylethyl)-4-ethyl-4H-1,2,4-triazol-3-yl)-N-(2,4-dimethylphenyl)propanamide",12.0,uM,=,1.0791812460476249,1,O=C(CCc1nnc(CCC2CCCCC2)[nH]1)Nc1ccccc1
488,1678561,10.1021/acs.jmedchem.7b01710,,,,Inhibition of CYP3A4 (unknown origin) using DBF as substrate,CC(=O)O[C@H]1C[C@H]2[C@@H]([C@H](OC(C)=O)C[C@@H]3C[C@H](N)CC[C@@]32C)[C@@H]2CC[C@H]([C@H](C)CCCNCCCCNc3ccnc4cc(Cl)ccc34)[C@@]12C,"(3alpha,5beta,7alpha,12alpha)-3-Amino-24-({4-[(7-chloroquinolin-4-yl)amino]butyl}amino)cholane-7,12-diyl diacetate",1.2,uM,=,0.0791812460476248,1,c1ccc2c(NCCCCNCCCC[C@H]3CC[C@@H]4C3CC[C@@H]3C5CCCC[C@H]5CC[C@H]34)ccnc2c1
489,774749,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O.CS(=O)(=O)O,Dihydroergocristine methanesulfonate,3.0,uM,=,0.4771212547196624,1,O=C(NC1OC2[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O)[C@H]1CN[C@@H]2Cc3c[nH]c4cccc(c34)[C@H]2C1
490,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2cccn2)c1,"US9150566, 16",43.0,uM,=,1.6334684555795866,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2cccn2)c1
491,619910,10.1016/j.bmcl.2009.09.104,,,,Inhibition of CYP3A4,COc1cccc(CN(C(=O)C2=C(c3ccc(CCCOc4c(F)ccc(F)c4Cl)cc3)C[C@H]3COC[C@H]2N3)C2CC2)c1C,"(1S,5S)-7-(4-(3-(2-chloro-3,6-difluorophenoxy)propyl)phenyl)-N-cyclopropyl-N-(3-methoxy-2-methylbenzyl)-3-oxa-9-azabicyclo[3.3.1]non-6-ene-6-carboxamide",1.0,uM,=,0.0,0,O=C(C1=C(c2ccc(CCCOc3ccccc3)cc2)C[C@H]2COC[C@H]1N2)N(Cc1ccccc1)C1CC1
492,632105,10.1016/j.bmcl.2010.03.057,,,,Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin,CCOC(=O)N1CCN(c2cc(C)c3nc(-c4c(NC[C@@H](O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1,"(S)-ethyl 4-(2-(4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-2-oxo-1,2-dihydropyridin-3-yl)-4-methyl-1H-benzo[d]imidazol-6-yl)piperazine-1-carboxylate",1.0,uM,=,0.0,0,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(N3CCNCC3)cc2[nH]1
493,1625990,10.1016/j.bmcl.2016.04.095,,,,Inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins after 30 secs by LC/MS/MS analysis,O=S(=O)(CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12)C[C@H]1CCCN1,"(R)-2-((2-((4S,4aS,10bS)-10b-(4-chlorophenylsulfonyl)-7,10-difluoro-1,2,4,4a,5,10b-hexahydropyrano[3,4-c]chromen-4-yl)ethylsulfonyl)methyl)pyrrolidine",1.0,uM,=,0.0,0,O=S(=O)(CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccccc3)c3ccccc3OC[C@@H]12)C[C@H]1CCCN1
494,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2C(CN(Cc3cccc4c(-c5ccc(S(C)(=O)=O)cc5)cn(C)c34)C(=O)[C@@H]2Cc2ccc(O)cc2)N1C(=O)NCc1ccccc1,"US8940739, H-3",10.0,uM,=,1.0,1,O=C1[C@H](Cc2ccccc2)N2C(=O)CNN(C(=O)NCc3ccccc3)C2CN1Cc1cccc2c(-c3ccccc3)c[nH]c12
495,1432845,10.1016/j.bmcl.2014.10.024,,,,Inhibition of CYP3A4 (unknown origin) using testosterone substrate,COc1nc(Nc2cccc3c2nc(-c2ccc(F)cc2)n3C)ccc1-n1cnc(C)c1,2-(4-fluorophenyl)-N-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)-1-methyl-1H-benzo[d]imidazol-4-amine,2.9,uM,=,0.4623979978989561,1,c1ccc(-c2nc3c(Nc4ccc(-n5ccnc5)cn4)cccc3[nH]2)cc1
496,773087,10.1016/j.bmcl.2011.08.074,,,,Inhibition of CYP3A4,Cn1nc(NCC(=O)NC2CN([C@H]3CC[C@@H](c4cncs4)CC3)C2)c2cc(C(F)(F)F)ccc21,cis-N-[1-(4-Hydroxy-4-thiazol-5-yl-cyclohexyl)-azetidin-3-yl]-2-(1-methyl-5-trifluoromethyl-1H-indazol-3-ylamino)-acetamide,6.8,uM,=,0.8325089127062363,1,O=C(CNc1n[nH]c2ccccc12)NC1CN([C@H]2CC[C@@H](c3cncs3)CC2)C1
497,449088,10.1016/j.bmcl.2007.08.028,,,,Inhibition of human CYP3A4,C[C@@H](O[C@H]1OCCN(Cc2n[nH]c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,"5-[2-[1-(3,5-Bis-trifluoromethyl-phenyl)-ethoxy]-3-(4-fluoro-phenyl)-morpholin-4-ylmethyl]-2,4-dihydro-[1,2,4]triazol-3-one",0.046,uM,=,-1.337242168318426,0,O=c1[nH]nc(CN2CCO[C@H](OCc3ccccc3)[C@@H]2c2ccccc2)[nH]1
498,1288280,10.1016/j.bmcl.2013.12.057,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,CNCC[C@H](NC(=O)N(C)Cc1csc(C(C)C)n1)C(=O)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1,"Thiazol-5-ylmethyl(2R,5R)-5-((S)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-4-(methylamino)butanamido)-1,6-diphenylhexan-2-ylcarbamate",0.13,uM,=,-0.8860566476931633,0,O=C(CNC(=O)NCc1cscn1)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
499,438520,10.1016/j.bmcl.2007.01.104,,,,Inhibition of CYP3A4,COc1cccc(N2C(=O)N(Cc3ccccc3F)C3(CCN(Cc4ccc(-c5cncc(C#N)c5)cc4)CC3)C2=O)c1,"5-{4-[1-(2-fluoro-benzyl)-3-(3-methoxy-phenyl)-2,4-dioxo-1,3,8-triaza-spiro[4.5]dec-8-ylmethyl]-phenyl}-nicotinonitrile",6.2,uM,=,0.7923916894982539,1,O=C1N(c2ccccc2)C(=O)C2(CCN(Cc3ccc(-c4cccnc4)cc3)CC2)N1Cc1ccccc1
500,1474044,10.1021/jm501740a,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,O=C(N[C@@H](c1ccccn1)C1CCCC1)c1ccc2[nH]nc(-c3ccc(N4C5CCC4COC5)cc3)c2c1,3-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)phenyl)-N-((R)-cyclopentyl(pyridin-2-yl)methyl)-1H-indazole-5-carboxamide,0.36,uM,=,-0.4436974992327127,0,O=C(N[C@@H](c1ccccn1)C1CCCC1)c1ccc2[nH]nc(-c3ccc(N4C5CCC4COC5)cc3)c2c1
501,443560,10.1016/j.bmc.2007.03.014,,,,Inhibition of human CYP2E1 expressed in insect microsome using 7-benzyloxyquinoline substrate after 30 mins,COc1ccc(CN2CCN(c3ccc(NC(=O)c4ccccc4NC(=O)c4cnc5ccccc5c4)cc3)CC2)cc1OC,"N-(2-(4-(4-(3,4-dimethoxybenzyl)piperazin-1-yl)phenylcarbamoyl)phenyl)quinoline-3-carboxamide",3.58,uM,=,0.5538830266438743,1,O=C(Nc1ccccc1C(=O)Nc1ccc(N2CCN(Cc3ccccc3)CC2)cc1)c1cnc2ccccc2c1
502,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1ccc(Cl)c(-c2ncon2)c1,"US9150566, 90",21.0,uM,=,1.3222192947339193,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2ncon2)c1
503,535882,10.1016/j.bmcl.2008.08.010,,,,"Inhibition of human CYP3A4 by microtiter plate assays using N-N,diethyl-formamide as substrate",O=S(=O)(c1ccsc1)n1ccc2cc3c(cc21)CCNCC3,"1-(thiophen-3-ylsulfonyl)-1,5,6,7,8,9-hexahydroazepino[4,5-f]indole",9.7,uM,=,0.9867717342662448,1,O=S(=O)(c1ccsc1)n1ccc2cc3c(cc21)CCNCC3
504,1760899,10.1021/acs.jmedchem.8b00521,,,,Inhibition of CYP3A4 in human liver microsomes assessed as decrease in midazolam 1-hydroxylation by LC-MS/MS analysis,Cc1ccc(NC(=O)N2CCN(c3nc(N)nc4sc(-c5cccnc5)nc34)CC2)cc1,"4-[5-Amino-2-(3-pyridyl)thiazolo[5,4-d]pyrimidin-7-yl]-N-(ptolyl)piperazine-1-carboxamide",0.9,uM,=,-0.0457574905606751,0,O=C(Nc1ccccc1)N1CCN(c2ncnc3sc(-c4cccnc4)nc23)CC1
505,1450858,10.1021/jm5005336,,,,Inhibition of CYP3A4 (unknown origin) using BFC substrate after 30 mins by fluorescence assay,O=C1Nc2ccccc2/C1=C/c1ccc2cn[nH]c2c1,indazol-6-ylmethyleneindolin-2-one,10.0,uM,=,1.0,1,O=C1Nc2ccccc2/C1=C/c1ccc2cn[nH]c2c1
506,863248,10.1021/jm300663n,,,,Inhibition of CYP3A4,CCOc1cc(C(=O)N[C@@H](CC(=O)O)c2ccccc2C)nn1-c1ccccc1F,((S)-3-{[5-Ethoxy-1-(2-fluoro-phenyl)-1H-pyrazole-3-carbonyl]-amino}-3-o-tolylpropionic acid,0.015,uM,=,-1.8239087409443189,0,O=C(NCc1ccccc1)c1ccn(-c2ccccc2)n1
507,1528565,,,,,"Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",CC(C)c1nc(CN(C)C(=O)N2C[C@@H](N(C)C)C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,"US8987313, 31",0.33,uM,=,-0.4814860601221125,0,O=C(N[C@H](CC[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)NCc1cscn1)Cc1ccccc1)OCc1cncs1
508,991614,10.1021/jm4008906,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(CC(=O)N(C)C)C2,"(S)-2-(3-(Aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide",36.0,uM,=,1.5563025007672873,1,O=C1NCc2nccc(-c3ccccc3)c21
509,455108,10.1016/j.bmcl.2006.12.043,,,,Inhibition of CYP3A4,O=C([C@H](O)c1ccccc1)N1CCC(Nc2ccc3[nH]ncc3c2)CC1,(R)-1-(4-(1H-indazol-5-ylamino)piperidin-1-yl)-2-hydroxy-2-phenylethanone,1.0,uM,=,0.0,0,O=C(Cc1ccccc1)N1CCC(Nc2ccc3[nH]ncc3c2)CC1
510,1661004,10.1016/j.bmcl.2017.02.047,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,CCCCC[C@H](O)CC(=O)CCc1ccc(O)c(OC)c1,[1-(4'-hydroxy-3'-methoxyphenyl)-5-hydroxy-3-decanone],73.4,uM,=,1.8656960599160703,1,c1ccccc1
511,774749,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21,"7-Methyl-4,6,6a,7,8,9-hexahydro-indolo[4,3-fg]quinoline-9-carboxylic acid (5-benzyl-10b-hydroxy-2-methyl-3,6-dioxo-octahydro-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl)-amide",1.0,uM,=,0.0,0,O=C(NC1OC2[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2NC1
512,1780160,10.1021/acs.jmedchem.8b01077,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as substrate,Cc1ccc([C@H](CCN2[C@@H]3CC[C@H]2C[C@H](n2c(C)nnc2C(C)C)C3)NC(=O)C2CCC(F)(F)CC2)s1,"4,4-Difluoro-N-((S)-3-((1R,3R,5S)-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-1-(5-methylthiophen-2-yl)propyl)cyclohexane-1-carboxamide",23.4,uM,=,1.3692158574101427,1,O=C(N[C@@H](CCN1[C@@H]2CC[C@H]1C[C@H](n1cnnc1)C2)c1cccs1)C1CCCCC1
513,1485439,10.1124/dmd.111.042739,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrates after 5 mins by LC/MS analysis in presence of NADPH,CC[C@@H](C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O,"trans-2-((R)-sec-Butyl)-4-[4-(4-{4-[(2R,4R)-2-(2,4-dichloro-phenyl)-2-[1,2,4]triazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-phe nyl]-2,4-dihydro-[1,2,4]triazol-3-one",0.026,uM,=,-1.585026652029182,0,O=c1[nH]ncn1-c1ccc(N2CCN(c3ccc(OC[C@@H]4CO[C@](Cn5cncn5)(c5ccccc5)O4)cc3)CC2)cc1
514,624295,10.1016/j.bmcl.2010.01.134,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,C[C@H](c1cccnc1)c1c(CCN(C)C)sc2ccccc12,"(-)-(R)-N,N-dimethyl-2-(3-(1-(pyridin-3-yl)ethyl)benzo[b]thiophen-2-yl)ethanamine",4.0,uM,=,0.6020599913279624,1,c1cncc(Cc2csc3ccccc23)c1
515,510198,10.1021/jm800355c,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,Cl.Fc1ccc(-c2ccc3c(c2)CCC3c2cccnc2)cc1,"3-(5-(4-Fluorophenyl)-2,3-dihydro-1H-inden-1-yl)pyridine Hydrochloride",1.697,uM,=,0.2296818423176758,1,c1ccc(-c2ccc3c(c2)CCC3c2cccnc2)cc1
516,1295469,10.1016/j.bmcl.2014.02.004,,,,Inhibition of human recombinant CYP3A4,O=C(O)c1sc(N2CCOCC2)nc1CC(=O)N1CCc2c(Cl)cccc21,4-(2-(4-chloroindolin-1-yl)-2-oxoethyl)-2-morpholinothiazole-5-carboxylic acid,40.0,uM,=,1.6020599913279625,1,O=C(Cc1csc(N2CCOCC2)n1)N1CCc2ccccc21
517,499144,10.1016/j.bmc.2009.03.041,,,,Inhibition of CYP3A4,C[C@@H](Nc1c(Nc2ccncc2)c(=O)c1=O)c1ccccc1,"3-((R)-1-Phenyl-ethylamino)-4-(pyridin-4-ylamino)-cyclobut-3-ene-1,2-dione",1.3,uM,=,0.1139433523068367,1,O=c1c(NCc2ccccc2)c(Nc2ccncc2)c1=O
518,815099,10.1016/j.bmcl.2012.03.040,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,COc1cc(NC(=O)c2ccccc2F)ccc1-c1nnc(NCCCN2CCCCC2)o1,"2-fluoro-N-(3-methoxy-4-(5-(3-(piperidin-1-yl)propylamino)-1,3,4-oxadiazol-2-yl)phenyl)benzamide",76.0,uM,=,1.880813592280792,1,O=C(Nc1ccc(-c2nnc(NCCCN3CCCCC3)o2)cc1)c1ccccc1
519,1641445,,,,,"CYP450 Inhibition Assay: The ability of the R and S enantiomers of (4-fluorophenyl)(4-((5-methyl-1H-pyrazol-3-yl)amino)quinazolin-2-yl)methanol to inhibit the common drug metabolizing isoforms of cytochrome P450 (CYP) was evaluated against the following isoforms: CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. The compounds were incubated in duplicate with eight test compound concentrations (final DMSO concentration of 0.20%) with human liver microsomes (0.25 or 0.50 mg/mL) and NADPH (1 mM) in the presence of CYP isoform specific probe substrates (phenacetin, bupropion, taxol, diclofenac, mephenyloin, dextromethorphan, testosterone) at the Km for 10-20 minutes at 37° C. Selective CYP isoform inhibitors (furafulline, ticlopidine, quercetin, sulfaphenazole, ticlopidine, quinidine, ketoconazole) were screened alongside the test compounds as positive controls.",Cc1cc(Nc2nc([C@H](O)c3ccc(F)cc3)nc3ccccc23)n[nH]1,"US9295672, (R)-(4-fluorophenyl)(4-((5-methyl-1H-pyrazol-3-yl)amino)quinazolin-2-yl)methanol",14.8,uM,=,1.1702617153949575,1,c1ccc(Cc2nc(Nc3cc[nH]n3)c3ccccc3n2)cc1
520,719028,10.1021/ml100249e,,,,Inhibition of CYP3A4 in human liver microsomes,O=C(Nc1cnc(-c2ccncc2)c(-c2cccnc2)n1)C1CC1,N-(6-Pyridin-3-yl-5-pyridin-4-ylpyrazin-2-yl)cyclopropanecarboxamide,5.0,uM,=,0.6989700043360189,1,O=C(Nc1cnc(-c2ccncc2)c(-c2cccnc2)n1)C1CC1
521,1465594,10.1016/j.bmcl.2015.02.039,,,,Inhibition of CYP3A4 (unknown origin) using midazolam fluorometric substrate,COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2NCc2ccc3ccccc3c2)C(C)C)ccc1OC,rac-N-isopropyl-4-methoxy-3-(3-methoxypropoxy)-N-((4-(naphthalen-2-ylmethylamino)pyrrolidin-3-yl)methyl)benzamide,1.4,uM,=,0.1461280356782379,1,O=C(NC[C@@H]1CNC[C@H]1NCc1ccc2ccccc2c1)c1ccccc1
522,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N(C)C)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, G-15",6.75,uM,=,0.829303772831025,1,O=C(Nc1cccnc1)c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12
523,304712,10.1021/jm048978k,,,,In vitro inhibitory concentration against Cytochrome P450 3A4,CC(C)S(=O)(=O)n1c(N)nc2ccc(-c3[nH]c(C(C)(C)C)nc3-c3ccc(F)cc3)cc21.CS(=O)(=O)O.CS(=O)(=O)O,6-[2-tert-Butyl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-1-(propane-2-sulfonyl)-1H-benzoimidazol-2-ylamine; Bismesylate salt,31.8,uM,=,1.5024271199844328,1,c1ccc(-c2nc[nH]c2-c2ccc3nc[nH]c3c2)cc1
524,519908,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,CCc1cccc(C)c1CNc1cc(-c2ncnn2C)cn2c(C)c(C)nc12,"N-(2-ethyl-6-methylbenzyl)-2,3-dimethyl-6-(1-methyl-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridin-8-amine",13.0,uM,=,1.1139433523068367,1,c1ccc(CNc2cc(-c3ncn[nH]3)cn3ccnc23)cc1
525,2240169,10.1021/acs.jmedchem.2c01383,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,Cc1nnc(C(C)C)n1[C@@H]1C[C@H]2CC[C@@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1,"4,4-Difluoro-cyclohexanecarboxylic acid {(S)-3-[(1S,5S)-3-(3-isopropyl-5-methyl-[1,2,4]triazol-4-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-1-phenyl-propyl}-amide",3.1,uM,=,0.4913616938342727,1,O=C(N[C@@H](CCN1[C@@H]2CC[C@H]1C[C@H](n1cnnc1)C2)c1ccccc1)C1CCCCC1
526,988938,10.1021/jm401094t,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of dextromethorphan metabolism by HPLC/MS analysis,CN1CCN(Cc2ccc(-c3cnc4[nH]cc(-c5ccc6[nH]ccc6c5)c4c3)cc2)CC1,"3-(1H-Indol-5-yl)-5-(4-((4-methylpiperazin-1-yl)methyl)-phenyl)-1H-pyrrolo[2,3-b]pyridine",16.2,uM,=,1.209515014542631,1,c1cc2cc(-c3c[nH]c4ncc(-c5ccc(CN6CCNCC6)cc5)cc34)ccc2[nH]1
527,558484,10.1016/j.bmcl.2008.10.128,,,,Inhibition of CYP3A4,CCN(CC(O)(CNC(=O)c1cnn(-c2ccc(F)cc2)c1N)C(F)(F)F)C(=O)c1ccccc1Cl,"5-amino-N-(2-((2-chloro-N-ethylbenzamido)methyl)-3,3,3-trifluoro-2-hydroxypropyl)-1-(4-fluorophenyl)-1H-pyrazole-4-carboxamide",4.0,uM,=,0.6020599913279624,1,O=C(NCCCNC(=O)c1cnn(-c2ccccc2)c1)c1ccccc1
528,1689562,10.1021/acs.jmedchem.7b00598,,,,Inhibition of CYP3A4 (unknown origin),N#Cc1cc(S(=O)(=O)Nc2ncns2)ccc1Oc1ccc(C(F)(F)F)cc1-c1ccnnc1,"3-cyano-4-(2-(pyridazin-4-yl)-4-(trifluoromethyl)phenoxy)-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide",1.271,uM,=,0.1041455505540081,1,O=S(=O)(Nc1ncns1)c1ccc(Oc2ccccc2-c2ccnnc2)cc1
529,51909,10.1021/jm010531d,,,,Inhibition of human Cytochrome P450 3A4 by macrocycles,N#Cc1ccc2cc1Oc1ccc3cccc(c3c1)N1CC[C@H](NCc3cncn3C2)C1=O,"30-oxo-(5S)-19-oxa-2,6,10,12-tetraazahexacyclo[18.6.2.12,5.114,18.08,12.023,27]triaconta-1(27),8,10,14(29),15,17,20(28),21,23,25-decaen-17-yl cyanide",8.0,uM,=,0.9030899869919436,1,O=C1[C@@H]2CCN1c1cccc3ccc(cc13)Oc1cccc(c1)Cn1cncc1CN2
530,1534761,,,,,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",COc1cc(CNc2ccc(Cc3c[nH]c4ncc(C)cc34)c(F)n2)c(F)cn1,"US9096593, P-2071",5.0,uM,=,0.6989700043360189,1,c1cnc2[nH]cc(Cc3ccc(NCc4ccncc4)nc3)c2c1
531,449485,10.1016/j.bmcl.2007.07.097,,,,Inhibition of microsomal CYP3A4,CC(C)C[C@H](NC(=O)CCN)c1cccc(F)c1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1,"3-amino-N-((S)-1-(2-(4-((R)-3-(2,4-dichlorophenyl)-2-(2-oxopyrrolidin-1-yl)propanoyl)piperazin-1-yl)-3-fluorophenyl)-3-methylbutyl)propanamide",6.7,uM,=,0.8260748027008264,1,O=C([C@@H](Cc1ccccc1)N1CCCC1=O)N1CCN(c2ccccc2)CC1
532,445935,10.1021/jm070436q,,,,Inhibition of CYP3A4,N#Cc1cnc2c(Cl)cc(NCc3cccc[n+]3[O-])cc2c1Nc1ccc(F)c(Cl)c1,8-chloro-4-[(3-chloro-4-fluorophenyl)amino]-6-{[(1-oxidopyridin-2-yl)methyl]amino}quinoline-3-carbonitrile,18.0,uM,=,1.255272505103306,1,c1ccc(Nc2ccnc3ccc(NCc4cccc[nH+]4)cc23)cc1
533,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CC(N7CCC(OC)CC7)C6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, G-63",2.56,uM,=,0.4082399653118496,1,O=C(Nc1ccc(N2CC(N3CCCCC3)C2)nc1)c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12
534,774749,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,"1-(4-{4-[2-(2,4-Dichloro-phenyl)-2-imidazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-ethanone (ketoconazole)",0.016,uM,=,-1.7958800173440752,0,c1ccc(C2(Cn3ccnc3)OCC(COc3ccc(N4CCNCC4)cc3)O2)cc1
535,1574682,10.1021/acs.jmedchem.5b01995,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone and midazolam as substrate preincubated for 30 mins followed substrate addition by LC-MS/MS analysis,COc1nc(N2C[C@H]3C(=O)N(C)C(=N)N[C@@]3(c3cc(-c4cccc(C#N)c4)cs3)C2)ncc1F,"3-(5-((4aR,7aR)-6-(5-fluoro-4-methoxypyrimidin-2-yl)-2-imino-3-methyl-4-oxooctahydro-1H-pyrrolo[3,4-d]pyrimidin-7a-yl)thiophen-3-yl)benzonitrile",2.0,uM,=,0.3010299956639812,1,N=C1NC(=O)[C@@H]2CN(c3ncccn3)C[C@]2(c2cc(-c3ccccc3)cs2)N1
536,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(C6CCN(C)CC6)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, E-64",8.55,uM,=,0.9319661147281728,1,O=C(c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12)N1CCN(C2CCNCC2)CC1
537,1614026,10.1016/j.bmcl.2016.09.043,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 1'-hydroxymidazolam metabolite formation using midazolam as substrate incubated for 10 mins by HPLC-MS method,Cn1c(NCCc2ccc(-n3cccn3)cc2)nc2cc(Cl)ccc2c1=O,7-Chloro-3-methyl-2-[2-(4-pyrazol-1-yl-phenyl)-ethylamino]-3H-quinazolin-4-one,27.0,uM,=,1.4313637641589874,1,O=c1[nH]c(NCCc2ccc(-n3cccn3)cc2)nc2ccccc12
538,1528565,,,,,"Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",CC(C)c1nc(CN(C)C(=O)N2CCN(C)C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,"US8987313, 25",0.14,uM,=,-0.8538719643217619,0,O=C(N[C@H](CC[C@H](Cc1ccccc1)NC(=O)[C@@H]1CNCCN1C(=O)NCc1cscn1)Cc1ccccc1)OCc1cncs1
539,827410,10.1016/j.bmc.2012.04.053,,,,Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture before addition of BFC substrate by fluorometric assay,CCc1ccc(Cc2cc([C@@H]3C[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c(OC)cc2OC)cc1,"(1R,2R,3S,4S,6R)-4-[5-(4-Ethylbenzyl)-2,4-dimethoxyphenyl]-6-(hydroxymethyl)cyclohexane-1,2,3-triol",40.3,uM,=,1.6053050461411094,1,c1ccc(Cc2cccc(C3CCCCC3)c2)cc1
540,519907,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,Cc1cccc(C)c1CNc1cc(N2CCCCC2=O)cn2c(C)c(C)nc12,"1-(8-(2,6-dimethylbenzylamino)-2,3-dimethylimidazo[1,2-a]pyridin-6-yl)piperidin-2-one",6.8,uM,=,0.8325089127062363,1,O=C1CCCCN1c1cc(NCc2ccccc2)c2nccn2c1
541,1291572,10.1016/j.bmcl.2013.12.058,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N2CCC(NC(=O)OCc3cncs3)CC2)C(C)C)cs1,(S)-thiazol-5-ylmethyl 1-(2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-3-methylbutanoyl)piperidin-4-ylcarbamate,1.84,uM,=,0.2648178230095365,1,O=C(NCC(=O)N1CCC(NC(=O)OCc2cncs2)CC1)NCc1cscn1
542,1527876,,,,,Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,C[C@@H](c1ccc(-c2ccc(=O)n(C)c2)cc1)N1CC[C@](CC(C)(C)C#N)(c2ccccc2)OC1=O,"US8575157, 49",32.0,uM,=,1.505149978319906,1,O=C1OC(c2ccccc2)CCN1Cc1ccc(-c2ccc(=O)[nH]c2)cc1
543,1624781,10.1021/acs.jmedchem.6b00697,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH by LC-MS/MS analysis,O=C(NCc1ccc(S(=O)(=O)c2cccc(C(F)(F)F)c2)cc1)c1cnc2[nH]ncc2c1,"N-(4-(3-(trifluoromethyl)phenylsulfonyl)benzyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide",9.0,uM,=,0.9542425094393248,1,O=C(NCc1ccc(S(=O)(=O)c2ccccc2)cc1)c1cnc2[nH]ncc2c1
544,1465595,10.1016/j.bmcl.2015.02.039,,,,Inhibition of CYP3A4 (unknown origin) using DBF fluorometric substrate,COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2NC(=O)OCc2ccccc2)C(C)C)ccc1OC,"benzyl (3S,4S)-4-((N-isopropyl-4-methoxy-3-(3-methoxypropoxy)benzamido)methyl)pyrrolidin-3-ylcarbamate",14.8,uM,=,1.1702617153949575,1,O=C(N[C@@H]1CNC[C@H]1CNC(=O)c1ccccc1)OCc1ccccc1
545,1511048,10.1021/acs.jmedchem.5b01078,,,,Inhibition of CYP3A4 in human liver microsomes incubated for 5 mins in presence of NADPH and specific substrates by LC/MS/MS method,CCn1c([C@@H](C)NS(=O)(=O)c2cccnc2)nc2ccc(C(F)(F)F)cc21,(R)-N-(1-(1-Ethyl-6-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)ethyl)pyridine-3-sulfonamide,0.83,uM,=,-0.0809219076239261,0,O=S(=O)(NCc1nc2ccccc2[nH]1)c1cccnc1
546,802673,10.1016/j.bmcl.2011.12.125,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,O=C(Nc1ccc(-c2ccnc3[nH]cnc23)cc1)Nc1cccc(C(=O)N2CCOCC2)c1,"1-(4-(3H-imidazo[4,5-b]pyridin-7-yl)phenyl)-3-(3-(morpholine-4-carbonyl)phenyl)urea",0.29,uM,=,-0.5376020021010439,0,O=C(Nc1ccc(-c2ccnc3[nH]cnc23)cc1)Nc1cccc(C(=O)N2CCOCC2)c1
547,1581635,10.1021/acs.jmedchem.5b01146,,,,Inhibition of C-terminal four-histidine tagged human CYP3A4delta3 to 24 residues expressed in Escherichia coli assessed as 7-benzyloxy-4-(trifluoromethyl)coumarin O-debenzylation pretreated 2 mins followed by NADPH addition by fluorometric method in presence of rat cytochrome P450 reductase,c1ccncc1,Pyridine,4000.0,uM,=,3.6020599913279625,1,c1ccncc1
548,1560508,10.1016/j.bmc.2016.02.014,,,,Inhibition of CYP3A4 (unknown origin),O=C(O)CCN1CCC2(CC1)C(=O)Nc1cc(/C=C3\c4ccccc4COc4cc(F)ccc43)ccc12,"3-(6-((3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)methyl)-2-oxospiro[indoline-3,4'-piperidine]-1'-yl)propanoic acid",25.988,uM,=,1.414772858093331,1,O=C1Nc2cc(/C=C3\c4ccccc4COc4ccccc43)ccc2C12CCNCC2
549,973418,10.1016/j.bmcl.2013.05.089,,,,Inhibition of human CYP3A4,O=CN(O)[C@@H](CCCc1ncccn1)CS(=O)(=O)N1CCN(c2ccc(C(F)(F)F)cn2)CC1,(S)-N-hydroxy-N-(5-(pyrimidin-2-yl)-1-(4-(5-(trifluoromethyl)pyridin-2-yl)piperazin-1-ylsulfonyl)pentan-2-yl)formamide,1.0,uM,=,0.0,0,O=S(=O)(CCCCCc1ncccn1)N1CCN(c2ccccn2)CC1
550,51899,10.1016/j.bmcl.2003.08.027,,,,Binding affinity for Cytochrome P450 3A4; Range = 1-10 uM,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,"17-Hydroxy-10,13-dimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-cyclopenta[a]phenanthren-3-one",10.0,uM,=,1.0,1,O=C1C=C2CC[C@H]3[C@@H]4CCCC4CC[C@@H]3C2CC1
551,1689562,10.1021/acs.jmedchem.7b00598,,,,Inhibition of CYP3A4 (unknown origin),N#Cc1cc(S(=O)(=O)Nc2ncns2)ccc1Oc1ccc(Cl)cc1-c1cn[nH]c1,"4-(4-chloro-2-(1H-pyrazol-4-yl)phenoxy)-3-cyano-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide",0.505,uM,=,-0.2967086218813386,0,O=S(=O)(Nc1ncns1)c1ccc(Oc2ccccc2-c2cn[nH]c2)cc1
552,1460909,10.1021/jm501326k,,,,Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase/human b5 reductase using 7-benzyloxyquinoline substrate,CCOC(=O)c1[nH]cc2c1NC1=C(C(=O)CCC1)C2c1ccc(Sc2nc3c(O)cccc3[nH]2)o1,"(+/-)-Ethyl 9-[5-[(4-hydroxy-1H-benzimidazol-2-yl)sulfanyl]-2-furyl]-8-oxo-2,4,5,6,7,9-hexahydropyrrolo[3,4-b]quinoline-3-carboxylate",0.49,uM,=,-0.3098039199714864,0,O=C1CCCC2=C1C(c1ccc(Sc3nc4ccccc4[nH]3)o1)c1c[nH]cc1N2
553,555225,10.1016/j.bmcl.2008.05.058,,,,Inhibition of CYP3A4,CN(CC(=O)N(C)C(CN1CCCC1)c1ccccc1)c1ccc(Cl)c(Cl)c1,"(+/-)-2-((3,4-dichlorophenyl)(methyl)amino)-N-methyl-N-(1-phenyl-2-(pyrrolidin-1-yl)ethyl)acetamide",3.3,uM,=,0.5185139398778875,1,O=C(CNc1ccccc1)NC(CN1CCCC1)c1ccccc1
554,1527962,,,,,"Inhibition Assay (Testosterone Hydroxylase): To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.",NCC1CCC(c2cccnc2)O1,"US8609708, 29::US8609708, 38",64.71,uM,=,1.810971399822208,1,c1cncc(C2CCCO2)c1
555,584299,10.1016/j.bmcl.2009.05.086,,,,Inhibition of CYP3A4,Fc1ccc(Cn2c(N3CCC(n4ccnc4)CC3)nc3ccccc32)cc1,2-(4-(1H-imidazol-1-yl)piperidin-1-yl)-1-(4-fluorobenzyl)-1H-benzo[d]imidazole,72.0,uM,=,1.8573324964312683,1,c1ccc(Cn2c(N3CCC(n4ccnc4)CC3)nc3ccccc32)cc1
556,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",O=C(c1ccc(Cl)cc1-n1nccn1)N1CCOC[C@H]1Cc1cc(-c2ncccn2)ccc1F,"US9150566, 160",17.0,uM,=,1.230448921378274,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2ncccn2)c1
557,495153,10.1021/jm8006454,,,,Inhibition of CYP3A4,COc1cccc(-c2c(C)n(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](NCCCCC(=O)O)c3ccccc3)c2=O)c1F,"(R)-5-{2-[5-(2-Fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}pentanoic acid",29.0,uM,=,1.462397997898956,1,O=c1c(-c2ccccc2)cn(Cc2ccccc2)c(=O)n1CCc1ccccc1
558,1791098,10.1039/C7MD00268H,,,,Inhibition of CYP3A4 (unknown origin),Nc1nc(OCc2ccccc2)c2[nH]nnc2n1,"7-Benzyloxy-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-ylamine",14.0,uM,=,1.146128035678238,1,c1ccc(COc2ncnc3nn[nH]c23)cc1
559,51895,10.1016/j.bmcl.2003.09.093,,,,Inhibition of cytochrome P450 3A4 of isolated guinea pig heart,Cc1nc2cc(OC[C@H](O)CN3CCN(CC(=O)Nc4cccc(-c5ccccc5)c4)CC3)ccc2s1,N-Biphenyl-3-yl-2-{4-[(R)-2-hydroxy-3-(2-methyl-benzothiazol-5-yloxy)-propyl]-piperazin-1-yl}-acetamide,37.0,uM,=,1.568201724066995,1,O=C(CN1CCN(CCCOc2ccc3scnc3c2)CC1)Nc1cccc(-c2ccccc2)c1
560,438600,10.1016/j.bmcl.2007.03.048,,,,Inhibition of CYP3A4 in microsomes,Cc1cc(C2=NCCN2C)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,"4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-3-(4-methyl-6-(1-methyl-4,5-dihydro-1H-imidazol-2-yl)-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one",35.0,uM,=,1.5440680443502757,1,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(C3=NCCN3)cc2[nH]1
561,461436,10.1016/j.bmcl.2007.10.092,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,CC[C@@H]1CCC[C@H](C2(Cc3noc(C)n3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1,"(2R,6R)-1-(4-chlorophenylsulfonyl)-2-ethyl-6-(1-((5-methyl-1,2,4-oxadiazol-3-yl)methyl)cyclopropyl)piperidine",16.9,uM,=,1.2278867046136734,1,O=S(=O)(c1ccccc1)N1CCCC[C@@H]1C1(Cc2ncon2)CC1
562,1653091,10.1016/j.bmc.2016.11.019,,,,Inhibition of human CYP3A4,Cl.NCCN(C(=O)c1ccc(Cl)cc1Cl)c1ccc(F)cc1,"N-(2-aminoethyl)-2,4-dichloro-N-(4-fluorophenyl)benzamide hydrochloride",0.074,uM,=,-1.1307682802690238,0,O=C(Nc1ccccc1)c1ccccc1
563,438600,10.1016/j.bmcl.2007.03.048,,,,Inhibition of CYP3A4 in microsomes,Cc1cc(C(=O)NC2CCCC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,"2-(4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-2-oxo-1,2-dihydropyridin-3-yl)-N-cyclopentyl-7-methyl-3H-benzo[d]imidazole-5-carboxamide",1.6,uM,=,0.2041199826559248,1,O=C(NC1CCCC1)c1ccc2nc(-c3c(NCCc4ccccc4)cc[nH]c3=O)[nH]c2c1
564,859942,10.1021/jm300122u,,,,Inhibition of human CYP3A4 using testosterone as substrate after 45 mins,NC1C[C@H]2CC[C@@H](C1)N2C(=O)[C@H](Cc1ccc(Cl)cc1Cl)NC(=O)C1(c2ccc(OC(F)(F)F)cc2)CC1,"N-((2S)-1-((1R,5S)-3-amino-8-azabicyclo[3.2.1]octan-8-yl)-3-(2,4-dichlorophenyl)-1-oxopropan-2-yl)-1-(4-(trifluoromethoxy)phenyl)cyclopropanecarboxamide",2.4,uM,=,0.380211241711606,1,O=C([C@H](Cc1ccccc1)NC(=O)C1(c2ccccc2)CC1)N1[C@@H]2CCC[C@H]1CC2
565,560756,10.1016/j.bmcl.2008.11.008,,,,Inhibition of CYP3A4 red,C[C@H]1CN(S(=O)(=O)C[C@]23CC[C@H](CC2=O)C3(C)C)CCN1c1ncc(C(F)(F)F)cc1F,"(1S,4R)-1-(((S)-4-(3-fluoro-5-(trifluoromethyl)pyridin-2-yl)-3-methylpiperazin-1-ylsulfonyl)methyl)-7,7-dimethylbicyclo[2.2.1]heptan-2-one",0.32,uM,=,-0.494850021680094,0,O=C1C[C@H]2CC[C@]1(CS(=O)(=O)N1CCN(c3ccccn3)CC1)C2
566,434712,10.1021/jm070104l,,,,Inhibition of human CYP3A4,COc1cc2nc(N3CCC[C@@H](N)C3)n(Cc3ccccc3C#N)c(=O)c2cc1OC,"(R)-2-((2-(3-aminopiperidin-1-yl)-6,7-dimethoxy-4-oxoquinazolin-3(4H)-yl)methyl)benzonitrile",0.5,uM,=,-0.3010299956639812,0,O=c1c2ccccc2nc(N2CCCCC2)n1Cc1ccccc1
567,828928,10.1016/j.bmcl.2012.06.022,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,CCN(C)c1nc2ccc(C(=O)N(CC(C)C)C[C@@H](O)[C@H](Cc3ccc(F)cc3)NC(=O)OCc3cncs3)cc2o1,"Thiazol-5-ylmethyl(2S,3R)-4-(2-(ethyl(methyl)amino)-N-isobutylbenzo[d]oxazole-6-carboxamido)-1-(4-fluorophenyl)-3-hydroxybutan-2-ylcarbamate",0.023,uM,=,-1.6382721639824072,0,O=C(N[C@H](CCNC(=O)c1ccc2ncoc2c1)Cc1ccccc1)OCc1cncs1
568,1465542,10.1016/j.bmcl.2015.01.051,,,,Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(CC6CN(C7COC7)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O,"(1S,4R,5R,6R,8R,10S,11R,12S,13R,16R,18S,21R)-8-[(1S)-1-ethoxy-2-hydroxy-2-methylpropyl]-4,6,12,17,17-pentamethyl-18-{[(2S)-4-{[1-(oxetan-3-yl)azetidin-3-yl]methyl}morpholin-2-yl]oxy}-9-oxahexacyclo[11.9.0.0^{1,21}.0^{4,12}.0^{5,10}.0^{16,21}]docosan-11-ol",1.9,uM,=,0.2787536009528289,1,C1CO[C@@H]2CC3C(CC[C@@]45C[C@@]46CC[C@H](O[C@H]4CN(CC7CN(C8COC8)C7)CCO4)C[C@@H]6CC[C@@H]35)[C@H]2C1
569,581617,10.1016/j.bmcl.2009.06.096,,,,Inhibition of CYP3A4 using testosterone as substrate,O=C(c1ccccc1C(F)(F)F)N(CC1CCC1)[C@H]1CCNC1,(S)-N-(cyclobutylmethyl)-N-(pyrrolidin-3-yl)-2-(trifluoromethyl)benzamide,31.2,uM,=,1.4941545940184429,1,O=C(c1ccccc1)N(CC1CCC1)[C@H]1CCNC1
570,859942,10.1021/jm300122u,,,,Inhibition of human CYP3A4 using testosterone as substrate after 45 mins,C[C@@H]1CN(C(=O)[C@H](Cc2ccc(Cl)cc2Cl)NC(=O)C2(c3ccc(Cl)cc3Cl)CC2)CCN1,"1-(2,4-Dichlorophenyl)-N-{(1S)-1-[(2,4-dichlorophenyl)-methyl]-2-[(3R)-3-methylpiperazin-1-yl]-2-oxoethyl}-cyclopropanecarboxamide",0.45,uM,=,-0.3467874862246563,0,O=C([C@H](Cc1ccccc1)NC(=O)C1(c2ccccc2)CC1)N1CCNCC1
571,598210,10.1016/j.bmcl.2009.08.024,,,,Inhibition of human CYP3A4,CC(C)(C)OC(=O)Nc1cccc(CCNC(=O)CC2(C)CC3(CCCCC3)OO2)c1,"tert-butyl 3-(2-(2-(3-methyl-1,2-dioxaspiro[4.5]decan-3-yl)acetamido)ethyl)phenylcarbamate",1.0,uM,=,0.0,0,O=C(CC1CC2(CCCCC2)OO1)NCCc1ccccc1
572,857201,10.1021/jm200900q,,,,Inhibition of CYP3A4,N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(Cc4ccccn4)CC3)cc2C2=CCCCC2)n1,4-Cyano-1H-imidazole-2-carboxylic Acid[2-Cyclohex-1-enyl-4-(1-pyridin-2-ylmethyl-piperidin-4-yl)-phenyl]-amide,5.6,uM,=,0.7481880270062004,1,O=C(Nc1ccc(C2CCN(Cc3ccccn3)CC2)cc1C1=CCCCC1)c1ncc[nH]1
573,51930,10.1016/s0960-894x(01)00614-x,,,,Inhibition of recombinant human Cytochrome P450 3A4,CCCCc1ccccc1/N=C/NO,N-(2-butylphenyl)-N'-hydroxyimidoformamide,51.0,uM,=,1.7075701760979365,1,c1ccccc1
574,449485,10.1016/j.bmcl.2007.07.097,,,,Inhibition of microsomal CYP3A4,CC(C)C[C@H](NC(=O)CN)c1cc(F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1,"2-amino-N-((S)-1-(2-(4-((R)-3-(2,4-dichlorophenyl)-2-(2-oxopyrrolidin-1-yl)propanoyl)piperazin-1-yl)-5-fluorophenyl)-3-methylbutyl)acetamide",3.6,uM,=,0.5563025007672873,1,O=C([C@@H](Cc1ccccc1)N1CCCC1=O)N1CCN(c2ccccc2)CC1
575,802673,10.1016/j.bmcl.2011.12.125,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Nc1ccc(-c2ccc(NC(=O)Nc3ccc(-c4ccnc5[nH]cnc45)cc3)cc2)cc1,"1-(4-(3H-imidazo[4,5-b]pyridin-7-yl)phenyl)-3-(4'-aminobiphenyl-4-yl)urea",0.2,uM,=,-0.6989700043360187,0,O=C(Nc1ccc(-c2ccccc2)cc1)Nc1ccc(-c2ccnc3[nH]cnc23)cc1
576,2217386,10.1021/acs.jmedchem.1c02141,,,,Competitive inhibition of human recombinant CYP3A4 using coumarin as substrate preincubated with enzyme for 10 mins followed by NADPH addition and measured after 20 to 50 mins by fluorescence based method,C[C@@H](N)c1cc(Cl)ccc1Cn1c(=S)[nH]c(=O)c2[nH]ccc21,MITIPERSTAT,6.0,uM,=,0.7781512503836436,1,O=c1[nH]c(=S)n(Cc2ccccc2)c2cc[nH]c12
577,2023287,10.1016/j.bmcl.2020.127636,,,,Inhibition of CYP3A4 (unknown origin),COc1ccccc1C1c2c(n[nH]c2C(C)(C)C)C(=O)N1c1ccc(-c2ncco2)cc1,"US8575197, II-209",8.0,uM,=,0.9030899869919436,1,O=C1c2n[nH]cc2C(c2ccccc2)N1c1ccc(-c2ncco2)cc1
578,1745612,10.1016/j.bmcl.2017.10.010,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins in presence of NADPH by LC-MS/MS analysis,CCN[C@@H]1CCC=C(c2ccc(F)cc2)[C@H]1COc1cc(F)c(S(=O)(=O)Nc2cscn2)cc1Cl.Cl,(+/-)-5-chloro-4-((6-(ethylamino)-2-(4-fluorophenyl)cyclohex-2-enyl)methoxy)-2-fluoro-N-(thiazol-4-yl)benzenesulfonamide hydrochloride,43.4,uM,=,1.6374897295125108,1,O=S(=O)(Nc1cscn1)c1ccc(OC[C@H]2CCCC=C2c2ccccc2)cc1
579,519907,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,Cc1cccc(C)c1CNc1cc(-n2cccn2)cn2c(C)c(C)nc12,"N-(2,6-dimethylbenzyl)-2,3-dimethyl-6-(1H-pyrazol-1-yl)imidazo[1,2-a]pyridin-8-amine",2.9,uM,=,0.4623979978989561,1,c1ccc(CNc2cc(-n3cccn3)cn3ccnc23)cc1
580,52064,10.1016/s0960-894x(03)00058-1,,,,Inhibitory activity against CYP450 3A4 isozyme,CCN(CC)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(=O)Cn1cc(Br)c(=O)nc1SCc1ccc(F)cc1,2-[5-Bromo-2-(4-fluoro-benzylsulfanyl)-4-oxo-4H-pyrimidin-1-yl]-N-(2-diethylamino-ethyl)-N-(4'-trifluoromethyl-biphenyl-4-ylmethyl)-acetamide,39.0,uM,=,1.591064607026499,1,O=C(Cn1ccc(=O)nc1SCc1ccccc1)NCc1ccc(-c2ccccc2)cc1
581,1527876,,,,,Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,C[C@@H](c1ccc(-c2ccc(=O)n(CC(F)(F)F)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O,"US8575157, 67",28.0,uM,=,1.4471580313422192,1,O=C1OC(c2ccccc2)CCN1Cc1ccc(-c2ccc(=O)[nH]c2)cc1
582,1651046,10.1021/acs.jmedchem.5b00507,,,,Inhibition of CYP3A4 (unknown origin),O=C(COc1ccc(-n2ccnc2)cc1)Nc1ccc(-c2ccccc2)cc1,"2-(4-(1H-Imidazol-1-yl)phenoxy)-N-([1,1'-biphenyl]-4-yl)-acetamide",0.02,uM,=,-1.6989700043360187,0,O=C(COc1ccc(-n2ccnc2)cc1)Nc1ccc(-c2ccccc2)cc1
583,1364175,10.1021/ml500019s,,,,Inhibition of CYP3A4 (unknown origin) pre-incubated with enzyme,COCCOc1ccccc1N1CCN(C(=O)[C@]2(Oc3ccc(C(F)(F)F)cc3)CCCN(C(=O)c3cnccc3C(F)(F)F)[C@@H]2CC(O)CO)CC1.Cl,"((2R,3S)-2-(2,3-dihydroxypropyl)-1-(4-(trifluoromethyl)nicotinoyl)-3-(4-(trifluoromethyl)phenoxy)piperidin-3-yl)(4-(2-(2-methoxyethoxy)phenyl)piperazin-1-yl)methanone hydrochloride",7.5,uM,=,0.8750612633917001,1,O=C(c1cccnc1)N1CCC[C@@](Oc2ccccc2)(C(=O)N2CCN(c3ccccc3)CC2)C1
584,2241392,10.1016/j.ejmech.2021.113981,,,,Inhibition of CYP3A4 in human liver microsomes assessed as reduction in 6-beta-hydroxy-testosterone formation using testosterone as substrate preincubated for 20 mins in presence of NADPH followed by incubation with substrate for 10 mins by LC-MS/MS analysis,O[C@H](c1cc(C(F)(F)F)nc2c(C(F)(F)F)cccc12)[C@@H]1CCCCN1,"(R)-(2,8-bis(trifluoromethyl)quinolin-4-yl)((S)-piperidin-2-yl)methanol",12.0,uM,=,1.0791812460476249,1,c1ccc2c(C[C@@H]3CCCCN3)ccnc2c1
585,536049,10.1016/j.bmcl.2008.08.010,,,,Inhibition of human CYP3A4 by microtiter plate assays using PPR substrate,COc1cccc(S(=O)(=O)n2ccc3cc4c(cc32)CCNCC4)c1,"1-(3-methoxyphenylsulfonyl)-1,5,6,7,8,9-hexahydroazepino[4,5-f]indole",27.0,uM,=,1.4313637641589874,1,O=S(=O)(c1ccccc1)n1ccc2cc3c(cc21)CCNCC3
586,536049,10.1016/j.bmcl.2008.08.010,,,,Inhibition of human CYP3A4 by microtiter plate assays using PPR substrate,O=S(=O)(c1ccccc1Cl)n1ccc2cc3c(cc21)CCNCC3,"1-(2-chlorophenylsulfonyl)-1,5,6,7,8,9-hexahydroazepino[4,5-f]indole",3.2,uM,=,0.505149978319906,1,O=S(=O)(c1ccccc1)n1ccc2cc3c(cc21)CCNCC3
587,774749,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1,"Acetic acid (2S,3S)-5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester",1.8366,uM,=,0.2640145799809782,1,O=C1C[C@H](c2ccccc2)Sc2ccccc2N1
588,1828801,10.1021/acs.jmedchem.8b01098,,,,Inhibition of C-terminal 4His-tagged CYP3A4 (unknown origin) expressed in Escherichia coli by spectrophotometric analysis,COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccnnc3)cc2)c1,(R)-N-(1-(3-Methoxyphenyl)ethyl)-4-(pyridazin-4-yl)-benzamide,16.7,uM,=,1.2227164711475833,1,O=C(NCc1ccccc1)c1ccc(-c2ccnnc2)cc1
589,1637154,,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins,N#Cc1cnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4cccnc4)c3F)c2c1,"Pyridine-3-sulfonic acid [3-(5-cyano-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-amide",5.0,uM,=,0.6989700043360189,1,O=C(c1cccc(NS(=O)(=O)c2cccnc2)c1)c1c[nH]c2ncccc12
590,649576,10.1021/jm100317b,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsome,Nc1ccc(-c2ccc(Cc3ccncc3)cc2)cc1,4'-(Pyridin-4-ylmethyl)biphenyl-4-amine,2.45,uM,=,0.3891660843645325,1,c1ccc(-c2ccc(Cc3ccncc3)cc2)cc1
591,1447575,10.1016/j.bmcl.2014.05.068,,,,Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method,C[C@@H](c1ncncc1F)[C@](O)(Cn1cnnn1)c1ccc(F)cc1F,"(2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-tetrazol-1-yl)butan-2-ol",32.0,uM,=,1.505149978319906,1,c1ccc(C(Cc2ccncn2)Cn2cnnn2)cc1
592,2103815,10.1016/j.bmcl.2021.128010,,,,Time dependent inhibition of CYP3A4 (unknown origin) measured at 30 mins,Nc1cc(Cc2ccn(Cc3cccc(Oc4cccc5c4CNC5)c3)n2)c2nn[nH]c2n1,"7-((1-(3-(isoindolin-4-yloxy)benzyl)-1H-pyrazol-3-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-amine",0.14,uM,=,-0.8538719643217619,0,c1cc(Cn2ccc(Cc3ccnc4[nH]nnc34)n2)cc(Oc2cccc3c2CNC3)c1
593,52064,10.1016/s0960-894x(03)00058-1,,,,Inhibitory activity against CYP450 3A4 isozyme,CCN(CC)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(=O)Cn1cc(SC)c(=O)nc1SCc1ccc(F)cc1,N-(2-Diethylamino-ethyl)-2-[2-(4-fluoro-benzylsulfanyl)-5-methylsulfanyl-4-oxo-4H-pyrimidin-1-yl]-N-(4'-trifluoromethyl-biphenyl-4-ylmethyl)-acetamide,15.0,uM,=,1.1760912590556811,1,O=C(Cn1ccc(=O)nc1SCc1ccccc1)NCc1ccc(-c2ccccc2)cc1
594,856843,10.1021/jm300356u,,,,Inhibition of human recombinant CYP3A4 using DEF as substrate preincubated for 5 to 10 mins before substrate addition,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H]3[C@H]2O/C(=N\C(C)(C)C)N3C)[C@](C)(OC)C[C@@H](C)C(=O)N[C@H](C)[C@@H](O)[C@]1(C)O,"(2R,3S,4R,5R,10R,11R,12S,13S,14R)-11-((3aR,4S,6R,7aS)-2-(tert-butylimino)-1,6-dimethylhexahydro-1H-pyrano[4,3-d]oxazol-4-yloxy)-2-ethyl-3,4-dihydroxy-13-((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yloxy)-10-methoxy-3,5,8,10,12,14-hexamethyl-1-oxa-6-azacyclopentadecane-7,15-dione",1.4,uM,=,0.1461280356782379,1,N=C1N[C@H]2CCO[C@@H](O[C@H]3CCCC(=O)NCCCCOC(=O)C[C@@H](O[C@H]4CCCCO4)C3)[C@@H]2O1
595,455108,10.1016/j.bmcl.2006.12.043,,,,Inhibition of CYP3A4,NC(C(=O)N1CCN(c2ccc3[nH]ncc3c2)CC1)c1ccc(Cl)cc1,1-(4-(1H-indazol-5-yl)piperazin-1-yl)-2-amino-2-(4-chlorophenyl)ethanone,0.53,uM,=,-0.2757241303992109,0,O=C(Cc1ccccc1)N1CCN(c2ccc3[nH]ncc3c2)CC1
596,471117,10.1016/j.bmc.2007.10.061,,,,Inhibition of CYP3A4,Nc1nccn2c1c(-c1ccc3ccc(-c4ccccc4)nc3c1)nc2[C@H]1C[C@@H](N2CCOCC2)C1,"cis-3-(3-morpholin-4-ylcyclobutyl)-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-8-ylamine",12.0,uM,=,1.0791812460476249,1,c1ccc(-c2ccc3ccc(-c4nc([C@H]5C[C@@H](N6CCOCC6)C5)n5ccncc45)cc3n2)cc1
597,2207924,10.1021/acsmedchemlett.2c00411,,,,Inhibition of CYP3A4 (unknown origin) in absence of NADPH,COc1ccc(Nc2ncc(C)c(Nc3ccc4oc(=O)[nH]c4c3)n2)cc1C(F)(F)F,5-((2-((4-methoxy-3-(trifluoromethyl)phenyl)amino)-5-methylpyrimidin-4-yl)amino)benzo[d]oxazol-2(3H)one,4.8,uM,=,0.6812412373755872,1,O=c1[nH]c2cc(Nc3ccnc(Nc4ccccc4)n3)ccc2o1
598,1625990,10.1016/j.bmcl.2016.04.095,,,,Inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins after 30 secs by LC/MS/MS analysis,NCCS(=O)(=O)CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12,"2-(2-((4S,4aS,10bS)-10b-(4-chlorophenylsulfonyl)-7,10-difluoro-1,2,4,4a,5,10b-hexahydropyrano[3,4-c]chromen-4-yl)ethylsulfonyl)ethanamine",2.8,uM,=,0.4471580313422192,1,O=S(=O)(c1ccccc1)[C@@]12CCOC[C@@H]1COc1ccccc12
599,461436,10.1016/j.bmcl.2007.10.092,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,CC[C@@H]1CCC[C@H](C2(CC(=O)N3CC[C@@H](O)C3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1,"2-(1-((2R,6R)-1-(4-chlorophenylsulfonyl)-6-ethylpiperidin-2-yl)cyclopropyl)-1-((R)-3-hydroxypyrrolidin-1-yl)ethanone",11.9,uM,=,1.0755469613925308,1,O=C(CC1([C@H]2CCCCN2S(=O)(=O)c2ccccc2)CC1)N1CCCC1
600,859942,10.1021/jm300122u,,,,Inhibition of human CYP3A4 using testosterone as substrate after 45 mins,NC1C[C@H]2CC[C@@H](C1)N2C(=O)[C@H](Cc1ccc(Br)cc1)NC(=O)C1(c2ccc(Cl)cc2Cl)CC1,"N-((2S)-1-((1R,5S)-3-amino-8-azabicyclo[3.2.1]octan-8-yl)-3-(4-bromophenyl)-1-oxopropan-2-yl)-1-(2,4-dichlorophenyl)cyclopropanecarboxamide",0.6,uM,=,-0.2218487496163563,0,O=C([C@H](Cc1ccccc1)NC(=O)C1(c2ccccc2)CC1)N1[C@@H]2CCC[C@H]1CC2
601,51907,10.1016/s0960-894x(03)00475-x,,,,In vitro inhibition of human liver microsome Cytochrome P450 3A4,CC(C)(c1ccc(-c2ccncc2)o1)N1CCN(C[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3OC[C@H]2O)[C@H](C(=O)NCC(F)(F)F)C1,"(S)-1-[(S)-2-Hydroxy-4-((R)-(S)-3-hydroxy-3,4,4a,8a-tetrahydro-2H-chromen-4-ylcarbamoyl)-5-phenyl-pentyl]-4-[1-methyl-1-(5-pyridin-4-yl-furan-2-yl)-ethyl]-piperazine-2-carboxylic acid (2,2,2-trifluoro-ethyl)-amide",0.01,uM,=,-2.0,0,O=C(N[C@@H]1CCOc2ccccc21)[C@@H](CCCN1CCN(Cc2ccc(-c3ccncc3)o2)CC1)Cc1ccccc1
602,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cccc(-n3cncn3)c2)c1,"US9150566, 23",6.0,uM,=,0.7781512503836436,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2cncn2)c1
603,2132129,10.1021/acs.jmedchem.1c01559,,,,Inhibition of CYP3A4T in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH by LC-MS/MS analysis,CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,SID144204227,0.022,uM,=,-1.6575773191777938,0,c1ccc([C@@]2(Cn3ccnc3)OC[C@H](COc3ccc(N4CCNCC4)cc3)O2)cc1
604,2068401,10.1016/j.bmcl.2020.127676,,,,Inhibition of CYP3A4 (unknown origin),CN[C@@H](C)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)Nc1cc2c(NC[C@H]3CC[C@H](CNc4ncnc5cc(OC)c(NC(=O)[C@@H]6CCCN6C(=O)[C@@H](NC(=O)[C@H](C)NC)C(C)(C)C)cc45)CC3)ncnc2cc1OC)C(C)(C)C,"(S,S,2S,2'S)-N,N'-(4,4'-(1r,4r)-cyclohexane-1,4-diylbis(methylene)bis(azanediyl)bis(7-methoxyquinazoline-6,4-diyl))bis(1-((S)-3,3-dimethyl-2-((S)-2-(methylamino)propanamido)butanoyl)pyrrolidine-2-carboxamide)",0.46,uM,=,-0.3372421683184259,0,O=C(Nc1ccc2ncnc(NC[C@H]3CC[C@H](CNc4ncnc5ccc(NC(=O)[C@@H]6CCCN6)cc45)CC3)c2c1)[C@@H]1CCCN1
605,1744980,10.1016/j.bmcl.2017.09.046,,,,Inhibition of human CYP3A4 expressed in Escherichia coli co-expressing CYP-reductase using diethoxyfluorescein as substrate measured after 10 mins by fluorescence assay,CCc1cccc(-c2c(Cl)cccc2C(O)(CCCNC(=O)OC)[C@@H]2CCCN(C(=O)[C@@H]3CC[C@H](N)C3)C2)c1,"methyl 4-((R)-1-((1R,3S)-3-aminocyclopentanecarbonyl)piperidin-3-yl)-4-(6-chloro-3'-ethylbiphenyl-2-yl)-4-hydroxybutylcarbamate",0.034,uM,=,-1.4685210829577449,0,O=C(C1CCCC1)N1CCC[C@@H](Cc2ccccc2-c2ccccc2)C1
606,1540696,10.1016/j.ejmech.2015.08.051,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 2 mins by LC-MS/MS analysis in presence of NADPH regeneration system,CC(C)c1nc(C(=O)NCC2CCN(CC3CCOCC3)CC2)c2ccccn12,"3-isopropyl-N-((1-((tetrahydro-2H-pyran-4-yl)methyl)piperidin-4-yl)methyl)imidazo[1,5-a]pyridine-1-carboxamide",25.5,uM,=,1.4065401804339552,1,O=C(NCC1CCN(CC2CCOCC2)CC1)c1ncn2ccccc12
607,51915,10.1016/s0960-894x(03)00680-2,,,,Inhibition of human liver microsome Cytochrome P450 3A4,O=C(N[C@H]1c2ccccc2OC[C@H]1O)[C@H](Cc1ccncc1)C[C@H](O)CN1CCN(Cc2ccc(-c3ccccc3)o2)C[C@H]1C(=O)NCC(F)(F)F,"(S)-1-[(2S,4R)-2-Hydroxy-4-((3S,4S)-3-hydroxy-chroman-4-ylcarbamoyl)-5-pyridin-4-yl-pentyl]-4-(5-phenyl-furan-2-ylmethyl)-piperazine-2-carboxylic acid (2,2,2-trifluoro-ethyl)-amide",1.5,uM,=,0.1760912590556812,1,O=C(N[C@@H]1CCOc2ccccc21)[C@@H](CCCN1CCN(Cc2ccc(-c3ccccc3)o2)CC1)Cc1ccncc1
608,1640557,,,,,"null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.",C=CN(C=N)C(c1ccccc1)c1ccc(-c2ccccc2)cc1,"US9138393, Bifonazole",0.8,uM,=,-0.0969100130080563,0,c1ccc(Cc2ccc(-c3ccccc3)cc2)cc1
609,772032,10.1021/jm2006222,,,,Inhibition of CYP3A4 using BFC as substrate,COc1cc(OC)c(Cl)c(NC(=O)N(C)c2cc(Nc3ccc(CCCN(C)C)cc3)ncn2)c1Cl,"3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(3-dimethylamino-propyl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea",1.0,uM,=,0.0,0,O=C(Nc1ccccc1)Nc1cc(Nc2ccccc2)ncn1
610,2246770,10.1016/j.ejmech.2022.114195,,,,Inhibition of CYP3A4 in human liver microsomes using as midazolam substrate incubated for 10 min followed by NADPH addition for 10 mins by LC-MS/MS analysis,Fc1cccc(F)c1CC1(Cn2cncn2)COC(c2ccc(-c3ccsc3)cc2)=N1,"4-((1H-1,2,4-triazol-1-yl)methyl)-4-(2,6-difluorobenzyl)-2-(4-(thiophen-3-yl)phenyl)-4,5-dihydrooxazole",1.81,uM,=,0.2576785748691845,1,c1ccc(CC2(Cn3cncn3)COC(c3ccc(-c4ccsc4)cc3)=N2)cc1
611,2166000,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH and measured by LC-MS/MS analysis,Cc1c(C(=O)Nc2cnn([C@H](C)c3ccc(C(F)(F)F)cc3C(F)(F)F)c2)noc1-c1ccccn1,"N-[1-[(1R)-1-[2,4-bis(trifluoromethyl)phenyl]ethyl]pyrazol-4-yl]-4-methyl-5-(2-pyridyl)isoxazole-3-carboxamide",15.83,uM,=,1.199480914862356,1,O=C(Nc1cnn(Cc2ccccc2)c1)c1cc(-c2ccccn2)on1
612,1301272,10.6019/CHEMBL3137386,,,,DNDI: CYP Inhibition,O=C(C(c1ccc(Cl)cc1)c1cccnc1)N1CCN(c2ccc(C(F)(F)F)cc2)CC1,rac-2-(4-Chlorophenyl)-1-{4-[4-(trifluoromethyl)phenyl]piperazin-1-yl}-2-(pyridin-3-yl)ethanone,1.2,uM,=,0.0791812460476248,1,O=C(C(c1ccccc1)c1cccnc1)N1CCN(c2ccccc2)CC1
613,479364,10.1016/j.bmcl.2008.05.027,,,,Inhibition of CYP3A4,COCCN(CC(=O)N1CCCC(c2ccccc2)C1CN1CCOCC1)c1ccc(Cl)c(Cl)c1,"rac-2-((3,4-dichlorophenyl)(2-methoxyethyl)amino)-1-(2-(morpholinomethyl)-3-phenylpiperidin-1-yl)ethanone",0.48,uM,=,-0.3187587626244128,0,O=C(CNc1ccccc1)N1CCCC(c2ccccc2)C1CN1CCOCC1
614,489969,10.1021/jm800566m,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein substrate,Cc1nn(C)c2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc12.Cl,"3-({4-[(1,3-Dimethyl-1H-indazol-6-yl)(methyl)amino]-2-pyrimidinyl}amino)benzenesulfonamide",13.0,uM,=,1.1139433523068367,1,c1ccc(Nc2nccc(Nc3ccc4cn[nH]c4c3)n2)cc1
615,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1ccc(C(=O)N2CCOC[C@H]2Cc2cccc(-c3ncon3)c2)c(-n2nccn2)c1,"US9150566, 81",33.0,uM,=,1.5185139398778875,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2ncon2)c1
616,1849384,10.1016/j.bmcl.2019.06.044,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis,O=C(O)c1ccc(-n2cc(C(=O)c3c(Cl)cccc3C(F)(F)F)c3ccccc32)cc1,4-[3-[2-chloro-6-(trifluoromethyl)benzoyl]indol-1-yl]benzoic acid,37.0,uM,=,1.568201724066995,1,O=C(c1ccccc1)c1cn(-c2ccccc2)c2ccccc12
617,552281,10.1016/j.bmcl.2008.04.036,,,,Inhibition of CYP3A4,COc1cccc(-c2cn(Cc3c(F)cccc3S(C)(=O)=O)c(=O)n(C[C@H](N)c3ccccc3)c2=O)c1F,"3-((R)-2-Amino-2-phenyl-ethyl)-1-(2-fluoro-6-methanesulfonyl-benzyl)-5-(2-fluoro-3-methoxy-phenyl)-1H-pyrimidine-2,4-dione",0.38,uM,=,-0.4202164033831898,0,O=c1c(-c2ccccc2)cn(Cc2ccccc2)c(=O)n1CCc1ccccc1
618,1447575,10.1016/j.bmcl.2014.05.068,,,,Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method,OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(OCC(F)(F)F)cn1,"2-(2,4-difluorophenyl)-1,1-difluoro-3-(1H-tetrazol-1-yl)-1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)propan-2-ol",72.0,uM,=,1.8573324964312683,1,c1ccc(C(Cc2ccccn2)Cn2cnnn2)cc1
619,1486438,10.1124/dmd.111.043018,,,,Inhibition of human CYP3A4 expressed in supersomes assessed inhibition of 1'-OH midazolam formation preincubated for 15 mins before substrate addition by LC-MS method,C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C,"30-Ethyl-33-(1-hydroxy-2-methyl-hex-4-enyl)-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31undecaaza-cyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone",1.45,uM,=,0.1613680022349748,1,O=C1CNC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)CN1
620,434712,10.1021/jm070104l,,,,Inhibition of human CYP3A4,COc1cccc2c(=O)n(Cc3ccccc3C#N)c(N3CCCC(N)C3)nc12,2-((2-(3-aminopiperidin-1-yl)-8-methoxy-4-oxoquinazolin-3(4H)-yl)methyl)benzonitrile,0.63,uM,=,-0.2006594505464183,0,O=c1c2ccccc2nc(N2CCCCC2)n1Cc1ccccc1
621,769156,10.1021/jm2003552,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,CCCCc1nc2cc(/C=C/C(=O)NO)ccc2n1CCN(CC)CC.Cl.Cl,(E)-3-[2-Butyl-1-(2-diethylaminoethyl)-1H-benzimidazol-5-yl]-N-hydroxyacrylamide Dihydrochloride Salt,2.73,uM,=,0.436162647040756,1,c1ccc2[nH]cnc2c1
622,1528565,,,,,"Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",CC(C)c1nc(CN(C)C(=O)N2C[C@H](N3CCOCC3)C[C@H]2C(=O)N[C@@H](CC[C@@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,"US8987313, 35",0.15,uM,=,-0.8239087409443188,0,O=C(N[C@@H](CC[C@@H](Cc1ccccc1)NC(=O)[C@@H]1C[C@@H](N2CCOCC2)CN1C(=O)NCc1cscn1)Cc1ccccc1)OCc1cncs1
623,717286,10.1021/np100665j,,,,Inhibition of CYP3A4 after 30 mins by fluorometric assay,COc1cc([C@@H]2Oc3cc(CCCO)ccc3O[C@H]2CO)ccc1O,"(7S,8S)-methoxy-3',7-epoxy-8,4'-oxyneoligna-4,9,9'-triol",54.2,uM,=,1.7339992865383869,1,c1ccc([C@H]2COc3ccccc3O2)cc1
624,1919651,,,,,"Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase",NCC#Cc1cccnc1,3-Pyridin-3-yl-prop-2-ynylamine,365.0,uM,=,2.562292864456474,1,c1ccncc1
625,1668102,10.1016/j.bmcl.2017.04.006,,,,Inhibition of recombinant human CYP3A4 expressed in insect cells using DBOMF as substrate pretreated for 10 mins followed by substrate addition measured every minute for 15 mins in presence of NADP+ by fluorescence assay,COc1ccc(CNc2c3c(nc4cc(Cl)ccc24)CCCC3)cc1OC,"6-chloro-N-(3,4-dimethoxybenzyl)-1,2,3,4-tetrahydroacridin-9-amine",13.8,uM,=,1.1398790864012365,1,c1ccc(CNc2c3c(nc4ccccc24)CCCC3)cc1
626,862399,10.1021/jm300601d,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis,N=C(N)NC(=O)c1ccc(C2CCN(C(=O)c3ccc(F)cc3)CC2)c(C(F)(F)F)c1,N-{4-[1-(4-Fluoro-benzoyl)-piperidin-4-yl]-3-trifluoromethyl-benzoyl}-guanidine,6.0,uM,=,0.7781512503836436,1,O=C(c1ccccc1)N1CCC(c2ccccc2)CC1
627,1467194,10.1021/jm5005336,,,,Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay,CN1CCN(c2ccc(/C=C/c3n[nH]c4cc([C@@H]5C[C@@]56C(=O)N(C)c5ccccc56)ccc34)cn2)CC1,"(1R,2S)-1'-Methyl-2-(3-((E)-2-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)vinyl)-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-one",2.9,uM,=,0.4623979978989561,1,O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccc(N4CCNCC4)nc3)n[nH]c2c1
628,448320,10.1016/j.bmc.2007.05.069,,,,Inhibition of CYP3A4,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(=O)OC)C(=O)C(C)(c1cc(F)cc(F)c1)O2,"methyl 2-(6-(2,4-diamino-6-ethylpyrimidin-5-yl)-2-(3,5-difluorophenyl)-2-methyl-3-oxo-2,3-dihydrobenzo[b][1,4]oxazin-4-yl)ethylcarbamate",0.67,uM,=,-0.1739251972991735,0,O=C1Nc2cc(-c3cncnc3)ccc2OC1c1ccccc1
629,657985,10.1021/jm100482n,,,,Inhibition of CYP3A4 in human liver microsomes measured after incubation,CNC(=O)c1ncn2c1COc1c(CCN3CCN(c4cccc5nc(C)ccc45)CC3)cccc1-2,"N-methyl-6-(2-(4-(2-methylquinolin-5-yl)piperazin-1-yl)ethyl)-4H-benzo[b]imidazo[1,5-d][1,4]oxazine-3-carboxamide",82.0,uM,=,1.9138138523837167,1,c1cc(CCN2CCN(c3cccc4ncccc34)CC2)c2c(c1)-n1cncc1CO2
630,1335568,10.1021/jm401731q,,,,Inhibition of CYP3A4 (unknown origin),CN1CCN(c2cc(N3CCC[C@H]3C(=O)NCCc3ccc(C#N)cc3)nc(C(F)(F)F)n2)CC1,(2S)-N-[2-(4-Cyanophenyl)ethyl]-1-[6-(4-methylpiperazin-1-yl)-2-(trifluoromethyl)pyrimidin-4-yl]pyrrolidine-2-carboxamide,2.2,uM,=,0.3424226808222063,1,O=C(NCCc1ccccc1)[C@@H]1CCCN1c1cc(N2CCNCC2)ncn1
631,1509544,10.1021/acs.jmedchem.5b00810,,,,Time dependent inhibition of CYP3A4 in human liver microsomes,COc1cc2c(cc1OC(C)C)[C@H](c1ccc(Cl)cc1)N(c1ccc(N(C)C[C@H]3CC[C@H](N4CC(=O)N(C)C4)CC3)nc1)C(=O)C2,"(trans)-(S)-1-(4-Chloro-phenyl)-7-isopropoxy-6-methoxy-2-(6-{methyl-[4-(3-methyl-4-oxo-imidazolidin-1-yl)-cyclohexylmethyl]-amino}-pyridin-3-yl)-1,4-dihydro-2H-isoquinolin-3-one",13.2,uM,=,1.1205739312058498,1,O=C1CN([C@H]2CC[C@H](CNc3ccc(N4C(=O)Cc5ccccc5[C@@H]4c4ccccc4)cn3)CC2)CN1
632,2012350,10.1016/j.bmcl.2018.10.050,,,,Inhibition of CYP3A4 (unknown origin),c1cnc2c(Nc3ccc4cnccc4c3)n[nH]c2c1,"N-(1H-pyrazolo[4,3-b]pyridin-3-yl)isoquinolin-6-amine",0.44,uM,=,-0.3565473235138126,0,c1cnc2c(Nc3ccc4cnccc4c3)n[nH]c2c1
633,2091855,10.1016/j.ejmech.2020.112604,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 5 mins followed by NADPH addition and measured after 5 mins by LC-MS/MS analysis,C=C[C@]1(C)C[C@@H](OC(=O)CSc2ccccc2NC(=O)Cn2cc(CN(C)C)nn2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O,"22-(2-(2-(4-((dimethylamino)methyl)-1H-1,2,3-triazol-1-yl)acetamido)phenyl)thioacety-1-yl-22-deoxypleuromutilin",6.148,uM,=,0.7887338588277075,1,O=C(Cn1ccnn1)Nc1ccccc1SCC(=O)O[C@@H]1CCCC[C@@]23CCCC1[C@@H]2C(=O)CC3
634,449485,10.1016/j.bmcl.2007.07.097,,,,Inhibition of microsomal CYP3A4,CC(C)C[C@H](N)c1cc(F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1,"1-[(R)-2-{4-[2-((S)-1-amino-3-methylbutyl)-4-fluorophenyl]piperazin-1-yl}-1-(2,4-dichlorobenzyl)-2-oxoethyl]pyrrolidin-2-one",0.22,uM,=,-0.6575773191777937,0,O=C([C@@H](Cc1ccccc1)N1CCCC1=O)N1CCN(c2ccccc2)CC1
635,851921,10.1016/j.bmcl.2012.08.072,,,,Inhibition of human recombinant CYP3A4,Cc1cc(NC(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)ccc1F,"N-(4-fluoro-3-methylphenyl)-2-(4-morpholino-6-oxo-1,6-dihydropyrimidin-2-yl)acetamide",40.0,uM,=,1.6020599913279625,1,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccccc1
636,52064,10.1016/s0960-894x(03)00058-1,,,,Inhibitory activity against CYP450 3A4 isozyme,CCN(CC)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(=O)Cn1c(SCc2ccc(F)cc2)nc(=O)c2c1CCCC2,"N-(2-Diethylamino-ethyl)-2-[2-(4-fluoro-benzylsulfanyl)-4-oxo-5,6,7,8-tetrahydro-4H-quinazolin-1-yl]-N-(4'-trifluoromethyl-biphenyl-4-ylmethyl)-acetamide",10.0,uM,=,1.0,1,O=C(Cn1c(SCc2ccccc2)nc(=O)c2c1CCCC2)NCc1ccc(-c2ccccc2)cc1
637,1475768,10.1021/jm5017413,,,,Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system,C[C@@H]1c2nnc(-c3csc(-c4ccccc4)n3)n2CCN1C(=O)c1ccc(F)cc1,"(R)-(4-Fluorophenyl)(8-methyl-3-(2-phenylthiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone",67.0,uM,=,1.8260748027008264,1,O=C(c1ccccc1)N1CCn2c(nnc2-c2csc(-c3ccccc3)n2)C1
638,1886565,10.1021/acs.jmedchem.8b02021,,,,Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay,Nc1nc2ccc(S(=O)(=O)Cc3ccc(Cl)c(Cl)c3)cc2s1,"6-((3,4-Dichlorobenzyl)sulfonyl)benzo[d]thiazol-2-amine",10.0,uM,=,1.0,1,O=S(=O)(Cc1ccccc1)c1ccc2ncsc2c1
639,775863,10.1016/j.bmcl.2011.09.037,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH,CN[C@H]1CCN(C(=O)[C@@H](COCc2ccccc2)NC(=O)c2cccnc2Oc2ccc(C(F)(F)F)cc2Cl)C1,N-((R)-3-(benzyloxy)-1-((S)-3-(methylamino)pyrrolidin-1-yl)-1-oxopropan-2-yl)-2-(2-chloro-4-(trifluoromethyl)phenoxy)nicotinamide,9.0,uM,=,0.9542425094393248,1,O=C(N[C@H](COCc1ccccc1)C(=O)N1CCCC1)c1cccnc1Oc1ccccc1
640,1797910,10.1021/acs.jmedchem.8b01326,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate/NADPH addition measured after 10 mins by LC-MS/MS analysis,CN1C(=N)N[C@@]2(c3cc(Br)cs3)CN(c3ncc(F)cn3)C[C@H]2C1=O,"(4aR,7aR)-7a-(4-Bromothiophen-2-yl)-6-(5-fluoropyrimidin-2-yl)-2-imino-3-methyloctahydro-4H-pyrrolo[3,4-d]-pyrimidin-4-one",0.9,uM,=,-0.0457574905606751,0,N=C1NC(=O)[C@@H]2CN(c3ncccn3)C[C@]2(c2cccs2)N1
641,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CC(O)C6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, G-61",4.87,uM,=,0.6875289612146344,1,O=C(Nc1ccc(N2CCC2)nc1)c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12
642,834635,10.1016/j.bmcl.2012.07.019,,,,Inhibition of CYP3A4,N[C@@H](CC(=O)N1CCN(C(=O)c2ccc(O)cc2)CC1)Cc1cc(F)c(F)cc1F,"(R)-3-amino-1-(4-(4-hydroxybenzoyl)piperazin-1-yl)-4-(2,4,5-trifluorophenyl)butan-1-one",1.0,uM,=,0.0,0,O=C(CCCc1ccccc1)N1CCN(C(=O)c2ccccc2)CC1
643,828928,10.1016/j.bmcl.2012.06.022,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,CC(C)CN(C[C@@H](O)[C@H](Cc1cccnc1)NC(=O)OCc1cncs1)C(=O)c1ccc2ncsc2c1,"Thiazol-5-ylmethyl(2S,3R)-3-hydroxy-4-(N-isobutylbenzo[d]thiazole-6-carboxamido)-1-(pyridin-3-yl)butan-2-ylcarbamate",0.09,uM,=,-1.0457574905606752,0,O=C(N[C@H](CCNC(=O)c1ccc2ncsc2c1)Cc1cccnc1)OCc1cncs1
644,373752,10.1021/jm060073e,,,,Inhibition of CYP450 3A4 transfected in human microsome using DEF fluorogenic substrate,CC(C)C[C@@H]1C(=O)N[C@H](C2Cc3ccccc3C2)C(=O)N1[C@@H](C(=O)NC(C)C)c1ccc2occc2c1,"(2R)-2-(1-benzofuran-5-yl)-2-[(3R,6R)-3-(2,3-dihydro-1H-inden-2-yl)-6-(2-methylpropyl)-2,5-dioxo-1-piperazinyl]-N-(1-methylethyl)ethanamide",2.5,uM,=,0.3979400086720376,1,O=C1CN(Cc2ccc3occc3c2)C(=O)[C@@H](C2Cc3ccccc3C2)N1
645,1446329,10.1021/ml500387y,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,CC(C)(CC(O)(Cc1cc2cc(S(C)(=O)=O)ncc2[nH]1)C(F)(F)F)c1ccc(Cl)cc1C(N)=O,"5-chloro-2-(5,5,5-trifluoro-4-hydroxy-2-methyl-4-((5-(methylsulfonyl)-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)pentan-2-yl)benzamide",15.0,uM,=,1.1760912590556811,1,c1ccc(CCCCc2cc3ccncc3[nH]2)cc1
646,2048449,10.1016/j.bmc.2020.115734,,,,Inhibition of recombinant CYP3A4 (unknown origin) by fluorescence-based assay,CCn1nc(C(F)(F)F)cc1Nc1nc(-c2ccc(-n3cnc(C)c3)c(OC)n2)cs1,N-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-5-yl)-4-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)thiazol-2-amine,5.3,uM,=,0.724275869600789,1,c1cn(-c2ccc(-c3csc(Nc4ccn[nH]4)n3)nc2)cn1
647,471117,10.1016/j.bmc.2007.10.061,,,,Inhibition of CYP3A4,Nc1nccn2c1c(-c1ccc3ccc(-c4ccccc4)nc3c1)nc2[C@H]1C[C@@H](N2CCCC2)C1,"cis-3-[3-(pyrrolidine)cyclobutyl]-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-8-ylamine",17.0,uM,=,1.230448921378274,1,c1ccc(-c2ccc3ccc(-c4nc([C@H]5C[C@@H](N6CCCC6)C5)n5ccncc45)cc3n2)cc1
648,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1ccc(-n2nccn2)cc1C[C@@H]1COCCN1C(=O)c1cccc(C)c1-n1nccn1,"US9150566, 124",22.0,uM,=,1.3424226808222062,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
649,51911,10.1016/s0960-894x(03)00474-8,,,,Inhibition of human liver microsome Cytochrome P450 3A4,COc1cncc(-c2cnc(C(C)(C)N3CCN(C[C@@H](O)C[C@@H](Cc4ccccc4)C(=O)N[C@H]4c5ccccc5OC[C@H]4O)[C@H](C(=O)NCC(F)(F)F)C3)o2)c1,"(S)-1-[(S)-2-Hydroxy-4-((R)-(S)-3-hydroxy-3,4,4a,8a-tetrahydro-2H-chromen-4-ylcarbamoyl)-5-phenyl-pentyl]-4-{1-[5-(5-methoxy-pyridin-3-yl)-oxazol-2-yl]-1-methyl-ethyl}-piperazine-2-carboxylic acid (2,2,2-trifluoro-ethyl)-amide",0.04,uM,=,-1.3979400086720375,0,O=C(N[C@@H]1CCOc2ccccc21)[C@@H](CCCN1CCN(Cc2ncc(-c3cccnc3)o2)CC1)Cc1ccccc1
650,1923841,10.1021/acs.jmedchem.6b00280,,,,Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase and human b5 reductase assessed as reduction in 7-Hydroxyquinoline production using 7-benzyloxyquinoline as substrate and NADPH incubated for 15 mins by fluorimetry,O=C(NCCN1CCOCC1)Nc1nc2ccc(Sc3nnc4cccnn34)cc2s1,"1-(6-([1,2,4]triazolo[4,3-b]pyridazin-3-ylthio)benzo[d]thiazol-2-yl)-3-(2-morpholinoethyl)urea",34.0,uM,=,1.5314789170422551,1,O=C(NCCN1CCOCC1)Nc1nc2ccc(Sc3nnc4cccnn34)cc2s1
651,2017934,10.1021/acs.jmedchem.0c00834,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis,Cc1c(-c2ccccc2)nc2ccc(Br)cc2c1C(=O)NC(C)Cc1ccccn1,(+/-)-6-Bromo-3-methyl-2-phenyl-N-[1-(pyridin-2-yl)propan-2-yl]quinoline-4-carboxamide,2.0,uM,=,0.3010299956639812,1,O=C(NCCc1ccccn1)c1cc(-c2ccccc2)nc2ccccc12
652,619265,10.1016/j.bmcl.2009.07.002,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate,Cc1cccc(C)c1COc1cccn2c(C)c(C)nc12,"8-(2,6-dimethylbenzyloxy)-2,3-dimethylimidazo[1,2-a]pyridine",18.0,uM,=,1.255272505103306,1,c1ccc(COc2cccn3ccnc23)cc1
653,305432,10.1016/j.bmcl.2005.01.044,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,CC(C(c1ccc2cc(OCc3cccc(C(=O)O)c3)ccc2c1)n1ccnc1)N(C)C,3-[6-(2-Dimethylamino-1-imidazol-1-yl-propyl)-naphthalen-2-yloxymethyl]-benzoic acid,3.79,uM,=,0.5786392099680724,1,c1ccc(COc2ccc3cc(Cn4ccnc4)ccc3c2)cc1
654,1637154,,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4cncnc4)cc23)c1F,"Propane-1-sulfonic acid [2,4-difluoro-3-(5-pyrimidin-5-yl-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phenyl]-amide",5.0,uM,=,0.6989700043360189,1,O=C(c1ccccc1)c1c[nH]c2ncc(-c3cncnc3)cc12
655,1919651,,,,,"Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase",O=Cc1ccc(-c2cccnc2)s1,5-Pyridin-3-yl-thiophene-2-carbaldehyde,23.93,uM,=,1.3789426986134374,1,c1cncc(-c2cccs2)c1
656,1744980,10.1016/j.bmcl.2017.09.046,,,,Inhibition of human CYP3A4 expressed in Escherichia coli co-expressing CYP-reductase using diethoxyfluorescein as substrate measured after 10 mins by fluorescence assay,CCc1cccc(-c2c(F)cccc2C(O)(CCCNC(=O)OC)[C@@H]2CCCN(C(=O)CC(O)CNC)C2)c1,methyl 4-(3'-ethyl-6-fluorobiphenyl-2-yl)-4-hydroxy-4-((3R)-1-(3-hydroxy-4-(methylamino)butanoyl)piperidin-3-yl)butylcarbamate,0.84,uM,=,-0.0757207139381183,0,c1ccc(-c2ccccc2C[C@@H]2CCCNC2)cc1
657,873423,10.1021/jm3006788,,,,Inhibition of CYP3A4,Cn1c(-c2ccccn2)c(C2CCCC2)c2ccc(C(=O)NC(C)(C)C(=O)Nc3ccc(/C=C/C(=O)O)cc3)cc21,3-(4-(2-(3-cyclopentyl-1-methyl-2-(pyridin-2-yl)-1H-indole-6-carboxamido)-2-methylpropanamido)phenyl)acrylic acid,7.9,uM,=,0.8976270912904415,1,O=C(CNC(=O)c1ccc2c(C3CCCC3)c(-c3ccccn3)[nH]c2c1)Nc1ccccc1
658,51898,10.1016/s0960-894x(98)00653-2,,,,Antiviral activity as inhibition of human liver microsomal Cytochrome P450 3A4,CC(C)c1nc(COC(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)[C@H](O)CN2CCN(Cc3cccnc3)C[C@H]2C(=O)NC(C)(C)C)C(C)C)cs1,"{(S)-1-[(1S,2R)-1-Benzyl-3-((S)-2-tert-butylcarbamoyl-4-pyridin-3-ylmethyl-piperazin-1-yl)-2-hydroxy-propylcarbamoyl]-2-methyl-propyl}-carbamic acid 2-isopropyl-thiazol-4-ylmethyl ester",2.3,uM,=,0.3617278360175928,1,O=C(CNC(=O)OCc1cscn1)N[C@H](CCN1CCN(Cc2cccnc2)CC1)Cc1ccccc1
659,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)Nc6ccc(OC)cc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, D-22",19.5,uM,=,1.290034611362518,1,O=C(Nc1ccccc1)c1ccc(-c2c[nH]c3c(CN4C[C@@H]5N(C(=O)NCc6ccccc6)NCC(=O)N5[C@@H](Cc5ccccc5)C4=O)cccc23)cc1
660,474877,10.1021/jm701097z,,,,Inhibition of CYP3A4,COc1cc2nccc(Oc3ccc4c(C(=O)Nc5ccccn5)cccc4c3)c2cc1OC,"6-(6,7-dimethoxyquinolin-4-yloxy)-N-(pyridin-2-yl)-1-naphthamide",13.0,uM,=,1.1139433523068367,1,O=C(Nc1ccccn1)c1cccc2cc(Oc3ccnc4ccccc34)ccc12
661,1288280,10.1016/j.bmcl.2013.12.057,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,CC(C)c1nc(CN(C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC[C@@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,"Thiazol-5-ylmethyl(2S,5S)-5-((S)-3-hydroxy-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)propanamido)-1,6-diphenylhexan-2-ylcarbamate",0.14,uM,=,-0.8538719643217619,0,O=C(CNC(=O)NCc1cscn1)N[C@@H](CC[C@@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
662,52065,10.1021/jm0310129,,,,Inhibitory activity against cytochrome P450 3A4,CN(C)c1nccc2c1c1ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c1n2C,"(4-{4-[2-(3,4-Difluoro-phenyl)-ethyl]-piperazin-1-yl}-5-methyl-5H-pyrido[3',4':4,5]pyrrolo[3,2-d]pyrimidin-9-yl)-dimethyl-amine",26.41,uM,=,1.421768401206924,1,c1ccc(CCN2CCN(c3ncnc4c3[nH]c3ccncc34)CC2)cc1
663,2023287,10.1016/j.bmcl.2020.127636,,,,Inhibition of CYP3A4 (unknown origin),COc1ccccc1C1c2c(C(C)(C)C)n[nH]c2C(=O)N1c1ccc(F)cc1,"3-tert-butyl-5-(4-fluorophenyl)-4-(2-methoxyphenyl)-4,5-dihydropyrrolo[3,4-c]pyrazol-6(1H)-one",18.0,uM,=,1.255272505103306,1,O=C1c2[nH]ncc2C(c2ccccc2)N1c1ccccc1
664,743387,10.1021/jm101488z,,,,Inhibition of CYP3A4,Nc1ncc(-c2cccnc2)nc1C(=O)Nc1ccccc1,3-amino-N-phenyl-6-(pyridin-3-yl)pyrazine-2-carboxamide,2.0,uM,=,0.3010299956639812,1,O=C(Nc1ccccc1)c1cncc(-c2cccnc2)n1
665,2133633,10.1021/acs.jmedchem.1c00679,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins in presence of NADPH by LCMS/MS analysis,O=C(NC[C@H]1[C@H]2C[C@@H](Oc3ccnc4ccc(F)cc34)C[C@@H]12)c1ccc(Cl)cc1,"4-chloro-N-(((1R,3s,5S,6r)-3-(6-fluoroquinolin-4-yloxy)bicyclo[3.1.0]hexan-6-yl)methyl)benzamide",6.7,uM,=,0.8260748027008264,1,O=C(NC[C@H]1[C@H]2C[C@@H](Oc3ccnc4ccccc34)C[C@@H]12)c1ccccc1
666,1709454,10.1016/j.ejmech.2017.05.043,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by NADPH addition measured after 10 mins by LC/MS/MS analysis,CC(C)OC(=O)[C@H](Cn1ccnc1)NC(=O)c1cc(-c2ccccc2F)on1,Isopropyl (S)-2-(5-(2-fluorophenyl)isoxazole-3-carboxamido)-3-(1H-imidazol-1-yl)propanoate,5.81,uM,=,0.7641761323903307,1,O=C(NCCn1ccnc1)c1cc(-c2ccccc2)on1
667,617698,10.1016/j.bmcl.2010.01.087,,,,Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay,Cc1cc(N2CCN(CCF)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,(S)-4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-3-(6-(4-(2-fluoroethyl)piperazin-1-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one,0.8,uM,=,-0.0969100130080563,0,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(N3CCNCC3)cc2[nH]1
668,555225,10.1016/j.bmcl.2008.05.058,,,,Inhibition of CYP3A4,CNC(=O)c1cccc(-c2ccc(C(CN3CCOCC3)N(C)C(=O)Cn3c(=O)cnc4cc(Cl)c(Cl)cc43)cc2)c1,"4'-(1-{[2-(6,7-Dichloro-2-oxo-2H-quinoxalin-1-yl)-acetyl]-methyl-amino}-2-morpholin-4-yl-ethyl)-biphenyl-3-carboxylic acid methylamide",5.0,uM,=,0.6989700043360189,1,O=C(Cn1c(=O)cnc2ccccc21)NC(CN1CCOCC1)c1ccc(-c2ccccc2)cc1
669,1778315,10.1016/j.bmcl.2018.06.040,,,,Inhibition of CYP3A4 (unknown origin),O=C(Cc1cccc(OCCCC2CCNCC2)c1)Nc1nc(-c2c[nH]c3ncccc23)cs1,"N-(4-(1H-pyrrolo[2,3-b]pyridin-3-yl)thiazol-2-yl)-2-(3-(3-(piperidin-4-yl)propoxy)phenyl)acetamide",20.8,uM,=,1.3180633349627615,1,O=C(Cc1cccc(OCCCC2CCNCC2)c1)Nc1nc(-c2c[nH]c3ncccc23)cs1
670,2246941,10.1021/acs.jmedchem.1c02132,,,,Inhibition of CYP3A4 (unknown origin) incubated for 10 mins in presence of NADPH by LC-MS/MS analysis,COC(=O)Nc1cc(-c2cc(C(F)(F)F)c(OC[C@@](C)(N)CC(C)C)cn2)ccn1,"(S)-methyl (5-((2-amino-2,4-dimethylpentyl)oxy)-4-(trifluoromethyl)-[2,4'-bipyridin]-2'-yl)carbamate",5.3,uM,=,0.724275869600789,1,c1ccc(-c2ccncc2)nc1
671,1535672,,,,,"Inhibition Assay: Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 μM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 μM. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 μM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 μM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v.",OC(Cn1cnnc1)(c1ccc(F)cc1F)C(F)(F)c1ccc2cc(Br)ccc2n1,"US8883797, 9",11.0,uM,=,1.0413926851582251,1,c1ccc(C(Cc2ccc3ccccc3n2)Cn2cnnc2)cc1
672,851921,10.1016/j.bmcl.2012.08.072,,,,Inhibition of human recombinant CYP3A4,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccc(F)cc1,"N-(4-fluorophenyl)-2-(4-morpholino-6-oxo-1,6-dihydropyrimidin-2-yl)acetamide",40.0,uM,=,1.6020599913279625,1,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccccc1
673,322414,10.1021/jm0502541,,,,Interaction with human cytochrome P450 isoform 3A4 expressed in baculovirus-insect cells,O=C(O)C1(c2ccc(-c3ccc(Cl)c(Cl)c3)c(F)c2)CC1,"1-(3',4'-Dichloro-2-fluoro-biphenyl-4-yl)-cyclopropanecarboxylic acid",48.0,uM,=,1.6812412373755872,1,c1ccc(-c2ccc(C3CC3)cc2)cc1
674,2170798,10.1021/acs.jmedchem.0c02143,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated 10 mins in presence of NADPH by solid phase extraction mass spectrometry analysis,C[C@@]1(c2cc(NC(=O)c3ncc(OC(F)F)cc3Cl)ccc2F)CO[C@@](C)(C(F)(F)F)C(N)=N1,"N-(3-((3R,6R)-5-amino-3,6-dimethyl-6-(trifluoromethyl)-3,6-dihydro-2H-1,4-oxazin-3-yl)-4-fluorophenyl)-3-chloro-5-(difluoromethoxy)picolinamide",4.0,uM,=,0.6020599913279624,1,O=C(Nc1cccc(C2COCC=N2)c1)c1ccccn1
675,2073864,10.1016/j.bmcl.2020.127428,,,,Inhibition of CYP3A4 (unknown origin),Nc1nc(-n2cc(C(=O)O)c(=O)c3cc(F)c(N4CC(N)C4)c(Cl)c32)c(F)cc1F,"7-(3-aminoazetidin-1-yl)-1-(6-amino-3,5-difluoro-2-pyridyl)-8-chloro-6-fluoro-4-oxo-quinoline-3-carboxylic acid",13.6,uM,=,1.1335389083702174,1,O=c1ccn(-c2ccccn2)c2cc(N3CCC3)ccc12
676,443560,10.1016/j.bmc.2007.03.014,,,,Inhibition of human CYP2E1 expressed in insect microsome using 7-benzyloxyquinoline substrate after 30 mins,COc1ccc(CN2CCN(c3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)CC2)cc1OC,"N-(2-(4-(4-(3,4-dimethoxybenzyl)piperazin-1-yl)phenylcarbamoyl)-4,5-dimethoxyphenyl)quinoline-3-carboxamide",2.48,uM,=,0.3944516808262163,1,O=C(Nc1ccccc1C(=O)Nc1ccc(N2CCN(Cc3ccccc3)CC2)cc1)c1cnc2ccccc2c1
677,2264099,10.1021/acs.jmedchem.1c00703,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 2 mins in presence of NADPH regenerating system by LC-MS/MS analysis,CC(C)n1nc(C(=O)NCC2C3CN(C4CCOCC4)CC23)c2ccccc21.O=C(O)C(=O)O,1-Isopropyl-1H-indazole-3-carboxylic acid [3-(tetrahydro-pyran-4-yl)-3-azabicyclo[3.1.0]hex-6-ylmethyl]-amide oxalate,20.4,uM,=,1.3096301674258988,1,O=C(NCC1C2CN(C3CCOCC3)CC12)c1n[nH]c2ccccc12
678,1558600,10.1016/j.bmcl.2015.06.020,,,,Inhibition of CYP3A4 (unknown origin) by fluorescence assay,COc1ccc(Cc2nc3c(n2C)CCc2cc(-n4cnc(C)c4)ccc2C3=O)cc1,"2-(4-Methoxy-benzyl)-1-methyl-7-(4-methyl-imidazol-1-yl)-9,10-dihydro-1H-1,3-diaza-benzo[f]azulen-4-one",0.3,uM,=,-0.5228787452803376,0,O=C1c2ccc(-n3ccnc3)cc2CCc2[nH]c(Cc3ccccc3)nc21
679,445973,10.1021/jm070428+,,,,Inhibition of human recombinant CYP3A4,Cc1cnc(C)n1CC(=O)c1ccc(-c2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)cn1,"(5R)-3-(4-{6-[(2,5-dimethyl-1H-imidazol-1-yl)acetyl]pyridin-3-yl}-3-fluorophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one",10.7,uM,=,1.0293837776852095,1,O=C(Cn1ccnc1)c1ccc(-c2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2)cn1
680,982809,10.1016/j.ejmech.2013.08.010,,,,Inhibition of CYP3A (unknown origin),CC#CCn1c(N2CCC[C@@H](N)C2)cc(=O)n(Cc2ccc3ccccc3n2)c1=O,"(R)-6-(3-Aminopiperidin-1-yl)-1-(but-2-yn-1-yl)-3-(quinolin-2-ylmethyl)pyrimidine-2,4(1H,3H)-dione",97.9,uM,=,1.990782691803138,1,O=c1cc(N2CCCCC2)[nH]c(=O)n1Cc1ccc2ccccc2n1
681,305432,10.1016/j.bmcl.2005.01.044,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,COC(=O)Cc1ccc(COc2ccc3cc(C(C(C)N(C)C)n4ccnc4)ccc3c2)cc1,{4-[6-(2-Dimethylamino-1-imidazol-1-yl-propyl)-naphthalen-2-yloxymethyl]-phenyl}-acetic acid methyl ester,0.004,uM,=,-2.397940008672037,0,c1ccc(COc2ccc3cc(Cn4ccnc4)ccc3c2)cc1
682,796228,10.1016/j.bmcl.2011.10.115,,,,Inhibition of CYP3A4,Cc1ccc(Cn2c(C3CNCCS3)nc3ccccc32)cc1,(+/-)-2-(1-(4-methylbenzyl)-1H-benzo[d]imidazol-2-yl)thiomorpholine,7.5,uM,=,0.8750612633917001,1,c1ccc(Cn2c(C3CNCCS3)nc3ccccc32)cc1
683,1668102,10.1016/j.bmcl.2017.04.006,,,,Inhibition of recombinant human CYP3A4 expressed in insect cells using DBOMF as substrate pretreated for 10 mins followed by substrate addition measured every minute for 15 mins in presence of NADP+ by fluorescence assay,Nc1c2c(nc3ccccc13)CCCC2,"1,2,3,4-Tetrahydro-acridin-9-ylamine",96.9,uM,=,1.986323777050765,1,c1ccc2nc3c(cc2c1)CCCC3
684,1778315,10.1016/j.bmcl.2018.06.040,,,,Inhibition of CYP3A4 (unknown origin),COCCNS(=O)(=O)c1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1,"N-(4-(1H-pyrrolo[2,3-b]pyridin-3-yl)thiazol-2-yl)-2-(3-(N-(2-methoxyethyl)sulfamoyl)phenyl)acetamide",3.4,uM,=,0.5314789170422551,1,O=C(Cc1ccccc1)Nc1nc(-c2c[nH]c3ncccc23)cs1
685,559938,10.1016/j.bmcl.2008.10.072,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,C[C@@H]1CN(Cc2ccc(-c3ccccc3CN(C)C(=O)CS(=O)(=O)c3ccccc3)cc2)C[C@H](C)N1,"2-Benzenesulfonyl-N-[4'-((3R,5S)-3,5-dimethyl-piperazin-1-ylmethyl)-biphenyl-2-ylmethyl]-N-methyl-acetamide",3.0,uM,=,0.4771212547196624,1,O=C(CS(=O)(=O)c1ccccc1)NCc1ccccc1-c1ccc(CN2CCNCC2)cc1
686,833037,10.1021/jm300248q,,,,Inhibition of CYP3A4,CN1CCN(c2cccc(Nc3nc4c(-c5ccc(S(C)(=O)=O)cc5)cccn4n3)c2)CC1,"[8-(4-Methanesulfonyl-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-[3-(4-methyl-piperazin-1-yl)-phenyl]-amine",11.0,uM,=,1.0413926851582251,1,c1ccc(-c2cccn3nc(Nc4cccc(N5CCNCC5)c4)nc23)cc1
687,2023287,10.1016/j.bmcl.2020.127636,,,,Inhibition of CYP3A4 (unknown origin),COc1ccccc1C1c2c(C(C)(C)C)n[nH]c2C(=O)N1c1ccc(-c2nnc(C)o2)cc1,"3-tert-butyl-4-(2-methoxyphenyl)-5-(4-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl)-4,5-dihydropyrrolo[3,4-c]pyrazol-6(1H)-one",8.0,uM,=,0.9030899869919436,1,O=C1c2[nH]ncc2C(c2ccccc2)N1c1ccc(-c2nnco2)cc1
688,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)NNC(C)(C)C)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, D-34",3.41,uM,=,0.5327543789924978,1,O=C1[C@H](Cc2ccccc2)N2C(=O)CNN(C(=O)NCc3ccccc3)[C@H]2CN1Cc1cccc2c(-c3ccccc3)c[nH]c12
689,473932,10.1021/jm701121y,,,,Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay,Cc1cc(C(C)(C)NC(=O)C(Br)C(C)(C)C)cc(C)n1,"2-bromo-N-(2-(2,6-dimethylpyridin-4-yl)propan-2-yl)-3,3-dimethylbutanamide",13.0,uM,=,1.1139433523068367,1,c1ccncc1
690,979124,10.1021/jm400484p,,,,Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes,COc1ccc2ccc(-c3cncc(O)c3)c(Cl)c2c1,5-(1-chloro-7-methoxynaphthalen-2-yl)pyridin-3-ol,6.72,uM,=,0.8273692730538252,1,c1cncc(-c2ccc3ccccc3c2)c1
691,51927,10.1021/jm034111v,,,,Inhibition of recombinant human Cytochrome P450 3A4 using BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 30 minutes,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,"1-(4-{4-[2-(2,4-Dichloro-phenyl)-2-imidazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-ethanone (ketoconazole)",0.017,uM,=,-1.769551078621726,0,c1ccc(C2(Cn3ccnc3)OCC(COc3ccc(N4CCNCC4)cc3)O2)cc1
692,1474044,10.1021/jm501740a,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,O=C(N[C@@H](c1ccccn1)C1CCCC1)c1ccc2[nH]nc(-c3ccc(N4[C@H]5COC[C@H]4CC(O)C5)cc3)c2c1,N-((R)-cyclopentyl(pyridin-2-yl)methyl)-3-(4-((endo)-7-hydroxy-3-oxa-9-azabicyclo[3.3.1]nonan-9-yl)phenyl)-1H-indazole-5-carboxamide,0.33,uM,=,-0.4814860601221125,0,O=C(N[C@@H](c1ccccn1)C1CCCC1)c1ccc2[nH]nc(-c3ccc(N4[C@@H]5CCC[C@@H]4COC5)cc3)c2c1
693,1288280,10.1016/j.bmcl.2013.12.057,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,CC(C)c1nc(CN(C)C(=O)N[C@@H](Cc2cn(C)cn2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,"Thiazol-5-ylmethyl(2R,5R)-5-((S)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-3-(1-methyl-1H-imidazol-4-yl)propanamido)-1,6-diphenylhexan-2-ylcarbamate",0.11,uM,=,-0.958607314841775,0,O=C(NCc1cscn1)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
694,450508,10.1021/jm070806a,,,,Inhibition of CYP3A4,Cc1ccc(N2CCN(C(=O)[C@H](C)Cc3ccc(Cl)cc3)CC2)c([C@@H](N)C(C)C)c1,1-{2-[(1S)-amino-2-methylpropyl]-4-methylphenyl}-4-[(2R)-methyl-3-(4-chlorophenyl)propionyl]piperazine,8.3,uM,=,0.919078092376074,1,O=C(CCc1ccccc1)N1CCN(c2ccccc2)CC1
695,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(NC6CC(C)(C)N(C)C(C)(C)C6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1,"US8940739, G-52",7.1,uM,=,0.8512583487190752,1,O=C(Nc1ccc(NC2CCNCC2)nc1)c1c[nH]c2c(CN3CC4N(C(=O)NCc5ccccc5)NCC(=O)N4C(Cc4ccccc4)C3=O)cccc12
696,973974,10.1021/jm400380m,,,,Inhibition of CYP3A4 (unknown origin) after 10 mins by fluorescence assay,O=C1Nc2ccccc2/C1=C\c1ccc2c(/C=C/c3ccncc3)n[nH]c2c1,(E)-3-((3-((E)-2-(Pyridin-4-yl)vinyl)-1H-indazol-6-yl)-methylene)-indolin-2-one,2.7,uM,=,0.4313637641589873,1,O=C1Nc2ccccc2/C1=C\c1ccc2c(/C=C/c3ccncc3)n[nH]c2c1
697,1353338,10.1021/ml400379x,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 30 mins preincubation by LC-MS/MS analysis in presence of NADPH,CNS(=O)(=O)Nc1cccc(Cc2c(C)c3ccc(OC(=O)N(C)C)cc3oc2=O)c1,4-Methyl-3-(3-(N-methylsulfamoylamino)benzyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate,5.6,uM,=,0.7481880270062004,1,O=c1oc2ccccc2cc1Cc1ccccc1
698,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)N6CCN(S(C)(=O)=O)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1,"US8940739, G-68",6.4,uM,=,0.8061799739838872,1,O=C(Nc1ccc(-c2c[nH]c3c(CN4CC5N(C(=O)NCc6ccccc6)NCC(=O)N5C(Cc5ccccc5)C4=O)cccc23)cn1)N1CCNCC1
699,1446329,10.1021/ml500387y,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,COc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2cc(S(C)(=O)=O)ncc2[nH]1)C(F)(F)F,"1,1,1-trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methyl-2-((5-(methylsulfonyl)-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)pentan-2-ol",2.0,uM,=,0.3010299956639812,1,c1ccc(CCCCc2cc3ccncc3[nH]2)cc1
700,52065,10.1021/jm0310129,,,,Inhibitory activity against cytochrome P450 3A4,Cn1c2ccnc(NCc3ccccn3)c2c2ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21,"(4-{4-[2-(3,4-Difluoro-phenyl)-ethyl]-piperazin-1-yl}-5-methyl-5H-pyrido[3',4':4,5]pyrrolo[3,2-d]pyrimidin-9-yl)-pyridin-2-ylmethyl-amine",18.48,uM,=,1.266701966884088,1,c1ccc(CCN2CCN(c3ncnc4c3[nH]c3ccnc(NCc5ccccn5)c34)CC2)cc1
701,619265,10.1016/j.bmcl.2009.07.002,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate,Cc1cccc(C)c1CNc1cccc2c1nc(C)n2C,"N-(2,6-dimethylbenzyl)-1,2-dimethyl-1H-benzo[d]imidazol-4-amine",9.0,uM,=,0.9542425094393248,1,c1ccc(CNc2cccc3[nH]cnc23)cc1
702,802673,10.1016/j.bmcl.2011.12.125,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,O=C(NCc1ccc(Br)cc1)Nc1ccc(-c2ccnc3[nH]cnc23)cc1,"1-(4-(3H-imidazo[4,5-b]pyridin-7-yl)phenyl)-3-(4-bromobenzyl)urea",0.27,uM,=,-0.5686362358410126,0,O=C(NCc1ccccc1)Nc1ccc(-c2ccnc3[nH]cnc23)cc1
703,1923489,10.1021/acs.jmedchem.6b00708,,,,Inhibition of CYP3A4 (unknown origin),Cc1cc(-c2n[nH]c3cc(NC(=O)N[C@H](C)c4ccccc4)ncc23)cc(C)n1,"US9023865, 31",0.78,uM,=,-0.1079053973095195,0,O=C(NCc1ccccc1)Nc1cc2[nH]nc(-c3ccncc3)c2cn1
704,1780283,10.1039/C6MD00406G,,,,Inhibition of CYP3A4 (unknown origin),Cc1cn(-c2ccc3n(c2=O)CCN(C[C@@]24C[C@@H]2C(C)(C)Oc2ccc(C(F)(F)F)cc24)C3=O)cn1,"2-(((1aS,7bS)-2,2-dimethyl-6-(trifluoromethyl)-1,1a,2,7b-tetrahydrocyclopropa[c]chromen-7b-yl)methyl)-7-(4-methyl-1H-imidazol-1-yl)-3,4-dihydro-1H-pyrido[1,2-a]pyrazine-1,6(2H)-dione",16.3,uM,=,1.212187604403958,1,O=C1c2ccc(-n3ccnc3)c(=O)n2CCN1C[C@@]12C[C@@H]1COc1ccccc12
705,487712,10.1016/j.bmcl.2008.05.104,,,,Inhibition of CYP3A4,COCC(=O)N1CCN(C2CCN(c3cc(C)c4nc(-c5c(NC[C@@H](O)c6cccc(Cl)c6)cc[nH]c5=O)[nH]c4c3)CC2)CC1,(S)-4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-3-(6-(4-(4-(2-methoxyacetyl)piperazin-1-yl)piperidin-1-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one,0.0056,uM,=,-2.2518119729938,0,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(N3CCC(N4CCNCC4)CC3)cc2[nH]1
706,2025932,10.1021/acsmedchemlett.0c00575,,,,Inhibition of CYP3A4 (unknown origin),CNS(=O)(=O)c1ccc(CNC(=O)N2CC3(CCCC3)c3nc(-c4ccc(O)cc4C)ccc32)cc1,"5'-(4-hydroxy-2-methylphenyl)-N-(4-(N-methylsulfamoyl)benzyl)spiro[cyclopentane-1,3'-pyrrolo[3,2-b]pyridine]-1'(2'H)-carboxamide",0.9,uM,=,-0.0457574905606751,0,O=C(NCc1ccccc1)N1CC2(CCCC2)c2nc(-c3ccccc3)ccc21
707,51908,10.1016/j.bmcl.2003.08.049,,,,In vitro inhibition of Cytochrome P450 3A4,O=C(N[C@H]1c2ccccc2OC[C@H]1O)[C@H](Cc1cccnc1)C[C@H](O)CN1CCN(Cc2ccn(-c3cccc(Cl)c3)c2)C[C@H]1C(=O)NCC(F)(F)F,"(S)-4-[1-(3-Chloro-phenyl)-1H-pyrrol-3-ylmethyl]-1-[(2S,4R)-2-hydroxy-4-((3S,4S)-3-hydroxy-chroman-4-ylcarbamoyl)-5-pyridin-3-yl-pentyl]-piperazine-2-carboxylic acid (2,2,2-trifluoro-ethyl)-amide",0.08,uM,=,-1.0969100130080565,0,O=C(N[C@@H]1CCOc2ccccc21)[C@@H](CCCN1CCN(Cc2ccn(-c3ccccc3)c2)CC1)Cc1cccnc1
708,802673,10.1016/j.bmcl.2011.12.125,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,O=C(Nc1ccc(-c2ccccc2)cc1)Nc1ccc(-c2ccnc3[nH]cnc23)cc1,"1-(4-(3H-imidazo[4,5-b]pyridin-7-yl)phenyl)-3-(biphenyl-4-yl)urea",0.026,uM,=,-1.585026652029182,0,O=C(Nc1ccc(-c2ccccc2)cc1)Nc1ccc(-c2ccnc3[nH]cnc23)cc1
709,643848,10.1016/j.bmcl.2010.06.063,,,,inhibition of CYP3A4,Cc1nc2nc(-c3ccccc3)cn2c(-c2ccc(Cl)cc2Cl)c1CN,"(5-(2,4-dichlorophenyl)-7-methyl-2-phenylimidazo[1,2-a]pyrimidin-6-yl)methanamine",1.0,uM,=,0.0,0,c1ccc(-c2cn3c(-c4ccccc4)ccnc3n2)cc1
710,519907,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,CCc1cccc(C)c1CNc1cccn2c(C)c(C)nc12,"N-(2-ethyl-6-methylbenzyl)-2,3-dimethylimidazo[1,2-a]pyridin-8-amine",4.7,uM,=,0.6720978579357175,1,c1ccc(CNc2cccn3ccnc23)cc1
711,44705,10.1016/s0960-894x(02)00473-0,,,,Inhibition of cytochrome P450 3A4,Cn1cc(Cc2cn(CC(=O)N(CCO)Cc3ccc(-c4ccc(Cl)cc4)cc3)c(SCc3ccc(F)cc3)nc2=O)cn1,N-(4'-Chloro-biphenyl-4-ylmethyl)-2-[2-(4-fluoro-benzylsulfanyl)-5-(1-methyl-1H-pyrazol-4-ylmethyl)-4-oxo-4H-pyrimidin-1-yl]-N-(2-hydroxy-ethyl)-acetamide,19.0,uM,=,1.2787536009528289,1,O=C(Cn1cc(Cc2cn[nH]c2)c(=O)nc1SCc1ccccc1)NCc1ccc(-c2ccccc2)cc1
712,1509544,10.1021/acs.jmedchem.5b00810,,,,Time dependent inhibition of CYP3A4 in human liver microsomes,COc1cc2c(cc1OC(C)C)[C@H](c1ccc(Cl)cc1)N(c1ccc(N(C)C[C@H]3CC[C@H](N(C)C)CC3)nc1)C(=O)C2,"(trans)-(S)-1-(4-Chloro-phenyl)-2-{6-[(4-dimethylamino-cyclohexylmethyl)-methyl-amino]-pyridin-3-yl}-7-isopropoxy-6-methoxy-1,4-dihydro-2H-isoquinolin-3-one",5.0,uM,=,0.6989700043360189,1,O=C1Cc2ccccc2[C@H](c2ccccc2)N1c1ccc(NCC2CCCCC2)nc1
713,993439,10.6019/CHEMBL2448688,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,CCN(Cc1cnc[nH]1)c1cc(F)cc(-c2nc3ccccc3s2)c1,,0.576,uM,=,-0.239577516576788,0,c1cc(NCc2cnc[nH]2)cc(-c2nc3ccccc3s2)c1
714,436456,10.1021/jm061195+,,,,Inhibition of human CYP3A4,O=C(NCC1CCOCC1)c1cnc(Nc2cc(Cl)ccc2F)nc1C(F)(F)F,2-(2-fluoro-5-chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid(tetrahydro-pyran-4-ylmethyl)-amide,68.0,uM,=,1.8325089127062364,1,O=C(NCC1CCOCC1)c1cnc(Nc2ccccc2)nc1
715,2134185,10.1021/acs.jmedchem.1c00855,,,,Inhibition of recombinant human CYP3A4 expressed in Escherichia coli using VG as probe substrate incubated for 15 to 60 mins by fluorometric assay,COC[C@@H](C)n1c(C2CCOCC2)nc2cnc3cc(-c4c(C)noc4C)c(OC)cc3c21,"4-(8-Methoxy-1-((R)-1-methoxypropan-2-yl)-2-(tetrahydro-2H-pyran-4-yl)-1H-imidazo[4,5-c]quinoline-7-yl)-3,5-dimethylisoxazole",25.1,uM,=,1.3996737214810382,1,c1cc2c(cc1-c1cnoc1)ncc1nc(C3CCOCC3)[nH]c12
716,495543,10.1021/jm801332q,,,,Inhibition of human CYP3A4 expressed in Escherichia coli using 7BQ substrate by time dependent inhibition assay,C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(Nc4ccc(F)cc4)CC3)cc2)CCN1,N-(4-Fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine,14.0,uM,=,1.146128035678238,1,O=C(Cc1ccc(CN2CCNCC2)cc1)N1CCC(Nc2ccccc2)CC1
717,2116571,10.1021/acsmedchemlett.1c00198,,,,Inhibition of CYP3A4 (unknown origin) expressed in baculovirus infected insect supersomes preincubated for 15 mins followed by addition of NADPH regenerating system by fluorescence based analysis,O=C(O)c1ccc(N2CCC3(C=C(c4c(-c5c(Cl)cccc5Cl)noc4C4CC4)C3)CC2)nc1,"6-(2-(5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)-7-azaspiro[3.5]non-1-en-7-yl)nicotinic acid",1.1,uM,=,0.041392685158225,1,C1=C(c2c(-c3ccccc3)noc2C2CC2)CC12CCN(c1ccccn1)CC2
718,673952,10.1016/j.bmcl.2010.08.086,,,,Inhibition of CYP3A4 using midazolam as substrate,CCNCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1,"(3R,4S)-N-(2-chloro-5-((ethylamino)methyl)benzyl)-N-cyclopropyl-4-(4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)phenyl)piperidine-3-carboxamide",14.0,uM,=,1.146128035678238,1,O=C([C@H]1CNCC[C@@H]1c1ccc(OCCOc2ccccc2)cc1)N(Cc1ccccc1)C1CC1
719,519908,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,Cc1cccc(C)c1CNc1cc(-n2ncnc2CO)cn2c(C)c(C)nc12,"(1-(8-(2,6-dimethylbenzylamino)-2,3-dimethylimidazo[1,2-a]pyridin-6-yl)-1H-1,2,4-triazol-5-yl)methanol",21.0,uM,=,1.3222192947339193,1,c1ccc(CNc2cc(-n3cncn3)cn3ccnc23)cc1
720,1747324,10.1021/acs.jmedchem.7b01236,,,,Inhibition of human CYP3A4,N#Cc1ccc(Cn2ccc(NC(=O)Cc3ccc(C4(C(F)(F)F)CC4)cc3)n2)nc1,N-(1-((5-cyanopyridin-2-yl)methyl)-1H-pyrazol-3-yl)-2-(4-(1-(trifluoromethyl)cyclopropyl)phenyl)acetamide,51.0,uM,=,1.7075701760979365,1,O=C(Cc1ccc(C2CC2)cc1)Nc1ccn(Cc2ccccn2)n1
721,699316,10.1016/j.bmc.2010.10.034,,,,Inhibition of CYP3A4,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21,"[4-(3,4-Dichloro-phenyl)-1,2,3,4-tetrahydro-naphthalen-1-yl]-methyl-amine (Sertraline)",0.8,uM,=,-0.0969100130080563,0,c1ccc([C@@H]2CCCc3ccccc32)cc1
722,828928,10.1016/j.bmcl.2012.06.022,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(-c3ccncc3)oc2c1,"Thiazol-5-ylmethyl(2S,3R)-3-hydroxy-4-(N-isobutyl-2-(pyridin-4-yl)benzo[d]oxazole-6-carboxamido)-1-phenylbutan-2-ylcarbamate",0.024,uM,=,-1.619788758288394,0,O=C(N[C@H](CCNC(=O)c1ccc2nc(-c3ccncc3)oc2c1)Cc1ccccc1)OCc1cncs1
723,988989,10.1021/jm400732v,,,,Inhibition of CYP3A4 (unknown origin),CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)CC(C)C)c2ccccc2N(Cc2cccc3ccccc23)C1=O.Cl,"(S)-2-(Methylamino)-N-((S)-5-(3-methylbutanoyl)-1-(naphthalen-1-ylmethyl)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-yl)propanamide hydrochloride",1.8,uM,=,0.255272505103306,1,O=C1CCNc2ccccc2N1Cc1cccc2ccccc12
724,790052,10.1016/j.bmc.2011.08.066,,,,Inhibition of recombinant human CYP3A4 assessed as conversion of testosterone into 6-hydroxytestosterone after 30 mins by HPLC analysis,CNC(=O)c1ccc2cc(C3(O)c4cncn4CC3(C)C)ccc2c1,"rac-6-(7-Hydroxy-6,7-dihydro-6,6-dimethyl-5H-pyrrolo[1,2-c]imidazol-7-yl)-N-methyl-2-naphthamide",3.2,uM,=,0.505149978319906,1,c1ccc2cc(C3CCn4cncc43)ccc2c1
725,448320,10.1016/j.bmc.2007.05.069,,,,Inhibition of CYP3A4,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)C(=O)[C@@](C)(c1ccccc1)O2,"N-(2-((R)-6-(2,4-diamino-6-ethylpyrimidin-5-yl)-2-methyl-3-oxo-2-phenyl-2,3-dihydrobenzo[b][1,4]oxazin-4-yl)ethyl)acetamide",0.53,uM,=,-0.2757241303992109,0,O=C1Nc2cc(-c3cncnc3)ccc2OC1c1ccccc1
726,1747252,10.1021/acs.jmedchem.7b01236,,,,Inhibition of human CYP3A4 using testosterone as substrate preincubated for 30 mins,Cc1cc(CC(=O)Nc2ccn(Cc3ccc(C#N)cn3)n2)ccc1OCC(F)(F)F,"N-(1-((5-Cyanopyridin-2-yl)methyl)-1H-pyrazol-3-yl)-2-(3-methyl-4-(2,2,2-trifluoroethoxy)-phenyl)acetamide",46.0,uM,=,1.662757831681574,1,O=C(Cc1ccccc1)Nc1ccn(Cc2ccccn2)n1
727,1558600,10.1016/j.bmcl.2015.06.020,,,,Inhibition of CYP3A4 (unknown origin) by fluorescence assay,Cc1cn(-c2ccc3c(c2)CCc2ccc(Cc4ccc(F)cc4)nc2C3=O)cn1,"2-(4-Fluoro-benzyl)-8-(4-methyl-imidazol-1-yl)-5,6-dihydro-benzo[5,6]cyclohepta[1,2-b]pyridin-11-one",0.3,uM,=,-0.5228787452803376,0,O=C1c2ccc(-n3ccnc3)cc2CCc2ccc(Cc3ccccc3)nc21
728,775863,10.1016/j.bmcl.2011.09.037,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH,CN1CCN(C(=O)[C@@H](COCc2ccc3c(c2)OCCO3)NC(=O)c2cccnc2Oc2ccc(C(F)(F)F)cc2Cl)CC1,"(R)-2-(2-chloro-4-(trifluoromethyl)phenoxy)-N-(3-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methoxy)-1-(4-methylpiperazin-1-yl)-1-oxopropan-2-yl)nicotinamide",3.3,uM,=,0.5185139398778875,1,O=C(N[C@H](COCc1ccc2c(c1)OCCO2)C(=O)N1CCNCC1)c1cccnc1Oc1ccccc1
729,1640556,,,,,"null: Microsomal preparation: One lobe of fresh pig liver is obtained (e.g., at about the time of slaughter from a food-processing company) and immediately placed in ice cold 15 mM KH2PO4/250 mM sucrose (pH 7.4) and kept on ice during transportation. A 10 g sample of liver is minced and homogenized in 30 mL of homogenization buffer (15 mM KH2PO4/250 mM sucrose) using a Tekmar homoginizer or equivalent by pulsing 3 times with 20 second pulses. This procedure is repeated for a total of 8x10 g samples of pig liver. The remaining pig liver may be stored at -80 C. The homogenates from the 8 samples are pooled and centrifuged at 13,000xg for 20 minutes at 4 C. to remove crude debris. The supernatant is further centrifuged at 100,000xg for 70 minutes at 4° C. The microsomal pellets are re-suspended into 50 mL of 150 mM KH2PO4/1 mM DTT (pH 7.4) and 1 mL aliquots are stored at -80 C.100-150 ug of pig liver microsomal protein in 150 mM KH2PO4 is incubated at 37° C.",c1ccc(-c2nc[nH]c2-c2ccccc2)cc1,"4,5-diphenyl-1H-imidazole",100.0,uM,=,2.0,1,c1ccc(-c2nc[nH]c2-c2ccccc2)cc1
730,676065,10.1016/j.bmcl.2010.09.028,,,,Inhibition of CYP3A4 after 30 mins,CC(C)[C@@H]1COC[C@H](C2(OC(=O)N3CCC(CO)CC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1,"1-((3R,5R)-4-(4-chlorophenylsulfonyl)-5-isopropylmorpholin-3-yl)cyclopropyl 4-(hydroxymethyl)piperidine-1-carboxylate",0.0138,uM,=,-1.8601209135987635,0,O=C(OC1([C@H]2COCCN2S(=O)(=O)c2ccccc2)CC1)N1CCCCC1
731,828928,10.1016/j.bmcl.2012.06.022,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(NCCCN(C)C)oc2c1,"thiazol-5-ylmethyl(2S,3R)-4-(2-(3-(dimethylamino)propylamino)-N-isobutylbenzo[d]oxazole-6-carboxamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate",0.2,uM,=,-0.6989700043360187,0,O=C(N[C@H](CCNC(=O)c1ccc2ncoc2c1)Cc1ccccc1)OCc1cncs1
732,874112,10.1021/jm300118s,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis,COCC(=O)N[C@@H](Cc1cccc(-c2cncs2)c1)[C@H](O)CN[C@H]1CC2(CCC2)Oc2ncc(CC(C)(C)C)cc21,"N-((2S,3R)-3-Hydroxy-4-((S)-6'-neopentyl-3',4'-dihydrospiro-[cyclobutane-1,2'-pyrano[2,3-b]pyridine]-4'-ylamino)-1-(3-(thiazol-5-yl)phenyl)butan-2-yl)-2-methoxyacetamide",0.03,uM,=,-1.5228787452803376,0,c1cc(CCCCN[C@H]2CC3(CCC3)Oc3ncccc32)cc(-c2cncs2)c1
733,1350938,10.1016/j.bmcl.2014.03.070,,,,Inhibition of CYP3A4 (unknown origin),Cc1nn(C2CCCC2)c(C)c1S(=O)(=O)N[C@@H](C)CNc1cccc2c1cnn2-c1ccc(F)nc1,"(S)-1-cyclopentyl-N-(1-(1-(6-fluoropyridin-3-yl)-1H-indazol-4-ylamino)propan-2-yl)-3,5-dimethyl-1H-pyrazole-4-sulfonamide",22.0,uM,=,1.3424226808222062,1,O=S(=O)(NCCNc1cccc2c1cnn2-c1cccnc1)c1cnn(C2CCCC2)c1
734,1854052,10.1016/j.ejmech.2019.07.003,,,,Inhibition of recombinant human CYP3A4 using Luciferin-PPXE as substrate preincubated for 10 mins followed by NADPH addition measured after 15 mins by luminometric method,CCN(CC)c1ccc2cc(C(=O)NCC(O)(Cn3cncn3)c3ccc(Cl)cc3Cl)c(=O)oc2c1,"rac-N-(2-(2,4-dichlorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl)-7-(diethylamino)-2-oxo-2H-chromene-3-carboxamide",0.3512,uM,=,-0.454445492765935,0,O=C(NCC(Cn1cncn1)c1ccccc1)c1cc2ccccc2oc1=O
735,1521329,10.1016/j.bmcl.2015.09.011,,,,Inhibition of CYP3A4 (unknown origin),Cc1cc(C)cc(Nc2nccc(-n3cc(C)c(CN4CC[C@@H](O)C4)c3)n2)c1,"(R)-1-((1-(2-(3,5-dimethylphenylamino)pyrimidin-4-yl)-4-methyl-1H-pyrrol-3-yl)methyl)pyrrolidin-3-ol",5.1,uM,=,0.7075701760979364,1,c1ccc(Nc2nccc(-n3ccc(CN4CCCC4)c3)n2)cc1
736,828928,10.1016/j.bmcl.2012.06.022,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,CCNc1nc2ccc(C(=O)N(C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)CC(C)(C)O)cc2o1,"thiazol-5-ylmethyl(2S,3R)-4-(2-(ethylamino)-N-(2-hydroxy-2-methylpropyl)benzo[d]oxazole-6-carboxamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate",0.097,uM,=,-1.0132282657337552,0,O=C(N[C@H](CCNC(=O)c1ccc2ncoc2c1)Cc1ccccc1)OCc1cncs1
737,768817,10.1021/jm2005354,,,,Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting,C[C@@H](c1ccc(-c2ccc(F)cc2F)cc1)N1CC[C@](CCN)(c2ccc(F)cc2)OC1=O,"(R)-6-(2-aminoethyl)-3-((S)-1-(2',4'-difluorobiphenyl-4-ylethyl)-6-(4-fluorophenyl)-1,3-oxazinan-2-one",3.0,uM,=,0.4771212547196624,1,O=C1OC(c2ccccc2)CCN1Cc1ccc(-c2ccccc2)cc1
738,2133633,10.1021/acs.jmedchem.1c00679,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins in presence of NADPH by LCMS/MS analysis,CCC(NC(=O)c1ccc(Cl)cc1)[C@@H]1[C@@H]2C[C@H](Oc3ccnc4cc(F)ccc34)C[C@@H]21,"4-chloro-N-(1-((1R,3s,5S,6r)-3-(7-fluoroquinolin-4-yloxy)bicyclo[3.1.0]hexan-6-yl)propyl)benzamide",5.4,uM,=,0.7323937598229685,1,O=C(NC[C@H]1[C@H]2C[C@@H](Oc3ccnc4ccccc34)C[C@@H]12)c1ccccc1
739,748201,10.1016/j.bmcl.2011.03.085,,,,Inhibition of CYP3A4,CN(C(=O)C1(c2ccc(F)cc2)CCCC1)[C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1,"(R)-2-(7-(1-(4-fluorophenyl)-N-methylcyclopentanecarboxamido)-6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl)acetic acid",37.0,uM,=,1.568201724066995,1,O=C(N[C@@H]1CCc2cc3ccccc3n2C1)C1(c2ccccc2)CCCC1
740,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCN(CCC)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1,"US8940739, G-43",6.94,uM,=,0.8413594704548549,1,O=C(Nc1ccc(N2CCNCC2)nc1)c1c[nH]c2c(CN3CC4N(C(=O)NCc5ccccc5)NCC(=O)N4C(Cc4ccccc4)C3=O)cccc12
741,759505,10.1016/j.bmcl.2011.06.015,,,,Inhibition of CYP3A4,O=C(/C=C/c1ccc(CN(CCO)CCc2c[nH]c3ccccc23)cc1)NO,(E)-N-Hydroxy-3-[4-({(2-hydroxy-ethyl)-[2-(1H-indol-3-yl)-ethyl]-amino}-methyl)-phenyl]-acrylamide,14.0,uM,=,1.146128035678238,1,c1ccc(CNCCc2c[nH]c3ccccc23)cc1
742,1488507,10.1124/dmd.112.045708,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis in presence of NADPH,CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1,"(R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide",25.0,uM,=,1.3979400086720375,1,O=C(Cc1ccccc1)N(Cc1cccnc1)Cc1nc2ncccc2c(=O)n1-c1ccccc1
743,1499751,10.1021/acs.jmedchem.5b00424,,,,Inhibition of CYP3A4 (unknown origin),COc1cccc(CC(=O)Nc2nc(-c3ccnc(Cl)c3)cs2)c1,N-(4-(2-chloropyridin-4-yl)thiazol-2-yl)-2-(3-methoxyphenyl)acetamide,3.6,uM,=,0.5563025007672873,1,O=C(Cc1ccccc1)Nc1nc(-c2ccncc2)cs1
744,686484,10.1016/j.bmcl.2010.09.122,,,,Inhibition of CYP3A4,O=c1cc(OCc2ccccc2)ccn1-c1ccc2c(cnn2CCN2CCCC2)c1,4-(benzyloxy)-1-(1-(2-(pyrrolidin-1-yl)ethyl)-1H-indazol-5-yl)pyridin-2(1H)-one,10.0,uM,=,1.0,1,O=c1cc(OCc2ccccc2)ccn1-c1ccc2c(cnn2CCN2CCCC2)c1
745,1474044,10.1021/jm501740a,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,CN1[C@@H]2CC[C@H]1C[C@@H](Oc1ccc(-c3n[nH]c4ccc(C(=O)NC(c5ccccc5)C5CC5)cc34)cc1)C2,rac-N-(Cyclopropyl(phenyl)methyl)-3-(4-((endo)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl)oxy)phenyl)-1H-indazole-5-carboxamide,2.4,uM,=,0.380211241711606,1,O=C(NC(c1ccccc1)C1CC1)c1ccc2[nH]nc(-c3ccc(O[C@H]4C[C@H]5CC[C@@H](C4)N5)cc3)c2c1
746,1730110,10.1021/acs.jmedchem.8b00335,,,,Inhibition of recombinant human CYP3A4 in presence of NADPH generating system by fluorescence assay,COc1cc(-c2nc(SCC(=O)NC(=O)Nc3ccccn3)nc(Nc3cccc(Cl)c3)c2C#N)cc(OC)c1OC,"2-((4-((3-chlorophenyl)amino)-5-cyano-6-(3,4,5-trimethoxyphenyl)pyrimidin-2-yl)thio)-N-(pyridin-2-ylcarbamoyl)acetamide",17.243,uM,=,1.2366128281997688,1,O=C(CSc1nc(Nc2ccccc2)cc(-c2ccccc2)n1)NC(=O)Nc1ccccn1
747,2125132,10.1021/acsmedchemlett.1c00540,,,,Inhibition of human CYP3A4 using testosterone as a substrate by LC/MS/MS analysis,O=C(c1nccs1)N1CC[C@@H](Nc2nccc(-n3cc(C4CC4)nc3-c3ccccc3)n2)C1,(R)-(3-(4-(4-cyclopropyl-2-phenyl-1H-imidazol-1-yl)pyrimidin-2-ylamino)pyrrolidin-1-yl)(thiazol-2-yl)methanone,0.29,uM,=,-0.5376020021010439,0,O=C(c1nccs1)N1CC[C@@H](Nc2nccc(-n3cc(C4CC4)nc3-c3ccccc3)n2)C1
748,552281,10.1016/j.bmcl.2008.04.036,,,,Inhibition of CYP3A4,N[C@@H](Cn1c(=O)c(-c2ccccc2)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1,"3-((R)-2-Amino-2-phenyl-ethyl)-1-(2-fluoro-6-trifluoromethyl-benzyl)-5-phenyl-1H-pyrimidine-2,4-dione",0.3,uM,=,-0.5228787452803376,0,O=c1c(-c2ccccc2)cn(Cc2ccccc2)c(=O)n1CCc1ccccc1
749,1534761,,,,,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",Cc1cnc2[nH]cc(Cc3ccc(NCc4ccc(Cl)nc4)nc3F)c2c1,"US9096593, P-2088",5.0,uM,=,0.6989700043360189,1,c1cncc(CNc2ccc(Cc3c[nH]c4ncccc34)cn2)c1
750,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)N6CCN(C)CC6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, D-91",6.51,uM,=,0.8135809885681919,1,O=C(c1ccc(-c2c[nH]c3c(CN4C[C@@H]5N(C(=O)NCc6ccccc6)NCC(=O)N5[C@@H](Cc5ccccc5)C4=O)cccc23)cn1)N1CCNCC1
751,742805,10.1016/j.bmc.2011.02.009,,,,Inhibition of human CYP3A4 after 30 mins,CC(=O)Nc1cccc(-c2ccc(C(O)(c3c[nH]cn3)C3CC3)cc2)c1,"rac-N-[4'-[Cyclopropyl(hydroxy)-1H-imidazol-4-ylmethyl][1,1'-biphenyl]-3-yl]acetamide",5.5,uM,=,0.7403626894942439,1,c1ccc(-c2ccc(C(c3c[nH]cn3)C3CC3)cc2)cc1
752,1534761,,,,,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",Cc1cnc2[nH]cc(Cc3ccc(NCc4ccnc(F)c4)nc3F)c2c1,"US9096593, P-2118",5.0,uM,=,0.6989700043360189,1,c1cnc2[nH]cc(Cc3ccc(NCc4ccncc4)nc3)c2c1
753,813159,10.1021/jm2011222,,,,Inhibition of CYP3A4,COc1ccc(-n2c(C)nnc2SCc2nc(-c3ccc(OC)c(OC)c3)no2)cc1,SID24390092,5.3,uM,=,0.724275869600789,1,c1ccc(-c2noc(CSc3nncn3-c3ccccc3)n2)cc1
754,455108,10.1016/j.bmcl.2006.12.043,,,,Inhibition of CYP3A4,N[C@@H](Cc1ccccc1)C(=O)N1CCC(Nc2ccc3[nH]ncc3c2)CC1,(S)-1-(4-(1H-indazol-5-ylamino)piperidin-1-yl)-2-amino-3-phenylpropan-1-one,1.0,uM,=,0.0,0,O=C(CCc1ccccc1)N1CCC(Nc2ccc3[nH]ncc3c2)CC1
755,828928,10.1016/j.bmcl.2012.06.022,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(-c3ccccc3)oc2c1,"Thiazol-5-ylmethyl(2S,3R)-3-hydroxy-4-(N-isobutyl-2-phenylbenzo[d]oxazole-6-carboxamido)-1-phenylbutan-2-ylcarbamate",0.024,uM,=,-1.619788758288394,0,O=C(N[C@H](CCNC(=O)c1ccc2nc(-c3ccccc3)oc2c1)Cc1ccccc1)OCc1cncs1
756,1675511,10.1016/j.ejmech.2017.03.037,,,,Inhibition of human hepatic CYP3A4,Oc1ccc2sc3c(c2c1)CCN(Cc1cccnc1)C3,"2-(Pyridin-3-ylmethyl)-1,2,3,4-tetrahydrobenzo[4,5]thieno[2,3-c]pyridin-6-ol",5.282,uM,=,0.7227983968709052,1,c1cncc(CN2CCc3c(sc4ccccc34)C2)c1
757,350785,10.1016/j.bmcl.2006.02.004,,,,Inhibition of human recombinant CYP3A4,C=CCc1ccc(C(=O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,1-(4-allylphenyl)-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butan-1-one,5.5,uM,=,0.7403626894942439,1,O=C(CCCN1CCC(C(c2ccccc2)c2ccccc2)CC1)c1ccccc1
758,51930,10.1016/s0960-894x(01)00614-x,,,,Inhibition of recombinant human Cytochrome P450 3A4,CCCCc1ccc(/N=C/NO)c(C)c1,N-(4-butyl-2-methylphenyl)-N'-hydroxyimidoformamide,71.0,uM,=,1.8512583487190752,1,c1ccccc1
759,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)NC6CCN(C)CC6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, D-98",2.92,uM,=,0.4653828514484183,1,O=C(Nc1ccc(-c2c[nH]c3c(CN4C[C@@H]5N(C(=O)NCc6ccccc6)NCC(=O)N5[C@@H](Cc5ccccc5)C4=O)cccc23)cn1)NC1CCNCC1
760,814102,10.1016/j.bmcl.2012.03.014,,,,Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins,CC(=O)NCCc1cc(F)ccc1-c1onc([C@H]2CNCC[C@]2(O)c2ccc(F)c(F)c2)c1Br,"N-(2-(4-bromo-3-((3R,4R)-4-(3,4-difluorophenyl)-4-hydroxypiperidin-3-yl)isoxazol-5-yl)-5-fluorophenethyl)acetamide",45.0,uM,=,1.6532125137753435,1,c1ccc(-c2cc([C@H]3CNCCC3c3ccccc3)no2)cc1
761,834635,10.1016/j.bmcl.2012.07.019,,,,Inhibition of CYP3A4,N[C@@H](CC(=O)N1CCN(C(=O)c2ccc(C(F)(F)F)cc2)CC1)Cc1cc(F)c(F)cc1F,"(R)-3-amino-1-(4-(4-(trifluoromethyl)benzoyl)piperazin-1-yl)-4-(2,4,5-trifluorophenyl)butan-1-one",1.0,uM,=,0.0,0,O=C(CCCc1ccccc1)N1CCN(C(=O)c2ccccc2)CC1
762,487712,10.1016/j.bmcl.2008.05.104,,,,Inhibition of CYP3A4,Cc1cc(N2CCC(OCCO)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,(S)-4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-3-(6-(4-(2-hydroxyethoxy)piperidin-1-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one,0.0013,uM,=,-2.886056647693163,0,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(N3CCCCC3)cc2[nH]1
763,509755,10.1016/j.bmcl.2008.07.035,,,,Inhibition of recombinant CYP3A4,O=C(Nc1ccc2c(c1)NC(=O)C(CCO)O2)C1CCN(c2cc(F)c(F)c(F)c2)CC1,"N-(2-(2-hydroxyethyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-1-(3,4,5-trifluorophenyl)piperidine-4-carboxamide",3.7,uM,=,0.568201724066995,1,O=C1COc2ccc(NC(=O)C3CCN(c4ccccc4)CC3)cc2N1
764,874112,10.1021/jm300118s,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis,CC#Cc1cccc(C[C@H](NC(=O)COC)[C@H](O)CN[C@H]2CC3(CCC3)Oc3ncc(CC(C)(C)C)cc32)c1,"N-((2S,3R)-3-Hydroxy-4-((S)-6'-neopentyl-3',4'-dihydrospiro-[cyclobutane-1,2'-pyrano[2,3-b]pyridine]-4'-ylamino)-1-(3-(prop-1-ynyl)phenyl)butan-2-yl)-2-methoxyacetamide",0.03,uM,=,-1.5228787452803376,0,c1ccc(CCCCN[C@H]2CC3(CCC3)Oc3ncccc32)cc1
765,1301328,10.6019/CHEMBL3137440,,,,DNDI: CYP Inhibition,COc1ccc(CN2CCC(N(c3ccc(C(F)(F)F)cc3)c3cccnc3)CC2)cc1,,8.0,uM,=,0.9030899869919436,1,c1ccc(CN2CCC(N(c3ccccc3)c3cccnc3)CC2)cc1
766,828928,10.1016/j.bmcl.2012.06.022,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,CCNc1nc2ccc(C(=O)N(CC(C)C)C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1,"Thiazol-5-ylmethyl(2S,3R)-4-(2-(ethylamino)-N-isobutylbenzo[d]oxazole-6-carboxamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate",0.028,uM,=,-1.5528419686577808,0,O=C(N[C@H](CCNC(=O)c1ccc2ncoc2c1)Cc1ccccc1)OCc1cncs1
767,455108,10.1016/j.bmcl.2006.12.043,,,,Inhibition of CYP3A4,O=C([C@H](O)c1cccc(Cl)c1)N1CCN(c2ccc3[nH]ncc3c2)CC1,(R)-1-(4-(1H-indazol-5-yl)piperazin-1-yl)-2-(3-chlorophenyl)-2-hydroxyethanone,3.5,uM,=,0.5440680443502757,1,O=C(Cc1ccccc1)N1CCN(c2ccc3[nH]ncc3c2)CC1
768,1778315,10.1016/j.bmcl.2018.06.040,,,,Inhibition of CYP3A4 (unknown origin),CCNS(=O)(=O)c1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1,"N-(4-(1H-pyrrolo[2,3-b]pyridin-3-yl)thiazol-2-yl)-2-(3-(N-ethylsulfamoyl)phenyl)acetamide",9.3,uM,=,0.9684829485539352,1,O=C(Cc1ccccc1)Nc1nc(-c2c[nH]c3ncccc23)cs1
769,982382,10.1016/j.bmcl.2013.07.071,,,,Inhibition of CYP3A4 (unknown origin),COC[C@@H](Oc1cc(C[C@@H]2C[S@@+]([O-])C[C@H](NCc3cc(C(C)(C)C)ccc3F)[C@H]2O)cc(F)c1N)C(F)(F)F,"(1R,3S,4S,5R)-3-[4-Amino-3-fluoro-5-((R)-2,2,2-trifluoro-1-methoxymethyl-ethoxy)-benzyl]-5-(5-tert-butyl-2-fluoro-benzylamino)-1-oxo-tetrahydro-thiopyran-4-ol",0.1,uM,=,-1.0,0,c1ccc(CN[C@H]2C[SH+]C[C@@H](Cc3ccccc3)C2)cc1
770,1984169,10.1016/j.bmc.2020.115349,,,,Inhibition of human full length CYP3A4 assessed using 7-benzyloxy-4 (trifluoromethyl)coumarin as substrate preincubated for 20 mins in presence of NADPH followed by substrate addition and measured for 2 mins by fluorometric analysis,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1,"((1R,2R,4R)-1-Benzyl-2-hydroxy-4-{(R)-2-[3-(2-isopropyl-1lambda*4*-[1,3]thiazin-5-ylmethyl)-3-methyl-ureido]-3-methyl-butyrylamino}-5-phenyl-pentyl)-carbamic acid thiazol-5-ylmethyl ester",0.13,uM,=,-0.8860566476931633,0,O=C(CNC(=O)NCc1cscn1)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
771,2158479,10.1021/acs.jmedchem.1c00926,,,,Inhibition of CYP3A4 (unknown origin),Cn1cc(Nc2nccc(-c3ccc4c(c3)CCCC[C@H]4NC(=O)c3nc(C(C)(C)C)no3)n2)cn1,"(R)-3-tert-butyl-N-(2-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-5-yl)-1,2,4-oxadiazole-5-carboxamide",2.6,uM,=,0.414973347970818,1,O=C(N[C@@H]1CCCCc2cc(-c3ccnc(Nc4cn[nH]c4)n3)ccc21)c1ncno1
772,673952,10.1016/j.bmcl.2010.08.086,,,,Inhibition of CYP3A4 using midazolam as substrate,CNC(=O)CCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1,"(3R,4S)-N-(2-chloro-5-(3-(methylamino)-3-oxopropyl)benzyl)-N-cyclopropyl-4-(4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)phenyl)piperidine-3-carboxamide",2.9,uM,=,0.4623979978989561,1,O=C([C@H]1CNCC[C@@H]1c1ccc(OCCOc2ccccc2)cc1)N(Cc1ccccc1)C1CC1
773,993439,10.6019/CHEMBL2448688,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,CO/N=C(\C)c1ccc(-n2ccnc2)c(NC(=O)c2cnn(-c3ccccn3)c2)c1,,1.4,uM,=,0.1461280356782379,1,O=C(Nc1ccccc1-n1ccnc1)c1cnn(-c2ccccn2)c1
774,51907,10.1016/s0960-894x(03)00475-x,,,,In vitro inhibition of human liver microsome Cytochrome P450 3A4,O=C(N[C@H]1c2ccccc2OC[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CN1CCN(Cc2ccc(-c3cccnc3)o2)C[C@H]1C(=O)NCC(F)(F)F,"(S)-1-[(S)-2-Hydroxy-4-((R)-(S)-3-hydroxy-3,4,4a,8a-tetrahydro-2H-chromen-4-ylcarbamoyl)-5-phenyl-pentyl]-4-(5-pyridin-3-yl-furan-2-ylmethyl)-piperazine-2-carboxylic acid (2,2,2-trifluoro-ethyl)-amide",0.44,uM,=,-0.3565473235138126,0,O=C(N[C@@H]1CCOc2ccccc21)[C@@H](CCCN1CCN(Cc2ccc(-c3cccnc3)o2)CC1)Cc1ccccc1
775,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N(C)CCO)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, G-18",3.45,uM,=,0.5378190950732742,1,O=C(Nc1cccnc1)c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12
776,349088,10.1016/j.bmcl.2006.01.084,,,,Inhibition of CYP3A4 using BFC fluorogenic substrate,COc1ccccc1COCCCOc1ccc(N2C(=O)CNC[C@@H]2COc2ccc3c(c2)N(CCCO)CCC3)cc1,"(R)-6-[1-(3-Hydroxy-propyl)-1,2,3,4-tetrahydro-quinolin-7-yloxymethyl]-1-{4-[3-(2-methoxy-benzyloxy)-propoxy]-phenyl}-piperazin-2-one",0.455,uM,=,-0.3419886033428876,0,O=C1CNC[C@H](COc2ccc3c(c2)NCCC3)N1c1ccc(OCCCOCc2ccccc2)cc1
777,1625607,10.1016/j.bmcl.2016.10.016,,,,Inhibition of human Cyp3A4 using testosterone as substrate by LC-MS/MS analysis,O=S(=O)(N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1)C(F)(F)F,"1-(4-{[(2S,4R)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)-4-trifluoromethanesulfonylpiperazine",0.336,uM,=,-0.4736607226101559,0,c1ccc([C@]2(Cn3ccnc3)OC[C@@H](COc3ccc(N4CCNCC4)cc3)O2)cc1
778,966467,10.1016/j.bmcl.2013.04.077,,,,Inhibition of CYP3A4 (unknown origin),Cc1nc(NC(=O)CN(Cc2ccccc2)C(=O)c2ccncc2)sc1-c1ccc(N)nc1,N-(2-(5-(6-aminopyridin-3-yl)-4-methylthiazol-2-ylamino)-2-oxoethyl)-N-benzylisonicotinamide,0.71,uM,=,-0.1487416512809247,0,O=C(CN(Cc1ccccc1)C(=O)c1ccncc1)Nc1ncc(-c2cccnc2)s1
779,1485703,10.1124/dmd.112.048264,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method,COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC,"2-(3,4-Dimethoxy-phenyl)-5-{[2-(3,4-dimethoxy-phenyl)-ethyl]-methyl-amino}-2-isopropyl-pentanenitrile",12.0,uM,=,1.0791812460476249,1,c1ccc(CCCCNCCc2ccccc2)cc1
780,1287294,10.1021/jm401639v,,,,Inhibition of CYP3A4 (unknown origin) by fluorescence assay,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1C[C@H](Cc1cccc(C(N)=O)c1)[C@@H]2O,"3-(3,17beta-dihydroxy-estra-1,3,5(10)-trien-16beta-ylmethyl)-benzamide",1.5,uM,=,0.1760912590556812,1,c1ccc(C[C@@H]2CC3CC[C@@H]4c5ccccc5CC[C@H]4[C@@H]3C2)cc1
781,1276541,10.1016/j.bmcl.2013.09.041,,,,Inhibition of CYP3A4 (unknown origin) after 5 mins,C=Cc1cc(-c2ccc(NS(=O)(=O)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)cc2)ccn1,"3,5-bis(trifluoromethyl)-N-(4-(2-vinylpyridin-4-yl)phenyl)benzenesulfonamide",4.5,uM,=,0.6532125137753437,1,O=S(=O)(Nc1ccc(-c2ccncc2)cc1)c1ccccc1
782,473932,10.1021/jm701121y,,,,Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay,CCn1c(SCc2ccc(OC)cc2)nnc1-c1ccncc1,"4-(5-(4-methoxybenzylthio)-4-ethyl-4H-1,2,4-triazol-3-yl)pyridine",28.0,uM,=,1.4471580313422192,1,c1ccc(CSc2nnc(-c3ccncc3)[nH]2)cc1
783,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(NCCN6CCCCC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1,"US8940739, G-27",2.53,uM,=,0.4031205211758178,1,O=C(Nc1ccc(NCCN2CCCCC2)nc1)c1c[nH]c2c(CN3CC4N(C(=O)NCc5ccccc5)NCC(=O)N4C(Cc4ccccc4)C3=O)cccc12
784,1523285,10.1016/j.bmcl.2015.06.066,,,,Inhibition of CYP3A4 (unknown origin),CCCCC(C(=O)COc1c(F)c(F)cc(F)c1F)n1cc([C@@](C)(NCc2ccc3ncsc3c2)C(C)C)nn1,"3-(4-((S)-2-(benzo[d]thiazol-6-ylmethylamino)-3-methylbutan-2-yl)-1H-1,2,3-triazol-1-yl)-1-(2,3,5,6-tetrafluorophenoxy)heptan-2-one",0.3,uM,=,-0.5228787452803376,0,O=C(COc1ccccc1)Cn1cc(CNCc2ccc3ncsc3c2)nn1
785,539794,10.1021/jm8005405,,,,Inhibition of CYP3A4 in human liver microsomes,Cc1ccc2c(N)nsc2c1-c1ccc2c(N3CCOC[C@@H]3C)nncc2c1,6-Methyl-7-(1-((S)-3-methylmorpholino)phthalazin-6-yl)benzo[d]isothiazol-3-amine,4.0,uM,=,0.6020599913279624,1,c1cc(-c2ccc3c(N4CCOCC4)nncc3c2)c2sncc2c1
786,423507,10.1021/jm060995h,,,,Inhibition of CYP3A4,CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3CC[C@@H](O)C3)c(Cc3ccnc4ccccc34)sc21,"(R)-5-(3-hydroxypyrrolidine-1-carbonyl)-1-isobutyl-3-methyl-6-(quinolin-4-ylmethyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione",16.0,uM,=,1.2041199826559248,1,O=C(c1c(Cc2ccnc3ccccc23)sc2[nH]c(=O)[nH]c(=O)c12)N1CCCC1
787,2188254,10.1021/acs.jmedchem.2c01366,,,,Inhibition of human liver microsomes CYP3A4 using midazolam or testosterone as substrate in presence of NADPH regenerating system by LC-MS/MS analysis,CNC(=O)c1cncc(-c2cnn3cc(-c4cnn(C(C)C)c4)c(O[C@H]4CCOC4)nc23)c1,"(S)-5-(6-(1-Isopropyl-1H-pyrazol-4-yl)-5-((tetrahydrofuran-3-yl)oxy)pyrazolo[1,5-a]pyrimidin-3-yl)-N-methylnicotinamide",9.0,uM,=,0.9542425094393248,1,c1cncc(-c2cnn3cc(-c4cn[nH]c4)c(O[C@H]4CCOC4)nc23)c1
788,512798,10.1021/jm800832q,,,,Inhibition of human recombinant CYP3A4 in human liver microsomes using BFC as a substrate,Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,4-[(S)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-(4-methyl-6-morpholin-4-yl-1H-benzoimidazol-2-yl)-1H-pyridin-2-one,0.05,uM,=,-1.3010299956639813,0,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(N3CCOCC3)cc2[nH]1
789,510198,10.1021/jm800355c,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,OC1(c2ccncc2)CCCc2cc(-c3ccc(F)c(F)c3)ccc21,"6-(3,4-Difluorophenyl)-1-(pyridin-4-yl)-1,2,3,4-tetrahydronaphthalen-1-ol",13.841,uM,=,1.1411674686462323,1,c1ccc(-c2ccc3c(c2)CCCC3c2ccncc2)cc1
790,2250329,10.1021/acs.jmedchem.2c00192,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 15 mins followed by NADPH addition and measured after 8 mins by LC-MS/MS analysis,Cn1ccnc1SC[C@H]1CCN(S(=O)(=O)c2ccc3c(c2)CCO3)C[C@@H]1F,"(3R,4S)-1-((2,3-dihydrobenzofuran-5-yl)sulfonyl)-3-fluoro-4-(((1-methyl-1H-imidazol-2-yl)thio)methyl)piperidine",8.1,uM,=,0.9084850188786496,1,O=S(=O)(c1ccc2c(c1)CCO2)N1CCC(CSc2ncc[nH]2)CC1
791,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(C)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, E-4",12.2,uM,=,1.0863598306747482,1,O=C(c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12)N1CCNCC1
792,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",COc1ccc(C[C@@H]2COCCN2C(=O)c2ccccc2-n2nccn2)cc1-c1nccs1,"US9150566, 8",3.2,uM,=,0.505149978319906,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2nccs2)c1
793,304834,10.1021/jm050261p,,,,Inhibitory concentration against Cytochrome P450 3A4,N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2,(S)-2-[2-Amino-2-(3-hydroxy-adamantan-1-yl)-acetyl]-2-aza-bicyclo[3.1.0]hexane-3-carbonitrile,100.0,uM,=,2.0,1,O=C(CC12CC3CC(CC(C3)C1)C2)N1CC[C@@H]2C[C@@H]21
794,487712,10.1016/j.bmcl.2008.05.104,,,,Inhibition of CYP3A4,Cc1cc(N2CCC(N(C)C)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,(S)-4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-3-(6-(4-(dimethylamino)piperidin-1-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one,0.0039,uM,=,-2.408935392973501,0,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(N3CCCCC3)cc2[nH]1
795,862399,10.1021/jm300601d,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis,CC(C)C(=O)N1CCC(c2ccc(C(=O)NC(=N)N)cc2C(F)(F)F)CC1,N-[4-(1-Isobutyryl-piperidin-4-yl)-3-trifluoromethyl-benzoyl]-guanidine,0.4,uM,=,-0.3979400086720376,0,c1ccc(C2CCNCC2)cc1
796,1925699,10.1016/j.bmcl.2016.07.011,,,,Inhibition of recombinant CYP3A4 (unknown origin) by fluorescence-based assay,CCn1nc(C(C)(C)C)cc1Nc1nc(-c2ccc(-n3cnc(C)c3)c(F)c2)cs1,N-(3-(Tert-butyl)-1-ethyl-1H-pyrazol-5-yl)-4-(3-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl)thiazol-2-amine,16.0,uM,=,1.2041199826559248,1,c1cn(-c2ccc(-c3csc(Nc4ccn[nH]4)n3)cc2)cn1
797,973974,10.1021/jm400380m,,,,Inhibition of CYP3A4 (unknown origin) after 10 mins by fluorescence assay,CN1CCN(c2ccc(/C=C/c3n[nH]c4cc(/C=C5/C(=O)Nc6ccccc65)ccc34)cn2)CC1,(E/Z)-3-((3-((E)-2-(6-(4-Methylpiperazin-1-yl)pyridin-3-yl)-vinyl)-1H-indazol-6-yl)methylene)-indolin-2-one,0.8,uM,=,-0.0969100130080563,0,O=C1Nc2ccccc2/C1=C\c1ccc2c(/C=C/c3ccc(N4CCNCC4)nc3)n[nH]c2c1
798,2014369,10.1021/acsmedchemlett.9b00123,,,,Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells using midazolam as substrate incubated for 30 mins in presence of NADPH-regenerating system by fluorescence based assay,CN(C)c1ccc(CC(=O)N[C@@H]2CNC[C@H]2c2ccc(C(F)(F)F)cc2)cc1,"(-)-2-(4-(Dimethylamino)phenyl)-N-((3S,4R)-4-(4-(trifluoromethyl)phenyl)pyrrolidin-3-yl)acetamide",0.871,uM,=,-0.0599818449923368,0,O=C(Cc1ccccc1)N[C@@H]1CNC[C@H]1c1ccccc1
799,1625990,10.1016/j.bmcl.2016.04.095,,,,Inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins after 30 secs by LC/MS/MS analysis,CNCCS(=O)(=O)CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12,"2-(2-((4S,4aS,10bS)-10b-(4-chlorophenylsulfonyl)-7,10-difluoro-1,2,4,4a,5,10b-hexahydropyrano[3,4-c]chromen-4-yl)ethylsulfonyl)-N-methylethanamine",8.4,uM,=,0.9242792860618816,1,O=S(=O)(c1ccccc1)[C@@]12CCOC[C@@H]1COc1ccccc12
800,2156515,10.1021/acs.jmedchem.1c01272,,,,Inhibition of CYP3A4 in human liver microsomes using IPA as substrate preincubated for 10 mins followed by NADPH generating system addition and measured after 20 mins,COc1cc(NC(=O)c2cc(=O)c3ccccc3o2)c(-c2nnn(-c3ccc(CCN4CCc5cnccc5C4)cc3)n2)cc1OCc1ccccc1,"N-(4-(benzyloxy)-2-(2-(4-(2-(3,4-dihydro-2,6-naphthyridin-2(1H)-yl)ethyl)phenyl)-2H-tetrazol-5-yl)-5-methoxyphenyl)-4-oxo-4H-chromene-2-carboxamide",1.237,uM,=,0.0923696996291207,1,O=C(Nc1ccc(OCc2ccccc2)cc1-c1nnn(-c2ccc(CCN3CCc4cnccc4C3)cc2)n1)c1cc(=O)c2ccccc2o1
801,559938,10.1016/j.bmcl.2008.10.072,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,CCN(CCc1ccccc1)C(=O)c1ccccc1-c1ccc(CN2C[C@@H](C)N[C@@H](C)C2)cc1,"4'-((3R,5S)-3,5-Dimethyl-piperazin-1-ylmethyl)-biphenyl-2-carboxylic acid ethyl-phenethyl-amide",0.9,uM,=,-0.0457574905606751,0,O=C(NCCc1ccccc1)c1ccccc1-c1ccc(CN2CCNCC2)cc1
802,2109894,10.1016/j.bmc.2021.116138,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate incubated for 5 mins followed by NADPH addition and measured after 5 mins by LC/MS/MS analysis,C=C[C@]1(C)C[C@@H](OC(=O)CSc2nc(N)n(C(=O)c3ccc(C)cc3)n2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O,"2-(3-amino-2-(4-methyl-benzoyl)-1,2,4-triazole-5-yl)-thioacetyl)-22-deoxypleuromutilin",3.95,uM,=,0.5965970956264602,1,O=C(CSc1ncn(C(=O)c2ccccc2)n1)O[C@@H]1CCCC[C@@]23CCCC1[C@@H]2C(=O)CC3
803,988989,10.1021/jm400732v,,,,Inhibition of CYP3A4 (unknown origin),CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2c(OC)ccc3ccccc23)c2ccc(C#N)cc2N(C(C)=O)[C@H]1C.Cl,"(S)-N-((3S,4S)-5-Acetyl-7-cyano-1-((2-methoxynaphthalen-1-yl)-methyl)-4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b][1,4]-diazepin-3-yl)-2-(methylamino)propanamide Hydrochloride",18.0,uM,=,1.255272505103306,1,O=C1CCNc2ccccc2N1Cc1cccc2ccccc12
804,1291572,10.1016/j.bmcl.2013.12.058,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1,"((1R,2R,4R)-1-Benzyl-2-hydroxy-4-{(R)-2-[3-(2-isopropyl-1lambda*4*-[1,3]thiazin-5-ylmethyl)-3-methyl-ureido]-3-methyl-butyrylamino}-5-phenyl-pentyl)-carbamic acid thiazol-5-ylmethyl ester",0.11,uM,=,-0.958607314841775,0,O=C(CNC(=O)NCc1cscn1)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
805,1870804,10.1016/j.bmcl.2018.11.048,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH cofactor addition and measured after 10 mins by LC-MS/MS analysis,O=C(NC1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1)c1cccnc1,(R)-N-(4-(3-(5-(trifluoromethyl)pyridin-2-yloxy)benzylidene)cyclohexyl)nicotinamide,0.0024,uM,=,-2.619788758288394,0,O=C(NC1CCC(=Cc2cccc(Oc3ccccn3)c2)CC1)c1cccnc1
806,51929,10.1021/jm034111v,,,,Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 5 minutes,C[C@H](NC(=O)/C=C/c1ccc(F)cc1)c1ccc(F)c(N2CCOCC2)c1,(E)-N-[1-((S)-4-Fluoro-3-morpholin-4-yl-phenyl)-ethyl]-3-(4-fluoro-phenyl)-acrylamide,18.0,uM,=,1.255272505103306,1,O=C(/C=C/c1ccccc1)NCc1cccc(N2CCOCC2)c1
807,305744,10.1021/jm049696n,,,,Inhibitory concentration value against human cytochrome P-450 3A4,O/N=C/c1ccc(-c2cccnc2)o1.O/N=C\c1ccc(-c2cccnc2)o1,5-Pyridin-3-yl-furan-2-carbaldehyde oxime; compound with 5-pyridin-3-yl-furan-2-carbaldehyde oxime,51.9,uM,=,1.715167357848458,1,c1cncc(-c2ccco2)c1.c1cncc(-c2ccco2)c1
808,2240606,10.1021/acs.jmedchem.2c01497,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH,CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,SID144204227,0.0423,uM,=,-1.3736596326249575,0,c1ccc([C@@]2(Cn3ccnc3)OC[C@H](COc3ccc(N4CCNCC4)cc3)O2)cc1
809,768817,10.1021/jm2005354,,,,Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting,C[C@@H](c1ccc(-c2ccc(F)cc2F)cc1)N1CC[C@](CCCNS(C)(=O)=O)(c2ccc(F)cc2)OC1=O,"N-(3-((R)-3-((S)-1-(2',4'-difluorobiphenyl-4-yl)ethyl)-6-(4-fluorophenyl)-2-oxo-1,3-oxazinan-6-yl)propyl)methanesulfonamide",7.0,uM,=,0.8450980400142568,1,O=C1OC(c2ccccc2)CCN1Cc1ccc(-c2ccccc2)cc1
810,862399,10.1021/jm300601d,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis,Cn1cncc1C(=O)N1CCC(c2ccc(C(=O)NC(=N)N)cc2C(F)(F)F)CC1,N-{4-[1-(3-Methyl-3H-imidazole-4-carbonyl)-piperidin-4-yl]-3-trifluoromethyl-benzoyl}-guanidine,3.0,uM,=,0.4771212547196624,1,O=C(c1cnc[nH]1)N1CCC(c2ccccc2)CC1
811,2048449,10.1016/j.bmc.2020.115734,,,,Inhibition of recombinant CYP3A4 (unknown origin) by fluorescence-based assay,COc1nc(-c2csc(Nc3c4c(nn3C(C)(C)C)CCCC4)n2)ccc1-n1cnc(C)c1,"N-(2-(tert-butyl)-4,5,6,7-tetrahydro-2H-indazol-3-yl)-4-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)thiazol-2-amine",5.3,uM,=,0.724275869600789,1,c1cn(-c2ccc(-c3csc(Nc4[nH]nc5c4CCCC5)n3)nc2)cn1
812,465432,10.1016/j.bmcl.2007.11.008,,,,Inhibition of CYP3A4,Cc1ccc([C@H](C(=O)NC(C)C)N2C(=O)[C@@H](C3Cc4ccccc4C3)NC(=O)[C@H]2CC(C)C)o1,"(2R)-2-[(3R,6R)-3-(2,3-dihydro-1H-inden-2-yl)-6-(2-methylpropyl)-2,5-dioxo-1-piperazinyl]-N-(1-methylethyl)-2-(5-methyl-2-furanyl)ethanamide",7.0,uM,=,0.8450980400142568,1,O=C1CN(Cc2ccco2)C(=O)[C@@H](C2Cc3ccccc3C2)N1
813,1327918,10.1039/C2MD20061A,,,,Inhibition of CYP3A4 in human pooled liver microsomes using testosterone as substrate by LC/MS/MS analysis,COc1cc(N2CCN(C)CC2)ccc1-c1nc2c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)c(Cl)cnc2[nH]1,"(1S,2S,3R,4R)-3-{6-Chloro-2-[2-methoxy-4-(4-methyl-piperazin-1-yl)-phenyl]-3Himidazo[4,5-b]pyridin-7-ylamino}-bicyclo[2.2.1]hept-5-ene-2-carboxylic",8.5,uM,=,0.9294189257142929,1,C1=C[C@H]2C[C@@H]1C[C@@H]2Nc1ccnc2[nH]c(-c3ccc(N4CCNCC4)cc3)nc12
814,1289880,10.1021/jm401642q,,,,Inhibition of recombinant human CYP3A4,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(F)cccc21,"2-[2-(4-Fluoro-2,3-dihydro-1H-indol-1-yl)-2-oxoethyl]-6-(morpholin-4-yl)pyrimidin-4(3H)-one",40.0,uM,=,1.6020599913279625,1,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2ccccc21
815,873423,10.1021/jm3006788,,,,Inhibition of CYP3A4,Cn1c(-c2ccc(Cl)cn2)c(C2CCCC2)c2ccc(C(=O)NC3(C(=O)Nc4ccc(/C=C/C(=O)O)cc4)CCCC3)cc21,3-(4-(1-(2-(5-chloropyridin-2-yl)-3-cyclopentyl-1-methyl-1H-indole-6-carboxamido)cyclopentanecarboxamido)phenyl)acrylic acid,10.7,uM,=,1.0293837776852095,1,O=C(NC1(C(=O)Nc2ccccc2)CCCC1)c1ccc2c(C3CCCC3)c(-c3ccccn3)[nH]c2c1
816,774749,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,FK-506,1.0,uM,=,0.0,0,O=C1CC=CCCCC[C@@H]2CCCC(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H](/C=C/C2CCCCC2)CCC1
817,1614026,10.1016/j.bmcl.2016.09.043,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 1'-hydroxymidazolam metabolite formation using midazolam as substrate incubated for 10 mins by HPLC-MS method,Cn1c(NCCc2ccc(Oc3ccc(Cl)cn3)cc2)nc2cc(Cl)ccc2c1=O,7-Chloro-2-{2-[4-(5-chloro-pyridin-2-yloxy)-phenyl]-ethylamino}-3-methyl-3H-quinazolin-4-one,9.8,uM,=,0.9912260756924948,1,O=c1[nH]c(NCCc2ccc(Oc3ccccn3)cc2)nc2ccccc12
818,1682566,10.1021/acs.jmedchem.7b00883,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 30 mins by LC-MS/MS analysis,N#Cc1ccc2c(c1)[nH]c(=O)n2[C@H]1C[C@H](c2nnc(-c3ccncn3)n2-c2ccccc2Cl)C1,"1-((trans)-3-(4-(2-Chlorophenyl)-5-(pyrimidin-4-yl)-4H-1,2,4-triazol-3-yl)cyclobutyl)-2,3-dihydro-2-oxo-1H-benzo[d]imidazole-5-carbonitrile",1.3,uM,=,0.1139433523068367,1,O=c1[nH]c2ccccc2n1[C@H]1C[C@H](c2nnc(-c3ccncn3)n2-c2ccccc2)C1
819,1925644,10.1021/acs.jmedchem.6b00827,,,,Inhibition of CYP3A4 (unknown origin) at 3 uM using midazolam substrate by LC-MS method,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2c(C(=O)N(C)C)c1-c1ccccc1,"2-((1S)-1-((6-Amino-5-cyano-4-pyrimidinyl)amino)ethyl)-6-fluoro-N,N-dimethyl-3-phenyl-4-quinolinecarboxamide",19.0,uM,=,1.2787536009528289,1,c1ccc(-c2cc3ccccc3nc2CNc2ccncn2)cc1
820,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",O=C(c1cccc(Cl)c1-n1nccn1)N1CCOC[C@H]1Cc1cc(-c2ncccn2)ccc1F,"US9150566, 161",33.0,uM,=,1.5185139398778875,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2ncccn2)c1
821,552281,10.1016/j.bmcl.2008.04.036,,,,Inhibition of CYP3A4,O=C(O)CCCN[C@@H](Cn1c(=O)c(-c2ccccc2Cl)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1,"(R)-4-(2-(3-(2-fluoro-6-(trifluoromethyl)benzyl)-5-(2-chlorophenyl)-2,6-dioxo-2,3-dihydropyrimidin-1(6H)-yl)-1-phenylethylamino)butanoic acid",17.0,uM,=,1.230448921378274,1,O=c1c(-c2ccccc2)cn(Cc2ccccc2)c(=O)n1CCc1ccccc1
822,1337236,10.1016/j.bmcl.2014.02.026,,,,Inhibition of CYP3A4 (unknown origin),Cc1ccc(-n2nccn2)c(C(=O)N2C[C@H](C#Cc3cccc(CO)c3)CC[C@H]2C)c1,"((2R,5S)-5-((3-(hydroxymethyl)phenyl)ethynyl)-2-methylpiperidin-1-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone",4.0,uM,=,0.6020599913279624,1,O=C(c1ccccc1-n1nccn1)N1CCC[C@@H](C#Cc2ccccc2)C1
823,774749,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1c1ccccc1/C=C/C(=O)OC(C)(C)C,Lacidipine,0.9,uM,=,-0.0457574905606751,0,C1=CC(c2ccccc2)C=CN1
824,2246941,10.1021/acs.jmedchem.1c02132,,,,Inhibition of CYP3A4 (unknown origin) incubated for 10 mins in presence of NADPH by LC-MS/MS analysis,CC(=O)Nc1cc(-c2ccc(OC[C@@H](N)CC(C)C)c(C)c2)ccn1,(S)-N-(4-(4-(2-amino-4-methylpentyloxy)-3-methylphenyl)pyridin-2-yl)acetamide,3.9,uM,=,0.5910646070264992,1,c1ccc(-c2ccncc2)cc1
825,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(OCCCN(C)C)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, G-13",13.03,uM,=,1.1149444157125847,1,O=C(Nc1cccnc1)c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12
826,1689562,10.1021/acs.jmedchem.7b00598,,,,Inhibition of CYP3A4 (unknown origin),N#Cc1cc(S(=O)(=O)Nc2ncns2)ccc1Oc1ccc(C(F)(F)F)cc1-c1cccnn1,"3-cyano-4-(2-(pyridazin-3-yl)-4-(trifluoromethyl)phenoxy)-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide",0.616,uM,=,-0.2104192878355745,0,O=S(=O)(Nc1ncns1)c1ccc(Oc2ccccc2-c2cccnn2)cc1
827,1686804,10.1021/acs.jmedchem.7b01337,,,,Inhibition of CYP3A4 (unknown origin),COc1cnc(-n2cncn2)c2[nH]cc(C(=O)C(=O)N3CCN(C(=O)c4ccccc4)CC3)c12,"1-(4-benzoylpiperazin-1-yl)-2-(4-methoxy-7-(1H-1,2,4-triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione",1.0,uM,=,0.0,0,O=C(C(=O)N1CCN(C(=O)c2ccccc2)CC1)c1c[nH]c2c(-n3cncn3)nccc12
828,617698,10.1016/j.bmcl.2010.01.087,,,,Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay,COC(=O)N1CCN(C2CCN(c3cc(C)c4nc(-c5c(NC[C@@H](O)c6cccc(Cl)c6)cc[nH]c5=O)[nH]c4c3)CC2)CC1,"(S)-methyl 4-(1-(2-(4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-2-oxo-1,2-dihydropyridin-3-yl)-7-methyl-3H-benzo[d]imidazol-5-yl)piperidin-4-yl)piperazine-1-carboxylate",3.5,uM,=,0.5440680443502757,1,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(N3CCC(N4CCNCC4)CC3)cc2[nH]1
829,774749,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,Rapamycin,2.0,uM,=,0.3010299956639812,1,O=C1CCC=CCC(=O)C[C@@H](CCC2CCCCC2)OC(=O)[C@@H]2CCCCN2C(=O)C(=O)C2CCC[C@@H](CC/C=C/C=C/C=C/CCC1)O2
830,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1ccc(C(=O)N2CCOC[C@H]2Cc2cc(-c3ncon3)ccc2F)c(-n2nccn2)c1,"US9150566, 175",35.0,uM,=,1.5440680443502757,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2ncon2)c1
831,461436,10.1016/j.bmcl.2007.10.092,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,CC[C@@H]1CCC[C@H](C2(Cc3nc(CN(C)C(C)(C)CO)no3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1,"2-(((5-((1-((2R,6R)-1-(4-chlorophenylsulfonyl)-6-ethylpiperidin-2-yl)cyclopropyl)methyl)-1,2,4-oxadiazol-3-yl)methyl)(methyl)amino)-2-methylpropan-1-ol",0.3,uM,=,-0.5228787452803376,0,O=S(=O)(c1ccccc1)N1CCCC[C@@H]1C1(Cc2ncno2)CC1
832,546181,10.1016/j.bmcl.2009.03.165,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,CCNc1cc(C(=O)N[C@@H](Cc2ccccc2)[C@H](O)CNCc2cccc(C(F)(F)F)c2)c(F)c(N2CCCCS2(=O)=O)c1,"N-[(1S,2R)-1-benzyl-2-hydroxy-3-(3-trifluoromethyl-benzylamino)-propyl]-3-(1,1-dioxo-1lambda*6*-[1,2]thiazinan-2-yl)-5-ethylamino-2-fluoro-benzamide",0.4,uM,=,-0.3979400086720376,0,O=C(N[C@H](CCNCc1ccccc1)Cc1ccccc1)c1cccc(N2CCCCS2(=O)=O)c1
833,1512779,10.1016/j.bmcl.2015.07.038,,,,Time dependent inhibition of CYP3A4 in human liver microsomes assessed as reduction in testosterone 6beta-hydroxylation incubated for 60 mins in presence of NADPH generating system by LC-MS/MS method,COc1cccc2nc(CCCN(C)CC[C@]3(OC(=O)C(C)C)C[C@H]4CCC[C@@H]3c3ccccc34)[nH]c12,"Isobutyric acid (1R,8R,12R)-12-(2-{[3-(4-methoxy-1H-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)-tricyclo[6.3.2.02,7]trideca-2,4,6-trien-12-yl ester",34.0,uM,=,1.5314789170422551,1,c1ccc2c(c1)[C@@H]1CCC[C@H]2C(CCNCCCc2nc3ccccc3[nH]2)C1
834,422039,10.1016/j.bmcl.2006.10.045,,,,Inhibition of CYP450 3A4,O=C(CCCCCCC(=O)Nc1ccccc1)NO,Octanedioic acid hydroxyamide phenylamide,12.0,uM,=,1.0791812460476249,1,c1ccccc1
835,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCCN(C)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, E-42",3.63,uM,=,0.5599066250361125,1,O=C(c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12)N1CCCNCC1
836,1758889,10.1021/acsmedchemlett.7b00230,,,,Inhibition of CYP3A4 (unknown origin),CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,SID144204227,0.0296,uM,=,-1.5287082889410617,0,c1ccc([C@@]2(Cn3ccnc3)OC[C@H](COc3ccc(N4CCNCC4)cc3)O2)cc1
837,1692884,10.1021/acs.jmedchem.7b00376,,,,Inhibition of CYP3A4 in human liver microsomes,Oc1ccc(-c2cc3cc(Br)cc(O)c3o2)cc1O,"4-(5-Bromo-7-hydroxybenzofuran-2-yl)benzene-1,2-diol",23.5,uM,=,1.3710678622717365,1,c1ccc(-c2cc3ccccc3o2)cc1
838,1873834,10.1021/acs.jmedchem.9b00134,,,,Inhibition of human CYP3A4,CCc1sc2ncnc(N[C@H](Cc3ccccc3)C(=O)O)c2c1-c1ccc(OCCN2CCN(C)CC2)c(Cl)c1C,"N-((5Sa)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl}-6-ethylthieno[2,3-d]pyrimidin-4-yl)-D-phenylalanine",5.2,uM,=,0.7160033436347992,1,c1ccc(CCNc2ncnc3scc(-c4ccc(OCCN5CCNCC5)cc4)c23)cc1
839,552281,10.1016/j.bmcl.2008.04.036,,,,Inhibition of CYP3A4,CS(=O)(=O)c1cccc(F)c1Cn1cc(-c2ccccc2Cl)c(=O)n(C[C@H](NCCCC(=O)O)c2ccccc2)c1=O,"(R)-4-(2-(3-(2-fluoro-6-(methylsulfonyl)benzyl)-5-(2-chlorophenyl)-2,6-dioxo-2,3-dihydropyrimidin-1(6H)-yl)-1-phenylethylamino)butanoic acid",48.0,uM,=,1.6812412373755872,1,O=c1c(-c2ccccc2)cn(Cc2ccccc2)c(=O)n1CCc1ccccc1
840,559938,10.1016/j.bmcl.2008.10.072,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,C[C@@H]1CN(Cc2ccc(-c3ccccc3C(=O)N3CCC(Nc4ccccc4)CC3)cc2)C[C@H](C)N1,"[4'-((3R,5S)-3,5-Dimethyl-piperazin-1-ylmethyl)-biphenyl-2-yl]-(4-phenylamino-piperidin-1-yl)-methanone",12.0,uM,=,1.0791812460476249,1,O=C(c1ccccc1-c1ccc(CN2CCNCC2)cc1)N1CCC(Nc2ccccc2)CC1
841,1465542,10.1016/j.bmcl.2015.01.051,,,,Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(C6CN(C7COC7)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O,"(1S,4R,5R,6R,8R,10S,11R,12S,13R,16R,18S,21R)-8-[(1S)-1-ethoxy-2-hydroxy-2-methylpropyl]-4,6,12,17,17-pentamethyl-18-{[(2S)-4-[1-(oxetan-3-yl)azetidin-3-yl]morpholin-2-yl]oxy}-9-oxahexacyclo[11.9.0.0^{1,21}.0^{4,12}.0^{5,10}.0^{16,21}]docosan-11-ol",1.6,uM,=,0.2041199826559248,1,C1CO[C@@H]2CC3C(CC[C@@]45C[C@@]46CC[C@H](O[C@H]4CN(C7CN(C8COC8)C7)CCO4)C[C@@H]6CC[C@@H]35)[C@H]2C1
842,863248,10.1021/jm300663n,,,,Inhibition of CYP3A4,Cc1ccccc1[C@H](CC(=O)O)NC(=O)c1cc(=O)n(-c2ccccc2F)[nH]1,(S)-3-{[1-(2-Fluorophenyl)-5-hydroxy-1H-pyrazole-3-carbonyl]amino}-3-o-tolylpropionic Acid,0.038,uM,=,-1.42021640338319,0,O=C(NCc1ccccc1)c1cc(=O)n(-c2ccccc2)[nH]1
843,52065,10.1021/jm0310129,,,,Inhibitory activity against cytochrome P450 3A4,COCc1nc(N2CCN(CCc3ccc(F)c(F)c3)CC2)c2c(n1)c1c(Cl)nccc1n2C,"9-Chloro-4-{4-[2-(3,4-difluoro-phenyl)-ethyl]-piperazin-1-yl}-2-methoxymethyl-5-methyl-5H-pyrido[3',4':4,5]pyrrolo[3,2-d]pyrimidine",36.82,uM,=,1.566083784167996,1,c1ccc(CCN2CCN(c3ncnc4c3[nH]c3ccncc34)CC2)cc1
844,423507,10.1021/jm060995h,,,,Inhibition of CYP3A4,CON(C)C(=O)c1c(Cn2c(C)nc(Cl)c2Cl)sc2c1c(=O)n(C)c(=O)n2CC(C)C,"6-[(4,5-dichloro-2-methyl-1H-imidazol-1-yl)methyl]-1-isobutyl-N-methoxy-N,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydrothieno-[2,3-d]pyrimidine-5-carboxamide",44.0,uM,=,1.6434526764861874,1,O=c1[nH]c(=O)c2cc(Cn3ccnc3)sc2[nH]1
845,1640557,,,,,"null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.",OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F,"2-(2,4-Difluoro-phenyl)-1,3-bis-[1,2,4]triazol-1-yl-propan-2-ol",10.0,uM,=,1.0,1,c1ccc(C(Cn2cncn2)Cn2cncn2)cc1
846,643713,10.1016/j.bmcl.2010.06.009,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader,C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(N5CCOCC5)c4)ccc32)sc1C(N)=O)c1ccccc1C(F)(F)F,(R)-5-(5-(2-morpholinopyridin-4-yl)-1H-benzo[d]imidazol-1-yl)-3-(1-(2-(trifluoromethyl)phenyl)ethoxy)thiophene-2-carboxamide,2.8,uM,=,0.4471580313422192,1,c1ccc(COc2csc(-n3cnc4cc(-c5ccnc(N6CCOCC6)c5)ccc43)c2)cc1
847,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1ccc(C(=O)N2C[C@@H](C)OC[C@H]2Cc2cccc(-n3nccn3)c2)c(-n2nccn2)c1C,"US9150566, 99",9.6,uM,=,0.9822712330395684,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
848,495153,10.1021/jm8006454,,,,Inhibition of CYP3A4,COc1cccc(-c2c(C)n(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](NCCC(=O)O)c3ccccc3)c2=O)c1F,"(R)-3-{2-[5-(2-Fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}propionic Acid",69.0,uM,=,1.8388490907372552,1,O=c1c(-c2ccccc2)cn(Cc2ccccc2)c(=O)n1CCc1ccccc1
849,479364,10.1016/j.bmcl.2008.05.027,,,,Inhibition of CYP3A4,Cc1cc2ncc(=O)n(CC(=O)N3CCCC(c4ccccc4)C3CN3CCCC3)c2cc1C,"rac-6,7-dimethyl-1-(2-oxo-2-(3-phenyl-2-(pyrrolidin-1-ylmethyl)piperidin-1-yl)ethyl)quinoxalin-2(1H)-one",6.8,uM,=,0.8325089127062363,1,O=C(Cn1c(=O)cnc2ccccc21)N1CCCC(c2ccccc2)C1CN1CCCC1
850,873336,10.1021/jm300065h,,,,Time dependent inhibition of CYP3A4 in human liver microsomes,CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CCOc1ccccc1,"2-{3-[4-(3-Chloro-phenyl)-piperazin-1-yl]-propyl}-5-ethyl-4-(2-phenoxy-ethyl)-2,4-dihydro-[1,2,4]triazol-3-one",0.015,uM,=,-1.8239087409443189,0,O=c1n(CCOc2ccccc2)cnn1CCCN1CCN(c2ccccc2)CC1
851,1886565,10.1021/acs.jmedchem.8b02021,,,,Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay,Nc1nc2ccc(C(=O)N(CCO)Cc3ccccc3)cc2s1,2-Amino-N-benzyl-N-(2-hydroxyethyl)benzo[d]thiazole-6-carboxamide,10.0,uM,=,1.0,1,O=C(NCc1ccccc1)c1ccc2ncsc2c1
852,772032,10.1021/jm2006222,,,,Inhibition of CYP3A4 using BFC as substrate,COc1cc(OC)c(Cl)c(NC(=O)N(C)c2cc(Nc3cccc(CN4CCN(C)CC4)c3)ncn2)c1Cl,"3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-methyl-1-{6-[3-(4-methyl-piperazin-1-ylmethyl)-phenylamino]-pyrimidin-4-yl}-urea",0.5,uM,=,-0.3010299956639812,0,O=C(Nc1ccccc1)Nc1cc(Nc2cccc(CN3CCNCC3)c2)ncn1
853,874112,10.1021/jm300118s,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis,COCC(=O)N[C@@H](Cc1cccc(-c2cscn2)c1)[C@H](O)CN[C@H]1CC2(CCC2)Oc2ncc(CC(C)(C)C)cc21,"N-((2S,3R)-3-Hydroxy-4-((S)-6'-neopentyl-3',4'-dihydrospiro-[cyclobutane-1,2'-pyrano[2,3-b]pyridine]-4'-ylamino)-1-(3-(thiazol-4-yl)phenyl)butan-2-yl)-2-methoxyacetamide",0.1,uM,=,-1.0,0,c1cc(CCCCN[C@H]2CC3(CCC3)Oc3ncccc32)cc(-c2cscn2)c1
854,438600,10.1016/j.bmcl.2007.03.048,,,,Inhibition of CYP3A4 in microsomes,Cc1cc(Br)cc2[nH]c(-c3c(N[C@H](CO)Cc4ccccc4)cc[nH]c3=O)nc12,(S)-3-(6-bromo-4-methyl-1H-benzo[d]imidazol-2-yl)-4-(1-hydroxy-3-phenylpropan-2-ylamino)pyridin-2(1H)-one,3.1,uM,=,0.4913616938342727,1,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccccc2[nH]1
855,2048449,10.1016/j.bmc.2020.115734,,,,Inhibition of recombinant CYP3A4 (unknown origin) by fluorescence-based assay,COc1nc(-c2csc(Nc3c4c(nn3CCCO)CCCC4)n2)ccc1-n1cnc(C)c1,"3-(3-((4-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)thiazol-2-yl)amino)-4,5,6,7-tetrahydro-2H-indazol-2-yl)propan-1-ol",2.2,uM,=,0.3424226808222063,1,c1cn(-c2ccc(-c3csc(Nc4[nH]nc5c4CCCC5)n3)nc2)cn1
856,2035531,10.1021/acsmedchemlett.0c00525,,,,Inhibition of CYP3A4 (unknown origin),C[C@@H](NC(=O)c1ccc(F)cc1)c1ccc2c(n1)CCCN2C(=O)OC1CC1,"cyclopropyl (R)-6-(1-(4-fluorobenzamido)ethyl)-3,4-dihydro-1,5-naphthyridine-1(2H)-carboxylate",60.0,uM,=,1.7781512503836436,1,O=C(NCc1ccc2c(n1)CCCN2C(=O)OC1CC1)c1ccccc1
857,52069,10.1021/jm021012t,,,,Inhibition of human cytochrome P450 3A4,Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,"8-Chloro-6-(2-fluoro-phenyl)-1-methyl-4H-2,5,10b-triaza-benzo[e]azulene",8.1,uM,=,0.9084850188786496,1,c1ccc(C2=NCc3cncn3-c3ccccc32)cc1
858,51750,10.1021/jm010531d,,,,Inhibition of dog Cytochrome P450 3A by macrocycles,CC1c2ccc(C#N)c(c2)Oc2cccc(c2)CN2CCC(NCc3cncn31)C2=O,"R-Diastereomer A-14-methyl-27-oxo-20-oxa-3,7,11,13-tetraazapentacyclo[19.3.1.13,6.115,19.09,13]heptacosa-1(24),9,11,15(26),16,18,21(25),22-octaen-18-yl cyanide",6.1,uM,=,0.785329835010767,1,O=C1C2CCN1Cc1cccc(c1)Oc1cccc(c1)Cn1cncc1CN2
859,1291572,10.1016/j.bmcl.2013.12.058,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N(CCCN(Cc2ccccc2)C(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1,(S)-thiazol-5-ylmethyl benzyl(3-(N-benzyl-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-3-methylbutanamido)propyl)carbamate,0.3,uM,=,-0.5228787452803376,0,O=C(NCC(=O)N(CCCN(Cc1ccccc1)C(=O)OCc1cncs1)Cc1ccccc1)NCc1cscn1
860,355280,10.1016/j.bmcl.2006.02.020,,,,Inhibition of CYP3A4,C[C@H]([C@@H](c1ccc2cc(OCC3(C(=O)O)CCC3)ccc2c1)n1ccnc1)N(C)C,"1-((6-((1R,2R)-2-(dimethylamino)-1-(1H-imidazol-1-yl)propyl)naphthalen-2-yloxy)methyl)cyclobutanecarboxylic acid",7.0,uM,=,0.8450980400142568,1,c1cn(Cc2ccc3cc(OCC4CCC4)ccc3c2)cn1
861,1474044,10.1021/jm501740a,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,O=C(N[C@H](c1ccccn1)C1CCCC1)c1ccc2[nH]nc(-c3ccc(N4[C@H]5CC[C@H]4CC(O)C5)cc3)c2c1,N-((S)-cyclopentyl(pyridin-2-yl)methyl)-3-(4-((endo)-3-hydroxy-8-azabicyclo[3.2.1]octan-8-yl)phenyl)-1H-indazole-5-carboxamide,0.82,uM,=,-0.0861861476162833,0,O=C(N[C@H](c1ccccn1)C1CCCC1)c1ccc2[nH]nc(-c3ccc(N4[C@@H]5CCC[C@@H]4CC5)cc3)c2c1
862,834635,10.1016/j.bmcl.2012.07.019,,,,Inhibition of CYP3A4,CN1CCN(c2ccc(C(=O)N3CCN(C(=O)C[C@H](N)Cc4cc(F)c(F)cc4F)CC3)cc2)CC1,"(R)-3-amino-1-(4-(4-(4-methylpiperazin-1-yl)benzoyl)piperazin-1-yl)-4-(2,4,5-trifluorophenyl)butan-1-one",1.0,uM,=,0.0,0,O=C(CCCc1ccccc1)N1CCN(C(=O)c2ccc(N3CCNCC3)cc2)CC1
863,1362982,10.1021/ml400492t,,,,Inhibition of CYP3A4 in human liver microsomes assessed as testosterone conversion to 6-hydroxy testosterone preincubated for 10 mins followed by NADPH addition measured after 15 mins by LC-MS/MS analysis,Fc1ccc2c(c1)c1c(n2CCCOc2ccc(Cl)cc2)CCNC1,"5-(3-(4-chlorophenoxy)propyl)-8-fluoro-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole",50.0,uM,=,1.6989700043360187,1,c1ccc(OCCCn2c3c(c4ccccc42)CNCC3)cc1
864,2221809,10.1016/j.bmcl.2022.128625,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as substrate in presence of NADPH,CCC[C@H]1N(C(=O)c2c(C(F)(F)F)ccnc2O)CCC[C@@]1(Oc1csc(C(F)(F)F)c1)C(=O)N1CCN(c2ccccc2OC)CC1,"((2R,3S)-1-(2-hydroxy-4-(trifluoromethyl)nicotinoyl)-2-propyl-3-(5-(trifluoromethyl)thiophen-3-yloxy)piperidin-3-yl)(4-(2-methoxyphenyl)piperazin-1-yl)methanone",20.0,uM,=,1.3010299956639813,1,O=C(c1cccnc1)N1CCC[C@@](Oc2ccsc2)(C(=O)N2CCN(c3ccccc3)CC2)C1
865,1451406,10.1021/jm500916t,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs,Cc1cc2c(NC(=O)N[C@@H]3CC(C)(C)Oc4c3ccc(C(F)(F)F)c4F)cccc2cn1,"(R)-1-(8-Fluoro-2,2-dimethyl-7-(trifluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea",18.0,uM,=,1.255272505103306,1,O=C(Nc1cccc2cnccc12)N[C@@H]1CCOc2ccccc21
866,1640368,,,,,"Inhibition Assay: CYP17 activity was assayed according to the following procedure. Solutions of each test compound and isozyme inhibitor (ketoconazole) were separately prepared at concentrations of 2700, 540, 90, 18, 3, 0.6 and 0.1 uM by serial dilution with DMSO:ACN (50:50 v/v). The individual test compound and isozyme inhibitor solutions were then diluted 20-fold with deionized water (50:950 v/v) to concentrations of 135, 27, 4.5, 0.9, 0.15, 0.03 and 0.005 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture is 1%. Pooled rat testicular microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 1.25 mg/mL suspension. A solution of NADPH was prepared in phosphate buffer at a concentration of 2.5x. A stock solution of the substrate was prepared in DMSO:MeCN (50:50 v/v), mixed, and diluted in phosphate buffer to obtain a single solution containing the substrate at 5 uM.",CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,"1-(4-{4-[2-(2,4-Dichloro-phenyl)-2-imidazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-ethanone (ketoconazole)",0.15,uM,=,-0.8239087409443188,0,c1ccc(C2(Cn3ccnc3)OCC(COc3ccc(N4CCNCC4)cc3)O2)cc1
867,473932,10.1021/jm701121y,,,,Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay,CS(=O)(=O)c1ccc(Cn2cc(-c3ccncc3)cn2)cc1,4-(1-(4-(methylsulfonyl)benzyl)-1H-pyrazol-4-yl)pyridine,26.0,uM,=,1.414973347970818,1,c1ccc(Cn2cc(-c3ccncc3)cn2)cc1
868,2024613,10.1016/j.bmcl.2020.127721,,,,Inhibition of CYP3A4 (unknown origin),CN1CCN(CCOc2cccc(CC(=O)Nc3nc(-c4c[nH]c5ncccc45)cs3)c2)CC1,"N-(4-(1H-pyrrolo[2,3-b]pyridin-3-yl)thiazol-2-yl)-2-(3-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)acetamide",18.0,uM,=,1.255272505103306,1,O=C(Cc1cccc(OCCN2CCNCC2)c1)Nc1nc(-c2c[nH]c3ncccc23)cs1
869,1491687,10.1124/dmd.112.045708,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate addition by LC-MS/MS analysis in presence of NADPH,COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1,"Acetic acid (2S,3S)-5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester",36.0,uM,=,1.5563025007672873,1,O=C1C[C@H](c2ccccc2)Sc2ccccc2N1
870,1744980,10.1016/j.bmcl.2017.09.046,,,,Inhibition of human CYP3A4 expressed in Escherichia coli co-expressing CYP-reductase using diethoxyfluorescein as substrate measured after 10 mins by fluorescence assay,CCc1cccc(-c2c(F)cccc2C(O)(CCCNC(=O)OC)[C@@H]2CCCN(C(=O)CCCNC)C2)c1,methyl 4-(3'-ethyl-6-fluorobiphenyl-2-yl)-4-hydroxy-4-((R)-1-(4-(methylamino)butanoyl)piperidin-3-yl)butylcarbamate,0.56,uM,=,-0.2518119729937995,0,c1ccc(-c2ccccc2C[C@@H]2CCCNC2)cc1
871,673952,10.1016/j.bmcl.2010.08.086,,,,Inhibition of CYP3A4 using midazolam as substrate,Cc1cc(Cl)c(OCCOc2ccc([C@H]3CCNC[C@@H]3C(=O)N(Cc3cc(CNC(=O)CC(F)(F)F)ccc3Cl)C3CC3)cc2)c(Cl)c1,"(3R,4S)-N-(2-chloro-5-((3,3,3-trifluoropropanamido)methyl)benzyl)-N-cyclopropyl-4-(4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)phenyl)piperidine-3-carboxamide",4.0,uM,=,0.6020599913279624,1,O=C([C@H]1CNCC[C@@H]1c1ccc(OCCOc2ccccc2)cc1)N(Cc1ccccc1)C1CC1
872,814102,10.1016/j.bmcl.2012.03.014,,,,Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins,O[C@]1(c2ccc(F)c(F)c2)CCNC[C@@H]1c1cc(-c2c(Cl)cccc2Cl)on1,"(3R,4R)-3-(5-(2,6-dichlorophenyl)isoxazol-3-yl)-4-(3,4-difluorophenyl)piperidin-4-ol",17.0,uM,=,1.230448921378274,1,c1ccc(-c2cc([C@H]3CNCCC3c3ccccc3)no2)cc1
873,1797910,10.1021/acs.jmedchem.8b01326,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate/NADPH addition measured after 10 mins by LC-MS/MS analysis,CN1C(=N)N[C@@]2(c3cc(-c4cccc(C#N)c4)cs3)CN(c3ccc(F)cn3)C[C@H]2C1=O,"3-(5-((4aR,7aR)-6-(5-Fluoropyridin-2-yl)-2-imino-3-methyl-4-oxooctahydro-1H-pyrrolo[3,4-d]pyrimidin-7a-yl)thiophen-3-yl)benzonitrile",6.4,uM,=,0.8061799739838872,1,N=C1NC(=O)[C@@H]2CN(c3ccccn3)C[C@]2(c2cc(-c3ccccc3)cs2)N1
874,1451406,10.1021/jm500916t,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs,CC1(C)C[C@@H](NC(=O)Nc2cccc3cnccc23)c2ccc(OC(F)(F)F)cc2O1,"(R)-1-(7-Trifluoromethoxy-2,2-dimethylchroman-4-yl)-3-(isoquinolin-5-yl)urea",2.2,uM,=,0.3424226808222063,1,O=C(Nc1cccc2cnccc12)N[C@@H]1CCOc2ccccc21
875,813216,10.1016/j.bmcl.2012.01.125,,,,Inhibition of CYP3A4,COc1cc2c(Nc3ccccc3C(=O)c3ccccn3)c(C(N)=O)cnc2cc1-c1c(C)noc1C,"7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-4-(2-picolinoylphenylamino)quinoline-3-carboxamide",3.1,uM,=,0.4913616938342727,1,O=C(c1ccccn1)c1ccccc1Nc1ccnc2cc(-c3cnoc3)ccc12
876,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NC5CCN(C(C)=O)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, F-64",5.12,uM,=,0.7092699609758308,1,O=C(NC1CCNCC1)c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12
877,1919651,,,,,"Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase",Nc1ccc(-c2cccnc2)s1,"US8609708, 21",1.59,uM,=,0.2013971243204514,1,c1cncc(-c2cccs2)c1
878,950702,10.1021/jm400288z,,,,Inhibition of C-terminal His-tagged wild type CYP3A4 (unknown origin)-mediated hydroxylation of 7-benzyloxy-4-trifluoromethylcoumarin expressed in Escherichia coli after 5 mins by fluorimetric analysis,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1,"((1R,2R,4R)-1-Benzyl-2-hydroxy-4-{(R)-2-[3-(2-isopropyl-1lambda*4*-[1,3]thiazin-5-ylmethyl)-3-methyl-ureido]-3-methyl-butyrylamino}-5-phenyl-pentyl)-carbamic acid thiazol-5-ylmethyl ester",0.55,uM,=,-0.2596373105057561,0,O=C(CNC(=O)NCc1cscn1)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
879,1336778,10.1021/jm401911v,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,CC(C)(C)S(=O)(=O)C[C@H](C1CC1)N1C(=O)[C@@](C)(Cc2ccccn2)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1,"(3R,5R,6S)-1-((S)-2-(tert-Butylsulfonyl)-1-cyclopropylethyl)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-3-methyl-3-(pyridin-2-ylmethyl)-piperidin-2-one",0.7,uM,=,-0.1549019599857432,0,O=C1C(Cc2ccccn2)C[C@H](c2ccccc2)[C@@H](c2ccccc2)N1CC1CC1
880,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCC(N7CCN(C)CC7)CC6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, G-57",6.32,uM,=,0.800717078282385,1,O=C(Nc1ccc(N2CCC(N3CCNCC3)CC2)nc1)c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12
881,1689562,10.1021/acs.jmedchem.7b00598,,,,Inhibition of CYP3A4 (unknown origin),CN1CC(n2nccc2-c2cc(Cl)ccc2Oc2cc(F)c(S(=O)(=O)Nc3cscn3)cc2F)C1,"4-(4-chloro-2-(1-(1-methylazetidin-3-yl)-1H-pyrazol-5-yl)phenoxy)-2,5-difluoro-N-(thiazol-4-yl)benzenesulfonamide",15.124,uM,=,1.179666668690498,1,O=S(=O)(Nc1cscn1)c1ccc(Oc2ccccc2-c2ccnn2C2CNC2)cc1
882,1828801,10.1021/acs.jmedchem.8b01098,,,,Inhibition of C-terminal 4His-tagged CYP3A4 (unknown origin) expressed in Escherichia coli by spectrophotometric analysis,CCOc1cccc(CNC(=O)c2ccc(-c3ccncc3)cc2)c1,N-(3-Ethoxybenzyl)-4-(pyridin-4-yl)benzamide,0.08,uM,=,-1.0969100130080565,0,O=C(NCc1ccccc1)c1ccc(-c2ccncc2)cc1
883,52065,10.1021/jm0310129,,,,Inhibitory activity against cytochrome P450 3A4,Cc1cccc2[nH]c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)ncnc3c12,"4-{4-[2-(3,4-Difluoro-phenyl)-ethyl]-piperazin-1-yl}-9-methyl-5H-pyrimido[5,4-b]indole",9.25,uM,=,0.9661417327390326,1,c1ccc(CCN2CCN(c3ncnc4c3[nH]c3ccccc34)CC2)cc1
884,774749,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",CC(C)(C(=O)c1cccnc1)c1cccnc1,"2-Methyl-1,2-di-pyridin-3-yl-propan-1-one",0.8,uM,=,-0.0969100130080563,0,O=C(Cc1cccnc1)c1cccnc1
885,469873,10.1016/j.bmcl.2008.01.012,,,,Inhibition of human CYP3A4,CNc1nnc(-c2cn3ncnc(Nc4cc(C(=O)NC5CC5)c(F)cc4F)c3c2C(C)C)o1,"N-cyclopropyl-2,4-difluoro-5-(5-isopropyl-6-(5-(methylamino)-1,3,4-oxadiazol-2-yl)pyrrolo[1,2-f][1,2,4]triazin-4-ylamino)benzamide",2.1,uM,=,0.3222192947339193,1,O=C(NC1CC1)c1cccc(Nc2ncnn3cc(-c4nnco4)cc23)c1
886,600767,10.1016/j.bmcl.2009.07.127,,,,Inhibition of human CYP3A4,COC(=O)c1cccc(NC(=O)COc2ccc(C34CC5CC(CC(C(=O)N6CCN(Cc7ccc(OC)cc7)CC6)(C5)C3)C4)cc2)c1,"3-[2-(4-{3-[4-(3-Methoxy-benzyl)-3,6-dihydro-2H-piperazine-1-carbonyl]-adamantan-1-yl}-phenoxy)-acetylamino]-benzoic acid methyl ester",0.89,uM,=,-0.0506099933550872,0,O=C(COc1ccc(C23CC4CC(CC(C(=O)N5CCN(Cc6ccccc6)CC5)(C4)C2)C3)cc1)Nc1ccccc1
887,859942,10.1021/jm300122u,,,,Inhibition of human CYP3A4 using testosterone as substrate after 45 mins,CN(C)CCN(C)C(=O)[C@H](Cc1ccc(Br)cc1)NC(=O)C1(c2ccc(Cl)cc2Cl)CC1,"4-Bromo-N-alpha-{[1-(2,4-dichlorophenyl)cyclopropyl]-carbonyl}-N-[2-(dimethylamino)ethyl]-N-methyl-L-phenylalaninamide",7.8,uM,=,0.8920946026904804,1,O=C(NCCc1ccccc1)C1(c2ccccc2)CC1
888,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1ccc(-n2nccn2)cc1C[C@@H]1COCCN1C(=O)c1ccc(Cl)cc1-n1nccn1,"US9150566, 191",14.0,uM,=,1.146128035678238,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
889,606328,10.1016/j.bmcl.2009.10.131,,,,Inhibition of CYP3A4,COc1cnc(-c2ccc(Cn3c(CC(C)(C)C(=O)O)c(SC(C)(C)C)c4cc(OC[C@@H]5Cc6ccccc6N5C(C)=O)ccc43)cc2)nc1,"(S)-3-(5-((1-acetylindolin-2-yl)methoxy)-3-(tert-butylthio)-1-(4-(5-methoxypyrimidin-2-yl)benzyl)-1H-indol-2-yl)-2,2-dimethylpropanoic acid",16.7,uM,=,1.2227164711475833,1,c1cnc(-c2ccc(Cn3ccc4cc(OC[C@@H]5Cc6ccccc6N5)ccc43)cc2)nc1
890,982809,10.1016/j.ejmech.2013.08.010,,,,Inhibition of CYP3A (unknown origin),CC#CCn1c(N2CCC[C@@H](N)C2)cc(=O)n(Cc2ccc3cc(C)ccc3n2)c1=O,"(R)-6-(3-Aminopiperidin-1-yl)-1-(but-2-yn-1-yl)-3-((6-methylquinolin-2-yl)methyl)pyrimidine-2,4(1H,3H)-dione",46.24,uM,=,1.6650178254124728,1,O=c1cc(N2CCCCC2)[nH]c(=O)n1Cc1ccc2ccccc2n1
891,52065,10.1021/jm0310129,,,,Inhibitory activity against cytochrome P450 3A4,Cn1c2ccnc(Cl)c2c2nc(CN3CCOCC3)nc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21,"9-Chloro-4-{4-[2-(3,4-difluoro-phenyl)-ethyl]-piperazin-1-yl}-5-methyl-2-morpholin-4-ylmethyl-5H-pyrido[3',4':4,5]pyrrolo[3,2-d]pyrimidine",20.03,uM,=,1.3016809492935764,1,c1ccc(CCN2CCN(c3nc(CN4CCOCC4)nc4c3[nH]c3ccncc34)CC2)cc1
892,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5cnc(N(C)C)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, H-7",6.41,uM,=,0.8068580295188175,1,O=C1[C@H](Cc2ccccc2)N2C(=O)CNN(C(=O)NCc3ccccc3)[C@H]2CN1Cc1cccc2c(-c3cncnc3)c[nH]c12
893,631458,10.1021/jm9013136,,,,Inhibition of human recombinant CYP3A4,COC(c1ccc(Cl)cc1)(c1ccc2c(c1)c(-c1ccccc1)cc(=O)n2C)c1cncn1C,4-(phenyl)-6-((4-chlorophenyl)(methoxy)(1-methyl-1H-imidazol-5-yl)methyl)-1-methylquinolin-2(1H)-one,2.345,uM,=,0.3701428470511021,1,O=c1cc(-c2ccccc2)c2cc(C(c3ccccc3)c3cnc[nH]3)ccc2[nH]1
894,1289880,10.1021/jm401642q,,,,Inhibition of recombinant human CYP3A4,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(-c3ccncc3)cccc21,"6-(Morpholin-4-yl)-2-{2-oxo-2-[4-(pyridin-4-yl)-2,3-dihydro-1Hindol-1-yl]ethyl}pyrimidin-4(3H)-one",31.0,uM,=,1.4913616938342726,1,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(-c3ccncc3)cccc21
895,1744980,10.1016/j.bmcl.2017.09.046,,,,Inhibition of human CYP3A4 expressed in Escherichia coli co-expressing CYP-reductase using diethoxyfluorescein as substrate measured after 10 mins by fluorescence assay,CCc1cccc(-c2c(Cl)cccc2C(O)(CCCNC(=O)OC)[C@@H]2CCCN(C(=O)[C@H]3C[C@@H](N)[C@@H](O)C3)C2)c1,"methyl 4-((R)-1-((1S,3R,4S)-3-amino-4-hydroxycyclopentanecarbonyl)piperidin-3-yl)-4-(6-chloro-3'-ethylbiphenyl-2-yl)-4-hydroxybutylcarbamate",0.25,uM,=,-0.6020599913279624,0,O=C(C1CCCC1)N1CCC[C@@H](Cc2ccccc2-c2ccccc2)C1
896,1352209,10.1021/jm4010835,,,,Inhibition of human recombinant CYP3A4,CCn1nc2c(-c3ccc(Cl)cc3)c(-c3ccncc3)c(=O)n(Cc3ccc(C(F)(F)F)nc3)n2c1=O,"8-(4-Chlorophenyl)-2-ethyl-7-(pyridin-4-yl)-5-((6-(trifluoromethyl)pyridin-3-yl)methyl)-[1,2,4]triazolo[4,3-b]-pyridazine-3,6(2H,5H)-dione",18.0,uM,=,1.255272505103306,1,O=c1c(-c2ccncc2)c(-c2ccccc2)c2n[nH]c(=O)n2n1Cc1cccnc1
897,790266,10.1021/jm2007062,,,,Inhibition of human CYP3A4,C[C@@H]1CN[C@@H](C2CC2)C(=O)N(C)[C@H](C)C(=O)N[C@H](Cc2ccc(F)cc2)C(=O)NCCCc2ccccc2O1.Cl.O,"(2R,5S,8R,11R)-5-cyclopropyl-11-(4-fluorobenzyl)-2,7,8-trimethyl-4,5,7,8,10,11,13,14,15,16-decahydro-2H-benzo[q][1,4,7,10,13]oxatetraazacyclooctadecine-6,9,12(3H)-trione hydrochloride hydrate",2.4,uM,=,0.380211241711606,1,O=C1CNC(=O)[C@H](C2CC2)NCCOc2ccccc2CCCNC(=O)[C@@H](Cc2ccccc2)N1
898,988989,10.1021/jm400732v,,,,Inhibition of CYP3A4 (unknown origin),CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)C2CCOCC2)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O.Cl,"(S)-N-((S)-1-((6-Bromo-2-methoxynaphthalen-1-yl)methyl)-2-oxo-5-(tetrahydro-2H-pyran-4-carbonyl)-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-yl)-2-(methylamino)propanamide hydrochloride",2.3,uM,=,0.3617278360175928,1,O=C1CCN(C(=O)C2CCOCC2)c2ccccc2N1Cc1cccc2ccccc12
899,774749,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",CCOc1nc2cccc(C(=O)O)c2n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,2-Ethoxy-3-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-benzoimidazole-4-carboxylic acid,9.0,uM,=,0.9542425094393248,1,c1ccc(-c2nnn[nH]2)c(-c2ccc(Cn3cnc4ccccc43)cc2)c1
900,949159,10.1016/j.bmcl.2013.01.011,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,CCc1cc(CC(NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12,"(+/-)-N-(1-(1,4'-bipiperidin-1'-yl)-3-(7-ethyl-1H-indazol-5-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide",25.0,uM,=,1.3979400086720375,1,O=C(NC(Cc1ccc2[nH]ncc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
901,872616,10.1021/jm200326p,,,,Inhibition of CYP3A4 in human liver microsomes assessed as decrease in formation of 1-hydroxymidazolam from midazolam substrate after 5 mins by LC-MS/MS,Cc1cnc2nc1-c1cccc(c1)COCC=CCOCc1cc(ccc1OCCN1CCCC1)N2,"3-methyl-11-[2-(pyrrolidin-1-yl)ethoxy]-14,19-dioxa-5,7,27-triazatetracyclo[19.3.1.1^{2,6}.1^{8,12}]heptacosa-1(25),2(27),3,5,8,10,12(26),16,21,23-decaene",2.5,uM,=,0.3979400086720376,1,C1=CCOCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC1
902,980735,10.1021/jm400820m,,,,Inhibition of human recombinant CYP3A4,CCOC(=O)c1cc(C#N)c(N2CCC(C(=O)NS(=O)(=O)Cc3ccccc3)CC2)nc1C,Ethyl 6-(4-[(Benzylsulfonyl)carbamoyl]piperidin-1-yl)-5-cyano-2-methylnicotinate,20.0,uM,=,1.3010299956639813,1,O=C(NS(=O)(=O)Cc1ccccc1)C1CCN(c2ccccn2)CC1
903,991614,10.1021/jm4008906,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(C[C@@H]1CCCN1S(=O)(=O)C1CC1)C2,"(S)-3-(Aminomethyl)-6-(((S)-1-(cyclopropylsulfonyl)-pyrrolidin-2-yl)methyl)-4-(2,4-dichlorophenyl)-2-methyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one",3.0,uM,=,0.4771212547196624,1,O=C1c2c(-c3ccccc3)ccnc2CN1C[C@@H]1CCCN1S(=O)(=O)C1CC1
904,775863,10.1016/j.bmcl.2011.09.037,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH,CN1CCN(C(=O)[C@@H](COCc2ccccc2)NC(=O)c2cccnc2Oc2ccc(C(F)(F)F)cc2Cl)CC1,(R)-N-(3-(benzyloxy)-1-(4-methylpiperazin-1-yl)-1-oxopropan-2-yl)-2-(2-chloro-4-(trifluoromethyl)phenoxy)nicotinamide,13.5,uM,=,1.130333768495006,1,O=C(N[C@H](COCc1ccccc1)C(=O)N1CCNCC1)c1cccnc1Oc1ccccc1
905,595638,10.1016/j.bmcl.2009.09.096,,,,Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH,COc1cnc2c(NCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1,"7-methoxy-N-((6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine",41.0,uM,=,1.6127838567197357,1,c1ccc(-c2ccc3nnc(CNc4ccnc5cccnc45)n3n2)cc1
906,813216,10.1016/j.bmcl.2012.01.125,,,,Inhibition of CYP3A4,Cc1noc(C)c1-c1ccc2c(Nc3ccccc3C(C)(C)C)c(C(N)=O)cnc2c1,"4-(2-tert-butylphenylamino)-7-(3,5-dimethylisoxazol-4-yl)quinoline-3-carboxamide",2.0,uM,=,0.3010299956639812,1,c1ccc(Nc2ccnc3cc(-c4cnoc4)ccc23)cc1
907,1919651,,,,,"Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase",NCc1ccc(-c2cccnc2)o1,C-(5-Pyridin-3-yl-furan-2-yl)-methylamine,47.1,uM,=,1.6730209071288962,1,c1cncc(-c2ccco2)c1
908,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",O=C(c1cc(Cl)ccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2ncon2)c1,"US9150566, 84",21.0,uM,=,1.3222192947339193,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2ncon2)c1
909,1523392,10.1021/acs.jmedchem.5b00774,,,,Inhibition of CYP3A4 (unknown origin) co-incubated with substrate and protein,O=S(=O)(N[C@H]1CC[C@@](c2cc(F)ccc2F)(S(=O)(=O)c2ccc(Cl)cc2)CC1)C(F)(F)F,"N-((syn)-4-(4-chlorophenylsulfonyl)-4-(2,5-difluorophenyl)cyclohexyl)trifluoromethanesulfonamide",16.6,uM,=,1.2201080880400552,1,O=S(=O)(c1ccccc1)C1(c2ccccc2)CCCCC1
910,449485,10.1016/j.bmcl.2007.07.097,,,,Inhibition of microsomal CYP3A4,CNCCC(=O)N[C@@H](CC(C)C)c1ccccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1,"N-((S)-1-(2-(4-((R)-3-(2,4-dichlorophenyl)-2-(2-oxopyrrolidin-1-yl)propanoyl)piperazin-1-yl)phenyl)-3-methylbutyl)-3-(methylamino)propanamide",1.3,uM,=,0.1139433523068367,1,O=C([C@@H](Cc1ccccc1)N1CCCC1=O)N1CCN(c2ccccc2)CC1
911,862399,10.1021/jm300601d,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis,N=C(N)NC(=O)c1ccc(N2CCN(C(=O)c3ccc[nH]3)CC2)c(C(F)(F)F)c1,SABIPORIDE,7.0,uM,=,0.8450980400142568,1,O=C(c1ccc[nH]1)N1CCN(c2ccccc2)CC1
912,481543,10.1021/np0400104,,,,Inhibition of human CYP3A4,O=C(/C=C/c1ccc(O)cc1)OC[C@H]1O[C@@H](Oc2c(-c3ccc(O)cc3)oc3cc(O)cc(O)c3c2=O)[C@H](O)[C@@H](O)[C@@H]1O,tiliroside,0.7,uM,=,-0.1549019599857432,0,O=C(/C=C/c1ccccc1)OC[C@@H]1CCC[C@H](Oc2c(-c3ccccc3)oc3ccccc3c2=O)O1
913,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5cccc(C(=O)Nc6ccccc6)c5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, D-14",2.13,uM,=,0.3283796034387377,1,O=C(Nc1ccccc1)c1cccc(-c2c[nH]c3c(CN4C[C@@H]5N(C(=O)NCc6ccccc6)NCC(=O)N5[C@@H](Cc5ccccc5)C4=O)cccc23)c1
914,1527876,,,,,Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,C[C@@H](c1ccc(-c2ccc(=O)n(C(F)F)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O,"US8575157, 4",21.0,uM,=,1.3222192947339193,1,O=C1OC(c2ccccc2)CCN1Cc1ccc(-c2ccc(=O)[nH]c2)cc1
915,305744,10.1021/jm049696n,,,,Inhibitory concentration value against human cytochrome P-450 3A4,c1cncc(-c2ccsc2)c1,3-Thiophen-3-yl-pyridine,56.9,uM,=,1.7551122663950711,1,c1cncc(-c2ccsc2)c1
916,1301328,10.6019/CHEMBL3137440,,,,DNDI: CYP Inhibition,N#Cc1ccc(N(c2cccnc2)C2CCN(c3ccc(F)c(F)c3)CC2)cc1,,4.3,uM,=,0.6334684555795865,1,c1ccc(N2CCC(N(c3ccccc3)c3cccnc3)CC2)cc1
917,676065,10.1016/j.bmcl.2010.09.028,,,,Inhibition of CYP3A4 after 30 mins,O=C(OC1([C@H]2COC[C@@H](CC3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CCC2(CCN2)CC1,"1-((3R,5R)-4-(4-chlorophenylsulfonyl)-5-(cyclopropylmethyl)morpholin-3-yl)cyclopropyl1,7-diazaspiro[3.5]nonane-7-carboxylate",0.0113,uM,=,-1.9469215565165805,0,O=C(OC1([C@H]2COC[C@@H](CC3CC3)N2S(=O)(=O)c2ccccc2)CC1)N1CCC2(CCN2)CC1
918,1661018,10.1016/j.bmcl.2017.02.047,,,,Inhibition of recombinant human CYP3A4 expressed in baculosomes using Vivid BOMR substrate red measured every 30 sec for 30 mins by fluorescence assay,CCCCCCCCC[C@H](O)CC(=O)CCc1ccc(O)c(OC)c1,10-gingerol,24.9,uM,=,1.3961993470957363,1,c1ccccc1
919,1923418,10.1021/acsmedchemlett.6b00056,,,,Inhibition of human CYP3A4 expressed in supersomes assessed as testosterone 6beta-hydroxylation after 15 mins by HPLC analysis,COc1ccc2c(c1)c(C1=CCNCC1)cn2S(=O)(=O)c1cncc2ccccc12,"4-{[5-Methoxy-3-(1,2,3,6-tetrahydropyridin-4yl)-1H-indol-1-yl]sulfonyl}isoquinoline",26.0,uM,=,1.414973347970818,1,O=S(=O)(c1cncc2ccccc12)n1cc(C2=CCNCC2)c2ccccc21
920,461436,10.1016/j.bmcl.2007.10.092,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,CN(Cc1nc(CC2([C@H]3CCC[C@@H](C4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)no1)C(C)(C)CO,"2-(((3-((1-((2R,6S)-1-(4-chlorophenylsulfonyl)-6-cyclopropylpiperidin-2-yl)cyclopropyl)methyl)-1,2,4-oxadiazol-5-yl)methyl)(methyl)amino)-2-methylpropan-1-ol",3.1,uM,=,0.4913616938342727,1,O=S(=O)(c1ccccc1)N1[C@H](C2CC2)CCC[C@@H]1C1(Cc2ncon2)CC1
921,2160653,10.1021/acs.jmedchem.1c01875,,,,Time dependent inhibition of recombinant human CYP3A4 incubated for 30 mins in presence of NADPH generating system by LC-MS/MS analysis,C[C@]12CC[C@H](O)C[C@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](c3ccc(=O)oc3)CC[C@]12O,"5-((3S,5R,10S,13R,14S,17R)-3,14-Dihydroxy-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthren-17-yl)-pyran-2-one",11.31,uM,=,1.0534626049254554,1,O=c1ccc([C@H]2CCC3C2CC[C@@H]2C4CCCC[C@H]4CC[C@@H]32)co1
922,1534761,,,,,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",FC(F)(F)c1ccncc1CNc1ccc(Cc2c[nH]c3ncc(Cl)cc23)cn1,"US9096593, P-2063",5.0,uM,=,0.6989700043360189,1,c1cncc(CNc2ccc(Cc3c[nH]c4ncccc34)cn2)c1
923,1653091,10.1016/j.bmc.2016.11.019,,,,Inhibition of human CYP3A4,Cl.NCCN(C(=O)c1ccc(Cl)cc1Cl)c1ccc(OCc2ccc(Cl)cc2)cc1,"N-(2-Aminoethyl)-2,4-dichloro-N-{4-[(4-chlorophenyl)methoxy]phenyl}benzamide hydrochloride",0.179,uM,=,-0.7471469690201069,0,O=C(Nc1ccc(OCc2ccccc2)cc1)c1ccccc1
924,774749,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",CC[C@H](C)[C@@H](CO[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCS(C)(=O)=O)C(=O)OC(C)C)NC[C@@H](N)CS,(S)-2-{(S)-2-[(S)-2-((R)-2-Amino-3-mercapto-propylamino)-3-methyl-pentyloxy]-3-phenyl-propionylamino}-4-methanesulfonyl-butyric acid isopropyl ester,3.0,uM,=,0.4771212547196624,1,c1ccccc1
925,993439,10.6019/CHEMBL2448688,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,Cl.NCC(=O)N(Cc1cccnc1)c1cc(F)cc(-c2nc3ccccc3s2)c1,,1.01,uM,=,0.0043213737826425,1,c1cncc(CNc2cccc(-c3nc4ccccc4s3)c2)c1
926,519907,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,Cc1nc2c(NCc3ccc(F)cc3Cl)cc(-n3cncn3)cn2c1C,"N-(2-chloro-4-fluorobenzyl)-2,3-dimethyl-6-(1H-1,2,4-triazol-1-yl)imidazo[1,2-a]pyridin-8-amine",5.2,uM,=,0.7160033436347992,1,c1ccc(CNc2cc(-n3cncn3)cn3ccnc23)cc1
927,2024613,10.1016/j.bmcl.2020.127721,,,,Inhibition of CYP3A4 (unknown origin),CS(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncc(F)cc34)cs2)c1,"N-[4-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-yl)thiazol-2-yl]-2-[3-(methanesulfonamido)phenyl]acetamide",6.0,uM,=,0.7781512503836436,1,O=C(Cc1ccccc1)Nc1nc(-c2c[nH]c3ncccc23)cs1
928,665571,10.1021/jm100832d,,,,Inhibition of human CYP3A4,c1ccc(COc2ccc3cccnc3c2)cc1,7-benzyloxyquinoline,25.0,uM,=,1.3979400086720375,1,c1ccc(COc2ccc3cccnc3c2)cc1
929,305432,10.1016/j.bmcl.2005.01.044,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,CC(C(c1ccc2cc(OCC(C)(C)C(=O)O)ccc2c1)n1ccnc1)N(C)C,"3-[6-(2-Dimethylamino-1-imidazol-1-yl-propyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid",6.3,uM,=,0.7993405494535817,1,c1ccc2cc(Cn3ccnc3)ccc2c1
930,469873,10.1016/j.bmcl.2008.01.012,,,,Inhibition of human CYP3A4,CCCNc1nnc(-c2cn3ncnc(Nc4cc(C(=O)NC5CC5)c(F)cc4F)c3c2C(C)C)o1,"N-cyclopropyl-2,4-difluoro-5-(5-isopropyl-6-(5-(propylamino)-1,3,4-oxadiazol-2-yl)pyrrolo[1,2-f][1,2,4]triazin-4-ylamino)benzamide",0.4,uM,=,-0.3979400086720376,0,O=C(NC1CC1)c1cccc(Nc2ncnn3cc(-c4nnco4)cc23)c1
931,1475768,10.1021/jm5017413,,,,Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system,Cc1csc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)[C@@H]3C)n1,"(R)-(8-Methyl-3-(4-methylthiazol-2-yl)-5,6-dihydro-[1,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(thiophen-2-yl)phenyl)-methanone",11.0,uM,=,1.0413926851582251,1,O=C(c1ccc(-c2cccs2)cc1)N1CCn2c(nnc2-c2nccs2)C1
932,438600,10.1016/j.bmcl.2007.03.048,,,,Inhibition of CYP3A4 in microsomes,Cc1cc(C(=O)N(C)C)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,"2-(4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-2-oxo-1,2-dihydropyridin-3-yl)-N,N,7-trimethyl-3H-benzo[d]imidazole-5-carboxamide",2.2,uM,=,0.3424226808222063,1,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccccc2[nH]1
933,642202,10.1021/jm100481d,,,,Inhibition of human CYP3A4 after 10 mins,C=CCC(OC)[C@]12CNCC[C@]1(c1ccc(Cl)c(Cl)c1)C2,"rac-6-(3,4-Dichlorophenyl)-1-[1-(methyloxy)-3-buten-1-yl]-3-azabicyclo[4.1.0]heptane",3.0,uM,=,0.4771212547196624,1,c1ccc([C@]23CCNCC2C3)cc1
934,461436,10.1016/j.bmcl.2007.10.092,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,CCCC1(O)CCN(C(=O)CC2([C@H]3CCC[C@@H](CC)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)CC1,"2-(1-((2R,6R)-1-(4-chlorophenylsulfonyl)-6-ethylpiperidin-2-yl)cyclopropyl)-1-(4-hydroxy-4-propylpiperidin-1-yl)ethanone",5.0,uM,=,0.6989700043360189,1,O=C(CC1([C@H]2CCCCN2S(=O)(=O)c2ccccc2)CC1)N1CCCCC1
935,1276541,10.1016/j.bmcl.2013.09.041,,,,Inhibition of CYP3A4 (unknown origin) after 5 mins,O=S(=O)(Nc1ccc(-c2ncccn2)cc1)c1cc(Cl)cc(Cl)c1,"3,5-dichloro-N-(4-(pyrimidin-2-yl)phenyl)benzenesulfonamide",16.2,uM,=,1.209515014542631,1,O=S(=O)(Nc1ccc(-c2ncccn2)cc1)c1ccccc1
936,52065,10.1021/jm0310129,,,,Inhibitory activity against cytochrome P450 3A4,Cn1c2cccnc2c2ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21,"1-{4-[2-(3,4-Difluoro-phenyl)-ethyl]-piperazin-1-yl}-9-methyl-9H-2,4,5,9-tetraaza-fluorene",19.3,uM,=,1.285557309007774,1,c1ccc(CCN2CCN(c3ncnc4c3[nH]c3cccnc34)CC2)cc1
937,1584799,10.1021/acs.jmedchem.6b00030,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 5 mins by LC-MS analysis,CCOC1(c2ccc(OC)cc2)SC=C(C)n2c1noc2=O,"8-Ethoxy-8-(4-methoxyphenyl)-5-methyl-8H-[1,2,4]oxadiazolo-[3,4-c][1,4]thiazin-3-one",19.4,uM,=,1.287801729930226,1,O=c1onc2n1C=CSC2c1ccccc1
938,676065,10.1016/j.bmcl.2010.09.028,,,,Inhibition of CYP3A4 after 30 mins,O=C(OC1([C@H]2COC[C@@H](CC3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CC2CC1CN2CCO,"1-((3R,5R)-4-(4-chlorophenylsulfonyl)-5-(cyclopropylmethyl)morpholin-3-yl)cyclopropyl 5-(2-hydroxyethyl)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate",0.0032,uM,=,-2.494850021680094,0,O=C(OC1([C@H]2COC[C@@H](CC3CC3)N2S(=O)(=O)c2ccccc2)CC1)N1CC2CC1CN2
939,1475768,10.1021/jm5017413,,,,Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system,Cc1cncc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)[C@@H]3C)n1,"(R)-(8-Methyl-3-(6-methylpyrazin-2-yl)-5,6-dihydro-[1,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(thiophen-2-yl)phenyl)-methanone",2.0,uM,=,0.3010299956639812,1,O=C(c1ccc(-c2cccs2)cc1)N1CCn2c(nnc2-c2cnccn2)C1
940,813216,10.1016/j.bmcl.2012.01.125,,,,Inhibition of CYP3A4,COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n(Cc3ccccc3)c12,"1-benzyl-7-(3,5-dimethylisoxazol-4-yl)-8-methoxy-1H-imidazo[4,5-c]quinolin-2(3H)-one",3.7,uM,=,0.568201724066995,1,O=c1[nH]c2cnc3cc(-c4cnoc4)ccc3c2n1Cc1ccccc1
941,2017934,10.1021/acs.jmedchem.0c00834,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis,Cc1c(-c2ccccc2)nc2ccc(Br)cc2c1C(=O)NCC(C(=O)O)c1ccccc1Cl,(+)-3-{[(6-Bromo-3-methyl-2-phenylquinolin-4-yl)carbonyl]amino}-2-(2-chlorophenyl)-propanoic acid,12.0,uM,=,1.0791812460476249,1,O=C(NCCc1ccccc1)c1cc(-c2ccccc2)nc2ccccc12
942,802673,10.1016/j.bmcl.2011.12.125,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,CC(C)N(C(=O)c1cccc(NC(=O)Nc2ccc(-c3ccnc4[nH]cnc34)cc2)c1)C(C)C,"3-(3-(4-(3H-imidazo[4,5-b]pyridin-7-yl)phenyl)ureido)-N,N-diisopropylbenzamide",0.06,uM,=,-1.2218487496163564,0,O=C(Nc1ccccc1)Nc1ccc(-c2ccnc3[nH]cnc23)cc1
943,746947,10.1021/jm200128m,,,,Inhibition of human CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,Cc1cc(Cl)cc(OCCn2cc(F)cn2)c1-c1nc(N)nc2c1CN(C(=O)NCC(F)(F)F)C2,"2-Amino-4-{4-chloro-2-[2-(4-fluoropyrazol-1-yl)ethoxy]-6-methylphenyl}-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carboxylic Acid(2,2,2-Trifluoroethyl)amide",1.4,uM,=,0.1461280356782379,1,c1ccc(-c2ncnc3c2CNC3)c(OCCn2cccn2)c1
944,1677687,10.1021/acs.jmedchem.7b01340,,,,Inhibition of CYP3A4 (unknown origin) expressed in baculosomes,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,"1-(4-{4-[2-(2,4-Dichloro-phenyl)-2-imidazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-ethanone (ketoconazole)",0.04,uM,=,-1.3979400086720375,0,c1ccc(C2(Cn3ccnc3)OCC(COc3ccc(N4CCNCC4)cc3)O2)cc1
945,494885,10.1021/jm8012618,,,,"Inhibition of human recombinant CYP3A4 using N-N,diethyl-formamide as substrate",CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O.Cl,4-(7-Chloro-quinolin-4-ylamino)-2-diethylaminomethyl-phenol (Amodiaquin),28.0,uM,=,1.4471580313422192,1,c1ccc(Nc2ccnc3ccccc23)cc1
946,559143,10.1016/j.bmcl.2008.10.061,,,,Inhibition of human CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,O=C(/C=C/c1cc(F)cc(F)c1)N1CCC([C@@H](CO)N2CCC(c3c[nH]c4ncccc34)CC2)CC1,"(S)-1-(4-(1-(4-(1H-pyrrolo[2,3-b]pyridin-3-yl)piperidin-1-yl)-2-hydroxyethyl)piperidin-1-yl)-3-(3,5-difluorophenyl)prop-2-en-1-one",25.2,uM,=,1.4014005407815442,1,O=C(/C=C/c1ccccc1)N1CCC(CN2CCC(c3c[nH]c4ncccc34)CC2)CC1
947,644697,10.1016/j.bmcl.2010.05.111,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,CS(=O)(=O)N(c1ccccc1)c1cc(C(=O)N[C@@H](Cc2ccccc2)[C@H](O)CNCc2cccc(C(F)(F)F)c2)cc(C2CCCC2)c1,"3-cyclopentyl-N-((2S,3R)-3-hydroxy-1-phenyl-4-(3-(trifluoromethyl)benzylamino)butan-2-yl)-5-(N-phenylmethylsulfonamido)benzamide",0.3,uM,=,-0.5228787452803376,0,O=C(N[C@H](CCNCc1ccccc1)Cc1ccccc1)c1cc(Nc2ccccc2)cc(C2CCCC2)c1
948,448320,10.1016/j.bmc.2007.05.069,,,,Inhibition of CYP3A4,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCOC)C(=O)C(C)(c1ccc(F)c(F)c1)O2,"6-(2,4-diamino-6-ethyl-pyrimidin-5-yl)-2-(3,4-difluoro-phenyl)-4-(3-methoxy-propyl)-2-methyl-4Hbenzo[1,4]oxazin-3-one",0.92,uM,=,-0.0362121726544447,0,O=C1Nc2cc(-c3cncnc3)ccc2OC1c1ccccc1
949,1785637,,,,,Inhibition of CYP3A4 (unknown origin),O=S(=O)(N1CCN(c2ccc(/C=C/c3cc(F)cc(-c4ccncc4)c3)cc2)CC1)C(F)(F)F,(E)-1-(4-(3-fluoro-5-(pyridin-4-yl)styryl)phenyl)-4-(trifluoromethylsulfonyl)piperazine,9.36,uM,=,0.9712758487381052,1,C(=C/c1cccc(-c2ccncc2)c1)\c1ccc(N2CCNCC2)cc1
950,51930,10.1016/s0960-894x(01)00614-x,,,,Inhibition of recombinant human Cytochrome P450 3A4,CCCCCCc1ccc(N/C=N/O)cc1,N-(4-hexylphenyl)-N'-hydroxyimidoformamide,50.0,uM,=,1.6989700043360187,1,c1ccccc1
951,560184,10.1016/j.bmcl.2008.10.118,,,,Inhibition of CYP3A4,CC(C)(C)c1cc(Nc2ccc(Cl)cc2Cl)ncc1C(=O)NCC1CCOCC1,"4-tert-butyl-6-(2,4-dichlorophenylamino)-N-((tetrahydro-2H-pyran-4-yl)methyl)nicotinamide",64.0,uM,=,1.806179973983887,1,O=C(NCC1CCOCC1)c1ccc(Nc2ccccc2)nc1
952,993439,10.6019/CHEMBL2448688,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,CCN(Cc1cccnc1)c1cccc(-c2nc3ccccc3s2)c1,,1.0,uM,=,0.0,0,c1cncc(CNc2cccc(-c3nc4ccccc4s3)c2)c1
953,988989,10.1021/jm400732v,,,,Inhibition of CYP3A4 (unknown origin),CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)c2ccc(F)cc2)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O.Cl,"(S)-N-((S)-1-((6-Bromo-2-methoxynaphthalen-1-yl)methyl)-5-(4-fluorobenzoyl)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-yl)-2-(methylamino)propanamide hydrochloride",1.5,uM,=,0.1760912590556812,1,O=C1CCN(C(=O)c2ccccc2)c2ccccc2N1Cc1cccc2ccccc12
954,1301328,10.6019/CHEMBL3137440,,,,DNDI: CYP Inhibition,CN(C)S(=O)(=O)c1cccc(N2CCC(N(c3ccc(C(F)(F)F)cc3)c3cccnc3)CC2)c1,,7.0,uM,=,0.8450980400142568,1,c1ccc(N2CCC(N(c3ccccc3)c3cccnc3)CC2)cc1
955,802673,10.1016/j.bmcl.2011.12.125,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,N#Cc1ccc(-c2ccc(NC(=O)Nc3ccc(-c4ccnc5[nH]cnc45)cc3)cc2)cc1,"1-(4-(3H-imidazo[4,5-b]pyridin-7-yl)phenyl)-3-(4'-cyanobiphenyl-4-yl)urea",0.011,uM,=,-1.958607314841775,0,O=C(Nc1ccc(-c2ccccc2)cc1)Nc1ccc(-c2ccnc3[nH]cnc23)cc1
956,1499751,10.1021/acs.jmedchem.5b00424,,,,Inhibition of CYP3A4 (unknown origin),COc1cccc(CC(=O)Nc2nc(-c3ccncn3)cs2)c1,2-(3-methoxyphenyl)-N-(4-(pyrimidin-4-yl)thiazol-2-yl)acetamide,10.0,uM,=,1.0,1,O=C(Cc1ccccc1)Nc1nc(-c2ccncn2)cs1
957,988989,10.1021/jm400732v,,,,Inhibition of CYP3A4 (unknown origin),CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)c2ccc(C)o2)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O.Cl,"(S)-N-((S)-1-((6-Bromo-2-methoxynaphthalen-1-yl)methyl)-5-(5-methylfuran-2-carbonyl)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-yl)-2-(methylamino)propanamide hydrochloride",1.9,uM,=,0.2787536009528289,1,O=C1CCN(C(=O)c2ccco2)c2ccccc2N1Cc1cccc2ccccc12
958,1660136,10.1021/acs.jmedchem.6b01918,,,,Inhibition of human CYP3A4 assessed as inhibition of dealkylation,O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCCC2CCCNC2)cc1F,rac-5-Chloro-2-fluoro-4-((2-(piperidin-3-yl)ethyl)amino)-N-(thiazol-2-yl)benzenesulfonamide,6.7,uM,=,0.8260748027008264,1,O=S(=O)(Nc1nccs1)c1ccc(NCCC2CCCNC2)cc1
959,1460909,10.1021/jm501326k,,,,Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase/human b5 reductase using 7-benzyloxyquinoline substrate,CCOC(=O)c1[nH]cc2c1NC1=C(C(=O)CCC1)C2c1ccc(Sc2nc3cccc(Cl)c3[nH]2)o1,"(+/-)-Ethyl 9-[5-[(7-chloro-1H-benzimidazol-2-yl)sulfanyl]-2-furyl]-8-oxo-2,4,5,6,7,9-hexahydropyrrolo[3,4-b]quinoline-3-carboxylate",0.05,uM,=,-1.3010299956639813,0,O=C1CCCC2=C1C(c1ccc(Sc3nc4ccccc4[nH]3)o1)c1c[nH]cc1N2
960,519908,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,Cc1cccc(C)c1CCc1cc(-n2ccccc2=O)cn2c(C)c(C)nc12,"1-(8-(2,6-dimethylphenethyl)-2,3-dimethylimidazo[1,2-a]pyridin-6-yl)pyridin-2(1H)-one",31.0,uM,=,1.4913616938342726,1,O=c1ccccn1-c1cc(CCc2ccccc2)c2nccn2c1
961,716789,10.1016/j.bmcl.2010.12.123,,,,Inhibition of CYP3A4,O=C(NC1CCCCC1)[C@H](C1CCCCC1)n1c(-c2ccc(Cl)cc2)nc2cc(F)c(Cl)cc21,"(S)-2-(6-chloro-2-(4-chlorophenyl)-5-fluoro-1H-benzo[d]imidazol-1-yl)-N,2-dicyclohexylacetamide",4.5,uM,=,0.6532125137753437,1,O=C(NC1CCCCC1)[C@H](C1CCCCC1)n1c(-c2ccccc2)nc2ccccc21
962,1705360,10.1016/j.bmcl.2017.06.037,,,,Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method,CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cncn6)(c6ccc(F)cc6F)C5)cc4)CC3)cc2)c1=O,Posaconazole,0.075,uM,=,-1.1249387366083,0,O=c1[nH]ncn1-c1ccc(N2CCN(c3ccc(OC[C@@H]4CO[C@@](Cn5cncn5)(c5ccccc5)C4)cc3)CC2)cc1
963,1553516,10.1016/j.bmc.2016.02.006,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins by LC-MS analysis,CC1(C)CCc2cc(S(=O)(=O)N(CC(=O)O)Cc3cccc(-c4ccccc4)c3)ccc2O1,"2-(N-([1,1'-Biphenyl]-3-ylmethyl)-2,2-dimethylchroman-6-sulfonamido)acetic acid",40.0,uM,=,1.6020599913279625,1,O=S(=O)(NCc1cccc(-c2ccccc2)c1)c1ccc2c(c1)CCCO2
964,1283600,10.1021/jm401610c,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone,O=C(C(c1ccc(Cl)cc1)c1cccnc1)N1CCN(c2ccc(C(F)(F)F)cc2)CC1,rac-2-(4-Chlorophenyl)-1-{4-[4-(trifluoromethyl)phenyl]piperazin-1-yl}-2-(pyridin-3-yl)ethanone,16.0,uM,=,1.2041199826559248,1,O=C(C(c1ccccc1)c1cccnc1)N1CCN(c2ccccc2)CC1
965,1923841,10.1021/acs.jmedchem.6b00280,,,,Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase and human b5 reductase assessed as reduction in 7-Hydroxyquinoline production using 7-benzyloxyquinoline as substrate and NADPH incubated for 15 mins by fluorimetry,O=C(NCCN1CCOCC1)Nc1nc2ccc(Sc3nnc4ccc(OC5CCCCC5)nn34)cc2s1,"1-(6-(6-(cyclohexyloxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-ylthio)benzo[d]thiazol-2-yl)-3-(2-morpholinoethyl)urea",2.7,uM,=,0.4313637641589873,1,O=C(NCCN1CCOCC1)Nc1nc2ccc(Sc3nnc4ccc(OC5CCCCC5)nn34)cc2s1
966,471117,10.1016/j.bmc.2007.10.061,,,,Inhibition of CYP3A4,Nc1nccn2c1c(-c1ccc3ccc(-c4ccccc4)nc3c1)nc2[C@H]1C[C@@H](N2CCCCC2)C1,"cis-1-(2-phenylquinolin-7-yl)-3-(3-piperidin-1-ylcyclobutyl)-imidazo[1,5-a]pyrazin-8-ylamine",7.5,uM,=,0.8750612633917001,1,c1ccc(-c2ccc3ccc(-c4nc([C@H]5C[C@@H](N6CCCCC6)C5)n5ccncc45)cc3n2)cc1
967,443644,10.1016/j.bmc.2007.03.047,,,,Inhibition of human recombinant CYP3A4,O=c1ccc2c(O)c3ccoc3cc2o1,bergaptol,24.92,uM,=,1.396548037987132,1,O=c1ccc2cc3ccoc3cc2o1
968,1301273,10.6019/CHEMBL3137386,,,,DNDI: CYP Inhibition,O=C(C(c1ccc(Cl)cc1)c1cccnc1)N1CCN(Cc2ccccc2C(F)(F)F)CC1,,15.0,uM,=,1.1760912590556811,1,O=C(C(c1ccccc1)c1cccnc1)N1CCN(Cc2ccccc2)CC1
969,1488509,10.1124/dmd.112.045708,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 90 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis in presence of NADPH,CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1,"(R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide",21.0,uM,=,1.3222192947339193,1,O=C(Cc1ccccc1)N(Cc1cccnc1)Cc1nc2ncccc2c(=O)n1-c1ccccc1
970,487712,10.1016/j.bmcl.2008.05.104,,,,Inhibition of CYP3A4,Cc1cc(N2CCC(N3CCN(C(=O)C4CC4)CC3)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,(S)-4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-3-(6-(4-(4-(cyclopropanecarbonyl)piperazin-1-yl)piperidin-1-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one,0.0017,uM,=,-2.7695510786217263,0,O=C(C1CC1)N1CCN(C2CCN(c3ccc4nc(-c5c(NCCc6ccccc6)cc[nH]c5=O)[nH]c4c3)CC2)CC1
971,813216,10.1016/j.bmcl.2012.01.125,,,,Inhibition of CYP3A4,COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n(C(C)c3ccccc3)c12,"rac-7-(3,5-dimethylisoxazol-4-yl)-8-methoxy-1-(1-phenylethyl)-1H-imidazo[4,5-c]quinolin-2(3H)-one",2.0,uM,=,0.3010299956639812,1,O=c1[nH]c2cnc3cc(-c4cnoc4)ccc3c2n1Cc1ccccc1
972,465260,10.1016/j.bmcl.2008.01.036,,,,Inhibition of CYP3A4,COc1ccc(CC(=O)Nc2cc(-n3nc(C)cc3C)nc(-c3ccccn3)n2)cc1,"N-(6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(pyridin-2-yl)pyrimidin-4-yl)-2-(4-methoxyphenyl)acetamide",1.8,uM,=,0.255272505103306,1,O=C(Cc1ccccc1)Nc1cc(-n2cccn2)nc(-c2ccccn2)n1
973,1523392,10.1021/acs.jmedchem.5b00774,,,,Inhibition of CYP3A4 (unknown origin) co-incubated with substrate and protein,O=S(=O)(N[C@@H]1CC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@H]2C1)C(F)(F)F,"N-((6aR,8R,10aS)-10a-(4-chlorophenylsulfonyl)-1,4-difluoro-6a,7,8,9,10,10a-hexahydro-6H-benzo[c]chromen-8-yl)-1,1,1-trifluoromethanesulfonamide",9.6,uM,=,0.9822712330395684,1,O=S(=O)(c1ccccc1)[C@@]12CCCC[C@@H]1COc1ccccc12
974,493017,10.1021/jm800851u,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,CCOC(=O)Nc1cc(-c2cncc(OC)c2)nc(-n2nc(C)cc2C)n1,"[2-(3,5-Dimethyl-pyrazol-1-yl)-6-(5-methoxy-pyridin-3-yl)-pyrimidin-4-yl]-carbamic acid ethyl ester",20.0,uM,=,1.3010299956639813,1,c1cncc(-c2ccnc(-n3cccn3)n2)c1
975,322377,10.1021/jm0502541,,,,Inhibition of cytochrome P450 3A4 at 100 uM; activation observed,O=C(O)C1(c2ccc(-c3ccc(C4CCCCC4)cc3)c(F)c2)CC1,1-(4'-Cyclohexyl-2-fluoro-biphenyl-4-yl)-cyclopropanecarboxylic acid,59.0,uM,=,1.7708520116421442,1,c1cc(C2CCCCC2)ccc1-c1ccc(C2CC2)cc1
976,52069,10.1021/jm021012t,,,,Inhibition of human cytochrome P450 3A4,Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1,"1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole",0.18,uM,=,-0.744727494896694,0,c1ccc(COC(Cn2ccnc2)c2ccccc2)cc1
977,742805,10.1016/j.bmc.2011.02.009,,,,Inhibition of human CYP3A4 after 30 mins,COc1ccc(-c2ccc(C(O)(c3c[nH]cn3)C(C)C)cc2)cc1,"rac-1-(1H-Imidazol-4-yl)-1-(4'-methoxy[1,1'-biphenyl]-4-yl)-2-methyl-1-propanol",4.9,uM,=,0.6901960800285137,1,c1ccc(-c2ccc(Cc3c[nH]cn3)cc2)cc1
978,1289880,10.1021/jm401642q,,,,Inhibition of recombinant human CYP3A4,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(OC(F)(F)F)cccc21,"6-(Morpholin-4-yl)-2-{2-oxo-2-[4-(trifluoromethoxy)-2,3-dihydro-1H-indol-1-yl]ethyl}pyrimidin-4(3H)-one",40.0,uM,=,1.6020599913279625,1,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2ccccc21
979,2093988,10.1021/acs.jmedchem.0c01296,,,,Inhibition of human CYP3A4 in human pooled liver microsomes in presence of testosterone as substrate preincubated for 30 mins in presence of NADPH followed by addition of substrate by LC-MS/MS analysis,CC[C@@H]1C[C@H](C)CC/C=C\[C@@H]2C[C@@]2(C(=O)NS(=O)(=O)C2(C)CC2)NC(=O)[C@@H]2C[C@@H](Oc3nccc4cc(OC)c(F)cc34)CN2C(=O)[C@H]1NC(=O)OC(C)(C)C(F)(F)F,"1,1,1-Trifluoro-2-methylpropan-2-yl-((2R,6S,7R,9R,13aS,14aR,16aS,Z)-7-ethyl-2-((7-fluoro-6-methoxyisoquinolin-1-yl)oxy)-9-methyl-14a-(((1-methylcyclopropyl)sulfonyl)carbamoyl)-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl)carbamate",3.02,uM,=,0.4800069429571506,1,O=C1N[C@]2(C(=O)NS(=O)(=O)C3CC3)C[C@H]2/C=C\CCCCCCC(=O)N2C[C@H](Oc3nccc4ccccc34)C[C@@H]12
980,2020193,10.1016/j.bmcl.2018.01.013,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,COc1cc(-c2ncc(COc3cccc([C@@H](CC(=O)O)C4CC4)c3)nc2CC(C)C)c(F)cn1,(3S)-3-cyclopropyl-3-[3-[[5-(5-fluoro-2-methoxy-4-pyridyl)-6-isobutylpyrazin-2-yl]methoxy]phenyl]propanoic acid,8.0,uM,=,0.9030899869919436,1,c1cc(CC2CC2)cc(OCc2cnc(-c3ccncc3)cn2)c1
981,1772538,10.1016/j.bmcl.2018.05.055,,,,Inhibition of CYP3A4 (unknown origin),CC(=O)N[C@@H](C)/C=C/c1ccc(Oc2ccc(OCC3CC3)cc2Cl)nn1,"(S,E)-N-(4-(6-(2-chloro-4-(cyclopropylmethoxy)phenoxy)pyridazin-3-yl)but-3-en-2-yl)acetamide",18.0,uM,=,1.255272505103306,1,c1cnnc(Oc2ccc(OCC3CC3)cc2)c1
982,1908478,10.1021/acsmedchemlett.9b00325,,,,Inhibition of human recombinant CYP3A4 using midazolam as substrate incubated for 40 to 130 mins in presence of NADPH by LC-MS/MS analysis,C[C@H](NC(=O)c1cccc(F)c1)c1ccc(NC(=O)N2CC(c3cccnc3)C2)cc1,(S)-N-(4-(1-(3-fluorobenzamido)ethyl)phenyl)-3-(pyridin-3-yl)azetidine-1-carboxamide,3.11,uM,=,0.4927603890268375,1,O=C(NCc1ccc(NC(=O)N2CC(c3cccnc3)C2)cc1)c1ccccc1
983,355280,10.1016/j.bmcl.2006.02.020,,,,Inhibition of CYP3A4,CC[C@H]([C@@H](c1ccc2cc(OCC(C)(C)C(=O)O)ccc2c1)n1ccnc1)N(C)C,"3-[6-(2-dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid",3.3,uM,=,0.5185139398778875,1,c1ccc2cc(Cn3ccnc3)ccc2c1
984,598210,10.1016/j.bmcl.2009.08.024,,,,Inhibition of human CYP3A4,CN(C)c1ccc(CNC(=O)CC2(C)CC3(CCCCC3)OO2)cc1,"N-(4-(dimethylamino)benzyl)-2-(3-methyl-1,2-dioxaspiro[4.5]decan-3-yl)acetamide",4.8,uM,=,0.6812412373755872,1,O=C(CC1CC2(CCCCC2)OO1)NCc1ccccc1
985,627010,10.1021/jm100095x,,,,Inhibition of CYP3A4,CCn1c(=O)c(-c2cc(C(=O)NC3CC3)ccc2C)cc2cnn(-c3ccc(F)cc3F)c21,"N-Cyclopropyl-3-(1-(2,4-difluorophenyl)-7-ethyl-6-oxo-6,7-dihydro-1H-pyrazolo[3,4-b]pyridin-5-yl)-4-methylbenzamide",1.6,uM,=,0.2041199826559248,1,O=C(NC1CC1)c1cccc(-c2cc3cnn(-c4ccccc4)c3[nH]c2=O)c1
986,991614,10.1021/jm4008906,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(C[C@@H]1CCCO1)C2,"(S)-3-(Aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-6-(((S)-tetrahydrofuran-2-yl)methyl)-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one",15.0,uM,=,1.1760912590556811,1,O=C1c2c(-c3ccccc3)ccnc2CN1C[C@@H]1CCCO1
987,1764722,10.1021/acsmedchemlett.8b00220,,,,Inhibition of CYP3A4 (unknown origin) preincubated followed by substrate addition,O=C(Nc1ccc2[nH]nc(-c3ccncc3)c2c1)[C@@H]1CCN(CC(=O)N2CCN(c3ccc(-c4ncccn4)cc3)CC2)C1,(R)-1-(2-oxo-2-(4-(4-(pyrimidin-2-yl)phenyl)piperazin-1-yl)ethyl)-N-(3-(pyridin-4-yl)-1H-indazol-5-yl)pyrrolidine-3-carboxamide,5700.0,uM,=,3.755874855672492,1,O=C(Nc1ccc2[nH]nc(-c3ccncc3)c2c1)[C@@H]1CCN(CC(=O)N2CCN(c3ccc(-c4ncccn4)cc3)CC2)C1
988,1459713,10.1016/j.ejmech.2014.08.059,,,,Inhibition of CYP3A4 (unknown origin),N#C[C@@H]1C[C@H](F)CN1C(=O)C[C@H](N)Cc1cc(F)c(F)cc1F,"(2S,4S)-1-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-4-fluoropyrrolidine-2-carbonitrile",56.49,uM,=,1.7519715747363274,1,O=C(CCCc1ccccc1)N1CCCC1
989,436456,10.1021/jm061195+,,,,Inhibition of human CYP3A4,O=C(NCC1CCOCC1)c1cnc(Nc2cc(Cl)cc(Cl)c2)nc1C(F)(F)F,"2-(3,5-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(tetrahydropyran-4-ylmethyl)amide",38.0,uM,=,1.57978359661681,1,O=C(NCC1CCOCC1)c1cnc(Nc2ccccc2)nc1
990,1696937,10.1016/j.bmcl.2017.09.042,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate pretreated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis,O=C(Nc1ccc(F)cn1)c1cc(Oc2cnc(F)c(F)c2)cn2ncnc12,"6-(5,6-difluoropyridin-3-yloxy)-N-(5-fluoropyridin-2-yl)-[1,2,4]triazolo[1,5-a]pyridine-8-carboxamide",23.0,uM,=,1.3617278360175928,1,O=C(Nc1ccccn1)c1cc(Oc2cccnc2)cn2ncnc12
991,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",O=C(c1cccc(C(F)(F)F)c1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1,"US9150566, 182",14.0,uM,=,1.146128035678238,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
992,741043,10.1016/j.bmcl.2011.02.067,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCC2(CC#N)CC2)c1,"(3R,4S)-N-(3-((1-(cyanomethyl)cyclopropyl)methoxy)-5-(3-methoxypropyl)benzyl)-N-cyclopropyl-4-(4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)phenyl)piperidine-3-carboxamide",1.4,uM,=,0.1461280356782379,1,O=C([C@H]1CNCC[C@@H]1c1ccc(OCCOc2ccccc2)cc1)N(Cc1cccc(OCC2CC2)c1)C1CC1
993,1984166,10.1016/j.bmc.2020.115349,,,,Inhibition of human full length CYP3A4 assessed using 7-benzyloxy-4 (trifluoromethyl)coumarin as substrate preincubated for 2 mins followed by substrate addition and measured for 2 mins by fluorometric analysis,CC(C)(C)OC(=O)N[C@@H](CSCC(Nc1ccccc1)C(=O)NCc1cccnc1)Cc1c[nH]c2ccccc12,Rac-tert-butyl N-[(1R)-1-[[2-anilino-3-oxo-3-(3-pyridylmethylamino)propyl]sulfanylmethyl]-2-(1H-indol-3-yl)ethyl]carbamate,0.085,uM,=,-1.0705810742857071,0,O=C(NCc1cccnc1)C(CSCCCc1c[nH]c2ccccc12)Nc1ccccc1
994,51908,10.1016/j.bmcl.2003.08.049,,,,In vitro inhibition of Cytochrome P450 3A4,O=C(N[C@H]1c2ccccc2OC[C@H]1O)[C@H](Cc1cccnc1)C[C@H](O)CN1CCN(Cc2ccn(-c3ccc(F)c(F)c3F)c2)C[C@H]1C(=O)NCC(F)(F)F,"(S)-1-[(2S,4R)-2-Hydroxy-4-((3S,4S)-3-hydroxy-chroman-4-ylcarbamoyl)-5-pyridin-3-yl-pentyl]-4-[1-(2,3,4-trifluoro-phenyl)-1H-pyrrol-3-ylmethyl]-piperazine-2-carboxylic acid (2,2,2-trifluoro-ethyl)-amide",0.05,uM,=,-1.3010299956639813,0,O=C(N[C@@H]1CCOc2ccccc21)[C@@H](CCCN1CCN(Cc2ccn(-c3ccccc3)c2)CC1)Cc1cccnc1
995,438520,10.1016/j.bmcl.2007.01.104,,,,Inhibition of CYP3A4,COc1cccc(N2C(=O)N(Cc3ccccc3F)C3(CCN(Cc4ccc(-c5cnccc5OC)cc4)CC3)C2=O)c1,"1-(2-fluoro-benzyl)-3-(3-methoxy-phenyl)-8-[4-(4-methoxy-pyridin-3-yl)-benzyl]-1,3,8-triaza-spiro[4.5]decane-2,4-dione",1.7,uM,=,0.2304489213782739,1,O=C1N(c2ccccc2)C(=O)C2(CCN(Cc3ccc(-c4cccnc4)cc3)CC2)N1Cc1ccccc1
996,1660136,10.1021/acs.jmedchem.6b01918,,,,Inhibition of human CYP3A4 assessed as inhibition of dealkylation,C[C@]1(CCOc2cc(F)c(S(=O)(=O)Nc3ncns3)cc2F)CC[C@@H](N)CC1,"cis-4-(2-((1S,4S)-4-Amino-1-methylcyclohexyl)ethoxy)-2,5-difluoro-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide",0.78,uM,=,-0.1079053973095195,0,O=S(=O)(Nc1ncns1)c1ccc(OCCC2CCCCC2)cc1
997,980735,10.1021/jm400820m,,,,Inhibition of human recombinant CYP3A4,CCOC(=O)c1cc(C#N)c(N2CCC(C(=O)NS(=O)(=O)Cc3ccc(F)cc3)CC2)nc1C,Ethyl 6-[4-({[(4-Fluorobenzyl)sulfonyl]amino}carbonyl)-piperidin-1-yl]-5-cyano-2-methylnicotinate,4.5,uM,=,0.6532125137753437,1,O=C(NS(=O)(=O)Cc1ccccc1)C1CCN(c2ccccn2)CC1
998,2062192,10.1016/j.bmcl.2016.04.018,,,,Inhibition of human liver microsomes CYP3A4 using testosterone as substrate by MUX-MS/MS analysis,FC(F)(F)Oc1cccc(Nc2nnc3n2CCOc2ccc(-c4ccncc4)cc2-3)c1,"10-(pyridin-4-yl)-N-(3-(trifluoromethoxy)phenyl)-5,6-dihydrobenzo[f][1,2,4]triazolo[4,3-d][1,4]oxazepin-3-amine",1.61,uM,=,0.2068258760318497,1,c1ccc(Nc2nnc3n2CCOc2ccc(-c4ccncc4)cc2-3)cc1
999,2103815,10.1016/j.bmcl.2021.128010,,,,Time dependent inhibition of CYP3A4 (unknown origin) measured at 30 mins,Nc1cc(Cc2ccn(Cc3cccc(O[C@H]4CCNC4)c3)n2)c2nn[nH]c2n1,"(S)-7-((1-(3-(pyrrolidin-3-yloxy)benzyl)-1H-pyrazol-3-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-amine",13.0,uM,=,1.1139433523068367,1,c1cc(Cn2ccc(Cc3ccnc4[nH]nnc34)n2)cc(O[C@H]2CCNC2)c1
1000,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2C(CN(Cc3cccc4c(C(=O)Nc5ccc(N6CCC7(CCN(CC)C7)C6)nc5)cn(C)c34)C(=O)[C@@H]2Cc2ccc(O)cc2)N1C(=O)NCc1ccccc1,"US8940739, G-65",3.91,uM,=,0.5921767573958668,1,O=C(Nc1ccc(N2CCC3(CCNC3)C2)nc1)c1c[nH]c2c(CN3CC4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12
1001,1625990,10.1016/j.bmcl.2016.04.095,,,,Inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins after 30 secs by LC/MS/MS analysis,O=S(=O)(CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12)CC1=NCCN1,"2-((2-((4S,4aS,10bS)-10b-(4-chlorophenylsulfonyl)-7,10-difluoro-1,2,4,4a,5,10b-hexahydropyrano[3,4-c]chromen-4-yl)ethylsulfonyl)methyl)-4,5-dihydro-1H-imidazole",1.0,uM,=,0.0,0,O=S(=O)(CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccccc3)c3ccccc3OC[C@@H]12)CC1=NCCN1
1002,834929,10.1016/j.bmcl.2012.07.020,,,,Inhibition of CYP3A4,CCS(=O)(=O)c1ccc2[nH]c(-c3cccc(-c4ccccc4)c3)nc2c1,2-(biphenyl-3-yl)-5-(ethylsulfonyl)-1H-benzo[d]imidazole,9.0,uM,=,0.9542425094393248,1,c1ccc(-c2cccc(-c3nc4ccccc4[nH]3)c2)cc1
1003,1662668,10.1021/acs.jmedchem.6b01850,,,,Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated with enzyme in presence of NADPH followed by substrate addition,COc1cc(-c2cccc(C(F)(F)F)c2)c(C)cc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3ccon3)ccc21,"US9212182, 419::US9212182, 420",2.8,uM,=,0.4471580313422192,1,O=c1ccc2cc(S(=O)(=O)Nc3ccon3)ccc2n1-c1ccc(-c2ccccc2)cc1
1004,1910981,10.1021/acs.jmedchem.8b01464,,,,Inhibition of human CYP3A4 in presence of NADPH by luciferase reporter gene assay,Cn1cc(C(c2ccc(Cl)cc2)n2ccnc2)cc1-c1ccc(Cl)cc1,1-[(4-Chlorophenyl)[5-(4-chlorophenyl)-1-methyl-1H-pyrrol-3-yl]methyl]-1H-imidazole,1.1,uM,=,0.041392685158225,1,c1ccc(-c2cc(C(c3ccccc3)n3ccnc3)c[nH]2)cc1
1005,688021,10.1016/j.bmcl.2010.10.101,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins,Cl.Cn1c(=O)c2c(cc(N3CCC[C@@](C)(N)C3)n2Cc2cc(F)ccc2Cl)n(C)c1=O,"(R)-6-(3-amino-3-methylpiperidin-1-yl)-5-(2-chloro-5-fluorobenzyl)-1,3-dimethyl-1H-pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione hydrochloride",10.2,uM,=,1.0086001717619175,1,O=c1[nH]c(=O)c2c(cc(N3CCCCC3)n2Cc2ccccc2)[nH]1
1006,103774,10.1021/jm031011g,,,,Inhibitory concentration to inhibit MRP1 in CYP 3A4 assay,O=C(NCc1ccccn1)c1c2n(c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)ncnc13)CCCC2,"4-{4-[2-(3,4-Difluoro-phenyl)-ethyl]-piperazin-1-yl}-6,7,8,9-tetrahydro-pyrimido[4,5-b]indolizine-10-carboxylic acid (pyridin-2-ylmethyl)-amide",30.15,uM,=,1.4792873164761702,1,O=C(NCc1ccccn1)c1c2n(c3c(N4CCN(CCc5ccccc5)CC4)ncnc13)CCCC2
1007,1288280,10.1016/j.bmcl.2013.12.057,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,CC(C)c1nc(CN(C)C(=O)NC(CN(C)C)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,"Thiazol-5-ylmethyl(2R,5R)-5-(3-(dimethylamino)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)propanamido)-1,6-diphenylhexan-2-ylcarbamate",0.14,uM,=,-0.8538719643217619,0,O=C(CNC(=O)NCc1cscn1)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
1008,1336778,10.1021/jm401911v,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,CC(C)(C)S(=O)(=O)C[C@H](C1CC1)N1C(=O)[C@@](C)(Cc2ncc(C(=O)CO)s2)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1,"(3R,5R,6S)-1-((S)-2-(tert-Butylsulfonyl)-1-cyclopropylethyl)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-3-((5-(2-hydroxyacetyl)thiazol-2-yl)methyl)-3-methylpiperidin-2-one",0.8,uM,=,-0.0969100130080563,0,O=C1C(Cc2nccs2)C[C@H](c2ccccc2)[C@@H](c2ccccc2)N1CC1CC1
1009,434712,10.1021/jm070104l,,,,Inhibition of human CYP3A4,N#Cc1ccccc1Cn1c(N2CCC[C@@H](N)C2)nc2cccc(F)c2c1=O,(R)-2-((2-(3-aminopiperidin-1-yl)-5-fluoro-4-oxoquinazolin-3(4H)-yl)methyl)benzonitrile,0.5,uM,=,-0.3010299956639812,0,O=c1c2ccccc2nc(N2CCCCC2)n1Cc1ccccc1
1010,2207925,10.1021/acsmedchemlett.2c00411,,,,Inhibition of CYP3A4 (unknown origin) in presence of NADPH,COc1cc(Nc2ncc(C)c(Nc3ccc4oc(=O)[nH]c4c3)n2)cc(C(F)(F)F)c1,5-((2-((3-methoxy-5-(trifluoromethyl)phenyl)amino)-5-methylpyrimidin-4-yl)amino)benzo[d]oxazol-2(3H)one,0.5,uM,=,-0.3010299956639812,0,O=c1[nH]c2cc(Nc3ccnc(Nc4ccccc4)n3)ccc2o1
1011,814102,10.1016/j.bmcl.2012.03.014,,,,Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins,O[C@]1(c2ccc(F)c(F)c2)CCNC[C@@H]1c1onc(-c2cccc(Cl)c2Cl)c1Br,"(3S,4R)-3-(4-bromo-3-(2,3-dichlorophenyl)isoxazol-5-yl)-4-(3,4-difluorophenyl)piperidin-4-ol",19.0,uM,=,1.2787536009528289,1,c1ccc(-c2cc([C@H]3CNCCC3c3ccccc3)on2)cc1
1012,1924430,10.1021/acsmedchemlett.5b00485,,,,Inhibition of CYP3A4 (unknown origin) preincubated for 10 mins followed by addition of BFC as substrate measured after 10 mins in presence of NADP by fluorescence analysis,Cc1cc(-c2cnn3c(NCC4CCOCC4)cc(N[C@@H](C4CC4)C(C)(C)O)nc23)ccc1C(=O)NC1CC1,"(S)-N-cyclopropyl-4-(5-((1-cyclopropyl-2-hydroxy-2-methylpropyl)amino)-7-(((tetrahydro-2Hpyran-4-yl)methyl)amino)-pyrazolo[1,5-a]pyrimidin-3-yl)-2-methylbenzamide",3.0,uM,=,0.4771212547196624,1,O=C(NC1CC1)c1ccc(-c2cnn3c(NCC4CCOCC4)cc(NCC4CC4)nc23)cc1
1013,984598,10.1021/jm401266k,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of midazolam turnover preincubated for 3 mins followed by midazolam and NADPH addition measured after 5 mins by HPLC-MS/MS analysis,COc1c(/C=C/c2ccc(NS(C)(=O)=O)cc2)cc(-c2ccc[nH]c2=O)cc1C(C)(C)C,N-[4-[(E)-2-[3-tert-Butyl-2-methoxy-5-(2-oxo-1H-pyridin-3-yl)phenyl]vinyl]phenyl]methanesulfonamide,1.1,uM,=,0.041392685158225,1,O=c1[nH]cccc1-c1cccc(/C=C/c2ccccc2)c1
1014,856844,10.1021/jm300356u,,,,Inhibition of human recombinant CYP3A4 using 7-BQ as substrate preincubated for 5 to 10 mins before substrate addition,CC/N=C1\O[C@H]2[C@H](O[C@@H]3[C@@H](C)[C@H](O[C@H]4C[C@@](C)(OC)[C@@H](O)[C@H](C)O4)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]3(C)O)O[C@H](C)C[C@@H]2N1C,"(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-14-ethyl-6-((3aR,4S,6R,7aS)-2-(ethylimino)-1,6-dimethylhexahydro-1H-pyrano[4,3-d]oxazol-4-yloxy)-7,12,13-trihydroxy-4-((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yloxy)-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione",5.7,uM,=,0.7558748556724915,1,N=C1N[C@H]2CCO[C@@H](O[C@H]3CCCC(=O)CCCCOC(=O)C[C@@H](O[C@H]4CCCCO4)C3)[C@@H]2O1
1015,979124,10.1021/jm400484p,,,,Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes,Oc1ccc2ccc(-c3cccnc3)c(Cl)c2c1,8-chloro-7-(pyridin-3-yl)naphthalen-2-ol,1.759,uM,=,0.2452658394574612,1,c1cncc(-c2ccc3ccccc3c2)c1
1016,1301324,10.6019/CHEMBL3137440,,,,DNDI: CYP Inhibition,CC(C)(C)CC(=O)N1CCC(N(c2ccc(Cl)cc2)c2cccnc2)CC1,"1-(4-((4-chlorophenyl)(pyridin-3-yl)amino)piperidin-1-yl)-3,3-dimethylbutan-1-one",0.8,uM,=,-0.0969100130080563,0,c1ccc(N(c2cccnc2)C2CCNCC2)cc1
1017,559939,10.1016/j.bmcl.2008.10.072,,,,Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate,C[C@@H]1CN(Cc2ccc(-c3ccccc3C(=O)N3CCC(Nc4ccc(Cl)cc4)CC3)cc2)C[C@H](C)N1,"[4-(4-Chloro-phenylamino)-piperidin-1-yl]-[4'-((3R,5S)-3,5-dimethyl-piperazin-1-ylmethyl)-biphenyl-2-yl]-methanone",3.5,uM,=,0.5440680443502757,1,O=C(c1ccccc1-c1ccc(CN2CCNCC2)cc1)N1CCC(Nc2ccccc2)CC1
1018,1447575,10.1016/j.bmcl.2014.05.068,,,,Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method,O[C@@](Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(C(F)(F)F)cc2)cn1,"(R)-2-(2,4-difluorophenyl)-1,1-difluoro-3-(1H-tetrazol-1-yl)-1-(5-(4-(trifluoromethyl)phenyl)pyridin-2-yl)propan-2-ol",54.0,uM,=,1.7323937598229686,1,c1ccc(-c2ccc(CC(Cn3cnnn3)c3ccccc3)nc2)cc1
1019,1625607,10.1016/j.bmcl.2016.10.016,,,,Inhibition of human Cyp3A4 using testosterone as substrate by LC-MS/MS analysis,CC(C)S(=O)(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,"1-(4-{[(2S,4R)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)-4-(propane-2-sulfonyl)piperazine",0.198,uM,=,-0.7033348097384688,0,c1ccc([C@]2(Cn3ccnc3)OC[C@@H](COc3ccc(N4CCNCC4)cc3)O2)cc1
1020,583357,10.1021/jm900945d,,,,Inhibition of CYP3A4,CC(C)(C)Sc1c(CC(C)(C)C(=O)O)n(Cc2ccc(-c3cccnc3)cc2)c2ccc(OCc3ccccn3)cc12,"3-(3-(tert-butylthio)-5-(pyridin-2-ylmethoxy)-1-(4-(pyridin-3-yl)benzyl)-1H-indol-2-yl)-2,2-dimethylpropanoic acid",0.0047,uM,=,-2.3279021420642825,0,c1ccc(COc2ccc3c(ccn3Cc3ccc(-c4cccnc4)cc3)c2)nc1
1021,1933089,10.1021/acs.jmedchem.6b00028,,,,Inhibition of human CYP3A4 expressed in Escherichia coli pre-incubated for 5 mins before regenerating cofactor solution addition using Diethoxyfluorescein/7-Benzyloxyquinoline as substrate by fluorescence assay,c1cncc(-c2cc(N3CCC(N4CCOCC4)CC3)nc(-c3ccncc3)n2)c1,4-(1-(6-(Pyridin-3-yl)-2-(pyridin-4-yl)pyrimidin-4-yl)-piperidin-4-yl)morpholine,0.1,uM,=,-1.0,0,c1cncc(-c2cc(N3CCC(N4CCOCC4)CC3)nc(-c3ccncc3)n2)c1
1022,1996656,10.1021/acs.jmedchem.0c00446,,,,Inhibition of CYP3A4 (unknown origin),COc1cc(C2=CC3=NOC[C@H](c4cc(F)c(F)c(F)c4)N3CCC2)ccc1-n1cnc(C)c1,"(S)-9-(3-Methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-4-(3,4,5-trifluorophenyl)-3,4,7,8-tetrahydro-6H-[1,2,4]oxadiazino[4,3-a]azepine",30.0,uM,=,1.4771212547196624,1,C1=C(c2ccc(-n3ccnc3)cc2)CCCN2C1=NOC[C@@H]2c1ccccc1
1023,1465542,10.1016/j.bmcl.2015.01.051,,,,Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(C6CN(C7CCC7)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O,"(1S,4R,5R,6R,8R,10S,11R,12S,13R,16R,18S,21R)-18-{[(2S)-4-(1-cyclobutylazetidin-3-yl)morpholin-2-yl]oxy}-8-[(1S)-1-ethoxy-2-hydroxy-2-methylpropyl]-4,6,12,17,17-pentamethyl-9-oxahexacyclo[11.9.0.0^{1,21}.0^{4,12}.0^{5,10}.0^{16,21}]docosan-11-ol",54.0,uM,=,1.7323937598229686,1,C1CC(N2CC(N3CCO[C@@H](O[C@H]4CC[C@]56C[C@]57CCC5C(C[C@H]8OCCC[C@H]58)[C@@H]7CC[C@H]6C4)C3)C2)C1
1024,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCN5CCN(C)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, F-27",11.51,uM,=,1.0610753236297918,1,O=C(NCCN1CCNCC1)c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12
1025,2048449,10.1016/j.bmc.2020.115734,,,,Inhibition of recombinant CYP3A4 (unknown origin) by fluorescence-based assay,COc1nc(-c2csc(Nc3c4c(nn3CCF)CCC4)n2)ccc1-n1cnc(C)c1,"N-(2-(2-fluoroethyl)-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-4-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)thiazol-2-amine",10.5,uM,=,1.021189299069938,1,c1cn(-c2ccc(-c3csc(Nc4[nH]nc5c4CCC5)n3)nc2)cn1
1026,1587034,10.1021/acs.jmedchem.6b00203,,,,Inhibition of CYP3A4 (unknown origin),Cc1nn(C2CCN(C(=O)CN)CC2)c(C)c1Nc1ncc(Cl)c(-c2cnn3ccccc23)n1,"2-amino-1-[4-(4-{[5-Chloro-4-(pyrazolo[1,5-a]pyridin-3-yl)-2-pyrimidinyl]amino}-3,5-dimethyl-1H-pyrazol-1-yl)-1-piperidinyl]ethanone",0.5,uM,=,-0.3010299956639812,0,c1ccn2ncc(-c3ccnc(Nc4cnn(C5CCNCC5)c4)n3)c2c1
1027,874112,10.1021/jm300118s,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis,C#Cc1ccc(C[C@H](NC(=O)COC)[C@H](O)CN[C@H]2CC3(CCC3)Oc3ncc(CC(C)(C)C)cc32)cc1,"N-((2S,3R)-1-(4-Ethynylphenyl)-3-hydroxy-4-((S)-6'-neopentyl-3',4'-dihydrospiro[cyclobutane-1,2'-pyrano[2,3-b]-pyridine]-4'-ylamino)butan-2-yl)-2-methoxyacetamide",0.1,uM,=,-1.0,0,c1ccc(CCCCN[C@H]2CC3(CCC3)Oc3ncccc32)cc1
1028,1859912,10.1021/acsmedchemlett.9b00114,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 10 mins in presence of NADPH by UHPLC-MS/MS analysis,Cc1cc(N2CCC(C3c4c(F)cccc4-c4cncn43)CC2)ccc1-c1cnn(C)c1,"6-fluoro-5-(1-(3-methyl-4-(1-methyl-1H-pyrazol-4-yl)phenyl)piperidin-4-yl)-5H-imidazo[5,1-a]isoindole",0.21,uM,=,-0.6777807052660807,0,c1ccc2c(c1)-c1cncn1C2C1CCN(c2ccc(-c3cn[nH]c3)cc2)CC1
1029,336550,10.1021/jm050736c,,,,Inhibition of cytochrome P450 3A4,Nc1c(C(=O)c2cccc(OC[C@@H](O)CO)c2)cnn1-c1ccc(F)cc1,"5-amino-1-(4-fluorophenyl)-4-[3-{2(S),3-dihydroxypropoxy}-benzoyl]pyrazole",25.0,uM,=,1.3979400086720375,1,O=C(c1ccccc1)c1cnn(-c2ccccc2)c1
1030,1870803,10.1016/j.bmcl.2018.11.048,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 5 mins followed by NADPH cofactor addition and measured after 10 mins by LC-MS/MS analysis,O=C(NC1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1)c1cccnc1,(R)-N-(4-(3-(5-(trifluoromethyl)pyridin-2-yloxy)benzylidene)cyclohexyl)nicotinamide,0.0004,uM,=,-3.397940008672037,0,O=C(NC1CCC(=Cc2cccc(Oc3ccccn3)c2)CC1)c1cccnc1
1031,804824,10.1016/j.bmcl.2011.12.080,,,,Reversible inhibition of CYP3A4,COc1cc(C)c2nc3[nH]nc(C)c3c(C(O)c3ccccn3)c2c1,"rac-(6-methoxy-3,8-dimethyl-1H-pyrazolo[3,4-b]quinolin-4-yl)(pyridin-2-yl)methanol",4.6,uM,=,0.6627578316815741,1,c1ccc(Cc2c3ccccc3nc3[nH]ncc23)nc1
1032,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1ccc(-n2nccn2)c(C(=O)N2C[C@@H](C)OC[C@H]2Cc2cccc(-c3ncccn3)c2)c1,"US9150566, 109",43.0,uM,=,1.6334684555795866,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2ncccn2)c1
1033,611722,10.1021/jm9014263,,,,Inhibition of human CYP3A4 using BFC substrate by fluorescence assay,COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc4c(c3)CN(C)CC4)c2)cc1OC,"3,4-Dimethoxy-N-[3-(2-methyl-1,2,3,4-tetrahydro-isoquinolin-7-ylcarbamoyl)-benzyl]-benzamide",1.7,uM,=,0.2304489213782739,1,O=C(NCc1cccc(C(=O)Nc2ccc3c(c2)CNCC3)c1)c1ccccc1
1034,802673,10.1016/j.bmcl.2011.12.125,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,O=C(Nc1ccc(-c2ccnc3[nH]cnc23)cc1)Nc1cccc(C(=O)NC2CCCC2)c1,"3-(3-(4-(3H-imidazo[4,5-b]pyridin-7-yl)phenyl)ureido)-N-cyclopentylbenzamide",0.07,uM,=,-1.154901959985743,0,O=C(Nc1ccc(-c2ccnc3[nH]cnc23)cc1)Nc1cccc(C(=O)NC2CCCC2)c1
1035,1288280,10.1016/j.bmcl.2013.12.057,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,CC(C)c1nc(CN(C(=O)N[C@H](C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)C(C)C)C2CC2)cs1,"Thiazol-5-ylmethyl(2R,5R)-5-((S)-2-(3-cyclopropyl-3-((2-isopropylthiazol-4-yl)methyl)ureido)-3-methylbutanamido)-1,6-diphenylhexan-2-ylcarbamate",0.21,uM,=,-0.6777807052660807,0,O=C(CNC(=O)N(Cc1cscn1)C1CC1)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
1036,814102,10.1016/j.bmcl.2012.03.014,,,,Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins,CC(=O)NCCc1ccccc1-c1ccc([C@H]2CNCC[C@@H]2c2ccc(F)c(F)c2)c(Cl)c1,"N-(2-(3'-chloro-4'-((3S,4S)-4-(3,4-difluorophenyl)piperidin-3-yl)biphenyl-2-yl)ethyl)acetamide",20.0,uM,=,1.3010299956639813,1,c1ccc(-c2ccc([C@H]3CNCC[C@@H]3c3ccccc3)cc2)cc1
1037,619264,10.1016/j.bmcl.2009.07.002,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,Cc1cccc(C)c1CNc1nccn2c(C)c(C)cc12,"N-(2,6-dimethylbenzyl)-6,7-dimethylpyrrolo[1,2-a]pyrazin-1-amine",4.7,uM,=,0.6720978579357175,1,c1ccc(CNc2nccn3cccc23)cc1
1038,489969,10.1021/jm800566m,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein substrate,Cc1n[nH]c2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc12,3-({4-[Methyl(3-methyl-1H-indazol-6-yl)amino]-2-pyrimidinyl}amino)benzenesulfonamide,7.6,uM,=,0.8808135922807914,1,c1ccc(Nc2nccc(Nc3ccc4cn[nH]c4c3)n2)cc1
1039,2165731,10.1021/acsmedchemlett.1c00696,,,,Inhibition of CYP3A4 (unknown origin),Cc1nccc(-c2cc3[nH]nc(N[C@H]4CCNC[C@@H]4F)c3cc2C2CC2)c1F,"5-cyclopropyl-6-(3-fluoro-2-methylpyridin-4-yl)-N-((3S,4S)-3-fluoropiperidin-4-yl)-1H-indazol-3-amine",4.5,uM,=,0.6532125137753437,1,c1cc(-c2cc3[nH]nc(NC4CCNCC4)c3cc2C2CC2)ccn1
1040,950702,10.1021/jm400288z,,,,Inhibition of C-terminal His-tagged wild type CYP3A4 (unknown origin)-mediated hydroxylation of 7-benzyloxy-4-trifluoromethylcoumarin expressed in Escherichia coli after 5 mins by fluorimetric analysis,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cccnc2)Cc2ccccc2)C(C)C)cs1,"Pyridin-3-ylmethyl(2R,5R)-5-((S)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-3-methylbutanamido)-1,6-diphenylhexan-2-ylcarbamate",0.13,uM,=,-0.8860566476931633,0,O=C(CNC(=O)NCc1cscn1)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cccnc1)Cc1ccccc1
1041,1849385,10.1016/j.bmcl.2019.06.044,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis,O=C(O)c1ccc(-n2cc(C(=O)c3c(Cl)cccc3C(F)(F)F)c3cccc(F)c32)cc1,4-(3-(2-chloro-6-(trifluoromethyl)benzoyl)-7-fluoro-1H-indol-1-yl)benzoic acid,13.9,uM,=,1.1430148002540952,1,O=C(c1ccccc1)c1cn(-c2ccccc2)c2ccccc12
1042,452862,10.1021/jm0708228,,,,Inhibition of human CYP3A4 using 7-benzloxyquinolone substrate,O=C(c1ccc(F)cc1)N1CCN(c2ccc(OCCCN3CCCCC3)cc2)C(=O)C1.O=CO,4-(4-fluoro-benzoyl)-1-[4-(3-piperidin-1-yl-propoxy)-phenyl]-piperazin-2-one formic acid,100.0,uM,=,2.0,1,O=C(c1ccccc1)N1CCN(c2ccc(OCCCN3CCCCC3)cc2)C(=O)C1
1043,1629312,10.1016/j.bmcl.2016.11.020,,,,Inhibition of CYP3A4 (unknown origin),Cc1ccc(OCCNc2nc(Nc3cc(C)[nH]n3)cc(C)c2C#N)cn1,4-methyl-6-(5-methyl-1H-pyrazol-3-ylamino)-2-(2-(6-methylpyridin-3-yloxy)ethylamino)nicotinonitrile,4.5,uM,=,0.6532125137753437,1,c1cncc(OCCNc2cccc(Nc3cc[nH]n3)n2)c1
1044,550965,10.1021/np030556a,,,,Inhibition of human CYP3A4 by radiometric assay,CC(=O)O[C@@H]1[C@@H](O)[C@H](C)O[C@@H](Oc2c(-c3ccc(O)cc3)oc3cc(O)cc(O)c3c2=O)[C@@H]1OC(C)=O,"kaempferol-3-O-(2,3-di-O-acetyl-alpha-L-rhamnopyranoside)",55.8,uM,=,1.7466341989375789,1,O=c1c(O[C@H]2CCCCO2)c(-c2ccccc2)oc2ccccc12
1045,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1ccc(C(=O)N2CCOC[C@H]2Cc2cccc(-n3nccn3)c2)c(-n2nccn2)c1,"US9150566, 27",31.0,uM,=,1.4913616938342726,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
1046,813216,10.1016/j.bmcl.2012.01.125,,,,Inhibition of CYP3A4,COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n(-c3ccccc3C(C)(C)C)c12,"1-(2-tert-butylphenyl)-7-(3,5-dimethylisoxazol-4-yl)-8-methoxy-1H-imidazo[4,5-c]quinolin-2(3H)-one",1.7,uM,=,0.2304489213782739,1,O=c1[nH]c2cnc3cc(-c4cnoc4)ccc3c2n1-c1ccccc1
1047,988989,10.1021/jm400732v,,,,Inhibition of CYP3A4 (unknown origin),CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)c2ccc(N)cc2)c2ccccc2N(Cc2c(OC)ccc3ccccc23)C1=O.Cl,"(S)-N-((S)-5-(4-Aminobenzoyl)-1-((2-methoxynaphthalen-1-yl)methyl)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-yl)-2-(methylamino)propanamide hydrochloride",10.2,uM,=,1.0086001717619175,1,O=C1CCN(C(=O)c2ccccc2)c2ccccc2N1Cc1cccc2ccccc12
1048,630896,10.1016/j.bmcl.2010.03.017,,,,Inhibition of CYP3A4,Cc1cc(OC[P@]2(=O)OCC[C@H](c3cccnc3C)O2)c2c(c1C)Cc1scnc1-2,"6,7-Dimethyl-4-[4-(2-methyl-pyridin-3-yl)-2-oxo-2lambda*5*-[1,3,2]dioxaphosphinan-2-ylmethoxy]-8H-indeno[1,2-d]thiazole",5.8,uM,=,0.7634279935629373,1,O=[P@@]1(COc2cccc3c2-c2ncsc2C3)OCC[C@H](c2cccnc2)O1
1049,342118,10.1021/jm051106d,,,,Inhibitory activity against CYP3A4,Cc1cc2c(F)c(Oc3ncnn4cc(OCCN5CC[C@H](O)C5)c(C)c34)ccc2[nH]1,"(R)-1-(2-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)ethyl)pyrrolidin-3-ol",10.0,uM,=,1.0,1,c1nc(Oc2ccc3[nH]ccc3c2)c2cc(OCCN3CCCC3)cn2n1
1050,813040,10.1021/jm201533b,,,,Inhibition of human CYP3A4 using testosterone as substrate by LC/MS/MS analysis,O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)[C@@H]1C[C@@H](Cc2ccccc2)CN1C(=O)Cc1cnc[nH]1,"(2S,4R)-1-(2-(1H-imidazol-5-yl)acetyl)-4-benzyl-N-(4-(4-fluorophenoxy)phenyl)pyrrolidine-2-carboxamide",7.146,uM,=,0.8540630118664212,1,O=C(Nc1ccc(Oc2ccccc2)cc1)[C@@H]1C[C@@H](Cc2ccccc2)CN1C(=O)Cc1cnc[nH]1
1051,991614,10.1021/jm4008906,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(c1ccn(C)n1)C2,"(S)-3-(Aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-6-(1-methyl-1H-pyrazol-3-yl)-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one",11.0,uM,=,1.0413926851582251,1,O=C1c2c(-c3ccccc3)ccnc2CN1c1cc[nH]n1
1052,2207925,10.1021/acsmedchemlett.2c00411,,,,Inhibition of CYP3A4 (unknown origin) in presence of NADPH,COc1cc(Nc2ncc(C)c(Nc3ccc4oc(=O)[nH]c4c3)n2)cc(C)c1C,"5-(2-(3-methoxy-4,5-dimethylphenylamino)-5-methylpyrimidin-4ylamino)benzo[d]oxazol-2(3H)-one",2.9,uM,=,0.4623979978989561,1,O=c1[nH]c2cc(Nc3ccnc(Nc4ccccc4)n3)ccc2o1
1053,1475768,10.1021/jm5017413,,,,Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system,Cc1nc(-c2nnc3n2CCN(C(=O)c2ccc(F)cc2)[C@@H]3C)cs1,"(R)-(4-Fluorophenyl)(8-methyl-3-(2-methylthiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone",63.0,uM,=,1.7993405494535817,1,O=C(c1ccccc1)N1CCn2c(nnc2-c2cscn2)C1
1054,461436,10.1016/j.bmcl.2007.10.092,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,CC[C@@H]1CCC[C@H](C2(CC(=O)N3CCN(C(C)(C)CO)CC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1,"2-(1-((2R,6R)-1-(4-chlorophenylsulfonyl)-6-ethylpiperidin-2-yl)cyclopropyl)-1-(4-(1-hydroxy-2-methylpropan-2-yl)piperazin-1-yl)ethanone",4.7,uM,=,0.6720978579357175,1,O=C(CC1([C@H]2CCCCN2S(=O)(=O)c2ccccc2)CC1)N1CCNCC1
1055,1350938,10.1016/j.bmcl.2014.03.070,,,,Inhibition of CYP3A4 (unknown origin),Cc1cc(C)c(S(=O)(=O)N[C@@H](C)CNc2cccc3c2cnn3-c2ccc(F)cc2)c(C)c1,"(S)-N-(1-(1-(4-fluorophenyl)-1H-indazol-4-ylamino)propan-2-yl)-2,4,6-trimethylbenzenesulfonamide",10.0,uM,=,1.0,1,O=S(=O)(NCCNc1cccc2c1cnn2-c1ccccc1)c1ccccc1
1056,859714,10.1021/jm3004637,,,,Inhibition of hepatic CYP3A4,CCOc1cc2c(cc1-c1cccnc1)CCC(=O)N2C,"7-Ethoxy-1-methyl-6-pyridin-3-yl-3,4-dihydro-1H-quinolin-2-one",90.0,uM,=,1.954242509439325,1,O=C1CCc2cc(-c3cccnc3)ccc2N1
1057,1301328,10.6019/CHEMBL3137440,,,,DNDI: CYP Inhibition,FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ncccn3)CC2)cc1,,1.8,uM,=,0.255272505103306,1,c1ccc(N(c2cccnc2)C2CCN(c3ncccn3)CC2)cc1
1058,464748,10.1016/j.bmcl.2008.01.126,,,,Inhibition of CYP3A4 in presence of 7-benzyloxyresorufin substrate,Cc1oc(-c2cccc(Cl)c2)nc1CCOc1cccc(C[C@@H]2C(=O)N(c3ccc(C(C)(C)C)cc3)[C@@H]2C(=O)O)c1,"(2S,3S)-3-(3-(2-(2-(3-chlorophenyl)-5-methyloxazol-4-yl)ethoxy)benzyl)-1-(4-tert-butylphenyl)-4-oxoazetidine-2-carboxylic acid",20.0,uM,=,1.3010299956639813,1,O=C1[C@@H](Cc2cccc(OCCc3coc(-c4ccccc4)n3)c2)CN1c1ccccc1
1059,537847,10.1021/jm800888q,,,,Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,O=C1CCc2cc(-c3cccnc3)ccc2C1,"6-Pyridin-3-yl-3,4-dihydronaphthalen-2(1H)-one",6.21,uM,=,0.7930916001765802,1,O=C1CCc2cc(-c3cccnc3)ccc2C1
1060,1933089,10.1021/acs.jmedchem.6b00028,,,,Inhibition of human CYP3A4 expressed in Escherichia coli pre-incubated for 5 mins before regenerating cofactor solution addition using Diethoxyfluorescein/7-Benzyloxyquinoline as substrate by fluorescence assay,c1cncc(-c2cc(N3CCc4ccccc4C3)nc(-c3ccncc3)n2)c1,TCMDC-125419,0.1,uM,=,-1.0,0,c1cncc(-c2cc(N3CCc4ccccc4C3)nc(-c3ccncc3)n2)c1
1061,437628,10.1016/j.bmcl.2006.10.036,,,,Inhibition of CYP3A4,CCCCc1ccc(S(=O)(=O)Nc2ccc3c(c2)CCN(C)CC3)cc1,"4-butyl-N-(3-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)benzenesulfonamide",12.0,uM,=,1.0791812460476249,1,O=S(=O)(Nc1ccc2c(c1)CCNCC2)c1ccccc1
1062,802673,10.1016/j.bmcl.2011.12.125,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,O=C(Nc1ccc(Br)cc1)Nc1ccc(-c2ccnc3[nH]cnc23)cc1,"1-(4-(3H-imidazo[4,5-b]pyridin-7-yl)phenyl)-3-(4-bromophenyl)urea",0.21,uM,=,-0.6777807052660807,0,O=C(Nc1ccccc1)Nc1ccc(-c2ccnc3[nH]cnc23)cc1
1063,487712,10.1016/j.bmcl.2008.05.104,,,,Inhibition of CYP3A4,CNC1CCN(c2cc(C)c3nc(-c4c(NC[C@@H](O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1,(S)-4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-3-(4-methyl-6-(4-(methylamino)piperidin-1-yl)-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one,0.0026,uM,=,-2.5850266520291822,0,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(N3CCCCC3)cc2[nH]1
1064,676065,10.1016/j.bmcl.2010.09.028,,,,Inhibition of CYP3A4 after 30 mins,CC(C)[C@@H]1COC[C@H](C2(OC(=O)N3CC4CCC(C3)N4)CC2)N1S(=O)(=O)c1ccc(Cl)cc1,"1-((3R,5R)-4-(4-chlorophenylsulfonyl)-5-isopropylmorpholin-3-yl)cyclopropyl 3,8-diazabicyclo[3.2.1]octane-3-carboxylate",0.0005,uM,=,-3.3010299956639813,0,O=C(OC1([C@H]2COCCN2S(=O)(=O)c2ccccc2)CC1)N1CC2CCC(C1)N2
1065,537516,10.1021/jm8005096,,,,Inhibition of CYP3A4,CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(Cl)cc2F)N=C(c2ccnc(Cl)c2)N1,"4-(4-chloro-2-fluorophenyl)-2-(2-chloropyridin-4-yl)-N-(1H-indazol-5-yl)-6-methyl-1,4-dihydropyrimidine-5-carboxamide",5.5,uM,=,0.7403626894942439,1,O=C(Nc1ccc2[nH]ncc2c1)C1=CNC(c2ccncc2)=NC1c1ccccc1
1066,355280,10.1016/j.bmcl.2006.02.020,,,,Inhibition of CYP3A4,C[C@H]([C@@H](c1ccc2cc(OCC3(C(=O)O)CCCC3)ccc2c1)n1ccnc1)N(C)C,"1-((6-((1R,2R)-2-(dimethylamino)-1-(1H-imidazol-1-yl)propyl)naphthalen-2-yloxy)methyl)cyclopentanecarboxylic acid",8.2,uM,=,0.9138138523837168,1,c1cn(Cc2ccc3cc(OCC4CCCC4)ccc3c2)cn1
1067,2017934,10.1021/acs.jmedchem.0c00834,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis,CCC1CCCN(c2nc3ccc(Br)cc3c(C(=O)NCC(CCC(=O)O)c3ccccc3Cl)c2C)C1,(+)-5-({[6-Bromo-2-(3-ethylpiperidin-1-yl)-3-methylquinolin-4-yl]carbonyl}amino)-4-(2-chlorophenyl)pentanoic acid,10.0,uM,=,1.0,1,O=C(NCCc1ccccc1)c1cc(N2CCCCC2)nc2ccccc12
1068,1660136,10.1021/acs.jmedchem.6b01918,,,,Inhibition of human CYP3A4 assessed as inhibition of dealkylation,O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCC2(CN3CCCC3)CC2)cc1F,5-Chloro-2-fluoro-4-(((1-(pyrrolidin-1-ylmethyl)cyclopropyl)-methyl)amino)-N-(thiazol-2-yl)benzenesulfonamide,20.0,uM,=,1.3010299956639813,1,O=S(=O)(Nc1nccs1)c1ccc(NCC2(CN3CCCC3)CC2)cc1
1069,51903,10.1021/jm020557k,,,,Concentration required to inhibit cytochrome P450 3A4.,CCCCOc1ccc(-c2c[nH]cn2)cc1,5-(4-Butoxy-phenyl)-1H-imidazole,0.883,uM,=,-0.0540392964224314,0,c1ccc(-c2c[nH]cn2)cc1
1070,1366300,10.1021/ml500110j,,,,Inhibition of CYP3A4 (unknown origin),Cc1noc(C)c1-c1ccc(-c2nc(C)c([C@H](OC(C)(C)C)C(=O)O)c(-c3ccc(Cl)cc3)c2C)cc1,"(S)-2-tert-butoxy-2-(4-(4-chlorophenyl)-6-(4-(3,5-dimethylisoxazol-4-yl)phenyl)-2,5-dimethylpyridin-3-yl)acetic acid",17.0,uM,=,1.230448921378274,1,c1ccc(-c2ccnc(-c3ccc(-c4cnoc4)cc3)c2)cc1
1071,1984169,10.1016/j.bmc.2020.115349,,,,Inhibition of human full length CYP3A4 assessed using 7-benzyloxy-4 (trifluoromethyl)coumarin as substrate preincubated for 20 mins in presence of NADPH followed by substrate addition and measured for 2 mins by fluorometric analysis,CC(C)(C)OC(=O)N[C@@H](CS[C@H](Cc1ccccc1)C(=O)NCCc1cccnc1)Cc1ccccc1,tert-butyl N-[(1R)-1-benzyl-2-[(1R)-1-benzyl-2-oxo-2-[2-(3-pyridyl)ethylamino]ethyl]sulfanyl-ethyl]carbamate,0.31,uM,=,-0.5086383061657274,0,O=C(NCCc1cccnc1)[C@@H](Cc1ccccc1)SCCCc1ccccc1
1072,649576,10.1021/jm100317b,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsome,Oc1ccc(-c2ccc(C(O)c3ccncc3)cc2)cc1,4-[(4'-Hydroxybiphenyl-4-yl)methyl]pyridine,3.21,uM,=,0.5065050324048721,1,c1ccc(-c2ccc(Cc3ccncc3)cc2)cc1
1073,675407,10.1016/j.bmcl.2010.08.142,,,,Inhibition of CYP3A4,NC(=O)[C@]12CC3CC(C1)[C@@H](OC(=O)N1CC[C@@H](Nc4cccc(C(F)(F)F)n4)C1)C(C3)C2,(R)-3-(6-Trifluoromethyl-pyridin-2-ylamino)-pyrrolidine-1-carboxylic acid 5-carbamoyl-adamantan-2-yl ester,4.8,uM,=,0.6812412373755872,1,O=C(OC1C2CC3CC(C2)CC1C3)N1CC[C@@H](Nc2ccccn2)C1
1074,1695601,10.1016/j.bmc.2017.08.012,,,,Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using 7-Benzoyloxy-4-trifluoromethyl coumarin substrate in presence of NADP+ by fluorescence based assay,O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCC2CCCC3(C2)OCCO3)cc1F,"4-((1,4-Dioxaspiro[4.5]decan-7-ylmethyl)amino)-5-chloro-2-fluoro-N-(thiazol-2-yl)benzenesulfonamide",16.5,uM,=,1.2174839442139065,1,O=S(=O)(Nc1nccs1)c1ccc(NCC2CCCC3(C2)OCCO3)cc1
1075,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",O=C(c1cccc(Cl)c1-n1nccn1)N1CCOC[C@H]1Cc1cc(-n2nccn2)ccc1F,"US9150566, 135",30.0,uM,=,1.4771212547196624,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
1076,2156515,10.1021/acs.jmedchem.1c01272,,,,Inhibition of CYP3A4 in human liver microsomes using IPA as substrate preincubated for 10 mins followed by NADPH generating system addition and measured after 20 mins,COc1cc(NC(=O)c2cc(=O)c3ccccc3o2)c(-c2nnn(-c3ccc(CCN4CCn5cncc5C4)cc3)n2)cc1OCc1ccccc1,"N-(4-(benzyloxy)-2-(2-(4-(2-(5,6-dihydroimidazo[1,5-a]pyrazin-7(8H)-yl)ethyl)phenyl)-2H-tetrazol-5-yl)-5-methoxyphenyl)-4-oxo-4H-chromene-2-carboxamide",2.037,uM,=,0.3089910290001641,1,O=C(Nc1ccc(OCc2ccccc2)cc1-c1nnn(-c2ccc(CCN3CCn4cncc4C3)cc2)n1)c1cc(=O)c2ccccc2o1
1077,2103815,10.1016/j.bmcl.2021.128010,,,,Time dependent inhibition of CYP3A4 (unknown origin) measured at 30 mins,Nc1cc(Cc2ccn(Cc3cccc(Oc4ccccc4)c3)n2)c2nn[nH]c2n1,"7-((1-(3-phenoxybenzyl)-1H-pyrazol-3-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-amine",0.011,uM,=,-1.958607314841775,0,c1ccc(Oc2cccc(Cn3ccc(Cc4ccnc5[nH]nnc45)n3)c2)cc1
1078,828928,10.1016/j.bmcl.2012.06.022,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(C(C)C)oc2c1,"Thiazol-5-ylmethyl(2S,3R)-3-hydroxy-4-(N-isobutyl-2-isopropylbenzo[d]oxazole-6-carboxamido)-1-phenylbutan-2-ylcarbamate",0.037,uM,=,-1.431798275933005,0,O=C(N[C@H](CCNC(=O)c1ccc2ncoc2c1)Cc1ccccc1)OCc1cncs1
1079,1491686,10.1124/dmd.112.045708,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by substrate addition by LC-MS/MS analysis in presence of NADPH,CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1,"(R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide",5.7,uM,=,0.7558748556724915,1,O=C(Cc1ccccc1)N(Cc1cccnc1)Cc1nc2ncccc2c(=O)n1-c1ccccc1
1080,514583,10.1016/j.bmcl.2008.06.072,,,,Inhibition of recombinant CYP3A4,Cc1cc(Cc2ccc(Cl)c(Oc3cc(F)cc(C#N)c3)c2F)n[nH]c1=O,"3-(6-chloro-2-fluoro-3-((5-methyl-6-oxo-1,6-dihydropyridazin-3-yl)methyl)phenoxy)-5-fluorobenzonitrile",24.0,uM,=,1.380211241711606,1,O=c1ccc(Cc2cccc(Oc3ccccc3)c2)n[nH]1
1081,1534761,,,,,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",Cc1cnc2[nH]cc(Cc3cnc(NCc4cccc(C)n4)nc3)c2c1,"US9096593, P-2079",5.0,uM,=,0.6989700043360189,1,c1ccc(CNc2ncc(Cc3c[nH]c4ncccc34)cn2)nc1
1082,1629312,10.1016/j.bmcl.2016.11.020,,,,Inhibition of CYP3A4 (unknown origin),Cc1cc(Nc2cc(C)c(C#N)c(NCCOc3ccccn3)n2)n[nH]1,4-methyl-6-(5-methyl-1H-pyrazol-3-ylamino)-2-(2-(pyridin-2-yloxy)ethylamino)nicotinonitrile,7.2,uM,=,0.8573324964312685,1,c1ccc(OCCNc2cccc(Nc3cc[nH]n3)n2)nc1
1083,1528565,,,,,"Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",CC(C)c1nc(CN(C)C(=O)N2C[C@@H](N3CCOCC3)C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,"US8987313, 32",0.35,uM,=,-0.4559319556497244,0,O=C(N[C@H](CC[C@H](Cc1ccccc1)NC(=O)[C@@H]1C[C@H](N2CCOCC2)CN1C(=O)NCc1cscn1)Cc1ccccc1)OCc1cncs1
1084,151524,10.1016/s0960-894x(02)00425-0,,,,Inhibition of cytochrome P450 3A4,CC(C)(C)NC(=O)[C@@H]1CN(C(C)(C)c2cc3cnccc3o2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2OC[C@H]1O,"(S)-4-(1-Furo[3,2-c]pyridin-2-yl-1-methyl-ethyl)-1-[(2S,4R)-2-hydroxy-4-((3S,4S)-3-hydroxy-chroman-4-ylcarbamoyl)-5-phenyl-pentyl]-piperazine-2-carboxylic acid tert-butylamide",0.31,uM,=,-0.5086383061657274,0,O=C(N[C@@H]1CCOc2ccccc21)[C@@H](CCCN1CCN(Cc2cc3cnccc3o2)CC1)Cc1ccccc1
1085,1637154,,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins,COc1ccnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4cccc(F)c4)c3F)c12,"N-[2,4-Difluoro-3-(4-methoxy-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phenyl]-3-fluoro-benzenesulfonamide",5.0,uM,=,0.6989700043360189,1,O=C(c1cccc(NS(=O)(=O)c2ccccc2)c1)c1c[nH]c2ncccc12
1086,1972822,10.1021/acsmedchemlett.9b00611,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,COc1nn(C)cc1C(=O)Nc1cccc(-c2cncn2C(C)C)n1,N-(6-(1-Isopropyl-1H-imidazol-5-yl)pyridin-2-yl)-3-methoxy-1-methyl-1H-pyrazole-4-carboxamide,5.9,uM,=,0.7708520116421442,1,O=C(Nc1cccc(-c2cnc[nH]2)n1)c1cn[nH]c1
1087,1558600,10.1016/j.bmcl.2015.06.020,,,,Inhibition of CYP3A4 (unknown origin) by fluorescence assay,COc1ccc(Cc2nc3c(n2C)CCc2cc(-c4ccnc(C)c4)ccc2C3=O)cc1,"2-(4-Methoxy-benzyl)-1-methyl-7-(2-methyl-pyridin-4-yl)-9,10-dihydro-1H-1,3-diaza-benzo[f]azulen-4-one",0.3,uM,=,-0.5228787452803376,0,O=C1c2ccc(-c3ccncc3)cc2CCc2[nH]c(Cc3ccccc3)nc21
1088,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(CCN6CCOCC6)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, E-25",6.09,uM,=,0.7846172926328754,1,O=C(c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12)N1CCN(CCN2CCOCC2)CC1
1089,1467195,10.1021/jm5005336,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay,COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc([C@H](C)N5CCOCC5)cc4)n[nH]c3c1)C(=O)N2C,"(1R,2S)-2-(3-((E)-4-((S)-1-Morpholinoethyl)styryl)-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-one",0.45,uM,=,-0.3467874862246563,0,O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccc(CN4CCOCC4)cc3)n[nH]c2c1
1090,1752996,10.1016/j.bmcl.2018.01.014,,,,Inhibition of CYP3A4 (unknown origin),CCCCNc1nc(N)nc2cccc(OCc3cccnc3)c12,"N4-butyl-5-(pyridin-3-ylmethoxy)quinazoline-2,4-diamine",6.7,uM,=,0.8260748027008264,1,c1cncc(COc2cccc3ncncc23)c1
1091,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1ccc(C(=O)N2CCOC[C@H]2Cc2cc(-n3nccn3)ccc2Cl)c(-n2nccn2)c1C,"US9150566, 169",29.0,uM,=,1.462397997898956,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
1092,2222748,10.1021/acs.jmedchem.2c00468,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 15 to 45 mins in presence of NADPH,CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,SID144204227,0.1222,uM,=,-0.9129287940934646,0,c1ccc([C@@]2(Cn3ccnc3)OC[C@H](COc3ccc(N4CCNCC4)cc3)O2)cc1
1093,1660136,10.1021/acs.jmedchem.6b01918,,,,Inhibition of human CYP3A4 assessed as inhibition of dealkylation,O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCCC2CNC2)cc1F,rac-4-((2-(Azetidin-3-yl)ethyl)amino)-5-chloro-2-fluoro-N-(thiazol-2-yl)benzenesulfonamide,20.0,uM,=,1.3010299956639813,1,O=S(=O)(Nc1nccs1)c1ccc(NCCC2CNC2)cc1
1094,851675,10.1016/j.bmcl.2012.08.044,,,,Inhibition of CYP3A4,O=C(C1CCC(F)(F)CC1)N1CC(c2nc(-c3cccc(Cl)c3)no2)C1,"(3-(3-(3-chlorophenyl)-1,2,4-oxadiazol-5-yl)azetidin-1-yl)(4,4-difluorocyclohexyl)methanone",25000.0,uM,=,4.3979400086720375,1,O=C(C1CCCCC1)N1CC(c2nc(-c3ccccc3)no2)C1
1095,630896,10.1016/j.bmcl.2010.03.017,,,,Inhibition of CYP3A4,Cc1cc(OC[P@@]2(=O)OCC[C@@H](c3cccnc3)O2)c2c(c1C)Cc1scnc1-2,"6,7-Dimethyl-4-(2-oxo-4-pyridin-3-yl-2lambda*5*-[1,3,2]dioxaphosphinan-2-ylmethoxy)-8H-indeno[1,2-d]thiazole",2.9,uM,=,0.4623979978989561,1,O=[P@]1(COc2cccc3c2-c2ncsc2C3)OCC[C@@H](c2cccnc2)O1
1096,873423,10.1021/jm3006788,,,,Inhibition of CYP3A4,Cn1c(-c2ccc(Cl)cc2)c(C2CCCC2)c2ccc(C(=O)NC3(C(=O)Nc4ccc(/C=C/C(=O)O)cc4)CCC3)cc21,(E)-3-(4-(1-(2-(4-chlorophenyl)-3-cyclopentyl-1-methyl-1H-indole-6-carboxamido)cyclobutanecarboxamido)phenyl)acrylic acid,8.3,uM,=,0.919078092376074,1,O=C(NC1(C(=O)Nc2ccccc2)CCC1)c1ccc2c(C3CCCC3)c(-c3ccccc3)[nH]c2c1
1097,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1ccc(-n2nccn2)c(C(=O)N2CCCC[C@H]2Cc2cccc(-n3nccn3)c2)c1,"US9150566, Ref. 4",7.7,uM,=,0.8864907251724818,1,O=C(c1ccccc1-n1nccn1)N1CCCC[C@H]1Cc1cccc(-n2nccn2)c1
1098,816384,10.1016/j.bmcl.2012.03.035,,,,Inhibition of CYP3A4,Cn1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1,SID103904314,7.9,uM,=,0.8976270912904415,1,O=C(Nc1ccccc1)Nc1ccc(-c2csc3c(-c4cn[nH]c4)cncc23)cc1
1099,1828801,10.1021/acs.jmedchem.8b01098,,,,Inhibition of C-terminal 4His-tagged CYP3A4 (unknown origin) expressed in Escherichia coli by spectrophotometric analysis,COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccncc3)cc2)c1,(R)-N-(1-(3-Methoxyphenyl)ethyl)-4-(pyridin-4-yl)-benzamide,0.08,uM,=,-1.0969100130080565,0,O=C(NCc1ccccc1)c1ccc(-c2ccncc2)cc1
1100,1619558,10.1021/acsmedchemlett.6b00327,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 10 mins in presence of NADP by rapidfire/MS analysis,C[C@H]1OC(=O)[C@]2(c3nnc(N)o3)CC(F)(F)[C@@H](C)[C@H](/C=C/c3ccc(-c4ccccc4C#N)cn3)[C@H]12,"2-(6-((E)-2-((3R,3aS,4R,5S,7aR)-7a-(5-amino-1,3,4-oxadiazol-2-yl)-6,6-difluoro-3,5-dimethyl-1-oxooctahydroisobenzofuran-4-yl)vinyl)pyridin-3-yl)benzonitrile",9.9,uM,=,0.99563519459755,1,O=C1OC[C@H]2[C@@H](/C=C/c3ccc(-c4ccccc4)cn3)CCC[C@@]12c1nnco1
1101,685791,10.1016/j.bmcl.2010.10.061,,,,Inhibition of human CYP3A4,COc1cccc2c(C(=O)N3CCN4CCCC[C@H]4C3)cn(CC3CCCCC3)c12,"(S)-(1-(cyclohexylmethyl)-7-methoxy-1H-indol-3-yl)(dihydro-1H-pyrido[1,2-a]pyrazin-2(6H,7H,8H,9H,9aH)-yl)methanone",6.0,uM,=,0.7781512503836436,1,O=C(c1cn(CC2CCCCC2)c2ccccc12)N1CCN2CCCC[C@H]2C1
1102,1446329,10.1021/ml500387y,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1[nH]c2cnccc2c1C)C(F)(F)F,"1,1,1-trifluoro-4-(5-fluoro-2-methylphenyl)-4-methyl-2-((3-methyl-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)pentan-2-ol",0.1,uM,=,-1.0,0,c1ccc(CCCCc2cc3ccncc3[nH]2)cc1
1103,1769255,10.1016/j.bmc.2018.02.026,,,,Inhibition of CYP3A4 in human liver microsomes after 20 mins,COc1cc2ccc(Br)cc2cc1[C@@H](c1cccnc1OC)[C@@](O)(CCN(C)C)c1cccc2ccoc12,"(1S,2S)-2-(benzofuran-7-yl)-1-(7-bromo-3-methoxynaphthalen-2-yl)-4-(dimethylamino)-1-(2-methoxypyridin-3-yl)butan-2-ol",7.8,uM,=,0.8920946026904804,1,c1cncc([C@@H](Cc2cccc3ccoc23)c2ccc3ccccc3c2)c1
1104,1301274,10.6019/CHEMBL3137386,,,,DNDI: CYP Inhibition,O=C(C(c1ccc(Cl)cc1)c1cccnc1)N1CCN(c2ccc(C(F)(F)F)cc2)CC1,rac-2-(4-Chlorophenyl)-1-{4-[4-(trifluoromethyl)phenyl]piperazin-1-yl}-2-(pyridin-3-yl)ethanone,20.0,uM,=,1.3010299956639813,1,O=C(C(c1ccccc1)c1cccnc1)N1CCN(c2ccccc2)CC1
1105,2221809,10.1016/j.bmcl.2022.128625,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as substrate in presence of NADPH,CCC[C@H]1N(C(=O)c2c(C(F)(F)F)ccnc2OCCN(C)C)CCC[C@@]1(Oc1csc(C(F)(F)F)c1)C(=O)N1CCN(c2ccccc2OCCO)CC1,"((2R,3S)-1-(2-(2-(dimethylamino)ethoxy)-4-(trifluoromethyl)nicotinoyl)-2-propyl-3-(5-(trifluoromethyl)thiophen-3-yloxy)piperidin-3-yl)(4-(2-(2-hydroxyethoxy)phenyl)piperazin-1-yl)methanone",20.0,uM,=,1.3010299956639813,1,O=C(c1cccnc1)N1CCC[C@@](Oc2ccsc2)(C(=O)N2CCN(c3ccccc3)CC2)C1
1106,493017,10.1021/jm800851u,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,CCC(=O)Nc1cc(-c2cncc(OC)c2)nc(-n2nc(C)cc2C)n1,"N-[2-(3,5-Dimethyl-pyrazol-1-yl)-6-(5-methoxy-pyridin-3-yl)-pyrimidin-4-yl]-propionamide",17.0,uM,=,1.230448921378274,1,c1cncc(-c2ccnc(-n3cccn3)n2)c1
1107,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cccc(-c3ncccn3)c2)c1F,"US9150566, 49",21.0,uM,=,1.3222192947339193,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2ncccn2)c1
1108,770526,10.1021/jm200609t,,,,Inhibition of CYP3A4 using vivid green as substrate,Cc1c(-c2noc(-c3ccc(OC(C)C)c(C#N)c3)n2)ccc2c1CCN(C(CO)CO)C2,"5-(3-{2-[2-hydroxy-1-(hydroxymethyl)ethyl]-5-methyl-1,2,3,4-tetrahydro-6-isoquinolinyl}-1,2,4-oxadiazol-5-yl)-2-[(1-methylethyl)oxy]benzonitrile",8.4,uM,=,0.9242792860618816,1,c1ccc(-c2nc(-c3ccc4c(c3)CCNC4)no2)cc1
1109,814102,10.1016/j.bmcl.2012.03.014,,,,Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins,O[C@]1(c2ccc(F)c(F)c2)CCNC[C@@H]1c1onc(-c2ccccc2Cl)c1Br,"(3S,4R)-3-(4-bromo-3-(2-chlorophenyl)isoxazol-5-yl)-4-(3,4-difluorophenyl)piperidin-4-ol",18.0,uM,=,1.255272505103306,1,c1ccc(-c2cc([C@H]3CNCCC3c3ccccc3)on2)cc1
1110,1985638,10.1021/acsmedchemlett.0c00095,,,,Inhibition of human CYP3A4,Cc1nc2c(-c3nnc[nH]3)cc(-c3ccnc(C#N)c3)cc2n1-c1ccnc2c(F)ccc(F)c12,"rac-4-(1-(5,8-difluoroquinolin-4-yl)-2-methyl-4-(4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)picolinonitrile",24.0,uM,=,1.380211241711606,1,c1ccc2c(-n3cnc4c(-c5nnc[nH]5)cc(-c5ccncc5)cc43)ccnc2c1
1111,1933089,10.1021/acs.jmedchem.6b00028,,,,Inhibition of human CYP3A4 expressed in Escherichia coli pre-incubated for 5 mins before regenerating cofactor solution addition using Diethoxyfluorescein/7-Benzyloxyquinoline as substrate by fluorescence assay,c1cncc(-c2cc(N3CCC(CN4CCOCC4)CC3)nc(-c3ccncc3)n2)c1,4-((1-(6-(Pyridin-3-yl)-2-(pyridin-4-yl)pyrimidin-4-yl)-piperidin-4-yl)methyl)morpholine,0.1,uM,=,-1.0,0,c1cncc(-c2cc(N3CCC(CN4CCOCC4)CC3)nc(-c3ccncc3)n2)c1
1112,2048449,10.1016/j.bmc.2020.115734,,,,Inhibition of recombinant CYP3A4 (unknown origin) by fluorescence-based assay,COc1nc(-c2csc(Nc3c4c(nn3CCF)CCCC4)n2)ccc1-n1cnc(C)c1,"N-(2-(2-fluoroethyl)-4,5,6,7-tetrahydro-2H-indazol-3-yl)-4-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)thiazol-2-amine",1.0,uM,=,0.0,0,c1cn(-c2ccc(-c3csc(Nc4[nH]nc5c4CCCC5)n3)nc2)cn1
1113,813216,10.1016/j.bmcl.2012.01.125,,,,Inhibition of CYP3A4,Cc1noc(C)c1-c1ccc2c(Nc3ccccc3)c(C(N)=O)cnc2c1,"7-(3,5-dimethylisoxazol-4-yl)-4-(phenylamino)quinoline-3-carboxamide",17.0,uM,=,1.230448921378274,1,c1ccc(Nc2ccnc3cc(-c4cnoc4)ccc23)cc1
1114,572636,10.1021/jm9002445,,,,Inhibition of human CYP3A4 by microtiter plate assay,Cc1cc(-c2ncsc2Cl)c2cccc(OCc3c(C)ccnc3Cn3cccc(C(F)(F)F)c3=O)c2n1,1-((3-((4-(5-chlorothiazol-4-yl)-2-methylquinolin-8-yloxy)methyl)-4-methylpyridin-2-yl)methyl)-3-(trifluoromethyl)pyridin-2(1H)-one,0.3,uM,=,-0.5228787452803376,0,O=c1ccccn1Cc1ncccc1COc1cccc2c(-c3cscn3)ccnc12
1115,1366898,10.1021/jm500312x,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 15 mins by LC/MS/MS analysis,C=C[C@]1(C)C[C@@H](OC(=O)CS[C@@H]2CC[C@@H](N)C[C@H]2O)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O,BC-3781,4.43,uM,=,0.6464037262230695,1,O=C(CSC1CCCCC1)O[C@@H]1CCCC[C@@]23CCCC1[C@@H]2C(=O)CC3
1116,1353338,10.1021/ml400379x,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 30 mins preincubation by LC-MS/MS analysis in presence of NADPH,CNS(=O)(=O)Nc1cccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F,3-(2-Fluoro-3-(N-methylsulfamoylamino)benzyl)-4-methyl-7-(pyrimidin-2-yloxy)-2H-chromen-2-one,11.0,uM,=,1.0413926851582251,1,O=c1oc2cc(Oc3ncccn3)ccc2cc1Cc1ccccc1
1117,2118300,10.1021/acs.jmedchem.1c00847,,,,Reversible inhibition of CYP3A4 in human liver microsomes at 10 uM using midazolam as substrate preincubated for 10 mins followed by NADPH addition by LC/MS/MS analysis,C[C@@H]1Cc2c([nH]c3ccc(F)cc23)[C@@H](c2c(F)cc(NC3CN(CCCF)C3)cc2F)N1CC(F)(F)CO,"3-((1R,3R)-1-(2,6-Difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-6-fluoro-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol",2.7,uM,=,0.4313637641589873,1,c1ccc2c3c([nH]c2c1)[C@@H](c1ccc(NC2CNC2)cc1)NCC3
1118,804823,10.1016/j.bmcl.2011.12.080,,,,Time dependent inhibition of CYP3A4,COc1cc(C)c2nc3[nH]nc(C)c3c(C(O)c3cccnc3)c2c1,"rac-(6-methoxy-3,8-dimethyl-1H-pyrazolo[3,4-b]quinolin-4-yl)(pyridin-3-yl)methanol",2.7,uM,=,0.4313637641589873,1,c1cncc(Cc2c3ccccc3nc3[nH]ncc23)c1
1119,52064,10.1016/s0960-894x(03)00058-1,,,,Inhibitory activity against CYP450 3A4 isozyme,CCN(CC)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(=O)Cn1cc(Cc2cnn(C)c2)c(=O)nc1SCc1ccc(F)cc1,N-(2-Diethylamino-ethyl)-2-[2-(4-fluoro-benzylsulfanyl)-5-(1-methyl-1H-pyrazol-4-ylmethyl)-4-oxo-4H-pyrimidin-1-yl]-N-(4'-trifluoromethyl-biphenyl-4-ylmethyl)-acetamide,10.0,uM,=,1.0,1,O=C(Cn1cc(Cc2cn[nH]c2)c(=O)nc1SCc1ccccc1)NCc1ccc(-c2ccccc2)cc1
1120,489969,10.1021/jm800566m,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein substrate,CN(c1ccc2cn(C)nc2c1)c1ccnc(Nc2cccc(S(N)(=O)=O)c2)n1,3-({4-[Methyl(2-methyl-2H-indazol-6-yl)amino]-2-pyrimidinyl}amino)benzenesulfonamide,4.7,uM,=,0.6720978579357175,1,c1ccc(Nc2nccc(Nc3ccc4c[nH]nc4c3)n2)cc1
1121,552281,10.1016/j.bmcl.2008.04.036,,,,Inhibition of CYP3A4,COC(=O)CCCN[C@@H](Cn1c(=O)c(-c2ccccc2Cl)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1,"(R)-methyl 4-(2-(3-(2-fluoro-6-(trifluoromethyl)benzyl)-5-(2-chlorophenyl)-2,6-dioxo-2,3-dihydropyrimidin-1(6H)-yl)-1-phenylethylamino)butanoate",0.13,uM,=,-0.8860566476931633,0,O=c1c(-c2ccccc2)cn(Cc2ccccc2)c(=O)n1CCc1ccccc1
1122,52064,10.1016/s0960-894x(03)00058-1,,,,Inhibitory activity against CYP450 3A4 isozyme,CCN(CC)CCN(Cc1ccc(-c2ccc(Cl)cc2)cc1)C(=O)Cn1c(SCc2ccc(F)cc2)nc(=O)c2c1CCC2,"N-(4'-Chloro-biphenyl-4-ylmethyl)-N-(2-diethylamino-ethyl)-2-[2-(4-fluoro-benzylsulfanyl)-4-oxo-4,5,6,7-tetrahydro-cyclopentapyrimidin-1-yl]-acetamide",18.0,uM,=,1.255272505103306,1,O=C(Cn1c(SCc2ccccc2)nc(=O)c2c1CCC2)NCc1ccc(-c2ccccc2)cc1
1123,776115,10.1016/j.bmcl.2011.09.074,,,,Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(Cc1ccccc1)C2=O,"3-(aminomethyl)-6-benzyl-4-(2,4-dichlorophenyl)-2-methyl-5H-pyrrolo[3,4-b]pyridin-7(6H)-one",2.8,uM,=,0.4471580313422192,1,O=C1c2nccc(-c3ccccc3)c2CN1Cc1ccccc1
1124,804823,10.1016/j.bmcl.2011.12.080,,,,Time dependent inhibition of CYP3A4,Cc1cc(Cl)cc2c(C(O)c3cncn3C)c3c(C)n[nH]c3nc12,"rac-(6-chloro-3,8-dimethyl-1H-pyrazolo[3,4-b]quinolin-4-yl)(1-methyl-1H-imidazol-5-yl)methanol",0.8,uM,=,-0.0969100130080563,0,c1ccc2c(Cc3cnc[nH]3)c3cn[nH]c3nc2c1
1125,1558600,10.1016/j.bmcl.2015.06.020,,,,Inhibition of CYP3A4 (unknown origin) by fluorescence assay,COc1ccc(Cc2nc3c(o2)CCc2cc(-c4ccnc(C)c4)ccc2C3=O)cc1,"2-(4-Methoxy-benzyl)-7-(2-methyl-pyridin-4-yl)-9,10-dihydro-1-oxa-3-aza-benzo[f]azulen-4-one",0.3,uM,=,-0.5228787452803376,0,O=C1c2ccc(-c3ccncc3)cc2CCc2oc(Cc3ccccc3)nc21
1126,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1cc(C)c(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cccc(-n3nccn3)c2)c1,"US9150566, 75",15.0,uM,=,1.1760912590556811,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
1127,982809,10.1016/j.ejmech.2013.08.010,,,,Inhibition of CYP3A (unknown origin),CC#CCn1c(N2CCC[C@@H](N)C2)cc(=O)n(Cc2ccc3cc(F)ccc3n2)c1=O,"(R)-6-(3-Aminopiperidin-1-yl)-1-(but-2-yn-1-yl)-3-((6-fluoroquinolin-2-yl)methyl)pyrimidine-2,4(1H,3H)-dione",58.28,uM,=,1.765519543097953,1,O=c1cc(N2CCCCC2)[nH]c(=O)n1Cc1ccc2ccccc2n1
1128,487712,10.1016/j.bmcl.2008.05.104,,,,Inhibition of CYP3A4,COCCOC1CCN(c2cc(C)c3nc(-c4c(NC[C@@H](O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1,(S)-4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-3-(6-(4-(2-methoxyethoxy)piperidin-1-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one,0.0009,uM,=,-3.0457574905606752,0,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(N3CCCCC3)cc2[nH]1
1129,993439,10.6019/CHEMBL2448688,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,CS(=O)(=O)N(Cc1cnc[nH]1)c1ccc(-c2nc3ccccc3s2)cc1,,1.5,uM,=,0.1760912590556812,1,c1ccc2sc(-c3ccc(NCc4cnc[nH]4)cc3)nc2c1
1130,804823,10.1016/j.bmcl.2011.12.080,,,,Time dependent inhibition of CYP3A4,COc1cc(C)c2nc3[nH]nc(C)c3c(C(O)c3ccccn3)c2c1,"rac-(6-methoxy-3,8-dimethyl-1H-pyrazolo[3,4-b]quinolin-4-yl)(pyridin-2-yl)methanol",10.6,uM,=,1.0253058652647702,1,c1ccc(Cc2c3ccccc3nc3[nH]ncc23)nc1
1131,1745612,10.1016/j.bmcl.2017.10.010,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins in presence of NADPH by LC-MS/MS analysis,CCN[C@@H]1CCC=C(c2ccc(F)cc2)[C@H]1COc1cc(F)c(S(=O)(=O)Nc2nccs2)cc1Cl.Cl,(+/-)-5-chloro-4-((6-(ethylamino)-2-(4-fluorophenyl)cyclohex-2-enyl)methoxy)-2-fluoro-N-(thiazol-2-yl)benzenesulfonamide hydrochloride,21.6,uM,=,1.334453751150931,1,O=S(=O)(Nc1nccs1)c1ccc(OC[C@H]2CCCC=C2c2ccccc2)cc1
1132,790266,10.1021/jm2007062,,,,Inhibition of human CYP3A4,C[C@@H]1C(=O)N[C@H](Cc2ccc(F)cc2)C(=O)NCCCc2ccc(F)cc2OCCN[C@@H](C2CC2)C(=O)N1C,"(5S,8R,11R)-5-cyclopropyl-19-fluoro-11-(4-fluorobenzyl)-7,8-dimethyl-4,5,7,8,10,11,13,14,15,16-decahydro-2H-benzo[q][1,4,7,10,13]oxatetraazacyclooctadecine-6,9,12(3H)-trione",1.2,uM,=,0.0791812460476248,1,O=C1CNC(=O)[C@H](C2CC2)NCCOc2ccccc2CCCNC(=O)[C@@H](Cc2ccccc2)N1
1133,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCc5ccc(N(C)C)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, F-47",2.05,uM,=,0.3117538610557542,1,O=C(NCc1cccnc1)c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12
1134,857201,10.1021/jm200900q,,,,Inhibition of CYP3A4,N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(C(=O)Cc4ccncc4)CC3)cc2C2=CCCCC2)n1,4-Cyano-1H-imidazole-2-carboxylic Acid{2-Cyclohex-1-enyl-4-[1-(2-pyridin-4-yl-acetyl)-piperidin-4-yl]-phenyl}-amide,1.0,uM,=,0.0,0,O=C(Nc1ccc(C2CCN(C(=O)Cc3ccncc3)CC2)cc1C1=CCCCC1)c1ncc[nH]1
1135,634898,10.1016/j.bmcl.2010.04.052,,,,Inhibition of CYP3A4,CCOc1ccccc1C[C@H](c1ccccc1)N1CCNCC1,(R)-1-(2-(2-ethoxyphenyl)-1-phenylethyl)piperazine,30.0,uM,=,1.4771212547196624,1,c1ccc(C[C@H](c2ccccc2)N2CCNCC2)cc1
1136,2170798,10.1021/acs.jmedchem.0c02143,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated 10 mins in presence of NADPH by solid phase extraction mass spectrometry analysis,C[C@@]1(c2cc(NC(=O)c3ccc(Br)cn3)ccc2F)CO[C@@](C)(C(F)(F)F)C(N)=N1,"US8846658, 68",17.0,uM,=,1.230448921378274,1,O=C(Nc1cccc(C2COCC=N2)c1)c1ccccn1
1137,1558600,10.1016/j.bmcl.2015.06.020,,,,Inhibition of CYP3A4 (unknown origin) by fluorescence assay,Cc1cn(-c2ccc3c(c2)NC(=O)c2ccc(Cc4ccccc4)nc2N3)cn1,"2-benzyl-8-(4-methyl-1H-imidazol-1-yl)-6,11-dihydro-5H-benzo[b]pyrido[2,3-e][1,4]diazepin-5-one",0.15,uM,=,-0.8239087409443188,0,O=C1Nc2cc(-n3ccnc3)ccc2Nc2nc(Cc3ccccc3)ccc21
1138,438600,10.1016/j.bmcl.2007.03.048,,,,Inhibition of CYP3A4 in microsomes,Cc1cc(-c2ccccc2)cc2[nH]c(-c3c(N[C@H](CO)Cc4ccccc4)cc[nH]c3=O)nc12,(S)-4-(1-hydroxy-3-phenylpropan-2-ylamino)-3-(4-methyl-6-phenyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one,3.6,uM,=,0.5563025007672873,1,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(-c3ccccc3)cc2[nH]1
1139,1528565,,,,,"Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",CC(C)c1nc(CN(C)C(=O)N2CCC[C@@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,"US8987313, 42",0.25,uM,=,-0.6020599913279624,0,O=C(N[C@H](CC[C@H](Cc1ccccc1)NC(=O)[C@H]1CCCN1C(=O)NCc1cscn1)Cc1ccccc1)OCc1cncs1
1140,2048449,10.1016/j.bmc.2020.115734,,,,Inhibition of recombinant CYP3A4 (unknown origin) by fluorescence-based assay,COc1nc(-c2csc(Nc3cc(C(C)(C)C)nn3CC(F)(F)F)n2)ccc1-n1cnc(C)c1,"N-(3-(tert-butyl)-1-(2,2,2-trifluoroethyl)-1H-pyrazol-5-yl)-4-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)thiazol-2-amine",1.0,uM,=,0.0,0,c1cn(-c2ccc(-c3csc(Nc4ccn[nH]4)n3)nc2)cn1
1141,1488503,10.1124/dmd.112.045708,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis,CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1,"(R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide",26.0,uM,=,1.414973347970818,1,O=C(Cc1ccccc1)N(Cc1cccnc1)Cc1nc2ncccc2c(=O)n1-c1ccccc1
1142,2116571,10.1021/acsmedchemlett.1c00198,,,,Inhibition of CYP3A4 (unknown origin) expressed in baculovirus infected insect supersomes preincubated for 15 mins followed by addition of NADPH regenerating system by fluorescence based analysis,O=C(O)c1ccc2cc(N3CCC4(C=C(c5c(-c6c(Cl)cccc6Cl)noc5C5CC5)C4)CC3)ccc2n1,"6-(2-(5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)-7-azaspiro[3.5]non-1-en-7-yl)quinoline-2-carboxylic acid",1.9,uM,=,0.2787536009528289,1,C1=C(c2c(-c3ccccc3)noc2C2CC2)CC12CCN(c1ccc3ncccc3c1)CC2
1143,631458,10.1021/jm9013136,,,,Inhibition of human recombinant CYP3A4,COC(c1ccc(Cl)cc1)(c1ccc2c(c1)c(-c1c(F)cccc1F)cc(=O)n2C)c1cncn1C,"6-((4-chlorophenyl)(methoxy)(1-methyl-1H-imidazol-5-yl)methyl)-4-(2,6-difluorophenyl)-1-methylquinolin-2(1H)-one",0.275,uM,=,-0.5606673061697374,0,O=c1cc(-c2ccccc2)c2cc(C(c3ccccc3)c3cnc[nH]3)ccc2[nH]1
1144,1567870,10.1021/acs.jmedchem.5b01780,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis in presence of NADPH,CC1(C)CCC(C)(C)c2cc(C3(c4ccc(CCC(=O)O)cc4)SCCS3)ccc21,"3-{4-[2-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-1,3-dithiolan-2-yl]phenyl}propanoic Acid",7.5,uM,=,0.8750612633917001,1,c1ccc(C2(c3ccc4c(c3)CCCC4)SCCS2)cc1
1145,448320,10.1016/j.bmc.2007.05.069,,,,Inhibition of CYP3A4,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCOC)C(=O)C(CC)(CC)O2,"6-(2,4-diamino-6-ethyl-pyrimidin-5-yl)-2,2-diethyl-4-(3-methoxy-propyl)-4H-benzo[1,4]oxazin-3-one",3.0,uM,=,0.4771212547196624,1,O=C1COc2ccc(-c3cncnc3)cc2N1
1146,774749,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",CN(C)c1ccc(C(=C2C=CC(=[N+](C)C)C=C2)c2ccc(N(C)C)cc2)cc1.[Cl-],"{4-[Bis-(4-dimethylamino-phenyl)-methylene]-cyclohexa-2,5-dienylidene}-dimethyl-ammonium chloride",3.6337,uM,=,0.5603490688931061,1,[N+]=C1C=CC(=C(c2ccccc2)c2ccccc2)C=C1
1147,461436,10.1016/j.bmcl.2007.10.092,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,O=S(=O)(c1ccc(Cl)cc1)N1[C@H](C2CC2)CCC[C@@H]1C1(Cc2nc(CN3CC[C@@H](O)C3)no2)CC1,"(R)-1-((5-((1-((2R,6S)-1-(4-chlorophenylsulfonyl)-6-cyclopropylpiperidin-2-yl)cyclopropyl)methyl)-1,2,4-oxadiazol-3-yl)methyl)pyrrolidin-3-ol",0.6,uM,=,-0.2218487496163563,0,O=S(=O)(c1ccccc1)N1[C@H](C2CC2)CCC[C@@H]1C1(Cc2nc(CN3CCCC3)no2)CC1
1148,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N(C)CCN5CCOCC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, F-26",2.86,uM,=,0.456366033129043,1,O=C(NCCN1CCOCC1)c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12
1149,519907,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,Cc1cccc(C)c1CNc1cc(-c2c[nH]c(=O)[nH]c2=O)cn2c(C)c(C)nc12,"5-(8-(2,6-dimethylbenzylamino)-2,3-dimethylimidazo[1,2-a]pyridin-6-yl)pyrimidine-2,4(1H,3H)-dione",1.7,uM,=,0.2304489213782739,1,O=c1[nH]cc(-c2cc(NCc3ccccc3)c3nccn3c2)c(=O)[nH]1
1150,552281,10.1016/j.bmcl.2008.04.036,,,,Inhibition of CYP3A4,N[C@@H](Cn1c(=O)c(-c2ccc(COCC(=O)O)cc2)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1,"(R)-2-(4-(1-(2-fluoro-6-(trifluoromethyl)benzyl)-3-(2-amino-2-phenylethyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)benzyloxy)acetic acid",20.0,uM,=,1.3010299956639813,1,O=c1c(-c2ccccc2)cn(Cc2ccccc2)c(=O)n1CCc1ccccc1
1151,52069,10.1021/jm021012t,,,,Inhibition of human cytochrome P450 3A4,C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C,"30-Ethyl-33-(1-hydroxy-2-methyl-hex-4-enyl)-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31undecaaza-cyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone",6.5,uM,=,0.8129133566428556,1,O=C1CNC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)CN1
1152,1301325,10.6019/CHEMBL3137440,,,,DNDI: CYP Inhibition,CC(C)(C)C(=O)N1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1,"2,2-dimethyl-1-(4-(pyridin-3-yl(4-(trifluoromethyl)phenyl)amino)piperidin-1-yl)propan-1-one",1.9,uM,=,0.2787536009528289,1,c1ccc(N(c2cccnc2)C2CCNCC2)cc1
1153,803275,10.1016/j.bmcl.2011.12.130,,,,Inhibition of human CYP3A4 by luminescent assay,COc1cc(NCC2CCNCC2)nc2c1nnn2-c1cccc(OC(F)(F)F)c1,"7-methoxy-N-(piperidin-4-ylmethyl)-3-(3-(trifluoromethoxy)phenyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-amine",4.5,uM,=,0.6532125137753437,1,c1ccc(-n2nnc3ccc(NCC4CCNCC4)nc32)cc1
1154,583357,10.1021/jm900945d,,,,Inhibition of CYP3A4,CC(C)(C)Sc1c(CC(C)(C)C(=O)O)n(Cc2ccc(Cl)cc2)c2ccc(OCc3ccccn3)cc12,"3-[3-tert-Butylsulfanyl-1-(4-chloro-benzyl)-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid",0.0115,uM,=,-1.9393021596463884,0,c1ccc(Cn2ccc3cc(OCc4ccccn4)ccc32)cc1
1155,991614,10.1021/jm4008906,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(CC(=O)N1CCCCC1)C2,"(S)-3-(Aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-6-(2-oxo-2-(piperidin-1-yl)ethyl)-6,7-dihydro-5H-pyrrolo[3,4-b]-pyridin-5-one",8.2,uM,=,0.9138138523837168,1,O=C(CN1Cc2nccc(-c3ccccc3)c2C1=O)N1CCCCC1
1156,2241412,10.1016/j.ejmech.2021.113981,,,,Inhibition of CYP3A4 in human liver microsomes assessed as reduction in 6-beta-hydroxy-testosterone formation using testosterone as substrate preincubated for 20 mins in absence of NADPH followed by incubation with substrate for 10 mins by LC-MS/MS analysis,COC[C@H](Cc1ccccc1)NC[C@@H](O)c1cc(C(F)(F)F)nc2c(C(F)(F)F)cccc12,"(S)-1-(2,8-Bis(trifluoromethyl)quinolin-4-yl)-2-(((S)-1-methoxy-3-phenylpropan-2-yl)amino)ethan-1-ol",2.9,uM,=,0.4623979978989561,1,c1ccc(CCNCCc2ccnc3ccccc23)cc1
1157,537516,10.1021/jm8005096,,,,Inhibition of CYP3A4,COc1ccc(C2=NC(c3ccc(Cl)cc3F)C(C(=O)Nc3ccc4[nH]ncc4c3)=C(C)N2)cn1,"4-(4-chloro-2-fluorophenyl)-N-(1H-indazol-5-yl)-2-(6-methoxypyridin-3-yl)-6-methyl-1,4-dihydropyrimidine-5-carboxamide",2.5,uM,=,0.3979400086720376,1,O=C(Nc1ccc2[nH]ncc2c1)C1=CNC(c2cccnc2)=NC1c1ccccc1
1158,1534761,,,,,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",Fc1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1,"US9096593, P-2004",5.0,uM,=,0.6989700043360189,1,c1cncc(CNc2ccc(Cc3c[nH]c4ncccc34)cn2)c1
1159,874112,10.1021/jm300118s,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis,COCC(=O)N[C@@H](Cc1cccc(-c2nc(C)cs2)c1)[C@H](O)CN[C@H]1CC2(CCC2)Oc2ncc(CC(C)(C)C)cc21,"N-((2S,3R)-3-Hydroxy-1-(3-(4-methylthiazol-2-yl)phenyl)-4-((S)-6'-neopentyl-3',4'-dihydrospiro[cyclobutane-1,2'-pyrano-[2,3-b]pyridine]-4'-ylamino)butan-2-yl)-2-methoxyacetamide",0.1,uM,=,-1.0,0,c1cc(CCCCN[C@H]2CC3(CCC3)Oc3ncccc32)cc(-c2nccs2)c1
1160,1555052,10.1016/j.ejmech.2015.12.028,,,,Inhibition of CYP3A4 (unknown origin),Cl.NOCc1cccc(Cl)c1,O-(3-chlorobenzyl)hydroxylamine hydrochloride,15.0,uM,=,1.1760912590556811,1,c1ccccc1
1161,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)NC6CCCC6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, D-79",7.8,uM,=,0.8920946026904804,1,O=C(Nc1ccc(-c2c[nH]c3c(CN4C[C@@H]5N(C(=O)NCc6ccccc6)NCC(=O)N5[C@@H](Cc5ccccc5)C4=O)cccc23)cc1)NC1CCCC1
1162,1923489,10.1021/acs.jmedchem.6b00708,,,,Inhibition of CYP3A4 (unknown origin),C[C@@H](NC(=O)Nc1cc2[nH]nc(-c3cnn(C)c3)c2cn1)c1ccccc1,"US9023865, 29",0.38,uM,=,-0.4202164033831898,0,O=C(NCc1ccccc1)Nc1cc2[nH]nc(-c3cn[nH]c3)c2cn1
1163,52065,10.1021/jm0310129,,,,Inhibitory activity against cytochrome P450 3A4,COC(=O)c1ccc2[nH]c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)ncnc3c2c1,"4-{4-[2-(3,4-Difluoro-phenyl)-ethyl]-piperazin-1-yl}-5H-pyrimido[5,4-b]indole-8-carboxylic acid methyl ester",2.53,uM,=,0.4031205211758178,1,c1ccc(CCN2CCN(c3ncnc4c3[nH]c3ccccc34)CC2)cc1
1164,449485,10.1016/j.bmcl.2007.07.097,,,,Inhibition of microsomal CYP3A4,CNCC(=O)N[C@@H](CC(C)C)c1ccccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1,"N-((S)-1-(2-(4-((R)-3-(2,4-dichlorophenyl)-2-(2-oxopyrrolidin-1-yl)propanoyl)piperazin-1-yl)phenyl)-3-methylbutyl)-2-(methylamino)acetamide",2.3,uM,=,0.3617278360175928,1,O=C([C@@H](Cc1ccccc1)N1CCCC1=O)N1CCN(c2ccccc2)CC1
1165,2104896,10.1016/j.bmc.2021.116251,,,,Inhibition of human CYP3A4 expressed in insect supersomes assessed as reduction in 10-hydroxymidazolam formation using midazolam as substrate measured after 30 mins in presence of NADPH by LC-MS/MS analysis,N=C(NO)c1ccc2nc(-c3cccc(-c4cn5ccccc5n4)c3)[nH]c2c1,"N-hydroxy-2-(3-(imidazo[1,2-a]pyridine-2-yl)phenyl)-1H-benzo[d]imidazole-6-carboximidamide",0.233,uM,=,-0.632644078973981,0,c1cc(-c2cn3ccccc3n2)cc(-c2nc3ccccc3[nH]2)c1
1166,422039,10.1016/j.bmcl.2006.10.045,,,,Inhibition of CYP450 3A4,O=C(NO)c1ccc(-c2ccc(CNCc3ccccc3)cn2)s1,5-(5-((benzylamino)methyl)pyridin-2-yl)-N-hydroxythiophene-2-carboxamide,26.0,uM,=,1.414973347970818,1,c1ccc(CNCc2ccc(-c3cccs3)nc2)cc1
1167,542857,10.1021/jm801313t,,,,Inhibition of human recombinant CYP3A4,CO[C@](c1ccc(Cl)cc1)(c1ccc2c(c1)c(-c1cccc(Cl)c1C)cc(=O)n2C)c1cncn1C,4-(3-Chloro-2-methylphenyl)-6-((4-chlorophenyl)(methoxy)(1-methyl-1H-imidazol-5-yl)methyl)-1-methylquinolin-2(1H)-one,0.87,uM,=,-0.0604807473813814,0,O=c1cc(-c2ccccc2)c2cc(C(c3ccccc3)c3cnc[nH]3)ccc2[nH]1
1168,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",O=C(c1cc(Cl)ccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1,"US9150566, 30",17.0,uM,=,1.230448921378274,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
1169,804823,10.1016/j.bmcl.2011.12.080,,,,Time dependent inhibition of CYP3A4,Cc1cc(Cl)cc2c(C(O)c3ccncc3)c3c(C)n[nH]c3nc12,"rac-(6-chloro-3,8-dimethyl-1H-pyrazolo[3,4-b]quinolin-4-yl)(pyridin-4-yl)methanol",0.5,uM,=,-0.3010299956639812,0,c1ccc2c(Cc3ccncc3)c3cn[nH]c3nc2c1
1170,552281,10.1016/j.bmcl.2008.04.036,,,,Inhibition of CYP3A4,NCc1ccc(-c2cn(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](N)c3ccccc3)c2=O)cc1,"(R)-1-(2-fluoro-6-(trifluoromethyl)benzyl)-3-(2-amino-2-phenylethyl)-5-(4-(aminomethyl)phenyl)pyrimidine-2,4(1H,3H)-dione",9.1,uM,=,0.9590413923210936,1,O=c1c(-c2ccccc2)cn(Cc2ccccc2)c(=O)n1CCc1ccccc1
1171,52067,10.1021/jm0201924,,,,Inhibition of Cytochrome P450 3A4 as BFC substrate,CC(C)C[C@H](C=O)NC(=O)[C@@H](NS(=O)(=O)c1ccc(F)cc1)C(C)C,2-(4-Fluoro-benzenesulfonylamino)-N-(1-formyl-3-methyl-butyl)-3-methyl-butyramide,81.0,uM,=,1.9084850188786493,1,c1ccccc1
1172,479805,10.1016/j.bmcl.2008.03.078,,,,Inhibition of CYP3A4,CN(CC(=O)N1CCC[C@H](c2ccccc2)[C@@H]1CN1CCCC1)c1ccc(Cl)c(Cl)c1,"2-((3,4-dichlorophenyl)(methyl)amino)-1-((2R,3R)-3-phenyl-2-(pyrrolidin-1-ylmethyl)piperidin-1-yl)ethanone",1.4,uM,=,0.1461280356782379,1,O=C(CNc1ccccc1)N1CCC[C@H](c2ccccc2)[C@@H]1CN1CCCC1
1173,2151593,10.1021/acs.jmedchem.1c01157,,,,Inhibition of CYP3A4 in human liver microsome using midazolam as substrate,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCc2cn(CCCNC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](Cc3ccccc3)NC(=O)CCC(=O)NCCCCCC(=O)N(CCCC[C@H](NC(=O)N[C@@H](CCC(=O)O)C(=O)O)C(=O)O)Cc3cccc(Cl)c3)nn2)C(C)C)cc1)C(C)C,"(3S,7S,25S,28S)-25-benzyl-33-(4-(4-((S)-1-((S)-1-(4-((5S,8S,11S,12R)-11-sec-butyl-12-(2-((S)-2-((1R,2R)-3-((1S,2R)-1-hydroxy-1-phenylpropan-2-ylamino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-2-oxoethyl)-5,8-diisopropyl-4,10-dimethyl-3,6,9-trioxo-2,13-dioxa-4,7,10-triazatetradecyl)phenylamino)-1-oxo-5-ureidopentan-2-ylamino)-3-methyl-1-oxobutan-2-ylamino)-4-oxobutyl)-1H-1,2,3-triazol-1-yl)-12-(3-chlorobenzyl)-28-(4-hydroxybenzyl)-5,13,20,23,26,29-hexaoxo-4,6,12,19,24,27,30-heptaazatritriacontane-1,3,7-tricarboxylic acid",11.2,uM,=,1.0492180226701815,1,O=C(CCC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCCCn1cc(CCCC(=O)NCC(=O)NCC(=O)Nc2ccc(COC(=O)NCC(=O)NCC(=O)NCCCC(=O)N3CCC[C@H]3CCC(=O)NCCc3ccccc3)cc2)nn1)NCCCCCC(=O)NCc1ccccc1
1174,1750153,10.1016/j.bmcl.2017.12.040,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins with substrate followed by NADPH addition measured after 15 mins by LC/MS/MS analysis,CC(C)(C)Cn1ncn(-c2ccc(C(F)(F)C(O)(Cn3cnnn3)c3ccc(F)cc3F)nc2)c1=O,"4-(6-(2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(1H-tetrazol-1-yl)propyl)pyridin-3-yl)-2-neopentyl-2,4-dihydro-3H-1,2,4-triazol-3-one",50.0,uM,=,1.6989700043360187,1,O=c1[nH]ncn1-c1ccc(CC(Cn2cnnn2)c2ccccc2)nc1
1175,1534761,,,,,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",Cc1cnc2[nH]cc(Cc3cnc(NCc4cccc(N5CCOCC5)n4)nc3)c2c1,"US9096593, P-2081",5.0,uM,=,0.6989700043360189,1,c1cc(CNc2ncc(Cc3c[nH]c4ncccc34)cn2)nc(N2CCOCC2)c1
1176,813216,10.1016/j.bmcl.2012.01.125,,,,Inhibition of CYP3A4,COc1cc2c(Nc3cccc4cccnc34)c(C(N)=O)cnc2cc1-c1c(C)noc1C,"7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-4-(quinolin-8-ylamino)quinoline-3-carboxamide",3.9,uM,=,0.5910646070264992,1,c1cnc2c(Nc3ccnc4cc(-c5cnoc5)ccc34)cccc2c1
1177,1509544,10.1021/acs.jmedchem.5b00810,,,,Time dependent inhibition of CYP3A4 in human liver microsomes,COc1cc2c(cc1OC(C)C)[C@H](c1ccc(Cl)cc1)N(c1ccc(N(C)C[C@H]3CC[C@H](N(C)C)CC3)cc1)C(=O)C2,"(trans)-(S)-1-(4-Chloro-phenyl)-2-{4-[(4-dimethylamino-cyclohexylmethyl)-methyl-amino]-phenyl}-7-isopropoxy-6-methoxy-1,4-dihydro-2H-isoquinolin-3-one",9.4,uM,=,0.9731278535996988,1,O=C1Cc2ccccc2[C@H](c2ccccc2)N1c1ccc(NCC2CCCCC2)cc1
1178,1625990,10.1016/j.bmcl.2016.04.095,,,,Inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins after 30 secs by LC/MS/MS analysis,O=S(=O)(CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12)C[C@@H]1CCCN1,"(S)-2-((2-((4S,4aS,10bS)-10b-(4-chlorophenylsulfonyl)-7,10-difluoro-1,2,4,4a,5,10b-hexahydropyrano[3,4-c]chromen-4-yl)ethylsulfonyl)methyl)pyrrolidine",1.0,uM,=,0.0,0,O=S(=O)(CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccccc3)c3ccccc3OC[C@@H]12)C[C@@H]1CCCN1
1179,1450858,10.1021/jm5005336,,,,Inhibition of CYP3A4 (unknown origin) using BFC substrate after 30 mins by fluorescence assay,CN(C)Cc1ccc(/C=C/c2n[nH]c3cc(/C=C4/C(=O)Nc5ccccc54)ccc23)cc1,3-((3-((E)-4-((Dimethylamino)methyl)styryl)-1H-indazol-6-yl)-methylene)indolin-2-one,0.94,uM,=,-0.0268721464003013,0,O=C1Nc2ccccc2/C1=C\c1ccc2c(/C=C/c3ccccc3)n[nH]c2c1
1180,1447575,10.1016/j.bmcl.2014.05.068,,,,Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method,OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(F)cc2)cn1,"2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-(4-fluorophenyl)pyridin-2-yl)-3-(1H-tetrazol-1-yl)propan-2-ol",53.0,uM,=,1.7242758696007892,1,c1ccc(-c2ccc(CC(Cn3cnnn3)c3ccccc3)nc2)cc1
1181,1919651,,,,,"Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase",Cc1cscc1-c1ccc(F)nc1,2-Fluoro-5-(4-methyl-thiophen-3-yl)-pyridine,114.0,uM,=,2.0569048513364727,1,c1cncc(-c2ccsc2)c1
1182,820357,10.1021/jm300138g,,,,Inhibition of CYP3A4,CN[C@H]1CC[C@@H](c2c[nH]c3ccc(NC(=N)c4cccs4)cc32)CC1.Cl,cis-N-(3-(4-(methylamino)cyclohexyl)-1H-indol-5-yl)thiophene-2-carboximidamide hydrochloride,57.3,uM,=,1.75815462196739,1,N=C(Nc1ccc2[nH]cc(C3CCCCC3)c2c1)c1cccs1
1183,52065,10.1021/jm0310129,,,,Inhibitory activity against cytochrome P450 3A4,Cc1cc(C(N)=O)c2c3ncnc(N4CCN(CCc5ccc(F)c(F)c5)CC4)c3n(C)c2n1,"8-{4-[2-(3,4-Difluoro-phenyl)-ethyl]-piperazin-1-yl}-2,9-dimethyl-9H-1,5,7,9-tetraaza-fluorene-4-carboxylic acid amide",0.21,uM,=,-0.6777807052660807,0,c1ccc(CCN2CCN(c3ncnc4c3[nH]c3ncccc34)CC2)cc1
1184,1641852,,,,,"CYP Inhibition Assay: Incubation of phenacetin, diclofenac, dextromethorphan, mephenotoin, albendazole and testosterone with human liver microsomes in the presence of in each case eight different concentrations of a compound formula (B) (as potential inhibitor) is carried out on a incubator shaker at 37 C. Standard incubation mixtures comprise NADPH and substrates in 100 mM phosphate buffer (pH 7.4) in a total volume of 200 μl. Test compound are dissolved in acetonitrile. Incubated with pooled human liver microsomes at 37° C. for a defined time. The reactions are stopped by adding 100 μl of acetonitrile in which a suitable internal standard is always present. Precipitated proteins are removed by centrifugation, and the supernatants analyzed by LC-MS/MS.",Cc1ccc(C(=O)NC[C@H]2CN(c3ccc(N4CCOCC4=O)cc3)C(=O)O2)s1,5-Methyl-thiophene-2-carboxylic acid {(S)-2-oxo-3-[4-(3-oxo-morpholin-4-yl)-phenyl]-oxazolidin-5-ylmethyl}-amide,9.7,uM,=,0.9867717342662448,1,O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1cccs1
1185,1662700,10.1021/acs.jmedchem.6b01850,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH,COc1cc(-c2ccc(Cl)c(C)c2)c(F)cc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3cnccn3)ccc21,"US9212182, 691",3.6,uM,=,0.5563025007672873,1,O=c1ccc2cc(S(=O)(=O)Nc3cnccn3)ccc2n1-c1ccc(-c2ccccc2)cc1
1186,991614,10.1021/jm4008906,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,COC[C@H](C)N1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O,"3-(Aminomethyl)-4-((S)-2,4-dichlorophenyl)-6-((S)-1-methoxypropan-2-yl)-2-methyl-6,7-dihydropyrrolo[3,4-b]pyridin-5-one",13.0,uM,=,1.1139433523068367,1,O=C1NCc2nccc(-c3ccccc3)c21
1187,443559,10.1016/j.bmc.2007.03.014,,,,Inhibition of human CYP3A4 expressed in insect microsome using 7-benzyloxy-4-trifluoromethylcoumarin substrate after 30 mins,COc1ccc(CCN(C)CCNC(=O)c2ccccc2NC(=O)c2cnc3ccccc3c2)cc1OC,"N-(2-((2-((3,4-dimethoxyphenethyl)(methyl)amino)ethyl)carbamoyl)phenyl)quinoline-3-carboxamide",1.62,uM,=,0.2095150145426309,1,O=C(Nc1ccccc1C(=O)NCCNCCc1ccccc1)c1cnc2ccccc2c1
1188,1577486,10.1021/acs.jmedchem.5b01712,,,,Inhibition of CYP3A4 (unknown origin),O=C(CNc1ccc(-c2ccc(NC(=O)C3CC3)nc2)cc1)Nc1ccc(CN2CCNCC2)c(C(F)(F)F)c1,N-(5-(4-((2-Oxo-2-((4-(piperazin-1-ylmethyl)-3-(trifluoromethyl)-phenyl)amino)ethyl)-amino)phenyl)pyridin-2-yl)-cyclopropanecarboxamide,1.1,uM,=,0.041392685158225,1,O=C(CNc1ccc(-c2ccc(NC(=O)C3CC3)nc2)cc1)Nc1ccc(CN2CCNCC2)cc1
1189,674732,10.1016/j.bmcl.2010.09.029,,,,Inhibition of CYP3A4,CN1C(=O)[C@@](c2ccc(OC(F)F)cc2)(c2cccc(C#CC3CC3)c2)N=C1N,(R)-2-amino-4-(3-(cyclopropylethynyl)phenyl)-4-(4-(difluoromethoxy)phenyl)-1-methyl-1H-imidazol-5(4H)-one,0.1,uM,=,-1.0,0,O=C1NC=N[C@]1(c1ccccc1)c1cccc(C#CC2CC2)c1
1190,2123617,10.1021/acs.jmedchem.1c01015,,,,Inhibition of CYP3A4M in human liver microsomes using midazolam as substrate in presence of NADPH incubated for 10 mins by LC-MS/MS analysis,CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,LEVOKETOCONAZOLE,0.0269,uM,=,-1.570247719997592,0,c1ccc([C@]2(Cn3ccnc3)OC[C@@H](COc3ccc(N4CCNCC4)cc3)O2)cc1
1191,495543,10.1021/jm801332q,,,,Inhibition of human CYP3A4 expressed in Escherichia coli using 7BQ substrate by time dependent inhibition assay,C[C@H]1CN(Cc2ccc(CCC(=O)N3CCC(Nc4cccc(F)c4)CC3)cc2)CCN1,N-(3-Fluorophenyl)-1-[3-(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)propanoyl]-4-piperidinamine,18.0,uM,=,1.255272505103306,1,O=C(CCc1ccc(CN2CCNCC2)cc1)N1CCC(Nc2ccccc2)CC1
1192,51903,10.1021/jm020557k,,,,Concentration required to inhibit cytochrome P450 3A4.,CCCCOc1ccc(-c2ccns2)cc1,5-(4-Butoxy-phenyl)-isothiazole,22.9,uM,=,1.359835482339888,1,c1ccc(-c2ccns2)cc1
1193,834635,10.1016/j.bmcl.2012.07.019,,,,Inhibition of CYP3A4,N[C@@H](CC(=O)N1CCN(C(=O)c2cccc(C(=O)O)c2)CC1)Cc1cc(F)c(F)cc1F,"(R)-3-(4-(3-amino-4-(2,4,5-trifluorophenyl)butanoyl)piperazine-1-carbonyl)benzoic acid",1.0,uM,=,0.0,0,O=C(CCCc1ccccc1)N1CCN(C(=O)c2ccccc2)CC1
1194,834929,10.1016/j.bmcl.2012.07.020,,,,Inhibition of CYP3A4,O=S(=O)(c1ccc2[nH]c(SCc3cccc(Cl)c3)nc2c1)N1CCOCC1,SID22410576,1.9,uM,=,0.2787536009528289,1,O=S(=O)(c1ccc2[nH]c(SCc3ccccc3)nc2c1)N1CCOCC1
1195,2048449,10.1016/j.bmc.2020.115734,,,,Inhibition of recombinant CYP3A4 (unknown origin) by fluorescence-based assay,CCn1nc2c(c1Nc1nc(-c3ccc(-n4cnc(C)c4)c(OC)n3)cs1)C(C)CC2(C)C,"(+/-)-N-(2-ethyl-4,6,6-trimethyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-4-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)thiazol-2-amine",1.5,uM,=,0.1760912590556812,1,c1cn(-c2ccc(-c3csc(Nc4[nH]nc5c4CCC5)n3)nc2)cn1
1196,1336778,10.1021/jm401911v,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,CC(C)(C)S(=O)(=O)C[C@H](C1CC1)N1C(=O)[C@@](C)(CC(N)=O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1,"2-((3R,5R,6S)-1-((S)-2-(tert-Butylsulfonyl)-1-cyclopropylethyl)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-3-methyl-2-oxopiperidin-3-yl)-acetamide",1.2,uM,=,0.0791812460476248,1,O=C1CC[C@H](c2ccccc2)[C@@H](c2ccccc2)N1CC1CC1
1197,2166204,,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate,COc1ccc(-c2cc(Nc3ccnc(N4CCOCC4)n3)on2)cc1,3-(4-methoxyphenyl)-N-(2-morpholinopyrimidin-4-yl)isoxazol-5-amine,8.59,uM,=,0.9339931638312424,1,c1ccc(-c2cc(Nc3ccnc(N4CCOCC4)n3)on2)cc1
1198,597664,10.1021/jm900843g,,,,Inhibition of recombinant CYP3A4 using 7-benzyloxyresorufin as substrate,C[C@@H]1CN(C(=O)c2ccccc2)CCN1C(=O)C(=O)c1c[nH]c2ccncc12,"(R)-1-(4-Benzoyl-2-methylpiperazin-1-yl)-2-(1H-pyrrolo[3,2-c]-pyridin-3-yl)ethane-1,2-dione",9.3,uM,=,0.9684829485539352,1,O=C(C(=O)N1CCN(C(=O)c2ccccc2)CC1)c1c[nH]c2ccncc12
1199,487712,10.1016/j.bmcl.2008.05.104,,,,Inhibition of CYP3A4,Cc1cc(N2CCC(NC(=O)C3CC3)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,"(S)-N-(1-(2-(4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-2-oxo-1,2-dihydropyridin-3-yl)-7-methyl-3H-benzo[d]imidazol-5-yl)piperidin-4-yl)cyclopropanecarboxamide",0.0007,uM,=,-3.154901959985743,0,O=C(NC1CCN(c2ccc3nc(-c4c(NCCc5ccccc5)cc[nH]c4=O)[nH]c3c2)CC1)C1CC1
1200,342118,10.1021/jm051106d,,,,Inhibitory activity against CYP3A4,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@H](C)O)c(C)c34)ccc2[nH]1,"(S)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-ol",4.0,uM,=,0.6020599913279624,1,c1cc2c(Oc3ccc4[nH]ccc4c3)ncnn2c1
1201,2103815,10.1016/j.bmcl.2021.128010,,,,Time dependent inhibition of CYP3A4 (unknown origin) measured at 30 mins,Nc1cc(Cc2ccn(-c3cccc(-c4ccccc4)c3)n2)c2nn[nH]c2n1,"7-((1-(biphenyl-3-yl)-1H-pyrazol-3-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-amine",0.0070999999999999,uM,=,-2.148741651280925,0,c1ccc(-c2cccc(-n3ccc(Cc4ccnc5[nH]nnc45)n3)c2)cc1
1202,1984166,10.1016/j.bmc.2020.115349,,,,Inhibition of human full length CYP3A4 assessed using 7-benzyloxy-4 (trifluoromethyl)coumarin as substrate preincubated for 2 mins followed by substrate addition and measured for 2 mins by fluorometric analysis,CC(C)(C)OC(=O)N[C@@H](CS[C@@H](Cc1ccccc1)C(=O)NCCc1cccnc1)Cc1c[nH]c2ccccc12,tert-butyl N-[(1R)-1-[[(1S)-1-benzyl-2-oxo-2-[2-(3-pyridyl)ethylamino]ethyl]sulfanylmethyl]-2-(1H-indol-3-yl)ethyl]carbamate,0.173,uM,=,-0.7619538968712046,0,O=C(NCCc1cccnc1)[C@H](Cc1ccccc1)SCCCc1c[nH]c2ccccc12
1203,522831,10.1021/jm900257b,,,,Inhibition of human CYP3A4,CCOC(=O)[C@H](Cc1ccc(NC(=O)c2c(Cl)cncc2Cl)cc1)NC(=O)[C@@H]1C[C@@H](NC2CCC2)CN1S(=O)(=O)c1cccc(C#N)c1,"(S)-ethyl 2-((2S,4R)-1-(3-cyanophenylsulfonyl)-4-(cyclobutylamino)pyrrolidine-2-carboxamido)-3-(4-(3,5-dichloroisonicotinamido)phenyl)propanoate",1.7,uM,=,0.2304489213782739,1,O=C(Nc1ccc(CCNC(=O)[C@@H]2C[C@@H](NC3CCC3)CN2S(=O)(=O)c2ccccc2)cc1)c1ccncc1
1204,828928,10.1016/j.bmcl.2012.06.022,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,CCc1nc2ccc(C(=O)N(CC(C)C)C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1,"Thiazol-5-ylmethyl(2S,3R)-4-(2-ethyl-N-isobutylbenzo[d]oxazole-6-carboxamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate",0.039,uM,=,-1.408935392973501,0,O=C(N[C@H](CCNC(=O)c1ccc2ncoc2c1)Cc1ccccc1)OCc1cncs1
1205,51903,10.1021/jm020557k,,,,Concentration required to inhibit cytochrome P450 3A4.,CCCCOc1ccc(-n2ccnc2)cc1,1-(4-Butoxy-phenyl)-1H-imidazole,0.348,uM,=,-0.4584207560534191,0,c1ccc(-n2ccnc2)cc1
1206,834929,10.1016/j.bmcl.2012.07.020,,,,Inhibition of CYP3A4,CCS(=O)(=O)c1ccc2[nH]c(-c3cncc(-c4ccccc4)c3)nc2c1,5-(ethylsulfonyl)-2-(5-phenylpyridin-3-yl)-1H-benzo[d]imidazole,7.8,uM,=,0.8920946026904804,1,c1ccc(-c2cncc(-c3nc4ccccc4[nH]3)c2)cc1
1207,619265,10.1016/j.bmcl.2009.07.002,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate,Cc1cccc(C)c1CNc1nc(N2CCOCC2=O)cc2c(C)c(C)n(CCO)c12,"4-(7-(2,6-dimethylbenzylamino)-1-(2-hydroxyethyl)-2,3-dimethyl-1H-pyrrolo[2,3-c]pyridin-5-yl)morpholin-3-one",11.0,uM,=,1.0413926851582251,1,O=C1COCCN1c1cc2cc[nH]c2c(NCc2ccccc2)n1
1208,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1ccc(-n2nccn2)c(C(=O)N2C[C@@H](C)OC[C@H]2Cc2cc(-n3nccn3)ccc2F)c1,"US9150566, 115",24.0,uM,=,1.380211241711606,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
1209,2214899,10.1016/j.ejmech.2022.114161,,,,Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone as substrate by LC-MS/MS analysis,C[C@@H](c1nc(-c2ccc(C#N)cc2)cs1)[C@](O)(Cn1cncn1)c1ccc(F)cc1F,"4-{2-[(1R,2R)-2-(2,4-Difluoro-phenyl)-2-hydroxy-1-methyl-3-[1,2,4]triazol-1-yl-propyl]-thiazol-4-yl}-benzonitrile",1.01,uM,=,0.0043213737826425,1,c1ccc(-c2csc(CC(Cn3cncn3)c3ccccc3)n2)cc1
1210,753597,10.1016/j.bmcl.2011.05.013,,,,Time dependent inhibition of CYP3A4 assessed as conversion of testosterone to 6-beta-hydroxytestosterone preincubated for 30 mins,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccn(C)c(=O)c2)C2CC2)cc(Br)c1C,"(3R,4S)-N-(3-bromo-5-(3-methoxypropyl)-4-methylbenzyl)-N-cyclopropyl-4-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)piperidine-3-carboxamide",16.0,uM,=,1.2041199826559248,1,O=C([C@H]1CNCC[C@@H]1c1cc[nH]c(=O)c1)N(Cc1ccccc1)C1CC1
1211,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",COc1cc(C(=O)N2CCOC[C@H]2Cc2cccc(-n3nccn3)c2)c(-n2nccn2)cc1C,"US9150566, 37",17.0,uM,=,1.230448921378274,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
1212,688021,10.1016/j.bmcl.2010.10.101,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins,CCn1c(=O)n(C)c(=O)c2c1cc(N1CCC[C@@](C)(N)C1)n2Cc1cc(F)ccc1C#N.Cl,"(R)-2-((6-(3-amino-3-methylpiperidin-1-yl)-1-ethyl-3-methyl-2,4-dioxo-3,4-dihydro-1H-pyrrolo[3,2-d]pyrimidin-5(2H)-yl)methyl)-4-fluorobenzonitrile hydrochloride",9.4,uM,=,0.9731278535996988,1,O=c1[nH]c(=O)c2c(cc(N3CCCCC3)n2Cc2ccccc2)[nH]1
1213,823023,10.1016/j.bmcl.2012.04.118,,,,Inhibition of CYP3A4,O=C(Nc1ccc(Cl)c(Cl)c1)N1CCN(C[C@@H]2CCCN(C3CC3)C2)CC1,"(S)-4-((1-cyclopropylpiperidin-3-yl)methyl)-N-(3,4-dichlorophenyl)piperazine-1-carboxamide",1.6,uM,=,0.2041199826559248,1,O=C(Nc1ccccc1)N1CCN(C[C@@H]2CCCN(C3CC3)C2)CC1
1214,827974,10.1016/j.bmcl.2012.05.087,,,,Inhibition of CYP3A4 using testosterone as substrate,CCCCNC(=O)c1ccc(OC)c(CSc2nc3cc(F)ccc3n2CC(=O)O)c1,2-(2-(5-(butylcarbamoyl)-2-methoxybenzylthio)-5-fluoro-1H-benzo[d]imidazol-1-yl)acetic acid,7.0,uM,=,0.8450980400142568,1,c1ccc(CSc2nc3ccccc3[nH]2)cc1
1215,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)Nc6cnccn6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, D-83",4.61,uM,=,0.6637009253896482,1,O=C(Nc1ccc(-c2c[nH]c3c(CN4C[C@@H]5N(C(=O)NCc6ccccc6)NCC(=O)N5[C@@H](Cc5ccccc5)C4=O)cccc23)cc1)Nc1cnccn1
1216,1297866,10.1021/jm401532g,,,,Inhibition of human CYP3A4 expressed in Escherichia coli using 7-benzyloxyquinoline as substrate,CC(=O)O.O=S(=O)(c1cccc(CCCCOCCCCCCNC[C@H](O)c2ccc(O)c(CO)c2)c1)C1CCCC1,4-((1R)-2-{[6-({4-[3-(Cyclopentylsulfonyl)phenyl]butyl}oxy)-hexyl]amino}-1-hydroxyethyl)-2-(hydroxymethyl)phenol acetate salt,3.8,uM,=,0.5797835966168101,1,O=S(=O)(c1cccc(CCCCOCCCCCCNCCc2ccccc2)c1)C1CCCC1
1217,1364172,10.1021/ml500019s,,,,Inhibition of CYP3A4 (unknown origin) co-incubated with enzyme,COCCOc1ccccc1N1CCN(C(=O)[C@]2(Oc3ccc(C(F)(F)F)cc3)CCCN(C(=O)c3cnccc3C(F)(F)F)[C@@H]2CCO)CC1.Cl,"((2R,3S)-2-(2-hydroxyethyl)-1-(4-(trifluoromethyl)nicotinoyl)-3-(4-(trifluoromethyl)phenoxy)piperidin-3-yl)(4-(2-(2-methoxyethoxy)phenyl)piperazin-1-yl)methanone hydrochloride",13.3,uM,=,1.1238516409670858,1,O=C(c1cccnc1)N1CCC[C@@](Oc2ccccc2)(C(=O)N2CCN(c3ccccc3)CC2)C1
1218,742805,10.1016/j.bmc.2011.02.009,,,,Inhibition of human CYP3A4 after 30 mins,CC(C)C(O)(c1ccc(-c2ccc(Cl)cc2)cc1)c1c[nH]cn1,"rac-1-(4'-Chloro[1,1'-biphenyl]-4-yl)-1-(1H-imidazol-4-yl)-2-methyl-1-propanol",7.6,uM,=,0.8808135922807914,1,c1ccc(-c2ccc(Cc3c[nH]cn3)cc2)cc1
1219,321500,10.1016/j.bmcl.2005.06.056,,,,Inhibition against Cytochrome P450 3A4 prepared from baculovirus-infected insect cells using 7-benzyloxy- 4-trifluoromethylcoumarin,NC(=O)Cn1c(=O)c(CCO)c(-c2cc(Cl)ccc2O)c2cc(C(F)(F)F)ccc21,2-[4-(5-Chloro-2-hydroxy-phenyl)-3-(2-hydroxy-ethyl)-2-oxo-6-trifluoromethyl-2H-quinolin-1-yl]-acetamide,26.0,uM,=,1.414973347970818,1,O=c1cc(-c2ccccc2)c2ccccc2[nH]1
1220,1290453,10.1016/j.bmcl.2014.01.026,,,,Inhibition of CYP3A4 (unknown origin) compound co-incubated with substrate,COCCOc1ccccc1N1CCN(C(=O)C2(Oc3ccc(C(F)(F)F)cc3)CCCN(C(=O)c3cnccc3C(F)(F)F)C2)CC1.Cl,(4-(2-(2-methoxyethoxy)phenyl)piperazin-1-yl)(1-(4-(trifluoromethyl)nicotinoyl)-3-(4-(trifluoromethyl)phenoxy)piperidin-3-yl)methanone hydrochloride,4.9,uM,=,0.6901960800285137,1,O=C(c1cccnc1)N1CCCC(Oc2ccccc2)(C(=O)N2CCN(c3ccccc3)CC2)C1
1221,1289880,10.1021/jm401642q,,,,Inhibition of recombinant human CYP3A4,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2cc(F)ccc21,"2-[2-(5-Fluoro-2,3-dihydroindol-1-yl)-2-oxoethyl]-6-morpholin-4-yl-3H-pyrimidin-4-one",40.0,uM,=,1.6020599913279625,1,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2ccccc21
1222,355280,10.1016/j.bmcl.2006.02.020,,,,Inhibition of CYP3A4,CCN(C)[C@H](C)[C@@H](c1ccc2cc(OCC(C)(C)C(=O)O)ccc2c1)n1ccnc1,"3-(6-((1R,2R)-2-(ethyl(methyl)amino)-1-(1H-imidazol-1-yl)propyl)naphthalen-2-yloxy)-2,2-dimethylpropanoic acid",1.7,uM,=,0.2304489213782739,1,c1ccc2cc(Cn3ccnc3)ccc2c1
1223,2110160,10.1016/j.ejmech.2021.113428,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis,CCN(C(=O)c1cc(C(C)C)c(O)cc1O)c1cccnc1,"N-Ethyl-2,4-dihydroxy-5-isopropyl-N-(pyridin-3-yl)benzamide",1.15,uM,=,0.0606978403536116,1,O=C(Nc1cccnc1)c1ccccc1
1224,1584799,10.1021/acs.jmedchem.6b00030,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 5 mins by LC-MS analysis,CCOC1(c2ccccc2)SC=C(C)n2c1noc2=O,"8-Ethoxy-5-methyl-8-phenyl-8H-[1,2,4]oxadiazolo[3,4-c][1,4]-thiazin-3-one",19.1,uM,=,1.2810333672477277,1,O=c1onc2n1C=CSC2c1ccccc1
1225,1436762,10.1021/ml500187a,,,,Inhibition of human recombinant CYP3A4 incubated for 5 mins by fluorescence assay,CC(C)N(Cc1ccc(Cl)c(Cl)c1)CC1CNC1.Cl,"N-(azetidin-3-ylmethyl)-N-(3,4-dichlorobenzyl)propan-2-amine hydrochloride",1.1,uM,=,0.041392685158225,1,c1ccc(CNCC2CNC2)cc1
1226,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",O=C(c1cc(Cl)ccc1-n1nccn1)N1CCOC[C@H]1Cc1cc(-c2ncccn2)ccc1F,"US9150566, 159",17.0,uM,=,1.230448921378274,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2ncccn2)c1
1227,619265,10.1016/j.bmcl.2009.07.002,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate,Cc1cccc(C)c1CNc1nccc2c1cc(C)n2C,"N-(2,6-dimethylbenzyl)-1,2-dimethyl-1H-pyrrolo[3,2-c]pyridin-4-amine",4.3,uM,=,0.6334684555795865,1,c1ccc(CNc2nccc3[nH]ccc23)cc1
1228,434712,10.1021/jm070104l,,,,Inhibition of human CYP3A4,COc1ccc2nc(N3CCC[C@@H](N)C3)n(Cc3ccccc3C#N)c(=O)c2c1,(R)-2-((2-(3-aminopiperidin-1-yl)-6-methoxy-4-oxoquinazolin-3(4H)-yl)methyl)benzonitrile,0.2,uM,=,-0.6989700043360187,0,O=c1c2ccccc2nc(N2CCCCC2)n1Cc1ccccc1
1229,861307,10.1021/jm201711b,,,,Inhibition of human CYP3A4,O=C(c1ccc(F)c(O)c1)c1nc2ccc(O)cc2s1,"(4-Fluoro-3-hydroxyphenyl)(6-hydroxy-1,3-benzothiazol-2-yl)methanone",54.0,uM,=,1.7323937598229686,1,O=C(c1ccccc1)c1nc2ccccc2s1
1230,642395,10.1021/jm100400a,,,,Inhibition of CYP3A4 expressed in baculovirus infected insect microsomes,CC(C)=C(c1ccncc1)c1ccc(-c2cccc(N)c2)cc1,4'-(2-methyl-1-(pyridin-4-yl)prop-1-enyl)biphenyl-3-amine,1.33,uM,=,0.1238516409670858,1,C=C(c1ccncc1)c1ccc(-c2ccccc2)cc1
1231,1644927,10.1021/acs.jmedchem.6b01706,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis,COc1cccc(C2=NC(C(F)(F)F)(C(F)(F)F)c3c(n(-c4ccc(Cl)cc4)c(=O)[nH]c3=O)N2)c1,"1-(4-chlorophenyl)-7-(3-methoxyphenyl)-5,5-bis(trifluoromethyl)-5,8-dihydropyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione",16.44,uM,=,1.2159018132040316,1,O=c1[nH]c(=O)n(-c2ccccc2)c2c1CN=C(c1ccccc1)N2
1232,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(NCCCN6CCCC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1,"US8940739, G-32",2.57,uM,=,0.4099331233312945,1,O=C(Nc1ccc(NCCCN2CCCC2)nc1)c1c[nH]c2c(CN3CC4N(C(=O)NCc5ccccc5)NCC(=O)N4C(Cc4ccccc4)C3=O)cccc12
1233,2243943,10.1021/acs.jmedchem.1c02057,,,,Inhibition of CYP3A4M in human liver microsomes in presence of NADPH incubated for 3 to 20 mins by LC-MS/MS analysis,CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,SID144204227,0.0355,uM,=,-1.449771646944906,0,c1ccc([C@@]2(Cn3ccnc3)OC[C@H](COc3ccc(N4CCNCC4)cc3)O2)cc1
1234,1474033,10.1021/jm501218e,,,,Inhibition of human recombinant CYP3A4 assessed as metabolism of 7-benzyloxy-4-trifluoromethylcoumarin to HFC after 30 mins by fluorescence assay,CC/C(=C(/c1ccc(O)cc1)c1ccc(OCCN)cc1)c1ccc(O)cc1,4'-Hydroxynorendoxifen,1.88,uM,=,0.2741578492636798,1,C(=C(c1ccccc1)c1ccccc1)c1ccccc1
1235,774749,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12,SID856021,0.5,uM,=,-0.3010299956639812,0,O=C(NC1OC2[C@@H]3CCCN3C(=O)CN2C1=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2NC1
1236,1512960,10.1021/acsmedchemlett.5b00117,,,,Inhibition of CYP3A4 (unknown origin),Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)[C@@H]3C)n1,"(R)-(8-Methyl-3-(3-methyl-1,2,4-thiadiazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(thiophen-2-yl)phenyl)-methanone",79.0,uM,=,1.8976270912904407,1,O=C(c1ccc(-c2cccs2)cc1)N1CCn2c(nnc2-c2ncns2)C1
1237,473932,10.1021/jm701121y,,,,Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay,Brc1ccc(-n2c(SCc3ccccc3)nnc2-c2ccncc2)cc1,"4-(5-(benzylthio)-4-(4-bromophenyl)-4H-1,2,4-triazol-3-yl)pyridine",1.3,uM,=,0.1139433523068367,1,c1ccc(CSc2nnc(-c3ccncc3)n2-c2ccccc2)cc1
1238,1291572,10.1016/j.bmcl.2013.12.058,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,CCC[C@@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)NC(=O)[C@@H](NC(=O)N(C)Cc1csc(C(C)C)n1)C(C)C,"Thiazol-5-ylmethyl(2R,5S)-5-((S)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-3-methylbutanamido)-1-phenyloctan-2-ylcarbamate",0.13,uM,=,-0.8860566476931633,0,O=C(CNC(=O)NCc1cscn1)NCCC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1
1239,1434728,10.1021/jm5010539,,,,Inhibition of human recombinant CYP3A4 expressed in Escherichia coli bactosomes using diethoxyfluorescein as substrate after 10 mins by fluorescence assay,CC(=O)N1c2ccc(-c3ccc(CN4CCCCC4)cc3)cc2[C@H](Nc2ccccc2)C[C@@H]1C,"rac-cis-1-((2S*,4R*)-2-Methyl-4-(phenylamino)-6-(4-(piperidin-1-ylmethyl)phenyl)-3,4-dihydroquinolin-1(2H)-yl)ethanone",2.0,uM,=,0.3010299956639812,1,c1ccc(N[C@@H]2CCNc3ccc(-c4ccc(CN5CCCCC5)cc4)cc32)cc1
1240,1614026,10.1016/j.bmcl.2016.09.043,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 1'-hydroxymidazolam metabolite formation using midazolam as substrate incubated for 10 mins by HPLC-MS method,Cn1c(NCCc2ccc(Oc3ccc(Cl)cc3)cc2)nc2cc(Cl)ccc2c1=O,7-Chloro-2-{2-[4-(4-chloro-phenoxy)-phenyl]-ethylamino}-3-methyl-3H-quinazolin-4-one,14.0,uM,=,1.146128035678238,1,O=c1[nH]c(NCCc2ccc(Oc3ccccc3)cc2)nc2ccccc12
1241,1288280,10.1016/j.bmcl.2013.12.057,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,CC(=O)NCC[C@H](NC(=O)N(C)Cc1csc(C(C)C)n1)C(=O)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1,"Thiazol-5-ylmethyl(2R,5R)-5-((S)-4-acetamido-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)butanamido)-1,6-diphenylhexan-2-ylcarbamate",0.15,uM,=,-0.8239087409443188,0,O=C(CNC(=O)NCc1cscn1)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
1242,1972830,10.1021/acsmedchemlett.9b00612,,,,Inhibition of human recombinant CYP3A4 expressed in insect cell microsomes in presence of NADPH by fluorescence assay,COCCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(C#Cc4cnc5cccnn45)c3)cc2C2CC2)CC1,"N-[3-cyclopropyl-4-[[4-(2-methoxyethyl)piperazin-1-yl]methyl]phenyl]-3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methylbenzamide",13.5,uM,=,1.130333768495006,1,O=C(Nc1ccc(CN2CCNCC2)c(C2CC2)c1)c1cccc(C#Cc2cnc3cccnn23)c1
1243,1446329,10.1021/ml500387y,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2cc(-c3ccccc3)ncc2[nH]1)C(F)(F)F,"1,1,1-trifluoro-4-(5-fluoro-2-methylphenyl)-4-methyl-2-((5-phenyl-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)pentan-2-ol",3.0,uM,=,0.4771212547196624,1,c1ccc(CCCCc2cc3cc(-c4ccccc4)ncc3[nH]2)cc1
1244,796228,10.1016/j.bmcl.2011.10.115,,,,Inhibition of CYP3A4,Cc1ccc(Cn2c(C3CNCCS3)nc3ccccc32)cc1,(+/-)-2-(1-(4-methylbenzyl)-1H-benzo[d]imidazol-2-yl)thiomorpholine,9.5,uM,=,0.9777236052888478,1,c1ccc(Cn2c(C3CNCCS3)nc3ccccc32)cc1
1245,1526216,10.1021/ml500526p,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,Cc1cnc(-c2cc(Oc3ccc4c(c3)nc(Nc3cc(C(F)(F)F)ccc3F)n4C)ccn2)[nH]1,N-(2-fluoro-5-(trifluoromethyl)phenyl)-1-methyl-5-(2-(5-methyl-1H-imidazol-2-yl)pyridin-4-yloxy)-1H-benzo[d]imidazol-2-amine,3.4,uM,=,0.5314789170422551,1,c1ccc(Nc2nc3cc(Oc4ccnc(-c5ncc[nH]5)c4)ccc3[nH]2)cc1
1246,1614026,10.1016/j.bmcl.2016.09.043,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 1'-hydroxymidazolam metabolite formation using midazolam as substrate incubated for 10 mins by HPLC-MS method,Cn1c(NCCc2ccc(-c3ccc(F)cc3)cc2)nc2cc(N)ccc2c1=O,7-amino-2-{[2-(4'-fluorobiphenyl-4-yl)ethyl]amino}-3-methylquinazolin-4(3H)-one,23.0,uM,=,1.3617278360175928,1,O=c1[nH]c(NCCc2ccc(-c3ccccc3)cc2)nc2ccccc12
1247,2264099,10.1021/acs.jmedchem.1c00703,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 2 mins in presence of NADPH regenerating system by LC-MS/MS analysis,CC(C)n1nc(C(=O)NC2C3CN(CC4CCOCC4)CC32)c2ccccc21.O=C(O)C(=O)O,1-Isopropyl-1H-indazole-3-carboxylic acid [3-(tetrahydro-pyran-4-ylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]-amide oxalate,9.1,uM,=,0.9590413923210936,1,O=C(NC1C2CN(CC3CCOCC3)CC21)c1n[nH]c2ccccc12
1248,51903,10.1021/jm020557k,,,,Concentration required to inhibit cytochrome P450 3A4.,CCCCOc1ccc(-c2cnco2)cc1,5-(4-Butoxy-phenyl)-oxazole,58.1,uM,=,1.7641761323903309,1,c1ccc(-c2cnco2)cc1
1249,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1cccc(C(=O)N2C[C@@H](C)OC[C@H]2Cc2cc(-n3nccn3)ccc2F)c1-n1nccn1,"US9150566, 118",23.0,uM,=,1.3617278360175928,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
1250,1281752,10.1021/ml400311r,,,,Inhibition of CYP3A4 in human liver microsomes assessed as midazolam 1'-hydroxylation and testosterone 6beta-hydroxylation after 20 mins by LC-MS/MS analysis,CC(C)(C)n1nnnc1C(NCCNc1ccnc2cc(Cl)ccc12)c1ccc(Cl)cc1,"N1-((1-tert-Butyl-1H-tetrazol-5-yl)(4-chlorophenyl)methyl)-N2-(7-chloroquinolin-4-yl)ethane-1,2-diamine",0.08,uM,=,-1.0969100130080565,0,c1ccc(C(NCCNc2ccnc3ccccc23)c2nnn[nH]2)cc1
1251,469873,10.1016/j.bmcl.2008.01.012,,,,Inhibition of human CYP3A4,CC(C)c1c(-c2nnc(NCCCCN)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12,"5-(6-(5-(4-aminobutylamino)-1,3,4-oxadiazol-2-yl)-5-isopropylpyrrolo[1,2-f][1,2,4]triazin-4-ylamino)-N-cyclopropyl-2,4-difluorobenzamide",25.0,uM,=,1.3979400086720375,1,O=C(NC1CC1)c1cccc(Nc2ncnn3cc(-c4nnco4)cc23)c1
1252,1661019,10.1016/j.bmcl.2017.02.047,,,,Inhibition of recombinant human CYP3A4 expressed in baculosomes using Vivid BOMCC substrate blue measured every 30 sec for 30 mins by fluorescence assay,CCCCC[C@H](O)CC(=O)CCc1ccc(O)c(OC)c1,[1-(4'-hydroxy-3'-methoxyphenyl)-5-hydroxy-3-decanone],21.8,uM,=,1.3384564936046048,1,c1ccccc1
1253,590750,10.1021/jm9010127,,,,Inhibition of human recombinant CYP3A4,CNCc1cc(=O)oc2cc(OCc3cccc(Cl)c3)ccc12.CS(=O)(=O)O,7-[(3-Chlorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one Methanesulfonate,5.0,uM,=,0.6989700043360189,1,O=c1ccc2ccc(OCc3ccccc3)cc2o1
1254,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1ccc(C(=O)N2[C@H](Cc3cccc(-n4nccn4)c3)COC[C@@H]2C)c(-n2nccn2)c1,"US9150566, 71",14.0,uM,=,1.146128035678238,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
1255,1446329,10.1021/ml500387y,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,CC(C)(CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F)c1cccc(F)c1,"1,1,1-trifluoro-4-(3-fluorophenyl)-4-methyl-2-((5-morpholino-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)pentan-2-ol",0.1,uM,=,-1.0,0,c1ccc(CCCCc2cc3cc(N4CCOCC4)ncc3[nH]2)cc1
1256,1465541,10.1016/j.bmcl.2015.01.051,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(C6CN(C7COC7)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O,"(1S,4R,5R,6R,8R,10S,11R,12S,13R,16R,18S,21R)-8-[(1S)-1-ethoxy-2-hydroxy-2-methylpropyl]-4,6,12,17,17-pentamethyl-18-{[(2S)-4-[1-(oxetan-3-yl)azetidin-3-yl]morpholin-2-yl]oxy}-9-oxahexacyclo[11.9.0.0^{1,21}.0^{4,12}.0^{5,10}.0^{16,21}]docosan-11-ol",12.0,uM,=,1.0791812460476249,1,C1CO[C@@H]2CC3C(CC[C@@]45C[C@@]46CC[C@H](O[C@H]4CN(C7CN(C8COC8)C7)CCO4)C[C@@H]6CC[C@@H]35)[C@H]2C1
1257,519908,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,Cc1cccc(C)c1CNc1cc(N2CCNC2=O)cn2c(C)c(C)nc12,"1-(8-(2,6-dimethylbenzylamino)-2,3-dimethylimidazo[1,2-a]pyridin-6-yl)imidazolidin-2-one",5.3,uM,=,0.724275869600789,1,O=C1NCCN1c1cc(NCc2ccccc2)c2nccn2c1
1258,592411,10.1021/jm901195w,,,,Inhibition of human hepatic CYP3A4,Oc1cccc(-c2ccc(-c3ccc(O)c(F)c3)s2)c1,2-Fluoro-4-[5-(3-hydroxyphenyl)-2-thienyl]phenol,0.82,uM,=,-0.0861861476162833,0,c1ccc(-c2ccc(-c3ccccc3)s2)cc1
1259,1276541,10.1016/j.bmcl.2013.09.041,,,,Inhibition of CYP3A4 (unknown origin) after 5 mins,O=S(=O)(Nc1ccc(-c2cnco2)cc1)c1cc(Cl)cc(Cl)c1,"3,5-dichloro-N-(4-(oxazol-5-yl)phenyl)benzenesulfonamide",1.6,uM,=,0.2041199826559248,1,O=S(=O)(Nc1ccc(-c2cnco2)cc1)c1ccccc1
1260,860549,10.1021/jm3003747,,,,Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins,CC(C)(C(N)=O)N1CCN(Cc2cc3nc(-c4cc(F)cc5[nH]ccc45)nc(N4CCOCC4)c3s2)CC1,"2-(4-((2-(6-Fluoro-1H-indol-4-yl)-4-morpholinothieno[3,2-d]-pyrimidin-6-yl)methyl)piperazin-1-yl)-2-methylpropanamide",0.51,uM,=,-0.2924298239020636,0,c1cc(-c2nc(N3CCOCC3)c3sc(CN4CCNCC4)cc3n2)c2cc[nH]c2c1
1261,651640,10.1016/j.bmcl.2010.07.009,,,,Inhibition of CYP3A4,c1ccc(Cn2nnnc2C(c2ccc3occc3c2)N2CCCN(C3CCC3)CC2)cc1,"1-(benzofuran-5-yl(1-benzyl-1H-tetrazol-5-yl)methyl)-4-cyclobutyl-1,4-diazepane",2.4,uM,=,0.380211241711606,1,c1ccc(Cn2nnnc2C(c2ccc3occc3c2)N2CCCN(C3CCC3)CC2)cc1
1262,619264,10.1016/j.bmcl.2009.07.002,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,Cc1cccc(C)c1CNc1nccc2c(C)c(C)[nH]c12,"N-(2,6-dimethylbenzyl)-2,3-dimethyl-1H-pyrrolo[2,3-c]pyridin-7-amine",9.0,uM,=,0.9542425094393248,1,c1ccc(CNc2nccc3cc[nH]c23)cc1
1263,512798,10.1021/jm800832q,,,,Inhibition of human recombinant CYP3A4 in human liver microsomes using BFC as a substrate,Cc1cc(C2CCN(C)CC2)cc2[nH]c(-c3c(NCCn4cc(Cl)cn4)cc[nH]c3=O)nc12,4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(4-methyl-6-(1-methylpiperidin-4-yl)-1H-benzo[d]imidazo-2-yl)pyridine-2(1H)-one,40.0,uM,=,1.6020599913279625,1,O=c1[nH]ccc(NCCn2cccn2)c1-c1nc2ccc(C3CCNCC3)cc2[nH]1
1264,1734268,10.1021/acsmedchemlett.8b00030,,,,Inhibition of CYP3A4 (unknown origin),c1cnc2c(c1)CCC[C@@H]2N(CCCN1CCNCC1)Cc1nc2ccccc2s1,"(S)-N-((1H-benzo[d]thiazol-2yl)methyl)-N-(3-(piperazine-1yl)propyl)-5,6,7,8-tetrahydroquinolin-8-amine",9.4,uM,=,0.9731278535996988,1,c1cnc2c(c1)CCC[C@@H]2N(CCCN1CCNCC1)Cc1nc2ccccc2s1
1265,716789,10.1016/j.bmcl.2010.12.123,,,,Inhibition of CYP3A4,O=C(O)c1ccc(NC(=O)[C@H](C2CCCCC2)n2c(-c3ccc(Cl)cc3)nc3ccccc32)c(C(F)(F)F)c1,(S)-4-(2-(2-(4-chlorophenyl)-1H-benzo[d]imidazol-1-yl)-2-cyclohexylacetamido)-3-(trifluoromethyl)benzoic acid,49.0,uM,=,1.6901960800285136,1,O=C(Nc1ccccc1)[C@H](C1CCCCC1)n1c(-c2ccccc2)nc2ccccc21
1266,1290952,10.1021/jm401178t,,,,Inhibition of human CYP3A4,O=C(Nc1ccc(F)c(-c2nc3cc(-c4ccccc4)cnc3[nH]2)c1)N1CCCC1,"N-(4-fluoro-3-(6-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)phenyl)pyrrolidine-1-carboxamide",1.5,uM,=,0.1760912590556812,1,O=C(Nc1cccc(-c2nc3cc(-c4ccccc4)cnc3[nH]2)c1)N1CCCC1
1267,742805,10.1016/j.bmc.2011.02.009,,,,Inhibition of human CYP3A4 after 30 mins,CC(=O)Nc1cccc(-c2ccc(C(O)(c3c[nH]cn3)C(C)C)cc2)c1,"rac-N-{4-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl][1,1'-biphenyl]-3-yl}acetamide",7.1,uM,=,0.8512583487190752,1,c1ccc(-c2ccc(Cc3c[nH]cn3)cc2)cc1
1268,1886565,10.1021/acs.jmedchem.8b02021,,,,Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay,COC(=O)C1CCN(C(=O)c2ccc3nc(N)sc3c2)CC1,Methyl 1-(2-Aminobenzo[d]thiazole-6-carbonyl)piperidine-4-carboxylate,10.0,uM,=,1.0,1,O=C(c1ccc2ncsc2c1)N1CCCCC1
1269,526157,10.1021/np0401765,,,,Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation,COc1cc(OC)c(C(=O)C(C)=O)cc1OC,"1-(2,4,5-trimethoxyphenyl)-1,2-propanedione",74.0,uM,=,1.869231719730976,1,c1ccccc1
1270,814102,10.1016/j.bmcl.2012.03.014,,,,Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins,CC(=O)NCCc1ccccc1-c1noc([C@H]2CNCC[C@]2(O)c2ccc(F)c(F)c2)c1Br,"N-(2-(4-bromo-5-((3S,4R)-4-(3,4-difluorophenyl)-4-hydroxypiperidin-3-yl)isoxazol-3-yl)phenethyl)acetamide",45.0,uM,=,1.6532125137753435,1,c1ccc(-c2cc([C@H]3CNCCC3c3ccccc3)on2)cc1
1271,572636,10.1021/jm9002445,,,,Inhibition of human CYP3A4 by microtiter plate assay,Cc1cc(-c2ccnn2C)c2cccc(OCc3c(C)ccnc3CNC(=O)C(C)C)c2n1,N-{4-methyl-3-[2-methyl-4-(2-methyl-2H-pyrazol-3-yl)-quinolin-8-yloxymethyl]-pyridin-2-ylmethyl}-isobutyramide,3.1,uM,=,0.4913616938342727,1,c1cncc(COc2cccc3c(-c4ccn[nH]4)ccnc23)c1
1272,448320,10.1016/j.bmc.2007.05.069,,,,Inhibition of CYP3A4,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)C(=O)C(C)(c1ccc(Cl)cc1)O2,"N-{2-[6-(2,4-diamino-6-ethyl-pyrimidin-5-yl)-2-methyl-3-oxo-2-(4-chloro-phenyl)-2,3-dihydro-benzo[1,4]-oxazin-4-yl]-ethyl}-acetamide",0.59,uM,=,-0.2291479883578558,0,O=C1Nc2cc(-c3cncnc3)ccc2OC1c1ccccc1
1273,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(S(C)(=O)=O)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, E-15",11.2,uM,=,1.0492180226701815,1,O=C(c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12)N1CCNCC1
1274,859942,10.1021/jm300122u,,,,Inhibition of human CYP3A4 using testosterone as substrate after 45 mins,CN1CCN(C(=O)[C@H](Cc2ccccc2)NC(=O)C2(c3ccc(Cl)cc3Cl)CC2)CC1,"1-(2,4-Dichlorophenyl)-N-[(1S)-2-(4-methylpiperazin-1-yl)-2-oxo-1-(phenylmethyl)ethyl]cyclopropanecarboxamide",1.36,uM,=,0.1335389083702175,1,O=C([C@H](Cc1ccccc1)NC(=O)C1(c2ccccc2)CC1)N1CCNCC1
1275,1491686,10.1124/dmd.112.045708,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by substrate addition by LC-MS/MS analysis in presence of NADPH,COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1,"Acetic acid (2S,3S)-5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester",62.0,uM,=,1.792391689498254,1,O=C1C[C@H](c2ccccc2)Sc2ccccc2N1
1276,519907,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,Cc1cccc(C)c1CNc1cc(-n2cncn2)cn2c(C)c(C)nc12,"N-(2,6-dimethylbenzyl)-2,3-dimethyl-6-(1H-1,2,4-triazol-1-yl)imidazo[1,2-a]pyridin-8-amine",17.0,uM,=,1.230448921378274,1,c1ccc(CNc2cc(-n3cncn3)cn3ccnc23)cc1
1277,2248278,10.1021/acs.jmedchem.1c01974,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as a substrate preincubated for 10 mins followed by NADPH addition and measured after 20 mins by LC/MS/MS analysis,CC(=O)Nc1ccc(Nc2ncnc(N[C@@H](CC(C)C)C(=O)OC(C)(C)C)n2)cc1,"tert-Butyl (4-((4-Acetamidophenyl)amino)-1,3,5-triazin-2-yl)-L-leucinate",29.9,uM,=,1.4756711883244296,1,c1ccc(Nc2ncncn2)cc1
1278,802673,10.1016/j.bmcl.2011.12.125,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,O=C(Nc1ccc(-c2ccnc3[nH]cnc23)cc1)Nc1cccc(Cl)c1,"1-(4-(3H-imidazo[4,5-b]pyridin-7-yl)phenyl)-3-(3-chlorophenyl)urea",0.48,uM,=,-0.3187587626244128,0,O=C(Nc1ccccc1)Nc1ccc(-c2ccnc3[nH]cnc23)cc1
1279,552281,10.1016/j.bmcl.2008.04.036,,,,Inhibition of CYP3A4,COc1cccc(-c2cn(Cc3c(F)cccc3F)c(=O)n(C[C@H](N)c3ccccc3)c2=O)c1F,"3-((R)-2-Amino-2-phenyl-ethyl)-1-(2,6-difluoro-benzyl)-5-(2-fluoro-3-methoxy-phenyl)-1H-pyrimidine-2,4-dione",0.6,uM,=,-0.2218487496163563,0,O=c1c(-c2ccccc2)cn(Cc2ccccc2)c(=O)n1CCc1ccccc1
1280,2221809,10.1016/j.bmcl.2022.128625,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as substrate in presence of NADPH,CCCC1N(C(=O)c2cnccc2C(F)(F)F)CCCC1(Oc1csc(C(F)(F)F)c1)C(=O)N1CCN(c2ccccc2OCCO)CC1,"(4-(2-(2-hydroxyethoxy)phenyl)piperazin-1-yl)((2R,3S)-2-propyl-1-(4-(trifluoromethyl)nicotinoyl)-3-(5-(trifluoromethyl)thiophen-3-yloxy)piperidin-3-yl)methanone",6.6,uM,=,0.8195439355418687,1,O=C(c1cccnc1)N1CCCC(Oc2ccsc2)(C(=O)N2CCN(c3ccccc3)CC2)C1
1281,305432,10.1016/j.bmcl.2005.01.044,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,COC(=O)COc1ccc(COc2ccc3cc(C(C(C)N(C)C)n4ccnc4)ccc3c2)cc1,{4-[6-(2-Dimethylamino-1-imidazol-1-yl-propyl)-naphthalen-2-yloxymethyl]-phenoxy}-acetic acid methyl ester,0.14,uM,=,-0.8538719643217619,0,c1ccc(COc2ccc3cc(Cn4ccnc4)ccc3c2)cc1
1282,445935,10.1021/jm070436q,,,,Inhibition of CYP3A4,N#Cc1cnc2c(Cl)cc(NCc3cnc[nH]3)cc2c1Nc1ccc(F)c(Cl)c1,8-chloro-4-[(3-chloro-4-fluorophenyl)amino]-6-[(1H-imidazol-5-ymethyl)amino]quinoline-3-carbonitrile,9.0,uM,=,0.9542425094393248,1,c1ccc(Nc2ccnc3ccc(NCc4cnc[nH]4)cc23)cc1
1283,1364172,10.1021/ml500019s,,,,Inhibition of CYP3A4 (unknown origin) co-incubated with enzyme,COCCOc1ccccc1N1CCN(C(=O)[C@]2(Oc3ccc(C(F)(F)F)cc3)CCCN(C(=O)c3cnccc3C(F)(F)F)C2)CC1.Cl,(S)-(4-(2-(2-methoxyethoxy)phenyl)piperazin-1-yl)(1-(4-(trifluoromethyl)nicotinoyl)-3-(4-(trifluoromethyl)phenoxy)piperidin-3-yl)methanone hydrochloride,4.9,uM,=,0.6901960800285137,1,O=C(c1cccnc1)N1CCC[C@@](Oc2ccccc2)(C(=O)N2CCN(c3ccccc3)CC2)C1
1284,1685713,10.1016/j.bmc.2017.04.033,,,,Inhibition of recombinant CYP3A4 (unknown origin),C[C@@H](c1ccc(-c2ccc(F)cn2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O,"(S)-3-((S)-1-(4-(5-fluoropyridin-2-yl)phenyl)ethyl)-6-(2-hydroxy-2-methylpropyl)-6-phenyl-1,3-oxazinan-2-one",24.1,uM,=,1.3820170425748683,1,O=C1OC(c2ccccc2)CCN1Cc1ccc(-c2ccccn2)cc1
1285,1447575,10.1016/j.bmcl.2014.05.068,,,,Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method,CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OCC5COC(Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O,"2-sec-Butyl-4-[4-(4-{4-[(2R,4S)-2-(2,4-dichloro-phenyl)-2-[1,2,4]triazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-phenyl]-2,4-dihydro-[1,2,4]triazol-3-one",0.07,uM,=,-1.154901959985743,0,O=c1[nH]ncn1-c1ccc(N2CCN(c3ccc(OCC4COC(Cn5cncn5)(c5ccccc5)O4)cc3)CC2)cc1
1286,1488505,10.1124/dmd.112.045708,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 90 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis,CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1,"(R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide",30.0,uM,=,1.4771212547196624,1,O=C(Cc1ccccc1)N(Cc1cccnc1)Cc1nc2ncccc2c(=O)n1-c1ccccc1
1287,450508,10.1021/jm070806a,,,,Inhibition of CYP3A4,Cc1ccc(N2CCN(C(=O)[C@H](C)Cc3ccc(Cl)cc3)CC2)c([C@@H](NC(=O)CCN)C(C)C)c1,1-{2-[(1S)-(aminopropionyl)amino-2-methylpropyl]-4-methylphenyl}-4-[(2R)-methyl-3-(4-chlorophenyl)propionyl]piperazine,10.0,uM,=,1.0,1,O=C(CCc1ccccc1)N1CCN(c2ccccc2)CC1
1288,2194843,10.1021/acs.jmedchem.2c00986,,,,Time-dependent inhibition of CYP3A4 (unknown origin) at 2 ul pre-incubated for 30 mins in presence or absence of NADPH incubated for 10 mins by LC/MS analysis,Cc1nc(N[C@H](C)c2cc(N)cc(C(F)(F)F)c2)c2cc(O[C@H]3CCOC3)c(O)cc2n1,4-(((R)-1-(3-amino-5-(trifluoromethyl)phenyl)ethyl)amino)-2-methyl-6-(((S)-tetrahydrofuran-3-yl)oxy)quinazolin-7-ol,1.9,uM,=,0.2787536009528289,1,c1ccc(CNc2ncnc3ccc(O[C@H]4CCOC4)cc23)cc1
1289,742780,10.1021/jm101583w,,,,Inhibition of CYP3A4 in human liver microsomes,C[C@H]([C@@H](c1ccc(Nc2nc3ccccc3s2)cc1)n1ccnc1)N(C)C,"Benzothiazol-2-yl-[4-((1S,2S)-2-dimethylamino-1-imidazol-1-yl-propyl)-phenyl]-amine",11.0,uM,=,1.0413926851582251,1,c1ccc2sc(Nc3ccc(Cn4ccnc4)cc3)nc2c1
1290,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NC5CCN(C(=O)OC(C)(C)C)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, F-61",5.65,uM,=,0.7520484478194386,1,O=C(NC1CCNCC1)c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12
1291,774749,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OCC5COC(Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O,"2-sec-Butyl-4-[4-(4-{4-[(2R,4S)-2-(2,4-dichloro-phenyl)-2-[1,2,4]triazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-phenyl]-2,4-dihydro-[1,2,4]triazol-3-one",0.9,uM,=,-0.0457574905606751,0,O=c1[nH]ncn1-c1ccc(N2CCN(c3ccc(OCC4COC(Cn5cncn5)(c5ccccc5)O4)cc3)CC2)cc1
1292,305744,10.1021/jm049696n,,,,Inhibitory concentration value against human cytochrome P-450 3A4,C[n+]1c[nH]cc1-c1cccnc1,3-(3-Methyl-1H-imidazol-4-yl)-pyridine,262.0,uM,=,2.4183012913197457,1,c1cncc(-c2c[nH]c[nH+]2)c1
1293,1919651,,,,,"Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase",c1ccc(Cn2cnc(-c3cccnc3)c2)cc1,3-(1-Benzyl-1H-imidazol-4-yl)-pyridine,75.1,uM,=,1.8756399370041683,1,c1ccc(Cn2cnc(-c3cccnc3)c2)cc1
1294,438520,10.1016/j.bmcl.2007.01.104,,,,Inhibition of CYP3A4,COc1cccc(N2C(=O)N(Cc3ccccc3F)C3(CCN(Cc4ccc(-c5ccncc5)cc4)CC3)C2=O)c1,"1-(2-fluoro-benzyl)-3-(3-methoxy-phenyl)-8-(4-pyridin-4-yl-benzyl)-1,3,8-triaza-spiro[4.5]decane-2,4-dione",0.3,uM,=,-0.5228787452803376,0,O=C1N(c2ccccc2)C(=O)C2(CCN(Cc3ccc(-c4ccncc4)cc3)CC2)N1Cc1ccccc1
1295,305432,10.1016/j.bmcl.2005.01.044,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,CC(C(c1ccc2cc(OCc3ccc(CC(=O)O)cc3)ccc2c1)n1ccnc1)N(C)C,{4-[6-(2-Dimethylamino-1-imidazol-1-yl-propyl)-naphthalen-2-yloxymethyl]-phenyl}-acetic acid,0.004,uM,=,-2.397940008672037,0,c1ccc(COc2ccc3cc(Cn4ccnc4)ccc3c2)cc1
1296,1752996,10.1016/j.bmcl.2018.01.014,,,,Inhibition of CYP3A4 (unknown origin),CCCCNc1nc(N)nc2cccc(OCc3nccc(OC)c3OC)c12,"N4-butyl-5-((3,4-dimethoxypyridin-2-yl)methoxy)quinazoline-2,4-diamine",9.9,uM,=,0.99563519459755,1,c1ccc(COc2cccc3ncncc23)nc1
1297,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1ccc(C(=O)N2C[C@@H](C)OC[C@H]2Cc2cc(-n3nccn3)ccc2F)c(-n2nccn2)c1,"US9150566, 117",23.0,uM,=,1.3617278360175928,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
1298,514583,10.1016/j.bmcl.2008.06.072,,,,Inhibition of recombinant CYP3A4,O=c1ccc(Cc2cc(Cc3cccc(Cl)c3)c3occc3c2)n[nH]1,6-((7-(3-chlorobenzyl)benzofuran-5-yl)methyl)pyridazin-3(2H)-one,0.18,uM,=,-0.744727494896694,0,O=c1ccc(Cc2cc(Cc3ccccc3)c3occc3c2)n[nH]1
1299,1288280,10.1016/j.bmcl.2013.12.057,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,CN(Cc1cncs1)C(=O)NCCC(=O)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1,"Thiazol-5-ylmethyl(2R,5R)-5-(3-(3-methyl-3-(thiazol-5-ylmethyl)ureido)propanamido)-1,6-diphenylhexan-2-ylcarbamate",0.13,uM,=,-0.8860566476931633,0,O=C(CCNC(=O)NCc1cncs1)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
1300,719028,10.1021/ml100249e,,,,Inhibition of CYP3A4 in human liver microsomes,O=C(Nc1cnc(-c2ccncc2F)c(-c2cccnc2)n1)C1CC1,N-[5-(3-Fluoropyridin-4-yl)-6-pyridin-3-ylpyrazin-2-yl]cyclopropanecarboxamide,5.0,uM,=,0.6989700043360189,1,O=C(Nc1cnc(-c2ccncc2)c(-c2cccnc2)n1)C1CC1
1301,827974,10.1016/j.bmcl.2012.05.087,,,,Inhibition of CYP3A4 using testosterone as substrate,COc1ccc(C(=O)N2CCc3ccccc32)cc1CSc1nc2cc(F)ccc2n1CC(=O)O,2-(5-fluoro-2-(5-(indoline-1-carbonyl)-2-methoxybenzylthio)-1H-benzo[d]imidazol-1-yl)acetic acid,13.0,uM,=,1.1139433523068367,1,O=C(c1cccc(CSc2nc3ccccc3[nH]2)c1)N1CCc2ccccc21
1302,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1ccc(C(=O)N2C[C@@H](C)OC[C@H]2Cc2cc(-c3ncccn3)ccc2F)c(-n2nccn2)c1,"US9150566, 149",31.0,uM,=,1.4913616938342726,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2ncccn2)c1
1303,555862,10.1016/j.bmcl.2008.04.047,,,,Inhibition of human CYP3A4,NCC#Cc1c(Oc2ccc(NC(=O)NC(=O)Cc3ccc(F)cc3)cc2F)ccnc1N,1-(4-(2-amino-3-(3-aminoprop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(2-(4-fluorophenyl)acetyl)urea,1.8,uM,=,0.255272505103306,1,O=C(Cc1ccccc1)NC(=O)Nc1ccc(Oc2ccncc2)cc1
1304,1883264,10.1021/acs.jmedchem.8b01344,,,,Reversible inhibition of CYP3A4 (unknown origin) in presence of NADPH by vivid red substrate-based assay,N#Cc1ccc(S(=O)(=O)N2C[C@H](S(=O)(=O)c3ccc(Cl)cc3)[C@](O)(CN)C2)c(Cl)c1,"4-(((3S,4S)-3-(Aminomethyl)-4-((4-chlorophenyl)sulfonyl)-3-hydroxypyrrolidin-1-yl)sulfonyl)-3-chlorobenzonitrile",0.1,uM,=,-1.0,0,O=S(=O)(c1ccccc1)[C@@H]1CCN(S(=O)(=O)c2ccccc2)C1
1305,1467194,10.1021/jm5005336,,,,Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay,O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccc(N4CCNCC4)cc3)n[nH]c2c1,"(1R,2S)-(E)-2-(3-(4-(Piperazin-1-yl)styryl)-1H-indazol-6-yl)spiro-[cyclopropane-1,3'-indolin]-2'-one",2.8,uM,=,0.4471580313422192,1,O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccc(N4CCNCC4)cc3)n[nH]c2c1
1306,1289880,10.1021/jm401642q,,,,Inhibition of recombinant human CYP3A4,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(-c3cccnc3)cccc21,"6-(Morpholin-4-yl)-2-{2-oxo-2-[4-(pyridin-3-yl)-2,3-dihydro-1Hindol-1-yl]ethyl}pyrimidin-4(3H)-one",40.0,uM,=,1.6020599913279625,1,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(-c3cccnc3)cccc21
1307,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cccc(-c3ccncc3)c2)c1,"US9150566, 28",0.3,uM,=,-0.5228787452803376,0,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2ccncc2)c1
1308,742805,10.1016/j.bmc.2011.02.009,,,,Inhibition of human CYP3A4 after 30 mins,CNS(=O)(=O)c1cccc(-c2ccc(C(O)(c3c[nH]cn3)C(C)C)cc2)c1,"rac-4'-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-methyl[1,1'-biphenyl]-3-sulfonamide",3.3,uM,=,0.5185139398778875,1,c1ccc(-c2ccc(Cc3c[nH]cn3)cc2)cc1
1309,2157308,10.1021/acs.jmedchem.1c01137,,,,Inhibition of CYP3A4 (unknown origin),Cc1cnc(Nc2cnn(C(F)F)c2)nc1N1CCC2(CCNC2=O)CC1,"8-(2-(1-(difluoromethyl)-1H-pyrazol-4-ylamino)-5-methylpyrimidin-4-yl)-2,8-diazaspiro[4.5]decan-1-one",5.2,uM,=,0.7160033436347992,1,O=C1NCCC12CCN(c1ccnc(Nc3cn[nH]c3)n1)CC2
1310,676065,10.1016/j.bmcl.2010.09.028,,,,Inhibition of CYP3A4 after 30 mins,CC(C)[C@@H]1COC[C@H](C2(OC(=O)N3CC[C@H](O)C3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1,"(S)-1-((3R,5R)-4-(4-chlorophenylsulfonyl)-5-isopropylmorpholin-3-yl)cyclopropyl3-hydroxypyrrolidine-1-carboxylate",0.03,uM,=,-1.5228787452803376,0,O=C(OC1([C@H]2COCCN2S(=O)(=O)c2ccccc2)CC1)N1CCCC1
1311,1919651,,,,,"Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase",Cn1cnc(-c2cccnc2)c1,3-(1-Methyl-1H-imidazol-4-yl)-pyridine,261.9,uM,=,2.418135498425232,1,c1cncc(-c2c[nH]cn2)c1
1312,455108,10.1016/j.bmcl.2006.12.043,,,,Inhibition of CYP3A4,C[C@@H](N)C(=O)N1CCN(c2ccc3[nH]ncc3c2)CC1,(R)-1-(4-(1H-indazol-5-yl)piperazin-1-yl)-2-aminopropan-1-one,10.0,uM,=,1.0,1,c1cc2[nH]ncc2cc1N1CCNCC1
1313,632105,10.1016/j.bmcl.2010.03.057,,,,Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin,Cc1cc(N2CCN(CCCO)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,(S)-4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-3-(6-(4-(3-hydroxypropyl)piperazin-1-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one,1.9,uM,=,0.2787536009528289,1,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(N3CCNCC3)cc2[nH]1
1314,1447575,10.1016/j.bmcl.2014.05.068,,,,Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method,OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(Cl)cn1,"(R)-1-(5-chloropyridin-2-yl)-2-(2,4-difluorophenyl)-1,1-difluoro-3-(1H-tetrazol-1-yl)propan-2-ol",74.0,uM,=,1.869231719730976,1,c1ccc(C(Cc2ccccn2)Cn2cnnn2)cc1
1315,1499751,10.1021/acs.jmedchem.5b00424,,,,Inhibition of CYP3A4 (unknown origin),CS(=O)(=O)Nc1cccc(CC(=O)Nc2cc(-c3ccnc(Cl)c3)cs2)c1,N-(4-(2-chloropyridin-4-yl)thiophen-2-yl)-2-(3-(methylsulfonamido)phenyl)acetamide,7.5,uM,=,0.8750612633917001,1,O=C(Cc1ccccc1)Nc1cc(-c2ccncc2)cs1
1316,2048449,10.1016/j.bmc.2020.115734,,,,Inhibition of recombinant CYP3A4 (unknown origin) by fluorescence-based assay,COc1nc(-c2csc(Nc3c4c(nn3C)CCC4)n2)ccc1-n1cnc(C)c1,"4-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)-N-(2-methyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)thiazol-2-amine",4.5,uM,=,0.6532125137753437,1,c1cn(-c2ccc(-c3csc(Nc4[nH]nc5c4CCC5)n3)nc2)cn1
1317,535882,10.1016/j.bmcl.2008.08.010,,,,"Inhibition of human CYP3A4 by microtiter plate assays using N-N,diethyl-formamide as substrate",O=S(=O)(c1ccccc1Cl)n1ccc2cc3c(cc21)CCNCC3,"1-(2-chlorophenylsulfonyl)-1,5,6,7,8,9-hexahydroazepino[4,5-f]indole",2.5,uM,=,0.3979400086720376,1,O=S(=O)(c1ccccc1)n1ccc2cc3c(cc21)CCNCC3
1318,1291572,10.1016/j.bmcl.2013.12.058,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@H](/C=C/[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1,"Thiazol-5-ylmethyl(2S,5S,E)-5-((S)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-3-methylbutanamido)-1,6-diphenylhex-3-en-2-ylcarbamate",0.15,uM,=,-0.8239087409443188,0,O=C(CNC(=O)NCc1cscn1)N[C@H](/C=C/[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
1319,969693,10.1021/jm400751p,,,,Inhibition of human CYP3A4,Cc1ccccc1[C@H]1[C@@H]2CN(C3=NC(=O)CO3)C[C@H]2CC[C@@H]1O[C@H](CO)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,"2-[(3aR,4R,5S,7aS)-5-{(1S)-1-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxyethoxy}-4-(2-methylphenyl)octahydro-2H-isoindol-2-yl]-1,3-oxazol-4(5H)-one",15.0,uM,=,1.1760912590556811,1,O=C1COC(N2C[C@H]3CC[C@H](OCc4ccccc4)[C@@H](c4ccccc4)[C@@H]3C2)=N1
1320,1527962,,,,,"Inhibition Assay (Testosterone Hydroxylase): To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.",CN1CCCC1c1cccnc1,3-(1-Methyl-pyrrolidin-2-yl)-pyridine,142.4,uM,=,2.153509989300838,1,c1cncc(C2CCCN2)c1
1321,559938,10.1016/j.bmcl.2008.10.072,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,C[C@@H]1CN(Cc2ccc(-c3cccnc3C(=O)N3CCC(Cc4ccc(F)cc4)CC3)cc2)C[C@H](C)N1,"{3-[4-((3R,5S)-3,5-Dimethyl-piperazin-1-ylmethyl)-phenyl]-pyridin-2-yl}-[4-(4-fluoro-benzyl)-piperidin-1-yl]-methanone",13.0,uM,=,1.1139433523068367,1,O=C(c1ncccc1-c1ccc(CN2CCNCC2)cc1)N1CCC(Cc2ccccc2)CC1
1322,673952,10.1016/j.bmcl.2010.08.086,,,,Inhibition of CYP3A4 using midazolam as substrate,COCCCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1,"(3R,4S)-N-(2-chloro-5-(3-methoxypropyl)benzyl)-N-cyclopropyl-4-(4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)phenyl)piperidine-3-carboxamide",4.8,uM,=,0.6812412373755872,1,O=C([C@H]1CNCC[C@@H]1c1ccc(OCCOc2ccccc2)cc1)N(Cc1ccccc1)C1CC1
1323,945618,10.1016/j.bmc.2012.11.058,,,,Inhibition of CYP3A4 (unknown origin),Cc1cncc(Oc2c(Cl)cc(NS(=O)(=O)c3ccc(Cl)cc3Cl)cc2Cl)c1,"2,4-Dichloro-N-(3,5-dichloro-4-(5-methylpyridin-3-yloxy)phenyl)benzenesulfonamide",0.001,uM,=,-3.0,0,O=S(=O)(Nc1ccc(Oc2cccnc2)cc1)c1ccccc1
1324,1581635,10.1021/acs.jmedchem.5b01146,,,,Inhibition of C-terminal four-histidine tagged human CYP3A4delta3 to 24 residues expressed in Escherichia coli assessed as 7-benzyloxy-4-(trifluoromethyl)coumarin O-debenzylation pretreated 2 mins followed by NADPH addition by fluorometric method in presence of rat cytochrome P450 reductase,NCCc1cccnc1,2-(Pyridine-3-yl)ethanamine,5000.0,uM,=,3.6989700043360174,1,c1ccncc1
1325,828928,10.1016/j.bmcl.2012.06.022,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(NCCN(C)C)oc2c1,"Thiazol-5-ylmethyl(2S,3R)-4-(2-(2-(dimethylamino)ethylamino)-N-isobutylbenzo[d]oxazole-6-carboxamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate",0.2,uM,=,-0.6989700043360187,0,O=C(N[C@H](CCNC(=O)c1ccc2ncoc2c1)Cc1ccccc1)OCc1cncs1
1326,1291572,10.1016/j.bmcl.2013.12.058,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CCN(Cc2ccc(Cl)cc2)C(=O)OCc2cncs2)Cc2ccccc2)cs1,Thiazol-5-ylmethyl 4-chlorobenzyl((S)-3-((S)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-4-morpholinobutanamido)-4-phenylbutyl)carbamate,0.44,uM,=,-0.3565473235138126,0,O=C(NCc1cscn1)N[C@@H](CCN1CCOCC1)C(=O)N[C@H](CCN(Cc1ccccc1)C(=O)OCc1cncs1)Cc1ccccc1
1327,2156398,10.1016/j.ejmech.2021.114040,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as substrate,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1ccc2c(c1)OC1(CCOCC1)CC(=O)N2,"N-(4-Methyl-3-(4-oxo-2',3',4,5,5',6'-hexahydro-3H-spiro[benzo[b][1,4]oxazepine-2,4'-pyran]-8-yl)phenyl)-2-(trifluoromethyl)isonicotinamide",13.2,uM,=,1.1205739312058498,1,O=C1CC2(CCOCC2)Oc2cc(-c3cccc(NC(=O)c4ccncc4)c3)ccc2N1
1328,813216,10.1016/j.bmcl.2012.01.125,,,,Inhibition of CYP3A4,COc1cc2c(Nc3ccccc3C(C)(C)C)c(C(N)=O)cnc2cc1-c1c(C)noc1C,"4-(2-tert-butylphenylamino)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxyquinoline-3-carboxamide",1.9,uM,=,0.2787536009528289,1,c1ccc(Nc2ccnc3cc(-c4cnoc4)ccc23)cc1
1329,1467195,10.1021/jm5005336,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay,Cc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5CCOCC5)cc4)n[nH]c3c1)C(=O)N2,"(1R*,2S*)-(E)-5'-Methyl-2-(3-(4-(morpholinomethyl)styryl)-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-one",3.0,uM,=,0.4771212547196624,1,O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccc(CN4CCOCC4)cc3)n[nH]c2c1
1330,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(OC)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, G-3",2.61,uM,=,0.4166405073382809,1,O=C(Nc1ccccc1)c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12
1331,1460848,10.1021/jm501038s,,,,Inhibition of CYP3A4 (unknown origin),O=C(NCc1ccncc1)c1ccc(Oc2ccc(F)cc2)cc1,4-(4-fluorophenoxy)-N-(pyridin-4-ylmethyl)benzamide,1.0,uM,=,0.0,0,O=C(NCc1ccncc1)c1ccc(Oc2ccccc2)cc1
1332,804824,10.1016/j.bmcl.2011.12.080,,,,Reversible inhibition of CYP3A4,Cc1cc(Cl)cc2c(C(O)c3cccnc3)c3c(C)n[nH]c3nc12,"rac-(6-chloro-3,8-dimethyl-1H-pyrazolo[3,4-b]quinolin-4-yl)(pyridin-3-yl)methanol",1.1,uM,=,0.041392685158225,1,c1cncc(Cc2c3ccccc3nc3[nH]ncc23)c1
1333,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cccc(-c3nccs3)c2)c1,"US9150566, 43",1.2,uM,=,0.0791812460476248,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2nccs2)c1
1334,1291572,10.1016/j.bmcl.2013.12.058,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@H](CCN(Cc2ccccc2)C(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1,Thiazol-5-ylmethyl benzyl((S)-3-((S)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-3-methylbutanamido)-4-phenylbutyl)carbamate,0.32,uM,=,-0.494850021680094,0,O=C(CNC(=O)NCc1cscn1)N[C@H](CCN(Cc1ccccc1)C(=O)OCc1cncs1)Cc1ccccc1
1335,1901061,10.1021/acs.jmedchem.9b00565,,,,Inhibition of CYP3A4 (unknown origin),CN(C)C(=O)c1ccc(N(Cc2ccc(O)cc2)C(=O)c2ccc(O)cc2O)cc1,"N-(4-(Dimethylcarbamoyl)phenyl)-2,4-dihydroxy-N-(4-hydroxybenzyl)benzamide",6.47,uM,=,0.8109042806687004,1,O=C(c1ccccc1)N(Cc1ccccc1)c1ccccc1
1336,479555,10.1016/j.bmcl.2008.03.057,,,,Inhibition of CYP3A4,Cc1cc2cc(Nc3ncnn4cc(-c5nnc(C)o5)c(C(C)C)c34)cnc2[nH]1,"5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine",11.5,uM,=,1.0606978403536118,1,c1nc(Nc2cnc3[nH]ccc3c2)c2cc(-c3nnco3)cn2n1
1337,988989,10.1021/jm400732v,,,,Inhibition of CYP3A4 (unknown origin),CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)c2ccc(S(C)(=O)=O)cc2)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O.Cl,"(S)-N-((S)-1-((6-bromo-2-methoxynaphthalen-1-yl)methyl)-5-(4-(methylsulfonyl)benzoyl)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-yl)-2-(methylamino)propanamide hydrochloride",2.0,uM,=,0.3010299956639812,1,O=C1CCN(C(=O)c2ccccc2)c2ccccc2N1Cc1cccc2ccccc12
1338,479364,10.1016/j.bmcl.2008.05.027,,,,Inhibition of CYP3A4,Cc1cc2ncc(=O)n(CC(=O)N3CCCC(c4ccccc4)C3CN3CCOCC3)c2cc1C,"rac-6,7-dimethyl-1-(2-(2-(morpholinomethyl)-3-phenylpiperidin-1-yl)-2-oxoethyl)quinoxalin-2(1H)-one",2.7,uM,=,0.4313637641589873,1,O=C(Cn1c(=O)cnc2ccccc21)N1CCCC(c2ccccc2)C1CN1CCOCC1
1339,305744,10.1021/jm049696n,,,,Inhibitory concentration value against human cytochrome P-450 3A4,N=Cc1ccc(-c2cccnc2)s1.N=Cc1ccc(-c2cccnc2)s1.NCc1ccc(-c2cccnc2)s1,C-(5-Pyridin-3-yl-thiophen-2-yl)-methylamine with C-[1-(5-Pyridin-3-yl-thiophen-2-yl)-meth-(E)-]-ylideneamine; compound with C-[1-(5-pyridin-3-yl-thiophen-2-yl)-meth-(E)-]-ylideneamine,77.5,uM,=,1.8893017025063104,1,c1cncc(-c2cccs2)c1.c1cncc(-c2cccs2)c1.c1cncc(-c2cccs2)c1
1340,51911,10.1016/s0960-894x(03)00474-8,,,,Inhibition of human liver microsome Cytochrome P450 3A4,CC(C)(c1ncc(-c2cccnc2)o1)N1CCN(C[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3OC[C@H]2O)[C@H](C(=O)NCC(F)(F)F)C1,"(S)-1-[(S)-2-Hydroxy-4-((R)-(S)-3-hydroxy-3,4,4a,8a-tetrahydro-2H-chromen-4-ylcarbamoyl)-5-phenyl-pentyl]-4-[1-methyl-1-(5-pyridin-3-yl-oxazol-2-yl)-ethyl]-piperazine-2-carboxylic acid (2,2,2-trifluoro-ethyl)-amide",0.11,uM,=,-0.958607314841775,0,O=C(N[C@@H]1CCOc2ccccc21)[C@@H](CCCN1CCN(Cc2ncc(-c3cccnc3)o2)CC1)Cc1ccccc1
1341,559938,10.1016/j.bmcl.2008.10.072,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,C[C@@H]1CN(Cc2ccc(-c3ccccc3CN(C)C(=O)Cc3cccc(Cl)c3)cc2)C[C@H](C)N1,"2-(3-Chloro-phenyl)-N-[4'-((3R,5S)-3,5-dimethyl-piperazin-1-ylmethyl)-biphenyl-2-ylmethyl]-N-methyl-acetamide",1.4,uM,=,0.1461280356782379,1,O=C(Cc1ccccc1)NCc1ccccc1-c1ccc(CN2CCNCC2)cc1
1342,2023287,10.1016/j.bmcl.2020.127636,,,,Inhibition of CYP3A4 (unknown origin),COc1ccccc1C1c2c(CCO)n[nH]c2C(=O)N1c1ccc(-c2ccon2)cc1,"3-(2-hydroxyethyl)-5-(4-(isoxazol-3-yl)phenyl)-4-(2-methoxyphenyl)-4,5-dihydropyrrolo[3,4-c]pyrazol-6(1H)-one",16.0,uM,=,1.2041199826559248,1,O=C1c2[nH]ncc2C(c2ccccc2)N1c1ccc(-c2ccon2)cc1
1343,1438704,10.1021/jm501375c,,,,Inhibition of CYP3A4 (unknown origin),CC(C)N1CCC[C@H]1CNC(=O)c1cn(C2CCCC2)c(=O)c2c1c1ccccc1n2C,"(S)-2-cyclopentyl-N-((1-isopropylpyrrolidin-2-yl)methyl)-9-methyl-1-oxo-2,9-dihydro-1H-pyrido[3,4-b]indole-4-carboxamide",10.1,uM,=,1.0043213737826426,1,O=C(NC[C@@H]1CCCN1)c1cn(C2CCCC2)c(=O)c2[nH]c3ccccc3c12
1344,1467194,10.1021/jm5005336,,,,Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay,COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN(C)C)cc4)n[nH]c3c1)C(=O)N2,"(1R*,2S*)-(E)-2-(3-(4-((Dimethylamino)methyl)styryl)-1H-indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one",7.5,uM,=,0.8750612633917001,1,O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccccc3)n[nH]c2c1
1345,1914337,10.1021/acs.jmedchem.9b00952,,,,Inhibition of recombinant human CYP3A4 expressed in supersomes using 7-benzyloxyquinoline as substrate by fluorescence method,CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,SID144204227,0.04,uM,=,-1.3979400086720375,0,c1ccc([C@@]2(Cn3ccnc3)OC[C@H](COc3ccc(N4CCNCC4)cc3)O2)cc1
1346,1785637,,,,,Inhibition of CYP3A4 (unknown origin),O=S(=O)(c1cccc(OC(F)(F)F)c1)N1CCN(c2ccc(/C=C/c3cc(Cl)cc(Cn4ccnc4)c3)cc2)CC1,1-(4-(3-((1H-imidazol-1-yl)methyl)-5-chlorostyryl)phenyl)-4-(3-(trifluoromethoxy)phenylsulfonyl)piperazine,0.873,uM,=,-0.0589857562944302,0,O=S(=O)(c1ccccc1)N1CCN(c2ccc(/C=C/c3cccc(Cn4ccnc4)c3)cc2)CC1
1347,988989,10.1021/jm400732v,,,,Inhibition of CYP3A4 (unknown origin),CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2c(OC)ccc3c(Br)cccc23)c2ccccc2N(C(=O)CS(C)(=O)=O)[C@H]1C.Cl,"(S)-N-((3S,4S)-1-((5-Bromo-2-methoxynaphthalen-1-yl)methyl)-4-methyl-5-(2-(methylsulfonyl)acetyl)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-yl)-2-(methylamino)propanamide hydrochloride",1.7,uM,=,0.2304489213782739,1,O=C1CCNc2ccccc2N1Cc1cccc2ccccc12
1348,1764722,10.1021/acsmedchemlett.8b00220,,,,Inhibition of CYP3A4 (unknown origin) preincubated followed by substrate addition,CS[C@@]1(C(=O)Nc2ccc3[nH]nc(-c4ccc(F)cc4)c3c2)CCN(CC(=O)N2CC=C(c3ccc(-c4ncccn4)cc3)CC2)C1,"US8546404, 613",2000.0,uM,=,3.3010299956639813,1,O=C(Nc1ccc2[nH]nc(-c3ccccc3)c2c1)C1CCN(CC(=O)N2CC=C(c3ccc(-c4ncccn4)cc3)CC2)C1
1349,495539,10.1021/jm801332q,,,,Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate measured in 0 to 5 mins by time dependent inhibition assay,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,"6-(4-Dimethylamino-3-hydroxy-6-methyl-tetrahydro-pyran-2-yloxy)-14-ethyl-7,12,13-trihydroxy-4-(5-hydroxy-4-methoxy-4,6-dimethyl-tetrahydro-pyran-2-yloxy)-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione",1.9,uM,=,0.2787536009528289,1,O=C1CCCCOC(=O)C[C@@H](O[C@H]2CCCCO2)C[C@@H](O[C@H]2CCCCO2)CCC1
1350,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCCCC6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, A::US8940739, G-35",12.24,uM,=,1.0877814178095424,1,O=C(Nc1ccc(N2CCCCC2)nc1)c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12
1351,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",COc1ccc(C(=O)N2CCOC[C@H]2Cc2cc(-n3nccn3)ccc2F)c(-n2nccn2)c1,"US9150566, 95",49.0,uM,=,1.6901960800285136,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
1352,1561646,10.1016/j.bmc.2016.02.031,,,,Inhibition of recombinant human CYP3A4 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins using 7-benzyloxyquinoline as substrate by CYPEX assay,Cn1c(SCCCN2CC3CCN(c4ccccc4C(F)(F)F)C3C2)nnc1-c1cccnc1,"rac-3-{4-Methyl-5-[(3-{1-[2-(trifluoromethyl)phenyl]-octahydropyrrolo[3,4-b]pyrrol-5-yl}propyl)sulfanyl]-4H-1,2,4-triazol-3-yl}pyridine",0.92,uM,=,-0.0362121726544447,0,c1ccc(N2CCC3CN(CCCSc4nnc(-c5cccnc5)[nH]4)CC32)cc1
1353,717286,10.1021/np100665j,,,,Inhibition of CYP3A4 after 30 mins by fluorometric assay,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,"1-(4-{4-[2-(2,4-Dichloro-phenyl)-2-imidazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-ethanone (ketoconazole)",0.0078,uM,=,-2.10790539730952,0,c1ccc(C2(Cn3ccnc3)OCC(COc3ccc(N4CCNCC4)cc3)O2)cc1
1354,1487309,10.1124/dmd.111.043505,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis,O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1,4-[4-(4-Chloro-phenyl)-4-hydroxy-piperidin-1-yl]-1-(4-fluoro-phenyl)-butan-1-one (Haloperidol),8.2,uM,=,0.9138138523837168,1,O=C(CCCN1CCC(c2ccccc2)CC1)c1ccccc1
1355,814102,10.1016/j.bmcl.2012.03.014,,,,Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins,O[C@]1(c2ccc(F)c(F)c2)CCNC[C@@H]1c1cc(-c2ccc(F)cc2Br)no1,"(3S,4R)-3-(3-(2-bromo-4-fluorophenyl)isoxazol-5-yl)-4-(3,4-difluorophenyl)piperidin-4-ol",3.0,uM,=,0.4771212547196624,1,c1ccc(-c2cc([C@H]3CNCCC3c3ccccc3)on2)cc1
1356,617698,10.1016/j.bmcl.2010.01.087,,,,Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay,Cc1cc(N2CCC(N3CCOCC3)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,(S)-4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-3-(4-methyl-6-(4-morpholinopiperidin-1-yl)-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one,1.7,uM,=,0.2304489213782739,1,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(N3CCC(N4CCOCC4)CC3)cc2[nH]1
1357,1289880,10.1021/jm401642q,,,,Inhibition of recombinant human CYP3A4,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(Br)cccc21,"2-[2-(4-Bromo-2,3-dihydroindol-1-yl)-2-oxoethyl]-6-morpholin-4-yl-3H-pyrimidin-4-one",40.0,uM,=,1.6020599913279625,1,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2ccccc21
1358,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCC(O)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1,"US8940739, G-37",6.95,uM,=,0.8419848045901139,1,O=C(Nc1ccc(N2CCCCC2)nc1)c1c[nH]c2c(CN3CC4N(C(=O)NCc5ccccc5)NCC(=O)N4C(Cc4ccccc4)C3=O)cccc12
1359,982382,10.1016/j.bmcl.2013.07.071,,,,Inhibition of CYP3A4 (unknown origin),[2H]C([2H])(N[C@H]1C[S@+]([O-])C[C@@H](Cc2cc(F)c(N)c(O[C@H](COC)C(F)(F)F)c2)[C@@H]1O)c1cccc(C(C)(C)C)c1,"[2H]-(1R,3S,4S,5R)-3-[[4-amino-3-fluoro-5-[(1R)-2,2,2-trifluoro-1-(methoxymethyl)ethoxy]phenyl]methyl]-5-[[(3-tert-butylphenyl)-dideuterio-methyl]amino]-1-oxido-tetrahydrothiopyran-1-ium-4-ol",0.1,uM,=,-1.0,0,c1ccc(CN[C@H]2C[SH+]C[C@@H](Cc3ccccc3)C2)cc1
1360,649576,10.1021/jm100317b,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsome,Nc1cccc(-c2ccc(Cc3ccncc3)cc2)c1,4'-(pyridin-4-ylmethyl)biphenyl-3-amine,1.52,uM,=,0.1818435879447725,1,c1ccc(-c2ccc(Cc3ccncc3)cc2)cc1
1361,1467194,10.1021/jm5005336,,,,Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay,C[C@@H]1CN(Cc2ccc(/C=C/c3n[nH]c4cc([C@@H]5C[C@@]56C(=O)Nc5ccccc56)ccc34)cc2)C[C@H](C)O1,"(1R,2S)-(E)-2-(3-(4-cis-2,6-Dimethylmorpholino)methyl)styryl)-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-one",5.0,uM,=,0.6989700043360189,1,O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccc(CN4CCOCC4)cc3)n[nH]c2c1
1362,1527876,,,,,Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,C[C@@H](c1ccc(-c2ccn(CC(F)(F)F)c(=O)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O,"US8575157, 66",18.0,uM,=,1.255272505103306,1,O=C1OC(c2ccccc2)CCN1Cc1ccc(-c2cc[nH]c(=O)c2)cc1
1363,2101223,10.1016/j.bmc.2021.116216,,,,Inhibition of CYP3A4 (unknown origin) using diethoxyfluorescein as substrate,CNc1nc(NC2CCC(C(=O)NCc3ccccc3C(F)(F)F)CC2)nc(N2CCN(C)CC2)n1,"Cis-4-((4-(methylamino)-6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-yl)amino)-N-(2-(trifluoromethyl)benzyl)cyclohexane-1-carboxamide",22.0,uM,=,1.3424226808222062,1,O=C(NCc1ccccc1)C1CCC(Nc2ncnc(N3CCNCC3)n2)CC1
1364,597665,10.1021/jm900843g,,,,Inhibition of recombinant CYP3A4 using benzyloxy-4-(trifluoromethyl)coumarin as substrate,C[C@@H]1CN(C(=O)c2ccccc2)CCN1C(=O)C(=O)c1c[nH]c2ccncc12,"(R)-1-(4-Benzoyl-2-methylpiperazin-1-yl)-2-(1H-pyrrolo[3,2-c]-pyridin-3-yl)ethane-1,2-dione",18.0,uM,=,1.255272505103306,1,O=C(C(=O)N1CCN(C(=O)c2ccccc2)CC1)c1c[nH]c2ccncc12
1365,1772941,10.1016/j.ejmech.2018.01.002,,,,Inhibition of human supersome CYP3A4 using testosterone as substrate assessed as testosterone 6beta-hydroxylation after 30 mins by HPLC-UV detection,O=S(=O)(c1cncc2ccccc12)N1CCC[C@H]1CCN1CCN(c2nsc3ccccc23)CC1,"(S)-3-(4-(2-(1-(Isoquinolin-4-ylsulfonyl)pyrrolidin-2-yl)ethyl)piperazin-1-yl)-1,2-benzothiazole",23.0,uM,=,1.3617278360175928,1,O=S(=O)(c1cncc2ccccc12)N1CCC[C@H]1CCN1CCN(c2nsc3ccccc23)CC1
1366,1535672,,,,,"Inhibition Assay: Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 μM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 μM. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 μM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 μM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v.",OC(Cn1cnnc1)(c1ccc(F)cc1F)C(F)(F)c1cnc2cc(Cl)ccc2n1,"US8883797, 10",45.0,uM,=,1.6532125137753435,1,c1ccc(C(Cc2cnc3ccccc3n2)Cn2cnnc2)cc1
1367,804823,10.1016/j.bmcl.2011.12.080,,,,Time dependent inhibition of CYP3A4,COc1ccc(C(C#N)c2c3cc(OC)cc(C)c3nc3[nH]nc(C)c23)cc1,"rac-2-(6-methoxy-3,8-dimethyl-1H-pyrazolo[3,4-b]quinolin-4-yl)-2-(4-methoxyphenyl)acetonitrile",12.9,uM,=,1.110589710299249,1,c1ccc(Cc2c3ccccc3nc3[nH]ncc23)cc1
1368,802673,10.1016/j.bmcl.2011.12.125,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,O=C(Nc1ccc(-c2ccncc2)cc1)Nc1ccc(-c2ccnc3[nH]cnc23)cc1,"1-(4-(3H-imidazo[4,5-b]pyridin-7-yl)phenyl)-3-(4-(pyridin-4-yl)phenyl)urea",0.36,uM,=,-0.4436974992327127,0,O=C(Nc1ccc(-c2ccncc2)cc1)Nc1ccc(-c2ccnc3[nH]cnc23)cc1
1369,1465542,10.1016/j.bmcl.2015.01.051,,,,Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(CC6CN(C7CCC7)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O,"(1S,4R,5R,6R,8R,10S,11R,12S,13R,16R,18S,21R)-18-{[(2S)-4-[(1-cyclobutylazetidin-3-yl)methyl]morpholin-2-yl]oxy}-8-[(1S)-1-ethoxy-2-hydroxy-2-methylpropyl]-4,6,12,17,17-pentamethyl-9-oxahexacyclo[11.9.0.0^{1,21}.0^{4,12}.0^{5,10}.0^{16,21}]docosan-11-ol",7.7,uM,=,0.8864907251724818,1,C1CC(N2CC(CN3CCO[C@@H](O[C@H]4CC[C@]56C[C@]57CCC5C(C[C@H]8OCCC[C@H]58)[C@@H]7CC[C@H]6C4)C3)C2)C1
1370,993440,10.6019/CHEMBL2448688,,,,DNDI: CYP Inhibition,Cl.OC(COc1ccc2cc(Br)ccc2c1)Cn1ccnc1,,0.7,uM,=,-0.1549019599857432,0,c1ccc2cc(OCCCn3ccnc3)ccc2c1
1371,598210,10.1016/j.bmcl.2009.08.024,,,,Inhibition of human CYP3A4,CC1(CC(=O)NCc2ccccc2N2CCCCC2)CC2(CCCCC2)OO1,"2-(3-methyl-1,2-dioxaspiro[4.5]decan-3-yl)-N-(2-(piperidin-1-yl)benzyl)acetamide",1.6,uM,=,0.2041199826559248,1,O=C(CC1CC2(CCCCC2)OO1)NCc1ccccc1N1CCCCC1
1372,462114,10.1016/j.bmcl.2007.12.028,,,,Inhibition of CYP3A4,COc1cccc(CNC[C@@H](O)[C@H](Cc2ccccc2)NC(=O)c2cc(C(=O)N[C@H](C)c3ccccc3)cc(N(C)S(C)(=O)=O)c2)c1,"N1-((2S,3R)-4-(3-methoxybenzylamino)-3-hydroxy-1-phenylbutan-2-yl)-5-(N-methylmethan-3-ylsulfonamido)-N3-((R)-1-phenylethyl)isophthalamide",0.696,uM,=,-0.1573907603894379,0,O=C(NCc1ccccc1)c1cccc(C(=O)N[C@H](CCNCc2ccccc2)Cc2ccccc2)c1
1373,764508,10.1016/j.bmc.2011.07.042,,,,Inhibition of CYP3A4,Cl.Cn1c(=O)c2c(cc(N3CCC[C@@H](N)C3)n2Cc2cc(F)ccc2C#N)n(C)c1=O,"2-({6-[(3R)-3-Amino-piperidin-1-yl]-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-5H-pyrrolo[3,2-d]pyrimidine-5-yl}methyl)-4-fluorobenzonitrile HCl salt",1.6,uM,=,0.2041199826559248,1,O=c1[nH]c(=O)c2c(cc(N3CCCCC3)n2Cc2ccccc2)[nH]1
1374,52069,10.1021/jm021012t,,,,Inhibition of human cytochrome P450 3A4,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1,"((1R,2R,4R)-1-Benzyl-2-hydroxy-4-{(R)-2-[3-(2-isopropyl-1lambda*4*-[1,3]thiazin-5-ylmethyl)-3-methyl-ureido]-3-methyl-butyrylamino}-5-phenyl-pentyl)-carbamic acid thiazol-5-ylmethyl ester",0.03,uM,=,-1.5228787452803376,0,O=C(CNC(=O)NCc1cscn1)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
1375,2246941,10.1021/acs.jmedchem.1c02132,,,,Inhibition of CYP3A4 (unknown origin) incubated for 10 mins in presence of NADPH by LC-MS/MS analysis,COc1cc(-c2ccnc(NC(C)=O)c2)ccc1OC[C@@H](N)CC(C)C,(S)-N-(4-(4-(2-amino-4-methylpentyloxy)-3-methoxyphenyl)pyridin-2-yl)acetamide,6.9,uM,=,0.8388490907372553,1,c1ccc(-c2ccncc2)cc1
1376,462758,10.1016/j.bmcl.2008.02.002,,,,Inhibition of human CYP3A4,O=C(Cn1cc(Nc2nncc3cc(OCCCN4CCC[C@@H]4COP(=O)(O)O)ccc23)cn1)Nc1cccc(F)c1F,"(R)-(1-(3-(1-(1-(2-(2,3-difluorophenylamino)-2-oxoethyl)-1H-pyrazol-4-ylamino)phthalazin-6-yloxy)propyl)pyrrolidin-2-yl)methyl dihydrogen phosphate",6.1,uM,=,0.785329835010767,1,O=C(Cn1cc(Nc2nncc3cc(OCCCN4CCCC4)ccc23)cn1)Nc1ccccc1
1377,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(CCN6CCCCC6)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, E-24",5.53,uM,=,0.7427251313046983,1,O=C(c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12)N1CCN(CCN2CCCCC2)CC1
1378,740075,10.1016/j.bmcl.2011.02.033,,,,Inhibition of CYP3A4,COc1ccccc1N1CCN(C(=O)c2cc(-c3ccc(Cl)cc3)n[nH]2)CC1,(3-(4-chlorophenyl)-1H-pyrazol-5-yl)(4-(2-methoxyphenyl)piperazin-1-yl)methanone,8.0,uM,=,0.9030899869919436,1,O=C(c1cc(-c2ccccc2)n[nH]1)N1CCN(c2ccccc2)CC1
1379,1301328,10.6019/CHEMBL3137440,,,,DNDI: CYP Inhibition,CS(=O)(=O)c1ccc(N2CCC(N(c3ccc(C#N)cc3)c3cccnc3)CC2)cc1,4-[(1-[4-(Methylsulfonyl)phenyl]piperidin-4-yl)(pyridin-3-yl)amino]benzonitrile,12.0,uM,=,1.0791812460476249,1,c1ccc(N2CCC(N(c3ccccc3)c3cccnc3)CC2)cc1
1380,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1ccc(C(=O)N2CCOC[C@H]2Cc2cc(Cl)cc(-n3nccn3)c2)c(-n2nccn2)c1,"US9150566, 105",21.0,uM,=,1.3222192947339193,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
1381,595638,10.1016/j.bmcl.2009.09.096,,,,Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH,COc1cnc2c(NCc3nnc4ccc(-c5cc(F)c(F)c(F)c5)nn34)ccnc2c1,"7-methoxy-N-((6-(3,4,5-trifluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine",16.0,uM,=,1.2041199826559248,1,c1ccc(-c2ccc3nnc(CNc4ccnc5cccnc45)n3n2)cc1
1382,1659434,10.1021/acs.jmedchem.6b01662,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH by LC-MS/MS analysis,COc1ccc2c(c1)c(CN1CCCN(C)CC1)cn2S(=O)(=O)c1ccc(C(C)C)cc1.Cl.Cl,"1-(4-Isopropylbenzenesulfonyl)-5-methoxy-3-(4-methyl-[1,4]-diazepan-1-ylmethyl)-1H-indole Dihydrochloride",2.2,uM,=,0.3424226808222063,1,O=S(=O)(c1ccccc1)n1cc(CN2CCCNCC2)c2ccccc21
1383,980053,10.1021/jm400240r,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy trifluoromethylcoumarin as substrate,Cc1cncc(Cc2ccc(-c3ccccc3)nc2)c1,5-((5-Methylpyridin-3-yl)methyl)-2-phenylpyridine,1.1,uM,=,0.041392685158225,1,c1ccc(-c2ccc(Cc3cccnc3)cn2)cc1
1384,643713,10.1016/j.bmcl.2010.06.009,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader,C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(N5CCN(C)CC5)c4)ccc32)sc1C(N)=O)c1ccccc1C(F)(F)F,(R)-5-(5-(2-(4-methylpiperazin-1-yl)pyridin-4-yl)-1H-benzo[d]imidazol-1-yl)-3-(1-(2-(trifluoromethyl)phenyl)ethoxy)thiophene-2-carboxamide,1.9,uM,=,0.2787536009528289,1,c1ccc(COc2csc(-n3cnc4cc(-c5ccnc(N6CCNCC6)c5)ccc43)c2)cc1
1385,51928,10.1021/jm034111v,,,,Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 45 minutes,C[C@H](NC(=O)/C=C/c1ccccc1)c1cccc(N2CCOCC2)c1,(E)-N-[1-((S)-3-Morpholin-4-yl-phenyl)-ethyl]-3-phenyl-acrylamide,22.0,uM,=,1.3424226808222062,1,O=C(/C=C/c1ccccc1)NCc1cccc(N2CCOCC2)c1
1386,1534761,,,,,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",COc1ccc(CNc2ccc(Cc3c[nH]c4ncc(C)cc34)c(F)n2)c(OC)n1,"US9096593, P-2097",5.0,uM,=,0.6989700043360189,1,c1cncc(CNc2ccc(Cc3c[nH]c4ncccc34)cn2)c1
1387,2017934,10.1021/acs.jmedchem.0c00834,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis,COc1ccccc1C(C)CNC(=O)c1c(C)c(-c2ccccc2)nc2ccc(Br)cc12,(+)-6-Bromo-N-[2-(2-methoxyphenyl)propyl]-3-methyl-2-phenylquinoline-4-carboxamide,0.7,uM,=,-0.1549019599857432,0,O=C(NCCc1ccccc1)c1cc(-c2ccccc2)nc2ccccc12
1388,1528565,,,,,"Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",CC(C)c1nc(CN(C)C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H](CC[C@@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,"US8987313, 11",0.12,uM,=,-0.9208187539523752,0,O=C(N[C@@H](CC[C@@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)NCc1cscn1)Cc1ccccc1)OCc1cncs1
1389,1911030,10.1021/acs.jmedchem.8b01226,,,,Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins,Cc1cccc(C#CC=C2CCN(S(=O)(=O)c3ccc(C#N)cc3)CC2)n1,4-({4-[3-(6-Methylpyridin-2-yl)prop-2-yn-1-ylidene]piperidin-1-yl}sulfonyl)benzonitrile,5.0,uM,=,0.6989700043360189,1,O=S(=O)(c1ccccc1)N1CCC(=CC#Cc2ccccn2)CC1
1390,1295000,10.1021/jm4017224,,,,Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation,Nc1nc2c(s1)CC[C@H]2C(=O)Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3ccccc3)N2)cc1,"(R)-2-Amino-N-(4-(((2S,5R)-5-((R)-hydroxy(phenyl)methyl)-pyrrolidin-2-yl)methyl)phenyl)-5,6-dihydro-4H-cyclopenta[d]-thiazole-4-carboxamide",86.0,uM,=,1.934498451243568,1,O=C(Nc1ccc(C[C@@H]2CC[C@H](Cc3ccccc3)N2)cc1)[C@@H]1CCc2scnc21
1391,1679904,10.1016/j.bmcl.2017.04.043,,,,Inhibition of CYP3A4 (unknown origin),Cc1nnc2sc(C(=O)NCc3ccc(-c4ccncc4)cc3)c(N)c2c1C,"5-amino-3,4-dimethyl-N-(4-(pyridin-4-yl)benzyl)thieno[2,3-c]pyridazine-6-carboxamide",0.34,uM,=,-0.4685210829577448,0,O=C(NCc1ccc(-c2ccncc2)cc1)c1cc2ccnnc2s1
1392,619910,10.1016/j.bmcl.2009.09.104,,,,Inhibition of CYP3A4,O=C(C1=C(c2ccc(CCCOc3c(F)ccc(F)c3Cl)cc2)CCNC1)N(Cc1cccc(Cl)c1Cl)C1CC1,"4-(4-(3-(2-chloro-3,6-difluorophenoxy)propyl)phenyl)-N-cyclopropyl-N-(2,3-dichlorobenzyl)-1,2,5,6-tetrahydropyridine-3-carboxamide",1.3,uM,=,0.1139433523068367,1,O=C(C1=C(c2ccc(CCCOc3ccccc3)cc2)CCNC1)N(Cc1ccccc1)C1CC1
1393,1828801,10.1021/acs.jmedchem.8b01098,,,,Inhibition of C-terminal 4His-tagged CYP3A4 (unknown origin) expressed in Escherichia coli by spectrophotometric analysis,COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccncc3F)cc2)c1,(R)-4-(3-Fluoropyridin-4-yl)-N-(1-(3-methoxyphenyl)ethyl)-benzamide,6.4,uM,=,0.8061799739838872,1,O=C(NCc1ccccc1)c1ccc(-c2ccncc2)cc1
1394,675407,10.1016/j.bmcl.2010.08.142,,,,Inhibition of CYP3A4,NC(=O)[C@]12CC3CC(C1)[C@@H](OC(=O)N1CC[C@H](Nc4ccc(C(F)(F)F)cn4)C1)C(C3)C2,(S)-3-(5-Trifluoromethyl-pyridin-2-ylamino)-pyrrolidine-1-carboxylic acid 5-carbamoyl-adamantan-2-yl ester,10.3,uM,=,1.0128372247051722,1,O=C(OC1C2CC3CC(C2)CC1C3)N1CC[C@H](Nc2ccccn2)C1
1395,988989,10.1021/jm400732v,,,,Inhibition of CYP3A4 (unknown origin),CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)c2ccccc2)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O.Cl,"(S)-N-((S)-5-Benzoyl-1-((6-bromo-2-methoxynaphthalen-1-yl)methyl)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-yl)-2-(methylamino)propanamide hydrochloride",1.2,uM,=,0.0791812460476248,1,O=C1CCN(C(=O)c2ccccc2)c2ccccc2N1Cc1cccc2ccccc12
1396,473932,10.1021/jm701121y,,,,Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay,O[C@](Cn1cccn1)(c1ccc(F)cc1F)n1cncn1,"(S)-1-(2,4-difluorophenyl)-2-(1H-pyrazol-1-yl)-1-(1H-1,2,4-triazol-1-yl)ethanol",44.0,uM,=,1.6434526764861874,1,c1ccc(C(Cn2cccn2)n2cncn2)cc1
1397,510198,10.1021/jm800355c,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,Cl.Fc1ccc(-c2ccc3c(c2)CCC3c2ccncc2)cc1,"4-(5-(4-Fluorophenyl)-2,3-dihydro-1H-inden-1-yl)pyridine Hydrochloride",1.093,uM,=,0.0386201619497027,1,c1ccc(-c2ccc3c(c2)CCC3c2ccncc2)cc1
1398,624295,10.1016/j.bmcl.2010.01.134,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,CC(c1ccncc1)c1c(CCN(C)C)sc2ccccc12,"rac-N,N-dimethyl-2-(3-(1-(pyridin-4-yl)ethyl)benzo[b]thiophen-2-yl)ethanamine",2.8,uM,=,0.4471580313422192,1,c1ccc2c(Cc3ccncc3)csc2c1
1399,2126504,10.1021/acs.jmedchem.1c00076,,,,Inhibition of CYP3A4 (unknown origin),COc1ccc(-c2ccc(CO[C@H]3C[C@@H](N=C=S)C3)nc2)cc1F,"5-(3-Fluoro-4-methoxyphenyl)-2-(((1s,3s)-3-isothiocyanatocyclobutoxy)methyl)pyridine",2.6,uM,=,0.414973347970818,1,c1ccc(-c2ccc(COC3CCC3)nc2)cc1
1400,1441252,10.1021/jm5010013,,,,Inhibition of CYP3A4 (unknown origin),CS(=O)(=O)c1ccc(NC(=O)N2C[C@H]3C[C@@H](c4ccccc4C(F)(F)F)C[C@H]3C2)c(C(=O)O)c1,"trans-5-(methylsulfonyl)-2-((3aR,6aS)-5-(2-(trifluoromethyl)phenyl)octahydrocyclopenta[c]pyrrole-2-carboxamido)benzoic acid",42.0,uM,=,1.6232492903979006,1,O=C(Nc1ccccc1)N1C[C@H]2C[C@@H](c3ccccc3)C[C@H]2C1
1401,1538966,10.1021/acs.jmedchem.5b01345,,,,Inhibition of CYP3A4 (unknown origin),Cc1noc([C@H]2C[C@@H]2C(=O)NCc2ccc(-c3cccc(OC(F)(F)F)c3)c3c2CN(C(=O)NC(C)(C)C)CC3)n1,"N-tert-butyl-8-(((trans)-2-(3-methyl-1,2,4-oxadiazol-5-yl)cyclopropanecarboxamido)methyl)-5-(3-(trifluoromethoxy)phenyl)-3,4-dihydroisoquinoline-2(1H)-carboxamide",13.0,uM,=,1.1139433523068367,1,O=C(NCc1ccc(-c2ccccc2)c2c1CNCC2)[C@H]1C[C@@H]1c1ncno1
1402,1912369,10.1021/acs.jmedchem.9b00687,,,,Inhibition of CYP3A4 in human liver microsomes at 1 uM using testosterone as substrate by LC-MS/MS analysis,C=CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1,"US9447106, 27b (peak 2)",60.6,uM,=,1.7824726241662865,1,c1ccc(Oc2ccc(-c3cc4n(n3)[C@H](C3CCNCC3)CCN4)cc2)cc1
1403,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCC(=O)OCC)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, F-22",3.58,uM,=,0.5538830266438743,1,O=C1[C@H](Cc2ccccc2)N2C(=O)CNN(C(=O)NCc3ccccc3)[C@H]2CN1Cc1cccc2cc[nH]c12
1404,473932,10.1021/jm701121y,,,,Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay,Cc1cnc(CNc2cc(-c3ccccc3)nc(-c3cccnc3)n2)nc1,N-((5-methylpyrimidin-2-yl)methyl)-6-phenyl-2-(pyridin-3-yl)pyrimidin-4-amine,9.6,uM,=,0.9822712330395684,1,c1ccc(-c2cc(NCc3ncccn3)nc(-c3cccnc3)n2)cc1
1405,945618,10.1016/j.bmc.2012.11.058,,,,Inhibition of CYP3A4 (unknown origin),N#Cc1cncc(Oc2c(Cl)cc(NS(=O)(=O)c3ccc(Cl)cc3Cl)cc2Cl)c1,"2,4-Dichloro-N-(3,5-dichloro-4-(5-cyanopyridin-3-yloxy)phenyl)benzenesulfonamide",0.01,uM,=,-2.0,0,O=S(=O)(Nc1ccc(Oc2cccnc2)cc1)c1ccccc1
1406,51909,10.1021/jm010531d,,,,Inhibition of human Cytochrome P450 3A4 by macrocycles,N#Cc1ccc2cc1Oc1cccc(c1)CN1CC[C@@H](NCc3cncn3C2)C1=O,"R-27-oxo-20-oxa-3,7,11,13-tetraazapentacyclo[19.3.1.13,6.115,19.09,13]heptacosa-1(24),9,11,15(26),16,18,21(25),22-octaen-18-yl cyanide",8.9,uM,=,0.9493900066449128,1,O=C1[C@H]2CCN1Cc1cccc(c1)Oc1cccc(c1)Cn1cncc1CN2
1407,464243,10.1021/jm7013309,,,,Inhibition of human CYP3A4 using 7-benzyloxyresorufin,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1,"(R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-ol",40.0,uM,=,1.6020599913279625,1,c1cc2c(Oc3ccc4[nH]ccc4c3)ncnn2c1
1408,962469,10.1021/jm4004895,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC/MS/MS analysis,C[C@@H](O)c1nc2cnc3[nH]ccc3c2n1[C@H]1CC[C@H](CCC#N)CC1,"3-(trans-4-(2-((R)-1-Hydroxyethyl)imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)cyclohexyl)propanenitrile",6.7,uM,=,0.8260748027008264,1,c1cc2c(ncc3ncn(C4CCCCC4)c32)[nH]1
1409,991614,10.1021/jm4008906,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,CCCN(C)C(=O)CN1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O,"(S)-2-(3-(Aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N-methyl-N-propylacetamide",5.5,uM,=,0.7403626894942439,1,O=C1NCc2nccc(-c3ccccc3)c21
1410,514583,10.1016/j.bmcl.2008.06.072,,,,Inhibition of recombinant CYP3A4,O=c1ccc(Cc2cc(Oc3cccc(Cl)c3)c3occc3c2)n[nH]1,6-((7-(3-chlorophenoxy)benzofuran-5-yl)methyl)pyridazin-3(2H)-one,0.41,uM,=,-0.3872161432802645,0,O=c1ccc(Cc2cc(Oc3ccccc3)c3occc3c2)n[nH]1
1411,555862,10.1016/j.bmcl.2008.04.047,,,,Inhibition of human CYP3A4,CN(C)CC#Cc1c(Oc2ccc(NC(=O)NC(=O)Cc3ccc(F)cc3)cc2F)ccnc1N,1-(4-(2-amino-3-(3-(dimethylamino)prop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(2-(4-fluorophenyl)acetyl)urea,2.7,uM,=,0.4313637641589873,1,O=C(Cc1ccccc1)NC(=O)Nc1ccc(Oc2ccncc2)cc1
1412,572636,10.1021/jm9002445,,,,Inhibition of human CYP3A4 by microtiter plate assay,Cc1cc(-c2ccnn2C)c2cccc(OCc3c(C)ccnc3CNC(=O)C3CCCCC3)c2n1,cyclohexanecarboxylic acid{4-methyl-3-[2-methyl-4-(2-methyl-2H-pyrazol-3-yl)-quinolin-8-yloxymethyl]-pyridin-2-ylmethyl}-amide,2.5,uM,=,0.3979400086720376,1,O=C(NCc1ncccc1COc1cccc2c(-c3ccn[nH]3)ccnc12)C1CCCCC1
1413,1637154,,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins,N#Cc1cnc2[nH]cc(C(=O)c3cccc(NS(=O)(=O)c4cc(F)ccc4F)c3F)c2c1,"N-[3-(5-Cyano-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2-fluoro-phenyl]-2,5-difluoro-benzenesulfonamide",5.0,uM,=,0.6989700043360189,1,O=C(c1cccc(NS(=O)(=O)c2ccccc2)c1)c1c[nH]c2ncccc12
1414,688021,10.1016/j.bmcl.2010.10.101,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins,Cl.Cn1c(=O)c2c(cc(N3CCC[C@@](C)(N)C3)n2Cc2cc(F)ccc2Cl)n(CCCO)c1=O,"(R)-6-(3-amino-3-methylpiperidin-1-yl)-5-(2-chloro-5-fluorobenzyl)-1-(3-hydroxypropyl)-3-methyl-1H-pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione hydrochloride",7.7,uM,=,0.8864907251724818,1,O=c1[nH]c(=O)c2c(cc(N3CCCCC3)n2Cc2ccccc2)[nH]1
1415,52090,10.1016/j.bmcl.2003.11.049,,,,Inhibition of CYP450 (Cytochrome P450) 3A4 with fluorogenic substrate BFC,CCN1c2ncc(CSc3cc(C)nc(C)c3)cc2C(=O)Nc2c(C)cc(F)nc21,"2-(2,6-Dimethyl-pyridin-4-ylsulfanylmethyl)-5-ethyl-7-fluoro-9-methyl-5,10-dihydro-4,5,6,10-tetraaza-dibenzo[a,d]cyclohepten-11-one",2.5,uM,=,0.3979400086720376,1,O=C1Nc2cccnc2Nc2ncc(CSc3ccncc3)cc21
1416,944981,10.1021/ml3003132,,,,Time-dependent inhibition of CYP3A4 in human liver microsome using midazolam as substrate by TDI shift assay,CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOC[C@@H]4C)n2)CCN(c2cc(C)ncn2)C3)cc1,"(S)-1-ethyl-3-(4-(4-(3-methylmorpholino)-7-(6-methylpyrimidin-4-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)phenyl)urea",8.4,uM,=,0.9242792860618816,1,c1ccc(-c2nc3c(c(N4CCOCC4)n2)CCN(c2ccncn2)C3)cc1
1417,986997,10.1016/j.bmcl.2013.08.012,,,,Inhibition of CYP3A4 in human liver microsomes,Nc1cc(CN2CCC(C(=O)N3CCC(n4c(=O)n(CCN5CCOCC5)c5ccccc54)CC3)CC2)ccn1,1-(1-(1-((2-aminopyridin-4-yl)methyl)piperidine-4-carbonyl)piperidin-4-yl)-3-(2-morpholinoethyl)-1H-benzo[d]imidazol-2(3H)-one,30.0,uM,=,1.4771212547196624,1,O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)n(CCN3CCOCC3)c3ccccc32)CC1
1418,988989,10.1021/jm400732v,,,,Inhibition of CYP3A4 (unknown origin),CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)CC(C)C)c2ccccc2N(Cc2ccccc2)C1=O.Cl,"(S)-N-((S)-1-Benzyl-5-(3-methylbutanoyl)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-yl)-2-(methylamino)propanamide hydrochloride",15.0,uM,=,1.1760912590556811,1,O=C1CCNc2ccccc2N1Cc1ccccc1
1419,2246941,10.1021/acs.jmedchem.1c02132,,,,Inhibition of CYP3A4 (unknown origin) incubated for 10 mins in presence of NADPH by LC-MS/MS analysis,COC(=O)Nc1cc(-c2ccc(OC[C@@H](N)CC(C)C)c(-c3ccno3)c2)ccn1,(S)-methyl (4-(4-((2-amino-4-methylpentyl)oxy)-3-(isoxazol-5-yl)phenyl)pyridin-2-yl)carbamate,0.18,uM,=,-0.744727494896694,0,c1cc(-c2ccncc2)cc(-c2ccno2)c1
1420,993439,10.6019/CHEMBL2448688,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,CN(C)S(=O)(=O)c1ccc(-n2ccnc2)c(NC(=O)c2cnc(-c3ccccc3)s2)c1,,10.0,uM,=,1.0,1,O=C(Nc1ccccc1-n1ccnc1)c1cnc(-c2ccccc2)s1
1421,542857,10.1021/jm801313t,,,,Inhibition of human recombinant CYP3A4,Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2c(c1)c(-c1cccc(Cl)c1)cc(=O)n2C,6-[Amino-(4-chloro-phenyl)-(1-methyl-1H-imidazol-2-yl)-methyl]-4-(3-chloro-phenyl)-1-methyl-1H-quinolin-2-one,1.7,uM,=,0.2304489213782739,1,O=c1cc(-c2ccccc2)c2cc(C(c3ccccc3)c3cnc[nH]3)ccc2[nH]1
1422,988989,10.1021/jm400732v,,,,Inhibition of CYP3A4 (unknown origin),CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2c(OC)ccc3cc(Br)ccc23)c2ccccc2N(C(=O)CS(C)(=O)=O)[C@H]1C.Cl,"(S)-N-((3S,4S)-1-((6-bromo-2-methoxynaphthalen-1-yl)methyl)-4-methyl-5-(2-(methylsulfonyl)acetyl)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-yl)-2-(methylamino)propanamide hydrochloride",4.8,uM,=,0.6812412373755872,1,O=C1CCNc2ccccc2N1Cc1cccc2ccccc12
1423,438164,10.1016/j.bmcl.2006.12.015,,,,Inhibition of CYP3A4,Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cccnc5)cnc(N)c34)cc2)c1,"1-(4-(4-amino-7-(pyridin-3-yl)thieno[3,2-c]pyridin-3-yl)phenyl)-3-m-tolylurea",0.25,uM,=,-0.6020599913279624,0,O=C(Nc1ccccc1)Nc1ccc(-c2csc3c(-c4cccnc4)cncc23)cc1
1424,2254484,10.1021/acs.jmedchem.2c00527,,,,Inhibition of CYP3A4 in human liver microsomes at 0.01 to 30 uM using phenacetin as substrate in presence of NADPH by UPLC-MS/MS analysis,CC(C)NC[C@@H](C(=O)N1CCN(c2ncnc3c2[C@H](C)CC(=O)N3)CC1)c1ccc(Cl)cc1,"(R)-4-(4-((S)-2-(4-chlorophenyl)-3-(isopropylamino)propionyl)piperazin-l-yl)-5-methyl-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one",39.2,uM,=,1.5932860670204574,1,O=C1CCc2c(ncnc2N2CCN(C(=O)Cc3ccccc3)CC2)N1
1425,559938,10.1016/j.bmcl.2008.10.072,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,C[C@@H]1CN(Cc2ccc(-c3ccccc3C(=O)N3CCC(C(=O)c4ccc(F)cc4)CC3)cc2)C[C@H](C)N1,"[4'-((3R,5S)-3,5-Dimethyl-piperazin-1-ylmethyl)-biphenyl-2-yl]-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-methanone",4.8,uM,=,0.6812412373755872,1,O=C(c1ccccc1)C1CCN(C(=O)c2ccccc2-c2ccc(CN3CCNCC3)cc2)CC1
1426,642395,10.1021/jm100400a,,,,Inhibition of CYP3A4 expressed in baculovirus infected insect microsomes,CC(C)=C(c1ccncc1)c1ccc(-c2ccc(O)c(O)c2)cc1,"4'-(2-methyl-1-(pyridin-4-yl)prop-1-enyl)biphenyl-3,4-diol",0.464,uM,=,-0.3334820194451191,0,C=C(c1ccncc1)c1ccc(-c2ccccc2)cc1
1427,1527876,,,,,Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,C[C@@H](c1ccc(-c2ccn(C(F)F)c(=O)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O,"US8575157, 5",29.0,uM,=,1.462397997898956,1,O=C1OC(c2ccccc2)CCN1Cc1ccc(-c2cc[nH]c(=O)c2)cc1
1428,1641445,,,,,"CYP450 Inhibition Assay: The ability of the R and S enantiomers of (4-fluorophenyl)(4-((5-methyl-1H-pyrazol-3-yl)amino)quinazolin-2-yl)methanol to inhibit the common drug metabolizing isoforms of cytochrome P450 (CYP) was evaluated against the following isoforms: CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. The compounds were incubated in duplicate with eight test compound concentrations (final DMSO concentration of 0.20%) with human liver microsomes (0.25 or 0.50 mg/mL) and NADPH (1 mM) in the presence of CYP isoform specific probe substrates (phenacetin, bupropion, taxol, diclofenac, mephenyloin, dextromethorphan, testosterone) at the Km for 10-20 minutes at 37° C. Selective CYP isoform inhibitors (furafulline, ticlopidine, quercetin, sulfaphenazole, ticlopidine, quinidine, ketoconazole) were screened alongside the test compounds as positive controls.",Cc1cc(Nc2nc([C@@H](O)c3ccc(F)cc3)nc3ccccc23)n[nH]1,"US9295672, (S)-(4-fluorophenyl)(4-((5-methyl-1H-pyrazol-3-yl)amino)quinazolin-2-yl)methanol",10.5,uM,=,1.021189299069938,1,c1ccc(Cc2nc(Nc3cc[nH]n3)c3ccccc3n2)cc1
1429,487712,10.1016/j.bmcl.2008.05.104,,,,Inhibition of CYP3A4,Cc1cc(N2CCC(N3C[C@@H](C)O[C@@H](C)C3)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,"4-((S)-2-(3-chlorophenyl)-2-hydroxyethylamino)-3-(6-(4-((2S,6R)-2,6-dimethylmorpholino)piperidin-1-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one",0.0031,uM,=,-2.508638306165728,0,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(N3CCC(N4CCOCC4)CC3)cc2[nH]1
1430,874112,10.1021/jm300118s,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis,CO[C@H](C)C(=O)N[C@@H](Cc1ccc2c(c1)OCO2)[C@H](O)CN[C@H]1CC2(CCC2)Oc2ncc(CC(C)(C)C)cc21,"(R)-N-((2S,3R)-1-(Benzo[d][1,3]dioxol-5-yl)-3-hydroxy-4-((S)-6'-neopentyl-3',4'-dihydrospiro[cyclobutane-1,2'-pyrano[2,3-b]pyridine]-4'-ylamino)butan-2-yl)-2-methoxypropanamide",0.05,uM,=,-1.3010299956639813,0,c1cnc2c(c1)[C@@H](NCCCCc1ccc3c(c1)OCO3)CC1(CCC1)O2
1431,1817350,10.1021/acs.jmedchem.8b01857,,,,Reversible inhibition of CYP3A4 (unknown origin) using testosterone as substrate,Cn1ncc(NC(=O)c2nc(-c3c(F)cccc3F)sc2N)c1N1CC[C@@H](N)[C@H](F)CC1,"US8614206, 139",6.3,uM,=,0.7993405494535817,1,O=C(Nc1cn[nH]c1N1CCCCCC1)c1csc(-c2ccccc2)n1
1432,632105,10.1016/j.bmcl.2010.03.057,,,,Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin,Cc1cc(N2CCN(S(C)(=O)=O)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,(S)-4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-3-(4-methyl-6-(4-(methylsulfonyl)piperazin-1-yl)-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one,0.6,uM,=,-0.2218487496163563,0,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(N3CCNCC3)cc2[nH]1
1433,973974,10.1021/jm400380m,,,,Inhibition of CYP3A4 (unknown origin) after 10 mins by fluorescence assay,COc1ccc2c(c1)/C(=C\c1ccc3c(/C=C/c4ccc(N5CCN(C)CC5)nc4)n[nH]c3c1)C(=O)N2,5-Methoxy-(E)-3-((3-((E)-2-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)vinyl)-1H-indazol-6-yl)methylene)indolin-2-one,10.0,uM,=,1.0,1,O=C1Nc2ccccc2/C1=C\c1ccc2c(/C=C/c3ccc(N4CCNCC4)nc3)n[nH]c2c1
1434,492191,10.1016/j.bmcl.2008.05.075,,,,Inhibition of CYP3A4,O=C(O)[C@H](Cc1ccc(-n2c(-c3cccnc3)nc3cccnc32)cc1)NC1=C(Br)C(=O)C12CCCCC2,"(S)-2-(2-Bromo-3-oxo-spiro[3.5]non-1-en-1-ylamino)-3-[4-(2-pyridin-3-yl-imidazo[4,5-b]pyridin-3-yl)-phenyl]-propionic acid",62.0,uM,=,1.792391689498254,1,O=C1C=C(NCCc2ccc(-n3c(-c4cccnc4)nc4cccnc43)cc2)C12CCCCC2
1435,1352209,10.1021/jm4010835,,,,Inhibition of human recombinant CYP3A4,Cc1nc(C(F)(F)F)ccc1Cn1c(=O)c(-c2ccncc2)c(-c2ccc(Cl)cc2)c2nn(C)c(=O)n21,"8-(4-Chlorophenyl)-2-methyl-5-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)methyl)-7-(pyridin-4-yl)-[1,2,4]-triazolo[4,3-b]pyridazine-3,6(2H,5H)-dione",6.8,uM,=,0.8325089127062363,1,O=c1c(-c2ccncc2)c(-c2ccccc2)c2n[nH]c(=O)n2n1Cc1cccnc1
1436,1558600,10.1016/j.bmcl.2015.06.020,,,,Inhibition of CYP3A4 (unknown origin) by fluorescence assay,Cc1cn(-c2ccc3c(c2)CCc2sc(Cc4ccccc4)nc2N3)cn1,"2-benzyl-7-(4-methyl-1H-imidazol-1-yl)-9,10-dihydro-4H-benzo[b]thiazolo[5,4-f]azepine",0.7,uM,=,-0.1549019599857432,0,c1ccc(Cc2nc3c(s2)CCc2cc(-n4ccnc4)ccc2N3)cc1
1437,519907,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,Cc1ccccc1CNc1cc(-n2cncn2)cn2c(C)c(C)nc12,"2,3-dimethyl-N-(2-methylbenzyl)-6-(1H-1,2,4-triazol-1-yl)imidazo[1,2-a]pyridin-8-amine",17.0,uM,=,1.230448921378274,1,c1ccc(CNc2cc(-n3cncn3)cn3ccnc23)cc1
1438,1660136,10.1021/acs.jmedchem.6b01918,,,,Inhibition of human CYP3A4 assessed as inhibition of dealkylation,N[C@H]1CC[C@@](CCNc2cc(F)c(S(=O)(=O)Nc3nccs3)cc2Cl)(c2ccccc2)CC1,"trans-4-((2-((1S,4S)-4-Amino-1-phenylcyclohexyl)ethyl)amino)-5-chloro-2-fluoro-N-(thiazol-2-yl)benzenesulfonamide",9.8,uM,=,0.9912260756924948,1,O=S(=O)(Nc1nccs1)c1ccc(NCCC2(c3ccccc3)CCCCC2)cc1
1439,2166205,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,COc1ccc(-c2cc(Nc3ccnc(N4CCOCC4)n3)on2)cc1,3-(4-methoxyphenyl)-N-(2-morpholinopyrimidin-4-yl)isoxazol-5-amine,30.04,uM,=,1.4776999283321308,1,c1ccc(-c2cc(Nc3ccnc(N4CCOCC4)n3)on2)cc1
1440,487712,10.1016/j.bmcl.2008.05.104,,,,Inhibition of CYP3A4,COCCOC(=O)N1CCN(C2CCN(c3cc(C)c4nc(-c5c(NC[C@@H](O)c6cccc(Cl)c6)cc[nH]c5=O)[nH]c4c3)CC2)CC1,"(S)-2-methoxyethyl 4-(1-(2-(4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-2-oxo-1,2-dihydropyridin-3-yl)-7-methyl-3H-benzo[d]imidazol-5-yl)piperidin-4-yl)piperazine-1-carboxylate",0.0024,uM,=,-2.619788758288394,0,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(N3CCC(N4CCNCC4)CC3)cc2[nH]1
1441,990449,10.1016/j.bmcl.2013.09.001,,,,Inhibition of CYP3A4 in human liver microsomes in presence of NADPH,O=C(Nc1ccc(F)cn1)c1cc(Cl)cc(Oc2cncnc2)c1,3-chloro-N-(5-fluoropyridin-2-yl)-5-(pyrimidin-5-yloxy)benzamide,6.2,uM,=,0.7923916894982539,1,O=C(Nc1ccccn1)c1cccc(Oc2cncnc2)c1
1442,1335568,10.1021/jm401731q,,,,Inhibition of CYP3A4 (unknown origin),CN1CCN(c2cc(N3CCC[C@@H]3C(=O)NCCc3ccc(C#N)cc3)nc(C(F)(F)F)n2)CC1,(2R)-N-[2-(4-Cyanophenyl)ethyl]-1-[6-(4-methylpiperazin-1-yl)-2-(trifluoromethyl)pyrimidin-4-yl]pyrrolidine-2-carboxamide,0.7,uM,=,-0.1549019599857432,0,O=C(NCCc1ccccc1)[C@H]1CCCN1c1cc(N2CCNCC2)ncn1
1443,2048449,10.1016/j.bmc.2020.115734,,,,Inhibition of recombinant CYP3A4 (unknown origin) by fluorescence-based assay,CCn1nc2c(c1Nc1nc(-c3ccc(-n4cnc(C)c4)c(OC)n3)cs1)CCC2,"N-(2-ethyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-4-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)thiazol-2-amine",20.0,uM,=,1.3010299956639813,1,c1cn(-c2ccc(-c3csc(Nc4[nH]nc5c4CCC5)n3)nc2)cn1
1444,701158,10.1016/j.bmcl.2010.11.074,,,,Inhibition of CYP3A4,O=C(O)CCNC(=O)c1ccc(Cn2nc(-c3cc(Cl)cc(Cl)c3)cc2-c2ccc(OC(F)(F)F)cc2)cc1,"3-(4-((3-(3,5-dichlorophenyl)-5-(4-(trifluoromethoxy)phenyl)-1H-pyrazol-1-yl)methyl)benzamido)propanoic acid",39.0,uM,=,1.591064607026499,1,c1ccc(Cn2nc(-c3ccccc3)cc2-c2ccccc2)cc1
1445,595638,10.1016/j.bmcl.2009.09.096,,,,Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH,COc1ccc2c(OCc3nnc4ccc(-c5cc(F)cc(F)c5)nn34)ccnc2c1,"4-((6-(3,5-difluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy)-7-methoxyquinoline",8.3,uM,=,0.919078092376074,1,c1ccc(-c2ccc3nnc(COc4ccnc5ccccc45)n3n2)cc1
1446,982382,10.1016/j.bmcl.2013.07.071,,,,Inhibition of CYP3A4 (unknown origin),COC[C@@H](Oc1cc(C[C@@H]2C[S@@+]([O-])C[C@H](NCc3cccc(C(C)C)c3)[C@H]2O)cc(F)c1N)C(F)(F)F,"(1R,3S,4S,5R)-3-[4-Amino-3-fluoro-5-((R)-2,2,2-trifluoro-1-methoxymethyl-ethoxy)-benzyl]-5-(3-isopropyl-benzylamino)-1-oxo-tetrahydro-thiopyran-4-ol",0.7,uM,=,-0.1549019599857432,0,c1ccc(CN[C@H]2C[SH+]C[C@@H](Cc3ccccc3)C2)cc1
1447,802673,10.1016/j.bmcl.2011.12.125,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,CCN(CC)C(=O)c1cccc(NC(=O)Nc2ccc(-c3ccnc4[nH]cnc34)cc2)c1,"3-(3-(4-(3H-imidazo[4,5-b]pyridin-7-yl)phenyl)ureido)-N,N-diethylbenzamide",0.047,uM,=,-1.3279021420642825,0,O=C(Nc1ccccc1)Nc1ccc(-c2ccnc3[nH]cnc23)cc1
1448,495542,10.1021/jm801332q,,,,Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate by time dependent inhibition assay,C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(Nc4cccc(C#N)c4)CC3)cc2)CCN1,3-((1-[(4-([(3S)-3-Methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinyl)amino)benzonitrile,36.0,uM,=,1.5563025007672873,1,O=C(Cc1ccc(CN2CCNCC2)cc1)N1CCC(Nc2ccccc2)CC1
1449,1364175,10.1021/ml500019s,,,,Inhibition of CYP3A4 (unknown origin) pre-incubated with enzyme,COCCOc1ccccc1N1CCN(C(=O)[C@]2(Oc3ccc(C(F)(F)F)cc3)CCCN(C(=O)c3cnccc3C(F)(F)F)[C@@H]2CCO)CC1.Cl,"((2R,3S)-2-(2-hydroxyethyl)-1-(4-(trifluoromethyl)nicotinoyl)-3-(4-(trifluoromethyl)phenoxy)piperidin-3-yl)(4-(2-(2-methoxyethoxy)phenyl)piperazin-1-yl)methanone hydrochloride",0.9,uM,=,-0.0457574905606751,0,O=C(c1cccnc1)N1CCC[C@@](Oc2ccccc2)(C(=O)N2CCN(c3ccccc3)CC2)C1
1450,461436,10.1016/j.bmcl.2007.10.092,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,CC[C@@H]1CCC[C@H](C2(OC(=O)N3CCN(C(C)(C)CO)CC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1,"1-((2R,6R)-1-(4-chlorophenylsulfonyl)-6-ethylpiperidin-2-yl)cyclopropyl 4-(1-hydroxy-2-methylpropan-2-yl)piperazine-1-carboxylate",2.2,uM,=,0.3424226808222063,1,O=C(OC1([C@H]2CCCCN2S(=O)(=O)c2ccccc2)CC1)N1CCNCC1
1451,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NNc5ccccc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, F-60",6.8,uM,=,0.8325089127062363,1,O=C(NNc1ccccc1)c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12
1452,595557,10.1016/j.bmcl.2009.10.084,,,,Inhibition of CYP3A4 using BFC as a substrate,Cc1cc2cc(N/C(=N\C(=O)c3ccc(C(N)=O)nc3)N[C@H]3CCCCN(CC(=O)N4CCCC4)C3=O)ccc2o1,"(S)-N5-((2-methylbenzofuran-5-ylamino)(2-oxo-1-(2-oxo-2-(pyrrolidin-1-yl)ethyl)azepan-3-ylamino)methylene)pyridine-2,5-dicarboxamide",18.0,uM,=,1.255272505103306,1,O=C(/N=C(\Nc1ccc2occc2c1)N[C@H]1CCCCN(CC(=O)N2CCCC2)C1=O)c1cccnc1
1453,493017,10.1021/jm800851u,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,COCCN(C)c1cccc(-c2cc(NC(C)=O)nc(-n3nc(C)cc3C)n2)n1,"N-(2-(3,5-Dimethyl-pyrazol-1-yl)-6-{6-[(2-methoxyethyl)-methylamino]-pyridin-2-yl}-pyrimidin-4-yl)-acetamide",2.5,uM,=,0.3979400086720376,1,c1ccc(-c2ccnc(-n3cccn3)n2)nc1
1454,1696937,10.1016/j.bmcl.2017.09.042,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate pretreated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis,O=C(Nc1ccc(F)cn1)c1cc(Oc2cncc(F)c2)cn2ccnc12,"N-(5-Fluoropyridin-2-yl)-6-((5-fluoropyridin-3-yl)oxy)imidazo[1,2-a]pyridine-8-carboxamide",3.9,uM,=,0.5910646070264992,1,O=C(Nc1ccccn1)c1cc(Oc2cccnc2)cn2ccnc12
1455,854487,10.1021/jm300579z,,,,Inhibition of human CYP3A4 in liver microsomes assessed as testosterone 6beta-hydroxylation after 48 hrs,COc1ccc2cc(-c3cc(-c4cc(Cl)cc(Cl)c4)nn3[C@@H](C)c3ccc(C(=O)NCCC(=O)O)cc3)ccc2c1,"(S)-3-(4-(1-(3-(3,5-dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl)ethyl)benzamido)propanoic acid",60.0,uM,=,1.7781512503836436,1,c1ccc(Cn2nc(-c3ccccc3)cc2-c2ccc3ccccc3c2)cc1
1456,51750,10.1021/jm010531d,,,,Inhibition of dog Cytochrome P450 3A by macrocycles,N#Cc1ccc2cc1Oc1ccc3c(c1)[C@@H](CC3)N1CC[C@@H](NCc3cncn3C2)C1=O,"R,R-A-29-oxo-19-oxa-2,6,10,12-tetraazahexacyclo[18.5.2.12,5.114,18.08,12.023,26]nonacosa-8,10,14(28),15,17,20(27),21,23(26)-octaen-17-yl cyanide",10.4,uM,=,1.0170333392987805,1,O=C1[C@H]2CCN1[C@@H]1CCc3ccc(cc31)Oc1cccc(c1)Cn1cncc1CN2
1457,461436,10.1016/j.bmcl.2007.10.092,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,O=C(CC1([C@H]2CCC[C@@H](C3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CC2CCC(C1)N2CCO,"2-(1-((2R,6S)-1-(4-chlorophenylsulfonyl)-6-cyclopropylpiperidin-2-yl)cyclopropyl)-1-(8-(2-hydroxyethyl)-3,8-diaza-bicyclo[3.2.1]octan-3-yl)ethanone",1.0,uM,=,0.0,0,O=C(CC1([C@H]2CCC[C@@H](C3CC3)N2S(=O)(=O)c2ccccc2)CC1)N1CC2CCC(C1)N2
1458,600767,10.1016/j.bmcl.2009.07.127,,,,Inhibition of human CYP3A4,COC(=O)c1cccc(NC(=O)COc2ccc(C34CC5CC(CC(C(=O)N6CCN(Cc7cccc(OC)c7)CC6)(C5)C3)C4)cc2)c1,3-[2-(4-{3-[4-(3-Methoxy-benzyl)-piperazine-1-carbonyl]-adamantan-1-yl}-phenoxy)-acetylamino]-benzoic acid methyl ester,0.82,uM,=,-0.0861861476162833,0,O=C(COc1ccc(C23CC4CC(CC(C(=O)N5CCN(Cc6ccccc6)CC5)(C4)C2)C3)cc1)Nc1ccccc1
1459,51898,10.1016/s0960-894x(98)00653-2,,,,Antiviral activity as inhibition of human liver microsomal Cytochrome P450 3A4,CC(C)c1nc(COC(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)[C@H](O)CN2CCN(Cc3cccc4c3COC4)C[C@H]2C(=O)NC(C)(C)C)C(C)C)cs1,"((S)-1-{(1S,2R)-1-Benzyl-3-[(S)-2-tert-butylcarbamoyl-4-(1,3,4,5-tetrahydro-isobenzofuran-4-ylmethyl)-piperazin-1-yl]-2-hydroxy-propylcarbamoyl}-2-methyl-propyl)-carbamic acid 2-isopropyl-thiazol-4-ylmethyl ester",12.0,uM,=,1.0791812460476249,1,O=C(CNC(=O)OCc1cscn1)N[C@H](CCN1CCN(Cc2cccc3c2COC3)CC1)Cc1ccccc1
1460,474877,10.1021/jm701097z,,,,Inhibition of CYP3A4,COc1cc2nccc(Oc3ccc4c(C(=O)Nc5cc(C)no5)cccc4c3)c2cc1OC,"6-(6,7-dimethoxyquinolin-4-yloxy)-N-(3-methylisoxazol-5-yl)-1-naphthamide",40.0,uM,=,1.6020599913279625,1,O=C(Nc1ccno1)c1cccc2cc(Oc3ccnc4ccccc34)ccc12
1461,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCC(N(C)C)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, E-61",2.23,uM,=,0.3483048630481606,1,O=C(c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12)N1CCCCC1
1462,539794,10.1021/jm8005405,,,,Inhibition of CYP3A4 in human liver microsomes,Cc1ccc2c(NC3CC3)noc2c1-c1ccc2c(N3CCOC[C@@H]3C)nncc2c1,N-Cyclopropyl-6-methyl-7-(1-((S)-3-methylmorpholino)phthalazin-6-yl)benzo[d]isoxazol-3-amine,5.6,uM,=,0.7481880270062004,1,c1cc(-c2ccc3c(N4CCOCC4)nncc3c2)c2onc(NC3CC3)c2c1
1463,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(CCOC)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, E-10",9.12,uM,=,0.959994838328416,1,O=C(c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12)N1CCNCC1
1464,673952,10.1016/j.bmcl.2010.08.086,,,,Inhibition of CYP3A4 using midazolam as substrate,Cc1cc(Cl)c(OCCOc2ccc([C@H]3CCNC[C@@H]3C(=O)N(Cc3cccc(C)c3C)C3CC3)cc2)c(Cl)c1,"rac-N-cyclopropyl-4-(4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)phenyl)-N-(2,3-dimethylbenzyl)piperidine-3-carboxamide",7.4,uM,=,0.8692317197309762,1,O=C([C@H]1CNCC[C@@H]1c1ccc(OCCOc2ccccc2)cc1)N(Cc1ccccc1)C1CC1
1465,1772291,10.1016/j.bmc.2018.04.054,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis,CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,SID144204227,0.0345,uM,=,-1.4621809049267258,0,c1ccc([C@@]2(Cn3ccnc3)OC[C@H](COc3ccc(N4CCNCC4)cc3)O2)cc1
1466,742805,10.1016/j.bmc.2011.02.009,,,,Inhibition of human CYP3A4 after 30 mins,CNC(=O)c1cccc(-c2ccc(C(O)(c3c[nH]cn3)C(C)C)cc2)c1,"rac-4'-[1-Hydroxy1-(1H-imidazol-4-yl)-2-methylpropyl]-Nmethyl[1,1'-biphenyl]-3-carboxamide",8.1,uM,=,0.9084850188786496,1,c1ccc(-c2ccc(Cc3c[nH]cn3)cc2)cc1
1467,2207925,10.1021/acsmedchemlett.2c00411,,,,Inhibition of CYP3A4 (unknown origin) in presence of NADPH,COc1ccc(Nc2ncc(C)c(Nc3ccc4oc(=O)[nH]c4c3)n2)cc1C(F)(F)F,5-((2-((4-methoxy-3-(trifluoromethyl)phenyl)amino)-5-methylpyrimidin-4-yl)amino)benzo[d]oxazol-2(3H)one,0.4,uM,=,-0.3979400086720376,0,O=c1[nH]c2cc(Nc3ccnc(Nc4ccccc4)n3)ccc2o1
1468,448320,10.1016/j.bmc.2007.05.069,,,,Inhibition of CYP3A4,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCO)C(=O)C(C)(c1cc(F)cc(F)c1)O2,"6-(2,4-diamino-6-ethyl-pyrimidin-5-yl)-2-(3,5-difluoro-phenyl)-4-(3-hydroxy-propyl)-2-methyl-4H-benzo-[1,4]oxazin-3-one",30.0,uM,=,1.4771212547196624,1,O=C1Nc2cc(-c3cncnc3)ccc2OC1c1ccccc1
1469,1289880,10.1021/jm401642q,,,,Inhibition of recombinant human CYP3A4,CC1CN(C(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)c2ccccc21,"rac-2-[2-(3-Methyl-2,3-dihydro-1H-indol-1-yl)-2-oxoethyl]-6-(morpholin-4-yl)pyrimidin-4(3H)-one",40.0,uM,=,1.6020599913279625,1,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2ccccc21
1470,2156515,10.1021/acs.jmedchem.1c01272,,,,Inhibition of CYP3A4 in human liver microsomes using IPA as substrate preincubated for 10 mins followed by NADPH generating system addition and measured after 20 mins,COc1cc2c(cc1OC)CN(CCc1ccc(-n3nnc(-c4cc(Oc5cccnc5)ccc4NC(=O)c4cc(=O)c5ccccc5o4)n3)cc1)CC2,"N-(2-(2-(4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)-2H-tetrazol-5-yl)-4-(pyridin-3-yloxy)phenyl)-4-oxo-4H-chromene-2-carboxamide",1.469,uM,=,0.1670217957902565,1,O=C(Nc1ccc(Oc2cccnc2)cc1-c1nnn(-c2ccc(CCN3CCc4ccccc4C3)cc2)n1)c1cc(=O)c2ccccc2o1
1471,1660136,10.1021/acs.jmedchem.6b01918,,,,Inhibition of human CYP3A4 assessed as inhibition of dealkylation,CN1C(C)(C)CC(Nc2cc(F)c(S(=O)(=O)Nc3nccs3)cc2Cl)CC1(C)C,"5-Chloro-2-fluoro-4-((1,2,2,6,6-pentamethylpiperidin-4-yl)-amino)-N-(thiazol-2-yl)benzenesulfonamide",20.0,uM,=,1.3010299956639813,1,O=S(=O)(Nc1nccs1)c1ccc(NC2CCNCC2)cc1
1472,802673,10.1016/j.bmcl.2011.12.125,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,COC(=O)c1cccc(NC(=O)Nc2ccc(-c3ccnc4[nH]cnc34)cc2)c1,"methyl 3-(3-(4-(3H-imidazo[4,5-b]pyridin-7-yl)phenyl)ureido)benzoate",0.082,uM,=,-1.0861861476162833,0,O=C(Nc1ccccc1)Nc1ccc(-c2ccnc3[nH]cnc23)cc1
1473,1295469,10.1016/j.bmcl.2014.02.004,,,,Inhibition of human recombinant CYP3A4,O=C(O)c1sc(N2CCOCC2)nc1CC(=O)N1CCc2cc(F)ccc21,4-(2-(5-fluoroindolin-1-yl)-2-oxoethyl)-2-morpholinothiazole-5-carboxylic acid,40.0,uM,=,1.6020599913279625,1,O=C(Cc1csc(N2CCOCC2)n1)N1CCc2ccccc21
1474,473932,10.1021/jm701121y,,,,Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay,CS(=O)(=O)OCC1COC(Cn2cncn2)(c2ccc(Cl)cc2Cl)O1,"(2-((1H-1,2,4-triazol-1-yl)methyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-4-yl)methyl methanesulfonate",7.7,uM,=,0.8864907251724818,1,c1ccc(C2(Cn3cncn3)OCCO2)cc1
1475,1911030,10.1021/acs.jmedchem.8b01226,,,,Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins,CCS(=O)(=O)N1CCC(=CC#Cc2cccc(C)n2)CC1,2-{3-[1-(Ethylsulfonyl)piperidin-4-ylidene]prop-1-yn-1-yl}-6-methylpyridine,17.2,uM,=,1.235528446907549,1,C(#Cc1ccccn1)C=C1CCNCC1
1476,1288280,10.1016/j.bmcl.2013.12.057,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,CC(C)[C@H](NC(=O)N(C)Cc1cscn1)C(=O)N[C@@H](CC[C@@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1,"Thiazol-5-ylmethyl(2S,5S)-5-((S)-3-methyl-2-(3-methyl-3-(thiazol-4-ylmethyl)ureido)butanamido)-1,6-diphenylhexan-2-ylcarbamate",0.12,uM,=,-0.9208187539523752,0,O=C(CNC(=O)NCc1cscn1)N[C@@H](CC[C@@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
1477,1447575,10.1016/j.bmcl.2014.05.068,,,,Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method,OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccccn1,"2-(2,4-difluorophenyl)-1,1-difluoro-1-(pyridin-2-yl)-3-(1H-tetrazol-1-yl)propan-2-ol",136.0,uM,=,2.133538908370217,1,c1ccc(C(Cc2ccccn2)Cn2cnnn2)cc1
1478,51909,10.1021/jm010531d,,,,Inhibition of human Cytochrome P450 3A4 by macrocycles,N#Cc1ccc2cc1Oc1ccc3c(c1)[C@@H](CC3)N1CC[C@@H](NCc3cncn3C2)C1=O,"R,R-A-29-oxo-19-oxa-2,6,10,12-tetraazahexacyclo[18.5.2.12,5.114,18.08,12.023,26]nonacosa-8,10,14(28),15,17,20(27),21,23(26)-octaen-17-yl cyanide",6.6,uM,=,0.8195439355418687,1,O=C1[C@H]2CCN1[C@@H]1CCc3ccc(cc31)Oc1cccc(c1)Cn1cncc1CN2
1479,1474044,10.1021/jm501740a,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,O=C(N[C@H](CC1CC1)c1ccccn1)c1ccc2[nH]nc(-c3ccc(N4[C@H]5CC[C@H]4CC(O)C5)cc3)c2c1,N-((R)-2-cyclopropyl-1-(pyridin-2-yl)ethyl)-3-(4-((endo)-3-hydroxy-8-azabicyclo[3.2.1]octan-8-yl)phenyl)-1H-indazole-5-carboxamide,1.3,uM,=,0.1139433523068367,1,O=C(N[C@H](CC1CC1)c1ccccn1)c1ccc2[nH]nc(-c3ccc(N4[C@@H]5CCC[C@@H]4CC5)cc3)c2c1
1480,873423,10.1021/jm3006788,,,,Inhibition of CYP3A4,Cn1c(-c2cnccn2)c(C2CCCC2)c2ccc(C(=O)NC3(C(=O)Nc4ccc(/C=C/C(=O)O)cc4)CCC3)cc21,(E)-3-(4-(1-(3-cyclopentyl-1-methyl-2-(pyrazin-2-yl)-1H-indole-6-carboxamido)cyclobutanecarboxamido)phenyl)acrylic acid,10.6,uM,=,1.0253058652647702,1,O=C(NC1(C(=O)Nc2ccccc2)CCC1)c1ccc2c(C3CCCC3)c(-c3cnccn3)[nH]c2c1
1481,552281,10.1016/j.bmcl.2008.04.036,,,,Inhibition of CYP3A4,N[C@@H](Cn1c(=O)c(-c2ccc(CO)cc2)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1,"(R)-1-(2-fluoro-6-(trifluoromethyl)benzyl)-3-(2-amino-2-phenylethyl)-5-(4-(hydroxymethyl)phenyl)pyrimidine-2,4(1H,3H)-dione",0.8,uM,=,-0.0969100130080563,0,O=c1c(-c2ccccc2)cn(Cc2ccccc2)c(=O)n1CCc1ccccc1
1482,673952,10.1016/j.bmcl.2010.08.086,,,,Inhibition of CYP3A4 using midazolam as substrate,CCNCCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1,"(3R,4S)-N-(2-chloro-5-(2-(ethylamino)ethyl)benzyl)-N-cyclopropyl-4-(4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)phenyl)piperidine-3-carboxamide",15.0,uM,=,1.1760912590556811,1,O=C([C@H]1CNCC[C@@H]1c1ccc(OCCOc2ccccc2)cc1)N(Cc1ccccc1)C1CC1
1483,1629312,10.1016/j.bmcl.2016.11.020,,,,Inhibition of CYP3A4 (unknown origin),CCc1ccc(OCCNc2nc(Nc3cc(C)[nH]n3)cc(C)c2C#N)cn1,2-(2-(6-ethylpyridin-3-yloxy)ethylamino)-4-methyl-6-(5-methyl-1H-pyrazol-3-ylamino)nicotinonitrile,1.6,uM,=,0.2041199826559248,1,c1cncc(OCCNc2cccc(Nc3cc[nH]n3)n2)c1
1484,2156515,10.1021/acs.jmedchem.1c01272,,,,Inhibition of CYP3A4 in human liver microsomes using IPA as substrate preincubated for 10 mins followed by NADPH generating system addition and measured after 20 mins,COc1cc(NC(=O)c2cc(=O)c3ccccc3o2)c(-c2nnn(-c3ccc(CCN4CCc5ccc(-n6ccnc6)cc5C4)cc3)n2)cc1OC,"N-(2-(2-(4-(2-(7-(1H-imidazol-1-yl)-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl)-4-oxo-4H-chromene-2-carboxamide",0.397,uM,=,-0.4012094932368849,0,O=C(Nc1ccccc1-c1nnn(-c2ccc(CCN3CCc4ccc(-n5ccnc5)cc4C3)cc2)n1)c1cc(=O)c2ccccc2o1
1485,1778315,10.1016/j.bmcl.2018.06.040,,,,Inhibition of CYP3A4 (unknown origin),CC(C)S(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1,"N-(4-(1H-pyrrolo[2,3-b]pyridin-3-yl)thiazol-2-yl)-2-(3-(1-methylethylsulfonamido)phenyl)acetamide",4.9,uM,=,0.6901960800285137,1,O=C(Cc1ccccc1)Nc1nc(-c2c[nH]c3ncccc23)cs1
1486,1560508,10.1016/j.bmc.2016.02.014,,,,Inhibition of CYP3A4 (unknown origin),C[N+]1([O-])CCC2(CC1)C(=O)Nc1cc(/C=C3\c4ccccc4COc4cc(F)ccc43)ccc12,"6-((3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)methyl)-1'-methyl-2-oxospiro[indoline-3,4'-piperidine]1'-oxide",26.139,uM,=,1.417288968753737,1,O=C1Nc2cc(/C=C3\c4ccccc4COc4ccccc43)ccc2C12CC[NH2+]CC2
1487,1684789,10.1016/j.ejmech.2017.04.023,,,,Inhibition of recombinant human CYP3A4 expressed in baculosomes using BOMR as substrate preincubated for 10 mins followed by substrate/NADP+ addition measured for 1 hr,Cc1cc(C(=O)N/N=C/c2ccc([N+](=O)[O-])cc2)c2c(C)nn(-c3ccccc3)c2n1,"N'-(4-nitrobenzylidene)-3,6-dimethyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine-4-carbohydrazide",155.7,uM,=,2.19228861256812,1,O=C(N/N=C/c1ccccc1)c1ccnc2c1cnn2-c1ccccc1
1488,464243,10.1021/jm7013309,,,,Inhibition of human CYP3A4 using 7-benzyloxyresorufin,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@@H](C)N)c(C)c34)ccc2[nH]1,"(S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl) 2-aminopropanoate",1.6,uM,=,0.2041199826559248,1,c1cc2c(Oc3ccc4[nH]ccc4c3)ncnn2c1
1489,796228,10.1016/j.bmcl.2011.10.115,,,,Inhibition of CYP3A4,COc1ccc(Cn2c([C@H]3CNCCS3)nc3ccccc32)cc1,(+)-(R)-2-(1-(4-methoxybenzyl)-1H-benzo[d]imidazol-2-yl)thiomorpholine,5.8,uM,=,0.7634279935629373,1,c1ccc(Cn2c([C@H]3CNCCS3)nc3ccccc32)cc1
1490,1908478,10.1021/acsmedchemlett.9b00325,,,,Inhibition of human recombinant CYP3A4 using midazolam as substrate incubated for 40 to 130 mins in presence of NADPH by LC-MS/MS analysis,C[C@@H](c1ccc(NC(=O)N2CC(c3cccnc3)C2)cc1)N1Cc2ccccc2C1=O,(S)-N-(4-(1-(1-oxoisoindolin-2-yl)ethyl)phenyl)-3-(pyridin-3-yl)azetidine-1-carboxamide,3.04,uM,=,0.4828735836087537,1,O=C(Nc1ccc(CN2Cc3ccccc3C2=O)cc1)N1CC(c2cccnc2)C1
1491,453158,10.1016/j.bmcl.2006.09.056,,,,Inhibition of CYP3A4 in presence of BFC substrate,NCC1CCC(CNc2nc(NCc3ccccc3Cl)ncc2[N+](=O)[O-])CC1,"N2-(2-chlorobenzyl)-N4-((4-(aminomethyl)cyclohexyl)methyl)-5-nitropyrimidine-2,4-diamine",0.7,uM,=,-0.1549019599857432,0,c1ccc(CNc2nccc(NCC3CCCCC3)n2)cc1
1492,1745612,10.1016/j.bmcl.2017.10.010,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins in presence of NADPH by LC-MS/MS analysis,Cl.N[C@@H]1CCC=C(c2ccc(F)cc2)[C@H]1CSc1cc(F)c(S(=O)(=O)Nc2nccs2)cc1Cl,(-)-4-((6-amino-2-(4-fluorophenyl)cyclohex-2-enyl)methylthio)-5-chloro-2-fluoro-N-(thiazol-2-yl)benzenesulfonamide hydrochloride,5.1,uM,=,0.7075701760979364,1,O=S(=O)(Nc1nccs1)c1ccc(SC[C@H]2CCCC=C2c2ccccc2)cc1
1493,1301328,10.6019/CHEMBL3137440,,,,DNDI: CYP Inhibition,CCC(C(C)=O)N1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1,,10.0,uM,=,1.0,1,c1ccc(N(c2cccnc2)C2CCNCC2)cc1
1494,625610,10.1016/j.bmcl.2010.02.036,,,,Inhibition of CYP3A4 after 30 mins,COCCCc1cc(CN(C(=O)[C@@H](CN)Cc2ccc(CCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCCOC)c1,"(R)-3-amino-N-cyclopropyl-2-(4-(3-(2,6-dichloro-4-methylphenoxy)propyl)benzyl)-N-(3-(2-methoxyethoxy)-5-(3-methoxypropyl)benzyl)propanamide",1.3,uM,=,0.1139433523068367,1,O=C(CCc1ccc(CCCOc2ccccc2)cc1)N(Cc1ccccc1)C1CC1
1495,598210,10.1016/j.bmcl.2009.08.024,,,,Inhibition of human CYP3A4,CC1(CC(=O)NCc2ccccc2N)CC2(CCCCC2)OO1,"N-(2-aminobenzyl)-2-(3-methyl-1,2-dioxaspiro[4.5]decan-3-yl)acetamide",1.9,uM,=,0.2787536009528289,1,O=C(CC1CC2(CCCCC2)OO1)NCc1ccccc1
1496,1288280,10.1016/j.bmcl.2013.12.057,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,CC(C)c1nc(CN(C)C(=O)N[C@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,"Thiazol-5-ylmethyl(2R,5R)-5-((R)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-4-morpholinobutanamido)-1,6-diphenylhexan-2-ylcarbamate",0.15,uM,=,-0.8239087409443188,0,O=C(NCc1cscn1)N[C@H](CCN1CCOCC1)C(=O)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
1497,519907,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,Cc1nc2c(N[C@@H]3CCc4ccccc43)cc(-n3ccccc3=O)cn2c1C,"(R)-1-(8-(2,3-dihydro-1H-inden-1-ylamino)-2,3-dimethylimidazo[1,2-a]pyridin-6-yl)pyridin-2(1H)-one",13.0,uM,=,1.1139433523068367,1,O=c1ccccn1-c1cc(N[C@@H]2CCc3ccccc32)c2nccn2c1
1498,1540696,10.1016/j.ejmech.2015.08.051,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 2 mins by LC-MS/MS analysis in presence of NADPH regeneration system,COCCCN1CCC(CNC(=O)c2nc(C(C)C)n3ccccc23)CC1,"3-isopropyl-N-((1-(3-methoxypropyl)piperidin-4-yl)methyl)imidazo[1,5-a]pyridine-1-carboxamide",27.2,uM,=,1.434568904034199,1,O=C(NCC1CCNCC1)c1ncn2ccccc12
1499,1778315,10.1016/j.bmcl.2018.06.040,,,,Inhibition of CYP3A4 (unknown origin),CS(=O)(=O)c1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1,"N-(4-(1H-pyrrolo[2,3-b]pyridin-3-yl)thiazol-2-yl)-2-(3-(methylsulfonyl)phenyl)acetamide",6.4,uM,=,0.8061799739838872,1,O=C(Cc1ccccc1)Nc1nc(-c2c[nH]c3ncccc23)cs1
1500,1695601,10.1016/j.bmc.2017.08.012,,,,Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using 7-Benzoyloxy-4-trifluoromethyl coumarin substrate in presence of NADP+ by fluorescence based assay,CON=C1CCC(CNc2cc(F)c(S(=O)(=O)Nc3nccs3)cc2Cl)CC1,5-Chloro-2-fluoro-4-(((4-(methoxyimino)cyclohexyl)methyl)amino)-N-(thiazol-2-yl)benzenesulfonamide,13.7,uM,=,1.136720567156407,1,N=C1CCC(CNc2ccc(S(=O)(=O)Nc3nccs3)cc2)CC1
1501,1366898,10.1021/jm500312x,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 15 mins by LC/MS/MS analysis,C=C[C@]1(C)C[C@@H](OC(=O)CSc2cncc(CO)c2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O,14-O-(((5-Hydroxymethylpyridin-3-yl)sulfanyl)acetyl)mutilin,0.216,uM,=,-0.6655462488490691,0,O=C(CSc1cccnc1)O[C@@H]1CCCC[C@@]23CCCC1[C@@H]2C(=O)CC3
1502,1805934,10.1021/acs.jmedchem.9b00352,,,,Inhibition of recombinant human CYP3A4 expressed in insect cell microsomes in presence of NADPH-regenerating system after 15 to 45 mins by fluorescence probe substrate-based assay,N#Cc1ccc2nnc(C(=O)N3CCC(c4ccccc4C(F)(F)F)CC3)n2c1,"3-(4-(2-(Trifluoromethyl)phenyl)piperidine-1-carbonyl)-[1,2,4]-triazolo[4,3-a]pyridine-6-carbonitrile",50.0,uM,=,1.6989700043360187,1,O=C(c1nnc2ccccn12)N1CCC(c2ccccc2)CC1
1503,305432,10.1016/j.bmcl.2005.01.044,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,CC(C(c1ccc2cc(OCc3ccc(OC(C)(C)C)cc3)ccc2c1)n1ccnc1)N(C)C,{2-[6-(4-tert-Butoxy-benzyloxy)-naphthalen-2-yl]-2-imidazol-1-yl-1-methyl-ethyl}-dimethyl-amine,0.04,uM,=,-1.3979400086720375,0,c1ccc(COc2ccc3cc(Cn4ccnc4)ccc3c2)cc1
1504,804824,10.1016/j.bmcl.2011.12.080,,,,Reversible inhibition of CYP3A4,COc1cc(C)c2nc3[nH]nc(C)c3c(C(C#N)c3ccccc3)c2c1,"rac-2-(6-methoxy-3,8-dimethyl-1H-pyrazolo[3,4-b]quinolin-4-yl)-2-phenylacetonitrile",0.8,uM,=,-0.0969100130080563,0,c1ccc(Cc2c3ccccc3nc3[nH]ncc23)cc1
1505,500259,10.1016/j.bmcl.2009.02.112,,,,Inhibition of human CYP3A4 using DEF substrate,O=C([O-])c1cccc(Cc2cc(Cl)ccc2OCc2ccc(F)cc2Cl)n1.[Na+],sodium 6-(5-chloro-2-(2-chloro-4-fluorobenzyloxy)benzyl)picolinate,35.0,uM,=,1.5440680443502757,1,c1ccc(COc2ccccc2Cc2ccccn2)cc1
1506,445973,10.1021/jm070428+,,,,Inhibition of human recombinant CYP3A4,O=C1O[C@@H](Cn2ccnn2)CN1c1ccc(-c2cccnc2)c(F)c1,"(5R)-3-(3-fluoro-4-pyridin-3-ylphenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one",6.8,uM,=,0.8325089127062363,1,O=C1O[C@@H](Cn2ccnn2)CN1c1ccc(-c2cccnc2)cc1
1507,1747140,10.1016/j.bmcl.2017.10.042,,,,Inhibition of CYP3A4 (unknown origin) after 20 mins,CCSc1ccc([C@H](c2cc3cc(Br)ccc3nc2OC)[C@@](O)(CCN(C)C)c2cccc(F)c2)cn1,"(1R,2S)-1-(6-bromo-2-methoxyquinolin-3-yl)-4-(dimethylamino)-1-(6-(ethylthio)pyridin-3-yl)-2-(3-fluorophenyl)butan-2-ol",10.0,uM,=,1.0,1,c1ccc(C[C@H](c2cccnc2)c2cnc3ccccc3c2)cc1
1508,450508,10.1021/jm070806a,,,,Inhibition of CYP3A4,CNCC(=O)N[C@H](c1cc(C)ccc1N1CCN(C(=O)[C@H](C)Cc2ccc(Cl)cc2F)CC1)C(C)C,1-{2-[(1S)-(methylaminoacetamido)-2-methylpropyl]-4-methylphenyl}-4-[(2R)-methyl-3-(2-fluoro-4-chlorophenyl)propionyl]piperazine,6.9,uM,=,0.8388490907372553,1,O=C(CCc1ccccc1)N1CCN(c2ccccc2)CC1
1509,546182,10.1016/j.bmcl.2009.03.165,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,CCNc1cc(C(=O)N[C@@H](Cc2ccccc2)[C@H](O)CNCc2cccc(C(F)(F)F)c2)c(F)c(N2CCCCS2(=O)=O)c1,"N-[(1S,2R)-1-benzyl-2-hydroxy-3-(3-trifluoromethyl-benzylamino)-propyl]-3-(1,1-dioxo-1lambda*6*-[1,2]thiazinan-2-yl)-5-ethylamino-2-fluoro-benzamide",1.6,uM,=,0.2041199826559248,1,O=C(N[C@H](CCNCc1ccccc1)Cc1ccccc1)c1cccc(N2CCCCS2(=O)=O)c1
1510,1698171,10.1021/acs.jmedchem.7b01869,,,,Inhibition of CYP3A4 in human liver microsomes using DBF as substrate by fluorescence assay,N#CC1(NC(=O)[C@@H]2Cc3ccc(c(Cl)c3)OCCCCOc3cc(C(F)(F)F)ccc3C(=O)N2)CC1,"US9290467, 23",43.0,uM,=,1.6334684555795866,1,O=C1N[C@H](C(=O)NC2CC2)Cc2ccc(cc2)OCCCCOc2ccccc21
1511,675407,10.1016/j.bmcl.2010.08.142,,,,Inhibition of CYP3A4,N#Cc1cccnc1N[C@@H]1CCN(C(=O)O[C@H]2C3CC4CC2C[C@](C(N)=O)(C4)C3)C1,(R)-3-(3-Cyano-pyridin-2-ylamino)-pyrrolidine-1-carboxylic acid 5-carbamoyl-adamantan-2-yl ester,17.1,uM,=,1.2329961103921538,1,O=C(OC1C2CC3CC(C2)CC1C3)N1CC[C@@H](Nc2ccccn2)C1
1512,617698,10.1016/j.bmcl.2010.01.087,,,,Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay,Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NCCn4cc(Cl)cn4)cc[nH]c3=O)nc12,4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(4-methyl-6-morpholino-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one,2.1,uM,=,0.3222192947339193,1,O=c1[nH]ccc(NCCn2cccn2)c1-c1nc2ccc(N3CCOCC3)cc2[nH]1
1513,700827,10.1016/j.bmcl.2010.11.080,,,,Inhibition of human CYP3A4,O=C(N[C@H]1CN2CCC1CC2)c1c[nH]c2ccsc2c1=O,"(R)-7-oxo-N-(quinuclidin-3-yl)-4,7-dihydrothieno[3,2-b]pyridine-6-carboxamide",9.3,uM,=,0.9684829485539352,1,O=C(N[C@H]1CN2CCC1CC2)c1c[nH]c2ccsc2c1=O
1514,2158479,10.1021/acs.jmedchem.1c00926,,,,Inhibition of CYP3A4 (unknown origin),Cn1cc(Nc2nccc(-c3ccc4c(c3)CCCC[C@H]4NC(=O)c3cn(C(C)(C)C)nn3)n2)cn1,"(R)-1-tert-butyl-N-(2-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-5-yl)-1H-1,2,3-triazole-4-carboxamide",6.4,uM,=,0.8061799739838872,1,O=C(N[C@@H]1CCCCc2cc(-c3ccnc(Nc4cn[nH]c4)n3)ccc21)c1c[nH]nn1
1515,1435228,10.1016/j.bmcl.2014.08.017,,,,Inhibition of CYP3A4 (unknown origin) using midazolam substrate,CN1CC[C@H](c2ccc(Cl)cc2)[C@@H](COc2cc(F)c(S(=O)(=O)Nc3ncns3)cc2F)C1,"4-(((3R,4S)-4-(4-chlorophenyl)-1-methylpiperidin-3-yl)methoxy)-2,5-difluoro-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide",0.14,uM,=,-0.8538719643217619,0,O=S(=O)(Nc1ncns1)c1ccc(OC[C@H]2CNCC[C@@H]2c2ccccc2)cc1
1516,2170798,10.1021/acs.jmedchem.0c02143,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated 10 mins in presence of NADPH by solid phase extraction mass spectrometry analysis,C[C@@]1(c2cc(NC(=O)c3ncc(Br)cn3)ccc2F)CO[C@@](C)(C(F)(F)F)C(N)=N1,"US8846658, 71",8.0,uM,=,0.9030899869919436,1,O=C(Nc1cccc(C2COCC=N2)c1)c1ncccn1
1517,52065,10.1021/jm0310129,,,,Inhibitory activity against cytochrome P450 3A4,COc1ccc2c3nc[nH]c(N4CCN(CCc5ccc(F)c(F)c5)CC4)c-3nc2c1[N+](=O)[O-],"4-{4-[2-(3,4-Difluoro-phenyl)-ethyl]-piperazin-1-yl}-7-methoxy-6-nitro-5H-pyrimido[5,4-b]indole",1.79,uM,=,0.2528530309798932,1,c1ccc(CCN2CCN(c3[nH]cnc4c5ccccc5nc3-4)CC2)cc1
1518,51907,10.1016/s0960-894x(03)00475-x,,,,In vitro inhibition of human liver microsome Cytochrome P450 3A4,CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O,"(S)-1-[(2S,4R)-2-Hydroxy-4-((1S,2R)-2-hydroxy-indan-1-ylcarbamoyl)-5-phenyl-pentyl]-4-pyridin-3-ylmethyl-piperazine-2-carboxylic acid tert-butylamide",0.15,uM,=,-0.8239087409443188,0,O=C(N[C@@H]1CCc2ccccc21)[C@@H](CCCN1CCN(Cc2cccnc2)CC1)Cc1ccccc1
1519,434712,10.1021/jm070104l,,,,Inhibition of human CYP3A4,N#Cc1ccccc1Cn1c(N2CCC[C@@H](N)C2)nc2ccc(Cl)cc2c1=O,(R)-2-((2-(3-aminopiperidin-1-yl)-6-chloro-4-oxoquinazolin-3(4H)-yl)methyl)benzonitrile,0.25,uM,=,-0.6020599913279624,0,O=c1c2ccccc2nc(N2CCCCC2)n1Cc1ccccc1
1520,349088,10.1016/j.bmcl.2006.01.084,,,,Inhibition of CYP3A4 using BFC fluorogenic substrate,COc1ccccc1COCCCOc1ccc(N2C(=O)CNC[C@@H]2COc2ccc3c(c2)N(CCN(C)C(C)=O)CCC3)cc1,"(R)-N-(2-(7-((1-(4-(3-(2-methoxybenzyloxy)propoxy)phenyl)-6-oxopiperazin-2-yl)methoxy)-3,4-dihydroquinolin-1(2H)-yl)ethyl)-N-methylacetamide",0.018,uM,=,-1.744727494896694,0,O=C1CNC[C@H](COc2ccc3c(c2)NCCC3)N1c1ccc(OCCCOCc2ccccc2)cc1
1521,1919651,,,,,"Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase",c1cncc(-n2ccnc2)c1,3-Imidazol-1-yl-pyridine,77.54,uM,=,1.889525796671192,1,c1cncc(-n2ccnc2)c1
1522,632105,10.1016/j.bmcl.2010.03.057,,,,Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin,Cc1cc(N2CCN(CCCF)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,(S)-4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-3-(6-(4-(3-fluoropropyl)piperazin-1-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one,0.45,uM,=,-0.3467874862246563,0,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(N3CCNCC3)cc2[nH]1
1523,510198,10.1021/jm800355c,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,COc1ccc(-c2ccc3c(c2)CCCC3(O)c2ccncc2)cc1F,"6-(3-Fluoro-4-methoxyphenyl)-1-(pyridin-4-yl)-1,2,3,4-tetrahydronaphthalen-1-ol",15.19,uM,=,1.1815577738627865,1,c1ccc(-c2ccc3c(c2)CCCC3c2ccncc2)cc1
1524,464748,10.1016/j.bmcl.2008.01.126,,,,Inhibition of CYP3A4 in presence of 7-benzyloxyresorufin substrate,Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@@H]2C(=O)N(c3ccc(C(C)(C)C)cc3)[C@@H]2C(=O)O)cc1,"(2S,3S)-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-(4-tert-butylphenyl)-4-oxoazetidine-2-carboxylic acid",28.0,uM,=,1.4471580313422192,1,O=C1[C@@H](Cc2ccc(OCCc3coc(-c4ccccc4)n3)cc2)CN1c1ccccc1
1525,1587699,10.1021/acs.jmedchem.5b01891,,,,Inhibition of recombinant human CYP3A4 by P450-Glo luminescence assay,COc1cccc(-c2nc(SC)c3ccccc3n2)c1,2-(3-methoxyphenyl)-4-methylsulfanylquinazoline,22.94,uM,=,1.3605934135652489,1,c1ccc(-c2ncc3ccccc3n2)cc1
1526,631458,10.1021/jm9013136,,,,Inhibition of human recombinant CYP3A4,Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2c(c1)c(-c1cccc(Cl)c1)cc(=O)n2C,6-[Amino-(4-chloro-phenyl)-(1-methyl-1H-imidazol-2-yl)-methyl]-4-(3-chloro-phenyl)-1-methyl-1H-quinolin-2-one,4.06,uM,=,0.608526033577194,1,O=c1cc(-c2ccccc2)c2cc(C(c3ccccc3)c3cnc[nH]3)ccc2[nH]1
1527,1685713,10.1016/j.bmc.2017.04.033,,,,Inhibition of recombinant CYP3A4 (unknown origin),C[C@@H](c1ccc(OC(F)F)cc1)N1CC[C@](CC(C)(C)O)(c2ccc(F)cc2)OC1=O,"(S)-3-((S)-1-(4-(difluoromethoxy)phenyl)ethyl)-6-(4-fluorophenyl)-6-(2-hydroxy-2-methylpropyl)-1,3-oxazinan-2-one",6.6,uM,=,0.8195439355418687,1,O=C1OC(c2ccccc2)CCN1Cc1ccccc1
1528,2069952,10.1021/acsmedchemlett.1c00014,,,,Inhibition of recombinant human CYP3A4,CCC(c1nc2ncc(Cl)cc2[nH]1)[C@H]1CC[C@@H](c2ccnc3ccc(C(F)(F)F)cc32)CC1,"4-((cis)-4-(1-(6-Chloro-1H-imidazo[4,5-b]pyridin-2-yl)propyl)cyclohexyl)-6-(trifluoromethyl)quinoline",1.93,uM,=,0.2855573090077737,1,c1ccc2c(c1)nccc2[C@H]1CC[C@@H](Cc2nc3ncccc3[nH]2)CC1
1529,304848,10.1016/j.bmcl.2004.10.024,,,,Inhibitory concentration against Cytochrome P450 3A4,O=C(O)c1cnc(N(C(=O)c2ccc(OCc3cccc(C(F)(F)F)c3)cc2)C2CCCCC2)s1,2-{Cyclohexyl-[4-(3-trifluoromethyl-benzyloxy)-benzoyl]-amino}-thiazole-5-carboxylic acid,30.0,uM,=,1.4771212547196624,1,O=C(c1ccc(OCc2ccccc2)cc1)N(c1nccs1)C1CCCCC1
1530,991614,10.1021/jm4008906,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,COCCN1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O,"rac-3-(Aminomethyl)-4-(2,4-dichlorophenyl)-6-(2-methoxyethyl)-2-methyl-6,7-dihydropyrrolo[3,4-b]pyridin-5-one",23.0,uM,=,1.3617278360175928,1,O=C1NCc2nccc(-c3ccccc3)c21
1531,1475768,10.1021/jm5017413,,,,Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system,Cc1nc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)C3)cs1,"(3-(2-Methylthiazol-4-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]-pyrazin-7(8H)-yl)(4-(thiophen-2yl)phenyl)methanone",30.0,uM,=,1.4771212547196624,1,O=C(c1ccc(-c2cccs2)cc1)N1CCn2c(nnc2-c2cscn2)C1
1532,1291572,10.1016/j.bmcl.2013.12.058,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)NC(Cc2ccccc2)CN(Cc2ccccc2)C(=O)OCc2cncs2)cs1,thiazol-5-ylmethyl benzyl(2-((S)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-4-morpholinobutanamido)-3-phenylpropyl)carbamate,0.5,uM,=,-0.3010299956639812,0,O=C(NCc1cscn1)N[C@@H](CCN1CCOCC1)C(=O)NC(Cc1ccccc1)CN(Cc1ccccc1)C(=O)OCc1cncs1
1533,305432,10.1016/j.bmcl.2005.01.044,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,CC(C(c1ccc2cc(OCc3ccc(C#N)cc3)ccc2c1)n1ccnc1)N(C)C,4-[6-(2-Dimethylamino-1-imidazol-1-yl-propyl)-naphthalen-2-yloxymethyl]-benzonitrile,0.26,uM,=,-0.585026652029182,0,c1ccc(COc2ccc3cc(Cn4ccnc4)ccc3c2)cc1
1534,559938,10.1016/j.bmcl.2008.10.072,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,C[C@@H]1CN(Cc2ccc(-n3ccnc3C(=O)N3CCC(Nc4cccc(F)c4)CC3)cc2)C[C@H](C)N1,"{1-[4-((3R,5S)-3,5-Dimethyl-piperazin-1-ylmethyl)-phenyl]-1H-imidazol-2-yl}-[4-(3-fluoro-phenylamino)-piperidin-1-yl]-methanone",58.0,uM,=,1.7634279935629371,1,O=C(c1nccn1-c1ccc(CN2CCNCC2)cc1)N1CCC(Nc2ccccc2)CC1
1535,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)N(C)C)o5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, D-102",3.42,uM,=,0.534026106056135,1,O=C1[C@H](Cc2ccccc2)N2C(=O)CNN(C(=O)NCc3ccccc3)[C@H]2CN1Cc1cccc2c(-c3ccco3)c[nH]c12
1536,611722,10.1021/jm9014263,,,,Inhibition of human CYP3A4 using BFC substrate by fluorescence assay,COc1ccc(C(=O)NCc2cccc(C(=O)NCCc3ccncc3)c2)cc1OC,"3,4-Dimethoxy-N-[3-(2-pyridin-4-yl-ethylcarbamoyl)-benzyl]-benzamide",4.0,uM,=,0.6020599913279624,1,O=C(NCCc1ccncc1)c1cccc(CNC(=O)c2ccccc2)c1
1537,1713508,10.1016/j.bmc.2018.05.006,,,,Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation after 4 to 40 mins in presence of NADPH by LCMS analysis,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,"1-(4-{4-[2-(2,4-Dichloro-phenyl)-2-imidazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-ethanone (ketoconazole)",0.013,uM,=,-1.8860566476931635,0,c1ccc(C2(Cn3ccnc3)OCC(COc3ccc(N4CCNCC4)cc3)O2)cc1
1538,510198,10.1021/jm800355c,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,Cl.Fc1ccc(-c2ccc3c(c2)CC=C3c2ccncc2)cc1,4-(5-(4-Fluorophenyl)-3H-inden-1-yl)pyridine Hydrochloride,0.159,uM,=,-0.7986028756795485,0,C1=C(c2ccncc2)c2ccc(-c3ccccc3)cc2C1
1539,1474044,10.1021/jm501740a,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,CC(C)C[C@H](NC(=O)c1ccc2[nH]nc(-c3ccc(N4[C@H]5CC[C@H]4CC(O)C5)cc3)c2c1)c1ccccn1,3-(4-((endo)-3-hydroxy-8-azabicyclo[3.2.1]octan-8-yl)phenyl)-N-((S)-3-methyl-1-(pyridin-2-yl)butyl)-1H-indazole-5-carboxamide,0.32,uM,=,-0.494850021680094,0,O=C(NCc1ccccn1)c1ccc2[nH]nc(-c3ccc(N4[C@@H]5CCC[C@@H]4CC5)cc3)c2c1
1540,355280,10.1016/j.bmcl.2006.02.020,,,,Inhibition of CYP3A4,CCC(CC)(COc1ccc2cc([C@H]([C@@H](C)N(C)C)n3ccnc3)ccc2c1)C(=O)O,"2-((6-((1R,2R)-2-(dimethylamino)-1-(1H-imidazol-1-yl)propyl)naphthalen-2-yloxy)methyl)-2-ethylbutanoic acid",5.3,uM,=,0.724275869600789,1,c1ccc2cc(Cn3ccnc3)ccc2c1
1541,701747,10.1021/ml100190t,,,,Inhibition of CYP3A4 uisng testosterone substrate,O=C(Nc1cccnc1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1,N-Pyridin-3-yl-4-(3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}benzylidene)piperidine-1-carboxamide,0.8,uM,=,-0.0969100130080563,0,O=C(Nc1cccnc1)N1CCC(=Cc2cccc(Oc3ccccn3)c2)CC1
1542,1661018,10.1016/j.bmcl.2017.02.047,,,,Inhibition of recombinant human CYP3A4 expressed in baculosomes using Vivid BOMR substrate red measured every 30 sec for 30 mins by fluorescence assay,CCCCCCC[C@H](O)CC(=O)CCc1ccc(O)c(OC)c1,8-Gingerol,10.5,uM,=,1.021189299069938,1,c1ccccc1
1543,1828801,10.1021/acs.jmedchem.8b01098,,,,Inhibition of C-terminal 4His-tagged CYP3A4 (unknown origin) expressed in Escherichia coli by spectrophotometric analysis,COc1cccc(CNC(=O)c2ccc(-c3ccncc3)cc2)c1,SID103904582,0.85,uM,=,-0.0705810742857072,0,O=C(NCc1ccccc1)c1ccc(-c2ccncc2)cc1
1544,51923,10.1021/jm031115r,,,,Inhibition of human cytochrome P450 3A4,Cc1cc(C)nc(O[C@H](C(=O)O)[C@@]2(c3cccc(-c4ccccc4)c3)NCC(=O)N(Cc3c(F)cc(F)cc3F)c3ccccc32)n1,"(S)-[(S)-5-Biphenyl-3-yl-2-oxo-1-(2,4,6-trifluoro-benzyl)-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-5-yl]-(4,6-dimethyl-pyrimidin-2-yloxy)-acetic acid",7.0,uM,=,0.8450980400142568,1,O=C1CN[C@@](COc2ncccn2)(c2cccc(-c3ccccc3)c2)c2ccccc2N1Cc1ccccc1
1545,550965,10.1021/np030556a,,,,Inhibition of human CYP3A4 by radiometric assay,C/C1=C\[C@H](O)C[C@@]2(C)O[C@@H]2CC(C)(C)/C=C/C1=O,"(2R,3S,5R)-2,3-epoxy-6,9-humuladien-5-ol-8-one",62.5,uM,=,1.7958800173440752,1,O=C1C=CCCC2O[C@@H]2CC/C=C/1
1546,1446329,10.1021/ml500387y,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,CC(C)(CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F)c1cccc(C(N)=O)c1,"3-(5,5,5-trifluoro-4-hydroxy-2-methyl-4-((5-morpholino-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)pentan-2-yl)benzamide",2.0,uM,=,0.3010299956639812,1,c1ccc(CCCCc2cc3cc(N4CCOCC4)ncc3[nH]2)cc1
1547,449485,10.1016/j.bmcl.2007.07.097,,,,Inhibition of microsomal CYP3A4,CNCC(=O)N[C@@H](CC(C)C)c1cc(F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1,"N-((S)-1-(2-(4-((R)-3-(2,4-dichlorophenyl)-2-(2-oxopyrrolidin-1-yl)propanoyl)piperazin-1-yl)-5-fluorophenyl)-3-methylbutyl)-2-(methylamino)acetamide",6.5,uM,=,0.8129133566428556,1,O=C([C@@H](Cc1ccccc1)N1CCCC1=O)N1CCN(c2ccccc2)CC1
1548,1911030,10.1021/acs.jmedchem.8b01226,,,,Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins,Cc1cccc(C#C/C=C2\CCN(C(=O)c3cccc(Cl)c3)C2)n1,(3-Chlorophenyl){(3E)-3-[3-(6-methylpyridin-2-yl)prop-2-yn-1-ylidene]pyrrolidin-1-yl}methanone,12.9,uM,=,1.110589710299249,1,O=C(c1ccccc1)N1CC/C(=C\C#Cc2ccccn2)C1
1549,1849385,10.1016/j.bmcl.2019.06.044,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis,O=C(O)c1ccc(-n2cc(C(=O)c3c(Cl)cccc3Cl)c3cccc(F)c32)c(F)c1,"4-(3-(2,6-dichlorobenzoyl)-7-fluoro-1H-indol-1-yl)-3-fluorobenzoic acid",30.8,uM,=,1.4885507165004443,1,O=C(c1ccccc1)c1cn(-c2ccccc2)c2ccccc12
1550,651747,10.1016/j.bmcl.2010.07.030,,,,Inhibition of CYP3A4 in human liver microsome preincubated for 30 mins,COCCCc1ccc(Cl)c(CN(C(=O)[C@@H](CN)Cc2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1,"(R)-3-amino-N-(2-chloro-5-(3-methoxypropyl)benzyl)-N-cyclopropyl-2-(4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)benzyl)propanamide",0.12,uM,=,-0.9208187539523752,0,O=C(CCc1ccc(OCCOc2ccccc2)cc1)N(Cc1ccccc1)C1CC1
1551,834929,10.1016/j.bmcl.2012.07.020,,,,Inhibition of CYP3A4,CCCS(=O)(=O)c1ccc2[nH]c(-c3cccc(OC(F)(F)F)c3)nc2c1,5-(propylsulfonyl)-2-(3-(trifluoromethoxy)phenyl)-1H-benzo[d]imidazole,10.0,uM,=,1.0,1,c1ccc(-c2nc3ccccc3[nH]2)cc1
1552,449485,10.1016/j.bmcl.2007.07.097,,,,Inhibition of microsomal CYP3A4,CC(C)C[C@H](NC(=O)[C@@H](C)N)c1cc(F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1,"(R)-2-amino-N-((S)-1-(2-(4-((R)-3-(2,4-dichlorophenyl)-2-(2-oxopyrrolidin-1-yl)propanoyl)piperazin-1-yl)-5-fluorophenyl)-3-methylbutyl)propanamide",5.3,uM,=,0.724275869600789,1,O=C([C@@H](Cc1ccccc1)N1CCCC1=O)N1CCN(c2ccccc2)CC1
1553,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N(C)CCn5ccnc5C)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, F-36",2.48,uM,=,0.3944516808262163,1,O=C(NCCn1ccnc1)c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12
1554,1436762,10.1021/ml500187a,,,,Inhibition of human recombinant CYP3A4 incubated for 5 mins by fluorescence assay,Clc1cccc(CN(CC2CNC2)c2ccccc2)c1Cl.O=C(O)C(F)(F)F,"N-(azetidin-3-ylmethyl)-N-(2,3-dichlorobenzyl)aniline 2,2,2-trifluoroacetate",32.7,uM,=,1.5145477526602862,1,c1ccc(CN(CC2CNC2)c2ccccc2)cc1
1555,2017934,10.1021/acs.jmedchem.0c00834,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis,Cc1c(-c2ccccc2)nc2ccc(Br)cc2c1C(=O)NCC(CCC(=O)O)c1c(F)ccc(F)c1Cl,"(+)-5-{[(6-Bromo-3-methyl-2-phenylquinolin-4-yl)carbonyl]amino}-4-(2-chloro-3,6-difluorophenyl)pentanoic acid",5.0,uM,=,0.6989700043360189,1,O=C(NCCc1ccccc1)c1cc(-c2ccccc2)nc2ccccc12
1556,1625607,10.1016/j.bmcl.2016.10.016,,,,Inhibition of human Cyp3A4 using testosterone as substrate by LC-MS/MS analysis,CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,SID144204227,0.136,uM,=,-0.8664610916297825,0,c1ccc([C@@]2(Cn3ccnc3)OC[C@H](COc3ccc(N4CCNCC4)cc3)O2)cc1
1557,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)N6CCOCC6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, D-59",2.19,uM,=,0.3404441148401183,1,O=C(Nc1ccc(-c2c[nH]c3c(CN4C[C@@H]5N(C(=O)NCc6ccccc6)NCC(=O)N5[C@@H](Cc5ccccc5)C4=O)cccc23)cc1)N1CCOCC1
1558,2188376,10.1021/acs.jmedchem.2c01170,,,,Inhibition of CYP3A4 in human liver Microsome using midazolam as substrate in presence of NADPH by LC-MS/MS analysis,Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1,"1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole",0.001,uM,=,-3.0,0,c1ccc(COC(Cn2ccnc2)c2ccccc2)cc1
1559,862399,10.1021/jm300601d,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis,N=C(N)NC(=O)c1ccc(C2CCN(C(=O)c3ccc(C(N)=O)cc3)CC2)c(C(F)(F)F)c1,4-[4-(4-Guanidinocarbonyl-2-trifluoromethyl-phenyl)-piperidine-1-carbonyl]-benzamide,24.5,uM,=,1.3891660843645326,1,O=C(c1ccccc1)N1CCC(c2ccccc2)CC1
1560,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cccc(-n3nccn3)c2)c1F,"US9150566, 29",39.0,uM,=,1.591064607026499,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
1561,510198,10.1021/jm800355c,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,Cl.Fc1ccc(-c2ccc3c(c2)CCCC3c2ccncc2)cc1F,"4-(6-(3,4-Difluorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl)pyridine Hydrochloride",2.3,uM,=,0.3617278360175928,1,c1ccc(-c2ccc3c(c2)CCCC3c2ccncc2)cc1
1562,1637155,,,,,Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins,Cc1cnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4cccc(F)c4)c3F)c2c1,"N-[2,4-Difluoro-3-(5-methyl-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phenyl]-3-fluoro-benzenesulfonamide",5.0,uM,=,0.6989700043360189,1,O=C(c1cccc(NS(=O)(=O)c2ccccc2)c1)c1c[nH]c2ncccc12
1563,2226868,10.1016/j.ejmech.2022.114512,,,,Inhibition of CYP3A4M in human liver microsomes incubated for 15 to 40 mins in presence of NADPH,Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,"8-Chloro-6-(2-fluoro-phenyl)-1-methyl-4H-2,5,10b-triaza-benzo[e]azulene",0.0662,uM,=,-1.1791420105603,0,c1ccc(C2=NCc3cncn3-c3ccccc32)cc1
1564,643713,10.1016/j.bmcl.2010.06.009,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader,C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(N5CCNCC5)c4)ccc32)sc1C(N)=O)c1ccccc1Cl,(R)-3-(1-(2-chlorophenyl)ethoxy)-5-(5-(2-(piperazin-1-yl)pyridin-4-yl)-1H-benzo[d]imidazol-1-yl)thiophene-2-carboxamide,5.9,uM,=,0.7708520116421442,1,c1ccc(COc2csc(-n3cnc4cc(-c5ccnc(N6CCNCC6)c5)ccc43)c2)cc1
1565,1849384,10.1016/j.bmcl.2019.06.044,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis,O=C(O)c1ccc(-n2cc(C(=O)c3c(Cl)cccc3Cl)c3ccccc32)c(F)c1,"4-[3-(2,6-dichlorobenzoyl)indol-1-yl]-3-fluoro-benzoic acid",38.0,uM,=,1.57978359661681,1,O=C(c1ccccc1)c1cn(-c2ccccc2)c2ccccc12
1566,1567870,10.1021/acs.jmedchem.5b01780,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis in presence of NADPH,CC1(C)CCC(C)(C)c2cc(C3(c4ccc(/C=C/C(=O)O)cc4)OCCO3)ccc21,"(E)-3-(4-(2-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-1,3-dioxolan-2-yl)phenyl)-acrylic Acid",30.0,uM,=,1.4771212547196624,1,c1ccc(C2(c3ccc4c(c3)CCCC4)OCCO2)cc1
1567,461436,10.1016/j.bmcl.2007.10.092,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,CC(C)(CO)N1CCN(C(=O)CC2([C@H]3CCC[C@@H](C4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)CC1,"2-(1-((2R,6S)-1-(4-chlorophenylsulfonyl)-6-cyclopropylpiperidin-2-yl)cyclopropyl)-1-(4-(1-hydroxy-2-methylpropan-2-yl)piperazin-1-yl)ethanone",1.5,uM,=,0.1760912590556812,1,O=C(CC1([C@H]2CCC[C@@H](C3CC3)N2S(=O)(=O)c2ccccc2)CC1)N1CCNCC1
1568,519908,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,Cc1nc2c(N[C@H]3c4ccccc4C[C@@H]3O)cc(-n3cncn3)cn2c1C,"(1S,2S)-1-(2,3-dimethyl-6-(1H-1,2,4-triazol-1-yl)imidazo[1,2-a]pyridin-8-ylamino)-2,3-dihydro-1H-inden-2-ol",15.0,uM,=,1.1760912590556811,1,c1ccc2c(c1)CC[C@H]2Nc1cc(-n2cncn2)cn2ccnc12
1569,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(NCC(C)(C)C)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1,"US8940739, G-22",2.38,uM,=,0.3765769570565119,1,O=C(Nc1cccnc1)c1c[nH]c2c(CN3CC4N(C(=O)NCc5ccccc5)NCC(=O)N4C(Cc4ccccc4)C3=O)cccc12
1570,1559225,10.1016/j.ejmech.2016.02.024,,,,Inhibition of recombinant human CYP3A4 by luminescence -based microplate reader assay,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,"1-(4-{4-[2-(2,4-Dichloro-phenyl)-2-imidazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-ethanone (ketoconazole)",0.14,uM,=,-0.8538719643217619,0,c1ccc(C2(Cn3ccnc3)OCC(COc3ccc(N4CCNCC4)cc3)O2)cc1
1571,558484,10.1016/j.bmcl.2008.10.128,,,,Inhibition of CYP3A4,CCN(CC(O)(CNC(=O)c1cnn(-c2ccc(F)cc2)c1N)C(F)(F)F)C(=O)c1c(Cl)cccc1Cl,"5-amino-N-(2-((2,6-dichloro-N-ethylbenzamido)methyl)-3,3,3-trifluoro-2-hydroxypropyl)-1-(4-fluorophenyl)-1H-pyrazole-4-carboxamide",0.7,uM,=,-0.1549019599857432,0,O=C(NCCCNC(=O)c1cnn(-c2ccccc2)c1)c1ccccc1
1572,1750153,10.1016/j.bmcl.2017.12.040,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins with substrate followed by NADPH addition measured after 15 mins by LC/MS/MS analysis,OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(OCC(F)(F)F)cc2)cn1,"(+/-)-2-(2,4-difluorophenyl)-1,1-difluoro-3-(1H-tetrazol-1-yl)-1-(5-(4-(2,2,2-trifluoroethoxy)phenyl)pyridin-2-yl)propan-2-ol",50.0,uM,=,1.6989700043360187,1,c1ccc(-c2ccc(CC(Cn3cnnn3)c3ccccc3)nc2)cc1
1573,802673,10.1016/j.bmcl.2011.12.125,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,CCc1c[nH]c2ncnc(-c3ccc(NC(=O)Nc4cccc(C(=O)NC(C)C)c4)cc3)c12,"3-(3-(4-(5-ethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)ureido)-N-isopropylbenzamide",4.6,uM,=,0.6627578316815741,1,O=C(Nc1ccccc1)Nc1ccc(-c2ncnc3[nH]ccc23)cc1
1574,510198,10.1021/jm800355c,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,Cl.Fc1ccc(-c2ccc3c(c2)CCC=C3c2ccncc2)cc1,"4-(6-(4-Fluorophenyl)-3,4-dihydronaphthalen-1-yl)pyridine Hydrochloride",4.199,uM,=,0.6231458746379397,1,C1=C(c2ccncc2)c2ccc(-c3ccccc3)cc2CC1
1575,863248,10.1021/jm300663n,,,,Inhibition of CYP3A4,COc1cc(C(=O)N[C@@H](CC(=O)O)c2ccccc2C)nn1-c1ccccc1F,(S)-3-{[1-(2-Fluorophenyl)-5-methoxy-1H-pyrazole-3-carbonyl]amino}-3-(2-methylphenyl)propionic acid,0.026,uM,=,-1.585026652029182,0,O=C(NCc1ccccc1)c1ccn(-c2ccccc2)n1
1576,825128,10.1016/j.bmcl.2012.03.070,,,,Inhibition of human CYP3A4 in liver microsomes,CN1CCN(C(=O)c2cn(Cc3cncn3Cc3ccc4c(c3)OCO4)cc2-c2cccc3ccccc23)CC1,"[1-(3-Benzo[1,3]dioxol-5-ylmethyl-3H-imidazol-4-ylmethyl)-4-naphthalen-1-yl-1H-pyrrol-3-yl]-(4-methyl-piperazin-1-yl)-methanone",0.14,uM,=,-0.8538719643217619,0,O=C(c1cn(Cc2cncn2Cc2ccc3c(c2)OCO3)cc1-c1cccc2ccccc12)N1CCNCC1
1577,1689562,10.1021/acs.jmedchem.7b00598,,,,Inhibition of CYP3A4 (unknown origin),N#Cc1cc(S(=O)(=O)Nc2ncns2)ccc1Oc1ccc(Cl)cc1-c1ccn[nH]1,"4-(4-chloro-2-(1H-pyrazol-5-yl)phenoxy)-3-cyano-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide",0.4,uM,=,-0.3979400086720376,0,O=S(=O)(Nc1ncns1)c1ccc(Oc2ccccc2-c2ccn[nH]2)cc1
1578,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCN(CCO)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1,"US8940739, G-44",6.04,uM,=,0.7810369386211319,1,O=C(Nc1ccc(N2CCNCC2)nc1)c1c[nH]c2c(CN3CC4N(C(=O)NCc5ccccc5)NCC(=O)N4C(Cc4ccccc4)C3=O)cccc12
1579,423507,10.1021/jm060995h,,,,Inhibition of CYP3A4,CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3C[C@H](O)CO3)c(Cc3c[nH]c4ncccc34)sc21,"5-{[(4S)-4-hydroxyisoxazolidin-2-yl]carbonyl}-1-isobutyl-3-methyl-6-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione",15.0,uM,=,1.1760912590556811,1,O=C(c1c(Cc2c[nH]c3ncccc23)sc2[nH]c(=O)[nH]c(=O)c12)N1CCCO1
1580,643713,10.1016/j.bmcl.2010.06.009,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader,C[C@@H](Oc1cc(-n2cnc3cc(-c4cnn(CCCN(C)C)c4)ccc32)sc1C(N)=O)c1ccccc1Cl,(R)-3-(1-(2-chlorophenyl)ethoxy)-5-(5-(1-(3-(dimethylamino)propyl)-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)thiophene-2-carboxamide,5.0,uM,=,0.6989700043360189,1,c1ccc(COc2csc(-n3cnc4cc(-c5cn[nH]c5)ccc43)c2)cc1
1581,1492824,10.1124/dmd.112.048355,,,,Inhibition of CYP3A4 activity in human liver microsomes assessed as dibenzo fluuorescene oxidation up to 40 uM,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,"1-(4-{4-[2-(2,4-Dichloro-phenyl)-2-imidazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-ethanone (ketoconazole)",0.0098,uM,=,-2.008773924307505,0,c1ccc(C2(Cn3ccnc3)OCC(COc3ccc(N4CCNCC4)cc3)O2)cc1
1582,774749,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",COc1cc(N)[nH]c2nc(-c3ccc(F)cc3)c(-c3ccncc3)c1-2,"2-(4-Fluoro-phenyl)-4-methoxy-3-pyridin-4-yl-1H-pyrrolo[2,3-b]pyridin-6-ylamine",1.0,uM,=,0.0,0,c1ccc(-c2nc3[nH]cccc-3c2-c2ccncc2)cc1
1583,519908,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,Cc1nc2c(N[C@@H]3CCc4ccccc43)cc(-n3ccccc3=O)cn2c1C,"(R)-1-(8-(2,3-dihydro-1H-inden-1-ylamino)-2,3-dimethylimidazo[1,2-a]pyridin-6-yl)pyridin-2(1H)-one",36.0,uM,=,1.5563025007672873,1,O=c1ccccn1-c1cc(N[C@@H]2CCc3ccccc32)c2nccn2c1
1584,51929,10.1021/jm034111v,,,,Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 5 minutes,CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@H](N(C)C)[C@H]3OC(C)=O)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O,"Acetic acid 14-(3-acetoxy-4-dimethylamino-6-methyl-tetrahydro-pyran-2-yloxy)-12-(5-acetoxy-4-methoxy-6-methyl-tetrahydro-pyran-2-yloxy)-5,7,8,11,13,15-hexamethyl-4,10-dioxo-1,9-dioxa-spiro[2.13]hexadec-6-yl ester",61.0,uM,=,1.7853298350107671,1,O=C1C[C@@H](O[C@H]2CCCCO2)C[C@@H](O[C@H]2CCCCO2)CC[C@@]2(CO2)C(=O)CCCCO1
1585,1919651,,,,,"Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase",Cc1ccsc1-c1ccc(F)nc1,2-Fluoro-5-(3-methyl-thiophen-2-yl)-pyridine,39.08,uM,=,1.5919545550467356,1,c1cncc(-c2cccs2)c1
1586,1446329,10.1021/ml500387y,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,CC(C)(CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F)c1ccccc1S(C)(=O)=O,"1,1,1-trifluoro-4-methyl-4-(2-(methylsulfonyl)phenyl)-2-((5-morpholino-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)pentan-2-ol",0.01,uM,=,-2.0,0,c1ccc(CCCCc2cc3cc(N4CCOCC4)ncc3[nH]2)cc1
1587,1661019,10.1016/j.bmcl.2017.02.047,,,,Inhibition of recombinant human CYP3A4 expressed in baculosomes using Vivid BOMCC substrate blue measured every 30 sec for 30 mins by fluorescence assay,CCCCCCCCC[C@H](O)CC(=O)CCc1ccc(O)c(OC)c1,10-gingerol,20.8,uM,=,1.3180633349627615,1,c1ccccc1
1588,1689562,10.1021/acs.jmedchem.7b00598,,,,Inhibition of CYP3A4 (unknown origin),Cn1nccc1-c1cc(Cl)ccc1Oc1cc(F)c(S(=O)(=O)Nc2ccncn2)cc1Cl,5-chloro-4-(4-chloro-2-(1-methyl-1H-pyrazol-5-yl)phenoxy)-2-fluoro-N-(pyrimidin-4-yl)benzenesulfonamide,1.058,uM,=,0.0244856676991669,1,O=S(=O)(Nc1ccncn1)c1ccc(Oc2ccccc2-c2ccn[nH]2)cc1
1589,1367425,10.1021/jm5003606,,,,Inhibition of recombinant CYP3A4 (unknown origin) by LC/MS/MS analysis,CCc1nc2ccc(Cl)cn2c1C(=O)NCc1ccc(N2CCN(c3ccc(OC(F)(F)F)cc3)CC2)cc1,"6-Chloro-2-ethyl-N-(4-{4-[4-(trifluoromethoxy)phenyl]piperazin-1-yl}benzyl)imidazo[1,2-a]pyridine-3-carboxamide",11.54,uM,=,1.0622058088197126,1,O=C(NCc1ccc(N2CCN(c3ccccc3)CC2)cc1)c1cnc2ccccn12
1590,559939,10.1016/j.bmcl.2008.10.072,,,,Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate,C[C@@H]1CN(Cc2ccc(-n3ccnc3C(=O)N3CCC(Nc4cccc(F)c4)CC3)cc2)C[C@H](C)N1,"{1-[4-((3R,5S)-3,5-Dimethyl-piperazin-1-ylmethyl)-phenyl]-1H-imidazol-2-yl}-[4-(3-fluoro-phenylamino)-piperidin-1-yl]-methanone",46.0,uM,=,1.662757831681574,1,O=C(c1nccn1-c1ccc(CN2CCNCC2)cc1)N1CCC(Nc2ccccc2)CC1
1591,828928,10.1016/j.bmcl.2012.06.022,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,CCN(C)c1nc2ccc(C(=O)N(CCN(C)C)C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1,"thiazol-5-ylmethyl(2S,3R)-4-(N-(2-(dimethylamino)ethyl)-2-(ethyl(methyl)amino)benzo[d]oxazole-6-carboxamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate",0.41,uM,=,-0.3872161432802645,0,O=C(N[C@H](CCNC(=O)c1ccc2ncoc2c1)Cc1ccccc1)OCc1cncs1
1592,643713,10.1016/j.bmcl.2010.06.009,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader,C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(NC5CCN(C)CC5)c4)ccc32)sc1C(N)=O)c1ccccc1Cl,(R)-3-(1-(2-chlorophenyl)ethoxy)-5-(5-(2-(1-methylpiperidin-4-ylamino)pyridin-4-yl)-1H-benzo[d]imidazol-1-yl)thiophene-2-carboxamide,4.7,uM,=,0.6720978579357175,1,c1ccc(COc2csc(-n3cnc4cc(-c5ccnc(NC6CCNCC6)c5)ccc43)c2)cc1
1593,51911,10.1016/s0960-894x(03)00474-8,,,,Inhibition of human liver microsome Cytochrome P450 3A4,CC(C)(c1ncc(-c2ccccn2)o1)N1CCN(C[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3OC[C@H]2O)[C@H](C(=O)NCC(F)(F)F)C1,"(S)-1-[(S)-2-Hydroxy-4-((R)-(S)-3-hydroxy-3,4,4a,8a-tetrahydro-2H-chromen-4-ylcarbamoyl)-5-phenyl-pentyl]-4-[1-methyl-1-(5-pyridin-2-yl-oxazol-2-yl)-ethyl]-piperazine-2-carboxylic acid (2,2,2-trifluoro-ethyl)-amide",5.0,uM,=,0.6989700043360189,1,O=C(N[C@@H]1CCOc2ccccc21)[C@@H](CCCN1CCN(Cc2ncc(-c3ccccn3)o2)CC1)Cc1ccccc1
1594,2024613,10.1016/j.bmcl.2020.127721,,,,Inhibition of CYP3A4 (unknown origin),CS(=O)(=O)Nc1cccc(CC(=O)Nc2ccc(-c3c[nH]c4ncccc34)s2)c1,"2-[3-(methanesulfonamido)phenyl]-N-[5-(1H-pyrrolo[2,3-b]pyridin-3-yl)-2-thienyl]acetamide",6.0,uM,=,0.7781512503836436,1,O=C(Cc1ccccc1)Nc1ccc(-c2c[nH]c3ncccc23)s1
1595,1291572,10.1016/j.bmcl.2013.12.058,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N2CCN(C(=O)OCc3cncs3)CC2)C(C)C)cs1,(S)-thiazol-5-ylmethyl 4-(2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-3-methylbutanoyl)piperazine-1-carboxylate,1.4,uM,=,0.1461280356782379,1,O=C(NCC(=O)N1CCN(C(=O)OCc2cncs2)CC1)NCc1cscn1
1596,1660136,10.1021/acs.jmedchem.6b01918,,,,Inhibition of human CYP3A4 assessed as inhibition of dealkylation,N[C@H]1CC[C@](CCOc2cc(F)c(S(=O)(=O)Nc3ncns3)cc2F)(c2ccccc2)CC1,"cis-4-(2-((1R,4R)-4-Amino-1-phenylcyclohexyl)ethoxy)-2,5-difluoro-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide",0.43,uM,=,-0.3665315444204134,0,O=S(=O)(Nc1ncns1)c1ccc(OCCC2(c3ccccc3)CCCCC2)cc1
1597,1467195,10.1021/jm5005336,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay,C[C@@H]1CN(Cc2ccc(/C=C/c3n[nH]c4cc([C@@H]5C[C@@]56C(=O)Nc5ccccc56)ccc34)cc2)C[C@H](C)O1,"(1R,2S)-(E)-2-(3-(4-cis-2,6-Dimethylmorpholino)methyl)styryl)-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-one",5.1,uM,=,0.7075701760979364,1,O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccc(CN4CCOCC4)cc3)n[nH]c2c1
1598,619264,10.1016/j.bmcl.2009.07.002,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,Cc1cccc(C)c1CNc1nc(-n2ccccc2=O)cc2c(C)c(C)n(CCO)c12,"1-(7-(2,6-dimethylbenzylamino)-1-(2-hydroxyethyl)-2,3-dimethyl-1H-pyrrolo[2,3-c]pyridin-5-yl)pyridin-2(1H)-one",5.6,uM,=,0.7481880270062004,1,O=c1ccccn1-c1cc2cc[nH]c2c(NCc2ccccc2)n1
1599,1625987,10.1016/j.bmcl.2016.04.095,,,,Inhibition of CYP3A4 in human liver microsomes after 30 secs by LC/MS/MS analysis,NCCS(=O)(=O)CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12,"2-(2-((4S,4aS,10bS)-10b-(4-chlorophenylsulfonyl)-7,10-difluoro-1,2,4,4a,5,10b-hexahydropyrano[3,4-c]chromen-4-yl)ethylsulfonyl)ethanamine",15.1,uM,=,1.1789769472931697,1,O=S(=O)(c1ccccc1)[C@@]12CCOC[C@@H]1COc1ccccc12
1600,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NC5CCN(CCCO)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, F-63",9.71,uM,=,0.9872192299080048,1,O=C(NC1CCNCC1)c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12
1601,1828801,10.1021/acs.jmedchem.8b01098,,,,Inhibition of C-terminal 4His-tagged CYP3A4 (unknown origin) expressed in Escherichia coli by spectrophotometric analysis,O=C(NCc1cccc2c1OCCO2)c1ccc(-c2ccncc2)cc1,"N-((2,3-Dihydrobenzo[b][1,4]dioxin-5-yl)methyl)-4-(pyridin-4-yl)benzamide",0.08,uM,=,-1.0969100130080565,0,O=C(NCc1cccc2c1OCCO2)c1ccc(-c2ccncc2)cc1
1602,449485,10.1016/j.bmcl.2007.07.097,,,,Inhibition of microsomal CYP3A4,Cc1ccc(N2CCN(C(=O)[C@@H](Cc3ccc(Cl)cc3Cl)N3CCCC3=O)CC2)c([C@H](CC(C)C)NC(=O)CCN(C)C)c1,"N-((S)-1-(2-(4-((R)-3-(2,4-dichlorophenyl)-2-(2-oxopyrrolidin-1-yl)propanoyl)piperazin-1-yl)-5-methylphenyl)-3-methylbutyl)-3-(dimethylamino)propanamide",6.0,uM,=,0.7781512503836436,1,O=C([C@@H](Cc1ccccc1)N1CCCC1=O)N1CCN(c2ccccc2)CC1
1603,1534761,,,,,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",COc1ncccc1CNc1ncc(Cc2c[nH]c3ncc(C)cc23)cn1,"US9096593, P-2139",5.0,uM,=,0.6989700043360189,1,c1cncc(CNc2ncc(Cc3c[nH]c4ncccc34)cn2)c1
1604,2017934,10.1021/acs.jmedchem.0c00834,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis,CCC1CCCN(c2nc3ccc(Br)cc3c(C(=O)NCC(CCC(=O)O)c3ccccc3Cl)c2C)C1,(+)-5-({[6-Bromo-2-(3-ethylpiperidin-1-yl)-3-methylquinolin-4-yl]carbonyl}amino)-4-(2-chlorophenyl)pentanoic acid,2.0,uM,=,0.3010299956639812,1,O=C(NCCc1ccccc1)c1cc(N2CCCCC2)nc2ccccc12
1605,2264099,10.1021/acs.jmedchem.1c00703,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 2 mins in presence of NADPH regenerating system by LC-MS/MS analysis,CC(C)n1nc(-c2nnc(C3CCN(CCc4ccccc4)CC3)o2)c2ccccc21.O=C(O)C(=O)O,"1-Isopropyl-3-[5-(1-phenethyl-piperidin-4-yl)-[1,3,4]oxadiazol-2-yl]-1H-indazole oxalate",11.2,uM,=,1.0492180226701815,1,c1ccc(CCN2CCC(c3nnc(-c4n[nH]c5ccccc45)o3)CC2)cc1
1606,2233885,10.1016/j.bmcl.2022.128734,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as substrate,CC/C(=C(/c1ccc(/C=C/C(=O)O)cc1)c1[nH]c2ccccc2c1Cl)c1ccc(F)cc1Cl,(E)-3-(4-((E)-1-(3-chloro-1H-indol-2-yl)-2-(2-chloro-4-fluorophenyl)but-1-enyl)phenyl)acrylic acid,7.0,uM,=,0.8450980400142568,1,C(=C(c1ccccc1)c1cc2ccccc2[nH]1)c1ccccc1
1607,1474044,10.1021/jm501740a,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,O=C(N[C@H](c1ncccn1)C1CCCC1)c1ccc2[nH]nc(-c3ccc(N4[C@H]5CC[C@H]4CC(O)C5)cc3)c2c1,N-((S)-cyclopentyl(pyrimidin-2-yl)methyl)-3-(4-((endo)-3-hydroxy-8-azabicyclo[3.2.1]octan-8-yl)phenyl)-1H-indazole-5-carboxamide,0.94,uM,=,-0.0268721464003013,0,O=C(N[C@H](c1ncccn1)C1CCCC1)c1ccc2[nH]nc(-c3ccc(N4[C@@H]5CCC[C@@H]4CC5)cc3)c2c1
1608,434712,10.1021/jm070104l,,,,Inhibition of human CYP3A4,COc1cc2c(=O)n(Cc3ccccc3C#N)c(N3CCC[C@@H](N)C3)nc2cc1F,(R)-2-((2-(3-aminopiperidin-1-yl)-7-fluoro-6-methoxy-4-oxoquinazolin-3(4H)-yl)methyl)benzonitrile,0.25,uM,=,-0.6020599913279624,0,O=c1c2ccccc2nc(N2CCCCC2)n1Cc1ccccc1
1609,438600,10.1016/j.bmcl.2007.03.048,,,,Inhibition of CYP3A4 in microsomes,COc1ccc(-c2cc(C)c3nc(-c4c(N[C@H](CO)Cc5ccccc5)cc[nH]c4=O)[nH]c3c2)cc1,(S)-4-(1-hydroxy-3-phenylpropan-2-ylamino)-3-(6-(4-methoxyphenyl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one,6.8,uM,=,0.8325089127062363,1,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(-c3ccccc3)cc2[nH]1
1610,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(C(C)C)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, E-7",2.24,uM,=,0.3502480183341628,1,O=C(c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12)N1CCNCC1
1611,512793,10.1021/jm800683c,,,,Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,"1-(4-{4-[2-(2,4-Dichloro-phenyl)-2-imidazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-ethanone (ketoconazole)",0.057,uM,=,-1.2441251443275083,0,c1ccc(C2(Cn3ccnc3)OCC(COc3ccc(N4CCNCC4)cc3)O2)cc1
1612,449485,10.1016/j.bmcl.2007.07.097,,,,Inhibition of microsomal CYP3A4,Cc1ccc(N2CCN(C(=O)[C@@H](Cc3ccc(Cl)cc3Cl)N3CCCC3=O)CC2)c([C@@H](N)CC(C)C)c1,"1-((R)-1-(4-(2-((S)-1-amino-3-methylbutyl)-4-methylphenyl)piperazin-1-yl)-3-(2,4-dichlorophenyl)-1-oxopropan-2-yl)pyrrolidin-2-one",1.9,uM,=,0.2787536009528289,1,O=C([C@@H](Cc1ccccc1)N1CCCC1=O)N1CCN(c2ccccc2)CC1
1613,449485,10.1016/j.bmcl.2007.07.097,,,,Inhibition of microsomal CYP3A4,CC(C)C[C@H](N)c1cc(C(F)(F)F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1,"1-[(R)-2-{4-[2-((S)-1-amino-3-methylbutyl)-4-trifluoromethylphenyl]piperazin-1-yl}-1-(2,4-dichlorobenzyl)-2-oxoethyl]pyrrolidin-2-one",49.0,uM,=,1.6901960800285136,1,O=C([C@@H](Cc1ccccc1)N1CCCC1=O)N1CCN(c2ccccc2)CC1
1614,834929,10.1016/j.bmcl.2012.07.020,,,,Inhibition of CYP3A4,CCS(=O)(=O)c1ccc2[nH]c(-c3cc(-c4ccccc4)ccn3)nc2c1,5-(ethylsulfonyl)-2-(4-phenylpyridin-2-yl)-1H-benzo[d]imidazole,7.0,uM,=,0.8450980400142568,1,c1ccc(-c2ccnc(-c3nc4ccccc4[nH]3)c2)cc1
1615,52064,10.1016/s0960-894x(03)00058-1,,,,Inhibitory activity against CYP450 3A4 isozyme,CCN(CC)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(=O)Cn1c(SCc2ccc(F)cc2)nc(=O)c2c1CCC2,"N-(2-Diethylamino-ethyl)-2-[2-(4-fluoro-benzylsulfanyl)-4-oxo-4,5,6,7-tetrahydro-cyclopentapyrimidin-1-yl]-N-(4'-trifluoromethyl-biphenyl-4-ylmethyl)-acetamide",27.0,uM,=,1.4313637641589874,1,O=C(Cn1c(SCc2ccccc2)nc(=O)c2c1CCC2)NCc1ccc(-c2ccccc2)cc1
1616,1486437,10.1124/dmd.111.043018,,,,Inhibition of human CYP3A4 expressed in supersomes assessed inhibition of 1'-OH midazolam formation after 7.5 mins by LC-MS method,C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C,"30-Ethyl-33-(1-hydroxy-2-methyl-hex-4-enyl)-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31undecaaza-cyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone",2.06,uM,=,0.3138672203691534,1,O=C1CNC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)CN1
1617,804823,10.1016/j.bmcl.2011.12.080,,,,Time dependent inhibition of CYP3A4,Cc1cc(Cl)cc2c(C(O)c3cccnc3)c3c(C)n[nH]c3nc12,"rac-(6-chloro-3,8-dimethyl-1H-pyrazolo[3,4-b]quinolin-4-yl)(pyridin-3-yl)methanol",2.1,uM,=,0.3222192947339193,1,c1cncc(Cc2c3ccccc3nc3[nH]ncc23)c1
1618,326552,10.1021/jm050645f,,,,Inhibitory activity against cytochrome P450 3A4 isoform,O=C(CN(c1ccc(Cl)cc1)S(=O)(=O)c1ccc(NCCN2CCOCC2)cc1)N/N=C1\C(=O)Nc2ccccc21,"N-(4-chlorophenyl)-4-{[2-(4-morpholinyl)ethyl]amino}-N-{2-oxo-2-[2-(2-oxo-1,2-dihydro-3H-indol-3-ylidene)hydrazino]ethyl}benzenesulfonamide",0.31,uM,=,-0.5086383061657274,0,O=C(CN(c1ccccc1)S(=O)(=O)c1ccc(NCCN2CCOCC2)cc1)N/N=C1\C(=O)Nc2ccccc21
1619,2156515,10.1021/acs.jmedchem.1c01272,,,,Inhibition of CYP3A4 in human liver microsomes using IPA as substrate preincubated for 10 mins followed by NADPH generating system addition and measured after 20 mins,COc1cc(NC(=O)c2cc(=O)c3ccccc3o2)c(-c2nnn(-c3ccc(CCN4CCc5cnccc5C4)cc3)n2)cc1OC,"N-(2-(2-(4-(2-(3,4-dihydro-2,6-naphthyridin-2(1H)-yl)ethyl)phenyl)-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl)-4-oxo-4H-chromene-2-carboxamide",1.074,uM,=,0.0310042813635368,1,O=C(Nc1ccccc1-c1nnn(-c2ccc(CCN3CCc4cnccc4C3)cc2)n1)c1cc(=O)c2ccccc2o1
1620,512798,10.1021/jm800832q,,,,Inhibition of human recombinant CYP3A4 in human liver microsomes using BFC as a substrate,Cc1cc(C2CCN(C)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,(S)-4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-3-(4-methyl-6-(1-methylpiperidin-4-yl)-1H-benzo[d]imidazol-2-yl)pyridin-1(1H)-one,14.0,uM,=,1.146128035678238,1,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(C3CCNCC3)cc2[nH]1
1621,1487664,10.1124/dmd.112.045302,,,,Reversible inhibition of midazolam 1'-hydroxylase activity of human recombinant CYP3A4 harboring human P450 oxidoreductase and b5,Cc1ccc(-c2c(-c3nn(C)c4ncnc(N5CC[C@H](N6CCCCC6)C5)c34)cnn2C)cc1,"1-methyl-3-[1-methyl-5-(4-methylphenyl)-1H-pyrazol-4-yl]-4-[(3S)-3-piperidin-1-ylpyrrolidin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine",0.3,uM,=,-0.5228787452803376,0,c1ccc(-c2[nH]ncc2-c2n[nH]c3ncnc(N4CC[C@H](N5CCCCC5)C4)c23)cc1
1622,2081967,10.1016/j.ejmech.2021.113248,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam 1-hydroxylation as substrate by LC-MS/MS analysis,O=C1NCCC12CCN(c1c(Cl)cncc1-c1cc3ccccc3s1)CC2,"8-(3-(Benzo[b]thiophen-2-yl)-5-chloropyridin-4-yl)-2,8-diazaspiro[4.5]decan-1-one",2.11,uM,=,0.3242824552976926,1,O=C1NCCC12CCN(c1ccncc1-c1cc3ccccc3s1)CC2
1623,860549,10.1021/jm3003747,,,,Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins,CC(C)(C(N)=O)N1CCN(Cc2cc3nc(-c4cncc5[nH]ccc45)nc(N4CCOCC4)c3s2)CC1,"2-Methyl-2-(4-((4-morpholino-2-(1H-pyrrolo[2,3-c]pyridin-4-yl)thieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-propanamide",3.2,uM,=,0.505149978319906,1,c1cc2c(-c3nc(N4CCOCC4)c4sc(CN5CCNCC5)cc4n3)cncc2[nH]1
1624,450508,10.1021/jm070806a,,,,Inhibition of CYP3A4,Cc1ccc(N2CCN(C(=O)[C@H](C)Cc3ccc(Cl)cc3)CC2)c([C@@H](NC(=O)CCN(C)C)C(C)C)c1,1-{2-[(1S)-(3-dimethylaminopropionyl)amino-2-methylpropyl]-4-methylphenyl}-4-[(2R)-methyl-3-(4-chlorophenyl)propionyl]piperazine,9.2,uM,=,0.9637878273455552,1,O=C(CCc1ccccc1)N1CCN(c2ccccc2)CC1
1625,2068401,10.1016/j.bmcl.2020.127676,,,,Inhibition of CYP3A4 (unknown origin),CN[C@@H](C)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)Nc1cc2c(N[C@H]3CC[C@@H](Nc4ncnc5cc(OC)c(NC(=O)[C@@H]6CCCN6C(=O)[C@@H](NC(=O)[C@H](C)NC)C(C)(C)C)cc45)CC3)ncnc2cc1OC)C(C)(C)C,"(S,S,2S,2'S)-N,N'-(4,4'-(1s,4s)-cyclohexane-1,4-diylbis(azanediyl)bis(7-methoxyquinazoline-6,4-diyl))bis(1-((S)-3,3-dimethyl-2-((S)-2-(methylamino)propanamido)butanoyl)pyrrolidine-2-carboxamide)",5.53,uM,=,0.7427251313046983,1,O=C(Nc1ccc2ncnc(N[C@H]3CC[C@@H](Nc4ncnc5ccc(NC(=O)[C@@H]6CCCN6)cc45)CC3)c2c1)[C@@H]1CCCN1
1626,461436,10.1016/j.bmcl.2007.10.092,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,CC[C@@H]1CCC[C@H](C2(Cc3noc(CN(C)C(C)(C)CO)n3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1,"2-(((3-((1-((2R,6R)-1-(4-chlorophenylsulfonyl)-6-ethylpiperidin-2-yl)cyclopropyl)methyl)-1,2,4-oxadiazol-5-yl)methyl)(methyl)amino)-2-methylpropan-1-ol",4.0,uM,=,0.6020599913279624,1,O=S(=O)(c1ccccc1)N1CCCC[C@@H]1C1(Cc2ncon2)CC1
1627,2048449,10.1016/j.bmc.2020.115734,,,,Inhibition of recombinant CYP3A4 (unknown origin) by fluorescence-based assay,COc1nc(-c2csc(Nc3cc(C(C)(C)C)nn3C(C)C)n2)ccc1-n1cnc(C)c1,N-(3-(tert-butyl)-1-isopropyl-1H-pyrazol-5-yl)-4-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)thiazol-2-amine,2.3,uM,=,0.3617278360175928,1,c1cn(-c2ccc(-c3csc(Nc4ccn[nH]4)n3)nc2)cn1
1628,834635,10.1016/j.bmcl.2012.07.019,,,,Inhibition of CYP3A4,N[C@@H](CC(=O)N1CCN(C(=O)c2ccc(F)cc2)CC1)Cc1cc(F)c(F)cc1F,"(R)-3-amino-1-(4-(4-fluorobenzoyl)piperazin-1-yl)-4-(2,4,5-trifluorophenyl)butan-1-one",1.0,uM,=,0.0,0,O=C(CCCc1ccccc1)N1CCN(C(=O)c2ccccc2)CC1
1629,555225,10.1016/j.bmcl.2008.05.058,,,,Inhibition of CYP3A4,CN(C(=O)CN1C(=O)COc2cc(Cl)c(Cl)cc21)[C@H](CN1CCOCC1)c1ccc(-c2ccccc2)cc1,"N-((S)-1-Biphenyl-4-yl-2-morpholin-4-yl-ethyl)-2-(6,7-dichloro-3-oxo-2,3-dihydro-benzo[1,4]oxazin-4-yl)-N-methyl-acetamide",4.2,uM,=,0.6232492903979004,1,O=C(CN1C(=O)COc2ccccc21)N[C@H](CN1CCOCC1)c1ccc(-c2ccccc2)cc1
1630,1288940,10.1016/j.bmcl.2013.12.046,,,,Inhibition of CYP3A4 (unknown origin),Cn1cncc1[C@@](C)(O)C1=Cc2cccnc2[C@@H](N2CCN(C(=O)OC(C)(C)C)CC2)c2ccc(Cl)cc21,"4-{(S)-8-Chloro-6-[(S)-1-hydroxy-1-(3-methyl-3H-imidazol-4-yl)-ethyl]-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl}-piperazine-1-carboxylic acid tert-butyl ester",0.3,uM,=,-0.5228787452803376,0,C1=C(Cc2cnc[nH]2)c2ccccc2[C@H](N2CCNCC2)c2ncccc21
1631,1498866,10.1021/acsmedchemlett.5b00054,,,,Inhibition of CYP3A4 (unknown origin),Cc1c(F)cncc1-c1nc2cc(F)c(F)cc2n1C1CC1,"1-cyclopropyl-5,6-difluoro-2-(5-fluoro-4-methylpyridin-3-yl)-1H-benzo[d]imidazole",8.235,uM,=,0.9156636035057732,1,c1cncc(-c2nc3ccccc3n2C2CC2)c1
1632,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1ccc(C(=O)N2CCOC[C@H]2Cc2cc(-n3nccn3)ccc2F)c(-n2nccn2)c1C,"US9150566, 94",30.0,uM,=,1.4771212547196624,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
1633,1553516,10.1016/j.bmc.2016.02.006,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins by LC-MS analysis,O=C(O)CN(Cc1cccc(-c2ccccc2OC(F)(F)F)c1)S(=O)(=O)c1ccc(OC(F)F)cc1,"2-(4-(Difluoromethoxy)-N-((2'-(trifluoromethoxy)-[1,1'-biphenyl]-3-yl)methyl)phenylsulfonamido)acetic acid",30.0,uM,=,1.4771212547196624,1,O=S(=O)(NCc1cccc(-c2ccccc2)c1)c1ccccc1
1634,876026,10.1021/jm3011838,,,,Inhibition of CYP3A4 in human liver microsomes in presence of NADPH by LC-MS/MS method,CN1C[C@@H](C(=O)Nc2ccc(Cl)cc2)[C@H](c2ccc(/C=C/C(=O)Nc3ccccc3N)cc2)C1,"(3S,4R)-4-(4-((E)-3-(2-aminophenylamino)-3-oxoprop-1-enyl)phenyl)-N-(4-chlorophenyl)-1-methylpyrrolidine-3-carboxamide",21.0,uM,=,1.3222192947339193,1,O=C(/C=C/c1ccc([C@@H]2CNC[C@H]2C(=O)Nc2ccccc2)cc1)Nc1ccccc1
1635,742805,10.1016/j.bmc.2011.02.009,,,,Inhibition of human CYP3A4 after 30 mins,CC(C)C(O)(c1ccc(-c2ccccn2)cc1)c1c[nH]cn1,rac-1-(1H-Imidazol-4-yl)-2-methyl-1-[4-(2-pyridinyl)phenyl]-1-propanol,5.2,uM,=,0.7160033436347992,1,c1ccc(-c2ccc(Cc3c[nH]cn3)cc2)nc1
1636,630896,10.1016/j.bmcl.2010.03.017,,,,Inhibition of CYP3A4,COc1cccc([C@@H]2CCO[P@](=O)(COc3cc(C)c(C)c4c3-c3ncsc3C4)O2)c1,"4-[4-(3-Methoxy-phenyl)-2-oxo-2lambda*5*-[1,3,2]dioxaphosphinan-2-ylmethoxy]-6,7-dimethyl-8H-indeno[1,2-d]thiazole",0.27,uM,=,-0.5686362358410126,0,O=[P@]1(COc2cccc3c2-c2ncsc2C3)OCC[C@@H](c2ccccc2)O1
1637,526157,10.1021/np0401765,,,,Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation,COc1cc(OC)c([C@@H]2[C@H](C)[C@@H](C)[C@H]2c2cc(OC)c(OC)cc2OC)cc1OC,"1-[2,3-dimethyl-4-(2,4,5-trimethoxyphenyl)-(1R,2R,3R,4R)-cyclobutyl]-2,4,5-trimethoxybenzene",85.4,uM,=,1.931457870689005,1,c1ccc([C@@H]2CC[C@H]2c2ccccc2)cc1
1638,555862,10.1016/j.bmcl.2008.04.047,,,,Inhibition of human CYP3A4,Nc1nccc(Oc2ccc(NC(=O)NC(=O)Cc3ccc(F)cc3)cc2F)c1C#CCO,1-(4-(2-amino-3-(3-hydroxyprop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(2-(4-fluorophenyl)acetyl)urea,0.7,uM,=,-0.1549019599857432,0,O=C(Cc1ccccc1)NC(=O)Nc1ccc(Oc2ccncc2)cc1
1639,1640557,,,,,"null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.",CC(C)(C(=O)c1cccnc1)c1cccnc1,"2-Methyl-1,2-di-pyridin-3-yl-propan-1-one",3.0,uM,=,0.4771212547196624,1,O=C(Cc1cccnc1)c1cccnc1
1640,355280,10.1016/j.bmcl.2006.02.020,,,,Inhibition of CYP3A4,CC(C)N(C)[C@H](C)[C@@H](c1ccc2cc(OCC(C)(C)C(=O)O)ccc2c1)n1ccnc1,"3-(6-((1R,2R)-1-(1H-imidazol-1-yl)-2-(isopropyl(methyl)amino)propyl)naphthalen-2-yloxy)-2,2-dimethylpropanoic acid",0.4,uM,=,-0.3979400086720376,0,c1ccc2cc(Cn3ccnc3)ccc2c1
1641,1485703,10.1124/dmd.112.048264,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method,CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1,"8-Chloro-11-(4-methyl-piperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine",46.3,uM,=,1.665580991017953,1,c1ccc2c(c1)N=C(N1CCNCC1)c1ccccc1N2
1642,434712,10.1021/jm070104l,,,,Inhibition of human CYP3A4,N#Cc1ccccc1Cn1c(N2CCC[C@@H](N)C2)nc2cc(N3CCOCC3)c(F)cc2c1=O,(R)-2-((2-(3-aminopiperidin-1-yl)-6-fluoro-7-morpholino-4-oxoquinazolin-3(4H)-yl)methyl)benzonitrile,0.79,uM,=,-0.1023729087095585,0,O=c1c2ccc(N3CCOCC3)cc2nc(N2CCCCC2)n1Cc1ccccc1
1643,519908,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,Cc1nc2c(N[C@@H]3CCc4ccccc43)cc(-n3cncn3)cn2c1C,"(R)-N-(2,3-dihydro-1H-inden-1-yl)-2,3-dimethyl-6-(1H-1,2,4-triazol-1-yl)imidazo[1,2-a]pyridin-8-amine",5.5,uM,=,0.7403626894942439,1,c1ccc2c(c1)CC[C@H]2Nc1cc(-n2cncn2)cn2ccnc12
1644,1465541,10.1016/j.bmcl.2015.01.051,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(CC6CN(C7COC7)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O,"(1S,4R,5R,6R,8R,10S,11R,12S,13R,16R,18S,21R)-8-[(1S)-1-ethoxy-2-hydroxy-2-methylpropyl]-4,6,12,17,17-pentamethyl-18-{[(2S)-4-{[1-(oxetan-3-yl)azetidin-3-yl]methyl}morpholin-2-yl]oxy}-9-oxahexacyclo[11.9.0.0^{1,21}.0^{4,12}.0^{5,10}.0^{16,21}]docosan-11-ol",6.6,uM,=,0.8195439355418687,1,C1CO[C@@H]2CC3C(CC[C@@]45C[C@@]46CC[C@H](O[C@H]4CN(CC7CN(C8COC8)C7)CCO4)C[C@@H]6CC[C@@H]35)[C@H]2C1
1645,651755,10.1016/j.bmcl.2010.07.030,,,,Inhibition of CYP3A4 in human liver microsome,COCCCc1ccc(Cl)c(CN(C(=O)[C@@H](CN)Cc2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1,"(R)-3-amino-N-(2-chloro-5-(3-methoxypropyl)benzyl)-N-cyclopropyl-2-(4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)benzyl)propanamide",14.0,uM,=,1.146128035678238,1,O=C(CCc1ccc(OCCOc2ccccc2)cc1)N(Cc1ccccc1)C1CC1
1646,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cc(-n2nccn2)ccc1Cl,"US9150566, 126",17.0,uM,=,1.230448921378274,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
1647,1512960,10.1021/acsmedchemlett.5b00117,,,,Inhibition of CYP3A4 (unknown origin),Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccc(F)cc2)[C@@H]3C)n1,"(R)-(4-Fluorophenyl)(8-methyl-3-(3-methyl-1,2,4-thiadiazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone",90.0,uM,=,1.954242509439325,1,O=C(c1ccccc1)N1CCn2c(nnc2-c2ncns2)C1
1648,1972830,10.1021/acsmedchemlett.9b00612,,,,Inhibition of human recombinant CYP3A4 expressed in insect cell microsomes in presence of NADPH by fluorescence assay,Cc1ccc(C(=O)Nc2ccc(CN3CCC4C=NNC4C3)c(Cl)c2)cc1C#Cc1cnc2cccnn12,"N-[3-chloro-4-(1,4,5,7-tetrahydropyrazolo[3,4-c]pyridin-6-ylmethyl)phenyl]-3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methylbenzamide",5.58,uM,=,0.7466341989375788,1,O=C(Nc1ccc(CN2CCC3C=NNC3C2)cc1)c1cccc(C#Cc2cnc3cccnn23)c1
1649,1637154,,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins,COc1ccnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4cccnc4)c3F)c12,"Pyridine-3-sulfonic acid [2,4-difluoro-3-(4-methoxy-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phenyl]-amide",5.0,uM,=,0.6989700043360189,1,O=C(c1cccc(NS(=O)(=O)c2cccnc2)c1)c1c[nH]c2ncccc12
1650,802673,10.1016/j.bmcl.2011.12.125,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,COc1cccc(-c2ccc(NC(=O)Nc3ccc(-c4ccnc5[nH]cnc45)cc3)cc2)c1,"1-(4-(3H-imidazo[4,5-b]pyridin-7-yl)phenyl)-3-(3'-methoxybiphenyl-4-yl)urea",0.048,uM,=,-1.3187587626244128,0,O=C(Nc1ccc(-c2ccccc2)cc1)Nc1ccc(-c2ccnc3[nH]cnc23)cc1
1651,2116571,10.1021/acsmedchemlett.1c00198,,,,Inhibition of CYP3A4 (unknown origin) expressed in baculovirus infected insect supersomes preincubated for 15 mins followed by addition of NADPH regenerating system by fluorescence based analysis,O=C(O)c1ccc2cc(N3CCC4(C=C(c5c(-c6c(Cl)cc(F)cc6Cl)noc5C5CC5)C4)CC3)ccc2n1,"6-(2-(5-cyclopropyl-3-(2,6-dichloro-4-fluorophenyl)isoxazol-4-yl)-7-azaspiro[3.5]non-1-en-7-yl)quinoline-2-carboxylic acid",3.1,uM,=,0.4913616938342727,1,C1=C(c2c(-c3ccccc3)noc2C2CC2)CC12CCN(c1ccc3ncccc3c1)CC2
1652,423507,10.1021/jm060995h,,,,Inhibition of CYP3A4,CNc1nc2ccccc2n1Cc1sc2c(c1C(=O)N1CCC1)c(=O)n(C)c(=O)n2CC(C)C,"5-(azetidin-1-ylcarbonyl)-1-isobutyl-3-methyl-6-{[2-(methylamino)-1H-benzimidazol-1-yl]methyl}thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione",1.0,uM,=,0.0,0,O=C(c1c(Cn2cnc3ccccc32)sc2[nH]c(=O)[nH]c(=O)c12)N1CCC1
1653,1668102,10.1016/j.bmcl.2017.04.006,,,,Inhibition of recombinant human CYP3A4 expressed in insect cells using DBOMF as substrate pretreated for 10 mins followed by substrate addition measured every minute for 15 mins in presence of NADP+ by fluorescence assay,Clc1ccc2c(NCc3ccccn3)c3c(nc2c1)CCCC3,"6-chloro-N-(pyridin-2-ylmethyl)-1,2,3,4-tetrahydroacridin-9-amine",9.1,uM,=,0.9590413923210936,1,c1ccc(CNc2c3c(nc4ccccc24)CCCC3)nc1
1654,595638,10.1016/j.bmcl.2009.09.096,,,,Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH,COc1cnc2c(NCc3nnc4ccc(-c5cc(C)ns5)nn34)ccnc2c1,"7-methoxy-N-((6-(3-methylisothiazol-5-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine",26.0,uM,=,1.414973347970818,1,c1cnc2c(NCc3nnc4ccc(-c5ccns5)nn34)ccnc2c1
1655,434712,10.1021/jm070104l,,,,Inhibition of human CYP3A4,N#Cc1ccccc1Cn1c(N2CCC[C@@H](N)C2)nc2ccc(F)cc2c1=O,(R)-2-((2-(3-aminopiperidin-1-yl)-6-fluoro-4-oxoquinazolin-3(4H)-yl)methyl)benzonitrile,2.5,uM,=,0.3979400086720376,1,O=c1c2ccccc2nc(N2CCCCC2)n1Cc1ccccc1
1656,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCCN(C)C)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, F-18",17.89,uM,=,1.252610340567373,1,O=C1[C@H](Cc2ccccc2)N2C(=O)CNN(C(=O)NCc3ccccc3)[C@H]2CN1Cc1cccc2cc[nH]c12
1657,949159,10.1016/j.bmcl.2013.01.011,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,Cc1cc(C[C@@H](NC(=O)N2CCC(N3Cc4cccc(F)c4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12,"(R)-N-(1-(1,4'-bipiperidin-1'-yl)-3-(7-methyl-1H-indazol-5-yl)-1-oxopropan-2-yl)-4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide",26.0,uM,=,1.414973347970818,1,O=C(N[C@H](Cc1ccc2[nH]ncc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
1658,988989,10.1021/jm400732v,,,,Inhibition of CYP3A4 (unknown origin),CN[C@@H](C)C(=O)N[C@H]1CN(C(C)=O)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O.Cl,"(S)-N-((S)-5-Acetyl-1-((6-bromo-2-methoxynaphthalen-1-yl)methyl)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-yl)-2-(methylamino)propanamide hydrochloride",3.2,uM,=,0.505149978319906,1,O=C1CCNc2ccccc2N1Cc1cccc2ccccc12
1659,455108,10.1016/j.bmcl.2006.12.043,,,,Inhibition of CYP3A4,O=C(C(O)c1ccc(Br)cc1)N1CCC(Nc2ccc3[nH]ncc3c2)CC1,1-(4-(1H-indazol-5-ylamino)piperidin-1-yl)-2-(4-bromophenyl)-2-hydroxyethanone,3.5,uM,=,0.5440680443502757,1,O=C(Cc1ccccc1)N1CCC(Nc2ccc3[nH]ncc3c2)CC1
1660,862399,10.1021/jm300601d,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis,CS(=O)(=O)c1ccc(C(=O)N2CCC(c3ccc(C(=O)NC(=N)N)cc3C(F)(F)F)CC2)cc1,N-{4-[1-(4-Methylsulfonyl-benzoyl)-piperidin-4-yl]-3-trifluoromethyl-benzoyl}-guanidine,15.0,uM,=,1.1760912590556811,1,O=C(c1ccccc1)N1CCC(c2ccccc2)CC1
1661,1912368,10.1021/acs.jmedchem.9b00687,,,,Inhibition of CYP3A4 in human liver microsomes at 1 uM using midazolam as substrate by LC-MS/MS analysis,C=CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1,"US9447106, 27b (peak 2)",14.3,uM,=,1.155336037465062,1,c1ccc(Oc2ccc(-c3cc4n(n3)[C@H](C3CCNCC3)CCN4)cc2)cc1
1662,465432,10.1016/j.bmcl.2007.11.008,,,,Inhibition of CYP3A4,CC(C)C[C@@H]1C(=O)N[C@H](C2Cc3ccccc3C2)C(=O)N1[C@@H](C(=O)NC(C)C)c1ccc(Br)s1,"(S)-2-(5-bromothiophen-2-yl)-2-((3R,6R)-3-(2,3-dihydro-1H-inden-2-yl)-6-isobutyl-2,5-dioxopiperazin-1-yl)-N-isopropylacetamide",1.0,uM,=,0.0,0,O=C1CN(Cc2cccs2)C(=O)[C@@H](C2Cc3ccccc3C2)N1
1663,2134029,10.1021/acs.jmedchem.1c00959,,,,Inhibition of CYP3A4 (unknown origin),COc1ccc(-c2ccc(C(=O)O)cc2C)cc1-c1ncc(C(F)(F)F)cc1[C@@H]1CC[C@H]2[C@@H](c3cc(C(F)(F)F)cc(C(F)(F)F)c3)OC(=O)N12,"3'-(3-(((1R,5S,7aS)-1-(3,5-bis(trifluoromethyl)phenyl)-3-oxohexahydropyrrolo[1,2-c]oxazol-5-yl)methyl)-5-(trifluoromethyl)pyridin-2-yl)-4'-methoxy-2-methylbiphenyl-4-carboxylic acid",9.0,uM,=,0.9542425094393248,1,O=C1O[C@H](c2ccccc2)[C@@H]2CC[C@@H](c3cccnc3-c3cccc(-c4ccccc4)c3)N12
1664,1499751,10.1021/acs.jmedchem.5b00424,,,,Inhibition of CYP3A4 (unknown origin),COc1cccc(CC(=O)Nc2cc(-c3ccnc(N)c3)cs2)c1,N-(4-(2-aminopyridin-4-yl)thiophen-2-yl)-2-(3-methoxyphenyl)acetamide,5.6,uM,=,0.7481880270062004,1,O=C(Cc1ccccc1)Nc1cc(-c2ccncc2)cs1
1665,632105,10.1016/j.bmcl.2010.03.057,,,,Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin,Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,4-[(S)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-(4-methyl-6-morpholin-4-yl-1H-benzoimidazol-2-yl)-1H-pyridin-2-one,0.5,uM,=,-0.3010299956639812,0,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(N3CCOCC3)cc2[nH]1
1666,1289880,10.1021/jm401642q,,,,Inhibition of recombinant human CYP3A4,C[C@H]1Cc2ccccc2N1C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1,"2-{2-[(2S)-2-Methyl-2,3-dihydro-1H-indol-1-yl]-2-oxoethyl}-6-(morpholin-4-yl)pyrimidin-4(3H)-one",40.0,uM,=,1.6020599913279625,1,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2ccccc21
1667,1446329,10.1021/ml500387y,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,CC(C)(CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F)c1cccc(O)c1,"3-(5,5,5-trifluoro-4-hydroxy-2-methyl-4-((5-morpholino-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)pentan-2-yl)phenol",4.0,uM,=,0.6020599913279624,1,c1ccc(CCCCc2cc3cc(N4CCOCC4)ncc3[nH]2)cc1
1668,828928,10.1016/j.bmcl.2012.06.022,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Cc1nc2ccc(C(=O)N(CC(C)C)C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1,"Thiazol-5-ylmethyl(2S,3R)-3-hydroxy-4-(N-isobutyl-2-methylbenzo[d]oxazole-6-carboxamido)-1-phenylbutan-2-ylcarbamate",0.052,uM,=,-1.2839966563652008,0,O=C(N[C@H](CCNC(=O)c1ccc2ncoc2c1)Cc1ccccc1)OCc1cncs1
1669,1919651,,,,,"Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase",Cc1ccsc1-c1cccnc1,3-(3-Methyl-thiophen-2-yl)-pyridine,0.75,uM,=,-0.1249387366082999,0,c1cncc(-c2cccs2)c1
1670,1911030,10.1021/acs.jmedchem.8b01226,,,,Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins,COc1ccccc1C(=O)N1CCC(=CC#Cc2cccc(C)n2)CC1,(2-Methoxyphenyl){4-[3-(6-methylpyridin-2-yl)prop-2-yn-1-ylidene]piperidin-1-yl}methanone,13.8,uM,=,1.1398790864012365,1,O=C(c1ccccc1)N1CCC(=CC#Cc2ccccn2)CC1
1671,1491684,10.1124/dmd.112.045708,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 90 mins followed by substrate addition by LC-MS/MS analysis,COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1,"Acetic acid (2S,3S)-5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester",146.0,uM,=,2.164352855784437,1,O=C1C[C@H](c2ccccc2)Sc2ccccc2N1
1672,631458,10.1021/jm9013136,,,,Inhibition of human recombinant CYP3A4,COC(c1ccc(Cl)cc1)(c1ccc2c(c1)c(-c1ccc(Cl)cc1)cc(=O)n2C)c1cncn1C,4-(4-chlorophenyl)-6-((4-chlorophenyl)(methoxy)(1-methyl-1H-imidazol-5-yl)methyl)-1-methylquinolin-2(1H)-one,0.923,uM,=,-0.0347982989740879,0,O=c1cc(-c2ccccc2)c2cc(C(c3ccccc3)c3cnc[nH]3)ccc2[nH]1
1673,559939,10.1016/j.bmcl.2008.10.072,,,,Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate,C[C@@H]1CN(Cc2ccc(-c3ccccc3C(=O)N3CCC(C(=O)c4ccc(F)cc4)CC3)cc2)C[C@H](C)N1,"[4'-((3R,5S)-3,5-Dimethyl-piperazin-1-ylmethyl)-biphenyl-2-yl]-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-methanone",3.6,uM,=,0.5563025007672873,1,O=C(c1ccccc1)C1CCN(C(=O)c2ccccc2-c2ccc(CN3CCNCC3)cc2)CC1
1674,495539,10.1021/jm801332q,,,,Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate measured in 0 to 5 mins by time dependent inhibition assay,C[C@@H]1CN(Cc2ccc(-c3cccnc3C(=O)N3CCC(Nc4ccc(F)cc4)CC3)cc2)C[C@H](C)N1,"(3-(4-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)pyridin-2-yl)(4-(4-fluorophenylamino)piperidin-1-yl)methanone",20.0,uM,=,1.3010299956639813,1,O=C(c1ncccc1-c1ccc(CN2CCNCC2)cc1)N1CCC(Nc2ccccc2)CC1
1675,828928,10.1016/j.bmcl.2012.06.022,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2ncoc2c1,"Thiazol-5-ylmethyl(2S,3R)-3-hydroxy-4-(N-isobutylbenzo[d]oxazole-6-carboxamido)-1-phenylbutan-2-ylcarbamate",0.055,uM,=,-1.259637310505756,0,O=C(N[C@H](CCNC(=O)c1ccc2ncoc2c1)Cc1ccccc1)OCc1cncs1
1676,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cc(-n3nccn3)ccc2C)c1,"US9150566, 119",19.0,uM,=,1.2787536009528289,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
1677,598210,10.1016/j.bmcl.2009.08.024,,,,Inhibition of human CYP3A4,CC1(CC(=O)NCc2cccc(C(F)(F)F)c2)CC2(CCCCC2)OO1,"2-(3-methyl-1,2-dioxaspiro[4.5]decan-3-yl)-N-(3-(trifluoromethyl)benzyl)acetamide",3.2,uM,=,0.505149978319906,1,O=C(CC1CC2(CCCCC2)OO1)NCc1ccccc1
1678,2207925,10.1021/acsmedchemlett.2c00411,,,,Inhibition of CYP3A4 (unknown origin) in presence of NADPH,COc1cc(Nc2ncc(C)c(Nc3ccc4oc(=O)[nH]c4c3)n2)cc(C(F)F)c1,5-(2-(3-(difluoromethyl)-5-methoxyphenylamino)-5methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-one,3.0,uM,=,0.4771212547196624,1,O=c1[nH]c2cc(Nc3ccnc(Nc4ccccc4)n3)ccc2o1
1679,1619192,10.1016/j.bmcl.2016.08.071,,,,Inhibition of CYP3A4 (unknown origin),Cc1cc(Cl)cc2c(-c3ccccc3)c(C(=O)O)c(N3CCCCC3)nc12,6-chloro-8-methyl-4-phenyl-2-(piperidin-1-yl)quinoline-3-carboxylic acid,16.0,uM,=,1.2041199826559248,1,c1ccc(-c2cc(N3CCCCC3)nc3ccccc23)cc1
1680,756007,10.1021/jm200112k,,,,Inhibition of CYP3A4,CN(C[C@@H]1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(-c4cnn(C)c4)cc3c(=O)c2c1,"N-[(2R)-1,4-dioxan-2-ylmethyl]-N-methyl{[5-(1-methyl-1H-pyrazol-4-yl)-2-oxo-7-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(15),3(8),4,6,9,11,13-heptaen-13-yl]amino}sulfonamide",7.1,uM,=,0.8512583487190752,1,O=c1c2cc(NS(=O)(=O)NC[C@@H]3COCCO3)ccc2ccc2ncc(-c3cn[nH]c3)cc12
1681,349088,10.1016/j.bmcl.2006.01.084,,,,Inhibition of CYP3A4 using BFC fluorogenic substrate,COCCCN1C(=O)CCc2ccc(OC[C@H]3CNCC(=O)N3c3ccc(OCCCOCc4ccccc4OC)cc3)cc21,"7-((R)-1-{4-[3-(2-Methoxy-benzyloxy)-propoxy]-phenyl}-6-oxo-piperazin-2-ylmethoxy)-1-(3-methoxy-propyl)-3,4-dihydro-1H-quinolin-2-one",0.035,uM,=,-1.4559319556497243,0,O=C1CCc2ccc(OC[C@H]3CNCC(=O)N3c3ccc(OCCCOCc4ccccc4)cc3)cc2N1
1682,1366898,10.1021/jm500312x,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 15 mins by LC/MS/MS analysis,C=C[C@]1(C)C[C@@H](OC(=O)CSc2cncc(NC(=O)CN3CCCC(O)C3)c2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O,14-O-(((5-((3-Hydroxylpiperidin-1-yl)acetamido)pyridin-3-yl)sulfanyl)acetyl)mutilin,1.24,uM,=,0.093421685162235,1,O=C(CN1CCCCC1)Nc1cncc(SCC(=O)O[C@@H]2CCCC[C@@]34CCCC2[C@@H]3C(=O)CC4)c1
1683,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1cccc(C(=O)N2CCOC[C@H]2Cc2cccc(-n3nccn3)c2)c1-n1nccn1,"US9150566, 64",33.0,uM,=,1.5185139398778875,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
1684,51898,10.1016/s0960-894x(98)00653-2,,,,Antiviral activity as inhibition of human liver microsomal Cytochrome P450 3A4,CC(C)c1nc(COC(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)[C@H](O)CN2CCN(Cc3cncs3)C[C@H]2C(=O)NC(C)(C)C)C(C)C)cs1,"{(S)-1-[(1S,2R)-1-Benzyl-3-((S)-2-tert-butylcarbamoyl-4-thiazol-5-ylmethyl-piperazin-1-yl)-2-hydroxy-propylcarbamoyl]-2-methyl-propyl}-carbamic acid 2-isopropyl-thiazol-4-ylmethyl ester",15.0,uM,=,1.1760912590556811,1,O=C(CNC(=O)OCc1cscn1)N[C@H](CCN1CCN(Cc2cncs2)CC1)Cc1ccccc1
1685,519907,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,Cc1cccc(C)c1CNc1cc(-n2ncnc2CO)cn2c(C)c(C)nc12,"(1-(8-(2,6-dimethylbenzylamino)-2,3-dimethylimidazo[1,2-a]pyridin-6-yl)-1H-1,2,4-triazol-5-yl)methanol",16.0,uM,=,1.2041199826559248,1,c1ccc(CNc2cc(-n3cncn3)cn3ccnc23)cc1
1686,51915,10.1016/s0960-894x(03)00680-2,,,,Inhibition of human liver microsome Cytochrome P450 3A4,O=C(N[C@H]1c2ccccc2OC[C@H]1O)[C@H](Cc1cccnc1)C[C@H](O)CN1CCN(Cc2cc3ccccc3o2)C[C@H]1C(=O)NCC(F)(F)F,"(S)-4-Benzofuran-2-ylmethyl-1-[(2S,4R)-2-hydroxy-4-((3S,4S)-3-hydroxy-chroman-4-ylcarbamoyl)-5-pyridin-3-yl-pentyl]-piperazine-2-carboxylic acid (2,2,2-trifluoro-ethyl)-amide",0.48,uM,=,-0.3187587626244128,0,O=C(N[C@@H]1CCOc2ccccc21)[C@@H](CCCN1CCN(Cc2cc3ccccc3o2)CC1)Cc1cccnc1
1687,2221809,10.1016/j.bmcl.2022.128625,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as substrate in presence of NADPH,CCC[C@H]1N(C(=O)c2ncccc2C(F)(F)F)CCC[C@@]1(Oc1csc(C(F)(F)F)c1)C(=O)N1CCN(c2ccccc2OCCO)CC1,"(4-(2-(2-hydroxyethoxy)phenyl)piperazin-1-yl)((2R,3S)-2-propyl-1-(3-(trifluoromethyl)picolinoyl)-3-(5-(trifluoromethyl)thiophen-3-yloxy)piperidin-3-yl)methanone",35.1,uM,=,1.545307116465824,1,O=C(c1ccccn1)N1CCC[C@@](Oc2ccsc2)(C(=O)N2CCN(c3ccccc3)CC2)C1
1688,659957,10.1021/jm100643t,,,,Inhibition of CYP3A4,FC(F)(F)c1ccc(SCC(c2c[nH]cn2)C2CCNCC2)cc1,4-(1-(1H-Imidazol-4-yl)-2-(4-(trifluoromethyl)phenylthio)ethyl)-piperidine,17.0,uM,=,1.230448921378274,1,c1ccc(SCC(c2c[nH]cn2)C2CCNCC2)cc1
1689,696217,10.1016/j.bmcl.2010.09.125,,,,Inhibition of CYP3A4,Cc1cc2c(cc1C(F)(F)F)NC(=O)CC(c1cccc(-c3cccnc3)c1)=N2,"7-methyl-4-(3-(pyridin-3-yl)phenyl)-8-(trifluoromethyl)-1H-benzo[b][1,4]diazepin-2(3H)-one",1.8,uM,=,0.255272505103306,1,O=C1CC(c2cccc(-c3cccnc3)c2)=Nc2ccccc2N1
1690,1528904,,,,,"Homogenous Time-Resolved Fluorescence Assay (HTRF): The standard assay conditions for the in vitro HTRF assay consisted of a 50 ul total reaction volume in black 384-well Costar polypropylene plates in 1PBS buffer pH 7.4, 1 mM DTT, 0.1% BSA, 2.5 nM GST-hMDM2 (aa 1-188), 5 nM biotinylated-p53 (aa 1-83), 1.8 nM SA-XLent (Cisbio; Bedford, Mass.), 0.6 nM anti-GST cryptate monoclonal antibody (Cisbio; Bedford, Mass.) and 200 mM KF. Amino acid residues 1-188 of human MDM2 were expressed as an amino-terminal glutathione S-transferase (GST) fusion protein (GST-hMDM2) in Escherichia coli. Residues 1-83 of human p53 were expressed as an amino-terminal AviTag-TrxA-6His fusion protein (biotinylated p53) in E. coli. Each protein was purified from cell paste by affinity chromatography.Specifically, 10 uL of GST-hMDM2 was incubated with 10 ul of diluted compound (various concentrations, serially diluted) in 10% DMSO for 20 minutes at room temperature. 20 uL of biotinylated-p53 was added to the GST-hMDM2+compound mixture.",CC(C)(C)S(=O)(=O)C[C@H](C1CC1)N1C(=O)[C@@](C)(CC(N)=O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1,"2-((3R,5R,6S)-1-((S)-2-(tert-Butylsulfonyl)-1-cyclopropylethyl)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-3-methyl-2-oxopiperidin-3-yl)-acetamide",0.00183,uM,=,-2.7375489102695707,0,O=C1CC[C@H](c2ccccc2)[C@@H](c2ccccc2)N1CC1CC1
1691,675407,10.1016/j.bmcl.2010.08.142,,,,Inhibition of CYP3A4,NC(=O)[C@]12CC3CC(C1)[C@H](OC(=O)N1CC[C@H](Nc4ncccc4C(F)(F)F)C1)C(C3)C2,(S)-3-(3-Trifluoromethyl-pyridin-2-ylamino)-pyrrolidine-1-carboxylic acid 5-carbamoyl-adamantan-2-yl ester,8.5,uM,=,0.9294189257142929,1,O=C(OC1C2CC3CC(C2)CC1C3)N1CC[C@H](Nc2ccccn2)C1
1692,1289880,10.1021/jm401642q,,,,Inhibition of recombinant human CYP3A4,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(Cl)cccc21,"2-[2-(4-Chloro-2,3-dihydro-1H-indol-1-yl)-2-oxoethyl]-6-(morpholin-4-yl)pyrimidin-4(3H)-one",40.0,uM,=,1.6020599913279625,1,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2ccccc21
1693,875916,10.1021/jm300955x,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 mins by LC-MS/MS analysis in presence of NADPH,COc1ccc(S(=O)(=O)n2cc(C)c3cc(Cl)cnc32)cc1NC1CCN(C)CC1,"1-[3-(1-Methylpiperidin-4-ylamino)-4-methoxybenzenesulfonyl]-5-chloro-3-methyl-1H-pyrrolo[2,3-b]pyridine",10.0,uM,=,1.0,1,O=S(=O)(c1cccc(NC2CCNCC2)c1)n1ccc2cccnc21
1694,449485,10.1016/j.bmcl.2007.07.097,,,,Inhibition of microsomal CYP3A4,CC(C)C[C@H](NC(=O)CCN)c1cc(C(F)(F)F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1,"3-amino-N-((S)-1-(2-(4-((R)-3-(2,4-dichlorophenyl)-2-(2-oxopyrrolidin-1-yl)propanoyl)piperazin-1-yl)-5-(trifluoromethyl)phenyl)-3-methylbutyl)propanamide",5.4,uM,=,0.7323937598229685,1,O=C([C@@H](Cc1ccccc1)N1CCCC1=O)N1CCN(c2ccccc2)CC1
1695,1441252,10.1021/jm5010013,,,,Inhibition of CYP3A4 (unknown origin),O=C(O)c1ccccc1NC(=O)N1C[C@H]2C[C@@H](c3ccccc3C(F)(F)F)C[C@H]2C1,"trans-2-((3aR,6aS)-5-(2-(trifluoromethyl)phenyl)octahydrocyclopenta[c]pyrrole-2-carboxamido)benzoic acid",28.0,uM,=,1.4471580313422192,1,O=C(Nc1ccccc1)N1C[C@H]2C[C@@H](c3ccccc3)C[C@H]2C1
1696,1295469,10.1016/j.bmcl.2014.02.004,,,,Inhibition of human recombinant CYP3A4,NC(=O)c1sc(N2CCOCC2)nc1CC(=O)N1CCc2ccccc21,4-(2-(indolin-1-yl)-2-oxoethyl)-2-morpholinothiazole-5-carboxamide,40.0,uM,=,1.6020599913279625,1,O=C(Cc1csc(N2CCOCC2)n1)N1CCc2ccccc21
1697,1640557,,,,,"null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.",CC(C)(C)C(=O)C(Oc1ccc(Cl)cc1)n1ccnc1,SID29217911,0.1,uM,=,-1.0,0,c1ccc(OCn2ccnc2)cc1
1698,804823,10.1016/j.bmcl.2011.12.080,,,,Time dependent inhibition of CYP3A4,COc1cc(C)c2nc3[nH]nc(C)c3c(C(O)c3ccnc(F)c3)c2c1,"rac-(2-fluoropyridin-4-yl)(6-methoxy-3,8-dimethyl-1H-pyrazolo[3,4-b]quinolin-4-yl)methanol",4.2,uM,=,0.6232492903979004,1,c1ccc2c(Cc3ccncc3)c3cn[nH]c3nc2c1
1699,461436,10.1016/j.bmcl.2007.10.092,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,CC[C@@H]1CCC[C@H](C2(Cc3noc(CN4CCOCC4)n3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1,"4-((3-((1-((2R,6R)-1-(4-chlorophenylsulfonyl)-6-ethylpiperidin-2-yl)cyclopropyl)methyl)-1,2,4-oxadiazol-5-yl)methyl)morpholine",2.6,uM,=,0.414973347970818,1,O=S(=O)(c1ccccc1)N1CCCC[C@@H]1C1(Cc2noc(CN3CCOCC3)n2)CC1
1700,1640557,,,,,"null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.",c1ccc(-c2c[nH]cn2)cc1,4-Phenyl-1H-imidazole,1.5,uM,=,0.1760912590556812,1,c1ccc(-c2c[nH]cn2)cc1
1701,1512960,10.1021/acsmedchemlett.5b00117,,,,Inhibition of CYP3A4 (unknown origin),Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccccc2)[C@@H]3C)n1,"(R)-(8-Methyl-3-(3-methyl-1,2,4-thiadiazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(phenyl)methanone",31.0,uM,=,1.4913616938342726,1,O=C(c1ccccc1)N1CCn2c(nnc2-c2ncns2)C1
1702,1661017,10.1016/j.bmcl.2017.02.047,,,,Inhibition of recombinant human CYP3A4 expressed in baculosomes using Vivid DBOMF substrate green measured every 30 sec for 30 mins by fluorescence assay,CCCCC[C@H](O)CC(=O)CCc1ccc(O)c(OC)c1,[1-(4'-hydroxy-3'-methoxyphenyl)-5-hydroxy-3-decanone],32.0,uM,=,1.505149978319906,1,c1ccccc1
1703,804823,10.1016/j.bmcl.2011.12.080,,,,Time dependent inhibition of CYP3A4,COc1ccc(C(O)c2c3cc(OC)cc(C)c3nc3[nH]nc(C)c23)cc1,"rac-(6-methoxy-3,8-dimethyl-1H-pyrazolo[3,4-b]quinolin-4-yl)(4-methoxyphenyl)methanol",1.2,uM,=,0.0791812460476248,1,c1ccc(Cc2c3ccccc3nc3[nH]ncc23)cc1
1704,776115,10.1016/j.bmcl.2011.09.074,,,,Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin,Cc1ccc(N2Cc3c(nc(C)c(CN)c3-c3ccc(Cl)cc3Cl)C2=O)cc1,"3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-6-p-tolyl-5H-pyrrolo[3,4-b]pyridin-7(6H)-one",0.27,uM,=,-0.5686362358410126,0,O=C1c2nccc(-c3ccccc3)c2CN1c1ccccc1
1705,1741066,10.1021/acs.jmedchem.8b00450,,,,Inhibition of human CYP3A4,CN(C[C@H]1Cc2c(cccc2N2CCN(c3cccc(C(F)(F)F)c3)CC2)CN1)[C@H]1CCCc2cccnc21,"(S)-N-methyl-N-(((R)-5-(4-(3-(trifluoromethyl)phenyl)piperazin-1-yl)-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)-5,6,7,8-tetrahydroquinolin-8-amine",2.21,uM,=,0.3443922736851107,1,c1ccc(N2CCN(c3cccc4c3C[C@H](CN[C@H]3CCCc5cccnc53)NC4)CC2)cc1
1706,657985,10.1021/jm100482n,,,,Inhibition of CYP3A4 in human liver microsomes measured after incubation,CNC(=O)c1ncn2c1COc1c(CCN3CCN(c4cccc5nc(C)ccc45)CC3)cccc1-2,"N-methyl-6-(2-(4-(2-methylquinolin-5-yl)piperazin-1-yl)ethyl)-4H-benzo[b]imidazo[1,5-d][1,4]oxazine-3-carboxamide",5.0,uM,=,0.6989700043360189,1,c1cc(CCN2CCN(c3cccc4ncccc34)CC2)c2c(c1)-n1cncc1CO2
1707,943410,10.1021/jm400194n,,,,Time dependent inhibition of human CYP3A4 preincubated for 30 mins in presence of NADPH,CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOC[C@@H]4C)n2)C[C@@H]2CC[C@H]3N2S(C)(=O)=O)cc1,"1-Ethyl-3-(4-((6S,9R)-4-((S)-3-methylmorpholino)-10-(methylsulfonyl)-6,7,8,9-tetrahydro-5H-6,9-epiminocyclohepta[d]-pyrimidin-2-yl)phenyl)urea",5.0,uM,=,0.6989700043360189,1,c1ccc(-c2nc3c(c(N4CCOCC4)n2)C[C@@H]2CC[C@H]3N2)cc1
1708,1528565,,,,,"Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",CC(C)c1nc(CN(C)C(=O)N2Cc3nc[nH]c3C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,"US8987313, 49",0.19,uM,=,-0.721246399047171,0,O=C(N[C@H](CC[C@H](Cc1ccccc1)NC(=O)[C@@H]1Cc2[nH]cnc2CN1C(=O)NCc1cscn1)Cc1ccccc1)OCc1cncs1
1709,1558600,10.1016/j.bmcl.2015.06.020,,,,Inhibition of CYP3A4 (unknown origin) by fluorescence assay,Clc1cn(-c2ccc3c(c2)CCc2cn(Cc4ccccc4)nc2N3)cn1,"2-benzyl-7-(4-chloro-1H-imidazol-1-yl)-2,4,5,10-tetrahydrobenzo[b]pyrazolo[4,3-f]azepine",0.3,uM,=,-0.5228787452803376,0,c1ccc(Cn2cc3c(n2)Nc2ccc(-n4ccnc4)cc2CC3)cc1
1710,519907,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,Cc1cccc(C)c1CNc1cc(N2CCNC2=O)cn2c(C)c(C)nc12,"1-(8-(2,6-dimethylbenzylamino)-2,3-dimethylimidazo[1,2-a]pyridin-6-yl)imidazolidin-2-one",6.5,uM,=,0.8129133566428556,1,O=C1NCCN1c1cc(NCc2ccccc2)c2nccn2c1
1711,1366897,10.1021/jm500312x,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 15 mins by LC/MS/MS analysis,C=C[C@]1(C)C[C@@H](OC(=O)CSc2cncc(NC(=O)CN3CCCC(O)C3)c2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O,14-O-(((5-((3-Hydroxylpiperidin-1-yl)acetamido)pyridin-3-yl)sulfanyl)acetyl)mutilin,1.08,uM,=,0.0334237554869497,1,O=C(CN1CCCCC1)Nc1cncc(SCC(=O)O[C@@H]2CCCC[C@@]34CCCC2[C@@H]3C(=O)CC4)c1
1712,2064643,10.1021/acs.jmedchem.6b01433,,,,Inhibition of CYP3A4 (unknown origin),CCCCCC[C@@H]1CCc2cc([C@H]3CC[C@](N)(CO)C3)ccc2C1,"((1R,3S)-1-amino-3-((R)-6-hexyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol",19.0,uM,=,1.2787536009528289,1,c1cc2c(cc1C1CCCC1)CCCC2
1713,469873,10.1016/j.bmcl.2008.01.012,,,,Inhibition of human CYP3A4,CC(C)c1c(-c2nnc(OCC3CCNCC3)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12,"N-cyclopropyl-2,4-difluoro-5-(5-isopropyl-6-(5-(piperidin-4-ylmethoxy)-1,3,4-oxadiazol-2-yl)pyrrolo[1,2-f][1,2,4]triazin-4-ylamino)benzamide",7.6,uM,=,0.8808135922807914,1,O=C(NC1CC1)c1cccc(Nc2ncnn3cc(-c4nnc(OCC5CCNCC5)o4)cc23)c1
1714,1715306,10.1021/acs.jmedchem.8b00346,,,,Inhibition of human CYP3A4 (unknown origin),C=CC(=O)Nc1cccc(-n2c(=O)n(C(C)C)c(=O)c3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1,"N-(3-(3-Isopropyl-7-((2-methoxy-4-(4-methylpiperazin-1-yl)-phenyl)amino)-2,4-dioxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide",23.9,uM,=,1.3783979009481375,1,O=c1[nH]c(=O)n(-c2ccccc2)c2nc(Nc3ccc(N4CCNCC4)cc3)ncc12
1715,2061612,10.1016/j.bmcl.2015.11.049,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,Cc1cc(Nc2nc(Nc3ccccc3S(=O)(=O)C(C)C)c3cc[nH]c3n2)c(OC(C)C)cc1C1CCNCC1,"N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine",4.6,uM,=,0.6627578316815741,1,c1ccc(Nc2nc(Nc3ccc(C4CCNCC4)cc3)nc3[nH]ccc23)cc1
1716,676065,10.1016/j.bmcl.2010.09.028,,,,Inhibition of CYP3A4 after 30 mins,O=C(OC1([C@H]2COC[C@@H](CC3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CC2CCC(C1)N2,"1-((3R,5R)-4-(4-chlorophenylsulfonyl)-5-(cyclopropylmethyl)morpholin-3-yl)cyclopropyl 3,8-diazabicyclo[3.2.1]octane-3-carboxylate",0.0008,uM,=,-3.096910013008056,0,O=C(OC1([C@H]2COC[C@@H](CC3CC3)N2S(=O)(=O)c2ccccc2)CC1)N1CC2CCC(C1)N2
1717,804823,10.1016/j.bmcl.2011.12.080,,,,Time dependent inhibition of CYP3A4,COc1cc(C)c2nc3[nH]nc(C)c3c(C(C#N)c3ccccc3)c2c1,"rac-2-(6-methoxy-3,8-dimethyl-1H-pyrazolo[3,4-b]quinolin-4-yl)-2-phenylacetonitrile",20.0,uM,=,1.3010299956639813,1,c1ccc(Cc2c3ccccc3nc3[nH]ncc23)cc1
1718,2080683,10.1021/acs.jmedchem.0c02005,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins in presence of NADPH generating system followed by substrate addition and measured after 10 mins by LC-MS/MS analysis,CS(=O)(=O)O.[2H]C([2H])=CC(=O)Nc1cc(Nc2nccc(-c3cn(C([2H])([2H])[2H])c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,"N-(2-((2-(Dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-(methyl-d3)-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide-3,3-d2 methanesulfonate",27.1,uM,=,1.4329692908744058,1,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
1719,1699178,10.1021/acs.jmedchem.6b01543,,,,Inhibition of CYP3A4 (unknown origin),O=C(O)CC1CCC2(CCN(c3ccc(-c4nc5cc(C(F)(F)F)ccc5[nH]4)cn3)CC2)OC1,2-(9-(5-(5-(Trifluoromethyl)-1H-benzo[d]imidazol-2-yl)pyridin-2-yl)-1-oxa-9-azaspiro[5.5]undecan-3-yl)acetic Acid,13.3,uM,=,1.1238516409670858,1,c1ccc2[nH]c(-c3ccc(N4CCC5(CCCCO5)CC4)nc3)nc2c1
1720,495153,10.1021/jm8006454,,,,Inhibition of CYP3A4,COc1cccc(-c2c(C)n(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@@H](c3ccccc3)N(C)CCCC(=O)O)c2=O)c1F,"R-4-{2-[5-(2-Fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethyl-N-methylamino}butyric Acid",69.0,uM,=,1.8388490907372552,1,O=c1c(-c2ccccc2)cn(Cc2ccccc2)c(=O)n1CCc1ccccc1
1721,2068401,10.1016/j.bmcl.2020.127676,,,,Inhibition of CYP3A4 (unknown origin),CN[C@@H](C)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)Nc1cc2c(OCC#CC#CCOc3ncnc4cc(OC)c(NC(=O)[C@@H]5CCCN5C(=O)[C@@H](NC(=O)[C@H](C)NC)C(C)(C)C)cc34)ncnc2cc1OC)C(C)(C)C,"(S,S,2S)-N,N'-(4,4'-(hexa-2,4-diyne-1,6-diylbis(oxy))bis(7-methoxyquinazoline-6,4-diyl))bis(1-((S)-3,3-dimethyl-2-((S)-2-(methylamino)propanamido)butanoyl)pyrrolidine-2-carboxamide)",0.24,uM,=,-0.619788758288394,0,O=C(Nc1ccc2ncnc(OCC#CC#CCOc3ncnc4ccc(NC(=O)[C@@H]5CCCN5)cc34)c2c1)[C@@H]1CCCN1
1722,1637154,,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins,COc1ccnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4cc(F)ccc4F)c3F)c12,"N-[2,4-Difluoro-3-(4-methoxy-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-phenyl]-2,5-difluoro-benzenesulfonamide",5.0,uM,=,0.6989700043360189,1,O=C(c1cccc(NS(=O)(=O)c2ccccc2)c1)c1c[nH]c2ncccc12
1723,1460909,10.1021/jm501326k,,,,Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase/human b5 reductase using 7-benzyloxyquinoline substrate,CCOC(=O)c1[nH]cc2c1NC1=C(C(=O)CCC1)C2c1ccc(Sc2nc3cc(F)c(F)cc3[nH]2)o1,"(+/-)-9-[5-(5,6-Difluoro-1H-benzimidazol-2-ylsulfanyl)-furan-2-yl]-8-oxo-4,5,6,7,8,9-hexahydro-2Hpyrrolo[3,4-b]quinoline-3-carboxylic acid ethyl ester",8.4,uM,=,0.9242792860618816,1,O=C1CCCC2=C1C(c1ccc(Sc3nc4ccccc4[nH]3)o1)c1c[nH]cc1N2
1724,51926,10.1021/jm034111v,,,,Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 15 minutes,CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@H](N(C)C)[C@H]3OC(C)=O)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O,"Acetic acid 14-(3-acetoxy-4-dimethylamino-6-methyl-tetrahydro-pyran-2-yloxy)-12-(5-acetoxy-4-methoxy-6-methyl-tetrahydro-pyran-2-yloxy)-5,7,8,11,13,15-hexamethyl-4,10-dioxo-1,9-dioxa-spiro[2.13]hexadec-6-yl ester",33.0,uM,=,1.5185139398778875,1,O=C1C[C@@H](O[C@H]2CCCCO2)C[C@@H](O[C@H]2CCCCO2)CC[C@@]2(CO2)C(=O)CCCCO1
1725,1446329,10.1021/ml500387y,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,CC(C)(CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F)c1ccccc1,"1,1,1-trifluoro-4-methyl-2-((5-morpholino-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)-4-phenylpentan-2-ol",0.1,uM,=,-1.0,0,c1ccc(CCCCc2cc3cc(N4CCOCC4)ncc3[nH]2)cc1
1726,495540,10.1021/jm801332q,,,,Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate measured in 25 to 30 mins by time dependent inhibition assay,C[C@@H]1CN(Cc2ccc(-c3cccnc3C(=O)N3CCC(Nc4ccc(F)cc4)CC3)cc2)C[C@H](C)N1,"(3-(4-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)pyridin-2-yl)(4-(4-fluorophenylamino)piperidin-1-yl)methanone",1.4,uM,=,0.1461280356782379,1,O=C(c1ncccc1-c1ccc(CN2CCNCC2)cc1)N1CCC(Nc2ccccc2)CC1
1727,776115,10.1016/j.bmcl.2011.09.074,,,,Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin,COc1ccc(N2Cc3c(nc(C)c(CN)c3-c3ccc(Cl)cc3Cl)C2=O)cc1,"3-(aminomethyl)-4-(2,4-dichlorophenyl)-6-(4-methoxyphenyl)-2-methyl-5H-pyrrolo[3,4-b]pyridin-7(6H)-one",2.5,uM,=,0.3979400086720376,1,O=C1c2nccc(-c3ccccc3)c2CN1c1ccccc1
1728,438520,10.1016/j.bmcl.2007.01.104,,,,Inhibition of CYP3A4,COc1cccc(N2C(=O)N(Cc3ccccc3F)C3(CCN(Cc4ccc(-n5ccnc5)cc4)CC3)C2=O)c1,"1-(2-fluoro-benzyl)-8-(4-imidazol-1-yl-benzyl)-3-(3-methoxy-phenyl)-1,3,8-triaza-spiro[4.5]decane-2,4-dione",0.035,uM,=,-1.4559319556497243,0,O=C1N(c2ccccc2)C(=O)C2(CCN(Cc3ccc(-n4ccnc4)cc3)CC2)N1Cc1ccccc1
1729,1659434,10.1021/acs.jmedchem.6b01662,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH by LC-MS/MS analysis,CN1CCN(Cc2cn(S(=O)(=O)c3ccc(F)cc3)c3ccccc23)CC1,1-[(4-Fluorophenyl)sulfonyl]-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole Dihydrochloride,1.82,uM,=,0.2600713879850748,1,O=S(=O)(c1ccccc1)n1cc(CN2CCNCC2)c2ccccc21
1730,1845477,10.1021/acsmedchemlett.0c00004,,,,Inhibition of CYP3A4 (unknown origin),N#Cc1ccc2c(c1)[C@@H](O)[C@H]([C@H]1c3ccccc3-c3cncn31)CC2,"(7S,8S)-8-hydroxy-7-((S)-5H-imidazo[5,1-a]isoindol-5-yl)-5,6,7,8-tetrahydronaphthalene-2-carbonitrile",3.3,uM,=,0.5185139398778875,1,c1ccc2c(c1)CC[C@@H]([C@H]1c3ccccc3-c3cncn31)C2
1731,972700,10.1021/ml400186z,,,,Inhibition of CYP3A4 (unknown origin),COCc1c(C(=O)NCc2ccncc2)cnn1-c1ncc(C)c(-c2cccs2)n1,5-(methoxymethyl)-1-(5-methyl-4-(thiophen-2-yl)pyrimidin-2-yl)-N-(pyridin-4-ylmethyl)-1H-pyrazole-4-carboxamide,2.9,uM,=,0.4623979978989561,1,O=C(NCc1ccncc1)c1cnn(-c2nccc(-c3cccs3)n2)c1
1732,1488502,10.1124/dmd.112.045708,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis,CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1,"(R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide",7.0,uM,=,0.8450980400142568,1,O=C(Cc1ccccc1)N(Cc1cccnc1)Cc1nc2ncccc2c(=O)n1-c1ccccc1
1733,1541293,10.1016/j.bmc.2015.11.017,,,,Inhibition of human recombinant CYP3A4 by fluorescence assay,COCCN1CCN(C(=O)c2nc3cc(C(F)(F)F)c(C)c([N+](=O)[O-])c3s2)CC1,(4-(2-Methoxyethyl)piperazin-1-yl)(6-methyl-7-nitro-5-(trifluoromethyl)benzo[d]thiazol-2-yl)methanone,95.0,uM,=,1.977723605288848,1,O=C(c1nc2ccccc2s1)N1CCNCC1
1734,974027,10.1016/j.bmcl.2013.06.017,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,Cc1cc(/C(CC(c2ccc(Br)cc2)c2ccccc2C)=N/O)ccn1,3-(4-bromophenyl)-1-(2-methylpyridin-4-yl)-3-o-tolylpropan-1-one oxime,5.0,uM,=,0.6989700043360189,1,N=C(CC(c1ccccc1)c1ccccc1)c1ccncc1
1735,1276541,10.1016/j.bmcl.2013.09.041,,,,Inhibition of CYP3A4 (unknown origin) after 5 mins,O=S(=O)(Nc1ccc(-c2ccco2)cc1)c1cc(Cl)cc(Cl)c1,"3,5-dichloro-N-(4-(furan-2-yl)phenyl)benzenesulfonamide",13.0,uM,=,1.1139433523068367,1,O=S(=O)(Nc1ccc(-c2ccco2)cc1)c1ccccc1
1736,1754798,10.1021/acs.jmedchem.8b00060,,,,Inhibition of CYP3A4 (unknown origin),COc1cc2c(cc1-n1cnc3ccc(-c4ccnc5[nH]ccc45)cc31)CNC2,"1-(6-methoxyisoindolin-5-yl)-6-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-benzo[d]imidazole",3.6,uM,=,0.5563025007672873,1,c1cc(-c2ccc3ncn(-c4ccc5c(c4)CNC5)c3c2)c2cc[nH]c2n1
1737,537516,10.1021/jm8005096,,,,Inhibition of CYP3A4,COc1cc(C2=NC(c3ccc(Cl)cc3F)C(C(=O)Nc3cc4cn[nH]c4cc3F)=C(C)N2)ccn1,"4-(4-chloro-2-fluorophenyl)-N-(6-fluoro-1H-indazol-5-yl)-2-(2-methoxypyridin-4-yl)-6-methyl-1,4-dihydropyrimidine-5-carboxamide",5.3,uM,=,0.724275869600789,1,O=C(Nc1ccc2[nH]ncc2c1)C1=CNC(c2ccncc2)=NC1c1ccccc1
1738,2152998,10.1021/acs.jmedchem.1c00635,,,,Inhibition of CYP3A4 in human liver microsomes using ketoconazole as substrate incubated for 5 mins in presence of NADPH by LC-MS/MS analysis,CCc1cccc(CC)c1NC(=O)c1ccn(-c2nc(Nc3ccc(N4CCC(N5CCN(C)CC5)CC4)cc3OC)nc3[nH]ccc23)c1,"N-(2,6-diethylphenyl)-1-[2-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)-1-piperidyl]anilino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]pyrrole-3-carboxamide",2.0,uM,=,0.3010299956639812,1,O=C(Nc1ccccc1)c1ccn(-c2nc(Nc3ccc(N4CCC(N5CCNCC5)CC4)cc3)nc3[nH]ccc23)c1
1739,423507,10.1021/jm060995h,,,,Inhibition of CYP3A4,CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3CC[C@@H](O)C3)c(Oc3cccc4ccccc34)sc21,"5-{[(3R)-3-hydroxypyrrolidin-1-yl]carbonyl}-1-isobutyl-3-methyl-6-(1-naphthyloxy)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione",7.2,uM,=,0.8573324964312685,1,O=C(c1c(Oc2cccc3ccccc23)sc2[nH]c(=O)[nH]c(=O)c12)N1CCCC1
1740,1629496,10.1016/j.bmcl.2016.12.003,,,,Inhibition of hepatic CYP3A4 (unknown origin),Cc1c(F)cncc1-c1nc2ccc(F)cn2c1C1CC1,"3-cyclopropyl-6-fluoro-2-(5-fluoro-4-methylpyridin-3-yl)imidazo[1,2-a]pyridine",11.0,uM,=,1.0413926851582251,1,c1cncc(-c2nc3ccccn3c2C2CC2)c1
1741,1660136,10.1021/acs.jmedchem.6b01918,,,,Inhibition of human CYP3A4 assessed as inhibition of dealkylation,O=S(=O)(Nc1ncns1)c1cc(F)c(OCC[C@]2(c3ccccc3)CC[C@H](NC3CC3)CC2)cc1F,"cis-4-(2-((1R,4R)-4-(Cyclopropylamino)-1-phenylcyclohexyl)ethoxy)-2,5-difluoro-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide",0.09,uM,=,-1.0457574905606752,0,O=S(=O)(Nc1ncns1)c1ccc(OCC[C@]2(c3ccccc3)CC[C@H](NC3CC3)CC2)cc1
1742,1284808,10.1021/jm4013246,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 15 mins followed by NADPH addition measured after 8 mins by LC/MS/MS analysis,O=C(c1ccc(F)c(F)c1)N1CCN2C(=O)c3ccccc3[C@@]12c1ccc(Cl)cc1,"(-)-(S)-9b-(4-chlorophenyl)-1-(3,4-difluorobenzoyl)-2,3-dihydro-1H-imidazo[2,1-a]isoindol-5(9bH)-one",16.0,uM,=,1.2041199826559248,1,O=C(c1ccccc1)N1CCN2C(=O)c3ccccc3[C@@]12c1ccccc1
1743,1614026,10.1016/j.bmcl.2016.09.043,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 1'-hydroxymidazolam metabolite formation using midazolam as substrate incubated for 10 mins by HPLC-MS method,Cn1c(NCCc2ccc(-c3ccc(F)cn3)cc2)nc2cc(Cl)ccc2c1=O,7-Chloro-2-{2-[4-(5-fluoro-pyridin-2-yl)-phenyl]-ethylamino}-3-methyl-3H-quinazolin-4-one,41.0,uM,=,1.6127838567197357,1,O=c1[nH]c(NCCc2ccc(-c3ccccn3)cc2)nc2ccccc12
1744,2048449,10.1016/j.bmc.2020.115734,,,,Inhibition of recombinant CYP3A4 (unknown origin) by fluorescence-based assay,CCn1nc(C2(C)CC2)cc1Nc1nc(-c2ccc(-n3cnc(C)c3)c(OC)n2)cs1,N-(1-ethyl-3-(1-methylcyclopropyl)-1H-pyrazol-5-yl)-4-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)thiazol-2-amine,4.1,uM,=,0.6127838567197355,1,c1cn(-c2ccc(-c3csc(Nc4cc(C5CC5)n[nH]4)n3)nc2)cn1
1745,44705,10.1016/s0960-894x(02)00473-0,,,,Inhibition of cytochrome P450 3A4,Cn1cc(Cc2cn(CC(=O)N(CC(=O)O)Cc3ccc(-c4ccc(C(F)(F)F)cc4)cc3)c(SCc3ccc(F)cc3)nc2=O)cn1,[{2-[2-(4-Fluoro-benzylsulfanyl)-5-(1-methyl-1H-pyrazol-4-ylmethyl)-4-oxo-4H-pyrimidin-1-yl]-acetyl}-(4'-trifluoromethyl-biphenyl-4-ylmethyl)-amino]-acetic acid,31.0,uM,=,1.4913616938342726,1,O=C(Cn1cc(Cc2cn[nH]c2)c(=O)nc1SCc1ccccc1)NCc1ccc(-c2ccccc2)cc1
1746,1845477,10.1021/acsmedchemlett.0c00004,,,,Inhibition of CYP3A4 (unknown origin),CS(=O)(=O)c1ccc2c(c1)CC[C@@H]([C@H]1c3ccccc3-c3cncn31)[C@@H]2O,"(1S,2S)-2-((S)-5H-imidazo[5,1-a]isoindol-5-yl)-6-(methylsulfonyl)-1,2,3,4-tetrahydronaphthalen-1-ol",2.8,uM,=,0.4471580313422192,1,c1ccc2c(c1)CC[C@@H]([C@H]1c3ccccc3-c3cncn31)C2
1747,1972830,10.1021/acsmedchemlett.9b00612,,,,Inhibition of human recombinant CYP3A4 expressed in insect cell microsomes in presence of NADPH by fluorescence assay,Cc1ccc(C(=O)Nc2ccc(CN3CCN(CCO)CC3)c(Cl)c2)cc1C#Cc1cnc2cccnn12,"N-[3-chloro-4-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]phenyl]-3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methylbenzamide",13.4,uM,=,1.1271047983648077,1,O=C(Nc1ccc(CN2CCNCC2)cc1)c1cccc(C#Cc2cnc3cccnn23)c1
1748,1436762,10.1021/ml500187a,,,,Inhibition of human recombinant CYP3A4 incubated for 5 mins by fluorescence assay,Clc1ccccc1CN(CC1CNC1)c1ccccc1.O=C(O)C(F)(F)F,"N-(azetidin-3-ylmethyl)-N-(2-chlorobenzyl)aniline 2,2,2-trifluoroacetate",0.12,uM,=,-0.9208187539523752,0,c1ccc(CN(CC2CNC2)c2ccccc2)cc1
1749,1660136,10.1021/acs.jmedchem.6b01918,,,,Inhibition of human CYP3A4 assessed as inhibition of dealkylation,O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCC2CNCCO2)cc1F,rac-5-Chloro-2-fluoro-4-((morpholin-2-ylmethyl)amino)-N-(thiazol-2-yl)benzenesulfonamide,20.0,uM,=,1.3010299956639813,1,O=S(=O)(Nc1nccs1)c1ccc(NCC2CNCCO2)cc1
1750,632105,10.1016/j.bmcl.2010.03.057,,,,Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin,CNC(=O)CN1CCN(c2cc(C)c3nc(-c4c(NC[C@@H](O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1,"(S)-2-(4-(2-(4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-2-oxo-1,2-dihydropyridin-3-yl)-4-methyl-1H-benzo[d]imidazol-6-yl)piperazin-1-yl)-N-methylacetamide",2.6,uM,=,0.414973347970818,1,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(N3CCNCC3)cc2[nH]1
1751,1845477,10.1021/acsmedchemlett.0c00004,,,,Inhibition of CYP3A4 (unknown origin),O[C@@H]1CCOC[C@H]1[C@H]1c2ccccc2-c2cncn21,"(3R,4R)-3-((S)-5H-imidazo[5,1-a]isoindol-5-yl)tetrahydro-2H-pyran-4-ol",0.65,uM,=,-0.1870866433571444,0,c1ccc2c(c1)-c1cncn1[C@H]2[C@H]1CCCOC1
1752,1527962,,,,,"Inhibition Assay (Testosterone Hydroxylase): To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.",O=NCc1ccc(-c2cccnc2)s1,"5-Pyridin-3-yl-thiophene-2-carbaldehyde oxime::CHEMBL178534::US8609708, 18",12.98,uM,=,1.1132746924643504,1,c1cncc(-c2cccs2)c1
1753,794356,10.1016/j.bmcl.2011.09.078,,,,Inhibition of CYP3A4,CN(C)CCN1CCN(C(=O)c2cc(C(C)(C)C)sc2NC(=O)Nc2cccc(Cl)c2Cl)CCC1=O,"1-(5-tert-Butyl-3-(4-(2-dimethylaminoethyl)-5-oxo-1,4-diazepane-1-carbonyl)-thiophen-2-yl)-3-(2,3-dichlorophenyl)urea",0.55,uM,=,-0.2596373105057561,0,O=C1CCN(C(=O)c2ccsc2NC(=O)Nc2ccccc2)CCN1
1754,2024613,10.1016/j.bmcl.2020.127721,,,,Inhibition of CYP3A4 (unknown origin),CS(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4nccc(Cl)c34)cs2)c1,"N-[4-(4-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)thiazol-2-yl]-2-[3-(methanesulfonamido)phenyl]acetamide",8.0,uM,=,0.9030899869919436,1,O=C(Cc1ccccc1)Nc1nc(-c2c[nH]c3ncccc23)cs1
1755,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CC(N6CCOCC6)C5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, E-72",5.99,uM,=,0.7774268223893114,1,O=C(c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12)N1CC(N2CCOCC2)C1
1756,1660136,10.1021/acs.jmedchem.6b01918,,,,Inhibition of human CYP3A4 assessed as inhibition of dealkylation,N[C@H]1CC[C@](CCOc2cc(F)c(S(=O)(=O)Nc3ncns3)cc2F)(c2ccc(Cl)cc2)CC1,"cis-4-(2-((1R,4R)-4-Amino-1-(4-chlorophenyl)cyclohexyl)ethoxy)-2,5-difluoro-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide",0.28,uM,=,-0.5528419686577808,0,O=S(=O)(Nc1ncns1)c1ccc(OCCC2(c3ccccc3)CCCCC2)cc1
1757,861307,10.1021/jm201711b,,,,Inhibition of human CYP3A4,Cc1ccc(C(=O)c2nc3ccc(O)cc3s2)cc1O,"(4-Methyl-3-hydroxyphenyl)(6-hydroxy-1,3-benzothiazol-2-yl)methanone",54.0,uM,=,1.7323937598229686,1,O=C(c1ccccc1)c1nc2ccccc2s1
1758,1467194,10.1021/jm5005336,,,,Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay,COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(N5CCN(C)CC5)nc4)n[nH]c3c1)C(=O)N2,"(1R*,2S*)-5'-Methoxy-2-(3-((E)-2-(6-(4-methylpiperazin-1-yl)-pyridin-3-yl)vinyl)-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-one",5.6,uM,=,0.7481880270062004,1,O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccc(N4CCNCC4)nc3)n[nH]c2c1
1759,1485439,10.1124/dmd.111.042739,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrates after 5 mins by LC/MS analysis in presence of NADPH,CC[C@H](C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@H]5CO[C@@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O,"trans-2-((S)-sec-Butyl)-4-[4-(4-{4-[(2S,4S)-2-(2,4-dichloro-phenyl)-2-[1,2,4]triazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-phenyl]-2,4-dihydro-[1,2,4]triazol-3-one",0.017,uM,=,-1.769551078621726,0,O=c1[nH]ncn1-c1ccc(N2CCN(c3ccc(OC[C@H]4CO[C@@](Cn5cncn5)(c5ccccc5)O4)cc3)CC2)cc1
1760,469879,10.1016/j.bmcl.2008.01.012,,,,Inhibition of human CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin substrate,CC(C)c1c(-c2nnc(NCCCN(C)C)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12,"N-cyclopropyl-5-(6-(5-(3-(dimethylamino)propylamino)-1,3,4-oxadiazol-2-yl)-5-isopropylpyrrolo[1,2-f][1,2,4]triazin-4-ylamino)-2,4-difluorobenzamide",37.0,uM,=,1.568201724066995,1,O=C(NC1CC1)c1cccc(Nc2ncnn3cc(-c4nnco4)cc23)c1
1761,862399,10.1021/jm300601d,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis,N=C(N)NC(=O)c1ccc(C2CCN(C(=O)c3ccc(S(N)(=O)=O)cc3)CC2)c(C(F)(F)F)c1,N-{4-[1-(4-Sulfamoyl-benzoyl)-piperidin-4-yl]-3-trifluoromethylbenzoyl}-guanidine,24.0,uM,=,1.380211241711606,1,O=C(c1ccccc1)N1CCC(c2ccccc2)CC1
1762,2194835,10.1021/acs.jmedchem.2c00986,,,,Inhibition of CYP3A4 in human liver microsomes at 10 uM using midazolam as substrate preincubated for 10 mins followed by NADPH addition by LC/MS analysis,Cc1nc(N[C@H](C)c2cc(N)cc(C(F)(F)F)c2)c2cc(O[C@H]3CCOC3)c(O)cc2n1,4-(((R)-1-(3-amino-5-(trifluoromethyl)phenyl)ethyl)amino)-2-methyl-6-(((S)-tetrahydrofuran-3-yl)oxy)quinazolin-7-ol,54.3,uM,=,1.734799829588847,1,c1ccc(CNc2ncnc3ccc(O[C@H]4CCOC4)cc23)cc1
1763,1625987,10.1016/j.bmcl.2016.04.095,,,,Inhibition of CYP3A4 in human liver microsomes after 30 secs by LC/MS/MS analysis,O=S(=O)(CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12)CC1=NCCN1,"2-((2-((4S,4aS,10bS)-10b-(4-chlorophenylsulfonyl)-7,10-difluoro-1,2,4,4a,5,10b-hexahydropyrano[3,4-c]chromen-4-yl)ethylsulfonyl)methyl)-4,5-dihydro-1H-imidazole",13.2,uM,=,1.1205739312058498,1,O=S(=O)(CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccccc3)c3ccccc3OC[C@@H]12)CC1=NCCN1
1764,1491682,10.1124/dmd.112.045708,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by substrate addition by LC-MS/MS analysis,CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1,"(R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide",8.3,uM,=,0.919078092376074,1,O=C(Cc1ccccc1)N(Cc1cccnc1)Cc1nc2ncccc2c(=O)n1-c1ccccc1
1765,459885,10.1021/np0704248,,,,Inhibition of human CYP3A4 expressed in Escherichia coli assessed as inhibition of nifedipine oxidation,COc1cc2c(cc1OC)-c1cc3ccc(OC)c(OC)c3c[n+]1CC2.[Cl-],"2,3,9,10-Tetramethoxy-5,6-dihydro-isoquino[3,2-a]isoquinolinylium chloride",0.9,uM,=,-0.0457574905606751,0,c1ccc2c(c1)CC[n+]1cc3ccccc3cc1-2
1766,591401,10.1021/jm9010065,,,,Inhibition of human CYP3A4,Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c12,"[4-[[1-(3-fluorophenyl)methyl]-1H-indazol-5-ylamino]-5-methyl-pyrrolo[2,1-f][1,2,4]triazin-6-yl]-carbamic acid,(3S)-3-morpholinylmethyl ester",1.6,uM,=,0.2041199826559248,1,O=C(Nc1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnn2c1)OC[C@@H]1COCCN1
1767,2129971,10.1021/acs.jmedchem.1c00762,,,,Competitive inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,FC(F)c1cncc(-c2ccc3ncc4nnc(C5=CCCOCC5)n4c3c2)c1,"8-[5-(Difluoromethyl)pyridin-3-yl]-1-(2,3,6,7-tetrahydrooxepin-4-yl)[1,2,4]triazolo[4,3-a]quinoxaline",15.0,uM,=,1.1760912590556811,1,C1=C(c2nnc3cnc4ccc(-c5cccnc5)cc4n23)CCOCC1
1768,1523285,10.1016/j.bmcl.2015.06.066,,,,Inhibition of CYP3A4 (unknown origin),CCCCC(C(=O)COc1c(F)c(F)cc(F)c1F)n1cc([C@@](C)(NCc2ccc3ncccc3c2)C(C)C)nn1,"3-(4-((S)-3-methyl-2-(quinolin-6-ylmethylamino)butan-2-yl)-1H-1,2,3-triazol-1-yl)-1-(2,3,5,6-tetrafluorophenoxy)heptan-2-one",3.8,uM,=,0.5797835966168101,1,O=C(COc1ccccc1)Cn1cc(CNCc2ccc3ncccc3c2)nn1
1769,559938,10.1016/j.bmcl.2008.10.072,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,Cc1cc(CC(=O)N(C)Cc2ccccc2-c2ccc(CN3C[C@@H](C)N[C@@H](C)C3)cc2)on1,"N-[4'-((3R,5S)-3,5-Dimethyl-piperazin-1-ylmethyl)-biphenyl-2-ylmethyl]-N-methyl-2-(3-methyl-isoxazol-5-yl)-acetamide",40.0,uM,=,1.6020599913279625,1,O=C(Cc1ccno1)NCc1ccccc1-c1ccc(CN2CCNCC2)cc1
1770,1523285,10.1016/j.bmcl.2015.06.066,,,,Inhibition of CYP3A4 (unknown origin),CCCCC(C(=O)COc1c(F)c(F)cc(F)c1F)n1cc([C@@](C)(NCc2ccn3nccc3n2)C(C)C)nn1,"3-(4-((S)-3-methyl-2-(pyrazolo[1,5-a]pyrimidin-5-ylmethylamino)butan-2-yl)-1H-1,2,3-triazol-1-yl)-1-(2,3,5,6-tetrafluorophenoxy)heptan-2-one",0.314,uM,=,-0.5030703519267851,0,O=C(COc1ccccc1)Cn1cc(CNCc2ccn3nccc3n2)nn1
1771,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2C(CN(Cc3cccc4c(C(=O)Nc5ccc6c(c5)OCCO6)cn(C)c34)C(=O)[C@@H]2Cc2ccc(O)cc2)N1C(=O)NCc1ccccc1,"US8940739, G-70",2.63,uM,=,0.4199557484897578,1,O=C(Nc1ccc2c(c1)OCCO2)c1c[nH]c2c(CN3CC4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12
1772,859714,10.1021/jm3004637,,,,Inhibition of hepatic CYP3A4,COc1cc2c(cc1-c1cccnc1)CCC(=O)N2C,"7-Methoxy-1-methyl-6-pyridin-3-yl-3,4-dihydro-1H-quinolin-2-one",90.0,uM,=,1.954242509439325,1,O=C1CCc2cc(-c3cccnc3)ccc2N1
1773,1436642,10.1021/jm501045e,,,,Inhibition of CYP3A4 (unknown origin),O=C(NC[C@@H]1OC(=O)N2c3ccc(N4CCOCC4=O)cc3OC[C@@H]12)c1ccc(Cl)s1,"5-Chloro-N-(((3S,3aS)-1-oxo-7-(3-oxomorpholino)-1,3,3a,4-tetrahydrobenzo[b]oxazolo[3,4-d][1,4]oxazin-3-yl)methyl)-thiophene-2-carboxamide",85.12,uM,=,1.930031614950973,1,O=C(NC[C@@H]1OC(=O)N2c3ccc(N4CCOCC4=O)cc3OC[C@@H]12)c1cccs1
1774,559938,10.1016/j.bmcl.2008.10.072,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,C[C@@H]1CN(Cc2ccc(-c3ccccc3CN(C)C(=O)COc3ccccc3)cc2)C[C@H](C)N1,"N-[4'-((3R,5S)-3,5-Dimethyl-piperazin-1-ylmethyl)-biphenyl-2-ylmethyl]-N-methyl-2-phenoxy-acetamide",7.0,uM,=,0.8450980400142568,1,O=C(COc1ccccc1)NCc1ccccc1-c1ccc(CN2CCNCC2)cc1
1775,1972830,10.1021/acsmedchemlett.9b00612,,,,Inhibition of human recombinant CYP3A4 expressed in insect cell microsomes in presence of NADPH by fluorescence assay,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)benzamide,0.58,uM,=,-0.2365720064370627,0,O=C(Nc1cccc(-n2ccnc2)c1)c1cccc(Nc2nccc(-c3cccnc3)n2)c1
1776,436456,10.1021/jm061195+,,,,Inhibition of human CYP3A4,O=C(NCc1ccc(F)cc1)c1cnc(Nc2cccc(Cl)c2)nc1C(F)(F)F,2-(3-chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid 4-fluorobenzylamide,5.0,uM,=,0.6989700043360189,1,O=C(NCc1ccccc1)c1cnc(Nc2ccccc2)nc1
1777,555225,10.1016/j.bmcl.2008.05.058,,,,Inhibition of CYP3A4,CN(C(=O)CN1C(=O)COc2cc(Cl)c(Cl)cc21)[C@@H](CN1CCOCC1)c1ccc(-c2ccccc2)cc1,"N-((R)-1-Biphenyl-4-yl-2-morpholin-4-yl-ethyl)-2-(6,7-dichloro-3-oxo-2,3-dihydro-benzo[1,4]oxazin-4-yl)-N-methyl-acetamide",9.1,uM,=,0.9590413923210936,1,O=C(CN1C(=O)COc2ccccc21)N[C@@H](CN1CCOCC1)c1ccc(-c2ccccc2)cc1
1778,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1ccc(-n2nccn2)c(C(=O)N2C[C@@H](C)OC[C@H]2Cc2cc(-c3ncccn3)ccc2F)c1,"US9150566, 147",28.0,uM,=,1.4471580313422192,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2ncccn2)c1
1779,449088,10.1016/j.bmcl.2007.08.028,,,,Inhibition of human CYP3A4,Cc1cnc(C(=O)N2C[C@H](C(=O)N(C)Cc3cc(C(F)(F)F)cc(C(F)(F)F)c3)[C@@H](c3ccc(F)cc3C)C2)cn1,"(3R,4S)-N-(3,5-bis(trifluoromethyl)benzyl)-4-(4-fluoro-2-methylphenyl)-N-methyl-1-(2-methylpyrazine-5-carbonyl)pyrrolidine-3-carboxamide",11.0,uM,=,1.0413926851582251,1,O=C(NCc1ccccc1)[C@H]1CN(C(=O)c2cnccn2)C[C@@H]1c1ccccc1
1780,2273353,10.1021/acs.jmedchem.8b01971,,,,Inhibition of CYP3A4 in human liver microsomes using Midazolam as substrate preincubated for 10 mins followed by NADPH addition and measured after 15 mins by LC-MS/MS analysis,N#Cc1cc2c(nc1N1CCC(C(=O)NS(=O)(=O)Cc3ccccc3)CC1)COC2=O,"N-(Benzylsulfonyl)-1-(3-cyano-5-oxo-5,7-dihydrofuro[3,4-b]-pyridin-2-yl)piperidine-4-carboxamide",8.01,uM,=,0.9036325160842376,1,O=C1OCc2nc(N3CCC(C(=O)NS(=O)(=O)Cc4ccccc4)CC3)ccc21
1781,1353337,10.1021/ml400379x,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 30 mins preincubation by LC-MS/MS analysis in absence of NADPH,CNS(=O)(=O)Nc1cccc(Cc2c(C)c3ccc(OC(=O)N(C)C)cc3oc2=O)c1,4-Methyl-3-(3-(N-methylsulfamoylamino)benzyl)-2-oxo-2H-chromen-7-yl dimethylcarbamate,13.0,uM,=,1.1139433523068367,1,O=c1oc2ccccc2cc1Cc1ccccc1
1782,487712,10.1016/j.bmcl.2008.05.104,,,,Inhibition of CYP3A4,Cc1cc(N2CCC(N3C[C@@H]4C[C@@H]3CO4)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,"3-(6-(4-((1R,4S)-5-oxa-2-aza-bicyclo[2.2.1]heptan-2-yl)piperidin-1-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)-4-((S)-2-(3-chlorophenyl)-2-hydroxyethylamino)pyridin-2(1H)-one",0.0005,uM,=,-3.3010299956639813,0,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(N3CCC(N4C[C@@H]5C[C@@H]4CO5)CC3)cc2[nH]1
1783,542857,10.1021/jm801313t,,,,Inhibition of human recombinant CYP3A4,Cc1ccccc1-c1cc(=O)n(C)c2ccc([C@](N)(c3ccc(Cl)cc3)c3cncn3C)cc12,(R)-6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-1-methyl-4-o-tolylquinolin-2(1H)-one,1.35,uM,=,0.1303337684950061,1,O=c1cc(-c2ccccc2)c2cc(C(c3ccccc3)c3cnc[nH]3)ccc2[nH]1
1784,526157,10.1021/np0401765,,,,Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation,COc1cc(OC)c(OC)cc1CC(C)=O,"2,4,5-trimethoxyphenylacetone",28.7,uM,=,1.4578818967339924,1,c1ccccc1
1785,493017,10.1021/jm800851u,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,COc1cc(OC)cc(-c2cc(NC(C)=O)nc(-n3nc(C)cc3C)n2)c1,"N-[6-(3,5-Dimethoxy-phenyl)-2-(3,5-dimethyl-pyrazol-1-yl)-pyrimidin-4-yl]-acetamide",0.38,uM,=,-0.4202164033831898,0,c1ccc(-c2ccnc(-n3cccn3)n2)cc1
1786,1695601,10.1016/j.bmc.2017.08.012,,,,Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using 7-Benzoyloxy-4-trifluoromethyl coumarin substrate in presence of NADP+ by fluorescence based assay,O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCC23CC4CC(CC(O)(C4)C2)C3)cc1F,"5-Chloro-2-fluoro-4-(((1R,3S,5R,7)-3-hydroxyadamantan-1-yl)amino)-N-(thiazol-2-yl)benzenesulfonamide",6.3,uM,=,0.7993405494535817,1,O=S(=O)(Nc1nccs1)c1ccc(NCC23CC4CC(CC(C4)C2)C3)cc1
1787,1567198,10.1039/C5MD00479A,,,,Inhibition of human CYP3A4 by HPLC analysis,CC(C)(C)[C@@H](O)C(=O)N1C[C@@H]2C[C@@H]2[C@H]1C(=O)NCc1cc(Cl)ccc1-n1cnnn1,"(1S,2S,5R)-3-((R)-2-Hydroxy-3,3-dimethyl-butyryl)-3-azabicyclo[3.1.0]hexane-2-carboxylic acid 5-chloro-2-tetrazol-1-yl-benzylamide",47.0,uM,=,1.6720978579357175,1,O=C(NCc1ccccc1-n1cnnn1)[C@H]1NC[C@@H]2C[C@@H]21
1788,774749,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21,"7-Methyl-4,6,6a,7,8,9,10,10a-octahydro-indolo[4,3-fg]quinoline-9-carboxylic acid ((2R,5S,10bS)-5-benzyl-10b-hydroxy-2-methyl-3,6-dioxo-octahydro-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl)-amide",5.0,uM,=,0.6989700043360189,1,O=C(NC1OC2[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O)[C@H]1CN[C@@H]2Cc3c[nH]c4cccc(c34)[C@H]2C1
1789,949159,10.1016/j.bmcl.2013.01.011,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,Cc1cc(C[C@@H](NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12,"(R)-N-(1-(1,4'-bipiperidin-1'-yl)-3-(7-methyl-1H-indazol-5-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide",36.0,uM,=,1.5563025007672873,1,O=C(N[C@H](Cc1ccc2[nH]ncc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
1790,489969,10.1021/jm800566m,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein substrate,Cc1nc2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2n1C,"3-({4-[(1,2-Dimethyl-1H-benzimidazol-6-yl)(methyl)amino]-2-pyrimidinyl}amino)benzenesulfonamide",26.0,uM,=,1.414973347970818,1,c1ccc(Nc2nccc(Nc3ccc4nc[nH]c4c3)n2)cc1
1791,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NN5CCOCC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, F-58",22.29,uM,=,1.3481100684802376,1,O=C(NN1CCOCC1)c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12
1792,428486,10.1021/jm0612968,,,,Inhibition of cytochrome P450 3A4,CCc1cc2c(c(C(F)(F)F)c1)C(=O)N1CCNC[C@@H]21,"(R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino-[2,1-a]isoindol-6(2H)-one",8.7,uM,=,0.9395192526186184,1,O=C1c2ccccc2[C@@H]2CNCCN12
1793,2118301,10.1021/acs.jmedchem.1c00847,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 10 mins followed by NADPH addition by LC/MS/MS analysis,C[C@@H]1Cc2c([nH]c3ccccc23)[C@@H](c2c(F)cc(NC3CN(CCCF)C3)cc2F)N1CC(F)(F)CO,GIREDESTRANT,26.0,uM,=,1.414973347970818,1,c1ccc2c3c([nH]c2c1)[C@@H](c1ccc(NC2CNC2)cc1)NCC3
1794,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CC(O)C5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, E-70",18.3,uM,=,1.2624510897304295,1,O=C(c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12)N1CCC1
1795,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(NCCN6CCOCC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1,"US8940739, G-28",2.32,uM,=,0.3654879848908996,1,O=C(Nc1ccc(NCCN2CCOCC2)nc1)c1c[nH]c2c(CN3CC4N(C(=O)NCc5ccccc5)NCC(=O)N4C(Cc4ccccc4)C3=O)cccc12
1796,612188,10.1016/j.bmcl.2009.12.071,,,,Inhibition of CYP3A4,CC(F)CN1C[C@H]2C[C@@H](N(Cc3cccc(OC(F)(F)F)c3)C(=O)c3cn(C)cn3)C[C@H]2C1,(exo)-N-(2-(2-fluoropropyl)octahydrocyclopenta[c]pyrrol-5-yl)-1-methyl-N-(3-(trifluoromethoxy)benzyl)-1H-imidazole-4-carboxamide,7.9,uM,=,0.8976270912904415,1,O=C(c1c[nH]cn1)N(Cc1ccccc1)[C@H]1C[C@H]2CNC[C@H]2C1
1797,1460848,10.1021/jm501038s,,,,Inhibition of CYP3A4 (unknown origin),O=C(NCc1ccncc1)c1ccc(Oc2ccccc2)cc1,SID24831614,1.0,uM,=,0.0,0,O=C(NCc1ccncc1)c1ccc(Oc2ccccc2)cc1
1798,1649460,10.1016/j.ejmech.2016.12.017,,,,Inhibition of human CYP3A4 expressed in baculovirus-infected insect cells using Luciferin-PFBE as substrate in presence of NADPH by P450-Glo luminescence assay,COc1cccc(/C=C/C(=O)c2cc(OC)c(OC)cc2O)c1,"(2E)-1-(2-hydroxy-4,5-dimethoxyphenyl)-3-(3-methoxyphenyl)prop-2-en-1-one",27.4,uM,=,1.437750562820388,1,O=C(/C=C/c1ccccc1)c1ccccc1
1799,1560508,10.1016/j.bmc.2016.02.014,,,,Inhibition of CYP3A4 (unknown origin),O=C1COc2ccc(CN3c4ccccc4COc4cc(F)ccc43)cc2N1,"6-((8-fluorodibenzo[b,e][1,4]oxazepin-5(11H)-yl)methyl)-2H-benzo[b][1,4]oxazin-3(4H)-one",5.544,uM,=,0.7438232216037504,1,O=C1COc2ccc(CN3c4ccccc4COc4ccccc43)cc2N1
1800,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5cnc(N6CCN(C(C)C)CC6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, G-47",3.67,uM,=,0.5646660642520893,1,O=C(Nc1cnc(N2CCNCC2)nc1)c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12
1801,438600,10.1016/j.bmcl.2007.03.048,,,,Inhibition of CYP3A4 in microsomes,CNC(=O)c1cc(C)c2nc(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)[nH]c2c1,"2-(4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-2-oxo-1,2-dihydropyridin-3-yl)-N,7-dimethyl-3H-benzo[d]imidazole-5-carboxamide",3.7,uM,=,0.568201724066995,1,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccccc2[nH]1
1802,2024613,10.1016/j.bmcl.2020.127721,,,,Inhibition of CYP3A4 (unknown origin),CS(=O)(=O)Nc1cccc(CC(=O)Nc2cc(-c3c[nH]c4ncccc34)cs2)c1,"2-[3-(methanesulfonamido)phenyl]-N-[4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-2-thienyl]acetamide",5.0,uM,=,0.6989700043360189,1,O=C(Cc1ccccc1)Nc1cc(-c2c[nH]c3ncccc23)cs1
1803,1745299,10.1016/j.bmcl.2017.09.056,,,,Inhibition of CYP3A4 (unknown origin),N#Cc1cc(S(=O)(=O)Nc2ncns2)ccc1Oc1ccc(-c2cccc(C(F)(F)F)c2)cc1-c1ccnc(CNCCC2CCNCC2)c1,"3-cyano-4-(3-(2-((2-(piperidin-4-yl)ethylamino)methyl)pyridin-4-yl)-3'-(trifluoromethyl)biphenyl-4-yloxy)-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide",1.15,uM,=,0.0606978403536116,1,O=S(=O)(Nc1ncns1)c1ccc(Oc2ccc(-c3ccccc3)cc2-c2ccnc(CNCCC3CCNCC3)c2)cc1
1804,789607,10.1021/jm2008369,,,,Inhibition of human CYP3A4,COc1cnc(-c2ccc(Cn3c(CC(C)(C)C(=O)O)c(SC(C)(C)C)c4cc(OCc5ccc(C)cn5)ccc43)cc2)nc1,"3-[3-tert-Butylsulfanyl-1-[4-(5-methoxypyrimidin-2-yl)-benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid",0.0088,uM,=,-2.055517327849832,0,c1ccc(COc2ccc3c(ccn3Cc3ccc(-c4ncccn4)cc3)c2)nc1
1805,1291572,10.1016/j.bmcl.2013.12.058,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](C)CC[C@H](C)NC(=O)OCc2cncs2)C(C)C)cs1,"Thiazol-5-ylmethyl(2S,5S)-5-((S)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-3-methylbutanamido)hexan-2-ylcarbamate",0.51,uM,=,-0.2924298239020636,0,O=C(CNC(=O)NCc1cscn1)NCCCCNC(=O)OCc1cncs1
1806,519908,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,Cc1nc2c(NCc3ccc(F)cc3Cl)cc(-n3cncn3)cn2c1C,"N-(2-chloro-4-fluorobenzyl)-2,3-dimethyl-6-(1H-1,2,4-triazol-1-yl)imidazo[1,2-a]pyridin-8-amine",2.9,uM,=,0.4623979978989561,1,c1ccc(CNc2cc(-n3cncn3)cn3ccnc23)cc1
1807,1460909,10.1021/jm501326k,,,,Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase/human b5 reductase using 7-benzyloxyquinoline substrate,CCOC(=O)c1[nH]cc2c1NC1=C(C(=O)CCC1)C2c1ccc(Sc2nc3c(F)cc(F)cc3[nH]2)o1,"(+)-9-[5-(4,6-Difluoro-1H-benzimidazol-2-ylsulfanyl)-furan-2-yl]-8-oxo-4,5,6,7,8,9-hexahydro-2Hpyrrolo[3,4-b]quinoline-3-carboxylic acid ethyl ester",1.0,uM,=,0.0,0,O=C1CCCC2=C1C(c1ccc(Sc3nc4ccccc4[nH]3)o1)c1c[nH]cc1N2
1808,305432,10.1016/j.bmcl.2005.01.044,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,CC(C(c1ccc2cc(OCc3ccc([N+](=O)[O-])cc3)ccc2c1)n1ccnc1)N(C)C,{2-Imidazol-1-yl-1-methyl-2-[6-(4-nitro-benzyloxy)-naphthalen-2-yl]-ethyl}-dimethyl-amine,0.344,uM,=,-0.4634415574284699,0,c1ccc(COc2ccc3cc(Cn4ccnc4)ccc3c2)cc1
1809,458550,10.1016/j.bmcl.2007.09.099,,,,Inhibition of human CYP3A4,CC(=O)N1CCN(CC(O)CN2CCN(CCc3c(-c4cc(C)cc(C)c4)[nH]c4sc(C(C)(C)C(=O)N5C6CCC5CC6)cc34)CC2)CC1,"1-(7-aza-bicyclo[2.2.1]heptan-7-yl)-2-(4-(2-(4-(3-(4-acetylpiperazin-1-yl)-2-hydroxypropyl)piperazin-1-yl)ethyl)-5-(3,5-dimethylphenyl)-6H-thieno[2,3-b]pyrrol-2-yl)-2-methylpropan-1-one",6.0,uM,=,0.7781512503836436,1,O=C(Cc1cc2c(CCN3CCN(CCCN4CCNCC4)CC3)c(-c3ccccc3)[nH]c2s1)N1C2CCC1CC2
1810,817424,10.1021/ml200137x,,,,Inhibition of CYP3A4 using testosterone as substrate in human liver microsome for 20 mins by HPLC analysis,CNC[C@@H](NC(=O)N1CCC[C@@H]([C@@H](OCCNC(=O)OC)c2cccc(Cl)c2)C1)[C@@H](O)C1CCCCC1,"Methyl(2-((R)-(3-chlorophenyl)((R)-1-(((1S,2R)-1-cyclohexyl-1-hydroxy-3-(methylamino)propan-2-yl)carbamoyl)piperidin-3-yl)methoxy)ethyl)carbamate",7.1,uM,=,0.8512583487190752,1,O=C(NCCC1CCCCC1)N1CCC[C@@H](Cc2ccccc2)C1
1811,814102,10.1016/j.bmcl.2012.03.014,,,,Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins,CC(=O)NCCc1ccccc1-c1onc([C@H]2CNCC[C@]2(C(N)=O)c2ccc(F)c(F)c2)c1Br,"(3R,4R)-3-(5-(2-(2-acetamidoethyl)phenyl)-4-bromoisoxazol-3-yl)-4-(3,4-difluorophenyl)piperidine-4-carboxamide",36.0,uM,=,1.5563025007672873,1,c1ccc(-c2cc([C@H]3CNCCC3c3ccccc3)no2)cc1
1812,858507,10.1021/jm300700v,,,,Inhibition of CYP3A4,CC[C@H](C(=O)Nc1ccccc1N1CCCC1)c1ccccc1,(S)-2-Phenyl-N-(2-(pyrrolidin-1-yl)phenyl)butanamide,3.9,uM,=,0.5910646070264992,1,O=C(Cc1ccccc1)Nc1ccccc1N1CCCC1
1813,1705360,10.1016/j.bmcl.2017.06.037,,,,Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method,O[C@@](Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(OCC(F)(F)F)cc2)cn1,"(R)-2-(2,4-difluorophenyl)-1,1-difluoro-3-(1H-tetrazol-1-yl)-1-(5-(4-(2,2,2-trifluoroethoxy)phenyl)pyridin-2-yl)propan-2-ol",65.0,uM,=,1.812913356642856,1,c1ccc(-c2ccc(CC(Cn3cnnn3)c3ccccc3)nc2)cc1
1814,1984169,10.1016/j.bmc.2020.115349,,,,Inhibition of human full length CYP3A4 assessed using 7-benzyloxy-4 (trifluoromethyl)coumarin as substrate preincubated for 20 mins in presence of NADPH followed by substrate addition and measured for 2 mins by fluorometric analysis,CC(C)(C)OC(=O)N[C@H](CSCC(Nc1ccccc1)C(=O)NCc1cccnc1)Cc1c[nH]c2ccccc12,Rac-tert-butyl N-[(1S)-1-[[2-anilino-3-oxo-3-(3-pyridylmethylamino)propyl]sulfanylmethyl]-2-(1H-indol-3-yl)ethyl]carbamate,0.43,uM,=,-0.3665315444204134,0,O=C(NCc1cccnc1)C(CSCCCc1c[nH]c2ccccc12)Nc1ccccc1
1815,1838867,10.1021/acsmedchemlett.9b00550,,,,Inhibition of human CYP3A4 using sorafenib as substrate by LC/MS/MS analysis,Nc1cc(F)c(S(=O)(=O)N2CCC(O)CC2)cc1C(=O)Nc1cc(F)c(F)c(F)c1,"2-amino-4-fluoro-5-((4-hydroxypiperidin-1-yl)sulfonyl)-N-(3,4,5-trifluorophenyl)benzamide",27.84,uM,=,1.4446692309385245,1,O=C(Nc1ccccc1)c1cccc(S(=O)(=O)N2CCCCC2)c1
1816,461436,10.1016/j.bmcl.2007.10.092,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,CC[C@@H]1CCC[C@H](C2(CC(=O)N3CCCCC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1,"2-(1-((2R,6R)-1-(4-chlorophenylsulfonyl)-6-ethylpiperidin-2-yl)cyclopropyl)-1-(piperidin-1-yl)ethanone",2.6,uM,=,0.414973347970818,1,O=C(CC1([C@H]2CCCCN2S(=O)(=O)c2ccccc2)CC1)N1CCCCC1
1817,1625987,10.1016/j.bmcl.2016.04.095,,,,Inhibition of CYP3A4 in human liver microsomes after 30 secs by LC/MS/MS analysis,O=S(=O)(CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12)[C@@H]1CCNC1,"(R)-3-(2-((4S,4aS,10bS)-10b-(4-chlorophenylsulfonyl)-7,10-difluoro-1,2,4,4a,5,10b-hexahydropyrano[3,4-c]chromen-4-yl)ethylsulfonyl)pyrrolidine",6.1,uM,=,0.785329835010767,1,O=S(=O)(CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccccc3)c3ccccc3OC[C@@H]12)[C@@H]1CCNC1
1818,1465542,10.1016/j.bmcl.2015.01.051,,,,Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(C6CN(C)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O,"(1S,4R,5R,6R,8R,10S,11R,12S,13R,16R,18S,21R)-8-[(1S)-1-ethoxy-2-hydroxy-2-methylpropyl]-4,6,12,17,17-pentamethyl-18-{[(2S)-4-(1-methylazetidin-3-yl)morpholin-2-yl]oxy}-9-oxahexacyclo[11.9.0.0^{1,21}.0^{4,12}.0^{5,10}.0^{16,21}]docosan-11-ol",3.9,uM,=,0.5910646070264992,1,C1CO[C@@H]2CC3C(CC[C@@]45C[C@@]46CC[C@H](O[C@H]4CN(C7CNC7)CCO4)C[C@@H]6CC[C@@H]35)[C@H]2C1
1819,1432845,10.1016/j.bmcl.2014.10.024,,,,Inhibition of CYP3A4 (unknown origin) using testosterone substrate,COc1nc(-c2nc(Nc3cc(C(F)(F)F)ccc3F)n(C)n2)ccc1-n1cnc(C)c1,"N-(2-fluoro-5-(trifluoromethyl)phenyl)-3-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)-1-methyl-1H-1,2,4-triazol-5-amine",25.4,uM,=,1.404833716619938,1,c1ccc(Nc2nc(-c3ccc(-n4ccnc4)cn3)n[nH]2)cc1
1820,2075218,10.1021/acsmedchemlett.9b00395,,,,Inhibition of human liver microsome CYP3A4 using midazolam as substrate preincubated for 10 mins followed by substrate and NADPH addition and measured after 10 mins by LC-MS/MS analysis,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,SID124898784,40.8,uM,=,1.61066016308988,1,c1ccc(Oc2ccc(-c3nn([C@@H]4CCCNC4)c4ncncc34)cc2)cc1
1821,51900,10.1021/jm990388c,,,,Inhibition of heterologously expressed human cytochrome P450 3A4,COc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1cc(F)cc(-c3cccnc3)c1)CC2,"5-Methoxy-6-trifluoromethyl-2,3-dihydro-indole-1-carboxylic acid (3-fluoro-5-pyridin-3-yl-phenyl)-amide",9.0,uM,=,0.9542425094393248,1,O=C(Nc1cccc(-c2cccnc2)c1)N1CCc2ccccc21
1822,304833,10.1021/jm050261p,,,,Inhibitory concentration against Cytochrome 450 3A4,N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(C3)C1)C2,(S)-2-(2-Adamantan-1-yl-2-amino-acetyl)-2-aza-bicyclo[3.1.0]hexane-3-carbonitrile,20.0,uM,=,1.3010299956639813,1,O=C(CC12CC3CC(CC(C3)C1)C2)N1CC[C@@H]2C[C@@H]21
1823,2060129,10.1021/acsmedchemlett.1c00112,,,,Inhibition of CYP3A4 (unknown origin),N#CCCN1C(=O)CC[C@H]1C(=O)N1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)nc3CC[C@@H]12,"3-((S)-2-((3aR,9bR)-9b-((4-Fluorophenyl)sulfonyl)-7-(perfluoropropan-2-yl)-2,3,3a,4,5,9b-hexahydro-1H-pyrrolo[3,2-f]quinoline-3-carbonyl)-5-oxopyrrolidin-1-yl)propanenitrile",19.0,uM,=,1.2787536009528289,1,O=C1CC[C@@H](C(=O)N2CC[C@@]3(S(=O)(=O)c4ccccc4)c4cccnc4CC[C@@H]23)N1
1824,676065,10.1016/j.bmcl.2010.09.028,,,,Inhibition of CYP3A4 after 30 mins,CC(C)[C@@H]1COC[C@H](C2(OC(=O)N3CCNCC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1,"1-((3R,5R)-4-(4-chlorophenylsulfonyl)-5-isopropylmorpholin-3-yl)cyclopropyl piperazine-1-carboxylate",0.0003,uM,=,-3.522878745280338,0,O=C(OC1([C@H]2COCCN2S(=O)(=O)c2ccccc2)CC1)N1CCNCC1
1825,1289242,10.1016/j.bmcl.2013.12.088,,,,Inhibition of CYP3A4 (unknown origin) using benzyloxyresorufin as substrate,O=C(NC1CCCC1)N[C@@](Cc1ccccc1)(c1cc(F)cc(OC(F)(F)C(F)F)c1)c1ccc(Cl)cn1,"(S)-1-(1-(5-chloropyridin-2-yl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-cyclopentylurea",3.6,uM,=,0.5563025007672873,1,O=C(NC1CCCC1)N[C@@](Cc1ccccc1)(c1ccccc1)c1ccccn1
1826,1327919,10.1039/C2MD20061A,,,,Inhibition of CYP3A4 in human pooled liver microsomes using midazolam as substrate by LC/MS/MS analysis,COc1cc(N2CCOCC2)ccc1-c1nc2c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)c(Cl)cnc2[nH]1,"(1S,2S,3R,4R)-3-[6-Chloro-2-(2-methoxy-4-morpholin-4-yl-phenyl)-3H-imidazo[4,5-b]pyridin-7-ylamino]-bicyclo[2.2.1]hept-5-ene-2-carboxylicacidamide",5.4,uM,=,0.7323937598229685,1,C1=C[C@H]2C[C@@H]1C[C@@H]2Nc1ccnc2[nH]c(-c3ccc(N4CCOCC4)cc3)nc12
1827,768817,10.1021/jm2005354,,,,Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting,C[C@@H](c1ccc(-c2ccc(F)cc2)cc1)N1CC[C@](CCO)(c2ccc(F)cc2)OC1=O,"(S)-3-((S)-1-(4'-fluorobiphenyl-4-yl)ethyl)-6-(4-fluorophenyl)-6-(2-hydroxyethyl)-1,3-oxazinan-2-one",21.0,uM,=,1.3222192947339193,1,O=C1OC(c2ccccc2)CCN1Cc1ccc(-c2ccccc2)cc1
1828,1886565,10.1021/acs.jmedchem.8b02021,,,,Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay,Nc1nc2ccc(SCc3ccccc3)cc2s1,6-(Benzylthio)benzo[d]thiazol-2-amine,10.0,uM,=,1.0,1,c1ccc(CSc2ccc3ncsc3c2)cc1
1829,1446329,10.1021/ml500387y,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Cc1ccc(C(C)(C)CC(O)(Cc2cc3cc(S(C)(=O)=O)ncc3[nH]2)C(F)(F)F)c(C(N)=O)c1,"5-methyl-2-(5,5,5-trifluoro-4-hydroxy-2-methyl-4-((5-(methylsulfonyl)-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)pentan-2-yl)benzamide",6.0,uM,=,0.7781512503836436,1,c1ccc(CCCCc2cc3ccncc3[nH]2)cc1
1830,813040,10.1021/jm201533b,,,,Inhibition of human CYP3A4 using testosterone as substrate by LC/MS/MS analysis,O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)[C@@H]1C[C@@H](c2ccccc2)CN1C(=O)Cc1cnc[nH]1,"(2S,4S)-1-(2-(1H-imidazol-5-yl)acetyl)-N-(4-(4-fluorophenoxy)phenyl)-4-phenylpyrrolidine-2-carboxamide",0.301,uM,=,-0.5214335044061567,0,O=C(Nc1ccc(Oc2ccccc2)cc1)[C@@H]1C[C@@H](c2ccccc2)CN1C(=O)Cc1cnc[nH]1
1831,2238300,10.1021/acs.jmedchem.1c01366,,,,Inhibition of CYP3A4M in human liver microsomes incubated for 20 mins in presence of NADPH by LC-MS/MS analysis,CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,SID144204227,0.039,uM,=,-1.408935392973501,0,c1ccc([C@@]2(Cn3ccnc3)OC[C@H](COc3ccc(N4CCNCC4)cc3)O2)cc1
1832,1653091,10.1016/j.bmc.2016.11.019,,,,Inhibition of human CYP3A4,Cl.NCCN(C(=O)c1ccc(Cl)cc1Cl)c1ccc(Cl)cc1,"N-(2-Aminoethyl)-2,4-dichloro-N-(4-chlorophenyl)benzamide hydrochloride",0.07,uM,=,-1.154901959985743,0,O=C(Nc1ccccc1)c1ccccc1
1833,501481,10.1021/jm8016514,,,,Inhibition of human CYP3A4,C[C@@H](O[C@H]1CC[C@@H]2CN(C3=CC(=O)CC3)C[C@H]2[C@@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,"3-[(3aR,4R,5S,7aS)-5-{(1R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy}-4-(4-fluorophenyl)octahydro-1H-isoindol-2-yl]cyclopent-2-en-1-one",39.0,uM,=,1.591064607026499,1,O=C1C=C(N2C[C@H]3CC[C@H](OCc4ccccc4)[C@@H](c4ccccc4)[C@@H]3C2)CC1
1834,2126605,10.1016/j.bmcl.2021.128077,,,,Time dependent inhibition of CYP3A4 (unknown origin) measured after 30 mins,Cn1c(=O)[nH]c2c(Cl)cc3c(c21)CN(CC(F)(F)F)C(=O)[C@H](CC(=O)N1CCC(N2CCc4ccccc4NC2=O)CC1)C3,"(S)-4-Chloro-1-methyl-7-{2-oxo-2-[4-(2-oxo-1,2,4,5-tetrahydro-benzo[d][1,3]diazepin-3-yl)-piperidin-1-yl]-ethyl}-9-(2,2,2-trifluoro-ethyl)-1,3,6,7,9,10-hexahydro-1,3,9-triaza-cyclohepta[e]indene-2,8-dione",8.1,uM,=,0.9084850188786496,1,O=C1NCc2c(ccc3[nH]c(=O)[nH]c23)C[C@H]1CC(=O)N1CCC(N2CCc3ccccc3NC2=O)CC1
1835,51916,10.1016/j.bmcl.2003.11.005,,,,Inhibition of cytochrome P450 3A4,c1ccc(CCCOc2ccc(-n3ccnc3)cc2)nc1,2-[3-(4-Imidazol-1-yl-phenoxy)-propyl]-pyridine,0.252,uM,=,-0.5985994592184559,0,c1ccc(CCCOc2ccc(-n3ccnc3)cc2)nc1
1836,2273353,10.1021/acs.jmedchem.8b01971,,,,Inhibition of CYP3A4 in human liver microsomes using Midazolam as substrate preincubated for 10 mins followed by NADPH addition and measured after 15 mins by LC-MS/MS analysis,N#Cc1cc2c(nc1N1CCC(C(=O)NS(=O)(=O)c3ccc(Cl)s3)CC1)COC2=O,"N-((5-Chlorothiophen-2-yl)sulfonyl)-1-(3-cyano-5-oxo-5,7-dihydrofuro[3,4-b]pyridin-2-yl)piperidine-4-carboxamide",50.0,uM,=,1.6989700043360187,1,O=C1OCc2nc(N3CCC(C(=O)NS(=O)(=O)c4cccs4)CC3)ccc21
1837,768817,10.1021/jm2005354,,,,Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting,C[C@@H](c1ccc(-c2ccc(F)cc2)cc1)N1CC[C@](CCCO)(c2ccccc2)OC1=O,"(R)-3-((S)-1-(4'-fluorobiphenyl-4-yl)ethyl)-6-(3-hydroxypropyl)-6-phenyl-1,3-oxazinan-2-one",11.0,uM,=,1.0413926851582251,1,O=C1OC(c2ccccc2)CCN1Cc1ccc(-c2ccccc2)cc1
1838,349088,10.1016/j.bmcl.2006.01.084,,,,Inhibition of CYP3A4 using BFC fluorogenic substrate,COc1ccccc1COCCCOc1ccc(N2C(=O)CNC[C@@H]2CSc2ccc3c(c2)N(CC(=O)O)C(=O)CO3)cc1,"(R)-2-(6-((1-(4-(3-(2-methoxybenzyloxy)propoxy)phenyl)-6-oxopiperazin-2-yl)methylthio)-3-oxo-2,3-dihydrobenzo[b][1,4]oxazin-4-yl)acetic acid",15.0,uM,=,1.1760912590556811,1,O=C1COc2ccc(SC[C@H]3CNCC(=O)N3c3ccc(OCCCOCc4ccccc4)cc3)cc2N1
1839,874035,10.1021/jm3012239,,,,Time dependent inhibition of CYP3A4,Cn1cc(NC(=O)c2cnn3ccc(N)nc23)c(-c2cc(Cl)ccc2Cl)n1,"5-amino-N-(3-(2,5-dichlorophenyl)-1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide",5.8,uM,=,0.7634279935629373,1,O=C(Nc1c[nH]nc1-c1ccccc1)c1cnn2cccnc12
1840,1778315,10.1016/j.bmcl.2018.06.040,,,,Inhibition of CYP3A4 (unknown origin),CN1CCN(CCCOc2cccc(CC(=O)Nc3nc(-c4c[nH]c5ncccc45)cs3)c2)CC1,"N-(4-(1H-pyrrolo[2,3-b]pyridin-3-yl)thiazol-2-yl)-2-(3-(3-(4-methylpiperazin-1-yl)propoxy)phenyl)acetamide",19.6,uM,=,1.292256071356476,1,O=C(Cc1cccc(OCCCN2CCNCC2)c1)Nc1nc(-c2c[nH]c3ncccc23)cs1
1841,1474044,10.1021/jm501740a,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,O=C(N[C@H](c1ccccn1)C1CC1)c1ccc2[nH]nc(-c3ccc(N4[C@H]5CC[C@H]4CC(O)C5)cc3)c2c1,N-((S)-Cyclopropyl(pyridin-2-yl)methyl)-3-(4-((endo)-3-hydroxy-8-azabicyclo[3.2.1]octan-8-yl)phenyl)-1H-indazole-5-carboxamide,1.7,uM,=,0.2304489213782739,1,O=C(N[C@H](c1ccccn1)C1CC1)c1ccc2[nH]nc(-c3ccc(N4[C@@H]5CCC[C@@H]4CC5)cc3)c2c1
1842,2246941,10.1021/acs.jmedchem.1c02132,,,,Inhibition of CYP3A4 (unknown origin) incubated for 10 mins in presence of NADPH by LC-MS/MS analysis,COC(=O)Nc1cc(-c2ccc(OC[C@@](C)(N)CC(C)C)c(C#N)c2)ccn1,"(S)-methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-cyanophenyl)pyridin-2-yl)carbamate",13.0,uM,=,1.1139433523068367,1,c1ccc(-c2ccncc2)cc1
1843,1752996,10.1016/j.bmcl.2018.01.014,,,,Inhibition of CYP3A4 (unknown origin),CCCCNc1nc(N)nc2cccc(C(=O)N(C)Cc3ccccc3)c12,2-amino-N-benzyl-4-(butylamino)-N-methylquinazoline-5-carboxamide,8.5,uM,=,0.9294189257142929,1,O=C(NCc1ccccc1)c1cccc2ncncc12
1844,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)Nc6ncccn6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, D-82",8.52,uM,=,0.9304395947667,1,O=C(Nc1ccc(-c2c[nH]c3c(CN4C[C@@H]5N(C(=O)NCc6ccccc6)NCC(=O)N5[C@@H](Cc5ccccc5)C4=O)cccc23)cc1)Nc1ncccn1
1845,449485,10.1016/j.bmcl.2007.07.097,,,,Inhibition of microsomal CYP3A4,CCN(CC)[C@@H](CC(C)C)c1cccc(F)c1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1,"1-((R)-3-(2,4-dichlorophenyl)-1-(4-(2-((S)-1-(diethylamino)-3-methylbutyl)-6-fluorophenyl)piperazin-1-yl)-1-oxopropan-2-yl)pyrrolidin-2-one",2.7,uM,=,0.4313637641589873,1,O=C([C@@H](Cc1ccccc1)N1CCCC1=O)N1CCN(c2ccccc2)CC1
1846,479364,10.1016/j.bmcl.2008.05.027,,,,Inhibition of CYP3A4,O=C(Cn1c(=O)oc2ccc(Cl)cc21)N1CCCC(c2ccccc2)C1CN1CCOCC1,rac-5-chloro-3-(2-(2-(morpholinomethyl)-3-phenylpiperidin-1-yl)-2-oxoethyl)benzo[d]oxazol-2(3H)-one,1.3,uM,=,0.1139433523068367,1,O=C(Cn1c(=O)oc2ccccc21)N1CCCC(c2ccccc2)C1CN1CCOCC1
1847,552281,10.1016/j.bmcl.2008.04.036,,,,Inhibition of CYP3A4,N[C@@H](Cn1c(=O)c(-c2ccc(CNCCC(=O)O)cc2)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1,"(R)-3-(4-(1-(2-fluoro-6-(trifluoromethyl)benzyl)-3-(2-amino-2-phenylethyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)benzylamino)propanoic acid",31.0,uM,=,1.4913616938342726,1,O=c1c(-c2ccccc2)cn(Cc2ccccc2)c(=O)n1CCc1ccccc1
1848,451143,10.1021/jm070521y,,,,Inhibition of human CYP3A4,NCCc1cn(S(=O)(=O)c2c(Cl)nc3sccn23)c2ccccc12,"N1-(6-chloroimidazo[2,1-b][1,3]thiazole-5-sulfonyl)tryptamine",33.0,uM,=,1.5185139398778875,1,O=S(=O)(c1cnc2sccn12)n1ccc2ccccc21
1849,1701374,10.1021/acs.jmedchem.7b00345,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC-MS/MS analysis,Cl.NCc1ccnc(Oc2cccc(C(=O)N3C[C@@H](O)[C@H](F)C3)c2)c1,"(R,R)-trans-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)-oxy)phenyl)(3-fluoro-4-hydroxypyrrolidin-1-yl)methanone Hydrochloride",30.0,uM,=,1.4771212547196624,1,O=C(c1cccc(Oc2ccccn2)c1)N1CCCC1
1850,1586691,10.1039/C6MD00128A,,,,Inhibition of CYP3A4 in human liver microsomes assessed as reduction in midazolam 1-hydroxylation/testosterone 6beta-hydroxylation by LC-MS/MS analysis,Cc1cc(C2C=CN=CN2)c(C)s1.Cl,"rac-6-(2,5-dimethylthiophen-3-yl)-1,6-dihydropyrimidine hydrochloride",19.8,uM,=,1.2966651902615312,1,C1=CC(c2ccsc2)NC=N1
1851,991614,10.1021/jm4008906,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,COc1ccccc1N1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O,"rac-3-(Aminomethyl)-4-(2,4-dichlorophenyl)-6-(2-methoxyphenyl)-2-methyl-6,7-dihydropyrrolo[3,4-b]pyridin-5-one",3.4,uM,=,0.5314789170422551,1,O=C1c2c(-c3ccccc3)ccnc2CN1c1ccccc1
1852,1485703,10.1124/dmd.112.048264,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method,CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21,[3-(2-Chloro-phenothiazin-10-yl)-propyl]-dimethyl-amine,23.3,uM,=,1.3673559210260189,1,c1ccc2c(c1)Nc1ccccc1S2
1853,1488509,10.1124/dmd.112.045708,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 90 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis in presence of NADPH,COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1,"Acetic acid (2S,3S)-5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester",0.1,uM,=,-1.0,0,O=C1C[C@H](c2ccccc2)Sc2ccccc2N1
1854,1462318,10.1016/j.bmcl.2014.12.056,,,,Inhibition of CYP3A4 (unknown origin),C[C@@H]1CC[C@@H](Oc2ccnc3c(F)cccc23)CN1C(=O)c1ccccc1-n1nccn1,"(2-(2H-1,2,3-triazol-2-yl)phenyl)((2R,5R)-5-(8-fluoroquinolin-4-yloxy)-2-methylpiperidin-1-yl)methanone",25.4,uM,=,1.404833716619938,1,O=C(c1ccccc1-n1nccn1)N1CCC[C@@H](Oc2ccnc3ccccc23)C1
1855,1625607,10.1016/j.bmcl.2016.10.016,,,,Inhibition of human Cyp3A4 using testosterone as substrate by LC-MS/MS analysis,N#CCS(=O)(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,"2-[4-(4-{[(2S,4R)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-ylsulfonyl]acetonitrile",0.153,uM,=,-0.8153085691824012,0,c1ccc([C@]2(Cn3ccnc3)OC[C@@H](COc3ccc(N4CCNCC4)cc3)O2)cc1
1856,2048449,10.1016/j.bmc.2020.115734,,,,Inhibition of recombinant CYP3A4 (unknown origin) by fluorescence-based assay,CCn1nc2c(c1Nc1nc(-c3ccc(-n4cnc(C)c4)c(OC)n3)cs1)CCC2(C)C,"N-(2-ethyl-6,6-dimethyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-4-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)thiazol-2-amine",0.75,uM,=,-0.1249387366082999,0,c1cn(-c2ccc(-c3csc(Nc4[nH]nc5c4CCC5)n3)nc2)cn1
1857,2017934,10.1021/acs.jmedchem.0c00834,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis,Cc1c(-c2ccccc2)nc2ccc(Br)cc2c1C(=O)NCC(CC(=O)O)c1ccccc1Cl,(+)-4-{[(6-Bromo-3-methyl-2-phenylquinolin-4-yl)carbonyl]amino}-3-(2-chlorophenyl)-butanoic acid,13.0,uM,=,1.1139433523068367,1,O=C(NCCc1ccccc1)c1cc(-c2ccccc2)nc2ccccc12
1858,1465542,10.1016/j.bmcl.2015.01.051,,,,Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(C6CN(CCOC)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O,"(1S,4R,5R,6R,8R,10S,11R,12S,13R,16R,18S,21R)-8-[(1S)-1-ethoxy-2-hydroxy-2-methylpropyl]-18-{[(2S)-4-[1-(2-methoxyethyl)azetidin-3-yl]morpholin-2-yl]oxy}-4,6,12,17,17-pentamethyl-9-oxahexacyclo[11.9.0.0^{1,21}.0^{4,12}.0^{5,10}.0^{16,21}]docosan-11-ol",2.7,uM,=,0.4313637641589873,1,C1CO[C@@H]2CC3C(CC[C@@]45C[C@@]46CC[C@H](O[C@H]4CN(C7CNC7)CCO4)C[C@@H]6CC[C@@H]35)[C@H]2C1
1859,51903,10.1021/jm020557k,,,,Concentration required to inhibit cytochrome P450 3A4.,CCCCc1ccc(/N=C/NO)c(C)c1,N-(4-butyl-2-methylphenyl)-N'-hydroxyimidoformamide,65.4,uM,=,1.8155777483242672,1,c1ccccc1
1860,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)Nc6ccc(OC)cc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, D-76",9.48,uM,=,0.9768083373380664,1,O=C(Nc1ccccc1)Nc1ccc(-c2c[nH]c3c(CN4C[C@@H]5N(C(=O)NCc6ccccc6)NCC(=O)N5[C@@H](Cc5ccccc5)C4=O)cccc23)cc1
1861,305744,10.1021/jm049696n,,,,Inhibitory concentration value against human cytochrome P-450 3A4,c1cncc(-c2cccnc2)c1,"[3,3'']Bipyridinyl",64.7,uM,=,1.8109042806687004,1,c1cncc(-c2cccnc2)c1
1862,1924446,10.1021/acsmedchemlett.5b00485,,,,Inhibition of CYP3A4 (unknown origin) preincubated for 10 mins followed by addition of DBF as substrate measured after 10 mins in presence of NADP by fluorescence analysis,Cc1cc(-c2cnn3c(NC[C@H]4C[C@@](C)(O)C4)cc(Oc4cccnc4)nc23)ccc1C(=O)NC1CC1,"N-cyclopropyl-4-(7-((cis-3-hydroxy-3-methylcyclobutyl)methylamino)-5-(pyridin-3-yloxy)pyrazolo[1,5-a]pyrimidin-3-yl)-2-methylbenzamide",14.0,uM,=,1.146128035678238,1,O=C(NC1CC1)c1ccc(-c2cnn3c(NCC4CCC4)cc(Oc4cccnc4)nc23)cc1
1863,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",O=C(c1ccc(Cl)cc1-n1nccn1)N1CCOC[C@H]1Cc1cc(-c2ncon2)ccc1F,"US9150566, 178",24.0,uM,=,1.380211241711606,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2ncon2)c1
1864,2291490,10.1021/acs.jmedchem.2c01938,,,,Inhibition of CYP3A4 in pooled human liver microsomes using midazolam as substrate assessed as reduction in OH-midazolam metabolite formation by LC-MS/MS analysis,C=CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4cc(OC)c(C)c(OC)c4)nn32)CC1,"(S)-7-(1-acryloylpiperidin-4-yl)-2-(3,5-dimethoxy-4-methylphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide",15.9,uM,=,1.2013971243204515,1,c1ccc(-c2cc3n(n2)[C@H](C2CCNCC2)CCN3)cc1
1865,755387,10.1021/jm101177s,,,,Inhibition of CYP3A4,O=C(NO)c1cnc(N2C[C@@H]3[C@H](C2)[C@H]3NS(=O)(=O)c2ccc3ccccc3c2)nc1,exo-N-Hydroxy-2-{6-[(2-naphthylsulfonyl)amino]-3-azabicyclo[3.1.0]-hex-3-yl}pyrimidine-5-carboxamide,10.0,uM,=,1.0,1,O=S(=O)(N[C@H]1[C@@H]2CN(c3ncccn3)C[C@@H]21)c1ccc2ccccc2c1
1866,1526216,10.1021/ml500526p,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,Cn1c(Nc2ccc(C(C)(C)C)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21,N-(4-tert-butylphenyl)-1-methyl-5-(2-(5-(trifluoromethyl)-1H-imidazol-2-yl)pyridin-4-yloxy)-1H-benzo[d]imidazol-2-amine,34.0,uM,=,1.5314789170422551,1,c1ccc(Nc2nc3cc(Oc4ccnc(-c5ncc[nH]5)c4)ccc3[nH]2)cc1
1867,592411,10.1021/jm901195w,,,,Inhibition of human hepatic CYP3A4,Cc1cc(-c2csc(-c3cccc(O)c3)c2)ccc1O,4-[5-(3-Hydroxyphenyl)-3-thienyl]-2-methylphenol,1.5,uM,=,0.1760912590556812,1,c1ccc(-c2csc(-c3ccccc3)c2)cc1
1868,2022325,10.1021/acs.jmedchem.0c01163,,,,Inhibition of CYP3A4 in human liver microsomes,COc1cc(NC2CN(CCCF)C2)ccc1[C@@H]1c2ccc3[nH]ncc3c2C[C@@H](C)N1CC1(F)CC1,"N-(4-((6S,8R)-7-((1-Fluorocyclopropyl)methyl)-8-methyl-6,7,8,9-tetrahydro-3H-pyrazolo[4,3-f]isoquinolin-6-yl)-3-methoxyphenyl)-1-(3-fluoropropyl)azetidin-3-amine",11.0,uM,=,1.0413926851582251,1,c1cc([C@@H]2c3ccc4[nH]ncc4c3CCN2CC2CC2)ccc1NC1CNC1
1869,774749,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1,{3-[(4-Amino-benzenesulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl}-carbamic acid tetrahydro-furan-3-yl ester,1.0,uM,=,0.0,0,O=C(N[C@H](CCNS(=O)(=O)c1ccccc1)Cc1ccccc1)O[C@H]1CCOC1
1870,767445,10.1016/j.bmcl.2011.06.129,,,,Inhibition of CYP3A4 using a fluorescent probe 7-benzyloxy-4(trifluoromethyl)-coumarin,CS(=O)(=O)N(CCN1CCOCC1)c1ccc(Nc2ncc3cnn(C4CCCCCC4)c3n2)cc1,"N-(4-(1-cycloheptyl-1H-pyrazolo[3,4-d]pyrimidin-6-ylamino)phenyl)-N-(2-morpholinoethyl)methanesulfonamide",0.04,uM,=,-1.3979400086720375,0,c1cc(Nc2ncc3cnn(C4CCCCCC4)c3n2)ccc1NCCN1CCOCC1
1871,598164,10.1016/j.bmcl.2009.07.046,,,,Inhibition of CYP3A4,C[C@H](NC(=O)C(C)(C)Nc1ccc(C(F)(F)F)cn1)[C@@H](Cc1ccc(Cl)cc1)c1cccc(C#N)c1,"N-((2S,3S)-4-(4-chlorophenyl)-3-(3-cyanophenyl)butan-2-yl)-2-methyl-2-(5-(trifluoromethyl)pyridin-2-ylamino)propanamide",2.03,uM,=,0.3074960379132129,1,O=C(CNc1ccccn1)NC[C@@H](Cc1ccccc1)c1ccccc1
1872,1637154,,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins,O=C(c1c(F)ccc(NS(=O)(=O)c2cccc(F)c2)c1F)c1c[nH]c2nccc(Cl)c12,"N-[3-(4-Chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-3-fluoro-benzenesulfonamide",5.0,uM,=,0.6989700043360189,1,O=C(c1cccc(NS(=O)(=O)c2ccccc2)c1)c1c[nH]c2ncccc12
1873,1291572,10.1016/j.bmcl.2013.12.058,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@H](CCN(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1,"(6S,9S)-thiazol-5-ylmethyl 3,6-dibenzyl-9-isopropyl-13-(2-isopropylthiazol-4-yl)-12-methyl-8,11-dioxo-2,3,7,10,12-pentaazatridecan-1-oate",0.3,uM,=,-0.5228787452803376,0,O=C(CNC(=O)NCc1cscn1)N[C@H](CCN(Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
1874,2123080,10.1016/j.ejmech.2021.113674,,,,Inhibition of CYP3A4 (unknown origin) using BOMCC as a substrate incubated for 20 mins by fluorescence based analysis,c1ccc(COc2cccc(-c3nc4sccn4c3-c3ccncn3)c2)cc1,"6-(3-(Benzyloxy)phenyl)-5-(pyrimidin-4-yl)imidazo[2,1-b]thiazole",20.91,uM,=,1.320354032817672,1,c1ccc(COc2cccc(-c3nc4sccn4c3-c3ccncn3)c2)cc1
1875,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2ccc(C)c(-n3nccn3)c2)c1,"US9150566, 65",22.0,uM,=,1.3424226808222062,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
1876,2045773,10.1039/d0md00174k,,,,Inhibition of CYP3A4 (unknown origin),Cc1c(-c2cc(F)c(N)cc2F)ccc2c3oc(CN)nc3c(=O)n(C3CC3)c12,"7-(4-amino-2,5-difluorophenyl)-2-(aminomethyl)-5-cyclopropyl-6-methyloxazolo[4,5-c]quinolin-4-one",12.9,uM,=,1.110589710299249,1,O=c1c2ncoc2c2ccc(-c3ccccc3)cc2n1C1CC1
1877,1467194,10.1021/jm5005336,,,,Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay,CC(C)N1CCC(Oc2ccc(/C=C/c3n[nH]c4cc([C@@H]5C[C@@]56C(=O)Nc5ccccc56)ccc34)cc2)CC1,"(1R,2S)-2-(3-((E)-4-((1-Isopropylpiperidin-4-yl)oxy)styryl)-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-one",1.6,uM,=,0.2041199826559248,1,O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccc(OC4CCNCC4)cc3)n[nH]c2c1
1878,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(NCCN(C(C)C)C(C)C)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1,"US8940739, G-25",4.05,uM,=,0.6074550232146685,1,O=C(Nc1cccnc1)c1c[nH]c2c(CN3CC4N(C(=O)NCc5ccccc5)NCC(=O)N4C(Cc4ccccc4)C3=O)cccc12
1879,1613611,10.1016/j.bmcl.2016.08.089,,,,Inhibition of CYP3A4 (unknown origin),COc1ncnc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)c1F,"(R)-5-(5-fluoro-6-methoxypyrimidin-4-yl)-6-isopropyl-2-(3-(methylsulfonyl)phenyl)-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole",2.5,uM,=,0.3979400086720376,1,c1ccc(-n2cc3c(n2)CN(c2ccncn2)C3)cc1
1880,459885,10.1021/np0704248,,,,Inhibition of human CYP3A4 expressed in Escherichia coli assessed as inhibition of nifedipine oxidation,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,"1-(4-{4-[2-(2,4-Dichloro-phenyl)-2-imidazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-ethanone (ketoconazole)",0.21,uM,=,-0.6777807052660807,0,c1ccc(C2(Cn3ccnc3)OCC(COc3ccc(N4CCNCC4)cc3)O2)cc1
1881,2298109,10.1016/j.bmc.2023.117273,,,,Inhibition of CYP3A4 in human liver microsomes,COCCCO[C@H]1CN(c2ccc(O[C@@H]3CCN(c4cc(OC)ncc4Cl)C[C@H]3C)cc2)[C@@H](CC(=O)O)[C@@H]1C,"2-((2S,3S,4R)-1-(4-(((3R,4R)-1-(5-chloro-2-methoxypyridin-4-yl)-3-methylpiperidin-4-yl)oxy)phenyl)-4-(3-methoxypropoxy)-3-methylpyrrolidin-2-yl)acetic acid",40.0,uM,=,1.6020599913279625,1,c1cc(N2CCC(Oc3ccc(N4CCCC4)cc3)CC2)ccn1
1882,1464796,10.1016/j.bmcl.2015.01.005,,,,Inhibition of recombinant human CYP3A4,C[C@@H]1[C@@H](C)OCCN1c1nc(-c2ccncc2F)cc(=O)n1C,"2-((2R,3R)-2,3-dimethylmorpholino)-6-(3-fluoropyridin-4-yl)-3-methylpyrimidin-4(3H)-one",485.0,uM,=,2.6857417386022635,1,O=c1cc(-c2ccncc2)nc(N2CCOCC2)[nH]1
1883,1698217,10.1021/acs.jmedchem.7b01870,,,,Inhibition of CYP3A4 in human liver microsomes using DBF as substrate by fluorescence assay,N#CC1(NC(=O)[C@H](Cc2ccc(OC(F)(F)F)c(Cl)c2)NC(=O)c2cnn(-c3ccc(F)nc3)n2)CC1,N-(1-Cyanocyclopropyl)-3-chloro-4-O-(trifluoromethyl)-Nalpha-[(2-(6-fluoropyridin-3-yl)-2H-triazol-4-ylcarbonyl]-L-tyrosinamide,47.0,uM,=,1.6720978579357175,1,O=C(N[C@@H](Cc1ccccc1)C(=O)NC1CC1)c1cnn(-c2cccnc2)n1
1884,1849385,10.1016/j.bmcl.2019.06.044,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis,Cc1cccc(Cl)c1C(=O)c1cn(-c2ccc(C(=O)O)cc2)c2c(F)cccc12,4-(3-(2-chloro-6-methylbenzoyl)-7-fluoro-1H-indol-1-yl)benzoic acid,27.2,uM,=,1.434568904034199,1,O=C(c1ccccc1)c1cn(-c2ccccc2)c2ccccc12
1885,857201,10.1021/jm200900q,,,,Inhibition of CYP3A4,CN(CCO)CC(=O)N1CCC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CC1,4-Cyano-1H-imidazole-2-carboxylic Acid(2-Cyclohex-1-enyl-4-{1-[2-(2-hydroxy-ethyl)-methyl-amino-acetyl]-piperidin-4-yl}-phenyl)-amide,6.7,uM,=,0.8260748027008264,1,O=C(Nc1ccc(C2CCNCC2)cc1C1=CCCCC1)c1ncc[nH]1
1886,495542,10.1021/jm801332q,,,,Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate by time dependent inhibition assay,C[C@@H]1CN(Cc2ccc(C(C)(C)C(=O)N3CCC(Nc4ccc(F)cc4)CC3)cc2)C[C@H](C)N1,"1-[2-(4-([(3R,5S)-3,5-Dimethyl-1-piperazinyl]methyl)phenyl)-2-methylpropanoyl]-N-(4-fluorophenyl)-4-piperidinamine",4.7,uM,=,0.6720978579357175,1,O=C(Cc1ccc(CN2CCNCC2)cc1)N1CCC(Nc2ccccc2)CC1
1887,479364,10.1016/j.bmcl.2008.05.027,,,,Inhibition of CYP3A4,O=C1COc2cc(Cl)c(Cl)cc2N1CC(=O)N1CCCC(c2ccccc2)C1CN1CCCC1,"rac-6,7-dichloro-4-(2-oxo-2-(3-phenyl-2-(pyrrolidin-1-ylmethyl)piperidin-1-yl)ethyl)-2H-benzo[b][1,4]oxazin-3(4H)-one",1.8,uM,=,0.255272505103306,1,O=C1COc2ccccc2N1CC(=O)N1CCCC(c2ccccc2)C1CN1CCCC1
1888,1555052,10.1016/j.ejmech.2015.12.028,,,,Inhibition of CYP3A4 (unknown origin),Cl.NOCc1ccc(I)cc1,4-(iodobenzyl)hydroxylamine hydrochloride,7.2,uM,=,0.8573324964312685,1,c1ccccc1
1889,1467194,10.1021/jm5005336,,,,Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay,COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5CCOCC5)cc4)n[nH]c3c1)C(=O)N2,"(1R*,2S*)-(E)-5'-Methoxy-2-(3-(4-(morpholinomethyl)styryl)-1H-indazol-6-yl)spiro [cyclopropane-1,3'-indolin]-2'-one",6.4,uM,=,0.8061799739838872,1,O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccc(CN4CCOCC4)cc3)n[nH]c2c1
1890,630896,10.1016/j.bmcl.2010.03.017,,,,Inhibition of CYP3A4,Cc1cc(OC[P@@]2(=O)OCC[C@@H](c3ccccn3)O2)c2c(c1C)Cc1scnc1-2,"6,7-Dimethyl-4-(2-oxo-4-pyridin-2-yl-2lambda*5*-[1,3,2]dioxaphosphinan-2-ylmethoxy)-8H-indeno[1,2-d]thiazole",8.4,uM,=,0.9242792860618816,1,O=[P@]1(COc2cccc3c2-c2ncsc2C3)OCC[C@@H](c2ccccn2)O1
1891,1301274,10.6019/CHEMBL3137386,,,,DNDI: CYP Inhibition,CS(=O)(=O)c1ccc(N2CCN(C(=O)C(c3ccc(Cl)cc3)c3cccnc3)CC2)cc1,2-(4-Chlorophenyl)-2-(pyridin-3-yl)-1-(4-[4-(methylsulfonyl)phenyl]piperazin-1-yl)ethanone,7.1,uM,=,0.8512583487190752,1,O=C(C(c1ccccc1)c1cccnc1)N1CCN(c2ccccc2)CC1
1892,1460909,10.1021/jm501326k,,,,Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase/human b5 reductase using 7-benzyloxyquinoline substrate,CCOC(=O)c1[nH]cc2c1NC1=C(C(=O)CCC1)C2c1ccc(Sc2nc3cccc(F)c3[nH]2)o1,"(+/-)-Ethyl 9-[5-[(6-fluoro-1H-benzimidazol-2-yl)sulfanyl]-2-furyl]-8-oxo-2,4,5,6,7,9-hexahydropyrrolo[3,4-b]quinoline-3-carboxylate",4.5,uM,=,0.6532125137753437,1,O=C1CCCC2=C1C(c1ccc(Sc3nc4ccccc4[nH]3)o1)c1c[nH]cc1N2
1893,1919651,,,,,"Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase",O/N=C/c1ccc(-c2cccnc2)s1,5-Pyridin-3-yl-thiophene-2-carbaldehyde oxime,12.98,uM,=,1.1132746924643504,1,c1cncc(-c2cccs2)c1
1894,2219884,10.1016/j.bmcl.2021.128479,,,,Inhibition of CYP3A4 in human liver microsomes using cocktail of isoform-specific probe substrate,[2H]C([2H])(C1CCOCC1)N1CCC2(CC1)C[C@H]2CNc1ccc(-c2cc(F)cc(F)c2F)nn1,"N-[[(2R)-6-[dideuterio(tetrahydropyran-4-yl)methyl]-6-azaspiro[2.5]octan-2-yl]methyl]-6-(2,3,5-trifluorophenyl)pyridazin-3-amine",27.6,uM,=,1.4409090820652175,1,c1ccc(-c2ccc(NC[C@@H]3CC34CCN(CC3CCOCC3)CC4)nn2)cc1
1895,1692884,10.1021/acs.jmedchem.7b00376,,,,Inhibition of CYP3A4 in human liver microsomes,CCOC(=O)/C=C/c1cc(O)c2oc(-c3cc(O)c(O)c(O)c3)cc2c1,"(E)-Ethyl3-(7-hydroxy-2-(3,4,5-trihydroxyphenyl)benzofuran-5-yl)acrylate",21.7,uM,=,1.3364597338485296,1,c1ccc(-c2cc3ccccc3o2)cc1
1896,1288280,10.1016/j.bmcl.2013.12.057,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,CC(C)c1nc(CN(C)C(=O)N[C@@H](CO)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,"Thiazol-5-ylmethyl(2R,5R)-5-((S)-3-hydroxy-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)propanamido)-1,6-diphenylhexan-2-ylcarbamate",0.15,uM,=,-0.8239087409443188,0,O=C(CNC(=O)NCc1cscn1)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
1897,993439,10.6019/CHEMBL2448688,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,O=C(Nc1ccccc1-n1ccnc1)c1cnc(-c2ccccc2)s1,,2.0,uM,=,0.3010299956639812,1,O=C(Nc1ccccc1-n1ccnc1)c1cnc(-c2ccccc2)s1
1898,473932,10.1021/jm701121y,,,,Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay,COc1ccc(CCCOC(Cn2ccnc2)c2ccc(OC)cc2)cc1,1-(2-(4-methoxyphenyl)-2-(3-(4-methoxyphenyl)propoxy)ethyl)-1H-imidazole,0.045,uM,=,-1.3467874862246565,0,c1ccc(CCCOC(Cn2ccnc2)c2ccccc2)cc1
1899,804824,10.1016/j.bmcl.2011.12.080,,,,Reversible inhibition of CYP3A4,Cc1cc(Cl)cc2c(C(O)c3ncco3)c3c(C)n[nH]c3nc12,"rac-(6-chloro-3,8-dimethyl-1H-pyrazolo[3,4-b]quinolin-4-yl)(oxazol-2-yl)methanol",7.4,uM,=,0.8692317197309762,1,c1ccc2c(Cc3ncco3)c3cn[nH]c3nc2c1
1900,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2C(CN(Cc3cccc4c(C(=O)Nc5ccc(N6CCN(C(C)C)CC6)nc5)cn(C)c34)C(=O)[C@@H]2Cc2ccc(O)cc2)N1C(=O)NCc1ccccc1,"US8940739, G-46",6.12,uM,=,0.7867514221455612,1,O=C(Nc1ccc(N2CCNCC2)nc1)c1c[nH]c2c(CN3CC4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12
1901,542857,10.1021/jm801313t,,,,Inhibition of human recombinant CYP3A4,Cc1c(Cl)cccc1-c1cc(=O)n(C)c2ccc([C@](N)(c3ccc(Cl)cc3)c3cncn3C)cc12,(R)-6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chloro-2-methylphenyl)-1-methylquinolin-2(1H)-one,1.3,uM,=,0.1139433523068367,1,O=c1cc(-c2ccccc2)c2cc(C(c3ccccc3)c3cnc[nH]3)ccc2[nH]1
1902,1352210,10.1021/jm4010835,,,,Inhibition of CYP3A4 in human hepatocytes,CCn1nc2c(-c3ccc(Cl)cc3)c(-c3ccncc3)c(=O)n(Cc3ccc(C(F)(F)F)nc3C)n2c1=O,"8-(4-Chlorophenyl)-2-ethyl-5-((2-methyl-6-(trifluoromethyl)-pyridin-3-yl)methyl)-7-(pyridin-4-yl)-[1,2,4]triazolo[4,3-b]-pyridazine-3,6(2H,5H)-dione",3.0,uM,=,0.4771212547196624,1,O=c1c(-c2ccncc2)c(-c2ccccc2)c2n[nH]c(=O)n2n1Cc1cccnc1
1903,535882,10.1016/j.bmcl.2008.08.010,,,,"Inhibition of human CYP3A4 by microtiter plate assays using N-N,diethyl-formamide as substrate",O=S(=O)(c1cccc(Cl)c1)n1ccc2cc3c(cc21)CCNCC3,"1-(3-chlorophenylsulfonyl)-1,5,6,7,8,9-hexahydroazepino[4,5-f]indole",3.0,uM,=,0.4771212547196624,1,O=S(=O)(c1ccccc1)n1ccc2cc3c(cc21)CCNCC3
1904,493017,10.1021/jm800851u,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,CC(=O)Nc1cc(-c2cncc(O)c2)nc(-n2nc(C)cc2C)n1,"N-[6-(5-Hydroxypyridin-3-yl)-2-(3,5-dimethyl-pyrazol-1-yl)-pyrimidin-4-yl]-acetamide",18.0,uM,=,1.255272505103306,1,c1cncc(-c2ccnc(-n3cccn3)n2)c1
1905,2023287,10.1016/j.bmcl.2020.127636,,,,Inhibition of CYP3A4 (unknown origin),COc1ccccc1C1c2c(C(C)(C)C)n[nH]c2C(=O)N1c1ccc(-c2cc(C)no2)cc1,"3-tert-butyl-4-(2-methoxyphenyl)-5-(4-(3-methylisoxazol-5-yl)phenyl)-4,5-dihydropyrrolo[3,4-c]pyrazol-6(1H)-one",2.0,uM,=,0.3010299956639812,1,O=C1c2[nH]ncc2C(c2ccccc2)N1c1ccc(-c2ccno2)cc1
1906,552281,10.1016/j.bmcl.2008.04.036,,,,Inhibition of CYP3A4,NCC(=O)OCc1ccc(-c2cn(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](N)c3ccccc3)c2=O)cc1,"(R)-4-(1-(2-fluoro-6-(trifluoromethyl)benzyl)-3-(2-amino-2-phenylethyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)benzyl 2-aminoacetate",0.67,uM,=,-0.1739251972991735,0,O=c1c(-c2ccccc2)cn(Cc2ccccc2)c(=O)n1CCc1ccccc1
1907,1301274,10.6019/CHEMBL3137386,,,,DNDI: CYP Inhibition,O=C(C(c1ccc(Cl)cc1)c1cccnc1)N1CCN(c2ccc(C(F)(F)F)cn2)CC1,2-(4-Chlorophenyl)-2-(pyridin-3-yl)-1-[4-[5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl]ethanone,6.6,uM,=,0.8195439355418687,1,O=C(C(c1ccccc1)c1cccnc1)N1CCN(c2ccccn2)CC1
1908,2160656,10.1021/acs.jmedchem.1c01875,,,,Time dependent inhibition of recombinant human CYP3A4 using midazolam as substrate preincubated for 30 mins in presence of NADPH generating system followed by substrate addition incubated for 30 mins by LC-MS/MS analysi,C[C@]12CC[C@H](O)C[C@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](c3ccc(=O)oc3)CC[C@]12O,"5-((3S,5R,10S,13R,14S,17R)-3,14-Dihydroxy-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthren-17-yl)-pyran-2-one",0.45,uM,=,-0.3467874862246563,0,O=c1ccc([C@H]2CCC3C2CC[C@@H]2C4CCCC[C@H]4CC[C@@H]32)co1
1909,1456764,10.1016/j.bmcl.2014.07.026,,,,Inhibition of CYP3A4 in human liver microsome,CN1CCN(C(=O)c2cnc(O)nc2Oc2cc(Cl)ccc2Cl)c2ccccc21,"(4-(2,5-dichlorophenoxy)-2-hydroxypyrimidin-5-yl)(4-methyl-3,4-dihydroquinoxalin-1(2H)-yl)methanone",0.26,uM,=,-0.585026652029182,0,O=C(c1cncnc1Oc1ccccc1)N1CCNc2ccccc21
1910,1441252,10.1021/jm5010013,,,,Inhibition of CYP3A4 (unknown origin),COc1ccc(NC(=O)N2C[C@H]3C[C@@H](c4ccccc4C(F)(F)F)C[C@H]3C2)c(C(=O)O)c1,"trans-5-methoxy-2-((3aR,6aS)-5-(2-(trifluoromethyl)phenyl)octahydrocyclopenta[c]pyrrole-2-carboxamido)benzoic acid",8.0,uM,=,0.9030899869919436,1,O=C(Nc1ccccc1)N1C[C@H]2C[C@@H](c3ccccc3)C[C@H]2C1
1911,632105,10.1016/j.bmcl.2010.03.057,,,,Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin,Cc1cc(N2CCN(C)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,(S)-4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-3-(4-methyl-6-(4-methylpiperazin-1-yl)-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one,3.5,uM,=,0.5440680443502757,1,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(N3CCNCC3)cc2[nH]1
1912,1919651,,,,,"Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase",NCc1ccc(-c2cccnc2)s1,C-(5-Pyridin-3-yl-thiophen-2-yl)-methylamine,58.7,uM,=,1.7686381012476144,1,c1cncc(-c2cccs2)c1
1913,1614025,10.1016/j.bmcl.2016.09.043,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 6-beta-hydroxytestosterone metabolite formation using testosterone as substrate incubated for 30 mins by HPLC-MS method,Cn1c(NCCc2ccc(-c3ccccn3)cc2)nc2cc(Cl)ccc2c1=O,7-Chloro-3-methyl-2-[2-(4-pyridin-2-yl-phenyl)-ethylamino]-3H-quinazolin-4-one,5.8,uM,=,0.7634279935629373,1,O=c1[nH]c(NCCc2ccc(-c3ccccn3)cc2)nc2ccccc12
1914,860549,10.1021/jm3003747,,,,Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins,CN(C)C1CCN(Cc2cc3nc(-c4c(F)ccc5[nH]ccc45)nc(N4CCOCC4)c3s2)CC1,"1-((2-(5-Fluoro-1H-indol-4-yl)-4-morpholinothieno[3,2-d]-pyrimidin-6-yl)methyl)-N,N-dimethylpiperidin-4-amine",9.1,uM,=,0.9590413923210936,1,c1cc(-c2nc(N3CCOCC3)c3sc(CN4CCCCC4)cc3n2)c2cc[nH]c2c1
1915,1613611,10.1016/j.bmcl.2016.08.089,,,,Inhibition of CYP3A4 (unknown origin),CC(C)[C@@H]1c2nn(-c3cccc(S(C)(=O)=O)c3)cc2CN1c1ccnc(C(F)(F)F)n1,"(R)-6-isopropyl-2-(3-(methylsulfonyl)phenyl)-5-(2-(trifluoromethyl)pyrimidin-4-yl)-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole",12.8,uM,=,1.1072099696478683,1,c1ccc(-n2cc3c(n2)CN(c2ccncn2)C3)cc1
1916,823567,10.1021/jm201542d,,,,Inhibition of CYP3A4,Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(C3CCCCC3)cc1)C(=O)N2c1cc(O)ncn1,"3-(4-Cyclohexyl-phenyl)-1-(6-hydroxy-pyrimidin-4-yl)-8-(3-methyl-pyridin-2-ylmethyl)-1,3,8-triaza-spiro[4.5]decane-2,4-dione",40.0,uM,=,1.6020599913279625,1,O=C1N(c2ccc(C3CCCCC3)cc2)C(=O)C2(CCN(Cc3ccccn3)CC2)N1c1ccncn1
1917,785354,10.1016/j.bmcl.2011.08.060,,,,Inhibition of CYP3A4,COc1ccc(Br)cc1-c1csc(Nc2ccc(-n3cnc(C)c3)cc2)n1,4-(5-bromo-2-methoxyphenyl)-N-(4-(4-methyl-1H-imidazol-1-yl)phenyl)thiazol-2-amine,1.2,uM,=,0.0791812460476248,1,c1ccc(-c2csc(Nc3ccc(-n4ccnc4)cc3)n2)cc1
1918,1465541,10.1016/j.bmcl.2015.01.051,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(CC6CN(C(C)C)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O,"(1S,4R,5R,6R,8R,10S,11R,12S,13R,16R,18S,21R)-8-[(1S)-1-ethoxy-2-hydroxy-2-methylpropyl]-4,6,12,17,17-pentamethyl-18-{[(2S)-4-{[1-(propan-2-yl)azetidin-3-yl]methyl}morpholin-2-yl]oxy}-9-oxahexacyclo[11.9.0.0^{1,21}.0^{4,12}.0^{5,10}.0^{16,21}]docosan-11-ol",15.0,uM,=,1.1760912590556811,1,C1CO[C@@H]2CC3C(CC[C@@]45C[C@@]46CC[C@H](O[C@H]4CN(CC7CNC7)CCO4)C[C@@H]6CC[C@@H]35)[C@H]2C1
1919,469879,10.1016/j.bmcl.2008.01.012,,,,Inhibition of human CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin substrate,CC(C)c1c(-c2nnc(OC3CCNCC3)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12,"N-cyclopropyl-2,4-difluoro-5-(5-isopropyl-6-(5-(piperidin-4-yloxy)-1,3,4-oxadiazol-2-yl)pyrrolo[1,2-f][1,2,4]triazin-4-ylamino)benzamide",10.0,uM,=,1.0,1,O=C(NC1CC1)c1cccc(Nc2ncnn3cc(-c4nnc(OC5CCNCC5)o4)cc23)c1
1920,856843,10.1021/jm300356u,,,,Inhibition of human recombinant CYP3A4 using DEF as substrate preincubated for 5 to 10 mins before substrate addition,CC/N=C1\O[C@H]2[C@H](O[C@@H]3[C@@H](C)[C@H](O[C@H]4C[C@@](C)(OC)[C@@H](O)[C@H](C)O4)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@]3(C)O)O[C@H](C)C[C@@H]2N1C,"2'-O,3'-N-(N'-Ethylcarbonimidoyl)-3'-N-demethyl-9-deoxo-9amethyl-9a-aza-9a-homoerythromycin A",7.9,uM,=,0.8976270912904415,1,N=C1N[C@H]2CCO[C@@H](O[C@H]3CCCCNCCCCOC(=O)C[C@@H](O[C@H]4CCCCO4)C3)[C@@H]2O1
1921,2273354,10.1021/acs.jmedchem.8b01971,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 10 mins followed by NADPH addition and measured after 15 mins by LC-MS/MS analysis,N#Cc1cc2c(nc1N1CCC(C(=O)NS(=O)(=O)Cc3ccccc3)CC1)COC2=O,"N-(Benzylsulfonyl)-1-(3-cyano-5-oxo-5,7-dihydrofuro[3,4-b]-pyridin-2-yl)piperidine-4-carboxamide",3.53,uM,=,0.5477747053878226,1,O=C1OCc2nc(N3CCC(C(=O)NS(=O)(=O)Cc4ccccc4)CC3)ccc21
1922,874112,10.1021/jm300118s,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis,C#Cc1cccc(C[C@H](NC(=O)COC)[C@H](O)CN[C@H]2CC3(CCC3)Oc3ncc(CC(C)(C)C)cc32)c1,"N-((2S,3R)-1-(3-Ethynylphenyl)-3-hydroxy-4-((S)-6'-neopentyl-3',4'-dihydrospiro[cyclobutane-1,2'-pyrano[2,3-b]-pyridine]-4'-ylamino)butan-2-yl)-2-methoxyacetamide",0.03,uM,=,-1.5228787452803376,0,c1ccc(CCCCN[C@H]2CC3(CCC3)Oc3ncccc32)cc1
1923,487712,10.1016/j.bmcl.2008.05.104,,,,Inhibition of CYP3A4,COCCOCC(=O)N1CCN(C2CCN(c3cc(C)c4nc(-c5c(NC[C@@H](O)c6cccc(Cl)c6)cc[nH]c5=O)[nH]c4c3)CC2)CC1,(S)-4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-3-(6-(4-(4-(2-(2-methoxyethoxy)acetyl)piperazin-1-yl)piperidin-1-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one,0.003,uM,=,-2.5228787452803374,0,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(N3CCC(N4CCNCC4)CC3)cc2[nH]1
1924,993439,10.6019/CHEMBL2448688,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,CCN(Cc1cccnc1)c1cncc(-c2nc3ccccc3s2)c1,,0.79,uM,=,-0.1023729087095585,0,c1cncc(CNc2cncc(-c3nc4ccccc4s3)c2)c1
1925,2273353,10.1021/acs.jmedchem.8b01971,,,,Inhibition of CYP3A4 in human liver microsomes using Midazolam as substrate preincubated for 10 mins followed by NADPH addition and measured after 15 mins by LC-MS/MS analysis,CC1(C(=O)NS(=O)(=O)c2ccc(Cl)s2)CCN(c2nc3c(cc2C#N)C(=O)OC3)CC1,"N-((5-Chlorothiophen-2-yl)sulfonyl)-1-(3-cyano-5-oxo-5,7-dihydrofuro[3,4-b]pyridin-2-yl)-4-methylpiperidine-4-carboxamide",50.0,uM,=,1.6989700043360187,1,O=C1OCc2nc(N3CCC(C(=O)NS(=O)(=O)c4cccs4)CC3)ccc21
1926,519908,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,Cc1ccccc1CNc1cc(-n2ccccc2=O)cn2c(C)c(C)nc12,"1-(2,3-dimethyl-8-(2-methylbenzylamino)imidazo[1,2-a]pyridin-6-yl)pyridin-2(1H)-one",17.0,uM,=,1.230448921378274,1,O=c1ccccn1-c1cc(NCc2ccccc2)c2nccn2c1
1927,1447575,10.1016/j.bmcl.2014.05.068,,,,Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method,C[C@@H](c1ncncc1F)[C@](O)(Cn1ccnn1)c1ccc(F)cc1F,"(2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,3-triazol-1-yl)butan-2-ol",8.0,uM,=,0.9030899869919436,1,c1ccc(C(Cc2ccncn2)Cn2ccnn2)cc1
1928,1487309,10.1124/dmd.111.043505,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis,O[C@@H](c1cc(C(F)(F)F)nc2c(C(F)(F)F)cccc12)[C@H]1CCCCN1,"(S)-(2,8-bis(trifluoromethyl)quinolin-4-yl)((R)-piperidin-2-yl)methanol",0.667,uM,=,-0.175874166083451,0,c1ccc2c(C[C@H]3CCCCN3)ccnc2c1
1929,1614025,10.1016/j.bmcl.2016.09.043,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 6-beta-hydroxytestosterone metabolite formation using testosterone as substrate incubated for 30 mins by HPLC-MS method,COc1cnc(-c2ccc(CCNc3nc4cc(Cl)ccc4c(=O)n3C)cc2)nc1,7-Chloro-2-{2-[4-(5-methoxy-pyrimidin-2-yl)-phenyl]-ethylamino}-3-methyl-3H-quinazolin-4-one,8.7,uM,=,0.9395192526186184,1,O=c1[nH]c(NCCc2ccc(-c3ncccn3)cc2)nc2ccccc12
1930,1445199,10.1021/ml5003376,,,,Inhibition of human CYP3A4 midazolam site in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,COc1ccc(Cl)c(S(=O)(=O)Nc2ccc(-c3cnc4c(C)n[nH]c4n3)cc2)c1,"2-chloro-5-methoxy-N-(4-(3-methyl-1H-pyrazolo[3,4-b]pyrazin-6-yl)phenyl)benzenesulfonamide",26.8,uM,=,1.428134794028789,1,O=S(=O)(Nc1ccc(-c2cnc3cn[nH]c3n2)cc1)c1ccccc1
1931,1301325,10.6019/CHEMBL3137440,,,,DNDI: CYP Inhibition,Cc1noc(C)c1C(=O)N1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1,,2.1,uM,=,0.3222192947339193,1,O=C(c1cnoc1)N1CCC(N(c2ccccc2)c2cccnc2)CC1
1932,51895,10.1016/j.bmcl.2003.09.093,,,,Inhibition of cytochrome P450 3A4 of isolated guinea pig heart,Cc1nc2cc(OC[C@H](O)CN3CCN(CC(=O)Nc4c(C)cccc4C)CC3)ccc2s1,"N-(2,6-Dimethyl-phenyl)-2-{4-[(R)-2-hydroxy-3-(2-methyl-benzothiazol-5-yloxy)-propyl]-piperazin-1-yl}-acetamide",23.0,uM,=,1.3617278360175928,1,O=C(CN1CCN(CCCOc2ccc3scnc3c2)CC1)Nc1ccccc1
1933,449485,10.1016/j.bmcl.2007.07.097,,,,Inhibition of microsomal CYP3A4,CC(C)C[C@H](NCCO)c1cccc(F)c1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1,"1-((R)-3-(2,4-dichlorophenyl)-1-(4-(2-fluoro-6-((S)-1-(2-hydroxyethylamino)-3-methylbutyl)phenyl)piperazin-1-yl)-1-oxopropan-2-yl)pyrrolidin-2-one",0.48,uM,=,-0.3187587626244128,0,O=C([C@@H](Cc1ccccc1)N1CCCC1=O)N1CCN(c2ccccc2)CC1
1934,355280,10.1016/j.bmcl.2006.02.020,,,,Inhibition of CYP3A4,CCN(CC)[C@H](C)[C@@H](c1ccc2cc(OCC(C)(C)C(=O)O)ccc2c1)n1ccnc1,"3-(6-((1R,2R)-2-(diethylamino)-1-(1H-imidazol-1-yl)propyl)naphthalen-2-yloxy)-2,2-dimethylpropanoic acid",0.58,uM,=,-0.2365720064370627,0,c1ccc2cc(Cn3ccnc3)ccc2c1
1935,519908,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,Cc1cccc(C)c1CNc1cc(-n2cncn2)cn2c(C)c(C)nc12,"N-(2,6-dimethylbenzyl)-2,3-dimethyl-6-(1H-1,2,4-triazol-1-yl)imidazo[1,2-a]pyridin-8-amine",6.7,uM,=,0.8260748027008264,1,c1ccc(CNc2cc(-n3cncn3)cn3ccnc23)cc1
1936,550965,10.1021/np030556a,,,,Inhibition of human CYP3A4 by radiometric assay,CC(=O)O[C@@H]1[C@@H](OC(C)=O)[C@@H](O)[C@H](Oc2c(-c3ccc(O)cc3)oc3cc(O)cc(O)c3c2=O)O[C@H]1C,"kaempferol 3-O-3'',4''-di-O-acetyl-alpha-L-rhamnopyranoside",20.6,uM,=,1.3138672203691537,1,O=c1c(O[C@H]2CCCCO2)c(-c2ccccc2)oc2ccccc12
1937,1640557,,,,,"null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.",c1ccc(-n2ccnc2)cc1,1-Phenyl-1H-imidazole,1.0,uM,=,0.0,0,c1ccc(-n2ccnc2)cc1
1938,686484,10.1016/j.bmcl.2010.09.122,,,,Inhibition of CYP3A4,Cn1c2c(c3ccc(-n4ccc(OCc5ccccc5)cc4=O)cc31)CCNC2,"4-(benzyloxy)-1-(9-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-7-yl)pyridin-2(1H)-one",12.0,uM,=,1.0791812460476249,1,O=c1cc(OCc2ccccc2)ccn1-c1ccc2c3c([nH]c2c1)CNCC3
1939,1351750,10.1016/j.bmcl.2014.02.075,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1nc(Nc2ccc(C(=O)N3CCOCC3)cc2)c2nc[nH]c2n1,4-tert-butyl-N-(2-methyl-3-(6-(4-(morpholine-4-carbonyl)phenylamino)-9H-purin-2-yl)phenyl)benzamide,9.8,uM,=,0.9912260756924948,1,O=C(Nc1cccc(-c2nc(Nc3ccc(C(=O)N4CCOCC4)cc3)c3nc[nH]c3n2)c1)c1ccccc1
1940,1706610,10.1016/j.bmcl.2017.06.077,,,,Inhibition of recombinant human CYP3A4,COc1ccc(N2CCN(c3nc(-c4ccncn4)cc(=O)n3C)[C@H](C)C2)cc1,(R)-2-(4-(4-methoxyphenyl)-2-methylpiperazin-1-yl)-3-methyl-6-(pyrimidin-4-yl)pyrimidin-4(3H)-one,25.0,uM,=,1.3979400086720375,1,O=c1cc(-c2ccncn2)nc(N2CCN(c3ccccc3)CC2)[nH]1
1941,1886565,10.1021/acs.jmedchem.8b02021,,,,Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay,N#Cc1ccc(COc2ccc3nc(N)sc3c2)cc1,4-(((2-Aminobenzo[d]thiazol-6-yl)oxy)methyl)benzonitrile,10.0,uM,=,1.0,1,c1ccc(COc2ccc3ncsc3c2)cc1
1942,1488507,10.1124/dmd.112.045708,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis in presence of NADPH,C[C@H](c1nc2ncccc2c(=O)n1-c1ccc(O)cc1)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1,"(R)-N-(1-(3-(4-hydroxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide",0.068,uM,=,-1.1674910872937636,0,O=C(Cc1ccccc1)N(Cc1cccnc1)Cc1nc2ncccc2c(=O)n1-c1ccccc1
1943,1984169,10.1016/j.bmc.2020.115349,,,,Inhibition of human full length CYP3A4 assessed using 7-benzyloxy-4 (trifluoromethyl)coumarin as substrate preincubated for 20 mins in presence of NADPH followed by substrate addition and measured for 2 mins by fluorometric analysis,CC(C)(C)OC(=O)N[C@H](CS[C@@H](Cc1ccccc1)C(=O)NCCc1cccnc1)Cc1ccccc1,tert-butyl N-[(1S)-1-benzyl-2-[(1S)-1-benzyl-2-oxo-2-[2-(3-pyridyl)ethylamino]ethyl]sulfanyl-ethyl]carbamate,0.31,uM,=,-0.5086383061657274,0,O=C(NCCc1cccnc1)[C@H](Cc1ccccc1)SCCCc1ccccc1
1944,1288280,10.1016/j.bmcl.2013.12.057,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCO)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,"Thiazol-5-ylmethyl(2R,5R)-5-((S)-4-hydroxy-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)butanamido)-1,6-diphenylhexan-2-ylcarbamate",0.14,uM,=,-0.8538719643217619,0,O=C(CNC(=O)NCc1cscn1)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
1945,526157,10.1021/np0401765,,,,Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation,O[C@H]1OC[C@H](Cc2ccc3c(c2)OCO3)[C@H]1Cc1ccc2c(c1)OCO2,"(2S,3R,4R)-3,4-bis(benzo[d][1,3]dioxol-5-ylmethyl)-tetrahydrofuran-2-ol",9.1,uM,=,0.9590413923210936,1,c1cc2c(cc1C[C@H]1COC[C@@H]1Cc1ccc3c(c1)OCO3)OCO2
1946,445935,10.1021/jm070436q,,,,Inhibition of CYP3A4,Cn1cnc(CNc2cc(Br)c3ncc(C#N)c(Nc4ccc(F)c(Cl)c4)c3c2)c1,8-bromo-4-[(3-chloro-4-fluorophenyl)amino]-6-{[(1-methyl-1H-imidazol-4-yl)methyl]amino}quinoline-3-carbonitrile,15.0,uM,=,1.1760912590556811,1,c1ccc(Nc2ccnc3ccc(NCc4c[nH]cn4)cc23)cc1
1947,1911030,10.1021/acs.jmedchem.8b01226,,,,Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins,Cc1cccc(C#CC=C2CCN(C(=O)N(C)C(C)c3ccccc3)CC2)n1,N-Methyl-4-[3-(6-methylpyridin-2-yl)prop-2-yn-1-ylidene]-N-(1-phenylethyl)piperidine-1-carboxamide,4.0,uM,=,0.6020599913279624,1,O=C(NCc1ccccc1)N1CCC(=CC#Cc2ccccn2)CC1
1948,1446329,10.1021/ml500387y,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,CC(C)S(=O)(=O)c1cc2cc(CC(O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1,"5-fluoro-2-(5,5,5-trifluoro-4-hydroxy-4-((5-(isopropylsulfonyl)-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)-2-methylpentan-2-yl)benzamide",4.0,uM,=,0.6020599913279624,1,c1ccc(CCCCc2cc3ccncc3[nH]2)cc1
1949,438600,10.1016/j.bmcl.2007.03.048,,,,Inhibition of CYP3A4 in microsomes,Cc1cc(-c2ccc(F)cc2)cc2[nH]c(-c3c(N[C@H](CO)Cc4ccccc4)cc[nH]c3=O)nc12,(S)-3-(6-(4-fluorophenyl)-4-methyl-1H-benzo[d]imidazol-2-yl)-4-(1-hydroxy-3-phenylpropan-2-ylamino)pyridin-2(1H)-one,6.3,uM,=,0.7993405494535817,1,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(-c3ccccc3)cc2[nH]1
1950,1447575,10.1016/j.bmcl.2014.05.068,,,,Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method,O[C@@](Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(Cl)cc2)cn1,"(R)-1-(5-(4-chlorophenyl)pyridin-2-yl)-2-(2,4-difluorophenyl)-1,1-difluoro-3-(1H-tetrazol-1-yl)propan-2-ol",36.0,uM,=,1.5563025007672873,1,c1ccc(-c2ccc(CC(Cn3cnnn3)c3ccccc3)nc2)cc1
1951,1685713,10.1016/j.bmc.2017.04.033,,,,Inhibition of recombinant CYP3A4 (unknown origin),C[C@@H](c1ccc(Br)cc1)N1CC[C@](CC(C)(C)O)(c2ccc(F)cc2)OC1=O,"US8575157, 201::US8592410, Comparator 13::US8598163, 71",3.5,uM,=,0.5440680443502757,1,O=C1OC(c2ccccc2)CCN1Cc1ccccc1
1952,945618,10.1016/j.bmc.2012.11.058,,,,Inhibition of CYP3A4 (unknown origin),CC(=O)c1cc(NS(=O)(=O)c2ccc(Cl)cc2Cl)ccc1Oc1cnc2ccccc2c1,"N-(3-Acetyl-4-(quinolin-3-yloxy)phenyl)-2,4-dichlorobenzenesulfonamide",3.0,uM,=,0.4771212547196624,1,O=S(=O)(Nc1ccc(Oc2cnc3ccccc3c2)cc1)c1ccccc1
1953,643713,10.1016/j.bmcl.2010.06.009,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader,C[C@@H](Oc1cc(-n2cnc3cc(-c4cnn(CCN5CCN(C)CC5)c4)ccc32)sc1C(N)=O)c1ccccc1Cl,(R)-3-(1-(2-chlorophenyl)ethoxy)-5-(5-(1-(2-(4-methylpiperazin-1-yl)ethyl)-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)thiophene-2-carboxamide,1.9,uM,=,0.2787536009528289,1,c1ccc(COc2csc(-n3cnc4cc(-c5cnn(CCN6CCNCC6)c5)ccc43)c2)cc1
1954,1446329,10.1021/ml500387y,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,CCS(=O)(=O)c1cc2cc(C[C@](O)(CC(C)(C)c3ccccc3C(N)=O)C(F)(F)F)[nH]c2cn1,"(R)-2-(4-((5-(ethylsulfonyl)-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)-5,5,5-trifluoro-4-hydroxy-2-methylpentan-2-yl)benzamide",34.0,uM,=,1.5314789170422551,1,c1ccc(CCCCc2cc3ccncc3[nH]2)cc1
1955,1288280,10.1016/j.bmcl.2013.12.057,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,CC(C)[C@H](NC(=O)N(C)Cc1cncs1)C(=O)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1,"Thiazol-5-ylmethyl(2R,5R)-5-((S)-3-methyl-2-(3-methyl-3-(thiazol-5-ylmethyl)ureido)butanamido)-1,6-diphenylhexan-2-ylcarbamate",0.08,uM,=,-1.0969100130080565,0,O=C(CNC(=O)NCc1cncs1)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
1956,646079,10.1128/aac.00660-09,,,,Inhibition of human recombinant CYP3A4 after 30 mins,C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C,"30-Ethyl-33-(1-hydroxy-2-methyl-hex-4-enyl)-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31undecaaza-cyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone",6.6,uM,=,0.8195439355418687,1,O=C1CNC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)CN1
1957,2254484,10.1021/acs.jmedchem.2c00527,,,,Inhibition of CYP3A4 in human liver microsomes at 0.01 to 30 uM using phenacetin as substrate in presence of NADPH by UPLC-MS/MS analysis,C[C@@H]1CC(=O)Nc2ncnc(N3CCN(C(=O)[C@H](CN)c4ccc(Cl)cc4)[C@@H]4C[C@@H]43)c21,"(5R)-4-[(1S,6R)-5-[(2S)-3-amino-2-(4-chlorophenyl)propanoyl]-2,5-diazabicyclo[4.1.0]heptan-2-yl]-5-methyl-6,8-dihydro-5H-pyrido[2,3-d]pyrimidin-7-one",10.08,uM,=,1.0034605321095065,1,O=C1CCc2c(ncnc2N2CCN(C(=O)Cc3ccccc3)[C@@H]3C[C@@H]32)N1
1958,1456481,10.1021/jm5001979,,,,Inhibition of CYP3A4 (unknown origin),Nc1ccc(S(=O)(=O)N2CCN(c3ncc(C(O)(C(F)(F)F)C(F)(F)F)cc3-c3cccnc3)CC2)cn1,"2-(2-(4-((6-Aminopyridin-3-yl)sulfonyl)piperazin-1-yl)-[3,3'-bipyridin]-5-yl)-1,1,1,3,3,3-hexafluoropropan-2-ol",27.0,uM,=,1.4313637641589874,1,O=S(=O)(c1cccnc1)N1CCN(c2ncccc2-c2cccnc2)CC1
1959,2246941,10.1021/acs.jmedchem.1c02132,,,,Inhibition of CYP3A4 (unknown origin) incubated for 10 mins in presence of NADPH by LC-MS/MS analysis,COC(=O)Nc1cc(-c2cnc(OC[C@@](C)(N)CC(C)C)c(C#N)c2)ccn1,"(S)-methyl (6-((2-amino-2,4-dimethylpentyl)oxy)-5-cyano-[3,4'-bipyridin]-2'-yl)carbamate",2.2,uM,=,0.3424226808222063,1,c1cncc(-c2ccncc2)c1
1960,464748,10.1016/j.bmcl.2008.01.126,,,,Inhibition of CYP3A4 in presence of 7-benzyloxyresorufin substrate,COc1cccc(-c2nc(CCOc3cccc(C[C@@H]4C(=O)N(c5ccc(C(C)(C)C)cc5)[C@@H]4C(=O)O)c3)c(C)o2)c1,"(2S,3S)-3-(3-(2-(2-(3-methoxyphenyl)-5-methyloxazol-4-yl)ethoxy)benzyl)-1-(4-tert-butylphenyl)-4-oxoazetidine-2-carboxylic acid",19.0,uM,=,1.2787536009528289,1,O=C1[C@@H](Cc2cccc(OCCc3coc(-c4ccccc4)n3)c2)CN1c1ccccc1
1961,51750,10.1021/jm010531d,,,,Inhibition of dog Cytochrome P450 3A by macrocycles,N#Cc1ccc2cc1Oc1ccc3cccc(c3c1)N1CCC(NCCc3cncn3C2)C1=O,"R-31-oxo-20-oxa-2,6,11,13-tetraazahexacyclo[19.6.2.12,5.115,19.09,13.024,28]hentriaconta-1(28),9,11,15(30),16,18,21(29),22,24,26-decaen-18-yl cyanide",0.6,uM,=,-0.2218487496163563,0,O=C1C2CCN1c1cccc3ccc(cc13)Oc1cccc(c1)Cn1cncc1CCN2
1962,1336037,10.1021/jm500118j,,,,Inhibition of CYP3A4 (unknown origin),CC1(C)CCC(n2c3cnccc3c3cnc(Nc4ccc(N5CCNCC5)cn4)nc32)CC1,"9-(4,4-Dimethylcyclohexyl)-N-(5-(1-piperazinyl)-2-pyridinyl)-9Hpyrido[4',3':4,5]-pyrrolo[2,3-d]pyrimidin-2-amine",9.5,uM,=,0.9777236052888478,1,c1cc2c3cnc(Nc4ccc(N5CCNCC5)cn4)nc3n(C3CCCCC3)c2cn1
1963,646079,10.1128/aac.00660-09,,,,Inhibition of human recombinant CYP3A4 after 30 mins,C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)[C@H](SCCN(C)C)C(=O)N(C)[C@@H](CC(C)(C)O)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C,[(40-OH) MeLeu]4-CsA derivatives,58.5,uM,=,1.7671558660821804,1,O=C1CNC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)CN1
1964,991614,10.1021/jm4008906,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(Cc1ncco1)C2,"(S)-3-(Aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-6-(oxazol-2-ylmethyl)-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one",7.7,uM,=,0.8864907251724818,1,O=C1c2c(-c3ccccc3)ccnc2CN1Cc1ncco1
1965,2294674,10.1016/j.bmcl.2023.129205,,,,Inhibition of CYP3A4 (unknown origin),Cc1cccc(-c2[nH]c(NCc3ccc(Cl)cc3F)nc2-c2ccc3[nH]ncc3c2)n1,N-(4-chloro-2-fluorobenzyl)-4-(1H-indazol-5-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-amine,8.7,uM,=,0.9395192526186184,1,c1ccc(CNc2nc(-c3ccc4[nH]ncc4c3)c(-c3ccccn3)[nH]2)cc1
1966,746947,10.1021/jm200128m,,,,Inhibition of human CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,CC(F)(F)CNC(=O)N1Cc2nc(N)nc(-c3c(Cl)cc(Cl)cc3OCCn3cc(F)cn3)c2C1,"2-Amino-4-{2,4-dichloro-6-[2-(4-fluoropyrazol-1-yl)ethoxy]phenyl}-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carboxylic Acid(2,2-Difluoropropyl)amide",0.6,uM,=,-0.2218487496163563,0,c1ccc(-c2ncnc3c2CNC3)c(OCCn2cccn2)c1
1967,1641039,,,,,"Inhibition Assay: Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 uM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 Î¼M. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:CH3CN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO: CH3CN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v. Pooled human liver microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 5 mg/mL suspension.",CCOC(=O)/C=C/c1ccc(C(F)(F)C(O)(Cn2cnnn2)c2ccc(F)cc2F)nc1,"US9221791, 4",83.0,uM,=,1.919078092376074,1,c1ccc(C(Cc2ccccn2)Cn2cnnn2)cc1
1968,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1ccc(C(=O)N2CCOC[C@H]2Cc2cc(-n3nccn3)ccc2F)c(-n2nccn2)c1,"US9150566, 62",29.0,uM,=,1.462397997898956,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
1969,1642014,,,,,"Inhibition Assay: The test compounds were incubated with pooled human liver microsomes at 37° C. in the presence of NADPH and appropriate concentrations of substrates specific for CYP2C9 and 3A4. 120 μL of a mixture of human liver microsomes (HLM) in 50 mM potassium phosphate/5 mM MgCl2 buffer was added into all wells of row A in a 96-well plate. The concentration of microsomal protein was 2-fold the intended protein concentration for the particular isozyme assay recorded in Table 4. In addition, 80 μL of this human liver microsome preparation spiked with 1% DMSO was dispensed into all wells of rows B through H. 1.2 μL of each individual test compound in DMSO (10 mM) was added to the first 10 wells of row A (5 different test compounds each in duplicate). Additionally, 1.2 μL of the DMSO stock of the control inhibitor for the isozyme under study was added into the final two wells of row A to give a concentration two-fold above the highest final concentration. Three-fold serial dilutions were performed by taking 40 μL from each solution in wells of row A (wells 1-12, both compounds and controls) and diluting into the wells of row B. After thorough mixing, 40 μL from each solution in wells of row B were dispensed with a multichannel pipette (12 channels) into the wells of row C and the controls and test compounds hence further diluted. This process was repeated for rows D through G. After mixing, 40 μL was removed and discarded from the wells of row G. This procedure resulted in 80 μL of solution being present in all wells of all rows A through H, with protein concentrations being twice the final intended concentrations in all wells of rows, and test compound and control concentration being twice the final intended concentrations in rows A through G. Row H was not spiked with a test compound or positive control. The plate was covered and pre-incubated for 10 minutes in a 37° C. incubator. The reaction was initiated by adding 80 μL of a solution of the substrate for the isozyme under investigation in 50 mM potassium phosphate/5 mM MgCl2 buffer solution with 4 mM NADPH present, at a substrate concentration two-fold the intended final substrate concentrations using a multichannel pipette. The substrate solution was added to all wells rows A to H excluding wells 95 and 96 (microsomal blanks). The plate was covered and incubated at 37° C. for the time listed in Table 4 for the isoform under investigation. The reaction was stopped by dispensing 120 μL of internal standard (200 ng/mL CCX915-6A) in acetonitrile to all wells. 80 μL of the specific substrate/NADPH solution described above was added into the well 95 and 96 after stopping the reaction to provide the blank. The plate was vortexed for 10 min and spun in a centrifuge at 4,450 rpm and 4° C. for 10 min. With a multichannel pipette, 80 μL of the supernatant was transferred into a sample plate wells containing 80 μL of 0.1% formic acid/water and mixed well for analysis on LC-MS/MS as described in sections E and F.",Cc1cnc(C(=O)c2ccnc3[nH]ncc23)c(NS(=O)(=O)c2ccc(Cl)c(C(F)(F)F)c2)c1,"US9394307, 4-chloro-N-(5-methyl-2-{1H-pyrazolo[3,4-b]pyridine-4-carbonyl}pyridin-3-yl)-3-(trifluoromethyl)benzene-1-sulfonamide",3.0,uM,=,0.4771212547196624,1,O=C(c1ncccc1NS(=O)(=O)c1ccccc1)c1ccnc2[nH]ncc12
1970,492191,10.1016/j.bmcl.2008.05.075,,,,Inhibition of CYP3A4,O=C(O)[C@H](Cc1ccc(-n2c(C3(C(F)(F)F)CC3)nc3cccnc32)cc1)NC1=C(Br)C(=O)C12CCCCC2,"(S)-2-(2-Bromo-3-oxo-spiro[3.5]non-1-en-1-ylamino)-3-{4-[2-(1-trifluoromethyl-cyclopropyl)-imidazo[4,5-b]pyridin-3-yl]-phenyl}-propionic acid",10.0,uM,=,1.0,1,O=C1C=C(NCCc2ccc(-n3c(C4CC4)nc4cccnc43)cc2)C12CCCCC2
1971,1509544,10.1021/acs.jmedchem.5b00810,,,,Time dependent inhibition of CYP3A4 in human liver microsomes,COc1cc2c(cc1OC(C)C)[C@H](c1ccc(Cl)cc1)N(c1ccc(N(C)C[C@H]3CC[C@H](N4CCN(C)C(=O)C4)CC3)cc1)C(=O)C2,"(trans)-(S)-1-(4-Chloro-phenyl)-7-isopropoxy-6-methoxy-2-(4-{methyl-[4-(4-methyl-3-oxo-piperazin-1-yl)-cyclohexylmethyl]-amino}-phenyl)-1,4-dihydro-2H-isoquinolin-3-one",17.0,uM,=,1.230448921378274,1,O=C1CN([C@H]2CC[C@H](CNc3ccc(N4C(=O)Cc5ccccc5[C@@H]4c4ccccc4)cc3)CC2)CCN1
1972,471117,10.1016/j.bmc.2007.10.061,,,,Inhibition of CYP3A4,CN(C)C[C@H]1C[C@H](c2nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c3c(N)nccn32)C1,"trans-3-{3-[(dimethylamino)methyl]cyclobutyl}-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-8-ylamine",15.0,uM,=,1.1760912590556811,1,c1ccc(-c2ccc3ccc(-c4nc(C5CCC5)n5ccncc45)cc3n2)cc1
1973,51895,10.1016/j.bmcl.2003.09.093,,,,Inhibition of cytochrome P450 3A4 of isolated guinea pig heart,CCn1c2ccccc2c2cc(NC(=O)CN3CCN(C[C@@H](O)COc4ccc5sc(C)nc5c4)CC3)ccc21,N-(9-Ethyl-9H-carbazol-3-yl)-2-{4-[(R)-2-hydroxy-3-(2-methyl-benzothiazol-5-yloxy)-propyl]-piperazin-1-yl}-acetamide,39.0,uM,=,1.591064607026499,1,O=C(CN1CCN(CCCOc2ccc3scnc3c2)CC1)Nc1ccc2[nH]c3ccccc3c2c1
1974,1528904,,,,,"Homogenous Time-Resolved Fluorescence Assay (HTRF): The standard assay conditions for the in vitro HTRF assay consisted of a 50 ul total reaction volume in black 384-well Costar polypropylene plates in 1PBS buffer pH 7.4, 1 mM DTT, 0.1% BSA, 2.5 nM GST-hMDM2 (aa 1-188), 5 nM biotinylated-p53 (aa 1-83), 1.8 nM SA-XLent (Cisbio; Bedford, Mass.), 0.6 nM anti-GST cryptate monoclonal antibody (Cisbio; Bedford, Mass.) and 200 mM KF. Amino acid residues 1-188 of human MDM2 were expressed as an amino-terminal glutathione S-transferase (GST) fusion protein (GST-hMDM2) in Escherichia coli. Residues 1-83 of human p53 were expressed as an amino-terminal AviTag-TrxA-6His fusion protein (biotinylated p53) in E. coli. Each protein was purified from cell paste by affinity chromatography.Specifically, 10 uL of GST-hMDM2 was incubated with 10 ul of diluted compound (various concentrations, serially diluted) in 10% DMSO for 20 minutes at room temperature. 20 uL of biotinylated-p53 was added to the GST-hMDM2+compound mixture.",CC(C)(C)S(=O)(=O)C[C@H](C1CC1)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1,"2-((3R,5R,6S)-1-((S)-2-(tert-Butylsulfonyl)-1-cyclopropylethyl)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-3-methyl-2-oxopiperidin-3-yl)acetic Acid",9.62e-05,uM,=,-4.016824927962187,0,O=C1CC[C@H](c2ccccc2)[C@@H](c2ccccc2)N1CC1CC1
1975,988989,10.1021/jm400732v,,,,Inhibition of CYP3A4 (unknown origin),CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)CC(C)C)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O.Cl,"(S)-N-((S)-1-((6-Bromo-2-methoxynaphthalen-1-yl)methyl)-5-(3-methylbutanoyl)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-yl)-2-(methylamino)propanamide hydrochloride",1.1,uM,=,0.041392685158225,1,O=C1CCNc2ccccc2N1Cc1cccc2ccccc12
1976,598210,10.1016/j.bmcl.2009.08.024,,,,Inhibition of human CYP3A4,CC1(CC(=O)NCc2ccc3c(c2)OCC3)CC2(CCCCC2)OO1,"N-((2,3-dihydrobenzofuran-6-yl)methyl)-2-(3-methyl-1,2-dioxaspiro[4.5]decan-3-yl)acetamide",2.6,uM,=,0.414973347970818,1,O=C(CC1CC2(CCCCC2)OO1)NCc1ccc2c(c1)OCC2
1977,950702,10.1021/jm400288z,,,,Inhibition of C-terminal His-tagged wild type CYP3A4 (unknown origin)-mediated hydroxylation of 7-benzyloxy-4-trifluoromethylcoumarin expressed in Escherichia coli after 5 mins by fluorimetric analysis,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cnc[nH]2)Cc2ccccc2)C(C)C)cs1,"(1H-Imidazol-5-yl)methyl(2R,5R)-5-((S)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-3-methylbutanamido)-1,6-diphenylhexan-2-ylcarbamate",0.28,uM,=,-0.5528419686577808,0,O=C(CNC(=O)NCc1cscn1)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cnc[nH]1)Cc1ccccc1
1978,813216,10.1016/j.bmcl.2012.01.125,,,,Inhibition of CYP3A4,COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n(-c3ccccc3OC(F)(F)F)c12,"7-(3,5-dimethylisoxazol-4-yl)-8-methoxy-1-(2-(trifluoromethoxy)phenyl)-1H-imidazo[4,5-c]quinolin-2(3H)-one",2.0,uM,=,0.3010299956639812,1,O=c1[nH]c2cnc3cc(-c4cnoc4)ccc3c2n1-c1ccccc1
1979,988447,10.1016/j.bmcl.2013.08.013,,,,Inhibition of CYP3A4 in human liver microsomes,Nc1cc(CN2CCC(F)(C(=O)N3CCC(N4Cc5ccccc5Cc5ccccc54)CC3)CC2)ccn1,"(1-((2-aminopyridin-4-yl)methyl)-4-fluoropiperidin-4-yl)(4-(6,11-dihydro-5H-dibenzo[b,e]azepin-5-yl)piperidin-1-yl)methanone",18.0,uM,=,1.255272505103306,1,O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(N2Cc3ccccc3Cc3ccccc32)CC1
1980,776446,10.1016/j.bmcl.2011.05.014,,,,Inhibition of CYP3A4,COCCCc1cc(CN(C(=O)C2CNCCC2(O)c2ccc(F)c(F)c2)C2CC2)cc(OCCOC)c1,"N-cyclopropyl-4-(3,4-difluorophenyl)-4-hydroxy-N-(3-(2-methoxyethoxy)-5-(3-methoxypropyl)benzyl)piperidine-3-carboxamide",0.9,uM,=,-0.0457574905606751,0,O=C(C1CNCCC1c1ccccc1)N(Cc1ccccc1)C1CC1
1981,676065,10.1016/j.bmcl.2010.09.028,,,,Inhibition of CYP3A4 after 30 mins,CC(C)[C@@H]1COC[C@H](C2(OC(=O)N3CC[C@@H](O)C3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1,"(R)-1-((3R,5R)-4-(4-chlorophenylsulfonyl)-5-isopropylmorpholin-3-yl)cyclopropyl 3-hydroxypyrrolidine-1-carboxylate",0.0136,uM,=,-1.8664610916297824,0,O=C(OC1([C@H]2COCCN2S(=O)(=O)c2ccccc2)CC1)N1CCCC1
1982,1625607,10.1016/j.bmcl.2016.10.016,,,,Inhibition of human Cyp3A4 using testosterone as substrate by LC-MS/MS analysis,CCS(=O)(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,"1-(4-{[(2S,4R)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)-4-(ethanesulfonyl)piperazine",0.162,uM,=,-0.790484985457369,0,c1ccc([C@]2(Cn3ccnc3)OC[C@@H](COc3ccc(N4CCNCC4)cc3)O2)cc1
1983,1660136,10.1021/acs.jmedchem.6b01918,,,,Inhibition of human CYP3A4 assessed as inhibition of dealkylation,N[C@H]1CC[C@@H](CCNc2cc(F)c(S(=O)(=O)Nc3nccs3)cc2Cl)CC1,"cis-4-((2-((1S,4S)-4-Aminocyclohexyl)ethyl)amino)-5-chloro-2-fluoro-N-(thiazol-2-yl)benzenesulfonamide",20.0,uM,=,1.3010299956639813,1,O=S(=O)(Nc1nccs1)c1ccc(NCCC2CCCCC2)cc1
1984,51903,10.1021/jm020557k,,,,Concentration required to inhibit cytochrome P450 3A4.,CCCCOc1ccc(-c2ccncc2)cc1,4-(4-Butoxy-phenyl)-pyridine,51.1,uM,=,1.7084209001347128,1,c1ccc(-c2ccncc2)cc1
1985,1433750,10.1016/j.bmcl.2014.10.007,,,,Inhibition of recombinant CYP3A4 (unknown origin) after 3 mins by LC-MS/MS analysis,COc1ccc(-c2nc(CS(=O)(=O)c3cccc(Cl)c3)nc3ccsc23)cn1,"2-((3-chlorophenylsulfonyl)methyl)-4-(6-methoxypyridin-3-yl)thieno[3,2-d]pyrimidine",6.71,uM,=,0.8267225201689921,1,O=S(=O)(Cc1nc(-c2cccnc2)c2sccc2n1)c1ccccc1
1986,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N(C)CCCO)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, F-5",3.68,uM,=,0.5658478186735176,1,O=C1[C@H](Cc2ccccc2)N2C(=O)CNN(C(=O)NCc3ccccc3)[C@H]2CN1Cc1cccc2cc[nH]c12
1987,1661018,10.1016/j.bmcl.2017.02.047,,,,Inhibition of recombinant human CYP3A4 expressed in baculosomes using Vivid BOMR substrate red measured every 30 sec for 30 mins by fluorescence assay,CCCCC/C=C/C(=O)CCc1ccc(O)c(OC)c1,(E)-1-(4-Hydroxy-3-methoxy-phenyl)-dec-4-en-3-one,4.0,uM,=,0.6020599913279624,1,c1ccccc1
1988,305432,10.1016/j.bmcl.2005.01.044,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,CC(C(c1ccc2cc(OCc3ccc(OC(C)(C)C)cc3)ccc2c1)n1ccnc1)N(C)C,{2-[6-(4-tert-Butoxy-benzyloxy)-naphthalen-2-yl]-2-imidazol-1-yl-1-methyl-ethyl}-dimethyl-amine,0.58,uM,=,-0.2365720064370627,0,c1ccc(COc2ccc3cc(Cn4ccnc4)ccc3c2)cc1
1989,945618,10.1016/j.bmc.2012.11.058,,,,Inhibition of CYP3A4 (unknown origin),N#Cc1cc(NS(=O)(=O)c2ccc(Cl)cc2Cl)ccc1Oc1cncc(Cl)c1,"2,4-Dichloro-N-(4-(5-chloropyridin-3-yloxy)-3-cyanophenyl)benzenesulfonamide",0.6,uM,=,-0.2218487496163563,0,O=S(=O)(Nc1ccc(Oc2cccnc2)cc1)c1ccccc1
1990,598210,10.1016/j.bmcl.2009.08.024,,,,Inhibition of human CYP3A4,CC1(CC(=O)NCc2cccc(Cl)c2)CC2(CCCCC2)OO1,"N-(3-chlorobenzyl)-2-(3-methyl-1,2-dioxaspiro[4.5]decan-3-yl)acetamide",4.9,uM,=,0.6901960800285137,1,O=C(CC1CC2(CCCCC2)OO1)NCc1ccccc1
1991,2026995,10.1021/acs.jmedchem.6b01099,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy resorufin as substrate,O=C(O)C1CN(Cc2ccc3c(c2)CCc2c-3noc2-c2onc(-c3ccccc3)c2C(F)(F)F)C1,"US9216972, 7",14.0,uM,=,1.146128035678238,1,c1ccc(-c2cc(-c3onc4c3CCc3cc(CN5CCC5)ccc3-4)on2)cc1
1992,632105,10.1016/j.bmcl.2010.03.057,,,,Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin,Cc1cc(N2CCN(CCF)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,(S)-4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-3-(6-(4-(2-fluoroethyl)piperazin-1-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one,2.2,uM,=,0.3424226808222063,1,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(N3CCNCC3)cc2[nH]1
1993,643713,10.1016/j.bmcl.2010.06.009,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader,C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(N5CCN(C)CC5)c4)ccc32)sc1C(N)=O)c1ccccc1Cl,(R)-3-(1-(2-chlorophenyl)ethoxy)-5-(5-(2-(4-methylpiperazin-1-yl)pyridin-4-yl)-1H-benzo[d]imidazol-1-yl)thiophene-2-carboxamide,27.0,uM,=,1.4313637641589874,1,c1ccc(COc2csc(-n3cnc4cc(-c5ccnc(N6CCNCC6)c5)ccc43)c2)cc1
1994,1291572,10.1016/j.bmcl.2013.12.058,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@H](CC(=O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1,"Thiazol-5-ylmethyl(2S,5S)-5-((S)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-3-methylbutanamido)-3-oxo-1,6-diphenylhexan-2-ylcarbamate",0.28,uM,=,-0.5528419686577808,0,O=C(CNC(=O)NCc1cscn1)N[C@H](CC(=O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
1995,539794,10.1021/jm8005405,,,,Inhibition of CYP3A4 in human liver microsomes,CC(C)Nc1noc2c(-c3ccc4c(N5CCOC[C@@H]5C)nncc4c3)c(Cl)ccc12,6-Chloro-N-isopropyl-7-(1-((S)-3-methylmorpholino)phthalazin-6-yl)benzo[d]isoxazol-3-amine,4.5,uM,=,0.6532125137753437,1,c1cc(-c2ccc3c(N4CCOCC4)nncc3c2)c2oncc2c1
1996,1528904,,,,,"Homogenous Time-Resolved Fluorescence Assay (HTRF): The standard assay conditions for the in vitro HTRF assay consisted of a 50 ul total reaction volume in black 384-well Costar polypropylene plates in 1PBS buffer pH 7.4, 1 mM DTT, 0.1% BSA, 2.5 nM GST-hMDM2 (aa 1-188), 5 nM biotinylated-p53 (aa 1-83), 1.8 nM SA-XLent (Cisbio; Bedford, Mass.), 0.6 nM anti-GST cryptate monoclonal antibody (Cisbio; Bedford, Mass.) and 200 mM KF. Amino acid residues 1-188 of human MDM2 were expressed as an amino-terminal glutathione S-transferase (GST) fusion protein (GST-hMDM2) in Escherichia coli. Residues 1-83 of human p53 were expressed as an amino-terminal AviTag-TrxA-6His fusion protein (biotinylated p53) in E. coli. Each protein was purified from cell paste by affinity chromatography.Specifically, 10 uL of GST-hMDM2 was incubated with 10 ul of diluted compound (various concentrations, serially diluted) in 10% DMSO for 20 minutes at room temperature. 20 uL of biotinylated-p53 was added to the GST-hMDM2+compound mixture.",COc1cc(NC(=O)C[C@@]2(C)C[C@H](c3cccc(Cl)c3)[C@@H](c3ccc(Cl)cc3)N([C@H](CS(=O)(=O)C(C)(C)C)C3CC3)C2=O)ccc1C(=O)O,"4-(2-((3R,5R,6S)-1-((S)-2-(tert-butylsulfonyl)-1-cyclopropylethyl)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-3-methyl-2-oxopiperidin-3-yl)acetamido)-2-methoxybenzoic acid",5.03e-05,uM,=,-4.298432014944073,0,O=C(CC1C[C@H](c2ccccc2)[C@@H](c2ccccc2)N(CC2CC2)C1=O)Nc1ccccc1
1997,1474044,10.1021/jm501740a,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,CC(C)CC(NC(=O)c1ccc2[nH]nc(-c3ccc(O[C@H]4C[C@H]5CC[C@@H](C4)N5C=O)cc3)c2c1)c1ccccn1,rac-3-((4-((endo)-8-Formyl-8-azabicyclo[3.2.1]octan-3-yl)oxy)-phenyl)-N-(3-methyl-1-(pyridin-2-yl)butyl)-1H-indazole-5-carboxamide,0.41,uM,=,-0.3872161432802645,0,O=C(NCc1ccccn1)c1ccc2[nH]nc(-c3ccc(O[C@H]4C[C@H]5CC[C@@H](C4)N5)cc3)c2c1
1998,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCC(N7CCCC7)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1,"US8940739, G-51",3.97,uM,=,0.5987905067631151,1,O=C(Nc1ccc(N2CCC(N3CCCC3)CC2)nc1)c1c[nH]c2c(CN3CC4N(C(=O)NCc5ccccc5)NCC(=O)N4C(Cc4ccccc4)C3=O)cccc12
1999,1924271,10.1016/j.bmcl.2016.06.048,,,,Inhibition of CYP3A4 (unknown origin),Cc1nc2c(c(-c3ccn[nH]3)n1)C[C@@H](C)N(C(=O)c1cccc(C(F)(F)F)c1Cl)C2,"US9096596, 58",3.3,uM,=,0.5185139398778875,1,O=C(c1ccccc1)N1CCc2c(ncnc2-c2ccn[nH]2)C1
2000,1985638,10.1021/acsmedchemlett.0c00095,,,,Inhibition of human CYP3A4,Cc1cc(-c2cc(-c3nnc[nH]3)c3nc(C)n(-c4ccnc5c(F)ccc(F)c45)c3c2)ccn1,"(P)-5,8-difluoro-4-(2-methyl-6-(2-methylpyridin-4-yl)-4-(4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-1-yl)quinoline",19.0,uM,=,1.2787536009528289,1,c1ccc2c(-n3cnc4c(-c5nnc[nH]5)cc(-c5ccncc5)cc43)ccnc2c1
2001,379074,10.1016/j.bmcl.2006.05.049,,,,Inhibition of CYP3A4,CCOc1ccccc1C[C@@H](c1ccccc1)N1CCNCC1.Cl,(S)-1-(2-(2-ethoxyphenyl)-1-phenylethyl)piperazine hydrochloride,10.0,uM,=,1.0,1,c1ccc(C[C@@H](c2ccccc2)N2CCNCC2)cc1
2002,802673,10.1016/j.bmcl.2011.12.125,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,O=C(Nc1ccc(-c2ccnc3[nH]cnc23)cc1)Nc1cccc(F)c1,"1-(4-(3H-imidazo[4,5-b]pyridin-7-yl)phenyl)-3-(3-fluorophenyl)urea",0.71,uM,=,-0.1487416512809247,0,O=C(Nc1ccccc1)Nc1ccc(-c2ccnc3[nH]cnc23)cc1
2003,1459302,10.1016/j.bmc.2014.06.027,,,,Inhibition of CYP3A4 in supersomes (unknown origin) using Dibenzylfluorescein as substrate after 10 mins,CCc1cccc(CC)c1NC(=O)Nc1ccc2[nH]nc(-c3cccc(S(N)(=O)=O)c3)c2c1,"3-(5-(3-(2,6-Diethylphenyl)ureido)-1H-indazol-3-yl)benzenesulfonamide",10.0,uM,=,1.0,1,O=C(Nc1ccccc1)Nc1ccc2[nH]nc(-c3ccccc3)c2c1
2004,1660136,10.1021/acs.jmedchem.6b01918,,,,Inhibition of human CYP3A4 assessed as inhibition of dealkylation,N[C@H]1CC[C@@H](CNc2cc(F)c(S(=O)(=O)Nc3nccs3)cc2Cl)CC1,"cis-4-((((1S,4S)-4-Aminocyclohexyl)methyl)amino)-5-chloro-2-fluoro-N-(thiazol-2-yl)benzenesulfonamide",20.0,uM,=,1.3010299956639813,1,O=S(=O)(Nc1nccs1)c1ccc(NCC2CCCCC2)cc1
2005,510198,10.1021/jm800355c,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,Cl.Fc1ccc(-c2ccc3c(c2)CCC=C3c2ccncc2)cc1F,"4-(6-(3,4-Difluorophenyl)-3,4-dihydronaphthalen-1-yl)pyridine Hydrochloride",3.643,uM,=,0.5614591712419159,1,C1=C(c2ccncc2)c2ccc(-c3ccccc3)cc2CC1
2006,1586157,10.1016/j.bmcl.2016.06.021,,,,Inhibition of CYP3A4 (unknown origin),Cc1cc(-c2cnn3c(NCC4CCOCC4)nc(Oc4ccccc4)nc23)ccc1C(=O)NC1CC1,"N-cyclopropyl-2-methyl-4-(2-phenoxy-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)pyrazolo[1,5-a][1,3,5]triazin-8-yl)benzamide",0.8,uM,=,-0.0969100130080563,0,O=C(NC1CC1)c1ccc(-c2cnn3c(NCC4CCOCC4)nc(Oc4ccccc4)nc23)cc1
2007,993439,10.6019/CHEMBL2448688,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,CO/N=C(\C)c1ccc(-n2ccnc2)c(NC(=O)c2ccc(-c3cccs3)nc2)c1,,1.4,uM,=,0.1461280356782379,1,O=C(Nc1ccccc1-n1ccnc1)c1ccc(-c2cccs2)nc1
2008,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2cccnn2)c1,"US9150566, 48",9.6,uM,=,0.9822712330395684,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2cccnn2)c1
2009,1553516,10.1016/j.bmc.2016.02.006,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins by LC-MS analysis,CC1(C)CCc2cc(S(=O)(=O)N(CC(=O)O)C3(c4cccc(-c5cc(Cl)cc(Cl)c5)c4)CCC3)ccc2O1,"2-(N-(1-(3',5'-Dichlorobiphenyl-3-yl)cyclobutyl)-2,2-dimethylchroman-6-sulfonamido)acetic acid",9.0,uM,=,0.9542425094393248,1,O=S(=O)(NC1(c2cccc(-c3ccccc3)c2)CCC1)c1ccc2c(c1)CCCO2
2010,1534761,,,,,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",COc1cnc2[nH]cc(Cc3cnc(NCc4ccc(C(F)(F)F)nc4)c(F)c3)c2c1,"US9096593, P-2147",5.0,uM,=,0.6989700043360189,1,c1cncc(CNc2ccc(Cc3c[nH]c4ncccc34)cn2)c1
2011,1275523,10.1016/j.bmcl.2013.09.094,,,,Inhibition of CYP3A4 (unknown origin),Cc1ccccc1[C@H]1C[C@@H](NCc2ccc(Cl)cc2)CC[C@@H]1C(=O)N1CC(c2ccccc2)(c2ccccc2)C1,"((1S,2S,4S)-4-(4-chlorobenzylamino)-2-o-tolylcyclohexyl)(3,3-diphenylazetidin-1-yl)methanone",25.0,uM,=,1.3979400086720375,1,O=C([C@H]1CC[C@H](NCc2ccccc2)C[C@@H]1c1ccccc1)N1CC(c2ccccc2)(c2ccccc2)C1
2012,544163,10.1016/j.bmcl.2008.11.032,,,,Inhibition of CYP3A4,O=C(O)c1cccc(C2=C(c3cc(Cl)ccc3OCc3ccc(F)cc3F)CCC2)n1,"6-(2-(2-(2,4-difluorobenzyloxy)-5-chlorophenyl)cyclopent-1-enyl)picolinic acid",89.0,uM,=,1.9493900066449128,1,c1ccc(COc2ccccc2C2=C(c3ccccn3)CCC2)cc1
2013,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",C[C@@H]1CN(C(=O)c2ccc(Cl)cc2-n2nccn2)[C@H](Cc2cc(-n3nccn3)ccc2F)CO1,"US9150566, 187",14.0,uM,=,1.146128035678238,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
2014,982382,10.1016/j.bmcl.2013.07.071,,,,Inhibition of CYP3A4 (unknown origin),COC[C@@H](Oc1cc(C[C@@H]2C[S@@+]([O-])C[C@H](NCc3cccc(C(C)(C)CO)c3)[C@H]2O)cc(F)c1N)C(F)(F)F,"(1R,3S,4S,5R)-3-[4-Amino-3-fluoro-5-((R)-2,2,2-trifluoro-1-methoxymethyl-ethoxy)-benzyl]-5-[3-(2-hydroxy-1,1-dimethyl-ethyl)-benzylamino]-1-oxo-tetrahydro-thiopyran-4-ol",1.0,uM,=,0.0,0,c1ccc(CN[C@H]2C[SH+]C[C@@H](Cc3ccccc3)C2)cc1
2015,2134029,10.1021/acs.jmedchem.1c00959,,,,Inhibition of CYP3A4 (unknown origin),COc1ccc([C@H]2C[C@H](C(=O)O)C2)cc1-c1ccc(C(F)(F)F)cc1[C@@H]1CC[C@H]2[C@@H](c3cc(C(F)(F)F)cc(C(F)(F)F)c3)OC(=O)N12,"US8871738, 8",6.0,uM,=,0.7781512503836436,1,O=C1O[C@H](c2ccccc2)[C@@H]2CC[C@@H](c3ccccc3-c3cccc(C4CCC4)c3)N12
2016,1640769,,,,,"Fluorescent High Throughput P450 Assays: The interaction of SC12 with cytochrome P450 enzymes was tested using Fluorescent High Throughput P450 assays (Gentest); The IC50s of the compounds was calculated on isoenzymes (CYP1A2, CYP2C9, CYP2C19, CYP2C8, CYP2B6, CYP2D6, CYP2E1, CYP3A4 and CYP3A5).Materials and Methods: Inhibition of the P450 isoforms was measured in specific assays using specific substrates that become fluorescent upon CYP metabolism. Compounds, dissolved in ACN (acetonitrile) (CYP2E1, CYP2C8, CYP2B6, CYP3A5) or DMSO (all remaining isoforms), were tested in duplicate (n=2) in concentration-response curves (eight concentrations) in a 96-well plate containing incubation/NADPH regenerating buffer. Specific isoenzymes and substrates were added and incubated at 37° C. Reactions were terminated at different times, depending on the assays, and plates read on a Fluoroskan Ascent at the appropriate emission/excitation wavelengths.",CCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCCNC(=O)c1ccc(Cn2c(=O)[nH]c3c(N)nc(OCCOC)nc32)cc1)OC(=O)CCCCCCCCCCC,"US9180183, SC12",13.6,uM,=,1.1335389083702174,1,O=c1[nH]c2cncnc2n1Cc1ccccc1
2017,2246941,10.1021/acs.jmedchem.1c02132,,,,Inhibition of CYP3A4 (unknown origin) incubated for 10 mins in presence of NADPH by LC-MS/MS analysis,CC(=O)Nc1cc(-c2ccc(OC[C@@H](N)CC(C)C)c(C#N)c2)ccn1,(S)-N-(4-(4-(2-amino-4-methylpentyloxy)-3-cyanophenyl)pyridin-2-yl)acetamide,2.6,uM,=,0.414973347970818,1,c1ccc(-c2ccncc2)cc1
2018,857201,10.1021/jm200900q,,,,Inhibition of CYP3A4,N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(C(=O)c4cccnc4)CC3)cc2C2=CCCCC2)n1,4-Cyano-1H-imidazole-2-carboxylic Acid{2-Cyclohex-1-enyl-4-[1-(pyridine-3-carbonyl)-piperidin-4-yl]-phenyl}-amide,6.1,uM,=,0.785329835010767,1,O=C(Nc1ccc(C2CCN(C(=O)c3cccnc3)CC2)cc1C1=CCCCC1)c1ncc[nH]1
2019,1527876,,,,,Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,CC[C@@H](c1ccc(-c2ccc(=O)n(CC)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O,"US8575157, 52",48.0,uM,=,1.6812412373755872,1,O=C1OC(c2ccccc2)CCN1Cc1ccc(-c2ccc(=O)[nH]c2)cc1
2020,449485,10.1016/j.bmcl.2007.07.097,,,,Inhibition of microsomal CYP3A4,CC(C)C[C@H](NCCCC(=O)O)c1cc(F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1,"4-((S)-1-(2-(4-((R)-3-(2,4-dichlorophenyl)-2-(2-oxopyrrolidin-1-yl)propanoyl)piperazin-1-yl)-5-fluorophenyl)-3-methylbutylamino)butanoic acid",21.0,uM,=,1.3222192947339193,1,O=C([C@@H](Cc1ccccc1)N1CCCC1=O)N1CCN(c2ccccc2)CC1
2021,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCc5ccnc(N(C)C)c5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, F-48",2.18,uM,=,0.3384564936046048,1,O=C(NCc1ccncc1)c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12
2022,1838768,10.1021/acsmedchemlett.9b00431,,,,Inhibition of CYP3A4 (unknown origin),O=C(O)c1ccc(-c2nn(C(=O)c3c(Cl)cccc3C(F)(F)F)c3cnccc23)c(F)c1,"4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]pyrazolo[3,4-c]pyridin-3-yl]-3-fluoro-benzoic acid",4.8,uM,=,0.6812412373755872,1,O=C(c1ccccc1)n1nc(-c2ccccc2)c2ccncc21
2023,2240607,10.1021/acs.jmedchem.2c01497,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate in presence of NADPH,CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,SID144204227,0.0338,uM,=,-1.4710832997223453,0,c1ccc([C@@]2(Cn3ccnc3)OC[C@H](COc3ccc(N4CCNCC4)cc3)O2)cc1
2024,1919651,,,,,"Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase",Cc1nccn1-c1cccnc1,3-(2-Methyl-imidazol-1-yl)-pyridine,152.0,uM,=,2.1818435879447726,1,c1cncc(-n2ccnc2)c1
2025,1577486,10.1021/acs.jmedchem.5b01712,,,,Inhibition of CYP3A4 (unknown origin),CCN1CCN(Cc2ccc(NC(=O)CNc3ccc(-c4ccc(NC(C)=O)nc4)cc3)cc2C(F)(F)F)CC1,2-(4-(6-Acetamidopyridin-3-yl)phenylamino)-N-(4-((4-ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)-phenyl)acetamide,3.2,uM,=,0.505149978319906,1,O=C(CNc1ccc(-c2cccnc2)cc1)Nc1ccc(CN2CCNCC2)cc1
2026,2221809,10.1016/j.bmcl.2022.128625,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as substrate in presence of NADPH,CCC[C@H]1N(C(=O)c2cnccc2C(F)(F)F)CCC[C@@]1(Oc1csc(C(F)(F)F)c1)C(=O)N1CCN(c2ccccc2OC)CC1,"(4-(2-methoxyphenyl)piperazin-1-yl)((2R,3S)-2-propyl-1-(4-(trifluoromethyl)nicotinoyl)-3-(5-(trifluoromethyl)thiophen-3-yloxy)piperidin-3-yl)methanone",10.0,uM,=,1.0,1,O=C(c1cccnc1)N1CCC[C@@](Oc2ccsc2)(C(=O)N2CCN(c3ccccc3)CC2)C1
2027,1301328,10.6019/CHEMBL3137440,,,,DNDI: CYP Inhibition,CN(C)S(=O)(=O)c1ccccc1N1CCC(N(c2ccc(C#N)cc2)c2cccnc2)CC1,,2.0,uM,=,0.3010299956639812,1,c1ccc(N2CCC(N(c3ccccc3)c3cccnc3)CC2)cc1
2028,1456481,10.1021/jm5001979,,,,Inhibition of CYP3A4 (unknown origin),Cn1cc(-c2cc(C(O)(C(F)(F)F)C(F)(F)F)cnc2N2CCN(S(=O)(=O)c3ccc(N)nc3)CC2)cn1,"2-(6-(4-((6-Aminopyridin-3-yl)sulfonyl)piperazin-1-yl)-5-(1-methyl-1H-pyrazol-4-yl)pyridin-3-yl)-1,1,1,3,3,3-hexafluoropropan-2-ol",27.0,uM,=,1.4313637641589874,1,O=S(=O)(c1cccnc1)N1CCN(c2ncccc2-c2cn[nH]c2)CC1
2029,851921,10.1016/j.bmcl.2012.08.072,,,,Inhibition of human recombinant CYP3A4,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccc(F)c(Br)c1,"N-(3-bromo-4-fluorophenyl)-2-(4-morpholino-6-oxo-1,6-dihydropyrimidin-2-yl)acetamide",40.0,uM,=,1.6020599913279625,1,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccccc1
2030,555225,10.1016/j.bmcl.2008.05.058,,,,Inhibition of CYP3A4,CN(C(=O)CN1C(=O)COc2cc(Cl)c(Cl)cc21)C(CN1CCOCC1)c1ccc(-c2ccccc2)cc1,"(+/-)N-(1-Biphenyl-4-yl-2-morpholin-4-yl-ethyl)-2-(6,7-dichloro-3-oxo-2,3-dihydro-benzo[1,4]oxazin-4-yl)-N-methyl-acetamide",4.6,uM,=,0.6627578316815741,1,O=C(CN1C(=O)COc2ccccc21)NC(CN1CCOCC1)c1ccc(-c2ccccc2)cc1
2031,1528565,,,,,"Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",CC(=O)N[C@H]1C[C@@H](C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)N(C(=O)N(C)Cc2csc(C(C)C)n2)C1,"US8987313, 36",0.37,uM,=,-0.431798275933005,0,O=C(N[C@H](CC[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)NCc1cscn1)Cc1ccccc1)OCc1cncs1
2032,943410,10.1021/jm400194n,,,,Time dependent inhibition of human CYP3A4 preincubated for 30 mins in presence of NADPH,CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOC[C@@H]4C)n2)[C@H]2CC[C@@H](C3)N2S(C)(=O)=O)cc1,"1-Ethyl-3-(4-((5R,8S)-4-((S)-3-methylmorpholino)-10-(methylsulfonyl)-6,7,8,9-tetrahydro-5H-5,8-epiminocyclohepta[d]-pyrimidin-2-yl)phenyl)urea",5.0,uM,=,0.6989700043360189,1,c1ccc(-c2nc3c(c(N4CCOCC4)n2)[C@H]2CC[C@@H](C3)N2)cc1
2033,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2C(CN(Cc3cccc4c(C(=O)Nc5ccc(NCCN6CCC(O)CC6)nc5)cn(C)c34)C(=O)[C@@H]2Cc2ccc(O)cc2)N1C(=O)NCc1ccccc1,"US8940739, G-29",5.8,uM,=,0.7634279935629373,1,O=C(Nc1ccc(NCCN2CCCCC2)nc1)c1c[nH]c2c(CN3CC4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12
2034,1581098,10.1021/acsmedchemlett.6b00064,,,,Inhibition of CYP3A4 (unknown origin),O=C(Nc1ccn(-c2cn(Cc3cccc(C(F)(F)F)c3)cn2)c(=O)c1)c1cscn1,"N-(2-oxo-1-(1-(3-(trifluoromethyl)benzyl)-1H-imidazol-4-yl)-1,2-dihydropyridin-4-yl)thiazole-4-carboxamide",1.9,uM,=,0.2787536009528289,1,O=C(Nc1ccn(-c2cn(Cc3ccccc3)cn2)c(=O)c1)c1cscn1
2035,775863,10.1016/j.bmcl.2011.09.037,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH,CN1CCN(C(=O)[C@@H](COCc2ccnc(Cl)c2)NC(=O)c2cccnc2Oc2ccc(C(F)(F)F)cc2Cl)CC1,(R)-2-(2-chloro-4-(trifluoromethyl)phenoxy)-N-(3-((2-chloropyridin-4-yl)methoxy)-1-(4-methylpiperazin-1-yl)-1-oxopropan-2-yl)nicotinamide,11.0,uM,=,1.0413926851582251,1,O=C(N[C@H](COCc1ccncc1)C(=O)N1CCNCC1)c1cccnc1Oc1ccccc1
2036,349088,10.1016/j.bmcl.2006.01.084,,,,Inhibition of CYP3A4 using BFC fluorogenic substrate,COc1ccccc1COCCCOc1ccc(N2C(=O)CNC[C@@H]2COc2ccc3c(c2)N(CCNC(C)=O)CCC3)cc1,"N-{2-[7-((R)-1-{4-[3-(2-Methoxy-benzyloxy)-propoxy]-phenyl}-6-oxo-piperazin-2-ylmethoxy)-3,4-dihydro-2H-quinolin-1-yl]-ethyl}-acetamide",0.082,uM,=,-1.0861861476162833,0,O=C1CNC[C@H](COc2ccc3c(c2)NCCC3)N1c1ccc(OCCCOCc2ccccc2)cc1
2037,1497735,10.1021/jm5020023,,,,Inhibition of human recombinant CYP3A4 using midazolam as substrate after 1 hr by LC-MS/MS analysis,CC1(C)CC[C@]23CC[C@@]4(C)[C@]5(C)CC[C@H]6C(C)(C)C(=O)C(C#N)=C[C@]6(C)C5=CC(=O)[C@@]4([C@@H]2C1)N(C1CCCCC1)C3=O,"(1S,4S,5R,8R,13S,17S,18R)-24-cyclohexyl-4,5,9,9,13,20,20-heptamethyl-10,16,23-trioxo-24-azahexacyclo[15.5.2.0^{1,18}.0^{4,17}.0^{5,14}.0^{8,13}]tetracosa-11,14-diene-11-carbonitrile",0.932,uM,=,-0.0305840876460186,0,O=C1C=CC2C3=CC(=O)[C@@]45C(CC[C@]6(CCCC[C@H]64)C(=O)N5C4CCCCC4)C3CC[C@H]2C1
2038,526157,10.1021/np0401765,,,,Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation,COc1cc(C[C@H]2C(O)OC[C@@H]2Cc2ccc3c(c2)OCO3)cc(OC)c1OC,(-)-clusin,0.83,uM,=,-0.0809219076239261,0,c1ccc(C[C@H]2COC[C@@H]2Cc2ccc3c(c2)OCO3)cc1
2039,1614025,10.1016/j.bmcl.2016.09.043,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 6-beta-hydroxytestosterone metabolite formation using testosterone as substrate incubated for 30 mins by HPLC-MS method,Cn1c(NCCc2ccc(-c3ncccn3)cc2)nc2cc(Cl)ccc2c1=O,7-Chloro-3-methyl-2-[2-(4-pyrimidin-2-yl-phenyl)-ethylamino]-3H-quinazolin-4-one,5.4,uM,=,0.7323937598229685,1,O=c1[nH]c(NCCc2ccc(-c3ncccn3)cc2)nc2ccccc12
2040,755481,10.1016/j.bmcl.2010.05.018,,,,Inhibition of CYP3A4 using diethoxyflourescein as a substrate,Cc1nc(-c2ccc(F)cc2F)n(C)c1CC(=O)NCc1ccc(F)cc1Cl.Cl,"N-(2-chloro-4-fluorobenzyl)-2-(2-(2,4-difluorophenyl)-1,4-dimethyl-1H-imidazol-5-yl)acetamide hydrochloride",5.5,uM,=,0.7403626894942439,1,O=C(Cc1cnc(-c2ccccc2)[nH]1)NCc1ccccc1
2041,1446329,10.1021/ml500387y,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1[nH]c2cnccc2c1C)C(F)(F)F,"1,1,1-trifluoro-4-(5-fluoro-2-methylphenyl)-4-methyl-2-((3-methyl-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)pentan-2-ol",3.8,uM,=,0.5797835966168101,1,c1ccc(CCCCc2cc3ccncc3[nH]2)cc1
2042,321462,10.1016/j.bmcl.2005.06.056,,,,Inhibition against Cytochrome P450 3A4 prepared from baculovirus-infected insect cells using resorufin benzyl ether,N#CCn1c(=O)c(CCO)c(-c2cc(Cl)ccc2O)c2cc(C(F)(F)F)ccc21,[4-(5-Chloro-2-hydroxy-phenyl)-3-(2-hydroxy-ethyl)-2-oxo-6-trifluoromethyl-2H-quinolin-1-yl]-acetonitrile,18.0,uM,=,1.255272505103306,1,O=c1cc(-c2ccccc2)c2ccccc2[nH]1
2043,1655304,10.1021/acsmedchemlett.6b00491,,,,Inhibition of CYP3A4 using in human liver microsomes using testosterone as substrate after 5 to 15 mins,CC(C)n1nccc1-c1ncccc1COc1cccc(O)c1C=O,2-Hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde,12.5,uM,=,1.0969100130080565,1,c1ccc(OCc2cccnc2-c2ccn[nH]2)cc1
2044,1923841,10.1021/acs.jmedchem.6b00280,,,,Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase and human b5 reductase assessed as reduction in 7-Hydroxyquinoline production using 7-benzyloxyquinoline as substrate and NADPH incubated for 15 mins by fluorimetry,O=C(NCCN1CCOCC1)Nc1nc2ccc(Sc3nnc4ccc(OC5CCCCCC5)nn34)cc2s1,"1-(6-(6-(cycloheptyloxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-ylthio)benzo[d]thiazol-2-yl)-3-(2-morpholinoethyl)urea",14.0,uM,=,1.146128035678238,1,O=C(NCCN1CCOCC1)Nc1nc2ccc(Sc3nnc4ccc(OC5CCCCCC5)nn34)cc2s1
2045,510198,10.1021/jm800355c,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,Br.Oc1ccc(-c2ccc3c(c2)CCC=C3c2ccncc2)cc1O,"4-(5-(Pyridin-4-yl)-7,8-dihydronaphthalen-2-yl)benzene-1,2-diol Hydrobromidebr",0.357,uM,=,-0.4473317838878068,0,C1=C(c2ccncc2)c2ccc(-c3ccccc3)cc2CC1
2046,857201,10.1021/jm200900q,,,,Inhibition of CYP3A4,CN(C)CC(=O)N1CCC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CC1,4-Cyano-1H-imidazole-2-carboxylic Acid{2-Cyclohex-1-enyl-4-[1-(2-dimethylamino-acetyl)-piperidin-4-yl]-phenyl}-amide,4.8,uM,=,0.6812412373755872,1,O=C(Nc1ccc(C2CCNCC2)cc1C1=CCCCC1)c1ncc[nH]1
2047,1573499,10.1016/j.bmcl.2016.04.041,,,,Inhibition of CYP3A4 in human liver microsomes using 1-hydroxymidazolam as substrate,CCc1cnc(Oc2ccc(NC(=O)c3ncccc3N)cc2Cl)nc1,3-amino-N-(3-chloro-4-(5-ethylpyrimidin-2-yloxy)phenyl)picolinamide,21.1,uM,=,1.3242824552976926,1,O=C(Nc1ccc(Oc2ncccn2)cc1)c1ccccn1
2048,526157,10.1021/np0401765,,,,Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation,C/C=C/c1cc(OC)c(OC)cc1OC,"1,2,4-Trimethoxy-5-propenyl-benzene",92.3,uM,=,1.965201701025912,1,c1ccccc1
2049,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NN5CCCC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, F-56",17.44,uM,=,1.2415464805965484,1,O=C(NN1CCCC1)c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12
2050,676065,10.1016/j.bmcl.2010.09.028,,,,Inhibition of CYP3A4 after 30 mins,CC(C)(C)[C@@H]1COC[C@H](COC(=O)N2CCC(CO)CC2)N1S(=O)(=O)c1ccc(Cl)cc1,"((3R,5R)-5-tert-butyl-4-(4-chlorophenylsulfonyl)morpholin-3-yl)methyl 4-(hydroxymethyl)piperidine-1-carboxylate",0.0070999999999999,uM,=,-2.148741651280925,0,O=C(OC[C@H]1COCCN1S(=O)(=O)c1ccccc1)N1CCCCC1
2051,802673,10.1016/j.bmcl.2011.12.125,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,CCOC(=O)c1cccc(NC(=O)Nc2ccc(-c3ccnc4[nH]cnc34)cc2)c1,"ethyl 3-(3-(4-(3H-imidazo[4,5-b]pyridin-7-yl)phenyl)ureido)benzoate",0.044,uM,=,-1.3565473235138126,0,O=C(Nc1ccccc1)Nc1ccc(-c2ccnc3[nH]cnc23)cc1
2052,676061,10.1016/j.bmcl.2010.09.090,,,,Inhibition of CYP3A4 using DEF substrate by CYPEX bactosome P450 inhibition assay,Cc1cc(C)cc(NC(=O)CSc2nnc(-c3ccoc3C)n2Cc2ccco2)c1,"N-(3,5-dimethylphenyl)-2-(4-(furan-2-ylmethyl)-5-(2-methylfuran-3-yl)-4H-1,2,4-triazol-3-ylthio)acetamide",2.0,uM,=,0.3010299956639812,1,O=C(CSc1nnc(-c2ccoc2)n1Cc1ccco1)Nc1ccccc1
2053,423507,10.1021/jm060995h,,,,Inhibition of CYP3A4,CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3C[C@H](O)CO3)c(Cc3ccccc3C(F)(F)F)sc21,"5-[(4S)-4-hydroxy-2-isoxazolidinylcarbonyl]-3-methyl-1-(isobutyl)-6-[2-(trifluoromethyl)phenylmethyl]thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione",8.3,uM,=,0.919078092376074,1,O=C(c1c(Cc2ccccc2)sc2[nH]c(=O)[nH]c(=O)c12)N1CCCO1
2054,1889156,10.1021/acs.jmedchem.8b01719,,,,Inhibition of CYP3A4 in human liver microsomes using atorvastatin as substrate preincubated for 7 mins followed by NADPH addition and measured by LC-MS/MS analysis,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(c3ccc(B(O)O)c(Cl)c3)S(C)(=O)=O)c(C3CC3)cc12,(2-Chloro-4-(N-(5-cyclopropyl-2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-6-yl)methylsulfonamido)phenyl)boronic acid,4.2,uM,=,0.6232492903979004,1,c1ccc(Nc2cc3oc(-c4ccccc4)cc3cc2C2CC2)cc1
2055,2290737,10.1021/acs.jmedchem.2c01933,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,CC(C)C[C@@H](NC(=O)C1(C(F)(F)F)CCCCC1)C(=O)Nc1nnc(Cc2ccc(C#N)cc2)s1,"N-[(1R)-1-[[5-((4-Cyanophenyl)methyl]-1,3,4-thiadiazol-2-yl]carbamoyl]1-3-methyl-butyl)-1-(trifluoromethyl)cydohexanecarboxamide",0.4,uM,=,-0.3979400086720376,0,O=C(CNC(=O)C1CCCCC1)Nc1nnc(Cc2ccccc2)s1
2056,741043,10.1016/j.bmcl.2011.02.067,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH,CCOC(=O)[C@H]1C[C@@H]1COc1cc(CCCOC)cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1,"(1S,2S)-ethyl 2-((3-(((3R,4S)-N-cyclopropyl-4-(4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)phenyl)piperidine-3-carboxamido)methyl)-5-(3-methoxypropyl)phenoxy)methyl)cyclopropanecarboxylate",1.4,uM,=,0.1461280356782379,1,O=C([C@H]1CNCC[C@@H]1c1ccc(OCCOc2ccccc2)cc1)N(Cc1cccc(OCC2CC2)c1)C1CC1
2057,1640557,,,,,"null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.",CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,"1-(4-{4-[2-(2,4-Dichloro-phenyl)-2-imidazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-ethanone (ketoconazole)",0.5,uM,=,-0.3010299956639812,0,c1ccc(C2(Cn3ccnc3)OCC(COc3ccc(N4CCNCC4)cc3)O2)cc1
2058,990449,10.1016/j.bmcl.2013.09.001,,,,Inhibition of CYP3A4 in human liver microsomes in presence of NADPH,N#Cc1cncc(Oc2cc(Cl)cc(C(=O)Nc3ccc(F)cn3)c2)c1,3-chloro-5-(5-cyanopyridin-3-yloxy)-N-(5-fluoropyridin-2-yl)benzamide,1.7,uM,=,0.2304489213782739,1,O=C(Nc1ccccn1)c1cccc(Oc2cccnc2)c1
2059,1584592,10.1021/acs.jmedchem.6b00030,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 4 mins by LC-MS analysis,CCOC1(c2ccc(OC)cc2)SC=C(C)n2c1noc2=O,"8-Ethoxy-8-(4-methoxyphenyl)-5-methyl-8H-[1,2,4]oxadiazolo-[3,4-c][1,4]thiazin-3-one",15.5,uM,=,1.1903316981702914,1,O=c1onc2n1C=CSC2c1ccccc1
2060,617698,10.1016/j.bmcl.2010.01.087,,,,Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay,COC(=O)N1CCN(C2CCN(c3cc(C)c4nc(-c5c(NCCc6ncn(C)c6Cl)cc[nH]c5=O)[nH]c4c3)CC2)CC1,"methyl 4-(1-(2-(4-(2-(5-chloro-1-methyl-1H-imidazol-4-yl)ethylamino)-2-oxo-1,2-dihydropyridin-3-yl)-4-methyl-1H-benzo[d]imidazol-6-yl)piperidin-4-yl)piperazine-1-carboxylate",0.7,uM,=,-0.1549019599857432,0,O=c1[nH]ccc(NCCc2c[nH]cn2)c1-c1nc2ccc(N3CCC(N4CCNCC4)CC3)cc2[nH]1
2061,966467,10.1016/j.bmcl.2013.04.077,,,,Inhibition of CYP3A4 (unknown origin),CC(=O)N1[C@@H](c2ccccc2)CC[C@H]1C(=O)Nc1ncc(-c2ccc(N)cc2)s1,"(2S,5R)-1-acetyl-N-(5-(4-aminophenyl)thiazol-2-yl)-5-phenylpyrrolidine-2-carboxamide",0.98,uM,=,-0.0087739243075051,0,O=C(Nc1ncc(-c2ccccc2)s1)[C@@H]1CC[C@H](c2ccccc2)N1
2062,993439,10.6019/CHEMBL2448688,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,CO/N=C(\C)c1ccc(-n2ccnc2)c(NC(=O)c2cnc(-c3ccccc3)s2)c1,,1.0,uM,=,0.0,0,O=C(Nc1ccccc1-n1ccnc1)c1cnc(-c2ccccc2)s1
2063,642395,10.1021/jm100400a,,,,Inhibition of CYP3A4 expressed in baculovirus infected insect microsomes,CC(C)=C(c1ccncc1)c1ccc(-c2ccc(O)c(F)c2)cc1,3-fluoro-4'-(2-methyl-1-(pyridin-4-yl)prop-1-enyl)biphenyl-4-ol,17.65,uM,=,1.246744709723841,1,C=C(c1ccncc1)c1ccc(-c2ccccc2)cc1
2064,305432,10.1016/j.bmcl.2005.01.044,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,CC(C(c1ccc2cc(OCC(C)(C)C)ccc2c1)n1ccnc1)N(C)C,"{2-[6-(2,2-Dimethyl-propoxy)-naphthalen-2-yl]-2-imidazol-1-yl-1-methyl-ethyl}-dimethyl-amine",0.7,uM,=,-0.1549019599857432,0,c1ccc2cc(Cn3ccnc3)ccc2c1
2065,1458157,10.1016/j.bmcl.2014.05.082,,,,Inhibition of human CYP3A4 using testosterone as substrate after 10 mins by SPE-MS analysis in presence of NADPH,CS(=O)(=O)NCCc1cc(-c2ccnc3[nH]nc(C(F)(F)F)c23)cc(C2(C#N)CC2)c1,"N-(3-(1-cyanocyclopropyl)-5-(3-(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-4-yl)phenethyl)methanesulfonamide",7.0,uM,=,0.8450980400142568,1,c1cc(-c2ccnc3[nH]ncc23)cc(C2CC2)c1
2066,1778315,10.1016/j.bmcl.2018.06.040,,,,Inhibition of CYP3A4 (unknown origin),O=C(Cc1cccc(OCCCN2CCNCC2)c1)Nc1nc(-c2c[nH]c3ncccc23)cs1,"N-(4-(1H-pyrrolo[2,3-b]pyridin-3-yl)thiazol-2-yl)-2-(3-(3-(piperazin-1-yl)propoxy)phenyl)acetamide",12.6,uM,=,1.100370545117563,1,O=C(Cc1cccc(OCCCN2CCNCC2)c1)Nc1nc(-c2c[nH]c3ncccc23)cs1
2067,1460848,10.1021/jm501038s,,,,Inhibition of CYP3A4 (unknown origin),Cc1ccc(Oc2ccc(C(=O)NCc3ccncc3)cc2)cc1,SID24822114,1.0,uM,=,0.0,0,O=C(NCc1ccncc1)c1ccc(Oc2ccccc2)cc1
2068,600767,10.1016/j.bmcl.2009.07.127,,,,Inhibition of human CYP3A4,COC(=O)c1ccccc1NC(=O)COc1ccc(C23CC4CC(CC(C(=O)N5CCc6cc(OC)c(OC)cc6C5)(C4)C2)C3)cc1,"2-(2-{4-[3-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinoline-2-carbonyl)-adamantan-1-yl]-phenoxy}-acetylamino)-benzoic acid methyl ester",3.79,uM,=,0.5786392099680724,1,O=C(COc1ccc(C23CC4CC(CC(C(=O)N5CCc6ccccc6C5)(C4)C2)C3)cc1)Nc1ccccc1
2069,455108,10.1016/j.bmcl.2006.12.043,,,,Inhibition of CYP3A4,NC(C(=O)N1CCN(c2ccc3[nH]ncc3c2)CC1)c1cccc(Cl)c1,1-(4-(1H-indazol-5-yl)piperazin-1-yl)-2-amino-2-(3-chlorophenyl)ethanone,0.25,uM,=,-0.6020599913279624,0,O=C(Cc1ccccc1)N1CCN(c2ccc3[nH]ncc3c2)CC1
2070,51903,10.1021/jm020557k,,,,Concentration required to inhibit cytochrome P450 3A4.,CCCCOc1ccc(-c2cccnc2)cc1,3-(4-Butoxy-phenyl)-pyridine,29.3,uM,=,1.4668676203541096,1,c1ccc(-c2cccnc2)cc1
2071,945618,10.1016/j.bmc.2012.11.058,,,,Inhibition of CYP3A4 (unknown origin),O=S(=O)(Nc1cc(Cl)c(Oc2cncc(Cl)c2)c(Cl)c1)c1ccc(Cl)cc1Cl,"2,4-Dichloro-N-(3,5-dichloro-4-(5-chloropyridin-3-yloxy)phenyl)benzenesulfonamide",1.2,uM,=,0.0791812460476248,1,O=S(=O)(Nc1ccc(Oc2cccnc2)cc1)c1ccccc1
2072,982809,10.1016/j.ejmech.2013.08.010,,,,Inhibition of CYP3A (unknown origin),CC#CCn1c(N2CCC[C@@H](N)C2)cc(=O)n(Cc2ccc3ccc(F)cc3n2)c1=O,"(R)-6-(3-Aminopiperidin-1-yl)-1-(but-2-yn-1-yl)-3-((7-fluoroquinolin-2-yl)methyl)pyrimidine-2,4(1H,3H)-dione",54.65,uM,=,1.7375901662857216,1,O=c1cc(N2CCCCC2)[nH]c(=O)n1Cc1ccc2ccccc2n1
2073,746947,10.1021/jm200128m,,,,Inhibition of human CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,Nc1nc2c(c(-c3c(Cl)cc(Cl)cc3OCCn3cccn3)n1)CN(C(=O)NC13CC(C1)C3)C2,"2-Amino-4-[2,4-dichloro-6-(2-pyrazol-1-ylethoxy)phenyl]-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carboxylic Acid Bicyclo[1.1.1]pent-1-ylamide",1.1,uM,=,0.041392685158225,1,O=C(NC12CC(C1)C2)N1Cc2ncnc(-c3ccccc3OCCn3cccn3)c2C1
2074,52555,10.1021/jm980532e,,,,Inhibition of human cytochrome P450 3A4 as total cyclosporin oxidation (1 uM),COc1ccc(NS(=O)(=O)c2ccc(Br)cc2)cc1N1CCN(C)CC1,4-Bromo-N-[4-methoxy-3-(4-methyl-piperazin-1-yl)-phenyl]-benzenesulfonamide,6.0,uM,=,0.7781512503836436,1,O=S(=O)(Nc1cccc(N2CCNCC2)c1)c1ccccc1
2075,495540,10.1021/jm801332q,,,,Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate measured in 25 to 30 mins by time dependent inhibition assay,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,"6-(4-Dimethylamino-3-hydroxy-6-methyl-tetrahydro-pyran-2-yloxy)-14-ethyl-7,12,13-trihydroxy-4-(5-hydroxy-4-methoxy-4,6-dimethyl-tetrahydro-pyran-2-yloxy)-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione",0.19,uM,=,-0.721246399047171,0,O=C1CCCCOC(=O)C[C@@H](O[C@H]2CCCCO2)C[C@@H](O[C@H]2CCCCO2)CCC1
2076,495543,10.1021/jm801332q,,,,Inhibition of human CYP3A4 expressed in Escherichia coli using 7BQ substrate by time dependent inhibition assay,C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(Nc4cccc(C#N)c4)CC3)cc2)CCN1,3-((1-[(4-([(3S)-3-Methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinyl)amino)benzonitrile,58.0,uM,=,1.7634279935629371,1,O=C(Cc1ccc(CN2CCNCC2)cc1)N1CCC(Nc2ccccc2)CC1
2077,774749,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",COc1cc([C@@H]2c3cc4c(cc3[C@H](O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1OC,"(5R,5aR,8aR,9R)-9-Hydroxy-5-(3,4,5-trimethoxy-phenyl)-5,8,8a,9-tetrahydro-5aH-furo[3',4':6,7]naphtho[2,3-d][1,3]dioxol-6-one",0.6,uM,=,-0.2218487496163563,0,O=C1OC[C@@H]2Cc3cc4c(cc3[C@@H](c3ccccc3)[C@@H]12)OCO4
2078,2241392,10.1016/j.ejmech.2021.113981,,,,Inhibition of CYP3A4 in human liver microsomes assessed as reduction in 6-beta-hydroxy-testosterone formation using testosterone as substrate preincubated for 20 mins in presence of NADPH followed by incubation with substrate for 10 mins by LC-MS/MS analysis,O[C@@H](c1cc(C(F)(F)F)nc2c(C(F)(F)F)cccc12)[C@H]1CCCCN1,"(S)-(2,8-bis(trifluoromethyl)quinolin-4-yl)((R)-piperidin-2-yl)methanol",18.0,uM,=,1.255272505103306,1,c1ccc2c(C[C@H]3CCCCN3)ccnc2c1
2079,1886565,10.1021/acs.jmedchem.8b02021,,,,Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay,Nc1nc2ccc(C(=O)NCc3ccccc3N)cc2s1,2-amino-N-(2-aminobenzyl)benzo[d]thiazole-6-carboxamide,10.0,uM,=,1.0,1,O=C(NCc1ccccc1)c1ccc2ncsc2c1
2080,2298109,10.1016/j.bmc.2023.117273,,,,Inhibition of CYP3A4 in human liver microsomes,COc1cc(N2CC[C@@H](Oc3ccc(N4N=C(C(F)(F)F)[C@@H](C)[C@@H]4CC(=O)O)cc3)[C@H](C)C2)c(Cl)cn1,"2-((4S,5S)-1-(4-(((3R,4R)-1-(5-Chloro-2-methoxypyridin-4-yl)-3-methylpiperidin-4-yl)oxy)phenyl)-4-methyl-3-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-5-yl)acetic acid",3.4,uM,=,0.5314789170422551,1,C1=NN(c2ccc(OC3CCN(c4ccncc4)CC3)cc2)CC1
2081,1460909,10.1021/jm501326k,,,,Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase/human b5 reductase using 7-benzyloxyquinoline substrate,CCOC(=O)c1[nH]cc2c1NC1=C(C(=O)CCC1)C2c1ccc(Sc2nc3c(F)c(F)c(F)cc3[nH]2)o1,"(+/-)-8-Oxo-9-[5-(4,5,6-trifluoro-1H-benzimidazol-2-ylsulfanyl)-furan-2-yl]-4,5,6,7,8,9-hexahydro-2Hpyrrolo[3,4-b]quinoline-3-carboxylic acid ethyl ester",23.0,uM,=,1.3617278360175928,1,O=C1CCCC2=C1C(c1ccc(Sc3nc4ccccc4[nH]3)o1)c1c[nH]cc1N2
2082,1859912,10.1021/acsmedchemlett.9b00114,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 10 mins in presence of NADPH by UHPLC-MS/MS analysis,Cn1cc(-c2ccc(N3CCC(C4c5c(F)cccc5-c5cncn54)CC3)cc2F)cn1,"6-fluoro-5-(1-(3-fluoro-4-(1-methyl-1H-pyrazol-4-yl)phenyl)piperidin-4-yl)-5H-imidazo[5,1-a]isoindole",4.57,uM,=,0.6599162000698503,1,c1ccc2c(c1)-c1cncn1C2C1CCN(c2ccc(-c3cn[nH]c3)cc2)CC1
2083,804824,10.1016/j.bmcl.2011.12.080,,,,Reversible inhibition of CYP3A4,COc1cc(C)c2nc3[nH]nc(C)c3c(C(F)c3ccncc3)c2c1,"(-)-4-(fluoro(pyridin-4-yl)methyl)-6-methoxy-3,8-dimethyl-1H-pyrazolo[3,4-b]quinoline",0.3,uM,=,-0.5228787452803376,0,c1ccc2c(Cc3ccncc3)c3cn[nH]c3nc2c1
2084,1911030,10.1021/acs.jmedchem.8b01226,,,,Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins,O=C(c1cccc(Cl)c1)N1CCC(=CC#Cc2cccc(Cl)n2)CC1,(3-Chlorophenyl){4-[3-(3-chlorophenyl)prop-2-yn-1-ylidene]-piperidin-1-yl}methanone,2.3,uM,=,0.3617278360175928,1,O=C(c1ccccc1)N1CCC(=CC#Cc2ccccn2)CC1
2085,449485,10.1016/j.bmcl.2007.07.097,,,,Inhibition of microsomal CYP3A4,CC(C)C[C@H](NC(=O)CN(C)C)c1cc(F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1,"N-((S)-1-(2-(4-((R)-3-(2,4-dichlorophenyl)-2-(2-oxopyrrolidin-1-yl)propanoyl)piperazin-1-yl)-5-fluorophenyl)-3-methylbutyl)-2-(dimethylamino)acetamide",15.0,uM,=,1.1760912590556811,1,O=C([C@@H](Cc1ccccc1)N1CCCC1=O)N1CCN(c2ccccc2)CC1
2086,510198,10.1021/jm800355c,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,Br.Oc1ccc(-c2ccc3c(c2)CCCC3c2ccncc2)cc1O,"4-(5-(Pyridin-4-yl)-5,6,7,8-tetrahydronaphthalen-2-yl)benzene-1,2-diol Hydrobromide",0.632,uM,=,-0.1992829217176149,0,c1ccc(-c2ccc3c(c2)CCCC3c2ccncc2)cc1
2087,1686497,10.1021/acsmedchemlett.7b00211,,,,Competitive inhibition of CYP3A4 in human liver microsomes in presence of NADPH by LC-MS/MS analysis,CNC(=O)c1c(-c2ccc(F)cc2)oc2nc(CCC(F)(F)F)c(-c3cc(C(=O)NC(C)(C)c4ncon4)c(=O)n(C)c3)cc12,"5-(5-(2-(1,2,4-oxadiazol-3-yl)propan-2-ylcarbamoyl)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-(4-fluorophenyl)-N-methyl-6-(3,3,3-trifluoropropyl)furo[2,3-b]pyridine-3-carboxamide",0.44,uM,=,-0.3565473235138126,0,O=C(NCc1ncon1)c1cc(-c2cnc3oc(-c4ccccc4)cc3c2)c[nH]c1=O
2088,632105,10.1016/j.bmcl.2010.03.057,,,,Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin,Cc1cc(N2CCN(CCC#N)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,"(S)-3-(4-(2-(4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-2-oxo-1,2-dihydropyridin-3-yl)-4-methyl-1H-benzo[d]imidazol-6-yl)piperazin-1-yl)propanenitrile",1.1,uM,=,0.041392685158225,1,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(N3CCNCC3)cc2[nH]1
2089,1528565,,,,,"Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",CC(C)c1nc(CN(C)C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,"US8987313, 5",0.23,uM,=,-0.6382721639824072,0,O=C(N[C@H](CC[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)NCc1cscn1)Cc1ccccc1)OCc1cncs1
2090,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCN(Cc7ccc(OC)cc7)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1,"US8940739, G-60",21.52,uM,=,1.3328422669943516,1,O=C(Nc1ccc(N2CCN(Cc3ccccc3)CC2)nc1)c1c[nH]c2c(CN3CC4N(C(=O)NCc5ccccc5)NCC(=O)N4C(Cc4ccccc4)C3=O)cccc12
2091,490925,10.1016/j.bmcl.2008.06.080,,,,Inhibition of CYP3A4,CC1OC(Cc2ccc(Cl)c(Oc3cc(Cl)cc(C#N)c3)c2F)=NNC1=O,"3-chloro-5-(6-chloro-2-fluoro-3-((6-methyl-5-oxo-5,6-dihydro-4H-1,3,4-oxadiazin-2-yl)methyl)phenoxy)benzonitrile",0.27,uM,=,-0.5686362358410126,0,O=C1COC(Cc2cccc(Oc3ccccc3)c2)=NN1
2092,1660136,10.1021/acs.jmedchem.6b01918,,,,Inhibition of human CYP3A4 assessed as inhibition of dealkylation,O=S(=O)(Nc1ncns1)c1cc(Cl)c(NCCC2CCCCN2)cc1F,rac-5-Chloro-2-fluoro-4-((2-(piperidin-2-yl)ethyl)amino)-N-(thiadizol-2-yl)benzenesulfonamide,5.9,uM,=,0.7708520116421442,1,O=S(=O)(Nc1ncns1)c1ccc(NCCC2CCCCN2)cc1
2093,875916,10.1021/jm300955x,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 mins by LC-MS/MS analysis in presence of NADPH,COc1ccc(S(=O)(=O)n2nc(C)c3cc(Cl)ccc32)cc1NC1CCN(C)CC1.O=C(O)[C@H](O)[C@@H](O)C(=O)O,1-[3-(1-Methylpiperidin-4-ylamino)-4-methoxybenzenesulfonyl]-5-chloro-3-methyl-1H-indazole L-(+)-Tartarate,10.0,uM,=,1.0,1,O=S(=O)(c1cccc(NC2CCNCC2)c1)n1ncc2ccccc21
2094,1755379,10.1021/acs.jmedchem.8b00419,,,,Inhibition of C-terminal His-tagged recombinant human CYP3A4 assessed as decrease in metabolism of luciferin isopropyl alcohol preincubated for 3 mins followed by NADPH addition measured after 30 mins,C[C@]12CC[C@H](O)C[C@@H]1/C(=N\O)C[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=CC[C@@H]12,3beta-Hydroxy-17-(3-pyridyl)-5alpha-androst-16-en-6-one Oxime,8.57,uM,=,0.9329808219231982,1,N=C1C[C@H]2[C@@H]3CC=C(c4cccnc4)C3CC[C@@H]2C2CCCC[C@H]12
2095,2045773,10.1039/d0md00174k,,,,Inhibition of CYP3A4 (unknown origin),Cc1c(-c2ccc3[nH]ncc3c2)ccc2c3oc(CN)nc3c(=O)n(C3CC3)c12,"2-(aminomethyl)-5-cyclopropyl-7-(1H-indazol-5-yl)-6-methyloxazolo[4,5-c]quinolin-4(5H)-one",1.3,uM,=,0.1139433523068367,1,O=c1c2ncoc2c2ccc(-c3ccc4[nH]ncc4c3)cc2n1C1CC1
2096,305432,10.1016/j.bmcl.2005.01.044,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,CC(C(c1ccc2cc(OCC(C)(C)C)ccc2c1)n1ccnc1)N(C)C,"{2-[6-(2,2-Dimethyl-propoxy)-naphthalen-2-yl]-2-imidazol-1-yl-1-methyl-ethyl}-dimethyl-amine",0.22,uM,=,-0.6575773191777937,0,c1ccc2cc(Cn3ccnc3)ccc2c1
2097,559939,10.1016/j.bmcl.2008.10.072,,,,Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate,C[C@@H]1CN(Cc2ccc(-c3ccccc3CN(C)C(=O)COc3ccccc3)cc2)C[C@H](C)N1,"N-[4'-((3R,5S)-3,5-Dimethyl-piperazin-1-ylmethyl)-biphenyl-2-ylmethyl]-N-methyl-2-phenoxy-acetamide",24.0,uM,=,1.380211241711606,1,O=C(COc1ccccc1)NCc1ccccc1-c1ccc(CN2CCNCC2)cc1
2098,479364,10.1016/j.bmcl.2008.05.027,,,,Inhibition of CYP3A4,N#CCN(CC(=O)N1CCCC(c2ccccc2)C1CN1CCCC1)c1ccc(Cl)c(Cl)c1,"rac-2-((3,4-dichlorophenyl)(2-oxo-2-(3-phenyl-2-(pyrrolidin-1-ylmethyl)piperidin-1-yl)ethyl)amino)acetonitrile",1.1,uM,=,0.041392685158225,1,O=C(CNc1ccccc1)N1CCCC(c2ccccc2)C1CN1CCCC1
2099,1845477,10.1021/acsmedchemlett.0c00004,,,,Inhibition of CYP3A4 (unknown origin),NC(=O)c1ccc2c(c1)[C@@H](O)[C@H]([C@H]1c3ccccc3-c3cncn31)CC2,"(7S,8S)-8-hydroxy-7-((S)-5H-imidazo[5,1-a]isoindol-5-yl)-5,6,7,8-tetrahydronaphthalene-2-carboxamide",3.6,uM,=,0.5563025007672873,1,c1ccc2c(c1)CC[C@@H]([C@H]1c3ccccc3-c3cncn31)C2
2100,1582658,10.1021/acs.jmedchem.5b02029,,,,Inhibition of CYP3A4 in human liver microsomes,CC(C)[C@@H]1CN(c2ccc(CO)c(S(C)(=O)=O)c2)CCN1c1ncc(CO)c(C(F)(F)F)n1,(R)-(2-(4-(4-(hydroxymethyl)-3-(methylsulfonyl)phenyl)-2-isopropylpiperazin-1-yl)-4-(trifluoromethyl)pyrimidin-5-yl)methanol,6.6,uM,=,0.8195439355418687,1,c1ccc(N2CCN(c3ncccn3)CC2)cc1
2101,872616,10.1021/jm200326p,,,,Inhibition of CYP3A4 in human liver microsomes assessed as decrease in formation of 1-hydroxymidazolam from midazolam substrate after 5 mins by LC-MS/MS,C1=CCOCc2cc(ccc2OCCN2CCCCC2)Nc2nccc(n2)-c2cccc(c2)COC1,"11-[2-(piperidin-1-yl)ethoxy]-14,19-dioxa-5,7,27-triazatetracyclo[19.3.1.1^{2,6}.1^{8,12}]heptacosa-1(25),2(27),3,5,8,10,12(26),16,21,23-decaene",0.37,uM,=,-0.431798275933005,0,C1=CCOCc2cc(ccc2OCCN2CCCCC2)Nc2nccc(n2)-c2cccc(c2)COC1
2102,1291572,10.1016/j.bmcl.2013.12.058,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,CC(C)CN(CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)[C@H](CCN1CCOCC1)NC(=O)N(C)Cc1csc(C(C)C)n1,Thiazol-5-ylmethyl(S)-4-((S)-N-isobutyl-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-4-morpholinobutanamido)-1-phenylbutan-2-ylcarbamate,0.27,uM,=,-0.5686362358410126,0,O=C(NCc1cscn1)N[C@@H](CCN1CCOCC1)C(=O)NCC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1
2103,957081,10.1016/j.bmcl.2013.02.118,,,,Inhibition of human recombinant CYP3A4,O[C@H]1CC[C@H](c2ccc(OCCCN3CCCCC3)cc2)CC1,trans-4-(4-(3-(piperidin-1-yl)propoxy)phenyl)cyclohexanol,30.3,uM,=,1.481442628502305,1,c1cc(C2CCCCC2)ccc1OCCCN1CCCCC1
2104,769156,10.1021/jm2003552,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,CN(C)CC(C)(C)Cn1c(CC(C)(C)C)nc2cc(/C=C/C(=O)NO)ccc21,"(E)-3-[1-(3-Dimethylamino-2,2-dimethylpropyl)-2-(2,2-dimethylpropyl)-1H-benzimidazol-5-yl]-N-hydroxyacrylamide",2.28,uM,=,0.3579348470004537,1,c1ccc2[nH]cnc2c1
2105,305744,10.1021/jm049696n,,,,Inhibitory concentration value against human cytochrome P-450 3A4,Cc1cn(-c2cccnc2)cn1,3-(4-Methyl-imidazol-1-yl)-pyridine,109.0,uM,=,2.037426497940624,1,c1cncc(-n2ccnc2)c1
2106,979397,10.1016/j.bmcl.2013.06.010,,,,Inhibition of CYP3A4 (unknown origin),CC(=O)Nc1nc2ccc(-c3ccc(N)nc3)cc2s1,N-(6-(6-aminopyridin-3-yl)benzo[d]thiazol-2-yl)acetamide,0.05,uM,=,-1.3010299956639813,0,c1cncc(-c2ccc3ncsc3c2)c1
2107,1476607,10.1021/acsmedchemlett.5b00008,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,O=c1n(Cc2nc3ccccc3n2CCCCO)c2cnccc2n1C1CC1,"1-cyclopropyl-3-((1-(4-hydroxybutyl)-1H-benzo[d]imidazol-2-yl)methyl)-1H-imidazo[4,5-c]pyridin-2(3H)-one",27.5,uM,=,1.4393326938302626,1,O=c1n(Cc2nc3ccccc3[nH]2)c2cnccc2n1C1CC1
2108,1523285,10.1016/j.bmcl.2015.06.066,,,,Inhibition of CYP3A4 (unknown origin),C[C@@](NCc1ccc2ncsc2c1)(c1cn(C(CCS(C)(=O)=O)C(=O)COc2c(F)c(F)cc(F)c2F)nn1)C1CCCC1,"3-(4-((S)-1-(benzo[d]thiazol-6-ylmethylamino)-1-cyclopentylethyl)-1H-1,2,3-triazol-1-yl)-5-(methylsulfonyl)-1-(2,3,5,6-tetrafluorophenoxy)pentan-2-one",0.2,uM,=,-0.6989700043360187,0,O=C(COc1ccccc1)Cn1cc(C(NCc2ccc3ncsc3c2)C2CCCC2)nn1
2109,595557,10.1016/j.bmcl.2009.10.084,,,,Inhibition of CYP3A4 using BFC as a substrate,Cc1cc2cc(/N=C(/NC(=O)c3cccnc3)N[C@H]3CCCCN(CC(=O)N4CCCC4)C3=O)ccc2o1,"5-(2-(((1R)-3-(2-cyclopentylallyl)-2-methylenecycloheptyl)methyl)-4-phenylpenta-2,4-dienyl)-2-methyl-1H-indene",0.3,uM,=,-0.5228787452803376,0,O=C(N/C(=N/c1ccc2occc2c1)N[C@H]1CCCCN(CC(=O)N2CCCC2)C1=O)c1cccnc1
2110,827973,10.1016/j.bmcl.2012.05.087,,,,Inhibition of CYP3A4 using midazolam as substrate,COc1ccc(C(C)=O)cc1CSc1nc2ccccc2n1CC(=O)O,2-(2-(5-acetyl-2-methoxybenzylthio)-1H-benzo[d]imidazol-1-yl)acetic acid,37.0,uM,=,1.568201724066995,1,c1ccc(CSc2nc3ccccc3[nH]2)cc1
2111,526157,10.1021/np0401765,,,,Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation,COc1cc(C[C@@H]2COC(=O)[C@H]2Cc2cc(OC)c(O)c(OC)c2)ccc1O,(-)-thujaplicatintrimethyl ether,1.1,uM,=,0.041392685158225,1,O=C1OC[C@@H](Cc2ccccc2)[C@@H]1Cc1ccccc1
2112,685163,10.1021/jm100773e,,,,Inhibition of human CYP3A4,Cc1c2c(=O)n(-c3ccccc3Cl)[nH]c2cc(=O)n1Cc1ccccn1,"2-(2-chlorophenyl)-4-methyl-5-(pyridin-2-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione",20.9,uM,=,1.320146286111054,1,O=c1cc2[nH]n(-c3ccccc3)c(=O)c2cn1Cc1ccccn1
2113,2235525,10.1021/acs.jmedchem.1c02227,,,,Inhibition of CYP3A4 in human liver microsome using midazolam and testostrone as substrate preincubated for 10 mins followed by NADPH addition and measured after 15 mins by LC-MS/MS analysis,CNCC(=O)N[C@@H]1[C@H](O)[C@H](O[C@H]2/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@]3(O)C[C@H](O)[C@@H](C(=O)NCCN)[C@H](C2)O3)O[C@H](C)[C@H]1O.NC(CCC(=O)O)C(=O)O,16-(((2-Aminoethyl)-amino)carbonyl)-3'-((methylamino)acetylamino)-amphotericin B L-Glutamate,36.9,uM,=,1.5670263661590604,1,O=C1CCCCCCCCCCCC2CCC[C@H](C[C@@H](O[C@H]3CCCCO3)/C=C/C=C/C=C/C=C/C=C/C=C/C=C/CCCCO1)O2
2114,448320,10.1016/j.bmc.2007.05.069,,,,Inhibition of CYP3A4,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(=O)CO)C(=O)C(C)(c1cc(F)cc(F)c1)O2,"N-(2-(6-(2,4-diamino-6-ethylpyrimidin-5-yl)-2-(3,5-difluorophenyl)-2-methyl-3-oxo-2,3-dihydrobenzo[b][1,4]oxazin-4-yl)ethyl)-2-hydroxyacetamide",1.67,uM,=,0.2227164711475832,1,O=C1Nc2cc(-c3cncnc3)ccc2OC1c1ccccc1
2115,659957,10.1021/jm100643t,,,,Inhibition of CYP3A4,FC(F)(F)c1ccc(SCC(c2ccncc2)c2c[nH]cn2)cc1,4-(1-(1H-Imidazole-4-yl)-2-(4-trifluoromeethylphenylthio)ethyl)-pyridine,0.35,uM,=,-0.4559319556497244,0,c1ccc(SCC(c2ccncc2)c2c[nH]cn2)cc1
2116,980735,10.1021/jm400820m,,,,Inhibition of human recombinant CYP3A4,CCOC(=O)c1cc(C#N)c(N2CC(C(=O)NS(=O)(=O)Cc3ccc(Cl)cc3)C2)nc1C,Ethyl 6-(3-{[(4-Chlorobenzyl)sulfonyl]carbamoyl}azetidin-1-yl)-5-cyano-2-methylnicotinate,3.3,uM,=,0.5185139398778875,1,O=C(NS(=O)(=O)Cc1ccccc1)C1CN(c2ccccn2)C1
2117,617698,10.1016/j.bmcl.2010.01.087,,,,Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay,Cc1cc(N2CC[C@@H](N)C2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,3-(6-((R)-3-aminopyrrolidin-1-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)-4-((S)-2-(3-chlorophenyl)-2-hydroxyethylamino)pyridin-2(1H)-one,18.0,uM,=,1.255272505103306,1,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(N3CCCC3)cc2[nH]1
2118,1747140,10.1016/j.bmcl.2017.10.042,,,,Inhibition of CYP3A4 (unknown origin) after 20 mins,COc1nc2ccc(Br)cc2cc1[C@@H](c1cncc(C)c1)[C@@](O)(CCN(C)C)c1cccc(F)c1,"(1R,2S)-1-(6-bromo-2-methoxyquinolin-3-yl)-4-(dimethylamino)-2-(3-fluorophenyl)-1-(5-methylpyridin-3-yl)butan-2-ol",4.6,uM,=,0.6627578316815741,1,c1ccc(C[C@H](c2cccnc2)c2cnc3ccccc3c2)cc1
2119,962469,10.1021/jm4004895,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC/MS/MS analysis,C[C@@H](O)c1nc2cnc3[nH]ccc3c2n1[C@H]1CC[C@H](C#N)CC1,"trans-4-(2-((R)-1-Hydroxyethyl)imidazo[4,5-d]pyrrolo[2,3-b]-pyridin-1(6H)-yl)cyclohexanecarbonitrile",7.9,uM,=,0.8976270912904415,1,c1cc2c(ncc3ncn(C4CCCCC4)c32)[nH]1
2120,1747140,10.1016/j.bmcl.2017.10.042,,,,Inhibition of CYP3A4 (unknown origin) after 20 mins,COc1nc2ccc(Br)cc2cc1[C@@H](c1cc(C)c(C)s1)[C@@](O)(CCN(C)C)c1cccc(F)c1,"(1R,2S)-1-(6-bromo-2-methoxyquinolin-3-yl)-4-(dimethylamino)-1-(4,5-dimethylthiophen-2-yl)-2-(3-fluorophenyl)butan-2-ol",10.0,uM,=,1.0,1,c1ccc(C[C@@H](c2cnc3ccccc3c2)c2cccs2)cc1
2121,1465541,10.1016/j.bmcl.2015.01.051,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(C6CN(CCOC)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O,"(1S,4R,5R,6R,8R,10S,11R,12S,13R,16R,18S,21R)-8-[(1S)-1-ethoxy-2-hydroxy-2-methylpropyl]-18-{[(2S)-4-[1-(2-methoxyethyl)azetidin-3-yl]morpholin-2-yl]oxy}-4,6,12,17,17-pentamethyl-9-oxahexacyclo[11.9.0.0^{1,21}.0^{4,12}.0^{5,10}.0^{16,21}]docosan-11-ol",5.3,uM,=,0.724275869600789,1,C1CO[C@@H]2CC3C(CC[C@@]45C[C@@]46CC[C@H](O[C@H]4CN(C7CNC7)CCO4)C[C@@H]6CC[C@@H]35)[C@H]2C1
2122,1637155,,,,,Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(S(=O)(=O)NC5CC5)cc4)cc23)c1F,"N-Cyclopropyl-4-{3-[2,6-difluoro-3-(propane-1-sulfonylamino)-benzoyl]-1H-pyrrolo[2,3-b]pyridin-5-yl}-benzenesulfonamide",5.0,uM,=,0.6989700043360189,1,O=C(c1ccccc1)c1c[nH]c2ncc(-c3ccc(S(=O)(=O)NC4CC4)cc3)cc12
2123,2048449,10.1016/j.bmc.2020.115734,,,,Inhibition of recombinant CYP3A4 (unknown origin) by fluorescence-based assay,COc1nc(-c2csc(Nc3cc(C(C)(C)C)nn3CCF)n2)ccc1-n1cnc(C)c1,N-(3-(tert-butyl)-1-(2-fluoroethyl)-1H-pyrazol-5-yl)-4-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)thiazol-2-amine,0.04,uM,=,-1.3979400086720375,0,c1cn(-c2ccc(-c3csc(Nc4ccn[nH]4)n3)nc2)cn1
2124,479364,10.1016/j.bmcl.2008.05.027,,,,Inhibition of CYP3A4,COCCN(CC(=O)N1CCCC(c2ccccc2)C1CN1CCCC1)c1ccc(Cl)c(Cl)c1,"2-((3,4-dichlorophenyl)(2-methoxyethyl)amino)-1-(3-phenyl-2-(pyrrolidin-1-ylmethyl)piperidin-1-yl)ethanone",1.2,uM,=,0.0791812460476248,1,O=C(CNc1ccccc1)N1CCCC(c2ccccc2)C1CN1CCCC1
2125,862399,10.1021/jm300601d,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis,CC(C)(C)C(=O)N1CCC(c2ccc(C(=O)NC(=N)N)cc2C(F)(F)F)CC1,"N-{4-[1-(2,2-Dimethyl-propionyl)-piperidin-4-yl]-3-trifluoromethyl-benzoyl}-guanidine",13.0,uM,=,1.1139433523068367,1,c1ccc(C2CCNCC2)cc1
2126,519908,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,Cc1nc2c3c(c(-n4cncn4)cn2c1C)CC[C@@H](c1ccccc1)N3,"(S)-2,3-dimethyl-9-phenyl-6-(1H-1,2,4-triazol-1-yl)-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine",2.6,uM,=,0.414973347970818,1,c1ccc([C@@H]2CCc3c(-n4cncn4)cn4ccnc4c3N2)cc1
2127,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cccc(-c3cccnn3)c2)c1,"US9150566, 47",6.0,uM,=,0.7781512503836436,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2cccnn2)c1
2128,1527876,,,,,Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,C#CC(C)(C)C[C@]1(c2ccccc2)CCN([C@@H](C)c2ccc(-c3ccc(=O)[nH]c3)cc2)C(=O)O1,"US8575157, 230",6.0,uM,=,0.7781512503836436,1,O=C1OC(c2ccccc2)CCN1Cc1ccc(-c2ccc(=O)[nH]c2)cc1
2129,873423,10.1021/jm3006788,,,,Inhibition of CYP3A4,Cn1c(-c2ccc(F)cn2)c(C2CCCC2)c2ccc(C(=O)NC3(C(=O)Nc4ccc(/C=C/C(=O)O)cc4)CCC3)cc21,(E)-3-(4-(1-(3-cyclopentyl-2-(5-fluoropyridin-2-yl)-1-methyl-1H-indole-6-carboxamido)cyclobutanecarboxamido)phenyl)acrylic acid,6.7,uM,=,0.8260748027008264,1,O=C(NC1(C(=O)Nc2ccccc2)CCC1)c1ccc2c(C3CCCC3)c(-c3ccccn3)[nH]c2c1
2130,1632088,10.1016/j.bmc.2016.11.051,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by NADPH addition measured after 10 mins by LC/MS/MS method,CC(C)COC(=O)[C@@H](Cn1cncn1)NC(=O)c1ccc(-c2ccccc2F)cc1,"Isobutyl (R)-2-(2'-fluoro-[1,1'-biphenyl]-4-carboxamido)-3-(1H-1,2,4-triazol-1-yl)propanoate",0.227,uM,=,-0.6439741428068773,0,O=C(NCCn1cncn1)c1ccc(-c2ccccc2)cc1
2131,1517864,10.1016/j.bmc.2015.08.019,,,,Inhibition of CYP3A4 (unknown origin) incubated for 45 mins using NADPH by fluorescence assay,Cc1nn(-c2ccccc2)c(Cl)c1C(=O)NC(Cn1ccnc1)C(=O)OC(C)C,Isopropyl 2-(5-chloro-3-methyl-1-phenyl-1H-pyrazole-4-carboxamido)-3-(1H-imidazol-1-yl)propanoate,4.92,uM,=,0.6919651027673603,1,O=C(NCCn1ccnc1)c1cnn(-c2ccccc2)c1
2132,796228,10.1016/j.bmcl.2011.10.115,,,,Inhibition of CYP3A4,Fc1ccc(Cn2c([C@H]3CNCCS3)nc3ccccc32)cc1,(+)-(R)-2-(1-(4-fluorobenzyl)-1H-benzo[d]imidazol-2-yl)thiomorpholine,15.6,uM,=,1.1931245983544616,1,c1ccc(Cn2c([C@H]3CNCCS3)nc3ccccc32)cc1
2133,1641293,,,,,"CYP Inhibition Assay (Without Preincubation): Without Preincubation: To a 96 deep well plate was added 2.5 uL, of the test substance solution (x200 concentration), 442.5 uL of Incubation Mixture, and 5 uL of the substrate solution, and the solution was mixed and warmed to 37° C. for 5 minutes. To this incubation solution 50 uL of 10 mM NADPH was added to start the reaction, and incubated at 37° C. for 5 minutes. After the incubation, 100 uL of the Incubation Mixture was removed, added to 150 uL of isopropanol containing IS and mixed. This mixture was transferred onto a multi-screen filter, centrifuged at 500xg at 4° C. for 10 minutes. The filtrate was used for LC-MS/MS analysis.",CCCCCCCC(F)(F)CCCCCC/C=C/[C@H](C(O)N[C@@H](Cc1ccc(OCCCC)cc1)C(=O)OC)[C@@](O)(CCOC)C(=O)O,"US9266853, 5514403",23.8,uM,=,1.376576957056512,1,c1ccccc1
2134,1665797,10.1021/acs.jmedchem.7b00328,,,,Inhibition of microsomal CYP3A4 (unknown origin),CNC(=O)c1c(-c2ccc(F)cc2)oc2ccc(-c3cc(C(=O)NC4(c5ncccn5)CC4)ccc3C)cc12,2-(4-Fluorophenyl)-N-methyl-5-(2-methyl-5-(1-(pyrimidin-2-yl)-cyclopropylcarbamoyl)phenyl)benzofuran-3-carboxamide,11.4,uM,=,1.0569048513364727,1,O=C(NC1(c2ncccn2)CC1)c1cccc(-c2ccc3oc(-c4ccccc4)cc3c2)c1
2135,2207924,10.1021/acsmedchemlett.2c00411,,,,Inhibition of CYP3A4 (unknown origin) in absence of NADPH,COc1cc(Nc2ncc(C)c(Nc3ccc4oc(=O)[nH]c4c3)n2)cc(C(F)(F)F)c1,5-((2-((3-methoxy-5-(trifluoromethyl)phenyl)amino)-5-methylpyrimidin-4-yl)amino)benzo[d]oxazol-2(3H)one,7.2,uM,=,0.8573324964312685,1,O=c1[nH]c2cc(Nc3ccnc(Nc4ccccc4)n3)ccc2o1
2136,1541293,10.1016/j.bmc.2015.11.017,,,,Inhibition of human recombinant CYP3A4 by fluorescence assay,O=C([C@@H]1COC(c2nc3cc(C(F)(F)F)cc([N+](=O)[O-])c3s2)=N1)N1CCCC1,"(S)-(2-(7-Nitro-5-(trifluoromethyl)benzo[d]thiazol-2-yl)-4,5-dihydrooxazol-4-yl)(pyrrolidin-1-yl)methanone",18.6,uM,=,1.2695129442179165,1,O=C([C@@H]1COC(c2nc3ccccc3s2)=N1)N1CCCC1
2137,448320,10.1016/j.bmc.2007.05.069,,,,Inhibition of CYP3A4,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)C(=O)C(C)(c1cc(F)ccc1F)O2,"N-{2-[6-(2,4-diamino-6-ethyl-pyrimidin-5-yl)-2-methyl-3-oxo-2-(2,5-difluoro-phenyl)-2,3-dihydro-benzo[1,4]-oxazin-4-yl]-ethyl}-acetamide",1.9,uM,=,0.2787536009528289,1,O=C1Nc2cc(-c3cncnc3)ccc2OC1c1ccccc1
2138,804823,10.1016/j.bmcl.2011.12.080,,,,Time dependent inhibition of CYP3A4,COc1cc(C)c2nc3[nH]nc(C)c3c(C(O)c3cncn3C)c2c1,"rac-(6-methoxy-3,8-dimethyl-1H-pyrazolo[3,4-b]quinolin-4-yl)(1-methyl-1H-imidazol-5-yl)methanol",4.9,uM,=,0.6901960800285137,1,c1ccc2c(Cc3cnc[nH]3)c3cn[nH]c3nc2c1
2139,774749,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1,"10-Dimethylaminomethyl-4-ethyl-4,9-dihydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione",1.5211,uM,=,0.1821577663347813,1,O=C1Cc2cc3n(c(=O)c2CO1)Cc1cc2ccccc2nc1-3
2140,2296580,10.1021/acs.jmedchem.5b02025,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate assessed as reduction in substrate hydroxylation incubated for 5 mins in presence of beta-NADPH measured by LC-MS/MS analysis,NCCCC[C@H](NC(=O)C(NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCCN)C(c1ccccc1)c1ccccc1)C(N)=O,"(2S)-2,6-diamino-N-((5S,11S,14S,17S,20S,23S,26S)-11,20,23-tris((1H-indol-3-yl)methyl)-1,30-diamino-14,17-bis(4-aminobutyl)-8-benzhydryl-5-carbamoyl-7,10,13,16,19,22,25-heptaoxo-6,9,12,15,18,21,24-heptaazatriacontan-26-yl)hexanamide",18.8,uM,=,1.2741578492636798,1,O=C(CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CCc1c[nH]c2ccccc12)NCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCC(c1ccccc1)c1ccccc1
2141,828928,10.1016/j.bmcl.2012.06.022,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N)sc2c1,"Thiazol-5-ylmethyl(2S,3R)-4-(2-amino-N-isobutylbenzo[d]thiazole-6-carboxamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate",0.019,uM,=,-1.7212463990471711,0,O=C(N[C@H](CCNC(=O)c1ccc2ncsc2c1)Cc1ccccc1)OCc1cncs1
2142,1637154,,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4cnc(N5CCCC5)nc4)cc23)c1F,"Propane-1-sulfonic acid {2,4-difluoro-3-[5-(2-pyrrolidin-1-yl-pyrimidin-5-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-phenyl}-amide",5.0,uM,=,0.6989700043360189,1,O=C(c1ccccc1)c1c[nH]c2ncc(-c3cnc(N4CCCC4)nc3)cc12
2143,1931140,10.1016/j.bmcl.2019.06.040,,,,Inhibition of CYP3A4 (unknown origin),Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1,"1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole",0.85,uM,=,-0.0705810742857072,0,c1ccc(COC(Cn2ccnc2)c2ccccc2)cc1
2144,1889156,10.1021/acs.jmedchem.8b01719,,,,Inhibition of CYP3A4 in human liver microsomes using atorvastatin as substrate preincubated for 7 mins followed by NADPH addition and measured by LC-MS/MS analysis,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(-n3ncnc3-c3ccc(B(O)O)c(F)c3)c(C3CC3)cc12,"(4-(1-(5-Cyclopropyl-2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-6-yl)-1H-1,2,4-triazol-5-yl)-2-fluorophenyl)boronic acid",8.9,uM,=,0.9493900066449128,1,c1ccc(-c2cc3cc(C4CC4)c(-n4ncnc4-c4ccccc4)cc3o2)cc1
2145,526157,10.1021/np0401765,,,,Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation,CO[C@@H]1OC[C@H](Cc2ccc3c(c2)OCO3)[C@H]1Cc1ccc2c(c1)OCO2,alpha-methylcubebin,7.7,uM,=,0.8864907251724818,1,c1cc2c(cc1C[C@H]1COC[C@@H]1Cc1ccc3c(c1)OCO3)OCO2
2146,1335568,10.1021/jm401731q,,,,Inhibition of CYP3A4 (unknown origin),CN1CCN(c2cc(N3CC[C@@H]3C(=O)NCCc3ccc(C#N)cc3)nc(C(F)(F)F)n2)CC1,(2R)-N-[2-(4-Cyanophenyl)ethyl]-1-[6-(4-methylpiperazin-1-yl)-2-(trifluoromethyl)pyrimidin-4-yl]azetidine-2-carboxamide,0.8,uM,=,-0.0969100130080563,0,O=C(NCCc1ccccc1)[C@H]1CCN1c1cc(N2CCNCC2)ncn1
2147,347904,10.1016/j.bmcl.2006.01.024,,,,Inhibition of CYP3A4,CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3CC[C@@H](O)C3)c(Cc3cccc4ncccc34)sc21,"(R)-5-(3-hydroxypyrrolidine-1-carbonyl)-1-isobutyl-3-methyl-6-(quinolin-5-ylmethyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione",20.0,uM,=,1.3010299956639813,1,O=C(c1c(Cc2cccc3ncccc23)sc2[nH]c(=O)[nH]c(=O)c12)N1CCCC1
2148,993439,10.6019/CHEMBL2448688,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,CCN(Cc1cccnc1)c1cc(F)cc(-c2nc3ccccc3s2)c1,,0.775,uM,=,-0.1106982974936897,0,c1cncc(CNc2cccc(-c3nc4ccccc4s3)c2)c1
2149,982809,10.1016/j.ejmech.2013.08.010,,,,Inhibition of CYP3A (unknown origin),CC#CCn1c(N2CCC[C@@H](N)C2)cc(=O)n(Cc2cc(Cl)c3ccccc3n2)c1=O,"(R)-6-(3-Aminopiperidin-1-yl)-1-(but-2-yn-1-yl)-3-((4-chloroquinolin-2-yl)methyl)pyrimidine-2,4(1H,3H)-dione",14.08,uM,=,1.1486026548060937,1,O=c1cc(N2CCCCC2)[nH]c(=O)n1Cc1ccc2ccccc2n1
2150,1301328,10.6019/CHEMBL3137440,,,,DNDI: CYP Inhibition,FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ccc(C(F)(F)F)cn3)CC2)cc1,N-[4-(Trifluoromethyl)phenyl]-N-(1-[5-(trifluoromethyl)pyridin-2-yl]piperidin-4-yl)pyridin-3-amine,6.0,uM,=,0.7781512503836436,1,c1ccc(N(c2cccnc2)C2CCN(c3ccccn3)CC2)cc1
2151,1485703,10.1124/dmd.112.048264,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method,OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1,2-{4-[3-(2-Chloro-phenothiazin-10-yl)-propyl]-piperazin-1-yl}-ethanol,13.9,uM,=,1.1430148002540952,1,c1ccc2c(c1)Sc1ccccc1N2CCCN1CCNCC1
2152,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",CC[C@@H]1CN(C(=O)c2ccc(C)cc2-n2nccn2)[C@H](Cc2cccc(-n3nccn3)c2)CO1,"US9150566, 144",9.6,uM,=,0.9822712330395684,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
2153,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N(C)CC(=O)N5CCN(C)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, F-32",5.04,uM,=,0.7024305364455253,1,O=C(NCC(=O)N1CCNCC1)c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12
2154,493017,10.1021/jm800851u,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,COCCOc1cncc(-c2cc(NC(C)=O)nc(-n3nc(C)cc3C)n2)c1,"N-{2-(3,5-Dimethyl-pyrazol-1-yl)-6-[5-(2-methoxy-ethoxy)-pyridin-3-yl]-pyrimidin-4-yl}-acetamide",14.0,uM,=,1.146128035678238,1,c1cncc(-c2ccnc(-n3cccn3)n2)c1
2155,991614,10.1021/jm4008906,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,CCN(CC)C(=O)CN1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O,"(S)-2-(3-(Aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-diethylacetamide",6.6,uM,=,0.8195439355418687,1,O=C1NCc2nccc(-c3ccccc3)c21
2156,814102,10.1016/j.bmcl.2012.03.014,,,,Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins,CC(=O)NCCc1ccccc1-c1onc([C@H]2CNCC[C@]2(O)c2ccc(F)c(F)c2)c1C(C)=O,"N-(2-(4-acetyl-3-((3R,4R)-4-(3,4-difluorophenyl)-4-hydroxypiperidin-3-yl)isoxazol-5-yl)phenethyl)acetamide",8.0,uM,=,0.9030899869919436,1,c1ccc(-c2cc([C@H]3CNCCC3c3ccccc3)no2)cc1
2157,768817,10.1021/jm2005354,,,,Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting,CC[C@@H](c1ccc(-c2ccc(F)cc2)cc1)N1CC[C@](CCCO)(c2ccccc2)OC1=O,"(R)-3-((S)-1-(4'-fluorobiphenyl-4-yl)propyl)-6-(3-hydroxypropyl)-6-phenyl-1,3-oxazinan-2-one",1.5,uM,=,0.1760912590556812,1,O=C1OC(c2ccccc2)CCN1Cc1ccc(-c2ccccc2)cc1
2158,1526216,10.1021/ml500526p,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,Cn1c(Nc2cccc(C(C)(C)C)c2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21,N-(3-tert-butylphenyl)-1-methyl-5-(2-(5-(trifluoromethyl)-1H-imidazol-2-yl)pyridin-4-yloxy)-1H-benzo[d]imidazol-2-amine,10.0,uM,=,1.0,1,c1ccc(Nc2nc3cc(Oc4ccnc(-c5ncc[nH]5)c4)ccc3[nH]2)cc1
2159,1441252,10.1021/jm5010013,,,,Inhibition of CYP3A4 (unknown origin),O=C(O)c1cnncc1NC(=O)N1C[C@H]2C[C@@H](c3ccccc3C(F)(F)F)C[C@H]2C1,"trans-5-((3aR,6aS)-5-(2-(trifluoromethyl)phenyl)octahydrocyclopenta[c]pyrrole-2-carboxamido)pyridazine-4-carboxylic acid",12.0,uM,=,1.0791812460476249,1,O=C(Nc1ccnnc1)N1C[C@H]2C[C@@H](c3ccccc3)C[C@H]2C1
2160,1523392,10.1021/acs.jmedchem.5b00774,,,,Inhibition of CYP3A4 (unknown origin) co-incubated with substrate and protein,O=S(=O)(c1ccc(Cl)cc1)[C@@]12CCCC(CO)(CO)[C@@H]1COc1c(F)ccc(F)c12,"((6aR,10aS)-10a-(4-chlorophenylsulfonyl)-1,4-difluoro-6a,7,8,9,10,10a-hexahydro-6H-benzo[c]chromene-7,7-diyl)dimethanol",11.0,uM,=,1.0413926851582251,1,O=S(=O)(c1ccccc1)[C@@]12CCCC[C@@H]1COc1ccccc12
2161,2017934,10.1021/acs.jmedchem.0c00834,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis,Cc1c(-c2ccccc2)cc2ccc(Br)cc2c1C(=O)Nc1ccc(C(=O)O)cc1F,4-[(7-Bromo-2-methyl-3-phenyl-1-naphthoyl)amino]-3-fluorobenzoic acid,19.0,uM,=,1.2787536009528289,1,O=C(Nc1ccccc1)c1cc(-c2ccccc2)cc2ccccc12
2162,449485,10.1016/j.bmcl.2007.07.097,,,,Inhibition of microsomal CYP3A4,CC(C)C[C@H](NCCCN)c1cccc(F)c1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1,"1-((R)-1-(4-(2-((S)-1-(3-aminopropylamino)-3-methylbutyl)-6-fluorophenyl)piperazin-1-yl)-3-(2,4-dichlorophenyl)-1-oxopropan-2-yl)pyrrolidin-2-one",16.0,uM,=,1.2041199826559248,1,O=C([C@@H](Cc1ccccc1)N1CCCC1=O)N1CCN(c2ccccc2)CC1
2163,1485703,10.1124/dmd.112.048264,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21,"[4-(3,4-Dichloro-phenyl)-1,2,3,4-tetrahydro-naphthalen-1-yl]-methyl-amine (Sertraline)",13.6,uM,=,1.1335389083702174,1,c1ccc([C@@H]2CCCc3ccccc32)cc1
2164,1925644,10.1021/acs.jmedchem.6b00827,,,,Inhibition of CYP3A4 (unknown origin) at 3 uM using midazolam substrate by LC-MS method,CNC(=O)c1c(-c2ccccc2)c([C@H](C)Nc2ncnc(N)c2C#N)nc2ccc(F)cc12,2-((1S)-1-((6-Amino-5-cyano-4-pyrimidinyl)amino)ethyl)-6-fluoro-N-methyl-3-phenyl-4-quinolinecarboxamide,14.0,uM,=,1.146128035678238,1,c1ccc(-c2cc3ccccc3nc2CNc2ccncn2)cc1
2165,619265,10.1016/j.bmcl.2009.07.002,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate,Cc1nc2c(OCc3ccccc3)cccn2c1CC#N,"(8-Benzyloxy-2-methyl-imidazo[1,2-a]pyridin-3-yl)-acetonitrile",12.0,uM,=,1.0791812460476249,1,c1ccc(COc2cccn3ccnc23)cc1
2166,2221809,10.1016/j.bmcl.2022.128625,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as substrate in presence of NADPH,CCC[C@H]1N(C(=O)c2cnccc2C(F)(F)F)CCC[C@@]1(Oc1csc(C(F)(F)F)c1)C(=O)N1CCN(c2ccccc2OCCCC(=O)O)CC1,"4-(2-(4-((2R,3S)-2-propyl-1-(4-(trifluoromethyl)nicotinoyl)-3-((5-(trifluoromethyl)thiophen-3-yl)oxy)piperidine-3-carbonyl)piperazin-1-yl)phenoxy)butanoic acid",20.0,uM,=,1.3010299956639813,1,O=C(c1cccnc1)N1CCC[C@@](Oc2ccsc2)(C(=O)N2CCN(c3ccccc3)CC2)C1
2167,51903,10.1021/jm020557k,,,,Concentration required to inhibit cytochrome P450 3A4.,CCCCOc1ccc(-n2cnc(C)c2)cc1,1-(4-Butoxy-phenyl)-4-methyl-1H-imidazole,9.17,uM,=,0.9623693356700213,1,c1ccc(-n2ccnc2)cc1
2168,2133951,10.1016/j.ejmech.2021.113715,,,,Inhibition of CYP3A4 in human liver microsome using Nifedipine as a substrate incubated for 10 mins in the presence of NADPH by LC-MS/MS analysis,Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1,"1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole",0.0742,uM,=,-1.1295960947209729,0,c1ccc(COC(Cn2ccnc2)c2ccccc2)cc1
2169,774749,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12,"5-Bromo-7-methyl-4,6,6a,7,8,9-hexahydro-indolo[4,3-fg]quinoline-9-carboxylic acid (10b-hydroxy-5-isobutyl-2-isopropyl-3,6-dioxo-octahydro-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl)-amide",2.0,uM,=,0.3010299956639812,1,O=C(NC1OC2[C@@H]3CCCN3C(=O)CN2C1=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2NC1
2170,1568323,10.1021/acs.jmedchem.5b01716,,,,Inhibition of CYP3A4 (unknown origin) in absence of NADPH,COCCOc1cnc2ccc([C@H](C)n3nnc4ccn(-c5cc(C)ns5)c(=O)c43)cc2c1,"(S)-3-(1-(3-(2-methoxyethoxy)quinolin-6-yl)ethyl)-5-(3-methylisothiazol-5-yl)-3H-[1,2,3]triazolo[4,5-c]pyridin-4(5H)-one",1.5,uM,=,0.1760912590556812,1,O=c1c2c(ccn1-c1ccns1)nnn2Cc1ccc2ncccc2c1
2171,814102,10.1016/j.bmcl.2012.03.014,,,,Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins,O[C@]1(c2ccc(F)c(F)c2)CCNC[C@@H]1c1cc(-c2c(Cl)cccc2Cl)no1,"(3S,4R)-3-(3-(2,6-dichlorophenyl)isoxazol-5-yl)-4-(3,4-difluorophenyl)piperidin-4-ol",8.0,uM,=,0.9030899869919436,1,c1ccc(-c2cc([C@H]3CNCCC3c3ccccc3)on2)cc1
2172,659957,10.1021/jm100643t,,,,Inhibition of CYP3A4,CC(C)(C)c1ccc(SCCc2c[nH]cn2)cc1,2-(2-(4-tert-Butylphenylthio)ethyl)-1H-imidazole,0.47,uM,=,-0.3279021420642826,0,c1ccc(SCCc2c[nH]cn2)cc1
2173,1446329,10.1021/ml500387y,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,CC(C)(CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F)c1cccc(S(C)(=O)=O)c1,"1,1,1-trifluoro-4-methyl-4-(3-(methylsulfonyl)phenyl)-2-((5-morpholino-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)pentan-2-ol",0.7,uM,=,-0.1549019599857432,0,c1ccc(CCCCc2cc3cc(N4CCOCC4)ncc3[nH]2)cc1
2174,862399,10.1021/jm300601d,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis,N#Cc1ccc(C(=O)N2CCC(c3ccc(C(=O)NC(=N)N)cc3C(F)(F)F)CC2)cc1,N-{4-[1-(4-Cyano-benzoyl)-piperidin-4-yl]-3-trifluoromethyl-benzoyl}-guanidine,11.0,uM,=,1.0413926851582251,1,O=C(c1ccccc1)N1CCC(c2ccccc2)CC1
2175,2060129,10.1021/acsmedchemlett.1c00112,,,,Inhibition of CYP3A4 (unknown origin),O=C(C1CCS(=O)(=O)CC1)N1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3CC[C@@H]12,"(1,1-Dioxidotetrahydro-2H-thiopyran-4-yl)((3aR,9bR)-9b-((4-fluorophenyl)sulfonyl)-7-(perfluoropropan-2-yl)-1,2,3a,4,5,9b-hexahydro-3H-benzo[e]indol-3-yl)methanone",13.0,uM,=,1.1139433523068367,1,O=C(C1CCS(=O)(=O)CC1)N1CC[C@@]2(S(=O)(=O)c3ccccc3)c3ccccc3CC[C@@H]12
2176,1289880,10.1021/jm401642q,,,,Inhibition of recombinant human CYP3A4,C[C@@H]1Cc2ccccc2N1C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1,"2-{2-[(2R)-2-Methyl-2,3-dihydro-1H-indol-1-yl]-2-oxoethyl}-6-(morpholin-4-yl)-pyrimidin-4(3H)-one",40.0,uM,=,1.6020599913279625,1,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2ccccc21
2177,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)Nc6cccc(OC(C)C)c6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, D-26",13.7,uM,=,1.136720567156407,1,O=C(Nc1ccccc1)c1ccc(-c2c[nH]c3c(CN4C[C@@H]5N(C(=O)NCc6ccccc6)NCC(=O)N5[C@@H](Cc5ccccc5)C4=O)cccc23)cc1
2178,51927,10.1021/jm034111v,,,,Inhibition of recombinant human Cytochrome P450 3A4 using BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 30 minutes,C[C@H](NC(=O)/C=C/c1ccccc1)c1cccc(N2CCOCC2)c1,(E)-N-[1-((S)-3-Morpholin-4-yl-phenyl)-ethyl]-3-phenyl-acrylamide,33.0,uM,=,1.5185139398778875,1,O=C(/C=C/c1ccccc1)NCc1cccc(N2CCOCC2)c1
2179,2246941,10.1021/acs.jmedchem.1c02132,,,,Inhibition of CYP3A4 (unknown origin) incubated for 10 mins in presence of NADPH by LC-MS/MS analysis,CC(=O)Nc1cc(-c2ccc(OC[C@@](C)(N)CC(C)C)c(C(F)(F)F)c2)ccn1,"(S)-N-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)acetamide",14.0,uM,=,1.146128035678238,1,c1ccc(-c2ccncc2)cc1
2180,988447,10.1016/j.bmcl.2013.08.013,,,,Inhibition of CYP3A4 in human liver microsomes,Nc1cc(CN2CCC(F)(C(=O)N3CCC(N4Cc5ccccc5-c5ccccc5C4)CC3)CC2)ccn1,"(4-(5H-dibenzo[c,e]azepin-6(7H)-yl)piperidin-1-yl)(1-((2-aminopyridin-4-yl)methyl)-4-fluoropiperidin-4-yl)methanone",18.0,uM,=,1.255272505103306,1,O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(N2Cc3ccccc3-c3ccccc3C2)CC1
2181,1446329,10.1021/ml500387y,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2cc(C(N)=O)ncc2[nH]1)C(F)(F)F,"2-(4-(5-fluoro-2-methylphenyl)-2-hydroxy-4-methyl-2-(trifluoromethyl)pentyl)-1H-pyrrolo[2,3-c]pyridine-5-carboxamide",2.0,uM,=,0.3010299956639812,1,c1ccc(CCCCc2cc3ccncc3[nH]2)cc1
2182,2273353,10.1021/acs.jmedchem.8b01971,,,,Inhibition of CYP3A4 in human liver microsomes using Midazolam as substrate preincubated for 10 mins followed by NADPH addition and measured after 15 mins by LC-MS/MS analysis,Cc1ccc(CS(=O)(=O)NC(=O)C2(C)CCN(c3nc4c(cc3C#N)C(=O)OC4)CC2)cc1,"1-(3-Cyano-5-oxo-5,7-dihydrofuro[3,4-b]pyridin-2-yl)-4-methyl-N-((4-methylbenzyl)sulfonyl)piperidine-4-carboxamide",1.64,uM,=,0.2148438480476978,1,O=C1OCc2nc(N3CCC(C(=O)NS(=O)(=O)Cc4ccccc4)CC3)ccc21
2183,804823,10.1016/j.bmcl.2011.12.080,,,,Time dependent inhibition of CYP3A4,COc1cc(C)c2nc3[nH]nc(C)c3c(C(O)c3cncs3)c2c1,"rac-(6-methoxy-3,8-dimethyl-1H-pyrazolo[3,4-b]quinolin-4-yl)(thiazol-5-yl)methanol",0.7,uM,=,-0.1549019599857432,0,c1ccc2c(Cc3cncs3)c3cn[nH]c3nc2c1
2184,966467,10.1016/j.bmcl.2013.04.077,,,,Inhibition of CYP3A4 (unknown origin),Cc1ccc(C(=O)N(CC(=O)Nc2ncc(-c3ccc(N)cc3)s2)Cc2ccccc2)cn1,N-(2-(5-(4-aminophenyl)thiazol-2-ylamino)-2-oxoethyl)-N-benzyl-6-methylnicotinamide,15.0,uM,=,1.1760912590556811,1,O=C(CN(Cc1ccccc1)C(=O)c1cccnc1)Nc1ncc(-c2ccccc2)s1
2185,993439,10.6019/CHEMBL2448688,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,CO/N=C(\C)c1ccc(-n2ccnc2)c(NC(=O)c2cnc(-c3ccccc3)nc2)c1,,18.0,uM,=,1.255272505103306,1,O=C(Nc1ccccc1-n1ccnc1)c1cnc(-c2ccccc2)nc1
2186,982809,10.1016/j.ejmech.2013.08.010,,,,Inhibition of CYP3A (unknown origin),CC#CCn1c(N2CCC[C@@H](N)C2)cc(=O)n(Cc2ccc3cc(Cl)ccc3n2)c1=O,"(R)-6-(3-Aminopiperidin-1-yl)-1-(but-2-yn-1-yl)-3-((6-chloroquinolin-2-yl)methyl)pyrimidine-2,4(1H,3H)-dione",91.93,uM,=,1.963457260116708,1,O=c1cc(N2CCCCC2)[nH]c(=O)n1Cc1ccc2ccccc2n1
2187,305432,10.1016/j.bmcl.2005.01.044,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,CC(C(c1ccc2cc(OCc3ccc(C(=O)O)cc3)ccc2c1)n1ccnc1)N(C)C,4-[6-(2-Dimethylamino-1-imidazol-1-yl-propyl)-naphthalen-2-yloxymethyl]-benzoic acid,0.64,uM,=,-0.1938200260161128,0,c1ccc(COc2ccc3cc(Cn4ccnc4)ccc3c2)cc1
2188,1276541,10.1016/j.bmcl.2013.09.041,,,,Inhibition of CYP3A4 (unknown origin) after 5 mins,O=S(=O)(Nc1ccc(-c2cncnc2)cc1)c1cc(Cl)cc(Cl)c1,"3,5-dichloro-N-(4-(pyrimidin-5-yl)phenyl)benzenesulfonamide",3.5,uM,=,0.5440680443502757,1,O=S(=O)(Nc1ccc(-c2cncnc2)cc1)c1ccccc1
2189,962469,10.1021/jm4004895,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC/MS/MS analysis,C[C@@H](O)c1nc2cnc3[nH]ccc3c2n1[C@H]1CC[C@H](CC#N)CC1,"2-(trans-4-(2-((R)-1-Hydroxyethyl)imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)cyclohexyl)acetonitrile",8.8,uM,=,0.9444826721501688,1,c1cc2c(ncc3ncn(C4CCCCC4)c32)[nH]1
2190,471117,10.1016/j.bmc.2007.10.061,,,,Inhibition of CYP3A4,Nc1nccn2c1c(-c1ccc3ccc(-c4ccccc4)nc3c1)nc2[C@H]1C[C@@H](N2CCSCC2)C1,"cis-1-(2-phenylquinolin-7-yl)-3-(3-thiomorpholin-4-ylcyclobutyl)-imidazo[1,5-a]pyrazin-8-ylamine",7.8,uM,=,0.8920946026904804,1,c1ccc(-c2ccc3ccc(-c4nc([C@H]5C[C@@H](N6CCSCC6)C5)n5ccncc45)cc3n2)cc1
2191,1289880,10.1021/jm401642q,,,,Inhibition of recombinant human CYP3A4,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2cc(Cl)ccc21,"2-[2-(5-Chloro-2,3-dihydroindol-1-yl)-2-oxoethyl]-6-morpholin-4-yl-3H-pyrimidin-4-one",40.0,uM,=,1.6020599913279625,1,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2ccccc21
2192,449088,10.1016/j.bmcl.2007.08.028,,,,Inhibition of human CYP3A4,CC(=O)N1CCC(C(=O)N2C[C@H](c3noc(C(C)(C)c4cc(C(F)(F)F)cc(C(F)(F)F)c4)n3)[C@@H](c3ccc(F)cc3C)C2)CC1,"1-(4-((3R,4S)-3-(5-(2-(3,5-bis(trifluoromethyl)phenyl)propan-2-yl)-1,2,4-oxadiazol-3-yl)-4-(4-fluoro-2-methylphenyl)pyrrolidine-1-carbonyl)piperidin-1-yl)ethanone",100.0,uM,=,2.0,1,O=C(C1CCNCC1)N1C[C@H](c2ccccc2)[C@@H](c2noc(Cc3ccccc3)n2)C1
2193,776115,10.1016/j.bmcl.2011.09.074,,,,Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin,COCCN1Cc2c(nc(C)c(CN)c2-c2ccc(Cl)cc2Cl)C1=O,"3-(aminomethyl)-4-(2,4-dichlorophenyl)-6-(2-methoxyethyl)-2-methyl-5H-pyrrolo[3,4-b]pyridin-7(6H)-one",22.0,uM,=,1.3424226808222062,1,O=C1NCc2c(-c3ccccc3)ccnc21
2194,813216,10.1016/j.bmcl.2012.01.125,,,,Inhibition of CYP3A4,Cc1noc(C)c1-c1ccc2c(Nc3ccccc3C(C)(C)C)c(C(=O)O)cnc2c1,"4-(2-tert-butylphenylamino)-7-(3,5-dimethylisoxazol-4-yl)quinoline-3-carboxylic acid",13.0,uM,=,1.1139433523068367,1,c1ccc(Nc2ccnc3cc(-c4cnoc4)ccc23)cc1
2195,1858698,10.1021/acs.jmedchem.0c00117,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam substrate incubated for 10 mins in presence of NADPH,Cc1cc(/C=C/C#N)cc(C)c1Oc1nc(NC2CCN(Cc3ccc(S(N)(=O)=O)cc3)CC2)nc2sccc12,"(E)-4-((4-((4-(4-(2-Cyanovinyl)-2,6-dimethylphenoxy)thieno[2,3-d]pyrimidin-2-yl)amino)piperidin-1-yl)methyl)benzenesulfonamide",7.95,uM,=,0.9003671286564703,1,c1ccc(CN2CCC(Nc3nc(Oc4ccccc4)c4ccsc4n3)CC2)cc1
2196,487712,10.1016/j.bmcl.2008.05.104,,,,Inhibition of CYP3A4,Cc1cc(N2CCC3(CC2)OCCO3)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,"4-[(S)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-[6-(1,4-dioxa-8-aza-spiro[4.5]dec-8-yl)-4-methyl-1H-benzoimidazol-2-yl]-1H-pyridin-2-one",0.0007,uM,=,-3.154901959985743,0,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(N3CCC4(CC3)OCCO4)cc2[nH]1
2197,619265,10.1016/j.bmcl.2009.07.002,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate,Cc1cccc(C)c1CNc1nc(-n2ccccc2=O)cc2c(C)c(C)[nH]c12,"1-(7-(2,6-dimethylbenzylamino)-2,3-dimethyl-1H-pyrrolo[2,3-c]pyridin-5-yl)pyridin-2(1H)-one",90.0,uM,=,1.954242509439325,1,O=c1ccccn1-c1cc2cc[nH]c2c(NCc2ccccc2)n1
2198,1499751,10.1021/acs.jmedchem.5b00424,,,,Inhibition of CYP3A4 (unknown origin),COc1cccc(CC(=O)Nc2cc(-c3ccncc3)cs2)c1,2-(3-Methoxyphenyl)-N-(4-(pyridin-4-yl)thiophen-2-yl)acetamide,0.48,uM,=,-0.3187587626244128,0,O=C(Cc1ccccc1)Nc1cc(-c2ccncc2)cs1
2199,1632088,10.1016/j.bmc.2016.11.051,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by NADPH addition measured after 10 mins by LC/MS/MS method,CC(C)COC(=O)[C@H](Cn1ccnc1)NC(=O)c1ccc(-c2ccccc2F)cc1,"Isobutyl (S)-2-(2'-fluoro-[1,1'-biphenyl]-4-carboxamido)-3-(1H-imidazol-1-yl)propanoate",0.155,uM,=,-0.8096683018297085,0,O=C(NCCn1ccnc1)c1ccc(-c2ccccc2)cc1
2200,51903,10.1021/jm020557k,,,,Concentration required to inhibit cytochrome P450 3A4.,CCCCOc1ccc(-c2ncc[nH]2)cc1,2-(4-Butoxy-phenyl)-1H-imidazole,44.3,uM,=,1.6464037262230695,1,c1ccc(-c2ncc[nH]2)cc1
2201,1436762,10.1021/ml500187a,,,,Inhibition of human recombinant CYP3A4 incubated for 5 mins by fluorescence assay,CNCC[C@H](Oc1cccc2ccccc12)c1cccs1,Methyl-[(S)-3-(naphthalen-1-yloxy)-3-thiophen-2-yl-propyl]-amine,0.44,uM,=,-0.3565473235138126,0,c1csc(COc2cccc3ccccc23)c1
2202,785354,10.1016/j.bmcl.2011.08.060,,,,Inhibition of CYP3A4,COc1ccc(Br)cc1-c1csc(Nc2ccc(-n3cnc(C)c3)c(OC)c2)n1,4-(5-bromo-2-methoxyphenyl)-N-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)thiazol-2-amine,2.2,uM,=,0.3424226808222063,1,c1ccc(-c2csc(Nc3ccc(-n4ccnc4)cc3)n2)cc1
2203,1923841,10.1021/acs.jmedchem.6b00280,,,,Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase and human b5 reductase assessed as reduction in 7-Hydroxyquinoline production using 7-benzyloxyquinoline as substrate and NADPH incubated for 15 mins by fluorimetry,O=C(NCCN1CCOCC1)Nc1nc2ccc(Sc3nnc4ccc(OC5CCCC5)nn34)cc2s1,"1-(6-(6-(cyclopentyloxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-ylthio)benzo[d]thiazol-2-yl)-3-(2-morpholinoethyl)urea",31.0,uM,=,1.4913616938342726,1,O=C(NCCN1CCOCC1)Nc1nc2ccc(Sc3nnc4ccc(OC5CCCC5)nn34)cc2s1
2204,495542,10.1021/jm801332q,,,,Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate by time dependent inhibition assay,CC(C(=O)N1CCC(Nc2ccc(F)cc2)CC1)c1ccc(CN2C[C@@H](C)N[C@@H](C)C2)cc1,"1-[2-(4-([(3R,5S)-3,5-Dimethyl-1-piperazinyl]methyl)phenyl)propanoyl]-N-(4-fluorophenyl)-4-piperidinamine",8.7,uM,=,0.9395192526186184,1,O=C(Cc1ccc(CN2CCNCC2)cc1)N1CCC(Nc2ccccc2)CC1
2205,1660136,10.1021/acs.jmedchem.6b01918,,,,Inhibition of human CYP3A4 assessed as inhibition of dealkylation,N[C@H]1CC[C@](CCNc2cc(F)c(S(=O)(=O)Nc3nccs3)cc2Cl)(c2ccccc2)CC1,"cis-4-((2-((1R,4R)-4-Amino-1-phenylcyclohexyl)ethyl)amino)-5-chloro-2-fluoro-N-(thiazol-2-yl)benzenesulfonamide",6.7,uM,=,0.8260748027008264,1,O=S(=O)(Nc1nccs1)c1ccc(NCCC2(c3ccccc3)CCCCC2)cc1
2206,1892125,10.1016/j.ejmech.2019.03.017,,,,Inhibition of human CYP3A4 measured after 30 mins in presence of NADPH regeneration system by luminescent CYP3A4 P450-Glo assay,CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,SID144204227,0.14,uM,=,-0.8538719643217619,0,c1ccc([C@@]2(Cn3ccnc3)OC[C@H](COc3ccc(N4CCNCC4)cc3)O2)cc1
2207,1931140,10.1016/j.bmcl.2019.06.040,,,,Inhibition of CYP3A4 (unknown origin),CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,SID144204227,0.2,uM,=,-0.6989700043360187,0,c1ccc([C@@]2(Cn3ccnc3)OC[C@H](COc3ccc(N4CCNCC4)cc3)O2)cc1
2208,2062192,10.1016/j.bmcl.2016.04.018,,,,Inhibition of human liver microsomes CYP3A4 using testosterone as substrate by MUX-MS/MS analysis,O=C(Nc1ccc(Cl)c(Cl)c1)N1CCOc2ccc(-c3ccncc3)cc2C1,"N-(3,4-dichlorophenyl)-7-(pyridin-4-yl)-2,3-dihydrobenzo[f][1,4]oxazepine-4(5H)-carboxamide",192.0,uM,=,2.2833012287035497,1,O=C(Nc1ccccc1)N1CCOc2ccc(-c3ccncc3)cc2C1
2209,825128,10.1016/j.bmcl.2012.03.070,,,,Inhibition of human CYP3A4 in liver microsomes,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1,"((1R,2R,4R)-1-Benzyl-2-hydroxy-4-{(R)-2-[3-(2-isopropyl-1lambda*4*-[1,3]thiazin-5-ylmethyl)-3-methyl-ureido]-3-methyl-butyrylamino}-5-phenyl-pentyl)-carbamic acid thiazol-5-ylmethyl ester",0.1,uM,=,-1.0,0,O=C(CNC(=O)NCc1cscn1)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
2210,1925644,10.1021/acs.jmedchem.6b00827,,,,Inhibition of CYP3A4 (unknown origin) at 3 uM using midazolam substrate by LC-MS method,C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2c(C(N)=O)c1-c1ccccc1,2-((1S)-1-((6-Amino-5-cyano-4-pyrimidinyl)amino)ethyl)-6-fluoro-3-phenyl-4-quinolinecarboxamide,13.0,uM,=,1.1139433523068367,1,c1ccc(-c2cc3ccccc3nc2CNc2ccncn2)cc1
2211,1561100,10.1021/acsmedchemlett.5b00253,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated with substrate for 5 mins followed by NADPH addition measured after 20 mins by HPLC analysis,Cc1ccc(NC(=O)[C@H]2C[C@@H](O)C[C@@H]2c2nnc([C@H]3C[C@@H](CC(C)C)C3)n2C2CC2)c(C)c1,"(1S,2S,4S)-2-(4-Cyclopropyl-5-(cis-3-isobutylcyclobutyl)-4H-1,2,4-triazol-3-yl)-N-(2,4-dimethylphenyl)-4-hydroxycyclopentanecarboxamide",3.0,uM,=,0.4771212547196624,1,O=C(Nc1ccccc1)[C@H]1CCC[C@@H]1c1nnc(C2CCC2)n1C1CC1
2212,1878505,10.1021/acs.jmedchem.9b01157,,,,Inhibition of CYP3A4 (unknown origin),COc1ccc(CC[C@@H](OC(=O)[C@@H]2CCCCN2C(=O)[C@@H]2CCC[C@@H]3CCCC[C@H]32)c2cccc(OCC(=O)O)c2)cc1OC,"2-(3-((R)-1-(((S)-1-((1R,4aS,8aR)-decahydronaphthalene-1-carbonyl)piperidine-2-carbonyl)oxy)-3-(3,4-dimethoxyphenyl)propyl)phenoxy)acetic acid",8.4,uM,=,0.9242792860618816,1,O=C(O[C@H](CCc1ccccc1)c1ccccc1)[C@@H]1CCCCN1C(=O)[C@@H]1CCC[C@@H]2CCCC[C@H]21
2213,1772538,10.1016/j.bmcl.2018.05.055,,,,Inhibition of CYP3A4 (unknown origin),CC(=O)N[C@@H](C)/C=C/c1ccc(Oc2ccc(OCC3CC3)cc2Cl)nc1,"(S,E)-N-(4-(6-(2-chloro-4-(cyclopropylmethoxy)phenoxy)pyridin-3-yl)but-3-en-2-yl)acetamide",16.0,uM,=,1.2041199826559248,1,c1ccc(Oc2ccc(OCC3CC3)cc2)nc1
2214,2133951,10.1016/j.ejmech.2021.113715,,,,Inhibition of CYP3A4 in human liver microsome using Nifedipine as a substrate incubated for 10 mins in the presence of NADPH by LC-MS/MS analysis,CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OCC5COC(Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O,"2-sec-Butyl-4-[4-(4-{4-[(2R,4S)-2-(2,4-dichloro-phenyl)-2-[1,2,4]triazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-phenyl]-2,4-dihydro-[1,2,4]triazol-3-one",0.0326,uM,=,-1.4867823999320608,0,O=c1[nH]ncn1-c1ccc(N2CCN(c3ccc(OCC4COC(Cn5cncn5)(c5ccccc5)O4)cc3)CC2)cc1
2215,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1ccc(C(=O)N2CCOC[C@H]2Cc2cc(-n3cccn3)ccc2C)c(-n2nccn2)c1,"US9150566, 189",17.0,uM,=,1.230448921378274,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2cccn2)c1
2216,519908,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,Cc1cccc(C)c1CNc1cc(-n2cccn2)cn2c(C)c(C)nc12,"N-(2,6-dimethylbenzyl)-2,3-dimethyl-6-(1H-pyrazol-1-yl)imidazo[1,2-a]pyridin-8-amine",2.1,uM,=,0.3222192947339193,1,c1ccc(CNc2cc(-n3cccn3)cn3ccnc23)cc1
2217,1625607,10.1016/j.bmcl.2016.10.016,,,,Inhibition of human Cyp3A4 using testosterone as substrate by LC-MS/MS analysis,O=S(=O)(C1CC1)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,"1-(cyclopropanesulfonyl)-4-(4-{[(2S,4R)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine",0.185,uM,=,-0.7328282715969863,0,O=S(=O)(C1CC1)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccccc4)O3)cc2)CC1
2218,2133633,10.1021/acs.jmedchem.1c00679,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins in presence of NADPH by LCMS/MS analysis,CCC(NC(=O)c1ccc(Cl)cc1)[C@H]1[C@@H]2C[C@@H](n3cnc4cc(F)ccc43)C[C@@H]21,"4-chloro-N-(1-((1R,3s,5S,6r)-3-(5-fluoro-1H-benzo[d]imidazol-1-yl)bicyclo[3.1.0]hexan-6-yl)propyl)benzamide",1.3,uM,=,0.1139433523068367,1,O=C(NC[C@@H]1[C@H]2C[C@H](n3cnc4ccccc43)C[C@@H]12)c1ccccc1
2219,349088,10.1016/j.bmcl.2006.01.084,,,,Inhibition of CYP3A4 using BFC fluorogenic substrate,COc1ccccc1COCCCOc1ccc(N2C(=O)CNC[C@@H]2COc2ccc3c(c2)N(CCC(=O)O)CCC3)cc1,"(R)-3-(7-((1-(4-(3-(2-methoxybenzyloxy)propoxy)phenyl)-6-oxopiperazin-2-yl)methoxy)-3,4-dihydroquinolin-1(2H)-yl)propanoic acid",10.0,uM,=,1.0,1,O=C1CNC[C@H](COc2ccc3c(c2)NCCC3)N1c1ccc(OCCCOCc2ccccc2)cc1
2220,449485,10.1016/j.bmcl.2007.07.097,,,,Inhibition of microsomal CYP3A4,CC(C)C[C@H](N)c1cccc(F)c1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1,"1-[(R)-2-{4-[2-((S)-1-amino-3-methylbutyl)-6-fluorophenyl]piperazin-1-yl}-1-(2,4-dichlorobenzyl)-2-oxoethyl]pyrrolidin-2-one",0.17,uM,=,-0.7695510786217261,0,O=C([C@@H](Cc1ccccc1)N1CCCC1=O)N1CCN(c2ccccc2)CC1
2221,52069,10.1021/jm021012t,,,,Inhibition of human cytochrome P450 3A4,CC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,1-(4-tert-Butyl-phenyl)-4-[4-(hydroxy-diphenyl-methyl)-piperidin-1-yl]-butan-1-ol,0.32,uM,=,-0.494850021680094,0,c1ccc(CCCCN2CCC(C(c3ccccc3)c3ccccc3)CC2)cc1
2222,686352,10.1016/j.bmcl.2010.09.037,,,,Inhibition of CYP3A4,O=c1cc(-c2ccc(Cl)cc2Cl)ccn1-c1ccc2c(cnn2CCN2CCCC2)c1,"4-(2,4-dichlorophenyl)-1-(1-(2-(pyrrolidin-1-yl)ethyl)-1H-indazol-5-yl)pyridin-2(1H)-one",1.7,uM,=,0.2304489213782739,1,O=c1cc(-c2ccccc2)ccn1-c1ccc2c(cnn2CCN2CCCC2)c1
2223,449485,10.1016/j.bmcl.2007.07.097,,,,Inhibition of microsomal CYP3A4,CC(C)C[C@H](NCCN)c1cccc(F)c1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1,"1-((R)-1-(4-(2-((S)-1-(2-aminoethylamino)-3-methylbutyl)-6-fluorophenyl)piperazin-1-yl)-3-(2,4-dichlorophenyl)-1-oxopropan-2-yl)pyrrolidin-2-one",4.9,uM,=,0.6901960800285137,1,O=C([C@@H](Cc1ccccc1)N1CCCC1=O)N1CCN(c2ccccc2)CC1
2224,1474033,10.1021/jm501218e,,,,Inhibition of human recombinant CYP3A4 assessed as metabolism of 7-benzyloxy-4-trifluoromethylcoumarin to HFC after 30 mins by fluorescence assay,CC/C(=C(/c1ccc(O)cc1)c1ccc(OCCN)cc1)c1ccccc1,(E)-4-(1-(4-(2-Aminoethoxy)phenyl)-2-phenylbut-1-enyl)phenol,0.285,uM,=,-0.5451551399914898,0,C(=C(c1ccccc1)c1ccccc1)c1ccccc1
2225,1289242,10.1016/j.bmcl.2013.12.088,,,,Inhibition of CYP3A4 (unknown origin) using benzyloxyresorufin as substrate,Fc1cc(OC(F)(F)C(F)F)cc([C@@](Cc2ccccc2)(Nc2nc3cc(F)ccc3[nH]2)c2ccc(Cl)cn2)c1,"(R)-N-(1-(5-chloropyridin-2-yl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-5-fluoro-1H-benzo[d]imidazol-2-amine",40.0,uM,=,1.6020599913279625,1,c1ccc(C[C@@](Nc2nc3ccccc3[nH]2)(c2ccccc2)c2ccccn2)cc1
2226,510198,10.1021/jm800355c,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,COc1ccc(-c2ccc3c(c2)CCC3(O)c2ccncc2)cc1,"5-(4-Methoxyphenyl)-1-(pyridin-4-yl)-2,3-dihydro-1H-inden-ol",3.291,uM,=,0.5173278822943735,1,c1ccc(-c2ccc3c(c2)CCC3c2ccncc2)cc1
2227,2164039,10.1021/acs.jmedchem.1c02110,,,,Inhibition of CYP3A4 (unknown origin),CCOP(=O)(Cn1ccc(NC(=O)c2cc(Oc3cnc(C(=O)N4CCC4)cn3)cc(OC(C)C)c2)n1)OCC,diethyl (3-(3-(5-(azetidine-1-carbonyl)pyrazin-2-yloxy)-5-isopropoxybenzamido)-1H-pyrazol-1-yl)methylphosphonate,30.0,uM,=,1.4771212547196624,1,O=C(Nc1cc[nH]n1)c1cccc(Oc2cnc(C(=O)N3CCC3)cn2)c1
2228,1845477,10.1021/acsmedchemlett.0c00004,,,,Inhibition of CYP3A4 (unknown origin),O[C@@H]1COCC[C@H]1[C@H]1c2ccccc2-c2cncn21,"(3S,4S)-4-((S)-5H-imidazo[5,1-a]isoindol-5-yl)tetrahydro-2H-pyran-3-ol",0.6,uM,=,-0.2218487496163563,0,c1ccc2c(c1)-c1cncn1[C@H]2C1CCOCC1
2229,1288280,10.1016/j.bmcl.2013.12.057,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,CC(C)c1nc(CN(C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,"Thiazol-5-ylmethyl(2R,5R)-5-((S)-4-amino-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-4-oxobutanamido)-1,6-diphenylhexan-2-ylcarbamate",0.13,uM,=,-0.8860566476931633,0,O=C(CNC(=O)NCc1cscn1)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
2230,2073753,10.1021/acs.jmedchem.0c00983,,,,Inhibition of CYP3A4 (unknown origin),COc1ccc2c3c([nH]c2c1)[C@@H]1N(CC3)C(=O)c2c(OC)cccc2N1C,"(S)-4,11-Dimethoxy-14-methyl-7,8,13b,14-tetrahydroindolo-[2',3':3,4]pyrido[2,1-b]quinazolin-5(13H)-one",10.0,uM,=,1.0,1,O=C1c2ccccc2N[C@@H]2c3[nH]c4ccccc4c3CCN12
2231,854798,10.1016/j.bmc.2012.08.056,,,,Inhibition of human CYP3A4 using 7-benzyloxy-4-(trifluoromethyl) coumarin as substrate,CN(Cc1cccs1)C(=O)CC12CC3CC(CC(C3)C1)C2,2-(Adamantan-1-yl)-N-methyl-N-(thiophen-2-ylmethyl)acetamide,0.15,uM,=,-0.8239087409443188,0,O=C(CC12CC3CC(CC(C3)C1)C2)NCc1cccs1
2232,1540696,10.1016/j.ejmech.2015.08.051,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 2 mins by LC-MS/MS analysis in presence of NADPH regeneration system,CC(C)c1nc(C(=O)NC[C@@H]2[C@H]3CN(CC4CCOCC4)C[C@@H]23)c2ccccn12,"3-isopropyl-N-(((1R,5S,6s)-3-((tetrahydro-2H-pyran-4-yl)methyl)-3-azabicyclo[3.1.0]hexan-6-yl)methyl)imidazo[1,5-a]pyridine-1-carboxamide",41.4,uM,=,1.6170003411208989,1,O=C(NC[C@@H]1[C@H]2CN(CC3CCOCC3)C[C@@H]12)c1ncn2ccccc12
2233,2296579,10.1021/acs.jmedchem.5b02025,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate assessed as reduction in substrate hydroxylation incubated for 5 mins in presence of beta-NADPH measured by LC-MS/MS analysis,NCCCC[C@H](NC(=O)C(NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCCN)C(c1ccccc1)c1ccccc1)C(N)=O,"(2S)-2,6-diamino-N-((5S,11S,14S,17S,20S,23S,26S)-11,20,23-tris((1H-indol-3-yl)methyl)-1,30-diamino-14,17-bis(4-aminobutyl)-8-benzhydryl-5-carbamoyl-7,10,13,16,19,22,25-heptaoxo-6,9,12,15,18,21,24-heptaazatriacontan-26-yl)hexanamide",9.3,uM,=,0.9684829485539352,1,O=C(CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CCc1c[nH]c2ccccc12)NCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCC(c1ccccc1)c1ccccc1
2234,465432,10.1016/j.bmcl.2007.11.008,,,,Inhibition of CYP3A4,CC(C)C[C@@H]1C(=O)N[C@H](C2Cc3ccccc3C2)C(=O)N1[C@@H](C(=O)NC(C)C)c1ccc(F)cc1F,"(R)-2-(2,4-Difluoro-phenyl)-2-((R)-3-(R)-indan-2-yl-6-isobutyl-2,5-dioxo-piperazin-1-yl)-N-isopropyl-acetamide",4.0,uM,=,0.6020599913279624,1,O=C1CN(Cc2ccccc2)C(=O)[C@@H](C2Cc3ccccc3C2)N1
2235,52064,10.1016/s0960-894x(03)00058-1,,,,Inhibitory activity against CYP450 3A4 isozyme,CCCc1cn(CC(=O)N(CCN(CC)CC)Cc2ccc(-c3ccc(C(F)(F)F)cc3)cc2)c(SCc2ccc(F)cc2)nc1=O,N-(2-Diethylamino-ethyl)-2-[2-(4-fluoro-benzylsulfanyl)-4-oxo-5-propyl-4H-pyrimidin-1-yl]-N-(4'-trifluoromethyl-biphenyl-4-ylmethyl)-acetamide,5.0,uM,=,0.6989700043360189,1,O=C(Cn1ccc(=O)nc1SCc1ccccc1)NCc1ccc(-c2ccccc2)cc1
2236,1474044,10.1021/jm501740a,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,O=C(N[C@H](c1ccccn1)C1CC1)c1ccc2[nH]nc(-c3ccc(N4[C@H]5CC[C@H]4CC(O)C5)cc3)c2c1,N-((S)-Cyclopropyl(pyridin-2-yl)methyl)-3-(4-((endo)-3-hydroxy-8-azabicyclo[3.2.1]octan-8-yl)phenyl)-1H-indazole-5-carboxamide,2.1,uM,=,0.3222192947339193,1,O=C(N[C@H](c1ccccn1)C1CC1)c1ccc2[nH]nc(-c3ccc(N4[C@@H]5CCC[C@@H]4CC5)cc3)c2c1
2237,1868061,10.1039/C8MD00313K,,,,Inhibition of CYP3A4 (unknown origin) using beetle D-luciferin as substrate by CYP450-Glo assay,Cn1cncc1-c1c[nH]c2ccc(C(N)=O)cc12,3-(1-methyl-1H-imidazol-5-yl)-1H-indole-5-carboxamide,3.53,uM,=,0.5477747053878226,1,c1ccc2c(-c3cnc[nH]3)c[nH]c2c1
2238,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CC(N7CCN(C)CC7)C6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, G-62",4.1,uM,=,0.6127838567197355,1,O=C(Nc1ccc(N2CC(N3CCNCC3)C2)nc1)c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12
2239,305432,10.1016/j.bmcl.2005.01.044,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,COC(=O)c1cccc(COc2ccc3cc(C(C(C)N(C)C)n4ccnc4)ccc3c2)c1,3-[6-(2-Dimethylamino-1-imidazol-1-yl-propyl)-naphthalen-2-yloxymethyl]-benzoic acid methyl ester,0.16,uM,=,-0.7958800173440752,0,c1ccc(COc2ccc3cc(Cn4ccnc4)ccc3c2)cc1
2240,2246941,10.1021/acs.jmedchem.1c02132,,,,Inhibition of CYP3A4 (unknown origin) incubated for 10 mins in presence of NADPH by LC-MS/MS analysis,CC(=O)Nc1cc(-c2cc(F)c(OC[C@@H](N)CC(C)C)cc2F)ccn1,"(S)-N-(4-(4-((2-amino-4-methylpentyl)oxy)-2,5-difluorophenyl)pyridin-2-yl)acetamide",7.0,uM,=,0.8450980400142568,1,c1ccc(-c2ccncc2)cc1
2241,1858698,10.1021/acs.jmedchem.0c00117,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam substrate incubated for 10 mins in presence of NADPH,Cc1cc(/C=C/C#N)cc(C)c1Oc1nc(NC2CCN(Cc3ccc(S(N)(=O)=O)cc3)CC2)nc2ccsc12,"(E)-4-((4-((4-(4-(2-Cyanovinyl)-2,6-dimethylphenoxy)thieno[3,2-d]pyrimidin-2-yl)amino)piperidin-1-yl)methyl)benzenesulfonamide",5.92,uM,=,0.7723217067229198,1,c1ccc(CN2CCC(Nc3nc(Oc4ccccc4)c4sccc4n3)CC2)cc1
2242,519907,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,Cc1nc2c(N[C@H]3c4ccccc4C[C@@H]3O)cc(-n3ccccc3=O)cn2c1C,"1-(8-((1S,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-ylamino)-2,3-dimethylimidazo[1,2-a]pyridin-6-yl)pyridin-2(1H)-one",62.0,uM,=,1.792391689498254,1,O=c1ccccn1-c1cc(N[C@@H]2CCc3ccccc32)c2nccn2c1
2243,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",O=C(c1cc(Cl)ccc1-n1nccn1)N1CCOC[C@H]1Cc1cc(-n2nccn2)ccc1F,"US9150566, 129",26.0,uM,=,1.414973347970818,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
2244,577748,10.1016/j.ejmech.2009.01.002,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsome at 1 uM,CCC(c1ccc(-c2ccc(O)c(Cl)c2)cc1)n1ccnc1,rac-3-Chloro-4'-(1-imidazol-1-yl-propyl)-biphenyl-4-ol,0.091,uM,=,-1.0409586076789064,0,c1ccc(-c2ccc(Cn3ccnc3)cc2)cc1
2245,2164346,10.1021/acs.jmedchem.1c02192,,,,Inhibition of CYP3A4 (unknown origin),Cc1nc2cnc3cc(F)c(-c4ccc(Oc5ncccn5)cc4Cl)cc3c2n1[C@H]1CC[C@](N)(CC#N)CC1,"cis-2-[1-amino-4-[8-(2-chloro-4-pyrimidin-2-yloxy-phenyl)-7-fluoro-2-methyl-imidazo[4,5-c]quinolin-1-yl]cyclohexyl]acetonitrile",12.1,uM,=,1.08278537031645,1,c1cnc(Oc2ccc(-c3ccc4ncc5ncn(C6CCCCC6)c5c4c3)cc2)nc1
2246,2017934,10.1021/acs.jmedchem.0c00834,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis,Cc1c(N2CCCCC2)nc2ccc(Br)cc2c1C(=O)NCC(CCC(=O)O)c1ccccc1Cl,(+)-5-({[6-Bromo-3-methyl-2-(piperidin-1-yl)quinolin-4-yl]carbonyl}amino)-4-(2-chlorophenyl)pentanoic acid,15.0,uM,=,1.1760912590556811,1,O=C(NCCc1ccccc1)c1cc(N2CCCCC2)nc2ccccc12
2247,51930,10.1016/s0960-894x(01)00614-x,,,,Inhibition of recombinant human Cytochrome P450 3A4,CCCCc1ccc(C)c(N/C=N/O)c1,N-(5-butyl-2-methylphenyl)-N'-hydroxyimidoformamide,94.0,uM,=,1.9731278535996988,1,c1ccccc1
2248,629565,10.1021/np1000329,,,,Inhibition of CYP3A4,O=c1c(-c2c(O)cc(O)c3c(=O)cc(-c4ccc(O)cc4)oc23)c(-c2ccc(O)cc2)oc2cc(O)cc(O)c12,"3,8''-biapigenin",0.08,uM,=,-1.0969100130080565,0,O=c1c(-c2cccc3c(=O)cc(-c4ccccc4)oc23)c(-c2ccccc2)oc2ccccc12
2249,519907,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,Cc1cccc(C)c1CCc1cc(-n2ccccc2=O)cn2c(C)c(C)nc12,"1-(8-(2,6-dimethylphenethyl)-2,3-dimethylimidazo[1,2-a]pyridin-6-yl)pyridin-2(1H)-one",10.0,uM,=,1.0,1,O=c1ccccn1-c1cc(CCc2ccccc2)c2nccn2c1
2250,1488448,10.1124/dmd.110.035071,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam substrate by HPLC-MS/MS method,CC(=O)N1CCN([C@H]2CCN(C(=O)N(C)[C@H](C)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)[C@@H](c3ccc(F)cc3C)C2)CC1,"cis-(1'-Acetyl-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]-ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4,4'-bipiperidine-1-carboxamide",9.86,uM,=,0.9938769149412112,1,O=C(NCc1ccccc1)N1CC[C@H](N2CCNCC2)C[C@@H]1c1ccccc1
2251,1488502,10.1124/dmd.112.045708,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis,COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1,"Acetic acid (2S,3S)-5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester",100.0,uM,=,2.0,1,O=C1C[C@H](c2ccccc2)Sc2ccccc2N1
2252,51910,10.1016/j.bmcl.2004.04.048,,,,Inhibition of human liver microsome Cytochrome P3A4,NCc1c(N)nc(-c2ccccc2)nc1-c1ccc(Cl)cc1Cl,"5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-phenyl-pyrimidin-4-ylamine",10.0,uM,=,1.0,1,c1ccc(-c2ccnc(-c3ccccc3)n2)cc1
2253,1659434,10.1021/acs.jmedchem.6b01662,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH by LC-MS/MS analysis,CC(C)c1ccc(S(=O)(=O)n2cc(CN3CCN(C)CC3)c3cc(F)ccc32)cc1.Cl.Cl,5-Fluoro-1-[(4-isopropylphenyl)sulfonyl]-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole Dihydrochloride,1.4,uM,=,0.1461280356782379,1,O=S(=O)(c1ccccc1)n1cc(CN2CCNCC2)c2ccccc21
2254,2164739,10.1021/acs.jmedchem.1c02131,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate,COc1cc(-c2ccc(OC[C@@H](N)CC(C)C)c(C#N)c2)ccn1,(S)-2-((2-Amino-4-methylpentyl)oxy)-5-(2-methoxypyridin-4-yl)-benzonitrile,0.54,uM,=,-0.2676062401770315,0,c1ccc(-c2ccncc2)cc1
2255,1558600,10.1016/j.bmcl.2015.06.020,,,,Inhibition of CYP3A4 (unknown origin) by fluorescence assay,Cc1ncn(-c2ccc3c(c2)NC(=O)c2ccc(Cc4ccccc4)nc2N3)n1,"2-benzyl-8-(3-methyl-1H-1,2,4-triazol-1-yl)-6,11-dihydro-5H-benzo[b]pyrido[2,3-e][1,4]diazepin-5-one",2.0,uM,=,0.3010299956639812,1,O=C1Nc2cc(-n3cncn3)ccc2Nc2nc(Cc3ccccc3)ccc21
2256,2128578,10.1016/j.ejmech.2021.113496,,,,Inhibition of recombinant human CYP3A4 using BFC as substrate,C[C@]12CC[C@H]3[C@@H]([C@H](/C=C/C=C/C=C/[C@@H]4CC5=CC(=O)CC[C@]5(C)[C@H]5CC[C@]6(C)[C@H](O)CC[C@H]6[C@H]45)CC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@H]2O,"trans,trans,trans-1,6-bis(17alpha-hydroxy-4-androsten-3-one-7alpha-yl)hexatriene",22.0,uM,=,1.3424226808222062,1,O=C1C=C2C[C@@H](/C=C/C=C/C=C/[C@@H]3CC4=CC(=O)CCC4[C@H]4CCC5CCC[C@H]5[C@H]34)[C@H]3[C@@H]4CCCC4CC[C@@H]3C2CC1
2257,1901061,10.1021/acs.jmedchem.9b00565,,,,Inhibition of CYP3A4 (unknown origin),CN(C)C(=O)c1ccc(N(Cc2ccc(Br)o2)C(=O)c2ccc(O)cc2O)cc1,"N-((5-Bromofuran-2-yl)methyl)-N-(4-(dimethylcarbamoyl)phenyl)-2,4-dihydroxybenzamide",1.4,uM,=,0.1461280356782379,1,O=C(c1ccccc1)N(Cc1ccco1)c1ccccc1
2258,1467194,10.1021/jm5005336,,,,Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay,O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccc(CN4CCOCC4)cc3)n[nH]c2c1,"(1R*,2S*)-(E)-2-(3-(4-(Morpholinomethyl)styryl)-1H-indazol-6-yl)-spiro[cyclopropane-1,3'-indolin]-2'-one",2.7,uM,=,0.4313637641589873,1,O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccc(CN4CCOCC4)cc3)n[nH]c2c1
2259,828928,10.1016/j.bmcl.2012.06.022,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,CNc1nc2ccc(C(=O)N(CC(C)C)C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1,"Thiazol-5-ylmethyl(2S,3R)-3-hydroxy-4-(N-isobutyl-2-(methylamino)benzo[d]oxazole-6-carboxamido)-1-phenylbutan-2-ylcarbamate",0.041,uM,=,-1.3872161432802643,0,O=C(N[C@H](CCNC(=O)c1ccc2ncoc2c1)Cc1ccccc1)OCc1cncs1
2260,2111978,10.1021/acs.jmedchem.0c01992,,,,Inhibition of CYP3A4 (unknown origin),CC(C)(O)C(=O)N[C@@H]1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3CC[C@@H]12,"N-((3R,3aS,9bS)-9b-(4-fluorophenylsulfonyl)-7-(perfluoropropan-2-yl)-2,3,3a,4,5,9b-hexahydro-1H-cyclopenta[a]naphthalen-3-yl)-2-hydroxy-2-methylpropanamide",11.0,uM,=,1.0413926851582251,1,O=S(=O)(c1ccccc1)[C@@]12CCC[C@@H]1CCc1ccccc12
2261,674732,10.1016/j.bmcl.2010.09.029,,,,Inhibition of CYP3A4,Cc1cc([C@]2(c3ccc(F)c(C#CC4CC4)c3)N=C(N)N(C)C2=O)ccc1OC(F)F,(R)-2-amino-4-(3-(cyclopropylethynyl)-4-fluorophenyl)-4-(4-(difluoromethoxy)-3-methylphenyl)-1-methyl-1H-imidazol-5(4H)-one,4.1,uM,=,0.6127838567197355,1,O=C1NC=N[C@]1(c1ccccc1)c1cccc(C#CC2CC2)c1
2262,873423,10.1021/jm3006788,,,,Inhibition of CYP3A4,Cn1c(-c2ccncc2)c(C2CCCC2)c2ccc(C(=O)NC3(C(=O)Nc4ccc(/C=C/C(=O)O)cc4)CCCC3)cc21,3-(4-(1-(3-cyclopentyl-1-methyl-2-(pyridin-4-yl)-1H-indole-6-carboxamido)cyclopentanecarboxamido)phenyl)acrylic acid,4.3,uM,=,0.6334684555795865,1,O=C(NC1(C(=O)Nc2ccccc2)CCCC1)c1ccc2c(C3CCCC3)c(-c3ccncc3)[nH]c2c1
2263,539794,10.1021/jm8005405,,,,Inhibition of CYP3A4 in human liver microsomes,Cc1ccc2c(N)noc2c1-c1ccc2c(N3CCOC[C@@H]3C)nncc2c1,6-Methyl-7-(1-((S)-3-methylmorpholino)phthalazin-6-yl)benzo[d]isoxazol-3-amine,12.0,uM,=,1.0791812460476249,1,c1cc(-c2ccc3c(N4CCOCC4)nncc3c2)c2oncc2c1
2264,1465542,10.1016/j.bmcl.2015.01.051,,,,Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(C6CN(CCO)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O,"(1S,4R,5R,6R,8R,10S,11R,12S,13R,16R,18S,21R)-8-[(1S)-1-ethoxy-2-hydroxy-2-methylpropyl]-18-{[(2S)-4-[1-(2-hydroxyethyl)azetidin-3-yl]morpholin-2-yl]oxy}-4,6,12,17,17-pentamethyl-9-oxahexacyclo[11.9.0.0^{1,21}.0^{4,12}.0^{5,10}.0^{16,21}]docosan-11-ol",3.2,uM,=,0.505149978319906,1,C1CO[C@@H]2CC3C(CC[C@@]45C[C@@]46CC[C@H](O[C@H]4CN(C7CNC7)CCO4)C[C@@H]6CC[C@@H]35)[C@H]2C1
2265,2164346,10.1021/acs.jmedchem.1c02192,,,,Inhibition of CYP3A4 (unknown origin),Cc1ccnc(Oc2ccc(-c3cc4c(cc3F)ncc3nc(C)n([C@H]5CCN(C(=O)CO)C[C@@H]5F)c34)c(Cl)c2)n1,"US9227969, 68",2.0,uM,=,0.3010299956639812,1,c1cnc(Oc2ccc(-c3ccc4ncc5ncn(C6CCNCC6)c5c4c3)cc2)nc1
2266,1465542,10.1016/j.bmcl.2015.01.051,,,,Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(C6CN(C(C)C)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O,SPI-1865,25.0,uM,=,1.3979400086720375,1,C1CO[C@@H]2CC3C(CC[C@@]45C[C@@]46CC[C@H](O[C@H]4CN(C7CNC7)CCO4)C[C@@H]6CC[C@@H]35)[C@H]2C1
2267,2300681,10.1021/acsmedchemlett.7b00112,,,,Inhibition of CYP3A4 (unknown origin),COCCCC(=O)NCCN1CCC[C@@H]1Cn1nc(Cc2ccc(Cl)cc2)c2ccccc2c1=O.Cl,(R)-N-(2-(2-((4-(4-chlorobenzyl)-1-oxophthalazin-2(1H)-yl)methyl)pyrrolidin-1-yl)ethyl)-4-methoxybutanamide Hydrochloride,1.3,uM,=,0.1139433523068367,1,O=c1c2ccccc2c(Cc2ccccc2)nn1C[C@H]1CCCN1
2268,322414,10.1021/jm0502541,,,,Interaction with human cytochrome P450 isoform 3A4 expressed in baculovirus-insect cells,CC(C(=O)O)c1ccc(-c2ccc(-c3ccc(O)cc3)cc2)c(F)c1,"2-(2-Fluoro-4''-hydroxy-[1,1';4',1'']terphenyl-4-yl)-propionic acid",74.0,uM,=,1.869231719730976,1,c1ccc(-c2ccc(-c3ccccc3)cc2)cc1
2269,526157,10.1021/np0401765,,,,Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,"1-(4-{4-[2-(2,4-Dichloro-phenyl)-2-imidazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-ethanone (ketoconazole)",0.72,uM,=,-0.1426675035687315,0,c1ccc(C2(Cn3ccnc3)OCC(COc3ccc(N4CCNCC4)cc3)O2)cc1
2270,1288280,10.1016/j.bmcl.2013.12.057,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,COBICISTAT,0.15,uM,=,-0.8239087409443188,0,O=C(NCc1cscn1)N[C@@H](CCN1CCOCC1)C(=O)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
2271,1637154,,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(NC(C)=O)nc4)cc23)c1F,"N-(5-{3-[2,6-Difluoro-3-(propane-1-sulfonylamino)-benzoyl]-1H-pyrrolo[2,3-b]pyridin-5-yl}-pyridin-2-yl)-acetamid",5.0,uM,=,0.6989700043360189,1,O=C(c1ccccc1)c1c[nH]c2ncc(-c3cccnc3)cc12
2272,52065,10.1021/jm0310129,,,,Inhibitory activity against cytochrome P450 3A4,Cn1c2ccnc(N3CCOCC3)c2c2ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21,"4-{4-[2-(3,4-Difluoro-phenyl)-ethyl]-piperazin-1-yl}-5-methyl-9-morpholin-4-yl-5H-pyrido[3',4':4,5]pyrrolo[3,2-d]pyrimidine",20.8,uM,=,1.3180633349627615,1,c1ccc(CCN2CCN(c3ncnc4c3[nH]c3ccnc(N5CCOCC5)c34)CC2)cc1
2273,834929,10.1016/j.bmcl.2012.07.020,,,,Inhibition of CYP3A4,CCS(=O)(=O)c1ccc2[nH]c(-c3ccc(C)c(-c4ccccc4)c3)nc2c1,5-(ethylsulfonyl)-2-(6-methylbiphenyl-3-yl)-1H-benzo[d]imidazole,5.7,uM,=,0.7558748556724915,1,c1ccc(-c2cccc(-c3nc4ccccc4[nH]3)c2)cc1
2274,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2C(CN(Cc3cccc4c(C(=O)Nc5ccc(N6CCNCC6)nc5)cn(C)c34)C(=O)[C@@H]2Cc2ccc(O)cc2)N1C(=O)NCc1ccccc1,"US8940739, G-39",2.73,uM,=,0.436162647040756,1,O=C(Nc1ccc(N2CCNCC2)nc1)c1c[nH]c2c(CN3CC4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12
2275,2103815,10.1016/j.bmcl.2021.128010,,,,Time dependent inhibition of CYP3A4 (unknown origin) measured at 30 mins,Nc1cc(Cc2ccn(Cc3cccc(-c4ccccc4)c3)n2)c2nn[nH]c2n1,"7-((1-(biphenyl-3-ylmethyl)-1H-pyrazol-3-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-amine",0.017,uM,=,-1.769551078621726,0,c1ccc(-c2cccc(Cn3ccc(Cc4ccnc5[nH]nnc45)n3)c2)cc1
2276,1474044,10.1021/jm501740a,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,O=CN1CCC(Oc2ccc(-c3n[nH]c4ccc(C(=O)NC(c5ccccn5)C5CC5)cc34)cc2)CC1,rac-N-(Cyclopropyl(pyridin-2-yl)methyl)-3-(4-((1-formylpiperidin-4-yl)oxy)phenyl)-1H-indazole-5-carboxamide,1.5,uM,=,0.1760912590556812,1,O=C(NC(c1ccccn1)C1CC1)c1ccc2[nH]nc(-c3ccc(OC4CCNCC4)cc3)c2c1
2277,617698,10.1016/j.bmcl.2010.01.087,,,,Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay,COC(=O)N1CCN(C2CCN(c3cc(C)c4nc(-c5c(NCCn6cc(Cl)cn6)cc[nH]c5=O)[nH]c4c3)CC2)CC1,"methyl 4-(1-(2-(4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-2-oxo-1,2-dihydropyridin-3-yl)-4-methyl-1H-benzo[d]imidazol-6-yl)piperidin-4-yl)piperazine-1-carboxylate",1.0,uM,=,0.0,0,O=c1[nH]ccc(NCCn2cccn2)c1-c1nc2ccc(N3CCC(N4CCNCC4)CC3)cc2[nH]1
2278,993439,10.6019/CHEMBL2448688,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,O=C(NCCc1cnc[nH]1)c1ccc2cc(Br)ccc2c1,,3.28,uM,=,0.5158738437116791,1,O=C(NCCc1cnc[nH]1)c1ccc2ccccc2c1
2279,2248038,10.1021/acs.jmedchem.1c01795,,,,Inhibition of CYP3A4 in human liver microsomes using sorafenib as cocktail probe substrate preincubated for 5 mins followed by NADPH addition and measured after 30 mins by HPLC-MS/MS analysis,CCn1nc(C)cc1C(=O)Nc1nc2cc(C(N)=O)cc(OC)c2n1C/C=C/Cn1c(NC(=O)c2cc(C)nn2CC)nc2cc(C(N)=O)cc(OCCCNC(=O)OC(C)(C)C)c21,tert-Butyl (E)-(3-((5-carbamoyl-1-(4-(5-carbamoyl-2-(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-7-methoxy-1H-benzo[d]imidazol-1-yl)but-2-en-1-yl)-2-(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-1H-benzo[d]imidazol-7-yl)oxy)propyl)carbamate,4.2,uM,=,0.6232492903979004,1,O=C(Nc1nc2ccccc2n1C/C=C/Cn1c(NC(=O)c2ccn[nH]2)nc2ccccc21)c1ccn[nH]1
2280,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",C[C@@H]1CN(C(=O)c2cc(Cl)ccc2-n2nccn2)[C@H](Cc2cc(-n3nccn3)ccc2F)CO1,"US9150566, 186",19.0,uM,=,1.2787536009528289,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
2281,1679904,10.1016/j.bmcl.2017.04.043,,,,Inhibition of CYP3A4 (unknown origin),Cc1nnc2sc(C(=O)NCc3ccc(-c4ccc(F)nc4)cc3)c(N)c2c1C,"5-amino-N-(4-(6-fluoropyridin-3-yl)benzyl)-3,4-dimethylthieno[2,3-c]pyridazine-6-carboxamide",25.0,uM,=,1.3979400086720375,1,O=C(NCc1ccc(-c2cccnc2)cc1)c1cc2ccnnc2s1
2282,770537,10.1021/jm200609t,,,,Inhibition of CYP3A4 using vivid red as substrate,Cc1c(-c2noc(-c3ccc(OC(C)C)c(C#N)c3)n2)ccc2c1CCN(C(CO)CO)C2,"5-(3-{2-[2-hydroxy-1-(hydroxymethyl)ethyl]-5-methyl-1,2,3,4-tetrahydro-6-isoquinolinyl}-1,2,4-oxadiazol-5-yl)-2-[(1-methylethyl)oxy]benzonitrile",15.3,uM,=,1.1846914308175989,1,c1ccc(-c2nc(-c3ccc4c(c3)CCNC4)no2)cc1
2283,816385,10.1016/j.bmcl.2012.03.035,,,,Inhibition of CYP3A4 preincubated for 15 mins,Cn1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1,SID103904314,2.7,uM,=,0.4313637641589873,1,O=C(Nc1ccccc1)Nc1ccc(-c2csc3c(-c4cn[nH]c4)cncc23)cc1
2284,2014369,10.1021/acsmedchemlett.9b00123,,,,Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells using midazolam as substrate incubated for 30 mins in presence of NADPH-regenerating system by fluorescence based assay,CN(C)c1ccc(CC(=O)N[C@@H]2CNC[C@H]2c2ccc(C(C)(F)F)cc2)cc1,"(-)-N-[(3S,4R)-4-[4-(1,1-difluoroethyl)phenyl]pyrrolidin-3-yl]-2-[4-(dimethylamino)phenyl]acetamide",2.5,uM,=,0.3979400086720376,1,O=C(Cc1ccccc1)N[C@@H]1CNC[C@H]1c1ccccc1
2285,390506,10.1016/j.bmcl.2006.05.066,,,,Inhibition of CYP3A4 in human liver microsome,c1cn(Cc2ccc3c(c2)-c2[nH]nc(-c4ccsc4)c2C3)cn1,"7-((1H-imidazol-1-yl)methyl)-3-(thiophen-3-yl)-1,4-dihydroindeno[1,2-c]pyrazole",0.254,uM,=,-0.595166283380062,0,c1cn(Cc2ccc3c(c2)-c2[nH]nc(-c4ccsc4)c2C3)cn1
2286,1446329,10.1021/ml500387y,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,CCS(=O)(=O)c1cc2cc(CC(O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1,"2-(4-((5-(ethylsulfonyl)-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)-5,5,5-trifluoro-4-hydroxy-2-methylpentan-2-yl)-5-fluorobenzamide",26.0,uM,=,1.414973347970818,1,c1ccc(CCCCc2cc3ccncc3[nH]2)cc1
2287,1453969,10.1021/ml5001728,,,,Inhibition of CYP3A4 (unknown origin),COc1cnc2ccc(=O)n(CCN3CCC(c4nc5cc(C#N)c(C)cc5[nH]4)CC3)c2c1,"2-(1-(2-(7-methoxy-2-oxo-1,5-naphthyridin-1(2H)-yl)ethyl)piperidin-4-yl)-6-methyl-1H-benzo[d]imidazole-5-carbonitrile",9.4,uM,=,0.9731278535996988,1,O=c1ccc2ncccc2n1CCN1CCC(c2nc3ccccc3[nH]2)CC1
2288,2164739,10.1021/acs.jmedchem.1c02131,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate,CC(C)C[C@](C)(N)COc1ccc(-c2ccnc(C(F)F)c2)cc1C(F)F,"(S)-1-(2-(Difluoromethyl)-4-(2-(difluoromethyl)pyridin-4-yl)-phenoxy)-2,4-dimethylpentan-2-amine",16.0,uM,=,1.2041199826559248,1,c1ccc(-c2ccncc2)cc1
2289,469873,10.1016/j.bmcl.2008.01.012,,,,Inhibition of human CYP3A4,CC(C)c1c(-c2nnc(N(C)C)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12,"N-cyclopropyl-5-(6-(5-(dimethylamino)-1,3,4-oxadiazol-2-yl)-5-isopropylpyrrolo[1,2-f][1,2,4]triazin-4-ylamino)-2,4-difluorobenzamide",0.8,uM,=,-0.0969100130080563,0,O=C(NC1CC1)c1cccc(Nc2ncnn3cc(-c4nnco4)cc23)c1
2290,2045812,10.1039/d0md00175a,,,,Inhibition of CYP3A4 (unknown origin),Cc1nc2c(=O)n(C3CC3)c3c(Cl)c(N4CC[C@@H]([C@H](C)N)C4)c(F)cc3c2o1,"7-((R)-3-((S)-1-aminoethyl)pyrrolidin-1-yl)-6-chloro-5-cyclopropyl-8-fluoro-2-methyloxazolo[4,5-c]quinolin-4(5H)-one",17.5,uM,=,1.2430380486862944,1,O=c1c2ncoc2c2ccc(N3CCCC3)cc2n1C1CC1
2291,702471,10.1021/jm100679e,,,,Inhibition of human CYP3A4 by fluorescence assay,O=C(Cc1ccc(-n2nc(C(F)(F)F)c3c2CCCC3)cc1)NC1CCCC1,"N-cyclopentyl-2-{4-[3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl]phenyl}acetamide",0.7,uM,=,-0.1549019599857432,0,O=C(Cc1ccc(-n2ncc3c2CCCC3)cc1)NC1CCCC1
2292,598210,10.1016/j.bmcl.2009.08.024,,,,Inhibition of human CYP3A4,CC1(CC(=O)NCc2ccc(Br)cc2F)CC2(CCCCC2)OO1,"N-(4-bromo-2-fluorobenzyl)-2-(3-methyl-1,2-dioxaspiro[4.5]decan-3-yl)acetamide",4.4,uM,=,0.6434526764861874,1,O=C(CC1CC2(CCCCC2)OO1)NCc1ccccc1
2293,686484,10.1016/j.bmcl.2010.09.122,,,,Inhibition of CYP3A4,O=c1cc(OCc2ccccc2)ccn1-c1ccc2c3c([nH]c2c1)CCNC3,"4-(benzyloxy)-1-(2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-7-yl)pyridin-2(1H)-one",68.0,uM,=,1.8325089127062364,1,O=c1cc(OCc2ccccc2)ccn1-c1ccc2c3c([nH]c2c1)CCNC3
2294,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1ccc(C(=O)N2CCOC[C@H]2Cc2cccc(-n3cccn3)c2)c(-n2nccn2)c1,"US9150566, 22",41.0,uM,=,1.6127838567197357,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2cccn2)c1
2295,595638,10.1016/j.bmcl.2009.09.096,,,,Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH,COc1ccc2c(OCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1,"7-methoxy-4-((6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy)quinoline",4.1,uM,=,0.6127838567197355,1,c1ccc(-c2ccc3nnc(COc4ccnc5ccccc45)n3n2)cc1
2296,876026,10.1021/jm3011838,,,,Inhibition of CYP3A4 in human liver microsomes in presence of NADPH by LC-MS/MS method,CC(C)(O)CN1C[C@H](C(=O)Nc2ccc(Cl)cc2)[C@@H](c2ccc(/C=C/C(=O)Nc3ccccc3N)cc2)C1,"rac-(trans-3,4)-4-{4-[(E)-2-(2-Amino-phenylcarbamoyl)-vinyl]-phenyl}-1-(2-hydroxy-2-methyl-propyl)-pyrrolidine-3-carboxylic acid(4-chloro-phenyl)-amide",3.0,uM,=,0.4771212547196624,1,O=C(/C=C/c1ccc([C@H]2CNC[C@@H]2C(=O)Nc2ccccc2)cc1)Nc1ccccc1
2297,986997,10.1016/j.bmcl.2013.08.012,,,,Inhibition of CYP3A4 in human liver microsomes,Nc1cc(CN2CCC(C(=O)N3CCC(n4c(=O)n(CC5CC5)c5cc(F)ccc54)CC3)CC2)ccn1,1-(1-(1-((2-aminopyridin-4-yl)methyl)piperidine-4-carbonyl)piperidin-4-yl)-3-(cyclopropylmethyl)-5-fluoro-1H-benzo[d]imidazol-2(3H)-one,30.0,uM,=,1.4771212547196624,1,O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)n(CC3CC3)c3ccccc32)CC1
2298,1366898,10.1021/jm500312x,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 15 mins by LC/MS/MS analysis,C=C[C@]1(C)C[C@@H](OC(=O)CSc2cccc(CO)c2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O,"(3-Hydroxymethyl-phenylsulfanyl)-acetic acid(1S,2R,3S,4S,6R,7R,8R,14R)-3-hydroxy-2,4,7,14-tetramethyl-9-oxo-4-vinyl-tricyclo[5.4.3.0(1,8)]tetradec-6-yl ester",1.9,uM,=,0.2787536009528289,1,O=C(CSc1ccccc1)O[C@@H]1CCCC[C@@]23CCCC1[C@@H]2C(=O)CC3
2299,699316,10.1016/j.bmc.2010.10.034,,,,Inhibition of CYP3A4,CN[C@H]1Cc2ccccc2[C@@H](c2ccc(Cl)c(Cl)c2)C1,"cis-(2R,4R)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-2-amine",17.1,uM,=,1.2329961103921538,1,c1ccc([C@H]2CCCc3ccccc32)cc1
2300,445935,10.1021/jm070436q,,,,Inhibition of CYP3A4,CCCc1[nH]cnc1CNc1cc(Cl)c2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2c1,8-chloro-4-[(3-chloro-4-fluorophenyl)amino]-6-{[(5-propyl-1H-imidazol-4-yl)methyl]amino}quinoline-3-carbonitrile,16.0,uM,=,1.2041199826559248,1,c1ccc(Nc2ccnc3ccc(NCc4c[nH]cn4)cc23)cc1
2301,675407,10.1016/j.bmcl.2010.08.142,,,,Inhibition of CYP3A4,N#Cc1ccc(N[C@@H]2CCN(C(=O)O[C@H]3C4CC5CC3C[C@](C(N)=O)(C5)C4)C2)nc1,(R)-3-(5-Cyano-pyridin-2-ylamino)-pyrrolidine-1-carboxylic acid 5-carbamoyl-adamantan-2-yl ester,14.2,uM,=,1.1522883443830565,1,O=C(OC1C2CC3CC(C2)CC1C3)N1CC[C@@H](Nc2ccccn2)C1
2302,1744982,10.1016/j.bmcl.2017.09.046,,,,Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated conversion of midazolam to 1-hydroxymidazolam measured after 5 mins by LC-MS analysis,CCc1cccc(-c2c(F)cccc2C(O)(CCCNC(=O)OC)[C@@H]2CCCN(C(=O)CCCNC)C2)c1,methyl 4-(3'-ethyl-6-fluorobiphenyl-2-yl)-4-hydroxy-4-((R)-1-(4-(methylamino)butanoyl)piperidin-3-yl)butylcarbamate,20.0,uM,=,1.3010299956639813,1,c1ccc(-c2ccccc2C[C@@H]2CCCNC2)cc1
2303,305432,10.1016/j.bmcl.2005.01.044,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,CC(C(c1ccc2cc(OCc3ccc(OCC(=O)O)cc3)ccc2c1)n1ccnc1)N(C)C,{4-[6-(2-Dimethylamino-1-imidazol-1-yl-propyl)-naphthalen-2-yloxymethyl]-phenoxy}-acetic acid,0.75,uM,=,-0.1249387366082999,0,c1ccc(COc2ccc3cc(Cn4ccnc4)ccc3c2)cc1
2304,973937,10.1021/jm400634n,,,,Inhibition of CYP3A4 (unknown origin) using vivid green as substrate,Nc1ccccc1NC(=O)c1ccc(CNC2=N[C@@H](c3ccccc3)CS2)cc1,"N-(2-Aminophenyl)-4-({[(4S)-4-phenyl-4,5-dihydro-1,3-thiazol-2-yl]amino}methyl)benzamide",16.0,uM,=,1.2041199826559248,1,O=C(Nc1ccccc1)c1ccc(CNC2=N[C@@H](c3ccccc3)CS2)cc1
2305,979124,10.1021/jm400484p,,,,Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes,Oc1cncc(-c2ccc3ccc(O)cc3c2Cl)c1,5-(1-chloro-7-hydroxynaphthalen-2-yl)pyridin-3-ol,5.046,uM,=,0.7029472461815558,1,c1cncc(-c2ccc3ccccc3c2)c1
2306,980735,10.1021/jm400820m,,,,Inhibition of human recombinant CYP3A4,CCOC(=O)c1cc(C#N)c(N2CCC(C(=O)NS(=O)(=O)Cc3ccc(F)cc3F)CC2)nc1C,"Ethyl 6-[4-({[(2,4-Difluorobenzyl)sulfonyl]amino}carbonyl)-piperidin-1-yl]-5-cyano-2-methylnicotinate",1.4,uM,=,0.1461280356782379,1,O=C(NS(=O)(=O)Cc1ccccc1)C1CCN(c2ccccn2)CC1
2307,1640556,,,,,"null: Microsomal preparation: One lobe of fresh pig liver is obtained (e.g., at about the time of slaughter from a food-processing company) and immediately placed in ice cold 15 mM KH2PO4/250 mM sucrose (pH 7.4) and kept on ice during transportation. A 10 g sample of liver is minced and homogenized in 30 mL of homogenization buffer (15 mM KH2PO4/250 mM sucrose) using a Tekmar homoginizer or equivalent by pulsing 3 times with 20 second pulses. This procedure is repeated for a total of 8x10 g samples of pig liver. The remaining pig liver may be stored at -80 C. The homogenates from the 8 samples are pooled and centrifuged at 13,000xg for 20 minutes at 4 C. to remove crude debris. The supernatant is further centrifuged at 100,000xg for 70 minutes at 4° C. The microsomal pellets are re-suspended into 50 mL of 150 mM KH2PO4/1 mM DTT (pH 7.4) and 1 mL aliquots are stored at -80 C.100-150 ug of pig liver microsomal protein in 150 mM KH2PO4 is incubated at 37° C.",c1ccc(-c2c[nH]cn2)cc1,4-Phenyl-1H-imidazole,58.8,uM,=,1.7693773260761383,1,c1ccc(-c2c[nH]cn2)cc1
2308,1465541,10.1016/j.bmcl.2015.01.051,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(C6CN(C7CCC7)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O,"(1S,4R,5R,6R,8R,10S,11R,12S,13R,16R,18S,21R)-18-{[(2S)-4-(1-cyclobutylazetidin-3-yl)morpholin-2-yl]oxy}-8-[(1S)-1-ethoxy-2-hydroxy-2-methylpropyl]-4,6,12,17,17-pentamethyl-9-oxahexacyclo[11.9.0.0^{1,21}.0^{4,12}.0^{5,10}.0^{16,21}]docosan-11-ol",100.0,uM,=,2.0,1,C1CC(N2CC(N3CCO[C@@H](O[C@H]4CC[C@]56C[C@]57CCC5C(C[C@H]8OCCC[C@H]58)[C@@H]7CC[C@H]6C4)C3)C2)C1
2309,991614,10.1021/jm4008906,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(Cc1ccccc1)C2,"rac-3-(aminomethyl)-6-benzyl-4-(2,4-dichlorophenyl)-2-methyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one",0.9,uM,=,-0.0457574905606751,0,O=C1c2c(-c3ccccc3)ccnc2CN1Cc1ccccc1
2310,742805,10.1016/j.bmc.2011.02.009,,,,Inhibition of human CYP3A4 after 30 mins,CC(C)C(O)(c1cccc(-c2ccccc2)c1)c1c[nH]cn1,"rac-1-[1,1'-biphenyl]-3-yl-1-(1H-imidazol-4-yl)-2-methyl-1-propanol",1.2,uM,=,0.0791812460476248,1,c1ccc(-c2cccc(Cc3c[nH]cn3)c2)cc1
2311,1441252,10.1021/jm5010013,,,,Inhibition of CYP3A4 (unknown origin),Cc1cc(NC(=O)N2C[C@H]3C[C@@H](c4ccccc4C(F)(F)F)C[C@H]3C2)c(C(=O)O)cn1,"trans-6-methyl-4-((3aR,6aS)-5-(2-(trifluoromethyl)phenyl)octahydrocyclopenta[c]pyrrole-2-carboxamido)nicotinic acid",1.1,uM,=,0.041392685158225,1,O=C(Nc1ccncc1)N1C[C@H]2C[C@@H](c3ccccc3)C[C@H]2C1
2312,716717,10.1016/j.bmcl.2010.12.109,,,,Inhibition of CYP3A4,CCCCN1C(=O)C(CC(C)C)NC(=O)C12CCN(Cc1ccc(Oc3ccccc3)cc1)CC2.Cl,"1-butyl-3-(2-methylpropyl)-9-(4-phenoxyphenylmethyl)-1,4,9-triazaspiro[5.5]undeca-2,5-dione hydrochloride",19.7,uM,=,1.294466226161593,1,O=C1CNC(=O)C2(CCN(Cc3ccc(Oc4ccccc4)cc3)CC2)N1
2313,1919651,,,,,"Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase",CN1CCC[C@H]1c1cccnc1,3-((S)-1-Methyl-pyrrolidin-2-yl)-pyridine,142.4,uM,=,2.153509989300838,1,c1cncc([C@@H]2CCCN2)c1
2314,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CC7CCN(C)C7C6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, G-64",7.64,uM,=,0.8830933585756899,1,O=C(Nc1ccc(N2CC3CCNC3C2)nc1)c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12
2315,827410,10.1016/j.bmc.2012.04.053,,,,Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture before addition of BFC substrate by fluorometric assay,OC[C@H]1C[C@@H](c2cccc(Cc3ccc(C4CC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,"(1R,2R,3S,4S,6R)-4-[3-(4-Cyclopropyl-benzyl)phenyl]-6-(hydroxymethyl)cyclohexane-1,2,3-triol",33.0,uM,=,1.5185139398778875,1,c1cc(Cc2ccc(C3CC3)cc2)cc(C2CCCCC2)c1
2316,813159,10.1021/jm2011222,,,,Inhibition of CYP3A4,COc1ccc(-n2c(SCc3nc(-c4ccc(C)cc4)no3)nnc2-c2ccncc2)cc1,SID24390028,1.7,uM,=,0.2304489213782739,1,c1ccc(-c2noc(CSc3nnc(-c4ccncc4)n3-c3ccccc3)n2)cc1
2317,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN6CCN(CC(C)C)CC6C5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, E-45",3.98,uM,=,0.5998830720736879,1,O=C(c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12)N1CCN2CCNCC2C1
2318,769156,10.1021/jm2003552,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,CCCCCCc1nc2cc(/C=C/C(=O)NO)ccc2n1CCN(C)C,(E)-3-[1-(2-Dimethylaminoethyl)-2-hexyl-1H-benzimidazol-5-yl]-N-hydroxyacrylamide,0.33,uM,=,-0.4814860601221125,0,c1ccc2[nH]cnc2c1
2319,2221809,10.1016/j.bmcl.2022.128625,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as substrate in presence of NADPH,CCC[C@H]1N(C(=O)c2c(F)cccc2C(F)(F)F)CCC[C@@]1(Oc1csc(C(F)(F)F)c1)C(=O)N1CCN(c2ccccc2OCCO)CC1,"((2R,3S)-1-(2-fluoro-6-(trifluoromethyl)benzoyl)-2-propyl-3-(5-(trifluoromethyl)thiophen-3-yloxy)piperidin-3-yl)(4-(2-(2-hydroxyethoxy)phenyl)piperazin-1-yl)methanone",50.0,uM,=,1.6989700043360187,1,O=C(c1ccccc1)N1CCC[C@@](Oc2ccsc2)(C(=O)N2CCN(c3ccccc3)CC2)C1
2320,1526543,10.1016/j.bmcl.2015.10.055,,,,Inhibition of CYP3A4 (unknown origin),COc1ccc([C@H](C)NC(=O)COc2cc(C(F)(F)F)c3c(-c4ccccc4)nn(C)c3n2)cc1,"(S)-N-(1-(4-methoxyphenyl)ethyl)-2-(1-methyl-3-phenyl-4-(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridin-6-yloxy)acetamide",8.0,uM,=,0.9030899869919436,1,O=C(COc1ccc2c(-c3ccccc3)n[nH]c2n1)NCc1ccccc1
2321,642395,10.1021/jm100400a,,,,Inhibition of CYP3A4 expressed in baculovirus infected insect microsomes,CC(C)=C(c1ccncc1)c1ccc(-c2ccc(N)c(N)c2)cc1,"4'-(2-methyl-1-(pyridin-4-yl)prop-1-enyl)biphenyl-3,4-diamine",1.77,uM,=,0.2479732663618066,1,C=C(c1ccncc1)c1ccc(-c2ccccc2)cc1
2322,874112,10.1021/jm300118s,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis,COCC(=O)N[C@@H](Cc1cccc(-c2ccncc2)c1)[C@H](O)CN[C@H]1CC2(CCC2)Oc2ncc(CC(C)(C)C)cc21,"N-((2S,3R)-3-Hydroxy-4-((S)-6'-neopentyl-3',4'-dihydrospiro-[cyclobutane-1,2'-pyrano[2,3-b]pyridine]-4'-ylamino)-1-(3-(pyridin-4-yl)phenyl)butan-2-yl)-2-methoxyacetamide",0.16,uM,=,-0.7958800173440752,0,c1cc(CCCCN[C@H]2CC3(CCC3)Oc3ncccc32)cc(-c2ccncc2)c1
2323,1660136,10.1021/acs.jmedchem.6b01918,,,,Inhibition of human CYP3A4 assessed as inhibition of dealkylation,O=S(=O)(Nc1nccs1)c1cc(Cl)c(NC[C@@H]2CCCNC2)cc1F,(R)-5-Chloro-2-fluoro-4-((piperidin-3-ylmethyl)amino)-N-(thiazol-2-yl)benzenesulfonamide,20.0,uM,=,1.3010299956639813,1,O=S(=O)(Nc1nccs1)c1ccc(NC[C@@H]2CCCNC2)cc1
2324,632105,10.1016/j.bmcl.2010.03.057,,,,Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin,CCN1CCN(c2cc(C)c3nc(-c4c(NC[C@@H](O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1,(S)-4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-3-(6-(4-ethylpiperazin-1-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one,2.2,uM,=,0.3424226808222063,1,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(N3CCNCC3)cc2[nH]1
2325,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NN5CCN(c6ccccn6)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, E-38",2.48,uM,=,0.3944516808262163,1,O=C(NN1CCN(c2ccccn2)CC1)c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12
2326,1641150,,,,,"Inhibition Assay: Inhibition of cytochromes P450 (CYPs) 2C9, 2D6 and 3A4 was assessed using human liver microsomes and CYP-selective substrate metabolism reactions. 50 μl incubations were made up containing (finally) 0.2 mg/ml pooled human liver microsomes, 5 μM substrate (diclofenac for CYP2C9 [4' hydroxylase], dextromethorphan for CYP2D6 [O-demethylase] or midazolam for CYP3A4 [1' hydroxylase]), 0.25 μl, DMSO containing test inhibitor and NADPH regenerating system. Test inhibitor concentrations of 50, 16.7, 5.6, 1.9, 0.6 and 0.2 μM were assessed in singlicate. Incubations were prewarmed to 37° C. for 10 minutes before initiation by addition of NADPH regenerating system. Incubations were quenched after 5 minutes (20 minutes for dextromethorphan) by addition of 50 μl cold acetonitrile containing 20 ng/ml 4-OH-diclofenac-13C6, 20 ng/mL dextrorphan-D3 and 20 ng/mL 1-OH-midazolam-D4. Quenched incubates were stored at -20° C. for at least 1 hour before centrifugation (20,000xg, 20 minutes). Supernatants were removed and diluted 1:1 with water prior to analysis using a RapidFire sample injector system and API4000 mass spectrometer.",Cn1nc(Nc2ccc(F)c([C@@]3(C)COCC(N)=N3)c2)c2ccc(Cl)cc21,"US9242943, 34",25.0,uM,=,1.3979400086720375,1,C1=NC(c2cccc(Nc3n[nH]c4ccccc34)c2)COC1
2327,2164739,10.1021/acs.jmedchem.1c02131,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate,CC(C)C[C@](C)(N)COc1ccc(-c2ccnc(C(F)F)c2)cc1C(F)(F)F,"(S)-1-(4-(2-(Difluoromethyl)pyridin-4-yl)-2-(trifluoromethyl)-phenoxy)-2,4-dimethylpentan-2-amine",18.0,uM,=,1.255272505103306,1,c1ccc(-c2ccncc2)cc1
2328,471117,10.1016/j.bmc.2007.10.061,,,,Inhibition of CYP3A4,CN(C)[C@H]1C[C@@H](c2nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c3c(N)nccn32)C1,"cis-3-[3-(dimethylamino)cyclobutyl]-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-8-ylamine",19.0,uM,=,1.2787536009528289,1,c1ccc(-c2ccc3ccc(-c4nc(C5CCC5)n5ccncc45)cc3n2)cc1
2329,1277670,10.1016/j.bmcl.2013.10.052,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,CC[C@@H](Cn1cc(C)c2ccccc21)NS(=O)(=O)c1c(N)cc(Cl)cc1Cl,"(S)-2-amino-4,6-dichloro-N-(1-(3-methyl-1H-indol-1-yl)butan-2-yl)benzenesulfonamide",0.94,uM,=,-0.0268721464003013,0,O=S(=O)(NCCn1ccc2ccccc21)c1ccccc1
2330,767875,10.1021/jm200758k,,,,Inhibition of CYP3A4,CN1CCN(c2ccc(Nc3ncc4ccc(-c5ccccc5N(C)S(C)(=O)=O)n4n3)cc2)CC1,"N-Methyl-N-(2-{2-[4-(4-methyl-piperazin-1-yl)phenylamino]-pyrrolo[2,1-f][1,2,4]triazin-7-yl}phenyl)methanesulfonamide",14.6,uM,=,1.1643528557844371,1,c1ccc(-c2ccc3cnc(Nc4ccc(N5CCNCC5)cc4)nn23)cc1
2331,1984166,10.1016/j.bmc.2020.115349,,,,Inhibition of human full length CYP3A4 assessed using 7-benzyloxy-4 (trifluoromethyl)coumarin as substrate preincubated for 2 mins followed by substrate addition and measured for 2 mins by fluorometric analysis,CC(C)(C)OC(=O)NC(CSC(Cc1cccc2ccccc12)C(=O)NCCc1cccnc1)Cc1cccc2ccccc12,Rac-tert-butyl N-[1-(1-naphthylmethyl)-2-[1-(1-naphthylmethyl)-2-oxo-2-[2-(3-pyridyl)ethylamino]ethyl]sulfanyl-ethyl]carbamate,0.218,uM,=,-0.6615435063953952,0,O=C(NCCc1cccnc1)C(Cc1cccc2ccccc12)SCCCc1cccc2ccccc12
2332,982382,10.1016/j.bmcl.2013.07.071,,,,Inhibition of CYP3A4 (unknown origin),COC[C@@H](Oc1cc(C[C@@H]2C[S@@+]([O-])C[C@H](NCc3cccc(OC(F)(F)F)c3)[C@H]2O)cc(F)c1N)C(F)(F)F,"(1R,3S,4S,5R)-3-[4-Amino-3-fluoro-5-((R)-2,2,2-trifluoro-1-methoxymethyl-ethoxy)-benzyl]-1-oxo-5-(3-trifluoromethoxy-benzylamino)-tetrahydro-thiopyran-4-ol",4.7,uM,=,0.6720978579357175,1,c1ccc(CN[C@H]2C[SH+]C[C@@H](Cc3ccccc3)C2)cc1
2333,1491689,10.1124/dmd.112.045708,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 90 mins followed by substrate addition by LC-MS/MS analysis in presence of NADPH,COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1,"Acetic acid (2S,3S)-5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester",9.6,uM,=,0.9822712330395684,1,O=C1C[C@H](c2ccccc2)Sc2ccccc2N1
2334,1560508,10.1016/j.bmc.2016.02.014,,,,Inhibition of CYP3A4 (unknown origin),CN(C)CC(=O)N1CCC2(CC1)C(=O)Nc1cc(/C=C3\c4ccccc4COc4cc(F)ccc43)ccc12,"1'-(2-(dimethylamino)acetyl)-6-((3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)methyl)spiro[indoline-3,4'-piperidin]-2-one",4.778,uM,=,0.6792461454138591,1,O=C1Nc2cc(/C=C3\c4ccccc4COc4ccccc43)ccc2C12CCNCC2
2335,1778315,10.1016/j.bmcl.2018.06.040,,,,Inhibition of CYP3A4 (unknown origin),CCS(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1,"N-(4-(1H-pyrrolo[2,3-b]pyridin-3-yl)thiazol-2-yl)-2-(3-(ethylsulfonamido)phenyl)acetamide",5.9,uM,=,0.7708520116421442,1,O=C(Cc1ccccc1)Nc1nc(-c2c[nH]c3ncccc23)cs1
2336,464554,10.1021/jm7010589,,,,Inhibition of human recombinant CYP3A4,CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(-c2ccccc2)n1)[C@@H](C)O)B(O)O,"[(1R)-1-[[(2S,3R)-3-hydroxy-2-[(6-phenylpyridine-2-carbonyl)amino]-1-oxobutyl]amino]-3-methylbutyl]boronic acid",3.5,uM,=,0.5440680443502757,1,c1ccc(-c2ccccn2)cc1
2337,716789,10.1016/j.bmcl.2010.12.123,,,,Inhibition of CYP3A4,O=C(NC1CCCCC1)[C@H](C1CCCCC1)n1c(-c2ccc(Cl)cc2)nc2cc(F)c(F)cc21,"(S)-2-(2-(4-chlorophenyl)-5,6-difluoro-1H-benzo[d]imidazol-1-yl)-N,2-dicyclohexylacetamide",7.6,uM,=,0.8808135922807914,1,O=C(NC1CCCCC1)[C@H](C1CCCCC1)n1c(-c2ccccc2)nc2ccccc21
2338,51903,10.1021/jm020557k,,,,Concentration required to inhibit cytochrome P450 3A4.,CCCCOc1ccc(-n2cncc2C)cc1,1-(4-Butoxy-phenyl)-5-methyl-1H-imidazole,0.116,uM,=,-0.9355420107730816,0,c1ccc(-n2ccnc2)cc1
2339,2248279,10.1021/acs.jmedchem.1c01974,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as a substrate preincubated for 10 mins followed by NADPH addition and measured after 10 mins by LC/MS/MS analysis,CC(=O)Nc1ccc(Nc2ncnc(N[C@@H](Cc3ccccc3)C(=O)OC(C)(C)C)n2)cc1,"tert-Butyl (4-((4-Acetamidophenyl)amino)-1,3,5-triazin-2-yl)-L-phenylalaninate",11.6,uM,=,1.0644579892269186,1,c1ccc(CCNc2ncnc(Nc3ccccc3)n2)cc1
2340,768817,10.1021/jm2005354,,,,Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting,C[C@@H](c1ccc(-c2ccc(F)cc2)cc1)N1CC[C@](CCCO)(c2ccccc2F)OC1=O,"(R)-3-((S)-1-(4'-fluorobiphenyl-4-yl)ethyl)-6-(2-fluorophenyl)-6-(3-hydroxypropyl)-1,3-oxazinan-2-one",6.0,uM,=,0.7781512503836436,1,O=C1OC(c2ccccc2)CCN1Cc1ccc(-c2ccccc2)cc1
2341,526157,10.1021/np0401765,,,,Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation,COc1cc(C[C@H]2COC(O)[C@@H]2Cc2cc(OC)c(OC)c(OC)c2)cc(OC)c1OC,(-)-cubebinin,15.0,uM,=,1.1760912590556811,1,c1ccc(C[C@H]2COC[C@@H]2Cc2ccccc2)cc1
2342,1831631,10.1016/j.ejmech.2018.11.056,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cncn6)(c6ccc(F)cc6F)C5)cc4)CC3)cc2)c1=O,Posaconazole,0.15,uM,=,-0.8239087409443188,0,O=c1[nH]ncn1-c1ccc(N2CCN(c3ccc(OC[C@@H]4CO[C@@](Cn5cncn5)(c5ccccc5)C4)cc3)CC2)cc1
2343,630896,10.1016/j.bmcl.2010.03.017,,,,Inhibition of CYP3A4,COc1cccc([C@@H]2CCO[P@@](=O)(COc3cc(C)c(C)c4c3-c3ncsc3C4)O2)c1,"4-[4-(3-Methoxy-phenyl)-2-oxo-2lambda*5*-[1,3,2]dioxaphosphinan-2-ylmethoxy]-6,7-dimethyl-8H-indeno[1,2-d]thiazole",0.3,uM,=,-0.5228787452803376,0,O=[P@@]1(COc2cccc3c2-c2ncsc2C3)OCC[C@@H](c2ccccc2)O1
2344,443560,10.1016/j.bmc.2007.03.014,,,,Inhibition of human CYP2E1 expressed in insect microsome using 7-benzyloxyquinoline substrate after 30 mins,COc1ccc(CCN(C)CCNC(=O)c2ccccc2NC(=O)c2cnc3ccccc3c2)cc1OC,"N-(2-((2-((3,4-dimethoxyphenethyl)(methyl)amino)ethyl)carbamoyl)phenyl)quinoline-3-carboxamide",7.75,uM,=,0.8893017025063102,1,O=C(Nc1ccccc1C(=O)NCCNCCc1ccccc1)c1cnc2ccccc2c1
2345,555225,10.1016/j.bmcl.2008.05.058,,,,Inhibition of CYP3A4,CN(C(=O)CN(CC#N)c1ccc(Cl)c(Cl)c1)C(CN1CCCC1)c1ccc(-c2cccc(C(N)=O)c2)cc1,"4'-[1-({2-[Cyanomethyl-(3,4-dichloro-phenyl)-amino]-acetyl}-methyl-amino)-2-pyrrolidin-1-yl-ethyl]-biphenyl-3-carboxylic acid amide",2.2,uM,=,0.3424226808222063,1,O=C(CNc1ccccc1)NC(CN1CCCC1)c1ccc(-c2ccccc2)cc1
2346,550965,10.1021/np030556a,,,,Inhibition of human CYP3A4 by radiometric assay,CC(=O)O[C@H]1[C@H](Oc2c(-c3ccc(O)cc3)oc3cc(O)cc(O)c3c2=O)O[C@@H](C)[C@H](O)[C@H]1O,kaempferol-3-O-(2-O-acetyl-alpha-L-rhamnopyranoside),59.0,uM,=,1.7708520116421442,1,O=c1c(O[C@H]2CCCCO2)c(-c2ccccc2)oc2ccccc12
2347,1474044,10.1021/jm501740a,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,O=CN1CCC(Oc2ccc(-c3n[nH]c4ccc(C(=O)NC(c5ccccc5)C5CC5)cc34)cc2)CC1,rac-N-(Cyclopropyl(phenyl)methyl)-3-(4-((1-formylpiperidin-4-yl)oxy)phenyl)-1H-indazole-5-carboxamide,1.5,uM,=,0.1760912590556812,1,O=C(NC(c1ccccc1)C1CC1)c1ccc2[nH]nc(-c3ccc(OC4CCNCC4)cc3)c2c1
2348,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",C[C@@H]1CN(C(=O)c2ccccc2-n2nccn2)[C@H](Cc2cc(-n3nccn3)ccc2F)CO1,"US9150566, 116",21.0,uM,=,1.3222192947339193,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
2349,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(CC)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, E-5",8.04,uM,=,0.9052560487484512,1,O=C(c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12)N1CCNCC1
2350,1436762,10.1021/ml500187a,,,,Inhibition of human recombinant CYP3A4 incubated for 5 mins by fluorescence assay,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,"1-(4-{4-[2-(2,4-Dichloro-phenyl)-2-imidazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-ethanone (ketoconazole)",2.5,uM,=,0.3979400086720376,1,c1ccc(C2(Cn3ccnc3)OCC(COc3ccc(N4CCNCC4)cc3)O2)cc1
2351,537847,10.1021/jm800888q,,,,Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,COc1cncc(-c2ccc3c(c2)CCC(=O)C3)c1,"6-(5-Methoxypyridin-3-yl)-3,4-dihydronaphthalen-2(1H)-one",3.8,uM,=,0.5797835966168101,1,O=C1CCc2cc(-c3cccnc3)ccc2C1
2352,422039,10.1016/j.bmcl.2006.10.045,,,,Inhibition of CYP450 3A4,O=C(NO)c1ccc(-c2ccn(CCNCc3ccc4c(c3)OCO4)n2)s1,"5-(1-(2-(benzo[d][1,3]dioxol-5-ylmethylamino)ethyl)-1H-pyrazol-3-yl)-N-hydroxythiophene-2-carboxamide",53.0,uM,=,1.7242758696007892,1,c1csc(-c2ccn(CCNCc3ccc4c(c3)OCO4)n2)c1
2353,1689562,10.1021/acs.jmedchem.7b00598,,,,Inhibition of CYP3A4 (unknown origin),N#Cc1cc(S(=O)(=O)Nc2ncns2)ccc1Oc1ccc(Cl)cc1-c1cn[nH]c1N,"4-(2-(5-amino-1H-pyrazol-4-yl)-4-chlorophenoxy)-3-cyano-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide",0.827,uM,=,-0.0824944904474533,0,O=S(=O)(Nc1ncns1)c1ccc(Oc2ccccc2-c2cn[nH]c2)cc1
2354,676065,10.1016/j.bmcl.2010.09.028,,,,Inhibition of CYP3A4 after 30 mins,CC1([C@@H]2COC[C@H](COC(=O)N3CCC(N4CCCCC4)CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1,"((3R,5R)-4-(4-chlorophenylsulfonyl)-5-(1-methylcyclopropyl)morpholin-3-yl)methyl1,4'-bipiperidine-1'-carboxylate",0.0015,uM,=,-2.8239087409443187,0,O=C(OC[C@H]1COC[C@@H](C2CC2)N1S(=O)(=O)c1ccccc1)N1CCC(N2CCCCC2)CC1
2355,51902,10.1016/s0960-894x(02)00026-4,,,,Inhibition of cytochrome P450 3A4 enzyme; Range 1-2 uM,Cc1cc(C)cc(-c2[nH]c3ccc(C(C)(C)C(=O)N4C5CCC4CC5)cc3c2[C@H](C)CNCCc2ccc3ncoc3c2)c1,"1-(7-Aza-bicyclo[2.2.1]hept-7-yl)-2-[3-[(S)-2-(2-benzooxazol-6-yl-ethylamino)-1-methyl-ethyl]-2-(3,5-dimethyl-phenyl)-1H-indol-5-yl]-2-methyl-propan-1-one",1.0,uM,=,0.0,0,O=C(Cc1ccc2[nH]c(-c3ccccc3)c(CCNCCc3ccc4ncoc4c3)c2c1)N1C2CCC1CC2
2356,993292,10.1021/ml400228e,,,,Inhibition of CYP3A4 in human liver microsomes using nifedipine as substrate after 5 to 60 mins by LC-MS/MS analysis,Cn1cc(-c2ccc3c(c2)CCN3C(=O)Cc2cccc(C(F)(F)F)c2)c2c(N)ncnc21,"7-Methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine",10.0,uM,=,1.0,1,O=C(Cc1ccccc1)N1CCc2cc(-c3c[nH]c4ncncc34)ccc21
2357,519907,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,Cc1cccc(C)c1CNc1cc(-n2cnccc2=O)cn2c(C)c(C)nc12,"3-(8-(2,6-dimethylbenzylamino)-2,3-dimethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-4(3H)-one",2.1,uM,=,0.3222192947339193,1,O=c1ccncn1-c1cc(NCc2ccccc2)c2nccn2c1
2358,2118301,10.1021/acs.jmedchem.1c00847,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 10 mins followed by NADPH addition by LC/MS/MS analysis,C[C@@H]1Cc2c([nH]c3ccc(F)cc23)[C@@H](c2c(F)cc(NC3CN(CCCF)C3)cc2F)N1CC(F)(F)CO,"3-((1R,3R)-1-(2,6-Difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-6-fluoro-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol",1.6,uM,=,0.2041199826559248,1,c1ccc2c3c([nH]c2c1)[C@@H](c1ccc(NC2CNC2)cc1)NCC3
2359,944981,10.1021/ml3003132,,,,Time-dependent inhibition of CYP3A4 in human liver microsome using midazolam as substrate by TDI shift assay,CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOC[C@@H]4C)n2)CCN(c2ncccn2)C3)cc1,"(S)-1-Ethyl-3-(4-(4-(3-methylmorpholino)-7-(pyrimidin-2-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)phenyl)urea",0.9,uM,=,-0.0457574905606751,0,c1ccc(-c2nc3c(c(N4CCOCC4)n2)CCN(c2ncccn2)C3)cc1
2360,1467194,10.1021/jm5005336,,,,Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay,COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5CCOCC5)cc4)n[nH]c3c1)C(=O)N2C,"(1R,2S)-(E)-5'-Methoxy-1'-methyl-2-(3-(4-(morpholinomethyl)-styryl)-1H-indazol-6-yl)spiro-[cyclopropane-1,3'-indolin]-2'-one",6.0,uM,=,0.7781512503836436,1,O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccc(CN4CCOCC4)cc3)n[nH]c2c1
2361,1653091,10.1016/j.bmc.2016.11.019,,,,Inhibition of human CYP3A4,CC(C)c1ccc(COc2ccc(N(CCN)C(=O)c3cccnc3C(F)(F)F)cc2)cc1.Cl,N-(2-aminoethyl)-N-(4-(4-isopropylbenzyloxy)phenyl)-2-(trifluoromethyl)nicotinamide hydrochloride,0.144,uM,=,-0.8416375079047503,0,O=C(Nc1ccc(OCc2ccccc2)cc1)c1cccnc1
2362,539794,10.1021/jm8005405,,,,Inhibition of CYP3A4 in human liver microsomes,Cc1ccccc1-c1nncc2cc(-c3c(C)ccc4c(NC5CC5)noc34)ccc12,N-Cyclopropyl-6-methyl-7-(1-o-tolylphthalazin-6-yl)benzo[d]-isoxazol-3-amine,1.8,uM,=,0.255272505103306,1,c1ccc(-c2nncc3cc(-c4cccc5c(NC6CC6)noc45)ccc23)cc1
2363,1919651,,,,,"Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase",CC(=O)c1ccc(-c2cccnc2)s1,1-(5-Pyridin-3-yl-thiophen-2-yl)-ethanone,26.9,uM,=,1.429752280002408,1,c1cncc(-c2cccs2)c1
2364,1984169,10.1016/j.bmc.2020.115349,,,,Inhibition of human full length CYP3A4 assessed using 7-benzyloxy-4 (trifluoromethyl)coumarin as substrate preincubated for 20 mins in presence of NADPH followed by substrate addition and measured for 2 mins by fluorometric analysis,CC(C)(C)OC(=O)N[C@@H](CS[C@@H](Cc1ccccc1)C(=O)NCCc1cccnc1)Cc1ccccc1,tert-butyl N-[(1R)-1-benzyl-2-[(1S)-1-benzyl-2-oxo-2-[2-(3-pyridyl)ethylamino]ethyl]sulfanyl-ethyl]carbamate,0.31,uM,=,-0.5086383061657274,0,O=C(NCCc1cccnc1)[C@H](Cc1ccccc1)SCCCc1ccccc1
2365,2017934,10.1021/acs.jmedchem.0c00834,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis,Cc1c(-c2ccccc2)nc2ccc(Br)cc2c1C(=O)NCCc1ccccn1,6-Bromo-3-methyl-2-phenyl-N-[2-(pyridin-2-yl)ethyl]quinoline-4-carboxamide,6.0,uM,=,0.7781512503836436,1,O=C(NCCc1ccccn1)c1cc(-c2ccccc2)nc2ccccc12
2366,552281,10.1016/j.bmcl.2008.04.036,,,,Inhibition of CYP3A4,CS(=O)(=O)c1cccc(F)c1Cn1cc(-c2ccccc2Cl)c(=O)n(C[C@H](N)c2ccccc2)c1=O,"3-((R)-2-Amino-2-phenyl-ethyl)-5-(2-chloro-phenyl)-1-(2-fluoro-6-methanesulfonyl-benzyl)-1H-pyrimidine-2,4-dione",0.18,uM,=,-0.744727494896694,0,O=c1c(-c2ccccc2)cn(Cc2ccccc2)c(=O)n1CCc1ccccc1
2367,44705,10.1016/s0960-894x(02)00473-0,,,,Inhibition of cytochrome P450 3A4,CN(C)CCCN(Cc1ccc(-c2ccc(Cl)cc2)cc1)C(=O)Cn1cc(Cc2cnn(C)c2)c(=O)nc1SCc1ccc(F)cc1,N-(4'-Chloro-biphenyl-4-ylmethyl)-N-(3-dimethylamino-propyl)-2-[2-(4-fluoro-benzylsulfanyl)-5-(1-methyl-1H-pyrazol-4-ylmethyl)-4-oxo-4H-pyrimidin-1-yl]-acetamide,17.0,uM,=,1.230448921378274,1,O=C(Cn1cc(Cc2cn[nH]c2)c(=O)nc1SCc1ccccc1)NCc1ccc(-c2ccccc2)cc1
2368,821185,10.1021/jm201287w,,,,Inhibition of human CYP3A4 using 7-benzyloxyquinoline as substrate,CC(C)C[C@@H]1C(=O)N[C@H](C2Cc3ccccc3C2)C(=O)N1[C@@H](C(=O)N(C)C)c1ccc(F)cc1F,"(2R)-2-(2,4-difluorophenyl)-2-[(3R,6R)-3-(2,3-dihydro-1H-inden-2-yl)-6-(2-methylpropyl)-2,5-dioxo-1-piperazinyl]-N,N-dimethylethanamide",31.0,uM,=,1.4913616938342726,1,O=C1CN(Cc2ccccc2)C(=O)[C@@H](C2Cc3ccccc3C2)N1
2369,1291572,10.1016/j.bmcl.2013.12.058,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CCN(Cc2ccccc2Cl)C(=O)OCc2cncs2)Cc2ccccc2)cs1,Thiazol-5-ylmethyl 2-chlorobenzyl((S)-3-((S)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-4-morpholinobutanamido)-4-phenylbutyl)carbamate,0.34,uM,=,-0.4685210829577448,0,O=C(NCc1cscn1)N[C@@H](CCN1CCOCC1)C(=O)N[C@H](CCN(Cc1ccccc1)C(=O)OCc1cncs1)Cc1ccccc1
2370,1509544,10.1021/acs.jmedchem.5b00810,,,,Time dependent inhibition of CYP3A4 in human liver microsomes,COc1cc2c(cc1OC(C)C)[C@H](c1ccc(Cl)cc1)N(c1ccc(N(C)C[C@H]3CC[C@H](N4CCNC(=O)C4)CC3)cc1)C(=O)C2,"(trans)-(S)-1-(4-Chloro-phenyl)-7-isopropoxy-6-methoxy-2-(4-{methyl-[4-(3-oxo-piperazin-1-yl)-cyclohexylmethyl]-amino}-phenyl)-1,4-dihydro-2H-isoquinolin-3-one",11.3,uM,=,1.0530784434834195,1,O=C1CN([C@H]2CC[C@H](CNc3ccc(N4C(=O)Cc5ccccc5[C@@H]4c4ccccc4)cc3)CC2)CCN1
2371,982809,10.1016/j.ejmech.2013.08.010,,,,Inhibition of CYP3A (unknown origin),CC#CCn1c(N2CCC[C@@H](N)C2)cc(=O)n(Cc2ccc3ccc(Cl)cc3n2)c1=O,"(R)-6-(3-Aminopiperidin-1-yl)-1-(but-2-yn-1-yl)-3-((7-chloroquinolin-2-yl)methyl)pyrimidine-2,4(1H,3H)-dione",46.18,uM,=,1.6644539285811577,1,O=c1cc(N2CCCCC2)[nH]c(=O)n1Cc1ccc2ccccc2n1
2372,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1cccc(C(=O)N2CCOC[C@H]2Cc2cccc(-c3ncon3)c2)c1-n1nccn1,"US9150566, 83",25.0,uM,=,1.3979400086720375,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2ncon2)c1
2373,1474044,10.1021/jm501740a,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,O=C(N[C@@H](c1ccccn1)C1CC1)c1ccc2[nH]nc(-c3ccc(N4C5CCC4COC5)cc3)c2c1,3-(4-(3-Oxa-8-azabicyclo[3.2.1]octan-8-yl)phenyl)-N-((R)-cyclopropyl(pyridin-2-yl)methyl)-1H-indazole-5-carboxamide,1.4,uM,=,0.1461280356782379,1,O=C(N[C@@H](c1ccccn1)C1CC1)c1ccc2[nH]nc(-c3ccc(N4C5CCC4COC5)cc3)c2c1
2374,802673,10.1016/j.bmcl.2011.12.125,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,O=C(Nc1ccc(-c2ccnc3[nH]cnc23)cc1)Nc1ccccc1Cl,"1-(4-(3H-imidazo[4,5-b]pyridin-7-yl)phenyl)-3-(2-chlorophenyl)urea",0.6,uM,=,-0.2218487496163563,0,O=C(Nc1ccccc1)Nc1ccc(-c2ccnc3[nH]cnc23)cc1
2375,526157,10.1021/np0401765,,,,Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation,CCOc1cc(C[C@H]2COC(O)[C@@H]2Cc2cc(OC)c(OC)c(OC)c2)cc2c1OCO2,ethoxyclusin,0.44,uM,=,-0.3565473235138126,0,c1ccc(C[C@H]2COC[C@@H]2Cc2ccc3c(c2)OCO3)cc1
2376,2248278,10.1021/acs.jmedchem.1c01974,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as a substrate preincubated for 10 mins followed by NADPH addition and measured after 20 mins by LC/MS/MS analysis,CC(=O)Nc1ccc(Nc2ncnc(N[C@@H](Cc3ccccc3)C(=O)OC(C)(C)C)n2)cc1,"tert-Butyl (4-((4-Acetamidophenyl)amino)-1,3,5-triazin-2-yl)-L-phenylalaninate",19.8,uM,=,1.2966651902615312,1,c1ccc(CCNc2ncnc(Nc3ccccc3)n2)cc1
2377,1911030,10.1021/acs.jmedchem.8b01226,,,,Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins,Cc1cccc(C#CC=C2CCN(c3ncccc3[N+](=O)[O-])CC2)n1,2-{4-[3-(6-Methylpyridin-2-yl)prop-2-yn-1-ylidene]piperidin-1-yl}-3-nitropyridine,4.5,uM,=,0.6532125137753437,1,C(#Cc1ccccn1)C=C1CCN(c2ccccn2)CC1
2378,676065,10.1016/j.bmcl.2010.09.028,,,,Inhibition of CYP3A4 after 30 mins,CN1CCC12CCN(C(=O)OC1([C@H]3COC[C@@H](CC4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC1)CC2,"1-((3R,5R)-4-(4-chlorophenylsulfonyl)-5-(cyclopropylmethyl)morpholin-3-yl)cyclopropyl1-methyl-1,7-diazaspiro[3.5]nonane-7-carboxylate",0.03,uM,=,-1.5228787452803376,0,O=C(OC1([C@H]2COC[C@@H](CC3CC3)N2S(=O)(=O)c2ccccc2)CC1)N1CCC2(CCN2)CC1
2379,1363229,10.1021/jm500109z,,,,Inhibition of recombinant CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,"1-(4-{4-[2-(2,4-Dichloro-phenyl)-2-imidazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-ethanone (ketoconazole)",0.28,uM,=,-0.5528419686577808,0,c1ccc(C2(Cn3ccnc3)OCC(COc3ccc(N4CCNCC4)cc3)O2)cc1
2380,1629312,10.1016/j.bmcl.2016.11.020,,,,Inhibition of CYP3A4 (unknown origin),Cc1cc(Nc2cc(C)c(C#N)c(NCCOc3cccnc3C)n2)n[nH]1,4-methyl-6-(5-methyl-1H-pyrazol-3-ylamino)-2-(2-(2-methylpyridin-3-yloxy)ethylamino)nicotinonitrile,1.8,uM,=,0.255272505103306,1,c1cncc(OCCNc2cccc(Nc3cc[nH]n3)n2)c1
2381,2133633,10.1021/acs.jmedchem.1c00679,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins in presence of NADPH by LCMS/MS analysis,CCC(NC(=O)c1ccc(Cl)cc1)[C@@H]1[C@@H]2C[C@H](Oc3ccnc4ccncc34)C[C@@H]21,"N-(1-((1R,3s,5S,6r)-3-(1,6-naphthyridin-4-yloxy)bicyclo[3.1.0]hexan-6-yl)propyl)-4-chlorobenzamide",18.0,uM,=,1.255272505103306,1,O=C(NC[C@H]1[C@H]2C[C@@H](Oc3ccnc4ccncc34)C[C@@H]12)c1ccccc1
2382,643713,10.1016/j.bmcl.2010.06.009,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader,C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(NCCS(C)(=O)=O)c4)ccc32)sc1C(N)=O)c1ccccc1Cl,(R)-3-(1-(2-chlorophenyl)ethoxy)-5-(5-(2-(2-(methylsulfonyl)ethylamino)pyridin-4-yl)-1H-benzo[d]imidazol-1-yl)thiophene-2-carboxamide,3.5,uM,=,0.5440680443502757,1,c1ccc(COc2csc(-n3cnc4cc(-c5ccncc5)ccc43)c2)cc1
2383,1614026,10.1016/j.bmcl.2016.09.043,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 1'-hydroxymidazolam metabolite formation using midazolam as substrate incubated for 10 mins by HPLC-MS method,COc1cnc(-c2ccc(CCNc3nc4cc(Cl)ccc4c(=O)n3C)cc2)nc1,7-Chloro-2-{2-[4-(5-methoxy-pyrimidin-2-yl)-phenyl]-ethylamino}-3-methyl-3H-quinazolin-4-one,11.0,uM,=,1.0413926851582251,1,O=c1[nH]c(NCCc2ccc(-c3ncccn3)cc2)nc2ccccc12
2384,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cccc(-n3nccn3)c2)c1,"US9150566, 11",43.0,uM,=,1.6334684555795866,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
2385,1614026,10.1016/j.bmcl.2016.09.043,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 1'-hydroxymidazolam metabolite formation using midazolam as substrate incubated for 10 mins by HPLC-MS method,Cn1c(NCCc2ccc(-c3ccccn3)cc2)nc2cc(Cl)ccc2c1=O,7-Chloro-3-methyl-2-[2-(4-pyridin-2-yl-phenyl)-ethylamino]-3H-quinazolin-4-one,15.0,uM,=,1.1760912590556811,1,O=c1[nH]c(NCCc2ccc(-c3ccccn3)cc2)nc2ccccc12
2386,305432,10.1016/j.bmcl.2005.01.044,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,COC(=O)COc1ccc(COc2ccc3cc(C(C(C)N(C)C)n4ccnc4)ccc3c2)cc1,{4-[6-(2-Dimethylamino-1-imidazol-1-yl-propyl)-naphthalen-2-yloxymethyl]-phenoxy}-acetic acid methyl ester,0.22,uM,=,-0.6575773191777937,0,c1ccc(COc2ccc3cc(Cn4ccnc4)ccc3c2)cc1
2387,464738,10.1016/j.bmcl.2008.01.126,,,,Inhibition of CYP3A4 in presence of 7-benzyloxy-4-trifluoromethyl coumarin substrate,Cc1oc(-c2ccccc2)nc1CCOc1cccc(C[C@@H]2C(=O)N(c3ccc(C(C)(C)C)cc3)[C@@H]2C(=O)O)c1,"(2S,3S)-3-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-(4-tert-butylphenyl)-4-oxoazetidine-2-carboxylic acid",17.0,uM,=,1.230448921378274,1,O=C1[C@@H](Cc2cccc(OCCc3coc(-c4ccccc4)n3)c2)CN1c1ccccc1
2388,464738,10.1016/j.bmcl.2008.01.126,,,,Inhibition of CYP3A4 in presence of 7-benzyloxy-4-trifluoromethyl coumarin substrate,COc1ccc(N2C(=O)[C@@H](Cc3cccc(OCCc4nc(-c5ccccc5)oc4C)c3)[C@H]2C(=O)O)cc1,"(2S,3S)-3-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-(4-methoxyphenyl)-4-oxoazetidine-2-carboxylic acid",50.0,uM,=,1.6989700043360187,1,O=C1[C@@H](Cc2cccc(OCCc3coc(-c4ccccc4)n3)c2)CN1c1ccccc1
2389,2133633,10.1021/acs.jmedchem.1c00679,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins in presence of NADPH by LCMS/MS analysis,CCC(NC(=O)c1ccc(Cl)cc1)[C@H]1[C@@H]2C[C@@H](n3cnc(C4CC4)n3)C[C@@H]21,"4-chloro-N-(1-((1R,3s,5S,6r)-3-(3-cyclopropyl-1H-1,2,4-triazol-1-yl)bicyclo[3.1.0]hexan-6-yl)propyl)benzamide",31.0,uM,=,1.4913616938342726,1,O=C(NC[C@@H]1[C@H]2C[C@H](n3cnc(C4CC4)n3)C[C@@H]12)c1ccccc1
2390,305432,10.1016/j.bmcl.2005.01.044,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,CNC(=O)C(C)(C)COc1ccc2cc(C(C(C)N(C)C)n3ccnc3)ccc2c1,"3-[6-(2-Dimethylamino-1-imidazol-1-yl-propyl)-naphthalen-2-yloxy]-2,2,N-trimethyl-propionamide",2.01,uM,=,0.3031960574204888,1,c1ccc2cc(Cn3ccnc3)ccc2c1
2391,453158,10.1016/j.bmcl.2006.09.056,,,,Inhibition of CYP3A4 in presence of BFC substrate,O=[N+]([O-])c1cnc(NCc2ccccc2Cl)nc1NCC1CCNCC1,"N2-(2-chlorobenzyl)-5-nitro-N4-(piperidin-4-ylmethyl)pyrimidine-2,4-diamine",28.0,uM,=,1.4471580313422192,1,c1ccc(CNc2nccc(NCC3CCNCC3)n2)cc1
2392,1660136,10.1021/acs.jmedchem.6b01918,,,,Inhibition of human CYP3A4 assessed as inhibition of dealkylation,O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCCC2CCNC2)cc1F,rac-5-Chloro-2-fluoro-4-((2-(pyrrolidin-3-yl)ethyl)amino)-N-(thiazol-2-yl)benzenesulfonamide,20.0,uM,=,1.3010299956639813,1,O=S(=O)(Nc1nccs1)c1ccc(NCCC2CCNC2)cc1
2393,629565,10.1021/np1000329,,,,Inhibition of CYP3A4,Cc1cc(O)c2c(=O)c3c(O)cc(O)c4c5c(O)cc(O)c6c(=O)c7c(O)cc(C)c8c1c2c(c34)c(c78)c65,"1,3,4,6,8,13-Hexahydroxy-10,11-dimethyl-phenanthro[1,10,9,8-opqra]perylene-7,14-dione",8.7,uM,=,0.9395192526186184,1,O=c1c2cccc3c4cccc5c(=O)c6cccc7c8cccc1c8c(c23)c(c54)c67
2394,1665797,10.1021/acs.jmedchem.7b00328,,,,Inhibition of microsomal CYP3A4 (unknown origin),CNC(=O)c1c(-c2ccc(F)cc2)oc2ccc(-c3cc(C(=O)NC4(c5ccccc5)CC4)ccc3C)cc12,2-(4-Fluorophenyl)-N-methyl-5-(2-methyl-5-(1-phenylcyclopropylcarbamoyl)phenyl)benzofuran-3-carboxamide,2.1,uM,=,0.3222192947339193,1,O=C(NC1(c2ccccc2)CC1)c1cccc(-c2ccc3oc(-c4ccccc4)cc3c2)c1
2395,944981,10.1021/ml3003132,,,,Time-dependent inhibition of CYP3A4 in human liver microsome using midazolam as substrate by TDI shift assay,CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOC[C@@H]4C)n2)CCN(c2ccnc(C)n2)C3)cc1,"(S)-1-ethyl-3-(4-(4-(3-methylmorpholino)-7-(2-methylpyrimidin-4-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)phenyl)urea",3.3,uM,=,0.5185139398778875,1,c1ccc(-c2nc3c(c(N4CCOCC4)n2)CCN(c2ccncn2)C3)cc1
2396,449485,10.1016/j.bmcl.2007.07.097,,,,Inhibition of microsomal CYP3A4,CC(C)C[C@H](NCC(N)=O)c1cc(F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1,"2-((S)-1-(2-(4-((R)-3-(2,4-dichlorophenyl)-2-(2-oxopyrrolidin-1-yl)propanoyl)piperazin-1-yl)-5-fluorophenyl)-3-methylbutylamino)acetamide",0.72,uM,=,-0.1426675035687315,0,O=C([C@@H](Cc1ccccc1)N1CCCC1=O)N1CCN(c2ccccc2)CC1
2397,1288280,10.1016/j.bmcl.2013.12.057,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,CC(C)c1nc(CN(C(=O)N[C@@H](CO)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)C2CC2)cs1,"Thiazol-5-ylmethyl(2R,5R)-5-((S)-2-(3-cyclopropyl-3-((2-isopropylthiazol-4-yl)methyl)ureido)-3-hydroxypropanamido)-1,6-diphenylhexan-2-ylcarbamate",0.11,uM,=,-0.958607314841775,0,O=C(CNC(=O)N(Cc1cscn1)C1CC1)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
2398,595638,10.1016/j.bmcl.2009.09.096,,,,Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH,COc1ccc2c(SCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1,"7-methoxy-4-((6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methylthio)quinoline",7.0,uM,=,0.8450980400142568,1,c1ccc(-c2ccc3nnc(CSc4ccnc5ccccc45)n3n2)cc1
2399,1534761,,,,,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",Cc1cnc2[nH]cc(Cc3ccc(NCc4cccnc4F)nc3F)c2c1,"US9096593, P-2103",5.0,uM,=,0.6989700043360189,1,c1cncc(CNc2ccc(Cc3c[nH]c4ncccc34)cn2)c1
2400,52069,10.1021/jm021012t,,,,Inhibition of human cytochrome P450 3A4,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1,"(S)-N*1*-[(1S,2R)-1-Benzyl-3-((3S,4aS,8aS)-3-tert-butylcarbamoyl-octahydro-isoquinolin-2-yl)-2-hydroxy-propyl]-2-[(quinoline-2-carbonyl)-amino]-succinamide",1.5,uM,=,0.1760912590556812,1,O=C(CNC(=O)c1ccc2ccccc2n1)N[C@H](CCN1CC[C@@H]2CCCC[C@@H]2C1)Cc1ccccc1
2401,740075,10.1016/j.bmcl.2011.02.033,,,,Inhibition of CYP3A4,CC(=O)N(C)C1(c2ccccc2)CCN(CCC[C@]2(c3ccc(Cl)c(Cl)c3)CCCN(C(=O)c3ccccc3)C2)CC1,"N-(3-{3-[1-Benzoyl-4-(3,4-dichloro-phenyl)-piperidin-4-yl]-propyl}-4-phenyl-piperidin-4-yl)-N-methyl-acetamide",1.0,uM,=,0.0,0,O=C(c1ccccc1)N1CCC[C@](CCCN2CCC(c3ccccc3)CC2)(c2ccccc2)C1
2402,469873,10.1016/j.bmcl.2008.01.012,,,,Inhibition of human CYP3A4,CC(C)c1c(-c2nnc(O[C@H]3CCNC3)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12,"N-cyclopropyl-2,4-difluoro-5-(5-isopropyl-6-(5-((S)-pyrrolidin-3-yloxy)-1,3,4-oxadiazol-2-yl)pyrrolo[1,2-f][1,2,4]triazin-4-ylamino)benzamide",4.8,uM,=,0.6812412373755872,1,O=C(NC1CC1)c1cccc(Nc2ncnn3cc(-c4nnc(O[C@H]5CCNC5)o4)cc23)c1
2403,1663621,10.1021/acs.jmedchem.7b00425,,,,Inhibition of CYP3A4 (unknown origin),NC(=O)c1nn(CC(=O)N2[C@@H]3C[C@@H]3C[C@H]2C(=O)Nc2cccc(Br)n2)c2ccccc12,"1-(2-((1R,3S,5R)-3-((6-Bromopyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1H-indazole-3-carboxamide (7)::US9085555, 727",17.0,uM,=,1.230448921378274,1,O=C(Nc1ccccn1)[C@@H]1C[C@H]2C[C@H]2N1C(=O)Cn1ncc2ccccc21
2404,2164346,10.1021/acs.jmedchem.1c02192,,,,Inhibition of CYP3A4 (unknown origin),N#CC[C@]1(N)CC[C@@H](n2cnc3cnc4cc(F)c(-c5ccc(Oc6ncccn6)cc5Cl)cc4c32)CC1,"cis-2-[1-amino-4-[8-(2-chloro-4-pyrimidin-2-yloxy-phenyl)-7-fluoro-imidazo[4,5-c]quinolin-1-yl]cyclohexyl]acetonitrile",5.7,uM,=,0.7558748556724915,1,c1cnc(Oc2ccc(-c3ccc4ncc5ncn(C6CCCCC6)c5c4c3)cc2)nc1
2405,1489010,10.1124/dmd.111.042739,,,,Inhibition of CYP3A4 (unknown origin),CC[C@H](C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O,"Cis-2-((S)-sec-Butyl)-4-[4-(4-{4-[(2S,4R)-2-(2,4-dichloro-phenyl)-2-[1,2,4]triazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-phenyl]-2,4-dihydro-[1,2,4]triazol-3-one",0.004,uM,=,-2.397940008672037,0,O=c1[nH]ncn1-c1ccc(N2CCN(c3ccc(OC[C@@H]4CO[C@@](Cn5cncn5)(c5ccccc5)O4)cc3)CC2)cc1
2406,543015,10.1016/j.bmcl.2008.12.114,,,,Inhibition of CYP3A4,C[C@@H]1CN(CC2(C(N)=O)CCC2)CCN1S(=O)(=O)c1ccc(C(C)(O)C(F)(F)F)cc1,"1-(((3R)-3-methyl-4-(4-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenylsulfonyl)piperazin-1-yl)methyl)cyclobutanecarboxamide",65.0,uM,=,1.812913356642856,1,O=S(=O)(c1ccccc1)N1CCN(CC2CCC2)CC1
2407,1353337,10.1021/ml400379x,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 30 mins preincubation by LC-MS/MS analysis in absence of NADPH,CNS(=O)(=O)Nc1cccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F,3-(2-Fluoro-3-(N-methylsulfamoylamino)benzyl)-4-methyl-7-(pyrimidin-2-yloxy)-2H-chromen-2-one,26.0,uM,=,1.414973347970818,1,O=c1oc2cc(Oc3ncccn3)ccc2cc1Cc1ccccc1
2408,873423,10.1021/jm3006788,,,,Inhibition of CYP3A4,Cn1c(-c2ccccn2)c(C2CCCC2)c2ccc(C(=O)NC3(C(=O)Nc4ccc(/C=C/C(=O)O)cc4)CCC3)cc21,(E)-3-[4-({1-[(3-Cyclopentyl-1-methyl-2-pyridin-2-yl-1H-indole-6-carbonyl)amino]cyclobutanecarbonyl}amino)phenyl]-acrylic Acid,9.5,uM,=,0.9777236052888478,1,O=C(NC1(C(=O)Nc2ccccc2)CCC1)c1ccc2c(C3CCCC3)c(-c3ccccn3)[nH]c2c1
2409,1854052,10.1016/j.ejmech.2019.07.003,,,,Inhibition of recombinant human CYP3A4 using Luciferin-PPXE as substrate preincubated for 10 mins followed by NADPH addition measured after 15 mins by luminometric method,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,"1-(4-{4-[2-(2,4-Dichloro-phenyl)-2-imidazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-ethanone (ketoconazole)",0.1826,uM,=,-0.7384992268017199,0,c1ccc(C2(Cn3ccnc3)OCC(COc3ccc(N4CCNCC4)cc3)O2)cc1
2410,1741066,10.1021/acs.jmedchem.8b00450,,,,Inhibition of human CYP3A4,CN(C[C@H]1Cc2c(cccc2N2CCN(C3CC3)CC2)CN1)[C@H]1CCCc2cccnc21,"(S)-N-(((R)-5-(4-cyclopropylpiperazin-1-yl)-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)-N-methyl-5,6,7,8-tetrahydroquinolin-8-amine",4.23,uM,=,0.6263403673750424,1,c1cnc2c(c1)CCC[C@@H]2NC[C@H]1Cc2c(cccc2N2CCN(C3CC3)CC2)CN1
2411,1301328,10.6019/CHEMBL3137440,,,,DNDI: CYP Inhibition,FC(F)(F)c1ccc(N2CCC(N(c3ccc(C(F)(F)F)cc3)c3cccnc3)CC2)cc1,N-4-Trifluoromethylphenyl-N-{1-[4-(trifluoromethyl)phenyl]piperidin-4-yl}pyridin-3-amine,30.2,uM,=,1.4800069429571507,1,c1ccc(N2CCC(N(c3ccccc3)c3cccnc3)CC2)cc1
2412,1696937,10.1016/j.bmcl.2017.09.042,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate pretreated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis,Cc1cccc(NC(=O)c2cc(Oc3cncc(F)c3)cn3ccnc23)n1,"6-(5-fluoropyridin-3-yloxy)-N-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine-8-carboxamide",2.1,uM,=,0.3222192947339193,1,O=C(Nc1ccccn1)c1cc(Oc2cccnc2)cn2ccnc12
2413,972700,10.1021/ml400186z,,,,Inhibition of CYP3A4 (unknown origin),CCOCc1c(C(=O)NCc2cncn2C)cnn1-c1ncc(C)c(N2CCCCC2)n1,5-(ethoxymethyl)-N-((1-methyl-1H-imidazol-5-yl)methyl)-1-(5-methyl-4-(piperidin-1-yl)pyrimidin-2-yl)-1H-pyrazole-4-carboxamide,1.0,uM,=,0.0,0,O=C(NCc1cnc[nH]1)c1cnn(-c2nccc(N3CCCCC3)n2)c1
2414,611722,10.1021/jm9014263,,,,Inhibition of human CYP3A4 using BFC substrate by fluorescence assay,N#Cc1ccc(NC(=O)NCc2cccc(C(=O)Nc3ccc4c(c3)CNCC4)c2)cc1,"3-[3-(4-Cyano-phenyl)-ureidomethyl]-N-(1,2,3,4-tetrahydro-isoquinolin-7-yl)-benzamide",5.9,uM,=,0.7708520116421442,1,O=C(NCc1cccc(C(=O)Nc2ccc3c(c2)CNCC3)c1)Nc1ccccc1
2415,51923,10.1021/jm031115r,,,,Inhibition of human cytochrome P450 3A4,Cc1cc(C)cc(O[C@H](C(=O)O)[C@@]2(c3ccccc3)NCC(=O)N(Cc3c(F)cc(F)cc3F)c3ccccc32)c1,"(S)-(3,5-Dimethyl-phenoxy)-[(S)-2-oxo-5-phenyl-1-(2,4,6-trifluoro-benzyl)-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-5-yl]-acetic acid",14.0,uM,=,1.146128035678238,1,O=C1CN[C@@](COc2ccccc2)(c2ccccc2)c2ccccc2N1Cc1ccccc1
2416,471117,10.1016/j.bmc.2007.10.061,,,,Inhibition of CYP3A4,Nc1nccn2c(C3CCC3)nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c12,"3-cyclobutyl-1-(2-phenylquinolin-7-yl)-imidazo[1,5-a]pyrazin-8-ylamine",3.4,uM,=,0.5314789170422551,1,c1ccc(-c2ccc3ccc(-c4nc(C5CCC5)n5ccncc45)cc3n2)cc1
2417,448320,10.1016/j.bmc.2007.05.069,,,,Inhibition of CYP3A4,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)C(=O)C(C)(c1cc(F)cc(F)c1)O2,"N-{2-[6-(2,4-diamino-6-ethyl-pyrimidin-5-yl)-2-(3,5-difluoro-phenyl)-2-methyl-3-oxo-2,3-dihydro-benzo-[1,4]oxazin-4-yl]-ethyl}-acetamide",0.86,uM,=,-0.0655015487564322,0,O=C1Nc2cc(-c3cncnc3)ccc2OC1c1ccccc1
2418,768817,10.1021/jm2005354,,,,Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting,C[C@@H](c1ccc(-c2ccc(F)cc2F)cc1)N1CC[C@](CCCO)(c2ccccc2)OC1=O,"(R)-3-((S)-1-(2',4'-difluorobiphenyl-4-yl)ethyl)-6-(3-hydroxypropyl)-6-phenyl-1,3-oxazinan-2-one",14.0,uM,=,1.146128035678238,1,O=C1OC(c2ccccc2)CCN1Cc1ccc(-c2ccccc2)cc1
2419,455108,10.1016/j.bmcl.2006.12.043,,,,Inhibition of CYP3A4,N[C@H](Cc1ccccc1)C(=O)N1CCN(c2ccc3[nH]ncc3c2)CC1,(R)-1-(4-(1H-indazol-5-yl)piperazin-1-yl)-2-amino-3-phenylpropan-1-one,7.0,uM,=,0.8450980400142568,1,O=C(CCc1ccccc1)N1CCN(c2ccc3[nH]ncc3c2)CC1
2420,519908,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,Cc1nc2c(N[C@H]3CCc4ccccc43)cc(-n3ccccc3=O)cn2c1C,"(S)-1-(8-(2,3-dihydro-1H-inden-1-ylamino)-2,3-dimethylimidazo[1,2-a]pyridin-6-yl)pyridin-2(1H)-one",86.0,uM,=,1.934498451243568,1,O=c1ccccn1-c1cc(N[C@H]2CCc3ccccc32)c2nccn2c1
2421,980735,10.1021/jm400820m,,,,Inhibition of human recombinant CYP3A4,CCOC(=O)c1cc(C#N)c(N2CC(C(=O)NS(=O)(=O)Cc3ccc(C)cc3)C2)nc1C,Ethyl 6-(3-{[(4-Methylbenzyl)sulfonyl]carbamoyl}azetidin-1-yl)-5-cyano-2-methylnicotinate,20.0,uM,=,1.3010299956639813,1,O=C(NS(=O)(=O)Cc1ccccc1)C1CN(c2ccccn2)C1
2422,1797910,10.1021/acs.jmedchem.8b01326,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate/NADPH addition measured after 10 mins by LC-MS/MS analysis,Cc1nc(N2C[C@H]3C(=O)N(C)C(=N)N[C@@]3(c3cc(-c4cccc(C#N)c4)cs3)C2)nc(C)c1F,"3-(5-((4aR,7aR)-6-(5-Fluoro-4,6-dimethylpyrimidin-2-yl)-2-imino-3-methyl-4-oxooctahydro-7aH-pyrrolo[3,4-d]pyrimidin-7a-yl)thiophen-3-yl)benzonitrile",13.0,uM,=,1.1139433523068367,1,N=C1NC(=O)[C@@H]2CN(c3ncccn3)C[C@]2(c2cc(-c3ccccc3)cs2)N1
2423,991614,10.1021/jm4008906,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(C[C@@H]1CCCN1)C2,"(S)-3-(Aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-6-((S)-pyrrolidin-2-ylmethyl)-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one",40.0,uM,=,1.6020599913279625,1,O=C1c2c(-c3ccccc3)ccnc2CN1C[C@@H]1CCCN1
2424,52069,10.1021/jm021012t,,,,Inhibition of human cytochrome P450 3A4,COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)Cc2ccccc2)C1c1cccc([N+](=O)[O-])c1,"2,6-Dimethyl-4-(3-nitro-phenyl)-1,4-dihydro-pyridine-3,5-dicarboxylic acid 3-[2-(benzyl-methyl-amino)-ethyl] ester 5-methyl ester",0.42,uM,=,-0.3767507096020995,0,O=C(OCCNCc1ccccc1)C1=CNC=CC1c1ccccc1
2425,526157,10.1021/np0401765,,,,Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation,COc1cc(C[C@H]2C(=O)OC[C@@H]2Cc2ccc3c(c2)OCO3)cc(OC)c1OC,(-)-deoxypodorhizone,1.0,uM,=,0.0,0,O=C1OC[C@H](Cc2ccc3c(c2)OCO3)[C@H]1Cc1ccccc1
2426,717286,10.1021/np100665j,,,,Inhibition of CYP3A4 after 30 mins by fluorometric assay,COc1cc([C@H]2c3cc(O)c(OC)cc3C[C@H]3C(=O)OC[C@H]23)ccc1O,alpha-Conidendrin,0.2,uM,=,-0.6989700043360187,0,O=C1OC[C@@H]2[C@@H](c3ccccc3)c3ccccc3C[C@@H]12
2427,597146,10.1021/jm9009857,,,,Inhibition of CYP3A4,Cc1c[nH]c2c(Nc3cccc(Cl)c3)ncc(C(=O)N3CCOCC3)c12,"1-[7-(3-Chloro-phenylamino)-3-methyl-1H-pyrrolo[2,3-c]pyridin-4-yl]-1-morpholin-4-yl-methanone",48.0,uM,=,1.6812412373755872,1,O=C(c1cnc(Nc2ccccc2)c2[nH]ccc12)N1CCOCC1
2428,2024613,10.1016/j.bmcl.2020.127721,,,,Inhibition of CYP3A4 (unknown origin),CS(=O)(=O)Nc1cccc(CC(=O)Nc2nnc(-c3c[nH]c4ncccc34)s2)c1,"2-[3-(methanesulfonamido)phenyl]-N-[5-(1H-pyrrolo[2,3-b]pyridin-3-yl)-1,3,4-thiadiazol-2-yl]acetamide",100.0,uM,=,2.0,1,O=C(Cc1ccccc1)Nc1nnc(-c2c[nH]c3ncccc23)s1
2429,814102,10.1016/j.bmcl.2012.03.014,,,,Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins,O[C@]1(c2ccc(F)c(F)c2)CCNC[C@@H]1c1onc(-c2c(Cl)cccc2Cl)c1Br,"(3S,4R)-3-(4-bromo-3-(2,6-dichlorophenyl)isoxazol-5-yl)-4-(3,4-difluorophenyl)piperidin-4-ol",15.0,uM,=,1.1760912590556811,1,c1ccc(-c2cc([C@H]3CNCCC3c3ccccc3)on2)cc1
2430,802673,10.1016/j.bmcl.2011.12.125,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Cc1c[nH]c2ncnc(-c3ccc(NC(=O)Nc4cccc(C(=O)NC(C)C)c4)cc3)c12,"N-isopropyl-3-(3-(4-(5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)ureido)benzamide",22.0,uM,=,1.3424226808222062,1,O=C(Nc1ccccc1)Nc1ccc(-c2ncnc3[nH]ccc23)cc1
2431,1467195,10.1021/jm5005336,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay,COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5CCOCC5)cc4)n[nH]c3c1)C(=O)N2C,"(1R,2S)-(E)-5'-Methoxy-1'-methyl-2-(3-(4-(morpholinomethyl)-styryl)-1H-indazol-6-yl)spiro-[cyclopropane-1,3'-indolin]-2'-one",20.0,uM,=,1.3010299956639813,1,O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccc(CN4CCOCC4)cc3)n[nH]c2c1
2432,449485,10.1016/j.bmcl.2007.07.097,,,,Inhibition of microsomal CYP3A4,CC(C)C[C@H](NC(=O)[C@H](C)N)c1cc(F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1,"(S)-2-amino-N-((S)-1-(2-(4-((R)-3-(2,4-dichlorophenyl)-2-(2-oxopyrrolidin-1-yl)propanoyl)piperazin-1-yl)-5-fluorophenyl)-3-methylbutyl)propanamide",8.6,uM,=,0.9344984512435676,1,O=C([C@@H](Cc1ccccc1)N1CCCC1=O)N1CCN(c2ccccc2)CC1
2433,873607,10.1016/j.bmcl.2012.02.041,,,,Inhibition of CYP3A4 using diethoxyfluoresin as substrate,COc1cc2c(NC3CCCCC3)c(C(N)=O)cnc2cc1-c1c(C)noc1C,"4-(cyclohexylamino)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxyquinoline-3-carboxamide",6.1,uM,=,0.785329835010767,1,c1cc(NC2CCCCC2)c2ccc(-c3cnoc3)cc2n1
2434,526157,10.1021/np0401765,,,,Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation,CC1=CC(=O)C2=C(C)C[C@@H]3OC(=O)C(C)=C3C[C@@H]12,"(5alpha,8alpha)-2-oxo-1(10),3,7(11)-guaiatrien-12,8-olide",8.8,uM,=,0.9444826721501688,1,O=C1C=C2C[C@H]3C=CC(=O)C3=CC[C@@H]2O1
2435,550965,10.1021/np030556a,,,,Inhibition of human CYP3A4 by radiometric assay,CC(=O)O[C@@H]1[C@@H](O)[C@H](C)O[C@@H](Oc2c(-c3ccc(O)cc3)oc3cc(O)cc(O)c3c2=O)[C@@H]1O,kaempferol-3-O-(3-O-acetyl-alpha-L-rhamnopyranoside),98.3,uM,=,1.992553517832136,1,O=c1c(O[C@H]2CCCCO2)c(-c2ccccc2)oc2ccccc12
2436,772033,10.1021/jm2006222,,,,Inhibition of CYP3A4 using DBF as substrate,COc1cc(OC)c(Cl)c(NC(=O)N(C)c2cc(Nc3ccc(OCCN4CCCC4)cc3)ncn2)c1Cl,"3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-methyl-1-{6-[4-(2-pyrrolidin-1-yl-ethoxy)-phenylamino]-pyrimidin-4-yl}-urea",2.5,uM,=,0.3979400086720376,1,O=C(Nc1ccccc1)Nc1cc(Nc2ccc(OCCN3CCCC3)cc2)ncn1
2437,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1cccc(C(=O)N2C[C@@H](C)OC[C@H]2Cc2cccc(-n3nccn3)c2)c1-n1nccn1,"US9150566, 97",11.0,uM,=,1.0413926851582251,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
2438,1755379,10.1021/acs.jmedchem.8b00419,,,,Inhibition of C-terminal His-tagged recombinant human CYP3A4 assessed as decrease in metabolism of luciferin isopropyl alcohol preincubated for 3 mins followed by NADPH addition measured after 30 mins,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=CC[C@@H]12,"10,13-Dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol",0.23,uM,=,-0.6382721639824072,0,C1=C2CCCCC2[C@H]2CCC3C(c4cccnc4)=CC[C@H]3[C@@H]2C1
2439,52065,10.1021/jm0310129,,,,Inhibitory activity against cytochrome P450 3A4,Cn1c2cccc(C(N)=O)c2c2nc(CN3CCOCC3)nc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21,"4-{4-[2-(3,4-Difluoro-phenyl)-ethyl]-piperazin-1-yl}-5-methyl-2-morpholin-4-ylmethyl-5H-pyrimido[5,4-b]indole-9-carboxylic acid amide",31.31,uM,=,1.4956830676169153,1,c1ccc(CCN2CCN(c3nc(CN4CCOCC4)nc4c3[nH]c3ccccc34)CC2)cc1
2440,1919651,,,,,"Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase",c1cncc(-c2c[nH]cn2)c1,3-(1H-Imidazol-4-yl)-pyridine,140.0,uM,=,2.146128035678238,1,c1cncc(-c2c[nH]cn2)c1
2441,2230759,10.1016/j.ejmech.2021.113925,,,,Inhibition of CYP3A4 (unknown origin),FC(F)(F)c1nccc(N[C@H]2CC[C@@H](Nc3ccc4nnc(Cl)n4n3)CC2)n1,"(1s,4s)-N1-(3-Chloro-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-N4-(2-(trifluoromethyl)pyrimidin-4-yl)cyclohexane-1,4-diamine",18.0,uM,=,1.255272505103306,1,c1cc(N[C@H]2CC[C@@H](Nc3ccc4nncn4n3)CC2)ncn1
2442,469873,10.1016/j.bmcl.2008.01.012,,,,Inhibition of human CYP3A4,CC(C)c1c(-c2nnc(OC3CCNCC3)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12,"N-cyclopropyl-2,4-difluoro-5-(5-isopropyl-6-(5-(piperidin-4-yloxy)-1,3,4-oxadiazol-2-yl)pyrrolo[1,2-f][1,2,4]triazin-4-ylamino)benzamide",5.0,uM,=,0.6989700043360189,1,O=C(NC1CC1)c1cccc(Nc2ncnn3cc(-c4nnc(OC5CCNCC5)o4)cc23)c1
2443,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCN(C)C)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, F-13",7.87,uM,=,0.8959747323590646,1,O=C1[C@H](Cc2ccccc2)N2C(=O)CNN(C(=O)NCc3ccccc3)[C@H]2CN1Cc1cccc2cc[nH]c12
2444,2156515,10.1021/acs.jmedchem.1c01272,,,,Inhibition of CYP3A4 in human liver microsomes using IPA as substrate preincubated for 10 mins followed by NADPH generating system addition and measured after 20 mins,COc1cc(NC(=O)c2cc(=O)c3ccccc3o2)c(-c2nnn(-c3ccc(CCN4CCn5cncc5C4)cc3)n2)cc1OC,"N-(2-(2-(4-(2-(5,6-dihydroimidazo[1,5-a]pyrazin-7(8H)-yl)ethyl)phenyl)-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl)-4-oxo-4H-chromene-2-carboxamide",0.149,uM,=,-0.826813731587726,0,O=C(Nc1ccccc1-c1nnn(-c2ccc(CCN3CCn4cncc4C3)cc2)n1)c1cc(=O)c2ccccc2o1
2445,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCC(N7CCC7)CC6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, G-54",3.29,uM,=,0.5171958979499743,1,O=C(Nc1ccc(N2CCC(N3CCC3)CC2)nc1)c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12
2446,828928,10.1016/j.bmcl.2012.06.022,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N(C)C)oc2c1,"thiazol-5-ylmethyl(2S,3R)-4-(2-(dimethylamino)-N-isobutylbenzo[d]oxazole-6-carboxamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate",0.053,uM,=,-1.275724130399211,0,O=C(N[C@H](CCNC(=O)c1ccc2ncoc2c1)Cc1ccccc1)OCc1cncs1
2447,1908478,10.1021/acsmedchemlett.9b00325,,,,Inhibition of human recombinant CYP3A4 using midazolam as substrate incubated for 40 to 130 mins in presence of NADPH by LC-MS/MS analysis,C[C@@H](c1ccc(NC(=O)N2CC(c3cncc(N)c3)C2)cc1)N1Cc2ccccc2C1=O,(S)-3-(5-Aminopyridin-3-yl)-N-(4-(1-(1-oxoisoindolin-2-yl)ethyl)phenyl)azetidine-1-carboxamide,4.69,uM,=,0.6711728427150834,1,O=C(Nc1ccc(CN2Cc3ccccc3C2=O)cc1)N1CC(c2cccnc2)C1
2448,1886565,10.1021/acs.jmedchem.8b02021,,,,Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay,Nc1nc2ccc(OCc3ccccc3)cc2s1,"6-(Benzyloxy)-1,3-benzothiazol-2-amine",10.0,uM,=,1.0,1,c1ccc(COc2ccc3ncsc3c2)cc1
2449,597146,10.1021/jm9009857,,,,Inhibition of CYP3A4,Cn1ccc2c(Nc3cccc(Cl)c3)ncc(C(=O)N3CCOCC3)c21,"(4-(3-chlorophenylamino)-1-methyl-1H-pyrrolo[3,2-c]pyridin-7-yl)(morpholino)methanone",24.0,uM,=,1.380211241711606,1,O=C(c1cnc(Nc2ccccc2)c2cc[nH]c12)N1CCOCC1
2450,305432,10.1016/j.bmcl.2005.01.044,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,COC(=O)c1ccc(COc2ccc3cc(C(C(C)N(C)C)n4ccnc4)ccc3c2)cc1,4-[6-(2-Dimethylamino-1-imidazol-1-yl-propyl)-naphthalen-2-yloxymethyl]-benzoic acid methyl ester,0.01,uM,=,-2.0,0,c1ccc(COc2ccc3cc(Cn4ccnc4)ccc3c2)cc1
2451,993439,10.6019/CHEMBL2448688,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,CCS(=O)(=O)N(Cc1cccnc1)c1cncc(-c2nc3ccccc3s2)c1,,1.04,uM,=,0.0170333392987803,1,c1cncc(CNc2cncc(-c3nc4ccccc4s3)c2)c1
2452,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)Nc6cccc(O)c6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, D-16",8.07,uM,=,0.9068735347220704,1,O=C(Nc1ccccc1)c1ccc(-c2c[nH]c3c(CN4C[C@@H]5N(C(=O)NCc6ccccc6)NCC(=O)N5[C@@H](Cc5ccccc5)C4=O)cccc23)cc1
2453,2246770,10.1016/j.ejmech.2022.114195,,,,Inhibition of CYP3A4 in human liver microsomes using as midazolam substrate incubated for 10 min followed by NADPH addition for 10 mins by LC-MS/MS analysis,Fc1cccc(F)c1CC1(Cn2ccnc2)COC(c2ccc(-c3ccsc3)cc2)=N1,"4-((1H-imidazole-1-yl)methyl)-4-(2,6-difluorobenzyl)-2-(4-(thiophen-3-yl)phenzyl)-4,5-dihydrooxazole",0.18,uM,=,-0.744727494896694,0,c1ccc(CC2(Cn3ccnc3)COC(c3ccc(-c4ccsc4)cc3)=N2)cc1
2454,465260,10.1016/j.bmcl.2008.01.036,,,,Inhibition of CYP3A4,COc1cc(CC(=O)Nc2cc(-n3nc(C)cc3C)nc(-c3ccccn3)n2)cc(OC)c1,"2-(3,5-dimethoxyphenyl)-N-(6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(pyridin-2-yl)pyrimidin-4-yl)acetamide",1.3,uM,=,0.1139433523068367,1,O=C(Cc1ccccc1)Nc1cc(-n2cccn2)nc(-c2ccccn2)n1
2455,1440787,10.1016/j.bmc.2014.09.026,,,,Inhibition of CYP3A4 (unknown origin) using AMMC by fluorescence assay,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,"1-(4-{4-[2-(2,4-Dichloro-phenyl)-2-imidazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-ethanone (ketoconazole)",0.025,uM,=,-1.6020599913279625,0,c1ccc(C2(Cn3ccnc3)OCC(COc3ccc(N4CCNCC4)cc3)O2)cc1
2456,665571,10.1021/jm100832d,,,,Inhibition of human CYP3A4,CCOc1ccc2c(c1)Oc1cc(OCC)ccc1C21OC(=O)c2ccccc21,diethoxyfluorescein,1.0,uM,=,0.0,0,O=C1OC2(c3ccccc3Oc3ccccc32)c2ccccc21
2457,991614,10.1021/jm4008906,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(CC(=O)N(C)C)C2,"(S)-2-(3-(Aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide",13.0,uM,=,1.1139433523068367,1,O=C1NCc2nccc(-c3ccccc3)c21
2458,1485703,10.1124/dmd.112.048264,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method,CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1,benzbromarone,29.2,uM,=,1.4653828514484184,1,O=C(c1ccccc1)c1coc2ccccc12
2459,1558600,10.1016/j.bmcl.2015.06.020,,,,Inhibition of CYP3A4 (unknown origin) by fluorescence assay,Cc1cn(-c2cc3c(cc2F)Nc2nc(Cc4ccccc4)ccc2C(=O)N3)cn1,"2-benzyl-9-fluoro-8-(4-methyl-1H-imidazol-1-yl)-6,11-dihydro-5H-benzo[b]pyrido[2,3-e][1,4]diazepin-5-one",0.03,uM,=,-1.5228787452803376,0,O=C1Nc2cc(-n3ccnc3)ccc2Nc2nc(Cc3ccccc3)ccc21
2460,2228824,10.1021/acs.jmedchem.1c01970,,,,Inhibition of CYP3A4 in human liver microsomes incubated for 10 mins in the presence of NADPH by high performance liquid chromatography-tandem mass spectrometry,CCC(CC)O[C@@H]1C=C(C(=O)O)C[C@H](NCc2ccc(-c3ccsc3)cc2Cl)[C@H]1NC(C)=O,"(3R,4R,5S)-4-Acetamido-5-((2-chloro-4-(thiophen-3-yl)benzyl)amino)-3-(pentan-3-yloxy)cyclohex-1-ene-1-carboxylic Acid",72.5,uM,=,1.8603380065709936,1,C1=CC[C@H](NCc2ccc(-c3ccsc3)cc2)CC1
2461,535882,10.1016/j.bmcl.2008.08.010,,,,"Inhibition of human CYP3A4 by microtiter plate assays using N-N,diethyl-formamide as substrate",O=S(=O)(c1ccccn1)n1ccc2cc3c(cc21)CCNCC3,"1-(pyridin-2-ylsulfonyl)-1,5,6,7,8,9-hexahydroazepino[4,5-f]indole",39.0,uM,=,1.591064607026499,1,O=S(=O)(c1ccccn1)n1ccc2cc3c(cc21)CCNCC3
2462,886888,10.1016/j.bmcl.2012.10.057,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 mins in presence of NADPH,CN1CCN(Cc2cccc3c2ccn3S(=O)(=O)c2ccccc2Br)CC1,1-(2-Bromobenzenesulfonyl)-4-(4-methylpiperazin-1-ylmethyl)-1H-indole,35.97,uM,=,1.555940437818511,1,O=S(=O)(c1ccccc1)n1ccc2c(CN3CCNCC3)cccc21
2463,688021,10.1016/j.bmcl.2010.10.101,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins,Cc1ccc(F)cc1Cn1c(N2CCC[C@@](C)(N)C2)cc2c1c(=O)n(C)c(=O)n2C.Cl,"(R)-6-(3-amino-3-methylpiperidin-1-yl)-5-(5-fluoro-2-methylbenzyl)-1,3-dimethyl-1H-pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione hydrochloride",20.2,uM,=,1.305351369446624,1,O=c1[nH]c(=O)c2c(cc(N3CCCCC3)n2Cc2ccccc2)[nH]1
2464,993439,10.6019/CHEMBL2448688,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,O=C(C1CC1)N(Cc1cccnc1)c1cncc(-c2nc3ccccc3s2)c1,,1.12,uM,=,0.0492180226701816,1,O=C(C1CC1)N(Cc1cccnc1)c1cncc(-c2nc3ccccc3s2)c1
2465,1613541,10.1021/acs.jmedchem.6b00756,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,O=C(Nc1ccc(F)cc1)N1N=C(c2ccncc2)CC1c1ccc(F)cc1,"N,5-Bis(4-fluorophenyl)-3-(pyridin-4-yl)-4,5-dihydro-1H-pyrazole-1-carboxamide",18.0,uM,=,1.255272505103306,1,O=C(Nc1ccccc1)N1N=C(c2ccncc2)CC1c1ccccc1
2466,1665797,10.1021/acs.jmedchem.7b00328,,,,Inhibition of microsomal CYP3A4 (unknown origin),CNC(=O)c1c(-c2ccc(F)cc2)oc2ccc(-c3cc(C(=O)NC4(c5ccncc5)CC4)ccc3C)cc12,2-(4-Fluorophenyl)-N-methyl-5-(2-methyl-5-(1-(pyridin-4-yl)-cyclopropylcarbamoyl)phenyl)benzofuran-3-carboxamide,0.073,uM,=,-1.136677139879544,0,O=C(NC1(c2ccncc2)CC1)c1cccc(-c2ccc3oc(-c4ccccc4)cc3c2)c1
2467,2068401,10.1016/j.bmcl.2020.127676,,,,Inhibition of CYP3A4 (unknown origin),CN[C@@H](C)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)Nc1cc2c(OCC#CCOc3ncnc4cc(OC)c(NC(=O)[C@@H]5CCCN5C(=O)[C@@H](NC(=O)[C@H](C)NC)C(C)(C)C)cc34)ncnc2cc1OC)C(C)(C)C,"(S,S,2S)-N,N'-(4,4'-(but-2-yne-1,4-diylbis(oxy))bis(7-methoxyquinazoline-6,4-diyl))bis(1-((S)-3,3-dimethyl-2-((S)-2-(methylamino)propanamido)butanoyl)pyrrolidine-2-carboxamide)",0.86,uM,=,-0.0655015487564322,0,O=C(Nc1ccc2ncnc(OCC#CCOc3ncnc4ccc(NC(=O)[C@@H]5CCCN5)cc34)c2c1)[C@@H]1CCCN1
2468,1301328,10.6019/CHEMBL3137440,,,,DNDI: CYP Inhibition,FC(F)(F)c1ccc(N2CCC(N(c3ccc(C(F)(F)F)cc3)c3cncnc3)CC2)cc1,,16.0,uM,=,1.2041199826559248,1,c1ccc(N2CCC(N(c3ccccc3)c3cncnc3)CC2)cc1
2469,51923,10.1021/jm031115r,,,,Inhibition of human cytochrome P450 3A4,Cc1cc(C)nc(O[C@H](C(=O)O)[C@@]2(c3ccccc3)NCC(=O)N(Cc3c(F)cc(F)cc3F)c3ccccc32)n1,"(S)-(4,6-Dimethyl-pyrimidin-2-yloxy)-[(S)-2-oxo-5-phenyl-1-(2,4,6-trifluoro-benzyl)-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-5-yl]-acetic acid",41.0,uM,=,1.6127838567197357,1,O=C1CN[C@@](COc2ncccn2)(c2ccccc2)c2ccccc2N1Cc1ccccc1
2470,1769255,10.1016/j.bmc.2018.02.026,,,,Inhibition of CYP3A4 in human liver microsomes after 20 mins,COc1cc2ccc(Br)cc2cc1[C@@H](c1ccnc(OC)c1OC)[C@@](O)(CCN(C)C)c1ccc2occc2c1,"(1S,2S)-2-(benzofuran-5-yl)-1-(7-bromo-3-methoxynaphthalen-2-yl)-1-(2,3-dimethoxypyridin-4-yl)-4-(dimethylamino)butan-2-ol",6.9,uM,=,0.8388490907372553,1,c1ccc2cc([C@H](Cc3ccc4occc4c3)c3ccncc3)ccc2c1
2471,1832208,10.1016/j.bmcl.2018.12.024,,,,Inhibition of CYP3A4 (unknown origin),CC[C@H](NC(=O)c1cncc2c1cnn2-c1ccc(F)cc1)c1ccnc(S(C)(=O)=O)c1,"(S)-1-(4-fluorophenyl)-N-(1-(2-(methylsulfonyl)pyridin-4-yl)propyl)-1H-pyrazolo[3,4-c]pyridine-4-carboxamide",17.0,uM,=,1.230448921378274,1,O=C(NCc1ccncc1)c1cncc2c1cnn2-c1ccccc1
2472,455108,10.1016/j.bmcl.2006.12.043,,,,Inhibition of CYP3A4,O=C([C@@H](O)c1ccccc1Cl)N1CCC(Nc2ccc3[nH]ncc3c2)CC1,(S)-1-(4-(1H-indazol-5-ylamino)piperidin-1-yl)-2-(2-chlorophenyl)-2-hydroxyethanone,4.0,uM,=,0.6020599913279624,1,O=C(Cc1ccccc1)N1CCC(Nc2ccc3[nH]ncc3c2)CC1
2473,1446063,10.1016/j.bmcl.2014.11.046,,,,Inhibition of human recombinant CYP3A4 expressed in insect cell microsomes preincubated for 10 mins by fluorescence assay,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,"1-(4-{4-[2-(2,4-Dichloro-phenyl)-2-imidazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-ethanone (ketoconazole)",0.2,uM,=,-0.6989700043360187,0,c1ccc(C2(Cn3ccnc3)OCC(COc3ccc(N4CCNCC4)cc3)O2)cc1
2474,1288242,10.1016/j.bmcl.2013.12.063,,,,Inhibition of CYP3A4 (unknown origin),CC(C)(C)OC(=O)N1CCC(n2ncc3c(Oc4ccc(S(C)(=O)=O)cc4)ncnc32)CC1,"tert-butyl 4-(4-(4-(methylsulfonyl)phenoxy)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate",3.1,uM,=,0.4913616938342727,1,c1ccc(Oc2ncnc3c2cnn3C2CCNCC2)cc1
2475,1688648,10.1021/acs.jmedchem.7b00410,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 8 mins by LC/MS/MS analysis,Cc1cc(Oc2cncc(F)c2)cc(C(=O)Nc2cc(F)ccn2)n1,N-(4-Fluoropyridin-2-yl)-4-((5-fluoropyridin-3-yl)oxy)-6-methylpicolinamide,27.4,uM,=,1.437750562820388,1,O=C(Nc1ccccn1)c1cc(Oc2cccnc2)ccn1
2476,595638,10.1016/j.bmcl.2009.09.096,,,,Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH,COc1ccc2c(OCc3nnc4ccc(-c5cc(C)ns5)nn34)ccnc2c1,"5-(3-((7-methoxyquinolin-4-yloxy)methyl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-3-methylisothiazole",4.8,uM,=,0.6812412373755872,1,c1ccc2c(OCc3nnc4ccc(-c5ccns5)nn34)ccnc2c1
2477,966467,10.1016/j.bmcl.2013.04.077,,,,Inhibition of CYP3A4 (unknown origin),Nc1ccc(-c2cnc(NC(=O)CN(Cc3ccccc3)C(=O)c3ccncc3)s2)cn1,N-(2-(5-(6-aminopyridin-3-yl)thiazol-2-ylamino)-2-oxoethyl)-N-phenylisonicotinamide,1.8,uM,=,0.255272505103306,1,O=C(CN(Cc1ccccc1)C(=O)c1ccncc1)Nc1ncc(-c2cccnc2)s1
2478,1295469,10.1016/j.bmcl.2014.02.004,,,,Inhibition of human recombinant CYP3A4,CC1Cc2c(Cl)cccc2N1C(=O)Cc1nc(N2CCOCC2)sc1C(N)=O,4-(2-(4-chloro-2-methylindolin-1-yl)-2-oxoethyl)-2-morpholinothiazole-5-carboxamide,40.0,uM,=,1.6020599913279625,1,O=C(Cc1csc(N2CCOCC2)n1)N1CCc2ccccc21
2479,1797910,10.1021/acs.jmedchem.8b01326,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate/NADPH addition measured after 10 mins by LC-MS/MS analysis,CN1C(=N)N[C@@]2(c3cc(-c4ccc(F)c(C#N)c4)cs3)CN(c3ncc(F)cn3)C[C@H]2C1=O,"2-Fluoro-5-(5-((4aR,7aR)-6-(5-fluoropyrimidin-2-yl)-2-imino-3-methyl-4-oxooctahydro-7aH-pyrrolo[3,4-d]pyrimidin-7a-yl)-thiophen-3-yl)benzonitrile",5.7,uM,=,0.7558748556724915,1,N=C1NC(=O)[C@@H]2CN(c3ncccn3)C[C@]2(c2cc(-c3ccccc3)cs2)N1
2480,768817,10.1021/jm2005354,,,,Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting,C[C@@H](c1ccc(-c2ccc(F)cc2F)cc1)N1CC[C@](CCNS(C)(=O)=O)(c2ccc(F)cc2)OC1=O,"N-(2-((S)-3-((S)-1-(2',4'-difluorobiphenyl-4-yl)ethyl)-6-(4-fluorophenyl)-2-oxo-1,3-oxazinan-6-yl)ethyl)methanesulfonamide",9.0,uM,=,0.9542425094393248,1,O=C1OC(c2ccccc2)CCN1Cc1ccc(-c2ccccc2)cc1
2481,1528565,,,,,"Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",CC(C)c1nc(CN(C)C(=O)N2CCC[C@@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,"US8987313, 42",0.11,uM,=,-0.958607314841775,0,O=C(N[C@H](CC[C@H](Cc1ccccc1)NC(=O)[C@H]1CCCN1C(=O)NCc1cscn1)Cc1ccccc1)OCc1cncs1
2482,1692884,10.1021/acs.jmedchem.7b00376,,,,Inhibition of CYP3A4 in human liver microsomes,CCOC(=O)/C=C/c1ccc(/C=C/c2cc(O)c(O)c(O)c2)cc1,"(E)-ethyl 3-(4-(3,4,5-trihydroxystyryl)phenyl)acrylate",36.2,uM,=,1.5587085705331658,1,C(=C/c1ccccc1)\c1ccccc1
2483,1752261,10.1016/j.bmc.2017.12.015,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,CC1(C)CCC(C)(C)c2c1cc(C(=O)Nc1cc(F)c(C(=O)O)c(F)c1)c(O)c2Cl,"4-[(4-Chloro-3-hydroxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalene-2-carbonyl)-amino]-2,6-difluoro-benzoic acid",25.0,uM,=,1.3979400086720375,1,O=C(Nc1ccccc1)c1ccc2c(c1)CCCC2
2484,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",C[C@@H]1CN(C(=O)c2cc(Cl)ccc2-n2nccn2)[C@H](Cc2cccc(-c3ncccn3)c2)CO1,"US9150566, 113",26.0,uM,=,1.414973347970818,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2ncccn2)c1
2485,802673,10.1016/j.bmcl.2011.12.125,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,O=C(Nc1ccc(-c2ccc(O)cc2)cc1)Nc1ccc(-c2ccnc3[nH]cnc23)cc1,"1-(4-(3H-imidazo[4,5-b]pyridin-7-yl)phenyl)-3-(4'-hydroxybiphenyl-4-yl)urea",0.03,uM,=,-1.5228787452803376,0,O=C(Nc1ccc(-c2ccccc2)cc1)Nc1ccc(-c2ccnc3[nH]cnc23)cc1
2486,2217386,10.1021/acs.jmedchem.1c02141,,,,Competitive inhibition of human recombinant CYP3A4 using coumarin as substrate preincubated with enzyme for 10 mins followed by NADPH addition and measured after 20 to 50 mins by fluorescence based method,NCc1cc(Cl)ccc1Cn1c(=S)[nH]c(=O)c2[nH]ccc21,"1-(2-(aminomethyl)-4-chlorobenzyl)-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-one",19.0,uM,=,1.2787536009528289,1,O=c1[nH]c(=S)n(Cc2ccccc2)c2cc[nH]c12
2487,1289242,10.1016/j.bmcl.2013.12.088,,,,Inhibition of CYP3A4 (unknown origin) using benzyloxyresorufin as substrate,Fc1cc(OC(F)(F)C(F)F)cc([C@@](Cc2ccccc2)(Nc2nc3ccccc3[nH]2)c2ccc(Cl)cn2)c1,"(R)-N-(1-(5-chloropyridin-2-yl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-1H-benzo[d]imidazol-2-amine",13.0,uM,=,1.1139433523068367,1,c1ccc(C[C@@](Nc2nc3ccccc3[nH]2)(c2ccccc2)c2ccccn2)cc1
2488,2165293,10.1021/acsmedchemlett.1c00666,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,c1ccc2oc(-c3csc(C4CCN(Cc5nc6cnccc6[nH]5)CC4)n3)cc2c1,"2-({4-[4-(1-Benzofuran-2-yl)-1,3-thiazol-2-yl]piperidin-1-yl}methyl)-1H-imidazo-[4,5-c]-pyridine",0.86,uM,=,-0.0655015487564322,0,c1ccc2oc(-c3csc(C4CCN(Cc5nc6cnccc6[nH]5)CC4)n3)cc2c1
2489,1668433,10.1016/j.bmcl.2017.04.014,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate pretreated for 10 mins followed by substrate addition measured after 10 mins in presence of NADPH by LC-MS/MS method,C=CC(=O)N[C@H]1COC[C@H]1Nc1ncc(OCc2c(F)c(OC)cc(OC)c2F)cn1,"N-((3R,4S)-4-((5-((2,6-difluoro-3,5-dimethoxybenzyl)oxy)pyrimidin-2-yl)amino)tetrahydrofuran-3-yl)acrylamide",13.3,uM,=,1.1238516409670858,1,c1ccc(COc2cnc(N[C@H]3CCOC3)nc2)cc1
2490,1622860,10.1021/acs.jmedchem.6b01356,,,,Inhibition of CYP3A4 (unknown origin),C[C@@H]1CN(Cc2ccccc2)c2cnccc2[C@H](C)N1C(=O)NCc1ccccc1,"(+/-)-N,1-Dibenzyl-3,5-cis-dimethyl-1,2,3,5-tetrahydro-4H-pyrido-[3,4-e][1,4]diazepine-4-carboxamide",0.023,uM,=,-1.6382721639824072,0,O=C(NCc1ccccc1)N1CCN(Cc2ccccc2)c2cnccc2C1
2491,44705,10.1016/s0960-894x(02)00473-0,,,,Inhibition of cytochrome P450 3A4,CCN(CC)CCN(Cc1ccc(-c2ccc(Cl)cc2)cc1)C(=O)Cn1cc(Cc2cnn(C)c2)c(=O)nc1SCc1ccc(F)cc1,N-(4'-Chloro-biphenyl-4-ylmethyl)-N-(2-diethylamino-ethyl)-2-[2-(4-fluoro-benzylsulfanyl)-5-(1-methyl-1H-pyrazol-4-ylmethyl)-4-oxo-4H-pyrimidin-1-yl]-acetamide,5.0,uM,=,0.6989700043360189,1,O=C(Cn1cc(Cc2cn[nH]c2)c(=O)nc1SCc1ccccc1)NCc1ccc(-c2ccccc2)cc1
2492,519907,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,Cc1nc2c(N[C@H]3c4ccccc4C[C@@H]3O)cc(-n3cncn3)cn2c1C,"(1S,2S)-1-(2,3-dimethyl-6-(1H-1,2,4-triazol-1-yl)imidazo[1,2-a]pyridin-8-ylamino)-2,3-dihydro-1H-inden-2-ol",3.1,uM,=,0.4913616938342727,1,c1ccc2c(c1)CC[C@H]2Nc1cc(-n2cncn2)cn2ccnc12
2493,1741066,10.1021/acs.jmedchem.8b00450,,,,Inhibition of human CYP3A4,Cc1cccnc1CN(C)C[C@H]1Cc2c(cccc2N2CCNCC2)CN1,"(R)-N-methyl-1-(3-methylpyridin-2-yl)-N-((5-(piperazin-1-yl)-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)methanamine",1.42,uM,=,0.1522883443830564,1,c1ccc(CNC[C@H]2Cc3c(cccc3N3CCNCC3)CN2)nc1
2494,305432,10.1016/j.bmcl.2005.01.044,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,CC(C(c1ccc2cc(OCc3ccc(C(=O)O)cc3)ccc2c1)n1ccnc1)N(C)C,4-[6-(2-Dimethylamino-1-imidazol-1-yl-propyl)-naphthalen-2-yloxymethyl]-benzoic acid,1.18,uM,=,0.0718820073061253,1,c1ccc(COc2ccc3cc(Cn4ccnc4)ccc3c2)cc1
2495,988989,10.1021/jm400732v,,,,Inhibition of CYP3A4 (unknown origin),CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2c(C#N)n(-c3ccccc3C#N)c3ccccc23)c2ccccc2OC12CCOCC2,"(2S)-N-((3S)-5-((2-cyano-1-(2-cyanophenyl)-1H-indol-3-yl)methyl)-4-oxo-2',3',4,5,5',6'-hexahydro-3H-spiro[benzo[b][1,4]oxazepine-2,4'-pyran]-3-yl)-2-(methylamino)propanamide",1.8,uM,=,0.255272505103306,1,O=C1CC2(CCOCC2)Oc2ccccc2N1Cc1cn(-c2ccccc2)c2ccccc12
2496,802673,10.1016/j.bmcl.2011.12.125,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,CC(C)NC(=O)c1cccc(NC(=O)Nc2ccc(-c3ncnc4[nH]cc(Cl)c34)cc2)c1,"3-(3-(4-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)ureido)-N-isopropylbenzamide",14.0,uM,=,1.146128035678238,1,O=C(Nc1ccccc1)Nc1ccc(-c2ncnc3[nH]ccc23)cc1
2497,1574682,10.1021/acs.jmedchem.5b01995,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone and midazolam as substrate preincubated for 30 mins followed substrate addition by LC-MS/MS analysis,COc1nc(N2C[C@H]3C(=O)N(C)C(=N)N[C@@]3(c3ccc(Cl)s3)C2)nc(C)c1F,"(4aR,7aR)-7a-(5-Chlorothiophen-2-yl)-6-(5-fluoro-4-methoxy-6-methylpyrimidin-2-yl)-2-imino-3-methylhexahydro-1H-pyrrolo[3,4-d]pyrimidin-4(4aH)-one",18.0,uM,=,1.255272505103306,1,N=C1NC(=O)[C@@H]2CN(c3ncccn3)C[C@]2(c2cccs2)N1
2498,1854052,10.1016/j.ejmech.2019.07.003,,,,Inhibition of recombinant human CYP3A4 using Luciferin-PPXE as substrate preincubated for 10 mins followed by NADPH addition measured after 15 mins by luminometric method,OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F,"2-(2,4-Difluoro-phenyl)-1,3-bis-[1,2,4]triazol-1-yl-propan-2-ol",23.9698,uM,=,1.379664410368291,1,c1ccc(C(Cn2cncn2)Cn2cncn2)cc1
2499,1434728,10.1021/jm5010539,,,,Inhibition of human recombinant CYP3A4 expressed in Escherichia coli bactosomes using diethoxyfluorescein as substrate after 10 mins by fluorescence assay,CC(=O)N1c2ccc(-c3ccc(C(=O)O)cc3)cc2[C@H](Nc2ccc(Cl)cc2)C[C@@H]1C,"4-((2S,4R)-1-acetyl-4-(4-chlorophenylamino)-2-methyl-1,2,3,4-tetrahydroquinolin-6-yl)benzoic acid",21.0,uM,=,1.3222192947339193,1,c1ccc(N[C@@H]2CCNc3ccc(-c4ccccc4)cc32)cc1
2500,52064,10.1016/s0960-894x(03)00058-1,,,,Inhibitory activity against CYP450 3A4 isozyme,CCN(CC)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(=O)Cn1cc(C)c(=O)nc1SCc1ccc(F)cc1,N-(2-Diethylamino-ethyl)-2-[2-(4-fluoro-benzylsulfanyl)-5-methyl-4-oxo-4H-pyrimidin-1-yl]-N-(4'-trifluoromethyl-biphenyl-4-ylmethyl)-acetamide,17.0,uM,=,1.230448921378274,1,O=C(Cn1ccc(=O)nc1SCc1ccccc1)NCc1ccc(-c2ccccc2)cc1
2501,2060129,10.1021/acsmedchemlett.1c00112,,,,Inhibition of CYP3A4 (unknown origin),N#CCCN1C(=O)CC[C@H]1C(=O)N1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3cnc(C(F)(C(F)(F)F)C(F)(F)F)cc3CC[C@@H]12,"3-((S)-2-((6aR,9aR)-9a-((4-Fluorophenyl)sulfonyl)-3-(perfluoropropan-2-yl)-6,6a,7,8,9,9a-hexahydro-5H-pyrrolo[2,3-h]isoquinoline-7-carbonyl)-5-oxopyrrolidin-1-yl)propanenitrile",12.0,uM,=,1.0791812460476249,1,O=C1CC[C@@H](C(=O)N2CC[C@@]3(S(=O)(=O)c4ccccc4)c4cnccc4CC[C@@H]23)N1
2502,2246941,10.1021/acs.jmedchem.1c02132,,,,Inhibition of CYP3A4 (unknown origin) incubated for 10 mins in presence of NADPH by LC-MS/MS analysis,COC(=O)Nc1cc(-c2ccc(OC[C@@](C)(N)CC(C)C)c(Cl)c2)ccn1,"rac-methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-chlorophenyl)pyridin-2-yl)carbamate",0.74,uM,=,-0.1307682802690238,0,c1ccc(-c2ccncc2)cc1
2503,1686180,10.1016/j.bmcl.2017.06.018,,,,Inhibition of CYP3A4 (unknown origin),CC(C)(O)CC(=O)N1CCC(c2ccc(NC(=O)N3Cc4ccccc4C3)cc2)CC1,N-(4-(1-(3-hydroxy-3-methylbutanoyl)piperidin-4-yl)phenyl)isoindoline-2-carboxamide,16.0,uM,=,1.2041199826559248,1,O=C(Nc1ccc(C2CCNCC2)cc1)N1Cc2ccccc2C1
2504,429179,10.1021/jm061159a,,,,Inhibition of human CYP3A4 expressed in insect cells,O=C1NC(c2ccc(F)cc2)(c2ccc(F)cc2)CN1C1CCN(Cc2ccccc2)CC1,"3-(1-benzyl-piperidin-4-yl)-5,5-di-(4-fluorophenyl)-imidazolidin-2-one",91.9,uM,=,1.963315511386112,1,O=C1NC(c2ccccc2)(c2ccccc2)CN1C1CCN(Cc2ccccc2)CC1
2505,495153,10.1021/jm8006454,,,,Inhibition of CYP3A4,COc1cccc(-c2c(C)n(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](NCCCC(=O)[O-])c3ccccc3)c2=O)c1F.[Na+],"(R)-4-{2-[5-(2-Fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyric Acid Sodium Salt",56.0,uM,=,1.7481880270062005,1,O=c1c(-c2ccccc2)cn(Cc2ccccc2)c(=O)n1CCc1ccccc1
2506,2053312,10.1016/j.ejmech.2020.112600,,,,Inhibition of CYP3A4 (unknown origin) in baculosomes preincubated for 20 mins followed by addition of CYP enzyme-specific substrate and NADP+ and measured after 30 mins by fluorescence based analysis,O=C(CNS(=O)(=O)c1ccccc1C(=O)NCCc1ccc(O)c(O)c1)Nc1ccc(O)cc1,"N-[2-(3,4-dihydroxyphenylethyl]-2-[[2-(4-hydroxyanilino)-2-oxo-ethyl]sulfamoyl]benzamide",4.82,uM,=,0.6830470382388496,1,O=C(CNS(=O)(=O)c1ccccc1C(=O)NCCc1ccccc1)Nc1ccccc1
2507,775863,10.1016/j.bmcl.2011.09.037,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH,CN(C)[C@@H]1CCN(C(=O)[C@@H](COCc2ccccc2)NC(=O)c2cccnc2Oc2ccc(C(F)(F)F)cc2Cl)C1,N-((R)-3-(benzyloxy)-1-((R)-3-(dimethylamino)pyrrolidin-1-yl)-1-oxopropan-2-yl)-2-(2-chloro-4-(trifluoromethyl)phenoxy)nicotinamide,7.2,uM,=,0.8573324964312685,1,O=C(N[C@H](COCc1ccccc1)C(=O)N1CCCC1)c1cccnc1Oc1ccccc1
2508,1845477,10.1021/acsmedchemlett.0c00004,,,,Inhibition of CYP3A4 (unknown origin),O[C@@H]1c2cnccc2CC[C@H]1[C@H]1c2ccccc2-c2cncn21,"(7S,8S)-7-((S)-5H-imidazo[5,1-a]isoindol-5-yl)-5,6,7,8-tetrahydroisoquinolin-8-ol",2.4,uM,=,0.380211241711606,1,c1ccc2c(c1)-c1cncn1[C@H]2[C@@H]1CCc2ccncc2C1
2509,828928,10.1016/j.bmcl.2012.06.022,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,CCN(C)c1nc2ccc(C(=O)N(CC(C)C)C[C@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1,"Thiazol-5-ylmethyl(2S,3S)-4-(2-(ethyl(methyl)amino)-N-isobutylbenzo[d]oxazole-6-carboxamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate",0.022,uM,=,-1.6575773191777938,0,O=C(N[C@H](CCNC(=O)c1ccc2ncoc2c1)Cc1ccccc1)OCc1cncs1
2510,1985264,10.1021/acs.jmedchem.0c00208,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,N#Cc1ccc2c(c1)[nH]c(=O)n2[C@H]1C[C@H](c2nnc(-c3ccncn3)n2-c2ccccc2Cl)C1,"1-((trans)-3-(4-(2-Chlorophenyl)-5-(pyrimidin-4-yl)-4H-1,2,4-triazol-3-yl)cyclobutyl)-2,3-dihydro-2-oxo-1H-benzo[d]imidazole-5-carbonitrile",1.26,uM,=,0.1003705451175629,1,O=c1[nH]c2ccccc2n1[C@H]1C[C@H](c2nnc(-c3ccncn3)n2-c2ccccc2)C1
2511,559938,10.1016/j.bmcl.2008.10.072,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,C[C@@H]1CN(Cc2ccc(-c3ccccc3C(=O)N3CCC(Cc4ccc(F)cc4)CC3)cc2)C[C@H](C)N1,"[4'-((3R,5S)-3,5-Dimethyl-piperazin-1-ylmethyl)-biphenyl-2-yl]-[4-(4-fluoro-benzyl)-piperidin-1-yl]-methanone",0.6,uM,=,-0.2218487496163563,0,O=C(c1ccccc1-c1ccc(CN2CCNCC2)cc1)N1CCC(Cc2ccccc2)CC1
2512,438520,10.1016/j.bmcl.2007.01.104,,,,Inhibition of CYP3A4,COc1cccc(N2C(=O)N(Cc3ccccc3F)C3(CCN(Cc4ccc(-c5cccnc5)cc4)CC3)C2=O)c1,"1-(2-fluoro-benzyl)-3-(3-methoxy-phenyl)-8-(4-pyridin-3-yl-benzyl)-1,3,8-triaza-spiro[4.5]decane-2,4-dione",1.1,uM,=,0.041392685158225,1,O=C1N(c2ccccc2)C(=O)C2(CCN(Cc3ccc(-c4cccnc4)cc3)CC2)N1Cc1ccccc1
2513,1911030,10.1021/acs.jmedchem.8b01226,,,,Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins,CCOC(=O)N1CCC(=CC#Cc2cccc(C)c2)CC1,Ethyl 4-[3-(3-Methylphenyl)prop-2-yn-1-ylidene]piperidine-1-carboxylate,5.4,uM,=,0.7323937598229685,1,C(#Cc1ccccc1)C=C1CCNCC1
2514,624295,10.1016/j.bmcl.2010.01.134,,,,Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay,CC(c1c(CCN(C)C)sc2ccccc12)n1ccnc1,"rac-2-(3-(1-(1H-imidazol-1-yl)ethyl)benzo[b]thiophen-2-yl)-N,N-dimethylethanamine",5.2,uM,=,0.7160033436347992,1,c1ccc2c(Cn3ccnc3)csc2c1
2515,452862,10.1021/jm0708228,,,,Inhibition of human CYP3A4 using 7-benzloxyquinolone substrate,C[C@@H]1CCCN1CCCOc1ccc(N2CCN(C(=O)c3ccc(F)cc3F)CC2=O)cc1.O=CO,"(R)-4-(2,4-difluorobenzoyl)-1-(4-(3-(2-methylpyrrolidin-1-yl)propoxy)phenyl)piperazin-2-one formic acid",100.0,uM,=,2.0,1,O=C(c1ccccc1)N1CCN(c2ccc(OCCCN3CCCC3)cc2)C(=O)C1
2516,1831631,10.1016/j.ejmech.2018.11.056,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OCC5COC(Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O,"2-sec-Butyl-4-[4-(4-{4-[(2R,4S)-2-(2,4-dichloro-phenyl)-2-[1,2,4]triazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-phenyl]-2,4-dihydro-[1,2,4]triazol-3-one",0.04,uM,=,-1.3979400086720375,0,O=c1[nH]ncn1-c1ccc(N2CCN(c3ccc(OCC4COC(Cn5cncn5)(c5ccccc5)O4)cc3)CC2)cc1
2517,1677534,10.1021/acs.jmedchem.7b01300,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate upto 10 uM after 5 mins in presence of NADPH by LC-MS/MS analysis,CN(C/C=C/c1ccc(-c2ccccc2)cc1)Cc1coc2ccccc12.Cl,"(E)-3-([1,1'-Biphenyl]-4-yl)-N-(benzofuran-3-ylmethyl)-N-methylprop-2-en-1-amine Hydrochloride",10.0,uM,=,1.0,1,C(=C/c1ccc(-c2ccccc2)cc1)\CNCc1coc2ccccc12
2518,2221809,10.1016/j.bmcl.2022.128625,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as substrate in presence of NADPH,C=CCOc1nccc(C(F)(F)F)c1C(=O)N1CCC[C@@](Oc2csc(C(F)(F)F)c2)(C(=O)N2CCN(c3ccccc3OCCO)CC2)[C@H]1CCC,"((2R,3S)-1-(2-(allyloxy)-4-(trifluoromethyl)nicotinoyl)-2-propyl-3-(5-(trifluoromethyl)thiophen-3-yloxy)piperidin-3-yl)(4-(2-(2-hydroxyethoxy)phenyl)piperazin-1-yl)methanone",50.0,uM,=,1.6989700043360187,1,O=C(c1cccnc1)N1CCC[C@@](Oc2ccsc2)(C(=O)N2CCN(c3ccccc3)CC2)C1
2519,742805,10.1016/j.bmc.2011.02.009,,,,Inhibition of human CYP3A4 after 30 mins,CC(=O)Nc1ccc(-c2ccc(C(O)(c3c[nH]cn3)C(C)C)cc2)cc1,"rac-N-{4'-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl][1,1'-biphenyl]-4-yl}acetamide",1.0,uM,=,0.0,0,c1ccc(-c2ccc(Cc3c[nH]cn3)cc2)cc1
2520,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCC(N6CCOCC6)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, E-65",2.11,uM,=,0.3242824552976926,1,O=C(c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12)N1CCC(N2CCOCC2)CC1
2521,945618,10.1016/j.bmc.2012.11.058,,,,Inhibition of CYP3A4 (unknown origin),NC(=O)c1cncc(Oc2c(Cl)cc(NS(=O)(=O)c3ccc(Cl)cc3Cl)cc2Cl)c1,"5-(2,6-Dichloro-4-(2,4-dichlorophenylsulfonamido)phenoxy)nicotinamide",0.03,uM,=,-1.5228787452803376,0,O=S(=O)(Nc1ccc(Oc2cccnc2)cc1)c1ccccc1
2522,1447575,10.1016/j.bmcl.2014.05.068,,,,Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method,C[C@@H](c1ncncc1F)[C@](O)(Cn1ccnc1)c1ccc(F)cc1F,"(2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-imidazol-1-yl)butan-2-ol",0.8,uM,=,-0.0969100130080563,0,c1ccc(C(Cc2ccncn2)Cn2ccnc2)cc1
2523,519908,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,Cc1cccc(C)c1CNc1cc(-n2cnccc2=O)cn2c(C)c(C)nc12,"3-(8-(2,6-dimethylbenzylamino)-2,3-dimethylimidazo[1,2-a]pyridin-6-yl)pyrimidin-4(3H)-one",4.8,uM,=,0.6812412373755872,1,O=c1ccncn1-c1cc(NCc2ccccc2)c2nccn2c1
2524,862399,10.1021/jm300601d,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis,CCC(=O)N1CCC(c2ccc(C(=O)NC(=N)N)cc2C(F)(F)F)CC1,N-[4-(1-Propionyl-piperidin-4-yl)-3-trifluoromethyl-benzoyl]-guanidine,26.0,uM,=,1.414973347970818,1,c1ccc(C2CCNCC2)cc1
2525,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1ccc(C(=O)N2C[C@@H](C)OC[C@H]2Cc2cc(-c3cccnn3)ccc2F)c(-n2nccn2)c1,"US9150566, 165",20.0,uM,=,1.3010299956639813,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2cccnn2)c1
2526,1335568,10.1021/jm401731q,,,,Inhibition of CYP3A4 (unknown origin),CCN1CCN(c2cc(N3CCC[C@@H](C(=O)NCCc4cnc(C#N)nc4)C3)nc(C(F)(F)F)n2)CC1,(R)-N-(2-(2-Cyanopyrimidin-5-yl)ethyl)-1-(6-(4-ethylpiperazin-1-yl)-2-(trifluoromethyl)pyrimidin-4-yl)piperidine-3-carboxamide,5.2,uM,=,0.7160033436347992,1,O=C(NCCc1cncnc1)[C@@H]1CCCN(c2cc(N3CCNCC3)ncn2)C1
2527,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCN(c7ccc(C(F)(F)F)cc7)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1,"US8940739, G-58",23.67,uM,=,1.3741982579290828,1,O=C(Nc1ccc(N2CCN(c3ccccc3)CC2)nc1)c1c[nH]c2c(CN3CC4N(C(=O)NCc5ccccc5)NCC(=O)N4C(Cc4ccccc4)C3=O)cccc12
2528,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",COc1ccc(C[C@@H]2COCCN2C(=O)c2ccccc2-n2nccn2)cc1-c1ccccn1,"US9150566, 3",21.0,uM,=,1.3222192947339193,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2ccccn2)c1
2529,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(S(=O)(=O)CC)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, E-16",2.82,uM,=,0.450249108319361,1,O=C(c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12)N1CCNCC1
2530,1467195,10.1021/jm5005336,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay,COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(N5CCN(C)CC5)nc4)n[nH]c3c1)C(=O)N2,"(1R*,2S*)-5'-Methoxy-2-(3-((E)-2-(6-(4-methylpiperazin-1-yl)-pyridin-3-yl)vinyl)-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-one",10.0,uM,=,1.0,1,O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccc(N4CCNCC4)nc3)n[nH]c2c1
2531,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",CC[C@@H]1CN(C(=O)c2cc(C)ccc2-n2nccn2)[C@H](Cc2cccc(-n3nccn3)c2)CO1,"US9150566, 142",9.2,uM,=,0.9637878273455552,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
2532,493017,10.1021/jm800851u,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,COC1CN(c2cccc(-c3cc(NC(C)=O)nc(-n4nc(C)cc4C)n3)n2)C1,"N-{2-(3,5-Dimethyl-pyrazol-1-yl)-6-[6-(3-methoxy-azetidin-1-yl)-pyridin-2-yl]-pyrimidin-4-yl}-acetamide",11.0,uM,=,1.0413926851582251,1,c1cc(-c2ccnc(-n3cccn3)n2)nc(N2CCC2)c1
2533,643713,10.1016/j.bmcl.2010.06.009,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader,CCN1CCN(CCCn2cc(-c3ccc4c(c3)ncn4-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)cn2)CC1,(R)-3-(1-(2-chlorophenyl)ethoxy)-5-(5-(1-(3-(4-ethylpiperazin-1-yl)propyl)-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)thiophene-2-carboxamide,4.5,uM,=,0.6532125137753437,1,c1ccc(COc2csc(-n3cnc4cc(-c5cnn(CCCN6CCNCC6)c5)ccc43)c2)cc1
2534,1758889,10.1021/acsmedchemlett.7b00230,,,,Inhibition of CYP3A4 (unknown origin),CN(C)c1ccc(N2C(=O)CN(Cc3ccc(F)cc3)C2=S)cc1Cl,3-[3-chloro-4-(dimethylamino)phenyl]-1-[(4-fluorophenyl)methyl]-2-sulfanylideneimidazolidin-4-one,1.279,uM,=,0.1068705444786539,1,O=C1CN(Cc2ccccc2)C(=S)N1c1ccccc1
2535,438520,10.1016/j.bmcl.2007.01.104,,,,Inhibition of CYP3A4,COc1cncc(-c2ccc(CN3CCC4(CC3)C(=O)N(c3cccc(OC)c3)C(=O)N4Cc3ccccc3F)cc2)c1,"1-(2-fluoro-benzyl)-3-(3-methoxy-phenyl)-8-[4-(5-methoxy-pyridin-3-yl)-benzyl]-1,3,8-triaza-spiro[4.5]decane-2,4-dione",2.0,uM,=,0.3010299956639812,1,O=C1N(c2ccccc2)C(=O)C2(CCN(Cc3ccc(-c4cccnc4)cc3)CC2)N1Cc1ccccc1
2536,1336778,10.1021/jm401911v,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,CC[C@@H](CS(=O)(=O)C(C)(C)C)N1C(=O)[C@@](C)(CC(=O)CO)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1,"(3R,5R,6S)-1-((S)-1-(tert-butylsulfonyl)butan-2-yl)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-3-(3-hydroxy-2-oxopropyl)-3-methylpiperidin-2-one",0.7,uM,=,-0.1549019599857432,0,O=C1CC[C@H](c2ccccc2)[C@@H](c2ccccc2)N1
2537,479364,10.1016/j.bmcl.2008.05.027,,,,Inhibition of CYP3A4,O=C(Cn1c(=O)oc2ccc(Cl)cc21)N1CCCC(c2ccccc2)C1CN1CCCC1,rac-5-chloro-3-(2-oxo-2-(3-phenyl-2-(pyrrolidin-1-ylmethyl)piperidin-1-yl)ethyl)benzo[d]oxazol-2(3H)-one,2.1,uM,=,0.3222192947339193,1,O=C(Cn1c(=O)oc2ccccc21)N1CCCC(c2ccccc2)C1CN1CCCC1
2538,2024613,10.1016/j.bmcl.2020.127721,,,,Inhibition of CYP3A4 (unknown origin),CN1CCN(CCCOc2cccc(CC(=O)Nc3nc(-c4c[nH]c5ncccc45)cs3)c2)CC1,"N-(4-(1H-pyrrolo[2,3-b]pyridin-3-yl)thiazol-2-yl)-2-(3-(3-(4-methylpiperazin-1-yl)propoxy)phenyl)acetamide",19.0,uM,=,1.2787536009528289,1,O=C(Cc1cccc(OCCCN2CCNCC2)c1)Nc1nc(-c2c[nH]c3ncccc23)cs1
2539,1475768,10.1021/jm5017413,,,,Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system,C[C@@H]1c2nnc(-c3csc(-c4ccc(F)cc4F)n3)n2CCN1C(=O)c1ccc(-c2cccs2)cc1,"[(8R)-3-[2-(2,4-Difluorophenyl)thiazol-4-yl]-8-methyl-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-[4-(2-thienyl)phenyl]-methanone",19.0,uM,=,1.2787536009528289,1,O=C(c1ccc(-c2cccs2)cc1)N1CCn2c(nnc2-c2csc(-c3ccccc3)n2)C1
2540,1845477,10.1021/acsmedchemlett.0c00004,,,,Inhibition of CYP3A4 (unknown origin),Cn1ncc2c1CC[C@@H]([C@H]1c3ccccc3-c3cncn31)[C@@H]2O,"(4S,5S)-5-((S)-5H-imidazo[5,1-a]isoindol-5-yl)-1-methyl-4,5,6,7-tetrahydro-1H-indazol-4-ol",3.3,uM,=,0.5185139398778875,1,c1ccc2c(c1)-c1cncn1[C@H]2[C@@H]1CCc2[nH]ncc2C1
2541,489963,10.1021/jm800566m,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline substrate,Cc1nn(C)c2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc12.Cl,"3-({4-[(1,3-Dimethyl-1H-indazol-6-yl)(methyl)amino]-2-pyrimidinyl}amino)benzenesulfonamide",1.7,uM,=,0.2304489213782739,1,c1ccc(Nc2nccc(Nc3ccc4cn[nH]c4c3)n2)cc1
2542,1823181,10.1021/acs.jmedchem.9b01247,,,,Inhibition of CYP3A4 (unknown origin),N#Cc1ccc(O[C@H]2CN(S(=O)(=O)c3ccc(Cl)cc3Cl)C[C@@]2(O)CN)cc1F,"(+/-)-trans-4-((-4-(Aminomethyl)-1-((2,4-dichlorophenyl)-sulfonyl)-4-hydroxypyrrolidin-3-yl)oxy)-2-fluorobenzonitrile",1.6,uM,=,0.2041199826559248,1,O=S(=O)(c1ccccc1)N1CC[C@@H](Oc2ccccc2)C1
2543,1301324,10.6019/CHEMBL3137440,,,,DNDI: CYP Inhibition,O=C(C1CC1)N1CCC(N(c2ccc(Cl)cc2)c2cccnc2)CC1,,1.5,uM,=,0.1760912590556812,1,O=C(C1CC1)N1CCC(N(c2ccccc2)c2cccnc2)CC1
2544,1288242,10.1016/j.bmcl.2013.12.063,,,,Inhibition of CYP3A4 (unknown origin),CS(=O)(=O)c1ccc(Oc2ncnc3c2cnn3C2CCN(Cc3ccc(C(F)(F)F)cc3)CC2)cc1,"4-(4-(methylsulfonyl)phenoxy)-1-(1-(4-(trifluoromethyl)benzyl)piperidin-4-yl)-1H-pyrazolo[3,4-d]pyrimidine",1.8,uM,=,0.255272505103306,1,c1ccc(CN2CCC(n3ncc4c(Oc5ccccc5)ncnc43)CC2)cc1
2545,1485703,10.1124/dmd.112.048264,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method,Clc1ccccc1CN1CCc2sccc2C1,"5-(2-Chloro-benzyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine",32.7,uM,=,1.5145477526602862,1,c1ccc(CN2CCc3sccc3C2)cc1
2546,1923841,10.1021/acs.jmedchem.6b00280,,,,Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase and human b5 reductase assessed as reduction in 7-Hydroxyquinoline production using 7-benzyloxyquinoline as substrate and NADPH incubated for 15 mins by fluorimetry,O=C(NCCN1CCOCC1)Nc1nc2ccc(Sc3nnc4ccc(NC5CCCCC5)nn34)cc2s1,"1-(6-(6-(cyclohexylamino)-[1,2,4]triazolo[4,3-b]pyridazin-3-ylthio)benzo[d]thiazol-2-yl)-3-(2-morpholinoethyl)urea",2.9,uM,=,0.4623979978989561,1,O=C(NCCN1CCOCC1)Nc1nc2ccc(Sc3nnc4ccc(NC5CCCCC5)nn34)cc2s1
2547,1641445,,,,,"CYP450 Inhibition Assay: The ability of the R and S enantiomers of (4-fluorophenyl)(4-((5-methyl-1H-pyrazol-3-yl)amino)quinazolin-2-yl)methanol to inhibit the common drug metabolizing isoforms of cytochrome P450 (CYP) was evaluated against the following isoforms: CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. The compounds were incubated in duplicate with eight test compound concentrations (final DMSO concentration of 0.20%) with human liver microsomes (0.25 or 0.50 mg/mL) and NADPH (1 mM) in the presence of CYP isoform specific probe substrates (phenacetin, bupropion, taxol, diclofenac, mephenyloin, dextromethorphan, testosterone) at the Km for 10-20 minutes at 37° C. Selective CYP isoform inhibitors (furafulline, ticlopidine, quercetin, sulfaphenazole, ticlopidine, quinidine, ketoconazole) were screened alongside the test compounds as positive controls.",Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1,AC-430,10.9,uM,=,1.0374264979406236,1,c1ccc(Cc2nc(Nc3cc[nH]n3)c3ccccc3n2)cc1
2548,1660136,10.1021/acs.jmedchem.6b01918,,,,Inhibition of human CYP3A4 assessed as inhibition of dealkylation,O=S(=O)(Nc1nccs1)c1cc(Cl)c(NC[C@H]2CCCNC2)cc1F,(S)-5-Chloro-2-fluoro-4-((piperidin-3-ylmethyl)amino)-N-(thiazol-2-yl)benzenesulfonamide,20.0,uM,=,1.3010299956639813,1,O=S(=O)(Nc1nccs1)c1ccc(NC[C@H]2CCCNC2)cc1
2549,1687952,10.1016/j.ejmech.2017.03.004,,,,Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using 7-benzyloxy-4-trifluoromethylcoumarin as substrate measured after 45 mins in presence of NADPH by spectrofluorometric method,O=c1cc(-c2ccccc2)oc2cc(O)c(O)c(O)c12,"5,6,7-Trihydroxy-2-phenyl-chromen-4-one",9.2,uM,=,0.9637878273455552,1,O=c1cc(-c2ccccc2)oc2ccccc12
2550,1295469,10.1016/j.bmcl.2014.02.004,,,,Inhibition of human recombinant CYP3A4,CC1Cc2c(Br)cccc2N1C(=O)Cc1nc(N2CCOCC2)sc1C(=O)O,(-)-4-(2-(4-bromo-2-methylindolin-1-yl)-2-oxoethyl)-2-morpholinothiazole-5-carboxylic acid,40.0,uM,=,1.6020599913279625,1,O=C(Cc1csc(N2CCOCC2)n1)N1CCc2ccccc21
2551,1510150,10.1016/j.bmcl.2015.05.004,,,,Inhibition of human CYP3A4,O=C(Nc1ccc(Cl)cc1Cl)c1cn[nH]n1,"N-(2,4-dichlorophenyl)-2H-1,2,3-triazole-4-carboxamide",58.1,uM,=,1.7641761323903309,1,O=C(Nc1ccccc1)c1cn[nH]n1
2552,774749,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1,"((1R,2R,4R)-1-Benzyl-2-hydroxy-4-{(R)-2-[3-(2-isopropyl-1lambda*4*-[1,3]thiazin-5-ylmethyl)-3-methyl-ureido]-3-methyl-butyrylamino}-5-phenyl-pentyl)-carbamic acid thiazol-5-ylmethyl ester",0.016,uM,=,-1.7958800173440752,0,O=C(CNC(=O)NCc1cscn1)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
2553,1523285,10.1016/j.bmcl.2015.06.066,,,,Inhibition of CYP3A4 (unknown origin),CCCCC(C(=O)COc1c(F)c(F)cc(F)c1F)n1cc([C@@](C)(NCc2ccc3ncccc3c2)C2CCCC2)nn1,"3-(4-((S)-1-cyclopentyl-1-(quinolin-6-ylmethylamino)ethyl)-1H-1,2,3-triazol-1-yl)-1-(2,3,5,6-tetrafluorophenoxy)heptan-2-one",0.26,uM,=,-0.585026652029182,0,O=C(COc1ccccc1)Cn1cc(C(NCc2ccc3ncccc3c2)C2CCCC2)nn1
2554,1558163,10.1021/acs.jmedchem.5b00832,,,,Inhibition of CYP3A4 (unknown origin),COc1ccc(CNC(=O)c2cc(-c3cncc(Cl)c3)cnc2-c2ccccn2)nc1OC,"5''-Chloro-[2,2':5',3'']terpyridine-3'-carboxylic acid(5,6-dimethoxy-pyridin-2-ylmethyl)-amide",28.0,uM,=,1.4471580313422192,1,O=C(NCc1ccccn1)c1cc(-c2cccnc2)cnc1-c1ccccn1
2555,993439,10.6019/CHEMBL2448688,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,CC(=O)N(Cc1cccnc1)c1ccc(-c2ccc(F)cc2)cc1F,,0.47,uM,=,-0.3279021420642826,0,c1ccc(-c2ccc(NCc3cccnc3)cc2)cc1
2556,802673,10.1016/j.bmcl.2011.12.125,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,O=C(Nc1ccc(-c2cccc3ccccc23)cc1)Nc1ccc(-c2ccnc3[nH]cnc23)cc1,"1-(4-(3H-imidazo[4,5-b]pyridin-7-yl)phenyl)-3-(4-(naphthalen-1-yl)phenyl)urea",1.7,uM,=,0.2304489213782739,1,O=C(Nc1ccc(-c2cccc3ccccc23)cc1)Nc1ccc(-c2ccnc3[nH]cnc23)cc1
2557,1688648,10.1021/acs.jmedchem.7b00410,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 8 mins by LC/MS/MS analysis,Cc1cc(Oc2cncc(Cl)c2)cc(C(=O)Nc2ccc(F)cn2)n1,4-((5-Chloropyridin-3-yl)oxy)-N-(5-fluoropyridin-2-yl)-6-methylpicolinamide,3.8,uM,=,0.5797835966168101,1,O=C(Nc1ccccn1)c1cc(Oc2cccnc2)ccn1
2558,1366897,10.1021/jm500312x,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 15 mins by LC/MS/MS analysis,C=C[C@]1(C)C[C@@H](OC(=O)CSc2cncc(CO)c2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O,14-O-(((5-Hydroxymethylpyridin-3-yl)sulfanyl)acetyl)mutilin,0.242,uM,=,-0.6161846340195687,0,O=C(CSc1cccnc1)O[C@@H]1CCCC[C@@]23CCCC1[C@@H]2C(=O)CC3
2559,1456764,10.1016/j.bmcl.2014.07.026,,,,Inhibition of CYP3A4 in human liver microsome,CN1CCN(C(=O)C2(C(=O)Nc3cc(Cl)ccc3Cl)CC2)c2ccccc21,"N-(2,5-dichlorophenyl)-1-(4-methyl-1,2,3,4-tetrahydroquinoxaline-1-carbonyl)cyclopropanecarboxamide",0.27,uM,=,-0.5686362358410126,0,O=C(Nc1ccccc1)C1(C(=O)N2CCNc3ccccc32)CC1
2560,1463550,10.1016/j.bmcl.2015.01.019,,,,Inhibition of CYP3A4 (unknown origin),COc1cc([C@H]2CCN(CCO)C[C@@H]2O)ccc1Nc1ncc2ccc(-c3ccccc3OC)n2n1,"(trans)-1-(2-hydroxyethyl)-4-(3-methoxy-4-(7-(2-methoxyphenyl)pyrrolo[1,2-f][1,2,4]triazin-2-ylamino)phenyl)piperidin-3-ol",12.0,uM,=,1.0791812460476249,1,c1ccc(-c2ccc3cnc(Nc4ccc(C5CCNCC5)cc4)nn23)cc1
2561,742805,10.1016/j.bmc.2011.02.009,,,,Inhibition of human CYP3A4 after 30 mins,COc1ccc(-c2cccc(C(O)(c3c[nH]cn3)C(C)C)c2)cc1,"rac-1-(1H-Imidazol-4-yl)-1-(4'-methoxy-[1,1'-biphenyl]-3-yl)-2-methyl-1-propanol",2.0,uM,=,0.3010299956639812,1,c1ccc(-c2cccc(Cc3c[nH]cn3)c2)cc1
2562,2193449,10.1016/j.bmcl.2022.128889,,,,Inhibition of CYP3A4 (unknown origin),CCc1ccc(CC(=O)NCC2COc3ccccc3O2)cc1,"N-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)-2-(4-ethylphenyl)acetamide",36.2,uM,=,1.5587085705331658,1,O=C(Cc1ccccc1)NCC1COc2ccccc2O1
2563,550965,10.1021/np030556a,,,,Inhibition of human CYP3A4 by radiometric assay,COc1ccc(-c2oc3cc(O)cc(O)c3c(=O)c2OC)cc1,"5,7-Dihydroxy-3-methoxy-2-(4-methoxy-phenyl)-chromen-4-one",21.8,uM,=,1.3384564936046048,1,O=c1cc(-c2ccccc2)oc2ccccc12
2564,579976,10.1021/jm900521k,,,,Inhibition of CYP3A4,c1ccc2nc(COc3ccc(-c4n[nH]cc4Cc4ccncc4)cc3)ccc2c1,2-((4-(4-(pyridin-4-ylmethyl)-1H-pyrazol-5-yl)phenoxy)methyl)quinoline,450.0,uM,=,2.6532125137753435,1,c1ccc2nc(COc3ccc(-c4n[nH]cc4Cc4ccncc4)cc3)ccc2c1
2565,1745612,10.1016/j.bmcl.2017.10.010,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins in presence of NADPH by LC-MS/MS analysis,CCN[C@@H]1CCC=C(c2ccc(F)cc2)[C@H]1CNc1cc(F)c(S(=O)(=O)Nc2nccs2)cc1Cl.Cl,(-)-5-chloro-4-((6-(ethylamino)-2-(4-fluorophenyl)cyclohex-2-enyl)methylamino)-2-fluoro-N-(thiazol-2-yl)benzenesulfonamide hydrochloride,16.5,uM,=,1.2174839442139065,1,O=S(=O)(Nc1nccs1)c1ccc(NC[C@H]2CCCC=C2c2ccccc2)cc1
2566,676065,10.1016/j.bmcl.2010.09.028,,,,Inhibition of CYP3A4 after 30 mins,CC1([C@@H]2COC[C@H](COC(=O)N3CCC(CO)CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1,"((3R,5R)-4-(4-chlorophenylsulfonyl)-5-(1-methylcyclopropyl)morpholin-3-yl)methyl 4-(hydroxymethyl)piperidine-1-carboxylate",0.0055,uM,=,-2.2596373105057563,0,O=C(OC[C@H]1COC[C@@H](C2CC2)N1S(=O)(=O)c1ccccc1)N1CCCCC1
2567,1744980,10.1016/j.bmcl.2017.09.046,,,,Inhibition of human CYP3A4 expressed in Escherichia coli co-expressing CYP-reductase using diethoxyfluorescein as substrate measured after 10 mins by fluorescence assay,CCc1cccc(-c2c(F)cccc2C(O)(CCCNC(=O)OC)[C@@H]2CCCN(C(=O)[C@@H]3CC[C@H](N)C3)C2)c1,"methyl 4-((R)-1-((1R,3S)-3-aminocyclopentanecarbonyl)piperidin-3-yl)-4-(3'-ethyl-6-fluorobiphenyl-2-yl)-4-hydroxybutylcarbamate",0.09,uM,=,-1.0457574905606752,0,O=C(C1CCCC1)N1CCC[C@@H](Cc2ccccc2-c2ccccc2)C1
2568,768817,10.1021/jm2005354,,,,Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting,C[C@@H](c1ccc(-c2ccc(F)cc2F)cc1)N1CC[C@](CCNS(N)(=O)=O)(c2ccc(F)cc2)OC1=O,"(6S)-6-(2-(aminosulfonylamino)ethyl)-3-((S)-1-(2',4'-difluorobiphenyl-4-yl)ethyl)-6-(4-fluorophenyl)-1,3-oxazinan-2-one",12.0,uM,=,1.0791812460476249,1,O=C1OC(c2ccccc2)CCN1Cc1ccc(-c2ccccc2)cc1
2569,1467194,10.1021/jm5005336,,,,Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay,COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5[C@H](C)CN(C)C[C@@H]5C)cc4)n[nH]c3c1)C(=O)N2,"(1R,2S)-5'-Methoxy-2-(3-((E)-4-(((2R,6S)-2,4,6-trimethylpiperazin-1-yl)methyl)styryl)-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-one",1.6,uM,=,0.2041199826559248,1,O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccc(CN4CCNCC4)cc3)n[nH]c2c1
2570,1778315,10.1016/j.bmcl.2018.06.040,,,,Inhibition of CYP3A4 (unknown origin),O=C(Cc1ccc2c(c1)OCO2)Nc1nc(-c2c[nH]c3ncccc23)cs1,"N-(4-(1H-pyrrolo[2,3-b]pyridin-3-yl)thiazol-2-yl)-2-(benzo[d][1,3]dioxol-5-yl)acetamide",2.0,uM,=,0.3010299956639812,1,O=C(Cc1ccc2c(c1)OCO2)Nc1nc(-c2c[nH]c3ncccc23)cs1
2571,1291572,10.1016/j.bmcl.2013.12.058,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N(CCCCN(Cc2ccccc2)C(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1,(S)-thiazol-5-ylmethyl benzyl(4-(N-benzyl-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-3-methylbutanamido)butyl)carbamate,0.24,uM,=,-0.619788758288394,0,O=C(NCC(=O)N(CCCCN(Cc1ccccc1)C(=O)OCc1cncs1)Cc1ccccc1)NCc1cscn1
2572,2158614,10.1016/j.ejmech.2021.113987,,,,Inhibition of CYP3A4 in human liver microsomes incubated for 10 mins in presence of NADPH by LC/MS/MS analysis,Clc1ccc(C2(Cn3cncn3)COC(c3cc4ccc(Cl)cc4s3)=N2)cc1,"4-((1H-1,2,4-triazol-1-ylmethyl)-2-(6-chlorobenzo[b]thiophen-2-yl)-4-(4-chlorophenyl)-4,5-dihydrooxazole",29.1,uM,=,1.4638929889859074,1,c1ccc(C2(Cn3cncn3)COC(c3cc4ccccc4s3)=N2)cc1
2573,1288242,10.1016/j.bmcl.2013.12.063,,,,Inhibition of CYP3A4 (unknown origin),CC(C)(C)OC(=O)N1CCC(n2ncc3c(Nc4ccc(S(C)(=O)=O)cc4F)ncnc32)CC1,"tert-butyl 4-(4-(2-fluoro-4-(methylsulfonyl)phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate",3.1,uM,=,0.4913616938342727,1,c1ccc(Nc2ncnc3c2cnn3C2CCNCC2)cc1
2574,802673,10.1016/j.bmcl.2011.12.125,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,CC(C)NC(=O)c1cccc(NC(=O)Nc2ccc(-c3ccncc3)cc2)c1,N-isopropyl-3-(3-(4-(pyridin-4-yl)phenyl)ureido)benzamide,0.13,uM,=,-0.8860566476931633,0,O=C(Nc1ccccc1)Nc1ccc(-c2ccncc2)cc1
2575,884208,10.1021/jm300007n,,,,Inhibition of CYP3A4,Cc1c(Cc2ccc(=O)n(Cc3ccc(F)cc3F)n2)c2cc(F)ccc2n1CC(=O)O,"2-(3-((1-(2,4-Difluorobenzyl)-6-oxo-1,6-dihydropyridazin-3-yl)methyl)-5-fluoro-2-methyl-1H-indol-1-yl)acetic Acid",16.0,uM,=,1.2041199826559248,1,O=c1ccc(Cc2c[nH]c3ccccc23)nn1Cc1ccccc1
2576,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NN5CCCCC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, F-57",4.78,uM,=,0.6794278966121189,1,O=C(NN1CCCCC1)c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12
2577,1467194,10.1021/jm5005336,,,,Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay,Cc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5CCOCC5)cc4)n[nH]c3c1)C(=O)N2,"(1R*,2S*)-(E)-5'-Methyl-2-(3-(4-(morpholinomethyl)styryl)-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-one",6.2,uM,=,0.7923916894982539,1,O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccc(CN4CCOCC4)cc3)n[nH]c2c1
2578,559939,10.1016/j.bmcl.2008.10.072,,,,Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate,COc1cccc(CCN(Cc2ccccc2-c2ccc(CN3C[C@@H](C)N[C@@H](C)C3)cc2)C(=O)NC2CCCCC2)c1,"3-Cyclohexyl-1-[4'-((3R,5S)-3,5-dimethyl-piperazin-1-ylmethyl)-biphenyl-2-ylmethyl]-1-[2-(3-methoxy-phenyl)-ethyl]-urea",0.4,uM,=,-0.3979400086720376,0,O=C(NC1CCCCC1)N(CCc1ccccc1)Cc1ccccc1-c1ccc(CN2CCNCC2)cc1
2579,1748557,10.1021/acs.jmedchem.7b01892,,,,Inhibition of CYP3A4-mediated testosterone metabolism in human liver microsomes,O=c1c2nccn2c2cc(F)c(-c3ccncc3)cc2n1C1CC1,"5-Cyclopropyl-8-fluoro-7-(pyridin-4-yl)imidazo[1,2-a]-quinoxalin-4(5H)-one",13.0,uM,=,1.1139433523068367,1,O=c1c2nccn2c2ccc(-c3ccncc3)cc2n1C1CC1
2580,1467194,10.1021/jm5005336,,,,Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay,O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccc(CN4CC[C@@H](F)C4)cc3)n[nH]c2c1,"(1R,2S)-(E)-2-(3-(4-(((R)-3-Fluoropyrrolidin-1-yl)methyl)styryl)-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-one",10.0,uM,=,1.0,1,O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccc(CN4CCCC4)cc3)n[nH]c2c1
2581,51916,10.1016/j.bmcl.2003.11.005,,,,Inhibition of cytochrome P450 3A4,c1cn(-c2ccc(OCCN3CCOCC3)cc2)cn1,4-[2-(4-Imidazol-1-yl-phenoxy)-ethyl]-morpholine,5.67,uM,=,0.7535830588929066,1,c1cn(-c2ccc(OCCN3CCOCC3)cc2)cn1
2582,1542222,10.1039/C5MD00074B,,,,Inhibition of CYP3A4 (unknown origin) assessed as testosterone-6beta hydroxylation,CCn1cc(C(=O)N2CCc3ccsc3C2Cc2ccc(OC)c(OC)c2)c2ccccc21,"(rac)-(7-(3,4-dimethoxybenzyl)-4,5-dihydrothieno[2,3-c]pyridin-6(7H)-yl)(1-ethyl-1H-indol-3-yl)methanone",3.0,uM,=,0.4771212547196624,1,O=C(c1c[nH]c2ccccc12)N1CCc2ccsc2C1Cc1ccccc1
2583,519908,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,Cc1cccc(C)c1CNc1cc(C(=O)NCCO)cn2c(C)c(C)nc12,"8-(2,6-dimethylbenzylamino)-N-(2-hydroxyethyl)-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxamide",14.0,uM,=,1.146128035678238,1,c1ccc(CNc2cccn3ccnc23)cc1
2584,1614025,10.1016/j.bmcl.2016.09.043,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 6-beta-hydroxytestosterone metabolite formation using testosterone as substrate incubated for 30 mins by HPLC-MS method,COc1ccc(CCNc2nc3cc(OC)ccc3c(=O)n2C)cc1,7-Methoxy-2-[2-(4-methoxy-phenyl)-ethylamino]-3-methyl-3H-quinazolin-4-one,10.0,uM,=,1.0,1,O=c1[nH]c(NCCc2ccccc2)nc2ccccc12
2585,519908,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,Cc1cccc(C)c1CNc1cc(-n2ccc(=O)cc2)cn2c(C)c(C)nc12,"1-(8-(2,6-dimethylbenzylamino)-2,3-dimethylimidazo[1,2-a]pyridin-6-yl)pyridin-4(1H)-one",28.0,uM,=,1.4471580313422192,1,O=c1ccn(-c2cc(NCc3ccccc3)c3nccn3c2)cc1
2586,1854052,10.1016/j.ejmech.2019.07.003,,,,Inhibition of recombinant human CYP3A4 using Luciferin-PPXE as substrate preincubated for 10 mins followed by NADPH addition measured after 15 mins by luminometric method,CCN(CC)c1ccc2cc(C(=O)NCC(O)(Cn3cncn3)c3ccc(F)cc3F)c(=O)oc2c1,"rac-7-(diethylamino)-N-(2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl)-2-oxo-2H-chromene-3-carboxamide",1.0223,uM,=,0.0095783607945421,1,O=C(NCC(Cn1cncn1)c1ccccc1)c1cc2ccccc2oc1=O
2587,2048413,10.1016/j.bmc.2020.115723,,,,Inhibition of CYP3A4 (unknown origin),Nc1cc([C@H](CCOCc2ccccc2)c2ccccc2)c2nn[nH]c2n1,"(R)-7-(3-(benzyloxy)-1-phenylpropyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-amine",2.6,uM,=,0.414973347970818,1,c1ccc(COCC[C@H](c2ccccc2)c2ccnc3[nH]nnc23)cc1
2588,1540696,10.1016/j.ejmech.2015.08.051,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 2 mins by LC-MS/MS analysis in presence of NADPH regeneration system,CC(C)c1nc(C(=O)NC2CCN(CC3CC3)CC2)c2ccccn12,"N-(1-(cyclopropylmethyl)piperidin-4-yl)-3-isopropylimidazo[1,5-a]pyridine-1-carboxamide",20.0,uM,=,1.3010299956639813,1,O=C(NC1CCN(CC2CC2)CC1)c1ncn2ccccc12
2589,592411,10.1021/jm901195w,,,,Inhibition of human hepatic CYP3A4,Cc1cc(-c2ccc(-c3cccc(O)c3)s2)ccc1O,4-[5-(3-Hydroxyphenyl)-2-thienyl)-2-methyl]phenol,0.5,uM,=,-0.3010299956639812,0,c1ccc(-c2ccc(-c3ccccc3)s2)cc1
2590,1869499,10.1021/acs.jmedchem.8b01729,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 10 mins in presence of NADP by LC-MS/MS analysis,CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,SID144204227,0.0563,uM,=,-1.2494916051486538,0,c1ccc([C@@]2(Cn3ccnc3)OC[C@H](COc3ccc(N4CCNCC4)cc3)O2)cc1
2591,1576886,10.1021/acs.jmedchem.6b00007,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,Nc1cccc(-c2cccc(-c3c(-c4ccc(O)cc4)n[nH]c3N)c2)c1,"4-(5-Amino-4-(3'-amino-[1,1'-biphenyl]-3-yl)-1H-pyrazol-3-yl)-phenol",11.3,uM,=,1.0530784434834195,1,c1ccc(-c2cccc(-c3c[nH]nc3-c3ccccc3)c2)cc1
2592,1854052,10.1016/j.ejmech.2019.07.003,,,,Inhibition of recombinant human CYP3A4 using Luciferin-PPXE as substrate preincubated for 10 mins followed by NADPH addition measured after 15 mins by luminometric method,CCC(CC)Oc1ccc2cc(C(=O)NCC(O)(Cn3ccnc3)c3ccc(Cl)cc3Cl)c(=O)oc2c1,"rac-N-(2-(2,4-dichlorophenyl)-2-hydroxy-3-(1H-imidazol-1-yl)propyl)-2-oxo-7-(pentan-3-yloxy)-2H-chromene-3-carboxamide",0.2515,uM,=,-0.5994620106080538,0,O=C(NCC(Cn1ccnc1)c1ccccc1)c1cc2ccccc2oc1=O
2593,1301328,10.6019/CHEMBL3137440,,,,DNDI: CYP Inhibition,FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3nccs3)CC2)cc1,,1.7,uM,=,0.2304489213782739,1,c1ccc(N(c2cccnc2)C2CCN(c3nccs3)CC2)cc1
2594,595557,10.1016/j.bmcl.2009.10.084,,,,Inhibition of CYP3A4 using BFC as a substrate,CNC(=O)c1ccc(C(=O)/N=C(\Nc2ccc3oc(C)cc3c2)N[C@H]2CCCCN(CC(=O)N3CCCC3)C2=O)cn1,"(S)-N2-methyl-N5-((2-methylbenzofuran-5-ylamino)(2-oxo-1-(2-oxo-2-(pyrrolidin-1-yl)ethyl)azepan-3-ylamino)methylene)pyridine-2,5-dicarboxamide",18.0,uM,=,1.255272505103306,1,O=C(/N=C(\Nc1ccc2occc2c1)N[C@H]1CCCCN(CC(=O)N2CCCC2)C1=O)c1cccnc1
2595,455108,10.1016/j.bmcl.2006.12.043,,,,Inhibition of CYP3A4,O=C([C@@H](O)c1cccc(Cl)c1)N1CCC(Nc2ccc3[nH]ncc3c2)CC1,(S)-1-(4-(1H-indazol-5-ylamino)piperidin-1-yl)-2-(3-chlorophenyl)-2-hydroxyethanone,2.0,uM,=,0.3010299956639812,1,O=C(Cc1ccccc1)N1CCC(Nc2ccc3[nH]ncc3c2)CC1
2596,304712,10.1021/jm048978k,,,,In vitro inhibitory concentration against Cytochrome P450 3A4,CCc1nc(-c2ccc(F)cc2)c(-c2ccc3nc(N)n(S(=O)(=O)C(C)C)c3c2)[nH]1.CS(=O)(=O)O,6-[2-Ethyl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-1-(propane-2-sulfonyl)-1H-benzoimidazol-2-ylamine; compound with methanesulfonic acid,4.4,uM,=,0.6434526764861874,1,c1ccc(-c2nc[nH]c2-c2ccc3nc[nH]c3c2)cc1
2597,1919651,,,,,"Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase",c1cncc(-c2ccsc2)c1,3-Thiophen-3-yl-pyridine,55.9,uM,=,1.7474118078864234,1,c1cncc(-c2ccsc2)c1
2598,984598,10.1021/jm401266k,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of midazolam turnover preincubated for 3 mins followed by midazolam and NADPH addition measured after 5 mins by HPLC-MS/MS analysis,COc1c(C2CC2c2ccc(NS(C)(=O)=O)cc2)cc(-c2ccc[nH]c2=O)cc1C(C)(C)C,"N-(4-(2-(3-tert-butyl-2-methoxy-5-(2-oxo-1,2-dihydropyridin-3-yl)phenyl)cyclopropyl)phenyl)methanesulfonamide",0.04,uM,=,-1.3979400086720375,0,O=c1[nH]cccc1-c1cccc(C2CC2c2ccccc2)c1
2599,449485,10.1016/j.bmcl.2007.07.097,,,,Inhibition of microsomal CYP3A4,CCN[C@@H](CC(C)C)c1cccc(F)c1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1,"1-((R)-3-(2,4-dichlorophenyl)-1-(4-(2-((S)-1-(ethylamino)-3-methylbutyl)-6-fluorophenyl)piperazin-1-yl)-1-oxopropan-2-yl)pyrrolidin-2-one",0.64,uM,=,-0.1938200260161128,0,O=C([C@@H](Cc1ccccc1)N1CCCC1=O)N1CCN(c2ccccc2)CC1
2600,103774,10.1021/jm031011g,,,,Inhibitory concentration to inhibit MRP1 in CYP 3A4 assay,NC(=O)c1c2n(c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)ncnc13)CCCC2,"4-{4-[2-(3,4-Difluoro-phenyl)-ethyl]-piperazin-1-yl}-6,7,8,9-tetrahydro-pyrimido[4,5-b]indolizine-10-carboxylic acid amide",45.8,uM,=,1.6608654780038692,1,c1ccc(CCN2CCN(c3ncnc4cc5n(c34)CCCC5)CC2)cc1
2601,1558600,10.1016/j.bmcl.2015.06.020,,,,Inhibition of CYP3A4 (unknown origin) by fluorescence assay,Cc1cn(-c2ccc3c(c2)NC(=O)c2ccc(C(C)c4ccccc4)nc2N3)cn1,"(+/-)-8-(4-methyl-1H-imidazol-1-yl)-2-(1-phenylethyl)-6,11-dihydro-5H-benzo[b]pyrido[2,3-e][1,4]diazepin-5-one",0.2,uM,=,-0.6989700043360187,0,O=C1Nc2cc(-n3ccnc3)ccc2Nc2nc(Cc3ccccc3)ccc21
2602,453158,10.1016/j.bmcl.2006.09.056,,,,Inhibition of CYP3A4 in presence of BFC substrate,CN(C)CC1CCC(CNc2nc(NCc3ccccc3Cl)ncc2[N+](=O)[O-])CC1,"N2-(2-chlorobenzyl)-N4-((4-((dimethylamino)methyl)cyclohexyl)methyl)-5-nitropyrimidine-2,4-diamine",1.7,uM,=,0.2304489213782739,1,c1ccc(CNc2nccc(NCC3CCCCC3)n2)cc1
2603,459885,10.1021/np0704248,,,,Inhibition of human CYP3A4 expressed in Escherichia coli assessed as inhibition of nifedipine oxidation,COc1cc2c(cc1O)CC[n+]1cc3c(OC)c(OC)ccc3cc1-2,jatrorrhizine,2.1,uM,=,0.3222192947339193,1,c1ccc2c(c1)CC[n+]1cc3ccccc3cc1-2
2604,536049,10.1016/j.bmcl.2008.08.010,,,,Inhibition of human CYP3A4 by microtiter plate assays using PPR substrate,O=S(=O)(c1ccccc1)n1ccc2cc3c(cc21)CCNCC3,"1-(phenylsulfonyl)-1,5,6,7,8,9-hexahydroazepino[4,5-f]indole",20.0,uM,=,1.3010299956639813,1,O=S(=O)(c1ccccc1)n1ccc2cc3c(cc21)CCNCC3
2605,768817,10.1021/jm2005354,,,,Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting,C[C@@H](c1ccc(-c2ccc(F)cc2F)cc1)N1CC[C@](CCCNC(N)=O)(c2ccc(F)cc2)OC1=O,"1-(3-((R)-3-((S)-1-(2',4'-difluorobiphenyl-4-yl)ethyl)-6-(4-fluorophenyl)-2-oxo-1,3-oxazinan-6-yl)propyl)urea",4.0,uM,=,0.6020599913279624,1,O=C1OC(c2ccccc2)CCN1Cc1ccc(-c2ccccc2)cc1
2606,1485691,10.1124/dmd.111.043018,,,,Inhibition of human CYP3A4 expressed in supersomes assessed inhibition of 1'-OH midazolam formation preincubated with compound before substrate addition by LC-MS method,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,FK-506,0.12,uM,=,-0.9208187539523752,0,O=C1CC=CCCCC[C@@H]2CCCC(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H](/C=C/C2CCCCC2)CCC1
2607,630896,10.1016/j.bmcl.2010.03.017,,,,Inhibition of CYP3A4,Cc1cc(OC[P@@]2(=O)OCC[C@@H](c3ccc(Cl)cc3)O2)c2c(c1C)Cc1scnc1-2,"4-[4-(4-Chloro-phenyl)-2-oxo-2lambda*5*-[1,3,2]dioxaphosphinan-2-ylmethoxy]-6,7-dimethyl-8H-indeno[1,2-d]thiazole",0.65,uM,=,-0.1870866433571444,0,O=[P@]1(COc2cccc3c2-c2ncsc2C3)OCC[C@@H](c2ccccc2)O1
2608,1931354,10.1016/j.bmcl.2019.07.037,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam pre-incubated for 10 mins before NADPH addition and measured after 10 mins by LC/MS/MS analysis,CC(C)OC(=O)[C@H](Cn1ccnc1)NC(=O)c1ccc(-c2ccccc2)cc1F,"isopropyl (S)-2-(3-fluoro-[1,1'-biphenyl]-4-carboxamido)-3-(1H-imidazol-1-yl)propanoate",0.0429,uM,=,-1.3675427078152758,0,O=C(NCCn1ccnc1)c1ccc(-c2ccccc2)cc1
2609,642202,10.1021/jm100481d,,,,Inhibition of human CYP3A4 after 10 mins,COC[C@@]12CNCC[C@]1(c1ccc(Cl)c(Cl)c1)C2,"1-(3,4-dichlorophenyl)-6-(methoxymethyl)-3-azabicyclo[4.1.0]heptane",10.0,uM,=,1.0,1,c1ccc([C@]23CCNCC2C3)cc1
2610,479364,10.1016/j.bmcl.2008.05.027,,,,Inhibition of CYP3A4,CN(CC(=O)N1CCCC(c2ccccc2)C1CN1CCOCC1)c1ccc(Cl)c(Cl)c1,"rac-2-((3,4-dichlorophenyl)(methyl)amino)-1-(2-(morpholinomethyl)-3-phenylpiperidin-1-yl)ethanone",0.77,uM,=,-0.1135092748275181,0,O=C(CNc1ccccc1)N1CCCC(c2ccccc2)C1CN1CCOCC1
2611,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(F)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, G-1",2.97,uM,=,0.4727564493172124,1,O=C(Nc1cccnc1)c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12
2612,463856,10.1016/j.bmcl.2008.01.100,,,,Inhibition of CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as a substrate,CC(C)(N)C(=O)N[C@H](COCc1ccccc1)c1nnnn1[C@H](CC#N)COc1ccccn1,2-amino-N-((S)-2-(benzyloxy)-1-(1-((R)-1-cyano-3-(pyridin-2-yloxy)propan-2-yl)-1H-tetrazol-5-yl)ethyl)-2-methylpropanamide,59.0,uM,=,1.7708520116421442,1,c1ccc(COCCc2nnnn2CCOc2ccccn2)cc1
2613,2254484,10.1021/acs.jmedchem.2c00527,,,,Inhibition of CYP3A4 in human liver microsomes at 0.01 to 30 uM using phenacetin as substrate in presence of NADPH by UPLC-MS/MS analysis,C[C@@H]1CC(=O)Nc2ncnc(N3CCN(C(=O)[C@H](CNC4CC4)c4ccc(Cl)cc4)[C@@H]4C[C@@H]43)c21,"(R)-4-((1S,6R)-5-((S)-2-(4-chlorophenyl)-3-(cyclopropylamino)propanoyl)-2,5-diazabicyclo[4.1.0]heptan-2-yl)-5-methyl-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one",1.09,uM,=,0.0374264979406236,1,O=C1CCc2c(ncnc2N2CCN(C(=O)[C@H](CNC3CC3)c3ccccc3)[C@@H]3C[C@@H]32)N1
2614,536049,10.1016/j.bmcl.2008.08.010,,,,Inhibition of human CYP3A4 by microtiter plate assays using PPR substrate,O=S(=O)(c1ccccn1)n1ccc2cc3c(cc21)CCNCC3,"1-(pyridin-2-ylsulfonyl)-1,5,6,7,8,9-hexahydroazepino[4,5-f]indole",77.0,uM,=,1.8864907251724816,1,O=S(=O)(c1ccccn1)n1ccc2cc3c(cc21)CCNCC3
2615,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)N6CCN(S(C)(=O)=O)CC6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, D-97",6.4,uM,=,0.8061799739838872,1,O=C(Nc1ccc(-c2c[nH]c3c(CN4C[C@@H]5N(C(=O)NCc6ccccc6)NCC(=O)N5[C@@H](Cc5ccccc5)C4=O)cccc23)cn1)N1CCNCC1
2616,519907,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,Cc1cccc(C)c1CNc1cc(-n2cc(C(N)=O)ccc2=O)cn2c(C)c(C)nc12,"1-(8-(2,6-dimethylbenzylamino)-2,3-dimethylimidazo[1,2-a]pyridin-6-yl)-6-oxo-1,6-dihydropyridine-3-carboxamide",7.2,uM,=,0.8573324964312685,1,O=c1ccccn1-c1cc(NCc2ccccc2)c2nccn2c1
2617,2264907,10.1016/j.bmcl.2022.128951,,,,Inhibition of recombinant human CYP3A4,Nc1ncncc1-c1ccnc2c1cnn2-c1ccc(F)cc1,"5-[1-(4-fluorophenyl)pyrazolo[3,4-b]pyridin-4-yl]pyrimidin-4-amine",36.0,uM,=,1.5563025007672873,1,c1ccc(-n2ncc3c(-c4cncnc4)ccnc32)cc1
2618,304712,10.1021/jm048978k,,,,In vitro inhibitory concentration against Cytochrome P450 3A4,CS(=O)(=O)O.CS(=O)(=O)O.Nc1nc2ccc(-c3[nH]c(-c4c(F)cccc4F)nc3-c3ccccc3)cc2n1S(=O)(=O)C1CCCC1,"1-Cyclopentanesulfonyl-6-[2-(2,6-difluoro-phenyl)-5-phenyl-3H-imidazol-4-yl]-1H-benzoimidazol-2-ylamine; Bismesylate salt",13.0,uM,=,1.1139433523068367,1,O=S(=O)(C1CCCC1)n1cnc2ccc(-c3[nH]c(-c4ccccc4)nc3-c3ccccc3)cc21
2619,1460909,10.1021/jm501326k,,,,Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase/human b5 reductase using 7-benzyloxyquinoline substrate,CCOC(=O)c1[nH]cc2c1NC1=C(C(=O)CCC1)C2c1ccc(Sc2nc3ccc(F)c(F)c3[nH]2)o1,"(+/-)-9-[5-(6,7-Difluoro-1H-benzimidazol-2-ylsulfanyl)-furan-2-yl]-8-oxo-4,5,6,7,8,9-hexahydro-2Hpyrrolo[3,4-b]quinoline-3-carboxylic acid ethyl ester",34.0,uM,=,1.5314789170422551,1,O=C1CCCC2=C1C(c1ccc(Sc3nc4ccccc4[nH]3)o1)c1c[nH]cc1N2
2620,1567198,10.1039/C5MD00479A,,,,Inhibition of human CYP3A4 by HPLC analysis,CCCCC(=O)O[C@@H](C(=O)N1N=CC[C@H]1C(=O)NCc1cc(Cl)ccc1-n1cnnn1)c1ccc(F)cc1,"(1R)-2-[(5S)-5-{[5-Chloro-2-(1H-tetrazol-1-yl)benzyl]carbamoyl}-4,5-dihydro-1H-pyrazol-1-yl]-1-(4-fluorophenyl)-2-oxoethyl pentanoate",1.2,uM,=,0.0791812460476248,1,O=C(NCc1ccccc1-n1cnnn1)[C@@H]1CC=NN1C(=O)Cc1ccccc1
2621,600767,10.1016/j.bmcl.2009.07.127,,,,Inhibition of human CYP3A4,COc1cc2c(cc1OC)CN(C(=O)C13CC4CC(C1)CC(c1ccc(OCC(=O)Nc5cccc6cccnc56)cc1)(C4)C3)CC2,"2-{4-[3-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinoline-2-carbonyl)-adamantan-1-yl]-phenoxy}-N-quinolin-8-yl-acetamide",2.84,uM,=,0.4533183400470376,1,O=C(COc1ccc(C23CC4CC(CC(C(=O)N5CCc6ccccc6C5)(C4)C2)C3)cc1)Nc1cccc2cccnc12
2622,449485,10.1016/j.bmcl.2007.07.097,,,,Inhibition of microsomal CYP3A4,CC(C)C[C@H](NC(=O)C(C)(C)N)c1cc(F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1,"2-amino-N-((S)-1-(2-(4-((R)-3-(2,4-dichlorophenyl)-2-(2-oxopyrrolidin-1-yl)propanoyl)piperazin-1-yl)-5-fluorophenyl)-3-methylbutyl)-2-methylpropanamide",28.0,uM,=,1.4471580313422192,1,O=C([C@@H](Cc1ccccc1)N1CCCC1=O)N1CCN(c2ccccc2)CC1
2623,2171309,10.1021/acs.jmedchem.1c00633,,,,Inhibition of CYP3A4 (unknown origin) using ketoconazole as substrate,CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,SID144204227,0.046,uM,=,-1.337242168318426,0,c1ccc([C@@]2(Cn3ccnc3)OC[C@H](COc3ccc(N4CCNCC4)cc3)O2)cc1
2624,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1cc(C(=O)N2CCOC[C@H]2Cc2cccc(-n3nccn3)c2)c(-n2nccn2)cc1C,"US9150566, 35",20.0,uM,=,1.3010299956639813,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
2625,673952,10.1016/j.bmcl.2010.08.086,,,,Inhibition of CYP3A4 using midazolam as substrate,CC(=O)NCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1,"(3R,4S)-N-(5-(acetamidomethyl)-2-chlorobenzyl)-N-cyclopropyl-4-(4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)phenyl)piperidine-3-carboxamide",5.1,uM,=,0.7075701760979364,1,O=C([C@H]1CNCC[C@@H]1c1ccc(OCCOc2ccccc2)cc1)N(Cc1ccccc1)C1CC1
2626,740075,10.1016/j.bmcl.2011.02.033,,,,Inhibition of CYP3A4,COc1ccccc1N1CCN(C(=O)c2cc(-c3ccc(Cl)cc3)nn2C)CC1,(3-(4-chlorophenyl)-1-methyl-1H-pyrazol-5-yl)(4-(2-methoxyphenyl)piperazin-1-yl)methanone,12.0,uM,=,1.0791812460476249,1,O=C(c1cc(-c2ccccc2)n[nH]1)N1CCN(c2ccccc2)CC1
2627,813216,10.1016/j.bmcl.2012.01.125,,,,Inhibition of CYP3A4,CC[C@H](c1ccccc1)n1c(=O)[nH]c2cnc3cc(-c4c(C)noc4C)c(OC)cc3c21,"7-(3,5-dimethylisoxazol-4-yl)-8-methoxy-1-((R)-1-phenylpropyl)-1H-imidazo[4,5-c]quinolin-2(3H)-one",2.4,uM,=,0.380211241711606,1,O=c1[nH]c2cnc3cc(-c4cnoc4)ccc3c2n1Cc1ccccc1
2628,611722,10.1021/jm9014263,,,,Inhibition of human CYP3A4 using BFC substrate by fluorescence assay,COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc(CN(C)C)cc3)c2)cc1OC,"N-[3-(4-Dimethylaminomethyl-phenylcarbamoyl)-benzyl]-3,4-dimethoxy-benzamide",8.1,uM,=,0.9084850188786496,1,O=C(NCc1cccc(C(=O)Nc2ccccc2)c1)c1ccccc1
2629,1528565,,,,,"Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",CC(C)c1nc(CN(C)C(=O)N2CSC[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,"US8987313, 16",0.2,uM,=,-0.6989700043360187,0,O=C(N[C@H](CC[C@H](Cc1ccccc1)NC(=O)[C@@H]1CSCN1C(=O)NCc1cscn1)Cc1ccccc1)OCc1cncs1
2630,644698,10.1016/j.bmcl.2010.05.111,,,,Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate,CS(=O)(=O)N(c1ccccc1)c1cc(C(=O)N[C@@H](Cc2ccccc2)[C@H](O)CNCc2cccc(C(F)(F)F)c2)cc(C2CCCC2)c1,"3-cyclopentyl-N-((2S,3R)-3-hydroxy-1-phenyl-4-(3-(trifluoromethyl)benzylamino)butan-2-yl)-5-(N-phenylmethylsulfonamido)benzamide",0.6,uM,=,-0.2218487496163563,0,O=C(N[C@H](CCNCc1ccccc1)Cc1ccccc1)c1cc(Nc2ccccc2)cc(C2CCCC2)c1
2631,448320,10.1016/j.bmc.2007.05.069,,,,Inhibition of CYP3A4,CCOCCCN1C(=O)C(C)(c2cc(F)cc(F)c2)Oc2ccc(-c3c(N)nc(N)nc3CC)cc21,"6-(2,4-diamino-6-ethylpyrimidin-5-yl)-2-(3,5-difluorophenyl)-4-(3-ethoxypropyl)-2-methyl-2H-benzo[b][1,4]oxazin-3(4H)-one",1.06,uM,=,0.0253058652647702,1,O=C1Nc2cc(-c3cncnc3)ccc2OC1c1ccccc1
2632,455108,10.1016/j.bmcl.2006.12.043,,,,Inhibition of CYP3A4,N[C@H](C(=O)N1CCC(Nc2ccc3[nH]ncc3c2)CC1)c1ccccc1,(S)-1-(4-(1H-indazol-5-ylamino)piperidin-1-yl)-2-amino-2-phenylethanone,0.45,uM,=,-0.3467874862246563,0,O=C(Cc1ccccc1)N1CCC(Nc2ccc3[nH]ncc3c2)CC1
2633,2246941,10.1021/acs.jmedchem.1c02132,,,,Inhibition of CYP3A4 (unknown origin) incubated for 10 mins in presence of NADPH by LC-MS/MS analysis,CC(=O)Nc1cc(-c2cc(F)c(OC[C@@H](N)CC(C)C)c(F)c2)ccn1,"(S)-N-(4-(4-((2-amino-4-methylpentyl)oxy)-3,5-difluorophenyl)pyridin-2-yl)acetamide",1.3,uM,=,0.1139433523068367,1,c1ccc(-c2ccncc2)cc1
2634,1528565,,,,,"Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",CC(C)c1nc(CN(C)C(=O)NC2(C(=O)N[C@H](CC[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)Cc3ccccc3)CCN(C)CC2)cs1,"US8987313, 21",0.34,uM,=,-0.4685210829577448,0,O=C(NCc1cscn1)NC1(C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)CCNCC1
2635,519907,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,CCc1cccc(C)c1CNc1cc(C(N)=O)cn2c(C)c(C)nc12,"8-(2-ethyl-6-methylbenzylamino)-2,3-dimethylH-imidazo[1,2-a]pyridine-6-carboxamide",3.8,uM,=,0.5797835966168101,1,c1ccc(CNc2cccn3ccnc23)cc1
2636,649576,10.1021/jm100317b,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsome,Oc1ccc2cc(-c3ccc(Cc4ccncc4)cc3)ccc2c1,6-[4-(Pyridin-4-ylmethyl)phenyl]naphthalen-2-ol,1.14,uM,=,0.0569048513364725,1,c1ccc2cc(-c3ccc(Cc4ccncc4)cc3)ccc2c1
2637,1642447,,,,,"Luciferase-Based P450-Glo Assay: Five CYP isoforms (0.5 pmol) were tested, namely 1A2, 2C9, 2C19, 2D6 and 3A4 (each isoform was assayed in a separate assay plate). Each assay plate contained several compounds at 2 concentrations (10 uM and 1 uM), with 2 replicates at each concentration or a small number of compounds per plate in dose response by duplicate (50, 16.5, 5.4, 1.8, 0.6, 0.2, 0.066, 0.022, 0.007 uM). In addition, each assay plate contained 8 different concentrations of an isoform-specific inhibitor (Furafylline, Sulfaphenazole, N-3-benzylnirvanol, Quinidine and Ketoconazole as inhibitors of CYP 1A2, 2C9, 2C19, 2D6 and 3A4, respectively), with two replicates at each concentration. The test compounds and the reference inhibitors were tested at a final DMSO concentration of 0.5%. The assay plate included also 8 replicates a vehicle control containing 0.5% DMSO/H2O. The membranes containing the CYPs, test compound and the probe substrate were pre-incubated 10 min at 37°C. in the absence of NADPH, NADPH was then added following incubation for 60 minutes at 37°C., the reaction was terminated by the addition of Luciferin detection reagent. After 20 min incubation at 37°C., the assay plate was read in the Envision 2104 Multilable reader. Values were normalized against the control activity included for each CYP. These values were plotted against the inhibitor concentration and were fitted to a sigmoid dose-response curve by using the model sigmoidal Four-Parameter Logistc inplement for Activity baseÂ  software.",CNc1nc2ccccc2n1-c1nc2c(c(C(C)(C)S(C)(=O)=O)n1)OC[C@@H]1COCCN21,"US9453031, 11",39.0,uM,=,1.591064607026499,1,c1ccc2c(c1)ncn2-c1ncc2c(n1)N1CCOC[C@H]1CO2
2638,355280,10.1016/j.bmcl.2006.02.020,,,,Inhibition of CYP3A4,CN(C)C(C)(C)[C@@H](c1ccc2cc(OCC(C)(C)C(=O)O)ccc2c1)n1ccnc1,"(R)-3-(6-(2-(dimethylamino)-1-(1H-imidazol-1-yl)-2-methylpropyl)naphthalen-2-yloxy)-2,2-dimethylpropanoic acid",2.1,uM,=,0.3222192947339193,1,c1ccc2cc(Cn3ccnc3)ccc2c1
2639,304712,10.1021/jm048978k,,,,In vitro inhibitory concentration against Cytochrome P450 3A4,CC(C)c1nc(-c2ccc(F)cc2)c(-c2ccc3nc(N)n(S(=O)(=O)C(C)C)c3c2)[nH]1.CS(=O)(=O)O,6-[5-(4-Fluoro-phenyl)-2-isopropyl-3H-imidazol-4-yl]-1-(propane-2-sulfonyl)-1H-benzoimidazol-2-ylamine; compound with methanesulfonic acid,6.1,uM,=,0.785329835010767,1,c1ccc(-c2nc[nH]c2-c2ccc3nc[nH]c3c2)cc1
2640,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(OCCCN6CCCCC6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, G-31",7.67,uM,=,0.884795363948981,1,O=C(Nc1ccc(OCCCN2CCCCC2)nc1)c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12
2641,1805934,10.1021/acs.jmedchem.9b00352,,,,Inhibition of recombinant human CYP3A4 expressed in insect cell microsomes in presence of NADPH-regenerating system after 15 to 45 mins by fluorescence probe substrate-based assay,N#Cc1ccc2nnc(C(=O)N3CCC(c4cccc(F)c4C(F)(F)F)CC3)n2c1,"US9434727, 65",74.0,uM,=,1.869231719730976,1,O=C(c1nnc2ccccn12)N1CCC(c2ccccc2)CC1
2642,1919651,,,,,"Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase",CCn1cnc(-c2cccnc2)c1,3-(1-Ethyl-1H-imidazol-4-yl)-pyridine,79.2,uM,=,1.8987251815894928,1,c1cncc(-c2c[nH]cn2)c1
2643,537516,10.1021/jm8005096,,,,Inhibition of CYP3A4,COc1ccc(C2=NC(c3ccc(Cl)cc3F)C(C(=O)Nc3ccc4[nH]ncc4c3)=C(C)N2)cc1,"4-(4-chloro-2-fluorophenyl)-N-(1H-indazol-5-yl)-2-(4-methoxyphenyl)-6-methyl-1,4-dihydropyrimidine-5-carboxamide",2.7,uM,=,0.4313637641589873,1,O=C(Nc1ccc2[nH]ncc2c1)C1=CNC(c2ccccc2)=NC1c1ccccc1
2644,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cc(-c3ncon3)ccc2F)c1,"US9150566, 174",50.0,uM,=,1.6989700043360187,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2ncon2)c1
2645,1491683,10.1124/dmd.112.045708,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate addition by LC-MS/MS analysis,COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1,"Acetic acid (2S,3S)-5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester",80.0,uM,=,1.9030899869919435,1,O=C1C[C@H](c2ccccc2)Sc2ccccc2N1
2646,643713,10.1016/j.bmcl.2010.06.009,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader,C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(NCCN(C)C)c4)ccc32)sc1C(N)=O)c1ccccc1C(F)(F)F,(R)-5-(5-(2-(2-(dimethylamino)ethylamino)pyridin-4-yl)-1H-benzo[d]imidazol-1-yl)-3-(1-(2-(trifluoromethyl)phenyl)ethoxy)thiophene-2-carboxamide,27.0,uM,=,1.4313637641589874,1,c1ccc(COc2csc(-n3cnc4cc(-c5ccncc5)ccc43)c2)cc1
2647,51903,10.1021/jm020557k,,,,Concentration required to inhibit cytochrome P450 3A4.,CCCCOc1ccc(-c2ccnn2C)cc1,5-(4-Butoxy-phenyl)-1-methyl-1H-pyrazole,93.8,uM,=,1.9722028383790644,1,c1ccc(-c2ccn[nH]2)cc1
2648,488046,10.1016/j.bmcl.2008.06.018,,,,Inhibition of CYP3A4 in human liver microsome,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,"1-(4-{4-[2-(2,4-Dichloro-phenyl)-2-imidazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-ethanone (ketoconazole)",0.02,uM,=,-1.6989700043360187,0,c1ccc(C2(Cn3ccnc3)OCC(COc3ccc(N4CCNCC4)cc3)O2)cc1
2649,461436,10.1016/j.bmcl.2007.10.092,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,CN(Cc1noc(CC2([C@H]3CCC[C@@H](C4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)n1)C(C)(C)CO,"2-(((5-((1-((2R,6S)-1-(4-chlorophenylsulfonyl)-6-cyclopropylpiperidin-2-yl)cyclopropyl)methyl)-1,2,4-oxadiazol-3-yl)methyl)(methyl)amino)-2-methylpropan-1-ol",0.3,uM,=,-0.5228787452803376,0,O=S(=O)(c1ccccc1)N1[C@H](C2CC2)CCC[C@@H]1C1(Cc2ncno2)CC1
2650,619264,10.1016/j.bmcl.2009.07.002,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,Cc1nc2c(OCc3ccccc3)cccn2c1CC#N,"(8-Benzyloxy-2-methyl-imidazo[1,2-a]pyridin-3-yl)-acetonitrile",9.0,uM,=,0.9542425094393248,1,c1ccc(COc2cccn3ccnc23)cc1
2651,559939,10.1016/j.bmcl.2008.10.072,,,,Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate,C[C@@H]1CN(Cc2ccc(-c3ccccc3CN(C)C(=O)Cc3cccc(Cl)c3)cc2)C[C@H](C)N1,"2-(3-Chloro-phenyl)-N-[4'-((3R,5S)-3,5-dimethyl-piperazin-1-ylmethyl)-biphenyl-2-ylmethyl]-N-methyl-acetamide",1.5,uM,=,0.1760912590556812,1,O=C(Cc1ccccc1)NCc1ccccc1-c1ccc(CN2CCNCC2)cc1
2652,559939,10.1016/j.bmcl.2008.10.072,,,,Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate,C[C@@H]1CN(Cc2ccc(-c3ccccc3C(=O)N3CCC(Nc4ccccc4)CC3)cc2)C[C@H](C)N1,"[4'-((3R,5S)-3,5-Dimethyl-piperazin-1-ylmethyl)-biphenyl-2-yl]-(4-phenylamino-piperidin-1-yl)-methanone",17.0,uM,=,1.230448921378274,1,O=C(c1ccccc1-c1ccc(CN2CCNCC2)cc1)N1CCC(Nc2ccccc2)CC1
2653,464748,10.1016/j.bmcl.2008.01.126,,,,Inhibition of CYP3A4 in presence of 7-benzyloxyresorufin substrate,COc1ccc(N2C(=O)[C@@H](Cc3cccc(OCCc4nc(-c5ccccc5)oc4C)c3)[C@H]2C(=O)O)cc1,"(2S,3S)-3-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-(4-methoxyphenyl)-4-oxoazetidine-2-carboxylic acid",0.83,uM,=,-0.0809219076239261,0,O=C1[C@@H](Cc2cccc(OCCc3coc(-c4ccccc4)n3)c2)CN1c1ccccc1
2654,630896,10.1016/j.bmcl.2010.03.017,,,,Inhibition of CYP3A4,Cc1ccc([C@@H]2CCO[P@](=O)(COc3cc(C)c(C)c4c3-c3ncsc3C4)O2)cn1,"6,7-Dimethyl-4-[4-(6-methyl-pyridin-3-yl)-2-oxo-2lambda*5*-[1,3,2]dioxaphosphinan-2-ylmethoxy]-8H-indeno[1,2-d]thiazole",5.2,uM,=,0.7160033436347992,1,O=[P@]1(COc2cccc3c2-c2ncsc2C3)OCC[C@@H](c2cccnc2)O1
2655,1797910,10.1021/acs.jmedchem.8b01326,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate/NADPH addition measured after 10 mins by LC-MS/MS analysis,CN1C(=N)N[C@@]2(c3cc(-c4cccc(C#N)c4)cs3)CN(c3ncc(F)cn3)C[C@H]2C1=O,"3-(5-((4aR,7aR)-6-(5-Fluoropyrimidin-2-yl)-2-imino-3-methyl-4-oxooctahydro-1H-pyrrolo[3,4-d]pyrimidin-7a-yl)thiophen-3-yl)benzonitrile",1.2,uM,=,0.0791812460476248,1,N=C1NC(=O)[C@@H]2CN(c3ncccn3)C[C@]2(c2cc(-c3ccccc3)cs2)N1
2656,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1,"US9150566, 12",30.0,uM,=,1.4771212547196624,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
2657,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(CCCO)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, E-11",11.3,uM,=,1.0530784434834195,1,O=C(c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12)N1CCNCC1
2658,1489010,10.1124/dmd.111.042739,,,,Inhibition of CYP3A4 (unknown origin),CC[C@@H](C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@H]5CO[C@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O,"Cis-2-((R)-sec-Butyl)-4-[4-(4-{4-[(2R,4S)-2-(2,4-dichloro-phenyl)-2-[1,2,4]triazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-pheny l]-2,4-dihydro-[1,2,4]triazol-3-one",0.004,uM,=,-2.397940008672037,0,O=c1[nH]ncn1-c1ccc(N2CCN(c3ccc(OC[C@H]4CO[C@](Cn5cncn5)(c5ccccc5)O4)cc3)CC2)cc1
2659,489963,10.1021/jm800566m,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline substrate,Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1C.Cl.Cl,"3-({4-[(2,3-Dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl}amino)benzenesulfonamide",31.0,uM,=,1.4913616938342726,1,c1ccc(Nc2nccc(Nc3ccc4c[nH]nc4c3)n2)cc1
2660,945618,10.1016/j.bmc.2012.11.058,,,,Inhibition of CYP3A4 (unknown origin),O=S(=O)(Nc1ccc(Oc2cnc3ccccc3c2)c(Cl)c1)c1ccc(Cl)cc1Cl,"2,4-dichloro-N-(3-chloro-4-(quinolin-3-yloxy)phenyl)benzenesulfonamide",2.6,uM,=,0.414973347970818,1,O=S(=O)(Nc1ccc(Oc2cnc3ccccc3c2)cc1)c1ccccc1
2661,1668102,10.1016/j.bmcl.2017.04.006,,,,Inhibition of recombinant human CYP3A4 expressed in insect cells using DBOMF as substrate pretreated for 10 mins followed by substrate addition measured every minute for 15 mins in presence of NADP+ by fluorescence assay,COc1ccc(CNc2c3c(nc4ccccc24)CCCC3)cc1OC,"N-(3,4-dimethoxybenzyl)-1,2,3,4-tetrahydroacridin-9-amine",3.7,uM,=,0.568201724066995,1,c1ccc(CNc2c3c(nc4ccccc24)CCCC3)cc1
2662,814102,10.1016/j.bmcl.2012.03.014,,,,Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins,CC(=O)NCCc1ccccc1-c1onc([C@H]2CNCC[C@]2(O)c2ccc(F)c(F)c2)c1Br,"N-(2-(4-bromo-3-((3R,4R)-4-(3,4-difluorophenyl)-4-hydroxypiperidin-3-yl)isoxazol-5-yl)phenethyl)acetamide",33.0,uM,=,1.5185139398778875,1,c1ccc(-c2cc([C@H]3CNCCC3c3ccccc3)no2)cc1
2663,1485703,10.1124/dmd.112.048264,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method,COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)Cc2ccccc2)C1c1cccc([N+](=O)[O-])c1,"2,6-Dimethyl-4-(3-nitro-phenyl)-1,4-dihydro-pyridine-3,5-dicarboxylic acid 3-[2-(benzyl-methyl-amino)-ethyl] ester 5-methyl ester",0.38,uM,=,-0.4202164033831898,0,O=C(OCCNCc1ccccc1)C1=CNC=CC1c1ccccc1
2664,1534761,,,,,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",Fc1cncc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)c(F)n2)c1,"US9096593, P-2001",5.0,uM,=,0.6989700043360189,1,c1cncc(CNc2ccc(Cc3c[nH]c4ncccc34)cn2)c1
2665,562431,10.1016/j.bmcl.2009.02.032,,,,Inhibition of CYP3A4 in human liver microsomes,C[C@H](Cc1cccc(F)c1)Oc1nc(N2CCNC[C@H]2C)ncc1F,5-fluoro-4-((R)-1-(3-fluorophenyl)propan-2-yloxy)-2-((R)-2-methylpiperazin-1-yl)pyrimidine,4.9,uM,=,0.6901960800285137,1,c1ccc(CCOc2ccnc(N3CCNCC3)n2)cc1
2666,1587034,10.1021/acs.jmedchem.6b00203,,,,Inhibition of CYP3A4 (unknown origin),Cc1nn(C2CCN(C(=O)[C@H](C)N)CC2)c(C)c1Nc1ncc(Cl)c(-c2cnn3ccccc23)n1,"(2S)-2-Amino-1-[4-(4-{[5-chloro-4-(pyrazolo[1,5-a]pyridin-3-yl)-2-pyrimidinyl]amino}-3,5-dimethyl-1H-pyrazol-1-yl)-1-piperidinyl]-1-propanone",0.3,uM,=,-0.5228787452803376,0,c1ccn2ncc(-c3ccnc(Nc4cnn(C5CCNCC5)c4)n3)c2c1
2667,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1ccc(C(=O)N2CCOC[C@H]2Cc2cc(F)cc(-n3nccn3)c2)c(-n2nccn2)c1,"US9150566, 146",40.0,uM,=,1.6020599913279625,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
2668,461436,10.1016/j.bmcl.2007.10.092,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,O=S(=O)(c1ccc(Cl)cc1)N1[C@H](C2CC2)CCC[C@@H]1C1(Cc2nc(CN3CCCC3)no2)CC1,"(2S,6R)-1-(4-chlorophenylsulfonyl)-2-cyclopropyl-6-(1-((3-(pyrrolidin-1-ylmethyl)-1,2,4-oxadiazol-5-yl)methyl)cyclopropyl)piperidine",0.3,uM,=,-0.5228787452803376,0,O=S(=O)(c1ccccc1)N1[C@H](C2CC2)CCC[C@@H]1C1(Cc2nc(CN3CCCC3)no2)CC1
2669,742805,10.1016/j.bmc.2011.02.009,,,,Inhibition of human CYP3A4 after 30 mins,CC(C)C(O)(c1ccc(-c2ccc(F)cc2)cc1)c1c[nH]cn1,"rac-1-(4'-Fluoro[1,1'-biphenyl]-4-yl)-1-(1H-imidazol-4-yl)-2-methyl-1-propanol",5.3,uM,=,0.724275869600789,1,c1ccc(-c2ccc(Cc3c[nH]cn3)cc2)cc1
2670,519908,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,COc1ccccc1CNc1cc(-n2ccccc2=O)cn2c(C)c(C)nc12,"1-(8-(2-methoxybenzylamino)-2,3-dimethylimidazo[1,2-a]pyridin-6-yl)pyridin-2(1H)-one",4.2,uM,=,0.6232492903979004,1,O=c1ccccn1-c1cc(NCc2ccccc2)c2nccn2c1
2671,1996656,10.1021/acs.jmedchem.0c00446,,,,Inhibition of CYP3A4 (unknown origin),COc1cc(C2=CC3=NO[C@H](c4cc(F)c(F)c(F)c4)CN3CCC2)ccc1-n1cnc(C)c1,"(R)-9-(3-Methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-3-(3,4,5-trifluorophenyl)-3,4,7,8-tetrahydro-6H-[1,2,4]oxadiazino[4,3-a]azepine",34.0,uM,=,1.5314789170422551,1,C1=C(c2ccc(-n3ccnc3)cc2)CCCN2C[C@@H](c3ccccc3)ON=C12
2672,510198,10.1021/jm800355c,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,Br.Oc1ccc(-c2ccc3c(c2)CCC=C3c2ccncc2)cc1F,"2-Fluoro-4-(5-(pyridin-4-yl)-7,8-dihydronaphthalen-2-yl)phenolHydrobromide",2.114,uM,=,0.3251049829714074,1,C1=C(c2ccncc2)c2ccc(-c3ccccc3)cc2CC1
2673,1706610,10.1016/j.bmcl.2017.06.077,,,,Inhibition of recombinant human CYP3A4,COc1cccc(N2CCN(c3nc(-c4ccncn4)cc(=O)n3C)[C@H](C)C2)c1,(R)-2-(4-(3-methoxyphenyl)-2-methylpiperazin-1-yl)-3-methyl-6-(pyrimidin-4-yl)pyrimidin-4(3H)-one,9.6,uM,=,0.9822712330395684,1,O=c1cc(-c2ccncn2)nc(N2CCN(c3ccccc3)CC2)[nH]1
2674,1446329,10.1021/ml500387y,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,CCS(=O)(=O)c1cc2cc(C[C@](O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1,"(R)-2-(4-((5-(ethylsulfonyl)-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)-5,5,5-trifluoro-4-hydroxy-2-methylpentan-2-yl)-5-fluorobenzamide",8.0,uM,=,0.9030899869919436,1,c1ccc(CCCCc2cc3ccncc3[nH]2)cc1
2675,51915,10.1016/s0960-894x(03)00680-2,,,,Inhibition of human liver microsome Cytochrome P450 3A4,O=C(N[C@H]1c2ccccc2OC[C@H]1O)[C@H](Cc1ccncc1)C[C@H](O)CN1CCN(CC2=CC3C=CSC3S2)C[C@H]1C(=O)NCC(F)(F)F,"(S)-4-(3a,6a-Dihydro-thieno[2,3-b]thiophen-2-ylmethyl)-1-[(2S,4R)-2-hydroxy-4-((3S,4S)-3-hydroxy-chroman-4-ylcarbamoyl)-5-pyridin-4-yl-pentyl]-piperazine-2-carboxylic acid (2,2,2-trifluoro-ethyl)-amide",0.47,uM,=,-0.3279021420642826,0,O=C(N[C@@H]1CCOc2ccccc21)[C@@H](CCCN1CCN(CC2=CC3C=CSC3S2)CC1)Cc1ccncc1
2676,619264,10.1016/j.bmcl.2009.07.002,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,Cc1cccc(C)c1CNc1nc(N2CCOCC2=O)cc2c(C)c(C)n(CCO)c12,"4-(7-(2,6-dimethylbenzylamino)-1-(2-hydroxyethyl)-2,3-dimethyl-1H-pyrrolo[2,3-c]pyridin-5-yl)morpholin-3-one",6.0,uM,=,0.7781512503836436,1,O=C1COCCN1c1cc2cc[nH]c2c(NCc2ccccc2)n1
2677,559939,10.1016/j.bmcl.2008.10.072,,,,Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate,C[C@@H]1CN(Cc2ccc(-c3ccccc3CN(C)C(=O)COc3ccc(F)cc3)cc2)C[C@H](C)N1,"N-[4'-((3R,5S)-3,5-Dimethyl-piperazin-1-ylmethyl)-biphenyl-2-ylmethyl]-2-(4-fluoro-phenoxy)-N-methyl-acetamide",7.3,uM,=,0.8633228601204559,1,O=C(COc1ccccc1)NCc1ccccc1-c1ccc(CN2CCNCC2)cc1
2678,473932,10.1021/jm701121y,,,,Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay,CCC1COC(Cn2cncn2)(c2ccc(Cl)cc2Cl)O1,"1-((2-(2,4-dichlorophenyl)-4-ethyl-1,3-dioxolan-2-yl)methyl)-1H-1,2,4-triazole",0.21,uM,=,-0.6777807052660807,0,c1ccc(C2(Cn3cncn3)OCCO2)cc1
2679,613752,10.1021/jm901818u,,,,Inhibition of human CYP3A4 by fluorescence assay,Clc1ccc([C@@]2(COCC3CC3)[C@@H]3CNC[C@@H]32)cc1Cl,"exo-6-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane",4.0,uM,=,0.6020599913279624,1,c1ccc([C@@]2(COCC3CC3)[C@@H]3CNC[C@@H]32)cc1
2680,1911030,10.1021/acs.jmedchem.8b01226,,,,Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins,CCOC(=O)N1CCC(=CC#Cc2cccc(F)c2)CC1,Ethyl 4-[3-(3-Fluorophenyl)prop-2-yn-1-ylidene]piperidine-1-carboxylate,4.2,uM,=,0.6232492903979004,1,C(#Cc1ccccc1)C=C1CCNCC1
2681,716717,10.1016/j.bmcl.2010.12.109,,,,Inhibition of CYP3A4,CCCCN1C(=O)C(CC2CCCCC2)NC(=O)C12CCN(Cc1ccc(Oc3ccccc3)cc1)CC2.Cl,"1-butyl-3-cyclohexylmethyl-9-(4-phenoxyphenylmethyl)-1,4,9-triazaspiro[5.5]undeca-2,5-dione hydrochloride",9.3,uM,=,0.9684829485539352,1,O=C1NC2(CCN(Cc3ccc(Oc4ccccc4)cc3)CC2)C(=O)NC1CC1CCCCC1
2682,2221809,10.1016/j.bmcl.2022.128625,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as substrate in presence of NADPH,CCC[C@H]1N(C(=O)c2c(C(F)(F)F)ccc[n+]2[O-])CCC[C@@]1(Oc1csc(C(F)(F)F)c1)C(=O)N1CCN(c2ccccc2OCCO)CC1,"2-((2R,3S)-3-(4-(2-(2-hydroxyethoxy)phenyl)piperazine-1-carbonyl)-2-propyl-3-(5-(trifluoromethyl)thiophen-3-yloxy)piperidine-1-carbonyl)-3-(trifluoromethyl)pyridine-1-oxide",50.0,uM,=,1.6989700043360187,1,O=C(c1cccc[nH+]1)N1CCC[C@@](Oc2ccsc2)(C(=O)N2CCN(c3ccccc3)CC2)C1
2683,991614,10.1021/jm4008906,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(CC(=O)N1CCCC1)C2,"(S)-3-(Aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-6-(2-oxo-2-(pyrrolidin-1-yl)ethyl)-6,7-dihydro-5H-pyrrolo[3,4-b]-pyridin-5-one",23.0,uM,=,1.3617278360175928,1,O=C(CN1Cc2nccc(-c3ccccc3)c2C1=O)N1CCCC1
2684,457745,10.1016/j.bmcl.2007.07.063,,,,Inhibition of CYP3A4,O=C(C1CCN(c2ccncc2)CC1)N1CC[C@@H](CNS(=O)(=O)/C=C/c2ccc(-c3ccc(Cl)s3)s2)C1,(E)-2-(5-(5-chlorothiophen-2-yl)thiophen-2-yl)-N-(((R)-1-(1-(pyridin-4-yl)piperidine-4-carbonyl)pyrrolidin-3-yl)methyl)ethenesulfonamide,2.33,uM,=,0.367355921026019,1,O=C(C1CCN(c2ccncc2)CC1)N1CC[C@@H](CNS(=O)(=O)/C=C/c2ccc(-c3cccs3)s2)C1
2685,2123080,10.1016/j.ejmech.2021.113674,,,,Inhibition of CYP3A4 (unknown origin) using BOMCC as a substrate incubated for 20 mins by fluorescence based analysis,CS(=O)(=O)c1nccc(-c2c(-c3cccc(OCc4ccccc4)c3)nc3sccn23)n1,"6-(3-(Benzyloxy)phenyl)-5-(2-(methylsulfonyl)pyrimidin-4-yl)imidazo[2,1-b]thiazole",17.8,uM,=,1.250420002308894,1,c1ccc(COc2cccc(-c3nc4sccn4c3-c3ccncn3)c2)cc1
2686,1748556,10.1021/acs.jmedchem.7b01892,,,,Inhibition of CYP3A4-mediated midazolam metabolism in human liver microsomes,O=c1c2nccn2c2cc(F)c(-c3ccncc3)cc2n1C1CC1,"5-Cyclopropyl-8-fluoro-7-(pyridin-4-yl)imidazo[1,2-a]-quinoxalin-4(5H)-one",15.0,uM,=,1.1760912590556811,1,O=c1c2nccn2c2ccc(-c3ccncc3)cc2n1C1CC1
2687,2221809,10.1016/j.bmcl.2022.128625,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as substrate in presence of NADPH,CCC[C@H]1N(C(=O)c2c(C(F)(F)F)ccnc2OCC(=O)O)CCC[C@@]1(Oc1csc(C(F)(F)F)c1)C(=O)N1CCN(c2ccccc2OCCO)CC1,"2-(3-((2R,3S)-3-(4-(2-(2-hydroxyethoxy)phenyl)piperazine-1-carbonyl)-2-propyl-3-(5-(trifluoromethyl)thiophen-3-yloxy)piperidine-1-carbonyl)-4-(trifluoromethyl)pyridin-2-yloxy)acetic acid",20.0,uM,=,1.3010299956639813,1,O=C(c1cccnc1)N1CCC[C@@](Oc2ccsc2)(C(=O)N2CCN(c3ccccc3)CC2)C1
2688,631458,10.1021/jm9013136,,,,Inhibition of human recombinant CYP3A4,CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cncn6)(c6ccc(F)cc6F)C5)cc4)CC3)cc2)c1=O,Posaconazole,0.082,uM,=,-1.0861861476162833,0,O=c1[nH]ncn1-c1ccc(N2CCN(c3ccc(OC[C@@H]4CO[C@@](Cn5cncn5)(c5ccccc5)C4)cc3)CC2)cc1
2689,2216964,10.1021/acs.jmedchem.2c00676,,,,Time dependent inhibition of CYP3A4 in human liver microsome using testosterone as substrate preincubated for 30 mins,Cc1nc(C)n(CC(=O)N2CCN(c3sc(C(F)(F)F)nc3-c3nc4ccc(-c5noc(C)n5)cc4[nH]3)C[C@H]2C)n1,"US9266876, 236",79.0,uM,=,1.8976270912904407,1,O=C(Cn1cncn1)N1CCN(c2scnc2-c2nc3ccc(-c4ncon4)cc3[nH]2)CC1
2690,1662668,10.1021/acs.jmedchem.6b01850,,,,Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated with enzyme in presence of NADPH followed by substrate addition,COc1cc(-c2ccc(Cl)c(C)c2)c(F)cc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3cnccn3)ccc21,"US9212182, 691",4.6,uM,=,0.6627578316815741,1,O=c1ccc2cc(S(=O)(=O)Nc3cnccn3)ccc2n1-c1ccc(-c2ccccc2)cc1
2691,1436762,10.1021/ml500187a,,,,Inhibition of human recombinant CYP3A4 incubated for 5 mins by fluorescence assay,Clc1ccc(CN(C2CCCCC2)C2CNC2)cc1,N-(4-chlorobenzyl)-N-cyclohexylazetidin-3-amine,0.81,uM,=,-0.0915149811213502,0,c1ccc(CN(C2CCCCC2)C2CNC2)cc1
2692,2017934,10.1021/acs.jmedchem.0c00834,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis,Cc1c(-c2ccccc2)nc2ccc(Br)cc2c1C(=O)NCC(C(=O)O)c1ccccc1Cl,(+)-3-{[(6-Bromo-3-methyl-2-phenylquinolin-4-yl)carbonyl]amino}-2-(2-chlorophenyl)-propanoic acid,15.0,uM,=,1.1760912590556811,1,O=C(NCCc1ccccc1)c1cc(-c2ccccc2)nc2ccccc12
2693,828928,10.1016/j.bmcl.2012.06.022,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,O=C(N[C@@H](Cc1ccccc1)[C@H](O)CN(CC1CCCCC1)C(=O)c1ccc2nc(N3CCCC3)oc2c1)OCc1cncs1,"Thiazol-5-ylmethyl(2S,3R)-4-(N-(cyclohexylmethyl)-2-(pyrrolidin-1-yl)benzo[d]oxazole-6-carboxamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate",0.026,uM,=,-1.585026652029182,0,O=C(N[C@H](CCN(CC1CCCCC1)C(=O)c1ccc2nc(N3CCCC3)oc2c1)Cc1ccccc1)OCc1cncs1
2694,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCCC(=O)OC)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, F-23",3.46,uM,=,0.5390760987927766,1,O=C1[C@H](Cc2ccccc2)N2C(=O)CNN(C(=O)NCc3ccccc3)[C@H]2CN1Cc1cccc2cc[nH]c12
2695,776115,10.1016/j.bmcl.2011.09.074,,,,Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin,Cc1nc2cn(Cc3ccccc3)cc2c(-c2ccc(Cl)cc2Cl)c1CN,"(6-benzyl-4-(2,4-dichlorophenyl)-2-methyl-6H-pyrrolo[3,4-b]pyridin-3-yl)methanamine",1.1,uM,=,0.041392685158225,1,c1ccc(Cn2cc3nccc(-c4ccccc4)c3c2)cc1
2696,1364175,10.1021/ml500019s,,,,Inhibition of CYP3A4 (unknown origin) pre-incubated with enzyme,COCCOc1ccccc1N1CCN(C(=O)[C@]2(Oc3ccc(C(F)(F)F)cc3)CCCN(C(=O)c3cnccc3C(F)(F)F)C2)CC1.Cl,(S)-(4-(2-(2-methoxyethoxy)phenyl)piperazin-1-yl)(1-(4-(trifluoromethyl)nicotinoyl)-3-(4-(trifluoromethyl)phenoxy)piperidin-3-yl)methanone hydrochloride,0.3,uM,=,-0.5228787452803376,0,O=C(c1cccnc1)N1CCC[C@@](Oc2ccccc2)(C(=O)N2CCN(c3ccccc3)CC2)C1
2697,103774,10.1021/jm031011g,,,,Inhibitory concentration to inhibit MRP1 in CYP 3A4 assay,COc1cccc(CNC(=O)c2c3n(c4c(N5CCN(CCc6ccc(F)c(F)c6)CC5)ncnc24)CCCC3)c1OC,"4-{4-[2-(3,4-Difluoro-phenyl)-ethyl]-piperazin-1-yl}-6,7,8,9-tetrahydro-pyrimido[4,5-b]indolizine-10-carboxylic acid 2,3-dimethoxy-benzylamide",2.44,uM,=,0.3873898263387294,1,O=C(NCc1ccccc1)c1c2n(c3c(N4CCN(CCc5ccccc5)CC4)ncnc13)CCCC2
2698,834169,10.1021/jm2013248,,,,Inhibition of human recombinant CYP3A4 coexpressed in Escherichia coli,c1cc(-c2noc(C3CCCCC3)n2)ccn1,"5-cyclohexyl-3-(pyridin-4-yl)-1,2,4-oxadiazole",10.2,uM,=,1.0086001717619175,1,c1cc(-c2noc(C3CCCCC3)n2)ccn1
2699,673952,10.1016/j.bmcl.2010.08.086,,,,Inhibition of CYP3A4 using midazolam as substrate,CCNC(=O)Cc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1,"(3R,4S)-N-(2-chloro-5-(2-(ethylamino)-2-oxoethyl)benzyl)-N-cyclopropyl-4-(4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)phenyl)piperidine-3-carboxamide",2.1,uM,=,0.3222192947339193,1,O=C([C@H]1CNCC[C@@H]1c1ccc(OCCOc2ccccc2)cc1)N(Cc1ccccc1)C1CC1
2700,1660935,10.1016/j.bmcl.2017.02.047,,,,Inhibition of CYP3A4 in human liver microsomes assessed as enzyme-mediated metabolite formation using testosterone as substrate incubated for 5 mins followed by NADPH addition measured after 30 mins by LC-MS/MS analysis,CCCCCCCC(=O)CCc1ccc(O)c(OC)c1,6-Paradol,30.0,uM,=,1.4771212547196624,1,c1ccccc1
2701,991614,10.1021/jm4008906,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,COCCN1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O,"rac-3-(Aminomethyl)-4-(2,4-dichlorophenyl)-6-(2-methoxyethyl)-2-methyl-6,7-dihydropyrrolo[3,4-b]pyridin-5-one",29.0,uM,=,1.462397997898956,1,O=C1NCc2nccc(-c3ccccc3)c21
2702,51926,10.1021/jm034111v,,,,Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 15 minutes,C[C@H](NC(=O)/C=C/c1ccc(F)cc1)c1ccc(F)c(N2CCOCC2)c1,(E)-N-[1-((S)-4-Fluoro-3-morpholin-4-yl-phenyl)-ethyl]-3-(4-fluoro-phenyl)-acrylamide,21.0,uM,=,1.3222192947339193,1,O=C(/C=C/c1ccccc1)NCc1cccc(N2CCOCC2)c1
2703,1301328,10.6019/CHEMBL3137440,,,,DNDI: CYP Inhibition,FC(F)(F)c1ccc(N(c2cncnc2)C2CCN(c3ccc(C(F)(F)F)nc3)CC2)cc1,,9.0,uM,=,0.9542425094393248,1,c1ccc(N(c2cncnc2)C2CCN(c3cccnc3)CC2)cc1
2704,51930,10.1016/s0960-894x(01)00614-x,,,,Inhibition of recombinant human Cytochrome P450 3A4,CCCCc1ccc(N/C=N/O)cc1,N-(4-butylphenyl)-N'-hydroxyimidoformamide,65.0,uM,=,1.812913356642856,1,c1ccccc1
2705,552281,10.1016/j.bmcl.2008.04.036,,,,Inhibition of CYP3A4,O=C(O)CCCN[C@@H](Cn1c(=O)c(-c2ccccc2Cl)cn(Cc2c(F)cccc2F)c1=O)c1ccccc1,"(R)-4-(2-(3-(2,6-difluorobenzyl)-5-(2-chlorophenyl)-2,6-dioxo-2,3-dihydropyrimidin-1(6H)-yl)-1-phenylethylamino)butanoic acid",20.0,uM,=,1.3010299956639813,1,O=c1c(-c2ccccc2)cn(Cc2ccccc2)c(=O)n1CCc1ccccc1
2706,657985,10.1021/jm100482n,,,,Inhibition of CYP3A4 in human liver microsomes measured after incubation,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(N)=O)ncn4-5)CC3)cccc2n1,"6-(2-(4-(2-methylquinolin-5-yl)piperazin-1-yl)ethyl)-4H-benzo[b]imidazo[1,5-d][1,4]oxazine-3-carboxamide",61.0,uM,=,1.7853298350107671,1,c1cc(CCN2CCN(c3cccc4ncccc34)CC2)c2c(c1)-n1cncc1CO2
2707,1637155,,,,,Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(OCCCN5CCOCC5)nc4)cc23)c1F,"Propane-1-sulfonic acid (2,4-difluoro-3-{5-[6-(3-morpholin-4-yl-propoxy)-pyridin-3-yl]-1H-pyrrolo[2,3-b]pyridine-3-carbonyl}-phenyl)-amide",5.0,uM,=,0.6989700043360189,1,O=C(c1ccccc1)c1c[nH]c2ncc(-c3ccc(OCCCN4CCOCC4)nc3)cc12
2708,1764721,10.1021/acsmedchemlett.8b00220,,,,Inhibition of CYP3A4 (unknown origin) co-incubated with substrate,O=C(Nc1ccc2[nH]nc(-c3ccncc3)c2c1)[C@@H]1CCN(CC(=O)N2CCN(c3ccc(-c4ncccn4)cc3)CC2)C1,(R)-1-(2-oxo-2-(4-(4-(pyrimidin-2-yl)phenyl)piperazin-1-yl)ethyl)-N-(3-(pyridin-4-yl)-1H-indazol-5-yl)pyrrolidine-3-carboxamide,7800.0,uM,=,3.89209460269048,1,O=C(Nc1ccc2[nH]nc(-c3ccncc3)c2c1)[C@@H]1CCN(CC(=O)N2CCN(c3ccc(-c4ncccn4)cc3)CC2)C1
2709,1729070,10.1021/acsmedchemlett.7b00395,,,,Inhibition of CYP3A4 (unknown origin),CNC(=O)Nc1ccc2c(c1)CC[C@@]21OC(=O)N(CC(=O)N(Cc2ccccc2)[C@@H](C)C(F)(F)F)C1=O,"N-(4-fluorobenzyl)-2-((R)-5-(3-methylureido)-2',4'-dioxo-2,3-dihydrospiro[indene-1,5'-oxazolidin]-3'-yl)-N-((S)-1,1,1-trifluoropropan-2-yl)acetamide",24.0,uM,=,1.380211241711606,1,O=C(CN1C(=O)O[C@@]2(CCc3ccccc32)C1=O)NCc1ccccc1
2710,1772291,10.1016/j.bmc.2018.04.054,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis,CC(C)OC(=O)[C@H](Cn1ccnc1)NC(=O)c1noc2c1ccc1ccccc12,"Isopropyl (S)-3-(1H-imidazol-1-yl)-2-(naphtho[2,1-d]isoxazole-3-carboxamido)propanoate",14.6,uM,=,1.1643528557844371,1,O=C(NCCn1ccnc1)c1noc2c1ccc1ccccc12
2711,993439,10.6019/CHEMBL2448688,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,CO/N=C(\C)c1ccc(-n2ccnc2)c(NC(=O)c2ccc(-c3ccccc3)cc2)c1,,3.0,uM,=,0.4771212547196624,1,O=C(Nc1ccccc1-n1ccnc1)c1ccc(-c2ccccc2)cc1
2712,552281,10.1016/j.bmcl.2008.04.036,,,,Inhibition of CYP3A4,COC(=O)CCCN[C@@H](Cn1c(=O)c(-c2cccc(OC)c2F)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1,"(R)-methyl 4-(2-(3-(2-fluoro-6-(trifluoromethyl)benzyl)-5-(2-fluoro-3-methoxyphenyl)-2,6-dioxo-2,3-dihydropyrimidin-1(6H)-yl)-1-phenylethylamino)butanoate",0.51,uM,=,-0.2924298239020636,0,O=c1c(-c2ccccc2)cn(Cc2ccccc2)c(=O)n1CCc1ccccc1
2713,1911030,10.1021/acs.jmedchem.8b01226,,,,Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins,CCOC(=O)N1CC/C(=C/C#Cc2cccc(C)n2)C1,Ethyl (3Z)-3-[3-(6-Methylpyridin-2-yl)prop-2-yn-1-ylidene]-pyrrolidine-1-carboxylate,9.7,uM,=,0.9867717342662448,1,C(#Cc1ccccn1)/C=C1/CCNC1
2714,1474044,10.1021/jm501740a,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,O=C(N[C@H](c1ccccn1)C1CCCC1)c1ccc2[nH]nc(-c3ccc(N4C5CCC4COC5)cc3)c2c1,3-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)phenyl)-N-((S)-cyclopentyl(pyridin-2-yl)methyl)-1H-indazole-5-carboxamide,0.93,uM,=,-0.0315170514460648,0,O=C(N[C@H](c1ccccn1)C1CCCC1)c1ccc2[nH]nc(-c3ccc(N4C5CCC4COC5)cc3)c2c1
2715,619264,10.1016/j.bmcl.2009.07.002,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,Cc1cccc(C)c1CNc1nccc2c1nc(C)n2C,"N-(2,6-dimethylbenzyl)-1,2-dimethyl-1H-imidazo[4,5-c]pyridin-4-amine",12.0,uM,=,1.0791812460476249,1,c1ccc(CNc2nccc3[nH]cnc23)cc1
2716,490925,10.1016/j.bmcl.2008.06.080,,,,Inhibition of CYP3A4,Cc1ccc(Cc2n[nH]c(=O)n2C)c(F)c1Oc1cc(Cl)cc(C#N)c1,"3-chloro-5-(2-fluoro-6-methyl-3-((4-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)methyl)phenoxy)benzonitrile",12.0,uM,=,1.0791812460476249,1,O=c1[nH]nc(Cc2cccc(Oc3ccccc3)c2)[nH]1
2717,455108,10.1016/j.bmcl.2006.12.043,,,,Inhibition of CYP3A4,NC(C(=O)N1CCC(Nc2ccc3[nH]ncc3c2)CC1)c1ccc(Br)cc1,1-(4-(1H-indazol-5-ylamino)piperidin-1-yl)-2-amino-2-(4-bromophenyl)ethanone,0.49,uM,=,-0.3098039199714864,0,O=C(Cc1ccccc1)N1CCC(Nc2ccc3[nH]ncc3c2)CC1
2718,982382,10.1016/j.bmcl.2013.07.071,,,,Inhibition of CYP3A4 (unknown origin),COc1cc(C[C@@H]2C[S@@+]([O-])C[C@H](NCc3cccc(C(C)(C)C)c3)[C@H]2O)cc(F)c1N,"(1R,3S,4S,5R)-3-(4-Amino-3-fluoro-5-methoxy-benzyl)-5-(3-tert-butyl-benzylamino)-1-oxo-tetrahydro-thiopyran-4-ol",0.3,uM,=,-0.5228787452803376,0,c1ccc(CN[C@H]2C[SH+]C[C@@H](Cc3ccccc3)C2)cc1
2719,1301273,10.6019/CHEMBL3137386,,,,DNDI: CYP Inhibition,O=C(C(c1ccc(Cl)cc1)c1cncnc1)N1CCN(c2ccc(C(F)(F)F)cc2)CC1,,20.0,uM,=,1.3010299956639813,1,O=C(C(c1ccccc1)c1cncnc1)N1CCN(c2ccccc2)CC1
2720,774749,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",NNc1ccccc1,Phenylhydrazine,0.9,uM,=,-0.0457574905606751,0,c1ccccc1
2721,973974,10.1021/jm400380m,,,,Inhibition of CYP3A4 (unknown origin) after 10 mins by fluorescence assay,CN(C)Cc1ccc(/C=C/c2n[nH]c3cc(/C=C4/C(=O)Nc5ccccc54)ccc23)cc1,3-((3-((E)-4-((Dimethylamino)methyl)styryl)-1H-indazol-6-yl)-methylene)indolin-2-one,10.0,uM,=,1.0,1,O=C1Nc2ccccc2/C1=C\c1ccc2c(/C=C/c3ccccc3)n[nH]c2c1
2722,1665797,10.1021/acs.jmedchem.7b00328,,,,Inhibition of microsomal CYP3A4 (unknown origin),CNC(=O)c1c(-c2ccc(F)cc2)oc2ccc(-c3cc(C(=O)NC4(c5ccccn5)CC4)ccc3C)cc12,2-(4-Fluorophenyl)-N-methyl-5-(2-methyl-5-(1-(pyridin-2-yl)-cyclopropylcarbamoyl)phenyl)benzofuran-3-carboxamide,4.1,uM,=,0.6127838567197355,1,O=C(NC1(c2ccccn2)CC1)c1cccc(-c2ccc3oc(-c4ccccc4)cc3c2)c1
2723,1675511,10.1016/j.ejmech.2017.03.037,,,,Inhibition of human hepatic CYP3A4,Cc1ccncc1CN1CCc2c(sc3ccc(F)cc23)C1,"6-Fluoro-2-((4-methylpyridin-3-yl)methyl)-1,2,3,4-tetrahydrobenzo[4,5]thieno[2,3-c]pyridine",8.561,uM,=,0.9325244970505424,1,c1cncc(CN2CCc3c(sc4ccccc34)C2)c1
2724,423303,10.1021/jm0602256,,,,Inhibition of human CYP3A4,Cc1ccc2c(C(=O)O)c(O)c(-c3ccc(Cl)cc3)nc2c1C,"2-(4-chlorophenyl)-3-hydroxy-7,8-dimethylquinoline-4-carboxylic acid",7.0,uM,=,0.8450980400142568,1,c1ccc(-c2ccc3ccccc3n2)cc1
2725,495543,10.1021/jm801332q,,,,Inhibition of human CYP3A4 expressed in Escherichia coli using 7BQ substrate by time dependent inhibition assay,C[C@@H]1CN(Cc2ccc(CC(=O)N3CCC(Nc4cccc(F)c4)CC3)cc2)CCN1,N-(3-Fluorophenyl)-1-[(4-([(3R)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine,69.0,uM,=,1.8388490907372552,1,O=C(Cc1ccc(CN2CCNCC2)cc1)N1CCC(Nc2ccccc2)CC1
2726,814102,10.1016/j.bmcl.2012.03.014,,,,Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins,CC(=O)NCCc1ccccc1-c1cc([C@H]2CNCC[C@]2(O)c2ccc(F)c(F)c2)no1,"N-(2-(3-((3R,4R)-4-(3,4-difluorophenyl)-4-hydroxypiperidin-3-yl)isoxazol-5-yl)phenethyl)acetamide",32.0,uM,=,1.505149978319906,1,c1ccc(-c2cc([C@H]3CNCCC3c3ccccc3)no2)cc1
2727,437628,10.1016/j.bmcl.2006.10.036,,,,Inhibition of CYP3A4,CN1CCc2ccc(NS(=O)(=O)c3ccc(-c4ccc(Cl)cc4)cc3)cc2CC1,"4'-chloro-biphenyl-4-sulfonic acid (3-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-amide",58.0,uM,=,1.7634279935629371,1,O=S(=O)(Nc1ccc2c(c1)CCNCC2)c1ccc(-c2ccccc2)cc1
2728,1854052,10.1016/j.ejmech.2019.07.003,,,,Inhibition of recombinant human CYP3A4 using Luciferin-PPXE as substrate preincubated for 10 mins followed by NADPH addition measured after 15 mins by luminometric method,CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cncn6)(c6ccc(F)cc6F)C5)cc4)CC3)cc2)c1=O,Posaconazole,0.6721,uM,=,-0.1725661045992207,0,O=c1[nH]ncn1-c1ccc(N2CCN(c3ccc(OC[C@@H]4CO[C@@](Cn5cncn5)(c5ccccc5)C4)cc3)CC2)cc1
2729,859942,10.1021/jm300122u,,,,Inhibition of human CYP3A4 using testosterone as substrate after 45 mins,CN1CCN(C(=O)[C@H](Cc2ccc(Cl)cc2)NC(=O)C2(c3ccc(Cl)cc3Cl)CC2)CC1,"N-[(1S)-1-[(4-Chlorophenyl)methyl]-2-(4-methylpiperazin-1-yl)-2-oxoethyl]-1-(2,4-dichlorophenyl)-cyclopropanecarboxamide",0.76,uM,=,-0.1191864077192086,0,O=C([C@H](Cc1ccccc1)NC(=O)C1(c2ccccc2)CC1)N1CCNCC1
2730,537516,10.1021/jm8005096,,,,Inhibition of CYP3A4,CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)N=C(c2ccccc2)N1,"4-(4-fluorophenyl)-N-(1H-indazol-5-yl)-6-methyl-2-phenyl-1,4-dihydropyrimidine-5-carboxamide",0.35,uM,=,-0.4559319556497244,0,O=C(Nc1ccc2[nH]ncc2c1)C1=CNC(c2ccccc2)=NC1c1ccccc1
2731,1614025,10.1016/j.bmcl.2016.09.043,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 6-beta-hydroxytestosterone metabolite formation using testosterone as substrate incubated for 30 mins by HPLC-MS method,Cn1c(NCCc2ccc(-c3ncc(Cl)cn3)cc2)nc2cc(Cl)ccc2c1=O,7-Chloro-2-{2-[4-(5-chloro-pyrimidin-2-yl)-phenyl]-ethylamino}-3-methyl-3H-quinazolin-4-one,16.0,uM,=,1.2041199826559248,1,O=c1[nH]c(NCCc2ccc(-c3ncccn3)cc2)nc2ccccc12
2732,770885,10.1016/j.bmcl.2011.06.124,,,,Inhibition of CYP3A4,CS(=O)(=O)NC[C@H]1CC[C@H](Nc2nc3c(s2)CCSc2ccccc2-3)CC1,"Trans-N-[4-(4,5-Dihydro-3,6-dithia-1-aza-benzo[e]azulen-2-ylamino)-cyclohexylmethyl]-methanesulfonamide",4.1,uM,=,0.6127838567197355,1,c1ccc2c(c1)SCCc1sc(NC3CCCCC3)nc1-2
2733,52065,10.1021/jm0310129,,,,Inhibitory activity against cytochrome P450 3A4,COc1ccc2c(c1)[nH]c1c(N3CCN(CCc4ccc(F)c(F)c4)CC3)ncnc12,"4-{4-[2-(3,4-Difluoro-phenyl)-ethyl]-piperazin-1-yl}-7-methoxy-5H-pyrimido[5,4-b]indole",1.53,uM,=,0.1846914308175988,1,c1ccc(CCN2CCN(c3ncnc4c3[nH]c3ccccc34)CC2)cc1
2734,2186328,10.1016/j.bmc.2021.116275,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as substrate,O=C1[C@H](Nc2cc(F)cc(Cl)c2)CCCN1[C@@H]1CCCN(c2ncnc3[nH]ccc23)C1,"(3R,3'R)-3-((3-chloro-5-fluorophenyl)amino)-1'-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-[1,3'-bipiperidin]-2-one",1.3,uM,=,0.1139433523068367,1,O=C1[C@H](Nc2ccccc2)CCCN1[C@@H]1CCCN(c2ncnc3[nH]ccc23)C1
2735,1797910,10.1021/acs.jmedchem.8b01326,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate/NADPH addition measured after 10 mins by LC-MS/MS analysis,COc1cc(C#N)cc(-c2csc([C@]34CN(c5ncc(F)cn5)C[C@H]3C(=O)N(C)C(=N)N4)c2)c1,"3-(5-((4aR,7aR)-6-(5-Fluoropyrimidin-2-yl)-2-imino-3-methyl-4-oxooctahydro-7aH-pyrrolo[3,4-d]pyrimidin-7a-yl)thiophen-3-yl)-5-methoxybenzonitrile",1.6,uM,=,0.2041199826559248,1,N=C1NC(=O)[C@@H]2CN(c3ncccn3)C[C@]2(c2cc(-c3ccccc3)cs2)N1
2736,1474044,10.1021/jm501740a,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,CN(C)CC(=O)N1CCC(Oc2ccc(-c3n[nH]c4ccc(C(=O)NC(c5ccccc5)C5CC5)cc34)cc2)CC1,rac-N-(Cyclopropyl(phenyl)methyl)-3-(4-((1-(2-(dimethylamino)-acetyl)piperidin-4-yl)oxy)phenyl)-1H-indazole-5-carboxamide,1.0,uM,=,0.0,0,O=C(NC(c1ccccc1)C1CC1)c1ccc2[nH]nc(-c3ccc(OC4CCNCC4)cc3)c2c1
2737,632105,10.1016/j.bmcl.2010.03.057,,,,Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin,COCCN1CCN(c2cc(C)c3nc(-c4c(NC[C@@H](O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1,(S)-4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-3-(6-(4-(2-methoxyethyl)piperazin-1-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one,2.9,uM,=,0.4623979978989561,1,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(N3CCNCC3)cc2[nH]1
2738,878389,10.1021/jm301056k,,,,Inhibition of CYP3A4,CS(=O)(=O)c1ccc(F)cc1C(=O)N1CCC(N(C2CC2)S(=O)(=O)c2cccc(C(F)(F)F)c2)CC1,N-Cyclopropyl-N-(1-{[5-fluoro-2-(methylsulfonyl)phenyl]-carbonyl}piperidin-4-yl)-3-(trifluoromethyl)-benzenesulfonamide,5.1,uM,=,0.7075701760979364,1,O=C(c1ccccc1)N1CCC(N(C2CC2)S(=O)(=O)c2ccccc2)CC1
2739,1352209,10.1021/jm4010835,,,,Inhibition of human recombinant CYP3A4,CCn1nc2c(-c3ccc(Cl)cc3)c(-c3ccncc3F)c(=O)n(Cc3ccc(C(F)(F)F)nc3C)n2c1=O,"8-(4-chlorophenyl)-2-ethyl-7-(3-fluoropyridin-4-yl)-5-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)methyl)-[1,2,4]triazolo[4,3-b]pyridazine-3,6(2H,5H)-dione",7.0,uM,=,0.8450980400142568,1,O=c1c(-c2ccncc2)c(-c2ccccc2)c2n[nH]c(=O)n2n1Cc1cccnc1
2740,449088,10.1016/j.bmcl.2007.08.028,,,,Inhibition of human CYP3A4,CC(=O)N1CCC(C(=O)N2C[C@@H](c3nc(C(C)(C)c4cc(C(F)(F)F)cc(C(F)(F)F)c4)no3)[C@H](c3ccc(F)cc3C)C2)CC1,"1-(4-((3S,4R)-3-(3-(2-(3,5-bis(trifluoromethyl)phenyl)propan-2-yl)-1,2,4-oxadiazol-5-yl)-4-(4-fluoro-2-methylphenyl)pyrrolidine-1-carbonyl)piperidin-1-yl)ethanone",28.0,uM,=,1.4471580313422192,1,O=C(C1CCNCC1)N1C[C@@H](c2ccccc2)[C@H](c2nc(Cc3ccccc3)no2)C1
2741,1754743,10.1021/acs.jmedchem.7b01714,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 5 mins by LC-MS/MS analysis,CN1CCN(C(=O)c2ccc(-c3ccc4ncc(-c5ccc(C#N)cc5)n4c3)cc2)CC1,"4-(6-(4-(4-Methylpiperazine-1-carbonyl)phenyl)imidazo[1,2-a]-pyridin-3-yl)benzonitrile",3.9,uM,=,0.5910646070264992,1,O=C(c1ccc(-c2ccc3ncc(-c4ccccc4)n3c2)cc1)N1CCNCC1
2742,1460909,10.1021/jm501326k,,,,Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase/human b5 reductase using 7-benzyloxyquinoline substrate,CCOC(=O)c1[nH]cc2c1NC1=C(C(=O)CCC1)C2c1ccc(Sc2nc3ccccc3[nH]2)o1,"(+/-)-9-[5-(1H-Benzimidazol-2-ylsulfanyl)-furan-2-yl]-8-oxo-4,5,6,7,8,9-hexahydro-2H-pyrrolo[3,4-b]quinoline-3-carboxylic acid ethyl ester",0.19,uM,=,-0.721246399047171,0,O=C1CCCC2=C1C(c1ccc(Sc3nc4ccccc4[nH]3)o1)c1c[nH]cc1N2
2743,1301274,10.6019/CHEMBL3137386,,,,DNDI: CYP Inhibition,O=C(C(c1ccc(Cl)cc1)c1cccnc1)N1CCN(c2ccc(C(F)(F)F)nc2)CC1,2-(4-Chlorophenyl)-2-(pyridin-3-yl)-1-[4-[6-(trifluoromethyl)pyridin-3-yl]piperazin-1-yl]ethanone,20.0,uM,=,1.3010299956639813,1,O=C(C(c1ccccc1)c1cccnc1)N1CCN(c2cccnc2)CC1
2744,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCCN(C)CC6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, G-67",11.24,uM,=,1.0507663112330423,1,O=C(Nc1ccc(N2CCCNCC2)nc1)c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12
2745,44705,10.1016/s0960-894x(02)00473-0,,,,Inhibition of cytochrome P450 3A4,CCN(CC)CCCN(Cc1ccc(-c2ccc(Cl)cc2)cc1)C(=O)Cn1cc(Cc2cnn(C)c2)c(=O)nc1SCc1ccc(F)cc1,N-(4'-Chloro-biphenyl-4-ylmethyl)-N-(3-diethylamino-propyl)-2-[2-(4-fluoro-benzylsulfanyl)-5-(1-methyl-1H-pyrazol-4-ylmethyl)-4-oxo-4H-pyrimidin-1-yl]-acetamide,2.0,uM,=,0.3010299956639812,1,O=C(Cn1cc(Cc2cn[nH]c2)c(=O)nc1SCc1ccccc1)NCc1ccc(-c2ccccc2)cc1
2746,766553,10.1016/j.bmcl.2011.06.102,,,,Inhibition of CYP3A4,c1cc([C@H]2CC[C@H](N3CCCC3)CC2)ccc1OCCCN1CCCCC1,trans-1-(3-(4-(-4-(pyrrolidin-1-yl)cyclohexyl)phenoxy)propyl)piperidine,48.0,uM,=,1.6812412373755872,1,c1cc([C@H]2CC[C@H](N3CCCC3)CC2)ccc1OCCCN1CCCCC1
2747,493017,10.1021/jm800851u,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,CC(=O)Nc1cc(-c2cccc(N(C)C)n2)nc(-n2nc(C)cc2C)n1,"N-[6-(6-Dimethylamino-pyridin-2-yl)-2-(3,5-dimethyl-pyrazol-1-yl)-pyrimidin-4-yl]-acetamide",25.0,uM,=,1.3979400086720375,1,c1ccc(-c2ccnc(-n3cccn3)n2)nc1
2748,649576,10.1021/jm100317b,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsome,Oc1ccc(-c2ccc(Cc3ccncc3)cc2)cc1O,"4'-(pyridin-4-ylmethyl)biphenyl-3,4-diol",7.58,uM,=,0.8796692056320535,1,c1ccc(-c2ccc(Cc3ccncc3)cc2)cc1
2749,828928,10.1016/j.bmcl.2012.06.022,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N(C)CCN(C)C)oc2c1,"thiazol-5-ylmethyl(2S,3R)-4-(2-((2-(dimethylamino)ethyl)(methyl)amino)-N-isobutylbenzo[d]oxazole-6-carboxamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate",0.18,uM,=,-0.744727494896694,0,O=C(N[C@H](CCNC(=O)c1ccc2ncoc2c1)Cc1ccccc1)OCc1cncs1
2750,1527876,,,,,Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,COC[C@]1(c2ccccc2)CCN([C@@H](C)c2ccc(-c3ccn(C)c(=O)c3)cc2)C(=O)O1,"US8575157, 78",47.0,uM,=,1.6720978579357175,1,O=C1OC(c2ccccc2)CCN1Cc1ccc(-c2cc[nH]c(=O)c2)cc1
2751,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCN(C7CCCC7)CC6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, G-50",17.24,uM,=,1.236537261488694,1,O=C(Nc1ccc(N2CCN(C3CCCC3)CC2)nc1)c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12
2752,1689562,10.1021/acs.jmedchem.7b00598,,,,Inhibition of CYP3A4 (unknown origin),CN1CC(n2nccc2-c2cc(Cl)ccc2Oc2cc(F)c(S(=O)(=O)Nc3ncns3)cc2F)C1,"4-(4-chloro-2-(1-(1-methylazetidin-3-yl)-1H-pyrazol-5-yl)phenoxy)-2,5-difluoro-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide",0.427,uM,=,-0.3695721249749761,0,O=S(=O)(Nc1ncns1)c1ccc(Oc2ccccc2-c2ccnn2C2CNC2)cc1
2753,1625607,10.1016/j.bmcl.2016.10.016,,,,Inhibition of human Cyp3A4 using testosterone as substrate by LC-MS/MS analysis,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,"1-(4-{4-[2-(2,4-Dichloro-phenyl)-2-imidazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-ethanone (ketoconazole)",0.146,uM,=,-0.835647144215563,0,c1ccc(C2(Cn3ccnc3)OCC(COc3ccc(N4CCNCC4)cc3)O2)cc1
2754,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1ccc(C(=O)N2CCOC[C@H]2Cc2cc(-n3nccn3)ccc2C)c(-n2nccn2)c1,"US9150566, 123",27.0,uM,=,1.4313637641589874,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
2755,449485,10.1016/j.bmcl.2007.07.097,,,,Inhibition of microsomal CYP3A4,CC(C)C[C@H](NCCCC(=O)O)c1cc(C(F)(F)F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1,"4-((S)-1-(2-(4-((R)-3-(2,4-dichlorophenyl)-2-(2-oxopyrrolidin-1-yl)propanoyl)piperazin-1-yl)-5-(trifluoromethyl)phenyl)-3-methylbutylamino)butanoic acid",25.0,uM,=,1.3979400086720375,1,O=C([C@@H](Cc1ccccc1)N1CCCC1=O)N1CCN(c2ccccc2)CC1
2756,990449,10.1016/j.bmcl.2013.09.001,,,,Inhibition of CYP3A4 in human liver microsomes in presence of NADPH,O=C(Nc1ccc(F)cn1)c1cc(Cl)cc(Oc2cncc(F)c2)c1,3-chloro-N-(5-fluoropyridin-2-yl)-5-(5-fluoropyridin-3-yloxy)benzamide,1.3,uM,=,0.1139433523068367,1,O=C(Nc1ccccn1)c1cccc(Oc2cccnc2)c1
2757,804823,10.1016/j.bmcl.2011.12.080,,,,Time dependent inhibition of CYP3A4,COc1cc(C)c2nc3[nH]nc(C)c3c(C(O)c3ncco3)c2c1,"rac-(6-methoxy-3,8-dimethyl-1H-pyrazolo[3,4-b]quinolin-4-yl)(oxazol-2-yl)methanol",7.8,uM,=,0.8920946026904804,1,c1ccc2c(Cc3ncco3)c3cn[nH]c3nc2c1
2758,1843044,10.1021/acs.jmedchem.9b01034,,,,Inhibition of CYP3A4 (unknown origin),C#CCOc1cnc(C(=O)Nc2cc(F)c(F)c([C@@]3(C)N=C(N)S[C@@]4(COC)C[C@H]43)c2)cn1,"N-(3-((1S,5S,6S)-3-Amino-1-(methoxymethyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-en-5-yl)-4,5-difluorophenyl)-5-(prop-2-yn-1-yloxy)pyrazine-2-carboxamide",27.0,uM,=,1.4313637641589874,1,O=C(Nc1cccc(C2N=CSC3C[C@H]32)c1)c1cnccn1
2759,2024795,10.1021/acs.jmedchem.0c01741,,,,Inhibition of CYP3A4 in in human liver microsomes at incubated for 10 mins in presence of CYP3A4 substrate/NADP+ by fluorescence based assay,CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,SID144204227,0.011,uM,=,-1.9586073148417749,0,c1ccc([C@@]2(Cn3ccnc3)OC[C@H](COc3ccc(N4CCNCC4)cc3)O2)cc1
2760,993439,10.6019/CHEMBL2448688,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,N#Cc1ccc(-n2ccnc2)c(NC(=O)c2cnc(-c3ccccc3)s2)c1,,4.5,uM,=,0.6532125137753437,1,O=C(Nc1ccccc1-n1ccnc1)c1cnc(-c2ccccc2)s1
2761,2264099,10.1021/acs.jmedchem.1c00703,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 2 mins in presence of NADPH regenerating system by LC-MS/MS analysis,COCCCN1CC2C(CNC(=O)c3nn(C(C)C)c4ccccc34)C2C1,1-Isopropyl-1H-indazole-3-carboxylic Acid[3-(3-Methoxy-propyl)-3-aza-bicyclo[3.1.0]hex-6-ylmethyl]-amide Oxalate,36.4,uM,=,1.561101383649056,1,O=C(NCC1C2CNCC21)c1n[nH]c2ccccc12
2762,453158,10.1016/j.bmcl.2006.09.056,,,,Inhibition of CYP3A4 in presence of BFC substrate,CSc1ccccc1CNc1ncc([N+](=O)[O-])c(NCC2CCC(CN)CC2)n1,"N2-(2-(methylthio)benzyl)-N4-((4-(aminomethyl)cyclohexyl)methyl)-5-nitropyrimidine-2,4-diamine",6.9,uM,=,0.8388490907372553,1,c1ccc(CNc2nccc(NCC3CCCCC3)n2)cc1
2763,1301328,10.6019/CHEMBL3137440,,,,DNDI: CYP Inhibition,Cc1ccccc1CN1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1,N-4-Trifluoromethylphenyl-N-[1-(2-methylbenzyl)piperidin-4-yl]pyridin-3-amine,18.0,uM,=,1.255272505103306,1,c1ccc(CN2CCC(N(c3ccccc3)c3cccnc3)CC2)cc1
2764,1290451,10.1016/j.bmcl.2014.01.026,,,,Inhibition of CYP3A4 (unknown origin) compound preincubated with substrate,COCCOc1ccccc1N1CCN(C(=O)C2(Oc3ccc(C(F)(F)F)cc3)CCCN(C(=O)c3cnccc3C(F)(F)F)C2)CC1.Cl,(4-(2-(2-methoxyethoxy)phenyl)piperazin-1-yl)(1-(4-(trifluoromethyl)nicotinoyl)-3-(4-(trifluoromethyl)phenoxy)piperidin-3-yl)methanone hydrochloride,0.3,uM,=,-0.5228787452803376,0,O=C(c1cccnc1)N1CCCC(Oc2ccccc2)(C(=O)N2CCN(c3ccccc3)CC2)C1
2765,1889156,10.1021/acs.jmedchem.8b01719,,,,Inhibition of CYP3A4 in human liver microsomes using atorvastatin as substrate preincubated for 7 mins followed by NADPH addition and measured by LC-MS/MS analysis,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(Cc3ccc(B(O)O)c(F)c3)S(C)(=O)=O)c(C3CC3)cc12,4-((N-(5-cyclopropyl-2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-6-yl)methylsulfonamido)methyl)-2-fluorophenylboronic acid,7.1,uM,=,0.8512583487190752,1,c1ccc(CNc2cc3oc(-c4ccccc4)cc3cc2C2CC2)cc1
2766,1869499,10.1021/acs.jmedchem.8b01729,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 10 mins in presence of NADP by LC-MS/MS analysis,Cc1cc(/C=C/C#N)cc(C)c1Oc1ccnc(Nc2ccc(CN3CCN(S(C)(=O)=O)CC3)cc2)n1,"(E)-3-(3,5-dimethyl-4-(2-(4-((4-(methylsulfonyl)piperazin-1-yl)methyl)phenylamino)pyrimidin-4-yloxy)phenyl)acrylonitrile",7.82,uM,=,0.893206753059848,1,c1ccc(Oc2ccnc(Nc3ccc(CN4CCNCC4)cc3)n2)cc1
2767,1625990,10.1016/j.bmcl.2016.04.095,,,,Inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins after 30 secs by LC/MS/MS analysis,CN(C)CCS(=O)(=O)CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12,"2-(2-((4S,4aS,10bS)-10b-(4-chlorophenylsulfonyl)-7,10-difluoro-1,2,4,4a,5,10b-hexahydropyrano[3,4-c]chromen-4-yl)ethylsulfonyl)-N,N-dimethylethanamine",9.0,uM,=,0.9542425094393248,1,O=S(=O)(c1ccccc1)[C@@]12CCOC[C@@H]1COc1ccccc12
2768,495153,10.1021/jm8006454,,,,Inhibition of CYP3A4,COc1cccc(-c2c(C)n(Cc3c(F)cccc3F)c(=O)n(C[C@H](N)c3ccccc3)c2=O)c1F,"3-((R)-2-Amino-2-phenyl-ethyl)-1-(2,6-difluoro-benzyl)-5-(2-fluoro-3-methoxy-phenyl)-6-methyl-1H-pyrimidine-2,4-dione",0.7,uM,=,-0.1549019599857432,0,O=c1c(-c2ccccc2)cn(Cc2ccccc2)c(=O)n1CCc1ccccc1
2769,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cc(-n3nccn3)ccc2Cl)c1,"US9150566, 125",22.0,uM,=,1.3424226808222062,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
2770,1301328,10.6019/CHEMBL3137440,,,,DNDI: CYP Inhibition,CC(C)(F)CN1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1,,16.0,uM,=,1.2041199826559248,1,c1ccc(N(c2cccnc2)C2CCNCC2)cc1
2771,1465542,10.1016/j.bmcl.2015.01.051,,,,Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(C6CN(CC(C)(C)O)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O,"(1S,4R,5R,6R,8R,10S,11R,12S,13R,16R,18S,21R)-8-[(1S)-1-ethoxy-2-hydroxy-2-methylpropyl]-18-{[(2S)-4-[1-(2-hydroxy-2-methylpropyl)azetidin-3-yl]morpholin-2-yl]oxy}-4,6,12,17,17-pentamethyl-9-oxahexacyclo[11.9.0.0^{1,21}.0^{4,12}.0^{5,10}.0^{16,21}]docosan-11-ol",2.7,uM,=,0.4313637641589873,1,C1CO[C@@H]2CC3C(CC[C@@]45C[C@@]46CC[C@H](O[C@H]4CN(C7CNC7)CCO4)C[C@@H]6CC[C@@H]35)[C@H]2C1
2772,2014369,10.1021/acsmedchemlett.9b00123,,,,Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells using midazolam as substrate incubated for 30 mins in presence of NADPH-regenerating system by fluorescence based assay,CN(C)c1ccc(CC(=O)N[C@@H]2CNC[C@H]2c2ccc(S(F)(F)(F)(F)F)cc2)cc1,"(-)-2-[4-(dimethylamino)phenyl]-N-[(3S,4R)-4-[4-(pentafluoro-lambda6-sulfanyl)phenyl]pyrrolidin-3-yl]acetamide",0.159,uM,=,-0.7986028756795485,0,O=C(Cc1ccccc1)N[C@@H]1CNC[C@H]1c1ccccc1
2773,2024613,10.1016/j.bmcl.2020.127721,,,,Inhibition of CYP3A4 (unknown origin),CS(=O)(=O)Nc1cccc(CC(=O)Nc2cc(-c3c[nH]c4ncccc34)ncn2)c1,"2-[3-(methanesulfonamido)phenyl]-N-[6-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl]acetamide",100.0,uM,=,2.0,1,O=C(Cc1ccccc1)Nc1cc(-c2c[nH]c3ncccc23)ncn1
2774,774749,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",NNCCc1ccccc1,Phenethyl-hydrazine,2.0,uM,=,0.3010299956639812,1,c1ccccc1
2775,1301273,10.6019/CHEMBL3137386,,,,DNDI: CYP Inhibition,O=C(C(c1ccc(Cl)cc1)c1cncnc1)N1CCN(c2ccc(C(F)(F)F)cn2)CC1,,18.0,uM,=,1.255272505103306,1,O=C(C(c1ccccc1)c1cncnc1)N1CCN(c2ccccn2)CC1
2776,322414,10.1021/jm0502541,,,,Interaction with human cytochrome P450 isoform 3A4 expressed in baculovirus-insect cells,O=C(O)C1(c2ccc(-c3ccc(-c4ccc(F)cc4)c(F)c3)c(F)c2)CC1,"1-(4,2',2''-Trifluoro-[1,1';4',1'']terphenyl-4''-yl)-cyclopropanecarboxylic acid",38.0,uM,=,1.57978359661681,1,c1ccc(-c2ccc(-c3ccc(C4CC4)cc3)cc2)cc1
2777,2296518,10.1021/acs.jmedchem.5b01461,,,,Inhibition of CYP3A4 (unknown origin),Cn1ccc(CN(C(=O)Cn2nnc3ccccc32)c2ccc(NC(=O)C3CC3)cc2)c1,"N-(4-(2-(1H-benzo[d][1,2,3]triazol-1-yl)-N-((1-methyl-1H-pyrrol-3-yl)methyl)acetamido)phenyl)cyclopropanecarboxamide",4.6,uM,=,0.6627578316815741,1,O=C(Nc1ccc(N(Cc2cc[nH]c2)C(=O)Cn2nnc3ccccc32)cc1)C1CC1
2778,959421,10.1021/jm4000038,,,,Inhibition of CYP3A4 (unknown origin),CC1(C)OC(=O)N([C@H]2CC[C@H](n3c(=O)[nH]c4c(F)c(C#N)ccc43)CC2)[C@H]1c1ccccc1,"trans-1-(4-((S)-5,5-Dimethyl-2-oxo-4-phenyloxazolidin-3-yl)cyclohexyl)-4-fluoro-2-oxo-2,3-dihydro-1Hbenzo[d]imidazole-5-carbonitrile",5.4,uM,=,0.7323937598229685,1,O=C1OC[C@H](c2ccccc2)N1[C@H]1CC[C@H](n2c(=O)[nH]c3ccccc32)CC1
2779,52090,10.1016/j.bmcl.2003.11.049,,,,Inhibition of CYP450 (Cytochrome P450) 3A4 with fluorogenic substrate BFC,CCN1c2ncc(CSc3cc(C)nc(C)c3)cc2C(=O)Nc2c(C)ccnc21,"2-(2,6-Dimethyl-pyridin-4-ylsulfanylmethyl)-5-ethyl-9-methyl-5,10-dihydro-4,5,6,10-tetraaza-dibenzo[a,d]cyclohepten-11-one",1.6,uM,=,0.2041199826559248,1,O=C1Nc2cccnc2Nc2ncc(CSc3ccncc3)cc21
2780,742805,10.1016/j.bmc.2011.02.009,,,,Inhibition of human CYP3A4 after 30 mins,CC(=O)Nc1cccc(-c2ccc([C@@](O)(c3c[nH]cn3)C(C)C)cc2)c1,(R)-N-(4'-(1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl)biphenyl-3-yl)acetamide,6.7,uM,=,0.8260748027008264,1,c1ccc(-c2ccc(Cc3c[nH]cn3)cc2)cc1
2781,2160653,10.1021/acs.jmedchem.1c01875,,,,Time dependent inhibition of recombinant human CYP3A4 incubated for 30 mins in presence of NADPH generating system by LC-MS/MS analysis,C[C@]12CCC(=O)C[C@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](c3ccc(=O)oc3)CC[C@]12O,"5-(14-Hydroxy-10,13-dimethyl-3-oxo-hexadecahydro-cyclopenta[a]phenanthren-17-yl)-pyran-2-one",1.56,uM,=,0.1931245983544616,1,O=C1CCC2[C@H](CC[C@H]3C4CC[C@H](c5ccc(=O)oc5)C4CC[C@H]23)C1
2782,1868061,10.1039/C8MD00313K,,,,Inhibition of CYP3A4 (unknown origin) using beetle D-luciferin as substrate by CYP450-Glo assay,CCn1cncc1-c1c[nH]c2ccc(C(N)=O)cc12,3-(1-ethyl-1H-imidazol-5-yl)-1H-indole-5-carboxamide,0.31,uM,=,-0.5086383061657274,0,c1ccc2c(-c3cnc[nH]3)c[nH]c2c1
2783,1697117,10.1021/acs.jmedchem.7b00932,,,,Inhibition of CYP3A4 (unknown origin),CN1[C@@H]2CC[C@H]1c1c(sc(NC(=O)Nc3ccc(Cl)cc3)c1C(N)=O)C2.Cl,"(+)-2-[3-(4-Chlorophenyl)ureido]-9-methyl-5,6,7,8-tetrahydro-4H-5,8-epiminocyclohepta[b]thiophene-3-carboxamide Hydrochloride",46.0,uM,=,1.662757831681574,1,O=C(Nc1ccccc1)Nc1cc2c(s1)C[C@H]1CC[C@@H]2N1
2784,512798,10.1021/jm800832q,,,,Inhibition of human recombinant CYP3A4 in human liver microsomes using BFC as a substrate,COCCN1CCC(c2cc(C)c3nc(-c4c(NC[C@@H](O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1,(S)-4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-3-(6-(1-(2-methoxyethyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridine-2(1H)-one,11.0,uM,=,1.0413926851582251,1,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(C3CCNCC3)cc2[nH]1
2785,510198,10.1021/jm800355c,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,OC1(c2ccncc2)CCc2cc(-c3ccc(F)cc3)ccc21,"5-(4-Fluorophenyl)-1-(pyridin-4-yl)-2,3-dihydro-1H-inden-1-ol",3.231,uM,=,0.509336958017644,1,c1ccc(-c2ccc3c(c2)CCC3c2ccncc2)cc1
2786,450508,10.1021/jm070806a,,,,Inhibition of CYP3A4,CNCCC(=O)N[C@H](c1cc(C)ccc1N1CCN(C(=O)[C@H](C)Cc2ccc(Cl)cc2)CC1)C(C)C,1-{2-[(1S)-(methylaminopropionyl)amino-2-methylpropyl]-4-methylphenyl}-4-[(2R)-methyl-3-(4-chlorophenyl)propionyl]piperazine,6.0,uM,=,0.7781512503836436,1,O=C(CCc1ccccc1)N1CCN(c2ccccc2)CC1
2787,1919651,,,,,"Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase",O=Cc1ccc(-c2cccnc2)o1,5-Pyridin-3-yl-furan-2-carbaldehyde,2.2,uM,=,0.3424226808222063,1,c1cncc(-c2ccco2)c1
2788,1695601,10.1016/j.bmc.2017.08.012,,,,Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using 7-Benzoyloxy-4-trifluoromethyl coumarin substrate in presence of NADP+ by fluorescence based assay,CC(C)(C)[C@H]1OCCC[C@@H]1CNc1cc(F)c(S(=O)(=O)Nc2nccs2)cc1Cl,"4-((((2SR,3RS)-2-(tert-Butyl)tetrahydro-2H-pyran-3-yl)methyl)amino)-5-chloro-2-fluoro-N-(thiazol-2-yl)benzenesulfonamide",4.9,uM,=,0.6901960800285137,1,O=S(=O)(Nc1nccs1)c1ccc(NC[C@H]2CCCOC2)cc1
2789,443559,10.1016/j.bmc.2007.03.014,,,,Inhibition of human CYP3A4 expressed in insect microsome using 7-benzyloxy-4-trifluoromethylcoumarin substrate after 30 mins,COc1ccc(CN2CCN(c3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)CC2)cc1OC,"N-(2-(4-(4-(3,4-dimethoxybenzyl)piperazin-1-yl)phenylcarbamoyl)-4,5-dimethoxyphenyl)quinoline-3-carboxamide",0.195,uM,=,-0.7099653886374819,0,O=C(Nc1ccccc1C(=O)Nc1ccc(N2CCN(Cc3ccccc3)CC2)cc1)c1cnc2ccccc2c1
2790,510165,10.1021/jm800377h,,,,Inhibition of human recombinant CYP3A4 expressed in insect microsomes,COc1cncc(-c2ccc3cc(OC)ccc3c2)c1,3-methoxy-5-(6-methoxynaphthalen-2-yl)pyridine,1.913,uM,=,0.2817149700272958,1,c1cncc(-c2ccc3ccccc3c2)c1
2791,2023287,10.1016/j.bmcl.2020.127636,,,,Inhibition of CYP3A4 (unknown origin),COc1ccccc1C1c2c(n[nH]c2C(C)(C)C)C(=O)N1c1ccc(-c2ccsc2)cc1,"US8575197, II-204",10.0,uM,=,1.0,1,O=C1c2n[nH]cc2C(c2ccccc2)N1c1ccc(-c2ccsc2)cc1
2792,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CC6CCN(C)C6C5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, E-68",2.45,uM,=,0.3891660843645325,1,O=C(c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12)N1CC2CCNC2C1
2793,481543,10.1021/np0400104,,,,Inhibition of human CYP3A4,O=C(/C=C\c1ccc(O)cc1)OC[C@H]1O[C@@H](Oc2c(-c3ccc(O)cc3)oc3cc(O)cc(O)c3c2=O)[C@H](O)[C@@H](O)[C@@H]1O,kaempferol-3-beta-D-(6-O-cis-p-coumaroyl)glucopyranoside,0.7,uM,=,-0.1549019599857432,0,O=C(/C=C\c1ccccc1)OC[C@@H]1CCC[C@H](Oc2c(-c3ccccc3)oc3ccccc3c2=O)O1
2794,1614025,10.1016/j.bmcl.2016.09.043,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 6-beta-hydroxytestosterone metabolite formation using testosterone as substrate incubated for 30 mins by HPLC-MS method,Cn1c(NCCc2ccc(-c3ccc(F)cc3)cc2)nc2cc(Cl)ccc2c1=O,7-Chloro-2-[2-(4'-fluoro-biphenyl-4-yl)-ethylamino]-3-methyl-3H-quinazolin-4-one,18.0,uM,=,1.255272505103306,1,O=c1[nH]c(NCCc2ccc(-c3ccccc3)cc2)nc2ccccc12
2795,1910981,10.1021/acs.jmedchem.8b01464,,,,Inhibition of human CYP3A4 in presence of NADPH by luciferase reporter gene assay,Clc1ccc(-c2c[nH]cc2C(c2ccc(Cl)cc2Cl)n2ccnc2)cc1,"1-[[4-(4-Chloro-phenyl)-1H-pyrrol-3-yl]-(2,4-dichloro-phenyl)-methyl]-1H-imidazole",0.8,uM,=,-0.0969100130080563,0,c1ccc(-c2c[nH]cc2C(c2ccccc2)n2ccnc2)cc1
2796,1984166,10.1016/j.bmc.2020.115349,,,,Inhibition of human full length CYP3A4 assessed using 7-benzyloxy-4 (trifluoromethyl)coumarin as substrate preincubated for 2 mins followed by substrate addition and measured for 2 mins by fluorometric analysis,CC(C)(C)OC(=O)N[C@H](CS[C@H](Cc1ccccc1)C(=O)NCCc1cccnc1)Cc1c[nH]c2ccccc12,tert-butyl N-[(1S)-1-[[(1R)-1-benzyl-2-oxo-2-[2-(3-pyridyl)ethylamino]ethyl]sulfanylmethyl]-2-(1H-indol-3-yl)ethyl]carbamate,0.102,uM,=,-0.9913998282380824,0,O=C(NCCc1cccnc1)[C@@H](Cc1ccccc1)SCCCc1c[nH]c2ccccc12
2797,512798,10.1021/jm800832q,,,,Inhibition of human recombinant CYP3A4 in human liver microsomes using BFC as a substrate,COCCN1CCC(c2cc(C)c3nc(-c4c(NC[C@@H](O)c5ccc(OC)c(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1,(S)-4-(2-(3-chloro-4-methoxyphenyl)-2-hydroxyethylamino)-3-(6-(1-(2-methoxyethyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridine-2(1H)-one,7.7,uM,=,0.8864907251724818,1,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(C3CCNCC3)cc2[nH]1
2798,1660136,10.1021/acs.jmedchem.6b01918,,,,Inhibition of human CYP3A4 assessed as inhibition of dealkylation,O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCCC2CCNCC2)cc1F,5-Chloro-2-fluoro-4-((2-(piperidin-4-yl)ethyl)amino)-N-(thiazol-2-yl)benzenesulfonamide,20.0,uM,=,1.3010299956639813,1,O=S(=O)(Nc1nccs1)c1ccc(NCCC2CCNCC2)cc1
2799,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)N6CCOCC6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, D-88",10.2,uM,=,1.0086001717619175,1,O=C(Nc1ccc(-c2c[nH]c3c(CN4C[C@@H]5N(C(=O)NCc6ccccc6)NCC(=O)N5[C@@H](Cc5ccccc5)C4=O)cccc23)cn1)N1CCOCC1
2800,2127944,10.1016/j.ejmech.2020.112373,,,,Direct inhibition of CYP3A4 in human hepatocytes,CCOC(=O)[C@@H](Cc1cn(C)c2ccccc12)NC(=O)[C@@H](N)CC(C)C.Cl,Ethyl Nalpha-(L-leucyl)-1-methyl-D-tryptophanate hydrochloride,5.0,uM,=,0.6989700043360189,1,c1ccc2[nH]ccc2c1
2801,643713,10.1016/j.bmcl.2010.06.009,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader,C[C@@H](Oc1cc(-n2cnc3cc(-c4cnn(C)c4)ccc32)sc1C(N)=O)c1ccccc1Cl,(R)-3-(1-(2-chlorophenyl)ethoxy)-5-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)thiophene-2-carboxamide,0.2,uM,=,-0.6989700043360187,0,c1ccc(COc2csc(-n3cnc4cc(-c5cn[nH]c5)ccc43)c2)cc1
2802,51926,10.1021/jm034111v,,,,Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 15 minutes,C[C@H](NC(=O)/C=C/c1ccccc1)c1cccc(N2CCOCC2)c1,(E)-N-[1-((S)-3-Morpholin-4-yl-phenyl)-ethyl]-3-phenyl-acrylamide,62.0,uM,=,1.792391689498254,1,O=C(/C=C/c1ccccc1)NCc1cccc(N2CCOCC2)c1
2803,2023287,10.1016/j.bmcl.2020.127636,,,,Inhibition of CYP3A4 (unknown origin),COc1ccccc1C1c2c(C(C)(C)C)n[nH]c2C(=O)N1c1ccc(-c2nccs2)cc1,"3-tert-butyl-4-(2-methoxyphenyl)-5-(4-(thiazol-2-yl)phenyl)-4,5-dihydropyrrolo[3,4-c]pyrazol-6(1H)-one",13.0,uM,=,1.1139433523068367,1,O=C1c2[nH]ncc2C(c2ccccc2)N1c1ccc(-c2nccs2)cc1
2804,4333,10.1021/jm00093a015,,,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,"1-(4-{4-[2-(2,4-Dichloro-phenyl)-2-imidazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-ethanone",0.897,uM,=,-0.0472075569559079,0,c1ccc([C@@]2(Cn3ccnc3)OC[C@@H](COc3ccc(N4CCNCC4)cc3)O2)cc1
2805,1295469,10.1016/j.bmcl.2014.02.004,,,,Inhibition of human recombinant CYP3A4,NC(=O)c1sc(N2CCOCC2)nc1CC(=O)N1CCc2c(Cl)cccc21,4-(2-(4-chloroindolin-1-yl)-2-oxoethyl)-2-morpholinothiazole-5-carboxamide,40.0,uM,=,1.6020599913279625,1,O=C(Cc1csc(N2CCOCC2)n1)N1CCc2ccccc21
2806,449485,10.1016/j.bmcl.2007.07.097,,,,Inhibition of microsomal CYP3A4,CC(C)C[C@H](NCCN)c1cc(F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1,"1-((R)-1-(4-(2-((S)-1-(2-aminoethylamino)-3-methylbutyl)-4-fluorophenyl)piperazin-1-yl)-3-(2,4-dichlorophenyl)-1-oxopropan-2-yl)pyrrolidin-2-one",8.9,uM,=,0.9493900066449128,1,O=C([C@@H](Cc1ccccc1)N1CCCC1=O)N1CCN(c2ccccc2)CC1
2807,1675511,10.1016/j.ejmech.2017.03.037,,,,Inhibition of human hepatic CYP3A4,COc1cncc(CN2CCc3c(sc4ccc(F)cc34)C2)c1,"6-Fluoro-2-[(5-methoxypyridin-3-yl)methyl]-1,2,3,4-tetrahydrobenzo[4,5]thieno[2,3-c]-pyridine",6.526,uM,=,0.814647069451856,1,c1cncc(CN2CCc3c(sc4ccccc34)C2)c1
2808,1291572,10.1016/j.bmcl.2013.12.058,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1,"Thiazol-5-ylmethyl(2S,3S)-3-((S)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-3-methylbutanamido)-1,4-diphenylbutan-2-ylcarbamate",0.22,uM,=,-0.6575773191777937,0,O=C(CNC(=O)NCc1cscn1)N[C@@H](Cc1ccccc1)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1
2809,550965,10.1021/np030556a,,,,Inhibition of human CYP3A4 by radiometric assay,COc1c(-c2ccc(O)cc2)oc2cc(O)cc(O)c2c1=O,"5,7-Dihydroxy-2-(4-hydroxy-phenyl)-3-methoxy-chromen-4-one",36.2,uM,=,1.5587085705331658,1,O=c1cc(-c2ccccc2)oc2ccccc12
2810,436456,10.1021/jm061195+,,,,Inhibition of human CYP3A4,O=C(NCC1CCCC1)c1cnc(Nc2cccc(Cl)c2)nc1C(F)(F)F,2-(3-chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acidcyclopentylmethylamide,65.0,uM,=,1.812913356642856,1,O=C(NCC1CCCC1)c1cnc(Nc2ccccc2)nc1
2811,982809,10.1016/j.ejmech.2013.08.010,,,,Inhibition of CYP3A (unknown origin),CC#CCn1c(N2CCC[C@@H](N)C2)cc(=O)n(Cc2ccc3cc(Br)ccc3n2)c1=O,"(R)-6-(3-Aminopiperidin-1-yl)-3-((6-bromoquinolin-2-yl)methyl)-1-(but-2-yn-1-yl)pyrimidine-2,4(1H,3H)-dione",79.36,uM,=,1.8996016591461224,1,O=c1cc(N2CCCCC2)[nH]c(=O)n1Cc1ccc2ccccc2n1
2812,2103815,10.1016/j.bmcl.2021.128010,,,,Time dependent inhibition of CYP3A4 (unknown origin) measured at 30 mins,Nc1cc(Cc2ccn(Cc3cccc(Cc4ccccc4)c3)n2)c2nn[nH]c2n1,"7-((1-(3-benzylbenzyl)-1H-pyrazol-3-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-amine",0.037,uM,=,-1.431798275933005,0,c1ccc(Cc2cccc(Cn3ccc(Cc4ccnc5[nH]nnc45)n3)c2)cc1
2813,1446329,10.1021/ml500387y,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,CC(C)(CC(O)(Cc1cc2cc(S(C)(=O)=O)ncc2[nH]1)C(F)(F)F)c1cccc2c1S(=O)(=O)CC2,"4-(1,1-Dioxo-2,3-dihydro-1H-1lambda*6*-benzo[b]thiophen-7-yl)-1,1,1-trifluoro-2-(5-methanesulfonyl-1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)-4-methyl-pentan-2-ol",2.0,uM,=,0.3010299956639812,1,O=S1(=O)CCc2cccc(CCCCc3cc4ccncc4[nH]3)c21
2814,772033,10.1021/jm2006222,,,,Inhibition of CYP3A4 using DBF as substrate,CCN1CCC(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1,"3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(1-ethyl-piperidin-4-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea",6.0,uM,=,0.7781512503836436,1,O=C(Nc1ccccc1)Nc1cc(Nc2ccc(C3CCNCC3)cc2)ncn1
2815,1923841,10.1021/acs.jmedchem.6b00280,,,,Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase and human b5 reductase assessed as reduction in 7-Hydroxyquinoline production using 7-benzyloxyquinoline as substrate and NADPH incubated for 15 mins by fluorimetry,O=C(NCCN1CCOCC1)Nc1nc2ccc(Sc3nnc4ccc(Oc5cccc(F)c5)nn34)cc2s1,"1-(6-(6-(3-fluorophenoxy)-[1,2,4]triazolo[4,3-b]pyridazin-3-ylthio)benzo[d]thiazol-2-yl)-3-(2-morpholinoethyl)urea",2.0,uM,=,0.3010299956639812,1,O=C(NCCN1CCOCC1)Nc1nc2ccc(Sc3nnc4ccc(Oc5ccccc5)nn34)cc2s1
2816,1489010,10.1124/dmd.111.042739,,,,Inhibition of CYP3A4 (unknown origin),CC[C@H](C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@H]5CO[C@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O,"Cis-2-((S)-sec-Butyl)-4-[4-(4-{4-[(2R,4S)-2-(2,4-dichloro-phenyl)-2-[1,2,4]triazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-phenyl]-2,4-dihydro-[1,2,4]triazol-3-one",0.004,uM,=,-2.397940008672037,0,O=c1[nH]ncn1-c1ccc(N2CCN(c3ccc(OC[C@H]4CO[C@](Cn5cncn5)(c5ccccc5)O4)cc3)CC2)cc1
2817,1527962,,,,,"Inhibition Assay (Testosterone Hydroxylase): To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.",NCC#Cc1cccnc1,3-Pyridin-3-yl-prop-2-ynylamine,128.0,uM,=,2.1072099696478683,1,c1ccncc1
2818,2152998,10.1021/acs.jmedchem.1c00635,,,,Inhibition of CYP3A4 in human liver microsomes using ketoconazole as substrate incubated for 5 mins in presence of NADPH by LC-MS/MS analysis,CNC(=O)c1ccc(Nc2nc(OC3CCCC3)c3c(-c4ccc5nc(C)oc5c4)c[nH]c3n2)c(OC)c1,"4-((4-(Cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-N-methylbenzamide",0.28,uM,=,-0.5528419686577808,0,c1ccc(Nc2nc(OC3CCCC3)c3c(-c4ccc5ncoc5c4)c[nH]c3n2)cc1
2819,1931140,10.1016/j.bmcl.2019.06.040,,,,Inhibition of CYP3A4 (unknown origin),Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1,"1-[2-(4-Chloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole (Econazole)",0.43,uM,=,-0.3665315444204134,0,c1ccc(COC(Cn2ccnc2)c2ccccc2)cc1
2820,851921,10.1016/j.bmcl.2012.08.072,,,,Inhibition of human recombinant CYP3A4,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccc(F)c(Cl)c1,"N-(3-chloro-4-fluorophenyl)-2-(4-morpholino-6-oxo-1,6-dihydropyrimidin-2-yl)acetamide",40.0,uM,=,1.6020599913279625,1,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccccc1
2821,1446329,10.1021/ml500387y,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2ccncc2[nH]1)C(F)(F)F,"1,1,1-Trifluoro-4-(5-fluoro-2-methylphenyl)-4-methyl-2-(1H-pyrrolo[2,3-c]pyridin-2-ylmethyl)pentan-2-ol",0.1,uM,=,-1.0,0,c1ccc(CCCCc2cc3ccncc3[nH]2)cc1
2822,2027342,10.1021/acs.jmedchem.6b01122,,,,Inhibition of CYP3A4 in pooled human liver microsomes using midazolam as substrate in presence of NADPH incubated for 10 mins by LC-MS/MS analysis,C[C@@H]1CN(c2ccc(S(C)(=O)=O)cc2)CCN1c1cccc(C(=O)NC2C3CC4CC2CC(O)(C4)C3)n1,6-[(R)-4-(4-Methanesulfonyl-phenyl)-2-methyl-piperazin-1-yl]-pyridine-2-carboxylic acid (5-hydroxy-adamantan-2-yl)-amide,0.97,uM,=,-0.0132282657337551,0,O=C(NC1C2CC3CC(C2)CC1C3)c1cccc(N2CCN(c3ccccc3)CC2)n1
2823,2133951,10.1016/j.ejmech.2021.113715,,,,Inhibition of CYP3A4 in human liver microsome using Nifedipine as a substrate incubated for 10 mins in the presence of NADPH by LC-MS/MS analysis,CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,SID144204227,0.0116999999999999,uM,=,-1.9318141382538383,0,c1ccc([C@@]2(Cn3ccnc3)OC[C@H](COc3ccc(N4CCNCC4)cc3)O2)cc1
2824,1459146,10.1016/j.bmcl.2014.06.010,,,,Inhibition of CYP3A4 (unknown origin),CC(C)(C(=O)Nc1nncs1)[C@@H]1c2ccc(-c3ccc(C(=O)N4CCOCC4)cc3)nc2Oc2c(F)cccc21,"(S)-2-(9-fluoro-2-(4-(morpholine-4-carbonyl)phenyl)-5H-chromeno[2,3-b]pyridin-5-yl)-2-methyl-N-(1,3,4-thiadiazol-2-yl)propanamide",0.3,uM,=,-0.5228787452803376,0,O=C(C[C@H]1c2ccccc2Oc2nc(-c3ccc(C(=O)N4CCOCC4)cc3)ccc21)Nc1nncs1
2825,449485,10.1016/j.bmcl.2007.07.097,,,,Inhibition of microsomal CYP3A4,CC(C)C[C@H](NCCCN)c1ccccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1,"1-((R)-1-(4-(2-((S)-1-(3-aminopropylamino)-3-methylbutyl)phenyl)piperazin-1-yl)-3-(2,4-dichlorophenyl)-1-oxopropan-2-yl)pyrrolidin-2-one",3.4,uM,=,0.5314789170422551,1,O=C([C@@H](Cc1ccccc1)N1CCCC1=O)N1CCN(c2ccccc2)CC1
2826,51909,10.1021/jm010531d,,,,Inhibition of human Cytochrome P450 3A4 by macrocycles,N#Cc1ccc2cc1Oc1ccc3c(c1)[C@H](CC3)N1CC[C@@H](NCc3cncn3C2)C1=O,"S,R-29-oxo-19-oxa-2,6,10,12-tetraazahexacyclo[18.5.2.12,5.114,18.08,12.023,26]nonacosa-8,10,14(28),15,17,20(27),21,23(26)-octaen-17-yl cyanide",2.8,uM,=,0.4471580313422192,1,O=C1[C@H]2CCN1[C@H]1CCc3ccc(cc31)Oc1cccc(c1)Cn1cncc1CN2
2827,305744,10.1021/jm049696n,,,,Inhibitory concentration value against human cytochrome P-450 3A4,CNc1ccc(-c2cccnc2)s1,Methyl-(5-pyridin-3-yl-thiophen-2-yl)-amine,6.3,uM,=,0.7993405494535817,1,c1cncc(-c2cccs2)c1
2828,982382,10.1016/j.bmcl.2013.07.071,,,,Inhibition of CYP3A4 (unknown origin),CC(C)(C)c1cccc(CN[C@H]2C[S@+]([O-])C[C@@H](Cc3cc(F)c(N)c(OCC(F)(F)F)c3)[C@@H]2O)c1,"(1R,3S,4S,5R)-3-[4-Amino-3-fluoro-5-(2,2,2-trifluoro-ethoxy)-benzyl]-5-(3-tert-butyl-benzylamino)-1-oxo-tetrahydro-thiopyran-4-ol",0.3,uM,=,-0.5228787452803376,0,c1ccc(CN[C@H]2C[SH+]C[C@@H](Cc3ccccc3)C2)cc1
2829,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",COc1ccc(C[C@@H]2COCCN2C(=O)c2ccccc2-n2nccn2)cc1-c1ncco1,"US9150566, 9",8.4,uM,=,0.9242792860618816,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2ncco2)c1
2830,2017934,10.1021/acs.jmedchem.0c00834,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis,CCC1CCCN(c2nc3ccc(Br)cc3c(C(=O)NCC(CCC(=O)O)c3ccccc3Cl)c2C)C1,(+)-5-({[6-Bromo-2-(3-ethylpiperidin-1-yl)-3-methylquinolin-4-yl]carbonyl}amino)-4-(2-chlorophenyl)pentanoic acid,5.0,uM,=,0.6989700043360189,1,O=C(NCCc1ccccc1)c1cc(N2CCCCC2)nc2ccccc12
2831,2128578,10.1016/j.ejmech.2021.113496,,,,Inhibition of recombinant human CYP3A4 using BFC as substrate,C[C@]12CCC(=O)C=C1C[C@@H](/C=C/C=C/C=C/[C@@H]1CC3=CC(=O)CC[C@]3(C)[C@H]3CC[C@]4(C)C(=O)CC[C@H]4[C@H]13)[C@@H]1[C@@H]2CC[C@]2(C)C(=O)CC[C@@H]12,"trans,trans,trans-1,6-bis(4-androsten-3,17-dione-7alpha-yl)hexatriene",3.6,uM,=,0.5563025007672873,1,O=C1C=C2C[C@@H](/C=C/C=C/C=C/[C@@H]3CC4=CC(=O)CCC4[C@H]4CCC5C(=O)CC[C@H]5[C@H]34)[C@H]3[C@@H]4CCC(=O)C4CC[C@@H]3C2CC1
2832,1625990,10.1016/j.bmcl.2016.04.095,,,,Inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins after 30 secs by LC/MS/MS analysis,O=S(=O)(CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12)[C@H]1CCNC1,"(S)-3-(2-((4S,4aS,10bS)-10b-(4-chlorophenylsulfonyl)-7,10-difluoro-1,2,4,4a,5,10b-hexahydropyrano[3,4-c]chromen-4-yl)ethylsulfonyl)pyrrolidine",1.0,uM,=,0.0,0,O=S(=O)(CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccccc3)c3ccccc3OC[C@@H]12)[C@H]1CCNC1
2833,1637154,,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(C#CCOC)cc23)c1F,"Propane-1-sulfonic acid {2,4-difluoro-3-[5-(3-methoxy-prop-1-ynyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-phenyl}-amide",5.0,uM,=,0.6989700043360189,1,O=C(c1ccccc1)c1c[nH]c2ncccc12
2834,519908,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,Cc1cccc(C)c1COc1cc(-n2ccccc2=O)cn2c(C)c(C)nc12,"1-(8-(2,6-dimethylbenzyloxy)-2,3-dimethylimidazo[1,2-a]pyridin-6-yl)pyridin-2(1H)-one",21.0,uM,=,1.3222192947339193,1,O=c1ccccn1-c1cc(OCc2ccccc2)c2nccn2c1
2835,741043,10.1016/j.bmcl.2011.02.067,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCCCNS(C)(=O)=O)c1,"(3R,4S)-N-cyclopropyl-4-(4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)phenyl)-N-(3-(3-methoxypropyl)-5-(3-(methylsulfonamido)propoxy)benzyl)piperidine-3-carboxamide",1.6,uM,=,0.2041199826559248,1,O=C([C@H]1CNCC[C@@H]1c1ccc(OCCOc2ccccc2)cc1)N(Cc1ccccc1)C1CC1
2836,2048413,10.1016/j.bmc.2020.115723,,,,Inhibition of CYP3A4 (unknown origin),Nc1cc([C@H](Cc2ccccc2)c2ccccc2)c2nn[nH]c2n1,"(R)-7-(1,2-diphenylethyl)-1-methyl-1H-[1,2,3]triazolo[4,5-b]pyridin-5-amine",3.4,uM,=,0.5314789170422551,1,c1ccc(C[C@H](c2ccccc2)c2ccnc3[nH]nnc23)cc1
2837,1584799,10.1021/acs.jmedchem.6b00030,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 5 mins by LC-MS analysis,CCOC1(c2ccc(Br)cc2)SC=C(C)n2c1noc2=O,"8-(4-bromophenyl)-8-ethoxy-5-methyl-[1,2,4]oxadiazolo[3,4-c][1,4]thiazin-3(8H)-one",19.2,uM,=,1.2833012287035497,1,O=c1onc2n1C=CSC2c1ccccc1
2838,988989,10.1021/jm400732v,,,,Inhibition of CYP3A4 (unknown origin),CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)c2ccccc2F)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O.Cl,"(S)-N-((S)-1-((6-Bromo-2-methoxynaphthalen-1-yl)methyl)-5-(2-fluorobenzoyl)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-yl)-2-(methylamino)propanamide hydrochloride",0.86,uM,=,-0.0655015487564322,0,O=C1CCN(C(=O)c2ccccc2)c2ccccc2N1Cc1cccc2ccccc12
2839,456988,10.1016/j.bmcl.2007.06.078,,,,Inhibition of CYP3A4,Cc1ccc2c(OCCN3CCN(Cc4ccc5c(c4)N(Cc4ccccc4)C(=O)CO5)CC3)cccc2n1,"4-benzyl-6-((4-(2-(2-methylquinolin-5-yloxy)ethyl)piperazin-1-yl)methyl)-2H-benzo[b][1,4]oxazin-3(4H)-one",12.0,uM,=,1.0791812460476249,1,O=C1COc2ccc(CN3CCN(CCOc4cccc5ncccc45)CC3)cc2N1Cc1ccccc1
2840,595638,10.1016/j.bmcl.2009.09.096,,,,Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH,COc1ccc2c(O[C@@H](C)c3nnc4ccc(-c5ccccc5)nn34)ccnc2c1,"(S)-7-methoxy-4-(1-(6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)ethoxy)quinoline",3.9,uM,=,0.5910646070264992,1,c1ccc(-c2ccc3nnc(COc4ccnc5ccccc45)n3n2)cc1
2841,945618,10.1016/j.bmc.2012.11.058,,,,Inhibition of CYP3A4 (unknown origin),CC(=O)c1cncc(Oc2c(Cl)cc(NS(=O)(=O)c3ccc(Cl)cc3Cl)cc2Cl)c1,"N-(4-(5-acetylpyridin-3-yloxy)-3,5-dichlorophenyl)-2,4-dichlorobenzenesulfonamide",0.36,uM,=,-0.4436974992327127,0,O=S(=O)(Nc1ccc(Oc2cccnc2)cc1)c1ccccc1
2842,1919651,,,,,"Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase",CN(C)Cc1ccc(-c2cccnc2)o1,Dimethyl-(5-pyridin-3-yl-furan-2-ylmethyl)-amine,294.0,uM,=,2.4683473304121573,1,c1cncc(-c2ccco2)c1
2843,1886565,10.1021/acs.jmedchem.8b02021,,,,Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay,COC(=O)c1ccc(CS(=O)(=O)c2ccc3nc(N)sc3c2)cc1,Methyl 4-(((2-Aminobenzo[d]thiazol-6-yl)sulfonyl)methyl)-benzoate,10.0,uM,=,1.0,1,O=S(=O)(Cc1ccccc1)c1ccc2ncsc2c1
2844,676065,10.1016/j.bmcl.2010.09.028,,,,Inhibition of CYP3A4 after 30 mins,C[C@@H]1CN(C(=O)OC2([C@H]3COC[C@@H](CC4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)C[C@H](C)N1CCO,"(3S,5R)-1-((3R,5R)-4-(4-chlorophenylsulfonyl)-5-(cyclopropylmethyl)morpholin-3-yl)cyclopropyl 4-(2-hydroxyethyl)-3,5-dimethylpiperazine-1-carboxylate",0.002,uM,=,-2.6989700043360187,0,O=C(OC1([C@H]2COC[C@@H](CC3CC3)N2S(=O)(=O)c2ccccc2)CC1)N1CCNCC1
2845,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N(C)NC)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, F-53",2.33,uM,=,0.367355921026019,1,O=C1[C@H](Cc2ccccc2)N2C(=O)CNN(C(=O)NCc3ccccc3)[C@H]2CN1Cc1cccc2cc[nH]c12
2846,526157,10.1021/np0401765,,,,Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation,COc1cc(C[C@H]2COC(=O)[C@@H]2Cc2cc(OC)c(OC)c(OC)c2)cc(OC)c1OC,(-)-cubebininolide,14.9,uM,=,1.173186268412274,1,O=C1OC[C@H](Cc2ccccc2)[C@H]1Cc1ccccc1
2847,1778315,10.1016/j.bmcl.2018.06.040,,,,Inhibition of CYP3A4 (unknown origin),CCCCS(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1,"N-(4-(1H-pyrrolo[2,3-b]pyridin-3-yl)thiazol-2-yl)-2-(3-(butylsulfonamido)phenyl)acetamide",3.7,uM,=,0.568201724066995,1,O=C(Cc1ccccc1)Nc1nc(-c2c[nH]c3ncccc23)cs1
2848,801015,10.1016/j.bmcl.2011.11.067,,,,Inhibition of CYP3A4,Cc1c(F)cc(C(=O)NC2CC2)cc1-c1cc2nnc(-c3c(F)cccc3Cl)n2n(C)c1=O,"3-(3-(2-chloro-6-fluorophenyl)-5-methyl-6-oxo-5,6-dihydro-[1,2,4]triazolo[4,3-b]pyridazin-7-yl)-N-cyclopropyl-5-fluoro-4-methylbenzamide",25.8,uM,=,1.4116197059632305,1,O=C(NC1CC1)c1cccc(-c2cc3nnc(-c4ccccc4)n3[nH]c2=O)c1
2849,2152998,10.1021/acs.jmedchem.1c00635,,,,Inhibition of CYP3A4 in human liver microsomes using ketoconazole as substrate incubated for 5 mins in presence of NADPH by LC-MS/MS analysis,CCc1cccc(CC)c1NC(=O)c1ccn(-c2nc(Nc3ccc(N4CCC(O)(C(=O)N5CCN(C)CC5)CC4)cc3OC)nc3[nH]ccc23)c1,"N-(2,6-diethylphenyl)-1-[2-[4-[4-hydroxy-4-(4-methylpiperazine-1-carbonyl)-1-piperidyl]-2-methoxy-anilino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]pyrrole-3-carboxamide",1.9,uM,=,0.2787536009528289,1,O=C(Nc1ccccc1)c1ccn(-c2nc(Nc3ccc(N4CCC(C(=O)N5CCNCC5)CC4)cc3)nc3[nH]ccc23)c1
2850,873423,10.1021/jm3006788,,,,Inhibition of CYP3A4,Cn1c(-c2ccc(Cl)cn2)c(C2CCCC2)c2ccc(C(=O)NC3(C(=O)Nc4ccc(/C=C/C(=O)O)cc4)CCC3)cc21,(E)-3-(4-(1-(2-(5-chloropyridin-2-yl)-3-cyclopentyl-1-methyl-1H-indole-6-carboxamido)cyclobutanecarboxamido)phenyl)acrylic acid,10.9,uM,=,1.0374264979406236,1,O=C(NC1(C(=O)Nc2ccccc2)CCC1)c1ccc2c(C3CCCC3)c(-c3ccccn3)[nH]c2c1
2851,526157,10.1021/np0401765,,,,Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation,COc1cc(C[C@H]2COC(=O)[C@@H]2Cc2cc(OC)c3c(c2)OCO3)cc(OC)c1O,"(8R,8'R)-4-hydroxycubebinone",7.4,uM,=,0.8692317197309762,1,O=C1OC[C@H](Cc2ccccc2)[C@H]1Cc1ccc2c(c1)OCO2
2852,1640557,,,,,"null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.",CC(=O)c1ccc(-n2ccnc2)cc1,TCMDC-125536,0.8,uM,=,-0.0969100130080563,0,c1ccc(-n2ccnc2)cc1
2853,820357,10.1021/jm300138g,,,,Inhibition of CYP3A4,CNC1CCCC(c2c[nH]c3ccc(NC(=N)c4cccs4)cc23)C1.Cl,cis-(+)-N-(3-(3-(methylamino)cyclohexyl)-1H-indol-5-yl)thiophene-2-carboximidamide hydrochloride,100.0,uM,=,2.0,1,N=C(Nc1ccc2[nH]cc(C3CCCCC3)c2c1)c1cccs1
2854,2249035,10.1021/acs.jmedchem.1c02148,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH by LC-MS/MS analysis,c1cncc(-c2cnc(NCc3cccc4c3CCO4)n3cnnc23)c1,"N-(2,3-dihydrobenzofuran-4-ylmethyl)-8-(3-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine",29.0,uM,=,1.462397997898956,1,c1cncc(-c2cnc(NCc3cccc4c3CCO4)n3cnnc23)c1
2855,1828801,10.1021/acs.jmedchem.8b01098,,,,Inhibition of C-terminal 4His-tagged CYP3A4 (unknown origin) expressed in Escherichia coli by spectrophotometric analysis,COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccnc(N)c3)cc2)c1,(R)-4-(2-Aminopyridin-4-yl)-N-(1-(3-methoxyphenyl)ethyl)-benzamide,11.9,uM,=,1.0755469613925308,1,O=C(NCc1ccccc1)c1ccc(-c2ccncc2)cc1
2856,510198,10.1021/jm800355c,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,COc1ccc(-c2ccc3c(c2)CC=C3c2ccncc2)cc1.Cl,4-(5-(4-Methoxyphenyl)-3H-inden-1-yl)pyridine Hydrochloride,2.394,uM,=,0.3791241460703919,1,C1=C(c2ccncc2)c2ccc(-c3ccccc3)cc2C1
2857,1488502,10.1124/dmd.112.045708,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis,C[C@H](c1nc2ncccc2c(=O)n1-c1ccc(O)cc1)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1,"(R)-N-(1-(3-(4-hydroxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide",0.65,uM,=,-0.1870866433571444,0,O=C(Cc1ccccc1)N(Cc1cccnc1)Cc1nc2ncccc2c(=O)n1-c1ccccc1
2858,1540696,10.1016/j.ejmech.2015.08.051,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 2 mins by LC-MS/MS analysis in presence of NADPH regeneration system,COCCCN1CCC(NC(=O)c2nc(C(C)C)n3ccccc23)CC1,"3-isopropyl-N-(1-(3-methoxypropyl)piperidin-4-yl)imidazo[1,5-a]pyridine-1-carboxamide",16.3,uM,=,1.212187604403958,1,O=C(NC1CCNCC1)c1ncn2ccccc12
2859,1778315,10.1016/j.bmcl.2018.06.040,,,,Inhibition of CYP3A4 (unknown origin),CN(C)S(=O)(=O)c1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1,"N-(4-(1H-pyrrolo[2,3-b]pyridin-3-yl)thiazol-2-yl)-2-(3-(N,N-dimethylsulfamoyl)phenyl)acetamide",2.3,uM,=,0.3617278360175928,1,O=C(Cc1ccccc1)Nc1nc(-c2c[nH]c3ncccc23)cs1
2860,1446329,10.1021/ml500387y,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F,"1,1,1-trifluoro-4-(5-fluoro-2-methylphenyl)-4-methyl-2-((5-morpholino-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)pentan-2-ol",0.01,uM,=,-2.0,0,c1ccc(CCCCc2cc3cc(N4CCOCC4)ncc3[nH]2)cc1
2861,1335568,10.1021/jm401731q,,,,Inhibition of CYP3A4 (unknown origin),CN1CCN(c2cc(C(F)(F)F)nc(N3CCC[C@@H](C(=O)NCCc4ccc(C#N)cc4)C3)n2)CC1,(R)-N-(4-Cyanophenethyl)-1-(4-(4-methylpiperazin-1-yl)-6-(trifluoromethyl)pyrimidin-2-yl)piperidine-3-carboxamide,2.0,uM,=,0.3010299956639812,1,O=C(NCCc1ccccc1)[C@@H]1CCCN(c2nccc(N3CCNCC3)n2)C1
2862,479364,10.1016/j.bmcl.2008.05.027,,,,Inhibition of CYP3A4,Cc1cc2c(cc1C)N(CC(=O)N1CCCC(c3ccccc3)C1CN1CCCC1)C(=O)CO2,"rac-6,7-dimethyl-4-(2-oxo-2-(3-phenyl-2-(pyrrolidin-1-ylmethyl)piperidin-1-yl)ethyl)-2H-benzo[b][1,4]oxazin-3(4H)-one",3.9,uM,=,0.5910646070264992,1,O=C1COc2ccccc2N1CC(=O)N1CCCC(c2ccccc2)C1CN1CCCC1
2863,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1ccc(C(=O)N2CCO[C@H](C)[C@H]2Cc2cccc(-n3nccn3)c2)c(-n2nccn2)c1,"US9150566, 168",8.5,uM,=,0.9294189257142929,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
2864,1613611,10.1016/j.bmcl.2016.08.089,,,,Inhibition of CYP3A4 (unknown origin),COc1cc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)nc(C)n1,"(R)-6-isopropyl-5-(6-methoxy-2-methylpyrimidin-4-yl)-2-(3-(methylsulfonyl)phenyl)-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole",12.92,uM,=,1.1112625136590653,1,c1ccc(-n2cc3c(n2)CN(c2ccncn2)C3)cc1
2865,2241412,10.1016/j.ejmech.2021.113981,,,,Inhibition of CYP3A4 in human liver microsomes assessed as reduction in 6-beta-hydroxy-testosterone formation using testosterone as substrate preincubated for 20 mins in absence of NADPH followed by incubation with substrate for 10 mins by LC-MS/MS analysis,O[C@H](c1cc(C(F)(F)F)nc2c(C(F)(F)F)cccc12)[C@@H]1CCCCN1,"(R)-(2,8-bis(trifluoromethyl)quinolin-4-yl)((S)-piperidin-2-yl)methanol",19.0,uM,=,1.2787536009528289,1,c1ccc2c(C[C@@H]3CCCCN3)ccnc2c1
2866,1849385,10.1016/j.bmcl.2019.06.044,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis,O=C(O)c1ccc(-n2cc(C(=O)c3c(Cl)cccc3C(F)(F)F)c3c(F)cccc32)cc1,4-(3-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indol-1-yl)benzoic acid,16.4,uM,=,1.214843848047698,1,O=C(c1ccccc1)c1cn(-c2ccccc2)c2ccccc12
2867,464243,10.1021/jm7013309,,,,Inhibition of human CYP3A4 using 7-benzyloxyresorufin,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@H](N)CC(C)C)c(C)c34)ccc2[nH]1,"(S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl) 2-amino-4-methylpentanoate",0.37,uM,=,-0.431798275933005,0,c1cc2c(Oc3ccc4[nH]ccc4c3)ncnn2c1
2868,988989,10.1021/jm400732v,,,,Inhibition of CYP3A4 (unknown origin),CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)Cc2cccnc2)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O.Cl,"(S)-N-((S)-1-((6-Bromo-2-methoxynaphthalen-1-yl)methyl)-2-oxo-5-(2-(pyridin-3-yl)acetyl)-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-yl)-2-(methylamino)propanamide hydrochloride",2.8,uM,=,0.4471580313422192,1,O=C(Cc1cccnc1)N1CCC(=O)N(Cc2cccc3ccccc23)c2ccccc21
2869,1474044,10.1021/jm501740a,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,O=C(N[C@H](c1ccccn1)C1CCCC1)c1ccc2[nH]nc(-c3ccc(N4[C@H]5CC[C@H]4CC(O)C5)cc3)c2c1,N-((S)-cyclopentyl(pyridin-2-yl)methyl)-3-(4-((endo)-3-hydroxy-8-azabicyclo[3.2.1]octan-8-yl)phenyl)-1H-indazole-5-carboxamide,0.8,uM,=,-0.0969100130080563,0,O=C(N[C@H](c1ccccn1)C1CCCC1)c1ccc2[nH]nc(-c3ccc(N4[C@@H]5CCC[C@@H]4CC5)cc3)c2c1
2870,2249035,10.1021/acs.jmedchem.1c02148,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH by LC-MS/MS analysis,c1cc(CNc2ncc(-c3ccncc3)c3nncn23)c2c(c1)OCC2,"N-(2,3-dihydrobenzofuran-4-ylmethyl)-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine",0.16,uM,=,-0.7958800173440752,0,c1cc(CNc2ncc(-c3ccncc3)c3nncn23)c2c(c1)OCC2
2871,1467194,10.1021/jm5005336,,,,Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay,COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc([C@H](C)N5CCOCC5)cc4)n[nH]c3c1)C(=O)N2C,"(1R,2S)-2-(3-((E)-4-((S)-1-Morpholinoethyl)styryl)-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-one",11.0,uM,=,1.0413926851582251,1,O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccc(CN4CCOCC4)cc3)n[nH]c2c1
2872,1327919,10.1039/C2MD20061A,,,,Inhibition of CYP3A4 in human pooled liver microsomes using midazolam as substrate by LC/MS/MS analysis,COc1cc(N2CCN(C)CC2)ccc1-c1nc2c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)c(Cl)cnc2[nH]1,"(1S,2S,3R,4R)-3-{6-Chloro-2-[2-methoxy-4-(4-methyl-piperazin-1-yl)-phenyl]-3Himidazo[4,5-b]pyridin-7-ylamino}-bicyclo[2.2.1]hept-5-ene-2-carboxylic",13.7,uM,=,1.136720567156407,1,C1=C[C@H]2C[C@@H]1C[C@@H]2Nc1ccnc2[nH]c(-c3ccc(N4CCNCC4)cc3)nc12
2873,464748,10.1016/j.bmcl.2008.01.126,,,,Inhibition of CYP3A4 in presence of 7-benzyloxyresorufin substrate,COc1ccc(-c2nc(CCOc3cccc(C[C@@H]4C(=O)N(c5ccc(C(C)(C)C)cc5)[C@@H]4C(=O)O)c3)c(C)o2)cc1,"(2S,3S)-3-(3-(2-(2-(4-methoxyphenyl)-5-methyloxazol-4-yl)ethoxy)benzyl)-1-(4-tert-butylphenyl)-4-oxoazetidine-2-carboxylic acid",12.0,uM,=,1.0791812460476249,1,O=C1[C@@H](Cc2cccc(OCCc3coc(-c4ccccc4)n3)c2)CN1c1ccccc1
2874,342118,10.1021/jm051106d,,,,Inhibitory activity against CYP3A4,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1,"(R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-ol",18.0,uM,=,1.255272505103306,1,c1cc2c(Oc3ccc4[nH]ccc4c3)ncnn2c1
2875,1984166,10.1016/j.bmc.2020.115349,,,,Inhibition of human full length CYP3A4 assessed using 7-benzyloxy-4 (trifluoromethyl)coumarin as substrate preincubated for 2 mins followed by substrate addition and measured for 2 mins by fluorometric analysis,CC(C)(C)OC(=O)N[C@H](CS[C@H](Cc1ccccc1)C(=O)NCCc1cccnc1)Cc1cccc2ccccc12,tert-butyl N-[(1S)-1-[[(1R)-1-benzyl-2-oxo-2-[2-(3-pyridyl)ethylamino]ethyl]sulfanylmethyl]-2-(1-naphthyl)ethyl]carbamate,0.075,uM,=,-1.1249387366083,0,O=C(NCCc1cccnc1)[C@@H](Cc1ccccc1)SCCCc1cccc2ccccc12
2876,1688648,10.1021/acs.jmedchem.7b00410,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 8 mins by LC/MS/MS analysis,Cc1cc(Oc2cncc(F)c2)cc(C(=O)Nc2cccc(F)n2)n1,N-(6-Fluoropyridin-2-yl)-4-((5-fluoropyridin-3-yl)oxy)-6-methylpicolinamide,8.0,uM,=,0.9030899869919436,1,O=C(Nc1ccccn1)c1cc(Oc2cccnc2)ccn1
2877,2217386,10.1021/acs.jmedchem.1c02141,,,,Competitive inhibition of human recombinant CYP3A4 using coumarin as substrate preincubated with enzyme for 10 mins followed by NADPH addition and measured after 20 to 50 mins by fluorescence based method,C[C@@H](N)c1cc(Cl)ccc1Cn1c(=S)[nH]c(=O)c2[nH]cnc21,"(R)-3-(2-(1-aminoethyl)-4-chlorobenzyl)-2-thioxo-2,3-dihydro-1H-purin-6-(7H)-one",8.8,uM,=,0.9444826721501688,1,O=c1[nH]c(=S)n(Cc2ccccc2)c2nc[nH]c12
2878,51750,10.1021/jm010531d,,,,Inhibition of dog Cytochrome P450 3A by macrocycles,N#Cc1ccc2cc1Oc1ccc3c(c1)[C@H](CC3)N1CC[C@@H](NCc3cncn3C2)C1=O,"S,R-29-oxo-19-oxa-2,6,10,12-tetraazahexacyclo[18.5.2.12,5.114,18.08,12.023,26]nonacosa-8,10,14(28),15,17,20(27),21,23(26)-octaen-17-yl cyanide",14.8,uM,=,1.1702617153949575,1,O=C1[C@H]2CCN1[C@H]1CCc3ccc(cc31)Oc1cccc(c1)Cn1cncc1CN2
2879,834929,10.1016/j.bmcl.2012.07.020,,,,Inhibition of CYP3A4,CCS(=O)(=O)c1ccc2[nH]c(-c3ccc(Cl)c(-c4ccccc4)c3)nc2c1,2-(6-chlorobiphenyl-3-yl)-5-(ethylsulfonyl)-1H-benzo[d]imidazole,2.6,uM,=,0.414973347970818,1,c1ccc(-c2cccc(-c3nc4ccccc4[nH]3)c2)cc1
2880,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2C(CN(Cc3cccc4c(C(=O)Nc5ccc(N6CCN(CC)CC6)nc5)cn(C)c34)C(=O)[C@@H]2Cc2ccc(O)cc2)N1C(=O)NCc1ccccc1,"US8940739, G-42",5.73,uM,=,0.75815462196739,1,O=C(Nc1ccc(N2CCNCC2)nc1)c1c[nH]c2c(CN3CC4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12
2881,828928,10.1016/j.bmcl.2012.06.022,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,CCN(C)c1nc2ccc(C(=O)N(CC(C)C)C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3ccncc3)cc2o1,"Pyridin-4-ylmethyl(2S,3R)-4-(2-(ethyl(methyl)amino)-N-isobutylbenzo[d]oxazole-6-carboxamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate",0.2,uM,=,-0.6989700043360187,0,O=C(N[C@H](CCNC(=O)c1ccc2ncoc2c1)Cc1ccccc1)OCc1ccncc1
2882,51898,10.1016/s0960-894x(98)00653-2,,,,Antiviral activity as inhibition of human liver microsomal Cytochrome P450 3A4,COc1ccc(CN2CCN(C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)[C@@H](NC(=O)OCc3csc(C)n3)C(C)C)[C@H](C(=O)NC(C)(C)C)C2)cc1OC,"((S)-1-{(1S,2R)-1-Benzyl-3-[(S)-2-tert-butylcarbamoyl-4-(3,4-dimethoxy-benzyl)-piperazin-1-yl]-2-hydroxy-propylcarbamoyl}-2-methyl-propyl)-carbamic acid 2-methyl-thiazol-4-ylmethyl ester",120.0,uM,=,2.0791812460476247,1,O=C(CNC(=O)OCc1cscn1)N[C@H](CCN1CCN(Cc2ccccc2)CC1)Cc1ccccc1
2883,1499751,10.1021/acs.jmedchem.5b00424,,,,Inhibition of CYP3A4 (unknown origin),COc1cccc(CC(=O)Nc2nc(-c3ccnc(OC)c3)cs2)c1,2-(3-methoxyphenyl)-N-(4-(2-methoxypyridin-4-yl)thiazol-2-yl)acetamide,8.3,uM,=,0.919078092376074,1,O=C(Cc1ccccc1)Nc1nc(-c2ccncc2)cs1
2884,434712,10.1021/jm070104l,,,,Inhibition of human CYP3A4,N#Cc1ccccc1Cn1c(N2CCCC(N)C2)nc2c(Cl)cccc2c1=O,2-((2-(3-aminopiperidin-1-yl)-8-chloro-4-oxoquinazolin-3(4H)-yl)methyl)benzonitrile,0.13,uM,=,-0.8860566476931633,0,O=c1c2ccccc2nc(N2CCCCC2)n1Cc1ccccc1
2885,1931140,10.1016/j.bmcl.2019.06.040,,,,Inhibition of CYP3A4 (unknown origin),OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F,"2-(2,4-Difluoro-phenyl)-1,3-bis-[1,2,4]triazol-1-yl-propan-2-ol",25.0,uM,=,1.3979400086720375,1,c1ccc(C(Cn2cncn2)Cn2cncn2)cc1
2886,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2C(CN(Cc3cccc4c(C(=O)Nc5ccc(NCC(O)CO)nc5)cn(C)c34)C(=O)[C@@H]2Cc2ccc(O)cc2)N1C(=O)NCc1ccccc1,"US8940739, G-21",2.55,uM,=,0.4065401804339551,1,O=C(Nc1cccnc1)c1c[nH]c2c(CN3CC4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12
2887,1487309,10.1124/dmd.111.043505,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis,O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12,"2-(3,4-Dihydroxy-phenyl)-3,5,7-trihydroxy-chromen-4-one",2.11,uM,=,0.3242824552976926,1,O=c1cc(-c2ccccc2)oc2ccccc12
2888,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCN(CC)CC)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, F-14",3.64,uM,=,0.561101383649056,1,O=C1[C@H](Cc2ccccc2)N2C(=O)CNN(C(=O)NCc3ccccc3)[C@H]2CN1Cc1cccc2cc[nH]c12
2889,1985395,10.1021/acsmedchemlett.9b00438,,,,Inhibition of CYP3A4 (unknown origin),CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cn4)CC3)cc2)c1=O,"4-(4-(4-(5-(((2S,4R)-2-((1H-1,2,4-triazol-1-yl)methyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-4-yl)methoxy)pyridin-2-yl)piperazin-1-yl)phenyl)-2-(sec-butyl)-2,4-dihydro-3H-1,2,4-triazol-3-one",3.4,uM,=,0.5314789170422551,1,O=c1[nH]ncn1-c1ccc(N2CCN(c3ccc(OC[C@@H]4CO[C@@](Cn5cncn5)(c5ccccc5)O4)cn3)CC2)cc1
2890,1291572,10.1016/j.bmcl.2013.12.058,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)[C@H]2OC(C)(C)O[C@@H]2[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1,"Thiazol-5-ylmethyl(S)-1-((4R,5R)-5-((S)-1-((S)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-3-methylbutanamido)-2-phenylethyl)-2,2-dimethyl-1,3-dioxolan-4-yl)-2-phenylethylcarbamate",0.31,uM,=,-0.5086383061657274,0,O=C(CNC(=O)NCc1cscn1)N[C@@H](Cc1ccccc1)[C@H]1OCO[C@@H]1[C@H](Cc1ccccc1)NC(=O)OCc1cncs1
2891,1279428,10.1021/ml400280z,,,,Inhibition of human CYP3A4 assessed as terfenadine hydroxylation after 20 mins by LC-MS/MS analysis,O=C1O[C@@H](Cn2ccnn2)CN1c1ccc(-c2ccn3ccnc3c2)c(F)c1,"(R)-3-(3-Fluoro-4-(imidazo[1,2-a]pyridin-7-yl)phenyl)-5-([1,2,3]triazol-1-yl)methyloxazolidin-2-one",15.0,uM,=,1.1760912590556811,1,O=C1O[C@@H](Cn2ccnn2)CN1c1ccc(-c2ccn3ccnc3c2)cc1
2892,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",COc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cc(-n3nccn3)ccc2F)c1F,"US9150566, 133",37.0,uM,=,1.568201724066995,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
2893,1534761,,,,,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",COc1ccc(CNc2ccc(Cc3c[nH]c4ncc(C)cc34)c(F)n2)cn1,"US9096593, P-2029",5.0,uM,=,0.6989700043360189,1,c1cncc(CNc2ccc(Cc3c[nH]c4ncccc34)cn2)c1
2894,1684789,10.1016/j.ejmech.2017.04.023,,,,Inhibition of recombinant human CYP3A4 expressed in baculosomes using BOMR as substrate preincubated for 10 mins followed by substrate/NADP+ addition measured for 1 hr,Cc1cc(C(=O)N/N=C/c2ccc(Br)cc2)c2c(C)nn(-c3ccccc3)c2n1,"N'-(4-bromobenzylidene)-3,6-dimethyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine-4-carbohydrazide",137.8,uM,=,2.139249217571607,1,O=C(N/N=C/c1ccccc1)c1ccnc2c1cnn2-c1ccccc1
2895,859942,10.1021/jm300122u,,,,Inhibition of human CYP3A4 using testosterone as substrate after 45 mins,CN1CCN(C(=O)[C@H](Cc2ccc(Br)cc2)NC(=O)C2(c3ccc(Cl)cc3Cl)CC2)CC1,"N-[(1S)-1-[(4-Bromophenyl)methyl]-2-(4-methylpiperazin-1-yl)-2-oxoethyl]-1-(2,4-dichlorophenyl)-cyclopropanecarboxamide",0.48,uM,=,-0.3187587626244128,0,O=C([C@H](Cc1ccccc1)NC(=O)C1(c2ccccc2)CC1)N1CCNCC1
2896,673952,10.1016/j.bmcl.2010.08.086,,,,Inhibition of CYP3A4 using midazolam as substrate,CNCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1,"(3R,4S)-N-(2-chloro-5-((methylamino)methyl)benzyl)-N-cyclopropyl-4-(4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)phenyl)piperidine-3-carboxamide",15.0,uM,=,1.1760912590556811,1,O=C([C@H]1CNCC[C@@H]1c1ccc(OCCOc2ccccc2)cc1)N(Cc1ccccc1)C1CC1
2897,1696937,10.1016/j.bmcl.2017.09.042,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate pretreated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis,COc1ccc(NC(=O)c2cc(Oc3cncc(F)c3)cn3ccnc23)nc1,"6-(5-fluoropyridin-3-yloxy)-N-(5-methoxypyridin-2-yl)imidazo[1,2-a]pyridine-8-carboxamide",2.0,uM,=,0.3010299956639812,1,O=C(Nc1ccccn1)c1cc(Oc2cccnc2)cn2ccnc12
2898,772032,10.1021/jm2006222,,,,Inhibition of CYP3A4 using BFC as substrate,COc1cc(OC)c(Cl)c(NC(=O)N(C)c2cc(Nc3cccc(N4CCN(C)CC4)c3)ncn2)c1Cl,"3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-methyl-1-{6-[3-(4-methyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-urea",1.1,uM,=,0.041392685158225,1,O=C(Nc1ccccc1)Nc1cc(Nc2cccc(N3CCNCC3)c2)ncn1
2899,619264,10.1016/j.bmcl.2009.07.002,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,Cc1cccc(C)c1CNc1nc(-n2ccccc2=O)cc2c(C)c(C)[nH]c12,"1-(7-(2,6-dimethylbenzylamino)-2,3-dimethyl-1H-pyrrolo[2,3-c]pyridin-5-yl)pyridin-2(1H)-one",3.0,uM,=,0.4771212547196624,1,O=c1ccccn1-c1cc2cc[nH]c2c(NCc2ccccc2)n1
2900,473932,10.1021/jm701121y,,,,Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay,Clc1ccc(Cn2cc(-c3ccncc3)cn2)c(Cl)c1,"4-(1-(2,4-dichlorobenzyl)-1H-pyrazol-4-yl)pyridine",0.23,uM,=,-0.6382721639824072,0,c1ccc(Cn2cc(-c3ccncc3)cn2)cc1
2901,2126605,10.1016/j.bmcl.2021.128077,,,,Time dependent inhibition of CYP3A4 (unknown origin) measured after 30 mins,O=C(C[C@@H]1Cc2cc(Cl)c3[nH]c(=O)n(CC(F)(F)F)c3c2CN(CC(F)(F)F)C1=O)N1CCC(N2CCc3ccccc3NC2=O)CC1,"(S)-4-Chloro-7-{2-oxo-2-[4-(2-oxo-1,2,4,5-tetrahydro-benzo[d][1,3]diazepin-3-yl)-piperidin-1-yl]-ethyl}-1,9-bis-(2,2,2-trifluoro-ethyl)-1,3,6,7,9,10-hexahydro-1,3,9-triaza-cyclohepta[e]indene-2,8-dione",8.4,uM,=,0.9242792860618816,1,O=C1NCc2c(ccc3[nH]c(=O)[nH]c23)C[C@H]1CC(=O)N1CCC(N2CCc3ccccc3NC2=O)CC1
2902,456988,10.1016/j.bmcl.2007.06.078,,,,Inhibition of CYP3A4,Cc1ccc2c(OCCN3CCN(Cc4ccc5c(c4)N(CCc4ccccc4)C(=O)CO5)CC3)cccc2n1,"6-((4-(2-(2-methylquinolin-5-yloxy)ethyl)piperazin-1-yl)methyl)-4-phenethyl-2H-benzo[b][1,4]oxazin-3(4H)-one",9.0,uM,=,0.9542425094393248,1,O=C1COc2ccc(CN3CCN(CCOc4cccc5ncccc45)CC3)cc2N1CCc1ccccc1
2903,1655304,10.1021/acsmedchemlett.6b00491,,,,Inhibition of CYP3A4 using in human liver microsomes using testosterone as substrate after 5 to 15 mins,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,"1-(4-{4-[2-(2,4-Dichloro-phenyl)-2-imidazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-ethanone (ketoconazole)",0.015,uM,=,-1.8239087409443189,0,c1ccc(C2(Cn3ccnc3)OCC(COc3ccc(N4CCNCC4)cc3)O2)cc1
2904,2017934,10.1021/acs.jmedchem.0c00834,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis,Cc1c(N2CCCCC2)nc2ccc(Br)cc2c1C(=O)NCC(CCC(=O)O)c1c(F)ccc(F)c1Cl,"(+)-5-({[6-Bromo-3-methyl-2-(piperidin-1-yl)quinolin-4-yl]carbonyl}amino)-4-(2-chloro-3,6-difluorophenyl)pentanoic acid",16.0,uM,=,1.2041199826559248,1,O=C(NCCc1ccccc1)c1cc(N2CCCCC2)nc2ccccc12
2905,873423,10.1021/jm3006788,,,,Inhibition of CYP3A4,Cn1c(-c2ccoc2)c(C2CCCC2)c2ccc(C(=O)NC3(C(=O)Nc4ccc(/C=C/C(=O)O)cc4)CCC3)cc21,(E)-3-(4-(1-(3-cyclopentyl-2-(furan-3-yl)-1-methyl-1H-indole-6-carboxamido)cyclobutanecarboxamido)phenyl)acrylic acid,9.2,uM,=,0.9637878273455552,1,O=C(NC1(C(=O)Nc2ccccc2)CCC1)c1ccc2c(C3CCCC3)c(-c3ccoc3)[nH]c2c1
2906,961060,10.1016/j.bmcl.2013.03.080,,,,Inhibition of CYP3A4 (unknown origin),Cc1cc(N2CCC(N3CCCC3C)C2)ccc1NC(=O)Nc1cc(Cl)cc(Cl)c1,"1-(3,5-dichlorophenyl)-3-(2-methyl-4-(2-methyl-1,3'-bipyrrolidin-1'-yl)phenyl)urea",13.0,uM,=,1.1139433523068367,1,O=C(Nc1ccccc1)Nc1ccc(N2CCC(N3CCCC3)C2)cc1
2907,1295469,10.1016/j.bmcl.2014.02.004,,,,Inhibition of human recombinant CYP3A4,NC(=O)c1sc(N2CCOCC2)nc1CC(=O)N1CCc2c(Br)cccc21,4-(2-(4-bromoindolin-1-yl)-2-oxoethyl)-2-morpholinothiazole-5-carboxamide,40.0,uM,=,1.6020599913279625,1,O=C(Cc1csc(N2CCOCC2)n1)N1CCc2ccccc21
2908,466342,10.1021/jm701447v,,,,Inhibition of human CYP3A4,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,"1-(4-{4-[2-(2,4-Dichloro-phenyl)-2-imidazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-ethanone (ketoconazole)",0.054,uM,=,-1.2676062401770316,0,c1ccc(C2(Cn3ccnc3)OCC(COc3ccc(N4CCNCC4)cc3)O2)cc1
2909,519908,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,Cc1cccc(C)c1CNc1cc(-c2c[nH]c(=O)[nH]c2=O)cn2c(C)c(C)nc12,"5-(8-(2,6-dimethylbenzylamino)-2,3-dimethylimidazo[1,2-a]pyridin-6-yl)pyrimidine-2,4(1H,3H)-dione",2.6,uM,=,0.414973347970818,1,O=c1[nH]cc(-c2cc(NCc3ccccc3)c3nccn3c2)c(=O)[nH]1
2910,979124,10.1021/jm400484p,,,,Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes,Oc1ccc2ccc(-c3cccnc3)c(F)c2c1,8-fluoro-7-(pyridin-3-yl)naphthalen-2-ol,1.262,uM,=,0.1010593549081155,1,c1cncc(-c2ccc3ccccc3c2)c1
2911,828928,10.1016/j.bmcl.2012.06.022,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,CCN(C)c1nc2ccc(C(=O)N(CC(C)C)C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3ccc4c(c3)OCO4)cc2o1,"Benzo[d][1,3]dioxol-5-ylmethyl(2S,3R)-4-(2-(ethyl(methyl)amino)-N-isobutylbenzo[d]oxazole-6-carboxamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate",0.044,uM,=,-1.3565473235138126,0,O=C(N[C@H](CCNC(=O)c1ccc2ncoc2c1)Cc1ccccc1)OCc1ccc2c(c1)OCO2
2912,461436,10.1016/j.bmcl.2007.10.092,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,CC[C@@H]1CCC[C@H](C2(CC(=O)N3CCC[C@H]3CO)CC2)N1S(=O)(=O)c1ccc(Cl)cc1,"2-(1-((2R,6R)-1-(4-chlorophenylsulfonyl)-6-ethylpiperidin-2-yl)cyclopropyl)-1-((S)-2-(hydroxymethyl)pyrrolidin-1-yl)ethanone",9.0,uM,=,0.9542425094393248,1,O=C(CC1([C@H]2CCCCN2S(=O)(=O)c2ccccc2)CC1)N1CCCC1
2913,1845477,10.1021/acsmedchemlett.0c00004,,,,Inhibition of CYP3A4 (unknown origin),CS(=O)(=O)c1ccc2c(c1)[C@@H](O)[C@H]([C@H]1c3ccccc3-c3cncn31)CC2,"(1S,2S)-2-((S)-5H-imidazo[5,1-a]isoindol-5-yl)-7-(methylsulfonyl)-1,2,3,4-tetrahydronaphthalen-1-ol",6.0,uM,=,0.7781512503836436,1,c1ccc2c(c1)CC[C@@H]([C@H]1c3ccccc3-c3cncn31)C2
2914,493017,10.1021/jm800851u,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,COC(=O)Nc1cc(-c2cncc(OC)c2)nc(-n2nc(C)cc2C)n1,"[2-(3,5-Dimethyl-pyrazol-1-yl)-6-(5-methoxy-pyridin-3-yl)-pyrimidin-4-yl]-carbamic acid methyl ester",16.0,uM,=,1.2041199826559248,1,c1cncc(-c2ccnc(-n3cccn3)n2)c1
2915,321493,10.1016/j.bmcl.2005.06.056,,,,Inhibition against Cytochrome P450 3A4 prepared from baculovirus-infected insect cells using 7-benzyloxy-4-trifluoromethylcoumarin,O=c1[nH]c2ccc(C(F)(F)F)cc2c(-c2cc(Cl)ccc2O)c1CCO,4-(5-Chloro-2-hydroxy-phenyl)-3-(2-hydroxy-ethyl)-6-trifluoromethyl-1H-quinolin-2-one,8.1,uM,=,0.9084850188786496,1,O=c1cc(-c2ccccc2)c2ccccc2[nH]1
2916,717286,10.1021/np100665j,,,,Inhibition of CYP3A4 after 30 mins by fluorometric assay,COc1cc(C[C@H]2CO[C@H](c3ccc(O)c(O)c3)[C@H]2CO)ccc1O,taxiresinol,85.6,uM,=,1.9324737646771533,1,c1ccc(C[C@H]2CO[C@H](c3ccccc3)C2)cc1
2917,1618210,10.1021/acs.jmedchem.5b01985,,,,Inhibition of CYP3A4 (unknown origin),Cc1cccc2nc(NC(=O)c3cccc(C(F)(F)F)c3)n([C@@H]3CCCCN(C(=O)/C=C/CN(C)C)C3)c12,"(R,E)-N-(1-(1-(4-(Dimethylamino)but-2-enoyl)azepan-3-yl)-7-methyl-1H-benzo[d]imidazol-2-yl)-3-(trifluoromethyl)-benzamide",22.2,uM,=,1.3463529744506386,1,O=C(Nc1nc2ccccc2n1[C@@H]1CCCCNC1)c1ccccc1
2918,1911030,10.1021/acs.jmedchem.8b01226,,,,Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins,Cc1ccc(S(=O)(=O)N2CCC(=CC#Cc3cccc(C)n3)CC2)cc1,2-(3-{1-[(4-Methylphenyl)sulfonyl]piperidin-4-ylidene}prop-1-yn-1-yl)-6-methylpyridine,1.9,uM,=,0.2787536009528289,1,O=S(=O)(c1ccccc1)N1CCC(=CC#Cc2ccccn2)CC1
2919,1517864,10.1016/j.bmc.2015.08.019,,,,Inhibition of CYP3A4 (unknown origin) incubated for 45 mins using NADPH by fluorescence assay,COC(=O)C(Cn1ccnc1)NC(=O)c1c(C)nn(-c2ccccc2)c1Cl,Methyl 2-(5-chloro-3-methyl-1-phenyl-1H-pyrazole-4-carboxamido)-3-(1H-imidazol-1-yl)propanoate,1.17,uM,=,0.0681858617461616,1,O=C(NCCn1ccnc1)c1cnn(-c2ccccc2)c1
2920,649576,10.1021/jm100317b,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsome,Fc1cccc(-c2ccc(Cc3ccncc3)cc2)c1,4-(4'-Fluoro-biphenyl-4-ylmethyl)pyridine,0.668,uM,=,-0.1752235375244543,0,c1ccc(-c2ccc(Cc3ccncc3)cc2)cc1
2921,1301325,10.6019/CHEMBL3137440,,,,DNDI: CYP Inhibition,COc1ccc(CN2CCC(N(c3ccc(C(F)(F)F)cc3)c3cccnc3)CC2)cc1,,15.0,uM,=,1.1760912590556811,1,c1ccc(CN2CCC(N(c3ccccc3)c3cccnc3)CC2)cc1
2922,1696887,10.1016/j.bmcl.2017.09.020,,,,Inhibition of human CYP3A4,CCCCc1cc(OC2CCN(CCCCNS(=O)(=O)CC)CC2)c2ncccc2c1.Cl.Cl,N-(4-{4-[(6-Butyl-8-quinolinyl)oxy]-1-piperidinyl}butyl)ethanesulfonamide dihydrochloride,4.0,uM,=,0.6020599913279624,1,c1cnc2c(OC3CCNCC3)cccc2c1
2923,552281,10.1016/j.bmcl.2008.04.036,,,,Inhibition of CYP3A4,N[C@@H](Cn1c(=O)c(-c2ccccc2Cl)cn(Cc2c(F)cccc2F)c1=O)c1ccccc1,"3-((R)-2-Amino-2-phenyl-ethyl)-5-(2-chloro-phenyl)-1-(2,6-difluoro-benzyl)-1H-pyrimidine-2,4-dione",0.44,uM,=,-0.3565473235138126,0,O=c1c(-c2ccccc2)cn(Cc2ccccc2)c(=O)n1CCc1ccccc1
2924,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",O=C(c1ccccc1-n1nccn1)N1CCCC[C@H]1Cc1cccc(-n2nccn2)c1,"US9150566, Ref. 3",6.1,uM,=,0.785329835010767,1,O=C(c1ccccc1-n1nccn1)N1CCCC[C@H]1Cc1cccc(-n2nccn2)c1
2925,321500,10.1016/j.bmcl.2005.06.056,,,,Inhibition against Cytochrome P450 3A4 prepared from baculovirus-infected insect cells using 7-benzyloxy- 4-trifluoromethylcoumarin,O=c1c(CCO)c(-c2cc(Cl)ccc2O)c2cc(C(F)(F)F)ccc2n1Cc1nn[nH]n1,4-(5-Chloro-2-hydroxy-phenyl)-3-(2-hydroxy-ethyl)-1-(2H-tetrazol-5-ylmethyl)-6-trifluoromethyl-1H-quinolin-2-one,30.0,uM,=,1.4771212547196624,1,O=c1cc(-c2ccccc2)c2ccccc2n1Cc1nn[nH]n1
2926,1685398,10.1016/j.bmcl.2017.05.014,,,,Inhibition of CYP3A4 (unknown origin),Cc1nnc2sc(C(=O)NC3CN(c4cccc(F)c4F)C3)c(N)c2c1C,"5-amino-N-(1-(2,3-difluorophenyl)azetidin-3-yl)-3,4-dimethylthieno[2,3-c]pyridazine-6-carboxamide",11.0,uM,=,1.0413926851582251,1,O=C(NC1CN(c2ccccc2)C1)c1cc2ccnnc2s1
2927,1641852,,,,,"CYP Inhibition Assay: Incubation of phenacetin, diclofenac, dextromethorphan, mephenotoin, albendazole and testosterone with human liver microsomes in the presence of in each case eight different concentrations of a compound formula (B) (as potential inhibitor) is carried out on a incubator shaker at 37 C. Standard incubation mixtures comprise NADPH and substrates in 100 mM phosphate buffer (pH 7.4) in a total volume of 200 μl. Test compound are dissolved in acetonitrile. Incubated with pooled human liver microsomes at 37° C. for a defined time. The reactions are stopped by adding 100 μl of acetonitrile in which a suitable internal standard is always present. Precipitated proteins are removed by centrifugation, and the supernatants analyzed by LC-MS/MS.",O=CN(C[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)C(=O)c1ccc(Cl)s1,"US9359341, Formula B",5.7,uM,=,0.7558748556724915,1,O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1cccs1
2928,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5cnc6ccccc6c5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, H-6",2.09,uM,=,0.320146286111054,1,O=C1[C@H](Cc2ccccc2)N2C(=O)CNN(C(=O)NCc3ccccc3)[C@H]2CN1Cc1cccc2c(-c3cnc4ccccc4c3)c[nH]c12
2929,1291572,10.1016/j.bmcl.2013.12.058,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)NCCCCNC(=O)OCc2cncs2)C(C)C)cs1,(S)-thiazol-5-ylmethyl 4-(2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-3-methylbutanamido)butylcarbamate,0.87,uM,=,-0.0604807473813814,0,O=C(CNC(=O)NCc1cscn1)NCCCCNC(=O)OCc1cncs1
2930,1919651,,,,,"Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase",CC(=O)SCc1ccc(-c2cccnc2)o1,S-(5-(Pyridin-3-yl)furan-2-yl)methyl ethanethioate,2.9,uM,=,0.4623979978989561,1,c1cncc(-c2ccco2)c1
2931,1362864,10.1016/j.bmcl.2014.04.049,,,,Inhibition of CYP3A4 (unknown origin),Cn1c2c(c(=O)n1-c1ccccc1C(F)(F)F)[C@H]1CC[C@]2(C)C1(C)C,"(4S,7R)-1,7,8,8-Tetramethyl-2-(2-trifluoromethyl-phenyl)-1,2,4,5,6,7-h exahydro-4,7-methano-indazol-3-one",22.6,uM,=,1.354108439147401,1,O=c1c2c([nH]n1-c1ccccc1)C1CC[C@H]2C1
2932,1653169,10.1021/acsmedchemlett.6b00465,,,,Inhibition of CYP3A4 (unknown origin),O=C(O)CSc1nnc(Br)n1-c1ccc(C2CC2)c2ccccc12,LESINURAD,74.4,uM,=,1.8715729355458788,1,c1ccc2c(-n3cnnc3)ccc(C3CC3)c2c1
2933,776115,10.1016/j.bmcl.2011.09.074,,,,Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(c1ccc(F)cc1)C2=O,"3-(aminomethyl)-4-(2,4-dichlorophenyl)-6-(4-fluorophenyl)-2-methyl-5H-pyrrolo[3,4-b]pyridin-7(6H)-one",1.4,uM,=,0.1461280356782379,1,O=C1c2nccc(-c3ccccc3)c2CN1c1ccccc1
2934,1283600,10.1021/jm401610c,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone,O=C([C@@H](c1ccc(Cl)cc1)c1cccnc1)N1CCN(c2ccc(C(F)(F)F)cc2)CC1,(S)-2-(4-Chlorophenyl)-1-{4-[4-(trifluoromethyl)phenyl]piperazin-1-yl}-2-(pyridin-3-yl)ethanone,15.0,uM,=,1.1760912590556811,1,O=C([C@@H](c1ccccc1)c1cccnc1)N1CCN(c2ccccc2)CC1
2935,619264,10.1016/j.bmcl.2009.07.002,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,Cc1cccc(C)c1CNc1nccc2c1cc(C)n2C,"N-(2,6-dimethylbenzyl)-1,2-dimethyl-1H-pyrrolo[3,2-c]pyridin-4-amine",3.1,uM,=,0.4913616938342727,1,c1ccc(CNc2nccc3[nH]ccc23)cc1
2936,52065,10.1021/jm0310129,,,,Inhibitory activity against cytochrome P450 3A4,Cn1c2nccc(C(N)=O)c2c2nc(CN3CCOCC3)nc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21,"8-{4-[2-(3,4-Difluoro-phenyl)-ethyl]-piperazin-1-yl}-9-methyl-6-morpholin-4-ylmethyl-9H-1,5,7,9-tetraaza-fluorene-4-carboxylic acid amide",33.69,uM,=,1.5275010109811202,1,c1ccc(CCN2CCN(c3nc(CN4CCOCC4)nc4c3[nH]c3ncccc34)CC2)cc1
2937,857201,10.1021/jm200900q,,,,Inhibition of CYP3A4,N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(C(=O)[C@H](O)CO)CC3)cc2C2=CCCCC2)n1,"5-Cyano-1H-imidazole-2-carboxylic Acid{2-Cyclohex-1-enyl-4-[1-(R)-(+)-(2,3-dihydroxy-propionyl)-piperidin-4-yl]-phenyl}-amide",8.2,uM,=,0.9138138523837168,1,O=C(Nc1ccc(C2CCNCC2)cc1C1=CCCCC1)c1ncc[nH]1
2938,1641039,,,,,"Inhibition Assay: Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 uM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 Î¼M. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:CH3CN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO: CH3CN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v. Pooled human liver microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 5 mg/mL suspension.",OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(Cl)nc2)cn1,"US9221791, 30",17.0,uM,=,1.230448921378274,1,c1ccc(C(Cc2ccc(-c3cccnc3)cn2)Cn2cnnn2)cc1
2939,2151593,10.1021/acs.jmedchem.1c01157,,,,Inhibition of CYP3A4 in human liver microsome using midazolam as substrate,CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,SID144204227,0.09,uM,=,-1.0457574905606752,0,c1ccc([C@@]2(Cn3ccnc3)OC[C@H](COc3ccc(N4CCNCC4)cc3)O2)cc1
2940,774749,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",COc1cc(N)c(Cl)cc1C(=O)NC1CCN(CCCOc2ccc(F)cc2)CC1OC,4-Amino-5-chloro-N-{1-[3-(4-fluoro-phenoxy)-propyl]-2-methoxy-piperidin-4-yl}-2-methoxy-benzamide,0.3,uM,=,-0.5228787452803376,0,O=C(NC1CCN(CCCOc2ccccc2)CC1)c1ccccc1
2941,651640,10.1016/j.bmcl.2010.07.009,,,,Inhibition of CYP3A4,c1ccc(Cn2nnnc2C(c2ccc(Cn3cncn3)cc2)N2CCCN(C3CCC3)CC2)cc1,"1-((4-((1H-1,2,4-triazol-1-yl)methyl)phenyl)(1-benzyl-1H-tetrazol-5-yl)methyl)-4-cyclobutyl-1,4-diazepane",12.0,uM,=,1.0791812460476249,1,c1ccc(Cn2nnnc2C(c2ccc(Cn3cncn3)cc2)N2CCCN(C3CCC3)CC2)cc1
2942,465432,10.1016/j.bmcl.2007.11.008,,,,Inhibition of CYP3A4,CC(C)C[C@@H]1C(=O)N[C@H](C2Cc3ccccc3C2)C(=O)N1[C@@H](C(=O)NC(C)C)c1ccc(C(F)(F)F)o1,"(R)-2-((3R,6R)-3-(2,3-dihydro-1H-inden-2-yl)-6-isobutyl-2,5-dioxopiperazin-1-yl)-N-isopropyl-2-(5-(trifluoromethyl)furan-2-yl)acetamide",3.0,uM,=,0.4771212547196624,1,O=C1CN(Cc2ccco2)C(=O)[C@@H](C2Cc3ccccc3C2)N1
2943,1528565,,,,,"Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",CC(C)c1nc(CN(C)C(=O)N2CSC[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,"US8987313, 16",0.3,uM,=,-0.5228787452803376,0,O=C(N[C@H](CC[C@H](Cc1ccccc1)NC(=O)[C@@H]1CSCN1C(=O)NCc1cscn1)Cc1ccccc1)OCc1cncs1
2944,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N(CCN(CC)CC)CCN(CC)CC)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1,"US8940739, G-26",5.35,uM,=,0.7283537820212285,1,O=C(Nc1cccnc1)c1c[nH]c2c(CN3CC4N(C(=O)NCc5ccccc5)NCC(=O)N4C(Cc4ccccc4)C3=O)cccc12
2945,643848,10.1016/j.bmcl.2010.06.063,,,,inhibition of CYP3A4,Cc1nc2cc(-c3ccccc3)nn2c(-c2ccc(Cl)cc2Cl)c1CN,"(7-(2,4-dichlorophenyl)-5-methyl-2-phenylpyrazolo[1,5-a]pyrimidin-6-yl)methanamine",1.0,uM,=,0.0,0,c1ccc(-c2cc3nccc(-c4ccccc4)n3n2)cc1
2946,1301328,10.6019/CHEMBL3137440,,,,DNDI: CYP Inhibition,CC(=O)C(C)N1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1,,5.0,uM,=,0.6989700043360189,1,c1ccc(N(c2cccnc2)C2CCNCC2)cc1
2947,1277670,10.1016/j.bmcl.2013.10.052,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,CC[C@@H](Cn1ccc2ccccc21)NS(=O)(=O)c1c(N)cc(Cl)cc1Cl,"(S)-N-(1-(1H-indol-1-yl)butan-2-yl)-2-amino-4,6-dichlorobenzenesulfonamide",0.57,uM,=,-0.2441251443275086,0,O=S(=O)(NCCn1ccc2ccccc21)c1ccccc1
2948,1846368,10.1016/j.ejmech.2019.02.073,,,,Inhibition of CYP3A4 (unknown origin),CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OCC=Cc2cnc3ccccc3c2)C[C@@H](C)C(=O)[C@H](C)[C@H]2NC(=O)O[C@@]21C,"10-(4-Dimethylamino-3-hydroxy-6-methyl-tetrahydro-pyran-2-yloxy)-4-ethyl-3a,7,9,11,13,15-hexamethyl-11-(3-quinolin-3-yl-allyloxy)-octahydro-3,5-dioxa-1-aza-cyclopentacyclotetradecene-2,6,8,14-tetraone",2.7,uM,=,0.4313637641589873,1,O=C1CCC(OCC=Cc2cnc3ccccc3c2)[C@H](O[C@H]2CCCCO2)CC(=O)CC(=O)OCC2OC(=O)N[C@@H]2C1
2949,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NC5CCN(C(=O)c6ccc(N7CCN(C)CC7)cc6)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, F-67",9.65,uM,=,0.9845273133437926,1,O=C(NC1CCN(C(=O)c2ccc(N3CCNCC3)cc2)CC1)c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12
2950,1447575,10.1016/j.bmcl.2014.05.068,,,,Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method,O[C@@](Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(OC(F)(F)F)cc2)cn1,"(R)-2-(2,4-difluorophenyl)-1,1-difluoro-3-(1H-tetrazol-1-yl)-1-(5-(4-(trifluoromethoxy)phenyl)pyridin-2-yl)propan-2-ol",79.0,uM,=,1.8976270912904407,1,c1ccc(-c2ccc(CC(Cn3cnnn3)c3ccccc3)nc2)cc1
2951,1467195,10.1021/jm5005336,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay,O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccc(CN4CCOCC4)cc3)n[nH]c2c1,"(1R*,2S*)-(E)-2-(3-(4-(Morpholinomethyl)styryl)-1H-indazol-6-yl)-spiro[cyclopropane-1,3'-indolin]-2'-one",6.3,uM,=,0.7993405494535817,1,O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccc(CN4CCOCC4)cc3)n[nH]c2c1
2952,2296589,10.1021/acs.jmedchem.5b02025,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate assessed as reduction in substrate hydroxylation incubated for 30 mins in presence of beta-NADPH measured by LC-MS/MS analysis,NCCCC[C@H](NC(=O)C(NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCCN)C(c1ccccc1)c1ccccc1)C(N)=O,"(2S)-2,6-diamino-N-((5S,11S,14S,17S,20S,23S,26S)-11,20,23-tris((1H-indol-3-yl)methyl)-1,30-diamino-14,17-bis(4-aminobutyl)-8-benzhydryl-5-carbamoyl-7,10,13,16,19,22,25-heptaoxo-6,9,12,15,18,21,24-heptaazatriacontan-26-yl)hexanamide",12.1,uM,=,1.08278537031645,1,O=C(CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CCc1c[nH]c2ccccc12)NCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCC(c1ccccc1)c1ccccc1
2953,1911030,10.1021/acs.jmedchem.8b01226,,,,Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins,CCN(C(=O)N1CCC(=CC#Cc2cccc(C)n2)CC1)C(C)C,N-Ethyl 4-[3-(6-Methylpyridin-2-yl)prop-2-yn-1-ylidene]-N-(propan-2-yl)piperidine-1-carboxamide,15.4,uM,=,1.187520720836463,1,C(#Cc1ccccn1)C=C1CCNCC1
2954,2278020,10.1021/acs.jmedchem.2c01517,,,,Inhibition of CYP3A4 in human liver microsome suspension using midazolam substrate incubated for 30 mins by LC/MS analysis,COc1cc2nc(C)nc(N[C@H](C)c3cc(N)cc(C(F)(F)F)c3)c2cc1O[C@H]1CCOC1,N-((R)-1-(3-amino-5-(trifluoromethyl)phenyl)ethyl)-7-methoxy-2-methyl-6-((S)-tetrahydrofuran-3-yloxy)quinazolin-4-amine,24.0,uM,=,1.380211241711606,1,c1ccc(CNc2ncnc3ccc(O[C@H]4CCOC4)cc23)cc1
2955,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCC(O)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, E-51",10.7,uM,=,1.0293837776852095,1,O=C(c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12)N1CCCCC1
2956,789607,10.1021/jm2008369,,,,Inhibition of human CYP3A4,Cc1ccc(COc2ccc3c(c2)c(SC(C)(C)C)c(CC(C)(C)C(=O)O)n3Cc2ccc(-c3ccc(C)cn3)cc2)nc1,"3-(3-(tert-butylthio)-1-(4-(5-methylpyridin-2-yl)benzyl)-5-((5-methylpyridin-2-yl)methoxy)-1H-indol-2-yl)-2,2-dimethylpropanoic acid",0.0085,uM,=,-2.070581074285707,0,c1ccc(COc2ccc3c(ccn3Cc3ccc(-c4ccccn4)cc3)c2)nc1
2957,449485,10.1016/j.bmcl.2007.07.097,,,,Inhibition of microsomal CYP3A4,CC(C)C[C@H](NCCO)c1cc(C(F)(F)F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1,"1-((R)-3-(2,4-dichlorophenyl)-1-(4-(2-((S)-1-(2-hydroxyethylamino)-3-methylbutyl)-4-(trifluoromethyl)phenyl)piperazin-1-yl)-1-oxopropan-2-yl)pyrrolidin-2-one",35.0,uM,=,1.5440680443502757,1,O=C([C@@H](Cc1ccccc1)N1CCCC1=O)N1CCN(c2ccccc2)CC1
2958,2085992,10.1021/acs.jmedchem.8b01695,,,,Inhibition of CYP3A4 (unknown origin),COc1ccccc1CC[C@@H]1CCc2cc([C@H]3CC[C@](N)(CO)C3)ccc2C1,"[(1R,3S)-1-amino-3-[(2S)-2-[2-(2-methoxyphenyl)ethyl]tetralin-6-yl]cyclopentyl]methanol",5.5,uM,=,0.7403626894942439,1,c1ccc(CC[C@@H]2CCc3cc(C4CCCC4)ccc3C2)cc1
2959,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",O=C(c1ccc(Cl)cc1-n1nccn1)N1CCOC[C@H]1Cc1cc(-n2nccn2)ccc1F,"US9150566, 130",20.0,uM,=,1.3010299956639813,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
2960,2277116,10.1021/acs.jmedchem.1c00864,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as substrate incubated for 10 to 20 mins in presence of NADPH-generating system by LC-MS/MS analysis,O=C(c1cccnc1-c1ccncc1)N1CCC(O)(Cc2ccccc2)CC1,SOTICLESTAT,6.6,uM,=,0.8195439355418687,1,O=C(c1cccnc1-c1ccncc1)N1CCC(Cc2ccccc2)CC1
2961,1985638,10.1021/acsmedchemlett.0c00095,,,,Inhibition of human CYP3A4,Cc1nc2c(-c3nnc[nH]3)cc(-c3ccncc3)cc2n1-c1ccnc2c(F)ccc(F)c12,"(P)-5,8-difluoro-4-(2-methyl-6-(pyridin-4-yl)-4-(4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-1-yl)quinoline",1.0,uM,=,0.0,0,c1ccc2c(-n3cnc4c(-c5nnc[nH]5)cc(-c5ccncc5)cc43)ccnc2c1
2962,495542,10.1021/jm801332q,,,,Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate by time dependent inhibition assay,C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(Nc4ccc(F)cc4)CC3)cc2)CCN1,N-(4-Fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine,4.9,uM,=,0.6901960800285137,1,O=C(Cc1ccc(CN2CCNCC2)cc1)N1CCC(Nc2ccccc2)CC1
2963,1614026,10.1016/j.bmcl.2016.09.043,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 1'-hydroxymidazolam metabolite formation using midazolam as substrate incubated for 10 mins by HPLC-MS method,Cn1c(NCCc2ccc(N3CCOCC3)cc2)nc2cc(Cl)ccc2c1=O,7-Chloro-3-methyl-2-[2-(4-morpholin-4-yl-phenyl)-ethylamino]-3H-quinazolin-4-one,11.0,uM,=,1.0413926851582251,1,O=c1[nH]c(NCCc2ccc(N3CCOCC3)cc2)nc2ccccc12
2964,2164739,10.1021/acs.jmedchem.1c02131,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate,Cc1cc(-c2ccc(OC[C@@H](N)CC(C)C)c(C#N)c2)ccn1,(S)-2-((2-Amino-4-methylpentyl)oxy)-5-(2-methylpyridin-4-yl)-benzonitrile,2.4,uM,=,0.380211241711606,1,c1ccc(-c2ccncc2)cc1
2965,1288280,10.1016/j.bmcl.2013.12.057,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,COC[C@H](NC(=O)N(C)Cc1csc(C(C)C)n1)C(=O)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1,"Thiazol-5-ylmethyl(2R,5R)-5-((S)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-3-methoxypropanamido)-1,6-diphenylhexan-2-ylcarbamate",0.15,uM,=,-0.8239087409443188,0,O=C(CNC(=O)NCc1cscn1)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
2966,619264,10.1016/j.bmcl.2009.07.002,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,CCn1c(C)c(C)c2cc(-n3ccccc3=O)nc(NCc3c(C)cccc3C)c21,"1-(7-(2,6-dimethylbenzylamino)-1-ethyl-2,3-dimethyl-1H-pyrrolo[2,3-c]pyridin-5-yl)pyridin-2(1H)-one",2.9,uM,=,0.4623979978989561,1,O=c1ccccn1-c1cc2cc[nH]c2c(NCc2ccccc2)n1
2967,1279390,10.1021/ml4002612,,,,Inhibition of CYP3A4 (unknown origin),CC(C)(C1CCN(C(=O)c2ccc(S(C)(=O)=O)cc2OC(F)(F)F)CC1)S(=O)(=O)c1cccc(C(F)(F)F)c1,(4-(methylsulfonyl)-2-(trifluoromethoxy)phenyl)(4-(2-((3-(trifluoromethyl)phenyl)sulfonyl)propan-2-yl)piperidin-1-yl)methanone,10.0,uM,=,1.0,1,O=C(c1ccccc1)N1CCC(CS(=O)(=O)c2ccccc2)CC1
2968,1797910,10.1021/acs.jmedchem.8b01326,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate/NADPH addition measured after 10 mins by LC-MS/MS analysis,CN1C(=N)N[C@@]2(c3cc(-c4cc(F)cc(C#N)c4)cs3)CN(c3ncc(F)cn3)C[C@H]2C1=O,"3-Fluoro-5-(5-((4aR,7aR)-6-(5-fluoropyrimidin-2-yl)-2-imino-3-methyl-4-oxooctahydro-7aH-pyrrolo[3,4-d]pyrimidin-7a-yl)-thiophen-3-yl)benzonitrile",1.6,uM,=,0.2041199826559248,1,N=C1NC(=O)[C@@H]2CN(c3ncccn3)C[C@]2(c2cc(-c3ccccc3)cs2)N1
2969,510165,10.1021/jm800377h,,,,Inhibition of human recombinant CYP3A4 expressed in insect microsomes,COc1ccc2cc(-c3cnccc3N)ccc2c1,3-(6-Methoxynaphthalen-2-yl)pyridin-4-amine,21.07,uM,=,1.3236645356081005,1,c1cncc(-c2ccc3ccccc3c2)c1
2970,791534,10.1016/j.ejmech.2011.10.053,,,,Inhibition of human recombinant CYP3A4,COc1ccc(-c2sc(/N=C/c3ccc(N(C)CCC#N)cc3)c(C#N)c2C)cc1OC,"2-({4-[(2-cyanoethyl)(methyl)amino]benzylidene}amino)-5-(3,4-dimethoxyphenyl)-4-methylthiophene-3-carbonitrile",33.2,uM,=,1.5211380837040362,1,C(=N/c1ccc(-c2ccccc2)s1)\c1ccccc1
2971,1584799,10.1021/acs.jmedchem.6b00030,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 5 mins by LC-MS analysis,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,"1-(4-{4-[2-(2,4-Dichloro-phenyl)-2-imidazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-ethanone (ketoconazole)",0.001,uM,=,-3.0,0,c1ccc(C2(Cn3ccnc3)OCC(COc3ccc(N4CCNCC4)cc3)O2)cc1
2972,2246941,10.1021/acs.jmedchem.1c02132,,,,Inhibition of CYP3A4 (unknown origin) incubated for 10 mins in presence of NADPH by LC-MS/MS analysis,COC(=O)Nc1cc(-c2cc(C)c(OC[C@@](C)(N)CC(C)C)cn2)ccn1,"(S)-methyl (5-((2-amino-2,4-dimethylpentyl)oxy)-4-methyl-[2,4'-bipyridin]-2'-yl)carbamate",13.0,uM,=,1.1139433523068367,1,c1ccc(-c2ccncc2)nc1
2973,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",C[C@@H]1CN(C(=O)c2ccc(Cl)cc2-n2nccn2)[C@H](Cc2cc(-c3ncccn3)ccc2F)CO1,"US9150566, 153",18.0,uM,=,1.255272505103306,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2ncccn2)c1
2974,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N[C@H](C)C(=O)OC)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, F-21",10.89,uM,=,1.037027879755775,1,O=C1[C@H](Cc2ccccc2)N2C(=O)CNN(C(=O)NCc3ccccc3)[C@H]2CN1Cc1cccc2cc[nH]c12
2975,449485,10.1016/j.bmcl.2007.07.097,,,,Inhibition of microsomal CYP3A4,CNCC(=O)N[C@@H](CC(C)C)c1cc(C)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1,"N-((S)-1-(2-(4-((R)-3-(2,4-dichlorophenyl)-2-(2-oxopyrrolidin-1-yl)propanoyl)piperazin-1-yl)-5-methylphenyl)-3-methylbutyl)-2-(methylamino)acetamide",3.6,uM,=,0.5563025007672873,1,O=C([C@@H](Cc1ccccc1)N1CCCC1=O)N1CCN(c2ccccc2)CC1
2976,949159,10.1016/j.bmcl.2013.01.011,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,O=C(N[C@H](Cc1cc2oc(=O)[nH]c2cc1Br)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1,"(R)-N-(1-(1,4'-bipiperidin-1'-yl)-3-(5-bromo-2-oxo-2,3-dihydrobenzo[d]oxazol-6-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide",18.0,uM,=,1.255272505103306,1,O=C(N[C@H](Cc1ccc2[nH]c(=O)oc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
2977,2024613,10.1016/j.bmcl.2020.127721,,,,Inhibition of CYP3A4 (unknown origin),CS(=O)(=O)Nc1cccc(CC(=O)Nc2cnc(-c3c[nH]c4ncccc34)s2)c1,"2-[3-(methanesulfonamido)phenyl]-N-[2-(1H-pyrrolo[2,3-b]pyridin-3-yl)thiazol-5-yl]acetamide",12.0,uM,=,1.0791812460476249,1,O=C(Cc1ccccc1)Nc1cnc(-c2c[nH]c3ncccc23)s1
2978,52069,10.1021/jm021012t,,,,Inhibition of human cytochrome P450 3A4,COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1,[1-(4-Fluoro-benzyl)-1H-benzoimidazol-2-yl]-{1-[2-(4-methoxy-phenyl)-ethyl]-piperidin-4-yl}-amine,3.3,uM,=,0.5185139398778875,1,c1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccccc3)CC2)cc1
2979,1520093,10.1021/acsmedchemlett.5b00207,,,,Inhibition of CYP3A4 (unknown origin),COCc1cnc(N2CCC([C@H]3C[C@H]3COCc3ccc(S(C)(=O)=O)cc3F)CC2)nc1,"2-(4-((1R,2R)-2-((2-fluoro-4-(methylsulfonyl)benzyloxy)methyl)cyclopropyl)piperidin-1-yl)-5-(methoxymethyl)pyrimidine",40.0,uM,=,1.6020599913279625,1,c1ccc(COC[C@@H]2C[C@@H]2C2CCN(c3ncccn3)CC2)cc1
2980,487712,10.1016/j.bmcl.2008.05.104,,,,Inhibition of CYP3A4,Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,4-[(S)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-(4-methyl-6-morpholin-4-yl-1H-benzoimidazol-2-yl)-1H-pyridin-2-one,0.0005,uM,=,-3.3010299956639813,0,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(N3CCOCC3)cc2[nH]1
2981,988989,10.1021/jm400732v,,,,Inhibition of CYP3A4 (unknown origin),CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2nn(-c3ccccc3C#N)c3ccccc23)c2ccccc2N(C(=O)CS(C)(=O)=O)[C@H]1C.Cl,"(S)-N-((3S,4S)-1-((1-(2-Cyanophenyl)-1H-indazol-3-yl)methyl)-4-methyl-5-(2-(methylsulfonyl)acetyl)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-yl)-2-(methylamino)propanamide hydrochloride",37.0,uM,=,1.568201724066995,1,O=C1CCNc2ccccc2N1Cc1nn(-c2ccccc2)c2ccccc12
2982,1446329,10.1021/ml500387y,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2cc(OC(C)C)ncc2[nH]1)C(F)(F)F,"1,1,1-trifluoro-4-(5-fluoro-2-methylphenyl)-2-((5-isopropoxy-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)-4-methylpentan-2-ol",0.3,uM,=,-0.5228787452803376,0,c1ccc(CCCCc2cc3ccncc3[nH]2)cc1
2983,644596,10.1016/j.bmcl.2010.06.011,,,,Inhibition of CYP3A4,COc1cnc(-c2ccc(Cn3c(CC(C)(C)C(=O)[O-])c(SC(C)(C)C)c4cc(OCc5ccc(C)cn5)ccc43)cc2)nc1.[Na+],"sodium 3-(3-(tert-butylthio)-1-(4-(5-methoxypyrimidin-2-yl)benzyl)-5-((5-methylpyridin-2-yl)methoxy)-1H-indol-2-yl)-2,2-dimethylpropanoate",8.8,uM,=,0.9444826721501688,1,c1ccc(COc2ccc3c(ccn3Cc3ccc(-c4ncccn4)cc3)c2)nc1
2984,617698,10.1016/j.bmcl.2010.01.087,,,,Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay,Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NCCc4ncn(C)c4Cl)cc[nH]c3=O)nc12,4-(2-(5-chloro-1-methyl-1H-imidazol-4-yl)ethylamino)-3-(4-methyl-6-morpholino-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one,1.9,uM,=,0.2787536009528289,1,O=c1[nH]ccc(NCCc2c[nH]cn2)c1-c1nc2ccc(N3CCOCC3)cc2[nH]1
2985,1465541,10.1016/j.bmcl.2015.01.051,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(CCOC)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O,"(1S,4R,5R,6R,8R,10S,11R,12S,13R,16R,18S,21R)-8-[(1S)-1-ethoxy-2-hydroxy-2-methylpropyl]-18-{[(2S)-4-(2-methoxyethyl)morpholin-2-yl]oxy}-4,6,12,17,17-pentamethyl-9-oxahexacyclo[11.9.0.0^{1,21}.0^{4,12}.0^{5,10}.0^{16,21}]docosan-11-ol",1.1,uM,=,0.041392685158225,1,C1CO[C@@H]2CC3C(CC[C@@]45C[C@@]46CC[C@H](O[C@H]4CNCCO4)C[C@@H]6CC[C@@H]35)[C@H]2C1
2986,2017934,10.1021/acs.jmedchem.0c00834,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis,Cc1c(-c2ccccc2)nc2ccc(Br)cc2c1CNc1ccc(C(=O)O)cc1F,4-{[(6-Bromo-3-methyl-2-phenylquinolin-4-yl)methyl]amino}-3-fluorobenzoic acid,9.0,uM,=,0.9542425094393248,1,c1ccc(NCc2cc(-c3ccccc3)nc3ccccc23)cc1
2987,1797910,10.1021/acs.jmedchem.8b01326,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate/NADPH addition measured after 10 mins by LC-MS/MS analysis,CCOc1nc(N2C[C@H]3C(=O)N(C)C(=N)N[C@@]3(c3cc(-c4cccc(C#N)c4)cs3)C2)ncc1F,"3-(5-((4aR,7aR)-6-(4-Ethoxy-5-fluoropyrimidin-2-yl)-2-imino-3-methyl-4-oxooctahydro-7aH-pyrrolo[3,4-d]pyrimidin-7a-yl)-thiophen-3-yl)benzonitrile",0.7,uM,=,-0.1549019599857432,0,N=C1NC(=O)[C@@H]2CN(c3ncccn3)C[C@]2(c2cc(-c3ccccc3)cs2)N1
2988,2171309,10.1021/acs.jmedchem.1c00633,,,,Inhibition of CYP3A4 (unknown origin) using ketoconazole as substrate,CN(C(=O)Cn1ccnc1)C(c1ccccc1)c1ccc(Cl)cc1,N-((4-Chlorophenyl)(phenyl)methyl)-2-(1H-imidozol-1-yl)-N-methylacetamide,0.18,uM,=,-0.744727494896694,0,O=C(Cn1ccnc1)NC(c1ccccc1)c1ccccc1
2989,945618,10.1016/j.bmc.2012.11.058,,,,Inhibition of CYP3A4 (unknown origin),CCNC(=O)c1cc(NS(=O)(=O)c2cc(C)c(Cl)cc2Cl)ccc1Oc1cncc(Cl)c1,"2-(5-Chloropyridin-3-yloxy)-5-(2,4-dichloro-5-methylphenylsulfonamido)-N-ethylbenzamide",0.36,uM,=,-0.4436974992327127,0,O=S(=O)(Nc1ccc(Oc2cccnc2)cc1)c1ccccc1
2990,2116571,10.1021/acsmedchemlett.1c00198,,,,Inhibition of CYP3A4 (unknown origin) expressed in baculovirus infected insect supersomes preincubated for 15 mins followed by addition of NADPH regenerating system by fluorescence based analysis,O=C(O)c1cc(F)c2nc(N3CCC4(C=C(c5c(-c6ccccc6C(F)(F)F)noc5C5CC5)C4)CC3)sc2c1,2-(2-(5-cyclopropyl-3-(2-(trifluoromethyl)phenyl)isoxazol-4-yl)-7-azaspiro[3.5]non-1-en-7-yl)-4-fluorobenzo[d]thiazole-6-carboxylic acid,10.8,uM,=,1.0334237554869496,1,C1=C(c2c(-c3ccccc3)noc2C2CC2)CC12CCN(c1nc3ccccc3s1)CC2
2991,1287294,10.1021/jm401639v,,,,Inhibition of CYP3A4 (unknown origin) by fluorescence assay,C[C@]12CC[C@@H]3c4ccc(CCBr)cc4CC[C@H]3[C@@H]1C[C@H](Cc1cccc(C(N)=O)c1)[C@@H]2O,"3-{[(16beta,17beta)-3-(2-bromoethyl)-17-hydroxyestra-1(10),2,4-trien-16-yl]methyl}benzamide",3.9,uM,=,0.5910646070264992,1,c1ccc(C[C@@H]2CC3CC[C@@H]4c5ccccc5CC[C@H]4[C@@H]3C2)cc1
2992,1288280,10.1016/j.bmcl.2013.12.057,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,CC(=O)NCC[C@H](NC(=O)N(C)Cc1csc(C(C)C)n1)C(=O)N[C@@H](CC[C@@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1,"Thiazol-5-ylmethyl(2S,5S)-5-((S)-4-acetamido-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)butanamido)-1,6-diphenylhexan-2-ylcarbamate",0.12,uM,=,-0.9208187539523752,0,O=C(CNC(=O)NCc1cscn1)N[C@@H](CC[C@@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
2993,1922952,10.1021/acs.jmedchem.6b00389,,,,Inhibition of CYP3A4 (unknown origin),Cc1cc(Nc2nccc(-c3ccn([C@H](CO)c4ccc(Cl)c(F)c4)c(=O)c3)n2)ccn1,(S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-(2-methylpyridin-4-ylamino)pyrimidin-4-yl)pyridin-2(1H)-one,0.34,uM,=,-0.4685210829577448,0,O=c1cc(-c2ccnc(Nc3ccncc3)n2)ccn1Cc1ccccc1
2994,2156515,10.1021/acs.jmedchem.1c01272,,,,Inhibition of CYP3A4 in human liver microsomes using IPA as substrate preincubated for 10 mins followed by NADPH generating system addition and measured after 20 mins,COc1cc(NC(=O)c2cnc3ccccc3c2)c(-c2nnn(-c3ccc(CCN4CCc5cnccc5C4)cc3)n2)cc1OCc1ccccc1,"N-(4-(benzyloxy)-2-(2-(4-(2-(3,4-dihydro-2,6-naphthyridin-2(1H)-yl)ethyl)phenyl)-2H-tetrazol-5-yl)-5-methoxyphenyl)quinoline-3-carboxamide",0.851,uM,=,-0.0700704399154121,0,O=C(Nc1ccc(OCc2ccccc2)cc1-c1nnn(-c2ccc(CCN3CCc4cnccc4C3)cc2)n1)c1cnc2ccccc2c1
2995,2024613,10.1016/j.bmcl.2020.127721,,,,Inhibition of CYP3A4 (unknown origin),CS(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncc(Cl)cc34)cs2)c1,"N-[4-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)thiazol-2-yl]-2-[3-(methanesulfonamido)phenyl]acetamide",8.0,uM,=,0.9030899869919436,1,O=C(Cc1ccccc1)Nc1nc(-c2c[nH]c3ncccc23)cs1
2996,1616389,10.1021/acs.jmedchem.6b00989,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate assessed as reduction in 1-OH-midazolam formation by LC/MS/MS analysis,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,"1-(4-{4-[2-(2,4-Dichloro-phenyl)-2-imidazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-ethanone (ketoconazole)",0.0091,uM,=,-2.0409586076789066,0,c1ccc(C2(Cn3ccnc3)OCC(COc3ccc(N4CCNCC4)cc3)O2)cc1
2997,1584592,10.1021/acs.jmedchem.6b00030,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 4 mins by LC-MS analysis,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,"1-(4-{4-[2-(2,4-Dichloro-phenyl)-2-imidazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-ethanone (ketoconazole)",0.004,uM,=,-2.397940008672037,0,c1ccc(C2(Cn3ccnc3)OCC(COc3ccc(N4CCNCC4)cc3)O2)cc1
2998,674732,10.1016/j.bmcl.2010.09.029,,,,Inhibition of CYP3A4,CCCC#Cc1cc([C@@]2(c3ccc(OC(F)F)c(C)c3)N=C(N)N(C)C2=O)ccc1F,(R)-2-amino-4-(4-(difluoromethoxy)-3-methylphenyl)-4-(4-fluoro-3-(pent-1-ynyl)phenyl)-1-methyl-1H-imidazol-5(4H)-one,3.4,uM,=,0.5314789170422551,1,O=C1NC=NC1(c1ccccc1)c1ccccc1
2999,449485,10.1016/j.bmcl.2007.07.097,,,,Inhibition of microsomal CYP3A4,CC(C)C[C@H](N)c1ccccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1,"1-[(R)-2-{4-[2-((S)-1-amino-3-methylbutyl)phenyl]-piperazin-1-yl}-1-(2,4-dichlorobenzyl)-2-oxoethyl]pyrrolidin-2-one",0.12,uM,=,-0.9208187539523752,0,O=C([C@@H](Cc1ccccc1)N1CCCC1=O)N1CCN(c2ccccc2)CC1
3000,1499751,10.1021/acs.jmedchem.5b00424,,,,Inhibition of CYP3A4 (unknown origin),COc1cccc(CC(=O)Nc2cc(-c3ccnc(Cl)c3)cs2)c1,N-(4-(2-chloropyridin-4-yl)thiophen-2-yl)-2-(3-methoxyphenyl)acetamide,5.0,uM,=,0.6989700043360189,1,O=C(Cc1ccccc1)Nc1cc(-c2ccncc2)cs1
3001,438600,10.1016/j.bmcl.2007.03.048,,,,Inhibition of CYP3A4 in microsomes,Cc1cc(C(=O)NC2CCCCC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,"2-(4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-2-oxo-1,2-dihydropyridin-3-yl)-N-cyclohexyl-7-methyl-3H-benzo[d]imidazole-5-carboxamide",11.0,uM,=,1.0413926851582251,1,O=C(NC1CCCCC1)c1ccc2nc(-c3c(NCCc4ccccc4)cc[nH]c3=O)[nH]c2c1
3002,988989,10.1021/jm400732v,,,,Inhibition of CYP3A4 (unknown origin),CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2c(OC)ccc3ccccc23)c2ccccc2N(C(=O)CS(C)(=O)=O)[C@H]1C.Cl,"(S)-N-((3S,4S)-1-((2-Methoxynaphthalen-1-yl)methyl)-4-methyl-5-(2-(methylsulfonyl)acetyl)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-yl)-2-(methylamino)propanamide hydrochloride",9.7,uM,=,0.9867717342662448,1,O=C1CCNc2ccccc2N1Cc1cccc2ccccc12
3003,1276541,10.1016/j.bmcl.2013.09.041,,,,Inhibition of CYP3A4 (unknown origin) after 5 mins,O=S(=O)(Nc1ccc(-n2ccnc2)cc1)c1cc(Cl)cc(Cl)c1,"N-(4-(1H-imidazol-1-yl)phenyl)-3,5-dichlorobenzenesulfonamide",0.1,uM,=,-1.0,0,O=S(=O)(Nc1ccc(-n2ccnc2)cc1)c1ccccc1
3004,1923841,10.1021/acs.jmedchem.6b00280,,,,Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase and human b5 reductase assessed as reduction in 7-Hydroxyquinoline production using 7-benzyloxyquinoline as substrate and NADPH incubated for 15 mins by fluorimetry,O=C(NCCN1CCOCC1)Nc1nc2ccc(Sc3nnc4ccc(-c5cccc(F)c5)nn34)cc2s1,"1-(6-(6-(3-fluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazin-3-ylthio)benzo[d]thiazol-2-yl)-3-(2-morpholinoethyl)urea",1.8,uM,=,0.255272505103306,1,O=C(NCCN1CCOCC1)Nc1nc2ccc(Sc3nnc4ccc(-c5ccccc5)nn34)cc2s1
3005,991614,10.1021/jm4008906,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,COc1ccccc1N1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O,"rac-3-(Aminomethyl)-4-(2,4-dichlorophenyl)-6-(2-methoxyphenyl)-2-methyl-6,7-dihydropyrrolo[3,4-b]pyridin-5-one",0.8,uM,=,-0.0969100130080563,0,O=C1c2c(-c3ccccc3)ccnc2CN1c1ccccc1
3006,465260,10.1016/j.bmcl.2008.01.036,,,,Inhibition of CYP3A4,CCOc1ccc(CC(=O)Nc2cc(-n3nc(C)cc3C)nc(-c3ccccn3)n2)cc1OC,"N-(6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(pyridin-2-yl)pyrimidin-4-yl)-2-(4-ethoxy-3-methoxyphenyl)acetamide",7.0,uM,=,0.8450980400142568,1,O=C(Cc1ccccc1)Nc1cc(-n2cccn2)nc(-c2ccccn2)n1
3007,449485,10.1016/j.bmcl.2007.07.097,,,,Inhibition of microsomal CYP3A4,CC(C)C[C@H](NC(=O)CCN(C)C)c1ccccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1,"N-((S)-1-(2-(4-((R)-3-(2,4-dichlorophenyl)-2-(2-oxopyrrolidin-1-yl)propanoyl)piperazin-1-yl)phenyl)-3-methylbutyl)-3-(dimethylamino)propanamide",6.9,uM,=,0.8388490907372553,1,O=C([C@@H](Cc1ccccc1)N1CCCC1=O)N1CCN(c2ccccc2)CC1
3008,598210,10.1016/j.bmcl.2009.08.024,,,,Inhibition of human CYP3A4,COc1cccc(CNC(=O)CC2(C)CC3(CCCCC3)OO2)c1,"N-(3-methoxybenzyl)-2-(3-methyl-1,2-dioxaspiro[4.5]decan-3-yl)acetamide",3.7,uM,=,0.568201724066995,1,O=C(CC1CC2(CCCCC2)OO1)NCc1ccccc1
3009,768817,10.1021/jm2005354,,,,Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting,C[C@@H](c1ccc(-c2ccc(F)cc2F)cc1)N1CC[C@](CCNC(N)=O)(c2ccc(F)cc2)OC1=O,"1-(2-((R)-3-((S)-1-(2',4'-difluorobiphenyl-4-yl)ethyl)-6-(4-fluorophenyl)-2-oxo-1,3-oxazinan-6-yl)ethyl)urea",5.0,uM,=,0.6989700043360189,1,O=C1OC(c2ccccc2)CCN1Cc1ccc(-c2ccccc2)cc1
3010,802673,10.1016/j.bmcl.2011.12.125,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,CCNC(=O)c1cccc(NC(=O)Nc2ccc(-c3ccnc4[nH]cnc34)cc2)c1,"3-(3-(4-(3H-imidazo[4,5-b]pyridin-7-yl)phenyl)ureido)-N-ethylbenzamide",0.055,uM,=,-1.259637310505756,0,O=C(Nc1ccccc1)Nc1ccc(-c2ccnc3[nH]cnc23)cc1
3011,2134185,10.1021/acs.jmedchem.1c00855,,,,Inhibition of recombinant human CYP3A4 expressed in Escherichia coli using VG as probe substrate incubated for 15 to 60 mins by fluorometric assay,COCCNc1nc2cnc3cc(-c4c(C)noc4C)c(OC)cc3c2n1[C@H](C)c1ccccn1,"7-(3,5-Dimethylisoxazol-4-yl)-8-methoxy-N-(2-methoxyethyl)-1-((R)-1-(pyridine-2-yl)ethyl)-1H-imidazo[4,5-c]quinoline-2-amine",7.9,uM,=,0.8976270912904415,1,c1ccc(Cn2cnc3cnc4cc(-c5cnoc5)ccc4c32)nc1
3012,828928,10.1016/j.bmcl.2012.06.022,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,CCN(C)c1nc2ccc(C(=O)N(CC3CCCCC3)C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1,"Thiazol-5-ylmethyl(2S,3R)-4-(N-(cyclohexylmethyl)-2-(ethyl(methyl)amino)benzo[d]oxazole-6-carboxamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate",0.026,uM,=,-1.585026652029182,0,O=C(N[C@H](CCN(CC1CCCCC1)C(=O)c1ccc2ncoc2c1)Cc1ccccc1)OCc1cncs1
3013,827973,10.1016/j.bmcl.2012.05.087,,,,Inhibition of CYP3A4 using midazolam as substrate,COc1ccc(C(=O)N2CCc3ccccc32)cc1CSc1nc2cc(F)ccc2n1CC(=O)O,2-(5-fluoro-2-(5-(indoline-1-carbonyl)-2-methoxybenzylthio)-1H-benzo[d]imidazol-1-yl)acetic acid,5.0,uM,=,0.6989700043360189,1,O=C(c1cccc(CSc2nc3ccccc3[nH]2)c1)N1CCc2ccccc21
3014,1849385,10.1016/j.bmcl.2019.06.044,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis,O=C(O)c1ccc(-n2cc(C(=O)c3c(Cl)cccc3Cl)c3ccccc32)cc1,"4-[3-(2,6-dichlorobenzoyl)indol-1-yl]benzoic acid",15.5,uM,=,1.1903316981702914,1,O=C(c1ccccc1)c1cn(-c2ccccc2)c2ccccc12
3015,1276541,10.1016/j.bmcl.2013.09.041,,,,Inhibition of CYP3A4 (unknown origin) after 5 mins,O=S(=O)(Nc1ccc(-c2cc[nH]n2)cc1)c1cc(Cl)cc(Cl)c1,"N-(4-(1H-pyrazol-3-yl)phenyl)-3,5-dichlorobenzenesulfonamide",15.3,uM,=,1.1846914308175989,1,O=S(=O)(Nc1ccc(-c2cc[nH]n2)cc1)c1ccccc1
3016,461436,10.1016/j.bmcl.2007.10.092,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,O=C(CC1([C@H]2CCC[C@@H](C3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CCC2(CCN2)CC1,"2-{1-[(2R,6S)-1-(4-chloro-benzenesulfonyl)-6-cyclopropyl-piperidin-2-yl]-cyclopropyl}-1-(1,7-diaza-spiro[3.5]non-7-yl)-ethanone",7.0,uM,=,0.8450980400142568,1,O=C(CC1([C@H]2CCC[C@@H](C3CC3)N2S(=O)(=O)c2ccccc2)CC1)N1CCC2(CCN2)CC1
3017,510165,10.1021/jm800377h,,,,Inhibition of human recombinant CYP3A4 expressed in insect microsomes,COc1ccc2cc(-c3cncc4ccccc34)ccc2c1,4-(6-Methoxynaphthalen-2-yl)isoquinoline,3.54,uM,=,0.5490032620257879,1,c1ccc2cc(-c3cncc4ccccc34)ccc2c1
3018,1446329,10.1021/ml500387y,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2cc(N(C)C)ncc2[nH]1)C(F)(F)F,"2-((5-(dimethylamino)-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)-1,1,1-trifluoro-4-(5-fluoro-2-methylphenyl)-4-methylpentan-2-ol",0.6,uM,=,-0.2218487496163563,0,c1ccc(CCCCc2cc3ccncc3[nH]2)cc1
3019,1527876,,,,,Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,CCn1cc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)cc(C)c1=O,"US8575157, 70",28.0,uM,=,1.4471580313422192,1,O=C1OC(c2ccccc2)CCN1Cc1ccc(-c2ccc(=O)[nH]c2)cc1
3020,448320,10.1016/j.bmc.2007.05.069,,,,Inhibition of CYP3A4,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCCO)C(=O)C(C)(c1cc(F)cc(F)c1)O2,"6-(2,4-diamino-6-ethylpyrimidin-5-yl)-2-(3,5-difluorophenyl)-4-(4-hydroxybutyl)-2-methyl-2H-benzo[b][1,4]oxazin-3(4H)-one",4.79,uM,=,0.6803355134145632,1,O=C1Nc2cc(-c3cncnc3)ccc2OC1c1ccccc1
3021,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(OC(C)(C)C)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, G-6",19.1,uM,=,1.2810333672477277,1,O=C(Nc1ccccc1)c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12
3022,1527876,,,,,Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,C[C@@H](c1ccc(-c2ccc(=O)n(CC3CC3)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O,"US8575157, 76",10.0,uM,=,1.0,1,O=C1OC(c2ccccc2)CCN1Cc1ccc(-c2ccc(=O)n(CC3CC3)c2)cc1
3023,461436,10.1016/j.bmcl.2007.10.092,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,CC[C@@H]1CCC[C@H](C2(CC(=O)N3CCC4(CCN4)CC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1,"2-{1-[(2R,6R)-1-(4-chloro-benzenesulfonyl)-6-ethyl-piperidin-2-yl]-cyclopropyl}-1-(1,7-diaza-spiro[3.5]no-7-yl)-ethanone",5.6,uM,=,0.7481880270062004,1,O=C(CC1([C@H]2CCCCN2S(=O)(=O)c2ccccc2)CC1)N1CCC2(CCN2)CC1
3024,632105,10.1016/j.bmcl.2010.03.057,,,,Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin,COCC(=O)N1CCN(c2cc(C)c3nc(-c4c(NC[C@@H](O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1,(S)-4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-3-(6-(4-(2-methoxyacetyl)piperazin-1-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one,0.8,uM,=,-0.0969100130080563,0,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(N3CCNCC3)cc2[nH]1
3025,559939,10.1016/j.bmcl.2008.10.072,,,,Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate,CCN(CCc1ccccc1)C(=O)c1ccccc1-c1ccc(CN2C[C@@H](C)N[C@@H](C)C2)cc1,"4'-((3R,5S)-3,5-Dimethyl-piperazin-1-ylmethyl)-biphenyl-2-carboxylic acid ethyl-phenethyl-amide",1.5,uM,=,0.1760912590556812,1,O=C(NCCc1ccccc1)c1ccccc1-c1ccc(CN2CCNCC2)cc1
3026,2156515,10.1021/acs.jmedchem.1c01272,,,,Inhibition of CYP3A4 in human liver microsomes using IPA as substrate preincubated for 10 mins followed by NADPH generating system addition and measured after 20 mins,COc1cc(NC(=O)c2cc(=O)c3ccccc3o2)c(-c2nnn(-c3ccc(CCN4CCc5ccncc5C4)cc3)n2)cc1OC,"N-(2-(2-(4-(2-(3,4-dihydro-2,7-naphthyridin-2(1H)-yl)ethyl)phenyl)-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl)-4-oxo-4H-chromene-2-carboxamide",1.054,uM,=,0.0228406108765278,1,O=C(Nc1ccccc1-c1nnn(-c2ccc(CCN3CCc4ccncc4C3)cc2)n1)c1cc(=O)c2ccccc2o1
3027,685163,10.1021/jm100773e,,,,Inhibition of human CYP3A4,CN(Cc1c2c(=O)n(-c3ccccc3Cl)[nH]c2cc(=O)n1Cc1ccncc1)c1ccccc1,"2-(2-chlorophenyl)-4-((methyl(phenyl)amino)methyl)-5-(pyridin-4-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione",1.1,uM,=,0.041392685158225,1,O=c1c2c(CNc3ccccc3)n(Cc3ccncc3)c(=O)cc2[nH]n1-c1ccccc1
3028,473932,10.1021/jm701121y,,,,Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay,COc1ccc(-c2cc(CNS(=O)(=O)c3ccccc3)on2)cc1,N-((3-(4-methoxyphenyl)isoxazol-5-yl)methyl)benzenesulfonamide,33.0,uM,=,1.5185139398778875,1,O=S(=O)(NCc1cc(-c2ccccc2)no1)c1ccccc1
3029,1668433,10.1016/j.bmcl.2017.04.014,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate pretreated for 10 mins followed by substrate addition measured after 10 mins in presence of NADPH by LC-MS/MS method,C=CC(=O)Nc1cccc(C)c1Nc1ncc2cc(-c3c(Cl)c(OC)cc(OC)c3Cl)ccc2n1,"N-(2-(6-(2,6-dichloro-3,5-dimethoxyphenyl)quinazolin-2-ylamino)-3-methylphenyl)acrylamide",3.0,uM,=,0.4771212547196624,1,c1ccc(Nc2ncc3cc(-c4ccccc4)ccc3n2)cc1
3030,519907,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,Cc1cccc(C)c1CNc1cc(C(=O)NCCO)cn2c(C)c(C)nc12,"8-(2,6-dimethylbenzylamino)-N-(2-hydroxyethyl)-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxamide",8.4,uM,=,0.9242792860618816,1,c1ccc(CNc2cccn3ccnc23)cc1
3031,51899,10.1016/j.bmcl.2003.08.027,,,,Binding affinity for Cytochrome P450 3A4; Range = 1-10 uM,OCc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,"[8-Chloro-6-(2-fluoro-phenyl)-4H-2,5,10b-triaza-benzo[e]azulen-1-yl]-methanol",10.0,uM,=,1.0,1,c1ccc(C2=NCc3cncn3-c3ccccc32)cc1
3032,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(OCCOC)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, G-11",7.62,uM,=,0.8819549713396005,1,O=C(Nc1cccnc1)c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12
3033,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)NN6CCN(C)CC6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, D-45",2.51,uM,=,0.3996737214810381,1,O=C(NN1CCNCC1)c1ccc(-c2c[nH]c3c(CN4C[C@@H]5N(C(=O)NCc6ccccc6)NCC(=O)N5[C@@H](Cc5ccccc5)C4=O)cccc23)cc1
3034,52069,10.1021/jm021012t,,,,Inhibition of human cytochrome P450 3A4,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,"6-(4-Dimethylamino-3-hydroxy-6-methyl-tetrahydro-pyran-2-yloxy)-14-ethyl-7,12,13-trihydroxy-4-(5-hydroxy-4-methoxy-4,6-dimethyl-tetrahydro-pyran-2-yloxy)-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione",33.0,uM,=,1.5185139398778875,1,O=C1CCCCOC(=O)C[C@@H](O[C@H]2CCCCO2)C[C@@H](O[C@H]2CCCCO2)CCC1
3035,461436,10.1016/j.bmcl.2007.10.092,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,CC[C@@H]1CCC[C@H](C2(Cc3nc(CN4CCCC4)no3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1,"(2R,6R)-1-(4-chlorophenylsulfonyl)-2-ethyl-6-(1-((3-(pyrrolidin-1-ylmethyl)-1,2,4-oxadiazol-5-yl)methyl)cyclopropyl)piperidine",0.7,uM,=,-0.1549019599857432,0,O=S(=O)(c1ccccc1)N1CCCC[C@@H]1C1(Cc2nc(CN3CCCC3)no2)CC1
3036,2164346,10.1021/acs.jmedchem.1c02192,,,,Inhibition of CYP3A4 (unknown origin),CC1(n2cnc3cnc4cc(F)c(-c5ccc(Oc6ncccn6)cc5Cl)cc4c32)CCN(CC#N)CC1,"2-[4-[8-(2-chloro-4-pyrimidin-2-yloxy-phenyl)-7-fluoro-imidazo[4,5-c]quinolin-1-yl]-4-methyl-1-piperidyl]acetonitrile",1.5,uM,=,0.1760912590556812,1,c1cnc(Oc2ccc(-c3ccc4ncc5ncn(C6CCNCC6)c5c4c3)cc2)nc1
3037,1499751,10.1021/acs.jmedchem.5b00424,,,,Inhibition of CYP3A4 (unknown origin),COc1cccc(CC(=O)Nc2nc(-c3ccnc(F)c3)cs2)c1,N-(4-(2-fluoropyridin-4-yl)thiazol-2-yl)-2-(3-methoxyphenyl)acetamide,1.5,uM,=,0.1760912590556812,1,O=C(Cc1ccccc1)Nc1nc(-c2ccncc2)cs1
3038,774749,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",CCOc1cc(N)c(Cl)cc1C(=O)NCC1CN(Cc2ccc(F)cc2)CCO1,4-Amino-5-chloro-2-ethoxy-N-[4-(4-fluoro-benzyl)-morpholin-2-ylmethyl]-benzamide,0.7,uM,=,-0.1549019599857432,0,O=C(NCC1CN(Cc2ccccc2)CCO1)c1ccccc1
3039,1637154,,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins,N#Cc1ccnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4cccnc4)c3F)c12,"Pyridine-3-sulfonic acid [3-(4-cyano-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-amide",5.0,uM,=,0.6989700043360189,1,O=C(c1cccc(NS(=O)(=O)c2cccnc2)c1)c1c[nH]c2ncccc12
3040,776115,10.1016/j.bmcl.2011.09.074,,,,Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(c1ccc(Cl)cc1)C2=O,"3-(aminomethyl)-6-(4-chlorophenyl)-4-(2,4-dichlorophenyl)-2-methyl-5H-pyrrolo[3,4-b]pyridin-7(6H)-one",0.39,uM,=,-0.4089353929735008,0,O=C1c2nccc(-c3ccccc3)c2CN1c1ccccc1
3041,686484,10.1016/j.bmcl.2010.09.122,,,,Inhibition of CYP3A4,CN1CCc2c(c3ccc(-n4ccc(OCc5ccccc5)cc4=O)cc3n2C)C1,"4-(benzyloxy)-1-(2,5-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-7-yl)pyridin-2(1H)-one",67.0,uM,=,1.8260748027008264,1,O=c1cc(OCc2ccccc2)ccn1-c1ccc2c3c([nH]c2c1)CCNC3
3042,489963,10.1021/jm800566m,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline substrate,CN(c1ccc2cn(C)nc2c1)c1ccnc(Nc2cccc(S(N)(=O)=O)c2)n1,3-({4-[Methyl(2-methyl-2H-indazol-6-yl)amino]-2-pyrimidinyl}amino)benzenesulfonamide,3.9,uM,=,0.5910646070264992,1,c1ccc(Nc2nccc(Nc3ccc4c[nH]nc4c3)n2)cc1
3043,1574682,10.1021/acs.jmedchem.5b01995,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone and midazolam as substrate preincubated for 30 mins followed substrate addition by LC-MS/MS analysis,COc1nc(N2C[C@H]3C(=O)N(C)C(N)=N[C@@]3(c3ccc(F)cc3)C2)nc(C)c1F,"US8541427, 17",34.1,uM,=,1.5327543789924978,1,O=C1NC=N[C@@]2(c3ccccc3)CN(c3ncccn3)C[C@@H]12
3044,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cc(-n3cccn3)ccc2C)c1,"US9150566, 188",14.0,uM,=,1.146128035678238,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2cccn2)c1
3045,1660136,10.1021/acs.jmedchem.6b01918,,,,Inhibition of human CYP3A4 assessed as inhibition of dealkylation,N[C@H]1CC[C@H](CCNc2cc(F)c(S(=O)(=O)Nc3nccs3)cc2Cl)CC1,"trans-4-((2-((1R,4R)-4-Aminocyclohexyl)ethyl)amino)-5-chloro-2-fluoro-N-(thiazol-2-yl)benzenesulfonamide",9.0,uM,=,0.9542425094393248,1,O=S(=O)(Nc1nccs1)c1ccc(NCCC2CCCCC2)cc1
3046,2200323,10.1021/acs.jmedchem.2c00921,,,,Inhibition of CYP3A4 in human liver microsomes assessed as reduction in 6beta-hydroxymidazolam metabolite formation using midazolam as substrate incubated for 30 mins in presence of NADPH by LC-MS/MS analysis,COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1c(F)ccc(OC)c1F,"N-(2,6-Difluoro-3-methoxybenzyl)-3-(methoxymethyl)-1-(4-((2-oxopyridin-1(2H)-yl)methyl)benzyl)-1H-pyrazole-4-carboxamide",19.0,uM,=,1.2787536009528289,1,O=C(NCc1ccccc1)c1cnn(Cc2ccc(Cn3ccccc3=O)cc2)c1
3047,622574,10.1016/j.bmcl.2009.09.027,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate,CCCCc1ccc(S(=O)(=O)Nc2ccc3c(c2)CCN(Cc2cc[nH]n2)CC3)cc1,"N-(3-((1H-pyrazol-3-yl)methyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-4-butylbenzenesulfonamide",0.8,uM,=,-0.0969100130080563,0,O=S(=O)(Nc1ccc2c(c1)CCN(Cc1cc[nH]n1)CC2)c1ccccc1
3048,305744,10.1021/jm049696n,,,,Inhibitory concentration value against human cytochrome P-450 3A4,c1cncc(-c2cccs2)c1,3-Thiophen-2-yl-pyridine,57.0,uM,=,1.7558748556724917,1,c1cncc(-c2cccs2)c1
3049,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCCN5CCOCC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, F-29",1.1,uM,=,0.041392685158225,1,O=C(NCCCN1CCOCC1)c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12
3050,595557,10.1016/j.bmcl.2009.10.084,,,,Inhibition of CYP3A4 using BFC as a substrate,Cc1cc2cc(N/C(=N\C(=O)c3ccc[n+]([O-])c3)N[C@H]3CCCCN(CC(=O)N4CCCC4)C3=O)ccc2o1,(S)-3-((2-methylbenzofuran-5-ylamino)(2-oxo-1-(2-oxo-2-(pyrrolidin-1-yl)ethyl)azepan-3-ylamino)methylenecarbamoyl)pyridine 1-oxide,0.9,uM,=,-0.0457574905606751,0,O=C(/N=C(\Nc1ccc2occc2c1)N[C@H]1CCCCN(CC(=O)N2CCCC2)C1=O)c1ccc[nH+]c1
3051,2133633,10.1021/acs.jmedchem.1c00679,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins in presence of NADPH by LCMS/MS analysis,CCC(NC(=O)c1ccc(Cl)cc1)[C@H]1[C@@H]2C[C@H](Oc3ccnc4ccccc34)C[C@@H]21,"4-chloro-N-(1-((1R,3r,5S,6r)-3-(quinolin-4-yloxy)bicyclo[3.1.0]hexan-6-yl)propyl)benzamide",1.1,uM,=,0.041392685158225,1,O=C(NC[C@@H]1[C@H]2C[C@@H](Oc3ccnc4ccccc34)C[C@@H]12)c1ccccc1
3052,617698,10.1016/j.bmcl.2010.01.087,,,,Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay,Cc1cc(N2CCC(N3C[C@@H]4C[C@H]3CO4)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,"3-(6-(4-((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)piperidin-1-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)-4-((S)-2-(3-chlorophenyl)-2-hydroxyethylamino)pyridin-2(1H)-one",0.5,uM,=,-0.3010299956639812,0,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(N3CCC(N4C[C@@H]5C[C@H]4CO5)CC3)cc2[nH]1
3053,1696937,10.1016/j.bmcl.2017.09.042,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate pretreated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis,N#Cc1cncc(Oc2cc(C(=O)Nc3ccc(F)cn3)c3ncnn3c2)c1,"6-(5-cyanopyridin-3-yloxy)-N-(5-fluoropyridin-2-yl)-[1,2,4]triazolo[1,5-a]pyridine-8-carboxamide",10.6,uM,=,1.0253058652647702,1,O=C(Nc1ccccn1)c1cc(Oc2cccnc2)cn2ncnc12
3054,52069,10.1021/jm021012t,,,,Inhibition of human cytochrome P450 3A4,COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C,"Methoxy-acetic acid (1S,2S)-2-(2-{[3-(1H-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)-6-fluoro-1-isopropyl-1,2,3,4-tetrahydro-naphthalen-2-yl ester",0.13,uM,=,-0.8860566476931633,0,c1ccc2c(c1)CCC(CCNCCCc1nc3ccccc3[nH]1)C2
3055,1778315,10.1016/j.bmcl.2018.06.040,,,,Inhibition of CYP3A4 (unknown origin),CCCS(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1,"N-(4-(1H-pyrrolo[2,3-b]pyridin-3-yl)thiazol-2-yl)-2-(3-(propylsulfonamido)phenyl)acetamide",3.6,uM,=,0.5563025007672873,1,O=C(Cc1ccccc1)Nc1nc(-c2c[nH]c3ncccc23)cs1
3056,1534761,,,,,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",Cc1cnc2[nH]cc(Cc3ccc(NCc4ccc(C(F)(F)F)nc4)nc3F)c2c1,"US9096593, P-2031",5.0,uM,=,0.6989700043360189,1,c1cncc(CNc2ccc(Cc3c[nH]c4ncccc34)cn2)c1
3057,2151594,10.1021/acs.jmedchem.1c01157,,,,Inhibition of CYP3A4 in human liver microsome using testosterone as substrate,CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,SID144204227,0.184,uM,=,-0.7351821769904636,0,c1ccc([C@@]2(Cn3ccnc3)OC[C@H](COc3ccc(N4CCNCC4)cc3)O2)cc1
3058,1446329,10.1021/ml500387y,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,CC(C)(CC(O)(Cc1cc2cc(S(C)(=O)=O)ncc2[nH]1)C(F)(F)F)c1ccccc1S(N)(=O)=O,"2-(5,5,5-trifluoro-4-hydroxy-2-methyl-4-((5-(methylsulfonyl)-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)pentan-2-yl)benzenesulfonamide",15.0,uM,=,1.1760912590556811,1,c1ccc(CCCCc2cc3ccncc3[nH]2)cc1
3059,657985,10.1021/jm100482n,,,,Inhibition of CYP3A4 in human liver microsomes measured after incubation,CNC(=O)c1ncn2c1COc1c(CCN3CCN(c4cccc5nc(C)ccc45)CC3)cccc1-2,"N-methyl-6-(2-(4-(2-methylquinolin-5-yl)piperazin-1-yl)ethyl)-4H-benzo[b]imidazo[1,5-d][1,4]oxazine-3-carboxamide",3.0,uM,=,0.4771212547196624,1,c1cc(CCN2CCN(c3cccc4ncccc34)CC2)c2c(c1)-n1cncc1CO2
3060,2022325,10.1021/acs.jmedchem.0c01163,,,,Inhibition of CYP3A4 in human liver microsomes,C[C@@H]1Cc2c(ccc3[nH]ncc23)[C@@H](c2ccc(NC3CN(CCCF)C3)cn2)N1CC(F)(F)F,CAMIZESTRANT,2.2,uM,=,0.3424226808222063,1,c1cc([C@H]2NCCc3c2ccc2[nH]ncc32)ncc1NC1CNC1
3061,1464796,10.1016/j.bmcl.2015.01.005,,,,Inhibition of recombinant human CYP3A4,Cn1c(N2CCO[C@@H]3CCCC[C@H]32)nc(-c2ccncc2F)cc1=O,"6-(3-Fluoro-pyridin-4-yl)-3-methyl-2-(5R,6R)-octahydro-benzo[1,4]oxazin-4-yl-3H-pyrimidin-4-one",418.0,uM,=,2.621176281775035,1,O=c1cc(-c2ccncc2)nc(N2CCO[C@@H]3CCCC[C@H]32)[nH]1
3062,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)c6ccc(CN(CC)CC)cc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, D-55",2.26,uM,=,0.3541084391474008,1,O=C(Nc1ccc(-c2c[nH]c3c(CN4C[C@@H]5N(C(=O)NCc6ccccc6)NCC(=O)N5[C@@H](Cc5ccccc5)C4=O)cccc23)cc1)c1ccccc1
3063,2216951,10.1021/acs.jmedchem.2c00676,,,,Inhibition of CYP3A4 in human liver microsome using testosterone as substrate,Cc1nc(C)n(CC(=O)N2CCN(c3sc(C(F)(F)F)nc3-c3nc4ccc(-c5noc(C)n5)cc4[nH]3)C[C@H]2C)n1,"US9266876, 236",19.0,uM,=,1.2787536009528289,1,O=C(Cn1cncn1)N1CCN(c2scnc2-c2nc3ccc(-c4ncon4)cc3[nH]2)CC1
3064,774749,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1,1-[(2-Chloro-phenyl)-diphenyl-methyl]-1H-imidazole,0.016,uM,=,-1.7958800173440752,0,c1ccc(C(c2ccccc2)(c2ccccc2)n2ccnc2)cc1
3065,2045773,10.1039/d0md00174k,,,,Inhibition of CYP3A4 (unknown origin),Cc1c(-c2cnc3[nH]ncc3c2)ccc2c3oc(CN)nc3c(=O)n(C3CC3)c12,"2-(aminomethyl)-5-cyclopropyl-6-methyl-7-(1H-pyrazolo[3,4-b]pyridin-5-yl)oxazolo[4,5-c]quinolin-4-one",22.6,uM,=,1.354108439147401,1,O=c1c2ncoc2c2ccc(-c3cnc4[nH]ncc4c3)cc2n1C1CC1
3066,774749,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",CNCCCC12CCC(c3ccccc31)c1ccccc12,"1N-methyl-3-tetracyclo[6.6.2.02,7.09,14]hexadeca-2(7),3,5,9(14),10,12-hexaen-1-yl-1-propanamine",4.322,uM,=,0.6356847625472225,1,c1ccc2c(c1)C1CCC2c2ccccc21
3067,4333,10.1021/jm00093a015,,,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,"1-(4-{4-[2-(2,4-Dichloro-phenyl)-2-imidazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-ethanone (ketoconazole)",1.26,uM,=,0.1003705451175629,1,c1ccc(C2(Cn3ccnc3)OCC(COc3ccc(N4CCNCC4)cc3)O2)cc1
3068,1289241,10.1016/j.bmcl.2013.12.088,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,Fc1cc(OC(F)(F)C(F)F)cc([C@@](Cc2ccccc2)(Nc2nc3cc(F)ccc3[nH]2)c2ccc(Cl)cn2)c1,"(R)-N-(1-(5-chloropyridin-2-yl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-5-fluoro-1H-benzo[d]imidazol-2-amine",32.0,uM,=,1.505149978319906,1,c1ccc(C[C@@](Nc2nc3ccccc3[nH]2)(c2ccccc2)c2ccccn2)cc1
3069,51916,10.1016/j.bmcl.2003.11.005,,,,Inhibition of cytochrome P450 3A4,CCCCCCOc1ccc(-n2ccnc2)cn1,2-Hexyloxy-5-imidazol-1-yl-pyridine,76.9,uM,=,1.885926339801431,1,c1cncc(-n2ccnc2)c1
3070,2024613,10.1016/j.bmcl.2020.127721,,,,Inhibition of CYP3A4 (unknown origin),CS(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4nccc(F)c34)cs2)c1,"N-[4-(4-fluoro-1H-pyrrolo[2,3-b]pyridin-3-yl)thiazol-2-yl]-2-[3-(methanesulfonamido)phenyl]acetamide",36.0,uM,=,1.5563025007672873,1,O=C(Cc1ccccc1)Nc1nc(-c2c[nH]c3ncccc23)cs1
3071,1972371,10.1021/acs.jmedchem.9b02121,,,,Inhibition of CYP3A4 (unknown origin),CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C)CC4)cn3)ncc2Cl)c1,N-(3-((5-Chloro-2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)amino)phenyl)acetamide,31.4,uM,=,1.4969296480732148,1,c1ccc(Nc2ccnc(Nc3ccc(N4CCNCC4)cn3)n2)cc1
3072,1653169,10.1021/acsmedchemlett.6b00465,,,,Inhibition of CYP3A4 (unknown origin),O=C(O)CSc1nnc(Br)n1-c1ccc(C2CC2)c2ccccc12,LESINURAD,32.4,uM,=,1.510545010206612,1,c1ccc2c(-n3cnnc3)ccc(C3CC3)c2c1
3073,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",COc1cc(C(=O)N2CCOC[C@H]2Cc2cccc(-n3nccn3)c2)c(-n2nccn2)cc1F,"US9150566, 78",22.0,uM,=,1.3424226808222062,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
3074,945618,10.1016/j.bmc.2012.11.058,,,,Inhibition of CYP3A4 (unknown origin),O=S(=O)(Nc1cc(Cl)c(Oc2ccc3ncccc3c2)c(Cl)c1)c1ccc(Cl)cc1Cl,"2,4-dichloro-N-(3,5-dichloro-4-(quinolin-6-yloxy)phenyl)benzenesulfonamide",1.0,uM,=,0.0,0,O=S(=O)(Nc1ccc(Oc2ccc3ncccc3c2)cc1)c1ccccc1
3075,673952,10.1016/j.bmcl.2010.08.086,,,,Inhibition of CYP3A4 using midazolam as substrate,CC(=O)NCCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1,"(3R,4S)-N-(5-(2-acetamidoethyl)-2-chlorobenzyl)-N-cyclopropyl-4-(4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)phenyl)piperidine-3-carboxamide",2.4,uM,=,0.380211241711606,1,O=C([C@H]1CNCC[C@@H]1c1ccc(OCCOc2ccccc2)cc1)N(Cc1ccccc1)C1CC1
3076,2024613,10.1016/j.bmcl.2020.127721,,,,Inhibition of CYP3A4 (unknown origin),CS(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncc(Br)cc34)cs2)c1,"N-[4-(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)thiazol-2-yl]-2-[3-(methanesulfonamido)phenyl]acetamide",35.0,uM,=,1.5440680443502757,1,O=C(Cc1ccccc1)Nc1nc(-c2c[nH]c3ncccc23)cs1
3077,51895,10.1016/j.bmcl.2003.09.093,,,,Inhibition of cytochrome P450 3A4 of isolated guinea pig heart,Cc1nc2cc(OC[C@H](O)CN3CCN(CC(=O)Nc4ccc(-c5ccccc5)cc4)CC3)ccc2s1,N-Biphenyl-4-yl-2-{4-[(R)-2-hydroxy-3-(2-methyl-benzothiazol-5-yloxy)-propyl]-piperazin-1-yl}-acetamide,7.9,uM,=,0.8976270912904415,1,O=C(CN1CCN(CCCOc2ccc3scnc3c2)CC1)Nc1ccc(-c2ccccc2)cc1
3078,860549,10.1021/jm3003747,,,,Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins,Fc1ccc2[nH]ccc2c1-c1nc(N2CCOCC2)c2sc(CN3CCN4CCOC[C@H]4C3)cc2n1,"(R)-8-((2-(5-Fluoro-1H-indol-4-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)octahydropyrazino[2,1-c][1,4]oxazine",7.0,uM,=,0.8450980400142568,1,c1cc(-c2nc(N3CCOCC3)c3sc(CN4CCN5CCOC[C@H]5C4)cc3n2)c2cc[nH]c2c1
3079,673968,10.1016/j.bmcl.2010.08.101,,,,Inhibition of CYP3A4,CC(C)(NCCCc1cc(-c2cccc(C(F)(F)F)c2)nc(C#N)n1)C(N)=O,2-(3-(2-cyano-6-(3-(trifluoromethyl)phenyl)pyrimidin-4-yl)propylamino)-2-methylpropanamide,35.0,uM,=,1.5440680443502757,1,c1ccc(-c2ccncn2)cc1
3080,1910981,10.1021/acs.jmedchem.8b01464,,,,Inhibition of human CYP3A4 in presence of NADPH by luciferase reporter gene assay,CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,SID144204227,0.4,uM,=,-0.3979400086720376,0,c1ccc([C@@]2(Cn3ccnc3)OC[C@H](COc3ccc(N4CCNCC4)cc3)O2)cc1
3081,1560508,10.1016/j.bmc.2016.02.014,,,,Inhibition of CYP3A4 (unknown origin),O=c1[nH]c2cc(/C=C3\c4ccccc4COc4cc(F)ccc43)ccc2n1[C@@H]1C[C@@H]2COCCN2C1,"5-((3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)methyl)-1-((7R,8aR)-hexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-7-yl)-1H-benzo[d]imidazol-2(3H)-one",5.81,uM,=,0.7641761323903307,1,O=c1[nH]c2cc(/C=C3\c4ccccc4COc4ccccc43)ccc2n1[C@@H]1C[C@@H]2COCCN2C1
3082,2273354,10.1021/acs.jmedchem.8b01971,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 10 mins followed by NADPH addition and measured after 15 mins by LC-MS/MS analysis,CCOC(=O)C1=C(C)Cc2nc(N3CCC(C(=O)NS(=O)(=O)Cc4ccccc4)CC3)c(C#N)cc2C1,"ethyl 2-(4-(benzylsulfonylcarbamoyl)piperidin-1-yl)-3-cyano-7-methyl-5,8-dihydroquinoline-6-carboxylate",3.64,uM,=,0.561101383649056,1,O=C(NS(=O)(=O)Cc1ccccc1)C1CCN(c2ccc3c(n2)CC=CC3)CC1
3083,2200324,10.1021/acs.jmedchem.2c00921,,,,Inhibition of CYP3A4 in human liver microsomes assessed as reduction in 6beta-hydroxytestosterone metabolite formation using testosterone as substrate incubated for 30 mins in presence of NADPH by LC-MS/MS analysis,COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1c(F)ccc(OC)c1F,"N-(2,6-Difluoro-3-methoxybenzyl)-3-(methoxymethyl)-1-(4-((2-oxopyridin-1(2H)-yl)methyl)benzyl)-1H-pyrazole-4-carboxamide",11.0,uM,=,1.0413926851582251,1,O=C(NCc1ccccc1)c1cnn(Cc2ccc(Cn3ccccc3=O)cc2)c1
3084,305432,10.1016/j.bmcl.2005.01.044,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,CC(C(c1ccc2cc(OCC(C)(C)C(=O)N(C)C)ccc2c1)n1ccnc1)N(C)C,"3-[6-(2-Dimethylamino-1-imidazol-1-yl-propyl)-naphthalen-2-yloxy]-2,2,N,N-tetramethyl-propionamide",2.032,uM,=,0.3079237036118816,1,c1ccc2cc(Cn3ccnc3)ccc2c1
3085,814102,10.1016/j.bmcl.2012.03.014,,,,Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins,O[C@]1(c2ccc(F)c(F)c2)CCNC[C@@H]1c1cc(-c2ccc(F)cc2Cl)no1,"(3S,4R)-3-(3-(2-chloro-4-fluorophenyl)isoxazol-5-yl)-4-(3,4-difluorophenyl)piperidin-4-ol",7.0,uM,=,0.8450980400142568,1,c1ccc(-c2cc([C@H]3CNCCC3c3ccccc3)on2)cc1
3086,774749,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1,"1-[2-(4-Chloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole (Econazole)",0.05,uM,=,-1.3010299956639813,0,c1ccc(COC(Cn2ccnc2)c2ccccc2)cc1
3087,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cccc(-n3cccn3)c2)c1,"US9150566, 19",32.0,uM,=,1.505149978319906,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2cccn2)c1
3088,857201,10.1021/jm200900q,,,,Inhibition of CYP3A4,N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(C(=O)NCCO)CC3)cc2C2=CCCCC2)n1,4-{4-[(4-Cyano-1H-imidazole-2-carbonyl)-amino]-3-cyclohex-1-enyl-phenyl}-piperidine-1-carboxylic Acid(2-Hydroxy-ethyl)-amide,6.4,uM,=,0.8061799739838872,1,O=C(Nc1ccc(C2CCNCC2)cc1C1=CCCCC1)c1ncc[nH]1
3089,1488504,10.1124/dmd.112.045708,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 90 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis,CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1,"(R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide",8.0,uM,=,0.9030899869919436,1,O=C(Cc1ccccc1)N(Cc1cccnc1)Cc1nc2ncccc2c(=O)n1-c1ccccc1
3090,986997,10.1016/j.bmcl.2013.08.012,,,,Inhibition of CYP3A4 in human liver microsomes,Nc1cc(CN2CCC(C(=O)N3CCC(n4c(=O)n(C5CCCC5)c5cc(F)ccc54)CC3)CC2)ccn1,1-(1-(1-((2-aminopyridin-4-yl)methyl)piperidine-4-carbonyl)piperidin-4-yl)-3-cyclopentyl-5-fluoro-1H-benzo[d]imidazol-2(3H)-one,22.0,uM,=,1.3424226808222062,1,O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)n(C3CCCC3)c3ccccc32)CC1
3091,1614025,10.1016/j.bmcl.2016.09.043,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 6-beta-hydroxytestosterone metabolite formation using testosterone as substrate incubated for 30 mins by HPLC-MS method,COc1ccc(CCNc2nc3cc(C)ccc3c(=O)n2C)cc1,"2-[2-(4-Methoxy-phenyl)-ethylamino]-3,7-dimethyl-3H-quinazolin-4-one",4.8,uM,=,0.6812412373755872,1,O=c1[nH]c(NCCc2ccccc2)nc2ccccc12
3092,742805,10.1016/j.bmc.2011.02.009,,,,Inhibition of human CYP3A4 after 30 mins,CNC(=O)Nc1cccc(-c2ccc(C(O)(c3c[nH]cn3)C(C)C)cc2)c1,"rac-N-{4'-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl][1,1'-biphenyl]-3-yl}-N'-methylurea",5.5,uM,=,0.7403626894942439,1,c1ccc(-c2ccc(Cc3c[nH]cn3)cc2)cc1
3093,51915,10.1016/s0960-894x(03)00680-2,,,,Inhibition of human liver microsome Cytochrome P450 3A4,O=C(N[C@H]1c2ccccc2OC[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CN1CCN(Cc2ccc(-c3ccncc3)o2)C[C@H]1C(=O)NCC(F)(F)F,"(S)-1-[(S)-2-Hydroxy-4-((R)-(S)-3-hydroxy-3,4,4a,8a-tetrahydro-2H-chromen-4-ylcarbamoyl)-5-phenyl-pentyl]-4-(5-pyridin-4-yl-furan-2-ylmethyl)-piperazine-2-carboxylic acid (2,2,2-trifluoro-ethyl)-amide",0.32,uM,=,-0.494850021680094,0,O=C(N[C@@H]1CCOc2ccccc21)[C@@H](CCCN1CCN(Cc2ccc(-c3ccncc3)o2)CC1)Cc1ccccc1
3094,438600,10.1016/j.bmcl.2007.03.048,,,,Inhibition of CYP3A4 in microsomes,Cc1cc(-n2ccnc2)cc2nc(-c3c(NCc4ccccn4)cc[nH]c3=O)[nH]c12,3-(6-(1H-imidazol-1-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)-4-(pyridin-2-ylmethylamino)pyridin-2(1H)-one,0.08,uM,=,-1.0969100130080565,0,O=c1[nH]ccc(NCc2ccccn2)c1-c1nc2cc(-n3ccnc3)ccc2[nH]1
3095,1625607,10.1016/j.bmcl.2016.10.016,,,,Inhibition of human Cyp3A4 using testosterone as substrate by LC-MS/MS analysis,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,"1-(4-{4-[2-(2,4-Dichloro-phenyl)-2-imidazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-ethanone (ketoconazole)",0.133,uM,=,-0.8761483590329142,0,c1ccc(C2(Cn3ccnc3)OCC(COc3ccc(N4CCNCC4)cc3)O2)cc1
3096,311625,10.1021/jm0501275,,,,Inhibitory concentration against human cytochrome P450 3A4,CONC(=O)c1cc(Nc2ncnn3cc(-c4ncc(C)o4)c(C(C)C)c23)c(F)cc1F,"2,4-Difluoro-5-[5-isopropyl-6-(5-methyl-oxazol-2-yl)-pyrrolo[2,1-f][1,2,4]triazin-4-ylamino]-N-methoxy-benzamide",5.1,uM,=,0.7075701760979364,1,c1ccc(Nc2ncnn3cc(-c4ncco4)cc23)cc1
3097,2017934,10.1021/acs.jmedchem.0c00834,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis,Cc1c(N2CCCCCC2)nc2ccc(Br)cc2c1C(=O)NCC(CCC(=O)O)c1ccccc1Cl,(+)-5-({[2-(Azepan-1-yl)-6-bromo-3-methylquinolin-4-yl]carbonyl}amino)-4-(2-chlorophenyl)pentanoic acid,9.0,uM,=,0.9542425094393248,1,O=C(NCCc1ccccc1)c1cc(N2CCCCCC2)nc2ccccc12
3098,1574682,10.1021/acs.jmedchem.5b01995,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone and midazolam as substrate preincubated for 30 mins followed substrate addition by LC-MS/MS analysis,COc1nc(N2C[C@H]3C(=O)N(C)C(=N)N[C@@]3(c3ccc(C#N)s3)C2)nc(C)c1F,"5-((4aR,7aR)-6-(5-Fluoro-4-methoxy-6-methylpyrimidin-2-yl)-2-imino-3-methyl-4-oxooctahydro-1H-pyrrolo[3,4-d]pyrimidin-7a-yl)-thiophene-2-carbonitrile",24.0,uM,=,1.380211241711606,1,N=C1NC(=O)[C@@H]2CN(c3ncccn3)C[C@]2(c2cccs2)N1
3099,2133633,10.1021/acs.jmedchem.1c00679,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins in presence of NADPH by LCMS/MS analysis,CCC(NC(=O)c1ccc(Cl)cc1)[C@@H]1[C@@H]2C[C@H](Oc3ccnc4cccnc34)C[C@@H]21,"N-(1-((1R,3s,5S,6r)-3-(1,5-naphthyridin-4-yloxy)bicyclo[3.1.0]hexan-6-yl)propyl)-4-chlorobenzamide",13.0,uM,=,1.1139433523068367,1,O=C(NC[C@H]1[C@H]2C[C@@H](Oc3ccnc4cccnc34)C[C@@H]12)c1ccccc1
3100,619264,10.1016/j.bmcl.2009.07.002,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,Cc1cccc(C)c1CNc1cccc2c1nc(C)n2C,"N-(2,6-dimethylbenzyl)-1,2-dimethyl-1H-benzo[d]imidazol-4-amine",13.0,uM,=,1.1139433523068367,1,c1ccc(CNc2cccc3[nH]cnc23)cc1
3101,2123617,10.1021/acs.jmedchem.1c01015,,,,Inhibition of CYP3A4M in human liver microsomes using midazolam as substrate in presence of NADPH incubated for 10 mins by LC-MS/MS analysis,Cc1cc(/C=C/C#N)cc(C)c1Oc1nc(Nc2ccc(C#N)cc2)nc2c1CSCC2,"(E)-4-(4-(4-(2-cyanovinyl)-2,6-dimethylphenoxy)-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidin-2-ylamino)benzonitrile",53.9,uM,=,1.7315887651867388,1,c1ccc(Nc2nc3c(c(Oc4ccccc4)n2)CSCC3)cc1
3102,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1cccc(C(=O)N2CCOC[C@H]2Cc2cc(-n3nccn3)ccc2Cl)c1-n1nccn1,"US9150566, 122",18.0,uM,=,1.255272505103306,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
3103,1629312,10.1016/j.bmcl.2016.11.020,,,,Inhibition of CYP3A4 (unknown origin),Cc1cc(Nc2cc(C)c(C#N)c(NCCOc3ccccc3F)n2)n[nH]1,2-(2-(2-fluorophenoxy)ethylamino)-4-methyl-6-(5-methyl-1H-pyrazol-3-ylamino)nicotinonitrile,1.6,uM,=,0.2041199826559248,1,c1ccc(OCCNc2cccc(Nc3cc[nH]n3)n2)cc1
3104,2019275,10.1021/acsmedchemlett.0c00335,,,,Inhibition of CYP3A4 (unknown origin),Cc1c(-c2c(Cl)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2c(Cl)cccn2c1=O,"US9334290, 32",11.0,uM,=,1.0413926851582251,1,O=c1cc2ccccn2c(=O)n1-c1cccc(-c2cccc3[nH]c4ccccc4c23)c1
3105,1702023,10.1021/acs.jmedchem.6b01559,,,,Inhibition of CYP3A4 (unknown origin),COc1ccc(F)c(-c2ccc(Cc3ccc(N4C[C@H](C(F)(F)F)C[C@@H]4CC(=O)O)cc3)c(C)c2)c1,"2-((2R,4R)-1-(4-((2'-fluoro-5'-methoxy-3-methylbiphenyl-4-yl)methyl)phenyl)-4-(trifluoromethyl)pyrrolidin-2-yl)acetic acid",1.7,uM,=,0.2304489213782739,1,c1ccc(-c2ccc(Cc3ccc(N4CCCC4)cc3)cc2)cc1
3106,613752,10.1021/jm901818u,,,,Inhibition of human CYP3A4 by fluorescence assay,Clc1ccc([C@@]2(COC3CCC3)[C@@H]3CNC[C@@H]32)cc1Cl,"exo-6-[(Cyclobutyloxy)methyl]-6-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane",3.0,uM,=,0.4771212547196624,1,c1ccc([C@@]2(COC3CCC3)[C@@H]3CNC[C@@H]32)cc1
3107,619265,10.1016/j.bmcl.2009.07.002,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate,Cc1cccc(C)c1CNc1nc(-c2cccc(=O)[nH]2)cc2c(C)c(C)[nH]c12,"6-(7-(2,6-dimethylbenzylamino)-2,3-dimethyl-1H-pyrrolo[2,3-c]pyridin-5-yl)pyridin-2(1H)-one",2.2,uM,=,0.3424226808222063,1,O=c1cccc(-c2cc3cc[nH]c3c(NCc3ccccc3)n2)[nH]1
3108,769541,10.1021/jm200695m,,,,Inhibition of CYP3A4 in human liver microsomes,COC(=O)C(C)(C)C(c1ccc(Nc2ccc3ccccc3c2)cc1)n1cncn1,"Methyl 2,2-Dimethyl-3-[4-(naphthalen-2-ylamino)phenyl]-3-(1H-1,2,4-triazol-1-yl)propanoate",0.33,uM,=,-0.4814860601221125,0,c1ccc2cc(Nc3ccc(Cn4cncn4)cc3)ccc2c1
3109,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCN(C(C)(C)C)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1,"US8940739, G-48",4.19,uM,=,0.6222140229662954,1,O=C(Nc1ccc(N2CCNCC2)nc1)c1c[nH]c2c(CN3CC4N(C(=O)NCc5ccccc5)NCC(=O)N4C(Cc4ccccc4)C3=O)cccc12
3110,461436,10.1016/j.bmcl.2007.10.092,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,O=C(OC1([C@H]2CCC[C@@H](c3cc(F)cc(F)c3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CCN(CCO)CC1,"1-((2R,6S)-1-(4-chlorophenylsulfonyl)-6-(3,5-difluorophenyl)piperidin-2-yl)cyclopropyl 4-(2-hydroxyethyl)piperazine-1-carboxylate",0.06,uM,=,-1.2218487496163564,0,O=C(OC1([C@H]2CCC[C@@H](c3ccccc3)N2S(=O)(=O)c2ccccc2)CC1)N1CCNCC1
3111,774749,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2,anhydrovinblastine,1.0,uM,=,0.0,0,C1=C[C@H]2CC(c3ccc4c(c3)[C@@]35CCN6CC=CC(CC[C@@H]3N4)[C@H]65)c3[nH]c4ccccc4c3CN(C1)C2
3112,449088,10.1016/j.bmcl.2007.08.028,,,,Inhibition of human CYP3A4,CC(=O)N1CCC(C(=O)N2C[C@H](C(=O)N(C)Cc3cc(C(F)(F)F)cc(C(F)(F)F)c3)[C@@H](c3ccccc3)C2)CC1,"(3R,4S)-N-(3,5-bis(trifluoromethyl)benzyl)-1-(1-acetylpiperidine-4-carbonyl)-N-methyl-4-phenylpyrrolidine-3-carboxamide",18.0,uM,=,1.255272505103306,1,O=C(NCc1ccccc1)[C@H]1CN(C(=O)C2CCNCC2)C[C@@H]1c1ccccc1
3113,526157,10.1021/np0401765,,,,Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation,COc1cc(C[C@@H](CO)[C@H](CO)Cc2ccc3c(c2)OCO3)cc(OC)c1OC,(-)-dihydroclusin,0.8,uM,=,-0.0969100130080563,0,c1ccc(CCCCc2ccc3c(c2)OCO3)cc1
3114,473932,10.1021/jm701121y,,,,Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay,Cc1cnc(CNc2cc(-c3ccccc3)nc(-c3ccncc3)n2)nc1,N-((5-methylpyrimidin-2-yl)methyl)-6-phenyl-2-(pyridin-4-yl)pyrimidin-4-amine,0.071,uM,=,-1.1487416512809248,0,c1ccc(-c2cc(NCc3ncccn3)nc(-c3ccncc3)n2)cc1
3115,702471,10.1021/jm100679e,,,,Inhibition of human CYP3A4 by fluorescence assay,O=C(N1CCCC1)C1(c2ccc(-n3nc(C(F)(F)F)c4c3CCCC4)cc2)CC1,"1-{4-[1-(1-pyrrolidinylcarbonyl)cyclopropyl]phenyl}-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1Hindazole",6.0,uM,=,0.7781512503836436,1,O=C(N1CCCC1)C1(c2ccc(-n3ncc4c3CCCC4)cc2)CC1
3116,876026,10.1021/jm3011838,,,,Inhibition of CYP3A4 in human liver microsomes in presence of NADPH by LC-MS/MS method,CN1C[C@H](C(=O)Nc2ccc(Cl)cc2)[C@@H](c2ccc(/C=C/C(=O)Nc3ccccc3N)cc2F)C1,"rac-(trans-3,4)-4-{4-[2-(2-Amino-phenylcarbamoyl)-vinyl]-2-fluoro-phenyl}-1-methyl-pyrrolidine-3-carboxylic acid(4-chloro-phenyl)-amide",4.0,uM,=,0.6020599913279624,1,O=C(/C=C/c1ccc([C@H]2CNC[C@@H]2C(=O)Nc2ccccc2)cc1)Nc1ccccc1
3117,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCN(C7CC7)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1,"US8940739, G-49",6.94,uM,=,0.8413594704548549,1,O=C(Nc1ccc(N2CCN(C3CC3)CC2)nc1)c1c[nH]c2c(CN3CC4N(C(=O)NCc5ccccc5)NCC(=O)N4C(Cc4ccccc4)C3=O)cccc12
3118,2254484,10.1021/acs.jmedchem.2c00527,,,,Inhibition of CYP3A4 in human liver microsomes at 0.01 to 30 uM using phenacetin as substrate in presence of NADPH by UPLC-MS/MS analysis,C[C@@H]1CC(=O)Nc2ncnc(N3CCN(C(=O)[C@H](CNC4C5COCC54)c4ccc(Cl)cc4)[C@@H]4C[C@@H]43)c21,"(4S)-5-((1S,6R)-5-((2S)-3-((3-oxabicyclo[3.1.0]hexan-6-yl)amino)-2-(4-chlorophenyl)propanoyl)-2,5-diazabicyclo[4.1.0]heptan-2-yl)-4-methyl-1,4-dihydro-2H-pyrimido[4,5-d][1,3]oxazin-2-one",4.33,uM,=,0.6364878963533654,1,O=C1CCc2c(ncnc2N2CCN(C(=O)[C@H](CNC3C4COCC43)c3ccccc3)[C@@H]3C[C@@H]32)N1
3119,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",O=C(c1cccc(Cl)c1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1,"US9150566, 107",22.0,uM,=,1.3424226808222062,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
3120,1625607,10.1016/j.bmcl.2016.10.016,,,,Inhibition of human Cyp3A4 using testosterone as substrate by LC-MS/MS analysis,O=S(=O)(C(F)F)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,"1-(4-{[(2S,4R)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)-4-difluoromethanesulfonylpiperazine",0.099,uM,=,-1.00436480540245,0,c1ccc([C@]2(Cn3ccnc3)OC[C@@H](COc3ccc(N4CCNCC4)cc3)O2)cc1
3121,834169,10.1021/jm2013248,,,,Inhibition of human recombinant CYP3A4 coexpressed in Escherichia coli,Clc1cc(-c2nc(CSc3nnc(-c4ccncc4)n3C3CC3)no2)ccn1,"5-(2-chloropyridin-4-yl)-3-((4-cyclopropyl-5-(pyridin-4-yl)-4H-1,2,4-triazol-3-ylthio)methyl)-1,2,4-oxadiazole",14.2,uM,=,1.1522883443830565,1,c1cc(-c2nc(CSc3nnc(-c4ccncc4)n3C3CC3)no2)ccn1
3122,993292,10.1021/ml400228e,,,,Inhibition of CYP3A4 in human liver microsomes using nifedipine as substrate after 5 to 60 mins by LC-MS/MS analysis,Cc1cc(C)n(CC(=O)N2CCc3c2ccc(-c2cn(C)c4ncnc(N)c24)c3F)n1,"5-{1-[(3,5-dimethyl-1H-pyrazol-1-yl)acetyl]-4-fluoro-2,3-dihydro-1H-indol-5-yl}-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine",20.5,uM,=,1.3117538610557542,1,O=C(Cn1cccn1)N1CCc2cc(-c3c[nH]c4ncncc34)ccc21
3123,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1ccc(C(=O)N2CCOC[C@H]2Cc2cc(-c3ncon3)ccc2F)c(-n2nccn2)c1C,"US9150566, 181",36.0,uM,=,1.5563025007672873,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2ncon2)c1
3124,449485,10.1016/j.bmcl.2007.07.097,,,,Inhibition of microsomal CYP3A4,CC(C)C[C@H](NCCCN)c1cc(C(F)(F)F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1,"1-((R)-1-(4-(2-((S)-1-(3-aminopropylamino)-3-methylbutyl)-4-(trifluoromethyl)phenyl)piperazin-1-yl)-3-(2,4-dichlorophenyl)-1-oxopropan-2-yl)pyrrolidin-2-one",15.0,uM,=,1.1760912590556811,1,O=C([C@@H](Cc1ccccc1)N1CCCC1=O)N1CCN(c2ccccc2)CC1
3125,1660136,10.1021/acs.jmedchem.6b01918,,,,Inhibition of human CYP3A4 assessed as inhibition of dealkylation,O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCC2CNC2)cc1F,4-((Azetidin-3-ylmethyl)amino)-5-chloro-2-fluoro-N-(thiazol-2-yl)benzenesulfonamide,20.0,uM,=,1.3010299956639813,1,O=S(=O)(Nc1nccs1)c1ccc(NCC2CNC2)cc1
3126,988938,10.1021/jm401094t,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of dextromethorphan metabolism by HPLC/MS analysis,Nc1ccc(-c2cnc3[nH]cc(-c4ccc5[nH]ccc5c4)c3c2)cn1,"5-(3-(1H-Indol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl)pyridin-2-amine",4.2,uM,=,0.6232492903979004,1,c1cncc(-c2cnc3[nH]cc(-c4ccc5[nH]ccc5c4)c3c2)c1
3127,1288280,10.1016/j.bmcl.2013.12.057,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,"Thiazol-5-ylmethyl(2R,5R)-5-((S)-6-amino-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)hexanamido)-1,6-diphenylhexan-2-ylcarbamate",0.12,uM,=,-0.9208187539523752,0,O=C(CNC(=O)NCc1cscn1)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
3128,856843,10.1021/jm300356u,,,,Inhibition of human recombinant CYP3A4 using DEF as substrate preincubated for 5 to 10 mins before substrate addition,CC/N=C1\O[C@H]2[C@H](O[C@@H]3[C@@H](C)[C@H](O[C@H]4C[C@@](C)(OC)[C@@H](O)[C@H](C)O4)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]3(C)O)O[C@H](C)C[C@@H]2N1C,"(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-14-ethyl-6-((3aR,4S,6R,7aS)-2-(ethylimino)-1,6-dimethylhexahydro-1H-pyrano[4,3-d]oxazol-4-yloxy)-7,12,13-trihydroxy-4-((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yloxy)-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione",0.5,uM,=,-0.3010299956639812,0,N=C1N[C@H]2CCO[C@@H](O[C@H]3CCCC(=O)CCCCOC(=O)C[C@@H](O[C@H]4CCCCO4)C3)[C@@H]2O1
3129,1695601,10.1016/j.bmc.2017.08.012,,,,Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using 7-Benzoyloxy-4-trifluoromethyl coumarin substrate in presence of NADP+ by fluorescence based assay,O=S(=O)(Nc1nccs1)c1cc(Cl)c(NC[C@]23CCC[C@@]2(O)CCC3)cc1F,"5-chloro-2-fluoro-4-(((3ar,6as)-6a-hydroxyoctahydropentalen-3a-yl)methylamino)-N-(thiazol-2-yl)benzenesulfonamide",6.3,uM,=,0.7993405494535817,1,O=S(=O)(Nc1nccs1)c1ccc(NCC23CCCC2CCC3)cc1
3130,2226867,10.1016/j.ejmech.2022.114512,,,,Inhibition of CYP3A4T in human liver microsomes incubated for 15 to 40 mins in presence of NADPH,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,"17-Hydroxy-10,13-dimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-cyclopenta[a]phenanthren-3-one",0.0472,uM,=,-1.3260580013659122,0,O=C1C=C2CC[C@H]3[C@@H]4CCCC4CC[C@@H]3C2CC1
3131,1886565,10.1021/acs.jmedchem.8b02021,,,,Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay,COc1ccc2nc(N)sc2c1,6-Methoxy-benzothiazol-2-ylamine,10.0,uM,=,1.0,1,c1ccc2scnc2c1
3132,982382,10.1016/j.bmcl.2013.07.071,,,,Inhibition of CYP3A4 (unknown origin),COC[C@@H](Oc1cc(C[C@@H]2C[S@@+]([O-])C[C@H](NCc3cnn(CC(C)(C)C)c3)[C@H]2O)cc(F)c1N)C(F)(F)F,"(1R,3S,4S,5R)-3-[4-Amino-3-fluoro-5-((R)-2,2,2-trifluoro-1-methoxymethyl-ethoxy)-benzyl]-5-{[1-(2,2-dimethyl-propyl)-1H-pyrazol-4-ylmethyl]-amino}-1-oxo-tetrahydro-thiopyran-4-ol",3.6,uM,=,0.5563025007672873,1,c1ccc(C[C@@H]2C[SH+]C[C@H](NCc3cn[nH]c3)C2)cc1
3133,1779276,10.1016/j.bmcl.2018.07.008,,,,Inhibition of CYP3A4 (unknown origin),C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,SID124898784,11.0,uM,=,1.0413926851582251,1,c1ccc(Oc2ccc(-c3nn([C@@H]4CCCNC4)c4ncncc34)cc2)cc1
3134,1301325,10.6019/CHEMBL3137440,,,,DNDI: CYP Inhibition,O=C(c1ccc(F)cc1)N1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1,,4.4,uM,=,0.6434526764861874,1,O=C(c1ccccc1)N1CCC(N(c2ccccc2)c2cccnc2)CC1
3135,2241108,10.1021/acs.jmedchem.1c01153,,,,Inhibition of CYP3A4 in human liver microsomes at 40 uM using midazolam as substrate measured after 5 to 20 mins in presence of NADPH by LC/MS/MS analysis,CC(C)S(=O)(=O)c1cc(-c2ccn3nc(N)c(C(=O)NC4CC4)c3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,"2-Amino-N-cyclopropyl-5-{2-[(1S)-1-cyclopropylethyl]-1-oxo-7-(propane-2-sulfonyl)-2,3-dihydro-1H-isoindol-5-yl}pyrazolo[1,5-a]-pyrimidine-3-carboxamide",3.7,uM,=,0.568201724066995,1,O=C(NC1CC1)c1cnn2ccc(-c3ccc4c(c3)CN(CC3CC3)C4=O)nc12
3136,509825,10.1021/jm800546t,,,,Inhibition of recombinant CYP3A4 expressed in insect microsomes after 20 mins in presence of BFC substrate,Cc1cc(C[C@@H](NC(=O)N2CCC(N3Cc4cccc(F)c4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12,"(R)-N-(1-(1,4'-bipiperidin-1'-yl)-3-(7-methyl-1H-indazol-5-yl)-1-oxopropan-2-yl)-4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide",7.8,uM,=,0.8920946026904804,1,O=C(N[C@H](Cc1ccc2[nH]ncc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
3137,487712,10.1016/j.bmcl.2008.05.104,,,,Inhibition of CYP3A4,Cc1cc(N2CCC(O)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,(S)-4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-3-(6-(4-hydroxypiperidin-1-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one,0.0004,uM,=,-3.397940008672037,0,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(N3CCCCC3)cc2[nH]1
3138,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N(C)C)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, F-1",3.16,uM,=,0.4996870826184038,1,O=C1[C@H](Cc2ccccc2)N2C(=O)CNN(C(=O)NCc3ccccc3)[C@H]2CN1Cc1cccc2cc[nH]c12
3139,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",O=C(c1ccc(F)cc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1,"US9150566, 36",36.0,uM,=,1.5563025007672873,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
3140,619265,10.1016/j.bmcl.2009.07.002,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate,Cc1c(C)n(C[C@H]2C[C@@H]2C)c2c(OCc3ccc(F)cc3)nncc12,"7-(4-fluorobenzyloxy)-2,3-dimethyl-1-(((1S,2S)-2-methylcyclopropyl)methyl)-1H-pyrrolo[2,3-d]pyridazine",14.0,uM,=,1.146128035678238,1,c1ccc(COc2nncc3ccn(CC4CC4)c23)cc1
3141,1276541,10.1016/j.bmcl.2013.09.041,,,,Inhibition of CYP3A4 (unknown origin) after 5 mins,O=S(=O)(Nc1ccc(-c2ccncc2)cc1)c1cc(Cl)cc(Cl)c1,"3,5-dichloro-N-(4-(pyridin-4-yl)phenyl)benzenesulfonamide",0.6,uM,=,-0.2218487496163563,0,O=S(=O)(Nc1ccc(-c2ccncc2)cc1)c1ccccc1
3142,804823,10.1016/j.bmcl.2011.12.080,,,,Time dependent inhibition of CYP3A4,COc1cc(C)c2nc3[nH]nc(C)c3c(C(F)c3ccncc3)c2c1,"(-)-4-(fluoro(pyridin-4-yl)methyl)-6-methoxy-3,8-dimethyl-1H-pyrazolo[3,4-b]quinoline",12.0,uM,=,1.0791812460476249,1,c1ccc2c(Cc3ccncc3)c3cn[nH]c3nc2c1
3143,643871,10.1016/j.bmcl.2010.06.019,,,,Inhibition of CYP3A4,C[C@H](NC(=O)[C@H]1NCC[C@@H]1O)c1ccc(-c2noc(CCC3CCCCC3)n2)cc1,"(2S,3S)-N-((S)-1-(4-(5-(2-cyclohexylethyl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)-3-hydroxypyrrolidine-2-carboxamide",4.3,uM,=,0.6334684555795865,1,O=C(NCc1ccc(-c2noc(CCC3CCCCC3)n2)cc1)[C@@H]1CCCN1
3144,1289242,10.1016/j.bmcl.2013.12.088,,,,Inhibition of CYP3A4 (unknown origin) using benzyloxyresorufin as substrate,Fc1cc(OC(F)(F)C(F)F)cc([C@@](Cc2ccccc2)(Nc2nc3cc(F)cc(F)c3[nH]2)c2ccc(Cl)cn2)c1,"(R)-N-(1-(5-chloropyridin-2-yl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-5,7-difluoro-1H-benzo[d]imidazol-2-amine",19.0,uM,=,1.2787536009528289,1,c1ccc(C[C@@](Nc2nc3ccccc3[nH]2)(c2ccccc2)c2ccccn2)cc1
3145,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",COc1ccc(C[C@@H]2COCCN2C(=O)c2cc(C)ccc2-n2nccn2)cc1-c1ncon1,"US9150566, 58",42.0,uM,=,1.6232492903979006,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2ncon2)c1
3146,875916,10.1021/jm300955x,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 mins by LC-MS/MS analysis in presence of NADPH,COc1ccc(S(=O)(=O)n2cc(C)c3cc(Cl)ccc32)cc1NC1CCN(C)CC1,1-[3-(1-Methylpiperidin-4-ylamino)-4-methoxybenzenesulfonyl]-5-chloro-3-methyl-1H-indole,6.46,uM,=,0.8102325179950841,1,O=S(=O)(c1cccc(NC2CCNCC2)c1)n1ccc2ccccc21
3147,1446329,10.1021/ml500387y,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,CC(C)(CC(O)(Cc1cc2cc(S(C)(=O)=O)ncc2[nH]1)C(F)(F)F)c1ccc(F)cc1C(N)=O,"5-fluoro-2-(5,5,5-trifluoro-4-hydroxy-2-methyl-4-((5-(methylsulfonyl)-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)pentan-2-yl)benzamide",3.0,uM,=,0.4771212547196624,1,c1ccc(CCCCc2cc3ccncc3[nH]2)cc1
3148,696217,10.1016/j.bmcl.2010.09.125,,,,Inhibition of CYP3A4,Cc1cc(-c2cccc(C3=Nc4cc(C)c(C(F)(F)F)cc4NC(=O)C3)c2)ccn1,"7-methyl-4-(3-(2-methylpyridin-4-yl)phenyl)-8-(trifluoromethyl)-1H-benzo[b][1,4]diazepin-2(3H)-one",1.9,uM,=,0.2787536009528289,1,O=C1CC(c2cccc(-c3ccncc3)c2)=Nc2ccccc2N1
3149,966467,10.1016/j.bmcl.2013.04.077,,,,Inhibition of CYP3A4 (unknown origin),Cc1nc(NC(=O)C(C)(C)CC(F)(F)F)sc1-c1ccc(N)nc1,"N-(5-(6-aminopyridin-3-yl)-4-methylthiazol-2-yl)-4,4,4-trifluoro-2,2-dimethylbutanamide",17.0,uM,=,1.230448921378274,1,c1cncc(-c2cncs2)c1
3150,716789,10.1016/j.bmcl.2010.12.123,,,,Inhibition of CYP3A4,O=C(O)c1ccc(NC(=O)[C@H](C2CCCCC2)n2c(-c3ccc(Cl)cc3)nc3cc(F)c(F)cc32)c(Cl)c1,"(S)-3-chloro-4-(2-(2-(4-chlorophenyl)-5,6-difluoro-1H-benzo[d]imidazol-1-yl)-2-cyclohexylacetamido)benzoic acid",23.0,uM,=,1.3617278360175928,1,O=C(Nc1ccccc1)[C@H](C1CCCCC1)n1c(-c2ccccc2)nc2ccccc21
3151,1667894,10.1016/j.bmcl.2017.03.043,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins in presence of NADPH by LC-MS/MS analysis,O=S(=O)(Nc1ncc(F)s1)c1cc(Cl)c(NC[C@H]2NCCC=C2c2ccc(F)cc2)cc1F,"(S)-5-chloro-2-fluoro-4-((3-(4-fluorophenyl)-1,2,5,6-tetrahydropyridin-2-yl)methylamino)-N-(5-fluorothiazol-2-yl)benzenesulfonamide",37.5,uM,=,1.5740312677277188,1,O=S(=O)(Nc1nccs1)c1ccc(NC[C@H]2NCCC=C2c2ccccc2)cc1
3152,749189,10.1016/j.bmcl.2011.04.029,,,,Inhibition of CYP3A4,COc1ccc(CN2CCN(C(=O)C[C@H](N)Cc3cc(F)c(F)cc3F)CC2=O)cc1,"(R)-4-(3-amino-4-(2,4,5-trifluorophenyl)butanoyl)-1-(4-methoxybenzyl)piperazin-2-one",1.075,uM,=,0.0314084642516241,1,O=C(CCCc1ccccc1)N1CCN(Cc2ccccc2)C(=O)C1
3153,657980,10.1021/jm100482n,,,,Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein/7-benzyloxyquinoline as substrate,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4cncn4-5)CC3)cccc2n1,"6-(2-(4-(2-methylquinolin-5-yl)piperazin-1-yl)ethyl)-4H-benzo[b]imidazo[1,5-d][1,4]oxazine",0.1,uM,=,-1.0,0,c1cc(CCN2CCN(c3cccc4ncccc34)CC2)c2c(c1)-n1cncc1CO2
3154,1699178,10.1021/acs.jmedchem.6b01543,,,,Inhibition of CYP3A4 (unknown origin),O=C(O)CC1CCC2(CC1)CCN(c1ccc(-c3nc4cc(C(F)(F)F)ccc4[nH]3)cn1)CC2,2-(3-(5-(5-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)pyridin-2-yl)-3-azaspiro[5.5]undecan-9-yl)acetic acid,6.4,uM,=,0.8061799739838872,1,c1ccc2[nH]c(-c3ccc(N4CCC5(CCCCC5)CC4)nc3)nc2c1
3155,790049,10.1016/j.bmc.2011.08.066,,,,Inhibition of CYP3A4,CNC(=O)c1ccc2cc([C@](O)(c3c[nH]cn3)C(C)C)ccc2c1,(S)-6-(1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl)-N-methyl-2-naphthamide,7.8,uM,=,0.8920946026904804,1,c1ccc2cc(Cc3c[nH]cn3)ccc2c1
3156,2152998,10.1021/acs.jmedchem.1c00635,,,,Inhibition of CYP3A4 in human liver microsomes using ketoconazole as substrate incubated for 5 mins in presence of NADPH by LC-MS/MS analysis,CCc1cccc(CC)c1NC(=O)c1ccn(-c2nc(Nc3ccc(N4CCC(O)(CN5CCN(C)CC5)CC4)cc3OC)nc3[nH]ccc23)c1,"N-(2,6-diethylphenyl)-1-[2-[4-[4-hydroxy-4-[(4-methylpiperazin-1-yl)methyl]-1-piperidyl]-2-methoxy-anilino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]pyrrole-3-carboxamide",1.2,uM,=,0.0791812460476248,1,O=C(Nc1ccccc1)c1ccn(-c2nc(Nc3ccc(N4CCC(CN5CCNCC5)CC4)cc3)nc3[nH]ccc23)c1
3157,1996656,10.1021/acs.jmedchem.0c00446,,,,Inhibition of CYP3A4 (unknown origin),COc1cc(/C=C2\CCCN3C2=NO[C@H](c2cc(F)cc(F)c2)[C@@H]3C)ccc1-n1cnc(C)c1,"(3R,4S)-3-(3,5-Difluorophenyl)-9-((E)-3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene)-4-methyl-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]oxadiazine",16.0,uM,=,1.2041199826559248,1,C(=C1\CCCN2C[C@@H](c3ccccc3)ON=C12)\c1ccc(-n2ccnc2)cc1
3158,448320,10.1016/j.bmc.2007.05.069,,,,Inhibition of CYP3A4,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCOC(F)(F)F)C(=O)C(C)(c1cc(F)cc(F)c1)O2,"6-(2,4-diamino-6-ethylpyrimidin-5-yl)-2-(3,5-difluorophenyl)-2-methyl-4-(3-(trifluoromethoxy)propyl)-2H-benzo[b][1,4]oxazin-3(4H)-one",0.27,uM,=,-0.5686362358410126,0,O=C1Nc2cc(-c3cncnc3)ccc2OC1c1ccccc1
3159,2164346,10.1021/acs.jmedchem.1c02192,,,,Inhibition of CYP3A4 (unknown origin),Cc1nc2cnc3cc(F)c(-c4ccc(Oc5ncccn5)cc4Cl)cc3c2n1C1CCN(CC#N)CC1,"US9227969, 84",1.6,uM,=,0.2041199826559248,1,c1cnc(Oc2ccc(-c3ccc4ncc5ncn(C6CCNCC6)c5c4c3)cc2)nc1
3160,510198,10.1021/jm800355c,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,Cl.Fc1ccc(-c2ccc3c(c2)CCCC3c2ccncc2)cc1,"4-(6-(4-Fluorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl)pyridine Hydrochloride",2.173,uM,=,0.3370597263205245,1,c1ccc(-c2ccc3c(c2)CCCC3c2ccncc2)cc1
3161,449485,10.1016/j.bmcl.2007.07.097,,,,Inhibition of microsomal CYP3A4,CC(C)C[C@H](NC(=O)CCN)c1ccccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1,"3-amino-N-((S)-1-(2-(4-((R)-3-(2,4-dichlorophenyl)-2-(2-oxopyrrolidin-1-yl)propanoyl)piperazin-1-yl)phenyl)-3-methylbutyl)propanamide",2.9,uM,=,0.4623979978989561,1,O=C([C@@H](Cc1ccccc1)N1CCCC1=O)N1CCN(c2ccccc2)CC1
3162,1637154,,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins,O=C(c1c(F)ccc(NS(=O)(=O)c2cc(F)ccc2F)c1F)c1c[nH]c2nccc(Cl)c12,"N-[3-(4-Chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-2,5-difluoro-benzenesulfonamide",5.0,uM,=,0.6989700043360189,1,O=C(c1cccc(NS(=O)(=O)c2ccccc2)c1)c1c[nH]c2ncccc12
3163,1754743,10.1021/acs.jmedchem.7b01714,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 5 mins by LC-MS/MS analysis,N#Cc1ccc(-c2cnc3ccc(-c4ccc(C(=O)N5CCNCC5)cc4)nn23)cc1,"4-(6-(4-(Piperazine-1-carbonyl)phenyl)imidazo[1,2-b]pyridazin-3-yl)benzonitrile",5.6,uM,=,0.7481880270062004,1,O=C(c1ccc(-c2ccc3ncc(-c4ccccc4)n3n2)cc1)N1CCNCC1
3164,449485,10.1016/j.bmcl.2007.07.097,,,,Inhibition of microsomal CYP3A4,CC(C)C[C@H](NCCN(C)C)c1cc(F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1,"1-((R)-3-(2,4-dichlorophenyl)-1-(4-(2-((S)-1-(2-(dimethylamino)ethylamino)-3-methylbutyl)-4-fluorophenyl)piperazin-1-yl)-1-oxopropan-2-yl)pyrrolidin-2-one",32.0,uM,=,1.505149978319906,1,O=C([C@@H](Cc1ccccc1)N1CCCC1=O)N1CCN(c2ccccc2)CC1
3165,1661010,10.1016/j.bmcl.2017.02.047,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 10 mins followed by NADPH addition measured after 10 mins,CCCCCCCCC[C@H](O)CC(=O)CCc1ccc(O)c(OC)c1,10-gingerol,7.1,uM,=,0.8512583487190752,1,c1ccccc1
3166,1780160,10.1021/acs.jmedchem.8b01077,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as substrate,Cc1nnc(C(C)C)n1[C@@H]1C[C@H]2CC[C@@H](C1)N2CC[C@H](NC(=O)C1CCCCC1)c1cccs1,"N-((S)-3-(exo-3-(3-Isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-1-(thiophen-2-yl)propyl)cyclohexane Carboxamide",21.7,uM,=,1.3364597338485296,1,O=C(N[C@@H](CCN1[C@@H]2CC[C@H]1C[C@H](n1cnnc1)C2)c1cccs1)C1CCCCC1
3167,617698,10.1016/j.bmcl.2010.01.087,,,,Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay,Cc1cc(N2CCC(NC(=O)OC(C)(C)C)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,"(S)-tert-butyl 1-(2-(4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-2-oxo-1,2-dihydropyridin-3-yl)-4-methyl-1H-benzo[d]imidazol-6-yl)piperidin-4-ylcarbamate",16.0,uM,=,1.2041199826559248,1,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(N3CCCCC3)cc2[nH]1
3168,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCCOC)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, F-6",3.84,uM,=,0.5843312243675308,1,O=C1[C@H](Cc2ccccc2)N2C(=O)CNN(C(=O)NCc3ccccc3)[C@H]2CN1Cc1cccc2cc[nH]c12
3169,552281,10.1016/j.bmcl.2008.04.036,,,,Inhibition of CYP3A4,N[C@@H](Cn1c(=O)c(-c2ccc(COC(=O)CO)cc2)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1,"(R)-4-(1-(2-fluoro-6-(trifluoromethyl)benzyl)-3-(2-amino-2-phenylethyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)benzyl 2-hydroxyacetate",0.12,uM,=,-0.9208187539523752,0,O=c1c(-c2ccccc2)cn(Cc2ccccc2)c(=O)n1CCc1ccccc1
3170,552281,10.1016/j.bmcl.2008.04.036,,,,Inhibition of CYP3A4,COc1cccc(-c2cn(Cc3c(F)cccc3F)c(=O)n(C[C@H](NCCCC(=O)O)c3ccccc3)c2=O)c1F,"(R)-4-(2-(3-(2,6-difluorobenzyl)-5-(2-fluoro-3-methoxyphenyl)-2,6-dioxo-2,3-dihydropyrimidin-1(6H)-yl)-1-phenylethylamino)butanoic acid",33.0,uM,=,1.5185139398778875,1,O=c1c(-c2ccccc2)cn(Cc2ccccc2)c(=O)n1CCc1ccccc1
3171,519907,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,Cc1ccccc1CNc1cc(-n2ccccc2=O)cn2c(C)c(C)nc12,"1-(2,3-dimethyl-8-(2-methylbenzylamino)imidazo[1,2-a]pyridin-6-yl)pyridin-2(1H)-one",7.2,uM,=,0.8573324964312685,1,O=c1ccccn1-c1cc(NCc2ccccc2)c2nccn2c1
3172,598210,10.1016/j.bmcl.2009.08.024,,,,Inhibition of human CYP3A4,CC1(CC(=O)NCc2ccc(OC(F)(F)F)cc2)CC2(CCCCC2)OO1,"2-(3-methyl-1,2-dioxaspiro[4.5]decan-3-yl)-N-(4-(trifluoromethoxy)benzyl)acetamide",2.9,uM,=,0.4623979978989561,1,O=C(CC1CC2(CCCCC2)OO1)NCc1ccccc1
3173,796228,10.1016/j.bmcl.2011.10.115,,,,Inhibition of CYP3A4,COc1ccc(Cn2c(C3CNCCS3)nc3ccccc32)cc1,(-)-2-(1-(4-methoxybenzyl)-1H-benzo[d]imidazol-2-yl)thiomorpholine,15.8,uM,=,1.1986570869544226,1,c1ccc(Cn2c(C3CNCCS3)nc3ccccc32)cc1
3174,1688699,10.1021/acs.jmedchem.7b00410,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 15 mins measured after 8 mins in presence or absence of NADPH by LC/MS/MS analysis,Cc1cc(Oc2cncnc2)cc(C(=O)Nc2ccc(F)cn2)n1,N-(5-fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide,133.0,uM,=,2.123851640967086,1,O=C(Nc1ccccn1)c1cc(Oc2cncnc2)ccn1
3175,461436,10.1016/j.bmcl.2007.10.092,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,CC[C@@H]1CCC[C@H](C2(CC(=O)N3CCNCC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1,"2-(1-((2R,6R)-1-(4-chlorophenylsulfonyl)-6-ethylpiperidin-2-yl)cyclopropyl)-1-(piperazin-1-yl)ethanone",0.3,uM,=,-0.5228787452803376,0,O=C(CC1([C@H]2CCCCN2S(=O)(=O)c2ccccc2)CC1)N1CCNCC1
3176,728438,10.1016/j.bmcl.2011.01.023,,,,Inhibition of CYP3A4,Cc1cccc(C)c1-c1nc2ccc(C(=O)Nc3ccc4ccccc4n3)cc2[nH]1,"2-(2,6-dimethylphenyl)-N-(quinolin-2-yl)-1H-benzo[d]imidazole-6-carboxamide",7.3,uM,=,0.8633228601204559,1,O=C(Nc1ccc2ccccc2n1)c1ccc2nc(-c3ccccc3)[nH]c2c1
3177,448320,10.1016/j.bmc.2007.05.069,,,,Inhibition of CYP3A4,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCC(F)(F)F)C(=O)[C@](C)(c1cc(F)cc(F)c1)O2,"(S)-6-(2,4-diamino-6-ethyl-pyrimidin-5-yl)-2-(3,5-difluoro-phenyl)-2-methyl-4-(4,4,4-trifluorobutyl)-4Hbenzo[1,4]oxazin-3-one",1.7,uM,=,0.2304489213782739,1,O=C1Nc2cc(-c3cncnc3)ccc2OC1c1ccccc1
3178,2253558,10.1021/acs.jmedchem.1c02071,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam and testosterone as substrate incubated for 5 to 45 mins in presence of NADPH by LC/MS analysis,CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,SID144204227,0.01,uM,=,-2.0,0,c1ccc([C@@]2(Cn3ccnc3)OC[C@H](COc3ccc(N4CCNCC4)cc3)O2)cc1
3179,1291572,10.1016/j.bmcl.2013.12.058,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](CC[C@@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1,"Thiazol-5-ylmethyl(2S,5S)-5-((S)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-3-methylbutanamido)-1,6-diphenylhexan-2-ylcarbamate",0.14,uM,=,-0.8538719643217619,0,O=C(CNC(=O)NCc1cscn1)N[C@@H](CC[C@@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
3180,2235751,10.1021/acs.jmedchem.2c00741,,,,Inhibition of CYP3A4 (unknown origin),Cc1c([C@@H](C)Nc2nnc(C)c3cnc(N4CCOCC4)cc23)cccc1C(F)(F)F,"(R)-4-methyl-N-(1-(2-methyl-3-(trifluoromethyl)phenyl)ethyl)-7-morpholinopyrido[3,4-d]pyridazin-1-amine",0.64,uM,=,-0.1938200260161128,0,c1ccc(CNc2nncc3cnc(N4CCOCC4)cc23)cc1
3181,993439,10.6019/CHEMBL2448688,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,CO/N=C(\C)c1ccc(-n2ccnc2)c(NC(=O)c2ccc(-c3ccccn3)s2)c1,,2.0,uM,=,0.3010299956639812,1,O=C(Nc1ccccc1-n1ccnc1)c1ccc(-c2ccccn2)s1
3182,526157,10.1021/np0401765,,,,Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation,COc1cc([C@H]2OC[C@@H]3C(c4cc(OC)c(O)c(OC)c4)OC[C@H]23)ccc1O,medioresinol,13.7,uM,=,1.136720567156407,1,c1ccc(C2OC[C@@H]3[C@@H](c4ccccc4)OC[C@H]23)cc1
3183,772032,10.1021/jm2006222,,,,Inhibition of CYP3A4 using BFC as substrate,CCN1CCC(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1,"3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(1-ethyl-piperidin-4-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea",1.2,uM,=,0.0791812460476248,1,O=C(Nc1ccccc1)Nc1cc(Nc2ccc(C3CCNCC3)cc2)ncn1
3184,1327919,10.1039/C2MD20061A,,,,Inhibition of CYP3A4 in human pooled liver microsomes using midazolam as substrate by LC/MS/MS analysis,COc1cc(N2CCC(N3CCOCC3)CC2)ccc1-c1nc2c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)c(Cl)cnc2[nH]1,"(1S,2S,3R,4R)-3-{6-Chloro-2-[2-methoxy-4-(4-morpholin-4-yl-piperidin-1-yl)-phenyl]-3H-imidazo[4,5-b]pyridin-7-ylamino}-bicyclo[2.2.1]hept-5-ene-2-carboxylicacidamide",14.2,uM,=,1.1522883443830565,1,C1=C[C@H]2C[C@@H]1C[C@@H]2Nc1ccnc2[nH]c(-c3ccc(N4CCC(N5CCOCC5)CC4)cc3)nc12
3185,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)N6CCSCC6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, D-5",1.76,uM,=,0.2455126678141498,1,O=C(c1ccc(-c2c[nH]c3c(CN4C[C@@H]5N(C(=O)NCc6ccccc6)NCC(=O)N5[C@@H](Cc5ccccc5)C4=O)cccc23)cc1)N1CCSCC1
3186,461436,10.1016/j.bmcl.2007.10.092,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,CC[C@@H]1CCC[C@H](C2(CC(=O)N3CCC(N4CCCCC4)CC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1,"2-(1-((2R,6R)-1-(4-chlorophenylsulfonyl)-6-ethylpiperidin-2-yl)cyclopropyl)-1-(4-(piperidin-1-yl)piperidin-1-yl)ethanone",1.2,uM,=,0.0791812460476248,1,O=C(CC1([C@H]2CCCCN2S(=O)(=O)c2ccccc2)CC1)N1CCC(N2CCCCC2)CC1
3187,552281,10.1016/j.bmcl.2008.04.036,,,,Inhibition of CYP3A4,N[C@@H](Cn1c(=O)c(-c2ccccc2Cl)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1,"3-((R)-2-Amino-2-phenyl-ethyl)-5-(2-chloro-phenyl)-1-(2-fluoro-6-trifluoromethyl-benzyl)-1H-pyrimidine-2,4-dione",0.16,uM,=,-0.7958800173440752,0,O=c1c(-c2ccccc2)cn(Cc2ccccc2)c(=O)n1CCc1ccccc1
3188,489963,10.1021/jm800566m,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline substrate,Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1Cc1ccccc1,3-[(4-{Methyl[3-methyl-2-(benzyl)-2H-indazol-6-yl]amino}-2-pyrimidinyl)amino]benzenesulfonamide,79.0,uM,=,1.8976270912904407,1,c1ccc(Cn2cc3ccc(Nc4ccnc(Nc5ccccc5)n4)cc3n2)cc1
3189,1661017,10.1016/j.bmcl.2017.02.047,,,,Inhibition of recombinant human CYP3A4 expressed in baculosomes using Vivid DBOMF substrate green measured every 30 sec for 30 mins by fluorescence assay,CCCCCCCCC[C@H](O)CC(=O)CCc1ccc(O)c(OC)c1,10-gingerol,21.8,uM,=,1.3384564936046048,1,c1ccccc1
3190,1447575,10.1016/j.bmcl.2014.05.068,,,,Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method,CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cncn6)(c6ccc(F)cc6F)C5)cc4)CC3)cc2)c1=O,Posaconazole,0.05,uM,=,-1.3010299956639813,0,O=c1[nH]ncn1-c1ccc(N2CCN(c3ccc(OC[C@@H]4CO[C@@](Cn5cncn5)(c5ccccc5)C4)cc3)CC2)cc1
3191,2133633,10.1021/acs.jmedchem.1c00679,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins in presence of NADPH by LCMS/MS analysis,O=C(NC[C@@H]1[C@H]2C[C@@H](Oc3ccnc4ccc(F)cc34)C[C@@H]12)c1ccc(Cl)cc1,"4-chloro-N-(((1R,3s,5S,6s)-3-(6-fluoroquinolin-4-yloxy)bicyclo[3.1.0]hexan-6-yl)methyl)benzamide",1.9,uM,=,0.2787536009528289,1,O=C(NC[C@@H]1[C@H]2C[C@@H](Oc3ccnc4ccccc34)C[C@@H]12)c1ccccc1
3192,959980,10.1016/j.bmcl.2013.04.023,,,,Inhibition of CYP3A4 (unknown origin) by fluorescence detection method,CC[C@H](NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccccc2)CN1C(C)=O)C(=O)c1nc2ccccc2o1,"(2S,4R)-1-acetyl-N-((S)-1-(benzo[d]oxazol-2-yl)-1-oxobutan-2-yl)-4-(phenylsulfonyl)pyrrolidine-2-carboxamide",9.95,uM,=,0.9978230807457256,1,O=C(CNC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccccc2)CN1)c1nc2ccccc2o1
3193,1854052,10.1016/j.ejmech.2019.07.003,,,,Inhibition of recombinant human CYP3A4 using Luciferin-PPXE as substrate preincubated for 10 mins followed by NADPH addition measured after 15 mins by luminometric method,CCN(CC)c1ccc2cc(C(=O)NCC(O)(Cn3ccnc3)c3ccc(F)cc3F)c(=O)oc2c1,"rac-7-(diethylamino)-N-(2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-imidazol-1-yl)propyl)-2-oxo-2H-chromene-3-carboxamide",1.3123,uM,=,0.1180331288285669,1,O=C(NCC(Cn1ccnc1)c1ccccc1)c1cc2ccccc2oc1=O
3194,2246941,10.1021/acs.jmedchem.1c02132,,,,Inhibition of CYP3A4 (unknown origin) incubated for 10 mins in presence of NADPH by LC-MS/MS analysis,COC(=O)Nc1cc(-c2ccc(OC[C@@](C)(N)CC(C)C)c(OC(F)(F)F)c2)ccn1,"(S)-methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethoxy)phenyl)pyridin-2-yl)carbamate",7.8,uM,=,0.8920946026904804,1,c1ccc(-c2ccncc2)cc1
3195,1288280,10.1016/j.bmcl.2013.12.057,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,CC(C)c1nc(CN(C)C(=O)N[C@@H](Cn2cccn2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,"Thiazol-5-ylmethyl(2R,5R)-5-((S)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-3-(1H-pyrazol-1-yl)propanamido)-1,6-diphenylhexan-2-ylcarbamate",0.1,uM,=,-1.0,0,O=C(NCc1cscn1)N[C@@H](Cn1cccn1)C(=O)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
3196,719028,10.1021/ml100249e,,,,Inhibition of CYP3A4 in human liver microsomes,O=C(Nc1cnc(-c2ccncc2F)c(-c2ccncc2)n1)C1CC1,N-(5-(3-chloropyridin-4-yl)-6-(pyridin-2-yl)pyrazin-2-yl)cyclopropanecarboxamide,1.0,uM,=,0.0,0,O=C(Nc1cnc(-c2ccncc2)c(-c2ccncc2)n1)C1CC1
3197,804824,10.1016/j.bmcl.2011.12.080,,,,Reversible inhibition of CYP3A4,Cc1cc(Cl)cc2c(C(O)c3ccncc3)c3c(C)n[nH]c3nc12,"rac-(6-chloro-3,8-dimethyl-1H-pyrazolo[3,4-b]quinolin-4-yl)(pyridin-4-yl)methanol",0.3,uM,=,-0.5228787452803376,0,c1ccc2c(Cc3ccncc3)c3cn[nH]c3nc2c1
3198,1629312,10.1016/j.bmcl.2016.11.020,,,,Inhibition of CYP3A4 (unknown origin),Cc1cc(Nc2cc(C)c(C#N)c(NCCOc3ccccc3)n2)n[nH]1,4-methyl-6-(5-methyl-1H-pyrazol-3-ylamino)-2-(2-phenoxyethylamino)nicotinonitrile,1.4,uM,=,0.1461280356782379,1,c1ccc(OCCNc2cccc(Nc3cc[nH]n3)n2)cc1
3199,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)Nc6cccc(OCc7ccccc7)c6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, D-20",17.2,uM,=,1.235528446907549,1,O=C(Nc1cccc(OCc2ccccc2)c1)c1ccc(-c2c[nH]c3c(CN4C[C@@H]5N(C(=O)NCc6ccccc6)NCC(=O)N5[C@@H](Cc5ccccc5)C4=O)cccc23)cc1
3200,632105,10.1016/j.bmcl.2010.03.057,,,,Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin,CC(=O)N1CCN(c2cc(C)c3nc(-c4c(NC[C@@H](O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1,(S)-3-(6-(4-acetylpiperazin-1-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)-4-(2-(3-chlorophenyl)-2-hydroxyethylamino)pyridin-2(1H)-one,1.1,uM,=,0.041392685158225,1,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(N3CCNCC3)cc2[nH]1
3201,2024613,10.1016/j.bmcl.2020.127721,,,,Inhibition of CYP3A4 (unknown origin),CS(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncc(O)cc34)cs2)c1,"N-[4-(5-hydroxy-1H-pyrrolo[2,3-b]pyridin-3-yl)thiazol-2-yl]-2-[3-(methanesulfonamido)phenyl]acetamide",5.0,uM,=,0.6989700043360189,1,O=C(Cc1ccccc1)Nc1nc(-c2c[nH]c3ncccc23)cs1
3202,1972830,10.1021/acsmedchemlett.9b00612,,,,Inhibition of human recombinant CYP3A4 expressed in insect cell microsomes in presence of NADPH by fluorescence assay,Cc1ccc(C(=O)Nc2ccc(CN3Cc4cn[nH]c4C3)c(Cl)c2)cc1C#Cc1cnc2cccnn12,"N-[3-chloro-4-(4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-5-ylmethyl)phenyl]-3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methylbenzamide",7.28,uM,=,0.8621313793130372,1,O=C(Nc1ccc(CN2Cc3cn[nH]c3C2)cc1)c1cccc(C#Cc2cnc3cccnn23)c1
3203,857201,10.1021/jm200900q,,,,Inhibition of CYP3A4,Cn1cnc(CC(=O)N2CCC(c3ccc(NC(=O)c4nc(C#N)c[nH]4)c(C4=CCCCC4)c3)CC2)c1,4-Cyano-1H-imidazole-2-carboxylic Acid(2-Cyclohex-1-enyl-4-{1-[2-(1-methyl-1H-imidazol-4-yl)-acetyl]-piperidin-4-yl}-phenyl)-amide,2.3,uM,=,0.3617278360175928,1,O=C(Nc1ccc(C2CCN(C(=O)Cc3c[nH]cn3)CC2)cc1C1=CCCCC1)c1ncc[nH]1
3204,448320,10.1016/j.bmc.2007.05.069,,,,Inhibition of CYP3A4,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCOC)C(=O)C(CC)(c1cc(F)cc(F)c1)O2,"6-(2,4-diamino-6-ethyl-pyrimidin-5-yl)-2-(3,5-difluoro-phenyl)-2-ethyl-4-(3-methoxy-propyl)-4H-benzo-[1,4]oxazin-3-one",0.46,uM,=,-0.3372421683184259,0,O=C1Nc2cc(-c3cncnc3)ccc2OC1c1ccccc1
3205,510165,10.1021/jm800377h,,,,Inhibition of human recombinant CYP3A4 expressed in insect microsomes,COc1ccc2cc(-c3cncc(C(C)=O)c3)ccc2c1,1-[5-(6-Methoxynaphthalen-2-yl)pyridin-3-yl]ethanone,9.07,uM,=,0.9576072870600952,1,c1cncc(-c2ccc3ccccc3c2)c1
3206,558484,10.1016/j.bmcl.2008.10.128,,,,Inhibition of CYP3A4,CCN(CC(O)(CNC(=O)c1cnn(-c2ccc(F)cc2)c1N)C(F)(F)F)C(=O)c1ccccc1Cl,"5-amino-N-(2-((2-chloro-N-ethylbenzamido)methyl)-3,3,3-trifluoro-2-hydroxypropyl)-1-(4-fluorophenyl)-1H-pyrazole-4-carboxamide",2.0,uM,=,0.3010299956639812,1,O=C(NCCCNC(=O)c1cnn(-c2ccccc2)c1)c1ccccc1
3207,1436762,10.1021/ml500187a,,,,Inhibition of human recombinant CYP3A4 incubated for 5 mins by fluorescence assay,Clc1ccc(CN(C2CC2)C2CNC2)cc1Cl,"N-cyclopropyl-N-(3,4-dichlorobenzyl)azetidin-3-amine",0.5,uM,=,-0.3010299956639812,0,c1ccc(CN(C2CC2)C2CNC2)cc1
3208,1778315,10.1016/j.bmcl.2018.06.040,,,,Inhibition of CYP3A4 (unknown origin),CN1CCN(CCOc2cccc(CC(=O)Nc3nc(-c4c[nH]c5ncccc45)cs3)c2)CC1,"N-(4-(1H-pyrrolo[2,3-b]pyridin-3-yl)thiazol-2-yl)-2-(3-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)acetamide",17.5,uM,=,1.2430380486862944,1,O=C(Cc1cccc(OCCN2CCNCC2)c1)Nc1nc(-c2c[nH]c3ncccc23)cs1
3209,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",C[C@@H]1CN(C(=O)c2cc(Cl)ccc2-n2nccn2)[C@H](Cc2cccc(-n3nccn3)c2)CO1,"US9150566, 184",19.0,uM,=,1.2787536009528289,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
3210,1288280,10.1016/j.bmcl.2013.12.057,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,CC(C)c1nc(CN(C)C(=O)N[C@@H](COCc2ccccc2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,"Thiazol-5-ylmethyl(2R,5R)-5-((S)-3-(benzyloxy)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)propanamido)-1,6-diphenylhexan-2-ylcarbamate",0.17,uM,=,-0.7695510786217261,0,O=C(NCc1cscn1)N[C@@H](COCc1ccccc1)C(=O)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
3211,991614,10.1021/jm4008906,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,Cc1cc(CN2Cc3nc(C)c(CN)c(-c4ccc(Cl)cc4Cl)c3C2=O)no1,"(S)-3-(Aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-6-((5-methylisoxazol-3-yl)methyl)-6,7-dihydro-5H-pyrrolo[3,4-b]-pyridin-5-one",4.7,uM,=,0.6720978579357175,1,O=C1c2c(-c3ccccc3)ccnc2CN1Cc1ccon1
3212,821184,10.1021/jm201287w,,,,Inhibition of human CYP3A4 using diethoxyfluorescein as substrate,CC(C)C[C@@H]1C(=O)N[C@H](C2Cc3ccccc3C2)C(=O)N1[C@@H](C(=O)N(C)C)c1ccc(F)cc1F,"(2R)-2-(2,4-difluorophenyl)-2-[(3R,6R)-3-(2,3-dihydro-1H-inden-2-yl)-6-(2-methylpropyl)-2,5-dioxo-1-piperazinyl]-N,N-dimethylethanamide",5.0,uM,=,0.6989700043360189,1,O=C1CN(Cc2ccccc2)C(=O)[C@@H](C2Cc3ccccc3C2)N1
3213,993439,10.6019/CHEMBL2448688,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,CO/N=C(\C)c1ccc(-n2ccnc2)c(NC(=O)c2ccc(-c3ccccc3)nc2)c1,,4.0,uM,=,0.6020599913279624,1,O=C(Nc1ccccc1-n1ccnc1)c1ccc(-c2ccccc2)nc1
3214,716789,10.1016/j.bmcl.2010.12.123,,,,Inhibition of CYP3A4,O=C(Nc1ccc(-c2nnn[nH]2)cc1F)[C@H](C1CCCCC1)n1c(-c2ccc(Cl)cc2)nc2cc(F)c(F)cc21,"(S)-2-(2-(4-chlorophenyl)-5,6-difluoro-1H-benzo[d]imidazol-1-yl)-2-cyclohexyl-N-(2-fluoro-4-(1H-tetrazol-5-yl)phenyl)acetamide",7.7,uM,=,0.8864907251724818,1,O=C(Nc1ccc(-c2nnn[nH]2)cc1)[C@H](C1CCCCC1)n1c(-c2ccccc2)nc2ccccc21
3215,1336778,10.1021/jm401911v,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,CC[C@@H](CS(=O)(=O)C(C)(C)C)N1C(=O)[C@@](C)(Cc2nnn[nH]2)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1,"(3R,5R,6S)-3-((1H-Tetrazol-5-yl)methyl)-1-((S)-1-(tertbutylsulfonyl)butan-2-yl)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-3-methylpiperidin-2-one",2.5,uM,=,0.3979400086720376,1,O=C1N[C@H](c2ccccc2)[C@@H](c2ccccc2)CC1Cc1nnn[nH]1
3216,859942,10.1021/jm300122u,,,,Inhibition of human CYP3A4 using testosterone as substrate after 45 mins,NC1C[C@H]2CC[C@@H](C1)N2C(=O)[C@H](Cc1ccc(Cl)cc1Cl)NC(=O)C1(c2ccc(Cl)cc2Cl)CC1,"N-((2S)-1-((1R,5S)-3-amino-8-azabicyclo[3.2.1]octan-8-yl)-3-(2,4-dichlorophenyl)-1-oxopropan-2-yl)-1-(2,4-dichlorophenyl)cyclopropanecarboxamide",0.43,uM,=,-0.3665315444204134,0,O=C([C@H](Cc1ccccc1)NC(=O)C1(c2ccccc2)CC1)N1[C@@H]2CCC[C@H]1CC2
3217,469873,10.1016/j.bmcl.2008.01.012,,,,Inhibition of human CYP3A4,CC(C)c1c(-c2nnc(NCCO)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12,"N-cyclopropyl-2,4-difluoro-5-(6-(5-(2-hydroxyethylamino)-1,3,4-oxadiazol-2-yl)-5-isopropylpyrrolo[1,2-f][1,2,4]triazin-4-ylamino)benzamide",5.2,uM,=,0.7160033436347992,1,O=C(NC1CC1)c1cccc(Nc2ncnn3cc(-c4nnco4)cc23)c1
3218,512798,10.1021/jm800832q,,,,Inhibition of human recombinant CYP3A4 in human liver microsomes using BFC as a substrate,Cc1cc(C2CCN(CCCF)CC2)cc2[nH]c(-c3c(NCCn4cc(Cl)cn4)cc[nH]c3=O)nc12,4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-bendo[d]imidazol-2-yl)pyridine-1-(1H)-one,26.0,uM,=,1.414973347970818,1,O=c1[nH]ccc(NCCn2cccn2)c1-c1nc2ccc(C3CCNCC3)cc2[nH]1
3219,449485,10.1016/j.bmcl.2007.07.097,,,,Inhibition of microsomal CYP3A4,CNCCN[C@@H](CC(C)C)c1cc(F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1,"1-((R)-3-(2,4-dichlorophenyl)-1-(4-(4-fluoro-2-((S)-3-methyl-1-(2-(methylamino)ethylamino)butyl)phenyl)piperazin-1-yl)-1-oxopropan-2-yl)pyrrolidin-2-one",11.0,uM,=,1.0413926851582251,1,O=C([C@@H](Cc1ccccc1)N1CCCC1=O)N1CCN(c2ccccc2)CC1
3220,991614,10.1021/jm4008906,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(Cc1ccn(C)n1)C2,"(S)-3-(Aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-6-((1-methyl-1H-pyrazol-3-yl)methyl)-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one",7.9,uM,=,0.8976270912904415,1,O=C1c2c(-c3ccccc3)ccnc2CN1Cc1cc[nH]n1
3221,643687,10.1016/j.bmcl.2010.06.060,,,,Inhibition of human CY3A4,CCc1ccc(S(=O)(=O)Nc2ccccc2Br)cc1NC1CCN(C)CC1,N-(2-Bromophenyl)-4-ethyl-3-[(1-methylpiperidin-4-yl)amino]benzenesulfonamide,9.62,uM,=,0.983175072037813,1,O=S(=O)(Nc1ccccc1)c1cccc(NC2CCNCC2)c1
3222,1447575,10.1016/j.bmcl.2014.05.068,,,,Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method,C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F,"(2R,3S)-2-(2,4-Difluoro-phenyl)-3-(5-fluoro-pyrimidin-4-yl)-1-[1,2,4]triazol-1-yl-butan-2-ol",13.0,uM,=,1.1139433523068367,1,c1ccc(C(Cc2ccncn2)Cn2cncn2)cc1
3223,1730110,10.1021/acs.jmedchem.8b00335,,,,Inhibition of recombinant human CYP3A4 in presence of NADPH generating system by fluorescence assay,COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC,"2-(3,4-Dimethoxy-phenyl)-5-{[2-(3,4-dimethoxy-phenyl)-ethyl]-methyl-amino}-2-isopropyl-pentanenitrile",8.193,uM,=,0.9134429548593958,1,c1ccc(CCCCNCCc2ccccc2)cc1
3224,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",COc1cc(C(=O)N2CCOC[C@H]2Cc2cc(-n3nccn3)ccc2F)c(-n2nccn2)cc1C,"US9150566, 134",19.0,uM,=,1.2787536009528289,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
3225,1291572,10.1016/j.bmcl.2013.12.058,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)NCCCNC(=O)OCc2cncs2)C(C)C)cs1,(S)-thiazol-5-ylmethyl 3-(2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-3-methylbutanamido)propylcarbamate,1.26,uM,=,0.1003705451175629,1,O=C(CNC(=O)NCc1cscn1)NCCCNC(=O)OCc1cncs1
3226,494885,10.1021/jm8012618,,,,"Inhibition of human recombinant CYP3A4 using N-N,diethyl-formamide as substrate",CCNCc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O,4-(7-Chloro-quinolin-4-ylamino)-2-ethylaminomethyl-phenol,24.0,uM,=,1.380211241711606,1,c1ccc(Nc2ccnc3ccccc23)cc1
3227,595557,10.1016/j.bmcl.2009.10.084,,,,Inhibition of CYP3A4 using BFC as a substrate,Cc1cc2cc(N/C(=N\C(=O)c3ccc(C(=O)N(C)C)nc3)N[C@H]3CCCCN(CC(=O)N4CCCC4)C3=O)ccc2o1,"(S)-N2,N2-dimethyl-N5-((2-methylbenzofuran-5-ylamino)(2-oxo-1-(2-oxo-2-(pyrrolidin-1-yl)ethyl)azepan-3-ylamino)methylene)pyridine-2,5-dicarboxamide",39.0,uM,=,1.591064607026499,1,O=C(/N=C(\Nc1ccc2occc2c1)N[C@H]1CCCCN(CC(=O)N2CCCC2)C1=O)c1cccnc1
3228,2048449,10.1016/j.bmc.2020.115734,,,,Inhibition of recombinant CYP3A4 (unknown origin) by fluorescence-based assay,CCn1nc2c(c1Nc1nc(-c3ccc(-n4cnc(C)c4)c(OC)n3)cs1)CCCCC2,"N-(2-ethyl-2,4,5,6,7,8-hexahydrocyclohepta[c]pyrazol-3-yl)-4-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)thiazol-2-amine",11.0,uM,=,1.0413926851582251,1,c1cn(-c2ccc(-c3csc(Nc4[nH]nc5c4CCCCC5)n3)nc2)cn1
3229,461436,10.1016/j.bmcl.2007.10.092,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,O=C(CC1([C@H]2CCC[C@@H](C3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CCN2CCCC[C@H]2C1,"2-(1-((2R,6S)-1-(4-chlorophenylsulfonyl)-6-cyclopropylpiperidin-2-yl)cyclopropyl)-1-((S)-hexahydro-1H-pyrido[1,2-a]pyrazin-2(6H)-yl)ethanone",1.8,uM,=,0.255272505103306,1,O=C(CC1([C@H]2CCC[C@@H](C3CC3)N2S(=O)(=O)c2ccccc2)CC1)N1CCN2CCCC[C@H]2C1
3230,1578569,10.1021/acs.jmedchem.5b01718,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 10 mins by LC/MS/MS analysis,CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OCC5COC(Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O,"2-sec-Butyl-4-[4-(4-{4-[(2R,4S)-2-(2,4-dichloro-phenyl)-2-[1,2,4]triazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-phenyl]-2,4-dihydro-[1,2,4]triazol-3-one",0.0504,uM,=,-1.2975694635544748,0,O=c1[nH]ncn1-c1ccc(N2CCN(c3ccc(OCC4COC(Cn5cncn5)(c5ccccc5)O4)cc3)CC2)cc1
3231,2164346,10.1021/acs.jmedchem.1c02192,,,,Inhibition of CYP3A4 (unknown origin),Cc1nc2cnc3cc(F)c(-c4ccc(Oc5ncccn5)cc4Cl)cc3c2n1C1CCN(C(=O)CO)CC1,"US9227969, 14",11.0,uM,=,1.0413926851582251,1,c1cnc(Oc2ccc(-c3ccc4ncc5ncn(C6CCNCC6)c5c4c3)cc2)nc1
3232,52064,10.1016/s0960-894x(03)00058-1,,,,Inhibitory activity against CYP450 3A4 isozyme,CCN(CC)CCN(Cc1ccc(-c2ccc(Cl)cc2)cc1)C(=O)Cn1cc(C)c(=O)nc1SCc1ccc(F)cc1,N-(4'-Chloro-biphenyl-4-ylmethyl)-N-(2-diethylamino-ethyl)-2-[2-(4-fluoro-benzylsulfanyl)-5-methyl-4-oxo-4H-pyrimidin-1-yl]-acetamide,13.0,uM,=,1.1139433523068367,1,O=C(Cn1ccc(=O)nc1SCc1ccccc1)NCc1ccc(-c2ccccc2)cc1
3233,828928,10.1016/j.bmcl.2012.06.022,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N3CCCC3)oc2c1,"Thiazol-5-ylmethyl(2S,3R)-3-hydroxy-4-(N-methyl-2-(pyrrolidin-1-yl)benzo[d]oxazole-6-carboxamido)-1-phenylbutan-2-ylcarbamate",0.084,uM,=,-1.0757207139381184,0,O=C(N[C@H](CCNC(=O)c1ccc2nc(N3CCCC3)oc2c1)Cc1ccccc1)OCc1cncs1
3234,1742659,10.1021/acs.jmedchem.8b01196,,,,Inhibition of of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins in presence of NADPH by LC-MS/MS analysis,N#Cc1cc(F)cc(Oc2ccc3c(c2C(F)F)[C@@H](O)C(F)(F)S3(=O)=O)c1,"(R)-3-((4-(Difluoromethyl)-2,2-difluoro-3-hydroxy-1,1-dioxido-2,3-dihydrobenzo[b]thiophen-5-yl)oxy)-5-fluorobenzonitrile",13.3,uM,=,1.1238516409670858,1,O=S1(=O)CCc2cc(Oc3ccccc3)ccc21
3235,851921,10.1016/j.bmcl.2012.08.072,,,,Inhibition of human recombinant CYP3A4,COc1cc(NC(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)ccc1F,"N-(4-fluoro-3-methoxyphenyl)-2-(4-morpholino-6-oxo-1,6-dihydropyrimidin-2-yl)acetamide",40.0,uM,=,1.6020599913279625,1,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccccc1
3236,519908,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,Cc1nc2c(NCc3ccccc3)cc(-n3ccccc3=O)cn2c1C,"1-(8-(benzylamino)-2,3-dimethylimidazo[1,2-a]pyridin-6-yl)pyridin-2(1H)-one",24.0,uM,=,1.380211241711606,1,O=c1ccccn1-c1cc(NCc2ccccc2)c2nccn2c1
3237,979641,10.1016/j.bmcl.2013.07.029,,,,Inhibition of CYP3A4 in human liver microsomes in presence of NADPH,O=C(N1C[C@@H]2CN(c3ccccn3)C[C@@H]2C1)C12CC3CC(CC(C3)C1)C2,"Adamantan-1-yl-((3aR,6aS)-5-pyridin-2-yl-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl)-methanone",6.2,uM,=,0.7923916894982539,1,O=C(N1C[C@@H]2CN(c3ccccn3)C[C@@H]2C1)C12CC3CC(CC(C3)C1)C2
3238,52064,10.1016/s0960-894x(03)00058-1,,,,Inhibitory activity against CYP450 3A4 isozyme,CCN(CC)CCN(Cc1ccc(-c2ccc(Cl)cc2)cc1)C(=O)Cn1c(SCc2ccc(F)cc2)nc(=O)c2c1CCCC2,"N-(4'-Chloro-biphenyl-4-ylmethyl)-N-(2-diethylamino-ethyl)-2-[2-(4-fluoro-benzylsulfanyl)-4-oxo-5,6,7,8-tetrahydro-4H-quinazolin-1-yl]-acetamide",5.0,uM,=,0.6989700043360189,1,O=C(Cn1c(SCc2ccccc2)nc(=O)c2c1CCCC2)NCc1ccc(-c2ccccc2)cc1
3239,856844,10.1021/jm300356u,,,,Inhibition of human recombinant CYP3A4 using 7-BQ as substrate preincubated for 5 to 10 mins before substrate addition,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H]3[C@H]2O/C(=N\CCCN(C)C)N3C)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,"(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-((3aR,4S,6R,7aS)-2-(3-(dimethylamino)propylimino)-1,6-dimethylhexahydro-1H-pyrano[4,3-d]oxazol-4-yloxy)-14-ethyl-12,13-dihydroxy-4-((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yloxy)-7-methoxy-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione",8.0,uM,=,0.9030899869919436,1,N=C1N[C@H]2CCO[C@@H](O[C@H]3CCCC(=O)CCCCOC(=O)C[C@@H](O[C@H]4CCCCO4)C3)[C@@H]2O1
3240,1451406,10.1021/jm500916t,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs,Cc1cc2c(NC(=O)N[C@@H]3CC(CF)(CF)Oc4ccc(F)cc43)cccc2cn1,"(R)-1-(6-Fluoro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea",15.0,uM,=,1.1760912590556811,1,O=C(Nc1cccc2cnccc12)N[C@@H]1CCOc2ccccc21
3241,2246941,10.1021/acs.jmedchem.1c02132,,,,Inhibition of CYP3A4 (unknown origin) incubated for 10 mins in presence of NADPH by LC-MS/MS analysis,COC(=O)Nc1cc(-c2ccc(OC[C@@](C)(N)CC(C)C)c(C(F)(F)F)c2)ccn1,"(S)-methyl (4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)carbamate",6.9,uM,=,0.8388490907372553,1,c1ccc(-c2ccncc2)cc1
3242,1518828,10.1021/acsmedchemlett.5b00225,,,,Inhibition of CYP3A4 in human liver microsomes,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3nc(C)c(C)s3)nc21,"N,N-dicyclopropyl-4-(4,5-dimethylthiazol-2-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide",3.0,uM,=,0.4771212547196624,1,O=C(c1cc2c(nc(Nc3nccs3)c3nc[nH]c32)[nH]1)N(C1CC1)C1CC1
3243,1624780,10.1021/acs.jmedchem.6b00697,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate in presence of NADPH by LC-MS/MS analysis,O=C(NCc1ccc(S(=O)(=O)c2cccc(C(F)(F)F)c2)cc1)c1cnc2[nH]ncc2c1,"N-(4-(3-(trifluoromethyl)phenylsulfonyl)benzyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide",7.9,uM,=,0.8976270912904415,1,O=C(NCc1ccc(S(=O)(=O)c2ccccc2)cc1)c1cnc2[nH]ncc2c1
3244,495542,10.1021/jm801332q,,,,Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate by time dependent inhibition assay,C[C@H]1CN(Cc2ccc(CCC(=O)N3CCC(Nc4cccc(F)c4)CC3)cc2)CCN1,N-(3-Fluorophenyl)-1-[3-(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)propanoyl]-4-piperidinamine,10.0,uM,=,1.0,1,O=C(CCc1ccc(CN2CCNCC2)cc1)N1CCC(Nc2ccccc2)CC1
3245,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1ccc(C(=O)N2C[C@H](C)OC[C@H]2Cc2cccc(-n3nccn3)c2)c(-n2nccn2)c1,"US9150566, 96",28.0,uM,=,1.4471580313422192,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
3246,833037,10.1021/jm300248q,,,,Inhibition of CYP3A4,CS(=O)(=O)c1ccc(-c2cccn3nc(Nc4cccc(N5CCC(N6CCOCC6)CC5)c4)nc23)cc1,"[8-(4-Methanesulfonyl-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-[3-(4-morpholin-4-yl-piperidin-1-yl)-phenyl]-amine",0.2,uM,=,-0.6989700043360187,0,c1ccc(-c2cccn3nc(Nc4cccc(N5CCC(N6CCOCC6)CC5)c4)nc23)cc1
3247,1289241,10.1016/j.bmcl.2013.12.088,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,Fc1cc(OC(F)(F)C(F)F)cc([C@@](Cc2ccccc2)(Nc2nc(C(F)(F)F)cs2)c2ccc(Cl)cn2)c1,"(R)-N-(1-(5-chloropyridin-2-yl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-4-(trifluoromethyl)thiazol-2-amine",40.0,uM,=,1.6020599913279625,1,c1ccc(C[C@@](Nc2nccs2)(c2ccccc2)c2ccccn2)cc1
3248,1919651,,,,,"Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase",SCc1ccc(-c2cccnc2)o1,(5-pyridin-3-yl-furan-2-yl)methanethiol,6.1,uM,=,0.785329835010767,1,c1cncc(-c2ccco2)c1
3249,519907,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,Cc1cccc(C)c1CNc1cc(-n2ccccc2=O)cn2c(C)c(C)nc12,"1-(8-(2,6-dimethylbenzylamino)-2,3-dimethylimidazo[1,2-a]pyridin-6-yl)pyridin-2(1H)-one",13.0,uM,=,1.1139433523068367,1,O=c1ccccn1-c1cc(NCc2ccccc2)c2nccn2c1
3250,664620,10.1016/j.bmcl.2010.08.009,,,,Inhibition of CYP3A4,CC(C)N1CCC(Oc2ccc3c(c2)cc2n3[C@@H](C)CNC2=O)CC1,"(S)-8-(1-isopropylpiperidin-4-yloxy)-4-methyl-3,4-dihydropyrazino[1,2-a]indol-1(2H)-one",26.0,uM,=,1.414973347970818,1,O=C1NCCn2c1cc1cc(OC3CCNCC3)ccc12
3251,51914,10.1016/s0960-894x(03)00680-2,,,,Inhibition of human liver microsome Cytochrome P450 3A4,O=C(N[C@H]1c2ccccc2OC[C@H]1O)[C@H](Cc1cccnc1)C[C@H](O)CN1CCN(Cc2cc3cccc(Cl)c3o2)C[C@H]1C(=O)NCC(F)(F)F,"(S)-4-(7-Chloro-benzofuran-2-ylmethyl)-1-[(2S,4R)-2-hydroxy-4-((3S,4S)-3-hydroxy-chroman-4-ylcarbamoyl)-5-pyridin-3-yl-pentyl]-piperazine-2-carboxylic acid (2,2,2-trifluoro-ethyl)-amide",0.5,uM,=,-0.3010299956639812,0,O=C(N[C@@H]1CCOc2ccccc21)[C@@H](CCCN1CCN(Cc2cc3ccccc3o2)CC1)Cc1cccnc1
3252,1744980,10.1016/j.bmcl.2017.09.046,,,,Inhibition of human CYP3A4 expressed in Escherichia coli co-expressing CYP-reductase using diethoxyfluorescein as substrate measured after 10 mins by fluorescence assay,CCc1cccc(-c2c(F)cccc2C(O)(CCCNC(=O)OC)[C@@H]2CCCN(C(=O)CCCN)C2)c1,methyl 4-((R)-1-(4-aminobutanoyl)piperidin-3-yl)-4-(3'-ethyl-6-fluorobiphenyl-2-yl)-4-hydroxybutylcarbamate,0.24,uM,=,-0.619788758288394,0,c1ccc(-c2ccccc2C[C@@H]2CCCNC2)cc1
3253,675407,10.1016/j.bmcl.2010.08.142,,,,Inhibition of CYP3A4,N#Cc1ccc(N[C@H]2CCN(C(=O)O[C@H]3C4CC5CC3C[C@](C(N)=O)(C5)C4)C2)nc1,(S)-3-(5-Cyano-pyridin-2-ylamino)-pyrrolidine-1-carboxylic acid 5-carbamoyl-adamantan-2-yl ester,26.6,uM,=,1.424881636631067,1,O=C(OC1C2CC3CC(C2)CC1C3)N1CC[C@H](Nc2ccccn2)C1
3254,555225,10.1016/j.bmcl.2008.05.058,,,,Inhibition of CYP3A4,CN(CC(=O)N(C)C(CN1CCCC1)c1ccc(-c2ccccc2)cc1)c1ccc(Cl)c(Cl)c1,"N-(1-Biphenyl-4-yl-2-pyrrolidin-1-yl-ethyl)-2-[(3,4-dichloro-phenyl)-methyl-amino]-N-methyl-acetamide",4.9,uM,=,0.6901960800285137,1,O=C(CNc1ccccc1)NC(CN1CCCC1)c1ccc(-c2ccccc2)cc1
3255,493017,10.1021/jm800851u,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,CC(=O)Nc1cc(-c2ccccc2)nc(-n2nc(C)cc2C)n1,"N-[2-(3,5-Dimethyl-pyrazol-1-yl)-6-phenyl-pyrimidin-4-yl]-acetamide",43.0,uM,=,1.6334684555795866,1,c1ccc(-c2ccnc(-n3cccn3)n2)cc1
3256,487712,10.1016/j.bmcl.2008.05.104,,,,Inhibition of CYP3A4,COC(=O)NC1CCN(c2cc(C)c3nc(-c4c(NC[C@@H](O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1,"(S)-methyl 1-(2-(4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-2-oxo-1,2-dihydropyridin-3-yl)-7-methyl-3H-benzo[d]imidazol-5-yl)piperidin-4-ylcarbamate",0.0005,uM,=,-3.3010299956639813,0,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(N3CCCCC3)cc2[nH]1
3257,1849384,10.1016/j.bmcl.2019.06.044,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis,O=C(O)c1ccc(-n2cc(C(=O)c3c(Cl)cccc3C(F)(F)F)c3cccc(F)c32)cc1,4-(3-(2-chloro-6-(trifluoromethyl)benzoyl)-7-fluoro-1H-indol-1-yl)benzoic acid,16.3,uM,=,1.212187604403958,1,O=C(c1ccccc1)c1cn(-c2ccccc2)c2ccccc12
3258,1761167,10.1016/j.ejmech.2018.01.043,,,,Inhibition of human microsomal CYP3A4 expressed in baculovirus infected BTI-TN-5B1-4 cells incubated for 30 mins by luciferase assay,O=C(Cn1ccnc1[N+](=O)[O-])NCc1ccccc1,N-Benzyl-2-(2-nitro-imidazol-1-yl)-acetamide,98.2,uM,=,1.9921114877869497,1,O=C(Cn1ccnc1)NCc1ccccc1
3259,1849384,10.1016/j.bmcl.2019.06.044,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis,O=C(O)c1ccc(-n2cc(C(=O)c3c(Cl)cccc3Cl)c3cccc(F)c32)c(F)c1,"4-(3-(2,6-dichlorobenzoyl)-7-fluoro-1H-indol-1-yl)-3-fluorobenzoic acid",26.0,uM,=,1.414973347970818,1,O=C(c1ccccc1)c1cn(-c2ccccc2)c2ccccc12
3260,550965,10.1021/np030556a,,,,Inhibition of human CYP3A4 by radiometric assay,CC(=O)O[C@@H]1[C@@H](O)[C@@H](O)[C@H](Oc2c(-c3ccc(O)cc3)oc3cc(O)cc(O)c3c2=O)O[C@H]1C,kaempferol-3-O-(4-O-acetyl-alpha-L-rhamnopyranoside),90.0,uM,=,1.954242509439325,1,O=c1c(O[C@H]2CCCCO2)c(-c2ccccc2)oc2ccccc12
3261,1528063,,,,,"Inhibtion Assay: Assays (200 μL final volume) were carried out in NUNC polypropylene deep well plates in 50 mM potassium phosphate buffer, pH 7.4, using a microtiter plate shaker in a 37° C. incubator. Pooled human liver microsomes (BD Gentest, 50 μg/mL) were incubated with 5 concentrations of test compound (from 0.1 μM to 10 μM), 1 mM NADPH (Sigma), and 2 μM midazolam (Sigma). A constant amount of dimethylsulfoxide (1%) was added to the incubations with the test compounds, and each analysis was performed in duplicate. For preincubation experiments (Pre), the microsomes, test compounds, and NADPH were mixed and incubated 30 minutes before addition of midazolam. For coincubation experiments (Co), the compounds, microsomes, and midazolam were mixed and the reaction initiated by addition of NADPH to the wells.",Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cn[nH]c5)cnc(N)c34)cc2)c1,SID103904308,0.3,uM,=,-0.5228787452803376,0,O=C(Nc1ccccc1)Nc1ccc(-c2csc3c(-c4cn[nH]c4)cncc23)cc1
3262,1828801,10.1021/acs.jmedchem.8b01098,,,,Inhibition of C-terminal 4His-tagged CYP3A4 (unknown origin) expressed in Escherichia coli by spectrophotometric analysis,CCCOc1cccc(CNC(=O)c2ccc(-c3ccncc3)cc2)c1,N-(3-Propoxybenzyl)-4-(pyridin-4-yl)benzamide,0.08,uM,=,-1.0969100130080565,0,O=C(NCc1ccccc1)c1ccc(-c2ccncc2)cc1
3263,982382,10.1016/j.bmcl.2013.07.071,,,,Inhibition of CYP3A4 (unknown origin),COC[C@@H](Oc1cc(C[C@@H]2C[S@@+]([O-])C[C@H](NCc3cc(C(C)(C)C)ccn3)[C@H]2O)cc(F)c1N)C(F)(F)F,"(1R,3S,4S,5R)-3-[4-Amino-3-fluoro-5-((R)-2,2,2-trifluoro-1-methoxymethyl-ethoxy)-benzyl]-5-[(4-tert-butyl-pyridin-2-ylmethyl)-amino]-1-oxo-tetrahydro-thiopyran-4-ol",1.6,uM,=,0.2041199826559248,1,c1ccc(C[C@@H]2C[SH+]C[C@H](NCc3ccccn3)C2)cc1
3264,766553,10.1016/j.bmcl.2011.06.102,,,,Inhibition of CYP3A4,c1cc([C@H]2CC[C@H](N3CCOCC3)CC2)ccc1OCCCN1CCCCC1,trans-4-(4-(4-(3-(piperidin-1-yl)propoxy)phenyl)cyclohexyl)morpholine,66.2,uM,=,1.8208579894397,1,c1cc([C@H]2CC[C@H](N3CCOCC3)CC2)ccc1OCCCN1CCCCC1
3265,2101223,10.1016/j.bmc.2021.116216,,,,Inhibition of CYP3A4 (unknown origin) using diethoxyfluorescein as substrate,CNc1nc(Nc2ccc(C(=O)NCc3ccccc3C(F)(F)F)cc2)nc(N2CCN(C)CC2)n1,"4-((4-(methylamino)-6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-yl)amino)-N-(2-(trifluoromethyl)benzyl)benzamide",19.0,uM,=,1.2787536009528289,1,O=C(NCc1ccccc1)c1ccc(Nc2ncnc(N3CCNCC3)n2)cc1
3266,1736291,10.1021/acs.jmedchem.8b00743,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,"11-(4-Dimethylamino-phenyl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-cyclopenta[a]phenanthren-3-one",9.5,uM,=,0.9777236052888478,1,O=C1C=C2CC[C@@H]3C(=C2CC1)[C@@H](c1ccccc1)CC1CCC[C@H]13
3267,804823,10.1016/j.bmcl.2011.12.080,,,,Time dependent inhibition of CYP3A4,COc1cc(C)c2nc3[nH]nc(C)c3c(C(O)c3ccncc3)c2c1,"(+)-(6-methoxy-3,8-dimethyl-1H-pyrazolo[3,4-b]quinolin-4-yl)(pyridin-4-yl)methanol",3.0,uM,=,0.4771212547196624,1,c1ccc2c(Cc3ccncc3)c3cn[nH]c3nc2c1
3268,851921,10.1016/j.bmcl.2012.08.072,,,,Inhibition of human recombinant CYP3A4,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccccc1,"2-[4-(Morpholin-4-yl)-6-oxo-1,6-dihydropyrimidin-2-yl]-N-phenylacetamide",40.0,uM,=,1.6020599913279625,1,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccccc1
3269,993439,10.6019/CHEMBL2448688,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,CS(=O)(=O)N(Cc1cccnc1)c1ccc(-c2ccc(F)cc2)cc1F,,0.612,uM,=,-0.2132485778544388,0,c1ccc(-c2ccc(NCc3cccnc3)cc2)cc1
3270,489963,10.1021/jm800566m,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline substrate,Cc1n[nH]c2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc12,3-({4-[Methyl(3-methyl-1H-indazol-6-yl)amino]-2-pyrimidinyl}amino)benzenesulfonamide,16.0,uM,=,1.2041199826559248,1,c1ccc(Nc2nccc(Nc3ccc4cn[nH]c4c3)n2)cc1
3271,776115,10.1016/j.bmcl.2011.09.074,,,,Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(c1ccccc1)C2=O,"3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-6-phenyl-5H-pyrrolo[3,4-b]pyridin-7(6H)-one",1.2,uM,=,0.0791812460476248,1,O=C1c2nccc(-c3ccccc3)c2CN1c1ccccc1
3272,1987746,10.1021/acs.jmedchem.0c00463,,,,Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cell microsomes using vivid DBOMF as substrate preincubated for 10 mins followed by substrate addition and measured after 25 mins in presence of NAD+ by fluorescence assay,CC(c1ccc(C(=O)N2CCc3cc(C(C)(C)C)ccc32)cc1)N1CCCCC1,(5-(tert-Butyl)indolin-1-yl)(4-(1-(piperidin-1-yl)ethyl)phenyl)methanone,24.0,uM,=,1.380211241711606,1,O=C(c1ccc(CN2CCCCC2)cc1)N1CCc2ccccc21
3273,2241392,10.1016/j.ejmech.2021.113981,,,,Inhibition of CYP3A4 in human liver microsomes assessed as reduction in 6-beta-hydroxy-testosterone formation using testosterone as substrate preincubated for 20 mins in presence of NADPH followed by incubation with substrate for 10 mins by LC-MS/MS analysis,COC[C@H](Cc1ccccc1)NC[C@@H](O)c1cc(C(F)(F)F)nc2c(C(F)(F)F)cccc12,"(S)-1-(2,8-Bis(trifluoromethyl)quinolin-4-yl)-2-(((S)-1-methoxy-3-phenylpropan-2-yl)amino)ethan-1-ol",2.3,uM,=,0.3617278360175928,1,c1ccc(CCNCCc2ccnc3ccccc23)cc1
3274,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cccc(-c3nccc(C)n3)c2)c1,"US9150566, 39",18.0,uM,=,1.255272505103306,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2ncccn2)c1
3275,463080,10.1016/j.bmcl.2008.02.032,,,,Inhibition of CYP3A4,COc1ccc(OCC(=O)Nc2cc(-n3nc(C)cc3C)nc(-c3ccc(C)o3)n2)c(CN(C)C)c1,"N-(6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methylfuran-2-yl)pyrimidin-4-yl)-2-(2-((dimethylamino)methyl)-4-methoxyphenoxy)acetamide",1.6,uM,=,0.2041199826559248,1,O=C(COc1ccccc1)Nc1cc(-n2cccn2)nc(-c2ccco2)n1
3276,1366300,10.1021/ml500110j,,,,Inhibition of CYP3A4 (unknown origin),Cc1nc2ccccc2c(-c2ccc3c4c(ccnc24)CCO3)c1[C@H](OC(C)(C)C)C(=O)O,"(2S)-2-tert-butoxy-2-(4-(2,3-dihydropyrano[4,3,2-de]quinolin-7-yl)-2-methylquinolin-3-yl)acetic acid",23.0,uM,=,1.3617278360175928,1,c1ccc2c(-c3ccc4c5c(ccnc35)CCO4)ccnc2c1
3277,1581635,10.1021/acs.jmedchem.5b01146,,,,Inhibition of C-terminal four-histidine tagged human CYP3A4delta3 to 24 residues expressed in Escherichia coli assessed as 7-benzyloxy-4-(trifluoromethyl)coumarin O-debenzylation pretreated 2 mins followed by NADPH addition by fluorometric method in presence of rat cytochrome P450 reductase,NCCCCCC(=O)NCc1cccnc1,6-amino-N-(pyridin-3-ylmethyl)hexanamide,1000.0,uM,=,3.0,1,c1ccncc1
3278,2207925,10.1021/acsmedchemlett.2c00411,,,,Inhibition of CYP3A4 (unknown origin) in presence of NADPH,COc1cc(Nc2ncc(C)c(Nc3ccc4oc(=O)[nH]c4c3)n2)cc(C)c1OC,"5-(2-(3,4-dimethoxy-5-methylphenylamino)-5-methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-one",2.7,uM,=,0.4313637641589873,1,O=c1[nH]c2cc(Nc3ccnc(Nc4ccccc4)n3)ccc2o1
3279,1474044,10.1021/jm501740a,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,CC(C)[C@H](NC(=O)c1ccc2[nH]nc(-c3ccc(N4C5CCC4COC5)cc3)c2c1)c1ccccc1Cl,3-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)phenyl)-N-((S)-1-(2-chlorophenyl)-2-methylpropyl)-1H-indazole-5-carboxamide,0.06,uM,=,-1.2218487496163564,0,O=C(NCc1ccccc1)c1ccc2[nH]nc(-c3ccc(N4C5CCC4COC5)cc3)c2c1
3280,2128578,10.1016/j.ejmech.2021.113496,,,,Inhibition of recombinant human CYP3A4 using BFC as substrate,C[C@]12CC[C@H]3[C@@H]([C@H](/C=C/C=C/C=C/[C@@H]4CC5=CC(=O)CC[C@]5(C)[C@H]5CC[C@]6(C)[C@@H](O)CC[C@H]6[C@H]45)CC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,"trans,trans,trans-1,6-bis(17beta-hydroxy-4-androsten-3-one-7alpha-yl)hexatriene",1.2,uM,=,0.0791812460476248,1,O=C1C=C2C[C@@H](/C=C/C=C/C=C/[C@@H]3CC4=CC(=O)CCC4[C@H]4CCC5CCC[C@H]5[C@H]34)[C@H]3[C@@H]4CCCC4CC[C@@H]3C2CC1
3281,2048413,10.1016/j.bmc.2020.115723,,,,Inhibition of CYP3A4 (unknown origin),Nc1cc(Cc2ccccc2)c2nn[nH]c2n1,"7-Benzyl-3H-[1,2,3]triazolo[4,5-b]pyridin-5-amine",6.6,uM,=,0.8195439355418687,1,c1ccc(Cc2ccnc3[nH]nnc23)cc1
3282,1825917,10.1021/acs.jmedchem.9b02067,,,,Inhibition of CYP3A4 in CRISPR/Cas9-mediated CYP3A5 knock-out and doxycycline-induced CYP3A4 overexpressing human AsPC1 cells assessed as decrease in 1-hydroxymidazolam formation using midazolam as substrate pretreated with doxycycline for 24 hrs followed by incubation with compound for 24 hrs by LC-MS/MS analysis,CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,SID144204227,0.117,uM,=,-0.9318141382538384,0,c1ccc([C@@]2(Cn3ccnc3)OC[C@H](COc3ccc(N4CCNCC4)cc3)O2)cc1
3283,1295000,10.1021/jm4017224,,,,Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation,Cc1nc2c(s1)CC[C@H]2C(=O)Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3cccnc3)N2)cc1,"(R)-N-(4-(((2S,5R)-5-((R)-Hydroxy(pyridin-3-yl)methyl)-pyrrolidin-2-yl)methyl)phenyl)-2-methyl-5,6-dihydro-4Hcyclopenta[d]thiazole-4-carboxamide",41.8,uM,=,1.6211762817750353,1,O=C(Nc1ccc(C[C@@H]2CC[C@H](Cc3cccnc3)N2)cc1)[C@@H]1CCc2scnc21
3284,2282763,10.1021/acs.jmedchem.1c01245,,,,Inhibition of CYP3A4 in human liver microsomes preincubated with compound followed by substrate addition using dextromethorphan as substrate by LC-MS/MS analysis,CC[C@@H](Nc1c(C#N)c(-c2ccc(-c3cccc(Cl)c3F)cc2)nc2cnccc12)C(N)=O,"(2R)-2-((2-(3'-Chloro-2'-fluorobiphenyl-4-yl)-3-cyano-1,7-naphthyridia-4-yl)amino)butanamide",8.35,uM,=,0.921686475483602,1,c1ccc(-c2ccc(-c3ccc4ccncc4n3)cc2)cc1
3285,796228,10.1016/j.bmcl.2011.10.115,,,,Inhibition of CYP3A4,Cc1ccc(Cn2c(C3CNCCO3)nc3ccccc32)cc1C,"(+)-2-(1-(3,4-dimethylbenzyl)-1H-benzo[d]imidazol-2-yl)morpholine",7.6,uM,=,0.8808135922807914,1,c1ccc(Cn2c(C3CNCCO3)nc3ccccc32)cc1
3286,1614025,10.1016/j.bmcl.2016.09.043,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 6-beta-hydroxytestosterone metabolite formation using testosterone as substrate incubated for 30 mins by HPLC-MS method,COc1ccc(CCNc2nc3cc(Cl)ccc3c(=O)n2C)cc1,7-chloro-2-{[2-(4-methoxyphenyl)ethyl]amino}-3-methylquinazolin-4(3H)-one,4.3,uM,=,0.6334684555795865,1,O=c1[nH]c(NCCc2ccccc2)nc2ccccc12
3287,1467194,10.1021/jm5005336,,,,Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay,COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5C[C@@H](C)O[C@@H](C)C5)cc4)n[nH]c3c1)C(=O)N2,"(1R,2S)-(E)-2-(3-(4-cis-2,6-Dimethylmorpholino)methyl)styryl)-1H-indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one",4.6,uM,=,0.6627578316815741,1,O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccc(CN4CCOCC4)cc3)n[nH]c2c1
3288,741043,10.1016/j.bmcl.2011.02.067,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCC(C)(C)O)c1,"(3R,4S)-N-cyclopropyl-4-(4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)phenyl)-N-(3-(2-hydroxy-2-methylpropoxy)-5-(3-methoxypropyl)benzyl)piperidine-3-carboxamide",5.6,uM,=,0.7481880270062004,1,O=C([C@H]1CNCC[C@@H]1c1ccc(OCCOc2ccccc2)cc1)N(Cc1ccccc1)C1CC1
3289,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cccc(-n3cccn3)c2)c1F,"US9150566, 21",20.0,uM,=,1.3010299956639813,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2cccn2)c1
3290,988989,10.1021/jm400732v,,,,Inhibition of CYP3A4 (unknown origin),CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)c2cccc(F)c2)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O.Cl,"(S)-N-((S)-1-((6-Bromo-2-methoxynaphthalen-1-yl)methyl)-5-(3-fluorobenzoyl)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-yl)-2-(methylamino)propanamide hydrochloride",1.2,uM,=,0.0791812460476248,1,O=C1CCN(C(=O)c2ccccc2)c2ccccc2N1Cc1cccc2ccccc12
3291,640296,10.1016/j.bmcl.2010.05.013,,,,Inhibition of CYP3A4,N#Cc1c[nH]c(C(=O)Nc2ccc(-c3ccncc3)cc2C2=CCCCC2)n1,4-cyano-N-(2-cyclohexenyl-4-(pyridin-4-yl)phenyl)-1H-imidazole-2-carboxamide,0.087,uM,=,-1.0604807473813815,0,O=C(Nc1ccc(-c2ccncc2)cc1C1=CCCCC1)c1ncc[nH]1
3292,2246941,10.1021/acs.jmedchem.1c02132,,,,Inhibition of CYP3A4 (unknown origin) incubated for 10 mins in presence of NADPH by LC-MS/MS analysis,CC(=O)Nc1cc(-c2ccc(OC[C@@H](N)CC(C)C)c(C(F)(F)F)c2)ccn1,(S)-N-(4-(4-((2-amino-4-methylpentyl)oxy)-3-(trifluoromethyl)phenyl)pyridin-2-yl)acetamide,0.33,uM,=,-0.4814860601221125,0,c1ccc(-c2ccncc2)cc1
3293,726119,10.1016/j.bmcl.2010.12.089,,,,Inhibition of CYP3A4 in human liver microsome,COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1ccccc1[N+](=O)[O-],"2,6-Dimethyl-4-(2-nitro-phenyl)-1,4-dihydro-pyridine-3,5-dicarboxylic acid dimethyl ester",11.0,uM,=,1.0413926851582251,1,C1=CC(c2ccccc2)C=CN1
3294,673952,10.1016/j.bmcl.2010.08.086,,,,Inhibition of CYP3A4 using midazolam as substrate,Cc1cc(Cl)c(OCCOc2ccc([C@H]3CCNC[C@@H]3C(=O)N(Cc3cc(CNCCF)ccc3Cl)C3CC3)cc2)c(Cl)c1,"(3R,4S)-N-(2-chloro-5-((2-fluoroethylamino)methyl)benzyl)-N-cyclopropyl-4-(4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)phenyl)piperidine-3-carboxamide",7.3,uM,=,0.8633228601204559,1,O=C([C@H]1CNCC[C@@H]1c1ccc(OCCOc2ccccc2)cc1)N(Cc1ccccc1)C1CC1
3295,775863,10.1016/j.bmcl.2011.09.037,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH,CN1CCN(C(=O)[C@@H](COCC(C)(C)C)NC(=O)c2cccnc2Oc2ccc(C(F)(F)F)cc2Cl)CC1,(R)-2-(2-chloro-4-(trifluoromethyl)phenoxy)-N-(1-(4-methylpiperazin-1-yl)-3-(neopentyloxy)-1-oxopropan-2-yl)nicotinamide,12.0,uM,=,1.0791812460476249,1,O=C(NCC(=O)N1CCNCC1)c1cccnc1Oc1ccccc1
3296,1849384,10.1016/j.bmcl.2019.06.044,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis,O=C(O)c1ccc(-n2cc(C(=O)c3c(Cl)cccc3Cl)c3cccc(F)c32)cc1,"4-(3-(2,6-dichlorobenzoyl)-7-fluoro-1H-indol-1-yl)benzoic acid",46.0,uM,=,1.662757831681574,1,O=C(c1ccccc1)c1cn(-c2ccccc2)c2ccccc12
3297,828928,10.1016/j.bmcl.2012.06.022,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,O=C(N[C@@H](Cc1ccccc1)[C@H](O)CN(CCN1CCCC1)C(=O)c1ccc2nc(N3CCCC3)oc2c1)OCc1cncs1,"thiazol-5-ylmethyl(2S,3R)-3-hydroxy-1-phenyl-4-(2-(pyrrolidin-1-yl)-N-(2-(pyrrolidin-1-yl)ethyl)benzo[d]oxazole-6-carboxamido)butan-2-ylcarbamate",0.13,uM,=,-0.8860566476931633,0,O=C(N[C@H](CCN(CCN1CCCC1)C(=O)c1ccc2nc(N3CCCC3)oc2c1)Cc1ccccc1)OCc1cncs1
3298,753596,10.1016/j.bmcl.2011.05.013,,,,Reversible inhibition of CYP3A4 assessed as conversion of testosterone to 6-beta-hydroxytestosterone,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccn(C)c(=O)c2)C2CC2)cc(Br)c1C,"(3R,4S)-N-(3-bromo-5-(3-methoxypropyl)-4-methylbenzyl)-N-cyclopropyl-4-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)piperidine-3-carboxamide",6.5,uM,=,0.8129133566428556,1,O=C([C@H]1CNCC[C@@H]1c1cc[nH]c(=O)c1)N(Cc1ccccc1)C1CC1
3299,857201,10.1021/jm200900q,,,,Inhibition of CYP3A4,N#Cc1cnc(C(=O)Nc2ccc(C3CCN(CCN4CCOCC4)CC3)cc2C2=CCCCC2)[nH]1,4-Cyano-1H-imidazole-2-carboxylic Acid{2-Cyclohex-1-enyl-4-[1-(2-morpholin-4-yl-ethyl)-piperidin-4-yl]-phenyl}-amide,3.8,uM,=,0.5797835966168101,1,O=C(Nc1ccc(C2CCN(CCN3CCOCC3)CC2)cc1C1=CCCCC1)c1ncc[nH]1
3300,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cc(-c3ncccn3)ccc2F)c1,"US9150566, 155",30.0,uM,=,1.4771212547196624,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2ncccn2)c1
3301,854798,10.1016/j.bmc.2012.08.056,,,,Inhibition of human CYP3A4 using 7-benzyloxy-4-(trifluoromethyl) coumarin as substrate,CN(Cc1cccn1C)C(=O)C12CC3CC(CC(C3)C1)C2,N-Methyl-N-((1-methyl-1H-pyrrol-2-yl)-methyl)adamantane-1-carboxamide,19.0,uM,=,1.2787536009528289,1,O=C(NCc1ccc[nH]1)C12CC3CC(CC(C3)C1)C2
3302,1637155,,,,,Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(C#CCN(CC)CC)nc4)cc23)c1F,"Propane-1-sulfonic acid (3-{5-[6-(3-diethylamino-prop-1-ynyl)-pyridin-3-yl]-1H-pyrrolo[2,3-b]pyridine-3-carbonyl}-2,4-difluoro-phenyl)-amide",5.0,uM,=,0.6989700043360189,1,O=C(c1ccccc1)c1c[nH]c2ncc(-c3cccnc3)cc12
3303,1613542,10.1021/acs.jmedchem.6b00756,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as substrate,O=C(Nc1ccc(F)cc1)N1N=C(c2ccncc2)CC1c1ccc(F)cc1,"N,5-Bis(4-fluorophenyl)-3-(pyridin-4-yl)-4,5-dihydro-1H-pyrazole-1-carboxamide",1.8,uM,=,0.255272505103306,1,O=C(Nc1ccccc1)N1N=C(c2ccncc2)CC1c1ccccc1
3304,1933020,10.1021/acs.jmedchem.6b00619,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Cl.Nc1ncccc1-c1nc2ccc(-c3ccccc3)nc2n1-c1ccc(C2(N)CCC2)cc1,"3-(3-(4-(1-Aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo-[4,5-b]pyridin-2-yl)pyridin-2-amine Hydrochloride",20.0,uM,=,1.3010299956639813,1,c1ccc(-c2ccc3nc(-c4cccnc4)n(-c4ccc(C5CCC5)cc4)c3n2)cc1
3305,559938,10.1016/j.bmcl.2008.10.072,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,C[C@@H]1CN(Cc2ccc(-c3ccccc3CN(C)C(=O)COc3ccc(F)cc3)cc2)C[C@H](C)N1,"N-[4'-((3R,5S)-3,5-Dimethyl-piperazin-1-ylmethyl)-biphenyl-2-ylmethyl]-2-(4-fluoro-phenoxy)-N-methyl-acetamide",6.0,uM,=,0.7781512503836436,1,O=C(COc1ccccc1)NCc1ccccc1-c1ccc(CN2CCNCC2)cc1
3306,572636,10.1021/jm9002445,,,,Inhibition of human CYP3A4 by microtiter plate assay,Cc1cc(-c2[nH]ncc2C)c2cccc(OCc3c(C)ccnc3Cn3cccc(C(F)(F)F)c3=O)c2n1,1-((4-methyl-3-((2-methyl-4-(4-methyl-1H-pyrazol-5-yl)quinolin-8-yloxy)methyl)pyridin-2-yl)methyl)-3-(trifluoromethyl)pyridin-2(1H)-one,3.8,uM,=,0.5797835966168101,1,O=c1ccccn1Cc1ncccc1COc1cccc2c(-c3ccn[nH]3)ccnc12
3307,1632089,10.1016/j.bmc.2016.11.051,,,,Inhibition of CYP3A4 in human liver microsomes assessed as reduction in nifedipine oxidation incubated for 10 mins,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,"1-(4-{4-[2-(2,4-Dichloro-phenyl)-2-imidazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-ethanone (ketoconazole)",0.0317,uM,=,-1.4989407377822486,0,c1ccc(C2(Cn3ccnc3)OCC(COc3ccc(N4CCNCC4)cc3)O2)cc1
3308,322414,10.1021/jm0502541,,,,Interaction with human cytochrome P450 isoform 3A4 expressed in baculovirus-insect cells,CC1(C)CCC(c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3F)cc2)CC1,"1-[4'-(4,4-Dimethyl-cyclohexyl)-2-fluoro-biphenyl-4-yl]-cyclopropanecarboxylic acid",84.0,uM,=,1.9242792860618816,1,c1cc(C2CCCCC2)ccc1-c1ccc(C2CC2)cc1
3309,983478,10.1021/jm400564j,,,,Inhibition of CYP3A4 (unknown origin) using Vivid BOMR as substrate,Cc1nc2cc(/C=C/C(=O)NO)ccc2c(=O)n1CCc1ccccc1,"(E)-N-Hydroxy-3-(2-methyl-4-oxo-3-phenethyl-3,4-dihydro-quinazolin-7-yl)-acrylamide",6.5,uM,=,0.8129133566428556,1,O=c1c2ccccc2ncn1CCc1ccccc1
3310,2017934,10.1021/acs.jmedchem.0c00834,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis,Cc1c(N2CCCCC2)nc2ccc(Br)cc2c1C(=O)NCC(CCC(=O)O)c1ccccc1Cl,(+)-5-({[6-Bromo-3-methyl-2-(piperidin-1-yl)quinolin-4-yl]carbonyl}amino)-4-(2-chlorophenyl)pentanoic acid,19.0,uM,=,1.2787536009528289,1,O=C(NCCc1ccccc1)c1cc(N2CCCCC2)nc2ccccc12
3311,1335568,10.1021/jm401731q,,,,Inhibition of CYP3A4 (unknown origin),CN1CCN(c2cc(N3CCCC[C@H]3C(=O)NCCc3ccc(C#N)cc3)nc(C(F)(F)F)n2)CC1,(2S)-N-[2-(4-Cyanophenyl)ethyl]-1-[6-(4-methylpiperazin-1-yl)-2-(trifluoromethyl)pyrimidin-4-yl]piperidine-2-carboxamide,0.4,uM,=,-0.3979400086720376,0,O=C(NCCc1ccccc1)[C@@H]1CCCCN1c1cc(N2CCNCC2)ncn1
3312,657984,10.1021/jm100482n,,,,Inhibition of CYP3A4 in human liver microsomes measured immediately,CNC(=O)c1ncn2c1COc1c(CCN3CCN(c4cccc5nc(C)ccc45)CC3)cccc1-2,"N-methyl-6-(2-(4-(2-methylquinolin-5-yl)piperazin-1-yl)ethyl)-4H-benzo[b]imidazo[1,5-d][1,4]oxazine-3-carboxamide",100.0,uM,=,2.0,1,c1cc(CCN2CCN(c3cccc4ncccc34)CC2)c2c(c1)-n1cncc1CO2
3313,1661014,10.1016/j.bmcl.2017.02.047,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by NADPH addition measured after 5 mins,CCCCC/C=C/C(=O)CCc1ccc(O)c(OC)c1,(E)-1-(4-Hydroxy-3-methoxy-phenyl)-dec-4-en-3-one,65.2,uM,=,1.81424759573192,1,c1ccccc1
3314,1485703,10.1124/dmd.112.048264,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method,CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1,Benzyl-(3-isobutoxy-2-pyrrolidin-1-yl-propyl)-phenyl-amine,23.6,uM,=,1.3729120029701067,1,c1ccc(CN(CCN2CCCC2)c2ccccc2)cc1
3315,1526216,10.1021/ml500526p,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,Cn1c(Nc2cccc(C(C)(C)C)c2)nc2cc(Oc3ccnc(-c4ncc[nH]4)c3)ccc21,5-(2-(1H-imidazol-2-yl)pyridin-4-yloxy)-N-(3-tert-butylphenyl)-1-methyl-1H-benzo[d]imidazol-2-amine,1.8,uM,=,0.255272505103306,1,c1ccc(Nc2nc3cc(Oc4ccnc(-c5ncc[nH]5)c4)ccc3[nH]2)cc1
3316,1660136,10.1021/acs.jmedchem.6b01918,,,,Inhibition of human CYP3A4 assessed as inhibition of dealkylation,N[C@H]1CC[C@@](CCOc2cc(F)c(S(=O)(=O)Nc3ncns3)cc2Cl)(c2ccccc2)CC1,"trans-4-(2-((1S,4S)-4-Amino-1-phenylcyclohexyl)ethoxy)-5-chloro-2-fluoro-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide",0.58,uM,=,-0.2365720064370627,0,O=S(=O)(Nc1ncns1)c1ccc(OCCC2(c3ccccc3)CCCCC2)cc1
3317,991614,10.1021/jm4008906,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,COc1ccc(N2Cc3nc(C)c(CN)c(-c4ccc(Cl)cc4Cl)c3C2=O)cc1,"rac-3-(Aminomethyl)-4-(2,4-dichlorophenyl)-6-(4-methoxyphenyl)-2-methyl-6,7-dihydropyrrolo[3,4-b]pyridin-5-one",0.9,uM,=,-0.0457574905606751,0,O=C1c2c(-c3ccccc3)ccnc2CN1c1ccccc1
3318,1613611,10.1016/j.bmcl.2016.08.089,,,,Inhibition of CYP3A4 (unknown origin),CC(C)[C@@H]1c2nn(-c3ccc(CO)c(S(C)(=O)=O)c3)cc2CN1c1ncc(CO)c(C(F)(F)F)n1,"(R)-(2-(2-(4-(hydroxymethyl)-3-(methylsulfonyl)phenyl)-6-isopropylpyrrolo[3,4-c]pyrazol-5(2H,4H,6H)-yl)-4-(trifluoromethyl)pyrimidin-5-yl)methanol",7.7,uM,=,0.8864907251724818,1,c1ccc(-n2cc3c(n2)CN(c2ncccn2)C3)cc1
3319,1465595,10.1016/j.bmcl.2015.02.039,,,,Inhibition of CYP3A4 (unknown origin) using DBF fluorometric substrate,COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2NCc2ccc3ccccc3c2)C(C)C)ccc1OC,rac-N-isopropyl-4-methoxy-3-(3-methoxypropoxy)-N-((4-(naphthalen-2-ylmethylamino)pyrrolidin-3-yl)methyl)benzamide,2.5,uM,=,0.3979400086720376,1,O=C(NC[C@@H]1CNC[C@H]1NCc1ccc2ccccc2c1)c1ccccc1
3320,305432,10.1016/j.bmcl.2005.01.044,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,CNC(=O)c1cccc(COc2ccc3cc(C(C(C)N(C)C)n4ccnc4)ccc3c2)c1,3-[6-(2-Dimethylamino-1-imidazol-1-yl-propyl)-naphthalen-2-yloxymethyl]-N-methyl-benzamide,0.397,uM,=,-0.4012094932368849,0,c1ccc(COc2ccc3cc(Cn4ccnc4)ccc3c2)cc1
3321,52069,10.1021/jm021012t,,,,Inhibition of human cytochrome P450 3A4,COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC,"2-(3,4-Dimethoxy-phenyl)-5-{[2-(3,4-dimethoxy-phenyl)-ethyl]-methyl-amino}-2-isopropyl-pentanenitrile",4.7,uM,=,0.6720978579357175,1,c1ccc(CCCCNCCc2ccccc2)cc1
3322,856843,10.1021/jm300356u,,,,Inhibition of human recombinant CYP3A4 using DEF as substrate preincubated for 5 to 10 mins before substrate addition,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H]3[C@H]2O/C(=N\C(C)C)N3C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,"2'-O,3'-N-(N'-Isopropylcarbonimidoyl)-3'-N-demethyl-9-deoxo-9a-methyl-9a-aza-9a-homoerythromycin A",7.8,uM,=,0.8920946026904804,1,N=C1N[C@H]2CCO[C@@H](O[C@H]3CCCCNCCCCOC(=O)C[C@@H](O[C@H]4CCCCO4)C3)[C@@H]2O1
3323,1655303,10.1021/acsmedchemlett.6b00491,,,,Inhibition of CYP3A4 using in human liver microsomes using midazolam as substrate after 5 to 15 mins,CC(C)n1nccc1-c1ncccc1COc1cccc(O)c1C=O,2-Hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde,81.9,uM,=,1.9132839017604184,1,c1ccc(OCc2cccnc2-c2ccn[nH]2)cc1
3324,2135244,10.1021/acs.jmedchem.1c01452,,,,Inhibition of human recombinant CYP3A4 by fluorescence assay,CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,SID144204227,0.08,uM,=,-1.0969100130080565,0,c1ccc([C@@]2(Cn3ccnc3)OC[C@H](COc3ccc(N4CCNCC4)cc3)O2)cc1
3325,559938,10.1016/j.bmcl.2008.10.072,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,C[C@@H]1CN(Cc2ccc(-c3ccccc3C(=O)N3CCC(Oc4ccc(F)cc4)CC3)cc2)C[C@H](C)N1,"[4'-((3R,5S)-3,5-Dimethyl-piperazin-1-ylmethyl)-biphenyl-2-yl]-[4-(4-fluoro-phenoxy)-piperidin-1-yl]-methanone",8.4,uM,=,0.9242792860618816,1,O=C(c1ccccc1-c1ccc(CN2CCNCC2)cc1)N1CCC(Oc2ccccc2)CC1
3326,2221809,10.1016/j.bmcl.2022.128625,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as substrate in presence of NADPH,CCC[C@H]1N(C(=O)c2cc(F)ccc2C(F)(F)F)CCC[C@@]1(Oc1csc(C(F)(F)F)c1)C(=O)N1CCN(c2ccccc2OCCO)CC1,"((2R,3S)-1-(5-fluoro-2-(trifluoromethyl)benzoyl)-2-propyl-3-(5-(trifluoromethyl)thiophen-3-yloxy)piperidin-3-yl)(4-(2-(2-hydroxyethoxy)phenyl)piperazin-1-yl)methanone",50.0,uM,=,1.6989700043360187,1,O=C(c1ccccc1)N1CCC[C@@](Oc2ccsc2)(C(=O)N2CCN(c3ccccc3)CC2)C1
3327,1845477,10.1021/acsmedchemlett.0c00004,,,,Inhibition of CYP3A4 (unknown origin),CP(C)(=O)c1ccc2c(c1)[C@@H](O)[C@H]([C@H]1c3ccccc3-c3cncn31)CC2,"((7S,8S)-8-hydroxy-7-((S)-5H-imidazo[5,1-a]isoindol-5-yl)-5,6,7,8-tetrahydronaphthalen-2-yl)dimethylphosphine oxide",1.6,uM,=,0.2041199826559248,1,c1ccc2c(c1)CC[C@@H]([C@H]1c3ccccc3-c3cncn31)C2
3328,802673,10.1016/j.bmcl.2011.12.125,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,CN(C)C(=O)c1cccc(NC(=O)Nc2ccc(-c3ccnc4[nH]cnc34)cc2)c1,"3-(3-(4-(3H-imidazo[4,5-b]pyridin-7-yl)phenyl)ureido)-N,N-dimethylbenzamide",0.11,uM,=,-0.958607314841775,0,O=C(Nc1ccccc1)Nc1ccc(-c2ccnc3[nH]cnc23)cc1
3329,802673,10.1016/j.bmcl.2011.12.125,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,O=C(Nc1ccc(-c2ccnc3[nH]cnc23)cc1)Nc1cccc(C(=O)Nc2ccccc2)c1,"3-(3-(4-(3H-imidazo[4,5-b]pyridin-7-yl)phenyl)ureido)-N-phenylbenzamide",0.053,uM,=,-1.275724130399211,0,O=C(Nc1ccc(-c2ccnc3[nH]cnc23)cc1)Nc1cccc(C(=O)Nc2ccccc2)c1
3330,2254484,10.1021/acs.jmedchem.2c00527,,,,Inhibition of CYP3A4 in human liver microsomes at 0.01 to 30 uM using phenacetin as substrate in presence of NADPH by UPLC-MS/MS analysis,COC1CCC(NC[C@@H](C(=O)N2CCN(c3ncnc4c3[C@H](C)CC(=O)N4)[C@H]3C[C@H]32)c2ccc(Cl)cc2)CC1,"(R)-5-((1S,6R)-5-((S)-2-(4-chlorophenyl)-3-((4-methoxycyclohexyl)amino)propanoyl)-2,5-diazabicyclo[4.1.0]heptan-2-yl)-4-methyl-1,4-dihydro-2H-pyrimido[4,5-d][1,3]oxazin-2-one",1.81,uM,=,0.2576785748691845,1,O=C1CCc2c(ncnc2N2CCN(C(=O)[C@H](CNC3CCCCC3)c3ccccc3)[C@@H]3C[C@@H]32)N1
3331,44705,10.1016/s0960-894x(02)00473-0,,,,Inhibition of cytochrome P450 3A4,Cn1cc(Cc2cn(CC(=O)N(CCN3CCCC3)Cc3ccc(-c4ccc(Cl)cc4)cc3)c(SCc3ccc(F)cc3)nc2=O)cn1,N-(4'-Chloro-biphenyl-4-ylmethyl)-2-[2-(4-fluoro-benzylsulfanyl)-5-(1-methyl-1H-pyrazol-4-ylmethyl)-4-oxo-4H-pyrimidin-1-yl]-N-(2-pyrrolidin-1-yl-ethyl)-acetamide,6.0,uM,=,0.7781512503836436,1,O=C(Cn1cc(Cc2cn[nH]c2)c(=O)nc1SCc1ccccc1)N(CCN1CCCC1)Cc1ccc(-c2ccccc2)cc1
3332,1336778,10.1021/jm401911v,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,CC[C@@H](CS(=O)(=O)C(C)(C)C)N1C(=O)[C@@](C)(Cc2noc(=O)[nH]2)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1,"3-(((3R,5R,6S)-1-((S)-1-(tert-Butylsulfonyl)butan-2-yl)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-3-methyl-2-oxopiperidin-3-yl)methyl)-1,2,4-oxadiazol-5(4H)-one",1.2,uM,=,0.0791812460476248,1,O=C1N[C@H](c2ccccc2)[C@@H](c2ccccc2)CC1Cc1noc(=O)[nH]1
3333,874112,10.1021/jm300118s,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis,COCC(=O)N[C@@H](Cc1ccc(-c2nccs2)cc1)[C@H](O)CN[C@H]1CC2(CCC2)Oc2ncc(CC(C)(C)C)cc21,"N-((2S,3R)-3-Hydroxy-4-((S)-6'-neopentyl-3',4'-dihydrospiro-[cyclobutane-1,2'-pyrano[2,3-b]pyridine]-4'-ylamino)-1-(4-(thiazol-2-yl)phenyl)butan-2-yl)-2-methoxyacetamide",0.03,uM,=,-1.5228787452803376,0,c1cnc2c(c1)[C@@H](NCCCCc1ccc(-c3nccs3)cc1)CC1(CCC1)O2
3334,2195259,10.1039/d2md00196a,,,,Inhibition of human CYP3A4 using luciferin-IPA as substrate preincubated for 10 mins followed by NADPH addition and measured after 30 mins by luminescence based assay,CC(C)(C)c1ccc(-c2nnc(Nc3ccc(Cl)cc3)o2)cc1,"[5-(4-tert-Butyl-phenyl)-[1,3,4]-oxadiazol-2-yl]-(4-chlorophenyl)-amine",30570.39715528616,uM,=,4.485301080899096,1,c1ccc(Nc2nnc(-c3ccccc3)o2)cc1
3335,1295469,10.1016/j.bmcl.2014.02.004,,,,Inhibition of human recombinant CYP3A4,CC1Cc2c(Cl)cccc2N1C(=O)Cc1nc(N2CCOCC2)sc1C(=O)O,4-(2-(4-chloro-2-methylindolin-1-yl)-2-oxoethyl)-2-morpholinothiazole-5-carboxylic acid,40.0,uM,=,1.6020599913279625,1,O=C(Cc1csc(N2CCOCC2)n1)N1CCc2ccccc21
3336,2246941,10.1021/acs.jmedchem.1c02132,,,,Inhibition of CYP3A4 (unknown origin) incubated for 10 mins in presence of NADPH by LC-MS/MS analysis,CC(=O)Nc1cc(-c2ccc(OC[C@@H](N)CC(C)C)c(Cl)c2)ccn1,(S)-N-(4-(4-((2-amino-4-methylpentyl)oxy)-3-chlorophenyl)pyridin-2-yl)acetamide,2.6,uM,=,0.414973347970818,1,c1ccc(-c2ccncc2)cc1
3337,1528565,,,,,"Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",CC(C)c1nc(CN(C)C(=O)N2Cc3nc[nH]c3C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,"US8987313, 49",0.37,uM,=,-0.431798275933005,0,O=C(N[C@H](CC[C@H](Cc1ccccc1)NC(=O)[C@@H]1Cc2[nH]cnc2CN1C(=O)NCc1cscn1)Cc1ccccc1)OCc1cncs1
3338,1475768,10.1021/jm5017413,,,,Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system,Cc1cccc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)[C@@H]3C)n1,"(R)-(8-Methyl-3-(6-methylpyridin-2-yl)-5,6-dihydro-[1,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(thiophen-2-yl)phenyl)-methanone",45.0,uM,=,1.6532125137753435,1,O=C(c1ccc(-c2cccs2)cc1)N1CCn2c(nnc2-c2ccccn2)C1
3339,1587034,10.1021/acs.jmedchem.6b00203,,,,Inhibition of CYP3A4 (unknown origin),Cc1nn(C2CCNCC2)c(C)c1Nc1ncc(Cl)c(-c2cnn3ccccc23)n1,"5-Chloro-N-[3,5-dimethyl-1-(piperidin-4-yl)-1H-pyrazol-4-yl]-4-(pyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-amine",4.8,uM,=,0.6812412373755872,1,c1ccn2ncc(-c3ccnc(Nc4cnn(C5CCNCC5)c4)n3)c2c1
3340,834635,10.1016/j.bmcl.2012.07.019,,,,Inhibition of CYP3A4,N[C@@H](CC(=O)N1CCN(C(=O)c2ccc(OC(F)(F)F)cc2)CC1)Cc1cc(F)c(F)cc1F,"(R)-3-amino-1-(4-(4-(trifluoromethoxy)benzoyl)piperazin-1-yl)-4-(2,4,5-trifluorophenyl)butan-1-one",1.0,uM,=,0.0,0,O=C(CCCc1ccccc1)N1CCN(C(=O)c2ccccc2)CC1
3341,776115,10.1016/j.bmcl.2011.09.074,,,,Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin,COc1ccccc1N1Cc2c(nc(C)c(CN)c2-c2ccc(Cl)cc2Cl)C1=O,"rac-3-(aminomethyl)-4-(2,4-dichlorophenyl)-6-(2-methoxyphenyl)-2-methyl-5H-pyrrolo[3,4-b]pyridin-7(6H)-one",1.3,uM,=,0.1139433523068367,1,O=C1c2nccc(-c3ccccc3)c2CN1c1ccccc1
3342,1467195,10.1021/jm5005336,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay,CN(C)Cc1ccc(/C=C/c2n[nH]c3cc([C@@H]4C[C@@]45C(=O)N(C)c4ccccc45)ccc23)cc1,"(1R,2S)-(E)-2-(3-(4-((Dimethylamino)methyl)styryl)-1H-indazol-6-yl)-1'-methylspiro[cyclopropane-1,3'-indolin]-2'-one",2.3,uM,=,0.3617278360175928,1,O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccccc3)n[nH]c2c1
3343,471117,10.1016/j.bmc.2007.10.061,,,,Inhibition of CYP3A4,CN(C)C[C@H]1C[C@@H](c2nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c3c(N)nccn32)C1,"cis-3-{3-[(dimethylamino)methyl]cyclobutyl}-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-8-ylamine",15.0,uM,=,1.1760912590556811,1,c1ccc(-c2ccc3ccc(-c4nc(C5CCC5)n5ccncc45)cc3n2)cc1
3344,1614025,10.1016/j.bmcl.2016.09.043,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 6-beta-hydroxytestosterone metabolite formation using testosterone as substrate incubated for 30 mins by HPLC-MS method,Cn1c(NCCc2ccc(Oc3ccc(Cl)cc3)cc2)nc2cc(Cl)ccc2c1=O,7-Chloro-2-{2-[4-(4-chloro-phenoxy)-phenyl]-ethylamino}-3-methyl-3H-quinazolin-4-one,29.0,uM,=,1.462397997898956,1,O=c1[nH]c(NCCc2ccc(Oc3ccccc3)cc2)nc2ccccc12
3345,2228824,10.1021/acs.jmedchem.1c01970,,,,Inhibition of CYP3A4 in human liver microsomes incubated for 10 mins in the presence of NADPH by high performance liquid chromatography-tandem mass spectrometry,CCC(CC)O[C@@H]1C=C(C(=O)O)C[C@H](NCc2ccc(-c3cccs3)cc2OC)[C@H]1NC(C)=O,"(3R,4R,5S)-4-Acetamido-5-((2-methoxy-4-(thiophen-2-yl)benzyl)amino)-3-(pentan-3-yloxy)cyclohex-1-ene-1-carboxylic Acid",87.6,uM,=,1.9425041061680808,1,C1=CC[C@H](NCc2ccc(-c3cccs3)cc2)CC1
3346,632105,10.1016/j.bmcl.2010.03.057,,,,Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin,COC(=O)N1CCN(c2cc(C)c3nc(-c4c(NC[C@@H](O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1,"(S)-methyl 4-(2-(4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-2-oxo-1,2-dihydropyridin-3-yl)-4-methyl-1H-benzo[d]imidazol-6-yl)piperazine-1-carboxylate",0.7,uM,=,-0.1549019599857432,0,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(N3CCNCC3)cc2[nH]1
3347,469873,10.1016/j.bmcl.2008.01.012,,,,Inhibition of human CYP3A4,CC(C)Nc1nnc(-c2cn3ncnc(Nc4cc(C(=O)NC5CC5)c(F)cc4F)c3c2C(C)C)o1,"N-cyclopropyl-2,4-difluoro-5-(5-isopropyl-6-(5-(isopropylamino)-1,3,4-oxadiazol-2-yl)pyrrolo[1,2-f][1,2,4]triazin-4-ylamino)benzamide",0.4,uM,=,-0.3979400086720376,0,O=C(NC1CC1)c1cccc(Nc2ncnn3cc(-c4nnco4)cc23)c1
3348,979397,10.1016/j.bmcl.2013.06.010,,,,Inhibition of CYP3A4 (unknown origin),CC(=O)Nc1nc2ccc(-c3cnc(N)c(C(F)(F)F)c3)cc2s1,N-(6-(6-amino-5-(trifluoromethyl)pyridin-3-yl)benzo[d]thiazol-2-yl)acetamide,0.8,uM,=,-0.0969100130080563,0,c1cncc(-c2ccc3ncsc3c2)c1
3349,479364,10.1016/j.bmcl.2008.05.027,,,,Inhibition of CYP3A4,O=C(Cn1c(=O)sc2ccc(Cl)cc21)N1CCCC(c2ccccc2)C1CN1CCOCC1,rac-5-chloro-3-(2-(2-(morpholinomethyl)-3-phenylpiperidin-1-yl)-2-oxoethyl)benzo[d]thiazol-2(3H)-one,0.68,uM,=,-0.1674910872937636,0,O=C(Cn1c(=O)sc2ccccc21)N1CCCC(c2ccccc2)C1CN1CCOCC1
3350,52065,10.1021/jm0310129,,,,Inhibitory activity against cytochrome P450 3A4,Cn1c2ccncc2c2ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21,"4-{4-[2-(3,4-Difluoro-phenyl)-ethyl]-piperazin-1-yl}-5-methyl-5H-pyrido[3',4':4,5]pyrrolo[3,2-d]pyrimidine",17.85,uM,=,1.251638220448212,1,c1ccc(CCN2CCN(c3ncnc4c3[nH]c3ccncc34)CC2)cc1
3351,1534761,,,,,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",COc1ccc(CNc2ncc(Cc3c[nH]c4ncc(C)cc34)cc2F)cn1,"US9096593, P-1562",5.0,uM,=,0.6989700043360189,1,c1cncc(CNc2ccc(Cc3c[nH]c4ncccc34)cn2)c1
3352,552281,10.1016/j.bmcl.2008.04.036,,,,Inhibition of CYP3A4,N[C@@H](Cn1c(=O)c(-c2ccc(CSCC(=O)O)cc2)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1,"(R)-2-(4-(1-(2-fluoro-6-(trifluoromethyl)benzyl)-3-(2-amino-2-phenylethyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)benzylthio)acetic acid",16.0,uM,=,1.2041199826559248,1,O=c1c(-c2ccccc2)cn(Cc2ccccc2)c(=O)n1CCc1ccccc1
3353,961188,10.1016/j.bmc.2013.03.069,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis,O=c1[nH]c2cc(-c3ccccc3)ccc2c2[nH]c(-c3c(Cl)cccc3C(F)(F)F)nc12,"2-(2-chloro-6-(trifluoromethyl)phenyl)-7-phenylimidazo[4,5-c]quinolin-4(5H)-one",7.5,uM,=,0.8750612633917001,1,O=c1[nH]c2cc(-c3ccccc3)ccc2c2[nH]c(-c3ccccc3)nc12
3354,993439,10.6019/CHEMBL2448688,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,CCN(CC)S(=O)(=O)c1ccc(-n2ccnc2)c(NC(=O)c2cnc(-c3ccccc3)nc2)c1,,20.0,uM,=,1.3010299956639813,1,O=C(Nc1ccccc1-n1ccnc1)c1cnc(-c2ccccc2)nc1
3355,1996656,10.1021/acs.jmedchem.0c00446,,,,Inhibition of CYP3A4 (unknown origin),COc1cc(/C=C2\CCCN3C2=NO[C@H](c2cc(F)c(F)c(F)c2)[C@@H]3C)ccc1-n1cnc(C)c1,"(3R,4S)-9-((E)-3-Methoxy-4-(4-methyl-1H-imidazol-1-yl)-benzylidene)-4-methyl-3-(3,4,5-trifluorophenyl)-3,4,6,7,8,9-hexahydropyrido[2,1-c][1,2,4]oxadiazine",29.0,uM,=,1.462397997898956,1,C(=C1\CCCN2C[C@@H](c3ccccc3)ON=C12)\c1ccc(-n2ccnc2)cc1
3356,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCCO)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, F-4",16.18,uM,=,1.2089785172762535,1,O=C1[C@H](Cc2ccccc2)N2C(=O)CNN(C(=O)NCc3ccccc3)[C@H]2CN1Cc1cccc2cc[nH]c12
3357,1660136,10.1021/acs.jmedchem.6b01918,,,,Inhibition of human CYP3A4 assessed as inhibition of dealkylation,O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCCC2CCCCN2)cc1F,rac-5-Chloro-2-fluoro-4-((2-(piperidin-2-yl)ethyl)amino)-N-(thiazol-2-yl)benzenesulfonamide,20.0,uM,=,1.3010299956639813,1,O=S(=O)(Nc1nccs1)c1ccc(NCCC2CCCCN2)cc1
3358,686352,10.1016/j.bmcl.2010.09.037,,,,Inhibition of CYP3A4,COc1cc(-n2cnc3cc(-c4ccc(Cl)cc4)sc3c2=O)ccc1OCCN1CCCC1,"6-(4-chlorophenyl)-3-(3-methoxy-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)thieno[3,2-d]pyrimidin-4(3H)-one",1.6,uM,=,0.2041199826559248,1,O=c1c2sc(-c3ccccc3)cc2ncn1-c1ccc(OCCN2CCCC2)cc1
3359,1435228,10.1016/j.bmcl.2014.08.017,,,,Inhibition of CYP3A4 (unknown origin) using midazolam substrate,O=S(=O)(Nc1ncns1)c1cc(F)c(OC[C@H]2CNCC[C@@H]2c2ccc(Cl)cc2)cc1F,"4-(((3R,4S)-4-(4-chlorophenyl)piperidin-3-yl)methoxy)-2,5-difluoro-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide",0.15,uM,=,-0.8239087409443188,0,O=S(=O)(Nc1ncns1)c1ccc(OC[C@H]2CNCC[C@@H]2c2ccccc2)cc1
3360,979124,10.1021/jm400484p,,,,Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes,Oc1ccc2ccc(-c3cncnc3)c(Cl)c2c1,8-chloro-7-(pyrimidin-5-yl)naphthalen-2-ol,2.145,uM,=,0.331427296520743,1,c1ccc2cc(-c3cncnc3)ccc2c1
3361,51903,10.1021/jm020557k,,,,Concentration required to inhibit cytochrome P450 3A4.,CCCCOc1ccc(-c2[nH]ncc2C)cc1,5-(4-Butoxy-phenyl)-4-methyl-1H-pyrazole,26.8,uM,=,1.428134794028789,1,c1ccc(-c2ccn[nH]2)cc1
3362,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",C[C@@H]1CN(C(=O)c2cc(Cl)ccc2-n2nccn2)[C@H](Cc2cc(-c3ncccn3)ccc2F)CO1,"US9150566, 152",15.0,uM,=,1.1760912590556811,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2ncccn2)c1
3363,44705,10.1016/s0960-894x(02)00473-0,,,,Inhibition of cytochrome P450 3A4,CN1CCN(CCCN(Cc2ccc(-c3ccc(Cl)cc3)cc2)C(=O)Cn2cc(Cc3cnn(C)c3)c(=O)nc2SCc2ccc(F)cc2)CC1,N-(4'-Chloro-biphenyl-4-ylmethyl)-2-[2-(4-fluoro-benzylsulfanyl)-5-(1-methyl-1H-pyrazol-4-ylmethyl)-4-oxo-4H-pyrimidin-1-yl]-N-[3-(4-methyl-piperazin-1-yl)-propyl]-acetamide,10.0,uM,=,1.0,1,O=C(Cn1cc(Cc2cn[nH]c2)c(=O)nc1SCc1ccccc1)N(CCCN1CCNCC1)Cc1ccc(-c2ccccc2)cc1
3364,1623139,10.1021/acsmedchemlett.6b00314,,,,Inhibition of CYP3A4 (unknown origin),Cc1nccn1-c1ccc(-c2cn(CC(=O)Nc3cccc(Cl)c3Cl)nn2)cn1,"N-(2,3-dichlorophenyl)-2-(4-(6-(2-methyl-1H-imidazol-1-yl)pyridin-3-yl)-1H-1,2,3-triazol-1-yl)acetamide",43.0,uM,=,1.6334684555795866,1,O=C(Cn1cc(-c2ccc(-n3ccnc3)nc2)nn1)Nc1ccccc1
3365,1706610,10.1016/j.bmcl.2017.06.077,,,,Inhibition of recombinant human CYP3A4,Cc1ccc(S(=O)(=O)N2CCN(c3nc(-c4ccncn4)cc(=O)n3C)[C@H](C)C2)cc1,(R)-3-methyl-2-(2-methyl-4-tosylpiperazin-1-yl)-6-(pyrimidin-4-yl)pyrimidin-4(3H)-one,1.4,uM,=,0.1461280356782379,1,O=c1cc(-c2ccncn2)nc(N2CCN(S(=O)(=O)c3ccccc3)CC2)[nH]1
3366,2128578,10.1016/j.ejmech.2021.113496,,,,Inhibition of recombinant human CYP3A4 using BFC as substrate,C[C@]12CC[C@H]3[C@@H]([C@H](C/C=C\C[C@@H]4CC5=CC(=O)CC[C@]5(C)[C@H]5CC[C@]6(C)[C@@H](O)CC[C@H]6[C@H]45)CC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,"(7R,7'R,8R,8'R,9S,9'S,10R,10'R,13S,13'S,14S,14'S,17S,17'S)-7,7'-((Z)-but-2-ene-1,4-diyl)bis(17-hydroxy-10,13-dimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one)",0.8,uM,=,-0.0969100130080563,0,O=C1C=C2C[C@@H](C/C=C\C[C@@H]3CC4=CC(=O)CCC4[C@H]4CCC5CCC[C@H]5[C@H]34)[C@H]3[C@@H]4CCCC4CC[C@@H]3C2CC1
3367,519908,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,CCc1cccc(C)c1CNc1cc(C(N)=O)cn2c(C)c(C)nc12,"8-(2-ethyl-6-methylbenzylamino)-2,3-dimethylH-imidazo[1,2-a]pyridine-6-carboxamide",3.9,uM,=,0.5910646070264992,1,c1ccc(CNc2cccn3ccnc23)cc1
3368,595638,10.1016/j.bmcl.2009.09.096,,,,Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH,COc1ccc2c(NCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1,"7-methoxy-N-((6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methyl)quinolin-4-amine",50.0,uM,=,1.6989700043360187,1,c1ccc(-c2ccc3nnc(CNc4ccnc5ccccc45)n3n2)cc1
3369,1438704,10.1021/jm501375c,,,,Inhibition of CYP3A4 (unknown origin),CCN1CCC[C@H]1CNC(=O)c1cn(C2CCCC2)c(=O)c2c1c1ccccc1n2C,"(S)-2-cyclopentyl-N-((1-ethylpyrrolidin-2-yl)methyl)-9-methyl-1-oxo-2,9-dihydro-1H-pyrido[3,4-b]indole-4-carboxamide",3.2,uM,=,0.505149978319906,1,O=C(NC[C@@H]1CCCN1)c1cn(C2CCCC2)c(=O)c2[nH]c3ccccc3c12
3370,856843,10.1021/jm300356u,,,,Inhibition of human recombinant CYP3A4 using DEF as substrate preincubated for 5 to 10 mins before substrate addition,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H]3[C@H]2O/C(=N\C(C)C)N3C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,"(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-14-ethyl-7,12,13-trihydroxy-4-((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yloxy)-6-((3aR,4S,6R,7aS)-2-(isopropylimino)-1,6-dimethylhexahydro-1H-pyrano[4,3-d]oxazol-4-yloxy)-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione",1.1,uM,=,0.041392685158225,1,N=C1N[C@H]2CCO[C@@H](O[C@H]3CCCC(=O)CCCCOC(=O)C[C@@H](O[C@H]4CCCCO4)C3)[C@@H]2O1
3371,857201,10.1021/jm200900q,,,,Inhibition of CYP3A4,N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(C(=O)c4ccc[n+]([O-])c4)CC3)cc2C2=CCCCC2)n1,4-Cyano-1H-imidazole-2-carboxylic Acid[2-Cyclohex-1-enyl-4-[1-(1-oxy-pyridine-3-carbonyl)-piperidin-4-yl]-phenyl}-amide,1.9,uM,=,0.2787536009528289,1,O=C(Nc1ccc(C2CCN(C(=O)c3ccc[nH+]c3)CC2)cc1C1=CCCCC1)c1ncc[nH]1
3372,802673,10.1016/j.bmcl.2011.12.125,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,CNC(=O)c1cccc(NC(=O)Nc2ccc(-c3ccnc4[nH]cnc34)cc2)c1,"3-(3-(4-(3H-imidazo[4,5-b]pyridin-7-yl)phenyl)ureido)-N-methylbenzamide",0.098,uM,=,-1.0087739243075051,0,O=C(Nc1ccccc1)Nc1ccc(-c2ccnc3[nH]cnc23)cc1
3373,1301328,10.6019/CHEMBL3137440,,,,DNDI: CYP Inhibition,CN(C)S(=O)(=O)c1cccc(N2CCC(N(c3ccc(C#N)cc3)c3cccnc3)CC2)c1,,6.0,uM,=,0.7781512503836436,1,c1ccc(N2CCC(N(c3ccccc3)c3cccnc3)CC2)cc1
3374,1451406,10.1021/jm500916t,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs,Cc1cc2c(NC(=O)N[C@@H]3CC(CF)(CF)Oc4cc(Cl)ccc43)cccc2cn1,"(R)-1-(7-Chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea",20.0,uM,=,1.3010299956639813,1,O=C(Nc1cccc2cnccc12)N[C@@H]1CCOc2ccccc21
3375,52064,10.1016/s0960-894x(03)00058-1,,,,Inhibitory activity against CYP450 3A4 isozyme,CCN(CC)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(=O)Cn1cc(Cl)c(=O)nc1SCc1ccc(F)cc1,2-[5-Chloro-2-(4-fluoro-benzylsulfanyl)-4-oxo-4H-pyrimidin-1-yl]-N-(2-diethylamino-ethyl)-N-(4'-trifluoromethyl-biphenyl-4-ylmethyl)-acetamide,29.0,uM,=,1.462397997898956,1,O=C(Cn1ccc(=O)nc1SCc1ccccc1)NCc1ccc(-c2ccccc2)cc1
3376,458550,10.1016/j.bmcl.2007.09.099,,,,Inhibition of human CYP3A4,Cc1cc(C)cc(-c2[nH]c3sc(C(C)(C)C(=O)N4C5CCC4CC5)cc3c2CCN2CCN(CC(=O)N3CCOCC3)CC2)c1,"1-(7-aza-bicyclo[2.2.1]heptan-7-yl)-2-(5-(3,5-dimethylphenyl)-4-(2-(4-(2-morpholino-2-oxoethyl)piperazin-1-yl)ethyl)-6H-thieno[2,3-b]pyrrol-2-yl)-2-methylpropan-1-one",0.1,uM,=,-1.0,0,O=C(CN1CCN(CCc2c(-c3ccccc3)[nH]c3sc(CC(=O)N4C5CCC4CC5)cc23)CC1)N1CCOCC1
3377,619264,10.1016/j.bmcl.2009.07.002,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,C=CCn1c(C)c(C)c2cc(-n3ccccc3=O)nc(NCc3c(C)cccc3C)c21,"1-(1-allyl-7-(2,6-dimethylbenzylamino)-2,3-dimethyl-1H-pyrrolo[2,3-c]pyridin-5-yl)pyridin-2(1H)-one",2.4,uM,=,0.380211241711606,1,O=c1ccccn1-c1cc2cc[nH]c2c(NCc2ccccc2)n1
3378,450508,10.1021/jm070806a,,,,Inhibition of CYP3A4,Cc1ccc(N2CCN(C(=O)[C@H](C)Cc3ccc(Cl)cc3C)CC2)c([C@@H](NC(=O)CCN(C)C)C(C)C)c1,1-{2-[(1S)-(3-dimethylaminopropionyl)amino-2-methylpropyl]-4-methylphenyl}-4-[(2R)-methyl-3-(2-methyl-4-chlorophenyl)propionyl]piperazine,6.8,uM,=,0.8325089127062363,1,O=C(CCc1ccccc1)N1CCN(c2ccccc2)CC1
3379,52069,10.1021/jm021012t,,,,Inhibition of human cytochrome P450 3A4,Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1,1-[(2-Chloro-phenyl)-diphenyl-methyl]-1H-imidazole,0.02,uM,=,-1.6989700043360187,0,c1ccc(C(c2ccccc2)(c2ccccc2)n2ccnc2)cc1
3380,305432,10.1016/j.bmcl.2005.01.044,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,CC(C(c1ccc2cc(OCc3cccc(C(=O)N(C)C)c3)ccc2c1)n1ccnc1)N(C)C,"3-[6-(2-Dimethylamino-1-imidazol-1-yl-propyl)-naphthalen-2-yloxymethyl]-N,N-dimethyl-benzamide",0.357,uM,=,-0.4473317838878068,0,c1ccc(COc2ccc3cc(Cn4ccnc4)ccc3c2)cc1
3381,1653091,10.1016/j.bmc.2016.11.019,,,,Inhibition of human CYP3A4,CC(C)c1ccc(COc2ccc(N(CCN)C(=O)c3ccc(Cl)cc3Cl)cc2)cc1.Cl,"N-(2-Aminoethyl)-2,4-dichloro-N-(4-{[4-(propan-2-yl)phenyl]methoxy}phenyl)benzamide hydrochloride",0.015,uM,=,-1.8239087409443189,0,O=C(Nc1ccc(OCc2ccccc2)cc1)c1ccccc1
3382,2164739,10.1021/acs.jmedchem.1c02131,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate,CC(C)C[C@H](N)COc1ccc(-c2ccncc2)cc1,(S)-4-Methyl-1-(4-(pyridin-4-yl)phenoxy)pentan-2-amine,8.7,uM,=,0.9395192526186184,1,c1ccc(-c2ccncc2)cc1
3383,455108,10.1016/j.bmcl.2006.12.043,,,,Inhibition of CYP3A4,N[C@@H](C(=O)N1CCN(c2ccc3[nH]ncc3c2)CC1)c1ccccc1,(R)-1-(4-(1H-indazol-5-yl)piperazin-1-yl)-2-amino-2-phenylethanone,0.47,uM,=,-0.3279021420642826,0,O=C(Cc1ccccc1)N1CCN(c2ccc3[nH]ncc3c2)CC1
3384,559145,10.1016/j.bmcl.2008.10.061,,,,Inhibition of human CYP3A4 using dibenzylfluorescein as substrate,O=C(/C=C/c1cc(F)cc(F)c1)N1CCC([C@@H](CO)N2CCC(c3c[nH]c4ncccc34)CC2)CC1,"(S)-1-(4-(1-(4-(1H-pyrrolo[2,3-b]pyridin-3-yl)piperidin-1-yl)-2-hydroxyethyl)piperidin-1-yl)-3-(3,5-difluorophenyl)prop-2-en-1-one",20.6,uM,=,1.3138672203691537,1,O=C(/C=C/c1ccccc1)N1CCC(CN2CCC(c3c[nH]c4ncccc34)CC2)CC1
3385,305432,10.1016/j.bmcl.2005.01.044,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,CC(C(c1ccc2cc(OCC(C)(C)C(=O)O)ccc2c1)n1ccnc1)N(C)C,"3-[6-(2-Dimethylamino-1-imidazol-1-yl-propyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid",1.488,uM,=,0.1726029312098599,1,c1ccc2cc(Cn3ccnc3)ccc2c1
3386,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NNCC(=O)OCC)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, F-55",6.15,uM,=,0.7888751157754168,1,O=C1[C@H](Cc2ccccc2)N2C(=O)CNN(C(=O)NCc3ccccc3)[C@H]2CN1Cc1cccc2cc[nH]c12
3387,2048449,10.1016/j.bmc.2020.115734,,,,Inhibition of recombinant CYP3A4 (unknown origin) by fluorescence-based assay,CCn1nc2c(c1Nc1nc(-c3ccc(-n4cnc(C)c4)c(OC)n3)cs1)CCCC2,"N-(2-ethyl-4,5,6,7-tetrahydro-2H-indazol-3-yl)-4-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)thiazol-2-amine",3.7,uM,=,0.568201724066995,1,c1cn(-c2ccc(-c3csc(Nc4[nH]nc5c4CCCC5)n3)nc2)cn1
3388,1713507,10.1016/j.bmc.2018.05.006,,,,Inhibition of CYP3A4 in human liver microsomes assessed as midazolam 1'-hydroxylation after 4 to 40 mins in presence of NADPH by LCMS analysis,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,"1-(4-{4-[2-(2,4-Dichloro-phenyl)-2-imidazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-ethanone (ketoconazole)",0.022,uM,=,-1.6575773191777938,0,c1ccc(C2(Cn3ccnc3)OCC(COc3ccc(N4CCNCC4)cc3)O2)cc1
3389,519908,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,Cc1cccc(C)c1CNc1cc(-n2cnc(CO)n2)cn2c(C)c(C)nc12,"(1-(8-(2,6-dimethylbenzylamino)-2,3-dimethylimidazo[1,2-a]pyridin-6-yl)-1H-1,2,4-triazol-3-yl)methanol",15.0,uM,=,1.1760912590556811,1,c1ccc(CNc2cc(-n3cncn3)cn3ccnc23)cc1
3390,1660136,10.1021/acs.jmedchem.6b01918,,,,Inhibition of human CYP3A4 assessed as inhibition of dealkylation,C[C@]1(CCOc2cc(F)c(S(=O)(=O)Nc3ncns3)cc2F)CC[C@H](N)CC1,"trans-4-(2-((1R,4R)-4-Amino-1-methylcyclohexyl)ethoxy)-2,5-difluoro-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide",3.0,uM,=,0.4771212547196624,1,O=S(=O)(Nc1ncns1)c1ccc(OCCC2CCCCC2)cc1
3391,986997,10.1016/j.bmcl.2013.08.012,,,,Inhibition of CYP3A4 in human liver microsomes,Nc1cc(CN2CCC(C(=O)N3CCC(n4c(=O)n(CCCC(F)(F)F)c5cc(F)ccc54)CC3)CC2)ccn1,"1-(1-(1-((2-aminopyridin-4-yl)methyl)piperidine-4-carbonyl)piperidin-4-yl)-5-fluoro-3-(4,4,4-trifluorobutyl)-1H-benzo[d]imidazol-2(3H)-one",30.0,uM,=,1.4771212547196624,1,O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1
3392,2060129,10.1021/acsmedchemlett.1c00112,,,,Inhibition of CYP3A4 (unknown origin),O=C(N[C@@H]1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3CC[C@@H]12)C1CCS(=O)(=O)CC1,"1,1-Dioxo-hexahydro-1lambda*6*-thiopyran-4-carboxylic acid [(3R,3aS,9bS)-9b-(4-fluoro-benzenesulfonyl)-7-(1,2,2,2-tetrafluoro-1-trifluoromethyl-ethyl)-2,3,3a,4,5,9b-hexahydro-1H-cyclopenta[a]naphthalen-3-yl]-amide",5.8,uM,=,0.7634279935629373,1,O=C(N[C@@H]1CC[C@@]2(S(=O)(=O)c3ccccc3)c3ccccc3CC[C@@H]12)C1CCS(=O)(=O)CC1
3393,1336778,10.1021/jm401911v,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,CC[C@@H](CS(=O)(=O)C(C)(C)C)N1C(=O)[C@@](C)(CC(N)=O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1,"2-((3R,5R,6S)-1-((S)-1-(tert-Butylsulfonyl)butan-2-yl)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-3-methyl-2-oxopiperidin-3-yl)-acetamide",1.3,uM,=,0.1139433523068367,1,O=C1CC[C@H](c2ccccc2)[C@@H](c2ccccc2)N1
3394,1446329,10.1021/ml500387y,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,COc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F,"1,1,1-trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methyl-2-((5-morpholino-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)pentan-2-ol",0.2,uM,=,-0.6989700043360187,0,c1ccc(CCCCc2cc3cc(N4CCOCC4)ncc3[nH]2)cc1
3395,438600,10.1016/j.bmcl.2007.03.048,,,,Inhibition of CYP3A4 in microsomes,CNC(=N)c1cc(C)c2nc(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)[nH]c2c1,"2-(4-{[2-(3-chlorophenyl)-2-hydroxyethyl]amino}-2-oxo-1,2-dihydropyridin-3-yl)-N,4-dimethyl-1H-1,3-benzodiazole-6-carboximidamide",15.0,uM,=,1.1760912590556811,1,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccccc2[nH]1
3396,1335568,10.1021/jm401731q,,,,Inhibition of CYP3A4 (unknown origin),Cc1nc(N2CCC[C@@H](C(=O)NCCc3ccc(C#N)cc3)C2)nc(N2CCN(C)CC2)c1F,(R)-N-(4-Cyanophenethyl)-1-(5-fluoro-4-methyl-6-(4-methylpiperazin-1-yl)pyrimidin-2-yl)piperidine-3-carboxamide,7.6,uM,=,0.8808135922807914,1,O=C(NCCc1ccccc1)[C@@H]1CCCN(c2nccc(N3CCNCC3)n2)C1
3397,1336778,10.1021/jm401911v,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,CC(C)(C)S(=O)(=O)C[C@H](C1CC1)N1C(=O)[C@@](C)(Cc2ccccc2)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1,"(3R,5R,6S)-3-Benzyl-1-((S)-2-(tert-butylsulfonyl)-1-cyclopropylethyl)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-3-methylpiperidin-2-one",1.7,uM,=,0.2304489213782739,1,O=C1C(Cc2ccccc2)C[C@H](c2ccccc2)[C@@H](c2ccccc2)N1CC1CC1
3398,2156515,10.1021/acs.jmedchem.1c01272,,,,Inhibition of CYP3A4 in human liver microsomes using IPA as substrate preincubated for 10 mins followed by NADPH generating system addition and measured after 20 mins,CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,SID144204227,0.077,uM,=,-1.1135092748275182,0,c1ccc([C@@]2(Cn3ccnc3)OC[C@H](COc3ccc(N4CCNCC4)cc3)O2)cc1
3399,815373,10.1016/j.bmcl.2012.03.062,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,O=C(Nc1ccc(-c2nnc(NCCCCN3CCOCC3)o2)c(F)c1)c1ccccc1F,"2-fluoro-N-(3-fluoro-4-(5-(4-morpholinobutylamino)-1,3,4-oxadiazol-2-yl)phenyl)benzamide",64.0,uM,=,1.806179973983887,1,O=C(Nc1ccc(-c2nnc(NCCCCN3CCOCC3)o2)cc1)c1ccccc1
3400,2116571,10.1021/acsmedchemlett.1c00198,,,,Inhibition of CYP3A4 (unknown origin) expressed in baculovirus infected insect supersomes preincubated for 15 mins followed by addition of NADPH regenerating system by fluorescence based analysis,O=C(O)c1cc(F)c2nc(N3CCC4(C=C(c5c(-c6c(Cl)cccc6Cl)noc5C5CC5)C4)CC3)sc2c1,"2-(2-(5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)-7-azaspiro[3.5]non-1-en-7-yl)-4-fluorobenzo[d]thiazole-6-carboxylic acid",0.9,uM,=,-0.0457574905606751,0,C1=C(c2c(-c3ccccc3)noc2C2CC2)CC12CCN(c1nc3ccccc3s1)CC2
3401,979124,10.1021/jm400484p,,,,Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes,COc1cncc(-c2ccc3ccc(O)cc3c2Cl)c1,8-chloro-7-(5-methoxypyridin-3-yl)naphthalen-2-ol,4.196,uM,=,0.6228354795215202,1,c1cncc(-c2ccc3ccccc3c2)c1
3402,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1ccc(C(=O)N2C[C@@H](C)OC[C@H]2Cc2cc(-n3ccnn3)ccc2F)c(-n2nccn2)c1,"US9150566, 141",19.0,uM,=,1.2787536009528289,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2ccnn2)c1
3403,1685713,10.1016/j.bmc.2017.04.033,,,,Inhibition of recombinant CYP3A4 (unknown origin),C[C@@H](c1ccc(-c2ccc3ncnn3c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O,"US8598163, 3",10.0,uM,=,1.0,1,O=C1OC(c2ccccc2)CCN1Cc1ccc(-c2ccc3ncnn3c2)cc1
3404,1295469,10.1016/j.bmcl.2014.02.004,,,,Inhibition of human recombinant CYP3A4,CC1Cc2cc(F)ccc2N1C(=O)Cc1nc(N2CCOCC2)sc1C(N)=O,4-(2-(5-fluoro-2-methylindolin-1-yl)-2-oxoethyl)-2-morpholinothiazole-5-carboxamide,0.04,uM,=,-1.3979400086720375,0,O=C(Cc1csc(N2CCOCC2)n1)N1CCc2ccccc21
3405,304712,10.1021/jm048978k,,,,In vitro inhibitory concentration against Cytochrome P450 3A4,CC(C)S(=O)(=O)n1c(N)nc2ccc(-c3[nH]cnc3-c3ccccc3)cc21,6-(5-Phenyl-3H-imidazol-4-yl)-1-(propane-2-sulfonyl)-1H-benzoimidazol-2-ylamine,1.6,uM,=,0.2041199826559248,1,c1ccc(-c2nc[nH]c2-c2ccc3nc[nH]c3c2)cc1
3406,1586157,10.1016/j.bmcl.2016.06.021,,,,Inhibition of CYP3A4 (unknown origin),Cc1cc(-c2cnn3c(NCC4CCOCC4)nc(Nc4cccc(F)c4)nc23)ccc1C(=O)NC1CC1,"N-cyclopropyl-4-(2-(3-fluorophenoxy)-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)pyrazolo [1,5-a][1,3,5]triazin-8-yl)-2-methylbenzamide",0.47,uM,=,-0.3279021420642826,0,O=C(NC1CC1)c1ccc(-c2cnn3c(NCC4CCOCC4)nc(Nc4ccccc4)nc23)cc1
3407,305432,10.1016/j.bmcl.2005.01.044,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,CC(C(c1ccc2cc(OCC(C)(C)C(N)=O)ccc2c1)n1ccnc1)N(C)C,"3-[6-(2-Dimethylamino-1-imidazol-1-yl-propyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionamide",1.835,uM,=,0.2636360685881081,1,c1ccc2cc(Cn3ccnc3)ccc2c1
3408,51927,10.1021/jm034111v,,,,Inhibition of recombinant human Cytochrome P450 3A4 using BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 30 minutes,CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@H](N(C)C)[C@H]3OC(C)=O)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O,"Acetic acid 14-(3-acetoxy-4-dimethylamino-6-methyl-tetrahydro-pyran-2-yloxy)-12-(5-acetoxy-4-methoxy-6-methyl-tetrahydro-pyran-2-yloxy)-5,7,8,11,13,15-hexamethyl-4,10-dioxo-1,9-dioxa-spiro[2.13]hexadec-6-yl ester",20.0,uM,=,1.3010299956639813,1,O=C1C[C@@H](O[C@H]2CCCCO2)C[C@@H](O[C@H]2CCCCO2)CC[C@@]2(CO2)C(=O)CCCCO1
3409,558484,10.1016/j.bmcl.2008.10.128,,,,Inhibition of CYP3A4,CCN(CC(O)(CNC(=O)c1cnn(-c2ccc(F)cc2)c1N)C(F)(F)F)C(=O)c1ncccc1Cl,"N-(2-((5-amino-1-(4-fluorophenyl)-1H-pyrazole-4-carboxamido)methyl)-3,3,3-trifluoro-2-hydroxypropyl)-3-chloro-N-ethylpicolinamide",4.0,uM,=,0.6020599913279624,1,O=C(NCCCNC(=O)c1ccccn1)c1cnn(-c2ccccc2)c1
3410,856844,10.1021/jm300356u,,,,Inhibition of human recombinant CYP3A4 using 7-BQ as substrate preincubated for 5 to 10 mins before substrate addition,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H]3[C@H]2O/C(=N/c2ccc(OC)cc2)N3C)[C@](C)(OC)C[C@@H](C)C(=O)N[C@H](C)[C@@H](O)[C@]1(C)O,"(2R,3S,4R,5R,10R,11R,12S,13S,14R)-2-ethyl-3,4-dihydroxy-13-((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yloxy)-10-methoxy-11-((3aR,4S,6R,7aS)-2-(4-methoxyphenylimino)-1,6-dimethylhexahydro-1H-pyrano[4,3-d]oxazol-4-yloxy)-3,5,8,10,12,14-hexamethyl-1-oxa-6-azacyclopentadecane-7,15-dione",4.7,uM,=,0.6720978579357175,1,O=C1CCC[C@H](O[C@@H]2OCC[C@@H]3N/C(=N\c4ccccc4)O[C@@H]23)C[C@H](O[C@H]2CCCCO2)CC(=O)OCCCCN1
3411,804824,10.1016/j.bmcl.2011.12.080,,,,Reversible inhibition of CYP3A4,COc1cc(C)c2nc3[nH]nc(C)c3c(C(C)(O)c3ccncc3)c2c1,"rac-1-(6-methoxy-3,8-dimethyl-1H-pyrazolo[3,4-b]quinolin-4-yl)-1-(pyridin-4-yl)ethanol",7.1,uM,=,0.8512583487190752,1,c1ccc2c(Cc3ccncc3)c3cn[nH]c3nc2c1
3412,1327918,10.1039/C2MD20061A,,,,Inhibition of CYP3A4 in human pooled liver microsomes using testosterone as substrate by LC/MS/MS analysis,COc1cc(N2CCOCC2)ccc1-c1nc2c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)c(Cl)cnc2[nH]1,"(1S,2S,3R,4R)-3-[6-Chloro-2-(2-methoxy-4-morpholin-4-yl-phenyl)-3H-imidazo[4,5-b]pyridin-7-ylamino]-bicyclo[2.2.1]hept-5-ene-2-carboxylicacidamide",5.3,uM,=,0.724275869600789,1,C1=C[C@H]2C[C@@H]1C[C@@H]2Nc1ccnc2[nH]c(-c3ccc(N4CCOCC4)cc3)nc12
3413,52065,10.1021/jm0310129,,,,Inhibitory activity against cytochrome P450 3A4,Cn1c2cccc(C(N)=O)c2c2ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21,"4-{4-[2-(3,4-Difluoro-phenyl)-ethyl]-piperazin-1-yl}-5-methyl-5H-pyrimido[5,4-b]indole-9-carboxylic acid amide",0.26,uM,=,-0.585026652029182,0,c1ccc(CCN2CCN(c3ncnc4c3[nH]c3ccccc34)CC2)cc1
3414,1778315,10.1016/j.bmcl.2018.06.040,,,,Inhibition of CYP3A4 (unknown origin),O=C(Cc1cccc(OCCN2CCNCC2)c1)Nc1nc(-c2c[nH]c3ncccc23)cs1,"N-(4-(1H-pyrrolo[2,3-b]pyridin-3-yl)thiazol-2-yl)-2-(3-(2-(piperazin-1-yl)ethoxy)phenyl)acetamide",14.9,uM,=,1.173186268412274,1,O=C(Cc1cccc(OCCN2CCNCC2)c1)Nc1nc(-c2c[nH]c3ncccc23)cs1
3415,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)CCCCCCC)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, D-52",21.7,uM,=,1.3364597338485296,1,O=C1[C@H](Cc2ccccc2)N2C(=O)CNN(C(=O)NCc3ccccc3)[C@H]2CN1Cc1cccc2c(-c3ccccc3)c[nH]c12
3416,766553,10.1016/j.bmcl.2011.06.102,,,,Inhibition of CYP3A4,CN(C)[C@H]1CC[C@H](c2ccc(OCCCN3CCCCC3)cc2)CC1,"trans-N,N-dimethyl-4-(4-(3-(piperidin-1-yl)propoxy)phenyl)cyclohexanamine",42.6,uM,=,1.6294095991027189,1,c1cc(C2CCCCC2)ccc1OCCCN1CCCCC1
3417,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1ccc(C(=O)N2CCOC[C@H]2Cc2ccc(C)c(-n3nccn3)c2)c(-n2nccn2)c1,"US9150566, 67",25.0,uM,=,1.3979400086720375,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
3418,664620,10.1016/j.bmcl.2010.08.009,,,,Inhibition of CYP3A4,CC(C)N1CCC(Oc2ccc3c(c2)cc2n3CCN(Cc3ccncc3)C2=O)CC1,"8-(1-isopropylpiperidin-4-yloxy)-2-(pyridin-4-ylmethyl)-3,4-dihydropyrazino[1,2-a]indol-1(2H)-one",6.0,uM,=,0.7781512503836436,1,O=C1c2cc3cc(OC4CCNCC4)ccc3n2CCN1Cc1ccncc1
3419,52065,10.1021/jm0310129,,,,Inhibitory activity against cytochrome P450 3A4,O=[N+]([O-])c1cc([N+](=O)[O-])c2[nH]c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)nc(CN4CCOCC4)nc3c2c1,"4-{4-[2-(3,4-Difluoro-phenyl)-ethyl]-piperazin-1-yl}-2-morpholin-4-ylmethyl-6,8-dinitro-5H-pyrimido[5,4-b]indole",42.26,uM,=,1.6259294927162946,1,c1ccc(CCN2CCN(c3nc(CN4CCOCC4)nc4c3[nH]c3ccccc34)CC2)cc1
3420,52064,10.1016/s0960-894x(03)00058-1,,,,Inhibitory activity against CYP450 3A4 isozyme,CCN(CC)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(=O)Cn1c(C)cc(=O)nc1SCc1ccc(F)cc1,N-(2-Diethylamino-ethyl)-2-[2-(4-fluoro-benzylsulfanyl)-6-methyl-4-oxo-4H-pyrimidin-1-yl]-N-(4'-trifluoromethyl-biphenyl-4-ylmethyl)-acetamide,22.0,uM,=,1.3424226808222062,1,O=C(Cn1ccc(=O)nc1SCc1ccccc1)NCc1ccc(-c2ccccc2)cc1
3421,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",O=C(c1ccc(Cl)cc1-n1nccn1)N1CCOC[C@H]1Cc1cc(-n2nccn2)ccc1Cl,"US9150566, 170",9.8,uM,=,0.9912260756924948,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
3422,776115,10.1016/j.bmcl.2011.09.074,,,,Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(Cc1ccccc1)C2,"(6-benzyl-4-(2,4-dichlorophenyl)-2-methyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-3-yl)methanamine",0.77,uM,=,-0.1135092748275181,0,c1ccc(CN2Cc3nccc(-c4ccccc4)c3C2)cc1
3423,495542,10.1021/jm801332q,,,,Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate by time dependent inhibition assay,C[C@@H]1CN(Cc2ccc(CC(=O)N3CCC(Nc4cccc(F)c4)CC3)cc2)CCN1,N-(3-Fluorophenyl)-1-[(4-([(3R)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine,29.0,uM,=,1.462397997898956,1,O=C(Cc1ccc(CN2CCNCC2)cc1)N1CCC(Nc2ccccc2)CC1
3424,2264099,10.1021/acs.jmedchem.1c00703,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 2 mins in presence of NADPH regenerating system by LC-MS/MS analysis,COCCCN1CCC(c2nnc(-c3nn(C(C)C)c4ccccc34)o2)CC1.O=C(O)C(=O)O,"1-lsopropyl-3-[5-(1-(3-methoxypropyl)-piperidin-4-yl]-[1,3,4]-oxadiazol-2-yl]-1H-indazole oxalate",9.1,uM,=,0.9590413923210936,1,c1ccc2c(-c3nnc(C4CCNCC4)o3)n[nH]c2c1
3425,1289880,10.1021/jm401642q,,,,Inhibition of recombinant human CYP3A4,COc1cccc2c1CCN2C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1,"2-[2-(4-Methoxy-2,3-dihydroindol-1-yl)-2-oxoethyl]-6-morpholin-4-yl-3H-pyrimidin-4-one",40.0,uM,=,1.6020599913279625,1,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2ccccc21
3426,619264,10.1016/j.bmcl.2009.07.002,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,Cc1cccc(C)c1CNc1nc(-c2cccc(=O)[nH]2)cc2c(C)c(C)[nH]c12,"6-(7-(2,6-dimethylbenzylamino)-2,3-dimethyl-1H-pyrrolo[2,3-c]pyridin-5-yl)pyridin-2(1H)-one",1.3,uM,=,0.1139433523068367,1,O=c1cccc(-c2cc3cc[nH]c3c(NCc3ccccc3)n2)[nH]1
3427,1653091,10.1016/j.bmc.2016.11.019,,,,Inhibition of human CYP3A4,Cc1cc(C)cc(COc2ccc(N(CCN)C(=O)c3ccc(Cl)cc3Cl)cc2)c1.Cl,"N-(2-Aminoethyl)-2,4-dichloro-N-{4-[(3,5-dimethylphenyl)methoxy]phenyl}benzamide hydrochloride",0.003,uM,=,-2.5228787452803374,0,O=C(Nc1ccc(OCc2ccccc2)cc1)c1ccccc1
3428,851921,10.1016/j.bmcl.2012.08.072,,,,Inhibition of human recombinant CYP3A4,COc1cccc(NC(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)c1,"N-(3-methoxyphenyl)-2-(4-morpholino-6-oxo-1,6-dihydropyrimidin-2-yl)acetamide",40.0,uM,=,1.6020599913279625,1,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccccc1
3429,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1cccc(C(=O)N2C[C@@H](C)OC[C@H]2Cc2cccc(-c3ncccn3)c2)c1-n1nccn1,"US9150566, 111",40.0,uM,=,1.6020599913279625,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2ncccn2)c1
3430,598210,10.1016/j.bmcl.2009.08.024,,,,Inhibition of human CYP3A4,CC1(CC(=O)NCCNc2ccnc3cc(Cl)ccc23)CC2(CCCCC2)OO1,"N-[2-(7-Chloro-quinolin-4-ylamino)-ethyl]-2-(3-methyl-1,2-dioxa-spiro[4.5]dec-3-yl)-acetamide",1.0,uM,=,0.0,0,O=C(CC1CC2(CCCCC2)OO1)NCCNc1ccnc2ccccc12
3431,2229240,10.1021/acs.jmedchem.2c00960,,,,Inhibition of CYP3A4 (unknown origin),CC(C)Oc1ccc(-c2nsc(Nc3ncccc3N(C)C)n2)nc1,"N2-(3-(5-isopropoxypyridin-2-yl)-1,2,4-thiadiazol-5-yl)-N3,N3-dimethylpyridine-2,3-diamine",22.0,uM,=,1.3424226808222062,1,c1ccc(Nc2nc(-c3ccccn3)ns2)nc1
3432,322414,10.1021/jm0502541,,,,Interaction with human cytochrome P450 isoform 3A4 expressed in baculovirus-insect cells,O=C(O)C1(c2ccc(-c3ccc(-c4ccc(O)cc4)c(F)c3)c(F)c2)CC1,"1-(2',2''-Difluoro-4-hydroxy-[1,1';4',1'']terphenyl-4''-yl)-cyclopropanecarboxylic acid",58.0,uM,=,1.7634279935629371,1,c1ccc(-c2ccc(-c3ccc(C4CC4)cc3)cc2)cc1
3433,1446329,10.1021/ml500387y,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,CC(C)(CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F)c1ccccc1S(N)(=O)=O,"2-(5,5,5-trifluoro-4-hydroxy-2-methyl-4-((5-morpholino-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)pentan-2-yl)benzenesulfonamide",0.5,uM,=,-0.3010299956639812,0,c1ccc(CCCCc2cc3cc(N4CCOCC4)ncc3[nH]2)cc1
3434,673952,10.1016/j.bmcl.2010.08.086,,,,Inhibition of CYP3A4 using midazolam as substrate,CNCCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1,"(3R,4S)-N-(2-chloro-5-(2-(methylamino)ethyl)benzyl)-N-cyclopropyl-4-(4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)phenyl)piperidine-3-carboxamide",14.0,uM,=,1.146128035678238,1,O=C([C@H]1CNCC[C@@H]1c1ccc(OCCOc2ccccc2)cc1)N(Cc1ccccc1)C1CC1
3435,1459713,10.1016/j.ejmech.2014.08.059,,,,Inhibition of CYP3A4 (unknown origin),N#C[C@@H]1C[C@@H]2CCC[C@@H]2N1C(=O)C[C@H](N)Cc1cc(F)c(F)cc1F,"(2S,3aS,6aS)-1-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]octahydrocyclopenta[b]pyrrole-2-carbonitrile",2.25,uM,=,0.3521825181113625,1,O=C(CCCc1ccccc1)N1CC[C@@H]2CCC[C@@H]21
3436,455108,10.1016/j.bmcl.2006.12.043,,,,Inhibition of CYP3A4,O=C(C(O)c1ccc(Cl)cc1)N1CCN(c2ccc3[nH]ncc3c2)CC1,1-(4-(1H-indazol-5-yl)piperazin-1-yl)-2-(4-chlorophenyl)-2-hydroxyethanone,3.0,uM,=,0.4771212547196624,1,O=C(Cc1ccccc1)N1CCN(c2ccc3[nH]ncc3c2)CC1
3437,1289880,10.1021/jm401642q,,,,Inhibition of recombinant human CYP3A4,Cn1c(CC(=O)N2CCc3ccccc32)nc(N2CCOCC2)cc1=O,"2-[2-(2,3-Dihydro-1H-indol-1-yl)-2-oxoethyl]-3-methyl-6-(morpholin-4-yl)pyrimidin-4(3H)-one",40.0,uM,=,1.6020599913279625,1,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2ccccc21
3438,518565,10.1021/jm801586s,,,,Inhibition of CYP3A4,Nc1nccc(Oc2ccc(NC(=O)c3cccn(-c4ccc(F)cc4)c3=O)cc2F)c1Cl,"N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide",4.0,uM,=,0.6020599913279624,1,O=C(Nc1ccc(Oc2ccncc2)cc1)c1cccn(-c2ccccc2)c1=O
3439,2207925,10.1021/acsmedchemlett.2c00411,,,,Inhibition of CYP3A4 (unknown origin) in presence of NADPH,Cc1cnc(Nc2ccc(N3CCN(C)CC3)nc2)nc1Nc1ccc2oc(=O)[nH]c2c1,5-((5-methyl-2-((6-(4-methylpiperazin-1yl)pyridin-3-yl)amino)pyrimidin-4yl)amino)benzo[d]oxazol-2(3H)-one,4.0,uM,=,0.6020599913279624,1,O=c1[nH]c2cc(Nc3ccnc(Nc4ccc(N5CCNCC5)nc4)n3)ccc2o1
3440,558484,10.1016/j.bmcl.2008.10.128,,,,Inhibition of CYP3A4,Nc1c(C(=O)NCC(O)(CN(CCO)C(=O)c2c(Cl)cccc2Cl)C(F)(F)F)cnn1-c1ccc(F)cc1,"5-amino-N-(2-((2,6-dichloro-N-(2-hydroxyethyl)benzamido)methyl)-3,3,3-trifluoro-2-hydroxypropyl)-1-(4-fluorophenyl)-1H-pyrazole-4-carboxamide",100.0,uM,=,2.0,1,O=C(NCCCNC(=O)c1cnn(-c2ccccc2)c1)c1ccccc1
3441,741043,10.1016/j.bmcl.2011.02.067,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCCOC)c1,"(3R,4S)-N-cyclopropyl-4-(4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)phenyl)-N-(3-(2-methoxyethoxy)-5-(3-methoxypropyl)benzyl)piperidine-3-carboxamide",2.4,uM,=,0.380211241711606,1,O=C([C@H]1CNCC[C@@H]1c1ccc(OCCOc2ccccc2)cc1)N(Cc1ccccc1)C1CC1
3442,583357,10.1021/jm900945d,,,,Inhibition of CYP3A4,COc1ccc(-c2ccc(Cn3c(CC(C)(C)C(=O)O)c(SC(C)(C)C)c4cc(OCc5ccccn5)ccc43)cc2)nn1,"3-(3-(tert-butylthio)-1-(4-(6-methoxypyridazin-3-yl)benzyl)-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl)-2,2-dimethylpropanoic acid",0.0150999999999999,uM,=,-1.8210230527068303,0,c1ccc(COc2ccc3c(ccn3Cc3ccc(-c4cccnn4)cc3)c2)nc1
3443,1764722,10.1021/acsmedchemlett.8b00220,,,,Inhibition of CYP3A4 (unknown origin) preincubated followed by substrate addition,CS[C@@]1(C(=O)Nc2ccc3[nH]nc(-c4ccc(OC(C)C)nc4)c3c2)CCN(CC(=O)N2CC=C(c3ccc(-c4ncn(C)n4)cc3)CC2)C1,MK-8353,1.7,uM,=,0.2304489213782739,1,O=C(Nc1ccc2[nH]nc(-c3cccnc3)c2c1)C1CCN(CC(=O)N2CC=C(c3ccc(-c4nc[nH]n4)cc3)CC2)C1
3444,1911030,10.1021/acs.jmedchem.8b01226,,,,Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins,CCOC(=O)N1CC2(CC(=CC#Cc3cccc(C)n3)C2)C1,Ethyl 6-[3-(6-Methylpyridin-2-yl)prop-2-yn-1-ylidene]-2-azaspiro[3.3]heptane-2-carboxylate,17.2,uM,=,1.235528446907549,1,C(#Cc1ccccn1)C=C1CC2(CNC2)C1
3445,2081967,10.1016/j.ejmech.2021.113248,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam 1-hydroxylation as substrate by LC-MS/MS analysis,O=C1NCCC12CCN(c1c(Cl)cncc1-c1cc3ccccc3o1)CC2,"8-(3-(Benzofuran-2-yl)-5-chloropyridin-4-yl)-2,8-diazaspiro[4.5]decan-1-one",4.59,uM,=,0.6618126855372612,1,O=C1NCCC12CCN(c1ccncc1-c1cc3ccccc3o1)CC2
3446,591402,10.1021/jm9010065,,,,Inhibition of CYP3A4 in pooled human liver microsome,Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c12,"[4-[[1-(3-fluorophenyl)methyl]-1H-indazol-5-ylamino]-5-methyl-pyrrolo[2,1-f][1,2,4]triazin-6-yl]-carbamic acid,(3S)-3-morpholinylmethyl ester",12.0,uM,=,1.0791812460476249,1,O=C(Nc1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnn2c1)OC[C@@H]1COCCN1
3447,1466989,10.1021/jm501719e,,,,Inhibition of human CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)coumarin as substrate assessed as formation of 7-hydroxy-4-trifluoromethylcoumarin incubated for 2 mins prior to NADPH addition by fluorimetric assay,Cl.Fc1cccc(C[C@@H]2C[C@H]2NCCc2ccnc(-n3ccnc3)n2)c1,"(R,R)-N-2-[2-(1H-Imidazol-1-yl)pyrimidin-4-yl]ethyl-2-(3-fluorobenzyl)-cyclopropan-1-amine Dihydrochloride",0.3,uM,=,-0.5228787452803376,0,c1ccc(C[C@@H]2C[C@H]2NCCc2ccnc(-n3ccnc3)n2)cc1
3448,2194835,10.1021/acs.jmedchem.2c00986,,,,Inhibition of CYP3A4 in human liver microsomes at 10 uM using midazolam as substrate preincubated for 10 mins followed by NADPH addition by LC/MS analysis,Cc1nc(N[C@H](C)c2cccc(C(F)F)c2F)c2cc3c(cc2n1)OCC[C@H]1CN(C(=O)C2(C#N)CC2)CCN31,"1-((S)-12-(((R)-1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)amino)-10-methyl-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1',2':4,5][1,4]oxazepino[3,2-g]quinazoline-3-carbonyl)cyclopropane-1-carbonitrile",22.1,uM,=,1.3443922736851108,1,O=C(C1CC1)N1CCN2c3cc4c(NCc5ccccc5)ncnc4cc3OCC[C@H]2C1
3449,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",O=C(c1cc(F)c(F)cc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1,"US9150566, 91",17.0,uM,=,1.230448921378274,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
3450,1679904,10.1016/j.bmcl.2017.04.043,,,,Inhibition of CYP3A4 (unknown origin),Cc1nnc2sc(C(=O)NCc3ccc(-c4ccnc(F)c4)cc3)c(N)c2c1C,"5-amino-N-(4-(2-fluoropyridin-4-yl)benzyl)-3,4-dimethylthieno[2,3-c]pyridazine-6-carboxamide",24.0,uM,=,1.380211241711606,1,O=C(NCc1ccc(-c2ccncc2)cc1)c1cc2ccnnc2s1
3451,461436,10.1016/j.bmcl.2007.10.092,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,CC[C@@H]1CCC[C@H](C2(CC(=O)N3CC4CCC(C3)N4C)CC2)N1S(=O)(=O)c1ccc(Cl)cc1,"2-(1-((2R,6R)-1-(4-chlorophenylsulfonyl)-6-ethylpiperidin-2-yl)cyclopropyl)-1-(8-methyl-3,8-diaza-bicyclo[3.2.1]octan-3-yl)ethanone",4.7,uM,=,0.6720978579357175,1,O=C(CC1([C@H]2CCCCN2S(=O)(=O)c2ccccc2)CC1)N1CC2CCC(C1)N2
3452,1540696,10.1016/j.ejmech.2015.08.051,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 2 mins by LC-MS/MS analysis in presence of NADPH regeneration system,CC(C)c1nc(C(=O)NC2CCN(C(C)C)CC2)c2ccccn12,"3-isopropyl-N-(1-isopropylpiperidin-4-yl)imidazo[1,5-a]pyridine-1-carboxamide",0.2,uM,=,-0.6989700043360187,0,O=C(NC1CCNCC1)c1ncn2ccccc12
3453,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)NCC(C)(C)C)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, D-96",2.19,uM,=,0.3404441148401183,1,O=C1[C@H](Cc2ccccc2)N2C(=O)CNN(C(=O)NCc3ccccc3)[C@H]2CN1Cc1cccc2c(-c3cccnc3)c[nH]c12
3454,1653091,10.1016/j.bmc.2016.11.019,,,,Inhibition of human CYP3A4,Cl.NCCN(C(=O)c1ccc(F)cc1C(F)(F)F)c1ccc(OCc2ccc(Cl)cc2)cc1,N-(2-Aminoethyl)-N-{4-[(4-chlorophenyl)methoxy]phenyl}-4-fluoro-2-(trifluoromethyl)benzamide hydrochloride,0.01,uM,=,-2.0,0,O=C(Nc1ccc(OCc2ccccc2)cc1)c1ccccc1
3455,1519419,10.1021/acsmedchemlett.5b00048,,,,Inhibition of human CYP3A4,c1ccc(-c2nnc3n2-c2ccc(-c4cccnc4)cc2CC3)cc1,"1-phenyl-7-(pyridin-3-yl)-4,5-dihydro-[1,2,4]triazolo[4,3-a]quinoline",36.51,uM,=,1.5624118329497274,1,c1ccc(-c2nnc3n2-c2ccc(-c4cccnc4)cc2CC3)cc1
3456,1291572,10.1016/j.bmcl.2013.12.058,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,CC(C)CN(CC[C@H](Cc1ccccc1)NC(=O)[C@H](CCN1CCOCC1)NC(=O)N(C)Cc1csc(C(C)C)n1)C(=O)OCc1cncs1,Thiazol-5-ylmethyl isobutyl((S)-3-((S)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-4-morpholinobutanamido)-4-phenylbutyl)carbamate,0.35,uM,=,-0.4559319556497244,0,O=C(NCc1cscn1)N[C@@H](CCN1CCOCC1)C(=O)N[C@H](CCNC(=O)OCc1cncs1)Cc1ccccc1
3457,988989,10.1021/jm400732v,,,,Inhibition of CYP3A4 (unknown origin),CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)c2cccnc2)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O.Cl,"(S)-N-((S)-1-((6-Bromo-2-methoxynaphthalen-1-yl)methyl)-5-nicotinoyl-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-yl)-2-(methylamino)propanamide hydrochloride",1.2,uM,=,0.0791812460476248,1,O=C1CCN(C(=O)c2cccnc2)c2ccccc2N1Cc1cccc2ccccc12
3458,537516,10.1021/jm8005096,,,,Inhibition of CYP3A4,COc1cc(C2=NC(c3ccc(Cl)cc3F)C(C(=O)Nc3ccc4[nH]ncc4c3)=C(C)N2)ccn1,"4-(4-chloro-2-fluorophenyl)-N-(1H-indazol-5-yl)-2-(2-methoxypyridin-4-yl)-6-methyl-1,4-dihydropyrimidine-5-carboxamide",4.3,uM,=,0.6334684555795865,1,O=C(Nc1ccc2[nH]ncc2c1)C1=CNC(c2ccncc2)=NC1c1ccccc1
3459,489963,10.1021/jm800566m,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline substrate,Cc1nc2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2n1C,"3-({4-[(1,2-Dimethyl-1H-benzimidazol-6-yl)(methyl)amino]-2-pyrimidinyl}amino)benzenesulfonamide",1.7,uM,=,0.2304489213782739,1,c1ccc(Nc2nccc(Nc3ccc4nc[nH]c4c3)n2)cc1
3460,464243,10.1021/jm7013309,,,,Inhibition of human CYP3A4 using 7-benzyloxyresorufin,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)CN)c(C)c34)ccc2[nH]1,"(R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl 2-aminoacetate",0.31,uM,=,-0.5086383061657274,0,c1cc2c(Oc3ccc4[nH]ccc4c3)ncnn2c1
3461,966467,10.1016/j.bmcl.2013.04.077,,,,Inhibition of CYP3A4 (unknown origin),Cc1nc(NC(=O)C2(C)CCCCC2)sc1-c1ccc(N)nc1,N-(5-(6-aminopyridin-3-yl)-4-methylthiazol-2-yl)-1-methylcyclohexanecarboxamide,17.0,uM,=,1.230448921378274,1,O=C(Nc1ncc(-c2cccnc2)s1)C1CCCCC1
3462,1699178,10.1021/acs.jmedchem.6b01543,,,,Inhibition of CYP3A4 (unknown origin),O=C(O)CC1CCC2(CCN(c3ccc(-c4nc5cc(C(F)(F)F)ccc5[nH]4)cn3)CC2)OC1,2-(9-(5-(5-(Trifluoromethyl)-1H-benzo[d]imidazol-2-yl)pyridin-2-yl)-1-oxa-9-azaspiro[5.5]undecan-3-yl)acetic Acid,19.5,uM,=,1.290034611362518,1,c1ccc2[nH]c(-c3ccc(N4CCC5(CCCCO5)CC4)nc3)nc2c1
3463,1447575,10.1016/j.bmcl.2014.05.068,,,,Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method,C[C@@H](c1ncncc1F)[C@](O)(Cn1ncnn1)c1ccc(F)cc1F,"(2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(2H-tetrazol-2-yl)butan-2-ol",46.0,uM,=,1.662757831681574,1,c1ccc(C(Cc2ccncn2)Cn2ncnn2)cc1
3464,674732,10.1016/j.bmcl.2010.09.029,,,,Inhibition of CYP3A4,CC#Cc1cc([C@@]2(c3ccc(OC(F)F)cc3)N=C(N)N(C)C2=O)ccc1F,(R)-2-amino-4-(4-(difluoromethoxy)phenyl)-4-(4-fluoro-3-(prop-1-ynyl)phenyl)-1-methyl-1H-imidazol-5(4H)-one,1.0,uM,=,0.0,0,O=C1NC=NC1(c1ccccc1)c1ccccc1
3465,988989,10.1021/jm400732v,,,,Inhibition of CYP3A4 (unknown origin),CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)c2ccc(C(C)=O)cc2)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O.Cl,"(S)-N-((S)-5-(4-Acetylbenzoyl)-1-((6-bromo-2-methoxynaphthalen-1-yl)methyl)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-yl)-2-(methylamino)propanamide hydrochloride",1.8,uM,=,0.255272505103306,1,O=C1CCN(C(=O)c2ccccc2)c2ccccc2N1Cc1cccc2ccccc12
3466,1985395,10.1021/acsmedchemlett.9b00438,,,,Inhibition of CYP3A4 (unknown origin),CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6ccnc6)(c6ccc(Cl)cc6Cl)O5)cn4)CC3)cc2)c1=O,"4-(4-(4-(5-(((2S,4R)-2-((1H-imidazol-1-yl)methyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-4-yl)methoxy)pyridin-2-yl)piperazin-1-yl)phenyl)-2-(sec-butyl)-2,4-dihydro-3H-1,2,4-triazol-3-one",2.6,uM,=,0.414973347970818,1,O=c1[nH]ncn1-c1ccc(N2CCN(c3ccc(OC[C@@H]4CO[C@@](Cn5ccnc5)(c5ccccc5)O4)cn3)CC2)cc1
3467,1675511,10.1016/j.ejmech.2017.03.037,,,,Inhibition of human hepatic CYP3A4,Fc1ccc2sc3c(c2c1)CCN(Cc1c[nH]cn1)C3,"2-[(1H-Imidazol-4-yl)methyl]-6-fluoro-1,2,3,4-tetrahydrobenzo[4,5]thieno[2,3-c]-pyridine",0.685,uM,=,-0.1643094285075744,0,c1ccc2c3c(sc2c1)CN(Cc1c[nH]cn1)CC3
3468,1526216,10.1021/ml500526p,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,Cn1c(Nc2cc(C(F)(F)F)ccc2F)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21,N-(2-fluoro-5-(trifluoromethyl)phenyl)-1-methyl-5-(2-(5-(trifluoromethyl)-1H-imidazol-2-yl)pyridin-4-yloxy)-1H-benzo[d]imidazol-2-amine,26.0,uM,=,1.414973347970818,1,c1ccc(Nc2nc3cc(Oc4ccnc(-c5ncc[nH]5)c4)ccc3[nH]2)cc1
3469,828928,10.1016/j.bmcl.2012.06.022,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,CCN(C)c1nc2ccc(C(=O)N(CC(C)C)C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1,"Thiazol-5-ylmethyl(2S,3R)-4-(2-(ethyl(methyl)amino)-N-isobutylbenzo[d]oxazole-6-carboxamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate",0.031,uM,=,-1.5086383061657274,0,O=C(N[C@H](CCNC(=O)c1ccc2ncoc2c1)Cc1ccccc1)OCc1cncs1
3470,625944,10.1016/j.bmcl.2010.02.080,,,,Inhibition of CYP3A4 preincubated for 30 mins,O=C1CCC2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OCC2C1,"rac-10a-(4-chlorophenylsulfonyl)-1,4-difluoro-6a,7,10,10a-tetrahydro-6H-benzo[c]chromen-8(9H)-one",1.2,uM,=,0.0791812460476248,1,O=C1CCC2(S(=O)(=O)c3ccccc3)c3ccccc3OCC2C1
3471,1366897,10.1021/jm500312x,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 15 mins by LC/MS/MS analysis,C=C[C@]1(C)C[C@@H](OC(=O)CSc2cccc(CO)c2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O,"(3-Hydroxymethyl-phenylsulfanyl)-acetic acid(1S,2R,3S,4S,6R,7R,8R,14R)-3-hydroxy-2,4,7,14-tetramethyl-9-oxo-4-vinyl-tricyclo[5.4.3.0(1,8)]tetradec-6-yl ester",1.95,uM,=,0.290034611362518,1,O=C(CSc1ccccc1)O[C@@H]1CCCC[C@@]23CCCC1[C@@H]2C(=O)CC3
3472,495153,10.1021/jm8006454,,,,Inhibition of CYP3A4,COc1cccc(-c2c(C)n(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](NCC(=O)O)c3ccccc3)c2=O)c1F,"(R)-2-{2-[5-(2-Fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}acetic Acid",36.0,uM,=,1.5563025007672873,1,O=c1c(-c2ccccc2)cn(Cc2ccccc2)c(=O)n1CCc1ccccc1
3473,1745612,10.1016/j.bmcl.2017.10.010,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins in presence of NADPH by LC-MS/MS analysis,Cl.N[C@@H]1CCC=C(c2ccc(F)cc2)[C@H]1CNc1cc(F)c(S(=O)(=O)Nc2cscn2)cc1Cl,(-)-4-((6-amino-2-(4-fluorophenyl)cyclohex-2-enyl)methylamino)-5-chloro-2-fluoro-N-(thiazol-4-yl)benzenesulfonamide hydrochloride,33.0,uM,=,1.5185139398778875,1,O=S(=O)(Nc1cscn1)c1ccc(NC[C@H]2CCCC=C2c2ccccc2)cc1
3474,1527876,,,,,Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,CCn1c(C)cc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)cc1=O,"US8575157, 72",41.0,uM,=,1.6127838567197357,1,O=C1OC(c2ccccc2)CCN1Cc1ccc(-c2cc[nH]c(=O)c2)cc1
3475,1785637,,,,,Inhibition of CYP3A4 (unknown origin),CC(=O)N1CCN(c2ccc(/C=C/c3cc(F)cc(-c4ccncc4)c3)cc2)CC1,(E)-1-(4-(4-(3-fluoro-5-(pyridin-4-yl)styryl)phenyl)piperazin-1-yl)ethanone,0.695,uM,=,-0.1580151954098861,0,C(=C/c1cccc(-c2ccncc2)c1)\c1ccc(N2CCNCC2)cc1
3476,993439,10.6019/CHEMBL2448688,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,CCN(c1ccccc1)S(=O)(=O)c1ccc(Cl)c(NC(=O)c2ccc3c(c2)CCNC3)c1,,5.83,uM,=,0.7656685547590141,1,O=C(Nc1cccc(S(=O)(=O)Nc2ccccc2)c1)c1ccc2c(c1)CCNC2
3477,878086,10.1021/jm3013147,,,,Inhibition of human recombinant CYP3A4 using benzoylresorufin as substrate after 45 mins by fluorescence assay,N[C@@H]1c2cccnc2[C@H](OC(=O)N2CCC(n3c(=O)[nH]c4ncccc43)CC2)CC[C@H]1c1cccc(F)c1F,"(5S,6S,9R)-5-Amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-Oxo-2,3-dihydro-1H-imidazo-[4,5-b]pyridin-1-yl)piperidine-1-carboxylate",17.0,uM,=,1.230448921378274,1,O=C(O[C@@H]1CC[C@@H](c2ccccc2)Cc2cccnc21)N1CCC(n2c(=O)[nH]c3ncccc32)CC1
3478,1755647,10.1039/C6MD00387G,,,,Inhibition of CYP3A4 (unknown origin),O=C(NC[C@@H](Cc1ccccc1)N1CCC(O)(C(F)(F)F)CC1)C1(c2ccc(Cl)cc2)CCCC1,(R)-1-(4-chlorophenyl)-N-(2-(4-hydroxy-4-(trifluoromethyl)piperidin-1-yl)-3-phenylpropyl)cyclopentanecarboxamide,2.164,uM,=,0.3352572564345318,1,O=C(NC[C@@H](Cc1ccccc1)N1CCCCC1)C1(c2ccccc2)CCCC1
3479,2062192,10.1016/j.bmcl.2016.04.018,,,,Inhibition of human liver microsomes CYP3A4 using testosterone as substrate by MUX-MS/MS analysis,Cc1cc(-c2ccc3c(c2)-c2nnc(Nc4cccc(C(F)(F)F)c4)n2CCO3)ccn1,"10-(2-methylpyridin-4-yl)-N-(3-(trifluoromethyl)phenyl)-5,6-dihydrobenzo[f][1,2,4]triazolo[4,3-d][1,4]oxazepin-3-amine",48.3,uM,=,1.683947130751512,1,c1ccc(Nc2nnc3n2CCOc2ccc(-c4ccncc4)cc2-3)cc1
3480,1352209,10.1021/jm4010835,,,,Inhibition of human recombinant CYP3A4,Cn1nc2c(-c3ccc(Cl)cc3)c(-c3ccncc3)c(=O)n(Cc3ccc(C(F)(F)F)nc3)n2c1=O,"8-(4-Chlorophenyl)-2-methyl-7-(pyridin-4-yl)-5-((6-(trifluoromethyl)pyridin-3-yl)methyl)-[1,2,4]triazolo[4,3-b]-pyridazine-3,6(2H,5H)-dione",6.6,uM,=,0.8195439355418687,1,O=c1c(-c2ccncc2)c(-c2ccccc2)c2n[nH]c(=O)n2n1Cc1cccnc1
3481,51925,10.1021/jm034111v,,,,Inhibition of recombinant human Cytochrome P450 3A4 with Benzoylresorufin,C[C@H](NC(=O)/C=C/c1ccccc1)c1cccc(N2CCOCC2)c1,(E)-N-[1-((S)-3-Morpholin-4-yl-phenyl)-ethyl]-3-phenyl-acrylamide,76.0,uM,=,1.880813592280792,1,O=C(/C=C/c1ccccc1)NCc1cccc(N2CCOCC2)c1
3482,495543,10.1021/jm801332q,,,,Inhibition of human CYP3A4 expressed in Escherichia coli using 7BQ substrate by time dependent inhibition assay,C[C@@H]1CN(Cc2ccc(CC(=O)N3CCC(Nc4ccc(F)cc4)CC3)cc2)C[C@H](C)N1,"1-[(4-([(3R,5S)-3,5-Dimethyl-1-piperazinyl]methyl)phenyl)acetyl]-N-(4-fluorophenyl)-4-piperidinamine",59.0,uM,=,1.7708520116421442,1,O=C(Cc1ccc(CN2CCNCC2)cc1)N1CCC(Nc2ccccc2)CC1
3483,1747252,10.1021/acs.jmedchem.7b01236,,,,Inhibition of human CYP3A4 using testosterone as substrate preincubated for 30 mins,Cc1cc(CC(=O)Nc2ccn(Cc3ccc(C#N)cn3)n2)ccc1OCCC(F)(F)F,"N-(1-((5-Cyanopyridin-2-yl)methyl)-1H-pyrazol-3-yl)-2-(3-methyl-4-(3,3,3-trifluoropropoxy)-phenyl)acetamide",23.0,uM,=,1.3617278360175928,1,O=C(Cc1ccccc1)Nc1ccn(Cc2ccccn2)n1
3484,1366898,10.1021/jm500312x,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 15 mins by LC/MS/MS analysis,C=C[C@]1(C)C[C@@H](OC(=O)CSc2ccccn2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O,14-O-(((Pyridin-2-yl)sulfanyl)acetyl)mutilin,1.36,uM,=,0.1335389083702175,1,O=C(CSc1ccccn1)O[C@@H]1CCCC[C@@]23CCCC1[C@@H]2C(=O)CC3
3485,559939,10.1016/j.bmcl.2008.10.072,,,,Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate,C[C@@H]1CN(Cc2ccc(-c3ccccc3CN(C)C(=O)CS(=O)(=O)c3ccccc3)cc2)C[C@H](C)N1,"2-Benzenesulfonyl-N-[4'-((3R,5S)-3,5-dimethyl-piperazin-1-ylmethyl)-biphenyl-2-ylmethyl]-N-methyl-acetamide",8.9,uM,=,0.9493900066449128,1,O=C(CS(=O)(=O)c1ccccc1)NCc1ccccc1-c1ccc(CN2CCNCC2)cc1
3486,1895186,10.1021/acs.jmedchem.9b00193,,,,Inhibition of CYP3A4 (unknown origin) by fluorescence-based assay,CCc1cc(Cc2ccc(CC(=O)NCCO)cc2)nc(-c2cccc(Cl)c2)n1,2-(4-((2-(3-Chlorophenyl)-6-ethylpyrimidin-4-yl)methyl)phenyl)-N-(2-hydroxyethyl)acetamide,3.1,uM,=,0.4913616938342727,1,c1ccc(Cc2ccnc(-c3ccccc3)n2)cc1
3487,1685713,10.1016/j.bmc.2017.04.033,,,,Inhibition of recombinant CYP3A4 (unknown origin),C[C@@H](c1ccc(-c2cccnc2)cc1)N1CC[C@](CCCO)(c2ccccc2)OC1=O,"(R)-6-(3-hydroxypropyl)-6-phenyl-3-((S)-1-(4-(pyridin-3-yl)phenyl)ethyl)-1,3-oxazinan-2-one",2.1,uM,=,0.3222192947339193,1,O=C1OC(c2ccccc2)CCN1Cc1ccc(-c2cccnc2)cc1
3488,612188,10.1016/j.bmcl.2009.12.071,,,,Inhibition of CYP3A4,CCN1C[C@H]2C[C@@H](N(Cc3ccc(F)c(C(F)(F)F)c3)C(=O)c3cn(C)cn3)C[C@H]2C1,(exo)-N-(2-ethyloctahydrocyclopenta[c]pyrrol-5-yl)-N-(4-fluoro-3-(trifluoromethyl)benzyl)-1-methyl-1H-imidazole-4-carboxamide,5.0,uM,=,0.6989700043360189,1,O=C(c1c[nH]cn1)N(Cc1ccccc1)[C@H]1C[C@H]2CNC[C@H]2C1
3489,1817350,10.1021/acs.jmedchem.8b01857,,,,Reversible inhibition of CYP3A4 (unknown origin) using testosterone as substrate,Cn1ncc(NC(=O)c2nc(-c3c(F)cccc3F)sc2N)c1N1CC[C@@H](N)CC(F)(F)C1,"(R)-5-Amino-N-(5-(5-amino-3,3-difluoroazepan-1-yl)-1-methyl-1H-pyrazol-4-yl)-2-(2,6-difluorophenyl)thiazole-4-carboxamide",4.9,uM,=,0.6901960800285137,1,O=C(Nc1cn[nH]c1N1CCCCCC1)c1csc(-c2ccccc2)n1
3490,1797910,10.1021/acs.jmedchem.8b01326,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate/NADPH addition measured after 10 mins by LC-MS/MS analysis,COc1nc(N2C[C@H]3C(=O)N(C)C(=N)N[C@@]3(c3cc(-c4cccc(C#N)c4)cs3)C2)ncc1F,"3-(5-((4aR,7aR)-6-(5-fluoro-4-methoxypyrimidin-2-yl)-2-imino-3-methyl-4-oxooctahydro-1H-pyrrolo[3,4-d]pyrimidin-7a-yl)thiophen-3-yl)benzonitrile",1.3,uM,=,0.1139433523068367,1,N=C1NC(=O)[C@@H]2CN(c3ncccn3)C[C@]2(c2cc(-c3ccccc3)cs2)N1
3491,489963,10.1021/jm800566m,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline substrate,Cc1nc2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc2n1C,"3-({4-[(1,2-Dimethyl-1H-benzimidazol-5-yl)(methyl)amino]pyrimidin-2-yl}amino)benzenesulfonamide",45.0,uM,=,1.6532125137753435,1,c1ccc(Nc2nccc(Nc3ccc4[nH]cnc4c3)n2)cc1
3492,598210,10.1016/j.bmcl.2009.08.024,,,,Inhibition of human CYP3A4,COc1cc(CNC(=O)CC2(C)CC3(CCCCC3)OO2)cc(OC)c1OC,"2-(3-methyl-1,2-dioxaspiro[4.5]decan-3-yl)-N-(3,4,5-trimethoxybenzyl)acetamide",1.9,uM,=,0.2787536009528289,1,O=C(CC1CC2(CCCCC2)OO1)NCc1ccccc1
3493,2262777,10.1021/acs.jmedchem.2c01319,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam and testosterone as substrate in presence NADPH regenerating system,C[C@@H](Oc1cc(NC(=O)c2cn(CCN3CCOCC3)c3cc(Br)c(C=O)nc23)ncc1C#N)c1c(Cl)cncc1Cl,"(R)-6-bromo-N-(5-cyano-4-(1-(3,5-dichloropyridin-4-yl)ethoxy)pyridin-2-yl)-5-formyl-1-(2-morpholinoethyl)-1H-pyrrolo[3,2-b]pyridine-3-carboxamide",2.71,uM,=,0.4329692908744057,1,O=C(Nc1cc(OCc2ccncc2)ccn1)c1cn(CCN2CCOCC2)c2cccnc12
3494,742780,10.1021/jm101583w,,,,Inhibition of CYP3A4 in human liver microsomes,COC(=O)C(C)(C)C(c1ccc(Nc2ccc3ccccc3c2)cc1)n1ccnc1,3-Imidazol-1-yl-2-methyl-3-[4-(naphthalen-2-ylamino)-phenyl]-propionic acid Methyl Ester,8.0,uM,=,0.9030899869919436,1,c1ccc2cc(Nc3ccc(Cn4ccnc4)cc3)ccc2c1
3495,945618,10.1016/j.bmc.2012.11.058,,,,Inhibition of CYP3A4 (unknown origin),O=S(=O)(Nc1ccc(Oc2cnc3ccccc3c2)c(F)c1)c1ccc(Cl)cc1Cl,"2,4-dichloro-N-(3-fluoro-4-(quinolin-3-yloxy)phenyl)benzenesulfonamide",10.0,uM,=,1.0,1,O=S(=O)(Nc1ccc(Oc2cnc3ccccc3c2)cc1)c1ccccc1
3496,1629496,10.1016/j.bmcl.2016.12.003,,,,Inhibition of hepatic CYP3A4 (unknown origin),CCc1c(F)cncc1-c1nc2ccc(F)cn2c1C1CC1,"3-cyclopropyl-2-(4-ethyl-5-fluoropyridin-3-yl)-6-fluoroimidazo[1,2-a]pyridine",2.8,uM,=,0.4471580313422192,1,c1cncc(-c2nc3ccccn3c2C2CC2)c1
3497,1797910,10.1021/acs.jmedchem.8b01326,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate/NADPH addition measured after 10 mins by LC-MS/MS analysis,Cc1nc(N2C[C@H]3C(=O)N(C)C(=N)N[C@@]3(c3cc(-c4cccc(C#N)c4)cs3)C2)ncc1F,"3-(5-((4aR,7aR)-6-(5-Fluoro-4-methylpyrimidin-2-yl)-2-imino-3-methyl-4-oxooctahydro-7aH-pyrrolo[3,4-d]pyrimidin-7a-yl)-thiophen-3-yl)benzonitrile",0.6,uM,=,-0.2218487496163563,0,N=C1NC(=O)[C@@H]2CN(c3ncccn3)C[C@]2(c2cc(-c3ccccc3)cs2)N1
3498,1528565,,,,,"Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",CC(C)c1nc(CN(C)C(=O)NC2(C(=O)N[C@H](CC[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)Cc3ccccc3)CCNCC2)cs1,"US8987313, 24",0.34,uM,=,-0.4685210829577448,0,O=C(NCc1cscn1)NC1(C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)CCNCC1
3499,834929,10.1016/j.bmcl.2012.07.020,,,,Inhibition of CYP3A4,CCS(=O)(=O)c1ccc2[nH]c(-c3cc(-c4ccccc4)ccc3Cl)nc2c1,2-(4-chlorobiphenyl-3-yl)-5-(ethylsulfonyl)-1H-benzo[d]imidazole,5.0,uM,=,0.6989700043360189,1,c1ccc(-c2cccc(-c3nc4ccccc4[nH]3)c2)cc1
3500,949159,10.1016/j.bmcl.2013.01.011,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,O=C(NC(Cc1cc(Cl)c2[nH]ncc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1,"(+/-)-N-(1-(1,4'-bipiperidin-1'-yl)-3-(7-chloro-1H-indazol-5-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide",13.0,uM,=,1.1139433523068367,1,O=C(NC(Cc1ccc2[nH]ncc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
3501,2165789,10.1021/acsmedchemlett.2c00089,,,,Inhibition of CYP3A4 (unknown origin),CC(C)O[C@H]1CC[C@H](C(=O)N2Cc3cccnc3Nc3ccc(N4CC5CCC4CO5)cc32)OC1,"(8-((1R,4R)-2-oxa-5-azabicyclo[2.2.2]octan-5-yl)-5,11-dihydro-6H-benzo[b]pyrido[2,3-e][1,4]diazepin-6-yl)((2R,5S)-5-isopropoxytetrahydro-2H-pyran-2-yl)methanone",0.001,uM,=,-3.0,0,O=C([C@H]1CCCCO1)N1Cc2cccnc2Nc2ccc(N3CC4CCC3CO4)cc21
3502,856843,10.1021/jm300356u,,,,Inhibition of human recombinant CYP3A4 using DEF as substrate preincubated for 5 to 10 mins before substrate addition,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H]3[C@H]2O/C(=N\C(C)C)N3C)[C@](C)(OC)C[C@@H](C)NC(=O)[C@H](C)[C@@H](O)[C@]1(C)O,"(2R,3S,4R,5R,10R,11R,12S,13S,14R)-2-ethyl-3,4-dihydroxy-13-((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yloxy)-11-((3aR,4S,6R,7aS)-2-(isopropylimino)-1,6-dimethylhexahydro-1H-pyrano[4,3-d]oxazol-4-yloxy)-10-methoxy-3,5,8,10,12,14-hexamethyl-1-oxa-7-azacyclopentadecane-6,15-dione",1.0,uM,=,0.0,0,N=C1N[C@H]2CCO[C@@H](O[C@H]3CCCNC(=O)CCCCOC(=O)C[C@@H](O[C@H]4CCCCO4)C3)[C@@H]2O1
3503,2133950,10.1016/j.ejmech.2021.113715,,,,Inhibition of CYP3A4 in human liver microsome incubated for 10 mins in the presence of NADPH by LC-MS/MS analysis,Fc1ccc(C2(Cn3cncn3)COC(c3ccc(-c4cccc(F)c4)cc3)=N2)cc1,"4-((1H-1,2,4-triazol-1-yl)methyl)-2-(3'-fluoro-[1,1'-biphenyl]-4-yl)-4-(4-fluorophenyl)-4,5-dihydrooxazole",15.2,uM,=,1.1818435879447726,1,c1ccc(-c2ccc(C3=NC(Cn4cncn4)(c4ccccc4)CO3)cc2)cc1
3504,649576,10.1021/jm100317b,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsome,Oc1ccc(-c2ccc(Cc3ccncc3)cc2)cc1F,3-fluoro-4'-(pyridin-4-ylmethyl)biphenyl-4-ol,0.896,uM,=,-0.0476919903378747,0,c1ccc(-c2ccc(Cc3ccncc3)cc2)cc1
3505,52090,10.1016/j.bmcl.2003.11.049,,,,Inhibition of CYP450 (Cytochrome P450) 3A4 with fluorogenic substrate BFC,CCN1c2ncc(CSc3cc(C)nc(C)c3)cc2C(=O)Nc2c(C)cc(Cl)nc21,"7-Chloro-2-(2,6-dimethyl-pyridin-4-ylsulfanylmethyl)-5-ethyl-9-methyl-5,10-dihydro-4,5,6,10-tetraaza-dibenzo[a,d]cyclohepten-11-one",2.3,uM,=,0.3617278360175928,1,O=C1Nc2cccnc2Nc2ncc(CSc3ccncc3)cc21
3506,474877,10.1021/jm701097z,,,,Inhibition of CYP3A4,COc1cc2nccc(Oc3ccc4c(C(=O)Nc5cccnc5)cccc4c3)c2cc1OC,"6-(6,7-dimethoxyquinolin-4-yloxy)-N-(pyridin-3-yl)-1-naphthamide",2.0,uM,=,0.3010299956639812,1,O=C(Nc1cccnc1)c1cccc2cc(Oc3ccnc4ccccc34)ccc12
3507,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1cccc(C(=O)N2CCOC[C@H]2Cc2cc(Cl)cc(-n3nccn3)c2)c1-n1nccn1,"US9150566, 106",14.0,uM,=,1.146128035678238,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
3508,2272999,10.1039/d2md00352j,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam/testosterone as substrate by LC-MS/MS analysis,CC#CCOc1ccc2cc(C(O)(c3ccc(Br)cc3)c3cccnc3)oc2c1,(4-bromophenyl)(6-(but-2-yn-1-yloxy)benzofuran-2-yl)(pyridin-3-yl)methanol,3.38,uM,=,0.5289167002776547,1,c1ccc(C(c2cccnc2)c2cc3ccccc3o2)cc1
3509,546181,10.1016/j.bmcl.2009.03.165,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,CCNc1cc(C(=O)N[C@@H](Cc2ccccc2)[C@H](O)CNCc2cccc(C(F)(F)F)c2)c(F)c(N2CCCC2=O)c1,"5-(ethylamino)-2-fluoro-N-((2S,3R)-3-hydroxy-1-phenyl-4-(3-(trifluoromethyl)benzylamino)butan-2-yl)-3-(2-oxopyrrolidin-1-yl)benzamide",75.0,uM,=,1.8750612633917,1,O=C(N[C@H](CCNCc1ccccc1)Cc1ccccc1)c1cccc(N2CCCC2=O)c1
3510,1696937,10.1016/j.bmcl.2017.09.042,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate pretreated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis,Cc1ccc(NC(=O)c2cc(Oc3cncc(F)c3)cn3ccnc23)nc1,"6-(5-fluoropyridin-3-yloxy)-N-(5-methylpyridin-2-yl)imidazo[1,2-a]pyridine-8-carboxamide",1.9,uM,=,0.2787536009528289,1,O=C(Nc1ccccn1)c1cc(Oc2cccnc2)cn2ccnc12
3511,461436,10.1016/j.bmcl.2007.10.092,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,CC[C@@H]1CCC[C@H](C2(CC(N)=O)CC2)N1S(=O)(=O)c1ccc(Cl)cc1,"2-(1-((2R,6R)-1-(4-chlorophenylsulfonyl)-6-ethylpiperidin-2-yl)cyclopropyl)acetamide",11.5,uM,=,1.0606978403536118,1,O=S(=O)(c1ccccc1)N1CCCC[C@@H]1C1CC1
3512,856843,10.1021/jm300356u,,,,Inhibition of human recombinant CYP3A4 using DEF as substrate preincubated for 5 to 10 mins before substrate addition,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H]3[C@H]2O/C(=N\CCCN(C)C)N3C)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,"(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-((3aR,4S,6R,7aS)-2-(3-(dimethylamino)propylimino)-1,6-dimethylhexahydro-1H-pyrano[4,3-d]oxazol-4-yloxy)-14-ethyl-12,13-dihydroxy-4-((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yloxy)-7-methoxy-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione",0.7,uM,=,-0.1549019599857432,0,N=C1N[C@H]2CCO[C@@H](O[C@H]3CCCC(=O)CCCCOC(=O)C[C@@H](O[C@H]4CCCCO4)C3)[C@@H]2O1
3513,1465542,10.1016/j.bmcl.2015.01.051,,,,Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(CC6CN(CCOC)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O,"(1S,4R,5R,6R,8R,10S,11R,12S,13R,16R,18S,21R)-8-[(1S)-1-ethoxy-2-hydroxy-2-methylpropyl]-18-{[(2S)-4-{[1-(2-methoxyethyl)azetidin-3-yl]methyl}morpholin-2-yl]oxy}-4,6,12,17,17-pentamethyl-9-oxahexacyclo[11.9.0.0^{1,21}.0^{4,12}.0^{5,10}.0^{16,21}]docosan-11-ol",7.8,uM,=,0.8920946026904804,1,C1CO[C@@H]2CC3C(CC[C@@]45C[C@@]46CC[C@H](O[C@H]4CN(CC7CNC7)CCO4)C[C@@H]6CC[C@@H]35)[C@H]2C1
3514,1527876,,,,,Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,C[C@@H](c1ccc(-c2ccn(CCF)c(=O)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O,"US8575157, 25",33.0,uM,=,1.5185139398778875,1,O=C1OC(c2ccccc2)CCN1Cc1ccc(-c2cc[nH]c(=O)c2)cc1
3515,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",COc1ccc(C[C@@H]2COCCN2C(=O)c2ccccc2-n2nccn2)cc1-c1ncon1,"US9150566, 59",32.0,uM,=,1.505149978319906,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2ncon2)c1
3516,988989,10.1021/jm400732v,,,,Inhibition of CYP3A4 (unknown origin),CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2c(C)ccc3ccccc23)c2ccc(C#N)cc2N(C(C)=O)[C@H]1C.Cl,"(S)-N-((3S,4S)-5-Acetyl-7-cyano-4-methyl-1-((2-methylnaphthalen-1-yl)methyl)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b][1,4]-diazepin-3-yl)-2-(methylamino)propanamide Hydrochloride",16.0,uM,=,1.2041199826559248,1,O=C1CCNc2ccccc2N1Cc1cccc2ccccc12
3517,698985,10.1016/j.bmcl.2010.10.115,,,,Inhibition of CYP3A4,COc1cc2c(cc1Nc1ncc(Cl)c(Nc3ccc(N4CCOCC4)cc3OC)n1)CCN(CC(=O)N(C)C)CC2,"2-(7-(5-chloro-4-(2-methoxy-4-morpholinophenylamino)pyrimidin-2-ylamino)-8-methoxy-4,5-dihydro-1H-benzo[d]azepin-3(2H)-yl)-N,N-dimethylacetamide",2.0,uM,=,0.3010299956639812,1,c1cc(Nc2ccc(N3CCOCC3)cc2)nc(Nc2ccc3c(c2)CCNCC3)n1
3518,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NC5CCN(C(=O)c6ccc(N(C)C)cc6)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, F-66",6.15,uM,=,0.7888751157754168,1,O=C(NC1CCN(C(=O)c2ccccc2)CC1)c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12
3519,772033,10.1021/jm2006222,,,,Inhibition of CYP3A4 using DBF as substrate,COc1cc(OC)c(Cl)c(NC(=O)N(C)c2cc(Nc3cccc(CN(C)C)c3)ncn2)c1Cl,"3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-[6-(3-dimethylaminomethyl-phenylamino)-pyrimidin-4-yl]-1-methyl-urea",2.5,uM,=,0.3979400086720376,1,O=C(Nc1ccccc1)Nc1cc(Nc2ccccc2)ncn1
3520,603292,10.1016/j.bmcl.2009.10.136,,,,Inhibition of human liver CYP3A4,C[C@@H](NC(=O)c1ccc2c(c1)nc(-c1ccoc1)n2C1CCCCC1)C(=O)Nc1ccc(/C=C/C(=O)O)cc1,(R)-3-(4-(2-(1-cyclohexyl-2-(furan-3-yl)-1H-benzo[d]imidazole-5-carboxamido)propanamido)phenyl)acrylic acid,12.3,uM,=,1.089905111439398,1,O=C(CNC(=O)c1ccc2c(c1)nc(-c1ccoc1)n2C1CCCCC1)Nc1ccccc1
3521,649576,10.1021/jm100317b,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsome,Oc1cccc(-c2ccc(Cc3ccncc3)cc2)c1,4'-(pyridin-4-ylmethyl)biphenyl-3-ol,0.538,uM,=,-0.2692177243336108,0,c1ccc(-c2ccc(Cc3ccncc3)cc2)cc1
3522,555862,10.1016/j.bmcl.2008.04.047,,,,Inhibition of human CYP3A4,C#Cc1c(Oc2ccc(NC(=O)NC(=O)Cc3ccc(F)cc3)cc2F)ccnc1N,1-(4-(2-amino-3-ethynylpyridin-4-yloxy)-3-fluorophenyl)-3-(2-(4-fluorophenyl)acetyl)urea,0.8,uM,=,-0.0969100130080563,0,O=C(Cc1ccccc1)NC(=O)Nc1ccc(Oc2ccncc2)cc1
3523,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1ccc(C(=O)N2C[C@@H](C)OC[C@H]2Cc2cccc(-n3nccn3)c2)c(-n2nccn2)c1,"US9150566, 101",9.7,uM,=,0.9867717342662448,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
3524,851921,10.1016/j.bmcl.2012.08.072,,,,Inhibition of human recombinant CYP3A4,Cn1c(CC(=O)Nc2ccc(F)c(Cl)c2)nc(N2CCOCC2)cc1=O,"N-(3-chloro-4-fluorophenyl)-2-(1-methyl-4-morpholino-6-oxo-1,6-dihydropyrimidin-2-yl)acetamide",40.0,uM,=,1.6020599913279625,1,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccccc1
3525,535882,10.1016/j.bmcl.2008.08.010,,,,"Inhibition of human CYP3A4 by microtiter plate assays using N-N,diethyl-formamide as substrate",Cn1cc(S(=O)(=O)c2ccccc2)c2cc3c(cc21)CCNCC3,"1-methyl-3-(phenylsulfonyl)-1,5,6,7,8,9-hexahydroazepino[4,5-f]indole",7.8,uM,=,0.8920946026904804,1,O=S(=O)(c1ccccc1)c1c[nH]c2cc3c(cc12)CCNCC3
3526,423507,10.1021/jm060995h,,,,Inhibition of CYP3A4,CNc1nc2ccccc2n1Cc1sc2c(c1C(=O)N1C[C@H](O)CO1)c(=O)n(C)c(=O)n2CC(C)C,"5-{[(4S)-4-hydroxyisoxazolidin-2-yl]carbonyl}-1-isobutyl-3-methyl-6-{[2-(methylamino)-1H-benzimidazol-1-yl]methyl}thieno-[2,3-d]pyrimidine-2,4(1H,3 H)-dione",22.0,uM,=,1.3424226808222062,1,O=C(c1c(Cn2cnc3ccccc32)sc2[nH]c(=O)[nH]c(=O)c12)N1CCCO1
3527,814102,10.1016/j.bmcl.2012.03.014,,,,Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins,CO[C@]1(c2ccc(F)c(F)c2)CCNC[C@@H]1c1noc(-c2ccccc2CCNC(C)=O)c1Br,"N-(2-(4-bromo-3-((3R,4R)-4-(3,4-difluorophenyl)-4-methoxypiperidin-3-yl)isoxazol-5-yl)phenethyl)acetamide",28.0,uM,=,1.4471580313422192,1,c1ccc(-c2cc([C@H]3CNCCC3c3ccccc3)no2)cc1
3528,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(CCO)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, E-9",6.82,uM,=,0.8337843746564789,1,O=C(c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12)N1CCNCC1
3529,988989,10.1021/jm400732v,,,,Inhibition of CYP3A4 (unknown origin),CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2c(C)ccc3ccccc23)c2ccccc2N(C(=O)CS(C)(=O)=O)[C@H]1C.Cl,"(S)-N-((2S,3S)-2-Methyl-5-((2-methylnaphthalen-1-yl)methyl)-1-(2-(methylsulfonyl)acetyl)-4-oxo-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-yl)-2-(methylamino)propanamide hydrochloride",32.0,uM,=,1.505149978319906,1,O=C1CCNc2ccccc2N1Cc1cccc2ccccc12
3530,2103815,10.1016/j.bmcl.2021.128010,,,,Time dependent inhibition of CYP3A4 (unknown origin) measured at 30 mins,Nc1cc(Cc2ccn(Cc3ccccc3)n2)c2nn[nH]c2n1,"7-((1-benzyl-1H-pyrazol-3-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-amine",0.31,uM,=,-0.5086383061657274,0,c1ccc(Cn2ccc(Cc3ccnc4[nH]nnc34)n2)cc1
3531,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCC6CN(C)CC65)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, E-69",4.49,uM,=,0.6522463410033232,1,O=C1[C@H](Cc2ccccc2)N2C(=O)CNN(C(=O)NCc3ccccc3)[C@H]2CN1Cc1cccc2c(C(=O)N3CCC4CNCC43)c[nH]c12
3532,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1cc(C(=O)N2C[C@@H](C)OC[C@H]2Cc2cccc(-n3nccn3)c2)c(-n2nccn2)cc1C,"US9150566, 98",9.7,uM,=,0.9867717342662448,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
3533,1696937,10.1016/j.bmcl.2017.09.042,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate pretreated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis,O=C(Nc1cccc(F)n1)c1cc(Oc2cncc(F)c2)cn2ccnc12,"N-(6-fluoropyridin-2-yl)-6-(5-fluoropyridin-3-yloxy)imidazo[1,2-a]pyridine-8-carboxamide",2.3,uM,=,0.3617278360175928,1,O=C(Nc1ccccn1)c1cc(Oc2cccnc2)cn2ccnc12
3534,774749,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O,"(S)-1-[(2S,4R)-2-Hydroxy-4-((1S,2R)-2-hydroxy-indan-1-ylcarbamoyl)-5-phenyl-pentyl]-4-pyridin-3-ylmethyl-piperazine-2-carboxylic acid tert-butylamide",0.4,uM,=,-0.3979400086720376,0,O=C(N[C@@H]1CCc2ccccc21)[C@@H](CCCN1CCN(Cc2cccnc2)CC1)Cc1ccccc1
3535,1301328,10.6019/CHEMBL3137440,,,,DNDI: CYP Inhibition,FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ccccc3)CC2)cc1,,11.0,uM,=,1.0413926851582251,1,c1ccc(N2CCC(N(c3ccccc3)c3cccnc3)CC2)cc1
3536,1335568,10.1021/jm401731q,,,,Inhibition of CYP3A4 (unknown origin),CCN1CCN(c2cc(N3CC[C@H]3C(=O)NCCc3ccc(C#N)nc3)nc(C(F)(F)F)n2)CC1,(2S)-N-[2-(6-Cyanopyridin-3-yl)ethyl]-1-[6-(4-ethylpiperazin-1-yl)-2-(trifluoromethyl)pyrimidin-4-yl]azetidine-2-carboxamide,7.8,uM,=,0.8920946026904804,1,O=C(NCCc1cccnc1)[C@@H]1CCN1c1cc(N2CCNCC2)ncn1
3537,1695601,10.1016/j.bmc.2017.08.012,,,,Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using 7-Benzoyloxy-4-trifluoromethyl coumarin substrate in presence of NADP+ by fluorescence based assay,O=S(=O)(Nc1nccs1)c1cc(Cl)c(NC[C@H]2CCCO[C@@H]2c2ccccc2)cc1F,"5-Chloro-2-fluoro-4-((((2SR,3RS)-2-phenyltetrahydro-2H-pyran-3-yl)methyl)amino)-N-(thiazol-2-yl)benzenesulfonamide",3.6,uM,=,0.5563025007672873,1,O=S(=O)(Nc1nccs1)c1ccc(NC[C@H]2CCCO[C@@H]2c2ccccc2)cc1
3538,742805,10.1016/j.bmc.2011.02.009,,,,Inhibition of human CYP3A4 after 30 mins,CC(C)C(O)(c1ccc(-c2ccccc2)cc1)c1c[nH]cn1,"rac-1-[1,1'-Biphenyl]-4-yl-1-(1H-imidazol-4-yl)-2-methyl-1-propanol",3.7,uM,=,0.568201724066995,1,c1ccc(-c2ccc(Cc3c[nH]cn3)cc2)cc1
3539,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cccc(-c3ncon3)c2)c1,"US9150566, 2",43.0,uM,=,1.6334684555795866,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2ncon2)c1
3540,1692884,10.1021/acs.jmedchem.7b00376,,,,Inhibition of CYP3A4 in human liver microsomes,CCOC(=O)/C=C/c1cc(O)c(O)cc1-c1cc2ccccc2o1,"(E)-Ethyl 3-(2-(benzofuran-2-yl)-4,5-dihydroxyphenyl)acrylate",11.2,uM,=,1.0492180226701815,1,c1ccc(-c2cc3ccccc3o2)cc1
3541,2221809,10.1016/j.bmcl.2022.128625,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as substrate in presence of NADPH,CCC[C@H]1N(C(=O)c2c(C(F)(F)F)ccnc2O)CCC[C@@]1(Oc1csc(C(F)(F)F)c1)C(=O)N1CCN(c2ccccc2OCCO)CC1,"((2R,3S)-1-(2-hydroxy-4-(trifluoromethyl)nicotinoyl)-2-propyl-3-(5-(trifluoromethyl)thiophen-3-yloxy)piperidin-3-yl)(4-(2-(2-hydroxyethoxy)phenyl)piperazin-1-yl)methanone",30.0,uM,=,1.4771212547196624,1,O=C(c1cccnc1)N1CCC[C@@](Oc2ccsc2)(C(=O)N2CCN(c3ccccc3)CC2)C1
3542,1641039,,,,,"Inhibition Assay: Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 uM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 Î¼M. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:CH3CN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO: CH3CN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v. Pooled human liver microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 5 mg/mL suspension.",OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(/C=C/COCC(F)(F)F)cn1,"US9221791, 6",81.0,uM,=,1.9084850188786493,1,c1ccc(C(Cc2ccccn2)Cn2cnnn2)cc1
3543,1467194,10.1021/jm5005336,,,,Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay,COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5CCCCC5)cc4)n[nH]c3c1)C(=O)N2,"(1R,2S)-(E)-5'-Methoxy-2-(3-(4-(piperidin-1-ylmethyl)styryl)-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-one",5.4,uM,=,0.7323937598229685,1,O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccc(CN4CCCCC4)cc3)n[nH]c2c1
3544,716789,10.1016/j.bmcl.2010.12.123,,,,Inhibition of CYP3A4,O=C(O)c1ccc(NC(=O)[C@H](C2CCCCC2)n2c(-c3ccc(Cl)cc3)nc3cc(F)c(F)cc32)cc1,"(S)-4-(2-(2-(4-chlorophenyl)-5,6-difluoro-1H-benzo[d]imidazol-1-yl)-2-cyclohexylacetamido)benzoic acid",37.0,uM,=,1.568201724066995,1,O=C(Nc1ccccc1)[C@H](C1CCCCC1)n1c(-c2ccccc2)nc2ccccc21
3545,1919651,,,,,"Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase",Fc1ccc(-c2ccsc2)cn1,2-Fluoro-5-thiophen-3-yl-pyridine,114.0,uM,=,2.0569048513364727,1,c1cncc(-c2ccsc2)c1
3546,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1cccc(C(=O)N2C[C@@H](C)OC[C@H]2Cc2cc(-c3ncccn3)ccc2F)c1-n1nccn1,"US9150566, 150",32.0,uM,=,1.505149978319906,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2ncccn2)c1
3547,2048449,10.1016/j.bmc.2020.115734,,,,Inhibition of recombinant CYP3A4 (unknown origin) by fluorescence-based assay,COc1nc(-c2csc(Nc3c4c(nn3CC(F)(F)F)CCC4)n2)ccc1-n1cnc(C)c1,"4-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)-N-(2-(2,2,2-trifluoroethyl)-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)thiazol-2-amine",1.4,uM,=,0.1461280356782379,1,c1cn(-c2ccc(-c3csc(Nc4[nH]nc5c4CCC5)n3)nc2)cn1
3548,1984166,10.1016/j.bmc.2020.115349,,,,Inhibition of human full length CYP3A4 assessed using 7-benzyloxy-4 (trifluoromethyl)coumarin as substrate preincubated for 2 mins followed by substrate addition and measured for 2 mins by fluorometric analysis,CC(C)(C)OC(=O)NC(CSCC(Nc1ccccc1)C(=O)NCc1cccnc1)Cc1cccc2ccccc12,Rac-tert-butyl N-[1-[[2-anilino-3-oxo-3-(3-pyridylmethylamino)propyl]sulfanylmethyl]-2-(1-naphthyl)ethyl]carbamate,0.055,uM,=,-1.259637310505756,0,O=C(NCc1cccnc1)C(CSCCCc1cccc2ccccc12)Nc1ccccc1
3549,355280,10.1016/j.bmcl.2006.02.020,,,,Inhibition of CYP3A4,CCN(C)[C@H](C)[C@@H](c1ccc2cc(OCC3(C(=O)O)CCCC3)ccc2c1)n1ccnc1,"1-((6-((1R,2R)-2-(ethyl(methyl)amino)-1-(1H-imidazol-1-yl)propyl)naphthalen-2-yloxy)methyl)cyclopentanecarboxylic acid",2.3,uM,=,0.3617278360175928,1,c1cn(Cc2ccc3cc(OCC4CCCC4)ccc3c2)cn1
3550,536049,10.1016/j.bmcl.2008.08.010,,,,Inhibition of human CYP3A4 by microtiter plate assays using PPR substrate,O=S(=O)(c1cccc(Cl)c1)n1cc(Cl)c2cc3c(cc21)CCNCC3,"3-chloro-1-(3-chlorophenylsulfonyl)-1,5,6,7,8,9-hexahydroazepino[4,5-f]indole",20.0,uM,=,1.3010299956639813,1,O=S(=O)(c1ccccc1)n1ccc2cc3c(cc21)CCNCC3
3551,1677534,10.1021/acs.jmedchem.7b01300,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate upto 10 uM after 5 mins in presence of NADPH by LC-MS/MS analysis,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,"1-(4-{4-[2-(2,4-Dichloro-phenyl)-2-imidazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-ethanone (ketoconazole)",80.0,uM,=,1.9030899869919435,1,c1ccc(C2(Cn3ccnc3)OCC(COc3ccc(N4CCNCC4)cc3)O2)cc1
3552,993439,10.6019/CHEMBL2448688,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,CCN(Cc1cccnc1)c1ccc(-c2ccc(F)cc2)cc1F,,1.0,uM,=,0.0,0,c1ccc(-c2ccc(NCc3cccnc3)cc2)cc1
3553,1283600,10.1021/jm401610c,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone,O=C(C(c1ccc(Cl)cc1)c1cccnc1)N1CCN(c2ccc(C(F)(F)F)cn2)CC1,2-(4-Chlorophenyl)-2-(pyridin-3-yl)-1-[4-[5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl]ethanone,7.0,uM,=,0.8450980400142568,1,O=C(C(c1ccccc1)c1cccnc1)N1CCN(c2ccccn2)CC1
3554,2068401,10.1016/j.bmcl.2020.127676,,,,Inhibition of CYP3A4 (unknown origin),CN[C@@H](C)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)Nc1cc2c(N[C@H]3CC[C@H](Nc4ncnc5cc(OC)c(NC(=O)[C@@H]6CCCN6C(=O)[C@@H](NC(=O)[C@H](C)NC)C(C)(C)C)cc45)CC3)ncnc2cc1OC)C(C)(C)C,"(S,S,2S,2'S)-N,N'-(4,4'-(1r,4r)-cyclohexane-1,4-diylbis(azanediyl)bis(7-methoxyquinazoline-6,4-diyl))bis(1-((S)-3,3-dimethyl-2-((S)-2-(methylamino)propanamido)butanoyl)pyrrolidine-2-carboxamide)",3.56,uM,=,0.5514499979728752,1,O=C(Nc1ccc2ncnc(N[C@H]3CC[C@H](Nc4ncnc5ccc(NC(=O)[C@@H]6CCCN6)cc45)CC3)c2c1)[C@@H]1CCCN1
3555,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCC(N7CCCCC7)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1,"US8940739, G-55",2.37,uM,=,0.3747483460101038,1,O=C(Nc1ccc(N2CCC(N3CCCCC3)CC2)nc1)c1c[nH]c2c(CN3CC4N(C(=O)NCc5ccccc5)NCC(=O)N4C(Cc4ccccc4)C3=O)cccc12
3556,619264,10.1016/j.bmcl.2009.07.002,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,Cc1cccc(C)c1CNc1ncnc2c(C)c(C)[nH]c12,"N-(2,6-dimethylbenzyl)-6,7-dimethyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine",8.8,uM,=,0.9444826721501688,1,c1ccc(CNc2ncnc3cc[nH]c23)cc1
3557,1629496,10.1016/j.bmcl.2016.12.003,,,,Inhibition of hepatic CYP3A4 (unknown origin),Fc1ccc2nc(-c3cncc4ccccc34)c(C3CC3)n2c1,"4-(3-cyclopropyl-6-fluoroimidazo[1,2-a]pyridin-2-yl)isoquinoline",3.5,uM,=,0.5440680443502757,1,c1ccc2c(-c3nc4ccccn4c3C3CC3)cncc2c1
3558,719028,10.1021/ml100249e,,,,Inhibition of CYP3A4 in human liver microsomes,O=C(Nc1cnc(-c2ccncc2)c(-c2ccncc2)n1)C1CC1,"N-(5,6-Dipyridin-4-ylpyrazin-2-yl)cyclopropanecarboxamide",1.0,uM,=,0.0,0,O=C(Nc1cnc(-c2ccncc2)c(-c2ccncc2)n1)C1CC1
3559,52065,10.1021/jm0310129,,,,Inhibitory activity against cytochrome P450 3A4,Cn1c2ccnc(Cl)c2c2ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21,"9-Chloro-4-{4-[2-(3,4-difluoro-phenyl)-ethyl]-piperazin-1-yl}-5-methyl-5H-pyrido[3',4':4,5]pyrrolo[3,2-d]pyrimidine",9.44,uM,=,0.974971994298069,1,c1ccc(CCN2CCN(c3ncnc4c3[nH]c3ccncc34)CC2)cc1
3560,1586691,10.1039/C6MD00128A,,,,Inhibition of CYP3A4 in human liver microsomes assessed as reduction in midazolam 1-hydroxylation/testosterone 6beta-hydroxylation by LC-MS/MS analysis,Cc1sc2ccccc2c1[C@@H]1C=CN=CN1,"(S)-6-(2-methylbenzo[b]thiophen-3-yl)-1,6-dihydropyrimidine",11.0,uM,=,1.0413926851582251,1,C1=C[C@@H](c2csc3ccccc23)NC=N1
3561,103774,10.1021/jm031011g,,,,Inhibitory concentration to inhibit MRP1 in CYP 3A4 assay,O=C(Nc1cccnc1)c1c2n(c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)ncnc13)CCCC2,"4-{4-[2-(3,4-Difluoro-phenyl)-ethyl]-piperazin-1-yl}-6,7,8,9-tetrahydro-pyrimido[4,5-b]indolizine-10-carboxylic acid pyridin-3-ylamide",9.73,uM,=,0.988112840268352,1,O=C(Nc1cccnc1)c1c2n(c3c(N4CCN(CCc5ccccc5)CC4)ncnc13)CCCC2
3562,51916,10.1016/j.bmcl.2003.11.005,,,,Inhibition of cytochrome P450 3A4,c1ccc(COc2ccc(-n3ccnc3)cc2)nc1,2-(4-Imidazol-1-yl-phenoxymethyl)-pyridine,0.63,uM,=,-0.2006594505464183,0,c1ccc(COc2ccc(-n3ccnc3)cc2)nc1
3563,2104174,10.1021/acs.jmedchem.1c00173,,,,Inhibition of CYP3A4 (unknown origin) by UPLC-MS analysis,Cc1c(Cc2ccc(C(F)(F)F)nc2)c[nH]c1C(=O)NC(C)c1cnn(C)c1,rac-3-Methyl-N-(1-(1-methyl-1H-pyrazol-4-yl)ethyl)-4-((6-(trifluoromethyl)pyridin-3-yl)methyl)-1H-pyrrole-2-carboxamide,8.5,uM,=,0.9294189257142929,1,O=C(NCc1cn[nH]c1)c1cc(Cc2cccnc2)c[nH]1
3564,768817,10.1021/jm2005354,,,,Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting,CNC(=O)NCC[C@]1(c2ccc(F)cc2)CCN([C@@H](C)c2ccc(-c3ccc(F)cc3F)cc2)C(=O)O1,"1-(2-((R)-3-((S)-1-(2',4'-difluorobiphenyl-4-yl)ethyl)-6-(4-fluorophenyl)-2-oxo-1,3-oxazinan-6-yl)ethyl)-3-methylurea",1.0,uM,=,0.0,0,O=C1OC(c2ccccc2)CCN1Cc1ccc(-c2ccccc2)cc1
3565,1972830,10.1021/acsmedchemlett.9b00612,,,,Inhibition of human recombinant CYP3A4 expressed in insect cell microsomes in presence of NADPH by fluorescence assay,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12,"3-[2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide",11.4,uM,=,1.0569048513364727,1,O=C(Nc1ccc(CN2CCNCC2)cc1)c1cccc(C#Cc2cnc3cccnn23)c1
3566,1301324,10.6019/CHEMBL3137440,,,,DNDI: CYP Inhibition,CS(=O)(=O)N1CCC(N(c2ccc(Cl)cc2)c2cccnc2)CC1,,2.6,uM,=,0.414973347970818,1,c1ccc(N(c2cccnc2)C2CCNCC2)cc1
3567,1335568,10.1021/jm401731q,,,,Inhibition of CYP3A4 (unknown origin),N#Cc1ccc(CCNC(=O)[C@@H]2CCCN(c3cc(N4CCN(C5COC5)CC4)nc(C(F)(F)F)n3)C2)cc1,(R)-N-(4-Cyanophenethyl)-1-(6-(4-(oxetan-3-yl)piperazin-1-yl)-2-(trifluoromethyl)pyrimidin-4-yl)piperidine-3-carboxamide,1.1,uM,=,0.041392685158225,1,O=C(NCCc1ccccc1)[C@@H]1CCCN(c2cc(N3CCN(C4COC4)CC3)ncn2)C1
3568,349088,10.1016/j.bmcl.2006.01.084,,,,Inhibition of CYP3A4 using BFC fluorogenic substrate,COc1ccccc1COCCCOc1ccc(N2C(=O)CNC[C@@H]2COc2ccc3c(c2)N(CCOC(=O)C(C)C)CCC3)cc1,"(R)-2-(7-((1-(4-(3-(2-methoxybenzyloxy)propoxy)phenyl)-6-oxopiperazin-2-yl)methoxy)-3,4-dihydroquinolin-1(2H)-yl)ethyl isobutyrate",0.054,uM,=,-1.2676062401770316,0,O=C1CNC[C@H](COc2ccc3c(c2)NCCC3)N1c1ccc(OCCCOCc2ccccc2)cc1
3569,1797910,10.1021/acs.jmedchem.8b01326,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate/NADPH addition measured after 10 mins by LC-MS/MS analysis,CN1C(=N)N[C@@]2(c3cc(-c4ccc(Cl)c(C#N)c4)cs3)CN(c3ncc(F)cn3)C[C@H]2C1=O,"2-Chloro-5-(5-((4aR,7aR)-6-(5-fluoropyrimidin-2-yl)-2-imino-3-methyl-4-oxooctahydro-7aH-pyrrolo[3,4-d]pyrimidin-7a-yl)-thiophen-3-yl)benzonitrile",5.5,uM,=,0.7403626894942439,1,N=C1NC(=O)[C@@H]2CN(c3ncccn3)C[C@]2(c2cc(-c3ccccc3)cs2)N1
3570,559939,10.1016/j.bmcl.2008.10.072,,,,Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate,C[C@@H]1CN(Cc2ccc(-c3cccnc3C(=O)N3CCC(Cc4ccc(F)cc4)CC3)cc2)C[C@H](C)N1,"{3-[4-((3R,5S)-3,5-Dimethyl-piperazin-1-ylmethyl)-phenyl]-pyridin-2-yl}-[4-(4-fluoro-benzyl)-piperidin-1-yl]-methanone",5.6,uM,=,0.7481880270062004,1,O=C(c1ncccc1-c1ccc(CN2CCNCC2)cc1)N1CCC(Cc2ccccc2)CC1
3571,1493641,10.1124/dmd.112.048918,,,,Metabolism-dependent inhibition of CYP3A4 in human liver microsomes using nifedipine as substrate preincubated for 20 mins with NADPH prior to initiation of reaction with probe substrate by HPLC analysis,C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12,DOLUTEGRAVIR,65.0,uM,=,1.812913356642856,1,O=C(NCc1ccccc1)c1cn2c(cc1=O)C(=O)N1CCCO[C@H]1C2
3572,1301328,10.6019/CHEMBL3137440,,,,DNDI: CYP Inhibition,Cc1cncc(N2CCC(N(c3ccc(C(F)(F)F)cc3)c3cccnc3)CC2)c1,,0.6,uM,=,-0.2218487496163563,0,c1ccc(N(c2cccnc2)C2CCN(c3cccnc3)CC2)cc1
3573,583357,10.1021/jm900945d,,,,Inhibition of CYP3A4,CC(C)(C)Sc1c(CC(C)(C)C(=O)O)n(Cc2ccc(Cl)cc2)c2ccc(OCc3ccc4ccccc4n3)cc12,"3-[3-tert-Butylsulfanyl-1-(4-chloro-benzyl)-5-(quinolin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid",0.0058,uM,=,-2.2365720064370627,0,c1ccc(Cn2ccc3cc(OCc4ccc5ccccc5n4)ccc32)cc1
3574,457745,10.1016/j.bmcl.2007.07.063,,,,Inhibition of CYP3A4,O=C(C1CCN(c2ccncc2)CC1)N1CC[C@@H](CNS(=O)(=O)/C=C/c2ccc(-c3ccc(Cl)s3)s2)C1,(E)-2-(5-(5-chlorothiophen-2-yl)thiophen-2-yl)-N-(((R)-1-(1-(pyridin-4-yl)piperidine-4-carbonyl)pyrrolidin-3-yl)methyl)ethenesulfonamide,1.0,uM,=,0.0,0,O=C(C1CCN(c2ccncc2)CC1)N1CC[C@@H](CNS(=O)(=O)/C=C/c2ccc(-c3cccs3)s2)C1
3575,1446329,10.1021/ml500387y,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,COc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2cc(C)nc(C)c2[nH]1)C(F)(F)F,"2-((5,7-dimethyl-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)-1,1,1-trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methylpentan-2-ol",0.2,uM,=,-0.6989700043360187,0,c1ccc(CCCCc2cc3ccncc3[nH]2)cc1
3576,2219884,10.1016/j.bmcl.2021.128479,,,,Inhibition of CYP3A4 in human liver microsomes using cocktail of isoform-specific probe substrate,Fc1ccc(F)c(-c2ccc(NC[C@@H]3CC34CCN(CC3CCOCC3)CC4)nn2)c1,"(R)-6-(2,5-difluorophenyl)-N-((6-((tetrahydro-2H-pyran-4-yl)methyl)-6-azaspiro[2.5]octan-1-yl)methyl)pyridazin-3-amine",17.0,uM,=,1.230448921378274,1,c1ccc(-c2ccc(NC[C@@H]3CC34CCN(CC3CCOCC3)CC4)nn2)cc1
3577,834635,10.1016/j.bmcl.2012.07.019,,,,Inhibition of CYP3A4,N[C@@H](CC(=O)N1CCN(C(=O)c2ccccc2)CC1)Cc1cc(F)c(F)cc1F,"(R)-3-amino-1-(4-benzoylpiperazin-1-yl)-4-(2,4,5-trifluorophenyl)butan-1-one",1.0,uM,=,0.0,0,O=C(CCCc1ccccc1)N1CCN(C(=O)c2ccccc2)CC1
3578,860625,10.1016/j.bmcl.2012.08.102,,,,Inhibition of CYP3A4,Cc1cc(-c2cc(=O)[nH]c(NCc3cccc4ccccc34)n2)ccn1,6-(2-methylpyridin-4-yl)-2-(naphthalen-1-ylmethylamino)pyrimidin-4(3H)-one,0.7,uM,=,-0.1549019599857432,0,O=c1cc(-c2ccncc2)nc(NCc2cccc3ccccc23)[nH]1
3579,676065,10.1016/j.bmcl.2010.09.028,,,,Inhibition of CYP3A4 after 30 mins,CC(C)[C@@H]1COC[C@H](C2(OC(=O)N3CC4CNCC4C3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1,"1-((3R,5R)-4-(4-chlorophenylsulfonyl)-5-isopropylmorpholin-3-yl)cyclopropyl hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate",0.0064,uM,=,-2.193820026016113,0,O=C(OC1([C@H]2COCCN2S(=O)(=O)c2ccccc2)CC1)N1CC2CNCC2C1
3580,51909,10.1021/jm010531d,,,,Inhibition of human Cytochrome P450 3A4 by macrocycles,N#Cc1ccc2cc1Oc1ccc(Br)c(c1)CN1CCC(NCc3cncn3C2)C1=O,"R-24-bromo-27-oxo-20-oxa-3,7,11,13-tetraazapentacyclo[19.3.1.13,6.115,19.09,13]heptacosa-1(24),9,11,15(26),16,18,21(25),22-octaen-18-yl cyanide",6.1,uM,=,0.785329835010767,1,O=C1C2CCN1Cc1cccc(c1)Oc1cccc(c1)Cn1cncc1CN2
3581,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",C[C@@H]1CN(C(=O)c2ccc(Cl)cc2-n2nccn2)[C@H](Cc2cccc(-c3ncccn3)c2)CO1,"US9150566, 114",35.0,uM,=,1.5440680443502757,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2ncccn2)c1
3582,2075218,10.1021/acsmedchemlett.9b00395,,,,Inhibition of human liver microsome CYP3A4 using midazolam as substrate preincubated for 10 mins followed by substrate and NADPH addition and measured after 10 mins by LC-MS/MS analysis,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)n[nH]c(=O)c32)C1,"(R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one",37.3,uM,=,1.5717088318086876,1,O=c1[nH]ncc2c(-c3ccc(Oc4ccccc4)cc3)nn([C@@H]3CCCNC3)c12
3583,1849385,10.1016/j.bmcl.2019.06.044,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis,O=C(O)c1ccc(-n2cc(C(=O)c3c(Cl)cccc3Cl)c3c(F)cccc32)c(F)c1,"4-(3-(2,6-dichlorobenzoyl)-4-fluoro-1H-indol-1-yl)-3-fluorobenzoic acid",8.34,uM,=,0.9211660506377388,1,O=C(c1ccccc1)c1cn(-c2ccccc2)c2ccccc12
3584,552281,10.1016/j.bmcl.2008.04.036,,,,Inhibition of CYP3A4,N[C@@H](Cn1c(=O)c(-c2ccc(COC(=O)C3CC3)cc2)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1,"(R)-4-(1-(2-fluoro-6-(trifluoromethyl)benzyl)-3-(2-amino-2-phenylethyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)benzyl cyclopropanecarboxylate",0.048,uM,=,-1.3187587626244128,0,O=C(OCc1ccc(-c2cn(Cc3ccccc3)c(=O)n(CCc3ccccc3)c2=O)cc1)C1CC1
3585,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N(C)CCN5CCN(C)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, F-28",7.8,uM,=,0.8920946026904804,1,O=C(NCCN1CCNCC1)c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12
3586,434712,10.1021/jm070104l,,,,Inhibition of human CYP3A4,N#Cc1ccccc1Cn1c(N2CCC[C@@H](N)C2)nc2cc(Cl)ccc2c1=O,(R)-2-((2-(3-aminopiperidin-1-yl)-7-chloro-4-oxoquinazolin-3(4H)-yl)methyl)benzonitrile,0.25,uM,=,-0.6020599913279624,0,O=c1c2ccccc2nc(N2CCCCC2)n1Cc1ccccc1
3587,1618210,10.1021/acs.jmedchem.5b01985,,,,Inhibition of CYP3A4 (unknown origin),C=CC(=O)N1CCCC[C@@H](n2c(NC(=O)c3cccc(C(F)(F)F)c3)nc3cccc(C)c32)C1,(R)-N-(1-(1-Acryloylazepan-3-yl)-7-methyl-1H-benzo[d]-imidazol-2-yl)-3-(trifluoromethyl)benzamide,3.5,uM,=,0.5440680443502757,1,O=C(Nc1nc2ccccc2n1[C@@H]1CCCCNC1)c1ccccc1
3588,804824,10.1016/j.bmcl.2011.12.080,,,,Reversible inhibition of CYP3A4,Cc1ncc(C(O)c2c3cc(Cl)cc(C)c3nc3[nH]nc(C)c23)cn1,"rac-(6-chloro-3,8-dimethyl-1H-pyrazolo[3,4-b]quinolin-4-yl)(2-methylpyrimidin-5-yl)methanol",7.9,uM,=,0.8976270912904415,1,c1ccc2c(Cc3cncnc3)c3cn[nH]c3nc2c1
3589,1436762,10.1021/ml500187a,,,,Inhibition of human recombinant CYP3A4 incubated for 5 mins by fluorescence assay,Clc1cccc(N(Cc2ccc3ccccc3c2)C2CNC2)c1,N-(3-chlorophenyl)-N-(naphthalen-2-ylmethyl)azetidin-3-amine,0.5,uM,=,-0.3010299956639812,0,c1ccc(N(Cc2ccc3ccccc3c2)C2CNC2)cc1
3590,851675,10.1016/j.bmcl.2012.08.044,,,,Inhibition of CYP3A4,CC1CCCCC1C(=O)N1CC(c2nc(-c3cccc(F)c3)no2)C1,"(3-(3-(3-fluorophenyl)-1,2,4-oxadiazol-5-yl)azetidin-1-yl)(2-methylcyclohexyl)methanone",25000.0,uM,=,4.3979400086720375,1,O=C(C1CCCCC1)N1CC(c2nc(-c3ccccc3)no2)C1
3591,1276541,10.1016/j.bmcl.2013.09.041,,,,Inhibition of CYP3A4 (unknown origin) after 5 mins,COc1cc(-c2ccnc(C)c2)ccc1NS(=O)(=O)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,"N-(2-methoxy-4-(2-methylpyridin-4-yl)phenyl)-3,5-bis(trifluoromethyl)benzenesulfonamide",2.2,uM,=,0.3424226808222063,1,O=S(=O)(Nc1ccc(-c2ccncc2)cc1)c1ccccc1
3592,2164346,10.1021/acs.jmedchem.1c02192,,,,Inhibition of CYP3A4 (unknown origin),COCC(=O)N1CC[C@H](n2c(C)nc3cnc4cc(F)c(-c5ccc(Oc6ncccn6)cc5Cl)cc4c32)[C@@H](F)C1,"US9227969, 52",5.0,uM,=,0.6989700043360189,1,c1cnc(Oc2ccc(-c3ccc4ncc5ncn(C6CCNCC6)c5c4c3)cc2)nc1
3593,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NN5CCN(C6CCCC6)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, F-59",2.39,uM,=,0.3783979009481377,1,O=C(NN1CCN(C2CCCC2)CC1)c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12
3594,617698,10.1016/j.bmcl.2010.01.087,,,,Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay,Cc1cc(N2CCC3(CC2)OCCO3)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,"4-[(S)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-[6-(1,4-dioxa-8-aza-spiro[4.5]dec-8-yl)-4-methyl-1H-benzoimidazol-2-yl]-1H-pyridin-2-one",0.7,uM,=,-0.1549019599857432,0,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(N3CCC4(CC3)OCCO4)cc2[nH]1
3595,1854052,10.1016/j.ejmech.2019.07.003,,,,Inhibition of recombinant human CYP3A4 using Luciferin-PPXE as substrate preincubated for 10 mins followed by NADPH addition measured after 15 mins by luminometric method,CCN(CC)c1ccc2cc(C(=O)NCC(O)(Cn3ccnc3)c3ccc(Cl)cc3Cl)c(=O)oc2c1,"rac-N-(2-(2,4-dichlorophenyl)-2-hydroxy-3-(1H-imidazol-1-yl)propyl)-7-(diethylamino)-2-oxo-2H-chromene-3-carboxamide",0.1272,uM,=,-0.8955128886876049,0,O=C(NCC(Cn1ccnc1)c1ccccc1)c1cc2ccccc2oc1=O
3596,2246941,10.1021/acs.jmedchem.1c02132,,,,Inhibition of CYP3A4 (unknown origin) incubated for 10 mins in presence of NADPH by LC-MS/MS analysis,COC(=O)Nc1cc(-c2ccc(OC[C@@H](N)CC(C)C)c(F)c2)ccn1,(S)-methyl (4-(4-((2-amino-4-methylpentyl)oxy)-3-fluorophenyl)pyridin-2-yl)carbamate,2.1,uM,=,0.3222192947339193,1,c1ccc(-c2ccncc2)cc1
3597,802673,10.1016/j.bmcl.2011.12.125,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,O=C(Nc1ccc(-c2cccnc2)cc1)Nc1ccc(-c2ccnc3[nH]cnc23)cc1,"1-(4-(3H-imidazo[4,5-b]pyridin-7-yl)phenyl)-3-(4-(pyridin-3-yl)phenyl)urea",0.22,uM,=,-0.6575773191777937,0,O=C(Nc1ccc(-c2cccnc2)cc1)Nc1ccc(-c2ccnc3[nH]cnc23)cc1
3598,2060129,10.1021/acsmedchemlett.1c00112,,,,Inhibition of CYP3A4 (unknown origin),CC(C)(O)CC(=O)N[C@@H]1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)nc3CC[C@@H]12,"N-((6aS,7R,9aS)-9a-((4-Fluorophenyl)sulfonyl)-3-(perfluoropropan-2-yl)-6,6a,7,8,9,9a-hexahydro-5H-cyclopenta[f]quinolin-7-yl)-3-hydroxy-3-methylbutanamide",9.1,uM,=,0.9590413923210936,1,O=S(=O)(c1ccccc1)[C@@]12CCC[C@@H]1CCc1ncccc12
3599,1485703,10.1124/dmd.112.048264,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method,COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C,"Methoxy-acetic acid (1S,2S)-2-(2-{[3-(1H-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)-6-fluoro-1-isopropyl-1,2,3,4-tetrahydro-naphthalen-2-yl ester",0.47,uM,=,-0.3279021420642826,0,c1ccc2c(c1)CCC(CCNCCCc1nc3ccccc3[nH]1)C2
3600,1828801,10.1021/acs.jmedchem.8b01098,,,,Inhibition of C-terminal 4His-tagged CYP3A4 (unknown origin) expressed in Escherichia coli by spectrophotometric analysis,COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccncn3)cc2)c1,(R)-N-(1-(3-Methoxyphenyl)ethyl)-4-(pyrimidin-4-yl)-benzamide,19.6,uM,=,1.292256071356476,1,O=C(NCc1ccccc1)c1ccc(-c2ccncn2)cc1
3601,874112,10.1021/jm300118s,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis,COCC(=O)N[C@@H](Cc1cccc(-c2nccn2C)c1)[C@H](O)CN[C@H]1CC2(CCC2)Oc2ncc(CC(C)(C)C)cc21,"N-((2S,3R)-3-Hydroxy-1-(3-(1-methyl-1H-imidazol-2-yl)-phenyl)-4-((S)-6'-neopentyl-3',4'-dihydrospiro[cyclobutane-1,2'-pyrano[2,3-b]pyridine]-4'-ylamino)butan-2-yl)-2-methoxyacetamide",0.05,uM,=,-1.3010299956639813,0,c1cc(CCCCN[C@H]2CC3(CCC3)Oc3ncccc32)cc(-c2ncc[nH]2)c1
3602,1534761,,,,,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",COc1ncc(F)cc1CNc1ccc(Cc2c[nH]c3ncc(NC(C)=O)cc23)c(F)n1,"US9096593, P-1669",5.0,uM,=,0.6989700043360189,1,c1cncc(CNc2ccc(Cc3c[nH]c4ncccc34)cn2)c1
3603,1930510,10.1021/acsmedchemlett.8b00565,,,,Inhibition of recombinant human microsomal CYP3A4 expressed in baculovirus infected BTI-TN-5B1-4 cell microsomes using CYP/Luciferin as substrate pre-incubated for 30 mins followed by NADPH regeneration mixture addition and measured after 30 mins by Promega P450-Glo assay,COc1ccc2c(=O)c(O)c(-c3ccc4c(c3)OCO4)oc2c1,"2-(benzo[d][1,3]dioxol-5-yl)-3-hydroxy-7-methoxy-4H-chromen-4-one",6.0,uM,=,0.7781512503836436,1,O=c1cc(-c2ccc3c(c2)OCO3)oc2ccccc12
3604,1653091,10.1016/j.bmc.2016.11.019,,,,Inhibition of human CYP3A4,CCN(C(=O)c1ccc(Cl)cc1Cl)c1ccc(Cl)cc1,"2,4-Dichloro-N-ethyl-N-(4-fluorophenyl)benzamide",11.9,uM,=,1.0755469613925308,1,O=C(Nc1ccccc1)c1ccccc1
3605,1689562,10.1021/acs.jmedchem.7b00598,,,,Inhibition of CYP3A4 (unknown origin),Cn1nccc1-c1cc(Cl)ccc1Oc1cc(F)c(S(=O)(=O)Nc2nncs2)cc1Cl,"5-chloro-4-(4-chloro-2-(1-methyl-1H-pyrazol-5-yl)phenoxy)-2-fluoro-N-(1,3,4-thiadiazol-2-yl)benzenesulfonamide",11.068,uM,=,1.0440691504689144,1,O=S(=O)(Nc1nncs1)c1ccc(Oc2ccccc2-c2ccn[nH]2)cc1
3606,51916,10.1016/j.bmcl.2003.11.005,,,,Inhibition of cytochrome P450 3A4,CN(C)CCCOc1ccc(-n2ccnc2)cc1,[3-(4-Imidazol-1-yl-phenoxy)-propyl]-dimethyl-amine,39.0,uM,=,1.591064607026499,1,c1ccc(-n2ccnc2)cc1
3607,828928,10.1016/j.bmcl.2012.06.022,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,C#CCN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N3CCCC3)oc2c1,"Thiazol-5-ylmethyl(2S,3R)-3-hydroxy-1-phenyl-4-(N-(prop-2-ynyl)-2-(pyrrolidin-1-yl)benzo[d]oxazole-6-carboxamido)butan-2-ylcarbamate",0.04,uM,=,-1.3979400086720375,0,O=C(N[C@H](CCNC(=O)c1ccc2nc(N3CCCC3)oc2c1)Cc1ccccc1)OCc1cncs1
3608,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1ccc(C[C@@H]2COCCN2C(=O)c2ccccc2-n2nccn2)cc1-c1nccs1,"US9150566, 193",0.6,uM,=,-0.2218487496163563,0,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2nccs2)c1
3609,874112,10.1021/jm300118s,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis,COCC(=O)N[C@@H](Cc1cccc(-c2ccccn2)c1)[C@H](O)CN[C@H]1CC2(CCC2)Oc2ncc(CC(C)(C)C)cc21,"N-((2S,3R)-3-Hydroxy-4-((S)-6'-neopentyl-3',4'-dihydrospiro-[cyclobutane-1,2'-pyrano[2,3-b]pyridine]-4'-ylamino)-1-(3-(pyridin-2-yl)phenyl)butan-2-yl)-2-methoxyacetamide",0.4,uM,=,-0.3979400086720376,0,c1ccc(-c2cccc(CCCCN[C@H]3CC4(CCC4)Oc4ncccc43)c2)nc1
3610,2204940,10.1016/j.ejmech.2022.114581,,,,Inhibition of CYP3A4M (unknown origin),Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,"8-Chloro-6-(2-fluoro-phenyl)-1-methyl-4H-2,5,10b-triaza-benzo[e]azulene",0.0618,uM,=,-1.209011524911184,0,c1ccc(C2=NCc3cncn3-c3ccccc32)cc1
3611,988989,10.1021/jm400732v,,,,Inhibition of CYP3A4 (unknown origin),CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)c2ccc(C)cc2)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O.Cl,"(S)-N-((S)-1-((6-Bromo-2-methoxynaphthalen-1-yl)methyl)-5-(4-methylbenzoyl)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-yl)-2-(methylamino)propanamide hydrochloride",1.4,uM,=,0.1461280356782379,1,O=C1CCN(C(=O)c2ccccc2)c2ccccc2N1Cc1cccc2ccccc12
3612,1527962,,,,,"Inhibition Assay (Testosterone Hydroxylase): To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.",NCc1ccc(-c2cccnc2)s1,C-(5-Pyridin-3-yl-thiophen-2-yl)-methylamine,56.99,uM,=,1.7557986569738306,1,c1cncc(-c2cccs2)c1
3613,1734268,10.1021/acsmedchemlett.8b00030,,,,Inhibition of CYP3A4 (unknown origin),c1cnc2c(c1)CCC[C@@H]2N(CCCN1CCNCC1)Cc1nc2ccccc2[nH]1,"(S)-N-((1H-benzo[d]imidazole-2yl)methyl)-N-(3-(piperazine-1yl)propyl)-5,6,7,8-tetrahydroquinolin-8-amine",12.7,uM,=,1.1038037209559568,1,c1cnc2c(c1)CCC[C@@H]2N(CCCN1CCNCC1)Cc1nc2ccccc2[nH]1
3614,716789,10.1016/j.bmcl.2010.12.123,,,,Inhibition of CYP3A4,O=C(N[C@H]1CC[C@H](O)CC1)[C@H](C1CCCCC1)n1c(-c2ccc(Cl)cc2)nc2cc(F)c(F)cc21,"trans-(S)-2-(2-(4-chlorophenyl)-5,6-difluoro-1H-benzo[d]imidazol-1-yl)-2-cyclohexyl-N-(4-hydroxycyclohexyl)acetamide",33.0,uM,=,1.5185139398778875,1,O=C(NC1CCCCC1)[C@H](C1CCCCC1)n1c(-c2ccccc2)nc2ccccc21
3615,776115,10.1016/j.bmcl.2011.09.074,,,,Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin,COC(=O)CN1Cc2c(nc(C)c(CN)c2-c2ccc(Cl)cc2Cl)C1=O,"methyl 2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-7-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)acetate",17.0,uM,=,1.230448921378274,1,O=C1NCc2c(-c3ccccc3)ccnc21
3616,1624780,10.1021/acs.jmedchem.6b00697,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate in presence of NADPH by LC-MS/MS analysis,N#CN=C(NCCCCCCOc1ccc(Cl)cc1)Nc1ccncc1,N-[6-(4-chlorophenoxy)hexyl]-N''-cyano-N'-pyridin-4-ylguanidine,0.22,uM,=,-0.6575773191777937,0,N=C(NCCCCCCOc1ccccc1)Nc1ccncc1
3617,1640557,,,,,"null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.",CCCN(CC)C(=O)/C=C/C=C/c1ccc2c(c1)OCO2,"US9138393, Piperine::US9144538, Piperine",10.0,uM,=,1.0,1,c1ccc2c(c1)OCO2
3618,1567198,10.1039/C5MD00479A,,,,Inhibition of human CYP3A4 by HPLC analysis,O=C(NCc1cc(Cl)ccc1-n1cnnn1)[C@@H]1CC=NN1C(=O)[C@H](O)c1ccccc1,"(5S)-N-[5-Chloro-2-(1H-tetrazol-1-yl)benzyl]-1-[(2R)-2-hydroxy-2-phenylacetyl]-4,5-dihydro-1H-pyrazole-5-carboxamide",28.0,uM,=,1.4471580313422192,1,O=C(NCc1ccccc1-n1cnnn1)[C@@H]1CC=NN1C(=O)Cc1ccccc1
3619,717286,10.1021/np100665j,,,,Inhibition of CYP3A4 after 30 mins by fluorometric assay,COc1cc(C[C@@H](CO)[C@H](CO)Cc2ccc(O)c(OC)c2)ccc1O,"(2R,3R)-2,3-Bis-(4-hydroxy-3-methoxy-benzyl)-butane-1,4-diol",47.3,uM,=,1.6748611407378116,1,c1ccc(CCCCc2ccccc2)cc1
3620,759505,10.1016/j.bmcl.2011.06.015,,,,Inhibition of CYP3A4,Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1,[4-(2-Amino-phenylcarbamoyl)-benzyl]-carbamic acid pyridin-3-ylmethyl ester,0.73,uM,=,-0.1366771398795441,0,O=C(NCc1ccc(C(=O)Nc2ccccc2)cc1)OCc1cccnc1
3621,990449,10.1016/j.bmcl.2013.09.001,,,,Inhibition of CYP3A4 in human liver microsomes in presence of NADPH,Cc1cccc(NC(=O)c2cc(Cl)cc(Oc3cncnc3)c2)n1,3-chloro-N-(6-methylpyridin-2-yl)-5-(pyrimidin-5-yloxy)benzamide,4.3,uM,=,0.6334684555795865,1,O=C(Nc1ccccn1)c1cccc(Oc2cncnc2)c1
3622,775863,10.1016/j.bmcl.2011.09.037,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH,CN[C@@H]1CCN(C(=O)[C@@H](COCc2ccccc2)NC(=O)c2cccnc2Oc2ccc(C(F)(F)F)cc2Cl)C1,N-((R)-3-(benzyloxy)-1-((R)-3-(methylamino)pyrrolidin-1-yl)-1-oxopropan-2-yl)-2-(2-chloro-4-(trifluoromethyl)phenoxy)nicotinamide,12.0,uM,=,1.0791812460476249,1,O=C(N[C@H](COCc1ccccc1)C(=O)N1CCCC1)c1cccnc1Oc1ccccc1
3623,342118,10.1021/jm051106d,,,,Inhibitory activity against CYP3A4,Cc1cc2c(F)c(Oc3ncnn4cc(OCCC5CCN(C)CC5)c(C)c34)ccc2[nH]1,"4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methyl-6-(2-(1-methylpiperidin-4-yl)ethoxy)pyrrolo[1,2-f][1,2,4]triazine",0.7,uM,=,-0.1549019599857432,0,c1nc(Oc2ccc3[nH]ccc3c2)c2cc(OCCC3CCNCC3)cn2n1
3624,555225,10.1016/j.bmcl.2008.05.058,,,,Inhibition of CYP3A4,COc1cccc(-c2ccc(C(CN3CCOCC3)N(C)C(=O)CN3C(=O)COc4cc(Cl)c(Cl)cc43)cc2)c1,"2-(6,7-Dichloro-3-oxo-2,3-dihydro-benzo[1,4]oxazin-4-yl)-N-[1-(3'-methoxy-biphenyl-4-yl)-2-morpholin-4-yl-ethyl]-N-methyl-acetamide",1.0,uM,=,0.0,0,O=C(CN1C(=O)COc2ccccc21)NC(CN1CCOCC1)c1ccc(-c2ccccc2)cc1
3625,555225,10.1016/j.bmcl.2008.05.058,,,,Inhibition of CYP3A4,CNC(=O)c1cccc(-c2ccc(C(CN3CCOCC3)N(C)C(=O)Cn3c(=O)cnc4cc(C)c(C)cc43)cc2)c1,"4'-(1-{[2-(6,7-Dimethyl-2-oxo-2H-quinoxalin-1-yl)-acetyl]-methyl-amino}-2-morpholin-4-yl-ethyl)-biphenyl-3-carboxylic acid methylamide",9.0,uM,=,0.9542425094393248,1,O=C(Cn1c(=O)cnc2ccccc21)NC(CN1CCOCC1)c1ccc(-c2ccccc2)cc1
3626,1288280,10.1016/j.bmcl.2013.12.057,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,"Thiazol-5-ylmethyl(2R,5R)-5-((S)-4-amino-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)butanamido)-1,6-diphenylhexan-2-ylcarbamate",0.21,uM,=,-0.6777807052660807,0,O=C(CNC(=O)NCc1cscn1)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
3627,1578010,10.1021/acsmedchemlett.5b00447,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone/midazolam as substrate after 30 mins by LC/MS/MS analysis,Nc1noc2ccc(-c3cc(Cl)ccc3Oc3cc(F)c(S(=O)(=O)Nc4ncns4)cc3F)cc12,"4-(2-(3-aminobenzo[d]isoxazol-5-yl)-4-chlorophenoxy)-2,5-difluoro-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide",0.077,uM,=,-1.1135092748275182,0,O=S(=O)(Nc1ncns1)c1ccc(Oc2ccccc2-c2ccc3oncc3c2)cc1
3628,1436762,10.1021/ml500187a,,,,Inhibition of human recombinant CYP3A4 incubated for 5 mins by fluorescence assay,Cl.c1ccc(N(Cc2ccc3ccccc3c2)C2CNC2)cc1,N-(naphthalen-2-ylmethyl)-N-phenylazetidin-3-amine hydrochloride,1.33,uM,=,0.1238516409670858,1,c1ccc(N(Cc2ccc3ccccc3c2)C2CNC2)cc1
3629,716954,10.1016/j.bmcl.2010.12.016,,,,Inhibition of human CYP3A4 by time-dependent inhibition assay,CCOc1ccc(-c2ccc(-c3cc(CC(=O)[O-])ccc3OC)c(CN(CC)C(=O)C3CC3)c2)cn1.[Na+],Sodium [2'-[(cyclopropanecarbonyl-ethyl-amino)-methyl]-4'-(6-ethoxy-pyridin-3-yl)-6-methoxy-biphenyl-3-yl]-acetate,0.002,uM,=,-2.6989700043360187,0,O=C(NCc1cc(-c2cccnc2)ccc1-c1ccccc1)C1CC1
3630,1488503,10.1124/dmd.112.045708,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis,COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1,"Acetic acid (2S,3S)-5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester",190.0,uM,=,2.278753600952829,1,O=C1C[C@H](c2ccccc2)Sc2ccccc2N1
3631,355280,10.1016/j.bmcl.2006.02.020,,,,Inhibition of CYP3A4,CCCCN(C)[C@H](C)[C@@H](c1ccc2cc(OCC(C)(C)C(=O)O)ccc2c1)n1ccnc1,"3-(6-((1R,2R)-2-(butyl(methyl)amino)-1-(1H-imidazol-1-yl)propyl)naphthalen-2-yloxy)-2,2-dimethylpropanoic acid",2.27,uM,=,0.3560258571931227,1,c1ccc2cc(Cn3ccnc3)ccc2c1
3632,619264,10.1016/j.bmcl.2009.07.002,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,Cc1cccc(C)c1CNc1nc(N2CCOCC2=O)cc2c(C)c(C)[nH]c12,"4-(7-(2,6-dimethylbenzylamino)-2,3-dimethyl-1H-pyrrolo[2,3-c]pyridin-5-yl)morpholin-3-one",22.0,uM,=,1.3424226808222062,1,O=C1COCCN1c1cc2cc[nH]c2c(NCc2ccccc2)n1
3633,1534761,,,,,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",COc1ccc(CNc2ccc(Cc3c[nH]c4ncc(F)cc34)c(F)n2)cn1,"US9096593, P-1622",5.0,uM,=,0.6989700043360189,1,c1cncc(CNc2ccc(Cc3c[nH]c4ncccc34)cn2)c1
3634,1619558,10.1021/acsmedchemlett.6b00327,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 10 mins in presence of NADP by rapidfire/MS analysis,C[C@H]1OC(=O)[C@]2(c3n[nH]c(=O)o3)CC(F)(F)[C@@H](C)[C@H](/C=C/c3ccc(-c4ccccc4C#N)cn3)[C@H]12,"2-(6-((E)-2-((3R,3aS,4R,5S,7aR)-6,6-difluoro-3,5-dimethyl-1-oxo-7a-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)octahydroisobenzofuran-4-yl)vinyl)pyridin-3-yl)benzonitrile",21.8,uM,=,1.3384564936046048,1,O=C1OC[C@H]2[C@@H](/C=C/c3ccc(-c4ccccc4)cn3)CCC[C@@]12c1n[nH]c(=O)o1
3635,817424,10.1021/ml200137x,,,,Inhibition of CYP3A4 using testosterone as substrate in human liver microsome for 20 mins by HPLC analysis,CNC[C@H](C[C@H]1CCCOC1)NC(=O)N1CCC[C@@H]([C@@H](OCCNC(=O)OC)c2cccc(Cl)c2)C1,Methyl2-((R)-(3-chlorophenyl)((R)-1-((S)-1-(methylamino)-3-((R)-tetrahydro-2H-pyran-3-yl)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate,28.0,uM,=,1.4471580313422192,1,O=C(NCC[C@H]1CCCOC1)N1CCC[C@@H](Cc2ccccc2)C1
3636,859942,10.1021/jm300122u,,,,Inhibition of human CYP3A4 using testosterone as substrate after 45 mins,C[C@H]1CN(C(=O)[C@H](Cc2ccc(Cl)cc2Cl)NC(=O)C2(c3ccc(Cl)cc3Cl)CC2)CCN1,"1-(2,4-Dichlorophenyl)-N-{(1S)-1-[(2,4-dichlorophenyl)-methyl]-2-[(3S)-3-methylpiperazin-1-yl]-2-oxoethyl}-cyclopropanecarboxamide",0.4,uM,=,-0.3979400086720376,0,O=C([C@H](Cc1ccccc1)NC(=O)C1(c2ccccc2)CC1)N1CCNCC1
3637,2025187,10.1016/j.bmc.2020.115859,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 3 mins followed by NADPH addition by LC-MS/MS analysis,COC(=O)NS(=O)(=O)c1sc(CC(C)C)cc1-c1cccc(C(=O)Cn2ccnc2C(C)(C)C)c1,Methyl ((3-(3-(2-(2-(tert-butyl)-1H-imidazol-1-yl)acetyl)phenyl)-5-isobutylthiophen-2-yl)sulfonyl)carbamate,50.0,uM,=,1.6989700043360187,1,O=C(Cn1ccnc1)c1cccc(-c2ccsc2)c1
3638,802673,10.1016/j.bmcl.2011.12.125,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,Cc1cccc(NC(=O)Nc2ccc(-c3ccnc4[nH]cnc34)cc2)c1,"1-(4-(3H-imidazo[4,5-b]pyridin-7-yl)phenyl)-3-m-tolylurea",1.5,uM,=,0.1760912590556812,1,O=C(Nc1ccccc1)Nc1ccc(-c2ccnc3[nH]cnc23)cc1
3639,959467,10.1016/j.bmcl.2013.02.093,,,,Inhibition of human recombinant CYP3A4 using BFC as substrate by fluorimetric assay,Cc1cc(C)nc(NC[C@@H]2CC3(CC3)CN2C(=O)c2nc(C)sc2-c2ccccc2)n1,"(S)-(6-((4,6-dimethylpyrimidin-2-ylamino)methyl)-5-azaspiro[2.4]heptan-5-yl)(2-methyl-5-phenylthiazol-4-yl)methanone",7.9,uM,=,0.8976270912904415,1,O=C(c1ncsc1-c1ccccc1)N1CC2(CC2)C[C@H]1CNc1ncccn1
3640,979124,10.1021/jm400484p,,,,Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes,Oc1ccc2ccc(-c3cncc4ccccc34)c(Cl)c2c1,8-chloro-7-(isoquinolin-4-yl)naphthalen-2-ol,1.739,uM,=,0.2402995820027124,1,c1ccc2cc(-c3cncc4ccccc34)ccc2c1
3641,2264099,10.1021/acs.jmedchem.1c00703,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 2 mins in presence of NADPH regenerating system by LC-MS/MS analysis,CC(C)n1nc(C(=O)NC2CC3CCC(C2)N3CC2(O)CCOCC2)c2ccccc21.O=C(O)C(O)C(O)C(=O)O,1-Isopropyl-1H-indazole-3-carboxylic acid[8-(4-hydroxy-tetrahydro-pyran-4-ylmethyl)-8-aza-bicyclo[3.2.1]oct-3-ylmethyl]-amide tartarate,26.7,uM,=,1.4265112613645752,1,O=C(NC1CC2CCC(C1)N2CC1CCOCC1)c1n[nH]c2ccccc12
3642,1625987,10.1016/j.bmcl.2016.04.095,,,,Inhibition of CYP3A4 in human liver microsomes after 30 secs by LC/MS/MS analysis,O=S(=O)(CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12)[C@H]1CCNC1,"(S)-3-(2-((4S,4aS,10bS)-10b-(4-chlorophenylsulfonyl)-7,10-difluoro-1,2,4,4a,5,10b-hexahydropyrano[3,4-c]chromen-4-yl)ethylsulfonyl)pyrrolidine",2.0,uM,=,0.3010299956639812,1,O=S(=O)(CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccccc3)c3ccccc3OC[C@@H]12)[C@H]1CCNC1
3643,438600,10.1016/j.bmcl.2007.03.048,,,,Inhibition of CYP3A4 in microsomes,Cc1cc(C2=NC(C)CN2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,"4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-3-(4-methyl-6-(4-methyl-4,5-dihydro-1H-imidazol-2-yl)-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one",4.3,uM,=,0.6334684555795865,1,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(C3=NCCN3)cc2[nH]1
3644,51909,10.1021/jm010531d,,,,Inhibition of human Cytochrome P450 3A4 by macrocycles,CN1Cc2cncn2Cc2ccc(C#N)c(c2)Oc2ccc3cccc(c3c2)N2CCC1C2=O,"S-6-methyl-30-oxo-19-oxa-2,6,10,12-tetraazahexacyclo[18.6.2.12,5.114,18.08,12.023,27]triaconta-1(27),8,10,14(29),15,17,20(28),21,23,25-decaen-17-yl cyanide",5.0,uM,=,0.6989700043360189,1,O=C1C2CCN1c1cccc3ccc(cc13)Oc1cccc(c1)Cn1cncc1CN2
3645,1291572,10.1016/j.bmcl.2013.12.058,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)NCCNC(=O)OCc2cncs2)C(C)C)cs1,(S)-thiazol-5-ylmethyl 2-(2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-3-methylbutanamido)ethylcarbamate,1.1,uM,=,0.041392685158225,1,O=C(CNC(=O)NCc1cscn1)NCCNC(=O)OCc1cncs1
3646,487712,10.1016/j.bmcl.2008.05.104,,,,Inhibition of CYP3A4,Cc1cc(N2CCC(N3CCOCC3)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,(S)-4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-3-(4-methyl-6-(4-morpholinopiperidin-1-yl)-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one,0.0040999999999999,uM,=,-2.3872161432802645,0,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(N3CCC(N4CCOCC4)CC3)cc2[nH]1
3647,630096,10.1016/j.bmcl.2010.03.027,,,,Inhibition of CYP3A4,COc1ccc(Cn2c(C3CCCN(C4CCCCC4)C3)nc3ccccc32)cc1,2-(1-cyclohexylpiperidin-3-yl)-1-(4-methoxybenzyl)-1H-benzo[d]imidazole,3.3,uM,=,0.5185139398778875,1,c1ccc(Cn2c(C3CCCN(C4CCCCC4)C3)nc3ccccc32)cc1
3648,1283600,10.1021/jm401610c,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone,FC(F)(F)c1ccc(N(c2cncnc2)C2CCN(c3ccc(C(F)(F)F)cn3)CC2)cc1,N-4-Trifluoromethylphenyl-N-{1-[5-(trifluoromethyl)pyrimidin-5-yl]piperidin-4-yl}pyridin-3-amine,6.3,uM,=,0.7993405494535817,1,c1ccc(N(c2cncnc2)C2CCN(c3ccccn3)CC2)cc1
3649,1301324,10.6019/CHEMBL3137440,,,,DNDI: CYP Inhibition,O=C(c1ccccc1)N1CCC(N(c2ccc(Cl)cc2)c2cccnc2)CC1,,1.9,uM,=,0.2787536009528289,1,O=C(c1ccccc1)N1CCC(N(c2ccccc2)c2cccnc2)CC1
3650,595638,10.1016/j.bmcl.2009.09.096,,,,Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH,COc1cnc2c(NCc3nnc4ccc(-c5cc(F)cc(F)c5)nn34)ccnc2c1,"N-((6-(3,5-difluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methyl)-7-methoxy-1,5-naphthyridin-4-amine",29.0,uM,=,1.462397997898956,1,c1ccc(-c2ccc3nnc(CNc4ccnc5cccnc45)n3n2)cc1
3651,746947,10.1021/jm200128m,,,,Inhibition of human CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,CC(F)(F)CNC(=O)N1Cc2nc(N)nc(-c3c(Cl)cc(Cl)cc3OCCn3cccn3)c2C1,"2-Amino-4-[2,4-dichloro-6-(2-pyrazol-1-ylethoxy)phenyl]-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carboxylic Acid(2,2-Difluoropropyl)amide",3.3,uM,=,0.5185139398778875,1,c1ccc(-c2ncnc3c2CNC3)c(OCCn2cccn2)c1
3652,1587699,10.1021/acs.jmedchem.5b01891,,,,Inhibition of recombinant human CYP3A4 by P450-Glo luminescence assay,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,"1-(4-{4-[2-(2,4-Dichloro-phenyl)-2-imidazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-ethanone (ketoconazole)",0.24,uM,=,-0.619788758288394,0,c1ccc(C2(Cn3ccnc3)OCC(COc3ccc(N4CCNCC4)cc3)O2)cc1
3653,1675511,10.1016/j.ejmech.2017.03.037,,,,Inhibition of human hepatic CYP3A4,Fc1ccc2sc3c(c2c1)CCN(Cc1cccnc1)C3,"6-Fluoro-2-(pyridin-3-ylmethyl)-1,2,3,4-tetrahydrobenzo[4,5]thieno[2,3-c]pyridine",7.897,uM,=,0.8974621380130631,1,c1cncc(CN2CCc3c(sc4ccccc34)C2)c1
3654,828928,10.1016/j.bmcl.2012.06.022,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N3CCCC3)oc2c1,"thiazol-5-ylmethyl(2S,3R)-3-hydroxy-4-(N-isobutyl-2-(pyrrolidin-1-yl)benzo[d]oxazole-6-carboxamido)-1-phenylbutan-2-ylcarbamate",0.033,uM,=,-1.4814860601221125,0,O=C(N[C@H](CCNC(=O)c1ccc2nc(N3CCCC3)oc2c1)Cc1ccccc1)OCc1cncs1
3655,305432,10.1016/j.bmcl.2005.01.044,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,CC(C(c1ccc2cc(OCc3ccc(C#N)cc3)ccc2c1)n1ccnc1)N(C)C,4-[6-(2-Dimethylamino-1-imidazol-1-yl-propyl)-naphthalen-2-yloxymethyl]-benzonitrile,0.32,uM,=,-0.494850021680094,0,c1ccc(COc2ccc3cc(Cn4ccnc4)ccc3c2)cc1
3656,740075,10.1016/j.bmcl.2011.02.033,,,,Inhibition of CYP3A4,COc1ccccc1N1CCN(C(=O)c2cc(-c3ccc(Cl)cc3)n(C)n2)CC1,(5-(4-chlorophenyl)-1-methyl-1H-pyrazol-3-yl)(4-(2-methoxyphenyl)piperazin-1-yl)methanone,20.0,uM,=,1.3010299956639813,1,O=C(c1cc(-c2ccccc2)[nH]n1)N1CCN(c2ccccc2)CC1
3657,2103815,10.1016/j.bmcl.2021.128010,,,,Time dependent inhibition of CYP3A4 (unknown origin) measured at 30 mins,Nc1cc(Cc2ccn(Cc3ccc4cnccc4c3)n2)c2nn[nH]c2n1,"7-((1-(isoquinolin-6-ylmethyl)-1H-pyrazol-3-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-amine",0.21,uM,=,-0.6777807052660807,0,c1cc2cc(Cn3ccc(Cc4ccnc5[nH]nnc45)n3)ccc2cn1
3658,1641293,,,,,"CYP Inhibition Assay (Without Preincubation): Without Preincubation: To a 96 deep well plate was added 2.5 uL, of the test substance solution (x200 concentration), 442.5 uL of Incubation Mixture, and 5 uL of the substrate solution, and the solution was mixed and warmed to 37° C. for 5 minutes. To this incubation solution 50 uL of 10 mM NADPH was added to start the reaction, and incubated at 37° C. for 5 minutes. After the incubation, 100 uL of the Incubation Mixture was removed, added to 150 uL of isopropanol containing IS and mixed. This mixture was transferred onto a multi-screen filter, centrifuged at 500xg at 4° C. for 10 minutes. The filtrate was used for LC-MS/MS analysis.",CCCCCCCC(F)(F)CCCCCC/C=C/[C@H](C(O)N[C@@H](Cc1ccc(OCCCC)cc1)C(=O)O)[C@@](O)(CCOC)C(=O)O,"US9266853, 5526064",16.2,uM,=,1.209515014542631,1,c1ccccc1
3659,51923,10.1021/jm031115r,,,,Inhibition of human cytochrome P450 3A4,CCCCc1cccc([C@]2([C@H](Oc3nc(C)cc(C)n3)C(=O)O)NCC(=O)N(Cc3c(F)cc(F)cc3F)c3ccccc32)c1,"(S)-[(S)-5-(3-Butyl-phenyl)-2-oxo-1-(2,4,6-trifluoro-benzyl)-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-5-yl]-(4,6-dimethyl-pyrimidin-2-yloxy)-acetic acid",5.0,uM,=,0.6989700043360189,1,O=C1CN[C@@](COc2ncccn2)(c2ccccc2)c2ccccc2N1Cc1ccccc1
3660,2060129,10.1021/acsmedchemlett.1c00112,,,,Inhibition of CYP3A4 (unknown origin),CC(C)(O)CC(=O)N[C@@H]1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3CC[C@@H]12,"N-((3R,3aS,9bS)-9b-(4-fluorophenylsulfonyl)-7-(perfluoropropan-2-yl)-2,3,3a,4,5,9b-hexahydro-1H-cyclopenta[a]naphthalen-3-yl)-3-hydroxy-3-methylbutanamide",11.0,uM,=,1.0413926851582251,1,O=S(=O)(c1ccccc1)[C@@]12CCC[C@@H]1CCc1ccccc12
3661,1289241,10.1016/j.bmcl.2013.12.088,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,Fc1cc(OC(F)(F)C(F)F)cc([C@@](Cc2ccccc2)(Nc2nc3ccccc3[nH]2)c2ccc(Cl)cn2)c1,"(R)-N-(1-(5-chloropyridin-2-yl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-1H-benzo[d]imidazol-2-amine",40.0,uM,=,1.6020599913279625,1,c1ccc(C[C@@](Nc2nc3ccccc3[nH]2)(c2ccccc2)c2ccccn2)cc1
3662,304712,10.1021/jm048978k,,,,In vitro inhibitory concentration against Cytochrome P450 3A4,CC(C)CN1CCC(c2nc(-c3ccc4nc(N)n(S(=O)(=O)C(C)C)c4c3)c(-c3ccccc3)[nH]2)CC1,6-[2-(1-Isobutyl-piperidin-4-yl)-5-phenyl-3H-imidazol-4-yl]-1-(propane-2-sulfonyl)-1H-benzoimidazol-2-ylamine,5.3,uM,=,0.724275869600789,1,c1ccc(-c2[nH]c(C3CCNCC3)nc2-c2ccc3nc[nH]c3c2)cc1
3663,305744,10.1021/jm049696n,,,,Inhibitory concentration value against human cytochrome P-450 3A4,Cc1cscc1-c1cccnc1,3-(4-Methyl-thiophen-3-yl)-pyridine,80.9,uM,=,1.907948521612272,1,c1cncc(-c2ccsc2)c1
3664,1534761,,,,,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",COc1ccnc2[nH]cc(Cc3ccc(NCc4ccc(Cl)cc4)nc3F)c12,"US9096593, P-2037",5.0,uM,=,0.6989700043360189,1,c1ccc(CNc2ccc(Cc3c[nH]c4ncccc34)cn2)cc1
3665,1614026,10.1016/j.bmcl.2016.09.043,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 1'-hydroxymidazolam metabolite formation using midazolam as substrate incubated for 10 mins by HPLC-MS method,Cn1c(NCCc2ccccc2)nc2cc(Cl)ccc2c1=O,7-Chloro-3-methyl-2-phenethylamino-3H-quinazolin-4-one,11.0,uM,=,1.0413926851582251,1,O=c1[nH]c(NCCc2ccccc2)nc2ccccc12
3666,619265,10.1016/j.bmcl.2009.07.002,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate,Cc1cccc(C)c1CNc1nccc2c(C)c(C)[nH]c12,"N-(2,6-dimethylbenzyl)-2,3-dimethyl-1H-pyrrolo[2,3-c]pyridin-7-amine",9.6,uM,=,0.9822712330395684,1,c1ccc(CNc2nccc3cc[nH]c23)cc1
3667,2103815,10.1016/j.bmcl.2021.128010,,,,Time dependent inhibition of CYP3A4 (unknown origin) measured at 30 mins,Nc1cc(Cc2ccn(-c3ccccn3)n2)c2nn[nH]c2n1,"7-((1-(pyridin-2-yl)-1H-pyrazol-3-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-amine",0.21,uM,=,-0.6777807052660807,0,c1ccc(-n2ccc(Cc3ccnc4[nH]nnc34)n2)nc1
3668,1883264,10.1021/acs.jmedchem.8b01344,,,,Reversible inhibition of CYP3A4 (unknown origin) in presence of NADPH by vivid red substrate-based assay,N#Cc1ccc(S(=O)(=O)N2C[C@H](S(=O)(=O)c3ccc(Cl)cn3)[C@@](O)(CN)C2)c(Cl)c1,"4-(((3R,4S)-3-(Aminomethyl)-4-((5-chloropyridin-2-yl)-sulfonyl)-3-hydroxypyrrolidin-1-yl)sulfonyl)-3-chlorobenzonitrile",4.0,uM,=,0.6020599913279624,1,O=S(=O)(c1ccccn1)[C@@H]1CCN(S(=O)(=O)c2ccccc2)C1
3669,1829871,10.1021/acsmedchemlett.8b00308,,,,Inhibition of CYP3A4 (unknown origin),Cc1c(COc2cc(N)nc3[nH]nnc23)cccc1-c1ccn(C)n1,"7-(2-Methyl-3-(1-methyl-1H-pyrazol-3-yl)benzyloxy)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-amine",1.5,uM,=,0.1760912590556812,1,c1cc(COc2ccnc3[nH]nnc23)cc(-c2cc[nH]n2)c1
3670,874112,10.1021/jm300118s,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis,COCC(=O)N[C@@H](Cc1cccc(-c2nccs2)c1)[C@H](O)CN[C@H]1CC2(CCC2)Oc2ncc(CC(C)(C)C)cc21,"N-((2S,3R)-3-Hydroxy-4-((S)-6'-neopentyl-3',4'-dihydrospiro-[cyclobutane-1,2'-pyrano[2,3-b]pyridine]-4'-ylamino)-1-(3-(thiazol-2-yl)phenyl)butan-2-yl)-2-methoxyacetamide",0.1,uM,=,-1.0,0,c1cc(CCCCN[C@H]2CC3(CCC3)Oc3ncccc32)cc(-c2nccs2)c1
3671,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCC(NC(=O)c6ccc(N7CCN(C)CC7)cc6)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, E-60",6.02,uM,=,0.7795964912578245,1,O=C(NC1CCN(C(=O)c2c[nH]c3c(CN4C[C@@H]5N(C(=O)NCc6ccccc6)NCC(=O)N5[C@@H](Cc5ccccc5)C4=O)cccc23)CC1)c1ccc(N2CCNCC2)cc1
3672,51903,10.1021/jm020557k,,,,Concentration required to inhibit cytochrome P450 3A4.,CCCCOc1ccc(-n2ccnc2C)cc1,1-(4-Butoxy-phenyl)-2-methyl-1H-imidazole,50.9,uM,=,1.7067177823367587,1,c1ccc(-n2ccnc2)cc1
3673,1640556,,,,,"null: Microsomal preparation: One lobe of fresh pig liver is obtained (e.g., at about the time of slaughter from a food-processing company) and immediately placed in ice cold 15 mM KH2PO4/250 mM sucrose (pH 7.4) and kept on ice during transportation. A 10 g sample of liver is minced and homogenized in 30 mL of homogenization buffer (15 mM KH2PO4/250 mM sucrose) using a Tekmar homoginizer or equivalent by pulsing 3 times with 20 second pulses. This procedure is repeated for a total of 8x10 g samples of pig liver. The remaining pig liver may be stored at -80 C. The homogenates from the 8 samples are pooled and centrifuged at 13,000xg for 20 minutes at 4 C. to remove crude debris. The supernatant is further centrifuged at 100,000xg for 70 minutes at 4° C. The microsomal pellets are re-suspended into 50 mL of 150 mM KH2PO4/1 mM DTT (pH 7.4) and 1 mL aliquots are stored at -80 C.100-150 ug of pig liver microsomal protein in 150 mM KH2PO4 is incubated at 37° C.",c1ccc(-n2ccnc2)cc1,1-Phenyl-1H-imidazole,52.5,uM,=,1.7201593034059568,1,c1ccc(-n2ccnc2)cc1
3674,1910981,10.1021/acs.jmedchem.8b01464,,,,Inhibition of human CYP3A4 in presence of NADPH by luciferase reporter gene assay,Clc1ccc(-n2ccc(C(c3ccc(Cl)cc3Cl)n3ccnc3)c2)cc1,"1-[[1-(4-Chlorophenyl)-1H-pyrrol-2-yl](2,4-dichlorophenyl)-methyl]-1H-imidazole",0.9,uM,=,-0.0457574905606751,0,c1ccc(C(c2ccn(-c3ccccc3)c2)n2ccnc2)cc1
3675,519908,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,Cc1cccc(C)c1CNc1cc(-c2ccccn2)cn2c(C)c(C)nc12,"N-(2,6-dimethylbenzyl)-2,3-dimethyl-6-(pyridin-2-yl)imidazo[1,2-a]pyridin-8-amine",1.8,uM,=,0.255272505103306,1,c1ccc(CNc2cc(-c3ccccn3)cn3ccnc23)cc1
3676,1301328,10.6019/CHEMBL3137440,,,,DNDI: CYP Inhibition,CS(=O)(=O)c1ccc(N2CCC(N(c3ccc(Cl)cc3)c3cccnc3)CC2)cc1,N-(4-Chlorophenyl)-N-(1-[4-(methylsulfonyl)phenyl]piperidin-4-yl)pyridin-3-amine,2.0,uM,=,0.3010299956639812,1,c1ccc(N2CCC(N(c3ccccc3)c3cccnc3)CC2)cc1
3677,595638,10.1016/j.bmcl.2009.09.096,,,,Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH,COc1ccc2c(OCc3nnc4ccc(-c5ccc(F)c(F)c5)nn34)ccnc2c1,"4-((6-(3,4-difluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy)-7-methoxyquinoline",6.4,uM,=,0.8061799739838872,1,c1ccc(-c2ccc3nnc(COc4ccnc5ccccc45)n3n2)cc1
3678,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2C(CN(Cc3cccc4c(C(=O)Nc5ccc(N6CCC7CCCN7C6)nc5)cn(C)c34)C(=O)[C@@H]2Cc2ccc(O)cc2)N1C(=O)NCc1ccccc1,"US8940739, G-66",4.6,uM,=,0.6627578316815741,1,O=C(Nc1ccc(N2CCC3CCCN3C2)nc1)c1c[nH]c2c(CN3CC4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12
3679,1493640,10.1124/dmd.112.048918,,,,Metabolism-dependent inhibition of CYP3A4 in human liver microsomes using atorvastatin as substrate preincubated for 20 mins with NADPH prior to initiation of reaction with probe substrate by HPLC analysis,C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12,DOLUTEGRAVIR,33.0,uM,=,1.5185139398778875,1,O=C(NCc1ccccc1)c1cn2c(cc1=O)C(=O)N1CCCO[C@H]1C2
3680,828928,10.1016/j.bmcl.2012.06.022,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N3CCN(C)CC3)oc2c1,"Thiazol-5-ylmethyl(2S,3R)-3-hydroxy-4-(N-isobutyl-2-(4-methylpiperazin-1-yl)benzo[d]oxazole-6-carboxamido)-1-phenylbutan-2-ylcarbamate",0.092,uM,=,-1.0362121726544449,0,O=C(N[C@H](CCNC(=O)c1ccc2nc(N3CCNCC3)oc2c1)Cc1ccccc1)OCc1cncs1
3681,552281,10.1016/j.bmcl.2008.04.036,,,,Inhibition of CYP3A4,N[C@@H](Cn1c(=O)c(-c2ccc(CNCC(=O)O)cc2)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1,"(R)-2-(4-(1-(2-fluoro-6-(trifluoromethyl)benzyl)-3-(2-amino-2-phenylethyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)benzylamino)acetic acid",36.0,uM,=,1.5563025007672873,1,O=c1c(-c2ccccc2)cn(Cc2ccccc2)c(=O)n1CCc1ccccc1
3682,1556414,10.1021/acs.jmedchem.5b01741,,,,Inhibition of CYP3A4 (unknown origin) using testostrone as substrate preincubated for 10 mins followed by NADPH addition by LC/MS/MS analysis,Cc1nc2c([N+](=O)[O-])c(Cl)c(Cl)cc2n1Cc1ccc(B2OC(=O)CN(C)CC(=O)O2)cc1,"2-(4-((5,6-Dichloro-2-methyl-4-nitro-1H-benzo[d]-imidazol-1-yl)methyl)phenyl)-6-methyl-1,3,6,2-dioxazaborocane-4,8-dione",21.94,uM,=,1.3412366232386923,1,O=C1CNCC(=O)OB(c2ccc(Cn3cnc4ccccc43)cc2)O1
3683,1362864,10.1016/j.bmcl.2014.04.049,,,,Inhibition of CYP3A4 (unknown origin),CC1(C)[C@@H]2CC[C@@]1(C)c1c2c(=O)n(-c2ccc(F)cc2F)n1Cc1ccccc1,"(4S,7R)-1-Benzyl-2-(2,4-difluoro-phenyl)-7,8,8-trimethyl-1,2,4,5,6,7-hexahydro-4,7-methano-indazol-3-one",6.1,uM,=,0.785329835010767,1,O=c1c2c(n(Cc3ccccc3)n1-c1ccccc1)C1CC[C@H]2C1
3684,2103389,10.1021/acs.jmedchem.0c01917,,,,Inhibition of CYP3A4 in human liver microsomes using terfenadine as substrate incubated for 15 mins in presence of NADPH by LC/MS/MS analysis,C[C@@]1(c2cc(NC(=O)c3ccc(C#N)cn3)ccc2F)C=CSC(N)=N1,"US9270353, 17",33.0,uM,=,1.5185139398778875,1,O=C(Nc1cccc(C2C=CSC=N2)c1)c1ccccn1
3685,2024613,10.1016/j.bmcl.2020.127721,,,,Inhibition of CYP3A4 (unknown origin),CN1CCN(CCOc2cccc(CC(=O)Nc3nc(-c4c[nH]c5ncc(F)cc45)cs3)c2)CC1,"N-[4-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-yl)thiazol-2-yl]-2-[3-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]acetamide",27.0,uM,=,1.4313637641589874,1,O=C(Cc1cccc(OCCN2CCNCC2)c1)Nc1nc(-c2c[nH]c3ncccc23)cs1
3686,1460848,10.1021/jm501038s,,,,Inhibition of CYP3A4 (unknown origin),O=C(NCc1ccncc1)c1ccc(Oc2ccc(Cl)cc2)cc1,4-(4-chlorophenoxy)-N-(pyridin-4-ylmethyl)benzamide,1.0,uM,=,0.0,0,O=C(NCc1ccncc1)c1ccc(Oc2ccccc2)cc1
3687,774749,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1,"1-[2-(4-Chloro-benzylsulfanyl)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole",0.07,uM,=,-1.154901959985743,0,c1ccc(CSC(Cn2ccnc2)c2ccccc2)cc1
3688,955730,10.1016/j.bmcl.2013.02.110,,,,Inhibition of CYP3A4 (unknown origin),O=C(O)c1cc(Oc2ccccc2)ccc1NS(=O)(=O)c1ccc(Br)cc1F,2-(4-bromo-2-fluorophenylsulfonamido)-5-phenoxybenzoic acid,26.0,uM,=,1.414973347970818,1,O=S(=O)(Nc1ccc(Oc2ccccc2)cc1)c1ccccc1
3689,2166000,,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH and measured by LC-MS/MS analysis,Cc1nn(C(C)c2ccc(C(F)(F)F)cc2C(F)(F)F)cc1NC(=O)c1nnc(-c2ccccn2)s1,"N-[1-[1-[2,4-bis(trifluoromethyl)phenyl]ethyl]-3-methyl-pyrazol-4-yl]-5-(2-pyridyl)-1,3,4-thiadiazole-2-carboxamide",2.4,uM,=,0.380211241711606,1,O=C(Nc1cnn(Cc2ccccc2)c1)c1nnc(-c2ccccn2)s1
3690,966467,10.1016/j.bmcl.2013.04.077,,,,Inhibition of CYP3A4 (unknown origin),Nc1ccc(-c2cnc(NC(=O)CN(Cc3ccccc3)C(=O)c3ccncc3)s2)cc1,N-(2-(5-(4-aminophenyl)thiazol-2-ylamino)-2-oxoethyl)-N-benzylisonicotinamide,0.5,uM,=,-0.3010299956639812,0,O=C(CN(Cc1ccccc1)C(=O)c1ccncc1)Nc1ncc(-c2ccccc2)s1
3691,596865,10.1021/jm9005912,,,,Inhibition of human CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,Cc1cn(Cc2ccc(Cl)cc2Cl)c2c(/C=C/C(=O)NS(=O)(=O)c3cc(Cl)c(Cl)s3)cc(F)cc12,"3-(1-(2,4-dichlorobenzyl)-5-fluoro-3-methyl-1H-indol-7-yl)-N-(4,5-dichlorothiophen-2-ylsulfonyl)acrylamide",1.5,uM,=,0.1760912590556812,1,O=C(/C=C/c1cccc2ccn(Cc3ccccc3)c12)NS(=O)(=O)c1cccs1
3692,1433194,10.1016/j.bmcl.2014.08.041,,,,Reversible inhibition of CYP3A4 (unknown origin),COc1ccc(CNC(=O)c2cc(-c3cncc(C)c3)ncc2-c2nccs2)nc1OC,"N-((5,6-dimethoxypyridin-2-yl)methyl)-5'-methyl-5-(thiazol-2-yl)-2,3'-bipyridine-4-carboxamide",17.0,uM,=,1.230448921378274,1,O=C(NCc1ccccn1)c1cc(-c2cccnc2)ncc1-c1nccs1
3693,2101223,10.1016/j.bmc.2021.116216,,,,Inhibition of CYP3A4 (unknown origin) using diethoxyfluorescein as substrate,CNc1nc(NC2CCC(C(=O)NCc3ccccc3C(F)(F)F)CC2)nc(N(C)CCN(C)C)n1,"Cis-4-((4-((2-(dimethylamino)ethyl)amino)-6-(methylamino)-1,3,5-triazin-2-yl)amino)-N-(2-(trifluoromethyl)benzyl)cyclohexane-1-carboxamide",22.0,uM,=,1.3424226808222062,1,O=C(NCc1ccccc1)C1CCC(Nc2ncncn2)CC1
3694,1534761,,,,,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",Cc1cnc2[nH]cc(Cc3ccc(NCc4cnccc4C(F)(F)F)nc3F)c2c1,"US9096593, P-2062",5.0,uM,=,0.6989700043360189,1,c1cncc(CNc2ccc(Cc3c[nH]c4ncccc34)cn2)c1
3695,1625990,10.1016/j.bmcl.2016.04.095,,,,Inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins after 30 secs by LC/MS/MS analysis,CCNCCS(=O)(=O)CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12,"2-(2-((4S,4aS,10bS)-10b-(4-chlorophenylsulfonyl)-7,10-difluoro-1,2,4,4a,5,10b-hexahydropyrano[3,4-c]chromen-4-yl)ethylsulfonyl)-N-ethylethanamine",1.4,uM,=,0.1461280356782379,1,O=S(=O)(c1ccccc1)[C@@]12CCOC[C@@H]1COc1ccccc12
3696,851921,10.1016/j.bmcl.2012.08.072,,,,Inhibition of human recombinant CYP3A4,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1cccc(Br)c1,"N-(3-bromophenyl)-2-(4-morpholino-6-oxo-1,6-dihydropyrimidin-2-yl)acetamide",40.0,uM,=,1.6020599913279625,1,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccccc1
3697,1764722,10.1021/acsmedchemlett.8b00220,,,,Inhibition of CYP3A4 (unknown origin) preincubated followed by substrate addition,CS[C@@]1(C(=O)Nc2ccc3[nH]nc(-c4ccc5c(c4)OCO5)c3c2)CCN(CC(=O)N2CC=C(c3ccc(-c4ncccn4)cc3)CC2)C1,"(S)-N-(3-(benzo[d][1,3]dioxol-5-yl)-1H-indazol-5-yl)-3-(methylthio)-1-(2-oxo-2-(4-(4-(pyrimidin-2-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)ethyl)pyrrolidine-3-carboxamide",0.3,uM,=,-0.5228787452803376,0,O=C(Nc1ccc2[nH]nc(-c3ccc4c(c3)OCO4)c2c1)C1CCN(CC(=O)N2CC=C(c3ccc(-c4ncccn4)cc3)CC2)C1
3698,1577486,10.1021/acs.jmedchem.5b01712,,,,Inhibition of CYP3A4 (unknown origin),CC(=O)Nc1ccc(-c2ccc(NCC(=O)Nc3ccc(CN4CCNCC4)c(C(F)(F)F)c3)cc2)cn1,2-((4-(6-Acetamidopyridin-3-yl)phenyl)amino)-N-(4-(piperazin-1-ylmethyl)-3-(trifluoromethyl)phenyl)acetamide,2.4,uM,=,0.380211241711606,1,O=C(CNc1ccc(-c2cccnc2)cc1)Nc1ccc(CN2CCNCC2)cc1
3699,425259,10.1021/jm060983w,,,,Inhibition of CYP3A4 in human liver microsomes,O=C(OCc1ccccc1)N1CCC(CNc2cnccn2)CC1,benzyl 4-[(pyrazin-2-ylamino)methyl]piperidine-1-carboxylate,22.0,uM,=,1.3424226808222062,1,O=C(OCc1ccccc1)N1CCC(CNc2cnccn2)CC1
3700,322414,10.1021/jm0502541,,,,Interaction with human cytochrome P450 isoform 3A4 expressed in baculovirus-insect cells,CC(C)(C(=O)O)c1ccc(-c2ccc(C3CCCCC3)cc2)c(F)c1,2-(4'-Cyclohexyl-2-fluoro-biphenyl-4-yl)-2-methyl-propionic acid,59.0,uM,=,1.7708520116421442,1,c1ccc(-c2ccc(C3CCCCC3)cc2)cc1
3701,487712,10.1016/j.bmcl.2008.05.104,,,,Inhibition of CYP3A4,CC(=O)N1CCN(C2CCN(c3cc(C)c4nc(-c5c(NC[C@@H](O)c6cccc(Cl)c6)cc[nH]c5=O)[nH]c4c3)CC2)CC1,(S)-3-(6-(4-(4-acetylpiperazin-1-yl)piperidin-1-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)-4-(2-(3-chlorophenyl)-2-hydroxyethylamino)pyridin-2(1H)-one,0.0008,uM,=,-3.096910013008056,0,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(N3CCC(N4CCNCC4)CC3)cc2[nH]1
3702,804824,10.1016/j.bmcl.2011.12.080,,,,Reversible inhibition of CYP3A4,COc1cc(C)c2nc3[nH]nc(C)c3c(C(O)c3cncn3C)c2c1,"rac-(6-methoxy-3,8-dimethyl-1H-pyrazolo[3,4-b]quinolin-4-yl)(1-methyl-1H-imidazol-5-yl)methanol",1.2,uM,=,0.0791812460476248,1,c1ccc2c(Cc3cnc[nH]3)c3cn[nH]c3nc2c1
3703,519907,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,COc1ccccc1CNc1cc(-n2ccccc2=O)cn2c(C)c(C)nc12,"1-(8-(2-methoxybenzylamino)-2,3-dimethylimidazo[1,2-a]pyridin-6-yl)pyridin-2(1H)-one",4.6,uM,=,0.6627578316815741,1,O=c1ccccn1-c1cc(NCc2ccccc2)c2nccn2c1
3704,495542,10.1021/jm801332q,,,,Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate by time dependent inhibition assay,C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(Nc4cccc(F)c4)CC3)cc2)CCN1,N-(3-Fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine,26.0,uM,=,1.414973347970818,1,O=C(Cc1ccc(CN2CCNCC2)cc1)N1CCC(Nc2ccccc2)CC1
3705,619910,10.1016/j.bmcl.2009.09.104,,,,Inhibition of CYP3A4,O=C(C1=C(c2ccc(CCCOc3c(F)ccc(F)c3Cl)cc2)C[C@H]2CC[C@H]1N2)N(Cc1cccc(Cl)c1Cl)C1CC1,"(1R,5R)-3-(4-(3-(2-chloro-3,6-difluorophenoxy)propyl)phenyl)-N-cyclopropyl-N-(2,3-dichlorobenzyl)-8-azabicyclo[3.2.1]oct-2-ene-2-carboxamide",1.9,uM,=,0.2787536009528289,1,O=C(C1=C(c2ccc(CCCOc3ccccc3)cc2)C[C@H]2CC[C@H]1N2)N(Cc1ccccc1)C1CC1
3706,558484,10.1016/j.bmcl.2008.10.128,,,,Inhibition of CYP3A4,Nc1c(C(=O)NCC(O)(CN(CCO)C(=O)c2c(F)cccc2F)C(F)(F)F)cnn1-c1ccc(F)cc1,"5-amino-N-(2-((2,6-difluoro-N-(2-hydroxyethyl)benzamido)methyl)-3,3,3-trifluoro-2-hydroxypropyl)-1-(4-fluorophenyl)-1H-pyrazole-4-carboxamide",76.0,uM,=,1.880813592280792,1,O=C(NCCCNC(=O)c1cnn(-c2ccccc2)c1)c1ccccc1
3707,1446329,10.1021/ml500387y,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,CCS(=O)(=O)c1cc2cc(CC(O)(CC(C)(C)c3ccccc3C(N)=O)C(F)(F)F)[nH]c2cn1,"2-(4-((5-(ethylsulfonyl)-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)-5,5,5-trifluoro-4-hydroxy-2-methylpentan-2-yl)benzamide",14.0,uM,=,1.146128035678238,1,c1ccc(CCCCc2cc3ccncc3[nH]2)cc1
3708,1528565,,,,,"Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",CC(C)c1nc(CN(C)C(=O)N2C[C@@H](N3CCOCC3)C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,"US8987313, 32",0.12,uM,=,-0.9208187539523752,0,O=C(N[C@H](CC[C@H](Cc1ccccc1)NC(=O)[C@@H]1C[C@H](N2CCOCC2)CN1C(=O)NCc1cscn1)Cc1ccccc1)OCc1cncs1
3709,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",O=C(c1ccc(C(F)(F)F)cc1-n1nccn1)N1CCOC[C@H]1Cc1cc(-n2nccn2)ccc1F,"US9150566, 138",7.4,uM,=,0.8692317197309762,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
3710,1474044,10.1021/jm501740a,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,CC(C)C[C@@H](NC(=O)c1ccc2[nH]nc(-c3ccc(N4[C@H]5CC[C@H]4CC(O)C5)cc3)c2c1)c1ccccn1,3-(4-((endo)-3-hydroxy-8-azabicyclo[3.2.1]octan-8-yl)phenyl)-N-((R)-3-methyl-1-(pyridin-2-yl)butyl)-1H-indazole-5-carboxamide,0.29,uM,=,-0.5376020021010439,0,O=C(NCc1ccccn1)c1ccc2[nH]nc(-c3ccc(N4[C@@H]5CCC[C@@H]4CC5)cc3)c2c1
3711,2272999,10.1039/d2md00352j,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam/testosterone as substrate by LC-MS/MS analysis,CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,SID144204227,0.076,uM,=,-1.1191864077192086,0,c1ccc([C@@]2(Cn3ccnc3)OC[C@H](COc3ccc(N4CCNCC4)cc3)O2)cc1
3712,51916,10.1016/j.bmcl.2003.11.005,,,,Inhibition of cytochrome P450 3A4,CN(C)CCCCCCOc1ccc(-n2ccnc2)cc1,[6-(4-Imidazol-1-yl-phenoxy)-hexyl]-dimethyl-amine,4.46,uM,=,0.6493348587121419,1,c1ccc(-n2ccnc2)cc1
3713,873423,10.1021/jm3006788,,,,Inhibition of CYP3A4,COc1ccc(-c2c(C3CCCC3)c3ccc(C(=O)NC4(C(=O)Nc5ccc(/C=C/C(=O)O)cc5)CCC4)cc3n2C)cn1,(E)-3-(4-(1-(3-cyclopentyl-2-(6-methoxypyridin-3-yl)-1-methyl-1H-indole-6-carboxamido)cyclobutanecarboxamido)phenyl)acrylic acid,1.5,uM,=,0.1760912590556812,1,O=C(NC1(C(=O)Nc2ccccc2)CCC1)c1ccc2c(C3CCCC3)c(-c3cccnc3)[nH]c2c1
3714,2158311,10.1021/acs.jmedchem.1c00598,,,,Inhibition of CYP3A4 (unknown origin),O=C(Nc1ccc(N(Cc2ccsc2)C(=O)Cn2nnc3ccccc32)cc1)C1CC1,"N-(4-(2-(1H-benzo[d][1,2,3]triazol-1-yl)-N-(thiophen-3-ylmethyl)acetamido)phenyl)cyclopropanecarboxamide",4.6,uM,=,0.6627578316815741,1,O=C(Nc1ccc(N(Cc2ccsc2)C(=O)Cn2nnc3ccccc32)cc1)C1CC1
3715,1987746,10.1021/acs.jmedchem.0c00463,,,,Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cell microsomes using vivid DBOMF as substrate preincubated for 10 mins followed by substrate addition and measured after 25 mins in presence of NAD+ by fluorescence assay,O=C(Nc1ccc(SC(F)(F)F)c(Cl)c1)c1ccc(CN2CCCCC2)cc1,N-(3-Chloro-4-((trifluoromethyl)thio)phenyl)-4-(piperidin-1-ylmethyl)benzamide,15.1,uM,=,1.1789769472931697,1,O=C(Nc1ccccc1)c1ccc(CN2CCCCC2)cc1
3716,466342,10.1021/jm701447v,,,,Inhibition of human CYP3A4,Oc1cccc(-c2ccc3cc(O)ccc3c2)c1,6-(3-Hydroxy-phenyl)-naphthalen-2-ol,1.58,uM,=,0.1986570869544226,1,c1ccc(-c2ccc3ccccc3c2)cc1
3717,1276541,10.1016/j.bmcl.2013.09.041,,,,Inhibition of CYP3A4 (unknown origin) after 5 mins,O=S(=O)(Nc1ccc(-c2nnco2)cc1)c1cc(Cl)cc(Cl)c1,"N-(4-(1,3,4-oxadiazol-2-yl)phenyl)-3,5-dichlorobenzenesulfonamide",27.0,uM,=,1.4313637641589874,1,O=S(=O)(Nc1ccc(-c2nnco2)cc1)c1ccccc1
3718,674732,10.1016/j.bmcl.2010.09.029,,,,Inhibition of CYP3A4,Cc1cc([C@]2(c3cccc(C#CC4CC4)c3)N=C(N)N(C)C2=O)ccc1OC(F)F,(S)-2-amino-4-(3-(cyclopropylethynyl)phenyl)-4-(4-(difluoromethoxy)-3-methylphenyl)-1-methyl-1H-imidazol-5(4H)-one,0.1,uM,=,-1.0,0,O=C1NC=N[C@]1(c1ccccc1)c1cccc(C#CC2CC2)c1
3719,857201,10.1021/jm200900q,,,,Inhibition of CYP3A4,N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(C(=O)CN4CCOCC4)CC3)cc2C2=CCCCC2)n1,4-Cyano-1H-imidazole-2-carboxylic Acid{2-Cyclohex-1-enyl-4-[1-(2-morpholin-4-yl-acetyl)-piperidin-4-yl]-phenyl}-amide,1.8,uM,=,0.255272505103306,1,O=C(Nc1ccc(C2CCN(C(=O)CN3CCOCC3)CC2)cc1C1=CCCCC1)c1ncc[nH]1
3720,834635,10.1016/j.bmcl.2012.07.019,,,,Inhibition of CYP3A4,N[C@@H](CC(=O)N1CCN(C(=O)c2ccc(C(=O)O)cc2)CC1)Cc1cc(F)c(F)cc1F,"(R)-4-(4-(3-amino-4-(2,4,5-trifluorophenyl)butanoyl)piperazine-1-carbonyl)benzoic acid",1.0,uM,=,0.0,0,O=C(CCCc1ccccc1)N1CCN(C(=O)c2ccccc2)CC1
3721,1933020,10.1021/acs.jmedchem.6b00619,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,Cl.Nc1ncccc1-c1nc2ccc(-c3cccnc3)nc2n1-c1ccc(C2(N)CCC2)cc1,"3-(3-(4-(1-Aminocyclobutyl)phenyl)-5-(pyridin-3-yl)-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine Hydrochloride",18.0,uM,=,1.255272505103306,1,c1cncc(-c2ccc3nc(-c4cccnc4)n(-c4ccc(C5CCC5)cc4)c3n2)c1
3722,988989,10.1021/jm400732v,,,,Inhibition of CYP3A4 (unknown origin),CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)CS(C)(=O)=O)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O.Cl,"(S)-N-((S)-1-((6-Bromo-2-methoxynaphthalen-1-yl)methyl)-5-(2-(methylsulfonyl)acetyl)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-yl)-2-(methylamino)propanamide hydrochloride",10.0,uM,=,1.0,1,O=C1CCNc2ccccc2N1Cc1cccc2ccccc12
3723,1528565,,,,,"Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",CC(C)c1nc(CN(C)C(=O)N2C[C@@H](N)C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,"US8987313, 29",0.31,uM,=,-0.5086383061657274,0,O=C(N[C@H](CC[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)NCc1cscn1)Cc1ccccc1)OCc1cncs1
3724,664437,10.1016/j.bmcl.2010.07.058,,,,Inhibition of CYP3A4,C[C@@H](O[C@H]1CN2C(=O)[C@H]3C[C@@](C)(O)C[C@H]3[C@H]2[C@@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,"(1S,2R,5aS,7S,8aR,8bS)-2-((R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-1-(4-fluorophenyl)-7-hydroxy-7-methyloctahydrocyclopenta[a]pyrrolizin-5(5aH)-one",22.68,uM,=,1.355643050220869,1,O=C1[C@H]2CCC[C@H]2[C@H]2[C@H](c3ccccc3)[C@@H](OCc3ccccc3)CN12
3725,495153,10.1021/jm8006454,,,,Inhibition of CYP3A4,COc1cccc(-c2c(C)n(Cc3c(F)cccc3Cl)c(=O)n(C[C@H](NCCCC(=O)O)c3ccccc3)c2=O)c1F,"(R)-4-{2-[5-(2-Fluoro-3-methoxyphenyl)-3-(2-chloro-6-fluorobenzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyric Acid",11.0,uM,=,1.0413926851582251,1,O=c1c(-c2ccccc2)cn(Cc2ccccc2)c(=O)n1CCc1ccccc1
3726,1854052,10.1016/j.ejmech.2019.07.003,,,,Inhibition of recombinant human CYP3A4 using Luciferin-PPXE as substrate preincubated for 10 mins followed by NADPH addition measured after 15 mins by luminometric method,CCC(CC)Oc1ccc2cc(C(=O)NCC(O)(Cn3ccnc3)c3ccc(F)cc3F)c(=O)oc2c1,"rac-N-(2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-imidazol-1-yl)propyl)-2-oxo-7-(pentan-3-yloxy)-2H-chromene-3-carboxamide",0.332,uM,=,-0.4788619162959637,0,O=C(NCC(Cn1ccnc1)c1ccccc1)c1cc2ccccc2oc1=O
3727,1496402,10.1021/jm501840b,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate incubated for 30 mins by LC-MS/MS method,CC12CCC(C(NC(=O)[C@@H](CC3CCCCC3)NC(=O)N[C@@H](CCCCN)C(=O)O)C1)C2(C)C.Cl,"(2S)-6-amino-2-[[(1R)-1-(cyclohexylmethyl)-2-oxo-2-[(4,7,7-trimethylnorbornan-2-yl)amino]ethyl]carbamoylamino]hexanoic acid hydrochloride",15.0,uM,=,1.1760912590556811,1,O=C(CCC1CCCCC1)NC1CC2CCC1C2
3728,1797910,10.1021/acs.jmedchem.8b01326,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate/NADPH addition measured after 10 mins by LC-MS/MS analysis,CN1C(=N)N[C@@]2(c3cc(-c4cccc(Cl)c4)cs3)CN(c3ncc(F)cn3)C[C@H]2C1=O,"(4aR,7aR)-7a-(4-(3-Chlorophenyl)thiophen-2-yl)-6-(5-fluoropyrimidin-2-yl)-2-imino-3-methyloctahydro-4H-pyrrolo[3,4-d]-pyrimidin-4-one",1.2,uM,=,0.0791812460476248,1,N=C1NC(=O)[C@@H]2CN(c3ncccn3)C[C@]2(c2cc(-c3ccccc3)cs2)N1
3729,802673,10.1016/j.bmcl.2011.12.125,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,CCn1c(=O)[nH]c2ncnc(-c3ccc(NC(=O)Nc4cccc(C(=O)NC(C)C)c4)cc3)c21,"3-(3-(4-(7-ethyl-8-oxo-8,9-dihydro-7H-purin-6-yl)phenyl)ureido)-N-isopropylbenzamide",26.0,uM,=,1.414973347970818,1,O=C(Nc1ccccc1)Nc1ccc(-c2ncnc3[nH]c(=O)[nH]c23)cc1
3730,961188,10.1016/j.bmc.2013.03.069,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis,O=c1[nH]c2cc(-c3cccnc3)ccc2c2[nH]c(-c3ccccc3Cl)nc12,"2-(2-chlorophenyl)-7-(pyridin-3-yl)imidazo[4,5-c]quinolin-4(5H)-one",24.0,uM,=,1.380211241711606,1,O=c1[nH]c2cc(-c3cccnc3)ccc2c2[nH]c(-c3ccccc3)nc12
3731,1460848,10.1021/jm501038s,,,,Inhibition of CYP3A4 (unknown origin),N#Cc1ccccc1Oc1ccc(C(=O)NCc2ccncc2)cc1,4-(2-cyanophenoxy)-N-(pyridin-4-ylmethyl)benzamide,1.0,uM,=,0.0,0,O=C(NCc1ccncc1)c1ccc(Oc2ccccc2)cc1
3732,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1ccc(C[C@@H]2COCCN2C(=O)c2ccccc2-n2nccn2)cc1-n1nccn1,"US9150566, 66",36.0,uM,=,1.5563025007672873,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
3733,803119,10.1016/j.bmcl.2011.12.117,,,,Inhibition of CYP3A4,CCN(C(=O)Cc1ccc(S(C)(=O)=O)cc1)C1CCN(CC[C@@H](c2cc(F)cc(F)c2)C2CCN(S(C)(=O)=O)CC2)CC1,"(R)-N-(1-(3-(3,5-difluorophenyl)-3-(1-(methylsulfonyl)piperidin-4-yl)propyl)piperidin-4-yl)-N-ethyl-2-(4-(methylsulfonyl)phenyl)acetamide",9.0,uM,=,0.9542425094393248,1,O=C(Cc1ccccc1)NC1CCN(CC[C@@H](c2ccccc2)C2CCNCC2)CC1
3734,676065,10.1016/j.bmcl.2010.09.028,,,,Inhibition of CYP3A4 after 30 mins,CC(C)(CO)N1CCN(C(=O)OC2([C@H]3CCC[C@@H](C4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)CC1,"1-((2R,6S)-1-(4-chlorophenylsulfonyl)-6-cyclopropylpiperidin-2-yl)cyclopropyl 4-(1-hydroxy-2-methylpropan-2-yl)piperazine-1-carboxylate",0.4,uM,=,-0.3979400086720376,0,O=C(OC1([C@H]2CCC[C@@H](C3CC3)N2S(=O)(=O)c2ccccc2)CC1)N1CCNCC1
3735,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2ncco2)c1,"US9150566, 42",5.1,uM,=,0.7075701760979364,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2ncco2)c1
3736,479364,10.1016/j.bmcl.2008.05.027,,,,Inhibition of CYP3A4,CN(CC(=O)N1CCCC(c2ccccc2)C1CN1CCCC1)c1ccc(Cl)c(Cl)c1,"rac-2-((3,4-dichlorophenyl)(methyl)amino)-1-(3-phenyl-2-(pyrrolidin-1-ylmethyl)piperidin-1-yl)ethanone",1.4,uM,=,0.1461280356782379,1,O=C(CNc1ccccc1)N1CCCC(c2ccccc2)C1CN1CCCC1
3737,828928,10.1016/j.bmcl.2012.06.022,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,CCN(C)c1nc2ccc(C(=O)N(C)C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1,"Thiazol-5-ylmethyl(2S,3R)-4-(2-(ethyl(methyl)amino)-N-methylbenzo[d]oxazole-6-carboxamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate",0.11,uM,=,-0.958607314841775,0,O=C(N[C@H](CCNC(=O)c1ccc2ncoc2c1)Cc1ccccc1)OCc1cncs1
3738,450508,10.1021/jm070806a,,,,Inhibition of CYP3A4,Cc1ccc(N2CCN(C(=O)[C@H](C)Cc3ccc(Cl)cc3F)CC2)c([C@@H](NC(=O)CCN(C)C)C(C)C)c1,1-{2-[(1S)-(3-dimethylaminopropionyl)amino-2-methylpropyl]-4-methylphenyl}-4-[(2R)-methyl-3-(2-fluoro-4-chlorophenyl)propionyl]piperazine,6.4,uM,=,0.8061799739838872,1,O=C(CCc1ccccc1)N1CCN(c2ccccc2)CC1
3739,1660136,10.1021/acs.jmedchem.6b01918,,,,Inhibition of human CYP3A4 assessed as inhibition of dealkylation,O=S(=O)(Nc1nccs1)c1cc(Cl)c(NC[C@H]2CCCN(O)C2)cc1F,(R)-5-Chloro-2-fluoro-4-(((1-hydroxypiperidin-3-yl)methyl)-amino)-N-(thiazol-2-yl)benzenesulfonamide,7.9,uM,=,0.8976270912904415,1,O=S(=O)(Nc1nccs1)c1ccc(NC[C@H]2CCCNC2)cc1
3740,659957,10.1021/jm100643t,,,,Inhibition of CYP3A4,CC(C)(C)c1ccc(SCC(c2ccccn2)c2c[nH]cn2)cc1,2-(2-(4-tert-Butylphenylthio)-1-(1H-imidazol-4-yl)ethyl)pyridine,0.27,uM,=,-0.5686362358410126,0,c1ccc(SCC(c2ccccn2)c2c[nH]cn2)cc1
3741,595557,10.1016/j.bmcl.2009.10.084,,,,Inhibition of CYP3A4 using BFC as a substrate,Cc1cc2cc(N/C(=N\C(=O)c3ccc(C(=O)O)nc3)N[C@H]3CCCCN(CC(=O)N4CCCC4)C3=O)ccc2o1,(S)-5-((2-methylbenzofuran-5-ylamino)(2-oxo-1-(2-oxo-2-(pyrrolidin-1-yl)ethyl)azepan-3-ylamino)methylenecarbamoyl)picolinic acid,87.0,uM,=,1.9395192526186185,1,O=C(/N=C(\Nc1ccc2occc2c1)N[C@H]1CCCCN(CC(=O)N2CCCC2)C1=O)c1cccnc1
3742,834635,10.1016/j.bmcl.2012.07.019,,,,Inhibition of CYP3A4,N[C@@H](CC(=O)N1CCN(C(=O)c2ccc(S(N)(=O)=O)cc2)CC1)Cc1cc(F)c(F)cc1F,"(R)-4-(4-(3-amino-4-(2,4,5-trifluorophenyl)butanoyl)piperazine-1-carbonyl)benzenesulfonamide",1.0,uM,=,0.0,0,O=C(CCCc1ccccc1)N1CCN(C(=O)c2ccccc2)CC1
3743,1696937,10.1016/j.bmcl.2017.09.042,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate pretreated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis,O=C(Nc1ccc(F)cn1)c1cc(Oc2cncc(F)c2)cn2cnnc12,"N-(5-Fluoropyridin-2-yl)-6-((5-fluoropyridin-3-yl)oxy)-[1,2,4]triazolo[4,3-a]pyridine-8-carboxamide",17.8,uM,=,1.250420002308894,1,O=C(Nc1ccccn1)c1cc(Oc2cccnc2)cn2cnnc12
3744,552281,10.1016/j.bmcl.2008.04.036,,,,Inhibition of CYP3A4,CCOC(=O)CNCc1ccc(-c2cn(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](N)c3ccccc3)c2=O)cc1,"(R)-ethyl 2-(4-(1-(2-fluoro-6-(trifluoromethyl)benzyl)-3-(2-amino-2-phenylethyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)benzylamino)acetate",0.35,uM,=,-0.4559319556497244,0,O=c1c(-c2ccccc2)cn(Cc2ccccc2)c(=O)n1CCc1ccccc1
3745,519908,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,Cc1nc2c(NCc3ccc(F)cc3Cl)cc(-n3ccccc3=O)cn2c1C,"1-(8-(2-chloro-4-fluorobenzylamino)-2,3-dimethylimidazo[1,2-a]pyridin-6-yl)pyridin-2(1H)-one",13.0,uM,=,1.1139433523068367,1,O=c1ccccn1-c1cc(NCc2ccccc2)c2nccn2c1
3746,1352209,10.1021/jm4010835,,,,Inhibition of human recombinant CYP3A4,CCn1nc2c(-c3ccc(Cl)cc3)c(-c3cnn(C)c3)c(=O)n(Cc3ccc(C#N)cc3)n2c1=O,"4-((8-(4-chlorophenyl)-2-ethyl-7-(1-methyl-1H-pyrazol-4-yl)-3,6-dioxo-2,3-dihydro-[1,2,4]triazolo[4,3-b]pyridazin-5(6H)-yl)methyl)benzonitrile",3.4,uM,=,0.5314789170422551,1,O=c1c(-c2cn[nH]c2)c(-c2ccccc2)c2n[nH]c(=O)n2n1Cc1ccccc1
3747,854798,10.1016/j.bmc.2012.08.056,,,,Inhibition of human CYP3A4 using 7-benzyloxy-4-(trifluoromethyl) coumarin as substrate,CN(Cc1cccs1)C(=O)C12CC3CC(CC(C3)C1)C2,Adamantane-1-carboxylic acid methyl-thiophen-2-ylmethyl-amide,10.0,uM,=,1.0,1,O=C(NCc1cccs1)C12CC3CC(CC(C3)C1)C2
3748,993292,10.1021/ml400228e,,,,Inhibition of CYP3A4 in human liver microsomes using nifedipine as substrate after 5 to 60 mins by LC-MS/MS analysis,Cn1cc(-c2ccc3c(c2F)CCN3C(=O)Cc2cccc(C(F)(F)F)n2)c2c(N)ncnc21,"5-(4-fluoro-1-{[6-(trifluoromethyl)-2-pyridinyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine",7.4,uM,=,0.8692317197309762,1,O=C(Cc1ccccn1)N1CCc2cc(-c3c[nH]c4ncncc34)ccc21
3749,643713,10.1016/j.bmcl.2010.06.009,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader,C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(NC5CCN(C)CC5)n4)ccc32)sc1C(N)=O)c1ccccc1Cl,(R)-3-(1-(2-chlorophenyl)ethoxy)-5-(5-(2-(1-methylpiperidin-4-ylamino)pyrimidin-4-yl)-1H-benzo[d]imidazol-1-yl)thiophene-2-carboxamide,15.0,uM,=,1.1760912590556811,1,c1ccc(COc2csc(-n3cnc4cc(-c5ccnc(NC6CCNCC6)n5)ccc43)c2)cc1
3750,673772,10.1016/j.bmcl.2010.08.102,,,,Inhibition of CYP3A4 by competitive inhibition assay,CC(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNC1(c2cccc(C(C)(C)C(F)F)c2)CC1,"N-((2S,3R)-4-(1-(3-(1,1-difluoro-2-methylpropan-2-yl)phenyl)cyclopropylamino)-1-(3,5-difluorophenyl)-3-hydroxybutan-2-yl)acetamide",0.11,uM,=,-0.958607314841775,0,c1ccc(CCCCNC2(c3ccccc3)CC2)cc1
3751,1688648,10.1021/acs.jmedchem.7b00410,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 8 mins by LC/MS/MS analysis,Cc1cc(Oc2cncnc2)cc(C(=O)Nc2ccc(Cl)cn2)n1,N-(5-Chloropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)-picolinamide,16.4,uM,=,1.214843848047698,1,O=C(Nc1ccccn1)c1cc(Oc2cncnc2)ccn1
3752,699316,10.1016/j.bmc.2010.10.034,,,,Inhibition of CYP3A4,CNC[C@H]1Cc2ccccc2[C@H](c2ccc(Cl)c(Cl)c2)C1,"trans-1-((2R,4S)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-2-yl)-N-methylmethanamine",20.1,uM,=,1.3031960574204888,1,c1ccc([C@@H]2CCCc3ccccc32)cc1
3753,796228,10.1016/j.bmcl.2011.10.115,,,,Inhibition of CYP3A4,Cc1ccc(Cn2c(C3CNCCO3)nc3ccccc32)cc1C,"(+)-2-(1-(3,4-dimethylbenzyl)-1H-benzo[d]imidazol-2-yl)morpholine",4.9,uM,=,0.6901960800285137,1,c1ccc(Cn2c(C3CNCCO3)nc3ccccc32)cc1
3754,2027342,10.1021/acs.jmedchem.6b01122,,,,Inhibition of CYP3A4 in pooled human liver microsomes using midazolam as substrate in presence of NADPH incubated for 10 mins by LC-MS/MS analysis,C[C@@H]1CN(c2ccc(C(C)(C)O)nc2)CCN1c1cccc(C(=O)NC2C3CC4CC2CC(O)(C4)C3)n1,"N-((1R,2s,3S,5S,7S)-5-Hydroxyadamantan-2-yl)-6-((R)-4-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-2-methylpiperazin-1-yl)picolinamide",5.4,uM,=,0.7323937598229685,1,O=C(NC1C2CC3CC(C2)CC1C3)c1cccc(N2CCN(c3cccnc3)CC2)n1
3755,1845477,10.1021/acsmedchemlett.0c00004,,,,Inhibition of CYP3A4 (unknown origin),O[C@@H]1c2ccccc2CC[C@H]1[C@H]1c2ccccc2-c2cncn21,"(1S,2S)-2-((S)-5H-imidazo[5,1-a]isoindol-5-yl)-1,2,3,4-tetrahydronaphthalen-1-ol",0.84,uM,=,-0.0757207139381183,0,c1ccc2c(c1)CC[C@@H]([C@H]1c3ccccc3-c3cncn31)C2
3756,1540696,10.1016/j.ejmech.2015.08.051,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 2 mins by LC-MS/MS analysis in presence of NADPH regeneration system,CC(C)c1nc(C(=O)NC2CCN(CCF)CC2)c2ccccn12,"N-(1-(2-fluoroethyl)piperidin-4-yl)-3-isopropylimidazo[1,5-a]pyridine-1-carboxamide",27.3,uM,=,1.436162647040756,1,O=C(NC1CCNCC1)c1ncn2ccccc12
3757,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2C(CN(Cc3cccc4c(C(=O)Nc5ccc(NCCN(CC)CC)nc5)cn(C)c34)C(=O)[C@@H]2Cc2ccc(O)cc2)N1C(=O)NCc1ccccc1,"US8940739, G-24",4.53,uM,=,0.6560982020128319,1,O=C(Nc1cccnc1)c1c[nH]c2c(CN3CC4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12
3758,1534761,,,,,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",COc1cnc2[nH]cc(Cc3ccc(NCc4ccc(OC)nc4)nc3F)c2c1,"US9096593, P-2030",5.0,uM,=,0.6989700043360189,1,c1cncc(CNc2ccc(Cc3c[nH]c4ncccc34)cn2)c1
3759,1485703,10.1124/dmd.112.048264,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method,COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1c1cccc([N+](=O)[O-])c1,"2,6-Dimethyl-4-(3-nitro-phenyl)-1,4-dihydro-pyridine-3,5-dicarboxylic acid 3-isopropyl ester 5-(2-methoxy-ethyl) ester",1.78,uM,=,0.250420002308894,1,C1=CC(c2ccccc2)C=CN1
3760,449485,10.1016/j.bmcl.2007.07.097,,,,Inhibition of microsomal CYP3A4,CC(C)C[C@H](NC(=O)CCN)c1cc(F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1,"3-amino-N-((S)-1-(2-(4-((R)-3-(2,4-dichlorophenyl)-2-(2-oxopyrrolidin-1-yl)propanoyl)piperazin-1-yl)-5-fluorophenyl)-3-methylbutyl)propanamide",6.4,uM,=,0.8061799739838872,1,O=C([C@@H](Cc1ccccc1)N1CCCC1=O)N1CCN(c2ccccc2)CC1
3761,2214899,10.1016/j.ejmech.2022.114161,,,,Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone as substrate by LC-MS/MS analysis,CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,SID144204227,0.0125,uM,=,-1.9030899869919435,0,c1ccc([C@@]2(Cn3ccnc3)OC[C@H](COc3ccc(N4CCNCC4)cc3)O2)cc1
3762,854798,10.1016/j.bmc.2012.08.056,,,,Inhibition of human CYP3A4 using 7-benzyloxy-4-(trifluoromethyl) coumarin as substrate,Cc1ccc(C2(C(=O)N(C)Cc3cccs3)CC2)cc1,N-Methyl-N-(thiophen-2-ylmethyl)-1-p-tolylcyclopropanecarboxamide,7.3,uM,=,0.8633228601204559,1,O=C(NCc1cccs1)C1(c2ccccc2)CC1
3763,2103815,10.1016/j.bmcl.2021.128010,,,,Time dependent inhibition of CYP3A4 (unknown origin) measured at 30 mins,Nc1cc(Cc2ccn(Cc3ccc4c(c3)CCNC4)n2)c2nn[nH]c2n1,"7-((1-((1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)-1H-pyrazol-3-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-amine",7.0,uM,=,0.8450980400142568,1,c1cc(Cc2ccn(Cc3ccc4c(c3)CCNC4)n2)c2nn[nH]c2n1
3764,856844,10.1021/jm300356u,,,,Inhibition of human recombinant CYP3A4 using 7-BQ as substrate preincubated for 5 to 10 mins before substrate addition,CC/N=C1\O[C@H]2[C@H](O[C@@H]3[C@@H](C)[C@H](O[C@H]4C[C@@](C)(OC)[C@@H](O)[C@H](C)O4)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]3(C)OC)O[C@H](C)C[C@@H]2N1C,"(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-14-ethyl-6-((3aR,4S,6R,7aS)-2-(ethylimino)-1,6-dimethylhexahydro-1H-pyrano[4,3-d]oxazol-4-yloxy)-12,13-dihydroxy-4-((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yloxy)-7-methoxy-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione",2.9,uM,=,0.4623979978989561,1,N=C1N[C@H]2CCO[C@@H](O[C@H]3CCCC(=O)CCCCOC(=O)C[C@@H](O[C@H]4CCCCO4)C3)[C@@H]2O1
3765,526157,10.1021/np0401765,,,,Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation,CC1=C[C@@H](O)[C@@]23O[C@]2(C)C[C@@H]2OC(=O)C(C)=C2C[C@@H]13,"(1alpha,2beta,5alpha,8alpha,10alpha)-1,10-epoxy-2-hydroxy-3,7(11)-guaiadien-12,8-olide",98.2,uM,=,1.9921114877869497,1,O=C1C=C2C[C@H]3C=CC[C@]34OC4C[C@@H]2O1
3766,550965,10.1021/np030556a,,,,Inhibition of human CYP3A4 by radiometric assay,CCCCC[C@H](O)CC(=O)CCc1ccc(OC)c(O)c1,(S)-6-gingerol,36.4,uM,=,1.561101383649056,1,c1ccccc1
3767,550965,10.1021/np030556a,,,,Inhibition of human CYP3A4 by radiometric assay,C/C1=C\CC(C)(C)/C=C/C(=O)/C(C)=C/[C@H](O)C1,"(5R)-2,6,9-humulatrien-5-ol-8-one",35.5,uM,=,1.5502283530550942,1,O=C1/C=C/CCC=CCC/C=C/1
3768,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCCN5CCN(C)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, F-30",2.54,uM,=,0.404833716619938,1,O=C(NCCCN1CCNCC1)c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12
3769,2048449,10.1016/j.bmc.2020.115734,,,,Inhibition of recombinant CYP3A4 (unknown origin) by fluorescence-based assay,COc1nc(-c2csc(Nc3c4c(nn3CC(C)(C)O)CCCC4)n2)ccc1-n1cnc(C)c1,"1-(3-((4-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)thiazol-2-yl)amino)-4,5,6,7-tetrahydro-2H-indazol-2-yl)-2-methylpropan-2-ol",1.1,uM,=,0.041392685158225,1,c1cn(-c2ccc(-c3csc(Nc4[nH]nc5c4CCCC5)n3)nc2)cn1
3770,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",CC[C@@H]1CN(C(=O)c2ccccc2-n2nccn2)[C@H](Cc2cccc(-n3nccn3)c2)CO1,"US9150566, 143",9.1,uM,=,0.9590413923210936,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
3771,2170798,10.1021/acs.jmedchem.0c02143,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated 10 mins in presence of NADPH by solid phase extraction mass spectrometry analysis,C[C@@]1(c2cc(NC(=O)c3ncc(C#N)cc3Cl)ccc2F)CO[C@@](C)(C(F)(F)F)C(N)=N1,"N-(3-((3R,6R)-5-amino-3,6-dimethyl-6-(trifluoromethyl)-3,6-dihydro-2H-1,4-oxazin-3-yl)-4-fluorophenyl)-3-chloro-5-cyanopicolinamide",17.0,uM,=,1.230448921378274,1,O=C(Nc1cccc(C2COCC=N2)c1)c1ccccn1
3772,1624781,10.1021/acs.jmedchem.6b00697,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH by LC-MS/MS analysis,N#CN=C(NCCCCCCOc1ccc(Cl)cc1)Nc1ccncc1,N-[6-(4-chlorophenoxy)hexyl]-N''-cyano-N'-pyridin-4-ylguanidine,0.32,uM,=,-0.494850021680094,0,N=C(NCCCCCCOc1ccccc1)Nc1ccncc1
3773,1298305,10.1016/j.ejmech.2014.01.021,,,,Inhibition of CYP3A4 (unknown origin),N#C[C@@H]1C[C@H](F)CN1C(=O)[C@@H](N)Cc1cc2c(cc1Br)OCO2,"(2S,4S)-1-[(2S)-2-Amino-3-(6-bromobenzo[d][1,3]dioxol-5-yl)propanoyl]-4-fluoropyrrolidine-2-carbonitrile",2.2,uM,=,0.3424226808222063,1,O=C(CCc1ccc2c(c1)OCO2)N1CCCC1
3774,686352,10.1016/j.bmcl.2010.09.037,,,,Inhibition of CYP3A4,O=c1cc(-c2ccc(C(F)(F)F)cc2)ccn1-c1ccc2c(cnn2CCN2CCCC2)c1,1-(1-(2-(pyrrolidin-1-yl)ethyl)-1H-indazol-5-yl)-4-(4-(trifluoromethyl)phenyl)pyridin-2(1H)-one,2.0,uM,=,0.3010299956639812,1,O=c1cc(-c2ccccc2)ccn1-c1ccc2c(cnn2CCN2CCCC2)c1
3775,1366898,10.1021/jm500312x,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 15 mins by LC/MS/MS analysis,C=C[C@]1(C)C[C@@H](OC(=O)CSc2cncc(NC(=O)CN3CCC(O)CC3)c2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O,14-O-(((5-((4-Hydroxylpiperidin-1-yl)acetamido)pyridin-3-yl)-sulfanyl)acetyl)mutilin,1.63,uM,=,0.2121876044039577,1,O=C(CN1CCCCC1)Nc1cncc(SCC(=O)O[C@@H]2CCCC[C@@]34CCCC2[C@@H]3C(=O)CC4)c1
3776,1797910,10.1021/acs.jmedchem.8b01326,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate/NADPH addition measured after 10 mins by LC-MS/MS analysis,CCCOc1nc(N2C[C@H]3C(=O)N(C)C(=N)N[C@@]3(c3cc(-c4cccc(C#N)c4)cs3)C2)ncc1F,"3-(5-((4aR,7aR)-6-(5-Fluoro-4-propoxypyrimidin-2-yl)-2-imino-3-methyl-4-oxooctahydro-7aH-pyrrolo[3,4-d]pyrimidin-7a-yl)-thiophen-3-yl)benzonitrile",1.2,uM,=,0.0791812460476248,1,N=C1NC(=O)[C@@H]2CN(c3ncccn3)C[C@]2(c2cc(-c3ccccc3)cs2)N1
3777,473932,10.1021/jm701121y,,,,Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay,COC(=O)[C@H](Cc1c[nH]cn1)NCc1ccccc1,(S)-methyl 2-(benzylamino)-3-(1H-imidazol-4-yl)propanoate,1.5,uM,=,0.1760912590556812,1,c1ccc(CNCCc2c[nH]cn2)cc1
3778,631458,10.1021/jm9013136,,,,Inhibition of human recombinant CYP3A4,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,"1-(4-{4-[2-(2,4-Dichloro-phenyl)-2-imidazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-ethanone (ketoconazole)",0.011,uM,=,-1.958607314841775,0,c1ccc(C2(Cn3ccnc3)OCC(COc3ccc(N4CCNCC4)cc3)O2)cc1
3779,495153,10.1021/jm8006454,,,,Inhibition of CYP3A4,COC(=O)CCCN[C@@H](Cn1c(=O)c(-c2cccc(OC)c2F)c(C)n(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1,"Methyl (R)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2Hpyrimidin-1-yl]-1-phenylethylamino}butyrate",0.44,uM,=,-0.3565473235138126,0,O=c1c(-c2ccccc2)cn(Cc2ccccc2)c(=O)n1CCc1ccccc1
3780,555862,10.1016/j.bmcl.2008.04.047,,,,Inhibition of human CYP3A4,Nc1nccc(Oc2ccc(NC(=O)NC(=O)Cc3ccc(F)cc3)cc2F)c1C#Cc1ccccn1,1-(4-(2-amino-3-(2-(pyridin-2-yl)ethynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(2-(4-fluorophenyl)acetyl)urea,37.0,uM,=,1.568201724066995,1,O=C(Cc1ccccc1)NC(=O)Nc1ccc(Oc2ccncc2C#Cc2ccccn2)cc1
3781,1625607,10.1016/j.bmcl.2016.10.016,,,,Inhibition of human Cyp3A4 using testosterone as substrate by LC-MS/MS analysis,O=S(=O)(c1cccs1)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,"1-(4-{[(2S,4R)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)-4-(thiophene-2-sulfonyl)piperazine",0.087,uM,=,-1.0604807473813815,0,O=S(=O)(c1cccs1)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccccc4)O3)cc2)CC1
3782,1919651,,,,,"Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase",CSCc1ccc(-c2cccnc2)o1,3-(5-((methylthio)methyl)furan-2-yl)pyridine,14.8,uM,=,1.1702617153949575,1,c1cncc(-c2ccco2)c1
3783,449088,10.1016/j.bmcl.2007.08.028,,,,Inhibition of human CYP3A4,CC(=O)N1CCC(C(=O)N2C[C@H](C(=O)N(C)Cc3cc(C(F)(F)F)cc(C(F)(F)F)c3)[C@@H](c3ccc(F)cc3C)C2)CC1,"(3R,4S)-N-(3,5-bis(trifluoromethyl)benzyl)-1-(1-acetylpiperidine-4-carbonyl)-4-(4-fluoro-2-methylphenyl)-N-methylpyrrolidine-3-carboxamide",11.0,uM,=,1.0413926851582251,1,O=C(NCc1ccccc1)[C@H]1CN(C(=O)C2CCNCC2)C[C@@H]1c1ccccc1
3784,993292,10.1021/ml400228e,,,,Inhibition of CYP3A4 in human liver microsomes using nifedipine as substrate after 5 to 60 mins by LC-MS/MS analysis,Cc1cccc(CC(=O)N2CCc3c2ccc(-c2cn(C)c4ncnc(N)c24)c3F)n1,"5-{4-fluoro-1-[(6-methyl-2-pyridinyl)acetyl]-2,3-dihydro-1H-indol-5-yl}-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine",19.7,uM,=,1.294466226161593,1,O=C(Cc1ccccn1)N1CCc2cc(-c3c[nH]c4ncncc34)ccc21
3785,598210,10.1016/j.bmcl.2009.08.024,,,,Inhibition of human CYP3A4,CC1(CC(=O)NCc2ccccc2OC(F)(F)F)CC2(CCCCC2)OO1,"2-(3-methyl-1,2-dioxaspiro[4.5]decan-3-yl)-N-(2-(trifluoromethoxy)benzyl)acetamide",4.2,uM,=,0.6232492903979004,1,O=C(CC1CC2(CCCCC2)OO1)NCc1ccccc1
3786,1705360,10.1016/j.bmcl.2017.06.037,,,,Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method,CNC(=O)c1ccc(COc2ccc(C#Cc3ccc(C(F)(F)C(O)(Cn4cnnn4)c4ccc(F)cc4F)nc3)cc2)cc1,"4-((4-((6-(2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(1H-tetrazol-1-yl)propyl)pyridin-3-yl)ethynyl)phenoxy)methyl)-N-methylbenzamide",122.0,uM,=,2.0863598306747484,1,C(#Cc1ccc(CC(Cn2cnnn2)c2ccccc2)nc1)c1ccc(OCc2ccccc2)cc1
3787,804823,10.1016/j.bmcl.2011.12.080,,,,Time dependent inhibition of CYP3A4,Cc1cc(Cl)cc2c(C(O)c3ncco3)c3c(C)n[nH]c3nc12,"rac-(6-chloro-3,8-dimethyl-1H-pyrazolo[3,4-b]quinolin-4-yl)(oxazol-2-yl)methanol",1.0,uM,=,0.0,0,c1ccc2c(Cc3ncco3)c3cn[nH]c3nc2c1
3788,1919651,,,,,"Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase",NC[C@@H]1CC[C@@H](c2cccnc2)O1,trans-(tetrahydro-5-(pyridin-3-yl)furan-2-yl)methanamine,64.71,uM,=,1.810971399822208,1,c1cncc([C@@H]2CCCO2)c1
3789,1625607,10.1016/j.bmcl.2016.10.016,,,,Inhibition of human Cyp3A4 using testosterone as substrate by LC-MS/MS analysis,O=S(=O)(C1CCOCC1)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,"1-(4-{[(2S,4R)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)-4-(oxane-4-sulfonyl)piperazine",0.226,uM,=,-0.645891560852599,0,O=S(=O)(C1CCOCC1)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccccc4)O3)cc2)CC1
3790,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cc(-n2nccn2)ccc1F,"US9150566, 57",20.0,uM,=,1.3010299956639813,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
3791,2025187,10.1016/j.bmc.2020.115859,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 3 mins followed by NADPH addition by LC-MS/MS analysis,CCCCOC(=O)NS(=O)(=O)c1sc(CC(C)C)cc1-c1cccc(Cn2ccnc2)c1,3-(3-Imidazol-1-ylmethylphenyl)-5-isobutylthiophene-2-(N-butyloxy carbonyl)sulfonamide,120.0,uM,=,2.0791812460476247,1,c1cc(Cn2ccnc2)cc(-c2ccsc2)c1
3792,789607,10.1021/jm2008369,,,,Inhibition of human CYP3A4,Cc1ccc(COc2ccc3c(c2)c(SC(C)(C)C)c(CC(C)(C)C(=O)O)n3Cc2ccc(-c3ccc(F)cn3)cc2)nc1,"3-[3-tert-Butylsulfanyl-1-[4-(5-fluoropyridin-2-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid",0.0055,uM,=,-2.2596373105057563,0,c1ccc(COc2ccc3c(ccn3Cc3ccc(-c4ccccn4)cc3)c2)nc1
3793,512798,10.1021/jm800832q,,,,Inhibition of human recombinant CYP3A4 in human liver microsomes using BFC as a substrate,COc1ccc([C@H](O)CNc2cc[nH]c(=O)c2-c2nc3c(C)cc(C4CCN(CCCF)CC4)cc3[nH]2)cc1Cl,(S)-4-(2-(3-chloro-4-methoxyphenyl)-2-hydroxyethlamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridine-2(1H)-one,10.0,uM,=,1.0,1,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(C3CCNCC3)cc2[nH]1
3794,851921,10.1016/j.bmcl.2012.08.072,,,,Inhibition of human recombinant CYP3A4,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1cccc(Cl)c1,"N-(3-chlorophenyl)-2-(4-morpholino-6-oxo-1,6-dihydropyrimidin-2-yl)acetamide",40.0,uM,=,1.6020599913279625,1,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccccc1
3795,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)Nc6ccccc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, D-17",7.63,uM,=,0.8825245379548805,1,O=C(Nc1ccccc1)c1ccc(-c2c[nH]c3c(CN4C[C@@H]5N(C(=O)NCc6ccccc6)NCC(=O)N5[C@@H](Cc5ccccc5)C4=O)cccc23)cc1
3796,559938,10.1016/j.bmcl.2008.10.072,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,COc1cccc(CCN(Cc2ccccc2-c2ccc(CN3C[C@@H](C)N[C@@H](C)C3)cc2)C(=O)NC2CCCCC2)c1,"3-Cyclohexyl-1-[4'-((3R,5S)-3,5-dimethyl-piperazin-1-ylmethyl)-biphenyl-2-ylmethyl]-1-[2-(3-methoxy-phenyl)-ethyl]-urea",0.2,uM,=,-0.6989700043360187,0,O=C(NC1CCCCC1)N(CCc1ccccc1)Cc1ccccc1-c1ccc(CN2CCNCC2)cc1
3797,461436,10.1016/j.bmcl.2007.10.092,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,CC[C@@H]1CCC[C@H](C2(CC(=O)N3CCN4CCCC[C@H]4C3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1,"2-(1-((2R,6R)-1-(4-chlorophenylsulfonyl)-6-ethylpiperidin-2-yl)cyclopropyl)-1-((S)-hexahydro-1H-pyrido[1,2-a]pyrazin-2(6H)-yl)ethanone",4.2,uM,=,0.6232492903979004,1,O=C(CC1([C@H]2CCCCN2S(=O)(=O)c2ccccc2)CC1)N1CCN2CCCC[C@H]2C1
3798,464923,10.1021/jm7011408,,,,Inhibition of CYP3A4,O=C(NO)c1ccc(-c2ccn(CCNCc3ccc4c(c3)OCO4)n2)s1,"5-(1-(2-(benzo[d][1,3]dioxol-5-ylmethylamino)ethyl)-1H-pyrazol-3-yl)-N-hydroxythiophene-2-carboxamide",0.51,uM,=,-0.2924298239020636,0,c1csc(-c2ccn(CCNCc3ccc4c(c3)OCO4)n2)c1
3799,355280,10.1016/j.bmcl.2006.02.020,,,,Inhibition of CYP3A4,C[C@H]([C@@H](c1ccc2cc(OCC(C)(C)C(=O)O)ccc2c1)n1ccnc1)N1CCOCC1,"3-(6-((1R,2R)-1-(1H-imidazol-1-yl)-2-morpholinopropyl)naphthalen-2-yloxy)-2,2-dimethylpropanoic acid",2.15,uM,=,0.3324384599156053,1,c1ccc2cc([C@H](CN3CCOCC3)n3ccnc3)ccc2c1
3800,643687,10.1016/j.bmcl.2010.06.060,,,,Inhibition of human CY3A4,COc1ccc(S(=O)(=O)Nc2cc(Cl)cc(Cl)c2OC)cc1NC1CCN(C)CC1,"N-(3,5-Dichloro-2-methoxyphenyl)-4-methoxy-[(1-methylpiperidin-4-yl)amino]benzenesulfonamide",8.44,uM,=,0.926342446625655,1,O=S(=O)(Nc1ccccc1)c1cccc(NC2CCNCC2)c1
3801,1709454,10.1016/j.ejmech.2017.05.043,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by NADPH addition measured after 10 mins by LC/MS/MS analysis,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,"1-(4-{4-[2-(2,4-Dichloro-phenyl)-2-imidazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-ethanone (ketoconazole)",0.0359,uM,=,-1.4449055514216809,0,c1ccc(C2(Cn3ccnc3)OCC(COc3ccc(N4CCNCC4)cc3)O2)cc1
3802,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(C(C)=O)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, E-14",10.9,uM,=,1.0374264979406236,1,O=C(c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12)N1CCNCC1
3803,834929,10.1016/j.bmcl.2012.07.020,,,,Inhibition of CYP3A4,CCS(=O)(=O)c1ccc2[nH]c(-c3ccc(F)c(-c4ccccc4)c3)nc2c1,5-(ethylsulfonyl)-2-(6-fluorobiphenyl-3-yl)-1H-benzo[d]imidazole,5.6,uM,=,0.7481880270062004,1,c1ccc(-c2cccc(-c3nc4ccccc4[nH]3)c2)cc1
3804,519907,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,Cc1cccc(C)c1CNc1cc(-n2cnc(CO)n2)cn2c(C)c(C)nc12,"(1-(8-(2,6-dimethylbenzylamino)-2,3-dimethylimidazo[1,2-a]pyridin-6-yl)-1H-1,2,4-triazol-3-yl)methanol",13.0,uM,=,1.1139433523068367,1,c1ccc(CNc2cc(-n3cncn3)cn3ccnc23)cc1
3805,353252,10.1021/jm0510979,,,,Inhibition of CYP3A4,NC(=O)c1sc(-c2ccccc2)cc1N,3-amino-5-phenyl-thiophene-2-carboxylic acid amide,3.5,uM,=,0.5440680443502757,1,c1ccc(-c2cccs2)cc1
3806,1528565,,,,,"Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",CC(C)c1nc(CN(C)C(=O)N2CCC[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,"US8987313, 39",0.13,uM,=,-0.8860566476931633,0,O=C(N[C@H](CC[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)NCc1cscn1)Cc1ccccc1)OCc1cncs1
3807,1491685,10.1124/dmd.112.045708,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 90 mins followed by substrate addition by LC-MS/MS analysis,COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1,"Acetic acid (2S,3S)-5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester",220.0,uM,=,2.342422680822206,1,O=C1C[C@H](c2ccccc2)Sc2ccccc2N1
3808,539794,10.1021/jm8005405,,,,Inhibition of CYP3A4 in human liver microsomes,CC(=O)N1CCN(c2nncc3cc(-c4c(C)ccc5c(NC6CC6)noc45)ccc23)[C@@H](C)C1,1-((S)-4-(6-(3-(Cyclopropylamino)-6-methylbenzo[d]isoxazol-7-yl)phthalazin-1-yl)-3-methylpiperazin-1-yl)ethanone,4.2,uM,=,0.6232492903979004,1,c1cc(-c2ccc3c(N4CCNCC4)nncc3c2)c2onc(NC3CC3)c2c1
3809,1859912,10.1021/acsmedchemlett.9b00114,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 10 mins in presence of NADPH by UHPLC-MS/MS analysis,Cn1cc(-c2ccc(N3CCC(C4c5c(F)cccc5-c5cncn54)CC3)cc2)cn1,"6-fluoro-5-(1-(4-(1-methyl-1H-pyrazol-4-yl)phenyl)piperidin-4-yl)-5H-imidazo[5,1-a]isoindole",8.4,uM,=,0.9242792860618816,1,c1ccc2c(c1)-c1cncn1C2C1CCN(c2ccc(-c3cn[nH]c3)cc2)CC1
3810,473932,10.1021/jm701121y,,,,Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay,CCOc1ccc(NC(=O)c2ccc(-n3cnnn3)cc2)cc1,N-(4-ethoxyphenyl)-4-(1H-tetrazol-1-yl)benzamide,34.0,uM,=,1.5314789170422551,1,O=C(Nc1ccccc1)c1ccc(-n2cnnn2)cc1
3811,305432,10.1016/j.bmcl.2005.01.044,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,CC(C(c1ccc2cc(OCc3cccc(C(=O)O)c3)ccc2c1)n1ccnc1)N(C)C,3-[6-(2-Dimethylamino-1-imidazol-1-yl-propyl)-naphthalen-2-yloxymethyl]-benzoic acid,1.59,uM,=,0.2013971243204514,1,c1ccc(COc2ccc3cc(Cn4ccnc4)ccc3c2)cc1
3812,2062192,10.1016/j.bmcl.2016.04.018,,,,Inhibition of human liver microsomes CYP3A4 using testosterone as substrate by MUX-MS/MS analysis,Cc1cc(-c2ccc3c(c2)-c2nnc(Oc4cccc(Cl)c4F)n2CCO3)ccn1,"3-(3-chloro-2-fluorophenoxy)-10-(2-methylpyridin-4-yl)-5,6-dihydrobenzo[f][1,2,4]triazolo[4,3-d][1,4]oxazepine",8.39,uM,=,0.9237619608287004,1,c1ccc(Oc2nnc3n2CCOc2ccc(-c4ccncc4)cc2-3)cc1
3813,1910981,10.1021/acs.jmedchem.8b01464,,,,Inhibition of human CYP3A4 in presence of NADPH by luciferase reporter gene assay,C=CCn1cc(C(c2ccc(Cl)cc2)n2ccnc2)cc1-c1ccc(Cl)cc1,1-[[1-Allyl-5-(4-chlorophenyl)-1H-pyrrol-3-yl](4-chlorophenyl)methyl]-1H-imidazole,0.9,uM,=,-0.0457574905606751,0,c1ccc(-c2cc(C(c3ccccc3)n3ccnc3)c[nH]2)cc1
3814,1451406,10.1021/jm500916t,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs,CC1(C)C[C@@H](NC(=O)Nc2cccc3cnccc23)c2ccc(F)cc2O1,"(R)-1-(7-Fluoro-2,2-dimethylchroman-4-yl)-3-(isoquinolin-5-yl)-urea",0.66,uM,=,-0.1804560644581313,0,O=C(Nc1cccc2cnccc12)N[C@@H]1CCOc2ccccc21
3815,634898,10.1016/j.bmcl.2010.04.052,,,,Inhibition of CYP3A4,COc1ccccc1CC(c1ccccc1)N1CCNCC1,1-(2-(2-methoxyphenyl)-1-phenylethyl)piperazine,194.0,uM,=,2.287801729930226,1,c1ccc(CC(c2ccccc2)N2CCNCC2)cc1
3816,828928,10.1016/j.bmcl.2012.06.022,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N3CCOCC3)oc2c1,"Thiazol-5-ylmethyl(2S,3R)-3-hydroxy-4-(N-isobutyl-2-morpholinobenzo[d]oxazole-6-carboxamido)-1-phenylbutan-2-ylcarbamate",0.038,uM,=,-1.42021640338319,0,O=C(N[C@H](CCNC(=O)c1ccc2nc(N3CCOCC3)oc2c1)Cc1ccccc1)OCc1cncs1
3817,1659434,10.1021/acs.jmedchem.6b01662,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH by LC-MS/MS analysis,COc1cccc2c1c(CN1CCN(C)CC1)cn2S(=O)(=O)c1ccc(C(C)C)cc1.Cl.Cl,1-[(4-Isopropylphenyl)sulfonyl]-4-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole Dihydrochloride,7.1,uM,=,0.8512583487190752,1,O=S(=O)(c1ccccc1)n1cc(CN2CCNCC2)c2ccccc21
3818,489969,10.1021/jm800566m,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein substrate,Cc1nc2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc2n1C,"3-({4-[(1,2-Dimethyl-1H-benzimidazol-5-yl)(methyl)amino]pyrimidin-2-yl}amino)benzenesulfonamide",27.0,uM,=,1.4313637641589874,1,c1ccc(Nc2nccc(Nc3ccc4[nH]cnc4c3)n2)cc1
3819,632105,10.1016/j.bmcl.2010.03.057,,,,Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin,Cc1cc(N2CCN(CCO)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,(S)-4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-3-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one,3.3,uM,=,0.5185139398778875,1,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(N3CCNCC3)cc2[nH]1
3820,1301328,10.6019/CHEMBL3137440,,,,DNDI: CYP Inhibition,FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(Cc3cccc(C(F)(F)F)c3)CC2)cc1,,10.7,uM,=,1.0293837776852095,1,c1ccc(CN2CCC(N(c3ccccc3)c3cccnc3)CC2)cc1
3821,1528904,,,,,"Homogenous Time-Resolved Fluorescence Assay (HTRF): The standard assay conditions for the in vitro HTRF assay consisted of a 50 ul total reaction volume in black 384-well Costar polypropylene plates in 1PBS buffer pH 7.4, 1 mM DTT, 0.1% BSA, 2.5 nM GST-hMDM2 (aa 1-188), 5 nM biotinylated-p53 (aa 1-83), 1.8 nM SA-XLent (Cisbio; Bedford, Mass.), 0.6 nM anti-GST cryptate monoclonal antibody (Cisbio; Bedford, Mass.) and 200 mM KF. Amino acid residues 1-188 of human MDM2 were expressed as an amino-terminal glutathione S-transferase (GST) fusion protein (GST-hMDM2) in Escherichia coli. Residues 1-83 of human p53 were expressed as an amino-terminal AviTag-TrxA-6His fusion protein (biotinylated p53) in E. coli. Each protein was purified from cell paste by affinity chromatography.Specifically, 10 uL of GST-hMDM2 was incubated with 10 ul of diluted compound (various concentrations, serially diluted) in 10% DMSO for 20 minutes at room temperature. 20 uL of biotinylated-p53 was added to the GST-hMDM2+compound mixture.",COc1cc(NC(=O)C[C@@]2(C)C[C@H](c3cccc(Cl)c3)[C@@H](c3ccc(Cl)c(F)c3)N([C@H](CS(=O)(=O)C(C)(C)C)C3CC3)C2=O)ccc1C(=O)O,"4-(2-((3R,5R,6S)-1-((S)-2-(tert-Butylsulfonyl)-1-cyclopropylethyl)-6-(4-chloro-3-fluorophenyl)-5-(3-chlorophenyl)-3-methyl-2-oxopiperidin-3-yl)acetamido)-2-methoxybenzoic Acid",0.00033,uM,=,-3.4814860601221125,0,O=C(CC1C[C@H](c2ccccc2)[C@@H](c2ccccc2)N(CC2CC2)C1=O)Nc1ccccc1
3822,2024613,10.1016/j.bmcl.2020.127721,,,,Inhibition of CYP3A4 (unknown origin),Cc1sc(NC(=O)Cc2cccc(NS(C)(=O)=O)c2)nc1-c1c[nH]c2ncccc12,"2-[3-(methanesulfonamido)phenyl]-N-[5-methyl-4-(1H-pyrrolo[2,3-b]pyridin-3-yl)thiazol-2-yl]acetamide",5.0,uM,=,0.6989700043360189,1,O=C(Cc1ccccc1)Nc1nc(-c2c[nH]c3ncccc23)cs1
3823,1678560,10.1021/acs.jmedchem.7b01710,,,,Inhibition of CYP3A4 (unknown origin) using BQ as substrate,CC(=O)O[C@H]1C[C@H]2[C@@H]([C@H](OC(C)=O)C[C@@H]3C[C@H](N)CC[C@@]32C)[C@@H]2CC[C@H]([C@H](C)CCCNCCCCNc3ccnc4cc(Cl)ccc34)[C@@]12C,"(3alpha,5beta,7alpha,12alpha)-3-Amino-24-({4-[(7-chloroquinolin-4-yl)amino]butyl}amino)cholane-7,12-diyl diacetate",1.1,uM,=,0.041392685158225,1,c1ccc2c(NCCCCNCCCC[C@H]3CC[C@@H]4C3CC[C@@H]3C5CCCC[C@H]5CC[C@H]34)ccnc2c1
3824,440070,10.1021/jm070299x,,,,Inhibition of CYP3A4,CCN1CCN(c2ccc(C(C)(C)NC(=O)c3cc4[nH]c5ccccc5c(=O)c4cc3F)cn2)CC1,"N-(2-(6-(4-ethylpiperazin-1-yl)pyridin-3-yl)propan-2-yl)-2-fluoro-9-oxo-9,10-dihydroacridine-3-carboxamide",13.0,uM,=,1.1139433523068367,1,O=C(NCc1ccc(N2CCNCC2)nc1)c1ccc2c(=O)c3ccccc3[nH]c2c1
3825,2110159,10.1016/j.ejmech.2021.113428,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,CCN(C(=O)c1cc(C(C)C)c(O)cc1O)c1cccnc1,"N-Ethyl-2,4-dihydroxy-5-isopropyl-N-(pyridin-3-yl)benzamide",3.23,uM,=,0.5092025223311029,1,O=C(Nc1cccnc1)c1ccccc1
3826,1665797,10.1021/acs.jmedchem.7b00328,,,,Inhibition of microsomal CYP3A4 (unknown origin),CNC(=O)c1c(-c2ccc(F)cc2)oc2ccc(-c3cc(C(=O)NC4(c5cccnc5)CC4)ccc3C)cc12,2-(4-Fluorophenyl)-N-methyl-5-(2-methyl-5-(1-(pyridin-3-yl)-cyclopropylcarbamoyl)phenyl)benzofuran-3-carboxamide,0.063,uM,=,-1.2006594505464183,0,O=C(NC1(c2cccnc2)CC1)c1cccc(-c2ccc3oc(-c4ccccc4)cc3c2)c1
3827,51909,10.1021/jm010531d,,,,Inhibition of human Cytochrome P450 3A4 by macrocycles,N#Cc1ccc2cc1Oc1ccc3cccc(c3c1)N1CCC(NCCc3cncn3C2)C1=O,"R-31-oxo-20-oxa-2,6,11,13-tetraazahexacyclo[19.6.2.12,5.115,19.09,13.024,28]hentriaconta-1(28),9,11,15(30),16,18,21(29),22,24,26-decaen-18-yl cyanide",6.0,uM,=,0.7781512503836436,1,O=C1C2CCN1c1cccc3ccc(cc13)Oc1cccc(c1)Cn1cncc1CCN2
3828,726119,10.1016/j.bmcl.2010.12.089,,,,Inhibition of CYP3A4 in human liver microsome,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,"(3R,5R)-7-[2-(4-Fluoro-phenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoyl-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid anion",5.1,uM,=,0.7075701760979364,1,O=C(Nc1ccccc1)c1c[nH]c(-c2ccccc2)c1-c1ccccc1
3829,2128578,10.1016/j.ejmech.2021.113496,,,,Inhibition of recombinant human CYP3A4 using BFC as substrate,C[C@]12CC[C@H]3[C@@H]([C@H](C/C=C/C[C@@H]4CC5=CC(=O)CC[C@]5(C)[C@H]5CC[C@]6(C)[C@@H](O)CC[C@H]6[C@H]45)CC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,"(7R,7'R,8R,8'R,9S,9'S,10R,10'R,13S,13'S,14S,14'S,17S,17'S)-7,7'-((E)-but-2-ene-1,4-diyl)bis(17-hydroxy-10,13-dimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one)",6.5,uM,=,0.8129133566428556,1,O=C1C=C2C[C@@H](C/C=C/C[C@@H]3CC4=CC(=O)CCC4[C@H]4CCC5CCC[C@H]5[C@H]34)[C@H]3[C@@H]4CCCC4CC[C@@H]3C2CC1
3830,813216,10.1016/j.bmcl.2012.01.125,,,,Inhibition of CYP3A4,COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n([C@H](C)c3ccccc3)c12,"7-(3,5-dimethylisoxazol-4-yl)-8-methoxy-1-((R)-1-phenylethyl)-1H-imidazo[4,5-c]quinolin-2(3H)-one",1.5,uM,=,0.1760912590556812,1,O=c1[nH]c2cnc3cc(-c4cnoc4)ccc3c2n1Cc1ccccc1
3831,1637155,,,,,Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins,C#Cc1cnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)CCC)c3F)c2c1,"Propane-1-sulfonic acid [3-(5-ethynyl-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-amide",5.0,uM,=,0.6989700043360189,1,O=C(c1ccccc1)c1c[nH]c2ncccc12
3832,2061612,10.1016/j.bmcl.2015.11.049,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,Cc1cc(Nc2nc(Nc3ccccc3S(=O)(=O)C(C)C)c3cc[nH]c3n2)c(OC(C)C)cc1C1CCN(C)CC1,"N2-(2-isopropoxy-5-methyl-4-(1-methylpiperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine",4.5,uM,=,0.6532125137753437,1,c1ccc(Nc2nc(Nc3ccc(C4CCNCC4)cc3)nc3[nH]ccc23)cc1
3833,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NC5CCN(C(=O)CCO)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, F-65",6.87,uM,=,0.8369567370595504,1,O=C(NC1CCNCC1)c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12
3834,373752,10.1021/jm060073e,,,,Inhibition of CYP450 3A4 transfected in human microsome using DEF fluorogenic substrate,CC(C)C[C@@H]1C(=O)N[C@H](C2Cc3ccccc3C2)C(=O)N1[C@@H](C(=O)N(C)C)c1ccc(F)cc1F,"(2R)-2-(2,4-difluorophenyl)-2-[(3R,6R)-3-(2,3-dihydro-1H-inden-2-yl)-6-(2-methylpropyl)-2,5-dioxo-1-piperazinyl]-N,N-dimethylethanamide",89.0,uM,=,1.9493900066449128,1,O=C1CN(Cc2ccccc2)C(=O)[C@@H](C2Cc3ccccc3C2)N1
3835,1534761,,,,,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",COc1ncc(CNc2ncc(Cc3c[nH]c4ncc(C)cc34)cn2)cc1F,"US9096593, P-2073",5.0,uM,=,0.6989700043360189,1,c1cncc(CNc2ncc(Cc3c[nH]c4ncccc34)cn2)c1
3836,748856,10.1016/j.bmcl.2011.04.059,,,,Inhibition of CYP3A4,Cn1c(-c2ccccn2)c(C2CCCCC2)c2ccc(C(=O)NC(C)(C)C(=O)Nc3ccc(/C=C/C(=O)O)cc3)cc21,3-(4-(2-(3-cyclohexyl-1-methyl-2-(pyridin-2-yl)-1H-indole-6-carboxamido)-2-methylpropanamido)phenyl)acrylic acid,8.9,uM,=,0.9493900066449128,1,O=C(CNC(=O)c1ccc2c(C3CCCCC3)c(-c3ccccn3)[nH]c2c1)Nc1ccccc1
3837,1560508,10.1016/j.bmc.2016.02.014,,,,Inhibition of CYP3A4 (unknown origin),CN1CCC2(CC1)C(=O)Nc1cc(/C=C3\c4ccccc4COc4cc(F)ccc43)ccc12,"6-((3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)methyl)-1'-methylspiro[indoline-3,4'-piperidin]-2-one",7.04,uM,=,0.8475726591421122,1,O=C1Nc2cc(/C=C3\c4ccccc4COc4ccccc43)ccc2C12CCNCC2
3838,2068401,10.1016/j.bmcl.2020.127676,,,,Inhibition of CYP3A4 (unknown origin),CN[C@@H](C)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)Nc1cc2c(NCCCCCCCCNc3ncnc4cc(OC)c(NC(=O)[C@@H]5CCCN5C(=O)[C@@H](NC(=O)[C@H](C)NC)C(C)(C)C)cc34)ncnc2cc1OC)C(C)(C)C,"(S,S,2S,2'S)-N,N'-(4,4'-(octane-1,8-diylbis(azanediyl))bis(7-methoxyquinazoline-6,4-diyl))bis(1-((S)-3,3-dimethyl-2-((S)-2-(methylamino)propanamido)butanoyl)pyrrolidine-2-carboxamide)",0.43,uM,=,-0.3665315444204134,0,O=C(Nc1ccc2ncnc(NCCCCCCCCNc3ncnc4ccc(NC(=O)[C@@H]5CCCN5)cc34)c2c1)[C@@H]1CCCN1
3839,2124470,10.1021/acs.jmedchem.1c01154,,,,Inhibition of CYP3A4 in human pooled liver microsomes using midazolam as substrate in presence of NADPH by LC-MS/MS analysis,CCN(C(=O)C1CC1)c1cc(-c2ccc(N3CCN(CC4CC4)CC3)nc2C)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C,"5-(6-(4-(cyclopropylmethyl)piperazin-1-yl)-2-methylpyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-(N-ethylcyclopropanecarboxamido)-2-methylbenzamide",7.58,uM,=,0.8796692056320535,1,O=C(NCc1ccc[nH]c1=O)c1cc(NC(=O)C2CC2)cc(-c2ccc(N3CCN(CC4CC4)CC3)nc2)c1
3840,775863,10.1016/j.bmcl.2011.09.037,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH,CN1CCN(C(=O)[C@@H](COCc2ccc(F)cc2)NC(=O)c2cccnc2Oc2ccc(C(F)(F)F)cc2Cl)CC1,(R)-2-(2-chloro-4-(trifluoromethyl)phenoxy)-N-(3-(4-fluorobenzyloxy)-1-(4-methylpiperazin-1-yl)-1-oxopropan-2-yl)nicotinamide,6.3,uM,=,0.7993405494535817,1,O=C(N[C@H](COCc1ccccc1)C(=O)N1CCNCC1)c1cccnc1Oc1ccccc1
3841,630896,10.1016/j.bmcl.2010.03.017,,,,Inhibition of CYP3A4,Cc1cc(OC[P@@]2(=O)OCC[C@@H](c3cccnc3C)O2)c2c(c1C)Cc1scnc1-2,"(2R,4S)-6,7-Dimethyl-4-[4-(2-methyl-pyridin-3-yl)-2-oxo-2lambda*5*-[1,3,2]dioxaphosphinan-2-ylmethoxy]-8H-indeno[1,2-d]thiazole",15.0,uM,=,1.1760912590556811,1,O=[P@]1(COc2cccc3c2-c2ncsc2C3)OCC[C@@H](c2cccnc2)O1
3842,487712,10.1016/j.bmcl.2008.05.104,,,,Inhibition of CYP3A4,COCCN(CCOC)C1CCN(c2cc(C)c3nc(-c4c(NC[C@@H](O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1,"(S)-methyl 1-(2-(4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-2-oxo-1,2-dihydropyridin-3-yl)-7-methyl-3H-benzo[d]imidazol-5-yl)piperidin-4-ylcarbamate",0.001,uM,=,-3.0,0,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(N3CCCCC3)cc2[nH]1
3843,558484,10.1016/j.bmcl.2008.10.128,,,,Inhibition of CYP3A4,CCN(CC(O)(CNC(=O)c1cnn(-c2ccc(F)cc2)c1N)C(F)(F)F)C(=O)c1c(F)cccc1F,"5-amino-N-(2-((N-ethyl-2,6-difluorobenzamido)methyl)-3,3,3-trifluoro-2-hydroxypropyl)-1-(4-fluorophenyl)-1H-pyrazole-4-carboxamide",2.0,uM,=,0.3010299956639812,1,O=C(NCCCNC(=O)c1cnn(-c2ccccc2)c1)c1ccccc1
3844,1785651,,,,,Inhibition of CYP3A4 (unknown origin),CC(=O)N1CCN(c2ccc(CO[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)OC3)cc2)CC1,"1-(4-(4-(((2s,5s)-2-((1H-imidazol-1-yl)methyl)-2-(2,4-dichlorophenyl)-1,3-dioxan-5-yloxy)methyl)phenyl)piperazin-1-yl)ethanone",0.109,uM,=,-0.9625735020593764,0,c1ccc([C@]2(Cn3ccnc3)OC[C@@H](OCc3ccc(N4CCNCC4)cc3)CO2)cc1
3845,560184,10.1016/j.bmcl.2008.10.118,,,,Inhibition of CYP3A4,CC(C)c1cc(Nc2ccc(Cl)cc2Cl)ncc1C(=O)NCC1CCOCC1,"6-(2,4-dichlorophenylamino)-4-isopropyl-N-((tetrahydro-2H-pyran-4-yl)methyl)nicotinamide",58.0,uM,=,1.7634279935629371,1,O=C(NCC1CCOCC1)c1ccc(Nc2ccccc2)nc1
3846,487712,10.1016/j.bmcl.2008.05.104,,,,Inhibition of CYP3A4,Cc1cc(N2CCC(N3CCN(C(=O)N4CCN(C)CC4)CC3)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,(S)-4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-3-(4-methyl-6-(4-(4-(1-methylpiperazine-4-carbonyl)piperazin-1-yl)piperidin-1-yl)-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one,0.04,uM,=,-1.3979400086720375,0,O=C(N1CCNCC1)N1CCN(C2CCN(c3ccc4nc(-c5c(NCCc6ccccc6)cc[nH]c5=O)[nH]c4c3)CC2)CC1
3847,512798,10.1021/jm800832q,,,,Inhibition of human recombinant CYP3A4 in human liver microsomes using BFC as a substrate,COCCN1CCC(c2cc(C)c3nc(-c4c(NCCn5cc(Cl)cn5)cc[nH]c4=O)[nH]c3c2)CC1,4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(2-methoxyethyl)pipeidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridine-2(1H)-one,19.5,uM,=,1.290034611362518,1,O=c1[nH]ccc(NCCn2cccn2)c1-c1nc2ccc(C3CCNCC3)cc2[nH]1
3848,1288280,10.1016/j.bmcl.2013.12.057,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,O=C(N[C@H](CC[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)N(Cc1cncs1)C1CC1)Cc1ccccc1)OCc1cncs1,"Thiazol-5-ylmethyl(2R,5R)-5-((S)-2-(3-cyclopropyl-3-(thiazol-5-ylmethyl)ureido)-3-hydroxypropanamido)-1,6-diphenylhexan-2-ylcarbamate",0.12,uM,=,-0.9208187539523752,0,O=C(CNC(=O)N(Cc1cncs1)C1CC1)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
3849,528535,10.1021/np058114h,,,,Inhibition of CYP3A4,CN1[C@H]2Cc3cc4c(cc3[C@@H]1Cc1cc3c(cc12)OCO3)OCO4,escholtzine,13.4,uM,=,1.1271047983648077,1,c1c2c(cc3c1OCO3)[C@@H]1Cc3cc4c(cc3[C@H](C2)N1)OCO4
3850,1560508,10.1016/j.bmc.2016.02.014,,,,Inhibition of CYP3A4 (unknown origin),O=C1COc2ccc(S(=O)(=O)N3c4ccccc4COc4cc(F)ccc43)cc2N1,"6-(8-fluorodibenzo[b,e][1,4]oxazepin-5(11H)-ylsulfonyl)-2H-benzo[b][1,4]oxazin-3(4H)-one",6.697,uM,=,0.8258802989361795,1,O=C1COc2ccc(S(=O)(=O)N3c4ccccc4COc4ccccc43)cc2N1
3851,1911030,10.1021/acs.jmedchem.8b01226,,,,Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins,CCCCN(C)C(=O)N1CCC(=CC#Cc2cccc(C)n2)CC1,N-Butyl-N-methyl-4-[3-(6-methylpyridin-2-yl)prop-2-yn-1-ylidene]piperidine-1-carboxamide,13.4,uM,=,1.1271047983648077,1,C(#Cc1ccccn1)C=C1CCNCC1
3852,52064,10.1016/s0960-894x(03)00058-1,,,,Inhibitory activity against CYP450 3A4 isozyme,CCc1cn(CC(=O)N(CCN(CC)CC)Cc2ccc(-c3ccc(C(F)(F)F)cc3)cc2)c(SCc2ccc(F)cc2)nc1=O,N-(2-Diethylamino-ethyl)-2-[5-ethyl-2-(4-fluoro-benzylsulfanyl)-4-oxo-4H-pyrimidin-1-yl]-N-(4'-trifluoromethyl-biphenyl-4-ylmethyl)-acetamide,11.0,uM,=,1.0413926851582251,1,O=C(Cn1ccc(=O)nc1SCc1ccccc1)NCc1ccc(-c2ccccc2)cc1
3853,1685713,10.1016/j.bmc.2017.04.033,,,,Inhibition of recombinant CYP3A4 (unknown origin),C[C@@H](c1ccc(OC(F)F)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O,"(S)-3-((S)-1-(4-(difluoromethoxy)phenyl)ethyl)-6-(2-hydroxy-2-methylpropyl)-6-phenyl-1,3-oxazinan-2-one",10.0,uM,=,1.0,1,O=C1OC(c2ccccc2)CCN1Cc1ccccc1
3854,1527876,,,,,Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,CCn1cc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccc(F)cc4)OC3=O)cc2)ccc1=O,"US8575157, 62",48.0,uM,=,1.6812412373755872,1,O=C1OC(c2ccccc2)CCN1Cc1ccc(-c2ccc(=O)[nH]c2)cc1
3855,988989,10.1021/jm400732v,,,,Inhibition of CYP3A4 (unknown origin),CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)CC(C)C)c2ccccc2N(Cc2c(OC)ccc3ccccc23)C1=O.Cl,"(S)-N-((S)-1-((2-Methoxynaphthalen-1-yl)methyl)-5-(3-methylbutanoyl)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-yl)-2-(methylamino)propanamide hydrochloride",1.5,uM,=,0.1760912590556812,1,O=C1CCNc2ccccc2N1Cc1cccc2ccccc12
3856,772722,10.1021/jm201063u,,,,Inhibition of CYP3A4 using BFC as substrate,CN1CC=C(c2c[nH]c3cc(NC(=N)c4cccs4)ccc23)CC1.Cl.Cl,"N-(3-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-6-yl)thiophene-2-carboximidamide dihydrochloride",74.8,uM,=,1.8739015978644613,1,N=C(Nc1ccc2c(C3=CCNCC3)c[nH]c2c1)c1cccs1
3857,1295469,10.1016/j.bmcl.2014.02.004,,,,Inhibition of human recombinant CYP3A4,CC1Cc2cc(F)ccc2N1C(=O)Cc1nc(N2CCOCC2)sc1C(=O)O,4-(2-(5-fluoro-2-methylindolin-1-yl)-2-oxoethyl)-2-morpholinothiazole-5-carboxylic acid,40.0,uM,=,1.6020599913279625,1,O=C(Cc1csc(N2CCOCC2)n1)N1CCc2ccccc21
3858,1528565,,,,,"Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",CC(C)c1nc(CN(C)C(=O)N2CCN(C)C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,"US8987313, 25",0.3,uM,=,-0.5228787452803376,0,O=C(N[C@H](CC[C@H](Cc1ccccc1)NC(=O)[C@@H]1CNCCN1C(=O)NCc1cscn1)Cc1ccccc1)OCc1cncs1
3859,1465594,10.1016/j.bmcl.2015.02.039,,,,Inhibition of CYP3A4 (unknown origin) using midazolam fluorometric substrate,COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2NC(=O)OCc2ccccc2)C(C)C)ccc1OC,"benzyl (3S,4S)-4-((N-isopropyl-4-methoxy-3-(3-methoxypropoxy)benzamido)methyl)pyrrolidin-3-ylcarbamate",6.4,uM,=,0.8061799739838872,1,O=C(N[C@@H]1CNC[C@H]1CNC(=O)c1ccccc1)OCc1ccccc1
3860,1689562,10.1021/acs.jmedchem.7b00598,,,,Inhibition of CYP3A4 (unknown origin),N#Cc1cc(S(=O)(=O)Nc2ncns2)ccc1Oc1ccc(C(F)(F)F)cc1-c1ccncn1,"3-cyano-4-(2-(pyrimidin-4-yl)-4-(trifluoromethyl)phenoxy)-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide",0.91,uM,=,-0.0409586076789063,0,O=S(=O)(Nc1ncns1)c1ccc(Oc2ccccc2-c2ccncn2)cc1
3861,814102,10.1016/j.bmcl.2012.03.014,,,,Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins,Cc1cccc(-c2noc([C@H]3CNCC[C@]3(O)c3ccc(F)c(F)c3)c2Br)c1C,"(3S,4R)-3-(4-bromo-3-(2,3-dimethylphenyl)isoxazol-5-yl)-4-(3,4-difluorophenyl)piperidin-4-ol",20.0,uM,=,1.3010299956639813,1,c1ccc(-c2cc([C@H]3CNCCC3c3ccccc3)on2)cc1
3862,748856,10.1016/j.bmcl.2011.04.059,,,,Inhibition of CYP3A4,Cn1c(-c2ccoc2)c(C2CCCCC2)c2ccc(C(=O)NC(C)(C)C(=O)Nc3ccc(/C=C/C(=O)O)cc3)cc21,3-(4-(2-(3-cyclohexyl-2-(furan-3-yl)-1-methyl-1H-indole-6-carboxamido)-2-methylpropanamido)phenyl)acrylic acid,8.7,uM,=,0.9395192526186184,1,O=C(CNC(=O)c1ccc2c(C3CCCCC3)c(-c3ccoc3)[nH]c2c1)Nc1ccccc1
3863,1614026,10.1016/j.bmcl.2016.09.043,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 1'-hydroxymidazolam metabolite formation using midazolam as substrate incubated for 10 mins by HPLC-MS method,Cn1c(NCCc2ccc(-c3ncccn3)cc2)nc2cc(Cl)ccc2c1=O,7-Chloro-3-methyl-2-[2-(4-pyrimidin-2-yl-phenyl)-ethylamino]-3H-quinazolin-4-one,13.0,uM,=,1.1139433523068367,1,O=c1[nH]c(NCCc2ccc(-c3ncccn3)cc2)nc2ccccc12
3864,814102,10.1016/j.bmcl.2012.03.014,,,,Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins,CC(=O)NCCc1ccccc1-c1onc([C@H]2CNCC[C@@H]2c2ccc(F)c(F)c2)c1Br,"N-(2-(4-bromo-3-((3R,4S)-4-(3,4-difluorophenyl)piperidin-3-yl)isoxazol-5-yl)phenethyl)acetamide",13.0,uM,=,1.1139433523068367,1,c1ccc(-c2cc([C@H]3CNCC[C@@H]3c3ccccc3)no2)cc1
3865,619264,10.1016/j.bmcl.2009.07.002,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,Cc1cccc(C)c1CNc1nc(-c2ccccc2)cc2c(C)c(C)[nH]c12,"N-(2,6-dimethylbenzyl)-2,3-dimethyl-5-phenyl-1H-pyrrolo[2,3-c]pyridin-7-amine",7.7,uM,=,0.8864907251724818,1,c1ccc(CNc2nc(-c3ccccc3)cc3cc[nH]c23)cc1
3866,449088,10.1016/j.bmcl.2007.08.028,,,,Inhibition of human CYP3A4,CC(=O)N1CCC(C(=O)N2C[C@H](c3nc(C(C)(C)c4cc(C(F)(F)F)cc(C(F)(F)F)c4)no3)[C@@H](c3ccc(F)cc3C)C2)CC1,"1-(4-((3R,4S)-3-(3-(2-(3,5-bis(trifluoromethyl)phenyl)propan-2-yl)-1,2,4-oxadiazol-5-yl)-4-(4-fluoro-2-methylphenyl)pyrrolidine-1-carbonyl)piperidin-1-yl)ethanone",23.0,uM,=,1.3617278360175928,1,O=C(C1CCNCC1)N1C[C@H](c2ccccc2)[C@@H](c2nc(Cc3ccccc3)no2)C1
3867,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1ccc(-n2nccn2)c(C(=O)N2[C@H](Cc3cccc(-n4nccn4)c3)COC[C@@H]2C)c1,"US9150566, 73",6.8,uM,=,0.8325089127062363,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
3868,775863,10.1016/j.bmcl.2011.09.037,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH,CN1CCN(C(=O)[C@@H](COCc2ccncc2)NC(=O)c2cccnc2Oc2ccc(C(F)(F)F)cc2Cl)CC1,(R)-2-(2-chloro-4-(trifluoromethyl)phenoxy)-N-(1-(4-methylpiperazin-1-yl)-1-oxo-3-(pyridin-4-ylmethoxy)propan-2-yl)nicotinamide,2.0,uM,=,0.3010299956639812,1,O=C(N[C@H](COCc1ccncc1)C(=O)N1CCNCC1)c1cccnc1Oc1ccccc1
3869,993439,10.6019/CHEMBL2448688,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,CCN(c1ccccc1)S(=O)(=O)c1ccc(NC(=O)CN(C)C2CCN(C)CC2)c(Cl)c1.Cl,,19.0,uM,=,1.2787536009528289,1,O=C(CNC1CCNCC1)Nc1ccc(S(=O)(=O)Nc2ccccc2)cc1
3870,51907,10.1016/s0960-894x(03)00475-x,,,,In vitro inhibition of human liver microsome Cytochrome P450 3A4,O=C(N[C@H]1c2ccccc2OC[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CN1CCN(Cc2ccc(-c3ccccn3)o2)C[C@H]1C(=O)NCC(F)(F)F,"(S)-1-[(S)-2-Hydroxy-4-((R)-(S)-3-hydroxy-3,4,4a,8a-tetrahydro-2H-chromen-4-ylcarbamoyl)-5-phenyl-pentyl]-4-(5-pyridin-2-yl-furan-2-ylmethyl)-piperazine-2-carboxylic acid (2,2,2-trifluoro-ethyl)-amide",5.2,uM,=,0.7160033436347992,1,O=C(N[C@@H]1CCOc2ccccc21)[C@@H](CCCN1CCN(Cc2ccc(-c3ccccn3)o2)CC1)Cc1ccccc1
3871,469879,10.1016/j.bmcl.2008.01.012,,,,Inhibition of human CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin substrate,CC(C)c1c(-c2nnc(NCCCCN)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12,"5-(6-(5-(4-aminobutylamino)-1,3,4-oxadiazol-2-yl)-5-isopropylpyrrolo[1,2-f][1,2,4]triazin-4-ylamino)-N-cyclopropyl-2,4-difluorobenzamide",27.0,uM,=,1.4313637641589874,1,O=C(NC1CC1)c1cccc(Nc2ncnn3cc(-c4nnco4)cc23)c1
3872,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCOCC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, E-3",3.9,uM,=,0.5910646070264992,1,O=C(c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12)N1CCOCC1
3873,886888,10.1016/j.bmcl.2012.10.057,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 mins in presence of NADPH,CN1CCN(Cc2cccc3c2ccn3S(=O)(=O)c2ccccc2)CC1,1-Benzenesulfonyl-4-(4-methylpiperazin-1-ylmethyl)-1H-indole,30.5,uM,=,1.484299839346786,1,O=S(=O)(c1ccccc1)n1ccc2c(CN3CCNCC3)cccc21
3874,1984166,10.1016/j.bmc.2020.115349,,,,Inhibition of human full length CYP3A4 assessed using 7-benzyloxy-4 (trifluoromethyl)coumarin as substrate preincubated for 2 mins followed by substrate addition and measured for 2 mins by fluorometric analysis,CC(C)(C)OC(=O)N[C@@H](CS[C@@H](Cc1ccccc1)C(=O)NCCc1cccnc1)Cc1cccc2ccccc12,tert-butyl N-[(1R)-1-[[(1S)-1-benzyl-2-oxo-2-[2-(3-pyridyl)ethylamino]ethyl]sulfanylmethyl]-2-(1-naphthyl)ethyl]carbamate,0.356,uM,=,-0.4485500020271248,0,O=C(NCCc1cccnc1)[C@H](Cc1ccccc1)SCCCc1cccc2ccccc12
3875,1336037,10.1021/jm500118j,,,,Inhibition of CYP3A4 (unknown origin),c1cc2c3cnc(Nc4ccc(N5CCNCC5)cn4)nc3n(C3CCCC3)c2cn1,"9-Cyclopentyl-N-(5-(1-piperazinyl)-2-pyridinyl)-9H-pyrido-[4',3':4,5]pyrrolo[2,3-d]pyrimidin-2-amine",0.55,uM,=,-0.2596373105057561,0,c1cc2c3cnc(Nc4ccc(N5CCNCC5)cn4)nc3n(C3CCCC3)c2cn1
3876,1689562,10.1021/acs.jmedchem.7b00598,,,,Inhibition of CYP3A4 (unknown origin),Cc1[nH]ncc1-c1cc(C(F)(F)F)ccc1Oc1ccc(S(=O)(=O)Nc2ncns2)cc1C#N,"3-cyano-4-(2-(5-methyl-1H-pyrazol-4-yl)-4-(trifluoromethyl)phenoxy)-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide",0.737,uM,=,-0.1325325121409485,0,O=S(=O)(Nc1ncns1)c1ccc(Oc2ccccc2-c2cn[nH]c2)cc1
3877,1276541,10.1016/j.bmcl.2013.09.041,,,,Inhibition of CYP3A4 (unknown origin) after 5 mins,CCc1cc(-c2ccc(NS(=O)(=O)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)cc2)ccn1,"N-(4-(2-ethylpyridin-4-yl)phenyl)-3,5-bis(trifluoromethyl)benzenesulfonamide",12.2,uM,=,1.0863598306747482,1,O=S(=O)(Nc1ccc(-c2ccncc2)cc1)c1ccccc1
3878,581616,10.1016/j.bmcl.2009.06.096,,,,Inhibition of CYP3A4 using midazolam as substrate,O=C(c1ccccc1C(F)(F)F)N(CC1CCC1)[C@H]1CCNC1,(S)-N-(cyclobutylmethyl)-N-(pyrrolidin-3-yl)-2-(trifluoromethyl)benzamide,12.2,uM,=,1.0863598306747482,1,O=C(c1ccccc1)N(CC1CCC1)[C@H]1CCNC1
3879,1760017,10.1016/j.bmcl.2018.04.053,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH by LC/MS/MS analysis,Cc1csc(NC(=O)c2cc(C(F)(F)c3cncnc3)cc3cccnc23)n1,6-(Difluoro(pyrimidin-5-yl)methyl)-N-(4-methylthiazol-2-yl)quinoline-8-carboxamide,5.9,uM,=,0.7708520116421442,1,O=C(Nc1nccs1)c1cc(Cc2cncnc2)cc2cccnc12
3880,1925819,10.1021/acs.jmedchem.6b00425,,,,Inhibition of CYP3A4 in human microsomes using midazolam as substrate coincubated with substrate for 30 mins measured after 5 mins in presence of NADPH by LC-MS/MS analysis,CC(C)COc1ncc(Oc2nccc3cc(C(=O)NS(C)(=O)=O)ccc23)cc1Cl,1-((5-Chloro-6-isobutoxypyridin-3-yl)oxy)-N-(methylsulfonyl)isoquinoline-6-carboxamide,30.7,uM,=,1.4871383754771863,1,c1cncc(Oc2nccc3ccccc23)c1
3881,52064,10.1016/s0960-894x(03)00058-1,,,,Inhibitory activity against CYP450 3A4 isozyme,CCN(CC)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(=O)Cn1c(SCc2ccc(F)cc2)nc(=O)c(C)c1C,"N-(2-Diethylamino-ethyl)-2-[2-(4-fluoro-benzylsulfanyl)-5,6-dimethyl-4-oxo-4H-pyrimidin-1-yl]-N-(4'-trifluoromethyl-biphenyl-4-ylmethyl)-acetamide",22.0,uM,=,1.3424226808222062,1,O=C(Cn1ccc(=O)nc1SCc1ccccc1)NCc1ccc(-c2ccccc2)cc1
3882,1366897,10.1021/jm500312x,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 15 mins by LC/MS/MS analysis,C=C[C@]1(C)C[C@@H](OC(=O)CSc2ccccn2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O,14-O-(((Pyridin-2-yl)sulfanyl)acetyl)mutilin,1.25,uM,=,0.0969100130080564,1,O=C(CSc1ccccn1)O[C@@H]1CCCC[C@@]23CCCC1[C@@H]2C(=O)CC3
3883,828928,10.1016/j.bmcl.2012.06.022,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,CCN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N(C)CC)oc2c1,"Thiazol-5-ylmethyl(2S,3R)-4-(N-ethyl-2-(ethyl(methyl)amino)benzo[d]oxazole-6-carboxamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate",0.079,uM,=,-1.1023729087095586,0,O=C(N[C@H](CCNC(=O)c1ccc2ncoc2c1)Cc1ccccc1)OCc1cncs1
3884,1540696,10.1016/j.ejmech.2015.08.051,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 2 mins by LC-MS/MS analysis in presence of NADPH regeneration system,COC(=O)N1CCC(CN2C[C@@H]3[C@@H](CNC(=O)c4nc(C(C)C)n5ccccc45)[C@@H]3C2)CC1,"methyl 4-(((1R,5S,6s)-6-((3-isopropylimidazo[1,5-a]pyridine-1-carboxamido)methyl)-3-azabicyclo[3.1.0]hexan-3-yl)methyl)piperidine-1-carboxylate",54.3,uM,=,1.734799829588847,1,O=C(NC[C@@H]1[C@H]2CN(CC3CCNCC3)C[C@@H]12)c1ncn2ccccc12
3885,342118,10.1021/jm051106d,,,,Inhibitory activity against CYP3A4,Cc1cc2c(F)c(Oc3ncnn4cc(OCCCN5CCCCC5)c(C)c34)ccc2[nH]1,"4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methyl-6-(3-(piperidin-1-yl)propoxy)pyrrolo[2,1-f][1,2,4]triazine",1.0,uM,=,0.0,0,c1nc(Oc2ccc3[nH]ccc3c2)c2cc(OCCCN3CCCCC3)cn2n1
3886,1527876,,,,,Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,C[C@@H](c1ccc(-c2ccc(=O)n(C3CC3)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O,"US8575157, 3",44.0,uM,=,1.6434526764861874,1,O=C1OC(c2ccccc2)CCN1Cc1ccc(-c2ccc(=O)n(C3CC3)c2)cc1
3887,550965,10.1021/np030556a,,,,Inhibition of human CYP3A4 by radiometric assay,C/C1=C\CC[C@@]2(C)O[C@@H]2CC(C)(C)/C=C/C1=O,zerumbone epoxide,48.4,uM,=,1.6848453616444126,1,O=C1C=CCCC2O[C@@H]2CC/C=C/1
3888,1528565,,,,,"Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",CC(C)c1nc(CN(C)C(=O)NC2(C(=O)N[C@H](CC[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)Cc3ccccc3)CCN(C)CC2)cs1,"US8987313, 21",0.19,uM,=,-0.721246399047171,0,O=C(NCc1cscn1)NC1(C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)CCNCC1
3889,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1cccc(C(=O)N2CCOC[C@H]2Cc2cc(-n3nccn3)ccc2F)c1-n1nccn1,"US9150566, 127",30.0,uM,=,1.4771212547196624,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
3890,1641039,,,,,"Inhibition Assay: Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 uM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 Î¼M. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:CH3CN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO: CH3CN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v. Pooled human liver microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 5 mg/mL suspension.",OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F,"2-(2,4-Difluoro-phenyl)-1,3-bis-[1,2,4]triazol-1-yl-propan-2-ol",8.0,uM,=,0.9030899869919436,1,c1ccc(C(Cn2cncn2)Cn2cncn2)cc1
3891,479364,10.1016/j.bmcl.2008.05.027,,,,Inhibition of CYP3A4,O=C1COc2cc(Cl)c(Cl)cc2N1CC(=O)N1CCCC(c2ccccc2)C1CN1CCOCC1,"rac-6,7-dichloro-4-(2-(2-(morpholinomethyl)-3-phenylpiperidin-1-yl)-2-oxoethyl)-2H-benzo[b][1,4]oxazin-3(4H)-one",0.73,uM,=,-0.1366771398795441,0,O=C1COc2ccccc2N1CC(=O)N1CCCC(c2ccccc2)C1CN1CCOCC1
3892,1760899,10.1021/acs.jmedchem.8b00521,,,,Inhibition of CYP3A4 in human liver microsomes assessed as decrease in midazolam 1-hydroxylation by LC-MS/MS analysis,COc1ccc(NC(=O)N2CCN(c3nc(N)nc4sc(-c5cccnc5)nc34)CC2)cc1,"4-(5-amino-2-(pyridin-3-yl)thiazolo[5,4-d]pyrimidin-7-yl)-N-(4-methoxyphenyl)piperazine-1-carboxamide",1.6,uM,=,0.2041199826559248,1,O=C(Nc1ccccc1)N1CCN(c2ncnc3sc(-c4cccnc4)nc23)CC1
3893,1534761,,,,,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",Cn1cc(F)cc(CNc2ncc(Cc3c[nH]c4ncc(Cl)cc34)cn2)c1=O,"US9096593, P-2157",5.0,uM,=,0.6989700043360189,1,O=c1[nH]cccc1CNc1ncc(Cc2c[nH]c3ncccc23)cn1
3894,1485703,10.1124/dmd.112.048264,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method,COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1ccccc1[N+](=O)[O-],"2,6-Dimethyl-4-(2-nitro-phenyl)-1,4-dihydro-pyridine-3,5-dicarboxylic acid dimethyl ester",5.62,uM,=,0.7497363155690611,1,C1=CC(c2ccccc2)C=CN1
3895,550965,10.1021/np030556a,,,,Inhibition of human CYP3A4 by radiometric assay,CCCCC/C=C/C(=O)CCc1ccc(O)c(OC)c1,(E)-1-(4-Hydroxy-3-methoxy-phenyl)-dec-4-en-3-one,77.7,uM,=,1.8904210188009145,1,c1ccccc1
3896,1440787,10.1016/j.bmc.2014.09.026,,,,Inhibition of CYP3A4 (unknown origin) using AMMC by fluorescence assay,C#C[C@]1(O)CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)[C@@H](N5CCN(C(=O)[C@@H]6CCCN6C(=O)c6ccc7ccccc7n6)CC5)C[C@]4(C)[C@H]3CC[C@@]21C,"(4-((2S,3S,5S,8R,9S,10S,13S,14S,17R)-17-ethynyl-3,17-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-2-yl)piperazin-1-yl)((S)-1-(quinoline-2-carbonyl)pyrrolidin-2-yl)methanone",3.8,uM,=,0.5797835966168101,1,O=C([C@@H]1CCCN1C(=O)c1ccc2ccccc2n1)N1CCN([C@@H]2CC[C@@H]3CC[C@H]4[C@@H]5CCCC5CC[C@@H]4C3C2)CC1
3897,349088,10.1016/j.bmcl.2006.01.084,,,,Inhibition of CYP3A4 using BFC fluorogenic substrate,COc1ccccc1COCCCOc1ccc(N2C(=O)CNC[C@@H]2COc2ccc3c(c2)N(CC(=O)O)C(=O)CO3)cc1,"(R)-2-(6-((1-(4-(3-(2-methoxybenzyloxy)propoxy)phenyl)-6-oxopiperazin-2-yl)methoxy)-3-oxo-2,3-dihydrobenzo[b][1,4]oxazin-4-yl)acetic acid",25.0,uM,=,1.3979400086720375,1,O=C1COc2ccc(OC[C@H]3CNCC(=O)N3c3ccc(OCCCOCc4ccccc4)cc3)cc2N1
3898,676065,10.1016/j.bmcl.2010.09.028,,,,Inhibition of CYP3A4 after 30 mins,CC(C)(C)[C@@H]1COC[C@H](COC(=O)N2CCN(C(C)(C)CO)CC2)N1S(=O)(=O)c1ccc(Cl)cc1,"((3R,5R)-5-tert-butyl-4-(4-chlorophenylsulfonyl)morpholin-3-yl)methyl 4-(1-hydroxy-2-methylpropan-2-yl)piperazine-1-carboxylate",0.0238,uM,=,-1.623423042943488,0,O=C(OC[C@H]1COCCN1S(=O)(=O)c1ccccc1)N1CCNCC1
3899,1528565,,,,,"Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",CC(C)c1nc(CN(C)C(=O)N2C[C@@H](N(C)C)C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,"US8987313, 31",0.15,uM,=,-0.8239087409443188,0,O=C(N[C@H](CC[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)NCc1cscn1)Cc1ccccc1)OCc1cncs1
3900,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cc(-n3nccn3)ccc2F)c1F,"US9150566, 132",19.0,uM,=,1.2787536009528289,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
3901,448320,10.1016/j.bmc.2007.05.069,,,,Inhibition of CYP3A4,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCOC)C(=O)C(C)(c1cc(F)cc(F)c1)O2,"6-(2,4-diamino-6-ethyl-pyrimidin-5-yl)-2-(3,5-difluoro-phenyl)-4-(3-methoxy-propyl)-2-methyl-4Hbenzo[1,4]oxazin-3-one",1.14,uM,=,0.0569048513364725,1,O=C1Nc2cc(-c3cncnc3)ccc2OC1c1ccccc1
3902,1527876,,,,,Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,C[C@@H](c1ccc(-c2ccn(C3CC3)c(=O)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O,"US8575157, 75",23.0,uM,=,1.3617278360175928,1,O=C1OC(c2ccccc2)CCN1Cc1ccc(-c2ccn(C3CC3)c(=O)c2)cc1
3903,550965,10.1021/np030556a,,,,Inhibition of human CYP3A4 by radiometric assay,CC(=O)O[C@@H]1[C@@H](OC(C)=O)[C@H](C)O[C@@H](Oc2c(-c3ccc(O)cc3)oc3cc(O)cc(O)c3c2=O)[C@@H]1OC(C)=O,"kaempferol-3-O-(2,3,4-tri-O-acetyl-alpha-L-rhamnopyranoside)",14.4,uM,=,1.1583624920952498,1,O=c1c(O[C@H]2CCCCO2)c(-c2ccccc2)oc2ccccc12
3904,52065,10.1021/jm0310129,,,,Inhibitory activity against cytochrome P450 3A4,O=[N+]([O-])c1cccc2c1c1ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c1n2Cc1ccncc1,"4-{4-[2-(3,4-Difluoro-phenyl)-ethyl]-piperazin-1-yl}-9-nitro-5-pyridin-4-ylmethyl-5H-pyrimido[5,4-b]indole",5.78,uM,=,0.761927838420529,1,c1ccc(CCN2CCN(c3ncnc4c5ccccc5n(Cc5ccncc5)c34)CC2)cc1
3905,859942,10.1021/jm300122u,,,,Inhibition of human CYP3A4 using testosterone as substrate after 45 mins,NC1CCN(C(=O)[C@H](Cc2ccc(Br)cc2)NC(=O)C2(c3ccc(Cl)cc3Cl)CC2)CC1,"N-{(1S)-2-(4-Aminopiperidin-1-yl)-1-[(4-bromophenyl)-methyl]-2-oxoethyl}-1-(2,4-dichlorophenyl)-cyclopropanecarboxamide",8.0,uM,=,0.9030899869919436,1,O=C([C@H](Cc1ccccc1)NC(=O)C1(c2ccccc2)CC1)N1CCCCC1
3906,349088,10.1016/j.bmcl.2006.01.084,,,,Inhibition of CYP3A4 using BFC fluorogenic substrate,COCCCN1C(=O)COc2ccc(SC[C@H]3CNCC(=O)N3c3ccc(OCCCOCc4ccccc4OC)cc3)cc21,"(R)-6-((1-(4-(3-(2-methoxybenzyloxy)propoxy)phenyl)-6-oxopiperazin-2-yl)methylthio)-4-(3-methoxypropyl)-2H-benzo[b][1,4]oxazin-3(4H)-one",0.014,uM,=,-1.853871964321762,0,O=C1COc2ccc(SC[C@H]3CNCC(=O)N3c3ccc(OCCCOCc4ccccc4)cc3)cc2N1
3907,1911030,10.1021/acs.jmedchem.8b01226,,,,Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins,COc1ccc(S(=O)(=O)N2CCC(=CC#Cc3cccc(C)n3)CC2)cc1,2-(3-{1-[(4-Methoxyphenyl)sulfonyl]piperidin-4-ylidene}prop-1-yn-1-yl)-6-methylpyridine,1.9,uM,=,0.2787536009528289,1,O=S(=O)(c1ccccc1)N1CCC(=CC#Cc2ccccn2)CC1
3908,353252,10.1021/jm0510979,,,,Inhibition of CYP3A4,NC(=O)c1sc(-c2ccc(F)cc2)cc1N,3-amino-5-(4-fluoro-phenyl)-thiophene-2-carboxylic acid amide,2.0,uM,=,0.3010299956639812,1,c1ccc(-c2cccs2)cc1
3909,580020,10.1021/jm900725r,,,,Inhibition of CYP3A4,O=C(NC1CCc2ccccc2CC1)N1CCC(c2nc(-c3ccccn3)no2)CC1,"4-(3-(pyridin-2-yl)-1,2,4-oxadiazol-5-yl)-N-(6,7,8,9-tetrahydro-5H-benzo[7]annulen-7-yl)piperidine-1-carboxamide",10.0,uM,=,1.0,1,O=C(NC1CCc2ccccc2CC1)N1CCC(c2nc(-c3ccccn3)no2)CC1
3910,1991934,10.1021/acsmedchemlett.0c00082,,,,Inhibition of CYP3A4 (unknown origin),CC(C)Nc1cc(Nc2ccc3ncsc3c2)ncc1C(=O)NCCc1ccc(S(N)(=O)=O)cc1,"6-(1,3-benzothiazol-6-ylamino)-4-(isopropylamino)-N-[2-(4-sulfamoylphenyl)ethyl]pyridine-3-carboxamide",0.0009,uM,=,-3.0457574905606752,0,O=C(NCCc1ccccc1)c1ccc(Nc2ccc3ncsc3c2)nc1
3911,1464637,10.1016/j.bmcl.2015.02.040,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyl-4-trifluoromethylcoumarin as fluorometric substrate,COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2OC(=O)NCc2ccccc2)C(C)C)ccc1OC,rac-(trans)-4-((N-isopropyl-4-methoxy-3-(3-methoxypropoxy)benzamido)methyl)pyrrolidin-3-yl benzylcarbamate,4.0,uM,=,0.6020599913279624,1,O=C(NCc1ccccc1)O[C@@H]1CNC[C@H]1CNC(=O)c1ccccc1
3912,2164346,10.1021/acs.jmedchem.1c02192,,,,Inhibition of CYP3A4 (unknown origin),Cc1nc2cnc3cc(F)c(-c4ccc(Oc5ncccn5)cc4Cl)cc3c2n1[C@H]1CC[C@@](N)(CC#N)CC1,"trans-2-[1-amino-4-[8-(2-chloro-4-pyrimidin-2-yloxy-phenyl)-7-fluoro-2-methyl-imidazo[4,5-c]quinolin-1-yl]cyclohexyl]acetonitrile",1.2,uM,=,0.0791812460476248,1,c1cnc(Oc2ccc(-c3ccc4ncc5ncn(C6CCCCC6)c5c4c3)cc2)nc1
3913,790052,10.1016/j.bmc.2011.08.066,,,,Inhibition of recombinant human CYP3A4 assessed as conversion of testosterone into 6-hydroxytestosterone after 30 mins by HPLC analysis,CNC(=O)c1ccc2cc(C(C)(O)c3cncn3C)ccc2c1,rac-6-[1-Hydroxy-1-(1-methyl-1H-imidazol-5-yl)ethyl]-N-methylnaphthalene-2-carboxamide,6.9,uM,=,0.8388490907372553,1,c1ccc2cc(Cc3cnc[nH]3)ccc2c1
3914,632105,10.1016/j.bmcl.2010.03.057,,,,Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin,Cc1cc(N2CCNCC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,(S)-4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-3-(4-methyl-6-(piperazin-1-yl)-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one,3.0,uM,=,0.4771212547196624,1,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(N3CCNCC3)cc2[nH]1
3915,833037,10.1021/jm300248q,,,,Inhibition of CYP3A4,CN1CCC(c2cccc(Nc3nc4c(-c5ccc(S(C)(=O)=O)cc5)cccn4n3)c2)CC1,"[8-(4-Methanesulfonyl-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-[3-(1-methyl-piperidin-4-yl)-phenyl]-amine",24.0,uM,=,1.380211241711606,1,c1ccc(-c2cccn3nc(Nc4cccc(C5CCNCC5)c4)nc23)cc1
3916,559938,10.1016/j.bmcl.2008.10.072,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,C[C@@H]1CN(Cc2ccc(-c3ccccc3C(=O)N3CCC(Nc4ccc(Cl)cc4)CC3)cc2)C[C@H](C)N1,"[4-(4-Chloro-phenylamino)-piperidin-1-yl]-[4'-((3R,5S)-3,5-dimethyl-piperazin-1-ylmethyl)-biphenyl-2-yl]-methanone",5.2,uM,=,0.7160033436347992,1,O=C(c1ccccc1-c1ccc(CN2CCNCC2)cc1)N1CCC(Nc2ccccc2)CC1
3917,673952,10.1016/j.bmcl.2010.08.086,,,,Inhibition of CYP3A4 using midazolam as substrate,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c(Cl)cn1,"(3R,4S)-N-((5-chloro-2-(3-methoxypropyl)pyridin-4-yl)methyl)-N-cyclopropyl-4-(4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)phenyl)piperidine-3-carboxamide",5.9,uM,=,0.7708520116421442,1,O=C([C@H]1CNCC[C@@H]1c1ccc(OCCOc2ccccc2)cc1)N(Cc1ccncc1)C1CC1
3918,493017,10.1021/jm800851u,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,CC(=O)Nc1cc(-c2ccncc2)nc(-n2nc(C)cc2C)n1,"N-[2-(3,5-Dimethyl-pyrazol-1-yl)-6-pyridin-4-yl-pyrimidin-4-yl]-acetamide",8.5,uM,=,0.9294189257142929,1,c1cnn(-c2nccc(-c3ccncc3)n2)c1
3919,1747252,10.1021/acs.jmedchem.7b01236,,,,Inhibition of human CYP3A4 using testosterone as substrate preincubated for 30 mins,N#Cc1ccc(Cn2ccc(NC(=O)Cc3ccc(C4(C(F)(F)F)CC4)cc3)n2)nc1,N-(1-((5-cyanopyridin-2-yl)methyl)-1H-pyrazol-3-yl)-2-(4-(1-(trifluoromethyl)cyclopropyl)phenyl)acetamide,46.0,uM,=,1.662757831681574,1,O=C(Cc1ccc(C2CC2)cc1)Nc1ccn(Cc2ccccn2)n1
3920,1460909,10.1021/jm501326k,,,,Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase/human b5 reductase using 7-benzyloxyquinoline substrate,CCOC(=O)c1[nH]cc2c1NC1=C(C(=O)CN(C(=O)CN)C1)[C@H]2c1ccc(Sc2nc3ccccc3[nH]2)o1.Cl,"(+)-Ethyl(9S)-6-(2-aminoacetyl)-9-[5-(1H-benzimidazol-2-ylsulfanyl)-2-furyl]-8-oxo-4,5,7,9-tetrahydro-2H-pyrrolo[3,4-b][1,7]naphthyridine-3-carboxylate hydrochloride",0.5,uM,=,-0.3010299956639812,0,O=C1CNCC2=C1[C@@H](c1ccc(Sc3nc4ccccc4[nH]3)o1)c1c[nH]cc1N2
3921,455108,10.1016/j.bmcl.2006.12.043,,,,Inhibition of CYP3A4,C[C@H](O)C(=O)N1CCC(Nc2ccc3[nH]ncc3c2)CC1,(S)-1-(4-(1H-indazol-5-ylamino)piperidin-1-yl)-2-hydroxypropan-1-one,1.0,uM,=,0.0,0,c1cc2[nH]ncc2cc1NC1CCNCC1
3922,1741066,10.1021/acs.jmedchem.8b00450,,,,Inhibition of human CYP3A4,CN(C[C@H]1Cc2c(cccc2N2CCN(c3ccccn3)CC2)CN1)[C@H]1CCCc2cccnc21,"(S)-N-methyl-N-(((R)-5-(4-(pyridin-2-yl)piperazin-1-yl)-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)-5,6,7,8-tetrahydroquinolin-8-amine",3.16,uM,=,0.4996870826184038,1,c1ccc(N2CCN(c3cccc4c3C[C@H](CN[C@H]3CCCc5cccnc53)NC4)CC2)nc1
3923,860549,10.1021/jm3003747,,,,Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins,CC(C)(C(N)=O)N1CCN(Cc2cc3nc(-c4cc(C#N)cc5[nH]ccc45)nc(N4CCOCC4)c3s2)CC1,"2-(4-((2-(6-Cyano-1H-indol-4-yl)-4-morpholinothieno[3,2-d]-pyrimidin-6-yl)methyl)piperazin-1-yl)-2-methylpropanamide",1.2,uM,=,0.0791812460476248,1,c1cc(-c2nc(N3CCOCC3)c3sc(CN4CCNCC4)cc3n2)c2cc[nH]c2c1
3924,1869046,10.1021/acs.jmedchem.8b01656,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins in presence of NADPH,CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,SID144204227,0.0366,uM,=,-1.4365189146055894,0,c1ccc([C@@]2(Cn3ccnc3)OC[C@H](COc3ccc(N4CCNCC4)cc3)O2)cc1
3925,834929,10.1016/j.bmcl.2012.07.020,,,,Inhibition of CYP3A4,CCS(=O)(=O)c1ccc2[nH]c(-c3cc(-c4ccccc4)ccc3F)nc2c1,5-(ethylsulfonyl)-2-(4-fluorobiphenyl-3-yl)-1H-benzo[d]imidazole,14.0,uM,=,1.146128035678238,1,c1ccc(-c2cccc(-c3nc4ccccc4[nH]3)c2)cc1
3926,676065,10.1016/j.bmcl.2010.09.028,,,,Inhibition of CYP3A4 after 30 mins,CN1CCN(C(=O)OC2([C@H]3COC[C@@H](CC4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)CC1=O,"1-((3R,5R)-4-(4-chlorophenylsulfonyl)-5-(cyclopropylmethyl)morpholin-3-yl)cyclopropyl 4-methyl-3-oxopiperazine-1-carboxylate",0.0014,uM,=,-2.853871964321762,0,O=C1CN(C(=O)OC2([C@H]3COC[C@@H](CC4CC4)N3S(=O)(=O)c3ccccc3)CC2)CCN1
3927,873423,10.1021/jm3006788,,,,Inhibition of CYP3A4,Cn1c(-c2ccccn2)c(C2CCCC2)c2ccc(C(=O)NC3(C(=O)Nc4ccc(/C=C/C(=O)O)cc4)CCCC3)cc21,3-(4-(1-(3-cyclopentyl-1-methyl-2-(pyridin-2-yl)-1H-indole-6-carboxamido)cyclopentanecarboxamido)phenyl)acrylic acid,6.3,uM,=,0.7993405494535817,1,O=C(NC1(C(=O)Nc2ccccc2)CCCC1)c1ccc2c(C3CCCC3)c(-c3ccccn3)[nH]c2c1
3928,1661017,10.1016/j.bmcl.2017.02.047,,,,Inhibition of recombinant human CYP3A4 expressed in baculosomes using Vivid DBOMF substrate green measured every 30 sec for 30 mins by fluorescence assay,CCCCCCC[C@H](O)CC(=O)CCc1ccc(O)c(OC)c1,8-Gingerol,11.6,uM,=,1.0644579892269186,1,c1ccccc1
3929,673952,10.1016/j.bmcl.2010.08.086,,,,Inhibition of CYP3A4 using midazolam as substrate,Cc1cc(Cl)c(OCCOc2ccc([C@H]3CCNC[C@@H]3C(=O)N(Cc3cc(CNCC(F)F)ccc3Cl)C3CC3)cc2)c(Cl)c1,"(3R,4S)-N-(2-chloro-5-((2,2-difluoroethylamino)methyl)benzyl)-N-cyclopropyl-4-(4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)phenyl)piperidine-3-carboxamide",3.1,uM,=,0.4913616938342727,1,O=C([C@H]1CNCC[C@@H]1c1ccc(OCCOc2ccccc2)cc1)N(Cc1ccccc1)C1CC1
3930,1659434,10.1021/acs.jmedchem.6b01662,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH by LC-MS/MS analysis,COc1ccc2c(c1)c(CN1CCN(C)CC1)cn2S(=O)(=O)c1ccccc1Br.CS(=O)(=O)O.O,1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole Dimesylate Monohydrate,1.5,uM,=,0.1760912590556812,1,O=S(=O)(c1ccccc1)n1cc(CN2CCNCC2)c2ccccc21
3931,2024613,10.1016/j.bmcl.2020.127721,,,,Inhibition of CYP3A4 (unknown origin),O=C(Cc1cccc(OCCCC2CCNCC2)c1)Nc1nc(-c2c[nH]c3nccc(F)c23)cs1,"N-[4-(4-fluoro-1H-pyrrolo[2,3-b]pyridin-3-yl)thiazol-2-yl]-2-[3-[3-(4-piperidyl)propoxy]phenyl]acetamide",100.0,uM,=,2.0,1,O=C(Cc1cccc(OCCCC2CCNCC2)c1)Nc1nc(-c2c[nH]c3ncccc23)cs1
3932,479364,10.1016/j.bmcl.2008.05.027,,,,Inhibition of CYP3A4,O=C(Cn1c(=O)sc2ccc(Cl)cc21)N1CCCC(c2ccccc2)C1CN1CCCC1,rac-5-chloro-3-(2-oxo-2-(3-phenyl-2-(pyrrolidin-1-ylmethyl)piperidin-1-yl)ethyl)benzo[d]thiazol-2(3H)-one,1.0,uM,=,0.0,0,O=C(Cn1c(=O)sc2ccccc21)N1CCCC(c2ccccc2)C1CN1CCCC1
3933,464748,10.1016/j.bmcl.2008.01.126,,,,Inhibition of CYP3A4 in presence of 7-benzyloxyresorufin substrate,Cc1oc(-c2ccccc2)nc1CCOc1cccc(C[C@@H]2C(=O)N(c3ccc(C(C)(C)C)cc3)[C@@H]2C(=O)O)c1,"(2S,3S)-3-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-(4-tert-butylphenyl)-4-oxoazetidine-2-carboxylic acid",19.0,uM,=,1.2787536009528289,1,O=C1[C@@H](Cc2cccc(OCCc3coc(-c4ccccc4)n3)c2)CN1c1ccccc1
3934,604766,10.1016/j.bmcl.2009.11.111,,,,Inhibition of CYP3A4,FC(F)(F)c1ccccc1OC1CCN(c2ccc(-n3ccnc3)nn2)CC1,3-(1H-imidazol-1-yl)-6-(4-(2-(trifluoromethyl)phenoxy)piperidin-1-yl)pyridazine,0.4,uM,=,-0.3979400086720376,0,c1ccc(OC2CCN(c3ccc(-n4ccnc4)nn3)CC2)cc1
3935,1288280,10.1016/j.bmcl.2013.12.057,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,CC(C)c1nc(CN(C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,"Thiazol-5-ylmethyl(2R,5R)-5-((S)-3-(1H-imidazol-4-yl)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)propanamido)-1,6-diphenylhexan-2-ylcarbamate",0.12,uM,=,-0.9208187539523752,0,O=C(NCc1cscn1)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
3936,804824,10.1016/j.bmcl.2011.12.080,,,,Reversible inhibition of CYP3A4,COc1ccc(C(C#N)c2c3cc(OC)cc(C)c3nc3[nH]nc(C)c23)cc1,"rac-2-(6-methoxy-3,8-dimethyl-1H-pyrazolo[3,4-b]quinolin-4-yl)-2-(4-methoxyphenyl)acetonitrile",0.3,uM,=,-0.5228787452803376,0,c1ccc(Cc2c3ccccc3nc3[nH]ncc23)cc1
3937,52069,10.1021/jm021012t,,,,Inhibition of human cytochrome P450 3A4,CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OCC5COC(Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O,"2-sec-Butyl-4-[4-(4-{4-[(2R,4S)-2-(2,4-dichloro-phenyl)-2-[1,2,4]triazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-phenyl]-2,4-dihydro-[1,2,4]triazol-3-one",0.7,uM,=,-0.1549019599857432,0,O=c1[nH]ncn1-c1ccc(N2CCN(c3ccc(OCC4COC(Cn5cncn5)(c5ccccc5)O4)cc3)CC2)cc1
3938,487712,10.1016/j.bmcl.2008.05.104,,,,Inhibition of CYP3A4,Cc1cc(N2CCC(N3CCN(C(=O)OCCO)CC3)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,"(S)-2-hydroxyethyl 4-(1-(2-(4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-2-oxo-1,2-dihydropyridin-3-yl)-7-methyl-3H-benzo[d]imidazol-5-yl)piperidin-4-yl)piperazine-1-carboxylate",0.0018,uM,=,-2.744727494896694,0,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(N3CCC(N4CCNCC4)CC3)cc2[nH]1
3939,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@@]2(C)Cc2cccc(-n3nccn3)c2)c1,"US9150566, 102",17.0,uM,=,1.230448921378274,1,O=C(c1ccccc1-n1nccn1)N1CCOCC1Cc1cccc(-n2nccn2)c1
3940,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCC(OC)CC6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, G-38",2.21,uM,=,0.3443922736851107,1,O=C(Nc1ccc(N2CCCCC2)nc1)c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12
3941,1744980,10.1016/j.bmcl.2017.09.046,,,,Inhibition of human CYP3A4 expressed in Escherichia coli co-expressing CYP-reductase using diethoxyfluorescein as substrate measured after 10 mins by fluorescence assay,CCc1cccc(-c2c(F)cccc2C(O)(CCCNC(=O)OC)[C@@H]2CCCN(C(=O)CC(CNC)OC)C2)c1,methyl 4-(3'-ethyl-6-fluorobiphenyl-2-yl)-4-hydroxy-4-((3R)-1-(3-methoxy-4-(methylamino)butanoyl)piperidin-3-yl)butylcarbamate,0.48,uM,=,-0.3187587626244128,0,c1ccc(-c2ccccc2C[C@@H]2CCCNC2)cc1
3942,355280,10.1016/j.bmcl.2006.02.020,,,,Inhibition of CYP3A4,C[C@H]([C@@H](c1ccc2cc(OCC3(C(=O)O)CC3)ccc2c1)n1ccnc1)N(C)C,"1-((6-((1R,2R)-2-(dimethylamino)-1-(1H-imidazol-1-yl)propyl)naphthalen-2-yloxy)methyl)cyclopropanecarboxylic acid",7.5,uM,=,0.8750612633917001,1,c1cn(Cc2ccc3cc(OCC4CC4)ccc3c2)cn1
3943,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1ccc(C(=O)N2CCO[C@@H](C)[C@H]2Cc2cccc(-n3nccn3)c2)c(-n2nccn2)c1,"US9150566, 163",14.0,uM,=,1.146128035678238,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
3944,689742,10.1021/jm100714c,,,,Inhibition of human recombinant CYP3A4,Cc1ccc2c(N3CCN(CCc4cccc(N5CCNC5=O)c4)CC3)cccc2n1,1-(3-{2-[4-(2-Methyl-5-quinolinyl)-1-piperazinyl]ethyl}phenyl)-2-imidazolidinone,67.0,uM,=,1.8260748027008264,1,O=C1NCCN1c1cccc(CCN2CCN(c3cccc4ncccc34)CC2)c1
3945,802673,10.1016/j.bmcl.2011.12.125,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,O=C(Nc1ccccc1)Nc1ccc(-c2ccnc3[nH]cnc23)cc1,"1-(4-(3H-imidazo[4,5-b]pyridin-7-yl)phenyl)-3-phenylurea",1.2,uM,=,0.0791812460476248,1,O=C(Nc1ccccc1)Nc1ccc(-c2ccnc3[nH]cnc23)cc1
3946,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1ccc(C(=O)N2CCOC[C@H]2Cc2cc(-c3cccnn3)ccc2F)c(-n2nccn2)c1,"US9150566, 166",19.0,uM,=,1.2787536009528289,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2cccnn2)c1
3947,2133633,10.1021/acs.jmedchem.1c00679,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins in presence of NADPH by LCMS/MS analysis,CCC(NC(=O)c1ccc(Cl)cc1)[C@@H]1[C@@H]2C[C@@H](Oc3ccnc4ccccc34)C[C@@H]21,"4-chloro-N-(1-((1R,3s,5S,6r)-3-(quinolin-4-yloxy)bicyclo[3.1.0]hexan-6-yl)propyl)benzamide",3.3,uM,=,0.5185139398778875,1,O=C(NC[C@H]1[C@H]2C[C@H](Oc3ccnc4ccccc34)C[C@@H]12)c1ccccc1
3948,473932,10.1021/jm701121y,,,,Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay,Clc1ccc(C2(Cn3cncn3)CC(Br)CO2)c(Cl)c1,"1-((4-bromo-2-(2,4-dichlorophenyl)-tetrahydrofuran-2-yl)methyl)-1H-1,2,4-triazole",0.13,uM,=,-0.8860566476931633,0,c1ccc(C2(Cn3cncn3)CCCO2)cc1
3949,1972822,10.1021/acsmedchemlett.9b00611,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,COc1nn(-c2cnccn2)cc1C(=O)Nc1cccc(-c2nncn2C(C)C)n1,"N-(6-(4-Isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-3-methoxy-1-(pyrazin-2-yl)-1H-pyrazole-4-carboxamide",8.8,uM,=,0.9444826721501688,1,O=C(Nc1cccc(-c2nnc[nH]2)n1)c1cnn(-c2cnccn2)c1
3950,774749,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1,"1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole",0.1,uM,=,-1.0,0,c1ccc(COC(Cn2ccnc2)c2ccccc2)cc1
3951,44705,10.1016/s0960-894x(02)00473-0,,,,Inhibition of cytochrome P450 3A4,Cn1cc(Cc2cn(CC(=O)N(CCN)Cc3ccc(-c4ccc(Cl)cc4)cc3)c(SCc3ccc(F)cc3)nc2=O)cn1,N-(2-Amino-ethyl)-N-(4'-chloro-biphenyl-4-ylmethyl)-2-[2-(4-fluoro-benzylsulfanyl)-5-(1-methyl-1H-pyrazol-4-ylmethyl)-4-oxo-4H-pyrimidin-1-yl]-acetamide,15.0,uM,=,1.1760912590556811,1,O=C(Cn1cc(Cc2cn[nH]c2)c(=O)nc1SCc1ccccc1)NCc1ccc(-c2ccccc2)cc1
3952,1613611,10.1016/j.bmcl.2016.08.089,,,,Inhibition of CYP3A4 (unknown origin),COc1ncc(F)c(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)n1,"(R)-5-(5-fluoro-2-methoxypyrimidin-4-yl)-6-isopropyl-2-(3-(methylsulfonyl)phenyl)-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole",15.4,uM,=,1.187520720836463,1,c1ccc(-n2cc3c(n2)CN(c2ccncn2)C3)cc1
3953,1450858,10.1021/jm5005336,,,,Inhibition of CYP3A4 (unknown origin) using BFC substrate after 30 mins by fluorescence assay,O=C1Nc2ccccc2/C1=C\c1ccc2c(/C=C/c3ccncc3)n[nH]c2c1,(E)-3-((3-((E)-2-(Pyridin-4-yl)vinyl)-1H-indazol-6-yl)-methylene)-indolin-2-one,1.0,uM,=,0.0,0,O=C1Nc2ccccc2/C1=C\c1ccc2c(/C=C/c3ccncc3)n[nH]c2c1
3954,2170798,10.1021/acs.jmedchem.0c02143,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated 10 mins in presence of NADPH by solid phase extraction mass spectrometry analysis,C[C@@]1(c2cc(NC(=O)c3ncc(C#N)cc3N)ccc2F)CO[C@@](C)(C(F)(F)F)C(N)=N1,"3-amino-N-(3-((3R,6R)-5-amino-3,6-dimethyl-6-(trifluoromethyl)-3,6-dihydro-2H-1,4-oxazin-3-yl)-4-fluorophenyl)-5-cyanopicolinamide",7.0,uM,=,0.8450980400142568,1,O=C(Nc1cccc(C2COCC=N2)c1)c1ccccn1
3955,1485439,10.1124/dmd.111.042739,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrates after 5 mins by LC/MS analysis in presence of NADPH,CC[C@@H](C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@H]5CO[C@@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O,"trans-2-((R)-sec-Butyl)-4-[4-(4-{4-[(2S,4S)-2-(2,4-dichloro-phenyl)-2-[1,2,4]triazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-phe nyl]-2,4-dihydro-[1,2,4]triazol-3-one",0.016,uM,=,-1.7958800173440752,0,O=c1[nH]ncn1-c1ccc(N2CCN(c3ccc(OC[C@H]4CO[C@@](Cn5cncn5)(c5ccccc5)O4)cc3)CC2)cc1
3956,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1ccc(-n2nccn2)c(C(=O)N2CCC[C@H]2Cc2cccc(-n3nccn3)c2)c1,"US9150566, Ref. 2",3.3,uM,=,0.5185139398778875,1,O=C(c1ccccc1-n1nccn1)N1CCC[C@H]1Cc1cccc(-n2nccn2)c1
3957,321500,10.1016/j.bmcl.2005.06.056,,,,Inhibition against Cytochrome P450 3A4 prepared from baculovirus-infected insect cells using 7-benzyloxy- 4-trifluoromethylcoumarin,N#CCn1c(=O)c(CCO)c(-c2cc(Cl)ccc2O)c2cc(C(F)(F)F)ccc21,[4-(5-Chloro-2-hydroxy-phenyl)-3-(2-hydroxy-ethyl)-2-oxo-6-trifluoromethyl-2H-quinolin-1-yl]-acetonitrile,13.0,uM,=,1.1139433523068367,1,O=c1cc(-c2ccccc2)c2ccccc2[nH]1
3958,1642014,,,,,"Inhibition Assay: The test compounds were incubated with pooled human liver microsomes at 37° C. in the presence of NADPH and appropriate concentrations of substrates specific for CYP2C9 and 3A4. 120 μL of a mixture of human liver microsomes (HLM) in 50 mM potassium phosphate/5 mM MgCl2 buffer was added into all wells of row A in a 96-well plate. The concentration of microsomal protein was 2-fold the intended protein concentration for the particular isozyme assay recorded in Table 4. In addition, 80 μL of this human liver microsome preparation spiked with 1% DMSO was dispensed into all wells of rows B through H. 1.2 μL of each individual test compound in DMSO (10 mM) was added to the first 10 wells of row A (5 different test compounds each in duplicate). Additionally, 1.2 μL of the DMSO stock of the control inhibitor for the isozyme under study was added into the final two wells of row A to give a concentration two-fold above the highest final concentration. Three-fold serial dilutions were performed by taking 40 μL from each solution in wells of row A (wells 1-12, both compounds and controls) and diluting into the wells of row B. After thorough mixing, 40 μL from each solution in wells of row B were dispensed with a multichannel pipette (12 channels) into the wells of row C and the controls and test compounds hence further diluted. This process was repeated for rows D through G. After mixing, 40 μL was removed and discarded from the wells of row G. This procedure resulted in 80 μL of solution being present in all wells of all rows A through H, with protein concentrations being twice the final intended concentrations in all wells of rows, and test compound and control concentration being twice the final intended concentrations in rows A through G. Row H was not spiked with a test compound or positive control. The plate was covered and pre-incubated for 10 minutes in a 37° C. incubator. The reaction was initiated by adding 80 μL of a solution of the substrate for the isozyme under investigation in 50 mM potassium phosphate/5 mM MgCl2 buffer solution with 4 mM NADPH present, at a substrate concentration two-fold the intended final substrate concentrations using a multichannel pipette. The substrate solution was added to all wells rows A to H excluding wells 95 and 96 (microsomal blanks). The plate was covered and incubated at 37° C. for the time listed in Table 4 for the isoform under investigation. The reaction was stopped by dispensing 120 μL of internal standard (200 ng/mL CCX915-6A) in acetonitrile to all wells. 80 μL of the specific substrate/NADPH solution described above was added into the well 95 and 96 after stopping the reaction to provide the blank. The plate was vortexed for 10 min and spun in a centrifuge at 4,450 rpm and 4° C. for 10 min. With a multichannel pipette, 80 μL of the supernatant was transferred into a sample plate wells containing 80 μL of 0.1% formic acid/water and mixed well for analysis on LC-MS/MS as described in sections E and F.",COC1=C(C(=O)c2ncc(C)cc2NS(=O)(=O)c2ccc(Cl)c(C(F)(F)F)c2)C2C=CNC2N=C1,"US9394307, 4-chloro-N-(2-{5-methoxy-1H,3aH,7aH-pyrrolo[2,3-b]pyridine-4-carbonyl}-5-methylpyridin-3-yl)-3-(trifluoromethyl)benzene-1-sulfonamide",3.0,uM,=,0.4771212547196624,1,O=C(C1=CC=NC2NC=CC12)c1ncccc1NS(=O)(=O)c1ccccc1
3959,464738,10.1016/j.bmcl.2008.01.126,,,,Inhibition of CYP3A4 in presence of 7-benzyloxy-4-trifluoromethyl coumarin substrate,Cc1oc(-c2ccc(Cl)cc2)nc1CCOc1cccc(C[C@@H]2C(=O)N(c3ccc(C(C)(C)C)cc3)[C@@H]2C(=O)O)c1,"(2S,3S)-3-(3-(2-(2-(4-chlorophenyl)-5-methyloxazol-4-yl)ethoxy)benzyl)-1-(4-tert-butylphenyl)-4-oxoazetidine-2-carboxylic acid",4.7,uM,=,0.6720978579357175,1,O=C1[C@@H](Cc2cccc(OCCc3coc(-c4ccccc4)n3)c2)CN1c1ccccc1
3960,495542,10.1021/jm801332q,,,,Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate by time dependent inhibition assay,C[C@@H]1CN(Cc2ccc(CC(=O)N3CCC(Nc4ccc(F)cc4)CC3)cc2)C[C@H](C)N1,"1-[(4-([(3R,5S)-3,5-Dimethyl-1-piperazinyl]methyl)phenyl)acetyl]-N-(4-fluorophenyl)-4-piperidinamine",41.0,uM,=,1.6127838567197357,1,O=C(Cc1ccc(CN2CCNCC2)cc1)N1CCC(Nc2ccccc2)CC1
3961,796228,10.1016/j.bmcl.2011.10.115,,,,Inhibition of CYP3A4,Fc1ccc(Cn2c(C3CNCCS3)nc3ccccc32)cc1,(+/-)-2-(1-(4-fluorobenzyl)-1H-benzo[d]imidazol-2-yl)thiomorpholine,10.6,uM,=,1.0253058652647702,1,c1ccc(Cn2c(C3CNCCS3)nc3ccccc32)cc1
3962,2156515,10.1021/acs.jmedchem.1c01272,,,,Inhibition of CYP3A4 in human liver microsomes using IPA as substrate preincubated for 10 mins followed by NADPH generating system addition and measured after 20 mins,COc1cc(NC(=O)c2cc(=O)c3ccccc3o2)c(-c2nnn(-c3ccc(CCN4CCc5cc(-n6ccnc6)ccc5C4)cc3)n2)cc1OC,"N-(2-(2-(4-(2-(6-(1H-imidazol-1-yl)-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl)-4-oxo-4H-chromene-2-carboxamide",0.305,uM,=,-0.5157001606532141,0,O=C(Nc1ccccc1-c1nnn(-c2ccc(CCN3CCc4cc(-n5ccnc5)ccc4C3)cc2)n1)c1cc(=O)c2ccccc2o1
3963,1641295,,,,,"CYP Inhibition Assay (With Preincubation): With Preincubation: To a 96 deep well plate was added 2.5 uL of the test substance solution (x200 concentration), and 442.5 uL of Incubation Mixture, and the solution was mixed and warmed to 37° C. for 5 minutes. To this incubation solution 50 uL of 10 mM NADPH was added and preincubated at 37° C. for 30 minutes. After the preincubation, 5 uL of the substrate solution was added and the solution was mixed and further incubated at 37° C. for 5 minutes for the reaction. After the reaction, 100 uL of the Incubation Mixture was removed, added to 150 uL of isopropanol containing IS and mixed. This mixture was transferred onto a multi-screen filter, centrifuged at 500xg at 4° C. for 10 minutes. The filtrate was used for LC-MS/MS analysis.",CCCCCCCC(F)(F)CCCCCC/C=C/[C@H](C(O)N[C@@H](Cc1ccc(OCCCC)cc1)C(=O)O)[C@@](O)(CCOC)C(=O)O,"US9266853, 5526064",11.8,uM,=,1.0718820073061257,1,c1ccccc1
3964,1465594,10.1016/j.bmcl.2015.02.039,,,,Inhibition of CYP3A4 (unknown origin) using midazolam fluorometric substrate,COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2NC(=O)CCc2ccccc2)C(C)C)ccc1OC,rac-N-isopropyl-4-methoxy-3-(3-methoxypropoxy)-N-((4-(3-phenylpropanamido)pyrrolidin-3-yl)methyl)benzamide,3.1,uM,=,0.4913616938342727,1,O=C(CCc1ccccc1)N[C@@H]1CNC[C@H]1CNC(=O)c1ccccc1
3965,563067,10.1021/jm900063x,,,,Inhibition of CYP3A4,O=C([C@@H]1C[C@H]1c1ccc(C(F)(F)F)cc1)N1CCN(S(=O)(=O)c2cc(-c3nnc[nH]3)cc(C(F)(F)F)c2)CC1,"(4-(3-(4H-1,2,4-triazol-3-yl)-5-(trifluoromethyl)phenylsulfonyl)piperazin-1-yl)((1R,2R)-2-(4-(trifluoromethyl)phenyl)cyclopropyl)methanone",4.7,uM,=,0.6720978579357175,1,O=C([C@@H]1C[C@H]1c1ccccc1)N1CCN(S(=O)(=O)c2cccc(-c3nnc[nH]3)c2)CC1
3966,1883264,10.1021/acs.jmedchem.8b01344,,,,Reversible inhibition of CYP3A4 (unknown origin) in presence of NADPH by vivid red substrate-based assay,N#Cc1ccc(S(=O)(=O)N2C[C@H](S(=O)(=O)c3ccc(Cl)cn3)[C@](O)(CN)C2)c(Cl)c1,"4-(((3S,4S)-3-(Aminomethyl)-4-((5-chloropyridin-2-yl)-sulfonyl)-3-hydroxypyrrolidin-1-yl)sulfonyl)-3-chlorobenzonitrile",0.3,uM,=,-0.5228787452803376,0,O=S(=O)(c1ccccn1)[C@@H]1CCN(S(=O)(=O)c2ccccc2)C1
3967,982382,10.1016/j.bmcl.2013.07.071,,,,Inhibition of CYP3A4 (unknown origin),COC[C@@H](Oc1cc(C[C@@H]2C[S@@+]([O-])C[C@H](NCc3cccc(C(C)(C)C)c3)[C@H]2O)cc(F)c1N)C(F)(F)F,"(1R,3S,4S,5R)-3-[4-Amino-3-fluoro-5-((R)-2,2,2-trifluoro-1-methoxymethyl-ethoxy)-benzyl]-5-(3-tert-butyl-benzylamino)-1-oxo-tetrahydro-thiopyran-4-ol",0.2,uM,=,-0.6989700043360187,0,c1ccc(CN[C@H]2C[SH+]C[C@@H](Cc3ccccc3)C2)cc1
3968,595638,10.1016/j.bmcl.2009.09.096,,,,Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH,COc1ccc2c(O[C@H](C)c3nnc4ccc(-c5ccccc5)nn34)ccnc2c1,"(R)-7-methoxy-4-(1-(6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)ethoxy)quinoline",8.9,uM,=,0.9493900066449128,1,c1ccc(-c2ccc3nnc(COc4ccnc5ccccc45)n3n2)cc1
3969,1581635,10.1021/acs.jmedchem.5b01146,,,,Inhibition of C-terminal four-histidine tagged human CYP3A4delta3 to 24 residues expressed in Escherichia coli assessed as 7-benzyloxy-4-(trifluoromethyl)coumarin O-debenzylation pretreated 2 mins followed by NADPH addition by fluorometric method in presence of rat cytochrome P450 reductase,CC(C)(C)OC(=O)N[C@H](CSCCC(=O)NCc1cccnc1)Cc1ccccc1,(S)-tert-butyl 1-(3-oxo-3-(pyridin-3-ylmethylamino)propylthio)-3-phenylpropan-2-ylcarbamate,0.52,uM,=,-0.2839966563652008,0,O=C(CCSCCCc1ccccc1)NCc1cccnc1
3970,1301328,10.6019/CHEMBL3137440,,,,DNDI: CYP Inhibition,CC(C)(O)CN1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1,,5.3,uM,=,0.724275869600789,1,c1ccc(N(c2cccnc2)C2CCNCC2)cc1
3971,1758889,10.1021/acsmedchemlett.7b00230,,,,Inhibition of CYP3A4 (unknown origin),COc1ccc(N2C(=O)CN(Cc3ccccc3)C2=S)cc1Cl,DNDI1318303,4.015,uM,=,0.6036855496146997,1,O=C1CN(Cc2ccccc2)C(=S)N1c1ccccc1
3972,555225,10.1016/j.bmcl.2008.05.058,,,,Inhibition of CYP3A4,COCCN(CC(=O)N(C)C(CN1CCCC1)c1ccc(-c2ccc(C(N)=O)cc2)cc1)c1ccc(Cl)c(Cl)c1,"4'-[1-({2-[(3,4-Dichloro-phenyl)-(2-methoxy-ethyl)-amino]-acetyl}-methyl-amino)-2-pyrrolidin-1-yl-ethyl]-biphenyl-4-carboxylic acid amide",2.6,uM,=,0.414973347970818,1,O=C(CNc1ccccc1)NC(CN1CCCC1)c1ccc(-c2ccccc2)cc1
3973,2017934,10.1021/acs.jmedchem.0c00834,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis,Cc1c(-c2ccccc2)nc2ccc(Br)cc2c1C(=O)NCC(CCCC(=O)O)c1ccccc1Cl,(+)-6-{[(6-Bromo-3-methyl-2-phenylquinolin-4-yl)carbonyl]amino}-5-(2-chlorophenyl)hexanoic acid,20.0,uM,=,1.3010299956639813,1,O=C(NCCc1ccccc1)c1cc(-c2ccccc2)nc2ccccc12
3974,519907,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,Cc1nc2c(N[C@H]3CCc4ccccc43)cc(-n3ccccc3=O)cn2c1C,"(S)-1-(8-(2,3-dihydro-1H-inden-1-ylamino)-2,3-dimethylimidazo[1,2-a]pyridin-6-yl)pyridin-2(1H)-one",18.0,uM,=,1.255272505103306,1,O=c1ccccn1-c1cc(N[C@H]2CCc3ccccc32)c2nccn2c1
3975,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",O=C(c1cccc(Cl)c1-n1nccn1)N1CCOC[C@H]1Cc1cc(-n2nccn2)ccc1Cl,"US9150566, 171",13.0,uM,=,1.1139433523068367,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
3976,425259,10.1021/jm060983w,,,,Inhibition of CYP3A4 in human liver microsomes,O=C(OCc1ccccc1)N1CCC(CNc2ccncn2)CC1,benzyl 4-[(pyrimidin-4-ylamino)methyl]piperidine-1-carboxylate,5.1,uM,=,0.7075701760979364,1,O=C(OCc1ccccc1)N1CCC(CNc2ccncn2)CC1
3977,1741066,10.1021/acs.jmedchem.8b00450,,,,Inhibition of human CYP3A4,FC1(F)CCC(CN(C[C@H]2Cc3c(cccc3N3CCNCC3)CN2)[C@H]2CCCc3cccnc32)CC1,"(S)-N-((4,4-difluorocyclohexyl)methyl)-N-(((R)-5-(piperazin-1-yl)-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)-5,6,7,8-tetrahydroquinolin-8-amine",5.62,uM,=,0.7497363155690611,1,c1cnc2c(c1)CCC[C@@H]2N(CC1CCCCC1)C[C@H]1Cc2c(cccc2N2CCNCC2)CN1
3978,2103815,10.1016/j.bmcl.2021.128010,,,,Time dependent inhibition of CYP3A4 (unknown origin) measured at 30 mins,Nc1cc(Cc2ccn(Cc3ccc4ccccc4c3)n2)c2nn[nH]c2n1,"7-((1-(naphthalen-2-ylmethyl)-1H-pyrazol-3-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-amine",0.04,uM,=,-1.3979400086720375,0,c1ccc2cc(Cn3ccc(Cc4ccnc5[nH]nnc45)n3)ccc2c1
3979,469873,10.1016/j.bmcl.2008.01.012,,,,Inhibition of human CYP3A4,CC(C)c1c(-c2nnc(NCC(C)(C)CN)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12,"5-(6-(5-(3-amino-2,2-dimethylpropylamino)-1,3,4-oxadiazol-2-yl)-5-isopropylpyrrolo[1,2-f][1,2,4]triazin-4-ylamino)-N-cyclopropyl-2,4-difluorobenzamide",1.4,uM,=,0.1461280356782379,1,O=C(NC1CC1)c1cccc(Nc2ncnn3cc(-c4nnco4)cc23)c1
3980,1567198,10.1039/C5MD00479A,,,,Inhibition of human CYP3A4 by HPLC analysis,CCCC(=O)O[C@@H](C(=O)N1N=CC[C@H]1C(=O)NCc1cc(Cl)ccc1-n1cnnn1)c1ccc(F)cc1,"(1R)-2-[(5S)-5-{[5-Chloro-2-(1H-tetrazol-1-yl)benzyl]carbamoyl}-4,5-dihydro-1H-pyrazol-1-yl]-1-(4-fluorophenyl)-2-oxoethyl butanoate",1.8,uM,=,0.255272505103306,1,O=C(NCc1ccccc1-n1cnnn1)[C@@H]1CC=NN1C(=O)Cc1ccccc1
3981,619264,10.1016/j.bmcl.2009.07.002,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,Cc1cccc(C)c1CNc1nc(N2CCCC2=O)cc2c(C)c(C)[nH]c12,"1-(7-(2,6-dimethylbenzylamino)-2,3-dimethyl-1H-pyrrolo[2,3-c]pyridin-5-yl)pyrrolidin-2-one",1.0,uM,=,0.0,0,O=C1CCCN1c1cc2cc[nH]c2c(NCc2ccccc2)n1
3982,51909,10.1021/jm010531d,,,,Inhibition of human Cytochrome P450 3A4 by macrocycles,N#Cc1ccc(Cn2cncc2CN[C@H]2CCN(Cc3cccc(Cl)c3)C2=O)cc1,4-(5-{[1-(3-Chloro-benzyl)-2-oxo-pyrrolidin-3-ylamino]-methyl}-imidazol-1-ylmethyl)-benzonitrile,1.0,uM,=,0.0,0,O=C1[C@@H](NCc2cncn2Cc2ccccc2)CCN1Cc1ccccc1
3983,1614025,10.1016/j.bmcl.2016.09.043,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 6-beta-hydroxytestosterone metabolite formation using testosterone as substrate incubated for 30 mins by HPLC-MS method,Cn1c(NCCc2ccccc2)nc2cc(Cl)ccc2c1=O,7-Chloro-3-methyl-2-phenethylamino-3H-quinazolin-4-one,18.0,uM,=,1.255272505103306,1,O=c1[nH]c(NCCc2ccccc2)nc2ccccc12
3984,1614025,10.1016/j.bmcl.2016.09.043,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 6-beta-hydroxytestosterone metabolite formation using testosterone as substrate incubated for 30 mins by HPLC-MS method,Cn1c(NCCc2ccc(-n3cccn3)cc2)nc2cc(Cl)ccc2c1=O,7-Chloro-3-methyl-2-[2-(4-pyrazol-1-yl-phenyl)-ethylamino]-3H-quinazolin-4-one,8.3,uM,=,0.919078092376074,1,O=c1[nH]c(NCCc2ccc(-n3cccn3)cc2)nc2ccccc12
3985,487712,10.1016/j.bmcl.2008.05.104,,,,Inhibition of CYP3A4,Cc1cc(N2CCC(N3CCN(C)CC3)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,(S)-4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-3-(4-methyl-6-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one,0.0024,uM,=,-2.619788758288394,0,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(N3CCC(N4CCNCC4)CC3)cc2[nH]1
3986,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",COc1ccc(C[C@@H]2COCCN2C(=O)c2ccc(F)cc2-n2nccn2)cc1-c1ncon1,"US9150566, 61",42.0,uM,=,1.6232492903979006,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2ncon2)c1
3987,1619558,10.1021/acsmedchemlett.6b00327,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 10 mins in presence of NADP by rapidfire/MS analysis,C[C@H]1OC(=O)[C@]2(c3n[nH]c(=O)o3)CC(F)(F)[C@@H](C)[C@H](/C=C/c3ccc(-c4cccc(F)c4)cn3)[C@H]12,"5-((1R,3aR,6S,7R,7aS)-5,5-difluoro-7-((E)-2-(5-(3-fluorophenyl)pyridin-2-yl)vinyl)-1,6-dimethyl-3-oxooctahydroisobenzofuran-3a-yl)-1,3,4-oxadiazol-2(3H)-one",50.0,uM,=,1.6989700043360187,1,O=C1OC[C@H]2[C@@H](/C=C/c3ccc(-c4ccccc4)cn3)CCC[C@@]12c1n[nH]c(=O)o1
3988,305432,10.1016/j.bmcl.2005.01.044,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,CC(C(c1ccc2cc(OCC(=O)O)ccc2c1)n1ccnc1)N(C)C,[6-(2-Dimethylamino-1-imidazol-1-yl-propyl)-naphthalen-2-yloxy]-acetic acid,2.2,uM,=,0.3424226808222063,1,c1ccc2cc(Cn3ccnc3)ccc2c1
3989,1685713,10.1016/j.bmc.2017.04.033,,,,Inhibition of recombinant CYP3A4 (unknown origin),C[C@@H](c1ccc(-c2cncc(F)c2)cc1)N1CC[C@](CCCO)(c2ccccc2)OC1=O,"(R)-3-((S)-1-(4-(5-fluoropyridin-3-yl)phenyl)ethyl)-6-(3-hydroxypropyl)-6-phenyl-1,3-oxazinan-2-one",11.0,uM,=,1.0413926851582251,1,O=C1OC(c2ccccc2)CCN1Cc1ccc(-c2cccnc2)cc1
3990,2126605,10.1016/j.bmcl.2021.128077,,,,Time dependent inhibition of CYP3A4 (unknown origin) measured after 30 mins,O=C(C[C@@H]1Cc2cc(Cl)c3[nH]ncc3c2CN(CC(F)(F)F)C1=O)N1CCC(N2CCc3ccccc3NC2=O)CC1,"(S)-4-chloro-7-(2-oxo-2-(4-(2-oxo-4,5-dihydro-1H-benzo[d][1,3]diazepin-3(2H)-yl)piperidin-1-yl)ethyl)-9-(2,2,2-trifluoroethyl)-6,7,9,10-tetrahydroazepino[3,4-e]indazol-8(3H)-one",0.1,uM,=,-1.0,0,O=C1NCc2c(ccc3[nH]ncc23)C[C@H]1CC(=O)N1CCC(N2CCc3ccccc3NC2=O)CC1
3991,492191,10.1016/j.bmcl.2008.05.075,,,,Inhibition of CYP3A4,CC(C)c1nc2cccnc2n1-c1ccc(C[C@H](NC2=C(Br)C(=O)C23CCCCC3)C(=O)O)cc1,"(S)-2-(2-Bromo-3-oxo-spiro[3.5]non-1-en-1-ylamino)-3-[4-(2-isopropyl-imidazo[4,5-b]pyridin-3-yl)-phenyl]-propionic acid",79.0,uM,=,1.8976270912904407,1,O=C1C=C(NCCc2ccc(-n3cnc4cccnc43)cc2)C12CCCCC2
3992,1787389,10.1039/C8MD00070K,,,,Inhibition of recombinant human CYP3A4 by bioluminescence method,CCCCn1c(=O)c2c(nc3n2CCCN3CCc2ccc(OCC(=O)NCCCN(CC)CC)cc2)n(CCCC)c1=O,"2-(4-(2-(1,3-dibutyl-2,4-dioxo-1,2,3,4,7,8-hexahydropyrimido[2,1-f]purin-9(6H)-yl)ethyl)phenoxy)-N-(3-(diethylamino)propyl)acetamide",0.23,uM,=,-0.6382721639824072,0,O=c1[nH]c(=O)c2c(nc3n2CCCN3CCc2ccccc2)[nH]1
3993,1499751,10.1021/acs.jmedchem.5b00424,,,,Inhibition of CYP3A4 (unknown origin),COc1cccc(CC(=O)Nc2cc(-c3ccncn3)cs2)c1,2-(3-methoxyphenyl)-N-(4-(pyrimidin-4-yl)thiophen-2-yl)acetamide,2.0,uM,=,0.3010299956639812,1,O=C(Cc1ccccc1)Nc1cc(-c2ccncn2)cs1
3994,519907,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,Cc1cccc(C)c1CNc1cc(-n2ccc(=O)cc2)cn2c(C)c(C)nc12,"1-(8-(2,6-dimethylbenzylamino)-2,3-dimethylimidazo[1,2-a]pyridin-6-yl)pyridin-4(1H)-one",16.0,uM,=,1.2041199826559248,1,O=c1ccn(-c2cc(NCc3ccccc3)c3nccn3c2)cc1
3995,1660136,10.1021/acs.jmedchem.6b01918,,,,Inhibition of human CYP3A4 assessed as inhibition of dealkylation,CN[C@H]1CC[C@](CCOc2cc(F)c(S(=O)(=O)Nc3ncns3)cc2F)(c2ccccc2)CC1,"cis-2,5-Difluoro-4-(2-((1R,4R)-4-(methylamino)-1-phenylcyclohexyl)-ethoxy)-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide",0.45,uM,=,-0.3467874862246563,0,O=S(=O)(Nc1ncns1)c1ccc(OCCC2(c3ccccc3)CCCCC2)cc1
3996,1288280,10.1016/j.bmcl.2013.12.057,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,CC(C)c1nc(CN(C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CC[C@@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,"Thiazol-5-ylmethyl(2S,5S)-5-((S)-3-(1H-imidazol-4-yl)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)propanamido)-1,6-diphenylhexan-2-ylcarbamate",0.09,uM,=,-1.0457574905606752,0,O=C(NCc1cscn1)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CC[C@@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
3997,817424,10.1021/ml200137x,,,,Inhibition of CYP3A4 using testosterone as substrate in human liver microsome for 20 mins by HPLC analysis,COCCCC[C@@](O)(c1cccc(Cl)c1F)[C@@H]1CCCN(C(=O)NC[C@@H](N)CC2CCCCC2)C1,(R)-N-((S)-2-amino-3-cyclohexylpropyl)-3-((S)-1-(3-chloro-2-fluorophenyl)-1-hydroxy-5-methoxypentyl)piperidine-1-carboxamide,2.91,uM,=,0.4638929889859073,1,O=C(NCCCC1CCCCC1)N1CCC[C@@H](Cc2ccccc2)C1
3998,519908,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,CCc1cccc(C)c1CNc1cccn2c(C)c(C)nc12,"N-(2-ethyl-6-methylbenzyl)-2,3-dimethylimidazo[1,2-a]pyridin-8-amine",6.3,uM,=,0.7993405494535817,1,c1ccc(CNc2cccn3ccnc23)cc1
3999,959467,10.1016/j.bmcl.2013.02.093,,,,Inhibition of human recombinant CYP3A4 using BFC as substrate by fluorimetric assay,Cc1ccc(-c2ccccc2)c(C(=O)N2CC3(CC3)C[C@H]2CNc2ccc(C(F)(F)F)cn2)n1,(S)-(6-methyl-3-phenylpyridin-2-yl)(6-((5-(trifluoromethyl)pyridin-2-ylamino)methyl)-5-azaspiro[2.4]heptan-5-yl)methanone,64.0,uM,=,1.806179973983887,1,O=C(c1ncccc1-c1ccccc1)N1CC2(CC2)C[C@H]1CNc1ccccn1
4000,1567198,10.1039/C5MD00479A,,,,Inhibition of human CYP3A4 by HPLC analysis,CCC(=O)O[C@@H](C(=O)N1N=CC[C@H]1C(=O)NCc1cc(Cl)ccc1-n1cnnn1)c1ccc(F)cc1,"(1R)-2-[(5S)-5-{[5-Chloro-2-(1H-tetrazol-1-yl)benzyl]carbamoyl}-4,5-dihydro-1H-pyrazol-1-yl]-1-(4-fluorophenyl)-2-oxoethyl propanoate",8.0,uM,=,0.9030899869919436,1,O=C(NCc1ccccc1-n1cnnn1)[C@@H]1CC=NN1C(=O)Cc1ccccc1
4001,563097,10.1016/j.bmc.2009.03.001,,,,Inhibition of CYP3A4 in human liver microsome assessed as 1'-hydroxymidazolam formation by competitive inhibition assay,Cc1ccn(-c2ccc(C(=O)N3CCC(F)(F)/C(=C\C(=O)NCc4cccnn4)c4ccccc43)c(Cl)c2)n1,"(Z)-2-{1-[2-Chloro-4-(3-methyl-1H-pyrazol-1-yl)benzoyl]-4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}-N-(pyridazin-3-ylmethyl)acetamide",7.9,uM,=,0.8976270912904415,1,O=C(/C=C1\CCCN(C(=O)c2ccc(-n3cccn3)cc2)c2ccccc21)NCc1cccnn1
4002,630896,10.1016/j.bmcl.2010.03.017,,,,Inhibition of CYP3A4,Cc1cc(OC[P@@]2(=O)OCC[C@@H](c3cccc(Cl)c3)O2)c2c(c1C)Cc1scnc1-2,"(2R,4S)-4-[4-(3-Chloro-phenyl)-2-oxo-2lambda*5*-[1,3,2]dioxaphosphinan-2-ylmethoxy]-6,7-dimethyl-8H-indeno[1,2-d]thiazole",0.42,uM,=,-0.3767507096020995,0,O=[P@]1(COc2cccc3c2-c2ncsc2C3)OCC[C@@H](c2ccccc2)O1
4003,861307,10.1021/jm201711b,,,,Inhibition of human CYP3A4,O=C(Nc1nc2ccc(O)cc2s1)c1c(F)ccc(O)c1F,"2,6-Difluoro-3-hydroxy-N-(6-hydroxy-1,3-benzothiazol-2-yl)benzamide",54.0,uM,=,1.7323937598229686,1,O=C(Nc1nc2ccccc2s1)c1ccccc1
4004,813216,10.1016/j.bmcl.2012.01.125,,,,Inhibition of CYP3A4,COc1cc2c(Nc3ccccc3C(=O)N3CCCCC3)c(C(N)=O)cnc2cc1-c1c(C)noc1C,"7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-4-(2-(piperidine-1-carbonyl)phenylamino)quinoline-3-carboxamide",1.8,uM,=,0.255272505103306,1,O=C(c1ccccc1Nc1ccnc2cc(-c3cnoc3)ccc12)N1CCCCC1
4005,828928,10.1016/j.bmcl.2012.06.022,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,O=C(N[C@@H](Cc1ccccc1)[C@H](O)CN(CC1CCC(F)(F)CC1)C(=O)c1ccc2nc(N3CCCC3)oc2c1)OCc1cncs1,"thiazol-5-ylmethyl(2S,3R)-4-(N-((4,4-difluorocyclohexyl)methyl)-2-(pyrrolidin-1-yl)benzo[d]oxazole-6-carboxamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate",0.03,uM,=,-1.5228787452803376,0,O=C(N[C@H](CCN(CC1CCCCC1)C(=O)c1ccc2nc(N3CCCC3)oc2c1)Cc1ccccc1)OCc1cncs1
4006,2158614,10.1016/j.ejmech.2021.113987,,,,Inhibition of CYP3A4 in human liver microsomes incubated for 10 mins in presence of NADPH by LC/MS/MS analysis,Fc1ccc(C2(Cn3cncn3)COC(c3cc4ccc(Cl)cc4s3)=N2)cc1,"4-((1H-1,2,4-triazol-1-yl)methyl)-2-(6-chlorobenzo[b]thiophen-2-yl)-4-(4-fluorophenyl)-4,5-dihydrooxazole",10.1,uM,=,1.0043213737826426,1,c1ccc(C2(Cn3cncn3)COC(c3cc4ccccc4s3)=N2)cc1
4007,1527962,,,,,"Inhibition Assay (Testosterone Hydroxylase): To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.",NCc1ccc(-c2cccnc2)s1,C-(5-Pyridin-3-yl-thiophen-2-yl)-methylamine,15.33,uM,=,1.1855421548543752,1,c1cncc(-c2cccs2)c1
4008,859942,10.1021/jm300122u,,,,Inhibition of human CYP3A4 using testosterone as substrate after 45 mins,CN(C)CCN(C)C(=O)[C@H](Cc1ccc(Cl)cc1Cl)NC(=O)C1(c2ccc(Cl)cc2Cl)CC1,"2,4-Dichloro-N-alpha-{[1-(2,4-dichlorophenyl)cyclopropyl]-carbonyl}-N-[2-(dimethylamino)ethyl]-N-methyl-L-phenylalaninamide",1.53,uM,=,0.1846914308175988,1,O=C(NCCc1ccccc1)C1(c2ccccc2)CC1
4009,827973,10.1016/j.bmcl.2012.05.087,,,,Inhibition of CYP3A4 using midazolam as substrate,COc1ccc(C(C)=O)cc1CSc1nc2cc(F)ccc2n1CC(=O)O,2-(2-(5-acetyl-2-methoxybenzylthio)-5-fluoro-1H-benzo[d]imidazol-1-yl)acetic acid,10.0,uM,=,1.0,1,c1ccc(CSc2nc3ccccc3[nH]2)cc1
4010,1288280,10.1016/j.bmcl.2013.12.057,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,CC(C)c1nc(CN(C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,"(S)-4-((2R,5R)-1,6-diphenyl-5-((thiazol-5-ylmethoxy)carbonylamino)hexan-2-ylamino)-3-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-4-oxobutanoic acid",0.5,uM,=,-0.3010299956639812,0,O=C(CNC(=O)NCc1cscn1)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
4011,1923841,10.1021/acs.jmedchem.6b00280,,,,Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase and human b5 reductase assessed as reduction in 7-Hydroxyquinoline production using 7-benzyloxyquinoline as substrate and NADPH incubated for 15 mins by fluorimetry,O=C(NCCN1CCOCC1)Nc1nc2ccc(Sc3nnc4ccc(NC5CC5)nn34)cc2s1,"1-(6-(6-(cyclopropylamino)-[1,2,4]triazolo[4,3-b]pyridazin-3-ylthio)benzo[d]thiazol-2-yl)-3-(2-morpholinoethyl)urea",0.2,uM,=,-0.6989700043360187,0,O=C(NCCN1CCOCC1)Nc1nc2ccc(Sc3nnc4ccc(NC5CC5)nn34)cc2s1
4012,675407,10.1016/j.bmcl.2010.08.142,,,,Inhibition of CYP3A4,N#Cc1cccnc1N[C@H]1CCN(C(=O)O[C@H]2C3CC4CC2C[C@](C(N)=O)(C4)C3)C1,(S)-3-(3-Cyano-pyridin-2-ylamino)-pyrrolidine-1-carboxylic acid 5-carbamoyl-adamantan-2-yl ester,18.6,uM,=,1.2695129442179165,1,O=C(OC1C2CC3CC(C2)CC1C3)N1CC[C@H](Nc2ccccn2)C1
4013,1465541,10.1016/j.bmcl.2015.01.051,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(CC6CN(C)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O,"(1S,4R,5R,6R,8R,10S,11R,12S,13R,16R,18S,21R)-8-[(1S)-1-ethoxy-2-hydroxy-2-methylpropyl]-4,6,12,17,17-pentamethyl-18-{[(2S)-4-[(1-methylazetidin-3-yl)methyl]morpholin-2-yl]oxy}-9-oxahexacyclo[11.9.0.0^{1,21}.0^{4,12}.0^{5,10}.0^{16,21}]docosan-11-ol",25.0,uM,=,1.3979400086720375,1,C1CO[C@@H]2CC3C(CC[C@@]45C[C@@]46CC[C@H](O[C@H]4CN(CC7CNC7)CCO4)C[C@@H]6CC[C@@H]35)[C@H]2C1
4014,993439,10.6019/CHEMBL2448688,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,CC(=O)N(Cc1cccnc1)c1ccc(-c2nc3ccccc3s2)cc1,,2.9,uM,=,0.4623979978989561,1,c1cncc(CNc2ccc(-c3nc4ccccc4s3)cc2)c1
4015,349088,10.1016/j.bmcl.2006.01.084,,,,Inhibition of CYP3A4 using BFC fluorogenic substrate,COc1ccccc1COCCCOc1ccc(N2C(=O)CNC[C@@H]2COc2ccc3c(c2)N(CCN2CCOC2=O)CCC3)cc1,"(R)-1-(4-(3-(2-methoxybenzyloxy)propoxy)phenyl)-6-((1-(2-(2-oxooxazolidin-3-yl)ethyl)-1,2,3,4-tetrahydroquinolin-7-yloxy)methyl)piperazin-2-one",3.79,uM,=,0.5786392099680724,1,O=C1OCCN1CCN1CCCc2ccc(OC[C@H]3CNCC(=O)N3c3ccc(OCCCOCc4ccccc4)cc3)cc21
4016,2246941,10.1021/acs.jmedchem.1c02132,,,,Inhibition of CYP3A4 (unknown origin) incubated for 10 mins in presence of NADPH by LC-MS/MS analysis,CC(=O)Nc1cc(-c2ccc(OC[C@@H](N)CC(C)C)c(F)c2)ccn1,(S)-N-(4-(4-((2-amino-4-methylpentyl)oxy)-3-fluorophenyl)pyridin-2-yl)acetamide,8.9,uM,=,0.9493900066449128,1,c1ccc(-c2ccncc2)cc1
4017,828928,10.1016/j.bmcl.2012.06.022,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,CCN(C)c1nc2ccc(C(=O)N(CCN3CCOCC3)C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1,"Thiazol-5-ylmethyl(2S,3R)-4-(2-(ethyl(methyl)amino)-N-(2-morpholinoethyl)benzo[d]oxazole-6-carboxamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate",0.14,uM,=,-0.8538719643217619,0,O=C(N[C@H](CCN(CCN1CCOCC1)C(=O)c1ccc2ncoc2c1)Cc1ccccc1)OCc1cncs1
4018,1487309,10.1124/dmd.111.043505,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis,COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC,"2-(3,4-Dimethoxy-phenyl)-5-{[2-(3,4-dimethoxy-phenyl)-ethyl]-methyl-amino}-2-isopropyl-pentanenitrile",17.6,uM,=,1.24551266781415,1,c1ccc(CCCCNCCc2ccccc2)cc1
4019,499144,10.1016/j.bmc.2009.03.041,,,,Inhibition of CYP3A4,C[C@@H](Nc1c(Nc2ccn[nH]2)c(=O)c1=O)c1ccccc1,"3-{[(1R)-1-Phenylethyl]amino}-4-(1H-pyrazol-3-ylamino)cyclobut-3-ene-1,2-dione",40.0,uM,=,1.6020599913279625,1,O=c1c(NCc2ccccc2)c(Nc2ccn[nH]2)c1=O
4020,305744,10.1021/jm049696n,,,,Inhibitory concentration value against human cytochrome P-450 3A4,Cc1cscc1-c1ccc(F)nc1,2-Fluoro-5-(4-methyl-thiophen-3-yl)-pyridine,39.1,uM,=,1.5921767573958667,1,c1cncc(-c2ccsc2)c1
4021,2207925,10.1021/acsmedchemlett.2c00411,,,,Inhibition of CYP3A4 (unknown origin) in presence of NADPH,COc1cc(Nc2ncc(C)c(Nc3ccc4oc(=O)[nH]c4c3)n2)cc(OC)c1OC,"5-((5-methyl-2-((3,4,5-trimethoxyphenyl)amino)pyrimidin-4yl)amino)benzo[d]oxazol-2(3H)-one",1.1,uM,=,0.041392685158225,1,O=c1[nH]c2cc(Nc3ccnc(Nc4ccccc4)n3)ccc2o1
4022,448320,10.1016/j.bmc.2007.05.069,,,,Inhibition of CYP3A4,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCC(=O)NC)C(=O)C(C)(c1cc(F)cc(F)c1)O2,"3-(6-(2,4-diamino-6-ethylpyrimidin-5-yl)-2-(3,5-difluorophenyl)-2-methyl-3-oxo-2,3-dihydrobenzo[b][1,4]oxazin-4-yl)-N-methylpropanamide",0.16,uM,=,-0.7958800173440752,0,O=C1Nc2cc(-c3cncnc3)ccc2OC1c1ccccc1
4023,873337,10.1021/jm300065h,,,,Competitive inhibition of CYP3A4 in human liver microsomes,CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CCOc1ccccc1,"2-{3-[4-(3-Chloro-phenyl)-piperazin-1-yl]-propyl}-5-ethyl-4-(2-phenoxy-ethyl)-2,4-dihydro-[1,2,4]triazol-3-one",1.5,uM,=,0.1760912590556812,1,O=c1n(CCOc2ccccc2)cnn1CCCN1CCN(c2ccccc2)CC1
4024,1301325,10.6019/CHEMBL3137440,,,,DNDI: CYP Inhibition,Cc1ncsc1C(=O)N1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1,,2.9,uM,=,0.4623979978989561,1,O=C(c1cncs1)N1CCC(N(c2ccccc2)c2cccnc2)CC1
4025,2125132,10.1021/acsmedchemlett.1c00540,,,,Inhibition of human CYP3A4 using testosterone as a substrate by LC/MS/MS analysis,O=C(c1nccs1)N1CC[C@@H](Nc2nccc(-n3cc(C4CC4)nc3-c3cccc(Cl)c3)n2)C1,(R)-(3-(4-(2-(3-chlorophenyl)-4-cyclopropyl-1H-imidazol-1-yl)pyrimidin-2-ylamino)pyrrolidin-1-yl)(thiazol-2-yl)methanone,0.19,uM,=,-0.721246399047171,0,O=C(c1nccs1)N1CC[C@@H](Nc2nccc(-n3cc(C4CC4)nc3-c3ccccc3)n2)C1
4026,2152998,10.1021/acs.jmedchem.1c00635,,,,Inhibition of CYP3A4 in human liver microsomes using ketoconazole as substrate incubated for 5 mins in presence of NADPH by LC-MS/MS analysis,CCc1cccc(CC)c1N1CCn2cc(-c3nc(Nc4ccc(N5CCC(C(=O)N(C)CCN(C)C)CC5)cc4OC)nc4[nH]ccc34)cc2C1=O,"1-[4-[[4-[2-(2,6-diethylphenyl)-1-oxo-3,4-dihydropyrrolo[1,2-a]pyrazin-7-yl]-7H-pyrrolo[2,3-d]pyrimidin-2-yl]amino]-3-methoxy-phenyl]-N-[2-(dimethylamino)ethyl]-N-methyl-piperidine-4-carboxamide",3.9,uM,=,0.5910646070264992,1,O=C1c2cc(-c3nc(Nc4ccc(N5CCCCC5)cc4)nc4[nH]ccc34)cn2CCN1c1ccccc1
4027,988989,10.1021/jm400732v,,,,Inhibition of CYP3A4 (unknown origin),CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)CC(C)C)c2ccccc2N(Cc2c(C)ccc3ccccc23)C1=O.Cl,"(S)-2-(Methylamino)-N-((S)-5-(3-methylbutanoyl)-1-((2-methylnaphthalen-1-yl)methyl)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-yl)propanamide hydrochloride",1.3,uM,=,0.1139433523068367,1,O=C1CCNc2ccccc2N1Cc1cccc2ccccc12
4028,493017,10.1021/jm800851u,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,COc1cncc(-c2cc(NC(C)=O)nc(-n3nc(C)cc3C)n2)c1,"N-(2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-(5-methoxypyridin-3-yl)pyrimidin-4-yl)acetamide",18.0,uM,=,1.255272505103306,1,c1cncc(-c2ccnc(-n3cccn3)n2)c1
4029,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN6CCN(C(C)=O)CC6C5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, E-44",15.0,uM,=,1.1760912590556811,1,O=C(c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12)N1CCN2CCNCC2C1
4030,355280,10.1016/j.bmcl.2006.02.020,,,,Inhibition of CYP3A4,C[C@H]([C@@H](c1ccc2cc(OCC(C)(C)C(=O)O)ccc2c1)n1ccnc1)N(C)C1CCCCC1,"3-(6-((1R,2R)-2-(cyclohexyl(methyl)amino)-1-(1H-imidazol-1-yl)propyl)naphthalen-2-yloxy)-2,2-dimethylpropanoic acid",0.448,uM,=,-0.348721986001856,0,c1ccc2cc([C@H](CNC3CCCCC3)n3ccnc3)ccc2c1
4031,1285465,10.1021/jm400870h,,,,Inhibition of CYP3A4 (unknown origin),C/C(=N\NC(=O)c1cccc(S(=O)(=O)N2CCOCC2)c1)c1cc(Cl)ccc1O,(E)-N'-(1-(5-Chloro-2-hydroxyphenyl)ethylidene)-3-(morpholinosulfonyl)Benzohydrazide,2.61,uM,=,0.4166405073382809,1,O=C(NN=Cc1ccccc1)c1cccc(S(=O)(=O)N2CCOCC2)c1
4032,51915,10.1016/s0960-894x(03)00680-2,,,,Inhibition of human liver microsome Cytochrome P450 3A4,O=C(N[C@H]1c2ccccc2OC[C@H]1O)[C@H](Cc1ccncc1)C[C@H](O)CN1CCN(Cc2cc3ccccc3o2)C[C@H]1C(=O)NCC(F)(F)F,"(S)-4-Benzofuran-2-ylmethyl-1-[(2S,4R)-2-hydroxy-4-((3S,4S)-3-hydroxy-chroman-4-ylcarbamoyl)-5-pyridin-4-yl-pentyl]-piperazine-2-carboxylic acid (2,2,2-trifluoro-ethyl)-amide",2.2,uM,=,0.3424226808222063,1,O=C(N[C@@H]1CCOc2ccccc21)[C@@H](CCCN1CCN(Cc2cc3ccccc3o2)CC1)Cc1ccncc1
4033,51899,10.1016/j.bmcl.2003.08.027,,,,Binding affinity for Cytochrome P450 3A4; Range = 1-10 uM,COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1ccccc1[N+](=O)[O-],"2,6-Dimethyl-4-(2-nitro-phenyl)-1,4-dihydro-pyridine-3,5-dicarboxylic acid dimethyl ester",10.0,uM,=,1.0,1,C1=CC(c2ccccc2)C=CN1
4034,1854052,10.1016/j.ejmech.2019.07.003,,,,Inhibition of recombinant human CYP3A4 using Luciferin-PPXE as substrate preincubated for 10 mins followed by NADPH addition measured after 15 mins by luminometric method,Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1,1-[(2-Chloro-phenyl)-diphenyl-methyl]-1H-imidazole,0.067,uM,=,-1.1739251972991736,0,c1ccc(C(c2ccccc2)(c2ccccc2)n2ccnc2)cc1
4035,991614,10.1021/jm4008906,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,CCN(CC)C(=O)CCN1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O,"(S)-3-(3-(Aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-diethylpropanamide",8.3,uM,=,0.919078092376074,1,O=C1NCc2nccc(-c3ccccc3)c21
4036,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCC(C(=O)OCC)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, E-53",3.86,uM,=,0.5865873046717549,1,O=C(c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12)N1CCCCC1
4037,796228,10.1016/j.bmcl.2011.10.115,,,,Inhibition of CYP3A4,Cc1ccc(Cn2c(C3CNCCS3)nc3ccccc32)cc1,(+/-)-2-(1-(4-methylbenzyl)-1H-benzo[d]imidazol-2-yl)thiomorpholine,7.8,uM,=,0.8920946026904804,1,c1ccc(Cn2c(C3CNCCS3)nc3ccccc32)cc1
4038,1295469,10.1016/j.bmcl.2014.02.004,,,,Inhibition of human recombinant CYP3A4,CC1Cc2c(Br)cccc2N1C(=O)Cc1nc(N2CCOCC2)sc1C(N)=O,(-)-4-(2-(4-bromo-2-methylindolin-1-yl)-2-oxoethyl)-2-morpholinothiazole-5-carboxamide,40.0,uM,=,1.6020599913279625,1,O=C(Cc1csc(N2CCOCC2)n1)N1CCc2ccccc21
4039,1434727,10.1021/jm5010539,,,,Inhibition of human recombinant CYP3A4 expressed in Escherichia coli bactosomes using 7-benzloxyquinolone as substrate after 10 mins by fluorescence assay,CC(=O)N1c2ccc(-c3ccc(C(=O)O)cc3)cc2[C@H](Nc2ccc(Cl)cc2)C[C@@H]1C,"4-((2S,4R)-1-acetyl-4-(4-chlorophenylamino)-2-methyl-1,2,3,4-tetrahydroquinolin-6-yl)benzoic acid",32.0,uM,=,1.505149978319906,1,c1ccc(N[C@@H]2CCNc3ccc(-c4ccccc4)cc32)cc1
4040,1558163,10.1021/acs.jmedchem.5b00832,,,,Inhibition of CYP3A4 (unknown origin),COc1ccc(S(=O)(=O)N2CCC[C@H]2C(=O)Nc2cccc(SC)c2)cc1,"US9000029, 6",8.0,uM,=,0.9030899869919436,1,O=C(Nc1ccccc1)[C@@H]1CCCN1S(=O)(=O)c1ccccc1
4041,2240606,10.1021/acs.jmedchem.2c01497,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH,C[C@@H](c1cn(-c2ccc(Cl)cc2F)nn1)[C@](O)(Cn1cncn1)c1ccc(F)cc1F,"(2R,3S)-3-(1-(4-chloro-2-fluorophenyl)-1H-1,2,3-triazol-4-yl)-2-(2,4-difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol",0.3389999999999999,uM,=,-0.4698003017969179,0,c1ccc(C(Cc2cn(-c3ccccc3)nn2)Cn2cncn2)cc1
4042,2134185,10.1021/acs.jmedchem.1c00855,,,,Inhibition of recombinant human CYP3A4 expressed in Escherichia coli using VG as probe substrate incubated for 15 to 60 mins by fluorometric assay,COc1cc2c(cc1-c1c(C)noc1C)ncc1nc(N(C)C)n(CC3CCOCC3)c12,"7-(3,5-Dimethylisoxazol-4-yl)-8-methoxy-N,N-dimethyl-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-imidazo[4,5-c]quinoline",10.0,uM,=,1.0,1,c1cc2c(cc1-c1cnoc1)ncc1ncn(CC3CCOCC3)c12
4043,1509172,10.1016/j.bmcl.2015.05.065,,,,Inhibition of CYP3A4 (unknown origin),COc1ccc(COc2cnn(CC(=O)c3ccc(CN(C)C)cc3C)c(=O)c2)nc1,2-(2-(4-((dimethylamino)methyl)-2-methylphenyl)-2-oxoethyl)-5-((5-methoxypyridin-2-yl)methoxy)pyridazin-3(2H)-one,18.0,uM,=,1.255272505103306,1,O=C(Cn1ncc(OCc2ccccn2)cc1=O)c1ccccc1
4044,560184,10.1016/j.bmcl.2008.10.118,,,,Inhibition of CYP3A4,O=C(NCC1CCOCC1)c1cnc(Nc2cccc(OC(F)(F)F)c2)cc1C1CC1,4-cyclopropyl-N-((tetrahydro-2H-pyran-4-yl)methyl)-6-(3-(trifluoromethoxy)phenylamino)nicotinamide,57.0,uM,=,1.7558748556724917,1,O=C(NCC1CCOCC1)c1cnc(Nc2ccccc2)cc1C1CC1
4045,1705360,10.1016/j.bmcl.2017.06.037,,,,Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method,OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(C#Cc2ccc(F)cc2)cn1,"2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-((4-fluorophenyl)ethynyl)pyridin-2-yl)-3-(1H-tetrazol-1-yl)propan-2-ol",198.0,uM,=,2.296665190261531,1,C(#Cc1ccc(CC(Cn2cnnn2)c2ccccc2)nc1)c1ccccc1
4046,776115,10.1016/j.bmcl.2011.09.074,,,,Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(c1ccc(C#N)cc1)C2=O,"4-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-7-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)benzonitrile",0.67,uM,=,-0.1739251972991735,0,O=C1c2nccc(-c3ccccc3)c2CN1c1ccccc1
4047,1625607,10.1016/j.bmcl.2016.10.016,,,,Inhibition of human Cyp3A4 using testosterone as substrate by LC-MS/MS analysis,Cn1ccnc1S(=O)(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,"1-(4-{[(2S,4R)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)-4-(1-methylimidazol-2-ylsulfonyl)piperazine",0.145,uM,=,-0.8386319977650252,0,O=S(=O)(c1ncc[nH]1)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccccc4)O3)cc2)CC1
4048,1895186,10.1021/acs.jmedchem.9b00193,,,,Inhibition of CYP3A4 (unknown origin) by fluorescence-based assay,CCc1cc(Cc2ccc(CC(N)=O)cc2)nc(-c2cccc(Cl)c2)n1,2-(4-((2-(3-Chlorophenyl)-6-ethylpyrimidin-4-yl)methyl)phenyl)acetamide,5.9,uM,=,0.7708520116421442,1,c1ccc(Cc2ccnc(-c3ccccc3)n2)cc1
4049,979752,10.1016/j.ejmech.2013.03.070,,,,Inhibition of CYP3A4 (unknown origin),O=C(Nc1ccncc1)c1c(Cl)cccc1Cl,SID49644368,4.7,uM,=,0.6720978579357175,1,O=C(Nc1ccncc1)c1ccccc1
4050,746947,10.1021/jm200128m,,,,Inhibition of human CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,Nc1nc2c(c(-c3c(Cl)cc(Cl)cc3OCCn3cc(F)cn3)n1)CN(C(=O)NCC(F)(F)F)C2,"2-Amino-4-{2,4-dichloro-6-[2-(4-fluoropyrazol-1-yl)ethoxy]phenyl}-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carboxylic Acid(2,2,2-Trifluoroethyl)amide",0.8,uM,=,-0.0969100130080563,0,c1ccc(-c2ncnc3c2CNC3)c(OCCn2cccn2)c1
4051,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2nccs2)c1,"US9150566, 44",2.0,uM,=,0.3010299956639812,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2nccs2)c1
4052,1534761,,,,,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",Cc1cc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)c(F)n2)ccn1,"US9096593, P-2075",5.0,uM,=,0.6989700043360189,1,c1cnc2[nH]cc(Cc3ccc(NCc4ccncc4)nc3)c2c1
4053,1750153,10.1016/j.bmcl.2017.12.040,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins with substrate followed by NADPH addition measured after 15 mins by LC/MS/MS analysis,O=c1n(-c2ccc(C(F)(F)C(O)(Cn3cnnn3)c3ccc(F)cc3F)nc2)cnn1C1CCCC1,"2-cyclopentyl-4-(6-(2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(1H-tetrazol-1-yl)propyl)pyridin-3-yl)-2,4-dihydro-3H-1,2,4-triazol-3-one",50.0,uM,=,1.6989700043360187,1,O=c1n(-c2ccc(CC(Cn3cnnn3)c3ccccc3)nc2)cnn1C1CCCC1
4054,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CC(N6CCC(OC)CC6)C5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, E-73",11.8,uM,=,1.0718820073061257,1,O=C(c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12)N1CC(N2CCCCC2)C1
4055,2240607,10.1021/acs.jmedchem.2c01497,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate in presence of NADPH,C[C@@H](c1cn(-c2ccc(Cl)cc2F)nn1)[C@](O)(Cn1cncn1)c1ccc(F)cc1F,"(2R,3S)-3-(1-(4-chloro-2-fluorophenyl)-1H-1,2,3-triazol-4-yl)-2-(2,4-difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol",0.652,uM,=,-0.1857524042680797,0,c1ccc(C(Cc2cn(-c3ccccc3)nn2)Cn2cncn2)cc1
4056,813159,10.1021/jm2011222,,,,Inhibition of CYP3A4,COc1ccc(-c2noc(CSc3nnc(C)n3-c3ccc(OC)cc3)n2)cc1,SID24390090,5.7,uM,=,0.7558748556724915,1,c1ccc(-c2noc(CSc3nncn3-c3ccccc3)n2)cc1
4057,1914337,10.1021/acs.jmedchem.9b00952,,,,Inhibition of recombinant human CYP3A4 expressed in supersomes using 7-benzyloxyquinoline as substrate by fluorescence method,CNC(=O)C(=O)NCCCC/C=C\CCCCCCCCCc1nnn[nH]1,N1-(15-(1H-tetrazol-5-yl)pentadec-5(Z)-enyl)-N2-methyloxalamide,4.7,uM,=,0.6720978579357175,1,c1nnn[nH]1
4058,1446329,10.1021/ml500387y,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,Cc1cc2cc(CC(O)(CC(C)(C)c3cc(F)ccc3C)C(F)(F)F)[nH]c2cn1,"1,1,1-trifluoro-4-(5-fluoro-2-methylphenyl)-4-methyl-2-((5-methyl-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)pentan-2-ol",0.6,uM,=,-0.2218487496163563,0,c1ccc(CCCCc2cc3ccncc3[nH]2)cc1
4059,1924430,10.1021/acsmedchemlett.5b00485,,,,Inhibition of CYP3A4 (unknown origin) preincubated for 10 mins followed by addition of BFC as substrate measured after 10 mins in presence of NADP by fluorescence analysis,Cc1cc(-c2cnn3c(NCC4CC4)cc(N[C@@H]4CCCC[C@H]4O)nc23)ccc1C(=O)NC1CC1,"N-cyclopropyl-4-(7-((cyclopropylmethyl)amino)-5-(((1S,2R)-2-hydroxycyclohexyl)-amino)pyrazolo[1,5-a]pyrimidin-3-yl)-2-methylbenzamide",2.0,uM,=,0.3010299956639812,1,O=C(NC1CC1)c1ccc(-c2cnn3c(NCC4CC4)cc(NC4CCCCC4)nc23)cc1
4060,966467,10.1016/j.bmcl.2013.04.077,,,,Inhibition of CYP3A4 (unknown origin),Cc1nc(NC(=O)Cc2nc(-c3ccccc3)c(C)o2)sc1-c1ccc(N)nc1,N-(5-(6-aminopyridin-3-yl)-4-methylthiazol-2-yl)-2-(5-methyl-4-phenyloxazol-2-yl)acetamide,7.7,uM,=,0.8864907251724818,1,O=C(Cc1nc(-c2ccccc2)co1)Nc1ncc(-c2cccnc2)s1
4061,519907,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,CCc1cccc(C)c1CNc1cc(-c2ncnn2C)cn2c(C)c(C)nc12,"N-(2-ethyl-6-methylbenzyl)-2,3-dimethyl-6-(1-methyl-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyridin-8-amine",7.5,uM,=,0.8750612633917001,1,c1ccc(CNc2cc(-c3ncn[nH]3)cn3ccnc23)cc1
4062,796228,10.1016/j.bmcl.2011.10.115,,,,Inhibition of CYP3A4,Fc1ccc(Cn2c(C3CNCCS3)nc3ccccc32)cc1,(+/-)-2-(1-(4-fluorobenzyl)-1H-benzo[d]imidazol-2-yl)thiomorpholine,16.7,uM,=,1.2227164711475833,1,c1ccc(Cn2c(C3CNCCS3)nc3ccccc32)cc1
4063,1684789,10.1016/j.ejmech.2017.04.023,,,,Inhibition of recombinant human CYP3A4 expressed in baculosomes using BOMR as substrate preincubated for 10 mins followed by substrate/NADP+ addition measured for 1 hr,Cc1cc(C(=O)N/N=C/c2ccc(Cl)cc2)c2c(C)nn(-c3ccccc3)c2n1,"N'-(4-chlorobenzylidene)-3,6-dimethyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine-4-carbohydrazide",94.6,uM,=,1.9758911364017928,1,O=C(N/N=C/c1ccccc1)c1ccnc2c1cnn2-c1ccccc1
4064,1637155,,,,,Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(S(=O)(=O)NC)cc4)cc23)c1F,"4-{3-[2,6-Difluoro-3-(propane-1-sulfonylamino)-benzoyl]-1H-pyrrolo[2,3-b]pyridin-5-yl}-N-methyl-benzenesulfonamide",5.0,uM,=,0.6989700043360189,1,O=C(c1ccccc1)c1c[nH]c2ncc(-c3ccccc3)cc12
4065,461436,10.1016/j.bmcl.2007.10.092,,,,Inhibition of CYP3A4 pre-incubated before 30 mins,CC[C@@H]1CCC[C@H](C2(CC(=O)N3CC4CCC(C3)N4CCO)CC2)N1S(=O)(=O)c1ccc(Cl)cc1,"2-(1-((2R,6R)-1-(4-chlorophenylsulfonyl)-6-ethylpiperidin-2-yl)cyclopropyl)-1-(8-(2-hydroxyethyl)-3,8-diaza-bicyclo[3.2.1]octan-3-yl)ethanone",2.2,uM,=,0.3424226808222063,1,O=C(CC1([C@H]2CCCCN2S(=O)(=O)c2ccccc2)CC1)N1CC2CCC(C1)N2
4066,1561100,10.1021/acsmedchemlett.5b00253,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated with substrate for 5 mins followed by NADPH addition measured after 20 mins by HPLC analysis,Cc1ccc(NC(=O)CCc2nnc([C@H]3C[C@@H](CC(C)C)C3)n2C2CC2)c(C)c1,"3-(4-Cyclopropyl-5-(cis-3-isobutylcyclobutyl)-4H-1, 2, 4-triazol-3-yl)-N-(2,4-dimethylphenyl)propanamide",5.0,uM,=,0.6989700043360189,1,O=C(CCc1nnc(C2CCC2)n1C1CC1)Nc1ccccc1
4067,1336778,10.1021/jm401911v,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,CC[C@@H](CS(=O)(=O)C(C)(C)C)N1C(=O)[C@@](C)(CC(=O)NS(=O)(=O)C(F)(F)F)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1,"2-((3R,5R,6S)-1-((S)-1-(tert-Butylsulfonyl)butan-2-yl)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-3-methyl-2-oxopiperidin-3-yl)-N-((trifluoromethyl)sulfonyl)acetamide",3.8,uM,=,0.5797835966168101,1,O=C1CC[C@H](c2ccccc2)[C@@H](c2ccccc2)N1
4068,688021,10.1016/j.bmcl.2010.10.101,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins,CN(C)C(=O)Cn1c(=O)n(C)c(=O)c2c1cc(N1CCC[C@@](C)(N)C1)n2Cc1cc(F)ccc1Cl.Cl,"(R)-2-(6-(3-amino-3-methylpiperidin-1-yl)-5-(2-chloro-5-fluorobenzyl)-3-methyl-2,4-dioxo-2,3,4,5-tetrahydro-1H-pyrrolo[3,2-d]pyrimidin-1-yl)-N,N-dimethylacetamide hydrochloride",13.4,uM,=,1.1271047983648077,1,O=c1[nH]c(=O)c2c(cc(N3CCCCC3)n2Cc2ccccc2)[nH]1
4069,535882,10.1016/j.bmcl.2008.08.010,,,,"Inhibition of human CYP3A4 by microtiter plate assays using N-N,diethyl-formamide as substrate",O=S(=O)(c1ccccc1)n1cc(Cl)c2cc3c(cc21)CCNCC3,"3-chloro-1-(phenylsulfonyl)-1,5,6,7,8,9-hexahydroazepino[4,5-f]indole",12.0,uM,=,1.0791812460476249,1,O=S(=O)(c1ccccc1)n1ccc2cc3c(cc21)CCNCC3
4070,304712,10.1021/jm048978k,,,,In vitro inhibitory concentration against Cytochrome P450 3A4,CC(C)S(=O)(=O)n1c(N)nc2ccc(-c3[nH]c(-c4c(F)cccc4F)nc3-c3ccccc3)cc21,"6-[2-(2,6-Difluoro-phenyl)-5-phenyl-3H-imidazol-4-yl]-1-(propane-2-sulfonyl)-1H-benzoimidazol-2-ylamine",0.0063,uM,=,-2.2006594505464183,0,c1ccc(-c2nc(-c3ccccc3)c(-c3ccc4nc[nH]c4c3)[nH]2)cc1
4071,1797910,10.1021/acs.jmedchem.8b01326,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate/NADPH addition measured after 10 mins by LC-MS/MS analysis,CCc1nc(N2C[C@H]3C(=O)N(C)C(=N)N[C@@]3(c3cc(-c4cccc(C#N)c4)cs3)C2)ncc1F,"3-(5-((4aR,7aR)-6-(4-Ethyl-5-fluoropyrimidin-2-yl)-2-imino-3-methyl-4-oxooctahydro-7aH-pyrrolo[3,4-d]pyrimidin-7a-yl)-thiophen-3-yl)benzonitrile",0.9,uM,=,-0.0457574905606751,0,N=C1NC(=O)[C@@H]2CN(c3ncccn3)C[C@]2(c2cc(-c3ccccc3)cs2)N1
4072,1660136,10.1021/acs.jmedchem.6b01918,,,,Inhibition of human CYP3A4 assessed as inhibition of dealkylation,CN1CCC(CCNc2cc(F)c(S(=O)(=O)Nc3nccs3)cc2Cl)CC1,5-Chloro-2-fluoro-4-((2-(1-methylpiperidin-4-yl)ethyl)amino)-N-(thiazol-2-yl)benzenesulfonamide,20.0,uM,=,1.3010299956639813,1,O=S(=O)(Nc1nccs1)c1ccc(NCCC2CCNCC2)cc1
4073,834929,10.1016/j.bmcl.2012.07.020,,,,Inhibition of CYP3A4,CCS(=O)(=O)c1ccc2[nH]c(-c3cccc(-c4ccccc4)c3Cl)nc2c1,2-(2-chlorobiphenyl-3-yl)-5-(ethylsulfonyl)-1H-benzo[d]imidazole,3.8,uM,=,0.5797835966168101,1,c1ccc(-c2cccc(-c3nc4ccccc4[nH]3)c2)cc1
4074,982809,10.1016/j.ejmech.2013.08.010,,,,Inhibition of CYP3A (unknown origin),CC#CCn1c(N2CCC[C@@H](N)C2)cc(=O)n(Cc2ccc3cc(OC)ccc3n2)c1=O,"(R)-6-(3-Aminopiperidin-1-yl)-1-(but-2-yn-1-yl)-3-((6-methoxyquinolin-2-yl)methyl)pyrimidine-2,4(1H,3H)-dione",42.19,uM,=,1.625209525381881,1,O=c1cc(N2CCCCC2)[nH]c(=O)n1Cc1ccc2ccccc2n1
4075,1624781,10.1021/acs.jmedchem.6b00697,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH by LC-MS/MS analysis,O=C(/C=C/c1cccnc1)NCCCCC1CCN(C(=O)c2ccccc2)CC1,N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide,0.54,uM,=,-0.2676062401770315,0,O=C(/C=C/c1cccnc1)NCCCCC1CCN(C(=O)c2ccccc2)CC1
4076,657984,10.1021/jm100482n,,,,Inhibition of CYP3A4 in human liver microsomes measured immediately,CNC(=O)c1ncn2c1COc1c(CCN3CCN(c4cccc5nc(C)ccc45)CC3)cccc1-2,"N-methyl-6-(2-(4-(2-methylquinolin-5-yl)piperazin-1-yl)ethyl)-4H-benzo[b]imidazo[1,5-d][1,4]oxazine-3-carboxamide",8.0,uM,=,0.9030899869919436,1,c1cc(CCN2CCN(c3cccc4ncccc34)CC2)c2c(c1)-n1cncc1CO2
4077,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",O=C(c1cc(F)ccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2cccn2)c1,"US9150566, 20",25.0,uM,=,1.3979400086720375,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2cccn2)c1
4078,606328,10.1016/j.bmcl.2009.10.131,,,,Inhibition of CYP3A4,CC(C)(C)Sc1c(CC(C)(C)C(=O)O)n(Cc2ccc(Cl)cc2)c2ccc(OCc3ccc4ccccc4n3)cc12,"3-[3-tert-Butylsulfanyl-1-(4-chloro-benzyl)-5-(quinolin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid",5.2,uM,=,0.7160033436347992,1,c1ccc(Cn2ccc3cc(OCc4ccc5ccccc5n4)ccc32)cc1
4079,559939,10.1016/j.bmcl.2008.10.072,,,,Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate,C[C@@H]1CN(Cc2ccc(-c3ccccc3C(=O)N3CCC(Cc4ccc(F)cc4)CC3)cc2)C[C@H](C)N1,"[4'-((3R,5S)-3,5-Dimethyl-piperazin-1-ylmethyl)-biphenyl-2-yl]-[4-(4-fluoro-benzyl)-piperidin-1-yl]-methanone",0.5,uM,=,-0.3010299956639812,0,O=C(c1ccccc1-c1ccc(CN2CCNCC2)cc1)N1CCC(Cc2ccccc2)CC1
4080,642395,10.1021/jm100400a,,,,Inhibition of CYP3A4 expressed in baculovirus infected insect microsomes,CC(C)=C(c1ccncc1)c1ccc(-c2cccc(O)c2)cc1,4'-(2-methyl-1-(pyridin-4-yl)prop-1-enyl)biphenyl-3-ol,0.73,uM,=,-0.1366771398795441,0,C=C(c1ccncc1)c1ccc(-c2ccccc2)cc1
4081,828928,10.1016/j.bmcl.2012.06.022,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,CCN(C)c1nc2ccc(C(=O)N(C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)CC(C)(C)C)cc2o1,"thiazol-5-ylmethyl(2S,3R)-4-(2-(ethyl(methyl)amino)-N-neopentylbenzo[d]oxazole-6-carboxamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate",0.037,uM,=,-1.431798275933005,0,O=C(N[C@H](CCNC(=O)c1ccc2ncoc2c1)Cc1ccccc1)OCc1cncs1
4082,1984169,10.1016/j.bmc.2020.115349,,,,Inhibition of human full length CYP3A4 assessed using 7-benzyloxy-4 (trifluoromethyl)coumarin as substrate preincubated for 20 mins in presence of NADPH followed by substrate addition and measured for 2 mins by fluorometric analysis,CC(C)(C)OC(=O)N[C@H](CS[C@H](Cc1ccccc1)C(=O)NCCc1cccnc1)Cc1ccccc1,tert-butyl N-[(1S)-1-benzyl-2-[(1R)-1-benzyl-2-oxo-2-[2-(3-pyridyl)ethylamino]ethyl]sulfanyl-ethyl]carbamate,0.31,uM,=,-0.5086383061657274,0,O=C(NCCc1cccnc1)[C@@H](Cc1ccccc1)SCCCc1ccccc1
4083,2188254,10.1021/acs.jmedchem.2c01366,,,,Inhibition of human liver microsomes CYP3A4 using midazolam or testosterone as substrate in presence of NADPH regenerating system by LC-MS/MS analysis,CNC(=O)c1cc(F)c(F)c(-c2cnc3cc(-c4cnn(C)c4)c(O[C@H]4CCOC4)nn23)c1,"(S)-3,4-difluoro-N-methyl-5-(7-(1-methyl-1H-pyrazol-4-yl)-6-((tetrohydrofuran-3-yl)oxy)imidazo[1,2-b]pyridazin-3-yl)-benzamide",3.9,uM,=,0.5910646070264992,1,c1ccc(-c2cnc3cc(-c4cn[nH]c4)c(O[C@H]4CCOC4)nn23)cc1
4084,423303,10.1021/jm0602256,,,,Inhibition of human CYP3A4,O=C(O)c1c(O)c(-c2ccc(Cl)cc2)nc2c(-c3ccccc3)cccc12,2-(4-chlorophenyl)-3-hydroxy-8-phenylquinoline-4-carboxylic acid,55.0,uM,=,1.740362689494244,1,c1ccc(-c2ccc3cccc(-c4ccccc4)c3n2)cc1
4085,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",O=C(c1cc(F)ccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1,"US9150566, 26",24.0,uM,=,1.380211241711606,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
4086,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)Nc6ccc(N7CCN(C)CC7)cc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, D-11",7.04,uM,=,0.8475726591421122,1,O=C(Nc1ccc(N2CCNCC2)cc1)c1ccc(-c2c[nH]c3c(CN4C[C@@H]5N(C(=O)NCc6ccccc6)NCC(=O)N5[C@@H](Cc5ccccc5)C4=O)cccc23)cc1
4087,673770,10.1016/j.bmcl.2010.08.102,,,,Inhibition of CYP3A4,CC(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNC1(c2cccc(C(C)(C)C(F)F)c2)CC1,"N-((2S,3R)-4-(1-(3-(1,1-difluoro-2-methylpropan-2-yl)phenyl)cyclopropylamino)-1-(3,5-difluorophenyl)-3-hydroxybutan-2-yl)acetamide",0.046,uM,=,-1.337242168318426,0,c1ccc(CCCCNC2(c3ccccc3)CC2)cc1
4088,1465541,10.1016/j.bmcl.2015.01.051,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(CC6CN(CCO)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O,"(1S,4R,5R,6R,8R,10S,11R,12S,13R,16R,18S,21R)-8-[(1S)-1-ethoxy-2-hydroxy-2-methylpropyl]-18-{[(2S)-4-{[1-(2-hydroxyethyl)azetidin-3-yl]methyl}morpholin-2-yl]oxy}-4,6,12,17,17-pentamethyl-9-oxahexacyclo[11.9.0.0^{1,21}.0^{4,12}.0^{5,10}.0^{16,21}]docosan-11-ol",17.0,uM,=,1.230448921378274,1,C1CO[C@@H]2CC3C(CC[C@@]45C[C@@]46CC[C@H](O[C@H]4CN(CC7CNC7)CCO4)C[C@@H]6CC[C@@H]35)[C@H]2C1
4089,1858698,10.1021/acs.jmedchem.0c00117,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam substrate incubated for 10 mins in presence of NADPH,Cc1cc(/C=C/C#N)cc(C)c1Nc1ccnc(Nc2ccc(C#N)cc2)n1,"4-{4-[4-((E)-2-Cyano-vinyl)-2,6-dimethyl-phenylamino]-pyrimidin-2-ylamino}-benzonitrile",2.17,uM,=,0.3364597338485295,1,c1ccc(Nc2ccnc(Nc3ccccc3)n2)cc1
4090,1614025,10.1016/j.bmcl.2016.09.043,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 6-beta-hydroxytestosterone metabolite formation using testosterone as substrate incubated for 30 mins by HPLC-MS method,Cn1c(NCCc2ccc(Oc3ccc(Cl)cn3)cc2)nc2cc(Cl)ccc2c1=O,7-Chloro-2-{2-[4-(5-chloro-pyridin-2-yloxy)-phenyl]-ethylamino}-3-methyl-3H-quinazolin-4-one,15.0,uM,=,1.1760912590556811,1,O=c1[nH]c(NCCc2ccc(Oc3ccccn3)cc2)nc2ccccc12
4091,2273353,10.1021/acs.jmedchem.8b01971,,,,Inhibition of CYP3A4 in human liver microsomes using Midazolam as substrate preincubated for 10 mins followed by NADPH addition and measured after 15 mins by LC-MS/MS analysis,CCOC(=O)C1=C(C)Cc2nc(N3CCC(C(=O)NS(=O)(=O)Cc4ccccc4)CC3)c(C#N)cc2C1,"ethyl 2-(4-(benzylsulfonylcarbamoyl)piperidin-1-yl)-3-cyano-7-methyl-5,8-dihydroquinoline-6-carboxylate",4.28,uM,=,0.631443769013172,1,O=C(NS(=O)(=O)Cc1ccccc1)C1CCN(c2ccc3c(n2)CC=CC3)CC1
4092,1640557,,,,,"null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.",Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1,"1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole",5.0,uM,=,0.6989700043360189,1,c1ccc(COC(Cn2ccnc2)c2ccccc2)cc1
4093,2133633,10.1021/acs.jmedchem.1c00679,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins in presence of NADPH by LCMS/MS analysis,NS(=O)(=O)NCCNc1nonc1/C(=N/O)Nc1ccc(F)c(Br)c1,EPACADOSTAT,28.0,uM,=,1.4471580313422192,1,N=C(Nc1ccccc1)c1cnon1
4094,448320,10.1016/j.bmc.2007.05.069,,,,Inhibition of CYP3A4,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)C(=O)C(C)(c1cccc(C(F)(F)F)c1)O2,"N-{2-[6-(2,4-diamino-6-ethyl-pyrimidin-5-yl)-2-methyl-3-oxo-2-(3-trifluoromethyl-phenyl)-2,3-dihydrobenzo[1,4]oxazin-4-yl]-ethyl}-acetamide",0.12,uM,=,-0.9208187539523752,0,O=C1Nc2cc(-c3cncnc3)ccc2OC1c1ccccc1
4095,519907,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,Cc1cccc(C)c1CNc1cc(-c2ccco2)cn2c(C)c(C)nc12,"N-(2,6-dimethylbenzyl)-6-(furan-2-yl)-2,3-dimethylimidazo[1,2-a]pyridin-8-amine",1.8,uM,=,0.255272505103306,1,c1ccc(CNc2cc(-c3ccco3)cn3ccnc23)cc1
4096,828928,10.1016/j.bmcl.2012.06.022,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,CCN(C)c1nc2ccc(C(=O)N(CC(C)C)C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cccnc3)cc2o1,"Pyridin-3-ylmethyl(2S,3R)-4-(2-(ethyl(methyl)amino)-N-isobutylbenzo[d]oxazole-6-carboxamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate",0.022,uM,=,-1.6575773191777938,0,O=C(N[C@H](CCNC(=O)c1ccc2ncoc2c1)Cc1ccccc1)OCc1cccnc1
4097,1614025,10.1016/j.bmcl.2016.09.043,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 6-beta-hydroxytestosterone metabolite formation using testosterone as substrate incubated for 30 mins by HPLC-MS method,Cn1c(NCCc2ccc(-c3ccc(F)cn3)cc2)nc2cc(Cl)ccc2c1=O,7-Chloro-2-{2-[4-(5-fluoro-pyridin-2-yl)-phenyl]-ethylamino}-3-methyl-3H-quinazolin-4-one,9.3,uM,=,0.9684829485539352,1,O=c1[nH]c(NCCc2ccc(-c3ccccn3)cc2)nc2ccccc12
4098,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",O=C(c1ccc(C(F)(F)F)cc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1,"US9150566, 76",7.5,uM,=,0.8750612633917001,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
4099,630896,10.1016/j.bmcl.2010.03.017,,,,Inhibition of CYP3A4,Cc1cc(OC[P@]2(=O)OCC[C@@H](c3ccc(Cl)cc3)O2)c2c(c1C)Cc1scnc1-2,"4-[4-(4-Chloro-phenyl)-2-oxo-2lambda*5*-[1,3,2]dioxaphosphinan-2-ylmethoxy]-6,7-dimethyl-8H-indeno[1,2-d]thiazole",0.73,uM,=,-0.1366771398795441,0,O=[P@@]1(COc2cccc3c2-c2ncsc2C3)OCC[C@@H](c2ccccc2)O1
4100,834929,10.1016/j.bmcl.2012.07.020,,,,Inhibition of CYP3A4,CCS(=O)(=O)c1ccc2[nH]c(-c3cc(-c4ccccc4)ccc3C)nc2c1,5-(ethylsulfonyl)-2-(4-methylbiphenyl-3-yl)-1H-benzo[d]imidazole,5.9,uM,=,0.7708520116421442,1,c1ccc(-c2cccc(-c3nc4ccccc4[nH]3)c2)cc1
4101,1528565,,,,,"Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",CC(C)c1nc(CN(C)C(=O)N2C[C@@H](O)C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,"US8987313, 8",0.24,uM,=,-0.619788758288394,0,O=C(N[C@H](CC[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)NCc1cscn1)Cc1ccccc1)OCc1cncs1
4102,51917,10.1016/j.bmcl.2003.08.027,,,,Inhibition of Cytochrome P450 3A4 with midazolam (1'-OH),CCOC(=O)CCCn1c(=O)nc2n(CCCCOC(=O)C[C@@H]3CC4C5CC[C@H](O)C5CCC4[C@@]4(C)CCC(=O)C=C34)c3ccccc3cc-2c1=O,"4-(10-{4-[2-((6S,10R,17S)-17-Hydroxy-10-methyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-6-yl)-acetoxy]-butyl}-2,4-dioxo-4,10-dihydro-2H-pyrimido[4,5-b]quinolin-3-yl)-butyric acid ethyl ester",1.1,uM,=,0.041392685158225,1,O=C1C=C2C(CC1)C1CCC3CCCC3C1C[C@H]2CC(=O)OCCCCn1c2nc(=O)[nH]c(=O)c-2cc2ccccc21
4103,982382,10.1016/j.bmcl.2013.07.071,,,,Inhibition of CYP3A4 (unknown origin),COC[C@@H](Oc1cc(C[C@@H]2C[S@@+]([O-])C[C@H](NCc3cccc(OC(C)C)c3)[C@H]2O)cc(F)c1N)C(F)(F)F,"(1R,3S,4S,5R)-3-[4-Amino-3-fluoro-5-((R)-2,2,2-trifluoro-1-methoxymethyl-ethoxy)-benzyl]-5-(3-isopropoxy-benzylamino)-1-oxo-tetrahydro-thiopyran-4-ol",0.9,uM,=,-0.0457574905606751,0,c1ccc(CN[C@H]2C[SH+]C[C@@H](Cc3ccccc3)C2)cc1
4104,1778315,10.1016/j.bmcl.2018.06.040,,,,Inhibition of CYP3A4 (unknown origin),CCCNS(=O)(=O)c1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1,"N-(4-(1H-pyrrolo[2,3-b]pyridin-3-yl)thiazol-2-yl)-2-(3-(N-propylsulfamoyl)phenyl)acetamide",5.7,uM,=,0.7558748556724915,1,O=C(Cc1ccccc1)Nc1nc(-c2c[nH]c3ncccc23)cs1
4105,438600,10.1016/j.bmcl.2007.03.048,,,,Inhibition of CYP3A4 in microsomes,Cc1cc(C2=NC(C)(C)CN2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,"4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-3-(6-(4,4-dimethyl-4,5-dihydro-1H-imidazol-2-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one",13.0,uM,=,1.1139433523068367,1,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(C3=NCCN3)cc2[nH]1
4106,1465541,10.1016/j.bmcl.2015.01.051,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(CC6CN(CC(C)(C)O)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O,"(1S,4R,5R,6R,8R,10S,11R,12S,13R,16R,18S,21R)-8-[(1S)-1-ethoxy-2-hydroxy-2-methylpropyl]-18-{[(2S)-4-{[1-(2-hydroxy-2-methylpropyl)azetidin-3-yl]methyl}morpholin-2-yl]oxy}-4,6,12,17,17-pentamethyl-9-oxahexacyclo[11.9.0.0^{1,21}.0^{4,12}.0^{5,10}.0^{16,21}]docosan-11-ol",14.0,uM,=,1.146128035678238,1,C1CO[C@@H]2CC3C(CC[C@@]45C[C@@]46CC[C@H](O[C@H]4CN(CC7CNC7)CCO4)C[C@@H]6CC[C@@H]35)[C@H]2C1
4107,1499751,10.1021/acs.jmedchem.5b00424,,,,Inhibition of CYP3A4 (unknown origin),COc1cccc(CC(=O)Nc2nc(-c3ccnc(C)c3)cs2)c1,2-(3-methoxyphenyl)-N-(4-(2-methylpyridin-4-yl)thiazol-2-yl)acetamide,7.4,uM,=,0.8692317197309762,1,O=C(Cc1ccccc1)Nc1nc(-c2ccncc2)cs1
4108,2035531,10.1021/acsmedchemlett.0c00525,,,,Inhibition of CYP3A4 (unknown origin),C[C@@H](NC(=O)c1ccc(F)cc1)c1ccc2c(n1)CCCN2c1ccnc(C(F)(F)F)n1,"(R)-4-fluoro-N-(1-(5-(2-(trifluoromethyl)pyrimidin-4-yl)-5,6,7,8-tetrahydro-1,5-naphthyridin-2-yl)ethyl)benzamide",43.0,uM,=,1.6334684555795866,1,O=C(NCc1ccc2c(n1)CCCN2c1ccncn1)c1ccccc1
4109,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",O=C(c1cc(Cl)ccc1-n1nccn1)N1CCOC[C@H]1Cc1cc(-c2ncon2)ccc1F,"US9150566, 176",22.0,uM,=,1.3424226808222062,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2ncon2)c1
4110,355280,10.1016/j.bmcl.2006.02.020,,,,Inhibition of CYP3A4,C[C@H]([C@@H](c1ccc2cc(OCC(C)(C)C(=O)O)ccc2c1)n1ccnc1)N(C)C,"3-[6-(2-dimethylamino-1-imidazol-1-yl-propyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid",6.3,uM,=,0.7993405494535817,1,c1ccc2cc(Cn3ccnc3)ccc2c1
4111,629565,10.1021/np1000329,,,,Inhibition of CYP3A4,CC(C)=CCC[C@]1(C)[C@@H](CC=C(C)C)C[C@@]2(CC=C(C)C)C(=O)[C@]1(C(=O)C(C)C)C(=O)C(CC=C(C)C)=C2O,Hyperforin,2.3,uM,=,0.3617278360175928,1,O=C1C=CC2CCCC1C2=O
4112,1712193,10.1016/j.bmcl.2018.04.051,,,,Inhibition of CYP3A4 (unknown origin),Cc1cc(N2CCOc3ncnc(N)c3C2=O)cc(C)c1C#CC(C)(C)CC(=O)O,"5-(4-(4-amino-5-oxo-7,8-dihydropyrimido[5,4f][1,4]oxazepin-6(5H)-yl)-2,6-dimethylphenyl)-3,3-dimethylpent-4-ynoic acid",45.5,uM,=,1.6580113966571124,1,O=C1c2cncnc2OCCN1c1ccccc1
4113,1689562,10.1021/acs.jmedchem.7b00598,,,,Inhibition of CYP3A4 (unknown origin),Cn1nccc1-c1cc(Cl)ccc1Oc1ccc(S(=O)(=O)Nc2ncns2)cc1C#N,"4-(4-chloro-2-(1-methyl-1H-pyrazol-5-yl)phenoxy)-3-cyano-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide",0.556,uM,=,-0.2549252084179425,0,O=S(=O)(Nc1ncns1)c1ccc(Oc2ccccc2-c2ccn[nH]2)cc1
4114,619265,10.1016/j.bmcl.2009.07.002,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate,Cc1cccc(C)c1CNc1cc(C(=O)NCCO)cn2c(C)c(C)nc12,"8-(2,6-dimethylbenzylamino)-N-(2-hydroxyethyl)-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxamide",12.0,uM,=,1.0791812460476249,1,c1ccc(CNc2cccn3ccnc23)cc1
4115,1432849,10.1016/j.bmcl.2014.10.024,,,,Inhibition of CYP3A4 (unknown origin) using midazolam substrate,COc1nc(Nc2cccc3c2nc(-c2ccc(F)cc2)n3C)ccc1-n1cnc(C)c1,2-(4-fluorophenyl)-N-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)-1-methyl-1H-benzo[d]imidazol-4-amine,8.7,uM,=,0.9395192526186184,1,c1ccc(-c2nc3c(Nc4ccc(-n5ccnc5)cn4)cccc3[nH]2)cc1
4116,347904,10.1016/j.bmcl.2006.01.024,,,,Inhibition of CYP3A4,CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3CC[C@@H](O)C3)c(Cc3c[nH]c4ccccc34)sc21,"(R)-6-((1H-indol-3-yl)methyl)-5-(3-hydroxypyrrolidine-1-carbonyl)-1-isobutyl-3-methylthieno[2,3-d]pyrimidine-2,4(1H,3H)-dione",1.0,uM,=,0.0,0,O=C(c1c(Cc2c[nH]c3ccccc23)sc2[nH]c(=O)[nH]c(=O)c12)N1CCCC1
4117,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",COc1ccc(C[C@@H]2COCCN2C(=O)c2ccccc2-n2nccn2)cc1-c1cccnc1,"US9150566, 4",1.2,uM,=,0.0791812460476248,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2cccnc2)c1
4118,1923489,10.1021/acs.jmedchem.6b00708,,,,Inhibition of CYP3A4 (unknown origin),C[C@@H](NC(=O)Nc1cc2[nH]nc(-c3ccnc(F)c3)c2cn1)c1ccccc1,"US9023865, 636",29.0,uM,=,1.462397997898956,1,O=C(NCc1ccccc1)Nc1cc2[nH]nc(-c3ccncc3)c2cn1
4119,804824,10.1016/j.bmcl.2011.12.080,,,,Reversible inhibition of CYP3A4,COc1cc(C)c2nc3[nH]nc(C)c3c(C(O)c3ncco3)c2c1,"rac-(6-methoxy-3,8-dimethyl-1H-pyrazolo[3,4-b]quinolin-4-yl)(oxazol-2-yl)methanol",4.4,uM,=,0.6434526764861874,1,c1ccc2c(Cc3ncco3)c3cn[nH]c3nc2c1
4120,719028,10.1021/ml100249e,,,,Inhibition of CYP3A4 in human liver microsomes,O=C(Nc1cnc(-c2ccncc2)c(-c2ccco2)n1)C1CC1,N-[6-(2-Furyl)-5-pyridin-4-ylpyrazin-2-yl]cyclopropanecarboxamide,25.0,uM,=,1.3979400086720375,1,O=C(Nc1cnc(-c2ccncc2)c(-c2ccco2)n1)C1CC1
4121,741043,10.1016/j.bmcl.2011.02.067,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCCN(C)C)c1,"(3R,4S)-N-cyclopropyl-4-(4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)phenyl)-N-(3-(2-(dimethylamino)ethoxy)-5-(3-methoxypropyl)benzyl)piperidine-3-carboxamide",1.4,uM,=,0.1461280356782379,1,O=C([C@H]1CNCC[C@@H]1c1ccc(OCCOc2ccccc2)cc1)N(Cc1ccccc1)C1CC1
4122,51902,10.1016/s0960-894x(02)00026-4,,,,Inhibition of cytochrome P450 3A4 enzyme; Range 1-2 uM,Cc1cc(C)cc(-c2[nH]c3ccc(C(C)(C)C(=O)N4CC5CCC4CC5)cc3c2[C@H](C)CNCCc2ccc3nsnc3c2)c1,"1-(2-Aza-bicyclo[2.2.2]oct-2-yl)-2-[3-[(S)-2-(2-benzo[1,2,5]thiadiazol-5-yl-ethylamino)-1-methyl-ethyl]-2-(3,5-dimethyl-phenyl)-1H-indol-5-yl]-2-methyl-propan-1-one",1.0,uM,=,0.0,0,O=C(Cc1ccc2[nH]c(-c3ccccc3)c(CCNCCc3ccc4nsnc4c3)c2c1)N1CC2CCC1CC2
4123,1887875,10.1016/j.bmc.2019.05.021,,,,Inhibition of CYP3A4 (unknown origin),O=C(Nc1cccc([C@H]2CCCN(c3ncnc4[nH]ccc34)C2)c1)Nc1ccccc1N1CCCC1,"(R)-1-(3-(1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-3-yl)phenyl)-3-(2-(pyrrolidin-1-yl)phenyl)urea",1.0,uM,=,0.0,0,O=C(Nc1cccc([C@H]2CCCN(c3ncnc4[nH]ccc34)C2)c1)Nc1ccccc1N1CCCC1
4124,663498,10.1021/jm100540x,,,,Inhibition of CYP3A4,CCCNC(=O)c1cn2ncnc(Nc3cc(C(=O)NC4CC4)ccc3C)c2c1C,"4-(5-(Cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2-f][1,2,4]triazine-6-carboxamide",18.0,uM,=,1.255272505103306,1,O=C(NC1CC1)c1cccc(Nc2ncnn3cccc23)c1
4125,2035531,10.1021/acsmedchemlett.0c00525,,,,Inhibition of CYP3A4 (unknown origin),C[C@@H](NC(=O)c1ccc(F)cc1)c1ccc2c(n1)CCCN2C(=O)c1cccc(Cl)c1,"(R)-N-(1-(5-(3-chlorobenzoyl)-5,6,7,8-tetrahydro-1,5-naphthyridin-2-yl)ethyl)-4-fluorobenzamide",20.0,uM,=,1.3010299956639813,1,O=C(NCc1ccc2c(n1)CCCN2C(=O)c1ccccc1)c1ccccc1
4126,993439,10.6019/CHEMBL2448688,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,CO/N=C(\C)c1ccc(-n2ccnc2)c(NC(=O)c2cnc(-c3ccccn3)s2)c1,,3.0,uM,=,0.4771212547196624,1,O=C(Nc1ccccc1-n1ccnc1)c1cnc(-c2ccccn2)s1
4127,1527876,,,,,Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,C[C@@H](c1ccc(-c2ccc(=O)n(C)c2)cc1)N1CC[C@](CC(C)(C)C#N)(c2ccc(F)cc2)OC1=O,"US8575157, 69",23.0,uM,=,1.3617278360175928,1,O=C1OC(c2ccccc2)CCN1Cc1ccc(-c2ccc(=O)[nH]c2)cc1
4128,1451406,10.1021/jm500916t,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs,CC1(C)C[C@@H](NC(=O)Nc2cccc3cnccc23)c2cc(F)ccc2O1,"(R)-1-(6-Fluoro-2,2-dimethylchroman-4-yl)-3-(isoquinolin-5-yl)urea",1.0,uM,=,0.0,0,O=C(Nc1cccc2cnccc12)N[C@@H]1CCOc2ccccc21
4129,2024613,10.1016/j.bmcl.2020.127721,,,,Inhibition of CYP3A4 (unknown origin),CS(=O)(=O)Nc1cccc(CC(=O)Nc2nccc(-c3c[nH]c4ncccc34)n2)c1,"2-[3-(methanesulfonamido)phenyl]-N-[4-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-yl]acetamide",48.0,uM,=,1.6812412373755872,1,O=C(Cc1ccccc1)Nc1nccc(-c2c[nH]c3ncccc23)n1
4130,862399,10.1021/jm300601d,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis,N=C(N)NC(=O)c1ccc(C2CCN(C(=O)C3CC3)CC2)c(C(F)(F)F)c1,N-[4-(1-Cyclopropanecarbonyl-piperidin-4-yl)-3-trifluoromethylbenzoyl]-guanidine,16.0,uM,=,1.2041199826559248,1,O=C(C1CC1)N1CCC(c2ccccc2)CC1
4131,631458,10.1021/jm9013136,,,,Inhibition of human recombinant CYP3A4,COC(c1ccc(Cl)cc1)(c1ccc2c(c1)c(-c1ccc(F)cc1)cc(=O)n2C)c1cncn1C,4-(4-Fluorophenyl)-6-((4-chlorophenyl)(methoxy)(1-methyl-1H-imidazol-5-yl)methyl)-1-methylquinolin-2(1H)-one,1.628,uM,=,0.2116544005531824,1,O=c1cc(-c2ccccc2)c2cc(C(c3ccccc3)c3cnc[nH]3)ccc2[nH]1
4132,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(CCCCO)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, E-12",9.3,uM,=,0.9684829485539352,1,O=C(c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12)N1CCNCC1
4133,52069,10.1021/jm021012t,,,,Inhibition of human cytochrome P450 3A4,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,vinblastine,26.0,uM,=,1.414973347970818,1,C1=CC2CC[C@@H]3Nc4ccc(C5C[C@@H]6CCCN(CCc7c5[nH]c5ccccc75)C6)cc4[C@@]34CCN(C1)[C@@H]24
4134,1688648,10.1021/acs.jmedchem.7b00410,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 8 mins by LC/MS/MS analysis,Cc1cc(Oc2cncc(F)c2)cc(C(=O)Nc2ccc(Cl)cn2)n1,N-(5-Chloropyridin-2-yl)-4-((5-fluoropyridin-3-yl)oxy)-6-methylpicolinamide,2.0,uM,=,0.3010299956639812,1,O=C(Nc1ccccn1)c1cc(Oc2cccnc2)ccn1
4135,1301325,10.6019/CHEMBL3137440,,,,DNDI: CYP Inhibition,O=C(c1ccccc1C(F)(F)F)N1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1,(4-(pyridin-3-yl(4-(trifluoromethyl)phenyl)amino)piperidin-1-yl)(2-(trifluoromethyl)phenyl)methanone,1.7,uM,=,0.2304489213782739,1,O=C(c1ccccc1)N1CCC(N(c2ccccc2)c2cccnc2)CC1
4136,512798,10.1021/jm800832q,,,,Inhibition of human recombinant CYP3A4 in human liver microsomes using BFC as a substrate,Cc1cc(C2CCN(CCCF)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,(S)-4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridine-1(1H)-one,28.0,uM,=,1.4471580313422192,1,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(C3CCNCC3)cc2[nH]1
4137,1700204,10.1021/acs.jmedchem.7b00162,,,,Inhibition of CYP3A4 (unknown origin),Cn1cc(S(=O)(=O)N2CCC3=Cc4c(cnn4-c4ccc(F)cc4)C[C@]3(C(=O)c3cc(C(F)(F)F)ccn3)C2)cn1,RELACORILANT,1.3,uM,=,0.1139433523068367,1,O=C(c1ccccn1)[C@]12Cc3cnn(-c4ccccc4)c3C=C1CCN(S(=O)(=O)c1cn[nH]c1)C2
4138,52069,10.1021/jm021012t,,,,Inhibition of human cytochrome P450 3A4,O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1,"1-{1-[4,4-Bis-(4-fluoro-phenyl)-butyl]-piperidin-4-yl}-1,3-dihydro-benzoimidazol-2-one",9.7,uM,=,0.9867717342662448,1,O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccccc2)c2ccccc2)CC1
4139,1465541,10.1016/j.bmcl.2015.01.051,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(C6CN(C)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O,"(1S,4R,5R,6R,8R,10S,11R,12S,13R,16R,18S,21R)-8-[(1S)-1-ethoxy-2-hydroxy-2-methylpropyl]-4,6,12,17,17-pentamethyl-18-{[(2S)-4-(1-methylazetidin-3-yl)morpholin-2-yl]oxy}-9-oxahexacyclo[11.9.0.0^{1,21}.0^{4,12}.0^{5,10}.0^{16,21}]docosan-11-ol",12.0,uM,=,1.0791812460476249,1,C1CO[C@@H]2CC3C(CC[C@@]45C[C@@]46CC[C@H](O[C@H]4CN(C7CNC7)CCO4)C[C@@H]6CC[C@@H]35)[C@H]2C1
4140,1474044,10.1021/jm501740a,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,O=C(N[C@@H](c1ccccc1F)C1CC1)c1ccc2[nH]nc(-c3ccc(N4C5CCC4COC5)cc3)c2c1,3-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)phenyl)-N-((R)-cyclopropyl(2-fluorophenyl)methyl)-1H-indazole-5-carboxamide,0.24,uM,=,-0.619788758288394,0,O=C(N[C@@H](c1ccccc1)C1CC1)c1ccc2[nH]nc(-c3ccc(N4C5CCC4COC5)cc3)c2c1
4141,804824,10.1016/j.bmcl.2011.12.080,,,,Reversible inhibition of CYP3A4,COc1cc(C)c2nc3[nH]nc(C)c3c(C(O)c3ccnc(F)c3)c2c1,"rac-(2-fluoropyridin-4-yl)(6-methoxy-3,8-dimethyl-1H-pyrazolo[3,4-b]quinolin-4-yl)methanol",0.6,uM,=,-0.2218487496163563,0,c1ccc2c(Cc3ccncc3)c3cn[nH]c3nc2c1
4142,598210,10.1016/j.bmcl.2009.08.024,,,,Inhibition of human CYP3A4,COc1cc(CNC(=O)CC2(C)CC3(CCCCC3)OO2)cc(OC)c1,"N-(3,5-dimethoxybenzyl)-2-(3-methyl-1,2-dioxaspiro[4.5]decan-3-yl)acetamide",1.7,uM,=,0.2304489213782739,1,O=C(CC1CC2(CCCCC2)OO1)NCc1ccccc1
4143,52555,10.1021/jm980532e,,,,Inhibition of human cytochrome P450 3A4 as total cyclosporin oxidation (1 uM),COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1.Cl,5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonic acid (4-methoxy-3-piperazin-1-yl-phenyl)-amide hydrochloride,40.0,uM,=,1.6020599913279625,1,O=S(=O)(Nc1cccc(N2CCNCC2)c1)c1cc2ccccc2s1
4144,342118,10.1021/jm051106d,,,,Inhibitory activity against CYP3A4,Cc1cc2c(F)c(Oc3ncnn4cc(OCCCNS(C)(=O)=O)c(C)c34)ccc2[nH]1,"N-(3-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propyl)methanesulfonamide",1.0,uM,=,0.0,0,c1cc2c(Oc3ccc4[nH]ccc4c3)ncnn2c1
4145,643715,10.1016/j.bmcl.2010.06.009,,,,Inhibition of human recombinant CYP3A4 using 7-{3-(4-phenylpiperazin-1-ylmethyl)benzyl}resorufin as substrate by fluorescence plate reader,C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(N)c4)ccc32)sc1C(N)=O)c1ccccc1C(F)(F)F,(R)-5-(5-(2-aminopyridin-4-yl)-1H-benzo[d]imidazol-1-yl)-3-(1-(2-(trifluoromethyl)phenyl)ethoxy)thiophene-2-carboxamide,6.5,uM,=,0.8129133566428556,1,c1ccc(COc2csc(-n3cnc4cc(-c5ccncc5)ccc43)c2)cc1
4146,1709454,10.1016/j.ejmech.2017.05.043,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by NADPH addition measured after 10 mins by LC/MS/MS analysis,CC(C)COC(=O)[C@H](Cn1ccnc1)NC(=O)c1cc(-c2ccccc2F)on1,Isobutyl (S)-2-(5-(2-fluorophenyl)isoxazole-3-carboxamido)-3-(1H-imidazol-1-yl)propanoate,8.38,uM,=,0.9232440186302766,1,O=C(NCCn1ccnc1)c1cc(-c2ccccc2)on1
4147,1614025,10.1016/j.bmcl.2016.09.043,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 6-beta-hydroxytestosterone metabolite formation using testosterone as substrate incubated for 30 mins by HPLC-MS method,COc1ccc(CCNc2nc3cc(Cl)ccc3c(=O)n2C)nc1,7-Chloro-2-[2-(6-methoxy-pyridin-2-yl)-ethylamino]-3-methyl-3H-quinazolin-4-one,7.4,uM,=,0.8692317197309762,1,O=c1[nH]c(NCCc2ccccn2)nc2ccccc12
4148,1459302,10.1016/j.bmc.2014.06.027,,,,Inhibition of CYP3A4 in supersomes (unknown origin) using Dibenzylfluorescein as substrate after 10 mins,CCc1ccccc1C(C(=O)Nc1ccc2[nH]nc(-c3cccc(S(N)(=O)=O)c3)c2c1)N(C)C,(+/-)-2-(Dimethylamino)-2-(2-ethylphenyl)-N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)acetamide,2.9,uM,=,0.4623979978989561,1,O=C(Cc1ccccc1)Nc1ccc2[nH]nc(-c3ccccc3)c2c1
4149,1519125,10.1021/acsmedchemlett.5b00226,,,,Inhibition of CYP3A4 in human liver microsomes,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21,BMS-911543,3.0,uM,=,0.4771212547196624,1,O=C(c1cc2c(nc(Nc3cc[nH]n3)c3nc[nH]c32)[nH]1)N(C1CC1)C1CC1
4150,1616350,10.1021/acs.jmedchem.6b00989,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 15 mins by HPLC analysis,C[C@@H]1c2ncn(-c3ccc(F)cn3)c2CCN1C(=O)c1cccc(C(F)(F)F)c1Cl,"(R)-(2-Chloro-3(trifluoromethyl)phenyl)(1-(5-fluoropyridin-2-yl)-4-methyl-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-methanone",2.0,uM,=,0.3010299956639812,1,O=C(c1ccccc1)N1CCc2c(ncn2-c2ccccn2)C1
4151,1558600,10.1016/j.bmcl.2015.06.020,,,,Inhibition of CYP3A4 (unknown origin) by fluorescence assay,Cc1ncn(-c2ccc3c(c2)CCc2cn(Cc4ccccc4)nc2N3)n1,"2-benzyl-7-(3-methyl-1H-1,2,4-triazol-1-yl)-2,4,5,10-tetrahydrobenzo[b]pyrazolo[4,3-f]azepine",0.3,uM,=,-0.5228787452803376,0,c1ccc(Cn2cc3c(n2)Nc2ccc(-n4cncn4)cc2CC3)cc1
4152,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)Nc6ccc(N)cc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, D-18",2.42,uM,=,0.3838153659804312,1,O=C(Nc1ccccc1)c1ccc(-c2c[nH]c3c(CN4C[C@@H]5N(C(=O)NCc6ccccc6)NCC(=O)N5[C@@H](Cc5ccccc5)C4=O)cccc23)cc1
4153,423507,10.1021/jm060995h,,,,Inhibition of CYP3A4,CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3C[C@H](O)CO3)c(Cc3ccnc4ccccc34)sc21,"5-{[(4S)-4-hydroxyisoxazolidin-2-yl]carbonyl}-1-isobutyl-3-methyl-6-(quinolin-4-ylmethyl)thieno[2,3-d]pyrimidin-2,4(1H,3H)dione",46.0,uM,=,1.662757831681574,1,O=C(c1c(Cc2ccnc3ccccc23)sc2[nH]c(=O)[nH]c(=O)c12)N1CCCO1
4154,1526216,10.1021/ml500526p,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,Cn1c(Nc2cccc(C(C)(C)C)c2)nc2cc(Oc3ccnc(-c4ncc(-c5ccccc5)[nH]4)c3)ccc21,N-(3-tert-butylphenyl)-1-methyl-5-(2-(5-phenyl-1H-imidazol-2-yl)pyridin-4-yloxy)-1H-benzo[d]imidazol-2-amine,7.1,uM,=,0.8512583487190752,1,c1ccc(Nc2nc3cc(Oc4ccnc(-c5ncc(-c6ccccc6)[nH]5)c4)ccc3[nH]2)cc1
4155,1705360,10.1016/j.bmcl.2017.06.037,,,,Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method,OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F,"2-(2,4-Difluoro-phenyl)-1,3-bis-[1,2,4]triazol-1-yl-propan-2-ol",32.0,uM,=,1.505149978319906,1,c1ccc(C(Cn2cncn2)Cn2cncn2)cc1
4156,717286,10.1021/np100665j,,,,Inhibition of CYP3A4 after 30 mins by fluorometric assay,COc1cc([C@H]2COc3ccccc3[C@@H]2O)ccc1O,"(3S,4R)-4'-hydroxy-6,3'-dimethoxyisoflavan-4-ol",99.5,uM,=,1.9978230807457256,1,c1ccc([C@H]2COc3ccccc3C2)cc1
4157,631008,10.1021/jm100023j,,,,Inhibition of CYP3A4,Cc1cc(C(=O)N[C@@H]2CC(C)(C)Oc3nc(-c4ccc(Cl)cc4Cl)c(-c4ccc(Cl)cc4)cc32)n[nH]1,"N-((4R)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl)-5-methyl-1H-pyrazole-3-carboxamide",3.3,uM,=,0.5185139398778875,1,O=C(N[C@@H]1CCOc2nc(-c3ccccc3)c(-c3ccccc3)cc21)c1cc[nH]n1
4158,438600,10.1016/j.bmcl.2007.03.048,,,,Inhibition of CYP3A4 in microsomes,Cc1cc(C2=NCCCN2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,"4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-3-(4-methyl-6-(1,4,5,6-tetrahydropyrimidin-2-yl)-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one",16.0,uM,=,1.2041199826559248,1,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(C3=NCCCN3)cc2[nH]1
4159,1281752,10.1021/ml400311r,,,,Inhibition of CYP3A4 in human liver microsomes assessed as midazolam 1'-hydroxylation and testosterone 6beta-hydroxylation after 20 mins by LC-MS/MS analysis,Cc1ccc(C(NCCNc2ccnc3cc(Cl)ccc23)c2nnnn2C(C)(C)C)cc1,"N1-((1-tert-butyl-1H-tetrazol-5-yl)(p-tolyl)methyl)-N2-(7-chloroquinolin-4-yl)ethane-1,2-diamine",0.17,uM,=,-0.7695510786217261,0,c1ccc(C(NCCNc2ccnc3ccccc23)c2nnn[nH]2)cc1
4160,1586157,10.1016/j.bmcl.2016.06.021,,,,Inhibition of CYP3A4 (unknown origin),Cc1cc(-c2cnn3c(NCC4CCOCC4)nc(Nc4ccccc4F)nc23)ccc1C(=O)NC1CC1,"N-cyclopropyl-4-(2-(2-fluorophenoxy)-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)pyrazolo [1,5-a][1,3,5]triazin-8-yl)-2-methylbenzamide",9.3,uM,=,0.9684829485539352,1,O=C(NC1CC1)c1ccc(-c2cnn3c(NCC4CCOCC4)nc(Nc4ccccc4)nc23)cc1
4161,1534761,,,,,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",Clc1cnc2[nH]cc(Cc3ccc(NCc4ccc(Cl)nc4)nc3)c2c1,"US9096593, P-2003",5.0,uM,=,0.6989700043360189,1,c1cncc(CNc2ccc(Cc3c[nH]c4ncccc34)cn2)c1
4162,1797910,10.1021/acs.jmedchem.8b01326,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate/NADPH addition measured after 10 mins by LC-MS/MS analysis,CN1C(=N)N[C@@]2(c3cc(-c4cc(F)cc(F)c4)cs3)CN(c3ncc(F)cn3)C[C@H]2C1=O,"(4aR,7aR)-7a-(4-(3,5-Difluorophenyl)thiophen-2-yl)-6-(5-fluoropyrimidin-2-yl)-2-imino-3-methyloctahydro-4H-pyrrolo[3,4-d]-pyrimidin-4-one",1.0,uM,=,0.0,0,N=C1NC(=O)[C@@H]2CN(c3ncccn3)C[C@]2(c2cc(-c3ccccc3)cs2)N1
4163,1828801,10.1021/acs.jmedchem.8b01098,,,,Inhibition of C-terminal 4His-tagged CYP3A4 (unknown origin) expressed in Escherichia coli by spectrophotometric analysis,CN(C)CCCOc1cccc(CNC(=O)c2ccc(-c3ccncc3)cc2)c1,N-(3-(3-(Dimethylamino)propoxy)benzyl)-4-(pyridin-4-yl)-benzamide,2.0,uM,=,0.3010299956639812,1,O=C(NCc1ccccc1)c1ccc(-c2ccncc2)cc1
4164,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCOCCO)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, F-7",16.36,uM,=,1.2137832993353042,1,O=C1[C@H](Cc2ccccc2)N2C(=O)CNN(C(=O)NCc3ccccc3)[C@H]2CN1Cc1cccc2cc[nH]c12
4165,2064643,10.1021/acs.jmedchem.6b01433,,,,Inhibition of CYP3A4 (unknown origin),CCCCCCCCC1CCc2cc(CCC(N)(CO)CO)ccc2C1,"2-amino-2-(2-(6-octyl-5,6,7,8-tetrahydronaphthalen-2-yl)ethyl)propane-1,3-diol",10.4,uM,=,1.0170333392987805,1,c1ccc2c(c1)CCCC2
4166,1474044,10.1021/jm501740a,,,,Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay,O=C(N[C@@H](c1ccccn1)C1CCCC1)c1ccc2[nH]nc(-c3ccc(N4[C@H]5CC[C@H]4CC(O)C5)cc3)c2c1,N-((R)-Cyclopentyl(pyridin-2-yl)methyl)-3-(4-((endo)-3-hydroxy-8-azabicyclo[3.2.1]octan-8-yl)phenyl)-1H-indazole-5-carboxamide,0.23,uM,=,-0.6382721639824072,0,O=C(N[C@@H](c1ccccn1)C1CCCC1)c1ccc2[nH]nc(-c3ccc(N4[C@@H]5CCC[C@@H]4CC5)cc3)c2c1
4167,1485703,10.1124/dmd.112.048264,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method,C[C@]12C=CC(=O)C=C1CC[C@H]1[C@@H]3C[C@@H](O)[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@]12F,"9-Fluoro-11,16,17-trihydroxy-17-(2-hydroxy-acetyl)-10,13-dimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-cyclopenta[a]phenanthren-3-one",49.1,uM,=,1.6910814921229684,1,O=C1C=CC2C(=C1)CC[C@@H]1C2CCC2CCC[C@H]21
4168,988989,10.1021/jm400732v,,,,Inhibition of CYP3A4 (unknown origin),CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)CC(C)C)c2ccccc2N(CCc2ccccc2)C1=O.Cl,"(S)-2-(Methylamino)-N-((S)-5-(3-methylbutanoyl)-2-oxo-1-phenethyl-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-yl)propanamide hydrochloride",3.3,uM,=,0.5185139398778875,1,O=C1CCNc2ccccc2N1CCc1ccccc1
4169,673952,10.1016/j.bmcl.2010.08.086,,,,Inhibition of CYP3A4 using midazolam as substrate,COCCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1,"(3R,4S)-N-(2-chloro-5-(2-methoxyethyl)benzyl)-N-cyclopropyl-4-(4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)phenyl)piperidine-3-carboxamide",3.2,uM,=,0.505149978319906,1,O=C([C@H]1CNCC[C@@H]1c1ccc(OCCOc2ccccc2)cc1)N(Cc1ccccc1)C1CC1
4170,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2C(CN(Cc3cccc4c(C(=O)Nc5ccc(N6CCOCC6)nc5)cn(C)c34)C(=O)[C@@H]2Cc2ccc(O)cc2)N1C(=O)NCc1ccccc1,"US8940739, G-36",21.06,uM,=,1.3234583668494675,1,O=C(Nc1ccc(N2CCOCC2)nc1)c1c[nH]c2c(CN3CC4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12
4171,1849385,10.1016/j.bmcl.2019.06.044,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis,O=C(O)c1ccc(-n2cc(C(=O)c3c(Cl)cccc3Cl)c3cccc(F)c32)cc1,"4-(3-(2,6-dichlorobenzoyl)-7-fluoro-1H-indol-1-yl)benzoic acid",44.7,uM,=,1.6503075231319366,1,O=C(c1ccccc1)c1cn(-c2ccccc2)c2ccccc12
4172,872616,10.1021/jm200326p,,,,Inhibition of CYP3A4 in human liver microsomes assessed as decrease in formation of 1-hydroxymidazolam from midazolam substrate after 5 mins by LC-MS/MS,CCN(CC)CCOc1ccc2cc1COCC=CCOCc1cccc(c1)-c1ccnc(n1)N2,"(2-{14,19-dioxa-5,7,27-triazatetracyclo[19.3.1.1^{2,6}.1^{8,12}]heptacosa-1(25),2(27),3,5,8,10,12(26),16,21,23-decaen-11-yloxy}ethyl)diethylamine",2.8,uM,=,0.4471580313422192,1,C1=CCOCc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)COC1
4173,1540696,10.1016/j.ejmech.2015.08.051,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 2 mins by LC-MS/MS analysis in presence of NADPH regeneration system,CC(C)c1nc(C(=O)NC[C@@H]2[C@H]3CN(CC(C)(C)F)C[C@@H]23)c2ccccn12,"N-[N-(2-fluoro-2-methyl-propyl)-3-azabicyclo[3.1.0]hexane-6-yl-methyl]-3-isopropylimidazo[1,5-a]pyridine-1-carboxamide",44.7,uM,=,1.6503075231319366,1,O=C(NC[C@H]1[C@@H]2CNC[C@@H]21)c1ncn2ccccc12
4174,1528565,,,,,"Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",CN[C@H]1C[C@@H](C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)N(C(=O)N(C)Cc2csc(C(C)C)n2)C1,"US8987313, 30",0.36,uM,=,-0.4436974992327127,0,O=C(N[C@H](CC[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)NCc1cscn1)Cc1ccccc1)OCc1cncs1
4175,2023287,10.1016/j.bmcl.2020.127636,,,,Inhibition of CYP3A4 (unknown origin),COc1ccccc1C1c2c(C(C)(C)C)n[nH]c2C(=O)N1c1ccc(-c2nc(C)no2)cc1,"3-tert-butyl-4-(2-methoxyphenyl)-5-(4-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl)-4,5-dihydropyrrolo[3,4-c]pyrazol-6(1H)-one",2.0,uM,=,0.3010299956639812,1,O=C1c2[nH]ncc2C(c2ccccc2)N1c1ccc(-c2ncno2)cc1
4176,1291572,10.1016/j.bmcl.2013.12.058,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)NC2CCN(C(=O)OCc3cncs3)CC2)C(C)C)cs1,(S)-thiazol-5-ylmethyl 4-(2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-3-methylbutanamido)piperidine-1-carboxylate,1.67,uM,=,0.2227164711475832,1,O=C(CNC(=O)NCc1cscn1)NC1CCN(C(=O)OCc2cncs2)CC1
4177,1523285,10.1016/j.bmcl.2015.06.066,,,,Inhibition of CYP3A4 (unknown origin),CC(C)[C@](C)(NCc1ccc2ncccc2c1)c1cn(C(CCS(C)(=O)=O)C(=O)COc2c(F)c(F)cc(F)c2F)nn1,"3-(4-((S)-3-methyl-2-(quinolin-6-ylmethylamino)butan-2-yl)-1H-1,2,3-triazol-1-yl)-5-(methylsulfonyl)-1-(2,3,5,6-tetrafluorophenoxy)pentan-2-one",1.2,uM,=,0.0791812460476248,1,O=C(COc1ccccc1)Cn1cc(CNCc2ccc3ncccc3c2)nn1
4178,1892125,10.1016/j.ejmech.2019.03.017,,,,Inhibition of human CYP3A4 measured after 30 mins in presence of NADPH regeneration system by luminescent CYP3A4 P450-Glo assay,CCn1cncc1-c1c[nH]c2ccc(I)c(F)c12,3-(1-Ethyl-1H-imidazol-5-yl)-4-fluoro-5-iodo-1H-indole,0.1,uM,=,-1.0,0,c1ccc2c(-c3cnc[nH]3)c[nH]c2c1
4179,834929,10.1016/j.bmcl.2012.07.020,,,,Inhibition of CYP3A4,CCS(=O)(=O)c1ccc2[nH]c(-c3ccnc(-c4ccccc4)c3)nc2c1,5-(ethylsulfonyl)-2-(2-phenylpyridin-4-yl)-1H-benzo[d]imidazole,8.7,uM,=,0.9395192526186184,1,c1ccc(-c2cc(-c3nc4ccccc4[nH]3)ccn2)cc1
4180,1465542,10.1016/j.bmcl.2015.01.051,,,,Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(CC6CN(CC(C)(C)O)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O,"(1S,4R,5R,6R,8R,10S,11R,12S,13R,16R,18S,21R)-8-[(1S)-1-ethoxy-2-hydroxy-2-methylpropyl]-18-{[(2S)-4-{[1-(2-hydroxy-2-methylpropyl)azetidin-3-yl]methyl}morpholin-2-yl]oxy}-4,6,12,17,17-pentamethyl-9-oxahexacyclo[11.9.0.0^{1,21}.0^{4,12}.0^{5,10}.0^{16,21}]docosan-11-ol",11.0,uM,=,1.0413926851582251,1,C1CO[C@@H]2CC3C(CC[C@@]45C[C@@]46CC[C@H](O[C@H]4CN(CC7CNC7)CCO4)C[C@@H]6CC[C@@H]35)[C@H]2C1
4181,595557,10.1016/j.bmcl.2009.10.084,,,,Inhibition of CYP3A4 using BFC as a substrate,Cc1cc2cc(N/C(=N\C(=O)c3cncc(C(N)=O)c3)N[C@H]3CCCCN(CC(=O)N4CCCC4)C3=O)ccc2o1,"(S)-N3-((2-methylbenzofuran-5-ylamino)(2-oxo-1-(2-oxo-2-(pyrrolidin-1-yl)ethyl)azepan-3-ylamino)methylene)pyridine-3,5-dicarboxamide",0.4,uM,=,-0.3979400086720376,0,O=C(/N=C(\Nc1ccc2occc2c1)N[C@H]1CCCCN(CC(=O)N2CCCC2)C1=O)c1cccnc1
4182,1641150,,,,,"Inhibition Assay: Inhibition of cytochromes P450 (CYPs) 2C9, 2D6 and 3A4 was assessed using human liver microsomes and CYP-selective substrate metabolism reactions. 50 μl incubations were made up containing (finally) 0.2 mg/ml pooled human liver microsomes, 5 μM substrate (diclofenac for CYP2C9 [4' hydroxylase], dextromethorphan for CYP2D6 [O-demethylase] or midazolam for CYP3A4 [1' hydroxylase]), 0.25 μl, DMSO containing test inhibitor and NADPH regenerating system. Test inhibitor concentrations of 50, 16.7, 5.6, 1.9, 0.6 and 0.2 μM were assessed in singlicate. Incubations were prewarmed to 37° C. for 10 minutes before initiation by addition of NADPH regenerating system. Incubations were quenched after 5 minutes (20 minutes for dextromethorphan) by addition of 50 μl cold acetonitrile containing 20 ng/ml 4-OH-diclofenac-13C6, 20 ng/mL dextrorphan-D3 and 20 ng/mL 1-OH-midazolam-D4. Quenched incubates were stored at -20° C. for at least 1 hour before centrifugation (20,000xg, 20 minutes). Supernatants were removed and diluted 1:1 with water prior to analysis using a RapidFire sample injector system and API4000 mass spectrometer.",C[C@@]1(c2cc(Nc3cc(Cl)cc4cc(Cl)cnc34)ccc2F)COCC(N)=N1,"US9242943, 27",33.0,uM,=,1.5185139398778875,1,C1=NC(c2cccc(Nc3cccc4cccnc34)c2)COC1
4183,828928,10.1016/j.bmcl.2012.06.022,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,C#CCN(C)c1nc2ccc(C(=O)N(CC(C)C)C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1,"thiazol-5-ylmethyl(2S,3R)-3-hydroxy-4-(N-isobutyl-2-(methyl(prop-2-ynyl)amino)benzo[d]oxazole-6-carboxamido)-1-phenylbutan-2-ylcarbamate",0.03,uM,=,-1.5228787452803376,0,O=C(N[C@H](CCNC(=O)c1ccc2ncoc2c1)Cc1ccccc1)OCc1cncs1
4184,1289241,10.1016/j.bmcl.2013.12.088,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,O=C(NC1CCCC1)N[C@@](Cc1ccccc1)(c1cc(F)cc(OC(F)(F)C(F)F)c1)c1ccc(Cl)cn1,"(S)-1-(1-(5-chloropyridin-2-yl)-1-(3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl)-2-phenylethyl)-3-cyclopentylurea",8.8,uM,=,0.9444826721501688,1,O=C(NC1CCCC1)N[C@@](Cc1ccccc1)(c1ccccc1)c1ccccn1
4185,305432,10.1016/j.bmcl.2005.01.044,,,,Selectivity towards cytochrome P450 3A4 enzyme activity,CC(C(c1ccc2cc(OCc3ccccc3)ccc2c1)n1ccnc1)N(C)C,[2-(6-Benzyloxy-naphthalen-2-yl)-2-imidazol-1-yl-1-methyl-ethyl]-dimethyl-amine,0.2,uM,=,-0.6989700043360187,0,c1ccc(COc2ccc3cc(Cn4ccnc4)ccc3c2)cc1
4186,1845477,10.1021/acsmedchemlett.0c00004,,,,Inhibition of CYP3A4 (unknown origin),O[C@@H]1c2nonc2CC[C@H]1[C@H]1c2ccccc2-c2cncn21,"(4S,5S)-5-((S)-5H-imidazo[5,1-a]isoindol-5-yl)-4,5,6,7-tetrahydrobenzo[c][1,2,5]oxadiazol-4-ol",8.2,uM,=,0.9138138523837168,1,c1ccc2c(c1)-c1cncn1[C@H]2[C@@H]1CCc2nonc2C1
4187,1925644,10.1021/acs.jmedchem.6b00827,,,,Inhibition of CYP3A4 (unknown origin) at 3 uM using midazolam substrate by LC-MS method,CC(C)NC(=O)c1c(-c2ccccc2)c([C@H](C)Nc2ncnc(N)c2C#N)nc2ccc(F)cc12,2-((1S)-1-((6-Amino-5-cyano-4-pyrimidinyl)amino)ethyl)-6-fluoro-N-(1-methylethyl)-3-phenyl-4-quinolinecarboxamide,13.0,uM,=,1.1139433523068367,1,c1ccc(-c2cc3ccccc3nc2CNc2ccncn2)cc1
4188,802673,10.1016/j.bmcl.2011.12.125,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,CC(C)NC(=O)c1cccc(NC(=O)Nc2ccc(-c3ncnc4[nH]ccc34)cc2)c1,"3-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)ureido)-N-isopropylbenzamide",0.56,uM,=,-0.2518119729937995,0,O=C(Nc1ccccc1)Nc1ccc(-c2ncnc3[nH]ccc23)cc1
4189,1895186,10.1021/acs.jmedchem.9b00193,,,,Inhibition of CYP3A4 (unknown origin) by fluorescence-based assay,O=C(O)Cc1ccc(Cc2cc(-c3cccc(Cl)c3)nc(C(F)(F)F)c2)cc1,ZATOLMILAST,15.0,uM,=,1.1760912590556811,1,c1ccc(Cc2ccnc(-c3ccccc3)c2)cc1
4190,988989,10.1021/jm400732v,,,,Inhibition of CYP3A4 (unknown origin),CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2noc3ccccc23)c2ccccc2N(C(=O)CS(C)(=O)=O)[C@H]1C.Cl,"(S)-N-((3S,4S)-1-(benzo[d]isoxazol-3-ylmethyl)-4-methyl-5-(2-(methylsulfonyl)acetyl)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-yl)-2-(methylamino)propanamide Hydrochloride",38.0,uM,=,1.57978359661681,1,O=C1CCNc2ccccc2N1Cc1noc2ccccc12
4191,2263748,10.1016/j.bmc.2020.115797,,,,Inhibition of CYP3A4 (unknown origin),O=C(Nc1ccc(-c2ccc(F)cn2)cc1)c1cc2sc(NCCN3CCOCC3)nc2s1,"N-(4-(5-fluoropyridin-2-yl)phenyl)-2-((2-morpholinoethyl)amino)thieno[2,3-d]thiazole-5-carboxamide",6.95,uM,=,0.8419848045901139,1,O=C(Nc1ccc(-c2ccccn2)cc1)c1cc2sc(NCCN3CCOCC3)nc2s1
4192,828928,10.1016/j.bmcl.2012.06.022,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,CCN(C)c1nc2ccc(C(=O)N(CC(C)C)C[C@H](O)[C@H](Cc3cccnc3)NC(=O)OCc3cncs3)cc2o1,"Thiazol-5-ylmethyl(2S,3R)-4-(2-(ethyl(methyl)amino)-N-isobutylbenzo[d]oxazole-6-carboxamido)-3-hydroxy-1-(pyridin-3-yl)butan-2-ylcarbamate",0.069,uM,=,-1.1611509092627446,0,O=C(N[C@H](CCNC(=O)c1ccc2ncoc2c1)Cc1cccnc1)OCc1cncs1
4193,1465594,10.1016/j.bmcl.2015.02.039,,,,Inhibition of CYP3A4 (unknown origin) using midazolam fluorometric substrate,COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2NS(=O)(=O)Cc2ccccc2)C(C)C)ccc1OC,rac-N-isopropyl-4-methoxy-3-(3-methoxypropoxy)-N-((4-(phenylmethylsulfonamido)pyrrolidin-3-yl)methyl)benzamide,4.4,uM,=,0.6434526764861874,1,O=C(NC[C@@H]1CNC[C@H]1NS(=O)(=O)Cc1ccccc1)c1ccccc1
4194,1730110,10.1021/acs.jmedchem.8b00335,,,,Inhibition of recombinant human CYP3A4 in presence of NADPH generating system by fluorescence assay,CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,SID144204227,0.065,uM,=,-1.1870866433571443,0,c1ccc([C@@]2(Cn3ccnc3)OC[C@H](COc3ccc(N4CCNCC4)cc3)O2)cc1
4195,473932,10.1021/jm701121y,,,,Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay,CCOC(=O)C(Cc1ccc(Cl)cc1Cl)c1ccno1,"ethyl 3-(2,4-dichlorophenyl)-2-(isoxazol-5-yl)propanoate",12.0,uM,=,1.0791812460476249,1,c1ccc(CCc2ccno2)cc1
4196,1919651,,,,,"Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase",ON=Cc1ccc(-c2cccnc2)o1,(cis/trans)-5-(pyridin-3-yl)furan-2-carbaldehyde oxime,51.9,uM,=,1.715167357848458,1,c1cncc(-c2ccco2)c1
4197,459885,10.1021/np0704248,,,,Inhibition of human CYP3A4 expressed in Escherichia coli assessed as inhibition of nifedipine oxidation,COc1cc2c(cc1O)-c1cc3ccc(OC)c(OC)c3c[n+]1CC2,columbamine,30.6,uM,=,1.48572142648158,1,c1ccc2c(c1)CC[n+]1cc3ccccc3cc1-2
4198,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cccc(-n3ccnn3)c2)c1,"US9150566, 15",14.0,uM,=,1.146128035678238,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2ccnn2)c1
4199,701747,10.1021/ml100190t,,,,Inhibition of CYP3A4 uisng testosterone substrate,Cc1ccc(NC(=O)N2CCC(=Cc3cccc(Oc4ccc(C(F)(F)F)cn4)c3)CC2)cn1,N-(6-Methylpyridin-3-yl)-4-(3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}benzylidene)piperidine-1-carboxamide,3.0,uM,=,0.4771212547196624,1,O=C(Nc1cccnc1)N1CCC(=Cc2cccc(Oc3ccccn3)c2)CC1
4200,944981,10.1021/ml3003132,,,,Time-dependent inhibition of CYP3A4 in human liver microsome using midazolam as substrate by TDI shift assay,CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOC[C@@H]4C)n2)CCN(c2ncc(F)cn2)C3)cc1,"(S)-1-ethyl-3-(4-(7-(5-fluoropyrimidin-2-yl)-4-(3-methylmorpholino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)phenyl)urea",1.4,uM,=,0.1461280356782379,1,c1ccc(-c2nc3c(c(N4CCOCC4)n2)CCN(c2ncccn2)C3)cc1
4201,1642014,,,,,"Inhibition Assay: The test compounds were incubated with pooled human liver microsomes at 37° C. in the presence of NADPH and appropriate concentrations of substrates specific for CYP2C9 and 3A4. 120 μL of a mixture of human liver microsomes (HLM) in 50 mM potassium phosphate/5 mM MgCl2 buffer was added into all wells of row A in a 96-well plate. The concentration of microsomal protein was 2-fold the intended protein concentration for the particular isozyme assay recorded in Table 4. In addition, 80 μL of this human liver microsome preparation spiked with 1% DMSO was dispensed into all wells of rows B through H. 1.2 μL of each individual test compound in DMSO (10 mM) was added to the first 10 wells of row A (5 different test compounds each in duplicate). Additionally, 1.2 μL of the DMSO stock of the control inhibitor for the isozyme under study was added into the final two wells of row A to give a concentration two-fold above the highest final concentration. Three-fold serial dilutions were performed by taking 40 μL from each solution in wells of row A (wells 1-12, both compounds and controls) and diluting into the wells of row B. After thorough mixing, 40 μL from each solution in wells of row B were dispensed with a multichannel pipette (12 channels) into the wells of row C and the controls and test compounds hence further diluted. This process was repeated for rows D through G. After mixing, 40 μL was removed and discarded from the wells of row G. This procedure resulted in 80 μL of solution being present in all wells of all rows A through H, with protein concentrations being twice the final intended concentrations in all wells of rows, and test compound and control concentration being twice the final intended concentrations in rows A through G. Row H was not spiked with a test compound or positive control. The plate was covered and pre-incubated for 10 minutes in a 37° C. incubator. The reaction was initiated by adding 80 μL of a solution of the substrate for the isozyme under investigation in 50 mM potassium phosphate/5 mM MgCl2 buffer solution with 4 mM NADPH present, at a substrate concentration two-fold the intended final substrate concentrations using a multichannel pipette. The substrate solution was added to all wells rows A to H excluding wells 95 and 96 (microsomal blanks). The plate was covered and incubated at 37° C. for the time listed in Table 4 for the isoform under investigation. The reaction was stopped by dispensing 120 μL of internal standard (200 ng/mL CCX915-6A) in acetonitrile to all wells. 80 μL of the specific substrate/NADPH solution described above was added into the well 95 and 96 after stopping the reaction to provide the blank. The plate was vortexed for 10 min and spun in a centrifuge at 4,450 rpm and 4° C. for 10 min. With a multichannel pipette, 80 μL of the supernatant was transferred into a sample plate wells containing 80 μL of 0.1% formic acid/water and mixed well for analysis on LC-MS/MS as described in sections E and F.",Cc1cnc(C(=O)c2ncnc3[nH]ccc23)c(NS(=O)(=O)c2ccc(Cl)c(C(F)(F)F)c2)c1,"4-chloro-N-(5-methyl-2-(7H-pyrrolo[2,3-d]pyrimidine-4-carbonyl)pyridin-3-yl)-3-(trifluoromethyl)benzenesulfonamide",20.0,uM,=,1.3010299956639813,1,O=C(c1ncccc1NS(=O)(=O)c1ccccc1)c1ncnc2[nH]ccc12
4202,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2ncccn2)c1,"US9150566, 18",39.0,uM,=,1.591064607026499,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2ncccn2)c1
4203,1291572,10.1016/j.bmcl.2013.12.058,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,CC[C@@H](CC[C@H](CC)NC(=O)[C@@H](NC(=O)N(C)Cc1csc(C(C)C)n1)C(C)C)NC(=O)OCc1cncs1,"Thiazol-5-ylmethyl(3S,6S)-6-((S)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-3-methylbutanamido)octan-3-ylcarbamate",0.19,uM,=,-0.721246399047171,0,O=C(CNC(=O)NCc1cscn1)NCCCCNC(=O)OCc1cncs1
4204,1713962,10.1016/j.bmcl.2018.05.040,,,,Inhibition of human CYP3A4 using testosterone as substrate by LC-MS/MS analysis,CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,SID144204227,0.146,uM,=,-0.835647144215563,0,c1ccc([C@@]2(Cn3ccnc3)OC[C@H](COc3ccc(N4CCNCC4)cc3)O2)cc1
4205,1923841,10.1021/acs.jmedchem.6b00280,,,,Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase and human b5 reductase assessed as reduction in 7-Hydroxyquinoline production using 7-benzyloxyquinoline as substrate and NADPH incubated for 15 mins by fluorimetry,CCOc1ccc2nnc(Sc3ccc4nc(NC(=O)NCCN5CCOCC5)sc4c3)n2n1,"1-(6-(6-ethoxy-[1,2,4]triazolo[4,3-b]pyridazin-3-ylthio)benzo[d]thiazol-2-yl)-3-(2-morpholinoethyl)urea",4.0,uM,=,0.6020599913279624,1,O=C(NCCN1CCOCC1)Nc1nc2ccc(Sc3nnc4cccnn34)cc2s1
4206,550965,10.1021/np030556a,,,,Inhibition of human CYP3A4 by radiometric assay,CC(=O)O[C@@H]1[C@@H](O)[C@@H](OC(C)=O)[C@H](Oc2c(-c3ccc(O)cc3)oc3cc(O)cc(O)c3c2=O)O[C@H]1C,"kaempferol-3-O-(2,4-di-O-acetyl-alpha-L-rhamnopyranoside)",31.6,uM,=,1.499687082618404,1,O=c1c(O[C@H]2CCCCO2)c(-c2ccccc2)oc2ccccc12
4207,1541293,10.1016/j.bmc.2015.11.017,,,,Inhibition of human recombinant CYP3A4 by fluorescence assay,O=C(c1sc2c([N+](=O)[O-])cc(C(F)(F)F)cc2[n+]1[O-])N1CCCCC1,7-Nitro-2-(piperidine-1-carbonyl)-5-(trifluoromethyl)benzo[d]thiazole 3-oxide,3.91,uM,=,0.5921767573958668,1,O=C(c1[nH+]c2ccccc2s1)N1CCCCC1
4208,643713,10.1016/j.bmcl.2010.06.009,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader,C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(NCCO)c4)ccc32)sc1C(N)=O)c1ccccc1Cl,(R)-3-(1-(2-chlorophenyl)ethoxy)-5-(5-(2-(2-hydroxyethylamino)pyridin-4-yl)-1H-benzo[d]imidazol-1-yl)thiophene-2-carboxamide,3.7,uM,=,0.568201724066995,1,c1ccc(COc2csc(-n3cnc4cc(-c5ccncc5)ccc43)c2)cc1
4209,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1cc(C(=O)N2CCOC[C@H]2Cc2cccc(-c3ncon3)c2)c(-n2nccn2)cc1C,"US9150566, 85",25.0,uM,=,1.3979400086720375,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2ncon2)c1
4210,1289880,10.1021/jm401642q,,,,Inhibition of recombinant human CYP3A4,CC1(C)CN(C(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)c2ccccc21,"2-[2-(3,3-Dimethyl-2,3-dihydro-1H-indol-1-yl)-2-oxoethyl]-6-(morpholin-4-yl)pyrimidin-4(3H)-one",40.0,uM,=,1.6020599913279625,1,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2ccccc21
4211,632105,10.1016/j.bmcl.2010.03.057,,,,Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin,Cc1cc(N2CCN(C(=O)OC(C)(C)C)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,"(S)-tert-butyl 4-(2-(4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-2-oxo-1,2-dihydropyridin-3-yl)-4-methyl-1H-benzo[d]imidazol-6-yl)piperazine-1-carboxylate",1.9,uM,=,0.2787536009528289,1,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(N3CCNCC3)cc2[nH]1
4212,463080,10.1016/j.bmcl.2008.02.032,,,,Inhibition of CYP3A4,Cc1cc(OCC(=O)Nc2cc(-n3nc(C)cc3C)nc(-c3ccc(C)o3)n2)cc(C)n1,"N-(6-(3,5-dimethyl-1H-pyrazol-1-yl)-2-(5-methylfuran-2-yl)pyrimidin-4-yl)-2-(2,6-dimethylpyridin-4-yloxy)acetamide",1.1,uM,=,0.041392685158225,1,O=C(COc1ccncc1)Nc1cc(-n2cccn2)nc(-c2ccco2)n1
4213,455108,10.1016/j.bmcl.2006.12.043,,,,Inhibition of CYP3A4,O=C([C@@H]1Cc2ccccc2CN1)N1CCN(c2ccc3[nH]ncc3c2)CC1,"(S)-(4-(1H-indazol-5-yl)piperazin-1-yl)(1,2,3,4-tetrahydroisoquinolin-3-yl)methanone",10.0,uM,=,1.0,1,O=C([C@@H]1Cc2ccccc2CN1)N1CCN(c2ccc3[nH]ncc3c2)CC1
4214,539794,10.1021/jm8005405,,,,Inhibition of CYP3A4 in human liver microsomes,CNc1noc2c(-c3ccc4c(N5CCOC[C@@H]5C)nncc4c3)c(Cl)ccc12,6-Chloro-N-cyclopropyl-7-(1-((S)-3-methylmorpholino)phthalazin-6-yl)benzo[d]isoxazol-3-amine,6.0,uM,=,0.7781512503836436,1,c1cc(-c2ccc3c(N4CCOCC4)nncc3c2)c2oncc2c1
4215,1499751,10.1021/acs.jmedchem.5b00424,,,,Inhibition of CYP3A4 (unknown origin),COc1cccc(CC(=O)Nc2nc(-c3ccnc(N(C)C)c3)cs2)c1,N-(4-(2-(dimethylamino)pyridin-4-yl)thiazol-2-yl)-2-(3-methoxyphenyl)acetamide,3.5,uM,=,0.5440680443502757,1,O=C(Cc1ccccc1)Nc1nc(-c2ccncc2)cs1
4216,1972830,10.1021/acsmedchemlett.9b00612,,,,Inhibition of human recombinant CYP3A4 expressed in insect cell microsomes in presence of NADPH by fluorescence assay,Cc1ccc(C(=O)Nc2ccc(CN3CCN(CCO)CC3)c(C3CC3)c2)cc1C#Cc1cnc2cccnn12,"N-[3-cyclopropyl-4-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]phenyl]-3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methylbenzamide",11.7,uM,=,1.0681858617461617,1,O=C(Nc1ccc(CN2CCNCC2)c(C2CC2)c1)c1cccc(C#Cc2cnc3cccnn23)c1
4217,1641653,,,,,"Inhibition Assay: Six test compound concentrations (0.1, 0.25, 1, 2.5, 10, 25 μM in DMSO; final DMSO concentration=0.275%) are incubated with human liver microsomes (0.5 mg/mL) and NADPH (1 mM) in the presence of the probe substrate testosterone (50 μM) for 5 min at 37° C. The selective CYP3A4 inhibitor, ketoconazole, is screened alongside the test compounds as a positive control.",C[C@]12CC[C@H]3[C@@H](C[C@@H](O)C4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,6beta-hydroxytestosterone,10.5,uM,=,1.021189299069938,1,O=C1C=C2CC[C@H]3[C@@H]4CCCC4CC[C@@H]3C2CC1
4218,625610,10.1016/j.bmcl.2010.02.036,,,,Inhibition of CYP3A4 after 30 mins,COCCCc1ccc(Cl)c(CN(C(=O)[C@H](CN)Cc2ccc(CCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1,"(S)-3-amino-N-(2-chloro-5-(3-methoxypropyl)benzyl)-N-cyclopropyl-2-(4-(3-(2,6-dichloro-4-methylphenoxy)propyl)benzyl)propanamide",0.13,uM,=,-0.8860566476931633,0,O=C(CCc1ccc(CCCOc2ccccc2)cc1)N(Cc1ccccc1)C1CC1
4219,51750,10.1021/jm010531d,,,,Inhibition of dog Cytochrome P450 3A by macrocycles,N#Cc1ccc2cc1Oc1ccc3cccc(c3c1)N1CC[C@H](NCc3cncn3C2)C1=O,"30-oxo-(5S)-19-oxa-2,6,10,12-tetraazahexacyclo[18.6.2.12,5.114,18.08,12.023,27]triaconta-1(27),8,10,14(29),15,17,20(28),21,23,25-decaen-17-yl cyanide",5.0,uM,=,0.6989700043360189,1,O=C1[C@@H]2CCN1c1cccc3ccc(cc13)Oc1cccc(c1)Cn1cncc1CN2
4220,455108,10.1016/j.bmcl.2006.12.043,,,,Inhibition of CYP3A4,O=C([C@H](O)c1ccccc1)N1CCN(c2ccc3[nH]ncc3c2)CC1,(R)-1-(4-(1H-indazol-5-yl)piperazin-1-yl)-2-hydroxy-2-phenylethanone,10.0,uM,=,1.0,1,O=C(Cc1ccccc1)N1CCN(c2ccc3[nH]ncc3c2)CC1
4221,1288280,10.1016/j.bmcl.2013.12.057,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,O=C(N[C@@H](CC[C@@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)N(Cc1cncs1)C1CC1)Cc1ccccc1)OCc1cncs1,"Thiazol-5-ylmethyl(2S,5S)-5-((S)-2-(3-cyclopropyl-3-(thiazol-5-ylmethyl)ureido)-3-hydroxypropanamido)-1,6-diphenylhexan-2-ylcarbamate",0.08,uM,=,-1.0969100130080565,0,O=C(CNC(=O)N(Cc1cncs1)C1CC1)N[C@@H](CC[C@@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
4222,1491684,10.1124/dmd.112.045708,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 90 mins followed by substrate addition by LC-MS/MS analysis,CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1,"(R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide",9.2,uM,=,0.9637878273455552,1,O=C(Cc1ccccc1)N(Cc1cccnc1)Cc1nc2ncccc2c(=O)n1-c1ccccc1
4223,990449,10.1016/j.bmcl.2013.09.001,,,,Inhibition of CYP3A4 in human liver microsomes in presence of NADPH,Cc1csc(NC(=O)c2cc(Cl)cc(Oc3cncnc3)c2)n1,3-chloro-N-(4-methylthiazol-2-yl)-5-(pyrimidin-5-yloxy)benzamide,2.2,uM,=,0.3424226808222063,1,O=C(Nc1nccs1)c1cccc(Oc2cncnc2)c1
4224,993439,10.6019/CHEMBL2448688,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,CCN(c1ccccc1)S(=O)(=O)c1ccc(Cl)c(NC(=O)CNC2CCCN(C)C2)c1.O=CO,,16.3,uM,=,1.212187604403958,1,O=C(CNC1CCCNC1)Nc1cccc(S(=O)(=O)Nc2ccccc2)c1
4225,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(NCCN(C)C)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, G-23",6.75,uM,=,0.829303772831025,1,O=C(Nc1cccnc1)c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12
4226,2048413,10.1016/j.bmc.2020.115723,,,,Inhibition of CYP3A4 (unknown origin),Nc1cc([C@H](CCCc2ccccc2)c2ccccc2)c2nn[nH]c2n1,"(R)-7-(1,4-diphenylbutyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-amine",1.8,uM,=,0.255272505103306,1,c1ccc(CCC[C@H](c2ccccc2)c2ccnc3[nH]nnc23)cc1
4227,2221809,10.1016/j.bmcl.2022.128625,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as substrate in presence of NADPH,CCC[C@H]1N(C(=O)c2c(C(F)(F)F)ccnc2O)CCC[C@@]1(Oc1csc(C(F)(F)F)c1)C(=O)N1CCN(c2ccccc2OCCCC(=O)O)CC1,"4-(2-(4-((2R,3S)-1-(2-hydroxy-4-(trifluoromethyl)nicotinoyl)-2-propyl-3-(5-(trifluoromethyl)thiophen-3-yloxy)piperidine-3-carbonyl)piperazin-1-yl)phenoxy)butanoic acid",50.0,uM,=,1.6989700043360187,1,O=C(c1cccnc1)N1CCC[C@@](Oc2ccsc2)(C(=O)N2CCN(c3ccccc3)CC2)C1
4228,1291572,10.1016/j.bmcl.2013.12.058,,,,Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity,CCC[C@@H](CC[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)N(C)Cc1csc(C(C)C)n1)C(C)C)NC(=O)OCc1cncs1,"Thiazol-5-ylmethyl(4S,7R)-7-((S)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-3-methylbutanamido)-8-phenyloctan-4-ylcarbamate",0.13,uM,=,-0.8860566476931633,0,O=C(CNC(=O)NCc1cscn1)N[C@H](CCCNC(=O)OCc1cncs1)Cc1ccccc1
4229,519907,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,Cc1nc2c(NCc3ccc(F)cc3Cl)cc(-n3ccccc3=O)cn2c1C,"1-(8-(2-chloro-4-fluorobenzylamino)-2,3-dimethylimidazo[1,2-a]pyridin-6-yl)pyridin-2(1H)-one",3.4,uM,=,0.5314789170422551,1,O=c1ccccn1-c1cc(NCc2ccccc2)c2nccn2c1
4230,542857,10.1021/jm801313t,,,,Inhibition of human recombinant CYP3A4,Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2c(c1)c(-c1cccc3ccccc13)cc(=O)n2C,(R)-6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-1-methyl-4-(naphthalen-1-yl)quinolin-2(1H)-one,0.55,uM,=,-0.2596373105057561,0,O=c1cc(-c2cccc3ccccc23)c2cc(C(c3ccccc3)c3cnc[nH]3)ccc2[nH]1
4231,769541,10.1021/jm200695m,,,,Inhibition of CYP3A4 in human liver microsomes,C[C@H]([C@@H](c1ccc(Nc2nc3ccccc3s2)cc1)n1ccnc1)N(C)C,"Benzothiazol-2-yl-[4-((1S,2S)-2-dimethylamino-1-imidazol-1-yl-propyl)-phenyl]-amine",0.35,uM,=,-0.4559319556497244,0,c1ccc2sc(Nc3ccc(Cn4ccnc4)cc3)nc2c1
4232,674732,10.1016/j.bmcl.2010.09.029,,,,Inhibition of CYP3A4,CN1C(=O)[C@@](c2ccc(OC(F)F)cc2)(c2ccc(F)c(C#CC3CC3)c2)N=C1N,(R)-2-amino-4-(3-(cyclopropylethynyl)-4-fluorophenyl)-4-(4-(difluoromethoxy)phenyl)-1-methyl-1H-imidazol-5(4H)-one,10.0,uM,=,1.0,1,O=C1NC=N[C@]1(c1ccccc1)c1cccc(C#CC2CC2)c1
4233,510198,10.1021/jm800355c,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,OC1(c2ccncc2)CCCc2cc(-c3ccc(F)cc3)ccc21,"6-(4-Fluorophenyl)-1-(pyridin-4-yl)-1,2,3,4-tetrahydronaphthalen-1-ol",8.757,uM,=,0.9423553497076768,1,c1ccc(-c2ccc3c(c2)CCCC3c2ccncc2)cc1
4234,1528565,,,,,"Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",CN[C@H]1C[C@@H](C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)N(C(=O)N(C)Cc2csc(C(C)C)n2)C1,"US8987313, 30",0.17,uM,=,-0.7695510786217261,0,O=C(N[C@H](CC[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)NCc1cscn1)Cc1ccccc1)OCc1cncs1
4235,943410,10.1021/jm400194n,,,,Time dependent inhibition of human CYP3A4 preincubated for 30 mins in presence of NADPH,CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOC[C@@H]4C)n2)CN(C2COC2)CC3)cc1,"(S)-1-Ethyl-3-(4-(4-(3-methylmorpholino)-6-(oxetan-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2-yl)phenyl)urea",2.5,uM,=,0.3979400086720376,1,c1ccc(-c2nc3c(c(N4CCOCC4)n2)CN(C2COC2)CC3)cc1
4236,434712,10.1021/jm070104l,,,,Inhibition of human CYP3A4,N#Cc1ccccc1Cn1c(N2CCC[C@@H](N)C2)nc2c(Cl)cc(Cl)cc2c1=O,"(R)-2-((2-(3-aminopiperidin-1-yl)-6,8-dichloro-4-oxoquinazolin-3(4H)-yl)methyl)benzonitrile",0.08,uM,=,-1.0969100130080565,0,O=c1c2ccccc2nc(N2CCCCC2)n1Cc1ccccc1
4237,806086,10.1016/j.bmcl.2012.01.064,,,,Inhibition of CYP3A4 in human microsome,NC(=O)C[S+]([O-])Cc1ccccc1-c1ccc(Cl)cc1,(-)-2-((4'-chlorobiphenyl-2-yl)methylsulfinyl)acetamide,139.0,uM,=,2.143014800254095,1,c1ccc(-c2ccccc2)cc1
4238,2068401,10.1016/j.bmcl.2020.127676,,,,Inhibition of CYP3A4 (unknown origin),CN[C@@H](C)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)Nc1cc2c(NCCOCCOCCNc3ncnc4cc(OC)c(NC(=O)[C@@H]5CCCN5C(=O)[C@@H](NC(=O)[C@H](C)NC)C(C)(C)C)cc34)ncnc2cc1OC)C(C)(C)C,"(S,S,2S,2'S)-N,N'-(4,4'-(2,2'-(ethane-1,2-diylbis(oxy))bis(ethane-2,1-diyl))bis(azanediyl)bis(7-methoxyquinazoline-6,4-diyl))bis(1-((S)-3,3-dimethyl-2-((S)-2-(methylamino)propanamido)butanoyl)pyrrolidine-2-carboxamide)",5.65,uM,=,0.7520484478194386,1,O=C(Nc1ccc2ncnc(NCCOCCOCCNc3ncnc4ccc(NC(=O)[C@@H]5CCCN5)cc34)c2c1)[C@@H]1CCCN1
4239,1659434,10.1021/acs.jmedchem.6b01662,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH by LC-MS/MS analysis,COc1ccc2c(c1)c(CN1CCN(C)CC1)cn2S(=O)(=O)c1ccc(C(C)C)cc1.CS(=O)(=O)O.CS(=O)(=O)O,1-[(4-Isopropylphenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole Dimesylate,1.85,uM,=,0.2671717284030138,1,O=S(=O)(c1ccccc1)n1cc(CN2CCNCC2)c2ccccc21
4240,1614025,10.1016/j.bmcl.2016.09.043,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 6-beta-hydroxytestosterone metabolite formation using testosterone as substrate incubated for 30 mins by HPLC-MS method,COc1ccc(-c2ccc(CCNc3nc4cc(Cl)ccc4c(=O)n3C)cc2)cc1,7-Chloro-2-[2-(4'-methoxy-biphenyl-4-yl)-ethylamino]-3-methyl-3H-quinazolin-4-one,7.9,uM,=,0.8976270912904415,1,O=c1[nH]c(NCCc2ccc(-c3ccccc3)cc2)nc2ccccc12
4241,768817,10.1021/jm2005354,,,,Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting,C[C@@H](c1ccc(-c2ccc(F)cc2F)cc1)N1CC[C@](CCO)(c2ccc(F)cc2)OC1=O,"(S)-3-((S)-1-(2',4'-Difluoro-[1,1'-biphenyl]-4-yl)ethyl)-6-(4-fluorophenyl)-6-(2-hydroxyethyl)-1,3-oxazinan-2-one",12.0,uM,=,1.0791812460476249,1,O=C1OC(c2ccccc2)CCN1Cc1ccc(-c2ccccc2)cc1
4242,1301328,10.6019/CHEMBL3137440,,,,DNDI: CYP Inhibition,Fc1cnc(N2CCC(N(c3ccc(C(F)(F)F)cc3)c3cccnc3)CC2)nc1,,0.7,uM,=,-0.1549019599857432,0,c1ccc(N(c2cccnc2)C2CCN(c3ncccn3)CC2)cc1
4243,828928,10.1016/j.bmcl.2012.06.022,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,CCN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N3CCCC3)oc2c1,"Thiazol-5-ylmethyl(2S,3R)-4-(N-ethyl-2-(pyrrolidin-1-yl)benzo[d]oxazole-6-carboxamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate",0.06,uM,=,-1.2218487496163564,0,O=C(N[C@H](CCNC(=O)c1ccc2nc(N3CCCC3)oc2c1)Cc1ccccc1)OCc1cncs1
4244,802673,10.1016/j.bmcl.2011.12.125,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,O=C(Nc1ccc(-c2ccnc3[nH]cnc23)cc1)Nc1cccc(Br)c1,"1-(4-(3H-imidazo[4,5-b]pyridin-7-yl)phenyl)-3-(3-bromophenyl)urea",0.092,uM,=,-1.0362121726544449,0,O=C(Nc1ccccc1)Nc1ccc(-c2ccnc3[nH]cnc23)cc1
4245,537516,10.1021/jm8005096,,,,Inhibition of CYP3A4,CC1=C(C(=O)Nc2cc3cn[nH]c3cc2F)C(c2ccc(Cl)cc2F)N=C(c2ccnc(Cl)c2)N1,"4-(4-chloro-2-fluorophenyl)-2-(2-chloropyridin-4-yl)-N-(6-fluoro-1H-indazol-5-yl)-6-methyl-1,4-dihydropyrimidine-5-carboxamide",2.5,uM,=,0.3979400086720376,1,O=C(Nc1ccc2[nH]ncc2c1)C1=CNC(c2ccncc2)=NC1c1ccccc1
4246,1436762,10.1021/ml500187a,,,,Inhibition of human recombinant CYP3A4 incubated for 5 mins by fluorescence assay,Fc1ccccc1N(Cc1ccc(Cl)cc1)C1CNC1,N-(4-chlorobenzyl)-N-(2-fluorophenyl)azetidin-3-amine,3.64,uM,=,0.561101383649056,1,c1ccc(CN(c2ccccc2)C2CNC2)cc1
4247,2204356,10.1016/j.bmc.2022.116894,,,,Inhibition of CYP3A4 (unknown origin) using BOMCC as a substrate,O=C(NCCCNc1cc(-c2cn(-c3ccccc3)nc2-c2cccc(O)c2)ccn1)Nc1ccc(F)cc1,1-(4-Fluorophenyl)-3-(3-((4-(3-(3-hydroxyphenyl)-1-phenyl-1H-pyrazol-4-yl)pyridin-2-yl)amino)propyl)urea,18.7,uM,=,1.271841606536499,1,O=C(NCCCNc1cc(-c2cn(-c3ccccc3)nc2-c2ccccc2)ccn1)Nc1ccccc1
4248,857201,10.1021/jm200900q,,,,Inhibition of CYP3A4,N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(C(=O)CNCCO)CC3)cc2C2=CCCCC2)n1,4-Cyano-1H-imidazole-2-carboxylic Acid(2-Cyclohex-1-enyl-4-{1-[2-(2-hydroxy-ethylamino)-acetyl]-piperidin-4-yl}-phenyl)-amide,5.1,uM,=,0.7075701760979364,1,O=C(Nc1ccc(C2CCNCC2)cc1C1=CCCCC1)c1ncc[nH]1
4249,804823,10.1016/j.bmcl.2011.12.080,,,,Time dependent inhibition of CYP3A4,COc1cc(C)c2nc3[nH]nc(C)c3c(C(C)(O)c3ccncc3)c2c1,"rac-1-(6-methoxy-3,8-dimethyl-1H-pyrazolo[3,4-b]quinolin-4-yl)-1-(pyridin-4-yl)ethanol",14.2,uM,=,1.1522883443830565,1,c1ccc2c(Cc3ccncc3)c3cn[nH]c3nc2c1
4250,2118300,10.1021/acs.jmedchem.1c00847,,,,Reversible inhibition of CYP3A4 in human liver microsomes at 10 uM using midazolam as substrate preincubated for 10 mins followed by NADPH addition by LC/MS/MS analysis,C[C@@H]1Cc2c([nH]c3ccccc23)[C@@H](c2c(F)cc(NC3CN(CCCF)C3)cc2F)N1CC(F)(F)CO,GIREDESTRANT,6.5,uM,=,0.8129133566428556,1,c1ccc2c3c([nH]c2c1)[C@@H](c1ccc(NC2CNC2)cc1)NCC3
4251,512798,10.1021/jm800832q,,,,Inhibition of human recombinant CYP3A4 in human liver microsomes using BFC as a substrate,Cc1cc(C2CCN(CCO)CC2)cc2[nH]c(-c3c(NCCn4cc(Cl)cn4)cc[nH]c3=O)nc12,4-(2-(4-chloro-1H-pyrazol-1-yl(ethylamino)-3-(6-(1-(2-hydroxyethyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one,23.0,uM,=,1.3617278360175928,1,O=c1[nH]ccc(NCCn2cccn2)c1-c1nc2ccc(C3CCNCC3)cc2[nH]1
4252,688021,10.1016/j.bmcl.2010.10.101,,,,Inhibition of CYP3A4 in human liver microsomes after 10 mins,Cc1ccc(F)cc1Cn1c(N2CCC[C@@](C)(N)C2)cc2ncn(C)c(=O)c21.Cl,"(R)-6-(3-amino-3-methylpiperidin-1-yl)-5-(5-fluoro-2-methylbenzyl)-3-methyl-3H-pyrrolo[3,2-d]pyrimidin-4(5H)-one hydrochloride",11.9,uM,=,1.0755469613925308,1,O=c1[nH]cnc2cc(N3CCCCC3)n(Cc3ccccc3)c12
4253,1624780,10.1021/acs.jmedchem.6b00697,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate in presence of NADPH by LC-MS/MS analysis,O=C(/C=C/c1cccnc1)NCCCCC1CCN(C(=O)c2ccccc2)CC1,N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide,1.5,uM,=,0.1760912590556812,1,O=C(/C=C/c1cccnc1)NCCCCC1CCN(C(=O)c2ccccc2)CC1
4254,1464796,10.1016/j.bmcl.2015.01.005,,,,Inhibition of recombinant human CYP3A4,Cn1c(N2CCO[C@@H]3COC[C@H]32)nc(-c2ccncc2F)cc1=O,"(-)-2-((4aR,7aS)-dihydro-2H-furo[3,4-b][1,4]oxazin-4(3H,7H,7aH)-yl)-6-(3-fluoropyridin-4-yl)-3-methylpyrimidin-4(3H)-one",545.0,uM,=,2.7363965022766426,1,O=c1cc(-c2ccncc2)nc(N2CCO[C@@H]3COC[C@H]32)[nH]1
4255,1460909,10.1021/jm501326k,,,,Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase/human b5 reductase using 7-benzyloxyquinoline substrate,CCOC(=O)c1[nH]cc2c1NC1=C(C(=O)CNC1)C2c1ccc(Sc2nc3ccccc3[nH]2)o1.Cl.O,"(+/-)-9-[5-(1H-Benzimidazol-2-ylsulfanyl)-furan-2-yl]-8-oxo-4,5,6,7,8,9-hexahydro-2H-pyrrolo[3,4-b]-1,7-naphthyridine-3-carboxylic acid ethyl ester dihydrochloride hydrate",0.17,uM,=,-0.7695510786217261,0,O=C1CNCC2=C1C(c1ccc(Sc3nc4ccccc4[nH]3)o1)c1c[nH]cc1N2
4256,993439,10.6019/CHEMBL2448688,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,NCC(=O)N(Cc1cccnc1)c1ccc(-c2nc3ccccc3s2)cc1,,13.04,uM,=,1.1152775913959014,1,c1cncc(CNc2ccc(-c3nc4ccccc4s3)cc2)c1
4257,1662668,10.1021/acs.jmedchem.6b01850,,,,Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated with enzyme in presence of NADPH followed by substrate addition,COc1cc(-c2cc(C(F)(F)F)ccc2C)ccc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3ccon3)ccc21,"US9212182, 1053",2.2,uM,=,0.3424226808222063,1,O=c1ccc2cc(S(=O)(=O)Nc3ccon3)ccc2n1-c1ccc(-c2ccccc2)cc1
4258,1911030,10.1021/acs.jmedchem.8b01226,,,,Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins,Cc1cccc(C#CC=C2CCN(C(=O)OCc3ccccc3)CC2)n1,Benzyl 4-[3-(6-Methylpyridin-2-yl)prop-2-yn-1-ylidene]-piperidine-1-carboxylate,7.7,uM,=,0.8864907251724818,1,O=C(OCc1ccccc1)N1CCC(=CC#Cc2ccccn2)CC1
4259,1465542,10.1016/j.bmcl.2015.01.051,,,,Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(CC6CN(C(C)C)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O,"(1S,4R,5R,6R,8R,10S,11R,12S,13R,16R,18S,21R)-8-[(1S)-1-ethoxy-2-hydroxy-2-methylpropyl]-4,6,12,17,17-pentamethyl-18-{[(2S)-4-{[1-(propan-2-yl)azetidin-3-yl]methyl}morpholin-2-yl]oxy}-9-oxahexacyclo[11.9.0.0^{1,21}.0^{4,12}.0^{5,10}.0^{16,21}]docosan-11-ol",16.0,uM,=,1.2041199826559248,1,C1CO[C@@H]2CC3C(CC[C@@]45C[C@@]46CC[C@H](O[C@H]4CN(CC7CNC7)CCO4)C[C@@H]6CC[C@@H]35)[C@H]2C1
4260,776115,10.1016/j.bmcl.2011.09.074,,,,Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin,COc1ccccc1N1Cc2c(nc(C)c(CN)c2-c2ccc(Cl)cc2Cl)C1=O,"rac-3-(aminomethyl)-4-(2,4-dichlorophenyl)-6-(2-methoxyphenyl)-2-methyl-5H-pyrrolo[3,4-b]pyridin-7(6H)-one",2.2,uM,=,0.3424226808222063,1,O=C1c2nccc(-c3ccccc3)c2CN1c1ccccc1
4261,949159,10.1016/j.bmcl.2013.01.011,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,Cc1cc(CC(NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12,"(+/-)-N-(1-(1,4'-bipiperidin-1'-yl)-3-(7-methyl-1H-indazol-5-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide",24.0,uM,=,1.380211241711606,1,O=C(NC(Cc1ccc2[nH]ncc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
4262,347904,10.1016/j.bmcl.2006.01.024,,,,Inhibition of CYP3A4,CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3CC[C@@H](O)C3)c(Cc3c[nH]c4ncccc34)sc21,"(R)-6-((1H-pyrrolo[2,3-b]pyridin-3-yl)methyl)-5-(3-hydroxypyrrolidine-1-carbonyl)-1-isobutyl-3-methylthieno[2,3-d]pyrimidine-2,4(1H,3H)-dione",6.7,uM,=,0.8260748027008264,1,O=C(c1c(Cc2c[nH]c3ncccc23)sc2[nH]c(=O)[nH]c(=O)c12)N1CCCC1
4263,2152076,10.1021/acs.jmedchem.1c00067,,,,Inhibition of CYP3A4 in human liver microsomes,CCN(C)c1nc(=O)n(-c2cccnc2)c2cc(Cl)ccc12,7-chloro-4-(ethyl(methyl)amino)-1-(pyridin-3-yl)quinazolin-2(1H)-one,24.0,uM,=,1.380211241711606,1,O=c1ncc2ccccc2n1-c1cccnc1
4264,1279390,10.1021/ml4002612,,,,Inhibition of CYP3A4 (unknown origin),CC(C)(C1CCN(C(=O)c2cc(F)ccc2S(C)(=O)=O)CC1)S(=O)(=O)c1cccc(C(F)(F)F)c1,(5-fluoro-2-(methylsulfonyl)phenyl)(4-(2-((3-(trifluoromethyl)phenyl)sulfonyl)propan-2-yl)piperidin-1-yl)methanone,10.0,uM,=,1.0,1,O=C(c1ccccc1)N1CCC(CS(=O)(=O)c2ccccc2)CC1
4265,1613611,10.1016/j.bmcl.2016.08.089,,,,Inhibition of CYP3A4 (unknown origin),CC(C)[C@@H]1c2nn(-c3cccc(S(C)(=O)=O)c3)cc2CN1c1ncc(CO)c(C(F)(F)F)n1,"(R)-(2-(6-isopropyl-2-(3-(methylsulfonyl)phenyl)pyrrolo[3,4-c]pyrazol-5(2H,4H,6H)-yl)-4-(trifluoromethyl)pyrimidin-5-yl)methanol",3.05,uM,=,0.4842998393467858,1,c1ccc(-n2cc3c(n2)CN(c2ncccn2)C3)cc1
4266,1488503,10.1124/dmd.112.045708,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis,C[C@H](c1nc2ncccc2c(=O)n1-c1ccc(O)cc1)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1,"(R)-N-(1-(3-(4-hydroxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide",2.1,uM,=,0.3222192947339193,1,O=C(Cc1ccccc1)N(Cc1cccnc1)Cc1nc2ncccc2c(=O)n1-c1ccccc1
4267,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",C[C@@H]1COC[C@@H](Cc2cccc(-n3nccn3)c2)N1C(=O)c1ccccc1-n1nccn1,"US9150566, 68",24.0,uM,=,1.380211241711606,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
4268,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cccc(-c3ncccn3)c2)c1,"US9150566, 17",33.0,uM,=,1.5185139398778875,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2ncccn2)c1
4269,1653169,10.1021/acsmedchemlett.6b00465,,,,Inhibition of CYP3A4 (unknown origin),O=C(O)CSc1nnc(Br)n1-c1ccc(C2CC2)c2ccccc12,LESINURAD,31.0,uM,=,1.4913616938342726,1,c1ccc2c(-n3cnnc3)ccc(C3CC3)c2c1
4270,1661018,10.1016/j.bmcl.2017.02.047,,,,Inhibition of recombinant human CYP3A4 expressed in baculosomes using Vivid BOMR substrate red measured every 30 sec for 30 mins by fluorescence assay,CCCCC[C@H](O)CC(=O)CCc1ccc(O)c(OC)c1,[1-(4'-hydroxy-3'-methoxyphenyl)-5-hydroxy-3-decanone],42.9,uM,=,1.6324572921847242,1,c1ccccc1
4271,52065,10.1021/jm0310129,,,,Inhibitory activity against cytochrome P450 3A4,NC(=O)c1cccc2c1c1ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c1n2Cc1ccncc1,"4-{4-[2-(3,4-Difluoro-phenyl)-ethyl]-piperazin-1-yl}-5-pyridin-4-ylmethyl-5H-pyrimido[5,4-b]indole-9-carboxylic acid amide",0.2,uM,=,-0.6989700043360187,0,c1ccc(CCN2CCN(c3ncnc4c5ccccc5n(Cc5ccncc5)c34)CC2)cc1
4272,1561108,10.1021/acsmedchemlett.5b00253,,,,Inhibition of human CYP3A4,CCn1c(SCC(=O)Nc2cccc3ccccc23)nnc1C1Cc2ccccc2C1,"2-(5-(2,3-Dihydro-1H-inden-2-yl)-4-ethyl-4H-1,2,4-triazol-3-ylthio)-N-(naphthalen-1-yl)acetamide",4.0,uM,=,0.6020599913279624,1,O=C(CSc1nnc(C2Cc3ccccc3C2)[nH]1)Nc1cccc2ccccc12
4273,993439,10.6019/CHEMBL2448688,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,CO/N=C(\C)c1ccc(-n2ccnc2)c(NC(=O)c2cnc(-c3ccccc3)cn2)c1,,8.0,uM,=,0.9030899869919436,1,O=C(Nc1ccccc1-n1ccnc1)c1cnc(-c2ccccc2)cn1
4274,2062192,10.1016/j.bmcl.2016.04.018,,,,Inhibition of human liver microsomes CYP3A4 using testosterone as substrate by MUX-MS/MS analysis,FC(F)(F)c1cccc(Nc2nnc3n2CCOc2ccc(-c4ccncc4)cc2-3)c1,"10-(pyridin-4-yl)-N-(3-(trifluoromethyl)phenyl)-5,6-dihydrobenzo[f][1,2,4]triazolo[4,3-d][1,4]oxazepin-3-amine",0.516,uM,=,-0.2873502983727886,0,c1ccc(Nc2nnc3n2CCOc2ccc(-c4ccncc4)cc2-3)cc1
4275,436456,10.1021/jm061195+,,,,Inhibition of human CYP3A4,O=C(NCC1CCOCC1)c1cnc(Nc2cccc(Cl)c2)nc1C(F)(F)F,2-(3-chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(tetrahydropyran-4-ylmethyl)amide,51.0,uM,=,1.7075701760979365,1,O=C(NCC1CCOCC1)c1cnc(Nc2ccccc2)nc1
4276,449485,10.1016/j.bmcl.2007.07.097,,,,Inhibition of microsomal CYP3A4,CC(C)C[C@H](NCCN)c1cc(C(F)(F)F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1,"1-((R)-1-(4-(2-((S)-1-(2-aminoethylamino)-3-methylbutyl)-4-(trifluoromethyl)phenyl)piperazin-1-yl)-3-(2,4-dichlorophenyl)-1-oxopropan-2-yl)pyrrolidin-2-one",6.3,uM,=,0.7993405494535817,1,O=C([C@@H](Cc1ccccc1)N1CCCC1=O)N1CCN(c2ccccc2)CC1
4277,1366898,10.1021/jm500312x,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 15 mins by LC/MS/MS analysis,C=C[C@]1(C)C[C@@H](OC(=O)CSc2cncc(N)c2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O,14-O-(((5-Aminopyridin-3-yl)sulfanyl)acetyl)mutilin,0.0444,uM,=,-1.35261702988538,0,O=C(CSc1cccnc1)O[C@@H]1CCCC[C@@]23CCCC1[C@@H]2C(=O)CC3
4278,1659434,10.1021/acs.jmedchem.6b01662,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH by LC-MS/MS analysis,COc1ccc2c(c1)c(CN1CCN(C)CC1)cn2S(=O)(=O)c1ccc(F)cc1.CS(=O)(=O)O.CS(=O)(=O)O,1-[(4-Fluorophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole Dimesylate,1.71,uM,=,0.2329961103921538,1,O=S(=O)(c1ccccc1)n1cc(CN2CCNCC2)c2ccccc21
4279,1441252,10.1021/jm5010013,,,,Inhibition of CYP3A4 (unknown origin),O=C(O)c1cc(F)ccc1NC(=O)N1C[C@H]2C[C@@H](c3ccccc3C(F)(F)F)C[C@H]2C1,"trans-5-fluoro-2-((3aR,6aS)-5-(2-(trifluoromethyl)phenyl)octahydrocyclopenta[c]pyrrole-2-carboxamido)benzoic acid",53.0,uM,=,1.7242758696007892,1,O=C(Nc1ccccc1)N1C[C@H]2C[C@@H](c3ccccc3)C[C@H]2C1
4280,1467194,10.1021/jm5005336,,,,Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay,CN(C)Cc1ccc(/C=C/c2n[nH]c3cc([C@@H]4C[C@@]45C(=O)Nc4ccccc45)ccc23)cc1,"(1R*,2S*)-(E)-2-(3-(4-((Dimethylamino)methyl)styryl)-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-one",10.0,uM,=,1.0,1,O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccccc3)n[nH]c2c1
4281,474877,10.1021/jm701097z,,,,Inhibition of CYP3A4,COc1cc2nccc(Oc3ccc4c(C(=O)Nc5ccncc5)cccc4c3)c2cc1OC,"6-(6,7-dimethoxyquinolin-4-yloxy)-N-(pyridin-4-yl)-1-naphthamide",0.1,uM,=,-1.0,0,O=C(Nc1ccncc1)c1cccc2cc(Oc3ccnc4ccccc34)ccc12
4282,1491683,10.1124/dmd.112.045708,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate addition by LC-MS/MS analysis,CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1,"(R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide",20.0,uM,=,1.3010299956639813,1,O=C(Cc1ccccc1)N(Cc1cccnc1)Cc1nc2ncccc2c(=O)n1-c1ccccc1
4283,1459303,10.1016/j.bmc.2014.06.027,,,,Inhibition of CYP3A4 in supersomes (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate after 30 mins,NS(=O)(=O)c1cccc(-c2n[nH]c3ccc(NC(=O)C(c4ccsc4)N4CCCC4)cc23)c1,(+/-)-2-(Pyrrolidin-1-yl)-N-(3-(3-sulfamoylphenyl)-1Hindazol-5-yl)-2-(thiophen-3-yl)acetamide,4.0,uM,=,0.6020599913279624,1,O=C(Nc1ccc2[nH]nc(-c3ccccc3)c2c1)C(c1ccsc1)N1CCCC1
4284,2164739,10.1021/acs.jmedchem.1c02131,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate,CC(C)C[C@](C)(N)COc1ccc(-c2ccncc2)cc1C(F)(F)F,"(S)-2,4-Dimethyl-1-(4-(pyridin-4-yl)-2-trifluoromethylphenoxy)-pentan-2-amine",0.63,uM,=,-0.2006594505464183,0,c1ccc(-c2ccncc2)cc1
4285,768817,10.1021/jm2005354,,,,Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting,CNC(=O)NCCC[C@]1(c2ccc(F)cc2)CCN([C@@H](C)c2ccc(-c3ccc(F)cc3F)cc2)C(=O)O1,"1-(3-((R)-3-((S)-1-(2',4'-difluorobiphenyl-4-yl)ethyl)-6-(4-fluorophenyl)-2-oxo-1,3-oxazinan-6-yl)propyl)-3-methylurea",0.6,uM,=,-0.2218487496163563,0,O=C1OC(c2ccccc2)CCN1Cc1ccc(-c2ccccc2)cc1
4286,1295469,10.1016/j.bmcl.2014.02.004,,,,Inhibition of human recombinant CYP3A4,O=C(O)c1sc(N2CCOCC2)nc1CC(=O)N1CCc2c(Br)cccc21,4-(2-(4-bromoindolin-1-yl)-2-oxoethyl)-2-morpholinothiazole-5-carboxylic acid,40.0,uM,=,1.6020599913279625,1,O=C(Cc1csc(N2CCOCC2)n1)N1CCc2ccccc21
4287,1661010,10.1016/j.bmcl.2017.02.047,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 10 mins followed by NADPH addition measured after 10 mins,CCCCC/C=C/C(=O)CCc1ccc(O)c(OC)c1,(E)-1-(4-Hydroxy-3-methoxy-phenyl)-dec-4-en-3-one,8.3,uM,=,0.919078092376074,1,c1ccccc1
4288,1434727,10.1021/jm5010539,,,,Inhibition of human recombinant CYP3A4 expressed in Escherichia coli bactosomes using 7-benzloxyquinolone as substrate after 10 mins by fluorescence assay,CC(=O)N1c2ccc(-c3ccc(CN4CCCCC4)cc3)cc2[C@H](Nc2ccccc2)C[C@@H]1C,"rac-cis-1-((2S*,4R*)-2-Methyl-4-(phenylamino)-6-(4-(piperidin-1-ylmethyl)phenyl)-3,4-dihydroquinolin-1(2H)-yl)ethanone",10.0,uM,=,1.0,1,c1ccc(N[C@@H]2CCNc3ccc(-c4ccc(CN5CCCCC5)cc4)cc32)cc1
4289,1886565,10.1021/acs.jmedchem.8b02021,,,,Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay,COC(=O)c1ccc(COc2ccc3nc(N)sc3c2)cc1,Methyl 4-(((2-Aminobenzo[d]thiazol-6-yl)oxy)methyl)benzoate,10.0,uM,=,1.0,1,c1ccc(COc2ccc3ncsc3c2)cc1
4290,1641295,,,,,"CYP Inhibition Assay (With Preincubation): With Preincubation: To a 96 deep well plate was added 2.5 uL of the test substance solution (x200 concentration), and 442.5 uL of Incubation Mixture, and the solution was mixed and warmed to 37° C. for 5 minutes. To this incubation solution 50 uL of 10 mM NADPH was added and preincubated at 37° C. for 30 minutes. After the preincubation, 5 uL of the substrate solution was added and the solution was mixed and further incubated at 37° C. for 5 minutes for the reaction. After the reaction, 100 uL of the Incubation Mixture was removed, added to 150 uL of isopropanol containing IS and mixed. This mixture was transferred onto a multi-screen filter, centrifuged at 500xg at 4° C. for 10 minutes. The filtrate was used for LC-MS/MS analysis.",CCCCCCCC(F)(F)CCCCCC/C=C/[C@H](C(O)N[C@@H](Cc1ccc(OCCCC)cc1)C(=O)OC)[C@@](O)(CCOC)C(=O)O,"US9266853, 5514403",11.9,uM,=,1.0755469613925308,1,c1ccccc1
4291,4333,10.1021/jm00093a015,,,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,"1-(4-{4-[2-(2,4-Dichloro-phenyl)-2-imidazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-ethanone (ketoconazole)",0.786,uM,=,-0.104577453960592,0,c1ccc(C2(Cn3ccnc3)OCC(COc3ccc(N4CCNCC4)cc3)O2)cc1
4292,970079,10.1021/jm4004076,,,,Inhibition of CYP3A4 in human liver microsomes assessed as midazolam hydroxylation to 1'-Hydroxymidazolam after 7 mins by LC-MS/MS analysis,CN1CCN(CCC(=O)Nc2ccc3ncnc(Nc4ccc(NC(=O)Nc5cc(C(C)(C)C)nn5-c5cccc(N)c5)cc4)c3c2)CC1,N-(4-(4-(3-(1-(3-Aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl)-ureido)phenylamino)quinazolin-6-yl)-3-(4-methylpiperazin-1-yl)-propanamide,1.95,uM,=,0.290034611362518,1,O=C(CCN1CCNCC1)Nc1ccc2ncnc(Nc3ccc(NC(=O)Nc4ccnn4-c4ccccc4)cc3)c2c1
4293,701747,10.1021/ml100190t,,,,Inhibition of CYP3A4 uisng testosterone substrate,O=C(Nc1cnccn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1,N-Pyrazin-2-yl-4-(3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}benzylidene)piperidine-1-carboxamide,23.5,uM,=,1.3710678622717365,1,O=C(Nc1cnccn1)N1CCC(=Cc2cccc(Oc3ccccn3)c2)CC1
4294,1526216,10.1021/ml500526p,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,Cn1c(Nc2cc(C(C)(C)C)ccc2F)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21,N-(5-tert-butyl-2-fluorophenyl)-1-methyl-5-(2-(5-(trifluoromethyl)-1H-imidazol-2-yl)pyridin-4-yloxy)-1H-benzo[d]imidazol-2-amine,3.3,uM,=,0.5185139398778875,1,c1ccc(Nc2nc3cc(Oc4ccnc(-c5ncc[nH]5)c4)ccc3[nH]2)cc1
4295,473932,10.1021/jm701121y,,,,Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay,CS(=O)(=O)Cc1cc(N2CCCC2)nc(-c2ccncc2)n1,4-(methylsulfonylmethyl)-2-(pyridin-4-yl)-6-(pyrrolidin-1-yl)pyrimidine,1.3,uM,=,0.1139433523068367,1,c1cc(-c2nccc(N3CCCC3)n2)ccn1
4296,1741066,10.1021/acs.jmedchem.8b00450,,,,Inhibition of human CYP3A4,CN(C[C@H]1Cc2c(cccc2N2CCN(Cc3ccccn3)CC2)CN1)[C@H]1CCCc2cccnc21,"(S)-N-methyl-N-(((R)-5-(4-(pyridin-2-ylmethyl)piperazin-1-yl)-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)-5,6,7,8-tetrahydroquinolin-8-amine",6.79,uM,=,0.8318697742805017,1,c1ccc(CN2CCN(c3cccc4c3C[C@H](CN[C@H]3CCCc5cccnc53)NC4)CC2)nc1
4297,1911030,10.1021/acs.jmedchem.8b01226,,,,Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins,CCOC(=O)N1CCC(=CC#Cc2cccc(Cl)c2)CC1,Ethyl 4-[3-(3-Chlorophenyl)prop-2-yn-1-ylidene]piperidine-1-carboxylate,12.8,uM,=,1.1072099696478683,1,C(#Cc1ccccc1)C=C1CCNCC1
4298,51928,10.1021/jm034111v,,,,Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 45 minutes,CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@H](N(C)C)[C@H]3OC(C)=O)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O,"Acetic acid 14-(3-acetoxy-4-dimethylamino-6-methyl-tetrahydro-pyran-2-yloxy)-12-(5-acetoxy-4-methoxy-6-methyl-tetrahydro-pyran-2-yloxy)-5,7,8,11,13,15-hexamethyl-4,10-dioxo-1,9-dioxa-spiro[2.13]hexadec-6-yl ester",16.0,uM,=,1.2041199826559248,1,O=C1C[C@@H](O[C@H]2CCCCO2)C[C@@H](O[C@H]2CCCCO2)CC[C@@]2(CO2)C(=O)CCCCO1
4299,1923723,10.1021/acs.jmedchem.5b01871,,,,Inhibition of human CYP3A4,CC1=C(CC(=O)NCc2cc(Cl)ccc2CN)C(=O)N(NCc2ccccc2)CC1,"N-(2-(aminomethyl)-5-chlorobenzyl)-2-(1-(benzylamino)-4-methyl-2-oxo-1,2,5,6-tetrahydropyridin-3-yl)acetamide",13.0,uM,=,1.1139433523068367,1,O=C(CC1=CCCN(NCc2ccccc2)C1=O)NCc1ccccc1
4300,860549,10.1021/jm3003747,,,,Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins,CC(C)(C(N)=O)N1CCN(Cc2cc3nc(-c4c(F)ccc5[nH]ccc45)nc(N4CCOCC4)c3s2)CC1,"2-(4-((2-(5-Fluoro-1H-indol-4-yl)-4-morpholinothieno[3,2-d]-pyrimidin-6-yl)methyl)piperazin-1-yl)-2-methylpropanamide",1.5,uM,=,0.1760912590556812,1,c1cc(-c2nc(N3CCOCC3)c3sc(CN4CCNCC4)cc3n2)c2cc[nH]c2c1
4301,862399,10.1021/jm300601d,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis,N#Cc1cccc(C(=O)N2CCC(c3ccc(C(=O)NC(=N)N)cc3C(F)(F)F)CC2)c1,N-{4-[1-(3-Cyano-benzoyl)-piperidin-4-yl]-3-trifluoromethyl-benzoyl}-guanidine,22.0,uM,=,1.3424226808222062,1,O=C(c1ccccc1)N1CCC(c2ccccc2)CC1
4302,539794,10.1021/jm8005405,,,,Inhibition of CYP3A4 in human liver microsomes,CCNc1noc2c(-c3ccc4c(N5CCOC[C@@H]5C)nncc4c3)c(C)ccc12,N-Ethyl-6-methyl-7-(1-((S)-3-methylmorpholino)phthalazin-6-yl)benzo[d]isoxazol-3-amine,10.0,uM,=,1.0,1,c1cc(-c2ccc3c(N4CCOCC4)nncc3c2)c2oncc2c1
4303,51903,10.1021/jm020557k,,,,Concentration required to inhibit cytochrome P450 3A4.,CCCCOc1ccc(-c2cc[nH]n2)cc1,5-(4-Butoxy-phenyl)-1H-pyrazole,70.6,uM,=,1.848804701051804,1,c1ccc(-c2cc[nH]n2)cc1
4304,1866304,10.1021/acs.jmedchem.9b00662,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as substrate,O[C@H](C[C@H]1c2c(F)cccc2-c2cncn21)[C@H]1CC[C@H](O)CC1,NAVOXIMOD,15.0,uM,=,1.1760912590556811,1,c1ccc2c(c1)-c1cncn1[C@H]2CCC1CCCCC1
4305,828928,10.1016/j.bmcl.2012.06.022,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(NC3CCN(C)CC3)oc2c1,"thiazol-5-ylmethyl(2S,3R)-3-hydroxy-4-(N-isobutyl-2-(1-methylpiperidin-4-ylamino)benzo[d]oxazole-6-carboxamido)-1-phenylbutan-2-ylcarbamate",2.7,uM,=,0.4313637641589873,1,O=C(N[C@H](CCNC(=O)c1ccc2nc(NC3CCNCC3)oc2c1)Cc1ccccc1)OCc1cncs1
4306,2246941,10.1021/acs.jmedchem.1c02132,,,,Inhibition of CYP3A4 (unknown origin) incubated for 10 mins in presence of NADPH by LC-MS/MS analysis,CC(=O)Nc1cc(-c2cc(F)c(OC[C@@H](N)CC(C)C)c(C(F)(F)F)c2)ccn1,(S)-N-(4-(4-((2-amino-4-methylpentyl)oxy)-3-fluoro-5-(trifluoromethyl)phenyl)pyridin-2-yl)acetamide,0.47,uM,=,-0.3279021420642826,0,c1ccc(-c2ccncc2)cc1
4307,834929,10.1016/j.bmcl.2012.07.020,,,,Inhibition of CYP3A4,CCCS(=O)(=O)c1ccc2[nH]c(-c3cccc(C(F)(F)F)c3)nc2c1,5-(propylsulfonyl)-2-(3-(trifluoromethyl)phenyl)-1H-benzo[d]imidazole,20.0,uM,=,1.3010299956639813,1,c1ccc(-c2nc3ccccc3[nH]2)cc1
4308,1625798,10.1016/j.bmcl.2016.10.054,,,,Inhibition of CYP3A4 (unknown origin),Cc1cc(-c2cc(OC(F)(F)F)ccc2Cl)cc(C)c1OCCCC(=O)O,"4-(2'-chloro-3,5-dimethyl-5'-(trifluoromethoxy)biphenyl-4-yloxy)butanoic acid",3.28,uM,=,0.5158738437116791,1,c1ccc(-c2ccccc2)cc1
4309,455108,10.1016/j.bmcl.2006.12.043,,,,Inhibition of CYP3A4,O=C([C@H](O)c1ccccc1Cl)N1CCN(c2ccc3[nH]ncc3c2)CC1,(R)-1-(4-(1H-indazol-5-yl)piperazin-1-yl)-2-(2-chlorophenyl)-2-hydroxyethanone,8.0,uM,=,0.9030899869919436,1,O=C(Cc1ccccc1)N1CCN(c2ccc3[nH]ncc3c2)CC1
4310,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)NCc6ccccc6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, D-93",20.39,uM,=,1.30941722577814,1,O=C(NCc1ccccc1)Nc1ccc(-c2c[nH]c3c(CN4C[C@@H]5N(C(=O)NCc6ccccc6)NCC(=O)N5[C@@H](Cc5ccccc5)C4=O)cccc23)cn1
4311,815100,10.1016/j.bmcl.2012.03.040,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,COc1cc(NC(=O)c2ccccc2F)ccc1-c1nnc(NCCCN2CCCCC2)o1,"2-fluoro-N-(3-methoxy-4-(5-(3-(piperidin-1-yl)propylamino)-1,3,4-oxadiazol-2-yl)phenyl)benzamide",48.0,uM,=,1.6812412373755872,1,O=C(Nc1ccc(-c2nnc(NCCCN3CCCCC3)o2)cc1)c1ccccc1
4312,753598,10.1016/j.bmcl.2011.05.013,,,,Time dependent inhibition of CYP3A4 assessed as conversion of testosterone to 6-beta-hydroxytestosterone,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccn(C)c(=O)c2)C2CC2)cc(Br)c1C,"(3R,4S)-N-(3-bromo-5-(3-methoxypropyl)-4-methylbenzyl)-N-cyclopropyl-4-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)piperidine-3-carboxamide",20.0,uM,=,1.3010299956639813,1,O=C([C@H]1CNCC[C@@H]1c1cc[nH]c(=O)c1)N(Cc1ccccc1)C1CC1
4313,766553,10.1016/j.bmcl.2011.06.102,,,,Inhibition of CYP3A4,c1cc([C@H]2CC[C@@H](N3CCCC3)CC2)ccc1OCCCN1CCCCC1,cis-1-(3-(4(4-(pyrrolidin-1-yl)cyclohexyl)phenoxy)propyl)piperidine,41.7,uM,=,1.6201360549737576,1,c1cc([C@H]2CC[C@@H](N3CCCC3)CC2)ccc1OCCCN1CCCCC1
4314,437628,10.1016/j.bmcl.2006.10.036,,,,Inhibition of CYP3A4,CC(C)Nc1cc2c(cc1NS(=O)(=O)c1ccc(-c3ccc(Cl)cc3)cc1)CCN(C)CC2,"4'-chloro-biphenyl-4-sulfonic acid (8-isopropylamino-3-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-amide",7.5,uM,=,0.8750612633917001,1,O=S(=O)(Nc1ccc2c(c1)CCNCC2)c1ccc(-c2ccccc2)cc1
4315,2278020,10.1021/acs.jmedchem.2c01517,,,,Inhibition of CYP3A4 in human liver microsome suspension using midazolam substrate incubated for 30 mins by LC/MS analysis,Cc1nc(N[C@H](C)c2cccc(C(F)F)c2F)c2cc3c(cc2n1)OC[C@H]1CN(C(=O)[C@H]2CCOC2)CCN31,"((R)-11-(((R)-1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)amino)-9-methyl-1,2,4a,5-tetrahydropyrazino[1',2':4,5][1,4]oxazino[3,2-g]quinazolin-3(4H)-yl)((S)-tetrahydrofuran-3-yl)methanone",79.0,uM,=,1.8976270912904407,1,O=C([C@H]1CCOC1)N1CCN2c3cc4c(NCc5ccccc5)ncnc4cc3OC[C@H]2C1
4316,1923841,10.1021/acs.jmedchem.6b00280,,,,Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase and human b5 reductase assessed as reduction in 7-Hydroxyquinoline production using 7-benzyloxyquinoline as substrate and NADPH incubated for 15 mins by fluorimetry,CCCCOc1ccc2nnc(Sc3ccc4nc(NC(=O)NCCN5CCOCC5)sc4c3)n2n1,"1-(6-(6-butoxy-[1,2,4]triazolo[4,3-b]pyridazin-3-ylthio)benzo[d]thiazol-2-yl)-3-(2-morpholinoethyl)urea",8.7,uM,=,0.9395192526186184,1,O=C(NCCN1CCOCC1)Nc1nc2ccc(Sc3nnc4cccnn34)cc2s1
4317,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",O=C(c1cc(Cl)ccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2ncccn2)c1,"US9150566, 51",20.0,uM,=,1.3010299956639813,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2ncccn2)c1
4318,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1ccc(C(=O)N2CCOC[C@H]2Cc2cc(-c3ncccn3)ccc2F)c(-n2nccn2)c1C,"US9150566, 158",40.0,uM,=,1.6020599913279625,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2ncccn2)c1
4319,1465594,10.1016/j.bmcl.2015.02.039,,,,Inhibition of CYP3A4 (unknown origin) using midazolam fluorometric substrate,COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2NC(=O)OCC2CCCCC2)C(C)C)ccc1OC,"cyclohexylmethyl (3S,4S)-4-((N-isopropyl-4-methoxy-3-(3-methoxypropoxy)benzamido)methyl)pyrrolidin-3-ylcarbamate",3.2,uM,=,0.505149978319906,1,O=C(N[C@@H]1CNC[C@H]1CNC(=O)c1ccccc1)OCC1CCCCC1
4320,479364,10.1016/j.bmcl.2008.05.027,,,,Inhibition of CYP3A4,O=C(Cn1c(=O)cnc2cc(Cl)c(Cl)cc21)N1CCCC(c2ccccc2)C1CN1CCOCC1,"rac-6,7-dichloro-1-(2-(2-(morpholinomethyl)-3-phenylpiperidin-1-yl)-2-oxoethyl)quinoxalin-2(1H)-one",1.0,uM,=,0.0,0,O=C(Cn1c(=O)cnc2ccccc21)N1CCCC(c2ccccc2)C1CN1CCOCC1
4321,983478,10.1021/jm400564j,,,,Inhibition of CYP3A4 (unknown origin) using Vivid BOMR as substrate,CCc1nc2c(Cc3ccc(C(=O)NO)cc3)cccc2c(=O)n1CCc1ccccc1,"4-((2-Ethyl-4-oxo-3-phenethyl-3,4-dihydroquinazolin-8-yl)-methyl)-N-hydroxybenzamide",0.1,uM,=,-1.0,0,O=c1c2cccc(Cc3ccccc3)c2ncn1CCc1ccccc1
4322,1453969,10.1021/ml5001728,,,,Inhibition of CYP3A4 (unknown origin),COc1cnc2ccc(=O)n(CCN3CCN(c4nc5cc(C#N)c(C)cc5[nH]4)CC3)c2c1,"2-(4-(2-(7-methoxy-2-oxo-1,5-naphthyridin-1(2H)-yl)ethyl)piperazin-1-yl)-6-methyl-1H-benzo[d]imidazole-5-carbonitrile",20.0,uM,=,1.3010299956639813,1,O=c1ccc2ncccc2n1CCN1CCN(c2nc3ccccc3[nH]2)CC1
4323,1301328,10.6019/CHEMBL3137440,,,,DNDI: CYP Inhibition,N#Cc1ccc(N2CCC(N(c3ccc(C(F)(F)F)cc3)c3cccnc3)CC2)cc1,4-(4-(pyridin-3-yl(4-(trifluoromethyl)phenyl)amino)piperidin-1-yl)benzonitrile,4.0,uM,=,0.6020599913279624,1,c1ccc(N2CCC(N(c3ccccc3)c3cccnc3)CC2)cc1
4324,555225,10.1016/j.bmcl.2008.05.058,,,,Inhibition of CYP3A4,CN(CC(=O)N(C)C(CN1CCOCC1)c1ccc(-c2ccccc2)cc1)c1ccc(Cl)c(Cl)c1,"N-(1-Biphenyl-4-yl-2-morpholin-4-yl-ethyl)-2-[(3,4-dichloro-phenyl)-methyl-amino]-N-methyl-acetamide",2.1,uM,=,0.3222192947339193,1,O=C(CNc1ccccc1)NC(CN1CCOCC1)c1ccc(-c2ccccc2)cc1
4325,2291491,10.1021/acs.jmedchem.2c01938,,,,Inhibition of CYP3A4 in pooled human liver microsomes using testosterone as substrate assessed as reduction in 6-OH-testosterone metabolite formation by LC-MS/MS analysis,C=CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4cc(OC)c(C)c(OC)c4)nn32)CC1,"(S)-7-(1-acryloylpiperidin-4-yl)-2-(3,5-dimethoxy-4-methylphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide",55.8,uM,=,1.7466341989375789,1,c1ccc(-c2cc3n(n2)[C@H](C2CCNCC2)CCN3)cc1
4326,519908,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate,Cc1ccccc1CNc1cc(-n2cncn2)cn2c(C)c(C)nc12,"2,3-dimethyl-N-(2-methylbenzyl)-6-(1H-1,2,4-triazol-1-yl)imidazo[1,2-a]pyridin-8-amine",3.8,uM,=,0.5797835966168101,1,c1ccc(CNc2cc(-n3cncn3)cn3ccnc23)cc1
4327,834929,10.1016/j.bmcl.2012.07.020,,,,Inhibition of CYP3A4,CCS(=O)(=O)c1ccc2[nH]c(-c3cccc(-c4ccccc4)n3)nc2c1,5-(ethylsulfonyl)-2-(6-phenylpyridin-2-yl)-1H-benzo[d]imidazole,7.7,uM,=,0.8864907251724818,1,c1ccc(-c2cccc(-c3nc4ccccc4[nH]3)n2)cc1
4328,1491689,10.1124/dmd.112.045708,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 90 mins followed by substrate addition by LC-MS/MS analysis in presence of NADPH,CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1,"(R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide",27.0,uM,=,1.4313637641589874,1,O=C(Cc1ccccc1)N(Cc1cccnc1)Cc1nc2ncccc2c(=O)n1-c1ccccc1
4329,828928,10.1016/j.bmcl.2012.06.022,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N)oc2c1,"Thiazol-5-ylmethyl(2S,3R)-4-(2-amino-N-isobutylbenzo[d]oxazole-6-carboxamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate",0.042,uM,=,-1.3767507096020994,0,O=C(N[C@H](CCNC(=O)c1ccc2ncoc2c1)Cc1ccccc1)OCc1cncs1
4330,768817,10.1021/jm2005354,,,,Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting,C[C@@H](c1ccc(-c2ccc(F)cc2F)cc1)N1CC[C@](CCCN)(c2ccc(F)cc2)OC1=O,"(R)-6-(3-aminopropyl)-3-((S)-1-(2',4'-difluorobiphenyl-4-yl)ethyl)-6-(4-fluorophenyl)-1,3-oxazinan-2-one",2.0,uM,=,0.3010299956639812,1,O=C1OC(c2ccccc2)CCN1Cc1ccc(-c2ccccc2)cc1
4331,1661019,10.1016/j.bmcl.2017.02.047,,,,Inhibition of recombinant human CYP3A4 expressed in baculosomes using Vivid BOMCC substrate blue measured every 30 sec for 30 mins by fluorescence assay,CCCCCCC[C@H](O)CC(=O)CCc1ccc(O)c(OC)c1,8-Gingerol,8.7,uM,=,0.9395192526186184,1,c1ccccc1
4332,2204356,10.1016/j.bmc.2022.116894,,,,Inhibition of CYP3A4 (unknown origin) using BOMCC as a substrate,CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,SID144204227,0.0551,uM,=,-1.2588484011482148,0,c1ccc([C@@]2(Cn3ccnc3)OC[C@H](COc3ccc(N4CCNCC4)cc3)O2)cc1
4333,1778315,10.1016/j.bmcl.2018.06.040,,,,Inhibition of CYP3A4 (unknown origin),N#Cc1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1,"N-(4-(1H-pyrrolo[2,3-b]pyridin-3-yl)thiazol-2-yl)-2-(3-cyanophenyl)acetamide",2.5,uM,=,0.3979400086720376,1,O=C(Cc1ccccc1)Nc1nc(-c2c[nH]c3ncccc23)cs1
4334,619265,10.1016/j.bmcl.2009.07.002,,,,Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate,Cc1cccc(C)c1CNc1nccc2c1nc(C)n2C,"N-(2,6-dimethylbenzyl)-1,2-dimethyl-1H-imidazo[4,5-c]pyridin-4-amine",21.0,uM,=,1.3222192947339193,1,c1ccc(CNc2nccc3[nH]cnc23)cc1
4335,686484,10.1016/j.bmcl.2010.09.122,,,,Inhibition of CYP3A4,CN1CCc2c(n(C)c3cc(-n4ccc(OCc5ccccc5)cc4=O)ccc23)C1,"4-(benzyloxy)-1-(2,9-dimethyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-7-yl)pyridin-2(1H)-one",24.0,uM,=,1.380211241711606,1,O=c1cc(OCc2ccccc2)ccn1-c1ccc2c3c([nH]c2c1)CNCC3
4336,2025266,10.1016/j.bmcl.2020.127738,,,,Inhibition of CYP3A4 (unknown origin),C[C@H](C(=O)Nc1ccc(Cl)cc1)[C@H]1CC[C@]2(CC1)COc1cc(C(F)(F)F)ccc12,"(S)-N-(4-chlorophenyl)-2-((1'R,4's)-6-(trifluoromethyl)-2H-spiro[benzofuran-3,1'-cyclohexane]-4'-yl)propanamide",3.1,uM,=,0.4913616938342727,1,O=C(C[C@H]1CC[C@]2(CC1)COc1ccccc12)Nc1ccccc1
4337,1619514,10.1021/acs.jmedchem.6b01276,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate assessed as suppression of 1'-hydroxymidazolam formation after 10 mins by LC-MS/MS analysis,CC1(C)[C@@H]2CC[C@@]1(C)[C@@H](NC(=O)[C@H](CC1CCCCC1)NS(=O)(=O)N[C@@H](CCCCN)C(=O)O)C2.Cl,"(S)-6-Amino-2-{[(S)-2-cyclohexyl-1-((1R,2S,4R)-1,7,7-trimethyl-bicyclo[2.2.1]hept-2-ylcarbamoyl)-ethylsulfamidyl]}-hexanoic acid hydrochloride",12.0,uM,=,1.0791812460476249,1,O=C(CCC1CCCCC1)N[C@H]1C[C@H]2CCC1C2
4338,464738,10.1016/j.bmcl.2008.01.126,,,,Inhibition of CYP3A4 in presence of 7-benzyloxy-4-trifluoromethyl coumarin substrate,COc1ccc(N2C(=O)[C@@H](Cc3ccc(OCCc4nc(-c5ccccc5)oc4C)cc3)[C@H]2C(=O)O)cc1,"(2S,3S)-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-1-(4-methoxyphenyl)-4-oxoazetidine-2-carboxylic acid",33.0,uM,=,1.5185139398778875,1,O=C1[C@@H](Cc2ccc(OCCc3coc(-c4ccccc4)n3)cc2)CN1c1ccccc1
4339,991614,10.1021/jm4008906,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,COCCN1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O,"rac-3-(Aminomethyl)-4-(2,4-dichlorophenyl)-6-(2-methoxyethyl)-2-methyl-6,7-dihydropyrrolo[3,4-b]pyridin-5-one",14.0,uM,=,1.146128035678238,1,O=C1NCc2nccc(-c3ccccc3)c21
4340,863248,10.1021/jm300663n,,,,Inhibition of CYP3A4,Cc1ccccc1[C@H](CC(=O)O)NC(=O)c1cc(OCC2CC2)n(-c2ccccc2F)n1,(S)-3-{[5-Cyclopropylmethoxy-1-(2-fluoro-phenyl)-1H-pyrazole-3-carbonyl]-amino}-3-o-tolyl-propionic acid,0.015,uM,=,-1.8239087409443189,0,O=C(NCc1ccccc1)c1cc(OCC2CC2)n(-c2ccccc2)n1
4341,828928,10.1016/j.bmcl.2012.06.022,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,CCN(C)c1nc2ccc(C(=O)N(CCN3CCCC3)C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1,"thiazol-5-ylmethyl(2S,3R)-4-(2-(ethyl(methyl)amino)-N-(2-(pyrrolidin-1-yl)ethyl)benzo[d]oxazole-6-carboxamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate",0.14,uM,=,-0.8538719643217619,0,O=C(N[C@H](CCN(CCN1CCCC1)C(=O)c1ccc2ncoc2c1)Cc1ccccc1)OCc1cncs1
4342,632105,10.1016/j.bmcl.2010.03.057,,,,Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin,Cc1cc(N2CCN(CC(=O)NCCF)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,"(S)-2-(4-(2-(4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-2-oxo-1,2-dihydropyridin-3-yl)-4-methyl-1H-benzo[d]imidazol-6-yl)piperazin-1-yl)-N-(2-fluoroethyl)acetamide",2.4,uM,=,0.380211241711606,1,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(N3CCNCC3)cc2[nH]1
4343,1640556,,,,,"null: Microsomal preparation: One lobe of fresh pig liver is obtained (e.g., at about the time of slaughter from a food-processing company) and immediately placed in ice cold 15 mM KH2PO4/250 mM sucrose (pH 7.4) and kept on ice during transportation. A 10 g sample of liver is minced and homogenized in 30 mL of homogenization buffer (15 mM KH2PO4/250 mM sucrose) using a Tekmar homoginizer or equivalent by pulsing 3 times with 20 second pulses. This procedure is repeated for a total of 8x10 g samples of pig liver. The remaining pig liver may be stored at -80 C. The homogenates from the 8 samples are pooled and centrifuged at 13,000xg for 20 minutes at 4 C. to remove crude debris. The supernatant is further centrifuged at 100,000xg for 70 minutes at 4° C. The microsomal pellets are re-suspended into 50 mL of 150 mM KH2PO4/1 mM DTT (pH 7.4) and 1 mL aliquots are stored at -80 C.100-150 ug of pig liver microsomal protein in 150 mM KH2PO4 is incubated at 37° C.",Cc1nccn1Cc1ccccc1,1-Benzyl-2-methyl-1H-imidazole,307.5,uM,=,2.4878451201114355,1,c1ccc(Cn2ccnc2)cc1
4344,828928,10.1016/j.bmcl.2012.06.022,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,CC(C)(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N3CCCC3)oc2c1,"thiazol-5-ylmethyl(2S,3R)-3-hydroxy-4-(N-neopentyl-2-(pyrrolidin-1-yl)benzo[d]oxazole-6-carboxamido)-1-phenylbutan-2-ylcarbamate",0.027,uM,=,-1.5686362358410126,0,O=C(N[C@H](CCNC(=O)c1ccc2nc(N3CCCC3)oc2c1)Cc1ccccc1)OCc1cncs1
4345,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2C(CN(Cc3cccc4c(C(=O)Nc5ccc(OC)nc5)cn(C)c34)C(=O)[C@@H]2Cc2ccc(O)cc2)N1C(=O)NCc1ccccc1,"US8940739, G-5",2.16,uM,=,0.3344537511509309,1,O=C(Nc1cccnc1)c1c[nH]c2c(CN3CC4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12
4346,1931354,10.1016/j.bmcl.2019.07.037,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam pre-incubated for 10 mins before NADPH addition and measured after 10 mins by LC/MS/MS analysis,CC(C)OC(=O)[C@H](Cn1ccnc1)NC(=O)c1ccc(-c2ccccc2)c(F)c1,"isopropyl (S)-2-(2-fluoro-[1,1'-biphenyl]-4-carboxamido)-3-(1H-imidazol-1-yl)propanoate",4.05,uM,=,0.6074550232146685,1,O=C(NCCn1ccnc1)c1ccc(-c2ccccc2)cc1
4347,1992483,10.1021/acs.jmedchem.0c01199,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate incubated for 10 mins in presence of NADPH by LC/MS/MS analysis,COc1cc(-c2cncc(-c3ccc(N4CCNCC4)cc3)c2C)cc(OC)c1F,"1-(4-(5-(4-Fluoro-3,5-dimethoxyphenyl)-4-methylpyridin-3-yl)phenyl)piperazine",14.3,uM,=,1.155336037465062,1,c1ccc(-c2cncc(-c3ccc(N4CCNCC4)cc3)c2)cc1
4348,775863,10.1016/j.bmcl.2011.09.037,,,,Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH,CN(C)C1CN(C(=O)[C@@H](COCc2ccccc2)NC(=O)c2cccnc2Oc2ccc(C(F)(F)F)cc2Cl)C1,(R)-N-(3-(benzyloxy)-1-(3-(dimethylamino)azetidin-1-yl)-1-oxopropan-2-yl)-2-(2-chloro-4-(trifluoromethyl)phenoxy)nicotinamide,5.4,uM,=,0.7323937598229685,1,O=C(N[C@H](COCc1ccccc1)C(=O)N1CCC1)c1cccnc1Oc1ccccc1
4349,1625607,10.1016/j.bmcl.2016.10.016,,,,Inhibition of human Cyp3A4 using testosterone as substrate by LC-MS/MS analysis,COCCS(=O)(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,"1-(4-{[(2S,4R)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)-4-(2-methoxyethanesulfonyl)piperazine",0.185,uM,=,-0.7328282715969863,0,c1ccc([C@]2(Cn3ccnc3)OC[C@@H](COc3ccc(N4CCNCC4)cc3)O2)cc1
4350,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN6CCN(C(=O)OC(C)(C)C)CC6C5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, E-47",2.2,uM,=,0.3424226808222063,1,O=C(c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12)N1CCN2CCNCC2C1
4351,519907,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,Cc1nc2c3c(c(-n4ccccc4=O)cn2c1C)CC[C@@H](c1ccccc1)N3,"(S)-1-(2,3-dimethyl-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridin-6-yl)pyridin-2(1H)-one",7.7,uM,=,0.8864907251724818,1,O=c1ccccn1-c1cn2ccnc2c2c1CC[C@@H](c1ccccc1)N2
4352,1534761,,,,,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",COc1ncc(F)cc1CNc1ncc(Cc2c[nH]c3ncc(C)cc23)cn1,"US9096593, P-2061",5.0,uM,=,0.6989700043360189,1,c1cncc(CNc2ncc(Cc3c[nH]c4ncccc34)cn2)c1
4353,509825,10.1021/jm800546t,,,,Inhibition of recombinant CYP3A4 expressed in insect microsomes after 20 mins in presence of BFC substrate,O=C(N[C@H](Cc1csc2ccccc12)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1,"(R)-N-(1-(1,4'-bipiperidin-1'-yl)-3-(benzo[b]thiophen-3-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide",0.084,uM,=,-1.0757207139381184,0,O=C(N[C@H](Cc1csc2ccccc12)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
4354,1823181,10.1021/acs.jmedchem.9b01247,,,,Inhibition of CYP3A4 (unknown origin),N#Cc1ccc(O[C@H]2CN(S(=O)(=O)c3ccc(Cl)cn3)C[C@@]2(O)CN)cc1F,"4-(((3S,4S)-4-(Aminomethyl)-1-((5-chloropyridin-2-yl)-sulfonyl)-4-hydroxypyrrolidin-3-yl)oxy)-2-fluorobenzonitrile",12.0,uM,=,1.0791812460476249,1,O=S(=O)(c1ccccn1)N1CC[C@@H](Oc2ccccc2)C1
4355,1295469,10.1016/j.bmcl.2014.02.004,,,,Inhibition of human recombinant CYP3A4,CC1Cc2c(Br)cccc2N1C(=O)Cc1nc(N2CCOCC2)sc1C(N)=O,(-)-4-(2-(4-bromo-2-methylindolin-1-yl)-2-oxoethyl)-2-morpholinothiazole-5-carboxamide,25.0,uM,=,1.3979400086720375,1,O=C(Cc1csc(N2CCOCC2)n1)N1CCc2ccccc21
4356,949159,10.1016/j.bmcl.2013.01.011,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,O=C(N[C@H](Cc1cc(I)c2[nH]c(=O)oc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1,"(R)-N-(1-(1,4'-bipiperidin-1'-yl)-3-(4-iodo-2-oxo-2,3-dihydrobenzo[d]oxazol-6-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide",32.0,uM,=,1.505149978319906,1,O=C(N[C@H](Cc1ccc2[nH]c(=O)oc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
4357,445973,10.1021/jm070428+,,,,Inhibition of human recombinant CYP3A4,O=C(Cn1ccnc1)c1ccc(-c2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)cn1,"(5R)-3-{3-fluoro-4-[6-(1H-imidazol-1-ylacetyl)pyridin-3-yl]-phenyl}-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one",0.3,uM,=,-0.5228787452803376,0,O=C(Cn1ccnc1)c1ccc(-c2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2)cn1
4358,742805,10.1016/j.bmc.2011.02.009,,,,Inhibition of human CYP3A4 after 30 mins,CC(C)C(O)(c1cccc(-c2ccc(F)cc2)c1)c1c[nH]cn1,"rac-1-(4'-Fluoro[1,1'-biphenyl]-3-yl)-1-(1H-imidazol-4-yl)-2-methyl-1-propanol",2.1,uM,=,0.3222192947339193,1,c1ccc(-c2cccc(Cc3c[nH]cn3)c2)cc1
4359,2133950,10.1016/j.ejmech.2021.113715,,,,Inhibition of CYP3A4 in human liver microsome incubated for 10 mins in the presence of NADPH by LC-MS/MS analysis,Fc1ccc(C2(Cn3cncn3)COC(c3ccc(-c4ccccc4F)cc3)=N2)cc1,"4-((1H-1,2,4-triazol-1-yl)methyl)-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-4-(4-fluorophenyl)-4,5-dihydrooxazole",14.8,uM,=,1.1702617153949575,1,c1ccc(-c2ccc(C3=NC(Cn4cncn4)(c4ccccc4)CO3)cc2)cc1
4360,449485,10.1016/j.bmcl.2007.07.097,,,,Inhibition of microsomal CYP3A4,Cc1ccc(N2CCN(C(=O)[C@@H](Cc3ccc(Cl)cc3Cl)N3CCCC3=O)CC2)c([C@H](CC(C)C)NC(=O)[C@@H](C)N)c1,"(R)-2-amino-N-((S)-1-(2-(4-((R)-3-(2,4-dichlorophenyl)-2-(2-oxopyrrolidin-1-yl)propanoyl)piperazin-1-yl)-5-methylphenyl)-3-methylbutyl)propanamide",2.9,uM,=,0.4623979978989561,1,O=C([C@@H](Cc1ccccc1)N1CCCC1=O)N1CCN(c2ccccc2)CC1
4361,856844,10.1021/jm300356u,,,,Inhibition of human recombinant CYP3A4 using 7-BQ as substrate preincubated for 5 to 10 mins before substrate addition,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H]3[C@H]2O/C(=N\C(C)C)N3C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,"(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-14-ethyl-7,12,13-trihydroxy-4-((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yloxy)-6-((3aR,4S,6R,7aS)-2-(isopropylimino)-1,6-dimethylhexahydro-1H-pyrano[4,3-d]oxazol-4-yloxy)-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione",9.8,uM,=,0.9912260756924948,1,N=C1N[C@H]2CCO[C@@H](O[C@H]3CCCC(=O)CCCCOC(=O)C[C@@H](O[C@H]4CCCCO4)C3)[C@@H]2O1
4362,2207925,10.1021/acsmedchemlett.2c00411,,,,Inhibition of CYP3A4 (unknown origin) in presence of NADPH,COc1cc(CF)cc(Nc2ncc(C)c(Nc3ccc4oc(=O)[nH]c4c3)n2)c1,5-(2-(3-(fluoromethyl)-5-methoxyphenylamino)-5methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)one,8.0,uM,=,0.9030899869919436,1,O=c1[nH]c2cc(Nc3ccnc(Nc4ccccc4)n3)ccc2o1
4363,950702,10.1021/jm400288z,,,,Inhibition of C-terminal His-tagged wild type CYP3A4 (unknown origin)-mediated hydroxylation of 7-benzyloxy-4-trifluoromethylcoumarin expressed in Escherichia coli after 5 mins by fluorimetric analysis,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cnco2)Cc2ccccc2)C(C)C)cs1,"Oxazol-5-ylmethyl(2R,5R)-5-((S)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-3-methylbutanamido)-1,6-diphenylhexan-2-ylcarbamate",3.4,uM,=,0.5314789170422551,1,O=C(CNC(=O)NCc1cscn1)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cnco1)Cc1ccccc1
4364,526157,10.1021/np0401765,,,,Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation,COc1cc(C[C@@H]2[C@@H](Cc3cc(OC)c4c(c3)OCO4)CO[C@@H]2O)cc(OC)c1OC,"(8R,8'R,9'S)-5-methoxyclusin",0.83,uM,=,-0.0809219076239261,0,c1ccc(C[C@H]2COC[C@@H]2Cc2ccc3c(c2)OCO3)cc1
4365,598210,10.1016/j.bmcl.2009.08.024,,,,Inhibition of human CYP3A4,CC1(CC(=O)NCc2ccccc2Sc2ccccc2CO)CC2(CCCCC2)OO1,"N-(2-(2-(hydroxymethyl)phenylthio)benzyl)-2-(3-methyl-1,2-dioxaspiro[4.5]decan-3-yl)acetamide",1.2,uM,=,0.0791812460476248,1,O=C(CC1CC2(CCCCC2)OO1)NCc1ccccc1Sc1ccccc1
4366,1465541,10.1016/j.bmcl.2015.01.051,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(C6CN(CC(C)(C)O)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O,"(1S,4R,5R,6R,8R,10S,11R,12S,13R,16R,18S,21R)-8-[(1S)-1-ethoxy-2-hydroxy-2-methylpropyl]-18-{[(2S)-4-[1-(2-hydroxy-2-methylpropyl)azetidin-3-yl]morpholin-2-yl]oxy}-4,6,12,17,17-pentamethyl-9-oxahexacyclo[11.9.0.0^{1,21}.0^{4,12}.0^{5,10}.0^{16,21}]docosan-11-ol",3.0,uM,=,0.4771212547196624,1,C1CO[C@@H]2CC3C(CC[C@@]45C[C@@]46CC[C@H](O[C@H]4CN(C7CNC7)CCO4)C[C@@H]6CC[C@@H]35)[C@H]2C1
4367,563097,10.1016/j.bmc.2009.03.001,,,,Inhibition of CYP3A4 in human liver microsome assessed as 1'-hydroxymidazolam formation by competitive inhibition assay,Cc1ccn(-c2ccc(C(=O)N3CCC(F)(F)/C(=C\C(=O)NCCO)c4ccccc43)c(Cl)c2)n1,"(Z)-2-{1-[2-Chloro-4-(3-methyl-1H-pyrazol-1-yl)benzoyl]-4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}-N-(2-hydroxyethyl)acetamide",47.0,uM,=,1.6720978579357175,1,C=C1CCCN(C(=O)c2ccc(-n3cccn3)cc2)c2ccccc21
4368,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",C[C@@H]1CN(C(=O)c2cccc(Cl)c2-n2nccn2)[C@H](Cc2cc(-n3nccn3)ccc2F)CO1,"US9150566, 173",21.0,uM,=,1.3222192947339193,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
4369,774749,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C.O.O.O,Taxol derivative,2.0,uM,=,0.3010299956639812,1,O=C(CCc1ccccc1)O[C@@H]1C=C2CC(=O)C3CC[C@H]4OCC4[C@H]3[C@H](OC(=O)c3ccccc3)C(C2)C1
4370,52065,10.1021/jm0310129,,,,Inhibitory activity against cytochrome P450 3A4,NC(=O)c1cccc2[nH]c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)ncnc3c12,"4-{4-[2-(3,4-Difluoro-phenyl)-ethyl]-piperazin-1-yl}-5H-pyrimido[5,4-b]indole-9-carboxylic acid amide",1.36,uM,=,0.1335389083702175,1,c1ccc(CCN2CCN(c3ncnc4c3[nH]c3ccccc34)CC2)cc1
4371,558484,10.1016/j.bmcl.2008.10.128,,,,Inhibition of CYP3A4,CN(CC(O)(CNC(=O)c1cnn(-c2ccc(F)cc2)c1N)C(F)(F)F)C(=O)c1c(F)cccc1F,"(+/-)-5-amino-N-(2-((2,6-difluoro-N-methylbenzamido)methyl)-3,3,3-trifluoro-2-hydroxypropyl)-1-(4-fluorophenyl)-1H-pyrazole-4-carboxamide",100.0,uM,=,2.0,1,O=C(NCCCNC(=O)c1cnn(-c2ccccc2)c1)c1ccccc1
4372,321462,10.1016/j.bmcl.2005.06.056,,,,Inhibition against Cytochrome P450 3A4 prepared from baculovirus-infected insect cells using resorufin benzyl ether,O=c1c(CCO)c(-c2cc(Cl)ccc2O)c2cc(C(F)(F)F)ccc2n1Cc1nn[nH]n1,4-(5-Chloro-2-hydroxy-phenyl)-3-(2-hydroxy-ethyl)-1-(2H-tetrazol-5-ylmethyl)-6-trifluoromethyl-1H-quinolin-2-one,13.0,uM,=,1.1139433523068367,1,O=c1cc(-c2ccccc2)c2ccccc2n1Cc1nn[nH]n1
4373,1447575,10.1016/j.bmcl.2014.05.068,,,,Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method,C[C@@H](c1ncncc1F)[C@](O)(Cn1cnnc1)c1ccc(F)cc1F,"(2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(4H-1,2,4-triazo l-4-yl)butan-2-ol",51.0,uM,=,1.7075701760979365,1,c1ccc(C(Cc2ccncn2)Cn2cnnc2)cc1
4374,1769255,10.1016/j.bmc.2018.02.026,,,,Inhibition of CYP3A4 in human liver microsomes after 20 mins,COc1cc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1ccc2occc2c1,"(1R,2S)-2-(benzofuran-5-yl)-1-(7-bromo-3-methoxynaphthalen-2-yl)-4-(dimethylamino)-1-phenylbutan-2-ol",9.7,uM,=,0.9867717342662448,1,c1ccc([C@@H](Cc2ccc3occc3c2)c2ccc3ccccc3c2)cc1
4375,1736291,10.1021/acs.jmedchem.8b00743,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,CC(C)N(C)c1ccc([C@H]2C[C@@]3(C)[C@@H](CC[C@@]3(O)C#CC(C)(C)C)[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]32)cc1,"(8R,9S,10R,11S,13S,14S,17S)-17-(3,3-dimethylbut-1-ynyl)-17-hydroxy-11-(4-(isopropyl(methyl)amino)phenyl)-13-methyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one",1.6,uM,=,0.2041199826559248,1,O=C1C=C2CC[C@@H]3[C@H]([C@@H](c4ccccc4)CC4CCC[C@H]43)[C@H]2CC1
4376,1288280,10.1016/j.bmcl.2013.12.057,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,CN(Cc1cncs1)C(=O)N[C@@H](CO)C(=O)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1,"Thiazol-5-ylmethyl(2R,5R)-5-((S)-3-hydroxy-2-(3-methyl-3-(thiazol-5-ylmethyl)ureido)propanamido)-1,6-diphenylhexan-2-ylcarbamate",0.17,uM,=,-0.7695510786217261,0,O=C(CNC(=O)NCc1cncs1)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
4377,2296518,10.1021/acs.jmedchem.5b01461,,,,Inhibition of CYP3A4 (unknown origin),CC(C)(C)NC(=O)C(c1cccnc1)N(C(=O)c1ccco1)c1ccc(C(C)(C)C)cc1,rac-N-(2-(tert-butylamino)-2-oxo-1-(pyridin-3-yl)ethyl)-N-(4-tert-butylphenyl)furan-2-carboxamide,1.7,uM,=,0.2304489213782739,1,O=C(c1ccco1)N(Cc1cccnc1)c1ccccc1
4378,434712,10.1021/jm070104l,,,,Inhibition of human CYP3A4,N#Cc1ccccc1Cn1c(N2CCC[C@@H](N)C2)nc2ccc(Br)cc2c1=O,(R)-2-((2-(3-aminopiperidin-1-yl)-6-bromo-4-oxoquinazolin-3(4H)-yl)methyl)benzonitrile,0.25,uM,=,-0.6020599913279624,0,O=c1c2ccccc2nc(N2CCCCC2)n1Cc1ccccc1
4379,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",C[C@@H]1CN(C(=O)c2ccccc2-n2nccn2)[C@H](Cc2cccc(-c3ncccn3)c2)CO1,"US9150566, 108",46.0,uM,=,1.662757831681574,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2ncccn2)c1
4380,817424,10.1021/ml200137x,,,,Inhibition of CYP3A4 using testosterone as substrate in human liver microsome for 20 mins by HPLC analysis,CNC[C@H](CC1CCCCC1)NC(=O)N1CCC[C@@H]([C@@H](OCCNC(=O)OC)c2cccc(Cl)c2)C1,methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-1-cyclohexyl-3-(methylamino)propan-2-ylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate,4.6,uM,=,0.6627578316815741,1,O=C(NCCC1CCCCC1)N1CCC[C@@H](Cc2ccccc2)C1
4381,621478,10.1016/j.bmcl.2009.07.138,,,,Inhibition of CYP3A4,CNC(=O)CCC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1,N-(4-chlorophenyl)-3-(3-(methylamino)-3-oxopropyl)-3-phenylpiperidine-1-carboxamide,10.0,uM,=,1.0,1,O=C(Nc1ccccc1)N1CCCC(c2ccccc2)C1
4382,1491688,10.1124/dmd.112.045708,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 90 mins followed by substrate addition by LC-MS/MS analysis in presence of NADPH,CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1,"(R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide",2.9,uM,=,0.4623979978989561,1,O=C(Cc1ccccc1)N(Cc1cccnc1)Cc1nc2ncccc2c(=O)n1-c1ccccc1
4383,1641834,,,,,"Inhibitory Assay: The cytochrome P450 inhibitory potentials of compounds for human recombinant CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A were determined using Vivid CYP450 blue screening kits (Invitrogen, USA). All of the procedures were performed according the instruction provided by the manufacturer. Briefly, serials of diluted compounds were incubated the vivid CYP450 reaction systems including CYP450 BACULOSOMES with different recombinant human CYP450 isozymes and the appropriate vivid CYP450 substrates, and rabbit NADPH-P450 reductase, and the regeneration system. Ketoconazole was used as reference CYP450 inhibitor. After 30 minutes incubation at room temperature, the fluorescence was measured with an excitation at 400 nm and an emission at 460 nm using Envision 2104 multi-label Reader (Perkin Elmer, USA).",COc1ccc(C2(c3ccc(OC)cc3)NC(=N)N(C3CCCCC3)C2=O)cc1,"3-cyclohexyl-2-imino-5,5-bis(4-methoxyphenyl)imidazolidin-4-one",0.449,uM,=,-0.3477536589966768,0,N=C1NC(c2ccccc2)(c2ccccc2)C(=O)N1C1CCCCC1
4384,2116571,10.1021/acsmedchemlett.1c00198,,,,Inhibition of CYP3A4 (unknown origin) expressed in baculovirus infected insect supersomes preincubated for 15 mins followed by addition of NADPH regenerating system by fluorescence based analysis,O=C(O)c1ccc2cc(N3CCC4(C=C(c5c(-c6c(Cl)cncc6Cl)noc5C5CC5)C4)CC3)ccc2n1,"6-(2-(5-cyclopropyl-3-(3,5-dichloropyridin-4-yl)isoxazol-4-yl)-7-azaspiro[3.5]non-1-en-7-yl)quinoline-2-carboxylic acid",4.7,uM,=,0.6720978579357175,1,C1=C(c2c(-c3ccncc3)noc2C2CC2)CC12CCN(c1ccc3ncccc3c1)CC2
4385,1560508,10.1016/j.bmc.2016.02.014,,,,Inhibition of CYP3A4 (unknown origin),CC1(C)OC(=S)Nc2ccc(S(=O)(=O)N3c4ccccc4COc4cc(F)ccc43)cc21,"6-(8-fluorodibenzo[b,e][1,4]oxazepin-5(11H)-ylsulfonyl)-4,4-dimethyl-1H-benzo[d][1,3]oxazine-2(4H)-thione",0.363,uM,=,-0.4400933749638875,0,O=S(=O)(c1ccc2c(c1)COC(=S)N2)N1c2ccccc2COc2ccccc21
4386,1675511,10.1016/j.ejmech.2017.03.037,,,,Inhibition of human hepatic CYP3A4,Fc1cncc(CN2CCc3c(sc4ccc(F)cc34)C2)c1,"6-Fluoro-2-((5-fluoropyridin-3-yl)methyl)-1,2,3,4-tetrahydrobenzo[4,5]thieno[2,3-c]pyridine",9.032,uM,=,0.9557839289169114,1,c1cncc(CN2CCc3c(sc4ccccc34)C2)c1
4387,834929,10.1016/j.bmcl.2012.07.020,,,,Inhibition of CYP3A4,CCS(=O)(=O)c1ccc2[nH]c(-c3cccc(-c4ccccc4)c3F)nc2c1,5-(ethylsulfonyl)-2-(2-fluorobiphenyl-3-yl)-1H-benzo[d]imidazole,6.6,uM,=,0.8195439355418687,1,c1ccc(-c2cccc(-c3nc4ccccc4[nH]3)c2)cc1
4388,823567,10.1021/jm201542d,,,,Inhibition of CYP3A4,COc1cc(N2C(=O)N(c3ccc(-c4ccc5nc[nH]c5c4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1,"3-[4-(3H-Benzoimidazol-5-yl)-phenyl]-1-(6-methoxy-pyrimidin-4-yl)-8-(3-methyl-pyridin-2-ylmethyl)-1,3,8-triaza-spiro[4.5]decane-2,4-dione",18.0,uM,=,1.255272505103306,1,O=C1N(c2ccc(-c3ccc4nc[nH]c4c3)cc2)C(=O)C2(CCN(Cc3ccccn3)CC2)N1c1ccncn1
4389,2062192,10.1016/j.bmcl.2016.04.018,,,,Inhibition of human liver microsomes CYP3A4 using testosterone as substrate by MUX-MS/MS analysis,O=C(Nc1cccc(Cl)c1)N1CCOc2ccc(-c3ccncc3)cc2C1,"N-(3-chlorophenyl)-7-(pyridin-4-yl)-2,3-dihydrobenzo[f][1,4]oxazepine-4(5H)-carboxamide",325.0,uM,=,2.5118833609788744,1,O=C(Nc1ccccc1)N1CCOc2ccc(-c3ccncc3)cc2C1
4390,1705360,10.1016/j.bmcl.2017.06.037,,,,Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method,OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(C#Cc2ccc(NCC(F)(F)F)cc2)cn1,"2-(2,4-difluorophenyl)-1,1-difluoro-3-(1H-tetrazol-1-yl)-1-(5-((4-(2,2,2-trifluoroethylamino)phenyl)ethynyl)pyridin-2-yl)propan-2-ol",10.0,uM,=,1.0,1,C(#Cc1ccc(CC(Cn2cnnn2)c2ccccc2)nc1)c1ccccc1
4391,1289880,10.1021/jm401642q,,,,Inhibition of recombinant human CYP3A4,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(-c3ccccn3)cccc21,"6-(Morpholin-4-yl)-2-{2-oxo-2-[4-(pyridin-2-yl)-2,3-dihydro-1Hindol-1-yl]ethyl}pyrimidin-4(3H)-one",11.0,uM,=,1.0413926851582251,1,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(-c3ccccn3)cccc21
4392,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)OC)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, H-1",3.85,uM,=,0.5854607295085007,1,O=C1[C@H](Cc2ccccc2)N2C(=O)CNN(C(=O)NCc3ccccc3)[C@H]2CN1Cc1cccc2c(-c3ccccc3)c[nH]c12
4393,1450858,10.1021/jm5005336,,,,Inhibition of CYP3A4 (unknown origin) using BFC substrate after 30 mins by fluorescence assay,COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(N5CCN(C)CC5)nc4)n[nH]c3c1)C(=O)N2,"(1R*,2S*)-5'-Methoxy-2-(3-((E)-2-(6-(4-methylpiperazin-1-yl)-pyridin-3-yl)vinyl)-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-one",2.1,uM,=,0.3222192947339193,1,O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccc(N4CCNCC4)nc3)n[nH]c2c1
4394,1528565,,,,,"Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",CC(C)c1nc(CN(C)C(=O)NC2(C(=O)N[C@H](CC[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)Cc3ccccc3)CCNCC2)cs1,"US8987313, 24",0.15,uM,=,-0.8239087409443188,0,O=C(NCc1cscn1)NC1(C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)CCNCC1
4395,51908,10.1016/j.bmcl.2003.08.049,,,,In vitro inhibition of Cytochrome P450 3A4,O=C(N[C@H]1c2ccccc2OC[C@H]1O)[C@H](Cc1cccnc1)C[C@H](O)CN1CCN(Cc2ccn(-c3ccc(Cl)cc3)c2)C[C@H]1C(=O)NCC(F)(F)F,"(S)-4-[1-(4-Chloro-phenyl)-1H-pyrrol-3-ylmethyl]-1-[(2S,4R)-2-hydroxy-4-((3S,4S)-3-hydroxy-chroman-4-ylcarbamoyl)-5-pyridin-3-yl-pentyl]-piperazine-2-carboxylic acid (2,2,2-trifluoro-ethyl)-amide",0.05,uM,=,-1.3010299956639813,0,O=C(N[C@@H]1CCOc2ccccc21)[C@@H](CCCN1CCN(Cc2ccn(-c3ccccc3)c2)CC1)Cc1cccnc1
4396,1685713,10.1016/j.bmc.2017.04.033,,,,Inhibition of recombinant CYP3A4 (unknown origin),C[C@@H](c1ccc(-c2ccc(C#N)cn2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O,"6-(4-((S)-1-((S)-6-(2-hydroxy-2-methylpropyl)-2-oxo-6-phenyl-1,3-oxazinan-3-yl)ethyl)phenyl)nicotinonitrile",12.7,uM,=,1.1038037209559568,1,O=C1OC(c2ccccc2)CCN1Cc1ccc(-c2ccccn2)cc1
4397,1540696,10.1016/j.ejmech.2015.08.051,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 2 mins by LC-MS/MS analysis in presence of NADPH regeneration system,CC(C)c1nc(C(=O)NC[C@@H]2[C@H]3CN(CC(C)(C)O)C[C@@H]23)c2ccccn12,"N-[N-(2-hydroxy-2-methyl-propyl)-3-azabicyclo[3.1.0]hexane-6-yl-methyl]-3-isopropylimidazo[1,5-a]pyridine-1-carboxamide",18.9,uM,=,1.276461804173244,1,O=C(NC[C@H]1[C@@H]2CNC[C@@H]21)c1ncn2ccccc12
4398,1475768,10.1021/jm5017413,,,,Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system,Cc1noc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)[C@@H]3C)n1,"(R)-(8-Methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)(4-(thiophen-2-yl)phenyl)-methanone",55.0,uM,=,1.740362689494244,1,O=C(c1ccc(-c2cccs2)cc1)N1CCn2c(nnc2-c2ncno2)C1
4399,619264,10.1016/j.bmcl.2009.07.002,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,Cc1cccc(C)c1CNc1nc(N2CCNC2=O)cc2c(C)c(C)[nH]c12,"1-(7-(2,6-dimethylbenzylamino)-2,3-dimethyl-1H-pyrrolo[2,3-c]pyridin-5-yl)imidazolidin-2-one",1.6,uM,=,0.2041199826559248,1,O=C1NCCN1c1cc2cc[nH]c2c(NCc2ccccc2)n1
4400,1984166,10.1016/j.bmc.2020.115349,,,,Inhibition of human full length CYP3A4 assessed using 7-benzyloxy-4 (trifluoromethyl)coumarin as substrate preincubated for 2 mins followed by substrate addition and measured for 2 mins by fluorometric analysis,CC(C)(C)OC(=O)N[C@H](CSCC(Nc1ccccc1)C(=O)NCc1cccnc1)Cc1c[nH]c2ccccc12,Rac-tert-butyl N-[(1S)-1-[[2-anilino-3-oxo-3-(3-pyridylmethylamino)propyl]sulfanylmethyl]-2-(1H-indol-3-yl)ethyl]carbamate,0.32,uM,=,-0.494850021680094,0,O=C(NCc1cccnc1)C(CSCCCc1c[nH]c2ccccc12)Nc1ccccc1
4401,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",C[C@@H]1CN(C(=O)c2ccccc2-n2nccn2)[C@H](Cc2cccc(-n3nccn3)c2)CO1,"US9150566, 100",13.0,uM,=,1.1139433523068367,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
4402,2103815,10.1016/j.bmcl.2021.128010,,,,Time dependent inhibition of CYP3A4 (unknown origin) measured at 30 mins,Nc1cc(Cc2ccn(-c3ccc(F)cc3)n2)c2nn[nH]c2n1,"7-((1-(4-fluorophenyl)-1H-pyrazol-3-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-amine",0.11,uM,=,-0.958607314841775,0,c1ccc(-n2ccc(Cc3ccnc4[nH]nnc34)n2)cc1
4403,993439,10.6019/CHEMBL2448688,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,CCN(Cc1c[nH]cn1)c1ccc(-c2ccc(F)cc2)cc1F,,4.0,uM,=,0.6020599913279624,1,c1ccc(-c2ccc(NCc3c[nH]cn3)cc2)cc1
4404,2080684,10.1021/acs.jmedchem.0c02005,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 10 mins in presence of NADPH generating system followed by substrate addition and measured after 10 mins by LC-MS/MS analysis,CS(=O)(=O)O.[2H]C([2H])=CC(=O)Nc1cc(Nc2nccc(-c3cn(C([2H])([2H])[2H])c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,"N-(2-((2-(Dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-(methyl-d3)-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide-3,3-d2 methanesulfonate",17.3,uM,=,1.2380461031287957,1,c1ccc(Nc2nccc(-c3c[nH]c4ccccc34)n2)cc1
4405,1287294,10.1021/jm401639v,,,,Inhibition of CYP3A4 (unknown origin) by fluorescence assay,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,"1-(4-{4-[2-(2,4-Dichloro-phenyl)-2-imidazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-ethanone (ketoconazole)",0.024,uM,=,-1.619788758288394,0,c1ccc(C2(Cn3ccnc3)OCC(COc3ccc(N4CCNCC4)cc3)O2)cc1
4406,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",COc1cc(C(=O)N2CCOC[C@H]2Cc2cccc(-n3nccn3)c2)c(-n2nccn2)cc1Cl,"US9150566, 104",13.0,uM,=,1.1139433523068367,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
4407,991614,10.1021/jm4008906,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(C[C@H]1CCCO1)C2,"(S)-3-(Aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-6-(((R)-tetrahydrofuran-2-yl)methyl)-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one",14.0,uM,=,1.146128035678238,1,O=C1c2c(-c3ccccc3)ccnc2CN1C[C@H]1CCCO1
4408,1613611,10.1016/j.bmcl.2016.08.089,,,,Inhibition of CYP3A4 (unknown origin),CC(C)[C@@H]1CN(c2ccc(CO)c(S(C)(=O)=O)c2)CCN1c1ncc(CO)c(C(F)(F)F)n1,(R)-(2-(4-(4-(hydroxymethyl)-3-(methylsulfonyl)phenyl)-2-isopropylpiperazin-1-yl)-4-(trifluoromethyl)pyrimidin-5-yl)methanol,29.45,uM,=,1.4690852991231205,1,c1ccc(N2CCN(c3ncccn3)CC2)cc1
4409,1758889,10.1021/acsmedchemlett.7b00230,,,,Inhibition of CYP3A4 (unknown origin),COc1cc(N2C(=O)CN(Cc3ccc(F)cc3Cl)C2=S)ccc1N(C)C,1-[(2-chloro-4-fluorophenyl)methyl]-3-[4-(dimethylamino)-3-methoxyphenyl]-2-sulfanylideneimidazolidin-4-one,7.76,uM,=,0.8898617212581884,1,O=C1CN(Cc2ccccc2)C(=S)N1c1ccccc1
4410,537847,10.1021/jm800888q,,,,Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,O=C1CCc2cc(-c3cccnc3)ccc2N1,"6-Pyridin-3-yl-3,4-dihydro-1H-quinolin-2-one",127.0,uM,=,2.103803720955957,1,O=C1CCc2cc(-c3cccnc3)ccc2N1
4411,1825899,10.1021/acs.jmedchem.9b02067,,,,Inhibition of human recombinant CYP3A4 expressed in supersomes assessed as decrease in formation of D-luciferin using luciferin-IPA as substrate incubated for 10 mins in presence of NADPH by P450-Glo luminescence assay,CCC(=O)O[C@]1(C(=O)CCl)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,"Propionic acid 17-(2-chloro-acetyl)-9-fluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl ester",0.206,uM,=,-0.6861327796308466,0,O=C1C=CC2C(=C1)CC[C@@H]1C2CCC2CCC[C@H]21
4412,1301328,10.6019/CHEMBL3137440,,,,DNDI: CYP Inhibition,FC(F)(F)c1ccc(CN2CCC(N(c3ccc(C(F)(F)F)cc3)c3cccnc3)CC2)cc1,,10.0,uM,=,1.0,1,c1ccc(CN2CCC(N(c3ccccc3)c3cccnc3)CC2)cc1
4413,804824,10.1016/j.bmcl.2011.12.080,,,,Reversible inhibition of CYP3A4,Cc1cc(Cl)cc2c(C(O)c3cncn3C)c3c(C)n[nH]c3nc12,"rac-(6-chloro-3,8-dimethyl-1H-pyrazolo[3,4-b]quinolin-4-yl)(1-methyl-1H-imidazol-5-yl)methanol",0.3,uM,=,-0.5228787452803376,0,c1ccc2c(Cc3cnc[nH]3)c3cn[nH]c3nc2c1
4414,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCN5CCOCC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, F-25",8.5,uM,=,0.9294189257142929,1,O=C(NCCN1CCOCC1)c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12
4415,834929,10.1016/j.bmcl.2012.07.020,,,,Inhibition of CYP3A4,CCCS(=O)(=O)c1ccc2[nH]c(-c3ccccc3-c3ccccc3)nc2c1,2-(biphenyl-2-yl)-5-(propylsulfonyl)-1H-benzo[d]imidazole,11.0,uM,=,1.0413926851582251,1,c1ccc(-c2ccccc2-c2nc3ccccc3[nH]2)cc1
4416,1553516,10.1016/j.bmc.2016.02.006,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins by LC-MS analysis,O=C(O)CN(C1(c2ccc(-c3ccccc3OC(F)(F)F)cc2)CCC1)S(=O)(=O)c1ccc(OC(F)F)cc1,2-(4-(Difluoromethoxy)-N-(1-(2'-(trifluoromethoxy)biphenyl-4-yl)cyclobutyl)phenylsulfonamido)acetic acid,6.0,uM,=,0.7781512503836436,1,O=S(=O)(NC1(c2ccc(-c3ccccc3)cc2)CCC1)c1ccccc1
4417,2116571,10.1021/acsmedchemlett.1c00198,,,,Inhibition of CYP3A4 (unknown origin) expressed in baculovirus infected insect supersomes preincubated for 15 mins followed by addition of NADPH regenerating system by fluorescence based analysis,O=C(O)c1ccc(N2CCC3(C=C(c4c(-c5c(Cl)cccc5Cl)noc4C4CC4)C3)CC2)cn1,"5-(2-(5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)-7-azaspiro[3.5]non-1-en-7-yl)picolinic acid",6.2,uM,=,0.7923916894982539,1,C1=C(c2c(-c3ccccc3)noc2C2CC2)CC12CCN(c1cccnc1)CC2
4418,876026,10.1021/jm3011838,,,,Inhibition of CYP3A4 in human liver microsomes in presence of NADPH by LC-MS/MS method,CN1C[C@H](C(=O)Nc2ccc(Cl)cc2)[C@@H](c2ccc(/C=C/C(=O)Nc3ccccc3N)cc2)C1,"(3R,4S)-4-{4-[(E)-2-(2-Amino-phenylcarbamoyl)-vinyl]-phenyl}-1-methyl-pyrrolidine-3-carboxylic acid(4-chloro-phenyl)-amide",14.0,uM,=,1.146128035678238,1,O=C(/C=C/c1ccc([C@H]2CNC[C@@H]2C(=O)Nc2ccccc2)cc1)Nc1ccccc1
4419,643713,10.1016/j.bmcl.2010.06.009,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader,C[C@@H](Oc1cc(-n2cnc3cc(-c4ccc(NC5CCN(C)CC5)nc4)ccc32)sc1C(N)=O)c1ccccc1Cl,(R)-3-(1-(2-chlorophenyl)ethoxy)-5-(5-(6-(1-methylpiperidin-4-ylamino)pyridin-3-yl)-1H-benzo[d]imidazol-1-yl)thiophene-2-carboxamide,16.0,uM,=,1.2041199826559248,1,c1ccc(COc2csc(-n3cnc4cc(-c5ccc(NC6CCNCC6)nc5)ccc43)c2)cc1
4420,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(OCCN(C)C)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, G-12",10.1,uM,=,1.0043213737826426,1,O=C(Nc1cccnc1)c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12
4421,1660136,10.1021/acs.jmedchem.6b01918,,,,Inhibition of human CYP3A4 assessed as inhibition of dealkylation,O=S(=O)(Nc1nccs1)c1cc(Cl)c(NC[C@@H]2CCCN(O)C2)cc1F,(S)-5-Chloro-2-fluoro-4-(((1-hydroxypiperidin-3-yl)methyl)-amino)-N-(thiazol-2-yl)benzenesulfonamide,17.0,uM,=,1.230448921378274,1,O=S(=O)(Nc1nccs1)c1ccc(NC[C@@H]2CCCNC2)cc1
4422,611721,10.1021/jm9014263,,,,Inhibition of human CYP3A4 by LCMS/MS assay,COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc(CN(C)C)cc3)c2)cc1C,N-[3-(4-Dimethylaminomethyl-phenylcarbamoyl)-benzyl]-4-methoxy-3-methyl-benzamide,13.5,uM,=,1.130333768495006,1,O=C(NCc1cccc(C(=O)Nc2ccccc2)c1)c1ccccc1
4423,859942,10.1021/jm300122u,,,,Inhibition of human CYP3A4 using testosterone as substrate after 45 mins,CN1CCN(C(=O)[C@H](COCc2ccccc2)NC(=O)C2(c3ccc(Cl)cc3Cl)CC2)CC1,"1-(2,4-Dichlorophenyl)-N-[(1S)-2-(4-methylpiperazin-1-yl)-2-oxo-1-{[(phenylmethyl)oxy]methyl}ethyl]-cyclopropanecarboxamide",2.2,uM,=,0.3424226808222063,1,O=C([C@H](COCc1ccccc1)NC(=O)C1(c2ccccc2)CC1)N1CCNCC1
4424,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(CC6CCNCC6)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, E-23",8.17,uM,=,0.9122220565324156,1,O=C(c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12)N1CCN(CC2CCNCC2)CC1
4425,2164739,10.1021/acs.jmedchem.1c02131,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate,CC(C)C[C@H](N)COc1ccc(-c2ccnc(C(F)(F)F)c2)cc1C#N,(S)-2-((2-Amino-4-methylpentyl)oxy)-5-(2-trifluoromethylpyridin-4-yl)-benzonitrile,1.3,uM,=,0.1139433523068367,1,c1ccc(-c2ccncc2)cc1
4426,993439,10.6019/CHEMBL2448688,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,CC(=O)N(Cc1cccnc1)c1ccc(-c2nc3ccccc3s2)cc1,,1.52,uM,=,0.1818435879447725,1,c1cncc(CNc2ccc(-c3nc4ccccc4s3)cc2)c1
4427,1525508,10.1016/j.ejmech.2015.08.001,,,,Inhibition of CYP3A4 (unknown origin) using luciferin tagged substrate preincubated for 10 mins before substrate addition,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,"1-(4-{4-[2-(2,4-Dichloro-phenyl)-2-imidazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-ethanone (ketoconazole)",0.06,uM,=,-1.2218487496163564,0,c1ccc(C2(Cn3ccnc3)OCC(COc3ccc(N4CCNCC4)cc3)O2)cc1
4428,676065,10.1016/j.bmcl.2010.09.028,,,,Inhibition of CYP3A4 after 30 mins,O=C(OC1([C@H]2COC[C@@H](CC3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CC2CCC(C1)N2CCO,"1-((3R,5R)-4-(4-chlorophenylsulfonyl)-5-(cyclopropylmethyl)morpholin-3-yl)cyclopropyl 8-(2-hydroxyethyl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate",0.0023,uM,=,-2.638272163982407,0,O=C(OC1([C@H]2COC[C@@H](CC3CC3)N2S(=O)(=O)c2ccccc2)CC1)N1CC2CCC(C1)N2
4429,813216,10.1016/j.bmcl.2012.01.125,,,,Inhibition of CYP3A4,COc1cc2c(Nc3ccccc3N3CCOCC3)c(C(N)=O)cnc2cc1-c1c(C)noc1C,"7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-4-(2-morpholinophenylamino)quinoline-3-carboxamide",1.5,uM,=,0.1760912590556812,1,c1ccc(N2CCOCC2)c(Nc2ccnc3cc(-c4cnoc4)ccc23)c1
4430,1869292,10.1021/acs.jmedchem.8b01837,,,,Inhibition of CYP3A4 in human liver microsomes,C[C@@H]1Cc2c(ccc3[nH]ncc23)[C@@H](c2c(F)cc(/C=C/C(=O)O)cc2F)N1CC(C)(C)F,"(E)-3-[3,5-Difluoro-4-[(6S,8R)-7-(2-fluoro-2-methyl-propyl)-8-methyl-3,6,8,9-tetrahydropyrazolo[4,3-f]isoquinolin-6-yl]phenyl]-prop-2-enoic Acid",13.0,uM,=,1.1139433523068367,1,c1ccc([C@H]2NCCc3c2ccc2[nH]ncc32)cc1
4431,1695601,10.1016/j.bmc.2017.08.012,,,,Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using 7-Benzoyloxy-4-trifluoromethyl coumarin substrate in presence of NADP+ by fluorescence based assay,CC(C)(C)[C@@H]1OCCC[C@@H]1CNc1cc(F)c(S(=O)(=O)Nc2nccs2)cc1Cl,"4-((((2SR,3SR)-2-(tert-Butyl)tetrahydro-2H-pyran-3-yl)methyl)amino)-5-chloro-2-fluoro-N-(thiazol-2-yl)benzenesulfonamide",5.5,uM,=,0.7403626894942439,1,O=S(=O)(Nc1nccs1)c1ccc(NC[C@H]2CCCOC2)cc1
4432,1581635,10.1021/acs.jmedchem.5b01146,,,,Inhibition of C-terminal four-histidine tagged human CYP3A4delta3 to 24 residues expressed in Escherichia coli assessed as 7-benzyloxy-4-(trifluoromethyl)coumarin O-debenzylation pretreated 2 mins followed by NADPH addition by fluorometric method in presence of rat cytochrome P450 reductase,CC(C)(C)OC(=O)NCCCCCC(=O)NCc1cccnc1,tert-butyl 6-oxo-6-(pyridin-3-ylmethylamino)hexylcarbamate,75.0,uM,=,1.8750612633917,1,c1ccncc1
4433,2246941,10.1021/acs.jmedchem.1c02132,,,,Inhibition of CYP3A4 (unknown origin) incubated for 10 mins in presence of NADPH by LC-MS/MS analysis,CC(=O)Nc1cc(-c2ccc(OC[C@@](C)(N)CC(C)C)c(OC(F)(F)F)c2)ccn1,"(S)-N-(4-(4-((2-amino-2,4-dimethylpentyl)oxy)-3-(trifluoromethoxy)phenyl)pyridin-2-yl)acetamide",9.5,uM,=,0.9777236052888478,1,c1ccc(-c2ccncc2)cc1
4434,449485,10.1016/j.bmcl.2007.07.097,,,,Inhibition of microsomal CYP3A4,CC(C)C[C@@H](c1cccc(F)c1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1)N(C)CCN,"1-((R)-1-(4-(2-((S)-1-((2-aminoethyl)(methyl)amino)-3-methylbutyl)-6-fluorophenyl)piperazin-1-yl)-3-(2,4-dichlorophenyl)-1-oxopropan-2-yl)pyrrolidin-2-one",0.65,uM,=,-0.1870866433571444,0,O=C([C@@H](Cc1ccccc1)N1CCCC1=O)N1CCN(c2ccccc2)CC1
4435,342038,10.1021/jm060055x,,,,Inhibition of human CYP3A4,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,"1-(4-{4-[2-(2,4-Dichloro-phenyl)-2-imidazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-ethanone (ketoconazole)",0.05,uM,=,-1.3010299956639813,0,c1ccc(C2(Cn3ccnc3)OCC(COc3ccc(N4CCNCC4)cc3)O2)cc1
4436,675407,10.1016/j.bmcl.2010.08.142,,,,Inhibition of CYP3A4,NC(=O)[C@]12CC3CC(C1)[C@@H](OC(=O)N1CC[C@@H](Nc4ccc(C(F)(F)F)cn4)C1)C(C3)C2,(R)-3-(5-Trifluoromethyl-pyridin-2-ylamino)-pyrrolidine-1-carboxylic acid 5-carbamoyl-adamantan-2-yl ester,7.2,uM,=,0.8573324964312685,1,O=C(OC1C2CC3CC(C2)CC1C3)N1CC[C@@H](Nc2ccccn2)C1
4437,493017,10.1021/jm800851u,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,COc1cccc(-c2cc(NC(C)=O)nc(-n3nc(C)cc3C)n2)c1,"N-[2-(3,5-Dimethyl-pyrazol-1-yl)-6-(3-methoxyphenyl)-pyrimidin-4-yl]-acetamide",0.74,uM,=,-0.1307682802690238,0,c1ccc(-c2ccnc(-n3cccn3)n2)cc1
4438,495543,10.1021/jm801332q,,,,Inhibition of human CYP3A4 expressed in Escherichia coli using 7BQ substrate by time dependent inhibition assay,C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(Nc4cccc(F)c4)CC3)cc2)CCN1,N-(3-Fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine,69.0,uM,=,1.8388490907372552,1,O=C(Cc1ccc(CN2CCNCC2)cc1)N1CCC(Nc2ccccc2)CC1
4439,717286,10.1021/np100665j,,,,Inhibition of CYP3A4 after 30 mins by fluorometric assay,COc1cc([C@H]2OC[C@H]([C@@H](O)c3ccc(O)c(OC)c3)[C@@H]2CO)ccc1O,(7R)-7-hydroxylariciresinol,66.5,uM,=,1.8228216453031043,1,c1ccc(C[C@H]2CO[C@H](c3ccccc3)C2)cc1
4440,804823,10.1016/j.bmcl.2011.12.080,,,,Time dependent inhibition of CYP3A4,Cc1cc(Cl)cc2c(C(O)c3ccccn3)c3c(C)n[nH]c3nc12,"rac-(6-chloro-3,8-dimethyl-1H-pyrazolo[3,4-b]quinolin-4-yl)(pyridin-2-yl)methanol",12.2,uM,=,1.0863598306747482,1,c1ccc(Cc2c3ccccc3nc3[nH]ncc23)nc1
4441,2248279,10.1021/acs.jmedchem.1c01974,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as a substrate preincubated for 10 mins followed by NADPH addition and measured after 10 mins by LC/MS/MS analysis,CC(=O)Nc1ccc(Nc2ncnc(N[C@@H](CC(C)C)C(=O)OC(C)(C)C)n2)cc1,"tert-Butyl (4-((4-Acetamidophenyl)amino)-1,3,5-triazin-2-yl)-L-leucinate",16.7,uM,=,1.2227164711475833,1,c1ccc(Nc2ncncn2)cc1
4442,1528565,,,,,"Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.",CC(C)c1nc(CN(C)C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,"US8987313, 5",0.16,uM,=,-0.7958800173440752,0,O=C(N[C@H](CC[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)NCc1cscn1)Cc1ccccc1)OCc1cncs1
4443,676065,10.1016/j.bmcl.2010.09.028,,,,Inhibition of CYP3A4 after 30 mins,CC1([C@@H]2COC[C@H](COC(=O)N3CCN(C(C)(C)CO)CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1,"((3R,5R)-4-(4-chlorophenylsulfonyl)-5-(1-methylcyclopropyl)morpholin-3-yl)methyl 4-(1-hydroxy-2-methylpropan-2-yl)piperazine-1-carboxylate",0.0005,uM,=,-3.3010299956639813,0,O=C(OC[C@H]1COC[C@@H](C2CC2)N1S(=O)(=O)c1ccccc1)N1CCNCC1
4444,51915,10.1016/s0960-894x(03)00680-2,,,,Inhibition of human liver microsome Cytochrome P450 3A4,O=C(N[C@H]1c2ccccc2OC[C@H]1O)[C@H](Cc1cccnc1)C[C@H](O)CN1CCN(Cc2ccc(-c3ccccc3)o2)C[C@H]1C(=O)NCC(F)(F)F,"(S)-1-[(2S,4R)-2-Hydroxy-4-((3S,4S)-3-hydroxy-chroman-4-ylcarbamoyl)-5-pyridin-3-yl-pentyl]-4-(5-phenyl-furan-2-ylmethyl)-piperazine-2-carboxylic acid (2,2,2-trifluoro-ethyl)-amide",0.43,uM,=,-0.3665315444204134,0,O=C(N[C@@H]1CCOc2ccccc21)[C@@H](CCCN1CCN(Cc2ccc(-c3ccccc3)o2)CC1)Cc1cccnc1
4445,1889156,10.1021/acs.jmedchem.8b01719,,,,Inhibition of CYP3A4 in human liver microsomes using atorvastatin as substrate preincubated for 7 mins followed by NADPH addition and measured by LC-MS/MS analysis,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(-n3nccc3-c3ccc(B(O)O)c(F)c3)c(C3CC3)cc12,(4-(1-(5-Cyclopropyl-2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-6-yl)-1H-pyrazol-5-yl)-2-fluorophenyl)boronic acid,2.0,uM,=,0.3010299956639812,1,c1ccc(-c2cc3cc(C4CC4)c(-n4nccc4-c4ccccc4)cc3o2)cc1
4446,1442888,10.1016/j.bmcl.2014.08.008,,,,Inhibition of CYP3A4 (unknown origin) using midazolam substrate,O=C(NOCCO)c1ccc2cnsc2c1Nc1ccc(I)cc1F,7-(2-Fluoro-4-iodo-phenylamino)-benzo[d]isothiazole-6-carboxylic acid(2-Hydroxy-ethoxy)-amide,9.0,uM,=,0.9542425094393248,1,c1ccc(Nc2cccc3cnsc23)cc1
4447,1661010,10.1016/j.bmcl.2017.02.047,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 10 mins followed by NADPH addition measured after 10 mins,CCCCC[C@H](O)CC(=O)CCc1ccc(O)c(OC)c1,[1-(4'-hydroxy-3'-methoxyphenyl)-5-hydroxy-3-decanone],37.4,uM,=,1.5728716022004805,1,c1ccccc1
4448,1625990,10.1016/j.bmcl.2016.04.095,,,,Inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins after 30 secs by LC/MS/MS analysis,O=S(=O)(CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12)[C@@H]1CCNC1,"(R)-3-(2-((4S,4aS,10bS)-10b-(4-chlorophenylsulfonyl)-7,10-difluoro-1,2,4,4a,5,10b-hexahydropyrano[3,4-c]chromen-4-yl)ethylsulfonyl)pyrrolidine",3.7,uM,=,0.568201724066995,1,O=S(=O)(CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccccc3)c3ccccc3OC[C@@H]12)[C@@H]1CCNC1
4449,536049,10.1016/j.bmcl.2008.08.010,,,,Inhibition of human CYP3A4 by microtiter plate assays using PPR substrate,CN1CCc2cc3ccn(S(=O)(=O)c4cccc(Cl)c4)c3cc2CC1,"1-(3-chlorophenylsulfonyl)-7-methyl-1,5,6,7,8,9-hexahydroazepino[4,5-f]indole",71.0,uM,=,1.8512583487190752,1,O=S(=O)(c1ccccc1)n1ccc2cc3c(cc21)CCNCC3
4450,449485,10.1016/j.bmcl.2007.07.097,,,,Inhibition of microsomal CYP3A4,CNCCN[C@@H](CC(C)C)c1ccccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1,"1-((R)-3-(2,4-dichlorophenyl)-1-(4-(2-((S)-3-methyl-1-(2-(methylamino)ethylamino)butyl)phenyl)piperazin-1-yl)-1-oxopropan-2-yl)pyrrolidin-2-one",4.8,uM,=,0.6812412373755872,1,O=C([C@@H](Cc1ccccc1)N1CCCC1=O)N1CCN(c2ccccc2)CC1
4451,802673,10.1016/j.bmcl.2011.12.125,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,CC(C)NC(=O)c1cccc(NC(=O)Nc2ccc(-c3ccnc4[nH]cnc34)cc2)c1,"3-(3-(4-(3H-imidazo[4,5-b]pyridin-7-yl)phenyl)ureido)-N-isopropylbenzamide",0.09,uM,=,-1.0457574905606752,0,O=C(Nc1ccccc1)Nc1ccc(-c2ccnc3[nH]cnc23)cc1
4452,970079,10.1021/jm4004076,,,,Inhibition of CYP3A4 in human liver microsomes assessed as midazolam hydroxylation to 1'-Hydroxymidazolam after 7 mins by LC-MS/MS analysis,CC(C)(C)c1cc(NC(=O)Nc2ccc(Nc3ncnc4ccccc34)cc2)n(-c2cccc(N)c2)n1,1-(1-(3-Aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl)-3-(4-(quinazolin-4-ylamino)phenyl)urea,14.8,uM,=,1.1702617153949575,1,O=C(Nc1ccc(Nc2ncnc3ccccc23)cc1)Nc1ccnn1-c1ccccc1
4453,2060129,10.1021/acsmedchemlett.1c00112,,,,Inhibition of CYP3A4 (unknown origin),N#CCCN1C(=O)CC[C@H]1C(=O)N1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3CC[C@@H]12,"3-((S)-2-((3aR,9bR)-9b-(4-fluorophenylsulfonyl)-7-(perfluoropropan-2-yl)-2,3,3a,4,5,9b-hexahydro-1H-benzo[e]indole-3-carbonyl)-5-oxopyrrolidin-1-yl)propanenitrile",10.0,uM,=,1.0,1,O=C1CC[C@@H](C(=O)N2CC[C@@]3(S(=O)(=O)c4ccccc4)c4ccccc4CC[C@@H]23)N1
4454,1619558,10.1021/acsmedchemlett.6b00327,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 10 mins in presence of NADP by rapidfire/MS analysis,C[C@H]1OC(=O)[C@]2(c3cc[nH]n3)CC(F)(F)[C@@H](C)[C@H](/C=C/c3ccc(-c4ccccc4C#N)cn3)[C@H]12,"2-(6-((E)-2-((3R,3aS,4R,5S,7aR)-6,6-difluoro-3,5-dimethyl-1-oxo-7a-(1H-pyrazol-3-yl)octahydroisobenzofuran-4-yl)vinyl)pyridin-3-yl)benzonitrile",2.4,uM,=,0.380211241711606,1,O=C1OC[C@H]2[C@@H](/C=C/c3ccc(-c4ccccc4)cn3)CCC[C@@]12c1cc[nH]n1
4455,514583,10.1016/j.bmcl.2008.06.072,,,,Inhibition of recombinant CYP3A4,O=C(c1cccc(Cl)c1)c1cc(Cc2ccc(=O)[nH]n2)cc2ccoc12,6-((7-(3-chlorobenzoyl)benzofuran-5-yl)methyl)pyridazin-3(2H)-one,0.6,uM,=,-0.2218487496163563,0,O=C(c1ccccc1)c1cc(Cc2ccc(=O)[nH]n2)cc2ccoc12
4456,526157,10.1021/np0401765,,,,Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation,O=C1OC[C@H](Cc2ccc3c(c2)OCO3)[C@H]1Cc1ccc2c(c1)OCO2,hinokinin,8.0,uM,=,0.9030899869919436,1,O=C1OC[C@H](Cc2ccc3c(c2)OCO3)[C@H]1Cc1ccc2c(c1)OCO2
4457,673952,10.1016/j.bmcl.2010.08.086,,,,Inhibition of CYP3A4 using midazolam as substrate,COC(=O)NCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1,"methyl 4-chloro-3-(((3R,4S)-N-cyclopropyl-4-(4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)phenyl)piperidine-3-carboxamido)methyl)benzylcarbamate",3.5,uM,=,0.5440680443502757,1,O=C([C@H]1CNCC[C@@H]1c1ccc(OCCOc2ccccc2)cc1)N(Cc1ccccc1)C1CC1
4458,768817,10.1021/jm2005354,,,,Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting,C[C@@H](c1ccc(-c2ccc(F)cc2)cc1)N1CC[C@](CCCO)(c2ccc(F)cc2)OC1=O,"(R)-3-((S)-1-(4'-fluorobiphenyl-4-yl)ethyl)-6-(4-fluorophenyl)-6-(3-hydroxypropyl)-1,3-oxazinan-2-one",8.0,uM,=,0.9030899869919436,1,O=C1OC(c2ccccc2)CCN1Cc1ccc(-c2ccccc2)cc1
4459,1660136,10.1021/acs.jmedchem.6b01918,,,,Inhibition of human CYP3A4 assessed as inhibition of dealkylation,N[C@H]1CC[C@@H](CNc2cc(F)c(S(=O)(=O)Nc3ncns3)cc2Cl)CC1,"cis-4-((((1S,4S)-4-Aminocyclohexyl)methyl)amino)-5-chloro-2-fluoro-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide",2.3,uM,=,0.3617278360175928,1,O=S(=O)(Nc1ncns1)c1ccc(NCC2CCCCC2)cc1
4460,828928,10.1016/j.bmcl.2012.06.022,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2ncsc2c1,"thiazol-5-ylmethyl(2S,3R)-3-hydroxy-4-(N-isobutylbenzo[d]thiazole-6-carboxamido)-1-phenylbutan-2-ylcarbamate",0.023,uM,=,-1.6382721639824072,0,O=C(N[C@H](CCNC(=O)c1ccc2ncsc2c1)Cc1ccccc1)OCc1cncs1
4461,993439,10.6019/CHEMBL2448688,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,O=C(NCCc1cnc[nH]1)c1cnc(-c2ccccc2)cn1,,16.0,uM,=,1.2041199826559248,1,O=C(NCCc1cnc[nH]1)c1cnc(-c2ccccc2)cn1
4462,51899,10.1016/j.bmcl.2003.08.027,,,,Binding affinity for Cytochrome P450 3A4; Range = 1-10 uM,OC1N=C(c2ccccc2F)c2cc(Cl)ccc2-n2cncc21,"8-Chloro-6-(2-fluoro-phenyl)-4H-2,5,10b-triaza-benzo[e]azulen-4-ol",10.0,uM,=,1.0,1,c1ccc(C2=NCc3cncn3-c3ccccc32)cc1
4463,875916,10.1021/jm300955x,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 mins by LC-MS/MS analysis in presence of NADPH,COc1ccc(S(=O)(=O)N2CCOc3ccc(Cl)cc32)cc1NC1CCN(C)CC1,"4-[3-(1-Methylpiperidin-4-ylamino)-4-methoxybenzenesulfonyl]-6-chloro-2,3-dihydrobenzo[1,4]oxazine",2.8,uM,=,0.4471580313422192,1,O=S(=O)(c1cccc(NC2CCNCC2)c1)N1CCOc2ccccc21
4464,2012350,10.1016/j.bmcl.2018.10.050,,,,Inhibition of CYP3A4 (unknown origin),c1cnc2c(Nc3ccc4c(-n5cccn5)nccc4c3)n[nH]c2c1,"1-(1H-pyrazol-1-yl)-N-(1H-pyrazolo[4,3-b]pyridin-3-yl)isoquinolin-6-amine",13.0,uM,=,1.1139433523068367,1,c1cnc2c(Nc3ccc4c(-n5cccn5)nccc4c3)n[nH]c2c1
4465,943410,10.1021/jm400194n,,,,Time dependent inhibition of human CYP3A4 preincubated for 30 mins in presence of NADPH,CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOC[C@@H]4C)n2)[C@H]2CC[C@@H](C3)N2C(C)=O)cc1,"1-(4-((5R,8S)-10-Acetyl-4-((S)-3-methylmorpholino)-6,7,8,9-tetrahydro-5H-5,8-epiminocyclohepta[d]pyrimidin-2-yl)-phenyl)-3-ethylurea",7.3,uM,=,0.8633228601204559,1,c1ccc(-c2nc3c(c(N4CCOCC4)n2)[C@H]2CC[C@@H](C3)N2)cc1
4466,51919,10.1016/j.bmcl.2003.08.027,,,,Inhibition of Cytochrome P450 3A4 with nifedipine,CCOC(=O)CCCn1c(=O)nc2n(CCCCOC(=O)C[C@@H]3CC4C5CC[C@H](O)C5CCC4[C@@]4(C)CCC(=O)C=C34)c3ccccc3cc-2c1=O,"4-(10-{4-[2-((6S,10R,17S)-17-Hydroxy-10-methyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-6-yl)-acetoxy]-butyl}-2,4-dioxo-4,10-dihydro-2H-pyrimido[4,5-b]quinolin-3-yl)-butyric acid ethyl ester",4.1,uM,=,0.6127838567197355,1,O=C1C=C2C(CC1)C1CCC3CCCC3C1C[C@H]2CC(=O)OCCCCn1c2nc(=O)[nH]c(=O)c-2cc2ccccc21
4467,1289880,10.1021/jm401642q,,,,Inhibition of recombinant human CYP3A4,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c1cccc2C(F)(F)F,"6-(Morpholin-4-yl)-2-{2-oxo-2-[4-(trifluoromethyl)-2,3-dihydro-1H-indol-1-yl]ethyl}pyrimidin-4(3H)-one",40.0,uM,=,1.6020599913279625,1,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2ccccc21
4468,813216,10.1016/j.bmcl.2012.01.125,,,,Inhibition of CYP3A4,COc1cc2c(Nc3ccccc3CCN3CCOCC3)c(C(N)=O)cnc2cc1-c1c(C)noc1C,"7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-4-(2-(2-morpholinoethyl)phenylamino)quinoline-3-carboxamide",1.9,uM,=,0.2787536009528289,1,c1ccc(Nc2ccnc3cc(-c4cnoc4)ccc23)c(CCN2CCOCC2)c1
4469,1451406,10.1021/jm500916t,,,,Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs,CCC1(CC)C[C@@H](NC(=O)Nc2cccc3cnccc23)c2cc(F)ccc2O1,"(R)-1-(2,2-Diethyl-6-fluorochroman-4-yl)-3-(isoquinolin-5-yl)urea",2.8,uM,=,0.4471580313422192,1,O=C(Nc1cccc2cnccc12)N[C@@H]1CCOc2ccccc21
4470,1446329,10.1021/ml500387y,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,CC(C)(CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F)c1cccc(S(N)(=O)=O)c1,"3-(5,5,5-trifluoro-4-hydroxy-2-methyl-4-((5-morpholino-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)pentan-2-yl)benzenesulfonamide",2.0,uM,=,0.3010299956639812,1,c1ccc(CCCCc2cc3cc(N4CCOCC4)ncc3[nH]2)cc1
4471,1849385,10.1016/j.bmcl.2019.06.044,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis,O=C(O)c1ccc(-n2cc(C(=O)c3c(Cl)cccc3Cl)c3c(F)cccc32)cc1,"4-[3-(2,6-dichlorobenzoyl)-4-fluoro-indol-1-yl]benzoic acid",49.0,uM,=,1.6901960800285136,1,O=C(c1ccccc1)c1cn(-c2ccccc2)c2ccccc12
4472,1919651,,,,,"Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase",Cc1ccc(-c2cccnc2)nc1,"5-Methyl-[2,3'']bipyridinyl",84.23,uM,=,1.9254668006915376,1,c1ccc(-c2cccnc2)nc1
4473,1295469,10.1016/j.bmcl.2014.02.004,,,,Inhibition of human recombinant CYP3A4,NC(=O)c1sc(N2CCOCC2)nc1CC(=O)N1CCc2cc(F)ccc21,4-(2-(5-fluoroindolin-1-yl)-2-oxoethyl)-2-morpholinothiazole-5-carboxamide,40.0,uM,=,1.6020599913279625,1,O=C(Cc1csc(N2CCOCC2)n1)N1CCc2ccccc21
4474,1705360,10.1016/j.bmcl.2017.06.037,,,,Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method,OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(C#Cc2ccc(F)cc2)cn1,"2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-((4-fluorophenyl)ethynyl)pyridin-2-yl)-3-(1H-tetrazol-1-yl)propan-2-ol",100.0,uM,=,2.0,1,C(#Cc1ccc(CC(Cn2cnnn2)c2ccccc2)nc1)c1ccccc1
4475,696217,10.1016/j.bmcl.2010.09.125,,,,Inhibition of CYP3A4,Cc1cc(-c2cccc(C3=Nc4cc(C)c(C(F)(F)F)cc4NC(=O)C3)c2)cc(C)n1,"4-(3-(2,6-dimethylpyridin-4-yl)phenyl)-7-methyl-8-(trifluoromethyl)-1H-benzo[b][1,4]diazepin-2(3H)-one",4.8,uM,=,0.6812412373755872,1,O=C1CC(c2cccc(-c3ccncc3)c2)=Nc2ccccc2N1
4476,1496401,10.1021/jm501840b,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam substrate incubated for 10 mins by LC-MS/MS method,CC12CCC(C(NC(=O)[C@@H](CC3CCCCC3)NC(=O)N[C@@H](CCCCN)C(=O)O)C1)C2(C)C.Cl,"(2S)-6-amino-2-[[(1R)-1-(cyclohexylmethyl)-2-oxo-2-[(4,7,7-trimethylnorbornan-2-yl)amino]ethyl]carbamoylamino]hexanoic acid hydrochloride",6.5,uM,=,0.8129133566428556,1,O=C(CCC1CCCCC1)NC1CC2CCC1C2
4477,1289880,10.1021/jm401642q,,,,Inhibition of recombinant human CYP3A4,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(-c3ccccc3)cccc21,"6-(Morpholin-4-yl)-2-[2-oxo-2-(4-phenyl-2,3-dihydro-1H-indol-1-yl)-ethyl]pyrimidin-4(3H)-one",40.0,uM,=,1.6020599913279625,1,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(-c3ccccc3)cccc21
4478,1971879,10.1021/acs.jmedchem.9b00790,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 2 min in presence of NADPH by LC-MS/MS analysis,Cl.c1cncc(OC[C@@H]2C[C@@H]3C[C@@H]3N2)c1,"(1S,3S,5S)-3-(pyridin-3-yloxymethyl)-2-azabicyclo[3.1.0]hexane hydrochloride",31.9,uM,=,1.5037906830571812,1,c1cncc(OC[C@@H]2C[C@@H]3C[C@@H]3N2)c1
4479,2164346,10.1021/acs.jmedchem.1c02192,,,,Inhibition of CYP3A4 (unknown origin),Cc1nc2cnc3cc(F)c(-c4ccc(Oc5ncccn5)cc4Cl)cc3c2n1[C@H]1CCN(C(=O)CO)C[C@@H]1F,"US9227969, 1A",7.7,uM,=,0.8864907251724818,1,c1cnc(Oc2ccc(-c3ccc4ncc5ncn(C6CCNCC6)c5c4c3)cc2)nc1
4480,746947,10.1021/jm200128m,,,,Inhibition of human CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as substrate,Cc1cc(Cl)cc(OCCn2cc(F)cn2)c1-c1nc(N)nc2c1CN(C(=O)NCC(C)(F)F)C2,"2-Amino-4-{4-chloro-2-[2-(4-fluoropyrazol-1-yl)ethoxy]-6-methylphenyl}-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carboxylic Acid(2,2-Difluoropropyl)amide",4.7,uM,=,0.6720978579357175,1,c1ccc(-c2ncnc3c2CNC3)c(OCCn2cccn2)c1
4481,993439,10.6019/CHEMBL2448688,,,,DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone,CCN(Cc1c[nH]cn1)c1ccc(-c2nc3ccccc3s2)cc1,,4.0,uM,=,0.6020599913279624,1,c1ccc2sc(-c3ccc(NCc4c[nH]cn4)cc3)nc2c1
4482,436456,10.1021/jm061195+,,,,Inhibition of human CYP3A4,O=C(NCC1(O)CCCCC1)c1cnc(Nc2cccc(Cl)c2)nc1C(F)(F)F,2-(3-chlorophenylamino)-4-carboxylic acid (1-hydroxycyclohexylmethyl)-amide,10.0,uM,=,1.0,1,O=C(NCC1CCCCC1)c1cnc(Nc2ccccc2)nc1
4483,873423,10.1021/jm3006788,,,,Inhibition of CYP3A4,Cn1c(-c2ccc(Cl)cn2)c(C2CCCC2)c2ccc(C(=O)NC(C)(C)C(=O)Nc3ccc(/C=C/C(=O)O)cc3)cc21,3-(4-(2-(2-(5-chloropyridin-2-yl)-3-cyclopentyl-1-methyl-1H-indole-6-carboxamido)-2-methylpropanamido)phenyl)acrylic acid,9.4,uM,=,0.9731278535996988,1,O=C(CNC(=O)c1ccc2c(C3CCCC3)c(-c3ccccn3)[nH]c2c1)Nc1ccccc1
4484,991614,10.1021/jm4008906,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate,CCOC(=O)N1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O,"rac-Ethyl 3-(Aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridine-6(7H)-carboxylate",6.4,uM,=,0.8061799739838872,1,O=C1NCc2nccc(-c3ccccc3)c21
4485,558484,10.1016/j.bmcl.2008.10.128,,,,Inhibition of CYP3A4,Nc1c(C(=O)NCC(O)(CN(CCF)C(=O)c2c(F)cccc2F)C(F)(F)F)cnn1-c1ccc(F)cc1,"(+/-)-5-amino-N-(2-((2,6-difluoro-N-(2-fluoroethyl)benzamido)methyl)-3,3,3-trifluoro-2-hydroxypropyl)-1-(4-fluorophenyl)-1H-pyrazole-4-carboxamide",0.5,uM,=,-0.3010299956639812,0,O=C(NCCCNC(=O)c1cnn(-c2ccccc2)c1)c1ccccc1
4486,375073,10.1016/j.bmcl.2006.01.102,,,,Inhibition of CYP3A4,CC[C@H](N)C(=O)N[C@H](C#N)Cc1ccc(-c2ccccc2)cc1,(S)-2-amino-N-((S)-2-biphenyl-4-yl-1-cyano-ethyl)-butyramide,3.604,uM,=,0.5567847823070253,1,c1ccc(-c2ccccc2)cc1
4487,1362864,10.1016/j.bmcl.2014.04.049,,,,Inhibition of CYP3A4 (unknown origin),Cn1c2c(c(=O)n1Cc1ccccc1C(F)(F)F)[C@H]1CC[C@]2(C)C1(C)C,"(4S,7R)-1,7,8,8-Tetramethyl-2-(2-trifluoromethyl-benzyl)-1,2,4,5,6,7-hexahydro-4,7-methano-indazol-3-one",4.8,uM,=,0.6812412373755872,1,O=c1c2c([nH]n1Cc1ccccc1)C1CC[C@H]2C1
4488,500935,10.1021/jm801180p,,,,Inhibition of human recombinant CYP3A4,NCc1noc(-c2nn(Cc3ccccc3)c3ccccc23)n1,"(5-(1-Benzyl-1H-indazol-3-yl)-1,2,4-oxadiazol-3-yl)methanamine",3.1,uM,=,0.4913616938342727,1,c1ccc(Cn2nc(-c3ncno3)c3ccccc32)cc1
4489,436456,10.1021/jm061195+,,,,Inhibition of human CYP3A4,O=C(NCC1CCC1)c1cnc(Nc2cccc(Cl)c2)nc1C(F)(F)F,2-(3-chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(cyclobutylmethyl)amide,75.0,uM,=,1.8750612633917,1,O=C(NCC1CCC1)c1cnc(Nc2ccccc2)nc1
4490,1689562,10.1021/acs.jmedchem.7b00598,,,,Inhibition of CYP3A4 (unknown origin),Cn1nccc1-c1cc(Cl)ccc1Oc1cc(F)c(S(=O)(=O)Nc2cscn2)cc1Cl,5-chloro-4-(4-chloro-2-(1-methyl-1H-pyrazol-5-yl)phenoxy)-2-fluoro-N-(thiazol-4-yl)benzenesulfonamide,26.588,uM,=,1.4246856701021031,1,O=S(=O)(Nc1cscn1)c1ccc(Oc2ccccc2-c2ccn[nH]2)cc1
4491,834929,10.1016/j.bmcl.2012.07.020,,,,Inhibition of CYP3A4,CCS(=O)(=O)c1ccc2[nH]c(-c3cccc(-c4ccccc4)c3C)nc2c1,5-(ethylsulfonyl)-2-(2-methylbiphenyl-3-yl)-1H-benzo[d]imidazole,5.2,uM,=,0.7160033436347992,1,c1ccc(-c2cccc(-c3nc4ccccc4[nH]3)c2)cc1
4492,322414,10.1021/jm0502541,,,,Interaction with human cytochrome P450 isoform 3A4 expressed in baculovirus-insect cells,CC1(C)CC(Oc2ccc(-c3ccc(C4(C(=O)O)CC4)cc3F)cc2)CC(C)(C)C1,"1-[2-Fluoro-4'-(3,3,5,5-tetramethyl-cyclohexyloxy)-biphenyl-4-yl]-cyclopropanecarboxylic acid",27.0,uM,=,1.4313637641589874,1,c1cc(-c2ccc(C3CC3)cc2)ccc1OC1CCCCC1
4493,1469227,10.1021/jm501436m,,,,Inhibition of CYP3A4 (unknown origin),O=C1NCCC12CCN(c1c(Cl)cncc1-c1ccc(N3CCOCC3)cc1)CC2,"8-(3-Chloro-5-(4-morpholin-4-ylphenyl)pyridin-4-yl)-2,8-diazaspiro[4.5]decan-1-one",2.1,uM,=,0.3222192947339193,1,O=C1NCCC12CCN(c1ccncc1-c1ccc(N3CCOCC3)cc1)CC2
4494,1616389,10.1021/acs.jmedchem.6b00989,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate assessed as reduction in 1-OH-midazolam formation by LC/MS/MS analysis,C[C@@H]1c2ncn(-c3ccc(F)cn3)c2CCN1C(=O)c1cccc(C(F)(F)F)c1Cl,"(R)-(2-Chloro-3(trifluoromethyl)phenyl)(1-(5-fluoropyridin-2-yl)-4-methyl-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-methanone",2.2,uM,=,0.3424226808222063,1,O=C(c1ccccc1)N1CCc2c(ncn2-c2ccccn2)C1
4495,535882,10.1016/j.bmcl.2008.08.010,,,,"Inhibition of human CYP3A4 by microtiter plate assays using N-N,diethyl-formamide as substrate",O=S(=O)(c1ccccc1)n1ccc2cc3c(cc21)CCNCC3,"1-(phenylsulfonyl)-1,5,6,7,8,9-hexahydroazepino[4,5-f]indole",12.0,uM,=,1.0791812460476249,1,O=S(=O)(c1ccccc1)n1ccc2cc3c(cc21)CCNCC3
4496,979124,10.1021/jm400484p,,,,Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes,Oc1ccc2ccc(-c3cncc(F)c3)c(Cl)c2c1,8-chloro-7-(5-fluoropyridin-3-yl)naphthalen-2-ol,3.581,uM,=,0.5540043210119029,1,c1cncc(-c2ccc3ccccc3c2)c1
4497,768817,10.1021/jm2005354,,,,Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting,C[C@@H](c1ccc(-c2ccc(F)cc2)cc1)N1CC[C@](CCCO)(c2cccc(F)c2)OC1=O,"(R)-3-((S)-1-(4'-fluorobiphenyl-4-yl)ethyl)-6-(3-fluorophenyl)-6-(3-hydroxypropyl)-1,3-oxazinan-2-one",7.0,uM,=,0.8450980400142568,1,O=C1OC(c2ccccc2)CCN1Cc1ccc(-c2ccccc2)cc1
4498,619264,10.1016/j.bmcl.2009.07.002,,,,Inhibition of CYP3A4 using diethoxyfluorescein substrate,Cc1c(C)n(C[C@H]2C[C@@H]2C)c2c(OCc3ccc(F)cc3)nncc12,"7-(4-fluorobenzyloxy)-2,3-dimethyl-1-(((1S,2S)-2-methylcyclopropyl)methyl)-1H-pyrrolo[2,3-d]pyridazine",6.0,uM,=,0.7781512503836436,1,c1ccc(COc2nncc3ccn(CC4CC4)c23)cc1
4499,774749,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Oc1ccc(/C=C/c2cc(O)cc(O)c2)cc1,"5-[2-((E)-4-Hydroxy-phenyl)-vinyl]-benzene-1,3-diol",0.6,uM,=,-0.2218487496163563,0,C(=C/c1ccccc1)\c1ccccc1
4500,1465595,10.1016/j.bmcl.2015.02.039,,,,Inhibition of CYP3A4 (unknown origin) using DBF fluorometric substrate,COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2NS(=O)(=O)CC2CCOCC2)C(C)C)ccc1OC,"N-isopropyl-4-methoxy-3-(3-methoxypropoxy)-N-(((3S,4S)-4-((tetrahydro-2H-pyran-4-yl)methylsulfonamido)pyrrolidin-3-yl)methyl)benzamide",10.0,uM,=,1.0,1,O=C(NC[C@@H]1CNC[C@H]1NS(=O)(=O)CC1CCOCC1)c1ccccc1
4501,982382,10.1016/j.bmcl.2013.07.071,,,,Inhibition of CYP3A4 (unknown origin),CC(C)(C)c1cccc(CN[C@H]2C[S@+]([O-])C[C@@H](Cc3cc(F)c(N)c(O[C@H](CO)C(F)(F)F)c3)[C@@H]2O)c1,"(1R,3S,4S,5R)-3-[4-Amino-3-fluoro-5-((R)-2,2,2-trifluoro-1-hydroxymethyl-ethoxy)-benzyl]-5-(3-tert-butyl-benzylamino)-1-oxo-tetrahydro-thiopyran-4-ol",0.9,uM,=,-0.0457574905606751,0,c1ccc(CN[C@H]2C[SH+]C[C@@H](Cc3ccccc3)C2)cc1
4502,2116571,10.1021/acsmedchemlett.1c00198,,,,Inhibition of CYP3A4 (unknown origin) expressed in baculovirus infected insect supersomes preincubated for 15 mins followed by addition of NADPH regenerating system by fluorescence based analysis,O=C(O)c1cc(F)c2nc(N3CCC4(C=C(c5c(-c6ccccc6OC(F)(F)F)noc5C5CC5)C4)CC3)sc2c1,2-(2-(5-cyclopropyl-3-(2-(trifluoromethoxy)phenyl)isoxazol-4-yl)-7-azaspiro[3.5]non-1-en-7-yl)-4-fluorobenzo[d]thiazole-6-carboxylic acid,1.0,uM,=,0.0,0,C1=C(c2c(-c3ccccc3)noc2C2CC2)CC12CCN(c1nc3ccccc3s1)CC2
4503,1527876,,,,,Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,CC[C@@H](c1ccc(-c2ccn(C)c(=O)c2)cc1)N1CC[C@](CC)(c2ccccc2)OC1=O,"US8575157, 58",8.0,uM,=,0.9030899869919436,1,O=C1OC(c2ccccc2)CCN1Cc1ccc(-c2cc[nH]c(=O)c2)cc1
4504,1366897,10.1021/jm500312x,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 15 mins by LC/MS/MS analysis,C=C[C@]1(C)C[C@@H](OC(=O)CSc2cncc(N)c2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O,14-O-(((5-Aminopyridin-3-yl)sulfanyl)acetyl)mutilin,0.135,uM,=,-0.8696662315049939,0,O=C(CSc1cccnc1)O[C@@H]1CCCC[C@@]23CCCC1[C@@H]2C(=O)CC3
4505,1283600,10.1021/jm401610c,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone,CS(=O)(=O)c1ccc(N2CCN(C(=O)C(c3ccc(Cl)cc3)c3cccnc3)CC2)cc1,2-(4-Chlorophenyl)-2-(pyridin-3-yl)-1-(4-[4-(methylsulfonyl)phenyl]piperazin-1-yl)ethanone,4.0,uM,=,0.6020599913279624,1,O=C(C(c1ccccc1)c1cccnc1)N1CCN(c2ccccc2)CC1
4506,462640,10.1016/j.bmcl.2008.01.108,,,,Inhibition of CYP3A4,Cc1cc[n+]([O-])c(C)c1C(=O)N1CCC(C)(N2CCC(N(c3ccccc3)c3cccnc3)CC2)CC1,"(2,4-dimethyl-1-oxy-pyridin-3-yl)-[4'-methyl-4-(phenyl-pyridin-3-yl-amino)-[1,4']bipiperidinyl-1'-yl]-methanone",5.3,uM,=,0.724275869600789,1,O=C(c1ccc[nH+]c1)N1CCC(N2CCC(N(c3ccccc3)c3cccnc3)CC2)CC1
4507,1288280,10.1016/j.bmcl.2013.12.057,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCNS(C)(=O)=O)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,"Thiazol-5-ylmethyl(2R,5R)-5-((S)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-4-(methylsulfonamido)butanamido)-1,6-diphenylhexan-2-ylcarbamate",0.12,uM,=,-0.9208187539523752,0,O=C(CNC(=O)NCc1cscn1)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
4508,630896,10.1016/j.bmcl.2010.03.017,,,,Inhibition of CYP3A4,Cc1cc(OC[P@]2(=O)OCC[C@@H](c3cccc(Cl)c3)O2)c2c(c1C)Cc1scnc1-2,"(2S,4S)-4-[4-(3-Chloro-phenyl)-2-oxo-2lambda*5*-[1,3,2]dioxaphosphinan-2-ylmethoxy]-6,7-dimethyl-8H-indeno[1,2-d]thiazole",2.7,uM,=,0.4313637641589873,1,O=[P@@]1(COc2cccc3c2-c2ncsc2C3)OCC[C@@H](c2ccccc2)O1
4509,1614025,10.1016/j.bmcl.2016.09.043,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 6-beta-hydroxytestosterone metabolite formation using testosterone as substrate incubated for 30 mins by HPLC-MS method,Cn1c(NCCc2ccc(-c3ncc(F)cn3)cc2)nc2cc(Cl)ccc2c1=O,7-Chloro-2-{2-[4-(5-fluoro-pyrimidin-2-yl)-phenyl]-ethylamino}-3-methyl-3H-quinazolin-4-one,9.9,uM,=,0.99563519459755,1,O=c1[nH]c(NCCc2ccc(-c3ncccn3)cc2)nc2ccccc12
4510,1990141,10.1021/acs.jmedchem.0c00259,,,,Inhibition of CYP3A4 (unknown origin),Cn1nccc1[C@H]1CCCC[C@@H]1Oc1cc(F)c(S(=O)(=O)Nc2ccncn2)cc1Cl,"rac-5-Chloro-2-fluoro-4-[[(1S*,2R*)-2-(1-methyl-1H-pyrazol-5-yl)cyclohexyl]oxy]-N-(pyrimidin-4-yl)benzene-1-sulfonamide",8.7,uM,=,0.9395192526186184,1,O=S(=O)(Nc1ccncn1)c1ccc(O[C@H]2CCCC[C@@H]2c2ccn[nH]2)cc1
4511,1613611,10.1016/j.bmcl.2016.08.089,,,,Inhibition of CYP3A4 (unknown origin),Cc1nc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)cc(C(F)(F)F)n1,"(R)-6-isopropyl-5-(2-methyl-6-(trifluoromethyl)pyrimidin-4-yl)-2-(3-(methylsulfonyl)phenyl)-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole",21.1,uM,=,1.3242824552976926,1,c1ccc(-n2cc3c(n2)CN(c2ccncn2)C3)cc1
4512,1485703,10.1124/dmd.112.048264,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method,O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1,4-[4-(4-Chloro-phenyl)-4-hydroxy-piperidin-1-yl]-1-(4-fluoro-phenyl)-butan-1-one (Haloperidol),33.1,uM,=,1.5198279937757189,1,O=C(CCCN1CCC(c2ccccc2)CC1)c1ccccc1
4513,1289880,10.1021/jm401642q,,,,Inhibition of recombinant human CYP3A4,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2ccccc21,"2-[2-(2,3-Dihydro-1H-indol-1-yl)-2-oxoethyl]-6-(morpholin-4-yl)-pyrimidin-4(3H)-one",40.0,uM,=,1.6020599913279625,1,O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2ccccc21
4514,510198,10.1021/jm800355c,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,COc1ccc(-c2ccc3c(c2)CCC3(O)c2ccncc2)cc1F,"5-(3-Fluoro-4-methoxyphenyl)-1-(pyridin-4-yl)-2,3-dihydro-1H-inden-1-ol",3.364,uM,=,0.5268559871258746,1,c1ccc(-c2ccc3c(c2)CCC3c2ccncc2)cc1
4515,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)Nc6cccc(OC)c6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, D-21",6.53,uM,=,0.814913181275074,1,O=C(Nc1ccccc1)c1ccc(-c2c[nH]c3c(CN4C[C@@H]5N(C(=O)NCc6ccccc6)NCC(=O)N5[C@@H](Cc5ccccc5)C4=O)cccc23)cc1
4516,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",Cc1cc(C(=O)N2CCOC[C@H]2Cc2cc(-c3ncon3)ccc2F)c(-n2nccn2)cc1C,"US9150566, 179",29.0,uM,=,1.462397997898956,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2ncon2)c1
4517,434712,10.1021/jm070104l,,,,Inhibition of human CYP3A4,N#Cc1ccccc1Cn1c(N2CCC[C@@H](N)C2)nc2ccccc2c1=O,2-((2-(3-aminopiperidin-1-yl)-4-oxoquinazolin-3(4H)-yl)methyl)benzonitrile,2.0,uM,=,0.3010299956639812,1,O=c1c2ccccc2nc(N2CCCCC2)n1Cc1ccccc1
4518,425259,10.1021/jm060983w,,,,Inhibition of CYP3A4 in human liver microsomes,O=C(OCc1ccccc1)N1CCC(CNc2cccnc2)CC1,benzyl 4-[(pyridin-3-ylamino)methyl]piperidine-1-carboxylate,9.1,uM,=,0.9590413923210936,1,O=C(OCc1ccccc1)N1CCC(CNc2cccnc2)CC1
4519,1931140,10.1016/j.bmcl.2019.06.040,,,,Inhibition of CYP3A4 (unknown origin),Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1,1-[(2-Chloro-phenyl)-diphenyl-methyl]-1H-imidazole,0.05,uM,=,-1.3010299956639813,0,c1ccc(C(c2ccccc2)(c2ccccc2)n2ccnc2)cc1
4520,52065,10.1021/jm0310129,,,,Inhibitory activity against cytochrome P450 3A4,Cn1c2nccc(C(N)=O)c2c2ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21,"8-{4-[2-(3,4-Difluoro-phenyl)-ethyl]-piperazin-1-yl}-9-methyl-9H-1,5,7,9-tetraaza-fluorene-4-carboxylic acid amide",1.23,uM,=,0.0899051114393979,1,c1ccc(CCN2CCN(c3ncnc4c3[nH]c3ncccc34)CC2)cc1
4521,2048413,10.1016/j.bmc.2020.115723,,,,Inhibition of CYP3A4 (unknown origin),Nc1cc([C@H](CCNCc2ccccc2)c2ccccc2)c2nn[nH]c2n1,"(R)-7-(3-(benzylamino)-1-phenylpropyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-amine",12.0,uM,=,1.0791812460476249,1,c1ccc(CNCC[C@H](c2ccccc2)c2ccnc3[nH]nnc23)cc1
4522,1456764,10.1016/j.bmcl.2014.07.026,,,,Inhibition of CYP3A4 in human liver microsome,CN1CCN(C(=O)c2cncnc2Oc2cc(Cl)ccc2Cl)c2ccccc21,"(4-(2,5-dichlorophenoxy)pyrimidin-5-yl)(4-methyl-3,4-dihydroquinoxalin-1(2H)-yl)methanone",0.25,uM,=,-0.6020599913279624,0,O=C(c1cncnc1Oc1ccccc1)N1CCNc2ccccc21
4523,1441252,10.1021/jm5010013,,,,Inhibition of CYP3A4 (unknown origin),O=C(O)c1cc(Cl)ccc1NC(=O)N1C[C@H]2C[C@@H](c3ccccc3C(F)(F)F)C[C@H]2C1,"trans-5-chloro-2-((3aR,6aS)-5-(2-(trifluoromethyl)phenyl)octahydrocyclopenta[c]pyrrole-2-carboxamido)benzoic acid",50.0,uM,=,1.6989700043360187,1,O=C(Nc1ccccc1)N1C[C@H]2C[C@@H](c3ccccc3)C[C@H]2C1
4524,630554,10.1021/jm901870q,,,,Inhibition of CYP3A4 in human liver microsomes using nifedipine as substrate,CCn1cc(-c2ccnc3[nH]c(-c4cccc(CN(C)C)c4)cc23)c(-c2ccc(NC(=O)N(C)C)cc2)n1,"3-(4-(4-(2-(3-((dimethylamino)methyl)phenyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)-1-ethyl-1H-pyrazol-3-yl)phenyl)-1,1-dimethylurea",15.0,uM,=,1.1760912590556811,1,c1ccc(-c2cc3c(-c4c[nH]nc4-c4ccccc4)ccnc3[nH]2)cc1
4525,1988789,10.1021/acs.jmedchem.0c00745,,,,Inhibition of CYP3A4 (unknown origin),O=C(O)c1cc(-c2ccc(C34CCN(CC3)CC4)cc2)c2ccc(-c3ccc(C(F)(F)F)cc3)cc2c1,4-(4-(Quinuclidin-4-yl)phenyl)-7-(4-(trifluoromethyl)phenyl)-2-naphthoic Acid,30.0,uM,=,1.4771212547196624,1,c1ccc(-c2ccc3c(-c4ccc(C56CCN(CC5)CC6)cc4)cccc3c2)cc1
4526,438600,10.1016/j.bmcl.2007.03.048,,,,Inhibition of CYP3A4 in microsomes,Cc1cnc(-c2cc(C)c3nc(-c4c(NCC(O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)[nH]1,4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-3-(4-methyl-6-(5-methyl-1H-imidazol-2-yl)-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one,0.36,uM,=,-0.4436974992327127,0,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(-c3ncc[nH]3)cc2[nH]1
4527,1772291,10.1016/j.bmc.2018.04.054,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis,CC(C)OC(=O)[C@H](Cn1ccnc1)NC(=O)c1noc2c1CCc1ccccc1-2,"Isopropyl (S)-2-(4,5-dihydronaphtho[2,1-d]isoxazole-3-carboxamido)-3-(1H-imidazol-1-yl)propanoate",7.27,uM,=,0.8615344108590378,1,O=C(NCCn1ccnc1)c1noc2c1CCc1ccccc1-2
4528,2111978,10.1021/acs.jmedchem.0c01992,,,,Inhibition of CYP3A4 (unknown origin),C[C@H]1C[C@H](C(=O)O)CC[C@H]1NN1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3CC[C@@H]12,"(1R,3S,4R)-4-((3aR,9bR)-9b-(4-fluorophenylsulfonyl)-7-(perfluoropropan-2-yl)-4,5-dihydro-1H-benzo[e]indol-3(2H,3aH,9bH)-ylamino)-3-methylcyclohexanecarboxylic acid",20.0,uM,=,1.3010299956639813,1,O=S(=O)(c1ccccc1)[C@@]12CCN(NC3CCCCC3)[C@@H]1CCc1ccccc12
4529,813216,10.1016/j.bmcl.2012.01.125,,,,Inhibition of CYP3A4,COc1cc2c(Nc3ccccc3F)c(C(N)=O)cnc2cc1-c1c(C)noc1C,"7-(3,5-dimethylisoxazol-4-yl)-4-(2-fluorophenylamino)-6-methoxyquinoline-3-carboxamide",4.7,uM,=,0.6720978579357175,1,c1ccc(Nc2ccnc3cc(-c4cnoc4)ccc23)cc1
4530,479364,10.1016/j.bmcl.2008.05.027,,,,Inhibition of CYP3A4,O=C(Cn1c(=O)cnc2cc(Cl)c(Cl)cc21)N1CCCC(c2ccccc2)C1CN1CCCC1,"rac-6,7-dichloro-1-(2-oxo-2-(3-phenyl-2-(pyrrolidin-1-ylmethyl)piperidin-1-yl)ethyl)quinoxalin-2(1H)-one",1.2,uM,=,0.0791812460476248,1,O=C(Cn1c(=O)cnc2ccccc21)N1CCCC(c2ccccc2)C1CN1CCCC1
4531,1464254,10.1016/j.bmcl.2015.02.058,,,,Inhibition of human CYP3A4,COc1ccc(C(=O)NC(C)Cc2ccccn2)cc1OC1CCN(C(C)C)CC1,SID160844212,28.2,uM,=,1.4502491083193612,1,O=C(NCCc1ccccn1)c1cccc(OC2CCNCC2)c1
4532,1527876,,,,,Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,CC(C)n1ccc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)cc1=O,"US8575157, 68",43.0,uM,=,1.6334684555795866,1,O=C1OC(c2ccccc2)CCN1Cc1ccc(-c2cc[nH]c(=O)c2)cc1
4533,1288280,10.1016/j.bmcl.2013.12.057,,,,Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN(C)C)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,"Thiazol-5-ylmethyl(2R,5R)-5-((S)-4-(dimethylamino)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)butanamido)-1,6-diphenylhexan-2-ylcarbamate",0.14,uM,=,-0.8538719643217619,0,O=C(CNC(=O)NCc1cscn1)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
4534,1558163,10.1021/acs.jmedchem.5b00832,,,,Inhibition of CYP3A4 (unknown origin),COc1ccc(S(=O)(=O)N2CCC[C@H]2C(=O)Nc2cc(C)cc(C)c2)cc1,"(S)-N-(3,5-dimethylphenyl)-1-(4-methoxyphenylsulfonyl)pyrrolidine-2-carboxamide",15.0,uM,=,1.1760912590556811,1,O=C(Nc1ccccc1)[C@@H]1CCCN1S(=O)(=O)c1ccccc1
4535,1660136,10.1021/acs.jmedchem.6b01918,,,,Inhibition of human CYP3A4 assessed as inhibition of dealkylation,N[C@H]1CC[C@](CCOc2cc(F)c(S(=O)(=O)Nc3ncns3)cc2Cl)(c2ccccc2)CC1,"cis-4-(2-((1R,4R)-4-Amino-1-phenylcyclohexyl)ethoxy)-5-chloro-2-fluoro-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide",0.27,uM,=,-0.5686362358410126,0,O=S(=O)(Nc1ncns1)c1ccc(OCCC2(c3ccccc3)CCCCC2)cc1
4536,802673,10.1016/j.bmcl.2011.12.125,,,,Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis,O=C(Nc1ccc(-c2ccnc3[nH]cnc23)cc1)Nc1cccc([N+](=O)[O-])c1,"1-(4-(3H-imidazo[4,5-b]pyridin-7-yl)phenyl)-3-(3-nitrophenyl)urea",0.061,uM,=,-1.214670164989233,0,O=C(Nc1ccccc1)Nc1ccc(-c2ccnc3[nH]cnc23)cc1
4537,1685713,10.1016/j.bmc.2017.04.033,,,,Inhibition of recombinant CYP3A4 (unknown origin),C[C@@H](c1ccc(OC(F)F)cc1)N1CC[C@](CCC(N)=O)(c2ccc(F)cc2)OC1=O,"3-((R)-3-((S)-1-(4-(difluoromethoxy)phenyl)ethyl)-6-(4-fluorophenyl)-2-oxo-1,3-oxazinan-6-yl)propanamide",27.0,uM,=,1.4313637641589874,1,O=C1OC(c2ccccc2)CCN1Cc1ccccc1
4538,1497735,10.1021/jm5020023,,,,Inhibition of human recombinant CYP3A4 using midazolam as substrate after 1 hr by LC-MS/MS analysis,CC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2,"methyl-2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oate",4.78,uM,=,0.6794278966121189,1,O=C1C=CC2C3=CC(=O)[C@H]4C(CCC5CCCC[C@H]54)C3CC[C@H]2C1
4539,1366897,10.1021/jm500312x,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 15 mins by LC/MS/MS analysis,C=C[C@]1(C)C[C@@H](OC(=O)CS[C@@H]2CC[C@@H](N)C[C@H]2O)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O,BC-3781,4.65,uM,=,0.667452952889954,1,O=C(CSC1CCCCC1)O[C@@H]1CCCC[C@@]23CCCC1[C@@H]2C(=O)CC3
4540,52065,10.1021/jm0310129,,,,Inhibitory activity against cytochrome P450 3A4,O=[N+]([O-])c1cccc2c1c1ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c1n2Cc1cccnc1,"4-{4-[2-(3,4-Difluoro-phenyl)-ethyl]-piperazin-1-yl}-9-nitro-5-pyridin-3-ylmethyl-5H-pyrimido[5,4-b]indole",8.1,uM,=,0.9084850188786496,1,c1ccc(CCN2CCN(c3ncnc4c5ccccc5n(Cc5cccnc5)c34)CC2)cc1
4541,1527876,,,,,Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,C[C@@H](c1ccc(-c2ccc(=O)n(C)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O,"US8575157, 37",48.0,uM,=,1.6812412373755872,1,O=C1OC(c2ccccc2)CCN1Cc1ccc(-c2ccc(=O)[nH]c2)cc1
4542,1616882,10.1021/acs.jmedchem.6b01088,,,,Inhibition of CYP3A4 (unknown origin),Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4c(c23)CC[C@H](C(C)(C)O)C4)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O,"6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide",8.5,uM,=,0.9294189257142929,1,O=c1[nH]c2ccccc2c(=O)n1-c1cccc(-c2cccc3[nH]c4c(c23)CCCC4)c1
4543,823567,10.1021/jm201542d,,,,Inhibition of CYP3A4,Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-c3ccccc3)cc1)C(=O)N2c1cc(O)ncn1,"3-(Biphenyl-4-yl)-8-[(3-methylpyridin-2-yl)methyl]-1-(6-hydroxypyrimidin-4-yl)-1,3,8-triazaspiro[4.5]decane-2,4-dione",69.0,uM,=,1.8388490907372552,1,O=C1N(c2ccc(-c3ccccc3)cc2)C(=O)C2(CCN(Cc3ccccn3)CC2)N1c1ccncn1
4544,495153,10.1021/jm8006454,,,,Inhibition of CYP3A4,COc1cccc(-c2c(C)n(Cc3c(F)cccc3F)c(=O)n(C[C@H](NCCCC(=O)O)c3ccccc3)c2=O)c1F,"(R)-4-{2-[5-(2-Fluoro-3-methoxyphenyl)-3-(2,6-difluorobenzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyric Acid",135.0,uM,=,2.130333768495006,1,O=c1c(-c2ccccc2)cn(Cc2ccccc2)c(=O)n1CCc1ccccc1
4545,674732,10.1016/j.bmcl.2010.09.029,,,,Inhibition of CYP3A4,CN1C(=O)[C@@](c2ccc(OC(F)F)cc2)(c2ccc(F)c(C#CCCCF)c2)N=C1N,(R)-2-amino-4-(4-(difluoromethoxy)phenyl)-4-(4-fluoro-3-(5-fluoropent-1-ynyl)phenyl)-1-methyl-1H-imidazol-5(4H)-one,0.9,uM,=,-0.0457574905606751,0,O=C1NC=NC1(c1ccccc1)c1ccccc1
4546,834929,10.1016/j.bmcl.2012.07.020,,,,Inhibition of CYP3A4,CCCS(=O)(=O)c1ccc2[nH]c(-c3cccc(-c4ccccc4)c3)nc2c1,2-(biphenyl-3-yl)-5-(propylsulfonyl)-1H-benzo[d]imidazole,6.0,uM,=,0.7781512503836436,1,c1ccc(-c2cccc(-c3nc4ccccc4[nH]3)c2)cc1
4547,379074,10.1016/j.bmcl.2006.05.049,,,,Inhibition of CYP3A4,CCOc1ccccc1C[C@H](c1ccccc1)N1CCNCC1.Cl,(R)-1-(2-(2-ethoxyphenyl)-1-phenylethyl)piperazine hydrochloride,30.0,uM,=,1.4771212547196624,1,c1ccc(C[C@H](c2ccccc2)N2CCNCC2)cc1
4548,1614026,10.1016/j.bmcl.2016.09.043,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 1'-hydroxymidazolam metabolite formation using midazolam as substrate incubated for 10 mins by HPLC-MS method,Cn1c(NCCc2ccc(-n3cc(Cl)cn3)cc2)nc2cc(Cl)ccc2c1=O,7-Chloro-2-{2-[4-(4-chloro-pyrazol-1-yl)-phenyl]-ethylamino}-3-methyl-3H-quinazolin-4-one,16.0,uM,=,1.2041199826559248,1,O=c1[nH]c(NCCc2ccc(-n3cccn3)cc2)nc2ccccc12
4549,52065,10.1021/jm0310129,,,,Inhibitory activity against cytochrome P450 3A4,O=[N+]([O-])c1cccc2c1c1ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c1n2CCc1ccccc1,"4-{4-[2-(3,4-Difluoro-phenyl)-ethyl]-piperazin-1-yl}-9-nitro-5-phenethyl-5H-pyrimido[5,4-b]indole",11.79,uM,=,1.0715138050950892,1,c1ccc(CCN2CCN(c3ncnc4c5ccccc5n(CCc5ccccc5)c34)CC2)cc1
4550,595638,10.1016/j.bmcl.2009.09.096,,,,Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH,COc1cnc2c(NCc3nnc4ccc(-c5ccc(F)c(F)c5)nn34)ccnc2c1,"N-((6-(3,4-difluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methyl)-7-methoxy-1,5-naphthyridin-4-amine",9.1,uM,=,0.9590413923210936,1,c1ccc(-c2ccc3nnc(CNc4ccnc5cccnc45)n3n2)cc1
4551,935884,10.1016/j.bmcl.2012.10.069,,,,Inhibition of human CYP3A4,CO[C@@H]1COCC[C@@H]1N[C@@H]1C[C@H]2CCC[C@@]2(C(=O)N2CCc3ncc(C(F)(F)F)cc3C2)C1,"((2R,3aR)-2-((3S)-3-methoxytetrahydro-2H-pyran-4-ylamino)octahydropentalen-3a-yl)(3-(trifluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)methanone",7.5,uM,=,0.8750612633917001,1,O=C(N1CCc2ncccc2C1)[C@@]12CCC[C@@H]1C[C@@H](NC1CCOCC1)C2
4552,813216,10.1016/j.bmcl.2012.01.125,,,,Inhibition of CYP3A4,COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n([C@H](C)c3ccccn3)c12,"7-(3,5-dimethyl-4-isoxazolyl)-8-(methyloxy)-1-[(1R)-1-(2-pyridinyl)ethyl]-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one",9.7,uM,=,0.9867717342662448,1,O=c1[nH]c2cnc3cc(-c4cnoc4)ccc3c2n1Cc1ccccn1
4553,751105,10.1016/j.bmcl.2011.04.028,,,,Inhibition of CYP3A4,CC(CS(=O)(=O)N1CCN(c2ccc(F)cc2)CC1)N(O)C=O,rac-N-(1-(4-(4-fluorophenyl)piperazin-1-ylsulfonyl)propan-2-yl)-N-hydroxyformamide,1.0,uM,=,0.0,0,c1ccc(N2CCNCC2)cc1
4554,774749,,,,,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12,"7-Methyl-4,6,6a,7,8,9,10,10a-octahydro-indolo[4,3-fg]quinoline-9-carboxylic acid ((2R,5S,10bS)-10b-hydroxy-5-isobutyl-2-isopropyl-3,6-dioxo-octahydro-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl)-amide",0.6,uM,=,-0.2218487496163563,0,O=C(NC1OC2[C@@H]3CCCN3C(=O)CN2C1=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2NC1
4555,1662668,10.1021/acs.jmedchem.6b01850,,,,Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated with enzyme in presence of NADPH followed by substrate addition,COc1cc(-c2ccc(Cl)c(C)c2)c(F)cc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3ncccn3)ccc21,"US9212182, 696",32.0,uM,=,1.505149978319906,1,O=c1ccc2cc(S(=O)(=O)Nc3ncccn3)ccc2n1-c1ccc(-c2ccccc2)cc1
4556,622575,10.1016/j.bmcl.2009.09.027,,,,Inhibition of human recombinant CYP3A4 using 7-{3-(4-phenylpiperazin-1-ylmethyl)benzyl}resorufin as substrate,CCCCc1ccc(S(=O)(=O)Nc2ccc3c(c2)CCN(Cc2cc[nH]n2)CC3)cc1,"N-(3-((1H-pyrazol-3-yl)methyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-4-butylbenzenesulfonamide",1.9,uM,=,0.2787536009528289,1,O=S(=O)(Nc1ccc2c(c1)CCN(Cc1cc[nH]n1)CC2)c1ccccc1
4557,816342,10.1021/jm201195m,,,,Inhibition of CYP3A4,Cc1cccc(C(CCCN)(c2ccccc2)c2ccccc2)c1,"4-(3-Methylphenyl)-4,4-diphenylbutan-1-amine",5.5,uM,=,0.7403626894942439,1,c1ccc(C(c2ccccc2)c2ccccc2)cc1
4558,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",C[C@@H]1CN(C(=O)c2cccc(Cl)c2-n2nccn2)[C@H](Cc2cccc(-n3nccn3)c2)CO1,"US9150566, 172",23.0,uM,=,1.3617278360175928,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
4559,519907,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,Cc1nc2c3c(c(-n4cncn4)cn2c1C)CC[C@@H](c1ccccc1)N3,"(S)-2,3-dimethyl-9-phenyl-6-(1H-1,2,4-triazol-1-yl)-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine",0.7,uM,=,-0.1549019599857432,0,c1ccc([C@@H]2CCc3c(-n4cncn4)cn4ccnc4c3N2)cc1
4560,51929,10.1021/jm034111v,,,,Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 5 minutes,C[C@H](NC(=O)/C=C/c1ccccc1)c1cccc(N2CCOCC2)c1,(E)-N-[1-((S)-3-Morpholin-4-yl-phenyl)-ethyl]-3-phenyl-acrylamide,96.0,uM,=,1.9822712330395684,1,O=C(/C=C/c1ccccc1)NCc1cccc(N2CCOCC2)c1
4561,828928,10.1016/j.bmcl.2012.06.022,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,CCN(C)c1nc2ccc(C(=O)N(C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)CC(C)(C)O)cc2o1,"Thiazol-5-ylmethyl(2S,3R)-4-(2-(ethyl(methyl)amino)-N-(2-hydroxy-2-methyl propyl)benzo[d]oxazole-6-carboxamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate",0.14,uM,=,-0.8538719643217619,0,O=C(N[C@H](CCNC(=O)c1ccc2ncoc2c1)Cc1ccccc1)OCc1cncs1
4562,873328,10.1021/jm300065h,,,,Reversible inhibition of CYP3A4,COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C,"Methoxy-acetic acid (1S,2S)-2-(2-{[3-(1H-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)-6-fluoro-1-isopropyl-1,2,3,4-tetrahydro-naphthalen-2-yl ester",0.3,uM,=,-0.5228787452803376,0,c1ccc2c(c1)CCC(CCNCCCc1nc3ccccc3[nH]1)C2
4563,1614025,10.1016/j.bmcl.2016.09.043,,,,Inhibition of CYP3A4 in human liver microsomes assessed as 6-beta-hydroxytestosterone metabolite formation using testosterone as substrate incubated for 30 mins by HPLC-MS method,Cn1c(NCCc2ccc(-c3ccc(Cl)cn3)cc2)nc2cc(Cl)ccc2c1=O,7-Chloro-2-{2-[4-(5-chloro-pyridin-2-yl)-phenyl]-ethylamino}-3-methyl-3H-quinazolin-4-one,8.4,uM,=,0.9242792860618816,1,O=c1[nH]c(NCCc2ccc(-c3ccccn3)cc2)nc2ccccc12
4564,1467195,10.1021/jm5005336,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay,CN1CCN(c2ccc(/C=C/c3n[nH]c4cc([C@@H]5C[C@@]56C(=O)N(C)c5ccccc56)ccc34)cn2)CC1,"(1R,2S)-1'-Methyl-2-(3-((E)-2-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)vinyl)-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-one",0.3,uM,=,-0.5228787452803376,0,O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccc(N4CCNCC4)nc3)n[nH]c2c1
4565,979124,10.1021/jm400484p,,,,Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes,COc1ccc2ccc(-c3cccnc3)c(Cl)c2c1F,3-(1-chloro-8-fluoro-7-methoxynaphthalen-2-yl)pyridine,1.009,uM,=,0.0038911662369104,1,c1cncc(-c2ccc3ccccc3c2)c1
4566,2207925,10.1021/acsmedchemlett.2c00411,,,,Inhibition of CYP3A4 (unknown origin) in presence of NADPH,Cc1cnc(Nc2ccc(F)c(C(F)(F)F)c2)nc1Nc1ccc2oc(=O)[nH]c2c1,5-((2-((4-fluoro-3-(trifluoromethyl)phenyl)amino)-5methylpyrimidin-4-yl)amino)benzo[d]oxazol-2(3H)one,0.7,uM,=,-0.1549019599857432,0,O=c1[nH]c2cc(Nc3ccnc(Nc4ccccc4)n3)ccc2o1
4567,2156515,10.1021/acs.jmedchem.1c01272,,,,Inhibition of CYP3A4 in human liver microsomes using IPA as substrate preincubated for 10 mins followed by NADPH generating system addition and measured after 20 mins,COc1cc2c(cc1OC)CN(CCc1ccc(-n3nnc(-c4cc(OCCc5cccnc5)ccc4NC(=O)c4cc(=O)c5ccccc5o4)n3)cc1)CC2,"N-(2-(2-(4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)-2H-tetrazol-5-yl)-4-(2-(pyridin-3-yl)ethoxy)phenyl)-4-oxo-4H-chromene-2-carboxamide",0.726,uM,=,-0.1390633792999063,0,O=C(Nc1ccc(OCCc2cccnc2)cc1-c1nnn(-c2ccc(CCN3CCc4ccccc4C3)cc2)n1)c1cc(=O)c2ccccc2o1
4568,558484,10.1016/j.bmcl.2008.10.128,,,,Inhibition of CYP3A4,CCN(CC(O)(CNC(=O)c1cnn(-c2ccc(F)cc2)c1N)C(F)(F)F)C(=O)c1ccccc1S(C)(=O)=O,"5-amino-N-(2-((N-ethyl-2-(methylsulfonyl)benzamido)methyl)-3,3,3-trifluoro-2-hydroxypropyl)-1-(4-fluorophenyl)-1H-pyrazole-4-carboxamide",3.0,uM,=,0.4771212547196624,1,O=C(NCCCNC(=O)c1cnn(-c2ccccc2)c1)c1ccccc1
4569,519907,10.1016/j.bmcl.2009.04.127,,,,Inhibition of CYP3A4 using diethoxyfluorescein as substrate,Cc1cccc(C)c1CNc1cc(-c2ccccn2)cn2c(C)c(C)nc12,"N-(2,6-dimethylbenzyl)-2,3-dimethyl-6-(pyridin-2-yl)imidazo[1,2-a]pyridin-8-amine",1.3,uM,=,0.1139433523068367,1,c1ccc(CNc2cc(-c3ccccn3)cn3ccnc23)cc1
4570,940630,10.1021/jm301619u,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS-MS analysis,Cn1cc(-c2cnc3ccc4ccc(CS(=O)(=O)NCc5ccccn5)cc4c(=O)c3c2)cn1,"C-[3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-pyridin-2-ylmethyl-methanesulfonamide",11.58,uM,=,1.0637085593914173,1,O=c1c2cc(CS(=O)(=O)NCc3ccccn3)ccc2ccc2ncc(-c3cn[nH]c3)cc12
4571,642202,10.1021/jm100481d,,,,Inhibition of human CYP3A4 after 10 mins,COC[C@@]12CNCC[C@]1(c1ccc3ccccc3c1)C2,rac-1-[(Methyloxy)methyl]-6-(2-naphthalenyl)-3-azabicyclo[4.1.0]-heptane,8.0,uM,=,0.9030899869919436,1,c1ccc2cc([C@]34CCNCC3C4)ccc2c1
4572,806086,10.1016/j.bmcl.2012.01.064,,,,Inhibition of CYP3A4 in human microsome,NC(=O)C[S+]([O-])Cc1ccccc1-c1ccc(Cl)cc1,(-)-2-((4'-chlorobiphenyl-2-yl)methylsulfinyl)acetamide,159.0,uM,=,2.201397124320452,1,c1ccc(-c2ccccc2)cc1
4573,814102,10.1016/j.bmcl.2012.03.014,,,,Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins,COC[C@H](C)COCc1ccc([C@@]2(O)CCNC[C@@H]2c2noc(-c3ccccc3CCNC(C)=O)c2Br)cc1,"N-(2-(4-bromo-3-((3R,4R)-4-hydroxy-4-(4-(((S)-3-methoxy-2-methylpropoxy)methyl)phenyl)piperidin-3-yl)isoxazol-5-yl)phenethyl)acetamide",29.0,uM,=,1.462397997898956,1,c1ccc(-c2cc([C@H]3CNCCC3c3ccccc3)no2)cc1
4574,772722,10.1021/jm201063u,,,,Inhibition of CYP3A4 using BFC as substrate,Cl.Cl.N=C(Nc1ccc2c(C3CN4CCC3CC4)c[nH]c2c1)c1cccs1,(+/-)-N-(3-(quinuclidin-8-yl)-1H-indol-6-yl)thiophene-2-carboximidamide dihydrochloride,100.0,uM,=,2.0,1,N=C(Nc1ccc2c(C3CN4CCC3CC4)c[nH]c2c1)c1cccs1
4575,1366897,10.1021/jm500312x,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 15 mins by LC/MS/MS analysis,C=C[C@]1(C)C[C@@H](OC(=O)CSc2cncc(NC(=O)CN3CCC(O)CC3)c2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O,14-O-(((5-((4-Hydroxylpiperidin-1-yl)acetamido)pyridin-3-yl)-sulfanyl)acetyl)mutilin,1.89,uM,=,0.2764618041732441,1,O=C(CN1CCCCC1)Nc1cncc(SCC(=O)O[C@@H]2CCCC[C@@]34CCCC2[C@@H]3C(=O)CC4)c1
4576,1446329,10.1021/ml500387y,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay,CC(C)(CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F)c1ccccc1C(N)=O,"2-(5,5,5-trifluoro-4-hydroxy-2-methyl-4-((5-morpholino-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)pentan-2-yl)benzamide",3.0,uM,=,0.4771212547196624,1,c1ccc(CCCCc2cc3cc(N4CCOCC4)ncc3[nH]2)cc1
4577,1467195,10.1021/jm5005336,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay,COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5C[C@@H](C)O[C@@H](C)C5)cc4)n[nH]c3c1)C(=O)N2,"(1R,2S)-(E)-2-(3-(4-cis-2,6-Dimethylmorpholino)methyl)styryl)-1H-indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one",3.1,uM,=,0.4913616938342727,1,O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccc(CN4CCOCC4)cc3)n[nH]c2c1
4578,657980,10.1021/jm100482n,,,,Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein/7-benzyloxyquinoline as substrate,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C#N)ncn4-5)CC3)cccc2n1,"6-(2-(4-(2-methylquinolin-5-yl)piperazin-1-yl)ethyl)-4H-benzo[b]imidazo[1,5-d][1,4]oxazine-3-carbonitrile",4.0,uM,=,0.6020599913279624,1,c1cc(CCN2CCN(c3cccc4ncccc34)CC2)c2c(c1)-n1cncc1CO2
4579,751105,10.1016/j.bmcl.2011.04.028,,,,Inhibition of CYP3A4,O=CN(O)C1(CS(=O)(=O)N2CCN(c3ccc(F)cc3)CC2)CCC1,N-(1-((4-(4-fluorophenyl)piperazin-1-ylsulfonyl)methyl)cyclobutyl)-N-hydroxyformamide,1.9,uM,=,0.2787536009528289,1,O=S(=O)(CC1CCC1)N1CCN(c2ccccc2)CC1
4580,816342,10.1021/jm201195m,,,,Inhibition of CYP3A4,Cc1ccc(C(=O)N(CCCN)[C@@H](c2nc3cc(Cl)ccc3c(=O)n2Cc2ccccc2)C(C)C)cc1,"(R)-N-(3-aminopropyl)-N-(1-(3-benzyl-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylpropyl)-4-methylbenzamide",4.1,uM,=,0.6127838567197355,1,O=C(NCc1nc2ccccc2c(=O)n1Cc1ccccc1)c1ccccc1
4581,1534761,,,,,"Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.",COc1cnc2[nH]cc(Cc3ccc(NCc4cccnc4OC)nc3F)c2c1,"US9096593, P-2043",5.0,uM,=,0.6989700043360189,1,c1cncc(CNc2ccc(Cc3c[nH]c4ncccc34)cn2)c1
4582,487712,10.1016/j.bmcl.2008.05.104,,,,Inhibition of CYP3A4,COC1CCN(c2cc(C)c3nc(-c4c(NC[C@@H](O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1,(S)-4-(2-(3-chlorophenyl)-2-hydroxyethylamino)-3-(6-(4-methoxypiperidin-1-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one,0.001,uM,=,-3.0,0,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(N3CCCCC3)cc2[nH]1
4583,510198,10.1021/jm800355c,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=CC[C@@H]12,"10,13-Dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol",2.704,uM,=,0.4320066872695983,1,C1=C2CCCCC2[C@H]2CCC3C(c4cccnc4)=CC[C@H]3[C@@H]2C1
4584,1528063,,,,,"Inhibtion Assay: Assays (200 μL final volume) were carried out in NUNC polypropylene deep well plates in 50 mM potassium phosphate buffer, pH 7.4, using a microtiter plate shaker in a 37° C. incubator. Pooled human liver microsomes (BD Gentest, 50 μg/mL) were incubated with 5 concentrations of test compound (from 0.1 μM to 10 μM), 1 mM NADPH (Sigma), and 2 μM midazolam (Sigma). A constant amount of dimethylsulfoxide (1%) was added to the incubations with the test compounds, and each analysis was performed in duplicate. For preincubation experiments (Pre), the microsomes, test compounds, and NADPH were mixed and incubated 30 minutes before addition of midazolam. For coincubation experiments (Co), the compounds, microsomes, and midazolam were mixed and the reaction initiated by addition of NADPH to the wells.",Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cn[nH]c5)cnc(N)c34)cc2)c1,SID103904308,0.76,uM,=,-0.1191864077192086,0,O=C(Nc1ccccc1)Nc1ccc(-c2csc3c(-c4cn[nH]c4)cncc23)cc1
4585,657984,10.1021/jm100482n,,,,Inhibition of CYP3A4 in human liver microsomes measured immediately,Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(N)=O)ncn4-5)CC3)cccc2n1,"6-(2-(4-(2-methylquinolin-5-yl)piperazin-1-yl)ethyl)-4H-benzo[b]imidazo[1,5-d][1,4]oxazine-3-carboxamide",88.0,uM,=,1.944482672150169,1,c1cc(CCN2CCN(c3cccc4ncccc34)CC2)c2c(c1)-n1cncc1CO2
4586,1335568,10.1021/jm401731q,,,,Inhibition of CYP3A4 (unknown origin),CN1CCN(c2cc(N3CC[C@H]3C(=O)NCCc3ccc(C#N)cc3)nc(C(F)(F)F)n2)CC1,(2S)-N-[2-(4-Cyanophenyl)ethyl]-1-[6-(4-methylpiperazin-1-yl)-2-(trifluoromethyl)pyrimidin-4-yl]azetidine-2-carboxamide,3.0,uM,=,0.4771212547196624,1,O=C(NCCc1ccccc1)[C@@H]1CCN1c1cc(N2CCNCC2)ncn1
4587,1640603,,,,,"CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.",O=C(c1ccc(Cl)cc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1,"US9150566, 77",16.0,uM,=,1.2041199826559248,1,O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1
4588,1466989,10.1021/jm501719e,,,,Inhibition of human CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)coumarin as substrate assessed as formation of 7-hydroxy-4-trifluoromethylcoumarin incubated for 2 mins prior to NADPH addition by fluorimetric assay,Cc1cncn1-c1nccc(CCNCCCc2cccc(F)c2)n1.Cl,3-(3-fluorophenyl)-N-(2-(2-(5-methyl-1H-imidazol-1-yl)pyrimidin-4-yl)ethyl)propan-1-amine dihydrochloride,0.9,uM,=,-0.0457574905606751,0,c1ccc(CCCNCCc2ccnc(-n3ccnc3)n2)cc1
4589,828928,10.1016/j.bmcl.2012.06.022,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis,O=C(N[C@@H](Cc1ccccc1)[C@H](O)CN(CCN1CCOCC1)C(=O)c1ccc2nc(N3CCCC3)oc2c1)OCc1cncs1,"thiazol-5-ylmethyl(2S,3R)-3-hydroxy-4-(N-(2-morpholinoethyl)-2-(pyrrolidin-1-yl)benzo[d]oxazole-6-carboxamido)-1-phenylbutan-2-ylcarbamate",0.12,uM,=,-0.9208187539523752,0,O=C(N[C@H](CCN(CCN1CCOCC1)C(=O)c1ccc2nc(N3CCCC3)oc2c1)Cc1ccccc1)OCc1cncs1
4590,1679702,10.1016/j.bmcl.2017.04.021,,,,Inhibition of hepatic CYP3A4 (unknown origin),CC(C)(O)c1cncc(-n2ncc3c(C(F)(F)F)cccc32)c1,2-(5-(4-(trifluoromethyl)-1H-indazol-1-yl)pyridin-3-yl)propan-2-ol,43.0,uM,=,1.6334684555795866,1,c1cncc(-n2ncc3ccccc32)c1
4591,1528855,,,,,"Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.",C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCCCC6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1,"US8940739, A::US8940739, G-35",14.7,uM,=,1.167317334748176,1,O=C(Nc1ccc(N2CCCCC2)nc1)c1c[nH]c2c(CN3C[C@@H]4N(C(=O)NCc5ccccc5)NCC(=O)N4[C@@H](Cc4ccccc4)C3=O)cccc12
4592,449088,10.1016/j.bmcl.2007.08.028,,,,Inhibition of human CYP3A4,CC(=O)N1CCC(C(=O)N2C[C@H](C(=O)N(C)C(C)(C)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)[C@@H](c3ccc(F)cc3C)C2)CC1,"(3R,4S)-N-(2-(3,5-bis(trifluoromethyl)phenyl)propan-2-yl)-1-(1-acetylpiperidine-4-carbonyl)-4-(4-fluoro-2-methylphenyl)-N-methylpyrrolidine-3-carboxamide",49.0,uM,=,1.6901960800285136,1,O=C(NCc1ccccc1)[C@H]1CN(C(=O)C2CCNCC2)C[C@@H]1c1ccccc1
4593,479555,10.1016/j.bmcl.2008.03.057,,,,Inhibition of CYP3A4,CNc1nnc(-c2cn3ncnc(Nc4cnc5[nH]c(C)cc5c4)c3c2C(C)C)o1,"5-isopropyl-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-6-(5-(methylamino)-1,3,4-oxadiazol-2-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine",6.4,uM,=,0.8061799739838872,1,c1nc(Nc2cnc3[nH]ccc3c2)c2cc(-c3nnco3)cn2n1
4594,2123080,10.1016/j.ejmech.2021.113674,,,,Inhibition of CYP3A4 (unknown origin) using BOMCC as a substrate incubated for 20 mins by fluorescence based analysis,CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,SID144204227,0.0023799999999999,uM,=,-2.623423042943488,0,c1ccc([C@@]2(Cn3ccnc3)OC[C@H](COc3ccc(N4CCNCC4)cc3)O2)cc1
4595,510198,10.1021/jm800355c,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes,Br.Oc1ccc(-c2ccc3c(c2)CCCC3c2ccncc2)cc1F,"2-Fluoro-4-(5-(pyridin-4-yl)-5,6,7,8-tetrahydronaphthalen-2-yl)phenol Hydrobromide",3.386,uM,=,0.5296869537729164,1,c1ccc(-c2ccc3c(c2)CCCC3c2ccncc2)cc1
4596,1705360,10.1016/j.bmcl.2017.06.037,,,,Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method,OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(C#Cc2ccc(OCC(F)F)cc2)cn1,"1-(5-((4-(2,2-difluoroethoxy)phenyl)ethynyl)pyridin-2-yl)-2-(2,4-difluorophenyl)-1,1-difluoro-3-(1H-tetrazol-1-yl)propan-2-ol",60.0,uM,=,1.7781512503836436,1,C(#Cc1ccc(CC(Cn2cnnn2)c2ccccc2)nc1)c1ccccc1
4597,1689562,10.1021/acs.jmedchem.7b00598,,,,Inhibition of CYP3A4 (unknown origin),CCN1CC(n2nccc2-c2cc(Cl)ccc2Oc2ccc(S(=O)(=O)Nc3cscn3)cc2C#N)C1,4-(4-chloro-2-(1-(1-ethylazetidin-3-yl)-1H-pyrazol-5-yl)phenoxy)-3-cyano-N-(thiazol-4-yl)benzenesulfonamide,12.239,uM,=,1.0877459347847338,1,O=S(=O)(Nc1cscn1)c1ccc(Oc2ccccc2-c2ccnn2C2CNC2)cc1
4598,1772538,10.1016/j.bmcl.2018.05.055,,,,Inhibition of CYP3A4 (unknown origin),CC(=O)N[C@@H](C)/C=C/c1ccc(Oc2ccc3nc(C(C)C)sc3c2Cl)nc1,"(S,E)-N-(4-(6-((7-chloro-2-isopropylbenzothiazol-6-yl)oxy)pyridin-3-yl)but-3-en-2-yl)acetamide",19.0,uM,=,1.2787536009528289,1,c1ccc(Oc2ccc3ncsc3c2)nc1
4599,51915,10.1016/s0960-894x(03)00680-2,,,,Inhibition of human liver microsome Cytochrome P450 3A4,O=C(N[C@H]1c2ccccc2OC[C@H]1O)[C@H](Cc1cccnc1)C[C@H](O)CN1CCN(CC2=CC3C=CSC3S2)C[C@H]1C(=O)NCC(F)(F)F,"(S)-4-(3a,6a-Dihydro-thieno[2,3-b]thiophen-2-ylmethyl)-1-[(2S,4R)-2-hydroxy-4-((3S,4S)-3-hydroxy-chroman-4-ylcarbamoyl)-5-pyridin-3-yl-pentyl]-piperazine-2-carboxylic acid (2,2,2-trifluoro-ethyl)-amide",0.31,uM,=,-0.5086383061657274,0,O=C(N[C@@H]1CCOc2ccccc21)[C@@H](CCCN1CCN(CC2=CC3C=CSC3S2)CC1)Cc1cccnc1
4600,2194843,10.1021/acs.jmedchem.2c00986,,,,Time-dependent inhibition of CYP3A4 (unknown origin) at 2 ul pre-incubated for 30 mins in presence or absence of NADPH incubated for 10 mins by LC/MS analysis,Cc1nc(N[C@H](C)c2cccc(C(F)F)c2F)c2cc3c(cc2n1)OCC[C@H]1CN(C(=O)C2(C#N)CC2)CCN31,"1-((S)-12-(((R)-1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)amino)-10-methyl-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1',2':4,5][1,4]oxazepino[3,2-g]quinazoline-3-carbonyl)cyclopropane-1-carbonitrile",15.8,uM,=,1.1986570869544226,1,O=C(C1CC1)N1CCN2c3cc4c(NCc5ccccc5)ncnc4cc3OCC[C@H]2C1
4601,674156,10.1016/j.bmcl.2010.08.100,,,,Inhibition of CYP3A4 in human liver microsomes by fluorometric assay,CS(=O)(=O)c1cccc(Nc2nccc(Nc3c(Cl)ccc4c3OCO4)n2)c1,"N4-(5-chlorobenzo[d][1,3]dioxol-4-yl)-N2-(3-(methylsulfonyl)phenyl)pyrimidine-2,4-diamine",2.6,uM,=,0.414973347970818,1,c1ccc(Nc2nccc(Nc3cccc4c3OCO4)n2)cc1
4602,827409,10.1016/j.bmc.2012.04.053,,,,Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture simultaneously with BFC substrate by fluorometric assay,OC[C@H]1C[C@@H](c2cccc(Cc3ccc(C4CC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,"(1R,2R,3S,4S,6R)-4-[3-(4-Cyclopropyl-benzyl)phenyl]-6-(hydroxymethyl)cyclohexane-1,2,3-triol",76.0,uM,=,1.880813592280792,1,c1cc(Cc2ccc(C3CC3)cc2)cc(C2CCCCC2)c1
4603,2066474,10.1016/j.ejmech.2018.04.062,,,,Inhibition of human liver microsome CYP3A4 using testosterone as substrate incubated for 20 mins by LC-MS/MS analysis,COc1cnc(-n2cnc(C)n2)c2[nH]cc(C(=O)C(=O)N3CCN(C(=O)c4ccccc4)CC3)c12,TEMSAVIR,25.0,uM,=,1.3979400086720375,1,O=C(C(=O)N1CCN(C(=O)c2ccccc2)CC1)c1c[nH]c2c(-n3cncn3)nccc12
4604,1628093,10.1016/j.ejmech.2016.08.024,,,,Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells preincubated for 30 mins using fluorescent substrate,O=C(CC1([C@H]2COC[C@@H](C3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1C2CCC1CC(N1CCCCC1)C2,"2-(1-((3S,5R)-4-(4-chlorophenylsulfonyl)-5-cyclopropylmorpholin-3-yl)cyclopropyl)-1-(3-(piperidin-1-yl)-8-azabicyclo[3.2.1]octan-8-yl)ethanone",2.0,uM,=,0.3010299956639812,1,O=C(CC1([C@H]2COC[C@@H](C3CC3)N2S(=O)(=O)c2ccccc2)CC1)N1C2CCC1CC(N1CCCCC1)C2
4605,606336,10.1016/j.bmcl.2009.11.061,,,,Inhibition of CYP3A4,Cc1occc1-c1nc(N)c(OC[C@@H](N)Cc2c[nH]c3ccccc23)cc1-c1ccc2[nH]nc(C)c2c1,3-((S)-2-amino-3-(1H-indol-3-yl)propoxy)-5-(3-methyl-1H-indazol-5-yl)-6-(2-methylfuran-3-yl)pyridin-2-amine,0.1,uM,=,-1.0,0,c1ccc2c(CCCOc3cnc(-c4ccoc4)c(-c4ccc5[nH]ncc5c4)c3)c[nH]c2c1
4606,2171279,10.1021/acs.jmedchem.1c01083,,,,Inhibition of human recombinant CYP3A4 expressed in insect microsome using 7-benzyloxy-4-trifluoromethylcoumarin as a substrate incubated for 30 mins followed by addition of NADPH regenerating system measured immediately by fluorescence based analysis,CCCCCCCCCCCCCCCOP(=O)(O)CO[C@H](C)Cn1cnc2c(N)ncnc21.N,Ammonium [(1R)-2-(6-Aminopurin-9-yl)-1-methyl-ethoxyl]methyl-pentadecoxy-phosphinate,54.9,uM,=,1.739572344450092,1,c1ncc2nc[nH]c2n1
4607,490337,10.1016/j.bmcl.2008.06.073,,,,Inhibition of CYP3A4 in pooled human liver microsome using atrovastatin substrate,CC(C)c1onc(-c2c(Cl)cccc2Cl)c1COc1ccc(-c2ccc3c(C(=O)O)cccc3c2)cc1,"6-(4-((3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl)methoxy)phenyl)-1-naphthoic acid",4.6,uM,=,0.6627578316815741,1,c1ccc(-c2nocc2COc2ccc(-c3ccc4ccccc4c3)cc2)cc1
4608,1871178,10.1016/j.bmcl.2018.11.037,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,Nc1ncnc2c(C(=O)Nc3cccc4c3c(Br)nn4Cc3cccnc3)csc12,"4-amino-N-(3-bromo-1-(pyridin-3-ylmethyl)-1H-indazol-4-yl)thieno[3,2-d]pyrimidine-7-carboxamide",0.31,uM,=,-0.5086383061657274,0,O=C(Nc1cccc2c1cnn2Cc1cccnc1)c1csc2cncnc12
4609,2193505,10.1016/j.bmcl.2022.128892,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 30 mins,CNC(=O)N(c1ccc(S(=O)(=O)Nc2ccon2)cn1)c1cc(Cl)c(-c2ccc(F)c(C(F)(F)F)c2)cc1OC,"6-(1-(2-chloro-4'-fluoro-5-methoxy-3'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)-3-methylureido)-N-(isoxazol-3-yl)pyridine-3-sulfonamide",12.0,uM,=,1.0791812460476249,1,O=S(=O)(Nc1ccon1)c1ccc(Nc2ccc(-c3ccccc3)cc2)nc1
4610,574223,10.1021/jm900374r,,,,Inhibition of CYP3A4 in human liver microsomes,Cc1ccc2c3c(ccc2n1)OC[C@H](CN1CCN(c2ccc4cc(C#N)ccc4n2)CC1)O3,"2-(4-{[(2S)-8-Methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinolin-2-yl]methyl}piperazin-1-yl)-quinoline-6-carbonitrile",10.0,uM,=,1.0,1,c1ccc2nc(N3CCN(C[C@H]4COc5ccc6ncccc6c5O4)CC3)ccc2c1
4611,950952,10.1016/j.bmcl.2013.02.023,,,,Inhibition of human CYP3A4,COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc(-c3ccc(CO)cc3)cc2)[nH]1)C(C)C,methyl(S)-1-((S)-2-(5-(4'-(hydroxymethyl)biphenyl-4-yl)-1H-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-ylcarbamate,6.9,uM,=,0.8388490907372553,1,c1ccc(-c2ccc(-c3cnc([C@@H]4CCCN4)[nH]3)cc2)cc1
4612,643712,10.1016/j.bmcl.2010.06.009,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader,C[C@@H](Oc1cc(-n2cnc3cc(-c4cnn(CCN5CCN(C)CC5)c4)ccc32)sc1C(N)=O)c1ccccc1Cl,(R)-3-(1-(2-chlorophenyl)ethoxy)-5-(5-(1-(2-(4-methylpiperazin-1-yl)ethyl)-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)thiophene-2-carboxamide,0.2,uM,=,-0.6989700043360187,0,c1ccc(COc2csc(-n3cnc4cc(-c5cnn(CCN6CCNCC6)c5)ccc43)c2)cc1
4613,1707938,10.1021/acs.jmedchem.7b01420,,,,Inhibition of CYP3A4 (unknown origin),c1ccc2c(c1)CN[C@@H](CN(CCCCNCc1ccncc1)[C@H]1CCCc3cccnc31)C2,"N1-(Pyridin-4-ylmethyl)-N4-(((R)-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)-N4-((S)-5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine",4.5,uM,=,0.6532125137753437,1,c1ccc2c(c1)CN[C@@H](CN(CCCCNCc1ccncc1)[C@H]1CCCc3cccnc31)C2
4614,643712,10.1016/j.bmcl.2010.06.009,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader,C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(N5CCNCC5)c4)ccc32)sc1C(N)=O)c1ccccc1Cl,(R)-3-(1-(2-chlorophenyl)ethoxy)-5-(5-(2-(piperazin-1-yl)pyridin-4-yl)-1H-benzo[d]imidazol-1-yl)thiophene-2-carboxamide,1.4,uM,=,0.1461280356782379,1,c1ccc(COc2csc(-n3cnc4cc(-c5ccnc(N6CCNCC6)c5)ccc43)c2)cc1
4615,643969,10.1016/j.bmcl.2010.06.086,,,,Inhibition of human CYP3A4-mediated midazolam oxidation,CC(C)CC1n2cncc2CN(Cc2ccccc2)S1(=O)=O,"6-Benzyl-4-isobutyl-6,7-dihydro-5-thia-2,3a,6-triaza-indene 5,5-dioxide",0.1,uM,=,-1.0,0,O=S1(=O)Cn2cncc2CN1Cc1ccccc1
4616,1866289,10.1021/acs.jmedchem.9b00662,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,OC(CC1c2ccccc2-c2cncn21)C1CCCCC1,"1-cyclohexyl-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethanol",0.17,uM,=,-0.7695510786217261,0,c1ccc2c(c1)-c1cncn1C2CCC1CCCCC1
4617,1866289,10.1021/acs.jmedchem.9b00662,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,O=C(Cc1ccncc1)N1CCC(C(O)CC2c3ccccc3-c3cncn32)CC1,"1-(4-(1-Hydroxy-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethyl)-piperidin-1-yl)-2-(pyridin-4-yl)ethan-1-one",3.8,uM,=,0.5797835966168101,1,O=C(Cc1ccncc1)N1CCC(CCC2c3ccccc3-c3cncn32)CC1
4618,1707938,10.1021/acs.jmedchem.7b01420,,,,Inhibition of CYP3A4 (unknown origin),FC1(F)CCC(NC/C=C/CN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)CC1,"(E)-N1-(4,4-Difluorocyclohexyl)-N4-(((R)-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)-N4-((S)-5,6,7,8-tetrahydroquinolin-8-yl)-but-2-ene-1,4-diamine",0.839,uM,=,-0.0762380391712997,0,C(=C/CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21)\CNC1CCCCC1
4619,2093989,10.1021/acs.jmedchem.0c01296,,,,Inhibition of human CYP3A4 in human pooled liver microsomes in presence of midazolam as substrate preincubated for 30 mins in presence of NADPH followed by addition of substrate by LC-MS/MS analysis,[2H]C([2H])([2H])Oc1cc2ccnc(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)NS(=O)(=O)C6(C)CC6)C[C@H]5/C=C\CC[C@@H](C)C[C@@H](CC)[C@H](NC(=O)OC(C)(C)C(F)(F)F)C(=O)N4C3)c2cc1F,"1,1,1-Trifluoro-2-methylpropan-2-yl-((2R,6S,7R,9R,13aS,14aR,16aS,Z)-7-Ethyl-2-((7-fluoro-6-(methoxy-d3)isoquinolin-1-yl)oxy)-9-methyl-14a-(((1-methylcyclopropyl)sulfonyl)carbamoyl)-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl)carbamate",16.4,uM,=,1.214843848047698,1,O=C1N[C@]2(C(=O)NS(=O)(=O)C3CC3)C[C@H]2/C=C\CCCCCCC(=O)N2C[C@H](Oc3nccc4ccccc34)C[C@@H]12
4620,1662545,10.1021/acs.jmedchem.6b01851,,,,Inhibition of CYP3A4 (unknown origin),COc1cc(-c2cccc(F)c2)ccc1-c1nccc2cc(S(=O)(=O)Nc3ccncn3)ccc12,"US9012443, 199",1.3,uM,=,0.1139433523068367,1,O=S(=O)(Nc1ccncn1)c1ccc2c(-c3ccc(-c4ccccc4)cc3)nccc2c1
4621,652208,10.1016/j.bmcl.2010.07.052,,,,Inhibition of CYP3A4 in human liver microsomes,O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)n(CCOc3ccccc3)c3ccccc32)CC1,1-(2-phenoxyethyl)-3-(1-(1-(pyridin-4-ylmethyl)piperidine-4-carbonyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one,9.0,uM,=,0.9542425094393248,1,O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)n(CCOc3ccccc3)c3ccccc32)CC1
4622,1347924,10.1016/j.bmcl.2014.04.024,,,,Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method,COc1cc2ccc(C(O)(c3nc[nH]n3)C(C)C)cc2cc1OC,"rac-1-(6,7-dimethoxynaphthalen-2-yl)-2-methyl-1-(1H-1,2,4-triazol-3-yl)propan-1-ol",100.0,uM,=,2.0,1,c1ccc2cc(Cc3nc[nH]n3)ccc2c1
4623,1572816,10.1016/j.bmcl.2016.04.024,,,,Inhibition of human recombinant CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate incubated for 30 mins by fluorescence analysis in presence of NADPH,CC(C)CS(=O)(=O)n1ccc2c(-c3ccc(C(F)(F)F)cc3)cc(N3CCN(C)CC3)nc21,"1-methyl-4-[1-(2-methylpropanesulfonyl)-4-[4-(trifluoromethyl)phenyl]-1H-pyrrolo[2,3-b]pyridin-6-yl]piperazine",1.1,uM,=,0.041392685158225,1,c1ccc(-c2cc(N3CCNCC3)nc3[nH]ccc23)cc1
4624,830173,10.1016/j.bmcl.2012.05.074,,,,Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay,Cn1cc(C[C@@H](NC(=O)N2CCC(n3c(=O)[nH]c4ccccc43)CC2)C(=O)N2CCC(N3CCCCC3)CC2)c2ccccc21,"(R)-N-(1-(1,4'-bipiperidin-1'-yl)-3-(1-methyl-1H-indol-3-yl)-1-oxopropan-2-yl)-4-(2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-1-carboxamide",0.1,uM,=,-1.0,0,O=C(N[C@H](Cc1c[nH]c2ccccc12)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1
4625,1729574,10.1021/acsmedchemlett.7b00406,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate,C/C(CN)=C(/F)CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21,"(Z)-2-fluoro-3-methyl-N1-(((R)-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)-N1-((S)-5,6,7,8-tetrahydroquinolin-8-yl)but-2-ene-1,4-diamine",2.4,uM,=,0.380211241711606,1,c1ccc2c(c1)CN[C@@H](CN[C@H]1CCCc3cccnc31)C2
4626,1276679,10.1021/jm4012033,,,,Inhibition of CYP3A4 (unknown origin),Cc1csc([C@](C)(O)c2nnc(Nc3ccn(Cc4c(F)cccc4F)n3)s2)n1,"(1S)-1-(5-{[1-(2,6-Difluorobenzyl)-1H-pyrazol-3-yl]amino}-1,3,4-thiadiazol-2-yl)-1-(4-methyl-1,3-thiazol-2-yl)ethanol",1.9,uM,=,0.2787536009528289,1,c1ccc(Cn2ccc(Nc3nnc(Cc4nccs4)s3)n2)cc1
4627,621523,10.1021/np900266m,,,,Inhibition of CYP3A4 after 30 mins by fluorescence microplate reader assay,CCCCCCCCCC1O[C@H](CC/C(C)=C/COc2c3ccoc3cc3oc(=O)ccc23)C(C)(C)O1,"6',7'-Dihydroxybergamottin Decanal Acetal",0.27,uM,=,-0.5686362358410126,0,O=c1ccc2c(OC/C=C/CC[C@@H]3COCO3)c3ccoc3cc2o1
4628,728151,10.1016/j.bmc.2011.01.017,,,,Inhibition of human CYP3A4,CC(C)C(O)(c1ccc2cc3c(cc2c1)CN(C)C3=O)c1c[nH]cn1,"rac-6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-methyl-2,3-dihydro-1H-benzo[f]isoindol-1-one",5.4,uM,=,0.7323937598229685,1,O=C1NCc2cc3cc(Cc4c[nH]cn4)ccc3cc21
4629,1488449,10.1124/dmd.110.035071,,,,Inhibition of CYP3A4 in human liver microsomes using nifedipine substrate by HPLC-MS/MS method,CC(=O)N1CCN([C@H]2CCN(C(=O)N(C)[C@H](C)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)[C@@H](c3ccc(F)cc3C)C2)CC1O,"(2R,4S)-4-(4-acetyl-3-hydroxypiperazin-1-yl)-N-((R)-1-(3,5-bis(trifluoromethyl)phenyl)ethyl)-2-(4-fluoro-2-methylphenyl)-N-methylpiperidine-1-carboxamide",5.6,uM,=,0.7481880270062004,1,O=C(NCc1ccccc1)N1CC[C@H](N2CCNCC2)C[C@@H]1c1ccccc1
4630,813105,10.1021/jm201346g,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,CCCCCCSc1nc2cc(OC)ccc2[nH]1,2-(hexylthio)-5-methoxy-1H-benzo[d]imidazole,5.33,uM,=,0.7267272090265723,1,c1ccc2[nH]cnc2c1
4631,1707938,10.1021/acs.jmedchem.7b01420,,,,Inhibition of CYP3A4 (unknown origin),NC/C=C\CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21,"(Z)-N1-(((R)-1,2,3,4-Tetrahydroisoquinolin-3-yl)methyl)-N1-((S)-5,6,7,8-tetrahydroquinolin-8-yl)but-2-ene-1,4-diamine",12.7,uM,=,1.1038037209559568,1,c1ccc2c(c1)CN[C@@H](CN[C@H]1CCCc3cccnc31)C2
4632,759487,10.1016/j.bmcl.2011.05.106,,,,Inhibition of CYP3A4,CN1CC(Cl)=C(c2cn(S(=O)(=O)c3ccccc3)c3ccccc23)C1,"1-Benzenesulfonyl-3-(4-chloro-1-methyl-2,5-dihydro-1H-pyrrol-3-yl)-1H-indole",14.7,uM,=,1.167317334748176,1,O=S(=O)(c1ccccc1)n1cc(C2=CCNC2)c2ccccc21
4633,1628093,10.1016/j.ejmech.2016.08.024,,,,Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells preincubated for 30 mins using fluorescent substrate,CC(=O)N1C2CCC1CN(C(=O)CC1([C@H]3CO[C@H]4CCC[C@H]4N3S(=O)(=O)c3ccc(Cl)cc3)CC1)C2,"1-(8-acetyl-3,8-diazabicyclo[3.2.1]octan-3-yl)-2-(1-((3S,4aR,7aS)-4-(4-chlorophenylsulfonyl)octahydrocyclopenta[b][1,4]oxazin-3-yl)cyclopropyl)ethanone",15.0,uM,=,1.1760912590556811,1,O=C(CC1([C@H]2CO[C@H]3CCC[C@H]3N2S(=O)(=O)c2ccccc2)CC1)N1CC2CCC(C1)N2
4634,936804,10.1021/jm301511h,,,,Inhibition of human recombinant CYP3A4 expressed in Escherichia coli cells,O=C(NCC1CCOCC1)c1ncccc1NC(=O)c1ccc(Cn2ccnn2)c2ccccc12,"N-[(Tetrahydro-2H-pyran-4-yl)methyl]-3-[[[4-(1H-1,2,3-triazol-1-ylmethyl)-1-naphthalenyl]carbonyl]amino]-2-pyridinecarboxamide",0.61,uM,=,-0.2146701649892329,0,O=C(NCC1CCOCC1)c1ncccc1NC(=O)c1ccc(Cn2ccnn2)c2ccccc12
4635,1707938,10.1021/acs.jmedchem.7b01420,,,,Inhibition of CYP3A4 (unknown origin),CC1(C)CCC(NCCCCN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)CC1,"N1-(4,4-Dimethylcyclohexyl)-N4-(((R)-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)-N4-((S)-5,6,7,8-tetrahydroquinolin-8-yl)-butane-1,4-diamine",12.9,uM,=,1.110589710299249,1,c1ccc2c(c1)CN[C@@H](CN(CCCCNC1CCCCC1)[C@H]1CCCc3cccnc31)C2
4636,464242,10.1021/jm7013309,,,,Inhibition of human CYP3A4 using 7-benzyl-trifluoromethyl coumarin,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)CN)c(C)c34)ccc2[nH]1,"(R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl 2-aminoacetate",0.16,uM,=,-0.7958800173440752,0,c1cc2c(Oc3ccc4[nH]ccc4c3)ncnn2c1
4637,1735372,10.1021/acs.jmedchem.8b00084,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis,CCCc1ccncc1-c1ccc(CN)o1.Cl.Cl,(5-(4-Propylpyridin-3-yl)furan-2-yl)methanamine Dihydrochloride,4.9,uM,=,0.6901960800285137,1,c1cncc(-c2ccco2)c1
4638,813105,10.1021/jm201346g,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Cc1ccc2[nH]c(SCc3ccccn3)nc2c1,5-methyl-2-(pyridin-2-ylmethylthio)-1H-benzo[d]imidazole,3.61,uM,=,0.557507201905658,1,c1ccc(CSc2nc3ccccc3[nH]2)nc1
4639,673953,10.1016/j.bmcl.2010.08.086,,,,Inhibition of CYP3A4 using testosterone as substrate,CNCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1,"(3R,4S)-N-(2-chloro-5-((methylamino)methyl)benzyl)-N-cyclopropyl-4-(4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)phenyl)piperidine-3-carboxamide",17.0,uM,=,1.230448921378274,1,O=C([C@H]1CNCC[C@@H]1c1ccc(OCCOc2ccccc2)cc1)N(Cc1ccccc1)C1CC1
4640,841307,10.1016/j.bmcl.2012.06.029,,,,Inhibition of CYP3A4,CCN1CCC(Nc2ccc3c(c2)C(=C(c2ccc(C)cc2)c2nc4ccccc4[nH]2)C(=O)N3)CC1,(E/Z)-3-((1H-benzo[d]imidazol-2-yl)(p-tolyl)methylene)-5-(1-ethylpiperidin-4-ylamino)indolin-2-one,12.0,uM,=,1.0791812460476249,1,O=C1Nc2ccc(NC3CCNCC3)cc2C1=C(c1ccccc1)c1nc2ccccc2[nH]1
4641,583696,10.1016/j.bmcl.2009.05.066,,,,Inhibition of human recombinant CYP3A4 after 45 mins,O=C(NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)NC(c1ccccc1)c1ncc[nH]1,1-((1H-imidazol-2-yl)(phenyl)methyl)-3-(1-((1-(4-(trifluoromethyl)phenyl)-1H-pyrrol-3-yl)methyl)piperidin-4-yl)urea,13.4,uM,=,1.1271047983648077,1,O=C(NC1CCN(Cc2ccn(-c3ccccc3)c2)CC1)NC(c1ccccc1)c1ncc[nH]1
4642,2240170,10.1021/acs.jmedchem.2c01383,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as substrate,Cc1nnc(C(C)C)n1[C@@H]1C[C@H]2CC[C@@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1,"4,4-Difluoro-cyclohexanecarboxylic acid {(S)-3-[(1S,5S)-3-(3-isopropyl-5-methyl-[1,2,4]triazol-4-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-1-phenyl-propyl}-amide",14.9,uM,=,1.173186268412274,1,O=C(N[C@@H](CCN1[C@@H]2CC[C@H]1C[C@H](n1cnnc1)C2)c1ccccc1)C1CCCCC1
4643,673953,10.1016/j.bmcl.2010.08.086,,,,Inhibition of CYP3A4 using testosterone as substrate,Cc1cc(Cl)c(OCCOc2ccc([C@H]3CCNC[C@@H]3C(=O)N(Cc3cc(CCNC(=O)CC(F)(F)F)ccc3Cl)C3CC3)cc2)c(Cl)c1,"(3R,4S)-N-(2-chloro-5-(2-(3,3,3-trifluoropropanamido)ethyl)benzyl)-N-cyclopropyl-4-(4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)phenyl)piperidine-3-carboxamide",4.5,uM,=,0.6532125137753437,1,O=C([C@H]1CNCC[C@@H]1c1ccc(OCCOc2ccccc2)cc1)N(Cc1ccccc1)C1CC1
4644,1973582,10.1021/acs.jmedchem.9b02016,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate measured after 15 mins by LC-MS/MS analysis,O=C(CCCCCCC(=O)Nc1ccccc1)NOC(c1ccccc1)(c1ccccc1)c1ccccc1,N-Phenyl-N'-(trityloxy)octanediamide,5.56,uM,=,0.7450747915820575,1,O=C(CCCCCCC(=O)Nc1ccccc1)NOC(c1ccccc1)(c1ccccc1)c1ccccc1
4645,1296352,10.1021/jm4015108,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,O=C(Nc1ccc(S(=O)(=O)c2cnn(C3CCOCC3)c2)cc1)[C@@H]1C[C@H]1c1cccnc1,rac-trans-2-(Pyridin-3-yl)-N-(4-((1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)sulfonyl)phenyl)cyclopropanecarboxamide,1.8,uM,=,0.255272505103306,1,O=C(Nc1ccc(S(=O)(=O)c2cnn(C3CCOCC3)c2)cc1)[C@@H]1C[C@H]1c1cccnc1
4646,538002,10.1021/jm8006917,,,,Inhibition of human hepatic CYP3A4,Oc1cccc(-c2ccc(-c3cccc(O)c3)cc2)c1,"1,1':4',1''-terphenyl-3,3''-diol",2.1,uM,=,0.3222192947339193,1,c1ccc(-c2ccc(-c3ccccc3)cc2)cc1
4647,874073,10.1021/jm3012239,,,,Inhibition of CYP3A4,Cc1nc(-c2cccc(Cl)c2)c(NC(=O)c2cnn3ccc(N)nc23)s1,"5-amino-N-(4-(3-chlorophenyl)-2-methylthiazol-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide",6.7,uM,=,0.8260748027008264,1,O=C(Nc1scnc1-c1ccccc1)c1cnn2cccnc12
4648,824335,10.1016/j.ejmech.2012.05.038,,,,Inhibition of CYP3A4,NC(=O)C[S+]([O-])Cc1ccccc1Oc1ccc(Cl)c(Cl)c1,"rac-2-(2-(3,4-dichlorophenoxy)benzylsulfinyl)acetamide",32.0,uM,=,1.505149978319906,1,c1ccc(Oc2ccccc2)cc1
4649,830173,10.1016/j.bmcl.2012.05.074,,,,Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay,O=C(N[C@H](Cc1ccc2[nH]nnc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1,"(R)-N-(1-(1,4'-bipiperidin-1'-yl)-3-(1H-benzo[d][1,2,3]triazol-5-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide",23.0,uM,=,1.3617278360175928,1,O=C(N[C@H](Cc1ccc2[nH]nnc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
4650,1933896,10.1021/acs.jmedchem.6b00928,,,,Inhibition of CYP3A4 in human liver microsomes incubated for 15 mins using midazolam substrate in presence of NADPH by LC-MS/MS method,COc1ccc(-c2c(CO)n(Cc3ccccc3Cl)c3ccc(OC(F)(F)F)cc23)cn1,(1-(2-chlorobenzyl)-3-(6-methoxypyridin-3-yl)-5-(trifluoromethoxy)-1H-indol-2-yl)methanol,14.0,uM,=,1.146128035678238,1,c1ccc(Cn2cc(-c3cccnc3)c3ccccc32)cc1
4651,2171279,10.1021/acs.jmedchem.1c01083,,,,Inhibition of human recombinant CYP3A4 expressed in insect microsome using 7-benzyloxy-4-trifluoromethylcoumarin as a substrate incubated for 30 mins followed by addition of NADPH regenerating system measured immediately by fluorescence based analysis,C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)OCCCCCCCCCCCCCCCCC#C[Si](C)(C)C.N,Ammonium ((1R)-2-(6-Aminopurin-9-yl)-1-methyl-ethoxyl-methyl-(18-trimethylsilyloctadec-17-ynoxy)phosphinate,27.0,uM,=,1.4313637641589874,1,c1ncc2nc[nH]c2n1
4652,1468060,10.1016/j.bmcl.2015.03.035,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as marker substrate,COc1cccc(OC)c1[C@@H]1C[C@@H](O)C(=O)N1Cc1ccc(OC(F)(F)F)cc1,"rac-(3R*,5S*)-5-(2,6-dimethoxyphenyl)-3-hydroxy-1-(4-(trifluoromethoxy)benzyl)pyrrolidin-2-one",25.0,uM,=,1.3979400086720375,1,O=C1CC[C@@H](c2ccccc2)N1Cc1ccccc1
4653,1707938,10.1021/acs.jmedchem.7b01420,,,,Inhibition of CYP3A4 (unknown origin),NC/C=C/CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21,"(E)-N1-(((R)-1,2,3,4-Tetrahydroisoquinolin-3-yl)methyl)-N1-((S)-5,6,7,8-tetrahydroquinolin-8-yl)but-2-ene-1,4-diamine",9.29,uM,=,0.9680157139936416,1,c1ccc2c(c1)CN[C@@H](CN[C@H]1CCCc3cccnc31)C2
4654,950952,10.1016/j.bmcl.2013.02.023,,,,Inhibition of human CYP3A4,COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc(N=[N+]=[N-])cc2)[nH]1)C(C)C,methyl(S)-1-((S)-2-(5-(4-azidophenyl)-1H-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-ylcarbamate,5.1,uM,=,0.7075701760979364,1,c1ccc(-c2cnc([C@@H]3CCCN3)[nH]2)cc1
4655,673953,10.1016/j.bmcl.2010.08.086,,,,Inhibition of CYP3A4 using testosterone as substrate,COCCCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1,"(3R,4S)-N-(2-chloro-5-(3-methoxypropyl)benzyl)-N-cyclopropyl-4-(4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)phenyl)piperidine-3-carboxamide",8.1,uM,=,0.9084850188786496,1,O=C([C@H]1CNCC[C@@H]1c1ccc(OCCOc2ccccc2)cc1)N(Cc1ccccc1)C1CC1
4656,2157144,10.1021/acsmedchemlett.1c00473,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by TDI- high-throughput based mass spectrometry method,CCc1c[nH]c2ncc(-c3cccc(C(=O)N(C)C)c3)cc12,"3-(3-Ethyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-N,N-dimethylbenzamide",1.7,uM,=,0.2304489213782739,1,c1ccc(-c2cnc3[nH]ccc3c2)cc1
4657,1296352,10.1021/jm4015108,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,O=C(Nc1ccc(S(=O)(=O)c2cccc(OC(F)(F)F)c2)cc1)[C@@H]1C[C@H]1c1cccnc1,rac-trans-2-(Pyridin-3-yl)-N-(4-((3-(trifluoromethoxy)phenyl)-sulfonyl)phenyl)cyclopropanecarboxamide,0.89,uM,=,-0.0506099933550872,0,O=C(Nc1ccc(S(=O)(=O)c2ccccc2)cc1)[C@@H]1C[C@H]1c1cccnc1
4658,1628093,10.1016/j.ejmech.2016.08.024,,,,Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells preincubated for 30 mins using fluorescent substrate,O=C(CC1([C@H]2COC[C@@H](C3CC3)N2S(=O)(=O)c2ccc(F)cc2)CC1)N1CCN(CCO)CC1,"2-(1-((3S,5R)-5-cyclopropyl-4-(4-fluorophenylsulfonyl)morpholin-3-yl)cyclopropyl)-1-(4-(2-hydroxyethyl)piperazin-1-yl)ethanone",6.9,uM,=,0.8388490907372553,1,O=C(CC1([C@H]2COC[C@@H](C3CC3)N2S(=O)(=O)c2ccccc2)CC1)N1CCNCC1
4659,643712,10.1016/j.bmcl.2010.06.009,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader,C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(N5CCN(C)CC5)c4)ccc32)sc1C(N)=O)c1ccccc1Cl,(R)-3-(1-(2-chlorophenyl)ethoxy)-5-(5-(2-(4-methylpiperazin-1-yl)pyridin-4-yl)-1H-benzo[d]imidazol-1-yl)thiophene-2-carboxamide,1.1,uM,=,0.041392685158225,1,c1ccc(COc2csc(-n3cnc4cc(-c5ccnc(N6CCNCC6)c5)ccc43)c2)cc1
4660,458143,10.1016/j.bmcl.2007.09.006,,,,Inhibition of CYP3A4 after 30 mins,CC[C@@H]1C[C@H](O)C[C@H](COC(=O)N2CCC(N3CCCCC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1,cis-1-(4-chlorophenylsulfonyl)-6-ethyl-4-hydroxypiperidin-2-yl)methyl 4-(piperidin-1-yl)piperidine-1-carboxylate,24.3,uM,=,1.385606273598312,1,O=C(OC[C@H]1CCCCN1S(=O)(=O)c1ccccc1)N1CCC(N2CCCCC2)CC1
4661,605306,10.1016/j.bmcl.2009.11.060,,,,Inhibition of CYP3A4,Cc1n[nH]c2ncc(-c3cc(OC[C@@H](N)Cc4c[nH]c5ccccc45)cnc3-c3ccoc3)cc12,"(S)-1-(6-(furan-3-yl)-5-(3-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yloxy)-3-(1H-indol-3-yl)propan-2-amine",0.2,uM,=,-0.6989700043360187,0,c1ccc2c(CCCOc3cnc(-c4ccoc4)c(-c4cnc5[nH]ncc5c4)c3)c[nH]c2c1
4662,462442,10.1016/j.bmcl.2008.01.047,,,,Inhibition of CYP3A4,CC(C)(C)OC(=O)N[C@H](Cc1ccccc1C(F)(F)F)C(=O)NCc1nc2cccnc2n1Cc1ccccc1,"(R)-tert-butyl 1-((3-benzyl-3H-imidazo[4,5-b]pyridin-2-yl)methylamino)-1-oxo-3-(2-(trifluoromethyl)phenyl)propan-2-ylcarbamate",0.98,uM,=,-0.0087739243075051,0,O=C(CCc1ccccc1)NCc1nc2cccnc2n1Cc1ccccc1
4663,1369168,10.1016/j.bmcl.2014.04.045,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS/competitive screening assay,COc1cc2ccnc(Oc3ccc(F)cc3)c2cc1OC,"1-(4-Fluorophenoxy)-6,7-dimethoxyisoquinoline",1.9,uM,=,0.2787536009528289,1,c1ccc(Oc2nccc3ccccc23)cc1
4664,2070622,10.1016/j.bmcl.2020.127240,,,,Inhibition of CYP3A4 (unknown origin),C[C@]1(c2cc(/C=C(\F)c3ccc(C#N)cn3)ccc2F)N=C(N)S[C@@]2(C(=O)N3CCOCC3)C[C@H]21,"6-((Z)-2-(3-((1S,5S,6S)-3-amino-5-methyl-1-(morpholine-4-carbonyl)-2-thia-4-azabicyclo[4.1.0]hept-3-en-5-yl)-4-fluorophenyl)-1-fluorovinyl)nicotinonitrile",5.3,uM,=,0.724275869600789,1,O=C(N1CCOCC1)[C@]12C[C@H]1C(c1cccc(C=Cc3ccccn3)c1)N=CS2
4665,462442,10.1016/j.bmcl.2008.01.047,,,,Inhibition of CYP3A4,CC(C)(C)OC(=O)N[C@H](Cc1ccccc1)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1,"(R)-tert-butyl 1-oxo-3-phenyl-1-((3-(1-phenylcyclopropyl)-3H-imidazo[4,5-b]pyridin-2-yl)methylamino)propan-2-ylcarbamate",6.0,uM,=,0.7781512503836436,1,O=C(CCc1ccccc1)NCc1nc2cccnc2n1C1(c2ccccc2)CC1
4666,942020,10.1021/jm301782e,,,,Inhibition of CYP3A4 (unknown origin),O=C(NCCN1CCC2(CC1)C(=O)NCN2c1cccc(F)c1)c1ccc(F)c(F)c1,"3,4-Difluoro-N-(2-(1-(3-fluorophenyl)-4-oxo-1,3,8-triazaspiro[4.5]decan-8yl)ethyl)benzamide",17.6,uM,=,1.24551266781415,1,O=C(NCCN1CCC2(CC1)C(=O)NCN2c1ccccc1)c1ccccc1
4667,2051319,10.1021/acs.jmedchem.0c01575,,,,Inhibition of CYP3A4 in human liver microsomes,CC(=O)N1CCN(CCOCc2ccn(-c3ccc(F)c(F)c3)n2)CC1.Cl,"1-(4-(2-((1-(3,4-Difluorophenyl)-1H-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)ethanone hydrochloride",100.0,uM,=,2.0,1,c1ccc(-n2ccc(COCCN3CCNCC3)n2)cc1
4668,949160,10.1016/j.bmcl.2013.01.011,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate,CCc1cc(CC(NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12,"(+/-)-N-(1-(1,4'-bipiperidin-1'-yl)-3-(7-ethyl-1H-indazol-5-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide",0.45,uM,=,-0.3467874862246563,0,O=C(NC(Cc1ccc2[nH]ncc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
4669,458143,10.1016/j.bmcl.2007.09.006,,,,Inhibition of CYP3A4 after 30 mins,O=C(OC[C@H]1CCC[C@@H](C2CC2)N1S(=O)(=O)c1ccc(Cl)cc1)N1CCN(CCO)CC1,"((2R,6S)-1-(4-chlorophenylsulfonyl)-6-cyclopropylpiperidin-2-yl)methyl 4-(2-hydroxyethyl)piperazine-1-carboxylate",0.3,uM,=,-0.5228787452803376,0,O=C(OC[C@H]1CCC[C@@H](C2CC2)N1S(=O)(=O)c1ccccc1)N1CCNCC1
4670,800399,10.1021/jm201061j,,,,Inhibition of CYP3A4,COc1ccc2c(-n3c(=O)n(Cc4cccc([C@@]5(C)OC(=O)NC5=O)c4)c4ccccc43)noc2c1,"(R)-5-(3-((3-(6-methoxybenzo[d]isoxazol-3-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)methyl)phenyl)-5-methyloxazolidine-2,4-dione",22.0,uM,=,1.3424226808222062,1,O=C1NC(=O)C(c2cccc(Cn3c(=O)n(-c4noc5ccccc45)c4ccccc43)c2)O1
4671,1866289,10.1021/acs.jmedchem.9b00662,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,OC1CCC(C(O)CC2c3c(F)cccc3-c3cncn32)CC1,"4-(2-(6-Fluoro-5H-imidazo[5,1-a]isoindol-5-yl)-1-hydroxyethyl)-cyclohexan-1-ol",3.3,uM,=,0.5185139398778875,1,c1ccc2c(c1)-c1cncn1C2CCC1CCCCC1
4672,1275553,10.1016/j.bmcl.2013.10.001,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 30 mins post NADPH addition followed by substrate addition measured after 5 mins by LC/MS/MS analysis,Cc1c(Cc2cccc(NS(N)(=O)=O)c2F)c(=O)oc2cc(OC(=O)N(C)C)c(F)cc12,Dimethylcarbamic acid 6-fluoro-3-[2-fluoro-3-(sulfamoylamino)benzyl]-4-methyl-2-oxo-2H-chromen-7-yl ester,18.0,uM,=,1.255272505103306,1,O=c1oc2ccccc2cc1Cc1ccccc1
4673,2221810,10.1016/j.bmcl.2022.128625,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as substrate pretreated with NADPH,CCC[C@H]1N(C(=O)c2c(C(F)(F)F)ccnc2OCCN(C)C)CCC[C@@]1(Oc1csc(C(F)(F)F)c1)C(=O)N1CCN(c2ccccc2OCCO)CC1,"((2R,3S)-1-(2-(2-(dimethylamino)ethoxy)-4-(trifluoromethyl)nicotinoyl)-2-propyl-3-(5-(trifluoromethyl)thiophen-3-yloxy)piperidin-3-yl)(4-(2-(2-hydroxyethoxy)phenyl)piperazin-1-yl)methanone",2.0,uM,=,0.3010299956639812,1,O=C(c1cccnc1)N1CCC[C@@](Oc2ccsc2)(C(=O)N2CCN(c3ccccc3)CC2)C1
4674,841307,10.1016/j.bmcl.2012.06.029,,,,Inhibition of CYP3A4,CCN1CCC(Nc2ccc3c(c2)C(=C(c2ccccc2)c2nc4ccccc4[nH]2)C(=O)N3)CC1,(E/Z)-3-((1H-benzo[d]imidazol-2-yl)(phenyl)methylene)-5-(1-ethylpiperidin-4-ylamino)indolin-2-one,3.0,uM,=,0.4771212547196624,1,O=C1Nc2ccc(NC3CCNCC3)cc2C1=C(c1ccccc1)c1nc2ccccc2[nH]1
4675,830173,10.1016/j.bmcl.2012.05.074,,,,Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay,O=C1Cc2cc(C[C@@H](NC(=O)N3CCC(N4Cc5ccccc5NC4=O)CC3)C(=O)N3CCC(N4CCCCC4)CC3)ccc2N1,"(R)-N-(1-(1,4'-bipiperidin-1'-yl)-1-oxo-3-(2-oxoindolin-5-yl)propan-2-yl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide",11.0,uM,=,1.0413926851582251,1,O=C1Cc2cc(C[C@@H](NC(=O)N3CCC(N4Cc5ccccc5NC4=O)CC3)C(=O)N3CCC(N4CCCCC4)CC3)ccc2N1
4676,761291,10.1021/jm101312a,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,c1ccc2cc([C@@]34CCC[C@@H]3CNC4)ccc2c1,"(3aR,6aS)-3a-(naphthalen-2-yl)octahydrocyclopenta[c]pyrrole",10.7,uM,=,1.0293837776852095,1,c1ccc2cc([C@@]34CCC[C@@H]3CNC4)ccc2c1
4677,2298667,10.1016/j.bmcl.2023.129280,,,,Inhibition of human CYP3A4,Cc1ccc(NC(=O)Nc2cc(-c3ccccc3-c3nnn[nH]3)ccc2N(CC(C)C)CC(C)C)cc1,1-(4-(diisobutylamino)-2'-(1H-tetrazol-5-yl)biphenyl-3-yl)-3-p-tolylurea,7.8,uM,=,0.8920946026904804,1,O=C(Nc1ccccc1)Nc1cccc(-c2ccccc2-c2nnn[nH]2)c1
4678,1468060,10.1016/j.bmcl.2015.03.035,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as marker substrate,COc1cccc(OC)c1[C@@H]1C[C@H](Cl)C(=O)N1Cc1ccc(OC(F)(F)F)cc1,"rac-(3S*,5S*)-3-chloro-5-(2,6-dimethoxyphenyl)-1-(4-(trifluoromethoxy)benzyl)pyrrolidin-2-one",6.6,uM,=,0.8195439355418687,1,O=C1CC[C@@H](c2ccccc2)N1Cc1ccccc1
4679,2202740,10.1016/j.ejmech.2022.114332,,,,Inhibition of CYP3A4 in human kidney microsomes assessed as inhibition of 20-HETE formation using 7-benzyl-oxyquinoline as substrate in presence of arachidonic acid and NADPH by fluorescence assay,O/N=C/Nc1ccc(N2CCOCC2)c(Cl)c1,N-(3-chloro-4-morpholinophenyl)-N'-hydroxyformimidamide,0.1,uM,=,-1.0,0,c1ccc(N2CCOCC2)cc1
4680,2241758,10.1016/j.ejmech.2021.113983,,,,Inhibition of CYP3A4 (unknown origin),COc1cc(CCNc2nc(C#Cc3ccccc3)nc3c2ncn3[C@H]2[C@H](O)[C@H](O)[C@@H]3C[C@@H]32)ccc1O,"(1R,2R,3S,4R,5S)-4-(6-((4-Hydroxy-3-methoxyphenethyl)amino)-2-(phenylethynyl)-9H-purin-9-yl)bicyclo[3.1.0]hexane-2,3-diol",2.23,uM,=,0.3483048630481606,1,C(#Cc1nc(NCCc2ccccc2)c2ncn([C@H]3CC[C@@H]4C[C@@H]43)c2n1)c1ccccc1
4681,841307,10.1016/j.bmcl.2012.06.029,,,,Inhibition of CYP3A4,CCN1CCC(Nc2ccc3c(c2)C(=C(c2ccc(OC)cc2)c2nc4ccccc4[nH]2)C(=O)N3)CC1,(E/Z)-3-((1H-benzo[d]imidazol-2-yl)(4-methoxyphenyl)methylene)-5-(1-ethylpiperidin-4-ylamino)indolin-2-one,9.0,uM,=,0.9542425094393248,1,O=C1Nc2ccc(NC3CCNCC3)cc2C1=C(c1ccccc1)c1nc2ccccc2[nH]1
4682,1880002,10.1021/acs.jmedchem.9b01769,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam substrate in presence of NADPH incubated for 10 mins,CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,SID144204227,0.0375,uM,=,-1.4259687322722812,0,c1ccc([C@@]2(Cn3ccnc3)OC[C@H](COc3ccc(N4CCNCC4)cc3)O2)cc1
4683,497350,10.1016/j.ejmech.2007.10.034,,,,Inhibition of human recombinant CYP3A4,COc1cc(/C=C2\CC/C(=C\c3cc(OC)c(O)c(OC)c3)C2=O)cc(OC)c1O,"2,5-bis(4-hydroxy-3,5-dimethoxybenzylidene)cyclopentanone",38.3,uM,=,1.5831987739686226,1,O=C1/C(=C/c2ccccc2)CC/C1=C\c1ccccc1
4684,1866289,10.1021/acs.jmedchem.9b00662,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,OC(CC1c2c(F)cccc2-c2cncn21)C1CCC(F)(F)CC1,"1-(4,4-Difluorocyclohexyl)-2-(6-fluoro-5H-imidazo[5,1-a]-isoindol-5-yl)ethanol",2.6,uM,=,0.414973347970818,1,c1ccc2c(c1)-c1cncn1C2CCC1CCCCC1
4685,1817349,10.1021/acs.jmedchem.8b01857,,,,Reversible inhibition of CYP3A4 (unknown origin) using midazolam as substrate,Cn1ncc(NC(=O)c2nc(-c3c(F)cccc3F)sc2N)c1N1CC[C@@H](N)CC(F)(F)C1,"(R)-5-Amino-N-(5-(5-amino-3,3-difluoroazepan-1-yl)-1-methyl-1H-pyrazol-4-yl)-2-(2,6-difluorophenyl)thiazole-4-carboxamide",3.8,uM,=,0.5797835966168101,1,O=C(Nc1cn[nH]c1N1CCCCCC1)c1csc(-c2ccccc2)n1
4686,1707938,10.1021/acs.jmedchem.7b01420,,,,Inhibition of CYP3A4 (unknown origin),c1ccc2c(c1)CN[C@@H](CN(Cc1ccc(CNCC3CCOCC3)cc1)[C@H]1CCCc3cccnc31)C2,"(S)-N-(4-((((Tetrahydro-2H-pyran-4-yl)methyl)amino)methyl)-benzyl)-N-(((R)-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)-5,6,7,8-tetrahydroquinolin-8-amine",0.994,uM,=,-0.0026136156026866,0,c1ccc2c(c1)CN[C@@H](CN(Cc1ccc(CNCC3CCOCC3)cc1)[C@H]1CCCc3cccnc31)C2
4687,2228092,10.1021/acs.jmedchem.2c00552,,,,Inhibition of CYP3A4 (unknown origin),Cc1ccc(O)c(C)c1-n1c(N)c(C(N)=O)c2nc(-c3nccs3)cnc21,"6-amino-5-(3-hydroxy-2,6-dimethylphenyl)-2-(thiazol-2-yl)-pyrrolo[2,3-b]pyrazine-7-carboxamide",23.0,uM,=,1.3617278360175928,1,c1ccc(-n2ccc3nc(-c4nccs4)cnc32)cc1
4688,605306,10.1016/j.bmcl.2009.11.060,,,,Inhibition of CYP3A4,Cc1[nH]nc2ccc(-c3cc(OC[C@@H](N)Cc4c[nH]c5ccccc45)cnc3-c3ccoc3)cc12,(S)-1-(6-(furan-3-yl)-5-(3-methyl-1H-indazol-5-yl)pyridin-3-yloxy)-3-(1H-indol-3-yl)propan-2-amine,0.05,uM,=,-1.3010299956639813,0,c1ccc2c(CCCOc3cnc(-c4ccoc4)c(-c4ccc5n[nH]cc5c4)c3)c[nH]c2c1
4689,652208,10.1016/j.bmcl.2010.07.052,,,,Inhibition of CYP3A4 in human liver microsomes,O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)n(Cc3ccccc3)c3ccccc32)CC1,1-benzyl-3-(1-(1-(pyridin-4-ylmethyl)piperidine-4-carbonyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one,0.4,uM,=,-0.3979400086720376,0,O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)n(Cc3ccccc3)c3ccccc32)CC1
4690,1707938,10.1021/acs.jmedchem.7b01420,,,,Inhibition of CYP3A4 (unknown origin),c1cncc(CN(CCCCN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)Cc2cccnc2)c1,"N1,N1-Bis(pyridin-3-ylmethyl)-N4-(((R)-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)-N4-((S)-5,6,7,8-tetrahydroquinolin-8-yl)-butane-1,4-diamine",1.29,uM,=,0.1105897102992489,1,c1cncc(CN(CCCCN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)Cc2cccnc2)c1
4691,718098,10.1016/j.bmcl.2010.12.053,,,,Inhibition of CYP3A4,FC1(F)CN(CCC2=C(Cc3cnccn3)c3ccccc3C2)C1,"2-((2-(2-(3,3-difluoroazetidin-1-yl)ethyl)-1H-inden-3-yl)methyl)pyrazine",3.871,uM,=,0.5878231713189551,1,c1ccc2c(c1)CC(CCN1CCC1)=C2Cc1cnccn1
4692,1667565,10.1021/acs.jmedchem.7b00067,,,,Inhibition of human CYP3A4 using ketoconazole as substrate,CC(C)OC(=O)[C@H](C)NP(=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@@](F)(Cl)[C@@H]1O)Oc1ccccc1,"(2S)-isopropyl 2-((((2R,3S,4R,5R)-4-chloro-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate",6.8,uM,=,0.8325089127062363,1,O=c1ccn([C@H]2CC[C@@H](CO[PH](=O)Oc3ccccc3)O2)c(=O)[nH]1
4693,2221810,10.1016/j.bmcl.2022.128625,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as substrate pretreated with NADPH,CCC[C@H]1N(C(=O)c2cc(F)ccc2C(F)(F)F)CCC[C@@]1(Oc1csc(C(F)(F)F)c1)C(=O)N1CCN(c2ccccc2OCCO)CC1,"((2R,3S)-1-(5-fluoro-2-(trifluoromethyl)benzoyl)-2-propyl-3-(5-(trifluoromethyl)thiophen-3-yloxy)piperidin-3-yl)(4-(2-(2-hydroxyethoxy)phenyl)piperazin-1-yl)methanone",0.6,uM,=,-0.2218487496163563,0,O=C(c1ccccc1)N1CCC[C@@](Oc2ccsc2)(C(=O)N2CCN(c3ccccc3)CC2)C1
4694,652208,10.1016/j.bmcl.2010.07.052,,,,Inhibition of CYP3A4 in human liver microsomes,O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)n(CCN3CCOCC3)c3ccccc32)CC1,1-(2-morpholinoethyl)-3-(1-(1-(pyridin-4-ylmethyl)piperidine-4-carbonyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one,30.0,uM,=,1.4771212547196624,1,O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)n(CCN3CCOCC3)c3ccccc32)CC1
4695,1628093,10.1016/j.ejmech.2016.08.024,,,,Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells preincubated for 30 mins using fluorescent substrate,O=C(CC1([C@H]2CO[C@H]3CCC[C@H]3N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CC[C@@H](CO)C1,"2-(1-((3S,4aR,7aS)-4-(4-chlorophenylsulfonyl)octahydrocyclopenta[b][1,4]oxazin-3-yl)cyclopropyl)-1-((R)-3-(hydroxymethyl)pyrrolidin-1-yl)ethanone",30.0,uM,=,1.4771212547196624,1,O=C(CC1([C@H]2CO[C@H]3CCC[C@H]3N2S(=O)(=O)c2ccccc2)CC1)N1CCCC1
4696,1707938,10.1021/acs.jmedchem.7b01420,,,,Inhibition of CYP3A4 (unknown origin),CC(C)(CCN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21)CNC1CCC(F)(F)CC1,"N1-(4,4-Difluorocyclohexyl)-2,2-dimethyl-N4-(((R)-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)-N4-((S)-5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine",5.58,uM,=,0.7466341989375788,1,c1ccc2c(c1)CN[C@@H](CN(CCCCNC1CCCCC1)[C@H]1CCCc3cccnc31)C2
4697,458143,10.1016/j.bmcl.2007.09.006,,,,Inhibition of CYP3A4 after 30 mins,CC[C@@H]1CCC[C@H](C2(OC(=O)N3CCN(CCO)CC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1,"1-((2R,6R)-1-(4-chlorophenylsulfonyl)-6-ethylpiperidin-2-yl)cyclopropyl 4-(2-hydroxyethyl)piperazine-1-carboxylate",0.4,uM,=,-0.3979400086720376,0,O=C(OC1([C@H]2CCCCN2S(=O)(=O)c2ccccc2)CC1)N1CCNCC1
4698,458143,10.1016/j.bmcl.2007.09.006,,,,Inhibition of CYP3A4 after 30 mins,CC(C)[C@@H]1CCC[C@H](COC(=O)N2CCN(CCO)CC2)N1S(=O)(=O)c1ccc(Cl)cc1,"((2R,6S)-1-(4-chlorophenylsulfonyl)-6-isopropylpiperidin-2-yl)methyl 4-(2-hydroxyethyl)piperazine-1-carboxylate",0.3,uM,=,-0.5228787452803376,0,O=C(OC[C@H]1CCCCN1S(=O)(=O)c1ccccc1)N1CCNCC1
4699,2164321,10.1021/acs.jmedchem.1c01784,,,,Inhibition of human recombinant CYP3A4 expressed in baculosomes by fluorescent homogenous assay,CN(Cc1ccccc1)Cc1ccc(COc2ccc3c(CO)cc(=O)oc3c2)cc1,7-(4-((benzyl(methyl)amino)methyl)benzyloxy)-4-(hydroxymethyl)-2H-chromen-2-one,7.0,uM,=,0.8450980400142568,1,O=c1ccc2ccc(OCc3ccc(CNCc4ccccc4)cc3)cc2o1
4700,1523393,10.1021/acs.jmedchem.5b00774,,,,Inhibition of CYP3A4 (unknown origin) preincubated with protein for 30 mins followed by substrate addition,O=S(=O)(N[C@H]1CC[C@@](c2cc(F)ccc2F)(S(=O)(=O)c2ccc(Cl)cc2)CC1)C(F)(F)F,"N-((syn)-4-(4-chlorophenylsulfonyl)-4-(2,5-difluorophenyl)cyclohexyl)trifluoromethanesulfonamide",9.3,uM,=,0.9684829485539352,1,O=S(=O)(c1ccccc1)C1(c2ccccc2)CCCCC1
4701,718098,10.1016/j.bmcl.2010.12.053,,,,Inhibition of CYP3A4,FC1(F)CCN(CCC2=C(Cc3cnccn3)c3ccccc3C2)C1,"2-((2-(2-(3,3-difluoropyrrolidin-1-yl)ethyl)-1H-inden-3-yl)methyl)pyrazine",1.405,uM,=,0.1476763242410987,1,c1ccc2c(c1)CC(CCN1CCCC1)=C2Cc1cnccn1
4702,1534814,,,,,Inhibition Assay: Inhibition assay using P450 CYP enzymes.,COc1ccc(-c2c(O)ccc3cc(-c4cccc(O)c4)ccc23)cn1,6-(3-hydroxyphenyl)-1-(6-methoxypyridin-3-yl)naphthalen-2-ol,2.05,uM,=,0.3117538610557542,1,c1ccc(-c2ccc3c(-c4cccnc4)cccc3c2)cc1
4703,643970,10.1016/j.bmcl.2010.06.086,,,,Inhibition of human CYP3A4-mediated testosterone oxidation,CC(C)CC1n2cncc2CN(Cc2ccc(OC(F)(F)F)cc2)S1(=O)=O,"4-Isobutyl-6-(4-trifluoromethoxy-benzyl)-6,7-dihydro-5-thia-2,3a,6-triaza-indene 5,5-dioxide",0.49,uM,=,-0.3098039199714864,0,O=S1(=O)Cn2cncc2CN1Cc1ccccc1
4704,373753,10.1021/jm060073e,,,,Inhibition of CYP450 3A4 transfected in human microsome using PPR fluorogenic substrate,CC(C)C[C@@H]1C(=O)N[C@H](C2Cc3ccccc3C2)C(=O)N1[C@@H](C(=O)N(C)C)c1ccc(F)cc1F,"(2R)-2-(2,4-difluorophenyl)-2-[(3R,6R)-3-(2,3-dihydro-1H-inden-2-yl)-6-(2-methylpropyl)-2,5-dioxo-1-piperazinyl]-N,N-dimethylethanamide",62.0,uM,=,1.792391689498254,1,O=C1CN(Cc2ccccc2)C(=O)[C@@H](C2Cc3ccccc3C2)N1
4705,52063,10.1016/j.bmcl.2003.08.049,,,,In vitro inhibition of Cytochrome P450 3A4,O=C(N[C@H]1c2ccccc2OC[C@H]1O)[C@H](Cc1cccnc1)C[C@H](O)CN1CCN(Cc2ccn(-c3ccccc3)c2)C[C@H]1C(=O)NCC(F)(F)F,"(S)-1-[(2S,4R)-2-Hydroxy-4-((3S,4S)-3-hydroxy-chroman-4-ylcarbamoyl)-5-pyridin-3-yl-pentyl]-4-(1-phenyl-1H-pyrrol-3-ylmethyl)-piperazine-2-carboxylic acid (2,2,2-trifluoro-ethyl)-amide",0.4,uM,=,-0.3979400086720376,0,O=C(N[C@@H]1CCOc2ccccc21)[C@@H](CCCN1CCN(Cc2ccn(-c3ccccc3)c2)CC1)Cc1cccnc1
4706,606336,10.1016/j.bmcl.2009.11.061,,,,Inhibition of CYP3A4,Cc1occc1-c1ncc(OC[C@@H](N)Cc2c[nH]c3ccccc23)cc1-c1cnc2[nH]nc(C)c2n1,"(2S)-1-(1H-indol-3-yl)-3-(5-(3-methyl-1H-pyrazolo[4,3-b]pyrazin-5-yl)-6-(2-methylfuran-3-yl)pyridin-3-yloxy)propan-2-amine",0.63,uM,=,-0.2006594505464183,0,c1ccc2c(CCCOc3cnc(-c4ccoc4)c(-c4cnc5[nH]ncc5n4)c3)c[nH]c2c1
4707,1296353,10.1021/jm4015108,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis,O=C(Nc1ccc(S(=O)(=O)c2ccccc2)cc1)[C@@H]1C[C@H]1c1cccnc1,rac-trans-N-(4-(Phenylsulfonyl)phenyl)-2-(pyridin-3-yl)-cyclopropanecarboxamide,0.11,uM,=,-0.958607314841775,0,O=C(Nc1ccc(S(=O)(=O)c2ccccc2)cc1)[C@@H]1C[C@H]1c1cccnc1
4708,1689465,10.1021/acs.jmedchem.7b00662,,,,Inhibition of CYP3A4 (unknown origin),Cc1ccc(-c2ccc(NC(=O)CN3CCCC4=C3C(=O)N(C3CC3)C4=O)nn2)cn1,"2-(6-Cyclopropyl-5,7-dioxooctahydro-1H-pyrrolo[3,4-b]-pyridin-1-yl)-N-(6-(6-methylpyridin-3-yl)pyridazin-3-yl)-acetamide",8.0,uM,=,0.9030899869919436,1,O=C(CN1CCCC2=C1C(=O)N(C1CC1)C2=O)Nc1ccc(-c2cccnc2)nn1
4709,621465,10.1016/j.bmcl.2009.07.118,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,CCN(C[C@H](Cc1ccccc1)NC(=O)OCc1cccnc1)C[C@H](Cc1ccccc1)NC(=O)OCc1cccnc1,Bis-N-[(S)-2-(pyridin-3-ylmethoxycarbonylamino)-3-phenylpropyl]ethylamine,3.0,uM,=,0.4771212547196624,1,O=C(N[C@H](CNC[C@H](Cc1ccccc1)NC(=O)OCc1cccnc1)Cc1ccccc1)OCc1cccnc1
4710,1642505,,,,,"Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).",CNC(C)C(=O)Nc1ccc(-c2c(-c3ccncc3)nc3cc(C)ccn23)c(C#Cc2ccc(-c3ccon3)cc2)n1,"US9481673, 82",2.3,uM,=,0.3617278360175928,1,C(#Cc1ncccc1-c1c(-c2ccncc2)nc2ccccn12)c1ccc(-c2ccon2)cc1
4711,1455473,10.1016/j.bmcl.2014.06.026,,,,Inhibition of recombinant human CYP3A4 preincubated for 5 mins before fluorescent substrate addition by fluorescence assay,Fc1cc(C(CC2CNC2)Oc2cccc(Cl)c2)ccc1Cl,3-(2-(4-chloro-3-fluorophenyl)-2-(3-chlorophenoxy)ethyl)azetidine,0.6,uM,=,-0.2218487496163563,0,c1ccc(OC(CC2CNC2)c2ccccc2)cc1
4712,1866289,10.1021/acs.jmedchem.9b00662,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,O=C(Cc1ccc(F)cc1)N1CCC(C(O)CC2c3ccccc3-c3cncn32)CC1,"2-(4-Fluorophenyl)-1-(4-(1-hydroxy-2-(5H-imidazo[5,1-a]-isoindol-5-yl)ethyl)piperidin-1-yl)ethanone",0.06,uM,=,-1.2218487496163564,0,O=C(Cc1ccccc1)N1CCC(CCC2c3ccccc3-c3cncn32)CC1
4713,463857,10.1016/j.bmcl.2008.01.100,,,,Inhibition of CYP3A4 using 7-benzyloxyresorufin as a substrate,CC(C)(N)C(=O)N[C@H](COCc1ccccc1)c1nnnn1[C@H](CC#N)COc1ccccc1O,2-amino-N-((S)-2-(benzyloxy)-1-(1-((R)-1-cyano-3-(2-hydroxyphenoxy)propan-2-yl)-1H-tetrazol-5-yl)ethyl)-2-methylpropanamide,5.5,uM,=,0.7403626894942439,1,c1ccc(COCCc2nnnn2CCOc2ccccc2)cc1
4714,788538,10.1016/j.bmcl.2011.01.024,,,,Inhibition of human CYP3A4,CCN(Cc1cc(C(F)(F)F)ccc1-c1cc(CC(=O)O)ccc1OC)C(=O)OCc1ccc(Cl)cc1,2-(2'-((((4-chlorobenzyloxy)carbonyl)(ethyl)amino)methyl)-6-methoxy-4'-(trifluoromethyl)biphenyl-3-yl)acetic acid,21.0,uM,=,1.3222192947339193,1,O=C(NCc1ccccc1-c1ccccc1)OCc1ccccc1
4715,595637,10.1016/j.bmcl.2009.09.096,,,,Inhibition of human CYP3A4,COc1ccc2c(OCc3nnc4ccc(-c5cc(F)c(F)c(F)c5)nn34)ccnc2c1,"7-methoxy-4-((6-(3,4,5-trifluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy)quinoline",29.0,uM,=,1.462397997898956,1,c1ccc(-c2ccc3nnc(COc4ccnc5ccccc45)n3n2)cc1
4716,581615,10.1016/j.bmcl.2009.06.096,,,,Inhibition of CYP3A4 using felodipine as substrate,O=C(c1ccccc1C(F)(F)F)N(CC1CCC1)[C@H]1CCNC1,(S)-N-(cyclobutylmethyl)-N-(pyrrolidin-3-yl)-2-(trifluoromethyl)benzamide,22.0,uM,=,1.3424226808222062,1,O=C(c1ccccc1)N(CC1CCC1)[C@H]1CCNC1
4717,643712,10.1016/j.bmcl.2010.06.009,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader,C[C@@H](Oc1cc(-n2cnc3cc(-c4cnn(CCCN(C)C)c4)ccc32)sc1C(N)=O)c1ccccc1Cl,(R)-3-(1-(2-chlorophenyl)ethoxy)-5-(5-(1-(3-(dimethylamino)propyl)-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)thiophene-2-carboxamide,0.9,uM,=,-0.0457574905606751,0,c1ccc(COc2csc(-n3cnc4cc(-c5cn[nH]c5)ccc43)c2)cc1
4718,606336,10.1016/j.bmcl.2009.11.061,,,,Inhibition of CYP3A4,Cc1occc1-c1nc(N)c(OC[C@@H](N)Cc2ccccc2)cc1-c1cnc2[nH]nc(C)c2n1,"3-((S)-2-amino-3-phenylpropoxy)-5-(3-methyl-1H-pyrazolo[4,3-b]pyrazin-5-yl)-6-(2-methylfuran-3-yl)pyridin-2-amine",3.2,uM,=,0.505149978319906,1,c1ccc(CCCOc2cnc(-c3ccoc3)c(-c3cnc4[nH]ncc4n3)c2)cc1
4719,621465,10.1016/j.bmcl.2009.07.118,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,O=C(N[C@@H](CNC[C@@H](Cc1ccccc1)NC(=O)OCc1nccs1)Cc1ccccc1)OCc1cncs1,Bis-N-[(R)-2-(thiazol-5-ylmethoxycarbonylamino)-3-phenylpropyl]amine,0.099,uM,=,-1.00436480540245,0,O=C(N[C@@H](CNC[C@@H](Cc1ccccc1)NC(=O)OCc1nccs1)Cc1ccccc1)OCc1cncs1
4720,2241391,10.1016/j.ejmech.2021.113981,,,,Inhibition of CYP3A4 in human liver microsomes assessed as reduction in 1'-hydroxy midazolam formation using midazolam as substrate preincubated for 20 mins in presence of NADPH followed by incubation with substrate for 10 mins by LC-MS/MS analysis,O[C@@H](c1cc(C(F)(F)F)nc2c(C(F)(F)F)cccc12)[C@H]1CCCCN1,"(S)-(2,8-bis(trifluoromethyl)quinolin-4-yl)((R)-piperidin-2-yl)methanol",30.0,uM,=,1.4771212547196624,1,c1ccc2c(C[C@H]3CCCCN3)ccnc2c1
4721,462442,10.1016/j.bmcl.2008.01.047,,,,Inhibition of CYP3A4,CC(C)(C)OC(=O)N[C@H](Cc1c(F)cccc1Cl)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1,"(R)-tert-butyl 3-(2-chloro-6-fluorophenyl)-1-oxo-1-((3-(1-phenylcyclopropyl)-3H-imidazo[4,5-b]pyridin-2-yl)methylamino)propan-2-ylcarbamate",5.3,uM,=,0.724275869600789,1,O=C(CCc1ccccc1)NCc1nc2cccnc2n1C1(c2ccccc2)CC1
4722,673953,10.1016/j.bmcl.2010.08.086,,,,Inhibition of CYP3A4 using testosterone as substrate,Cc1cc(Cl)c(OCCOc2ccc([C@H]3CCNC[C@@H]3C(=O)N(Cc3cccc(C)c3C)C3CC3)cc2)c(Cl)c1,"rac-N-cyclopropyl-4-(4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)phenyl)-N-(2,3-dimethylbenzyl)piperidine-3-carboxamide",11.0,uM,=,1.0413926851582251,1,O=C([C@H]1CNCC[C@@H]1c1ccc(OCCOc2ccccc2)cc1)N(Cc1ccccc1)C1CC1
4723,1707938,10.1021/acs.jmedchem.7b01420,,,,Inhibition of CYP3A4 (unknown origin),C(=C/CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21)\CNCc1cccnc1,"(E)-N1-(Pyridin-3-ylmethyl)-N4-(((R)-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)-N4-((S)-5,6,7,8-tetrahydroquinolin-8-yl)-but-2-ene-1,4-diamine",1.25,uM,=,0.0969100130080564,1,C(=C/CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21)\CNCc1cccnc1
4724,458143,10.1016/j.bmcl.2007.09.006,,,,Inhibition of CYP3A4 after 30 mins,CC[C@@H]1C[C@@H](O)C[C@H](COC(=O)N2CCN(CCO)CC2)N1S(=O)(=O)c1ccc(Cl)cc1,trans-1-(4-chlorophenylsulfonyl)-6-ethyl-4-hydroxypiperidin-2-yl)methyl 4-(2-hydroxyethyl)piperazine-1-carboxylate,30.0,uM,=,1.4771212547196624,1,O=C(OC[C@H]1CCCCN1S(=O)(=O)c1ccccc1)N1CCNCC1
4725,1859913,10.1021/acsmedchemlett.9b00114,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate measured after 10 mins in presence of NADPH by UHPLC-MS/MS analysis,Cn1cc(-c2ccc(N3CCC(C4c5c(F)cccc5-c5cncn54)CC3)c(F)c2)cn1,"6-fluoro-5-(1-(2-fluoro-4-(1-methyl-1H-pyrazol-4-yl)phenyl)piperidin-4-yl)-5H-imidazo[5,1-a]isoindole",0.95,uM,=,-0.0222763947111522,0,c1ccc2c(c1)-c1cncn1C2C1CCN(c2ccc(-c3cn[nH]c3)cc2)CC1
4726,1846363,10.1016/j.ejmech.2019.02.073,,,,Inhibition of CYP3A4 in human liver microsomes assessed as reduction in metabolite formation using midazolam as substrate incubated for 10 mins in presence of NADPH by HPLC based mass spectrometric method,CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cnc(-c4cccnc4)c3)C(=O)O[C@]12C,"10-(4-Dimethylamino-3-hydroxy-6-methyl-tetrahydro-pyran-2-yloxy)-4-ethyl-11-methoxy-3a,7,9,11,13,15-hexamethyl-1-[4-(4-pyridin-3-yl-4H-imidazol-1-yl)-butyl]-octahydro-3,5-dioxa-1-aza-cyclopentacyclotetradecene-2,6,8,14-tetraone",11.8,uM,=,1.0718820073061257,1,O=C1CC(=O)OCC2OC(=O)N(CCCCn3cnc(-c4cccnc4)c3)[C@@H]2CC(=O)CCC[C@H](O[C@H]2CCCCO2)C1
4727,2135699,10.1021/acs.jmedchem.1c01451,,,,Inhibition of CYP3A4 in human liver microsomes using probe substrate in presence of NADPH regenerating system incubated for 60 mins by UFLC-MS/MS analysis,COc1ccc(N(C)c2nc(C)nc3ccccc23)cc1OC(C(=O)NO)C(C)C,N-Hydroxy-2-((2-methoxy-5-(methyl(2-methylquinazolin-4-yl)-amino)phenoxy)-3-methylbutanamide,92.79,uM,=,1.9675011747228413,1,c1ccc(Nc2ncnc3ccccc23)cc1
4728,874983,10.1021/jm301039c,,,,Inhibition of CYP3A4,CN1C(=N)N[C@@]2(c3cc(-c4cccc(C#N)c4)cs3)CN(c3ccc(F)cn3)C[C@H]2C1=O,"3-(5-((4aR,7aR)-6-(5-Fluoropyridin-2-yl)-2-imino-3-methyl-4-oxooctahydro-1H-pyrrolo[3,4-d]pyrimidin-7a-yl)thiophen-3-yl)benzonitrile",6.0,uM,=,0.7781512503836436,1,N=C1NC(=O)[C@@H]2CN(c3ccccn3)C[C@]2(c2cc(-c3ccccc3)cs2)N1
4729,761291,10.1021/jm101312a,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,Clc1ccc([C@]23CCCC[C@H]2CNC3)cc1Cl,"cis-rac-3a-(3,4-dichlorophenyl)octahydro-1H-isoindole",8.39,uM,=,0.9237619608287004,1,c1ccc([C@]23CCCC[C@H]2CNC3)cc1
4730,476993,10.1016/j.bmcl.2008.02.076,,,,Inhibition of CYP3A4,O=C1CC(c2cccc(-n3ccnc3)c2)=Nc2cc(O)c(-c3ccccc3F)cc2N1,"4-(3-(1H-imidazol-1-yl)phenyl)-8-(2-fluorophenyl)-7-hydroxy-1H-benzo[b][1,4]diazepin-2(3H)-one",0.001,uM,=,-3.0,0,O=C1CC(c2cccc(-n3ccnc3)c2)=Nc2ccc(-c3ccccc3)cc2N1
4731,1296353,10.1021/jm4015108,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis,O=C(Nc1ccc(S(=O)(=O)c2ccccc2)cc1)[C@H]1C[C@@H]1c1cccnc1,trans-N-(4-(Phenylsulfonyl)phenyl)-2-(pyridin-3-yl)-cyclopropanecarboxamide,0.09,uM,=,-1.0457574905606752,0,O=C(Nc1ccc(S(=O)(=O)c2ccccc2)cc1)[C@H]1C[C@@H]1c1cccnc1
4732,880247,10.1021/jm101459g,,,,Inhibition of human recombinant CYP3A4 using resorufin benzyl ether after 30 mins by fluorescence spectrophotometric analysis,Cl.Clc1ccc(Sc2ccccc2N2CCNCC2)cc1,1-[2-(4-Chloro-phenylsulfanyl)-phenyl]-piperazine hydrochloride,6.8,uM,=,0.8325089127062363,1,c1ccc(Sc2ccccc2N2CCNCC2)cc1
4733,643712,10.1016/j.bmcl.2010.06.009,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader,C[C@@H](Oc1cc(-n2cnc3cc(-c4ccc(NC5CCN(C)CC5)nc4)ccc32)sc1C(N)=O)c1ccccc1Cl,(R)-3-(1-(2-chlorophenyl)ethoxy)-5-(5-(6-(1-methylpiperidin-4-ylamino)pyridin-3-yl)-1H-benzo[d]imidazol-1-yl)thiophene-2-carboxamide,3.4,uM,=,0.5314789170422551,1,c1ccc(COc2csc(-n3cnc4cc(-c5ccc(NC6CCNCC6)nc5)ccc43)c2)cc1
4734,977237,10.1016/j.bmc.2013.06.067,,,,Inhibition of CYP3A4 in human liver microsomes assessed as midazolam 1'-hydroxylation after 20 mins by LCMS analysis,CC(C)(C)n1nnnc1C(c1cccc(Nc2ccnc3cc(Cl)ccc23)c1)N1CCCC1,N-{3-[(1-tert-butyl-1H-tetrazol-5-yl)(pyrrolidin-1-yl)methyl]phenyl}-7-Chloroquinolin-4-amine,1.45,uM,=,0.1613680022349748,1,c1cc(Nc2ccnc3ccccc23)cc(C(c2nnn[nH]2)N2CCCC2)c1
4735,673953,10.1016/j.bmcl.2010.08.086,,,,Inhibition of CYP3A4 using testosterone as substrate,Cc1cc(Cl)c(OCCOc2ccc([C@H]3CCNC[C@@H]3C(=O)N(Cc3cc(CNCC(F)F)ccc3Cl)C3CC3)cc2)c(Cl)c1,"(3R,4S)-N-(2-chloro-5-((2,2-difluoroethylamino)methyl)benzyl)-N-cyclopropyl-4-(4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)phenyl)piperidine-3-carboxamide",4.8,uM,=,0.6812412373755872,1,O=C([C@H]1CNCC[C@@H]1c1ccc(OCCOc2ccccc2)cc1)N(Cc1ccccc1)C1CC1
4736,438793,10.1016/j.bmcl.2007.04.052,,,,Inhibition of CYP3A4,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)CCC2,"N-(2-(7-(2,4-diamino-6-ethylpyrimidin-5-yl)-3,4-dihydroquinolin-1(2H)-yl)ethyl)acetamide",8.0,uM,=,0.9030899869919436,1,c1ncc(-c2ccc3c(c2)NCCC3)cn1
4737,51901,10.1016/s0960-894x(02)00026-4,,,,Inhibition of cytochrome P450 3A4 enzyme,Cc1cc(C)cc(-c2[nH]c3ccc(C(C)(C)C(=O)N4CC5CCC4CC5)cc3c2[C@H](C)CNCCc2ccc3[nH]nnc3c2)c1,"1-(2-Aza-bicyclo[2.2.2]oct-2-yl)-2-[3-{(S)-2-[2-(1H-benzotriazol-5-yl)-ethylamino]-1-methyl-ethyl}-2-(3,5-dimethyl-phenyl)-1H-indol-5-yl]-2-methyl-propan-1-one",7.5,uM,=,0.8750612633917001,1,O=C(Cc1ccc2[nH]c(-c3ccccc3)c(CCNCCc3ccc4[nH]nnc4c3)c2c1)N1CC2CCC1CC2
4738,673771,10.1016/j.bmcl.2010.08.102,,,,Inhibition of CYP3A4 in presence of NADPH,CC(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNC1(c2cccc(C(C)(C)C(F)F)c2)CC1,"N-((2S,3R)-4-(1-(3-(1,1-difluoro-2-methylpropan-2-yl)phenyl)cyclopropylamino)-1-(3,5-difluorophenyl)-3-hydroxybutan-2-yl)acetamide",0.004,uM,=,-2.397940008672037,0,c1ccc(CCCCNC2(c3ccccc3)CC2)cc1
4739,652628,10.1016/j.bmcl.2010.07.080,,,,Inhibition of CYP3A4,Cc1cc(C(N)=O)nn1-c1cccc(-c2cc(C(F)(F)F)ccc2C(F)(F)F)c1,"1-(2',5'-bis(trifluoromethyl)biphenyl-3-yl)-5-methyl-1H-pyrazole-3-carboxamide",51.0,uM,=,1.7075701760979365,1,c1ccc(-c2cccc(-n3cccn3)c2)cc1
4740,1642505,,,,,"Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).",CNC(C)C(=O)Nc1ccc(-c2c(-c3ccncc3)nc3cc(C)ccn23)c(C#Cc2ccccc2)n1,"US9481673, 185",3.0,uM,=,0.4771212547196624,1,C(#Cc1ncccc1-c1c(-c2ccncc2)nc2ccccn12)c1ccccc1
4741,1628093,10.1016/j.ejmech.2016.08.024,,,,Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells preincubated for 30 mins using fluorescent substrate,CC(C)(CO)N1CCN(C(=O)CC2([C@H]3COC[C@@H](C4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)CC1,"2-(1-((3S,5R)-4-(4-chlorophenylsulfonyl)-5-cyclopropylmorpholin-3-yl)cyclopropyl)-1-(4-(1-hydroxy-2-methylpropan-2-yl)piperazin-1-yl)ethanone",1.9,uM,=,0.2787536009528289,1,O=C(CC1([C@H]2COC[C@@H](C3CC3)N2S(=O)(=O)c2ccccc2)CC1)N1CCNCC1
4742,830173,10.1016/j.bmcl.2012.05.074,,,,Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay,O=C(N[C@H](Cc1ccc2ccccc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1,"(R)-N-(1-(1,4'-bipiperidin-1'-yl)-3-(naphthalen-2-yl)-1-oxopropan-2-yl)-4-(2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-1-carboxamide",0.03,uM,=,-1.5228787452803376,0,O=C(N[C@H](Cc1ccc2ccccc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1
4743,643712,10.1016/j.bmcl.2010.06.009,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader,C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(NCCN(C)C)c4)ccc32)sc1C(N)=O)c1ccccc1C(F)(F)F,(R)-5-(5-(2-(2-(dimethylamino)ethylamino)pyridin-4-yl)-1H-benzo[d]imidazol-1-yl)-3-(1-(2-(trifluoromethyl)phenyl)ethoxy)thiophene-2-carboxamide,0.8,uM,=,-0.0969100130080563,0,c1ccc(COc2csc(-n3cnc4cc(-c5ccncc5)ccc43)c2)cc1
4744,1707938,10.1021/acs.jmedchem.7b01420,,,,Inhibition of CYP3A4 (unknown origin),C(=C/CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21)\CNC1CCOCC1,"(E)-N1-(Tetrahydro-2H-pyran-4-yl)-N4-(((R)-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)-N4-((S)-5,6,7,8-tetrahydroquinolin-8-yl)-but-2-ene-1,4-diamine",7.73,uM,=,0.888179493918325,1,C(=C/CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21)\CNC1CCOCC1
4745,789986,10.1016/j.bmcl.2011.10.013,,,,Reversible inhibition of CYP3A4,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@]23OCCc2ccccc23)C2CC2)cc(OCCOC)c1,"(1R,3'S)-N-cyclopropyl-N-(3-(2-methoxyethoxy)-5-(3-methoxypropyl)benzyl)spiro[isochroman-1,4'-piperidine]-3'-carboxamide",6.4,uM,=,0.8061799739838872,1,O=C([C@H]1CNCC[C@@]12OCCc1ccccc12)N(Cc1ccccc1)C1CC1
4746,462442,10.1016/j.bmcl.2008.01.047,,,,Inhibition of CYP3A4,CC(C)(C)OC(=O)N[C@H](Cc1ccccc1C(F)(F)F)C(=O)NCc1nc2cccnc2n1CC1CC1,"(R)-tert-butyl 1-((3-(cyclopropylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl)methylamino)-1-oxo-3-(2-(trifluoromethyl)phenyl)propan-2-ylcarbamate",2.43,uM,=,0.3856062735983122,1,O=C(CCc1ccccc1)NCc1nc2cccnc2n1CC1CC1
4747,1707938,10.1021/acs.jmedchem.7b01420,,,,Inhibition of CYP3A4 (unknown origin),c1ccc(CN(CCCCN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)Cc2ccccn2)nc1,"N1,N1-Bis(pyridin-2-ylmethyl)-N4-(((R)-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)-N4-((S)-5,6,7,8-tetrahydroquinolin-8-yl)-butane-1,4-diamine",6.01,uM,=,0.7788744720027395,1,c1ccc(CN(CCCCN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)Cc2ccccn2)nc1
4748,813105,10.1021/jm201346g,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,COc1ccc2[nH]c(SCc3ccc(Cl)cc3)nc2c1,2-(4-chlorobenzylthio)-5-methoxy-1H-benzo[d]imidazole,4.86,uM,=,0.6866362692622934,1,c1ccc(CSc2nc3ccccc3[nH]2)cc1
4749,1527906,,,,,Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,C[C@@H](c1ccc(-c2ccc(F)cc2F)cc1)N1CC[C@](CCO)(c2ccc(F)cc2)OC1=O,"(S)-3-((S)-1-(2',4'-Difluoro-[1,1'-biphenyl]-4-yl)ethyl)-6-(4-fluorophenyl)-6-(2-hydroxyethyl)-1,3-oxazinan-2-one",7.4,uM,=,0.8692317197309762,1,O=C1OC(c2ccccc2)CCN1Cc1ccc(-c2ccccc2)cc1
4750,510060,10.1016/j.bmcl.2008.07.059,,,,Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay,Cc1c(-c2cccc(OCCCCC(=O)O)c2F)c(=O)n(C[C@@H](c2ccccc2)N(C)C)c(=O)n1Cc1c(F)cccc1C(F)(F)F,"(R)-5-(3-(1-(2-fluoro-6-(trifluoromethyl)benzyl)-3-(2-(dimethylamino)-2-phenylethyl)-6-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-2-fluorophenoxy)pentanoic acid",42.0,uM,=,1.6232492903979006,1,O=c1c(-c2ccccc2)cn(Cc2ccccc2)c(=O)n1CCc1ccccc1
4751,643970,10.1016/j.bmcl.2010.06.086,,,,Inhibition of human CYP3A4-mediated testosterone oxidation,C[C@@H](c1ccc(Cl)cc1)N1Cc2cncn2C(C[C@@H](O)c2ccccc2)S1(=O)=O,"(R)-2-{6-[(S)-1-(4-Chloro-phenyl)-ethyl]-5,5-dioxo-4,5,6,7-tetrahydro-5lambda*6*-thia-2,3a,6-triaza-inden-4-yl}-1-phenyl-ethanol",0.9,uM,=,-0.0457574905606751,0,O=S1(=O)C(CCc2ccccc2)n2cncc2CN1Cc1ccccc1
4752,728151,10.1016/j.bmc.2011.01.017,,,,Inhibition of human CYP3A4,CC(C)C(O)(c1ccc2c3c(ccc2c1)C(=O)NC3)c1c[nH]cn1,"rac-7-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-1,2-dihydro-3H-benzo[e]isoindol-3-one",7.4,uM,=,0.8692317197309762,1,O=C1NCc2c1ccc1cc(Cc3c[nH]cn3)ccc21
4753,462442,10.1016/j.bmcl.2008.01.047,,,,Inhibition of CYP3A4,O=C(N[C@H](Cc1ccccc1C(F)(F)F)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1)c1ccccc1OC(F)(F)F,"(R)-N-(1-oxo-1-((3-(1-phenylcyclopropyl)-3H-imidazo[4,5-b]pyridin-2-yl)methylamino)-3-(2-(trifluoromethyl)phenyl)propan-2-yl)-2-(trifluoromethoxy)benzamide",1.8,uM,=,0.255272505103306,1,O=C(N[C@H](Cc1ccccc1)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1)c1ccccc1
4754,2157144,10.1021/acsmedchemlett.1c00473,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by TDI- high-throughput based mass spectrometry method,CCc1c[nH]c2ncc(-c3ccc(N)c(C(=O)N(C)C)c3)cc12,"2-Amino-5-(3-ethyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-N,N-dimethylbenzamide",0.5,uM,=,-0.3010299956639812,0,c1ccc(-c2cnc3[nH]ccc3c2)cc1
4755,949160,10.1016/j.bmcl.2013.01.011,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate,Cc1cc(CC(NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12,"(+/-)-N-(1-(1,4'-bipiperidin-1'-yl)-3-(7-methyl-1H-indazol-5-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide",1.1,uM,=,0.041392685158225,1,O=C(NC(Cc1ccc2[nH]ncc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
4756,1455473,10.1016/j.bmcl.2014.06.026,,,,Inhibition of recombinant human CYP3A4 preincubated for 5 mins before fluorescent substrate addition by fluorescence assay,Fc1cccc(OC(CC2CNC2)c2ccc(Cl)c(F)c2)c1,3-(2-(4-chloro-3-fluorophenyl)-2-(3-fluorophenoxy)ethyl)azetidine,0.51,uM,=,-0.2924298239020636,0,c1ccc(OC(CC2CNC2)c2ccccc2)cc1
4757,652208,10.1016/j.bmcl.2010.07.052,,,,Inhibition of CYP3A4 in human liver microsomes,CC(C)Cn1c(=O)n(C2CCN(C(=O)C3CCN(Cc4ccncc4)CC3)CC2)c2ccccc21,1-isobutyl-3-(1-(1-(pyridin-4-ylmethyl)piperidine-4-carbonyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one,1.5,uM,=,0.1760912590556812,1,O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1
4758,1366633,10.1021/jm500535j,,,,Inhibition of CYP3A4 (unknown origin),CC(Oc1ccc2nc(N)n(CC(O)c3ccc(C(F)(F)F)cc3Cl)c2n1)C(F)(F)F,"rac-2-(2-Amino-5-((1,1,1-trifluoropropan-2-yl)oxy)-3H-imidazo[4,5-b]pyridin-3-yl)-1-(2-chloro-4-(trifluoromethyl)phenyl)ethanol",20.3,uM,=,1.307496037913213,1,c1ccc(CCn2cnc3cccnc32)cc1
4759,306900,10.1021/jm050255t,,,,Inhibitory concentration (1.5 mM) against human CYP450 3A4 dissolved in acetonitrile/methanol using 7-Benzyloxy-4-(trifluoromethyl)coumarin (BFC) as fluorogenic substrate,CCN1c2ncc(CCOc3ccc(C(=O)O)cc3C)cc2C(=O)N(C)c2ccc(F)nc21,"4-[2-(5-Ethyl-7-fluoro-10-methyl-11-oxo-10,11-dihydro-5H-4,5,6,10-tetraaza-dibenzo[a,d]cyclohepten-2-yl)-ethoxy]-3-methyl-benzoic acid",10.0,uM,=,1.0,1,O=C1Nc2cccnc2Nc2ncc(CCOc3ccccc3)cc21
4760,437775,10.1016/j.bmcl.2006.11.006,,,,Inhibition of CYP3A4,Cc1cc(-c2c(Cl)cccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12,"7-(2,6-dichlorophenyl)-5-methyl-N-(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)benzo[e][1,2,4]triazin-3-amine",62.0,uM,=,1.792391689498254,1,c1ccc(-c2ccc3nc(Nc4ccc(OCCN5CCCC5)cc4)nnc3c2)cc1
4761,2111417,10.1016/j.ejmech.2020.113109,,,,Inhibition of CYP3A4 (unknown origin) using Luciferin-PPXE as substrate at 10 uM preincubated with enzyme and substrate for 5 mins followed by addition of NADPH regeneration system and measured after 60 mins by luminescence method,COc1ncc2cc1NS(=O)(=O)c1cccc(c1)C(=O)NCc1cncc(c1)-c1ccnc3ccc-2cc13,,19.6,uM,=,1.292256071356476,1,O=C1NCc2cncc(c2)-c2ccnc3ccc(cc23)-c2cncc(c2)NS(=O)(=O)c2cccc1c2
4762,1729574,10.1021/acsmedchemlett.7b00406,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate,FC1(F)CCC(NC/C=C\CN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)CC1,"(Z)-N1-(4,4-difluorocyclohexyl)-N4-(((R)-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)-N4-((S)-5,6,7,8-tetrahydroquinolin-8-yl)but-2-ene-1,4-diamine",12.0,uM,=,1.0791812460476249,1,C(=C\CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21)\CNC1CCCCC1
4763,2069798,10.1021/acsmedchemlett.0c00606,,,,Inhibition of human liver microsome CYP3A4 using sorafenib as substrate incubated for 20 mins by LC-MS/MS with HPLC analysis,Nc1cc(F)c(S(=O)(=O)N2CCC(O)CC2)cc1C(=O)Nc1ccc(F)c(F)c1,"2-amino-N-(3,4-difluorophenyl)-4-fluoro-5-((4-hydroxypiperidin-1-yl)sulfonyl)benzamide",41.0,uM,=,1.6127838567197357,1,O=C(Nc1ccccc1)c1cccc(S(=O)(=O)N2CCCCC2)c1
4764,2193505,10.1016/j.bmcl.2022.128892,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 30 mins,CNC(=O)N(c1ccc(S(=O)(=O)Nc2ccon2)cn1)c1cc(Cl)c(-c2cc(OC)cc(C(F)(F)F)c2)cc1OC,"6-(1-(2-chloro-3',5-dimethoxy-5'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)-3-methylureido)-N-(isoxazol-3-yl)pyridine-3-sulfonamide",17.0,uM,=,1.230448921378274,1,O=S(=O)(Nc1ccon1)c1ccc(Nc2ccc(-c3ccccc3)cc2)nc1
4765,718343,10.1021/jm101063h,,,,Inhibition of CYP3A4,COC(=O)c1ccc(Oc2ccc(/C=C3\SC(=O)NC3=O)cc2OC)c2ccccc12,"4-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)-2-methoxyphenoxy]-naphthalene-1-carboxylic Acid Methyl Ester",0.8,uM,=,-0.0969100130080563,0,O=C1NC(=O)/C(=C/c2ccc(Oc3cccc4ccccc34)cc2)S1
4766,490335,10.1016/j.bmcl.2008.06.073,,,,Inhibition of CYP3A4 in pooled human liver microsome using nifedipine substrate,CC(C)c1onc(-c2c(Cl)cccc2Cl)c1COc1ccc(-c2ccc3c(C(=O)O)cccc3c2)cc1,"6-(4-((3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl)methoxy)phenyl)-1-naphthoic acid",8.8,uM,=,0.9444826721501688,1,c1ccc(-c2nocc2COc2ccc(-c3ccc4ccccc4c3)cc2)cc1
4767,1866289,10.1021/acs.jmedchem.9b00662,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,O=C(C1CCCCC1)N1CCC(C(O)CC2c3ccccc3-c3cncn32)CC1,"Cyclohexyl(4-(1-hydroxy-2-(5H-imidazo[5,1-a]isoindol-5-yl)-ethyl)piperidin-1-yl)methanone",0.7,uM,=,-0.1549019599857432,0,O=C(C1CCCCC1)N1CCC(CCC2c3ccccc3-c3cncn32)CC1
4768,2157079,10.1021/acsmedchemlett.1c00445,,,,Inhibition of human CYP3A4 by fluorescence plate reader analysis,C[C@@]1(c2cc(NC(=O)c3ccc(Cl)cn3)ccc2F)Cn2c(C#N)cnc2C(N)=N1,"(R)-N-(3-(8-amino-3-cyano-6-methyl-5,6-dihydroimidazo[1,2-a]pyrazin-6-yl)-4-fluorophenyl)-5-chloropicolinamide",0.9,uM,=,-0.0457574905606751,0,O=C(Nc1cccc(C2Cn3ccnc3C=N2)c1)c1ccccn1
4769,1735372,10.1021/acs.jmedchem.8b00084,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis,Cl.Cl.NCc1ccc(-c2cnccc2-c2ccco2)s1,(5-(4-(Furan-2-yl)pyridin-3-yl)thiophen-2-yl)methanamine Dihydrochloride,7.0,uM,=,0.8450980400142568,1,c1coc(-c2ccncc2-c2cccs2)c1
4770,1729574,10.1021/acsmedchemlett.7b00406,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate,C/C(CN)=C(\F)CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21,"(E)-2-fluoro-3-methyl-N1-(((R)-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)-N1-((S)-5,6,7,8-tetrahydroquinolin-8-yl)but-2-ene-1,4-diamine",15.0,uM,=,1.1760912590556811,1,c1ccc2c(c1)CN[C@@H](CN[C@H]1CCCc3cccnc31)C2
4771,1554473,10.1021/acs.jmedchem.5b01372,,,,Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation,O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2nc(-c3ccc(C(F)(F)F)cc3)cs2)cc1,N-{4-[2-((R)-2-Hydroxy-2-pyridin-3-yl-ethylamino)-ethyl]-phenyl}-4-[4-(4-trifluoromethyl-phenyl)-thiazol-2-yl]-benzenesulfonamide,9.3,uM,=,0.9684829485539352,1,O=S(=O)(Nc1ccc(CCNCCc2cccnc2)cc1)c1ccc(-c2nc(-c3ccccc3)cs2)cc1
4772,621465,10.1016/j.bmcl.2009.07.118,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,O=C(N[C@H](Cc1ccccc1)CN(Cc1ccccc1)C[C@@H](Cc1ccccc1)NC(=O)OCc1nccs1)OCc1cncs1,Bis-N-[(R)-2-(thiazol-5-ylmethoxycarbonylamino)-3-phenylpropyl]-N-[benzyl]amine,0.06,uM,=,-1.2218487496163564,0,O=C(N[C@H](Cc1ccccc1)CN(Cc1ccccc1)C[C@@H](Cc1ccccc1)NC(=O)OCc1nccs1)OCc1cncs1
4773,1659863,10.1016/j.ejmech.2017.02.016,,,,Inhibition of human liver CYP3A4 expressed in Saccharomyces cerevisiae YY7 microsomal membranes using DBF as substrate after 10 mins by fluorescence assay,COc1ccccc1/C=C/C(=O)c1cccnc1,(E)-3-(2-Methoxyphenyl)-1-(3-pyridyl)prop-2-en-1-one,1.52,uM,=,0.1818435879447725,1,O=C(/C=C/c1ccccc1)c1cccnc1
4774,813105,10.1021/jm201346g,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,CCCSc1nc2cc(OC)ccc2[nH]1,5-methoxy-2-(propylthio)-1H-benzo[d]imidazole,27.1,uM,=,1.4329692908744058,1,c1ccc2[nH]cnc2c1
4775,463857,10.1016/j.bmcl.2008.01.100,,,,Inhibition of CYP3A4 using 7-benzyloxyresorufin as a substrate,CC(C)(N)C(=O)N[C@H](COCc1ccccc1)c1nnnn1[C@H](CC#N)COc1ccccn1,2-amino-N-((S)-2-(benzyloxy)-1-(1-((R)-1-cyano-3-(pyridin-2-yloxy)propan-2-yl)-1H-tetrazol-5-yl)ethyl)-2-methylpropanamide,11.0,uM,=,1.0413926851582251,1,c1ccc(COCCc2nnnn2CCOc2ccccn2)cc1
4776,1735372,10.1021/acs.jmedchem.8b00084,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis,Cl.Cl.NCC#Cc1cnccc1-c1ccccc1,3-(4-Phenylpyridin-3-yl)prop-2-yn-1-amine Dihydrochloride,39.0,uM,=,1.591064607026499,1,c1ccc(-c2ccncc2)cc1
4777,1914413,10.1021/acs.jmedchem.9b01194,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate,Cn1c(Sc2ccc(C(=O)NO)cc2)nnc1-c1cccs1,"N-hydroxy-4-((4-methyl-5-(thiophen-2-yl)-4H-1,2,4-triazol-3-yl)thio)benzamide",26.6,uM,=,1.424881636631067,1,c1ccc(Sc2nnc(-c3cccs3)[nH]2)cc1
4778,813105,10.1021/jm201346g,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,COc1ccc2[nH]c(SCc3ccc(C)cc3)nc2c1,5-methoxy-2-(4-methylbenzylthio)-1H-benzo[d]imidazole,8.86,uM,=,0.9474337218870508,1,c1ccc(CSc2nc3ccccc3[nH]2)cc1
4779,789986,10.1016/j.bmcl.2011.10.013,,,,Reversible inhibition of CYP3A4,COCCCc1cccc2cccc(CN(C(=O)[C@H]3CNCC[C@@]34OCc3cc(F)c(F)cc34)C3CC3)c12,"(1R,3'S)-N-cyclopropyl-5,6-difluoro-N-((8-(3-methoxypropyl)naphthalen-1-yl)methyl)-3H-spiro[isobenzofuran-1,4'-piperidine]-3'-carboxamide",15.0,uM,=,1.1760912590556811,1,O=C([C@H]1CNCC[C@@]12OCc1ccccc12)N(Cc1cccc2ccccc12)C1CC1
4780,2093989,10.1021/acs.jmedchem.0c01296,,,,Inhibition of human CYP3A4 in human pooled liver microsomes in presence of midazolam as substrate preincubated for 30 mins in presence of NADPH followed by addition of substrate by LC-MS/MS analysis,CC[C@@H]1C[C@H](C)CC/C=C\[C@@H]2C[C@@]2(C(=O)NS(=O)(=O)C2(C)CC2)NC(=O)[C@@H]2C[C@@H](Oc3nccc4cc(OC)c(F)cc34)CN2C(=O)[C@H]1NC(=O)OC(C)(C)C(F)(F)F,"1,1,1-Trifluoro-2-methylpropan-2-yl-((2R,6S,7R,9R,13aS,14aR,16aS,Z)-7-ethyl-2-((7-fluoro-6-methoxyisoquinolin-1-yl)oxy)-9-methyl-14a-(((1-methylcyclopropyl)sulfonyl)carbamoyl)-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl)carbamate",2.85,uM,=,0.4548448600085102,1,O=C1N[C@]2(C(=O)NS(=O)(=O)C3CC3)C[C@H]2/C=C\CCCCCCC(=O)N2C[C@H](Oc3nccc4ccccc34)C[C@@H]12
4781,949160,10.1016/j.bmcl.2013.01.011,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate,Cc1cc(C[C@@H](NC(=O)N2CCC(N3Cc4cccc(F)c4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12,"(R)-N-(1-(1,4'-bipiperidin-1'-yl)-3-(7-methyl-1H-indazol-5-yl)-1-oxopropan-2-yl)-4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide",6.7,uM,=,0.8260748027008264,1,O=C(N[C@H](Cc1ccc2[nH]ncc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
4782,510060,10.1016/j.bmcl.2008.07.059,,,,Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay,CN[C@@H](Cn1c(=O)c(-c2cccc(OCCCCC(=O)O)c2F)c(C)n(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1,"(R)-5-(3-(1-(2-fluoro-6-(trifluoromethyl)benzyl)-6-methyl-3-(2-(methylamino)-2-phenylethyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-2-fluorophenoxy)pentanoic acid",13.0,uM,=,1.1139433523068367,1,O=c1c(-c2ccccc2)cn(Cc2ccccc2)c(=O)n1CCc1ccccc1
4783,643712,10.1016/j.bmcl.2010.06.009,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader,C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(NC5CCN(C)CC5)c4)ccc32)sc1C(N)=O)c1ccccc1Cl,(R)-3-(1-(2-chlorophenyl)ethoxy)-5-(5-(2-(1-methylpiperidin-4-ylamino)pyridin-4-yl)-1H-benzo[d]imidazol-1-yl)thiophene-2-carboxamide,1.1,uM,=,0.041392685158225,1,c1ccc(COc2csc(-n3cnc4cc(-c5ccnc(NC6CCNCC6)c5)ccc43)c2)cc1
4784,621465,10.1016/j.bmcl.2009.07.118,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,CCN(C[C@@H](Cc1ccccc1)NC(=O)OCc1cncs1)C[C@@H](Cc1ccccc1)NC(=O)OCc1nccs1,Bis-N-[(R)-2-(thiazol-5-ylmethoxycarbonylamino)-3-phenylpropyl]ethylamine,0.11,uM,=,-0.958607314841775,0,O=C(N[C@@H](CNC[C@@H](Cc1ccccc1)NC(=O)OCc1nccs1)Cc1ccccc1)OCc1cncs1
4785,827667,10.1016/j.bmcl.2012.05.039,,,,Inhibition of CYP3A4,COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1nc(Cl)c(-c2ccc(-c3ccc(-c4[nH]c([C@@H]5CCCN5C(=O)[C@@H](NC(=O)OC)C(C)C)nc4Cl)cc3)cc2)[nH]1)C(C)C,"dimethyl-(2S,2'S)-1,1'-((2S,2'S)-2,2'-(5,5'-(biphenyl-4,4'-diyl)bis(4-chloro-1H-imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl)dicarbamate",13.8,uM,=,1.1398790864012365,1,c1cc(-c2cnc([C@@H]3CCCN3)[nH]2)ccc1-c1ccc(-c2cnc([C@@H]3CCCN3)[nH]2)cc1
4786,1689465,10.1021/acs.jmedchem.7b00662,,,,Inhibition of CYP3A4 (unknown origin),CN1C(=O)C2=C(C1=O)N(CC(=O)Nc1ccc(-c3cncc(F)c3)nn1)CCC2,"N-(6-(5-Fluoropyridin-3-yl)pyridazin-3-yl)-2-(6-methyl-5,7-dioxo-2,3,4,5,6,7-hexahydro-1H-pyrrolo[3,4-b]pyridin-1-yl)-acetamide",7.1,uM,=,0.8512583487190752,1,O=C(CN1CCCC2=C1C(=O)NC2=O)Nc1ccc(-c2cccnc2)nn1
4787,1296352,10.1021/jm4015108,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,CC(C)n1cc(S(=O)(=O)c2ccc(NC(=O)[C@@H]3C[C@H]3c3cccnc3)cc2)cn1,rac-trans-N-(4-((1-Isopropyl-1H-pyrazol-4-yl)sulfonyl)phenyl)-2-(pyridin-3-yl)cyclopropanecarboxamide,0.96,uM,=,-0.0177287669604316,0,O=C(Nc1ccc(S(=O)(=O)c2cn[nH]c2)cc1)[C@@H]1C[C@H]1c1cccnc1
4788,1925822,10.1021/acs.jmedchem.6b00425,,,,Inhibition of CYP3A4 in human microsomes using midazolam as substrate preincubated with enzyme and NADPH prior to substrate addition by LC-MS/MS analysis,CC(C)COc1ncc(Oc2nccc3cc(C(=O)NS(C)(=O)=O)ccc23)cc1Cl,1-((5-Chloro-6-isobutoxypyridin-3-yl)oxy)-N-(methylsulfonyl)isoquinoline-6-carboxamide,18.4,uM,=,1.2648178230095364,1,c1cncc(Oc2nccc3ccccc23)c1
4789,652208,10.1016/j.bmcl.2010.07.052,,,,Inhibition of CYP3A4 in human liver microsomes,O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)n(Cc3ccc(Cl)cc3)c3ccccc32)CC1,1-(4-chlorobenzyl)-3-(1-(1-(pyridin-4-ylmethyl)piperidine-4-carbonyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one,0.4,uM,=,-0.3979400086720376,0,O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)n(Cc3ccccc3)c3ccccc32)CC1
4790,476993,10.1016/j.bmcl.2008.02.076,,,,Inhibition of CYP3A4,O=C1CC(c2cccc(-n3ccnc3)c2)=Nc2ccc(-c3ccccc3F)cc2N1,"4-(3-(1H-imidazol-1-yl)phenyl)-8-(2-fluorophenyl)-1H-benzo[b][1,4]diazepin-2(3H)-one",0.001,uM,=,-3.0,0,O=C1CC(c2cccc(-n3ccnc3)c2)=Nc2ccc(-c3ccccc3)cc2N1
4791,802875,10.1016/j.bmcl.2011.12.127,,,,Inhibition of human CYP3A4 using midazolam as substrate by LC-MS/MS analysis,CCCOc1sc(C(=O)N2[C@H]3CC[C@H]2CC(c2cc(CN)ccc2F)C3)c(C)c1Br,"((1S,5S)-3-(5-(aminomethyl)-2-fluorophenyl)-8-azabicyclo[3.2.1]octan-8-yl)(4-bromo-3-methyl-5-propoxythiophen-2-yl)methanone",5.3,uM,=,0.724275869600789,1,O=C(c1cccs1)N1[C@H]2CC[C@H]1CC(c1ccccc1)C2
4792,789986,10.1016/j.bmcl.2011.10.013,,,,Reversible inhibition of CYP3A4,O=C([C@H]1CNCC[C@@]12OCc1cc(F)c(F)cc12)N(Cc1cc(Cl)ccc1Cl)C1CC1,"(1R,3'S)-N-cyclopropyl-N-(2,5-dichlorobenzyl)-5,6-difluoro-3H-spiro[isobenzofuran-1,4'-piperidine]-3'-carboxamide",1.6,uM,=,0.2041199826559248,1,O=C([C@H]1CNCC[C@@]12OCc1ccccc12)N(Cc1ccccc1)C1CC1
4793,510060,10.1016/j.bmcl.2008.07.059,,,,Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay,CN[C@@H](Cn1c(=O)c(-c2cccc(OCCOCC(=O)O)c2F)c(C)n(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1,"(R)-2-(2-(3-(1-(2-fluoro-6-(trifluoromethyl)benzyl)-6-methyl-3-(2-(methylamino)-2-phenylethyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-2-fluorophenoxy)ethoxy)acetic acid",10.0,uM,=,1.0,1,O=c1c(-c2ccccc2)cn(Cc2ccccc2)c(=O)n1CCc1ccccc1
4794,1296352,10.1021/jm4015108,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,O=C(Nc1ccc(S(=O)(=O)c2ccccc2)cc1)[C@@H]1C[C@H]1c1cccnc1,rac-trans-N-(4-(Phenylsulfonyl)phenyl)-2-(pyridin-3-yl)-cyclopropanecarboxamide,1.2,uM,=,0.0791812460476248,1,O=C(Nc1ccc(S(=O)(=O)c2ccccc2)cc1)[C@@H]1C[C@H]1c1cccnc1
4795,813105,10.1021/jm201346g,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,COc1ccc2[nH]c(SCc3ccc(OCc4ccccc4)cc3)nc2c1,2-(4-(benzyloxy)benzylthio)-5-methoxy-1H-benzo[d]imidazole,3.56,uM,=,0.5514499979728752,1,c1ccc(COc2ccc(CSc3nc4ccccc4[nH]3)cc2)cc1
4796,621465,10.1016/j.bmcl.2009.07.118,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,CCN(CC(COCc1ccccc1)NC(=O)OCc1cncs1)CC(COCc1ccccc1)NC(=O)OCc1nccs1,N-[(S)-2-(thiazol-5-ylmethoxycarbonylamino)-3-phenylmethoxypropyl]-N-[2-(thiazol-5-ylmethoxycarbonylamino)-3-phenylmethoxypropyl]ethylamine,0.135,uM,=,-0.8696662315049939,0,O=C(NC(CNCC(COCc1ccccc1)NC(=O)OCc1nccs1)COCc1ccccc1)OCc1cncs1
4797,51901,10.1016/s0960-894x(02)00026-4,,,,Inhibition of cytochrome P450 3A4 enzyme,Cc1cc(C)cc(-c2[nH]c3ccc(C(C)(C)C(=O)N4CC5CCC4CC5)cc3c2[C@H](C)CNCCc2c[nH]c3ncnc-3c2)c1,"1-(2-Aza-bicyclo[2.2.2]oct-2-yl)-2-(2-(3,5-dimethyl-phenyl)-3-{(S)-2-[2-(3H-imidazo[4,5-b]pyridin-6-yl)-ethylamino]-1-methyl-ethyl}-1H-indol-5-yl)-2-methyl-propan-1-one",4.0,uM,=,0.6020599913279624,1,O=C(Cc1ccc2[nH]c(-c3ccccc3)c(CCNCCc3c[nH]c4ncnc-4c3)c2c1)N1CC2CCC1CC2
4798,1515918,10.1016/j.ejmech.2015.06.029,,,,Inhibition of CYP3A4 (unknown origin),CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,"1-(4-{4-[2-(2,4-Dichloro-phenyl)-2-imidazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-ethanone (ketoconazole)",0.18,uM,=,-0.744727494896694,0,c1ccc(C2(Cn3ccnc3)OCC(COc3ccc(N4CCNCC4)cc3)O2)cc1
4799,2221810,10.1016/j.bmcl.2022.128625,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as substrate pretreated with NADPH,CCC[C@H]1N(C(=O)c2cnccc2C(F)(F)F)CCC[C@@]1(Oc1csc(C(F)(F)F)c1)C(=O)N1CCN(c2ccccc2OCCCC(=O)O)CC1,"4-(2-(4-((2R,3S)-2-propyl-1-(4-(trifluoromethyl)nicotinoyl)-3-((5-(trifluoromethyl)thiophen-3-yl)oxy)piperidine-3-carbonyl)piperazin-1-yl)phenoxy)butanoic acid",0.9,uM,=,-0.0457574905606751,0,O=C(c1cccnc1)N1CCC[C@@](Oc2ccsc2)(C(=O)N2CCN(c3ccccc3)CC2)C1
4800,1347924,10.1016/j.bmcl.2014.04.024,,,,Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method,COc1cc2ccc(C(O)(c3cncs3)C(C)C)cc2cc1OC,"rac-1-(6,7-dimethoxynaphthalen-2-yl)-2-methyl-1-(thiazol-5-yl)propan-1-ol",0.77,uM,=,-0.1135092748275181,0,c1ccc2cc(Cc3cncs3)ccc2c1
4801,2241391,10.1016/j.ejmech.2021.113981,,,,Inhibition of CYP3A4 in human liver microsomes assessed as reduction in 1'-hydroxy midazolam formation using midazolam as substrate preincubated for 20 mins in presence of NADPH followed by incubation with substrate for 10 mins by LC-MS/MS analysis,O[C@H](c1cc(C(F)(F)F)nc2c(C(F)(F)F)cccc12)[C@@H]1CCCCN1,"(R)-(2,8-bis(trifluoromethyl)quinolin-4-yl)((S)-piperidin-2-yl)methanol",43.0,uM,=,1.6334684555795866,1,c1ccc2c(C[C@@H]3CCCCN3)ccnc2c1
4802,841307,10.1016/j.bmcl.2012.06.029,,,,Inhibition of CYP3A4,CCN1CCC(Nc2ccc3c(c2)C(=C(c2cccc(F)c2)c2ncc[nH]2)C(=O)N3)CC1,(E/Z)-5-(1-ethylpiperidin-4-ylamino)-3-((3-fluorophenyl)(1H-imidazol-2-yl)methylene)indolin-2-one,23.0,uM,=,1.3617278360175928,1,O=C1Nc2ccc(NC3CCNCC3)cc2C1=C(c1ccccc1)c1ncc[nH]1
4803,621465,10.1016/j.bmcl.2009.07.118,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,CCN(C[C@@H](C)NC(=O)OCc1cncs1)C[C@@H](C)NC(=O)OCc1nccs1,Bis-N-[(R)-2-(thiazol-5-ylmethoxycarbonylamino)propyl]ethylamine,1.33,uM,=,0.1238516409670858,1,O=C(NCCNCCNC(=O)OCc1nccs1)OCc1cncs1
4804,1889158,10.1021/acs.jmedchem.8b01719,,,,Inhibition of CYP3A4 in human liver microsomes using nifedipine as substrate preincubated for 7 mins followed by NADPH addition and measured by LC-MS/MS analysis,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(Cc3ccc(B(O)O)c(F)c3)S(C)(=O)=O)c(C3CC3)cc12,4-((N-(5-cyclopropyl-2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-6-yl)methylsulfonamido)methyl)-2-fluorophenylboronic acid,28.0,uM,=,1.4471580313422192,1,c1ccc(CNc2cc3oc(-c4ccccc4)cc3cc2C2CC2)cc1
4805,2221810,10.1016/j.bmcl.2022.128625,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as substrate pretreated with NADPH,CCC[C@H]1N(C(=O)c2c(C(F)(F)F)ccnc2OCC(=O)O)CCC[C@@]1(Oc1csc(C(F)(F)F)c1)C(=O)N1CCN(c2ccccc2OCCO)CC1,"2-(3-((2R,3S)-3-(4-(2-(2-hydroxyethoxy)phenyl)piperazine-1-carbonyl)-2-propyl-3-(5-(trifluoromethyl)thiophen-3-yloxy)piperidine-1-carbonyl)-4-(trifluoromethyl)pyridin-2-yloxy)acetic acid",4.4,uM,=,0.6434526764861874,1,O=C(c1cccnc1)N1CCC[C@@](Oc2ccsc2)(C(=O)N2CCN(c3ccccc3)CC2)C1
4806,1707938,10.1021/acs.jmedchem.7b01420,,,,Inhibition of CYP3A4 (unknown origin),C(=C/CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21)\CNCc1ccncc1,"(E)-N1-(Pyridin-4-ylmethyl)-N4-(((R)-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)-N4-((S)-5,6,7,8-tetrahydroquinolin-8-yl)-but-2-ene-1,4-diamine",0.35,uM,=,-0.4559319556497244,0,C(=C/CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21)\CNCc1ccncc1
4807,652208,10.1016/j.bmcl.2010.07.052,,,,Inhibition of CYP3A4 in human liver microsomes,CCOCCn1c(=O)n(C2CCN(C(=O)C3CCN(Cc4ccncc4)CC3)CC2)c2ccccc21,1-(2-ethoxyethyl)-3-(1-(1-(pyridin-4-ylmethyl)piperidine-4-carbonyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one,13.5,uM,=,1.130333768495006,1,O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1
4808,652208,10.1016/j.bmcl.2010.07.052,,,,Inhibition of CYP3A4 in human liver microsomes,CC(C)OCCn1c(=O)n(C2CCN(C(=O)C3CCN(Cc4ccncc4)CC3)CC2)c2ccccc21,1-(2-isopropoxyethyl)-3-(1-(1-(pyridin-4-ylmethyl)piperidine-4-carbonyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one,6.0,uM,=,0.7781512503836436,1,O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1
4809,1846363,10.1016/j.ejmech.2019.02.073,,,,Inhibition of CYP3A4 in human liver microsomes assessed as reduction in metabolite formation using midazolam as substrate incubated for 10 mins in presence of NADPH by HPLC based mass spectrometric method,CC[C@H]1OC(=O)[C@@](C)(F)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)/C(=N\OC/C=C/c2ccc3c(c2)c(=O)c(C(N)=O)cn3CC)[C@H](C)[C@H]2OC(=O)O[C@@]21C,"2-Fluoro-3-O-descladinosyl-3-oxo-6-O-methylerythromycin A 9-O-[3-(3'-carbamoyl-1',4'-dihydro-1'-ethyl-4'-oxo-quinol-6'-yl)-E-prop-2-enyl]oxime-11,12-cyclic carbonate",5.14,uM,=,0.7109631189952758,1,O=C1CC(=O)OCC2OC(=O)O[C@@H]2C/C(=N/OC/C=C/c2ccc3[nH]ccc(=O)c3c2)CCC[C@H](O[C@H]2CCCCO2)C1
4810,497350,10.1016/j.ejmech.2007.10.034,,,,Inhibition of human recombinant CYP3A4,CCc1cc(/C=C2\CC/C(=C\c3cc(CC)c(O)c(CC)c3)C2=O)cc(CC)c1O,"2,5-bis(3,5-diethyl-4-hydroxybenzylidene)cyclopentanone",73.5,uM,=,1.866287339084195,1,O=C1/C(=C/c2ccccc2)CC/C1=C\c1ccccc1
4811,813105,10.1021/jm201346g,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,COc1ccc2[nH]c(SCC3CCCCC3)nc2c1,2-(cyclohexylmethylthio)-5-methoxy-1H-benzo[d]imidazole,6.23,uM,=,0.7944880466591696,1,c1ccc2[nH]c(SCC3CCCCC3)nc2c1
4812,1296353,10.1021/jm4015108,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis,CCCn1cc(S(=O)(=O)c2ccc(NC(=O)[C@@H]3C[C@H]3c3cccnc3)cc2)cn1,rac-trans-N-(4-((1-Propyl-1H-pyrazol-4-yl)sulfonyl)phenyl)-2-(pyridin-3-yl)cyclopropanecarboxamide,0.27,uM,=,-0.5686362358410126,0,O=C(Nc1ccc(S(=O)(=O)c2cn[nH]c2)cc1)[C@@H]1C[C@H]1c1cccnc1
4813,2132130,10.1021/acs.jmedchem.1c01559,,,,Inhibition of CYP3A4M in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH by LC-MS/MS analysis,CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,SID144204227,0.0069999999999999,uM,=,-2.154901959985743,0,c1ccc([C@@]2(Cn3ccnc3)OC[C@H](COc3ccc(N4CCNCC4)cc3)O2)cc1
4814,1866289,10.1021/acs.jmedchem.9b00662,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,O[C@@H](C[C@H]1c2c(F)cccc2-c2cncn21)[C@H]1CC[C@H](O)CC1,"(1S,4r)-4-((S)-2-((S)-6-Fluoro-5H-imidazo[5,1-a]isoindol-5-yl)-1-hydroxyethyl)cyclohexan-1-ol",5.6,uM,=,0.7481880270062004,1,c1ccc2c(c1)-c1cncn1[C@H]2CCC1CCCCC1
4815,437775,10.1016/j.bmcl.2006.11.006,,,,Inhibition of CYP3A4,Cc1cccc(C)c1-c1cc(C)c2nc(Nc3ccc(OCCN4CCCC4)cc3)nnc2c1,"7-(2,6-dimethylphenyl)-5-methyl-N-(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)benzo[e][1,2,4]triazin-3-amine",42.0,uM,=,1.6232492903979006,1,c1ccc(-c2ccc3nc(Nc4ccc(OCCN5CCCC5)cc4)nnc3c2)cc1
4816,1659863,10.1016/j.ejmech.2017.02.016,,,,Inhibition of human liver CYP3A4 expressed in Saccharomyces cerevisiae YY7 microsomal membranes using DBF as substrate after 10 mins by fluorescence assay,O=C(/C=C/c1cccnc1)c1cccc(Br)c1,(E)-1-(3-Bromophenyl)-3-(3-pyridinyl)prop-2-en-1-one,14.0,uM,=,1.146128035678238,1,O=C(/C=C/c1cccnc1)c1ccccc1
4817,1678562,10.1021/acs.jmedchem.7b01710,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate,CC(=O)O[C@H]1C[C@H]2[C@@H]([C@H](OC(C)=O)C[C@@H]3C[C@H](N)CC[C@@]32C)[C@@H]2CC[C@H]([C@H](C)CCCNCCCCNc3ccnc4cc(Cl)ccc34)[C@@]12C,"(3alpha,5beta,7alpha,12alpha)-3-Amino-24-({4-[(7-chloroquinolin-4-yl)amino]butyl}amino)cholane-7,12-diyl diacetate",1.4,uM,=,0.1461280356782379,1,c1ccc2c(NCCCCNCCCC[C@H]3CC[C@@H]4C3CC[C@@H]3C5CCCC[C@H]5CC[C@H]34)ccnc2c1
4818,1527906,,,,,Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,Cc1cc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)nn(C)c1=O,"US8592410, 17",31.0,uM,=,1.4913616938342726,1,O=C1OC(c2ccccc2)CCN1Cc1ccc(-c2ccc(=O)[nH]n2)cc1
4819,813105,10.1021/jm201346g,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,CCOc1ccc2[nH]c(SCc3ccccn3)nc2c1,5-ethoxy-2-(pyridin-2-ylmethylthio)-1H-benzo[d]imidazole,0.4,uM,=,-0.3979400086720376,0,c1ccc(CSc2nc3ccccc3[nH]2)nc1
4820,583696,10.1016/j.bmcl.2009.05.066,,,,Inhibition of human recombinant CYP3A4 after 45 mins,O=C(NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)NC(Cn1cncn1)c1ccccc1,"1-(1-phenyl-2-(1H-1,2,4-triazol-1-yl)ethyl)-3-(1-((1-(4-(trifluoromethyl)phenyl)-1H-pyrrol-3-yl)methyl)piperidin-4-yl)urea",0.57,uM,=,-0.2441251443275086,0,O=C(NC1CCN(Cc2ccn(-c3ccccc3)c2)CC1)NC(Cn1cncn1)c1ccccc1
4821,583696,10.1016/j.bmcl.2009.05.066,,,,Inhibition of human recombinant CYP3A4 after 45 mins,O=C(NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)N1CCn2cccc2C1c1ccccc1,"1-phenyl-N-(1-((1-(4-(trifluoromethyl)phenyl)-1H-pyrrol-3-yl)methyl)piperidin-4-yl)-3,4-dihydropyrrolo[1,2-a]pyrazine-2(1H)-carboxamide",2.49,uM,=,0.3961993470957364,1,O=C(NC1CCN(Cc2ccn(-c3ccccc3)c2)CC1)N1CCn2cccc2C1c1ccccc1
4822,686510,10.1016/j.bmcl.2010.09.039,,,,Inhibition of CYP3A4,O=c1cc(OCc2ccccc2)ccn1-c1ccc2c(cnn2CCN2CC[C@H](O)C2)c1,(S)-4-(benzyloxy)-1-(1-(2-(3-hydroxypyrrolidin-1-yl)ethyl)-1H-indazol-5-yl)pyridin-2(1H)-one,7.7,uM,=,0.8864907251724818,1,O=c1cc(OCc2ccccc2)ccn1-c1ccc2c(cnn2CCN2CCCC2)c1
4823,497350,10.1016/j.ejmech.2007.10.034,,,,Inhibition of human recombinant CYP3A4,Cc1cc(/C=C/C(=O)/C=C/c2cc(C)c(O)c(C)c2)cc(C)c1O,"1,5-bis(4-hydroxy-3,5-dimethylphenyl)penta-1,4-dien-3-one",40.3,uM,=,1.6053050461411096,1,O=C(/C=C/c1ccccc1)/C=C/c1ccccc1
4824,813105,10.1021/jm201346g,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,COc1ccc2[nH]c(SCc3cccc(-c4ccccc4)c3)nc2c1,2-(biphenyl-3-ylmethylthio)-5-methoxy-1H-benzo[d]imidazole,1.87,uM,=,0.2718416065364989,1,c1ccc(-c2cccc(CSc3nc4ccccc4[nH]3)c2)cc1
4825,497350,10.1016/j.ejmech.2007.10.034,,,,Inhibition of human recombinant CYP3A4,COc1cc(/C=C/C(=O)/C=C(O)/C=C/c2ccc(O)c(OC)c2)ccc1O,"1,7-Bis-(4-hydroxy-3-methoxy-phenyl)-hepta-1,6-diene-3,5-dione",16.3,uM,=,1.212187604403958,1,O=C(/C=C/C=C/c1ccccc1)/C=C/c1ccccc1
4826,1866289,10.1021/acs.jmedchem.9b00662,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,OC(CC1c2ccccc2-c2cncn21)C1CCC(F)(F)CC1,"1-(4,4-Difluorocyclohexyl)-2-(5H-imidazo[5,1-a]isoindol-5-yl)-ethanol",1.2,uM,=,0.0791812460476248,1,c1ccc2c(c1)-c1cncn1C2CCC1CCCCC1
4827,556964,10.1021/jm801065q,,,,Inhibition of CYP3A4,C1=C(CS/C(=N\C2CCCCC2)NC2CCCCC2)N2CCN=C2S1,"1,3-dicyclohexyl-2-((5,6-dihydroimidazo[2,1-b]thiazol-3-yl)methyl)isothiourea",3.86,uM,=,0.5865873046717549,1,C1=C(CS/C(=N\C2CCCCC2)NC2CCCCC2)N2CCN=C2S1
4828,833383,10.1021/jm300241b,,,,Inhibition of human recombinant CPY3A4,O=c1cc(N2CCOCC2)nc(Cc2nc3c(-c4cccs4)cccc3o2)[nH]1,"6-(Morpholin-4-yl)-2-{[4-(thiophen-2-yl)-1,3-benzoxazol-2-yl]methyl}pyrimidin-4(3H)-one",19.0,uM,=,1.2787536009528289,1,O=c1cc(N2CCOCC2)nc(Cc2nc3c(-c4cccs4)cccc3o2)[nH]1
4829,51924,10.1021/jm034111v,,,,Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin],C[C@H](NC(=O)/C=C/c1ccccc1)c1cccc(N2CCOCC2)c1,(E)-N-[1-((S)-3-Morpholin-4-yl-phenyl)-ethyl]-3-phenyl-acrylamide,27.0,uM,=,1.4313637641589874,1,O=C(/C=C/c1ccccc1)NCc1cccc(N2CCOCC2)c1
4830,1659863,10.1016/j.ejmech.2017.02.016,,,,Inhibition of human liver CYP3A4 expressed in Saccharomyces cerevisiae YY7 microsomal membranes using DBF as substrate after 10 mins by fluorescence assay,O=C(/C=C/c1ccc2c(c1)OCO2)c1cccnc1,SID49648061,12.0,uM,=,1.0791812460476249,1,O=C(/C=C/c1ccc2c(c1)OCO2)c1cccnc1
4831,718343,10.1021/jm101063h,,,,Inhibition of CYP3A4,COc1cc(/C=C2\SC(=O)NC2=O)ccc1Oc1ccc(C(F)(F)F)cc1Br,"5-[4-(2-Bromo-4-trifluoromethylphenoxy)-3-methoxybenzylidene]thiazolidine-2,4-dione",3.8,uM,=,0.5797835966168101,1,O=C1NC(=O)/C(=C/c2ccc(Oc3ccccc3)cc2)S1
4832,1735372,10.1021/acs.jmedchem.8b00084,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis,Cl.Cl.Cl.NCc1ccc(-c2cnccc2-c2cccnc2)s1,"(5-([3,4'-Bipyridin]-3'-yl)thiophen-2-yl)methanamine Trihydrochloride",42.0,uM,=,1.6232492903979006,1,c1cncc(-c2ccncc2-c2cccs2)c1
4833,1468060,10.1016/j.bmcl.2015.03.035,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as marker substrate,COc1cccc(OC)c1[C@@H]1C[C@@H](O)C(=O)N1Cc1ccc2oc3ccccc3c2c1,"rac-(3R*,5S*)-1-(dibenzo[b,d]furan-2-ylmethyl)-5-(2,6-dimethoxyphenyl)-3-hydroxypyrrolidin-2-one",18.0,uM,=,1.255272505103306,1,O=C1CC[C@@H](c2ccccc2)N1Cc1ccc2oc3ccccc3c2c1
4834,1536230,,,,,"Inhibition Assay: Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v. Pooled human liver microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 5 mg/mL suspension. A solution of NADPH was prepared in phosphate buffer at a concentration of 5 mM. Separate stock solutions of each substrate were prepared in DMSO:MeCN (50:50 v/v), mixed, and diluted in phosphate buffer to obtain a single solution.",OC(Cn1cncn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(F)cc2)cn1,"US8754227, 16",1.4,uM,=,0.1461280356782379,1,c1ccc(-c2ccc(CC(Cn3cncn3)c3ccccc3)nc2)cc1
4835,621465,10.1016/j.bmcl.2009.07.118,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,O=C(N[C@@H](Cc1ccccc1)CN(Cc1ccncc1)C[C@H](Cc1ccccc1)NC(=O)OCc1nccs1)OCc1cncs1,Bis-N-[(S)-2-(thiazol-5-ylmethoxycarbonylamino)-3-phenylpropyl]-N-[4-pyridylmethyl]amine,0.049,uM,=,-1.3098039199714864,0,O=C(N[C@@H](Cc1ccccc1)CN(Cc1ccncc1)C[C@H](Cc1ccccc1)NC(=O)OCc1nccs1)OCc1cncs1
4836,813105,10.1021/jm201346g,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,COc1cc(CSc2nc3ccc(OC)cc3[nH]2)cc(OC)c1,"2-(3,5-dimethoxybenzylthio)-6-methoxy-1H-benzo[d]imidazole",0.72,uM,=,-0.1426675035687315,0,c1ccc(CSc2nc3ccccc3[nH]2)cc1
4837,2171279,10.1021/acs.jmedchem.1c01083,,,,Inhibition of human recombinant CYP3A4 expressed in insect microsome using 7-benzyloxy-4-trifluoromethylcoumarin as a substrate incubated for 30 mins followed by addition of NADPH regenerating system measured immediately by fluorescence based analysis,C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O,[(R)-2-(6-Amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid,45.8,uM,=,1.6608654780038692,1,c1ncc2nc[nH]c2n1
4838,643970,10.1016/j.bmcl.2010.06.086,,,,Inhibition of human CYP3A4-mediated testosterone oxidation,C[C@@H](c1ccc(Cl)cc1)N1Cc2cncn2C(CC2CC2)S1(=O)=O,"6-[(S)-1-(4-Chloro-phenyl)-ethyl]-4-cyclopropylmethyl-6,7-dihydro-5-thia-2,3a,6-triaza-indene 5,5-dioxide",0.18,uM,=,-0.744727494896694,0,O=S1(=O)C(CC2CC2)n2cncc2CN1Cc1ccccc1
4839,621465,10.1016/j.bmcl.2009.07.118,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,O=C(N[C@@H](Cc1ccccc1)CN(Cc1cccnc1)C[C@H](Cc1ccccc1)NC(=O)OCc1nccs1)OCc1cncs1,Bis-N-[(S)-2-(thiazol-5-ylmethoxycarbonylamino)-3-phenylpropyl]-N-[3-pyridylmethyl]amine,0.066,uM,=,-1.1804560644581312,0,O=C(N[C@@H](Cc1ccccc1)CN(Cc1cccnc1)C[C@H](Cc1ccccc1)NC(=O)OCc1nccs1)OCc1cncs1
4840,1611658,10.1039/C6MD00190D,,,,Inhibition of CYP3A4 (unknown origin),N#Cc1ccc(Oc2ccc(S(=O)(=O)Nc3ccc(F)cn3)cc2C#N)cc1Cl,"US9067922, 1",17.5,uM,=,1.2430380486862944,1,O=S(=O)(Nc1ccccn1)c1ccc(Oc2ccccc2)cc1
4841,438793,10.1016/j.bmcl.2007.04.052,,,,Inhibition of CYP3A4,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCC(=O)OC)CCC2,"methyl 3-(7-(2,4-diamino-6-ethylpyrimidin-5-yl)-3,4-dihydroquinolin-1(2H)-yl)propanoate",10.0,uM,=,1.0,1,c1ncc(-c2ccc3c(c2)NCCC3)cn1
4842,758414,10.1016/j.bmcl.2011.05.091,,,,Inhibition of CYP3A4,Cc1ccc(NC(=O)c2cc(F)cc(N3CCOCC3)c2)cc1Nc1ncnn2cc(C(=O)c3ccccc3)c(C)c12,"N-(3-(6-benzoyl-5-methylpyrrolo[1,2-f][1,2,4]triazin-4-ylamino)-4-methylphenyl)-3-fluoro-5-morpholinobenzamide",0.47,uM,=,-0.3279021420642826,0,O=C(Nc1cccc(Nc2ncnn3cc(C(=O)c4ccccc4)cc23)c1)c1cccc(N2CCOCC2)c1
4843,2193505,10.1016/j.bmcl.2022.128892,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 30 mins,COc1cc(-c2ccc(Cl)c(C)c2)ccc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3ccon3)ccc21,"US9212182, 431",32.0,uM,=,1.505149978319906,1,O=c1ccc2cc(S(=O)(=O)Nc3ccon3)ccc2n1-c1ccc(-c2ccccc2)cc1
4844,673953,10.1016/j.bmcl.2010.08.086,,,,Inhibition of CYP3A4 using testosterone as substrate,CNCCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1,"(3R,4S)-N-(2-chloro-5-(2-(methylamino)ethyl)benzyl)-N-cyclopropyl-4-(4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)phenyl)piperidine-3-carboxamide",16.0,uM,=,1.2041199826559248,1,O=C([C@H]1CNCC[C@@H]1c1ccc(OCCOc2ccccc2)cc1)N(Cc1ccccc1)C1CC1
4845,594887,10.1021/jm901230r,,,,Inhibition of CYP3A4,N#Cc1cc(Cl)cc(Oc2cc(OCc3n[nH]c4nc(N)ccc34)cc(F)c2Cl)c1,"3-{5-[(6-Amino-1H-pyrazolo[3,4-b]pyridin-3-yl)methoxy]-2-chloro-3-fluorophenoxy}-5-chlorobenzonitrile",4.4,uM,=,0.6434526764861874,1,c1ccc(Oc2cccc(OCc3n[nH]c4ncccc34)c2)cc1
4846,621465,10.1016/j.bmcl.2009.07.118,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,O=C(N[C@H](Cc1ccccc1)CN(Cc1ccccc1)C[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)OCc1nccs1,N-[(S)-2-(thiazol-5-ylmethoxycarbonylamino)-3-phenylpropyl][(R)-2-(thiazol-5-ylmethoxycarbonylamino)-3-phenylpropyl]-N-benzylamine,0.087,uM,=,-1.0604807473813815,0,O=C(N[C@H](Cc1ccccc1)CN(Cc1ccccc1)C[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)OCc1nccs1
4847,813105,10.1021/jm201346g,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,COc1ccc2[nH]c(SCCCO)nc2c1,3-(5-methoxy-1H-benzo[d]imidazol-2-ylthio)propan-1-ol,5.49,uM,=,0.7395723444500919,1,c1ccc2[nH]cnc2c1
4848,1642505,,,,,"Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).",CNC(C)C(=O)Nc1ccc(-c2c(-c3ccncc3)nc3cc(C)ccn23)c(C#Cc2ccc3nc(C)ccc3c2)n1,"US9481673, 64",2.1,uM,=,0.3222192947339193,1,C(#Cc1ncccc1-c1c(-c2ccncc2)nc2ccccn12)c1ccc2ncccc2c1
4849,949160,10.1016/j.bmcl.2013.01.011,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate,O=C(N[C@H](Cc1cc2oc(=O)[nH]c2cc1Br)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1,"(R)-N-(1-(1,4'-bipiperidin-1'-yl)-3-(5-bromo-2-oxo-2,3-dihydrobenzo[d]oxazol-6-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide",2.3,uM,=,0.3617278360175928,1,O=C(N[C@H](Cc1ccc2[nH]c(=O)oc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
4850,615765,10.1016/j.bmcl.2010.02.003,,,,Inhibition of CYP3A4,O=C(O)/C=C/c1ccc(NC(=O)C2(NC(=O)c3ccc4c(c3)nc(-c3ccccn3)n4C3CCCCC3)CCCC2)cc1,3-(4-(1-(1-cyclohexyl-2-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)cyclopentanecarboxamido)phenyl)acrylic acid,30.0,uM,=,1.4771212547196624,1,O=C(NC1(C(=O)Nc2ccccc2)CCCC1)c1ccc2c(c1)nc(-c1ccccn1)n2C1CCCCC1
4851,52091,10.1016/j.bmcl.2003.11.049,,,,Inhibition of CYP450 (Cytochrome P450) 3A4 with fluorogenic substrate BQ,CCN1c2ncc(CSc3cc(C)nc(C)c3)cc2C(=O)Nc2c(C)cc(F)nc21,"2-(2,6-Dimethyl-pyridin-4-ylsulfanylmethyl)-5-ethyl-7-fluoro-9-methyl-5,10-dihydro-4,5,6,10-tetraaza-dibenzo[a,d]cyclohepten-11-one",10.0,uM,=,1.0,1,O=C1Nc2cccnc2Nc2ncc(CSc3ccncc3)cc21
4852,976812,10.1016/j.bmcl.2013.06.100,,,,Inhibition of CYP3A4 (unknown origin),COc1cc(-c2nc3n(n2)CCC[C@H]3c2ccc(F)cc2C)ccc1-n1cnc(C)c1,"(S)-8-(4-fluoro-2-methylphenyl)-2-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyridine",6.94,uM,=,0.8413594704548549,1,c1ccc([C@@H]2CCCn3nc(-c4ccc(-n5ccnc5)cc4)nc32)cc1
4853,621465,10.1016/j.bmcl.2009.07.118,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,CC(C)CCN(C[C@@H](Cc1ccccc1)NC(=O)OCc1cncs1)C[C@@H](Cc1ccccc1)NC(=O)OCc1nccs1,Bis-N-[(R)-2-(thiazol-5-ylmethoxycarbonylamino)-3-phenylpropyl]-N-[isopropylmethyl]amine,0.05,uM,=,-1.3010299956639813,0,O=C(N[C@@H](CNC[C@@H](Cc1ccccc1)NC(=O)OCc1nccs1)Cc1ccccc1)OCc1cncs1
4854,949160,10.1016/j.bmcl.2013.01.011,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate,CC(C)c1cc(CC(NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12,"(+/-)-N-(1-(1,4'-bipiperidin-1'-yl)-3-(7-isopropyl-1H-indazol-5-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide",0.37,uM,=,-0.431798275933005,0,O=C(NC(Cc1ccc2[nH]ncc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
4855,649881,10.1021/jm100506y,,,,Inhibition of CYP3A4,COC(=O)C1=C(Cn2cnnn2)NC(C)=C(C#N)C1c1ccc(F)cc1Cl,"Methyl 2-((1H-Tetrazol-1-yl)methyl)-4-(2-chloro-4-fluorophenyl)-5-cyano-6-methyl-1,4-dihydropyridine-3-carboxylate",1.2,uM,=,0.0791812460476248,1,C1=CC(c2ccccc2)C=C(Cn2cnnn2)N1
4856,841307,10.1016/j.bmcl.2012.06.029,,,,Inhibition of CYP3A4,CCN1CCC(Nc2ccc3c(c2)C(=C(c2cc(F)cc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1,"(E/Z)-3-((3,5-difluorophenyl)(4-methyl-1H-imidazol-2-yl)methylene)-5-(1-ethylpiperidin-4-ylamino)indolin-2-one",10.0,uM,=,1.0,1,O=C1Nc2ccc(NC3CCNCC3)cc2C1=C(c1ccccc1)c1ncc[nH]1
4857,606336,10.1016/j.bmcl.2009.11.061,,,,Inhibition of CYP3A4,Cc1occc1-c1nc(N)c(OC[C@@H](N)Cc2c(C#N)[nH]c3ccccc23)cc1-c1cnc2[nH]nc(C)c2n1,"3-((2S)-2-amino-3-(2-amino-5-(3-methyl-1H-pyrazolo[4,3-b]pyrazin-5-yl)-6-(2-methylfuran-3-yl)pyridin-3-yloxy)propyl)-1H-indole-2-carbonitrile",1.6,uM,=,0.2041199826559248,1,c1ccc2c(CCCOc3cnc(-c4ccoc4)c(-c4cnc5[nH]ncc5n4)c3)c[nH]c2c1
4858,1707938,10.1021/acs.jmedchem.7b01420,,,,Inhibition of CYP3A4 (unknown origin),NCc1ccc(CN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)cc1,"(S)-N-(4-(Aminomethyl)benzyl)-N-(((R)-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)-5,6,7,8-tetrahydroquinolin-8-amine",7.44,uM,=,0.8715729355458788,1,c1ccc(CN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)cc1
4859,880247,10.1021/jm101459g,,,,Inhibition of human recombinant CYP3A4 using resorufin benzyl ether after 30 mins by fluorescence spectrophotometric analysis,Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1.Cl,"1-[2-(2,4-Dimethyl-phenylsulfanyl)-phenyl]-piperazine Hydrochloride",10.0,uM,=,1.0,1,c1ccc(Sc2ccccc2N2CCNCC2)cc1
4860,789986,10.1016/j.bmcl.2011.10.013,,,,Reversible inhibition of CYP3A4,COCCCc1cc(CCCN2CCS(=O)(=O)CC2)c(Cl)c(CN(C(=O)[C@H]2CNCC[C@@]23OCc2cc(F)c(F)cc23)C2CC2)c1,"(1R,5'S)-N-({2-chloro-3-[3-(1,1-dioxo-1{6},4- thiomorpholin-4-yl)propyl]-5-(3- methoxypropyl)phenyl}methyl)-N-cyclopropyl-5,6- difluoro-3H-spiro[2-benzofuran-1,4'-piperidine]-5'- carboxamide",2.4,uM,=,0.380211241711606,1,O=C([C@H]1CNCC[C@@]12OCc1ccccc12)N(Cc1cccc(CCCN2CCS(=O)(=O)CC2)c1)C1CC1
4861,1455473,10.1016/j.bmcl.2014.06.026,,,,Inhibition of recombinant human CYP3A4 preincubated for 5 mins before fluorescent substrate addition by fluorescence assay,Clc1ccc(C23CNCC2C3)cc1Cl,"1-(3,4-dichlorophenyl)-3-aza-bicyclo[3.1.0]hexane",1.3,uM,=,0.1139433523068367,1,c1ccc(C23CNCC2C3)cc1
4862,761291,10.1021/jm101312a,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,CN1C[C@@H]2CCCC[C@]2(c2ccc(Cl)c(Cl)c2)C1,"cis-(3aS,7aR)-3a-(3,4-dichlorophenyl)-2-methyloctahydro-1H-isoindole",5.28,uM,=,0.7226339225338123,1,c1ccc([C@]23CCCC[C@H]2CNC3)cc1
4863,606336,10.1016/j.bmcl.2009.11.061,,,,Inhibition of CYP3A4,Cc1n[nH]c2ncc(-c3cc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c(C#N)nc3-c3ccoc3)nc12,"(S)-3-(2-amino-3-(1H-indol-3-yl)propoxy)-6-(furan-3-yl)-5-(3-methyl-1H-pyrazolo[4,3-b]pyrazin-5-yl)picolinonitrile",0.79,uM,=,-0.1023729087095585,0,c1ccc2c(CCCOc3cnc(-c4ccoc4)c(-c4cnc5[nH]ncc5n4)c3)c[nH]c2c1
4864,936804,10.1021/jm301511h,,,,Inhibition of human recombinant CYP3A4 expressed in Escherichia coli cells,C[S+]([O-])Cc1ccc(C(=O)Nc2ccc(OCCOCCO)nc2C(=O)NCC2CCC2)c2ccccc12,N-(Cyclobutylmethyl)-6-[2-(2-hydroxyethoxy)ethoxy]-3-({4-[(methylsulfinyl)methyl]-1-naphthoyl}amino)pyridine-2-carboxamide,5.5,uM,=,0.7403626894942439,1,O=C(NCC1CCC1)c1ncccc1NC(=O)c1cccc2ccccc12
4865,621465,10.1016/j.bmcl.2009.07.118,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,CCN(C[C@@H](Cc1ccccc1)NC(=O)OCc1nccs1)C[C@H](Cc1ccccc1)NC(=O)OCc1cncs1,N-[(S)-2-(thiazol-5-ylmethoxycarbonylamino)-3-phenylpropyl][(R)-2-(thiazol-5-ylmethoxycarbonylamino)-3-phenylpropyl]ethylamine,0.11,uM,=,-0.958607314841775,0,O=C(N[C@H](CNC[C@@H](Cc1ccccc1)NC(=O)OCc1nccs1)Cc1ccccc1)OCc1cncs1
4866,1824514,10.1021/acs.jmedchem.9b01562,,,,Inhibition of CYP3A4 in pooled human liver microsomes pre-incubated for 5 mins before NADPH addition and measured after 10 mins by UPLC-MS/MS analysis relative to control,CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,SID144204227,0.017,uM,=,-1.769551078621726,0,c1ccc([C@@]2(Cn3ccnc3)OC[C@H](COc3ccc(N4CCNCC4)cc3)O2)cc1
4867,949160,10.1016/j.bmcl.2013.01.011,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate,O=C(N[C@H](Cc1ccc2[nH]ncc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1,"(R)-N-(1-(1,4'-bipiperidin-1'-yl)-3-(1H-indazol-5-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide",4.0,uM,=,0.6020599913279624,1,O=C(N[C@H](Cc1ccc2[nH]ncc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
4868,652208,10.1016/j.bmcl.2010.07.052,,,,Inhibition of CYP3A4 in human liver microsomes,O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)n(CCN3CCCCC3)c3ccccc32)CC1,1-(2-(piperidin-1-yl)ethyl)-3-(1-(1-(pyridin-4-ylmethyl)piperidine-4-carbonyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one,30.0,uM,=,1.4771212547196624,1,O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)n(CCN3CCCCC3)c3ccccc32)CC1
4869,673953,10.1016/j.bmcl.2010.08.086,,,,Inhibition of CYP3A4 using testosterone as substrate,CNC(=O)CCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1,"(3R,4S)-N-(2-chloro-5-(3-(methylamino)-3-oxopropyl)benzyl)-N-cyclopropyl-4-(4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)phenyl)piperidine-3-carboxamide",8.9,uM,=,0.9493900066449128,1,O=C([C@H]1CNCC[C@@H]1c1ccc(OCCOc2ccccc2)cc1)N(Cc1ccccc1)C1CC1
4870,813105,10.1021/jm201346g,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,COc1ccc2[nH]c(SCC3CC3)nc2c1,2-(cyclopropylmethylthio)-5-methoxy-1H-benzo[d]imidazole,16.4,uM,=,1.214843848047698,1,c1ccc2[nH]c(SCC3CC3)nc2c1
4871,1493572,10.1124/dmd.112.048918,,,,Inhibition of CYP3A4 in human liver microsomes using atorvastatin as substrate preincubated for 20 mins with substrate prior to initiation of reaction with NADPH by HPLC analysis,C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12,DOLUTEGRAVIR,54.0,uM,=,1.7323937598229686,1,O=C(NCc1ccccc1)c1cn2c(cc1=O)C(=O)N1CCCO[C@H]1C2
4872,1488449,10.1124/dmd.110.035071,,,,Inhibition of CYP3A4 in human liver microsomes using nifedipine substrate by HPLC-MS/MS method,CC(=O)N1CCN([C@H]2CCN(C(=O)N(C)[C@H](C)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)[C@@H](c3ccc(F)cc3C)C2)CC1,"cis-(1'-Acetyl-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]-ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4,4'-bipiperidine-1-carboxamide",9.72,uM,=,0.9876662649262746,1,O=C(NCc1ccccc1)N1CC[C@H](N2CCNCC2)C[C@@H]1c1ccccc1
4873,1817349,10.1021/acs.jmedchem.8b01857,,,,Reversible inhibition of CYP3A4 (unknown origin) using midazolam as substrate,Cn1ncc(NC(=O)c2nc(-c3c(F)cccc3F)sc2N)c1N1CC[C@@H](N)[C@H](F)CC1,"US8614206, 139",7.5,uM,=,0.8750612633917001,1,O=C(Nc1cn[nH]c1N1CCCCCC1)c1csc(-c2ccccc2)n1
4874,728439,10.1016/j.bmcl.2011.01.023,,,,Inhibition of CYP3A4 in human liver microsome measured after 30 mins preincubation in presence of NADPH,Cc1cccc(C)c1-c1nc2ccc(C(=O)Nc3ccc4ccccc4n3)cc2[nH]1,"2-(2,6-dimethylphenyl)-N-(quinolin-2-yl)-1H-benzo[d]imidazole-6-carboxamide",2.7,uM,=,0.4313637641589873,1,O=C(Nc1ccc2ccccc2n1)c1ccc2nc(-c3ccccc3)[nH]c2c1
4875,2298667,10.1016/j.bmcl.2023.129280,,,,Inhibition of human CYP3A4,Cc1ccc(NC(=O)Nc2cc(-c3ccccc3-c3nn[nH]n3)cc3c2OCCCC3c2ccccc2)cc1,"1-(7-(2-(2H-tetrazol-5-yl)phenyl)-5-phenyl-2,3,4,5-tetrahydrobenzo[b]oxepin-9-yl)-3-(p-tolyl)urea",8.4,uM,=,0.9242792860618816,1,O=C(Nc1ccccc1)Nc1cc(-c2ccccc2-c2nn[nH]n2)cc2c1OCCCC2c1ccccc1
4876,1640400,,,,,"Fluorescent High Throughput P450 Assay: The interaction of SC12 with cytochrome P450 enzymes was tested using Fluorescent High Throughput P450 assays (Gentest); The IC50s of the compounds was calculated on isoenzymes (CYP1A2, CYP2C9, CYP2C19, CYP2C8, CYP2B6, CYP2D6, CYP2E1, CYP3A4 and CYP3A5). Inhibition of the P450 isoforms was measured in specific assays using specific substrates that become fluorescent upon CYP metabolism. Compounds, dissolved in ACN (acetonitrile) (CYP2E1, CYP2C8, CYP2B6, CYP3A5) or DMSO (all remaining isoforms), were tested in duplicate (n=2) in concentration-response curves (eight concentrations) in a 96-well plate containing incubation/NADPH regenerating buffer. Specific isoenzymes and substrates were added and incubated at 37° C. Reactions were terminated at different times, depending on the assays, and plates read on a Fluoroskan Ascent at the appropriate emission/excitation wavelengths. Concentration-response curves performed in duplicate for known inhibitors for each isoenzyme were tested in ever",CCCCCCCCCCCC(=O)OCC(CCP(=O)(O)OCCNC(=O)c1ccc(Cn2c(=O)[nH]c3c(N)nc(OCCOC)nc32)cc1)OC(=O)CCCCCCCCCCC,"US9173935, SC12",13.6,uM,=,1.1335389083702174,1,O=c1[nH]c2cncnc2n1Cc1ccccc1
4877,824335,10.1016/j.ejmech.2012.05.038,,,,Inhibition of CYP3A4,NC(=O)C[S+]([O-])Cc1ccccc1Oc1ccc(Cl)c(Cl)c1,"rac-2-(2-(3,4-dichlorophenoxy)benzylsulfinyl)acetamide",40.0,uM,=,1.6020599913279625,1,c1ccc(Oc2ccccc2)cc1
4878,621465,10.1016/j.bmcl.2009.07.118,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,CC(C)CN(C[C@@H](Cc1ccccc1)NC(=O)OCc1nccs1)C[C@H](Cc1ccccc1)NC(=O)OCc1cncs1,N-[(S)-2-(thiazol-5-ylmethoxycarbonylamino)-3-phenylpropyl][(R)-2-(thiazol-5-ylmethoxycarbonylamino)-3-phenylpropyl]-N-isopropylamine,0.09,uM,=,-1.0457574905606752,0,O=C(N[C@H](CNC[C@@H](Cc1ccccc1)NC(=O)OCc1nccs1)Cc1ccccc1)OCc1cncs1
4879,438793,10.1016/j.bmcl.2007.04.052,,,,Inhibition of CYP3A4,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCCC(=O)OC)CCC2,"methyl 5-(7-(2,4-diamino-6-ethylpyrimidin-5-yl)-3,4-dihydroquinolin-1(2H)-yl)pentanoate",12.0,uM,=,1.0791812460476249,1,c1ncc(-c2ccc3c(c2)NCCC3)cn1
4880,830173,10.1016/j.bmcl.2012.05.074,,,,Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay,O=C(N[C@@H](Cc1ccc2[nH]ncc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1,"(S)-N-(1-(1,4'-bipiperidin-1'-yl)-3-(1H-indazol-5-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide",7.3,uM,=,0.8633228601204559,1,O=C(N[C@@H](Cc1ccc2[nH]ncc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
4881,789986,10.1016/j.bmcl.2011.10.013,,,,Reversible inhibition of CYP3A4,O=C([C@H]1CNCC[C@@]12OCc1cc(F)c(F)cc12)N(Cc1nccc2ccccc12)C1CC1,"(1R,3'S)-N-cyclopropyl-5,6-difluoro-N-(isoquinolin-1-ylmethyl)-3H-spiro[isobenzofuran-1,4'-piperidine]-3'-carboxamide",9.3,uM,=,0.9684829485539352,1,O=C([C@H]1CNCC[C@@]12OCc1ccccc12)N(Cc1nccc2ccccc12)C1CC1
4882,880247,10.1021/jm101459g,,,,Inhibition of human recombinant CYP3A4 using resorufin benzyl ether after 30 mins by fluorescence spectrophotometric analysis,Cc1ccc(Sc2ccccc2N2CCNCC2)cc1.Cl,1-(2-p-Tolylsulfanyl-phenyl)-piperazine hydrochloride,16.0,uM,=,1.2041199826559248,1,c1ccc(Sc2ccccc2N2CCNCC2)cc1
4883,1659863,10.1016/j.ejmech.2017.02.016,,,,Inhibition of human liver CYP3A4 expressed in Saccharomyces cerevisiae YY7 microsomal membranes using DBF as substrate after 10 mins by fluorescence assay,O=C(/C=C/c1ccc2ccccc2c1)c1cccnc1,(E)-3-(2-Naphthyl)-1-(3-pyridyl)prop-2-en-1-one,18.0,uM,=,1.255272505103306,1,O=C(/C=C/c1ccc2ccccc2c1)c1cccnc1
4884,52091,10.1016/j.bmcl.2003.11.049,,,,Inhibition of CYP450 (Cytochrome P450) 3A4 with fluorogenic substrate BQ,CCN1c2ncc(CSc3cc(C)nc(C)c3)cc2C(=O)Nc2c(C)ccnc21,"2-(2,6-Dimethyl-pyridin-4-ylsulfanylmethyl)-5-ethyl-9-methyl-5,10-dihydro-4,5,6,10-tetraaza-dibenzo[a,d]cyclohepten-11-one",10.0,uM,=,1.0,1,O=C1Nc2cccnc2Nc2ncc(CSc3ccncc3)cc21
4885,1640400,,,,,"Fluorescent High Throughput P450 Assay: The interaction of SC12 with cytochrome P450 enzymes was tested using Fluorescent High Throughput P450 assays (Gentest); The IC50s of the compounds was calculated on isoenzymes (CYP1A2, CYP2C9, CYP2C19, CYP2C8, CYP2B6, CYP2D6, CYP2E1, CYP3A4 and CYP3A5). Inhibition of the P450 isoforms was measured in specific assays using specific substrates that become fluorescent upon CYP metabolism. Compounds, dissolved in ACN (acetonitrile) (CYP2E1, CYP2C8, CYP2B6, CYP3A5) or DMSO (all remaining isoforms), were tested in duplicate (n=2) in concentration-response curves (eight concentrations) in a 96-well plate containing incubation/NADPH regenerating buffer. Specific isoenzymes and substrates were added and incubated at 37° C. Reactions were terminated at different times, depending on the assays, and plates read on a Fluoroskan Ascent at the appropriate emission/excitation wavelengths. Concentration-response curves performed in duplicate for known inhibitors for each isoenzyme were tested in ever",CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,"1-(4-{4-[2-(2,4-Dichloro-phenyl)-2-imidazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-ethanone (ketoconazole)",0.012,uM,=,-1.9208187539523751,0,c1ccc(C2(Cn3ccnc3)OCC(COc3ccc(N4CCNCC4)cc3)O2)cc1
4886,874073,10.1021/jm3012239,,,,Inhibition of CYP3A4,Cc1cc(NC(=O)c2cnn3cccnc23)n(-c2cccc(Cl)c2)n1,"N-(1-(3-Chlorophenyl)-3-methyl-1H-pyrazol-5-yl)pyrazolo[1,5-a]-pyrimidine-3-carboxamide",4.6,uM,=,0.6627578316815741,1,O=C(Nc1ccnn1-c1ccccc1)c1cnn2cccnc12
4887,728151,10.1016/j.bmc.2011.01.017,,,,Inhibition of human CYP3A4,COC(=O)c1ccc2cc(C(O)(c3c[nH]cn3)C(C)C)ccc2c1,rac-Methyl 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthoate,1.4,uM,=,0.1461280356782379,1,c1ccc2cc(Cc3c[nH]cn3)ccc2c1
4888,789986,10.1016/j.bmcl.2011.10.013,,,,Reversible inhibition of CYP3A4,COCCCc1cc(CCCNS(C)(=O)=O)c(Cl)c(CN(C(=O)[C@H]2CNCC[C@@]23OCc2cc(F)c(F)cc23)C2CC2)c1,"(1R,3'S)-N-(2-chloro-5-(3-methoxypropyl)-3-(3-(methylsulfonamido)propyl)benzyl)-N-cyclopropyl-5,6-difluoro-3H-spiro[isobenzofuran-1,4'-piperidine]-3'-carboxamide",2.0,uM,=,0.3010299956639812,1,O=C([C@H]1CNCC[C@@]12OCc1ccccc12)N(Cc1ccccc1)C1CC1
4889,1628094,10.1016/j.ejmech.2016.08.024,,,,Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells using fluorescent substrate,O=C(CC1([C@H]2CO[C@H]3CCC[C@H]3N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CCC(N2CCCCC2)CC1,"1-(1,4'-bipiperidin-1'-yl)-2-(1-((3S,4aR,7aS)-4-(4-chlorophenylsulfonyl)octahydrocyclopenta[b][1,4]oxazin-3-yl)cyclopropyl)ethanone",21.0,uM,=,1.3222192947339193,1,O=C(CC1([C@H]2CO[C@H]3CCC[C@H]3N2S(=O)(=O)c2ccccc2)CC1)N1CCC(N2CCCCC2)CC1
4890,1816858,10.1016/j.ejmech.2019.111857,,,,Inhibition of human CYP3A4 preincubated for 5 mins followed by NADPH addition and measured after 30 mins by luminescence based microplate reader analysis,Oc1ccc(-c2ccc(CNCCc3c[nH]c4ncc(F)cc34)o2)cc1,"4-(5-{[(2-{5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-yl}ethyl)amino]methyl}furan-2-yl)phenol",7.8,uM,=,0.8920946026904804,1,c1ccc(-c2ccc(CNCCc3c[nH]c4ncccc34)o2)cc1
4891,1455473,10.1016/j.bmcl.2014.06.026,,,,Inhibition of recombinant human CYP3A4 preincubated for 5 mins before fluorescent substrate addition by fluorescence assay,Fc1cc(C(CC2CNC2)Oc2ccccc2F)ccc1Cl,3-(2-(4-chloro-3-fluorophenyl)-2-(2-fluorophenoxy)ethyl)azetidine,0.71,uM,=,-0.1487416512809247,0,c1ccc(OC(CC2CNC2)c2ccccc2)cc1
4892,1527906,,,,,Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,C[C@@H](c1ccc(-c2ccc(F)cc2)cc1)N1CC[C@](CCCO)(c2ccccc2)OC1=O,"(R)-3-((S)-1-(4'-fluorobiphenyl-4-yl)ethyl)-6-(3-hydroxypropyl)-6-phenyl-1,3-oxazinan-2-one",7.0,uM,=,0.8450980400142568,1,O=C1OC(c2ccccc2)CCN1Cc1ccc(-c2ccccc2)cc1
4893,1527906,,,,,Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,C[C@@H](c1ccc(-c2ccc(=O)n(C3CC3)n2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O,"US8592410, 20",15.7,uM,=,1.1958996524092338,1,O=C1OC(c2ccccc2)CCN1Cc1ccc(-c2ccc(=O)n(C3CC3)n2)cc1
4894,1707938,10.1021/acs.jmedchem.7b01420,,,,Inhibition of CYP3A4 (unknown origin),FC1(F)CCC(NCCCCN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)CC1,"N1-(4,4-Difluorocyclohexyl)-N4-(((R)-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)-N4-((S)-5,6,7,8-tetrahydroquinolin-8-yl)-butane-1,4-diamine",11.3,uM,=,1.0530784434834195,1,c1ccc2c(c1)CN[C@@H](CN(CCCCNC1CCCCC1)[C@H]1CCCc3cccnc31)C2
4895,1468060,10.1016/j.bmcl.2015.03.035,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as marker substrate,COc1cccc(OC)c1[C@@H]1C[C@H](OC)C(=O)N1Cc1ccc(OC(F)(F)F)cc1,"rac-(3S*,5S*)-5-(2,6-dimethoxyphenyl)-3-methoxy-1-(4-(trifluoromethoxy)benzyl)pyrrolidin-2-one",1.4,uM,=,0.1461280356782379,1,O=C1CC[C@@H](c2ccccc2)N1Cc1ccccc1
4896,643970,10.1016/j.bmcl.2010.06.086,,,,Inhibition of human CYP3A4-mediated testosterone oxidation,CC(C)OCC1n2cncc2CN([C@@H](C)c2ccc(Cl)cc2)S1(=O)=O,"6-[(S)-1-(4-Chloro-phenyl)-ethyl]-4-isopropoxymethyl-6,7-dihydro-5-thia-2,3a,6-triaza-indene 5,5-dioxide",0.12,uM,=,-0.9208187539523752,0,O=S1(=O)Cn2cncc2CN1Cc1ccccc1
4897,1689465,10.1021/acs.jmedchem.7b00662,,,,Inhibition of CYP3A4 (unknown origin),O=C(CN1CCCC2=C1C(=O)N(C1CC1)C2=O)Nc1ccc(-c2cncc(F)c2)nn1,"2-(6-Cyclopropyl-5,7-dioxo-2,3,4,5,6,7-hexahydro-1H-pyrrolo[3,4-b]pyridin-1-yl)-N-(6-(5-fluoropyridin-3-yl)-pyridazin-3-yl)acetamide",16.0,uM,=,1.2041199826559248,1,O=C(CN1CCCC2=C1C(=O)N(C1CC1)C2=O)Nc1ccc(-c2cccnc2)nn1
4898,2164321,10.1021/acs.jmedchem.1c01784,,,,Inhibition of human recombinant CYP3A4 expressed in baculosomes by fluorescent homogenous assay,CN(CCCC(F)F)Cc1ccc(COc2ccc3c(CO)cc(=O)oc3c2)cc1,"7-((4-(((4,4-difluorobutyl)(methyl)amino)methyl)benzyl)oxy)-4-(hydroxymethyl)-2H-chromen-2-one",10.0,uM,=,1.0,1,O=c1ccc2ccc(OCc3ccccc3)cc2o1
4899,438793,10.1016/j.bmcl.2007.04.052,,,,Inhibition of CYP3A4,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCOC)CCC2,"6-ethyl-5-(1-(3-methoxypropyl)-1,2,3,4-tetrahydroquinolin-7-yl)pyrimidine-2,4-diamine",2.8,uM,=,0.4471580313422192,1,c1ncc(-c2ccc3c(c2)NCCC3)cn1
4900,776116,10.1016/j.bmcl.2011.09.074,,,,Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy resorufin,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(Cc1ccccc1)C2,"(6-benzyl-4-(2,4-dichlorophenyl)-2-methyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-3-yl)methanamine",0.34,uM,=,-0.4685210829577448,0,c1ccc(CN2Cc3nccc(-c4ccccc4)c3C2)cc1
4901,510060,10.1016/j.bmcl.2008.07.059,,,,Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay,Cc1c(-c2cccc(OCCCCC(=O)O)c2)c(=O)n(C[C@H](N)c2ccccc2)c(=O)n1Cc1c(F)cccc1C(F)(F)F,"(R)-5-(3-(1-(2-fluoro-6-(trifluoromethyl)benzyl)-3-(2-amino-2-phenylethyl)-6-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)phenoxy)pentanoic acid",22.0,uM,=,1.3424226808222062,1,O=c1c(-c2ccccc2)cn(Cc2ccccc2)c(=O)n1CCc1ccccc1
4902,2221810,10.1016/j.bmcl.2022.128625,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as substrate pretreated with NADPH,CCC[C@H]1N(C(=O)c2c(C(F)(F)F)ccc[n+]2[O-])CCC[C@@]1(Oc1csc(C(F)(F)F)c1)C(=O)N1CCN(c2ccccc2OCCO)CC1,"2-((2R,3S)-3-(4-(2-(2-hydroxyethoxy)phenyl)piperazine-1-carbonyl)-2-propyl-3-(5-(trifluoromethyl)thiophen-3-yloxy)piperidine-1-carbonyl)-3-(trifluoromethyl)pyridine-1-oxide",1.9,uM,=,0.2787536009528289,1,O=C(c1cccc[nH+]1)N1CCC[C@@](Oc2ccsc2)(C(=O)N2CCN(c3ccccc3)CC2)C1
4903,2172302,10.1021/acs.jmedchem.1c01498,,,,Inhibition of human CYP3A4 preincubated for 10 mins followed by substrate and NADP addition measured after 30 mins by fluorescence assay,CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,SID144204227,21.33,uM,=,1.3289908554494287,1,c1ccc([C@@]2(Cn3ccnc3)OC[C@H](COc3ccc(N4CCNCC4)cc3)O2)cc1
4904,1986041,10.1021/acs.jmedchem.0c00564,,,,Inhibition of CYP3A4 (unknown origin) expressed in insect cell microsomes using dibenzylfluorescein substrate by fluorescence based assay,CC1=C(C(=O)OC(C)C)C(c2cocn2)n2c(nc3ccccc32)N1,"(+/-)-Isopropyl 2-Methyl-4-(oxazol-4-yl)-1,4-dihydrobenzo[4,5]imidazo[1,2-a]pyrimidine-3-carboxylate",5.92,uM,=,0.7723217067229198,1,C1=CC(c2cocn2)n2c(nc3ccccc32)N1
4905,880247,10.1021/jm101459g,,,,Inhibition of human recombinant CYP3A4 using resorufin benzyl ether after 30 mins by fluorescence spectrophotometric analysis,Cc1ccc(Sc2ccccc2N2CCNCC2)c(Cl)c1.Cl,1-[2-(2-Chloro-4-methyl-phenylsulfanyl)-phenyl]-piperazine Hydrochloride,5.5,uM,=,0.7403626894942439,1,c1ccc(Sc2ccccc2N2CCNCC2)cc1
4906,2164321,10.1021/acs.jmedchem.1c01784,,,,Inhibition of human recombinant CYP3A4 expressed in baculosomes by fluorescent homogenous assay,CN(Cc1ccc(COc2ccc3c(CO)cc(=O)oc3c2)cc1)Cc1cccc(F)c1,7-((4-(((3-fluorobenzyl)(methyl)amino)methyl)benzyl)oxy)-4-(hydroxymethyl)-2H-chromen-2-one,3.5,uM,=,0.5440680443502757,1,O=c1ccc2ccc(OCc3ccc(CNCc4ccccc4)cc3)cc2o1
4907,621465,10.1016/j.bmcl.2009.07.118,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,CCN(C[C@H](CC(C)C)NC(=O)OCc1cncs1)C[C@H](CC(C)C)NC(=O)OCc1nccs1,Bis-N-[(S)-2-(thiazol-5-ylmethoxycarbonylamino)-4-methylpentyl]ethylamine,0.136,uM,=,-0.8664610916297825,0,O=C(NCCNCCNC(=O)OCc1nccs1)OCc1cncs1
4908,772681,10.1021/jm201109t,,,,Inhibition of CYP3A4,COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C[C@H](O)[C@H](Cc1ccc(-c2cncc(F)c2)cc1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C,"Dimethyl(2S,20S)-1,10-((2S,3S,5S)-1-(4-(5-Fluoropyridin-3-yl)phenyl)-3-hydroxy-6-phenylhexane-2,5-diyl)bis(azanediyl)bis(3,3-dimethyl-1-oxobutane-2,1-diyl)dicarbamate",0.14,uM,=,-0.8538719643217619,0,c1ccc(CCCCCCc2ccc(-c3cccnc3)cc2)cc1
4909,621465,10.1016/j.bmcl.2009.07.118,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,CCN(C[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C[C@H](Cc1ccccc1)NC(=O)OCc1nccs1,Bis-N-[(S)-2-(thiazol-5-ylmethoxycarbonylamino)-3-phenylpropyl]ethylamine,0.15,uM,=,-0.8239087409443188,0,O=C(N[C@H](CNC[C@H](Cc1ccccc1)NC(=O)OCc1nccs1)Cc1ccccc1)OCc1cncs1
4910,458143,10.1016/j.bmcl.2007.09.006,,,,Inhibition of CYP3A4 after 30 mins,CC(C)[C@@H]1CCC[C@H](C2(OC(=O)N3CCN(C(C)(C)CO)CC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1,"1-((2R,6S)-1-(4-chlorophenylsulfonyl)-6-isopropylpiperidin-2-yl)cyclopropyl 4-(1-hydroxy-2-methylpropan-2-yl)piperazine-1-carboxylate",0.5,uM,=,-0.3010299956639812,0,O=C(OC1([C@H]2CCCCN2S(=O)(=O)c2ccccc2)CC1)N1CCNCC1
4911,1877247,10.1021/acs.jmedchem.9b01547,,,,Inhibition of human CYP3A4,C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12,(6-Methoxy-quinolin-4-yl)-(5-vinyl-1-aza-bicyclo[2.2.2]oct-2-yl)-methanol,28.0,uM,=,1.4471580313422192,1,c1ccc2c(C[C@H]3CC4CCN3CC4)ccnc2c1
4912,2169650,10.1021/acs.jmedchem.1c01300,,,,Irreversible inhibition of CYP3A4 in human liver microsomes incubated for 10 mins in presence of NADPH by mass spectrometry,C[C@@]1(c2nc(NC(=O)c3ncc(C(F)(F)F)cc3Cl)ccc2F)CO[C@@](C)(C(F)(F)F)C(N)=N1,"US8637508, 34",10.9,uM,=,1.0374264979406236,1,O=C(Nc1cccc(C2COCC=N2)n1)c1ccccn1
4913,827409,10.1016/j.bmc.2012.04.053,,,,Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture simultaneously with BFC substrate by fluorometric assay,CCc1ccc(Cc2cc([C@]3(O)C[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c(OC)cc2OC)cc1,"(1R,2R,3S,4R,5R)-1-[5-(4-Ethylbenzyl)-2,4-dimethoxyphenyl]-5-(hydroxymethyl)cyclohexane-1,2,3,4-tetraol",29.0,uM,=,1.462397997898956,1,c1ccc(Cc2cccc(C3CCCCC3)c2)cc1
4914,789986,10.1016/j.bmcl.2011.10.013,,,,Reversible inhibition of CYP3A4,O=C1O[C@@]2(CCNC[C@@H]2C(=O)N(Cc2cccc(C(F)(F)F)c2Cl)C2CC2)c2cc(F)c(F)cc21,"(1R,3'S)-N-(2-chloro-3-(trifluoromethyl)benzyl)-N-cyclopropyl-5,6-difluoro-3-oxo-3H-spiro[isobenzofuran-1,4'-piperidine]-3'-carboxamide",0.7,uM,=,-0.1549019599857432,0,O=C1O[C@@]2(CCNC[C@@H]2C(=O)N(Cc2ccccc2)C2CC2)c2ccccc21
4915,813105,10.1021/jm201346g,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,COc1ccc2[nH]c(SCc3ccc(I)cc3)nc2c1,2-(4-iodobenzylthio)-5-methoxy-1H-benzo[d]imidazole,4.91,uM,=,0.6910814921229685,1,c1ccc(CSc2nc3ccccc3[nH]2)cc1
4916,1707938,10.1021/acs.jmedchem.7b01420,,,,Inhibition of CYP3A4 (unknown origin),CC(C)(CCN)CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21,"2,2-Dimethyl-N1-(((R)-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)-N1-((S)-5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine",10.8,uM,=,1.0334237554869496,1,c1ccc2c(c1)CN[C@@H](CN[C@H]1CCCc3cccnc31)C2
4917,827409,10.1016/j.bmc.2012.04.053,,,,Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture simultaneously with BFC substrate by fluorometric assay,CCOc1ccc(Cc2ccc(CC)cc2)cc1[C@@H]1C[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O,"(1R,2R,3S,4S,6R)-4-[2-Ethoxy-5-(4-ethylbenzyl)phenyl]-6-(hydroxymethyl)cyclohexane-1,2,3-triol",36.6,uM,=,1.5634810853944108,1,c1ccc(Cc2cccc(C3CCCCC3)c2)cc1
4918,1866289,10.1021/acs.jmedchem.9b00662,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,O[C@H](C[C@H]1c2c(F)cccc2-c2cncn21)[C@H]1CC[C@@H](O)CC1,"(1S,4s)-4-((R)-2-((S)-6-Fluoro-5H-imidazo[5,1-a]isoindol-5-yl)-1-hydroxyethyl)cyclohexan-1-ol",3.1,uM,=,0.4913616938342727,1,c1ccc2c(c1)-c1cncn1[C@H]2CCC1CCCCC1
4919,1523393,10.1021/acs.jmedchem.5b00774,,,,Inhibition of CYP3A4 (unknown origin) preincubated with protein for 30 mins followed by substrate addition,O=S(=O)(c1ccc(Cl)cc1)[C@@]12CCCC(CO)(CO)[C@@H]1COc1c(F)ccc(F)c12,"((6aR,10aS)-10a-(4-chlorophenylsulfonyl)-1,4-difluoro-6a,7,8,9,10,10a-hexahydro-6H-benzo[c]chromene-7,7-diyl)dimethanol",11.5,uM,=,1.0606978403536118,1,O=S(=O)(c1ccccc1)[C@@]12CCCC[C@@H]1COc1ccccc12
4920,1735372,10.1021/acs.jmedchem.8b00084,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis,Cl.Cl.Cl.NCc1ccc(-c2cnccc2-c2ccncc2)s1,"(5-([4,4'-Bipyridin]-3'-yl)thiophen-2-yl)methanamine Trihydrochloride",214.0,uM,=,2.330413773349191,1,c1csc(-c2cnccc2-c2ccncc2)c1
4921,1527906,,,,,Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,C[C@@H](c1ccc(-c2ccc(F)cc2F)cc1)N1CC[C@](CCCO)(c2ccccc2)OC1=O,"(R)-3-((S)-1-(2',4'-difluorobiphenyl-4-yl)ethyl)-6-(3-hydroxypropyl)-6-phenyl-1,3-oxazinan-2-one",5.3,uM,=,0.724275869600789,1,O=C1OC(c2ccccc2)CCN1Cc1ccc(-c2ccccc2)cc1
4922,605306,10.1016/j.bmcl.2009.11.060,,,,Inhibition of CYP3A4,Cc1n[nH]c2ncc(-c3cc(OC[C@@H](N)Cc4c[nH]c5ccccc45)cnc3-c3ccoc3)nc12,"(S)-1-(6-(furan-3-yl)-5-(3-methyl-1H-pyrazolo[4,3-b]pyrazin-5-yl)pyridin-3-yloxy)-3-(1H-indol-3-yl)propan-2-amine",0.4,uM,=,-0.3979400086720376,0,c1ccc2c(CCCOc3cnc(-c4ccoc4)c(-c4cnc5[nH]ncc5n4)c3)c[nH]c2c1
4923,605306,10.1016/j.bmcl.2009.11.060,,,,Inhibition of CYP3A4,Cc1n[nH]c2cnc(-c3cc(OC[C@@H](N)Cc4c[nH]c5ccccc45)cnc3-c3ccoc3)nc12,"(S)-1-(6-(furan-3-yl)-5-(3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)pyridin-3-yloxy)-3-(1H-indol-3-yl)propan-2-amine",1.3,uM,=,0.1139433523068367,1,c1ccc2c(CCCOc3cnc(-c4ccoc4)c(-c4ncc5[nH]ncc5n4)c3)c[nH]c2c1
4924,826125,10.1021/jm300069y,,,,Inhibition of CYP3A4,CC(C)(C)Cn1cc(CN[C@H]2CS(=O)(=O)C[C@@H](Cc3cc(F)c(N)c(OC(C(F)(F)F)C(F)(F)F)c3)[C@@H]2O)cn1,"(3S,4S,5R)-3-(4-Amino-3-fluoro-5-((1,1,1,3,3,3-hexafluoropropan-2-yl)oxy)benzyl)-4-hydroxy-5-(((1-neopentyl-1H-pyrazol-4-yl)methyl)amino)tetrahydro-2H-thiopyran 1,1-dioxide",6.7,uM,=,0.8260748027008264,1,O=S1(=O)C[C@@H](Cc2ccccc2)C[C@@H](NCc2cn[nH]c2)C1
4925,854796,10.1016/j.bmc.2012.08.056,,,,Inhibition of human CYP3A4 using 7-benzyloxyquinoline as substrate,CN(Cc1cccn1C)C(=O)C12CC3CC(CC(C3)C1)C2,N-Methyl-N-((1-methyl-1H-pyrrol-2-yl)-methyl)adamantane-1-carboxamide,18.0,uM,=,1.255272505103306,1,O=C(NCc1ccc[nH]1)C12CC3CC(CC(C3)C1)C2
4926,1707938,10.1021/acs.jmedchem.7b01420,,,,Inhibition of CYP3A4 (unknown origin),c1ccc(CNCCCCN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)cc1,"N1-Benzyl-N4-(((R)-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)-N4-((S)-5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine",6.15,uM,=,0.7888751157754168,1,c1ccc(CNCCCCN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)cc1
4927,936804,10.1021/jm301511h,,,,Inhibition of human recombinant CYP3A4 expressed in Escherichia coli cells,COc1ccc(NC(=O)c2ccc(C[S+](C)[O-])c3ccccc23)c(C(=O)NCC2CCOCC2)n1,6-Methoxy-3-({4-[(methylsulfinyl)methyl]-1-naphthoyl}-amino)-N-(tetrahydro-2H-pyran-4-ylmethyl)pyridine-2-carboxamide,8.8,uM,=,0.9444826721501688,1,O=C(NCC1CCOCC1)c1ncccc1NC(=O)c1cccc2ccccc12
4928,643970,10.1016/j.bmcl.2010.06.086,,,,Inhibition of human CYP3A4-mediated testosterone oxidation,CC(C)CC1n2cncc2CN(Cc2ccccc2)S1(=O)=O,"6-Benzyl-4-isobutyl-6,7-dihydro-5-thia-2,3a,6-triaza-indene 5,5-dioxide",1.4,uM,=,0.1461280356782379,1,O=S1(=O)Cn2cncc2CN1Cc1ccccc1
4929,827409,10.1016/j.bmc.2012.04.053,,,,Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture simultaneously with BFC substrate by fluorometric assay,CCc1ccc(Cc2cc([C@@H]3C[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c(OC)cc2OC)cc1,"(1R,2R,3S,4S,6R)-4-[5-(4-Ethylbenzyl)-2,4-dimethoxyphenyl]-6-(hydroxymethyl)cyclohexane-1,2,3-triol",25.7,uM,=,1.4099331233312946,1,c1ccc(Cc2cccc(C3CCCCC3)c2)cc1
4930,621465,10.1016/j.bmcl.2009.07.118,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1,"((1R,2R,4R)-1-Benzyl-2-hydroxy-4-{(R)-2-[3-(2-isopropyl-1lambda*4*-[1,3]thiazin-5-ylmethyl)-3-methyl-ureido]-3-methyl-butyrylamino}-5-phenyl-pentyl)-carbamic acid thiazol-5-ylmethyl ester",0.05,uM,=,-1.3010299956639813,0,O=C(CNC(=O)NCc1cscn1)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1
4931,949160,10.1016/j.bmcl.2013.01.011,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate,Cc1cc(C[C@@H](NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)c(Cl)c2cn[nH]c12,"(R)-N-(1-(1,4'-bipiperidin-1'-yl)-3-(4-chloro-7-methyl-1H-indazol-5-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide",1.6,uM,=,0.2041199826559248,1,O=C(N[C@H](Cc1ccc2[nH]ncc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
4932,1347924,10.1016/j.bmcl.2014.04.024,,,,Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method,COc1cc2ccc(C(O)(c3cnco3)C(C)C)cc2cc1OC,"rac-1-(6,7-dimethoxynaphthalen-2-yl)-2-methyl-1-(oxazol-5-yl)propan-1-ol",6.5,uM,=,0.8129133566428556,1,c1ccc2cc(Cc3cnco3)ccc2c1
4933,674334,10.1016/j.bmcl.2010.09.038,,,,Inhibition of human CYP3A4,Cc1[nH]cnc1CN1CCc2c(c3ccccc3n2C)C1=O,"5-Methyl-2-(5-methyl-1H-imidazol-4-ylmethyl)-2,3,4,5-tetrahydro-pyrido[4,3-b]indol-1-one",0.6,uM,=,-0.2218487496163563,0,O=C1c2c([nH]c3ccccc23)CCN1Cc1c[nH]cn1
4934,1347924,10.1016/j.bmcl.2014.04.024,,,,Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method,COc1cc2ccc(C(O)(c3cc[nH]n3)C(C)C)cc2cc1OC,"rac-1-(6,7-dimethoxynaphthalen-2-yl)-2-methyl-1-(1H-pyrazol-3-yl)propan-1-ol",1.8,uM,=,0.255272505103306,1,c1ccc2cc(Cc3cc[nH]n3)ccc2c1
4935,1735372,10.1021/acs.jmedchem.8b00084,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis,Cl.Cl.Cl.NCC#Cc1cnccc1-c1cccnc1,"3-([3,4'-Bipyridin]-3'-yl)prop-2-yn-1-amine Trihydrochloride",92.0,uM,=,1.963787827345556,1,c1cncc(-c2ccncc2)c1
4936,1296353,10.1021/jm4015108,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis,O=C(Nc1ccc(S(=O)(=O)c2cccc(OC(F)(F)F)c2)cc1)[C@@H]1C[C@H]1c1cccnc1,rac-trans-2-(Pyridin-3-yl)-N-(4-((3-(trifluoromethoxy)phenyl)-sulfonyl)phenyl)cyclopropanecarboxamide,0.065,uM,=,-1.1870866433571443,0,O=C(Nc1ccc(S(=O)(=O)c2ccccc2)cc1)[C@@H]1C[C@H]1c1cccnc1
4937,2198263,10.1016/j.bmc.2022.116951,,,,Inhibition of CYP3A4 (unknown origin) in presence of NADPH,N#Cc1ccc(CN2CCC(NC(=O)c3ccc(C(=O)N4CCC(C(F)c5ccc(F)cc5)CC4)cn3)CC2)cc1,N-(1-(4-cyanobenzyl)piperidin-4-yl)-5-(4-(fluoro(4-fluorophenyl)methyl)piperidine-1-carbonyl)picolinamide,9.8,uM,=,0.9912260756924948,1,O=C(NC1CCN(Cc2ccccc2)CC1)c1ccc(C(=O)N2CCC(Cc3ccccc3)CC2)cn1
4938,718098,10.1016/j.bmcl.2010.12.053,,,,Inhibition of CYP3A4,C[C@H](C1=C(CCN(C)Cc2nccs2)Cc2ccccc21)c1cnccn1,(R)-N-methyl-2-(3-(1-(pyrazin-2-yl)ethyl)-1H-inden-2-yl)-N-(thiazol-2-ylmethyl)ethanamine,2.82,uM,=,0.450249108319361,1,c1ccc2c(c1)CC(CCNCc1nccs1)=C2Cc1cnccn1
4939,458143,10.1016/j.bmcl.2007.09.006,,,,Inhibition of CYP3A4 after 30 mins,O=C(OC[C@H]1CCC[C@@H](C2CC2)N1S(=O)(=O)c1ccc(Cl)cc1)N1CCC(N2CCCCC2)CC1,"((2R,6S)-1-(4-chlorophenylsulfonyl)-6-cyclopropylpiperidin-2-yl)methyl 4-(piperidin-1-yl)piperidine-1-carboxylate",1.2,uM,=,0.0791812460476248,1,O=C(OC[C@H]1CCC[C@@H](C2CC2)N1S(=O)(=O)c1ccccc1)N1CCC(N2CCCCC2)CC1
4940,1659863,10.1016/j.ejmech.2017.02.016,,,,Inhibition of human liver CYP3A4 expressed in Saccharomyces cerevisiae YY7 microsomal membranes using DBF as substrate after 10 mins by fluorescence assay,O=C(/C=C/c1cccnc1)c1cccc(Cl)c1,(E)-1-(3-Chlorophenyl)-3-(3-pyridinyl)prop-2-en-1-one,12.5,uM,=,1.0969100130080565,1,O=C(/C=C/c1cccnc1)c1ccccc1
4941,813105,10.1021/jm201346g,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,COc1ccc2[nH]c(SCC(C)C)nc2c1,2-(isobutylthio)-5-methoxy-1H-benzo[d]imidazole,50.0,uM,=,1.6989700043360187,1,c1ccc2[nH]cnc2c1
4942,510060,10.1016/j.bmcl.2008.07.059,,,,Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay,N[C@@H](Cn1c(=O)c(-c2cccc(OCCCCCC(=O)O)c2F)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1,"(R)-6-(3-(1-(2-fluoro-6-(trifluoromethyl)benzyl)-3-(2-amino-2-phenylethyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-2-fluorophenoxy)hexanoic acid",25.0,uM,=,1.3979400086720375,1,O=c1c(-c2ccccc2)cn(Cc2ccccc2)c(=O)n1CCc1ccccc1
4943,2278329,10.1021/acs.jmedchem.2c01438,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate incubated for 10 to 30 mins in presence of NADPH by LC-MS/MS method,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5C)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,1-(6-(4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one,6.23,uM,=,0.7944880466591696,1,c1cc(-c2cn(C3CC4(CNC4)C3)nc2-c2ccc3[nH]ncc3c2)c2cn[nH]c2c1
4944,701746,10.1021/ml100190t,,,,Inhibition of CYP3A4 uisng midazolam substrate,O=C(Nc1cccnn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1,N-Pyridazin-3-yl-4-(3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}benzylidene)piperidine-1-carboxamide,30.0,uM,=,1.4771212547196624,1,O=C(Nc1cccnn1)N1CCC(=Cc2cccc(Oc3ccccn3)c2)CC1
4945,1735372,10.1021/acs.jmedchem.8b00084,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis,Cc1ccncc1C#CCN.Cl.Cl,3-(4-Methylpyridin-3-yl)prop-2-yn-1-amine Dihydrochloride,5.6,uM,=,0.7481880270062004,1,c1ccncc1
4946,789986,10.1016/j.bmcl.2011.10.013,,,,Reversible inhibition of CYP3A4,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@]23OC=Cc2ccccc23)C2CC2)cc(OCCOC)c1,"(1R,3'S)-N-cyclopropyl-N-(3-(2-methoxyethoxy)-5-(3-methoxypropyl)benzyl)spiro[isochromene-1,4'-piperidine]-3'-carboxamide",1.1,uM,=,0.041392685158225,1,O=C([C@H]1CNCC[C@@]12OC=Cc1ccccc12)N(Cc1ccccc1)C1CC1
4947,2221810,10.1016/j.bmcl.2022.128625,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as substrate pretreated with NADPH,CCC[C@H]1N(C(=O)c2cnccc2C)CCC[C@@]1(Oc1csc(C(F)(F)F)c1)C(=O)N1CCN(c2ccccc2OCCO)CC1,"(4-(2-(2-hydroxyethoxy)phenyl)piperazin-1-yl)((2R,3S)-1-(4-methylnicotinoyl)-2-propyl-3-(5-(trifluoromethyl)thiophen-3-yloxy)piperidin-3-yl)methanone",1.2,uM,=,0.0791812460476248,1,O=C(c1cccnc1)N1CCC[C@@](Oc2ccsc2)(C(=O)N2CCN(c3ccccc3)CC2)C1
4948,1296353,10.1021/jm4015108,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis,O=C(Nc1ccc(S(=O)(=O)N2CC3CCC(C2)O3)cc1)[C@@H]1C[C@H]1c1cccnc1,rac-trans-N-(4-(8-Oxa-3-azabicyclo[3.2.1]octan-3-ylsulfonyl)-phenyl)-2-(pyridin-3-yl)cyclopropanecarboxamide,2.5,uM,=,0.3979400086720376,1,O=C(Nc1ccc(S(=O)(=O)N2CC3CCC(C2)O3)cc1)[C@@H]1C[C@H]1c1cccnc1
4949,577740,10.1016/j.ejmech.2009.01.002,,,,Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsome,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,"1-(4-{4-[2-(2,4-Dichloro-phenyl)-2-imidazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-ethanone (ketoconazole)",0.072,uM,=,-1.1426675035687317,0,c1ccc(C2(Cn3ccnc3)OCC(COc3ccc(N4CCNCC4)cc3)O2)cc1
4950,579857,10.1016/j.bmcl.2009.06.014,,,,Inhibition of CYP3A4 using BFC as substrate,Cc1cc2cc(/N=C(/NC#N)N[C@H]3CCCCN(CC(=O)N4CCCC4)C3=O)ccc2o1,(S)-2-cyano-1-(2-methylbenzofuran-5-yl)-3-(2-oxo-1-(2-oxo-2-(pyrrolidin-1-yl)ethyl)azepan-3-yl)guanidine,18.5,uM,=,1.2671717284030135,1,O=C(CN1CCCC[C@H](NC=Nc2ccc3occc3c2)C1=O)N1CCCC1
4951,949160,10.1016/j.bmcl.2013.01.011,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate,O=C(N[C@H](Cc1cc2oc(=O)[nH]c2cc1Cl)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1,"(R)-N-(1-(1,4'-bipiperidin-1'-yl)-3-(5-chloro-2-oxo-2,3-dihydrobenzo[d]oxazol-6-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide",5.0,uM,=,0.6989700043360189,1,O=C(N[C@H](Cc1ccc2[nH]c(=O)oc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
4952,1296353,10.1021/jm4015108,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis,O=C(Nc1ccc(S(=O)(=O)c2cnn(C3CCOCC3)c2)cc1)[C@@H]1C[C@H]1c1cccnc1,rac-trans-2-(Pyridin-3-yl)-N-(4-((1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)sulfonyl)phenyl)cyclopropanecarboxamide,1.4,uM,=,0.1461280356782379,1,O=C(Nc1ccc(S(=O)(=O)c2cnn(C3CCOCC3)c2)cc1)[C@@H]1C[C@H]1c1cccnc1
4953,2157144,10.1021/acsmedchemlett.1c00473,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by TDI- high-throughput based mass spectrometry method,CCc1c[nH]c2ncc(-c3ccc(N)c(C(=O)N(C)C)c3F)cc12,"6-Amino-3-(3-ethyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-2-fluoro-N,N-dimethylbenzamide",0.7,uM,=,-0.1549019599857432,0,c1ccc(-c2cnc3[nH]ccc3c2)cc1
4954,510060,10.1016/j.bmcl.2008.07.059,,,,Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay,N[C@@H](Cn1c(=O)c(-c2cccc(OCCCCC(=O)O)c2F)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1,"(R)-5-(3-(1-(2-fluoro-6-(trifluoromethyl)benzyl)-3-(2-amino-2-phenylethyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-2-fluorophenoxy)pentanoic acid",36.0,uM,=,1.5563025007672873,1,O=c1c(-c2ccccc2)cn(Cc2ccccc2)c(=O)n1CCc1ccccc1
4955,1611776,10.1039/C6MD00191B,,,,Inhibition of CYP3A4 (unknown origin),O=S(=O)(Nc1cncc(C(F)(F)F)c1)c1ccccc1C(F)(F)F,2-(Trifluoromethyl)-N-(5-(trifluoromethyl)pyridin-3-yl)-benzenesulfonamide,0.62,uM,=,-0.2076083105017461,0,O=S(=O)(Nc1cccnc1)c1ccccc1
4956,1707938,10.1021/acs.jmedchem.7b01420,,,,Inhibition of CYP3A4 (unknown origin),c1ccc2c(c1)CN[C@@H](CN(CCCCNC1CCCCC1)[C@H]1CCCc3cccnc31)C2,"N1-Cyclohexyl-N4-(((R)-1,2,3,4-tetrahydroisoquinolin-3-yl)-methyl)-N4-((S)-5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine",11.7,uM,=,1.0681858617461617,1,c1ccc2c(c1)CN[C@@H](CN(CCCCNC1CCCCC1)[C@H]1CCCc3cccnc31)C2
4957,970229,10.1016/j.bmcl.2013.05.074,,,,Inhibition of CP3A4 (unknown origin),C#CCC(Oc1c(N)ncc2c(-c3cnn(C4CCNCC4)c3)coc12)c1c(Cl)ccc(F)c1Cl,"rac-7-(1-(2,6-dichloro-3-fluorophenyl)but-3-ynyloxy)-3-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)furo[3,2-c]pyridin-6-amine",1.6,uM,=,0.2041199826559248,1,c1ccc(COc2cncc3c(-c4cnn(C5CCNCC5)c4)coc23)cc1
4958,462442,10.1016/j.bmcl.2008.01.047,,,,Inhibition of CYP3A4,CC(C)(C)OC(=O)N[C@H](Cc1cc(F)ccc1Cl)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1,"(R)-tert-butyl 3-(2-chloro-5-fluorophenyl)-1-oxo-1-((3-(1-phenylcyclopropyl)-3H-imidazo[4,5-b]pyridin-2-yl)methylamino)propan-2-ylcarbamate",2.0,uM,=,0.3010299956639812,1,O=C(CCc1ccccc1)NCc1nc2cccnc2n1C1(c2ccccc2)CC1
4959,1667565,10.1021/acs.jmedchem.7b00067,,,,Inhibition of human CYP3A4 using ketoconazole as substrate,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,"(R)-2-{[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-ylmethoxy]phenoxyphosphorylamino}propionic Acid Isopropyl Ester",8.4,uM,=,0.9242792860618816,1,O=c1ccn([C@H]2CC[C@@H](CO[PH](=O)Oc3ccccc3)O2)c(=O)[nH]1
4960,1347924,10.1016/j.bmcl.2014.04.024,,,,Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method,COc1cc2ccc(C(O)(c3cnn[nH]3)C(C)C)cc2cc1OC,"rac-1-(6,7-dimethoxynaphthalen-2-yl)-2-methyl-1-(1H-1,2,3-triazol-4-yl)propan-1-ol",57.0,uM,=,1.7558748556724917,1,c1ccc2cc(Cc3cnn[nH]3)ccc2c1
4961,701746,10.1021/ml100190t,,,,Inhibition of CYP3A4 uisng midazolam substrate,O=C(Nc1cccnc1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1,N-Pyridin-3-yl-4-(3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}benzylidene)piperidine-1-carboxamide,4.3,uM,=,0.6334684555795865,1,O=C(Nc1cccnc1)N1CCC(=Cc2cccc(Oc3ccccn3)c2)CC1
4962,874073,10.1021/jm3012239,,,,Inhibition of CYP3A4,O=C(Nc1c[nH]nc1-c1cccc(Cl)c1)c1cnn2cccnc12,"N-(3-(3-chlorophenyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide",7.2,uM,=,0.8573324964312685,1,O=C(Nc1c[nH]nc1-c1ccccc1)c1cnn2cccnc12
4963,649881,10.1021/jm100506y,,,,Inhibition of CYP3A4,COC(=O)C1=C(Cn2ccnc2)NC(C)=C(C#N)C1c1ccc(F)cc1Cl,"Methyl 2-((1H-Imidazol-1-yl)methyl)-4-(2-chloro-4-fluorophenyl)-5-cyano-6-methyl-1,4-dihydropyridine-3-carboxylate",0.2,uM,=,-0.6989700043360187,0,C1=CC(c2ccccc2)C=C(Cn2ccnc2)N1
4964,1717434,10.1016/j.ejmech.2017.07.050,,,,Inhibition of CYP3A4 in human liver microsomes preincubated for 5 mins followed by NADPH/substrate addition measured after 20 mins by LC-MS/MS analysis,Cc1cccc2c(Nc3cccc(-c4nc5c(C(N)=O)cccc5[nH]4)c3)c3ccccc3nc12,2-(3-((4-methylacridin-9-yl)amino)phenyl)-1H-benzo[d]imidazole-4-carboxamide,6.8,uM,=,0.8325089127062363,1,c1cc(Nc2c3ccccc3nc3ccccc23)cc(-c2nc3ccccc3[nH]2)c1
4965,1640571,,,,,"In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.",c1ccc(-c2ccc(C(c3ccccc3)n3ccnc3)cc2)cc1,1-(Biphenyl-4-yl-phenyl-methyl)-1H-imidazole,0.8,uM,=,-0.0969100130080563,0,c1ccc(-c2ccc(C(c3ccccc3)n3ccnc3)cc2)cc1
4966,2198263,10.1016/j.bmc.2022.116951,,,,Inhibition of CYP3A4 (unknown origin) in presence of NADPH,N#Cc1ccc(CN2CCC(NC(=O)c3ccc(C(=O)N4CCC(Oc5ccc(C#N)cc5)CC4)cn3)CC2)cc1,N-(1-(4-cyanobenzyl)piperidin-4-yl)-5-(4-(4-cyanophenoxy)piperidine-1-carbonyl)picolinamide,3.5,uM,=,0.5440680443502757,1,O=C(NC1CCN(Cc2ccccc2)CC1)c1ccc(C(=O)N2CCC(Oc3ccccc3)CC2)cn1
4967,649881,10.1021/jm100506y,,,,Inhibition of CYP3A4,COC(=O)C1=C(Cn2cncn2)NC(C)=C(C#N)C1c1ccc(F)cc1Cl,"Methyl 2-((1H-1,2,4-Triazol-1-yl)methyl)-4-(2-chloro-4-fluorophenyl)-5-cyano-6-methyl-1,4-dihydropyridine-3-carboxylate",0.8,uM,=,-0.0969100130080563,0,C1=CC(c2ccccc2)C=C(Cn2cncn2)N1
4968,2193505,10.1016/j.bmcl.2022.128892,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 30 mins,CNC(=O)N(c1ccc(S(=O)(=O)Nc2ncccn2)cn1)c1cc(Cl)c(-c2ccc(F)c(OC(F)(F)F)c2)cc1OC,"6-(1-(2-chloro-4'-fluoro-5-methoxy-3'-(trifluoromethoxy)-[1,1'-biphenyl]-4-yl)-3-methylureido)-N-(pyrimidin-2-yl)pyridine-3-sulfonamide",11.0,uM,=,1.0413926851582251,1,O=S(=O)(Nc1ncccn1)c1ccc(Nc2ccc(-c3ccccc3)cc2)nc1
4969,761291,10.1021/jm101312a,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,Clc1ccc([C@@]23CCCC[C@@H]2CNC3)cc1Cl,"(3aR,7aS)-3a-(3,4-dichlorophenyl)octahydro-1H-isoindole",12.8,uM,=,1.1072099696478683,1,c1ccc([C@@]23CCCC[C@@H]2CNC3)cc1
4970,458143,10.1016/j.bmcl.2007.09.006,,,,Inhibition of CYP3A4 after 30 mins,CC(C)(CO)N1CCN(C(=O)OC2([C@H]3CCC[C@@H](c4cc(F)cc(F)c4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)CC1,"1-((2R,6S)-1-(4-chlorophenylsulfonyl)-6-(3,5-difluorophenyl)piperidin-2-yl)cyclopropyl 4-(1-hydroxy-2-methylpropan-2-yl)piperazine-1-carboxylate",0.4,uM,=,-0.3979400086720376,0,O=C(OC1([C@H]2CCC[C@@H](c3ccccc3)N2S(=O)(=O)c2ccccc2)CC1)N1CCNCC1
4971,652208,10.1016/j.bmcl.2010.07.052,,,,Inhibition of CYP3A4 in human liver microsomes,COCCn1c(=O)n(C2CCN(C(=O)C3CCN(Cc4ccncc4)CC3)CC2)c2ccccc21,1-(2-methoxyethyl)-3-(1-(1-(pyridin-4-ylmethyl)piperidine-4-carbonyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one,11.0,uM,=,1.0413926851582251,1,O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1
4972,652888,10.1016/j.bmcl.2010.07.064,,,,Inhibition of CYP3A4,NC(=O)c1nc(-c2cccc(-c3ccccc3OC(F)(F)F)c2)cs1,4-(2'-(trifluoromethoxy)biphenyl-3-yl)thiazole-2-carboxamide,18.0,uM,=,1.255272505103306,1,c1ccc(-c2cccc(-c3cscn3)c2)cc1
4973,1735372,10.1021/acs.jmedchem.8b00084,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis,CCc1ccncc1-c1ccc(CN)o1.Cl.Cl,(5-(4-Ethylpyridin-3-yl)furan-2-yl)methanamine Dihydrochloride,181.0,uM,=,2.257678574869185,1,c1cncc(-c2ccco2)c1
4974,950952,10.1016/j.bmcl.2013.02.023,,,,Inhibition of human CYP3A4,COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc(-c3ccc(C(F)(F)F)cc3)cc2)[nH]1)C(C)C,methyl(S)-3-methyl-1-oxo-1-((S)-2-(5-(4'-(trifluoromethyl)biphenyl-4-yl)-1H-imidazol-2-yl)pyrrolidin-1-yl)butan-2-ylcarbamate,6.5,uM,=,0.8129133566428556,1,c1ccc(-c2ccc(-c3cnc([C@@H]4CCCN4)[nH]3)cc2)cc1
4975,1729574,10.1021/acsmedchemlett.7b00406,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate,N[C@H]1CC[C@H](CN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)CC1,"(S)-N-(((1r,4S)-4-aminocyclohexyl)methyl)-N-(((R)-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)-5,6,7,8-tetrahydroquinolin-8-amine",10.0,uM,=,1.0,1,c1ccc2c(c1)CN[C@@H](CN(CC1CCCCC1)[C@H]1CCCc3cccnc31)C2
4976,652208,10.1016/j.bmcl.2010.07.052,,,,Inhibition of CYP3A4 in human liver microsomes,O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1,1-(1-(1-(pyridin-4-ylmethyl)piperidine-4-carbonyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one,9.5,uM,=,0.9777236052888478,1,O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1
4977,673953,10.1016/j.bmcl.2010.08.086,,,,Inhibition of CYP3A4 using testosterone as substrate,CCNCCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1,"(3R,4S)-N-(2-chloro-5-(2-(ethylamino)ethyl)benzyl)-N-cyclopropyl-4-(4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)phenyl)piperidine-3-carboxamide",18.0,uM,=,1.255272505103306,1,O=C([C@H]1CNCC[C@@H]1c1ccc(OCCOc2ccccc2)cc1)N(Cc1ccccc1)C1CC1
4978,1544115,10.1016/j.bmcl.2015.11.013,,,,Inhibition of CYP3A4 (unknown origin),Cc1nc(C)c(CNc2nc(C3CC3)nc(Cl)c2C)s1,"6-chloro-2-cyclopropyl-N-((2,4-dimethylthiazol-5-yl)methyl)-5-methylpyrimidin-4-amine",17.0,uM,=,1.230448921378274,1,c1cc(NCc2cncs2)nc(C2CC2)n1
4979,652208,10.1016/j.bmcl.2010.07.052,,,,Inhibition of CYP3A4 in human liver microsomes,COc1cccc(Cn2c(=O)n(C3CCN(C(=O)C4CCN(Cc5ccncc5)CC4)CC3)c3ccccc32)c1,1-(3-methoxybenzyl)-3-(1-(1-(pyridin-4-ylmethyl)piperidine-4-carbonyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one,0.2,uM,=,-0.6989700043360187,0,O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)n(Cc3ccccc3)c3ccccc32)CC1
4980,621465,10.1016/j.bmcl.2009.07.118,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,CCN(C[C@@H](C)NC(=O)OCc1nccs1)C[C@H](C)NC(=O)OCc1cncs1,N-[(S)-2-(thiazol-5-ylmethoxycarbonylamino)propyl]-N-[(R)-2-(thiazol-5-ylmethoxycarbonylamino)propyl]ethylamine,1.79,uM,=,0.2528530309798932,1,O=C(NCCNCCNC(=O)OCc1nccs1)OCc1cncs1
4981,813105,10.1021/jm201346g,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,CCCCSc1nc2cc(OC)ccc2[nH]1,2-(butylthio)-5-methoxy-1H-benzo[d]imidazole,50.0,uM,=,1.6989700043360187,1,c1ccc2[nH]cnc2c1
4982,718098,10.1016/j.bmcl.2010.12.053,,,,Inhibition of CYP3A4,CCCN(C)CCC1=C(Cc2cnccn2)c2ccccc2C1,N-methyl-N-(2-(3-(pyrazin-2-ylmethyl)-1H-inden-2-yl)ethyl)propan-1-amine,4.038,uM,=,0.6061663146076205,1,C1=C(Cc2cnccn2)c2ccccc2C1
4983,306900,10.1021/jm050255t,,,,Inhibitory concentration (1.5 mM) against human CYP450 3A4 dissolved in acetonitrile/methanol using 7-Benzyloxy-4-(trifluoromethyl)coumarin (BFC) as fluorogenic substrate,CCN1c2ncc(CCOc3ccc(C(=O)O)cc3C)cc2C(=O)N(C)c2cccnc21,"4-[2-(5-Ethyl-10-methyl-11-oxo-10,11-dihydro-5H-4,5,6,10-tetraaza-dibenzo[a,d]cyclohepten-2-yl)-ethoxy]-3-methyl-benzoic acid",24.0,uM,=,1.380211241711606,1,O=C1Nc2cccnc2Nc2ncc(CCOc3ccccc3)cc21
4984,52091,10.1016/j.bmcl.2003.11.049,,,,Inhibition of CYP450 (Cytochrome P450) 3A4 with fluorogenic substrate BQ,CCN1c2ncc(CSc3cc(C)nc(C)c3)cc2C(=O)Nc2c(C)cc(Cl)nc21,"7-Chloro-2-(2,6-dimethyl-pyridin-4-ylsulfanylmethyl)-5-ethyl-9-methyl-5,10-dihydro-4,5,6,10-tetraaza-dibenzo[a,d]cyclohepten-11-one",8.1,uM,=,0.9084850188786496,1,O=C1Nc2cccnc2Nc2ncc(CSc3ccncc3)cc21
4985,2280218,10.1016/j.bmcl.2022.129108,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate measured after 15 mins in the presence of NADPH by LC/MS/MS analysis,C[C@@H]1[C@H](Nc2ncnc3[nH]ccc23)CCCN1C(=O)CNc1cc(Cl)cc(Cl)c1,"1-((2R,3R)-3-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)-2-((3,5-dichlorophenyl)amino)ethan-1-one",1.59,uM,=,0.2013971243204514,1,O=C(CNc1ccccc1)N1CCC[C@@H](Nc2ncnc3[nH]ccc23)C1
4986,2134699,10.1021/acs.jmedchem.1c01121,,,,Inhibition of CYP3A4 (unknown origin),Cc1cn(-c2c(Cl)cccc2Cl)c(=O)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc12,"6-(2,6-dichlorophenyl)-8-methyl-2-(4-(4-methylpiperazin-1-yl)phenylamino)pyrido[4,3-d]pyrimidin-5(6H)-one",4.5,uM,=,0.6532125137753437,1,O=c1c2cnc(Nc3ccc(N4CCNCC4)cc3)nc2ccn1-c1ccccc1
4987,1296352,10.1021/jm4015108,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,O=C(Nc1ccc(S(=O)(=O)N2CC3CCC(C2)O3)cc1)[C@@H]1C[C@H]1c1cccnc1,rac-trans-N-(4-(8-Oxa-3-azabicyclo[3.2.1]octan-3-ylsulfonyl)-phenyl)-2-(pyridin-3-yl)cyclopropanecarboxamide,8.9,uM,=,0.9493900066449128,1,O=C(Nc1ccc(S(=O)(=O)N2CC3CCC(C2)O3)cc1)[C@@H]1C[C@H]1c1cccnc1
4988,880247,10.1021/jm101459g,,,,Inhibition of human recombinant CYP3A4 using resorufin benzyl ether after 30 mins by fluorescence spectrophotometric analysis,Cc1ccc(Sc2ccccc2N2CCNCC2)cc1C.Cl,"1-[2-(3,4-Dimethyl-phenylsulfanyl)-phenyl]-piperazine Hydrochloride",11.0,uM,=,1.0413926851582251,1,c1ccc(Sc2ccccc2N2CCNCC2)cc1
4989,673953,10.1016/j.bmcl.2010.08.086,,,,Inhibition of CYP3A4 using testosterone as substrate,Cc1cc(Cl)c(OCCOc2ccc([C@H]3CCNC[C@@H]3C(=O)N(Cc3cc(CNC(=O)CC(F)(F)F)ccc3Cl)C3CC3)cc2)c(Cl)c1,"(3R,4S)-N-(2-chloro-5-((3,3,3-trifluoropropanamido)methyl)benzyl)-N-cyclopropyl-4-(4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)phenyl)piperidine-3-carboxamide",7.9,uM,=,0.8976270912904415,1,O=C([C@H]1CNCC[C@@H]1c1ccc(OCCOc2ccccc2)cc1)N(Cc1ccccc1)C1CC1
4990,699595,10.1016/j.bmcl.2010.11.001,,,,Inhibition of human CYP3A4,CC(C)c1ccc(S(=O)(=O)n2cc(N3CCN(C)CC3)c3ccccc32)cc1,1-(4-Isopropylbenzenesulfonyl)-3-(4-methylpiperazin-1-yl)-1H-indole,5.54,uM,=,0.7435097647284298,1,O=S(=O)(c1ccccc1)n1cc(N2CCNCC2)c2ccccc21
4991,1729574,10.1021/acsmedchemlett.7b00406,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate,C/C(CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21)=C(/F)CN,"(Z)-3-fluoro-2-methyl-N1-(((R)-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)-N1-((S)-5,6,7,8-tetrahydroquinolin-8-yl)but-2-ene-1,4-diamine",1.8,uM,=,0.255272505103306,1,c1ccc2c(c1)CN[C@@H](CN[C@H]1CCCc3cccnc31)C2
4992,2157079,10.1021/acsmedchemlett.1c00445,,,,Inhibition of human CYP3A4 by fluorescence plate reader analysis,C[C@@]1(c2cc(NC(=O)c3ccc(C#N)cn3)ccc2F)Cn2c(C#N)cnc2C(N)=N1,"(R)-N-(3-(8-amino-3-cyano-6-methyl-5,6-dihydroimidazo[1,2-a]pyrazin-6-yl)-4-fluorophenyl)-5-cyanopicolinamide",6.7,uM,=,0.8260748027008264,1,O=C(Nc1cccc(C2Cn3ccnc3C=N2)c1)c1ccccn1
4993,1689465,10.1021/acs.jmedchem.7b00662,,,,Inhibition of CYP3A4 (unknown origin),CN1C(=O)C2=C(C1=O)N(CC(=O)Nc1ccc(-c3nccs3)cc1)CCC2,"2-(6-methyl-5,7-dioxo-2,3,4,5,6,7-hexahydro-1H-pyrrolo[3,4-b]pyridin-1-yl)-N-(4-(thiazol-2-yl)phenyl)acetamide",5.2,uM,=,0.7160033436347992,1,O=C(CN1CCCC2=C1C(=O)NC2=O)Nc1ccc(-c2nccs2)cc1
4994,2202740,10.1016/j.ejmech.2022.114332,,,,Inhibition of CYP3A4 in human kidney microsomes assessed as inhibition of 20-HETE formation using 7-benzyl-oxyquinoline as substrate in presence of arachidonic acid and NADPH by fluorescence assay,CCCCc1ccc(/N=C/NO)c(C)c1,N-(4-butyl-2-methylphenyl)-N'-hydroxyimidoformamide,0.1,uM,=,-1.0,0,c1ccccc1
4995,321431,10.1021/jm050392q,,,,Concentration required to inhibit cytochrome P450 isozyme CYP3A4-BzRes in vitro by 50%,Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12,4-[(S)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-(4-methyl-6-morpholin-4-yl-1H-benzoimidazol-2-yl)-1H-pyridin-2-one,5.3,uM,=,0.724275869600789,1,O=c1[nH]ccc(NCCc2ccccc2)c1-c1nc2ccc(N3CCOCC3)cc2[nH]1
4996,1677688,10.1021/acs.jmedchem.7b01340,,,,Inhibition of CYP3A4 (unknown origin),COc1cc(C(=O)NC(c2nc(C(=O)Nc3ccccc3C(=O)c3ccccc3)cs2)C(C)C)cc(OC)c1OC,"N-(2-benzoylphenyl)-2-(2-methyl-1-(3,4,5-trimethoxybenzamido)propyl)thiazole-4-carboxamide",8.23,uM,=,0.91539983521227,1,O=C(NCc1nc(C(=O)Nc2ccccc2C(=O)c2ccccc2)cs1)c1ccccc1
4997,1527906,,,,,Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,C[C@@H](c1ccc(-c2ccc(F)cc2)cc1)N1CC[C@](CCO)(c2ccc(F)cc2)OC1=O,"(S)-3-((S)-1-(4'-fluorobiphenyl-4-yl)ethyl)-6-(4-fluorophenyl)-6-(2-hydroxyethyl)-1,3-oxazinan-2-one",9.9,uM,=,0.99563519459755,1,O=C1OC(c2ccccc2)CCN1Cc1ccc(-c2ccccc2)cc1
4998,880247,10.1021/jm101459g,,,,Inhibition of human recombinant CYP3A4 using resorufin benzyl ether after 30 mins by fluorescence spectrophotometric analysis,Cl.Clc1ccc(Sc2ccccc2N2CCNCC2)c(Cl)c1,"1-[2-(2,4-Dichloro-phenylsulfanyl)-phenyl]-piperazine Hydrochloride",4.4,uM,=,0.6434526764861874,1,c1ccc(Sc2ccccc2N2CCNCC2)cc1
4999,615765,10.1016/j.bmcl.2010.02.003,,,,Inhibition of CYP3A4,O=C(N[C@@H](Cc1c[nH]c2ccc(O)cc12)c1cscn1)c1ccc2c(c1)nc(-c1ccoc1)n2C1CCCCC1,1-cyclohexyl-2-(furan-3-yl)-N-((S)-2-(5-hydroxy-1H-indol-3-yl)-1-(thiazol-4-yl)ethyl)-1H-benzo[d]imidazole-5-carboxamide,0.44,uM,=,-0.3565473235138126,0,O=C(N[C@@H](Cc1c[nH]c2ccccc12)c1cscn1)c1ccc2c(c1)nc(-c1ccoc1)n2C1CCCCC1
5000,715320,10.1021/jm1009082,,,,Inhibition of human CYP3A4,Oc1cccc(-c2ccc3c(-c4ccccc4)c(O)ccc3c2)c1,6-(3-Hydroxyphenyl)-1-phenyl-2-naphthol,2.77,uM,=,0.4424797690644485,1,c1ccc(-c2ccc3c(-c4ccccc4)cccc3c2)cc1
5001,718098,10.1016/j.bmcl.2010.12.053,,,,Inhibition of CYP3A4,C[C@H](C1=C(CCN(C)Cc2ccco2)Cc2ccccc21)c1cnccn1,(R)-N-(furan-2-ylmethyl)-N-methyl-2-(3-(1-(pyrazin-2-yl)ethyl)-1H-inden-2-yl)ethanamine,2.751,uM,=,0.4394905903896835,1,c1coc(CNCCC2=C(Cc3cnccn3)c3ccccc3C2)c1
5002,1523393,10.1021/acs.jmedchem.5b00774,,,,Inhibition of CYP3A4 (unknown origin) preincubated with protein for 30 mins followed by substrate addition,O=S(=O)(N[C@@H]1CC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@H]2C1)C(F)(F)F,"N-((6aR,8R,10aS)-10a-(4-chlorophenylsulfonyl)-1,4-difluoro-6a,7,8,9,10,10a-hexahydro-6H-benzo[c]chromen-8-yl)-1,1,1-trifluoromethanesulfonamide",3.5,uM,=,0.5440680443502757,1,O=S(=O)(c1ccccc1)[C@@]12CCCC[C@@H]1COc1ccccc12
5003,2241758,10.1016/j.ejmech.2021.113983,,,,Inhibition of CYP3A4 (unknown origin),CNC(=O)[C@@]12C[C@@H]1[C@@H](n1cnc3c(NCCc4ccc(OC)c(O)c4)nc(OCC(C)C)nc31)[C@H](O)[C@@H]2O,"(1S,2R,3S,4R,5S)-2,3-dihydroxy-4-[6-[2-(3-hydroxy-4-methoxy-phenyl)ethylamino]-2-isobutoxy-purin-9-yl]-N-methyl-bicyclo[3.1.0]hexane-1-carboxamide",0.83,uM,=,-0.0809219076239261,0,c1ccc(CCNc2ncnc3c2ncn3[C@H]2CCC3C[C@@H]32)cc1
5004,621465,10.1016/j.bmcl.2009.07.118,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,CC(C)CN(C[C@@H](Cc1ccccc1)NC(=O)OCc1cncs1)C[C@@H](Cc1ccccc1)NC(=O)OCc1nccs1,Bis-N-[(R)-2-(thiazol-5-ylmethoxycarbonylamino)-3-phenylpropyl]-N-[isopropyl]amine,0.067,uM,=,-1.1739251972991736,0,O=C(N[C@@H](CNC[C@@H](Cc1ccccc1)NC(=O)OCc1nccs1)Cc1ccccc1)OCc1cncs1
5005,1707938,10.1021/acs.jmedchem.7b01420,,,,Inhibition of CYP3A4 (unknown origin),c1cncc(CNCCCCN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)c1,"N1-(Pyridin-3-ylmethyl)-N4-(((R)-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)-N4-((S)-5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine",8.45,uM,=,0.9268567089496924,1,c1cncc(CNCCCCN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)c1
5006,1301271,10.6019/CHEMBL3137386,,,,DNDI: CYP Inhibition,O=C(C(c1ccc(Cl)cc1)c1cccnc1)N1CCN(c2ccc(C(F)(F)F)cc2)CC1,rac-2-(4-Chlorophenyl)-1-{4-[4-(trifluoromethyl)phenyl]piperazin-1-yl}-2-(pyridin-3-yl)ethanone,7.4,uM,=,0.8692317197309762,1,O=C(C(c1ccccc1)c1cccnc1)N1CCN(c2ccccc2)CC1
5007,1439020,10.1021/ml500267c,,,,Inhibition of human CYP3A4 by electrospray ionization,Clc1ccc(CN2CCO[C@H](CCc3ccccc3)C2)cc1,(R)-4-(4-chlorobenzyl)-2-phenethylmorpholine,15.6,uM,=,1.1931245983544616,1,c1ccc(CC[C@@H]2CN(Cc3ccccc3)CCO2)cc1
5008,606336,10.1016/j.bmcl.2009.11.061,,,,Inhibition of CYP3A4,Cc1nc(-c2ccoc2)c(-c2cnc3[nH]nc(C)c3n2)cc1OC[C@@H](N)Cc1c[nH]c2ccccc12,"(S)-1-(6-(furan-3-yl)-2-methyl-5-(3-methyl-1H-pyrazolo[4,3-b]pyrazin-5-yl)pyridin-3-yloxy)-3-(1H-indol-3-yl)propan-2-amine",0.63,uM,=,-0.2006594505464183,0,c1ccc2c(CCCOc3cnc(-c4ccoc4)c(-c4cnc5[nH]ncc5n4)c3)c[nH]c2c1
5009,789986,10.1016/j.bmcl.2011.10.013,,,,Reversible inhibition of CYP3A4,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@]23OCc2cc(F)c(F)cc23)C2CC2)c2ccccc2c1,"(1R,3'S)-N-cyclopropyl-5,6-difluoro-N-((3-(3-methoxypropyl)naphthalen-1-yl)methyl)-3H-spiro[isobenzofuran-1,4'-piperidine]-3'-carboxamide",1.6,uM,=,0.2041199826559248,1,O=C([C@H]1CNCC[C@@]12OCc1ccccc12)N(Cc1cccc2ccccc12)C1CC1
5010,606336,10.1016/j.bmcl.2009.11.061,,,,Inhibition of CYP3A4,Cc1occc1-c1nc(N)c(OC[C@@H](N)Cc2c[nH]c3ccccc23)cc1-c1cnc2[nH]nc(C)c2n1,"3-((S)-2-amino-3-(1H-indol-3-yl)propoxy)-5-(3-methyl-1H-pyrazolo[4,3-b]pyrazin-5-yl)-6-(2-methylfuran-3-yl)pyridin-2-amine",5.0,uM,=,0.6989700043360189,1,c1ccc2c(CCCOc3cnc(-c4ccoc4)c(-c4cnc5[nH]ncc5n4)c3)c[nH]c2c1
5011,718098,10.1016/j.bmcl.2010.12.053,,,,Inhibition of CYP3A4,C[C@H](C1=C(CCN(C)Cc2nccn2C)Cc2ccccc21)c1cnccn1,(R)-N-methyl-N-((1-methyl-1H-imidazol-2-yl)methyl)-2-(3-(1-(pyrazin-2-yl)ethyl)-1H-inden-2-yl)ethanamine,1.535,uM,=,0.1861083798132052,1,c1ccc2c(c1)CC(CCNCc1ncc[nH]1)=C2Cc1cnccn1
5012,595637,10.1016/j.bmcl.2009.09.096,,,,Inhibition of human CYP3A4,COc1ccc2c(SCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1,"7-methoxy-4-((6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methylthio)quinoline",4.5,uM,=,0.6532125137753437,1,c1ccc(-c2ccc3nnc(CSc4ccnc5ccccc45)n3n2)cc1
5013,1488506,10.1124/dmd.112.045708,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis in presence of NADPH,C[C@H](c1nc2ncccc2c(=O)n1-c1ccc(O)cc1)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1,"(R)-N-(1-(3-(4-hydroxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide",0.027,uM,=,-1.5686362358410126,0,O=C(Cc1ccccc1)N(Cc1cccnc1)Cc1nc2ncccc2c(=O)n1-c1ccccc1
5014,718098,10.1016/j.bmcl.2010.12.053,,,,Inhibition of CYP3A4,C[C@H](C1=C(CCN(C)Cc2ccccn2)Cc2ccccc21)c1cnccn1,(R)-N-methyl-2-(3-(1-(pyrazin-2-yl)ethyl)-1H-inden-2-yl)-N-(pyridin-2-ylmethyl)ethanamine,4.783,uM,=,0.6797003808719642,1,c1ccc(CNCCC2=C(Cc3cnccn3)c3ccccc3C2)nc1
5015,673950,10.1016/j.bmcl.2010.08.086,,,,Inhibition of CYP3A4,Cc1cc(Cl)c(OCCOc2ccc(C3=C(C(=O)N(Cc4cccc(Cl)c4Cl)C4CC4)CNCC3)cc2)c(Cl)c1,"N-cyclopropyl-4-(4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)phenyl)-N-(2,3-dichlorobenzyl)-1,2,5,6-tetrahydropyridine-3-carboxamide",0.8,uM,=,-0.0969100130080563,0,O=C(C1=C(c2ccc(OCCOc3ccccc3)cc2)CCNC1)N(Cc1ccccc1)C1CC1
5016,1642505,,,,,"Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).",CN[C@@H](C)C(=O)Nc1ccc(-c2c(-c3ccnc(C)c3)nc3cc(C)ccn23)c(C#Cc2ccccc2)n1,"US9481673, (S)-11",46.0,uM,=,1.662757831681574,1,C(#Cc1ncccc1-c1c(-c2ccncc2)nc2ccccn12)c1ccccc1
5017,1933896,10.1021/acs.jmedchem.6b00928,,,,Inhibition of CYP3A4 in human liver microsomes incubated for 15 mins using midazolam substrate in presence of NADPH by LC-MS/MS method,CSc1ncc(-c2c(CO)n(Cc3ccccc3Cl)c3ccc(OC(F)(F)F)cc23)cn1,(1-(2-chlorobenzyl)-3-(2-(methylthio)pyrimidin-5-yl)-5-(trifluoromethoxy)-1H-indol-2-yl)methanol,17.6,uM,=,1.24551266781415,1,c1ccc(Cn2cc(-c3cncnc3)c3ccccc32)cc1
5018,715320,10.1021/jm1009082,,,,Inhibition of human CYP3A4,Oc1cccc(-c2ccc3c(-c4cccc(O)c4)c(O)ccc3c2)c1,"1,6-Bis(3-hydroxyphenyl)-2-naphthol",0.04,uM,=,-1.3979400086720375,0,c1ccc(-c2ccc3c(-c4ccccc4)cccc3c2)cc1
5019,1445200,10.1021/ml5003376,,,,Inhibition of human CYP3A4 testosterone site in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,Nc1n[nH]c2nc(-c3ccc(NS(=O)(=O)c4cccc(Cl)c4Cl)cc3)cnc12,"N-(4-(3-amino-1H-pyrazolo[3,4-b]pyrazin-6-yl)phenyl)-2,3-dichlorobenzenesulfonamide",14.5,uM,=,1.1613680022349748,1,O=S(=O)(Nc1ccc(-c2cnc3cn[nH]c3n2)cc1)c1ccccc1
5020,1659863,10.1016/j.ejmech.2017.02.016,,,,Inhibition of human liver CYP3A4 expressed in Saccharomyces cerevisiae YY7 microsomal membranes using DBF as substrate after 10 mins by fluorescence assay,O=C(/C=C/c1cccnc1)c1cccc2ccccc12,(E)-1-(1-Naphthyl)-3-(3-pyridyl)prop-2-en-1-one,6.0,uM,=,0.7781512503836436,1,O=C(/C=C/c1cccnc1)c1cccc2ccccc12
5021,649881,10.1021/jm100506y,,,,Inhibition of CYP3A4,COC(=O)C1=C(Cn2cccn2)NC(C)=C(C#N)C1c1ccc(F)cc1Cl,"Methyl 2-((1H-Pyrazol-1-yl)methyl)-4-(2-chloro-4-fluorophenyl)-5-cyano-6-methyl-1,4-dihydropyridine-3-carboxylate",1.1,uM,=,0.041392685158225,1,C1=CC(c2ccccc2)C=C(Cn2cccn2)N1
5022,728151,10.1016/j.bmc.2011.01.017,,,,Inhibition of human CYP3A4,CC(C)C(O)(c1ccc2cc(C(N)=O)ccc2c1)c1c[nH]cn1,rac-6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide,3.7,uM,=,0.568201724066995,1,c1ccc2cc(Cc3c[nH]cn3)ccc2c1
5023,811669,10.1016/j.bmcl.2012.01.117,,,,Inhibition of CYP3A4,CC(C)S(=O)(=O)NC[C@H]1CC[C@H](NC(=O)CN2CCc3cc(Cl)ccc32)CC1,2-(5-chloroindolin-1-yl)-N-(4-((1-methylethylsulfonamido)methyl)cyclohexyl)acetamide,0.7,uM,=,-0.1549019599857432,0,O=C(CN1CCc2ccccc21)NC1CCCCC1
5024,580964,10.1016/j.bmcl.2009.06.085,,,,Inhibition of human CYP3A4,CN([C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1)S(=O)(=O)c1ccc(F)cc1,"(R)-2-(7-(4-fluoro-N-methylphenylsulfonamido)-6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl)acetic acid",7.0,uM,=,0.8450980400142568,1,O=S(=O)(N[C@@H]1CCc2cc3ccccc3n2C1)c1ccccc1
5025,1297867,10.1021/jm401532g,,,,Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein as substrate,CC(=O)O.O=S(=O)(c1cccc(CCCCOCCCCCCNC[C@H](O)c2ccc(O)c(CO)c2)c1)C1CCCC1,4-((1R)-2-{[6-({4-[3-(Cyclopentylsulfonyl)phenyl]butyl}oxy)-hexyl]amino}-1-hydroxyethyl)-2-(hydroxymethyl)phenol acetate salt,1.6,uM,=,0.2041199826559248,1,O=S(=O)(c1cccc(CCCCOCCCCCCNCCc2ccccc2)c1)C1CCCC1
5026,1903445,10.1021/acs.jmedchem.9b01713,,,,Inhibition of human liver microsome CYP3A4 using midazolam as substrate incubated for 5 to 20 mins by LC-MS/MS analysis,N#Cc1ccc(Cn2nccc2-c2cc(Cl)c3nnn(-c4ccc5cn[nH]c5c4)c3c2)cc1,"4-((5-(4-Chloro-1-(1H-indazol-6-yl)-1H-benzo[d][1,2,3]triazol-6-yl)-1H-pyrazol-1-yl)methyl)benzonitrile",19.7,uM,=,1.294466226161593,1,c1ccc(Cn2nccc2-c2ccc3nnn(-c4ccc5cn[nH]c5c4)c3c2)cc1
5027,949160,10.1016/j.bmcl.2013.01.011,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate,O=C(N[C@H](Cc1cc(Br)c2[nH]c(=O)oc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1,"(R)-N-(1-(1,4'-bipiperidin-1'-yl)-3-(4-bromo-2-oxo-2,3-dihydrobenzo[d]oxazol-6-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide",7.2,uM,=,0.8573324964312685,1,O=C(N[C@H](Cc1ccc2[nH]c(=O)oc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
5028,2221810,10.1016/j.bmcl.2022.128625,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as substrate pretreated with NADPH,CCC[C@H]1N(C(=O)c2c(F)cccc2C(F)(F)F)CCC[C@@]1(Oc1csc(C(F)(F)F)c1)C(=O)N1CCN(c2ccccc2OCCO)CC1,"((2R,3S)-1-(2-fluoro-6-(trifluoromethyl)benzoyl)-2-propyl-3-(5-(trifluoromethyl)thiophen-3-yloxy)piperidin-3-yl)(4-(2-(2-hydroxyethoxy)phenyl)piperazin-1-yl)methanone",0.4,uM,=,-0.3979400086720376,0,O=C(c1ccccc1)N1CCC[C@@](Oc2ccsc2)(C(=O)N2CCN(c3ccccc3)CC2)C1
5029,2016610,10.1021/acs.jmedchem.0c01203,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 to 20 mins in presence of NADPH by LC-MS/MS analysis,CC(=O)Nc1cc2nc(-c3cc4c(c(C(F)(F)F)c3)C(=O)N([C@@H](C)C3CC3)C4)ccn2n1,"N-(5-{2-[(1S)-1-Cyclopropylethyl]-1-oxo-7-(trifluoromethyl)-2,3-dihydro-1H-isoindol-5-yl}pyrazolo[1,5-a]pyrimidin-2-yl)acetamide",4.6,uM,=,0.6627578316815741,1,O=C1c2ccc(-c3ccn4nccc4n3)cc2CN1CC1CC1
5030,1707938,10.1021/acs.jmedchem.7b01420,,,,Inhibition of CYP3A4 (unknown origin),c1ccc2c(c1)CN[C@@H](CN(CCCCNCC1CCCCC1)[C@H]1CCCc3cccnc31)C2,"N1-(Cyclohexylmethyl)-N4-(((R)-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)-N4-((S)-5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine",2.78,uM,=,0.4440447959180762,1,c1ccc2c(c1)CN[C@@H](CN(CCCCNCC1CCCCC1)[C@H]1CCCc3cccnc31)C2
5031,450887,10.1016/j.bmcl.2007.09.076,,,,Inhibition of human CYP3A4 after 10 mins,CN(C)c1ccc(-c2nc3c(N4CCN(CC(=O)Nc5nccs5)CC4)c(Cl)cnc3[nH]2)cc1,"2-(4-(6-chloro-2-(4-(dimethylamino)phenyl)-3H-imidazo[4,5-b]pyridin-7-yl)piperazin-1-yl)-N-(thiazol-2-yl)acetamide",10.0,uM,=,1.0,1,O=C(CN1CCN(c2ccnc3[nH]c(-c4ccccc4)nc23)CC1)Nc1nccs1
5032,462442,10.1016/j.bmcl.2008.01.047,,,,Inhibition of CYP3A4,CC(C)(C)OC(=O)N[C@H](Cc1ccccc1C(F)(F)F)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1,"(R)-tert-butyl 1-oxo-1-((3-(1-phenylcyclopropyl)-3H-imidazo[4,5-b]pyridin-2-yl)methylamino)-3-(2-(trifluoromethyl)phenyl)propan-2-ylcarbamate",0.82,uM,=,-0.0861861476162833,0,O=C(CCc1ccccc1)NCc1nc2cccnc2n1C1(c2ccccc2)CC1
5033,4334,10.1021/jm00093a015,,,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,"1-(4-{4-[2-(2,4-Dichloro-phenyl)-2-imidazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-ethanone",0.57,uM,=,-0.2441251443275086,0,c1ccc([C@]2(Cn3ccnc3)OC[C@H](COc3ccc(N4CCNCC4)cc3)O2)cc1
5034,458143,10.1016/j.bmcl.2007.09.006,,,,Inhibition of CYP3A4 after 30 mins,CC[C@@H]1C[C@H](OC)C[C@H](COC(=O)N2CCN(CCO)CC2)N1S(=O)(=O)c1ccc(Cl)cc1,cis-1-(4-chlorophenylsulfonyl)-6-ethyl-4-methoxypiperidin-2-yl)methyl 4-(2-hydroxyethyl)piperazine-1-carboxylate,30.0,uM,=,1.4771212547196624,1,O=C(OC[C@H]1CCCCN1S(=O)(=O)c1ccccc1)N1CCNCC1
5035,2016610,10.1021/acs.jmedchem.0c01203,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 to 20 mins in presence of NADPH by LC-MS/MS analysis,C[C@@H](C1CC1)N1Cc2cc(-c3ccn4nc(N)c(-c5cnn(C)c5)c4n3)cc(C(F)(F)F)c2C1=O,"5-[2-amino-3-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-5-yl]-2-[(1S)-1-cyclopropylethyl]-7-(trifluoromethyl)-2,3-dihydro-1H-isoindol-1-one",0.6,uM,=,-0.2218487496163563,0,O=C1c2ccc(-c3ccn4ncc(-c5cn[nH]c5)c4n3)cc2CN1CC1CC1
5036,813105,10.1021/jm201346g,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,CCCCCCCSc1nc2cc(OC)ccc2[nH]1,2-(heptylthio)-5-methoxy-1H-benzo[d]imidazole,15.7,uM,=,1.1958996524092338,1,c1ccc2[nH]cnc2c1
5037,1347924,10.1016/j.bmcl.2014.04.024,,,,Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method,COc1cc2ccc(C(O)(c3ccncc3)C(C)C)cc2cc1OC,"rac-1-(6,7-dimethoxynaphthalen-2-yl)-2-methyl-1-(pyridin-4-yl)propan-1-ol",4.5,uM,=,0.6532125137753437,1,c1ccc2cc(Cc3ccncc3)ccc2c1
5038,510060,10.1016/j.bmcl.2008.07.059,,,,Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay,CN[C@@H](Cn1c(=O)c(-c2cccc(OCCC(C)(C)CC(=O)O)c2F)c(C)n(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1,"(R)-5-(3-(1-(2-fluoro-6-(trifluoromethyl)benzyl)-6-methyl-3-(2-(methylamino)-2-phenylethyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-2-fluorophenoxy)-3,3-dimethylpentanoic acid",10.0,uM,=,1.0,1,O=c1c(-c2ccccc2)cn(Cc2ccccc2)c(=O)n1CCc1ccccc1
5039,789986,10.1016/j.bmcl.2011.10.013,,,,Reversible inhibition of CYP3A4,COCCCc1cc(C)c(C)c(CN(C(=O)[C@H]2CNCC[C@@]23OCc2cc(F)c(F)cc23)C2CC2)c1,"(1R,3'S)-N-cyclopropyl-5,6-difluoro-N-(5-(3-methoxypropyl)-2,3-dimethylbenzyl)-3H-spiro[isobenzofuran-1,4'-piperidine]-3'-carboxamide",3.5,uM,=,0.5440680443502757,1,O=C([C@H]1CNCC[C@@]12OCc1ccccc12)N(Cc1ccccc1)C1CC1
5040,2172302,10.1021/acs.jmedchem.1c01498,,,,Inhibition of human CYP3A4 preincubated for 10 mins followed by substrate and NADP addition measured after 30 mins by fluorescence assay,COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC,"2-(3,4-Dimethoxy-phenyl)-5-{[2-(3,4-dimethoxy-phenyl)-ethyl]-methyl-amino}-2-isopropyl-pentanenitrile",0.011,uM,=,-1.9586073148417749,0,c1ccc(CCCCNCCc2ccccc2)cc1
5041,2015855,10.1016/j.bmcl.2020.127391,,,,Inhibition of CYP3A4 (unknown origin),Cc1cc(Cl)cc(N2C=Nc3cc(C)c(-c4cc(F)cc(C(N)=O)c4)cc3C2C(=O)N(C)C[C@@H]2CCCN2)c1,"6-(3-carbamoyl-5-fluorophenyl)-3-(3-chloro-5-methylphenyl)-N,7-dimethyl-N-((S)-pyrrolidin-2-ylmethyl)-3,4-dihydroquinazoline-4-carboxamide",1.0,uM,=,0.0,0,O=C(NC[C@@H]1CCCN1)C1c2cc(-c3ccccc3)ccc2N=CN1c1ccccc1
5042,1707938,10.1021/acs.jmedchem.7b01420,,,,Inhibition of CYP3A4 (unknown origin),NCc1cccc(CN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)c1,"(S)-N-(3-(Aminomethyl)benzyl)-N-(((R)-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)-5,6,7,8-tetrahydroquinolin-8-amine",4.63,uM,=,0.6655809910179531,1,c1ccc(CN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)cc1
5043,609086,10.1016/j.bmc.2010.01.039,,,,Inhibition of CYP3A4-mediated hydroxylation of testosterone in human liver microsomes in NADPH co-factor system by RP-HPLC,COc1c(C(C)(C)C)cc(C(=O)Cn2c(NCCCO)nc3cc(C)c(C)cc32)cc1C(C)(C)C,"1-(3,5-Di-tert-butyl-4-methoxyphenyl)-2-(2-(3-hydroxypropylamino)-5,6-dimethyl-1H-benzo[d]imidazol-1-yl)ethanone",67.0,uM,=,1.8260748027008264,1,O=C(Cn1cnc2ccccc21)c1ccccc1
5044,1628093,10.1016/j.ejmech.2016.08.024,,,,Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells preincubated for 30 mins using fluorescent substrate,O=C(CC1([C@H]2CO[C@H]3CCC[C@H]3N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CCC(CO)CC1,"2-(1-((3S,4aR,7aS)-4-(4-chlorophenylsulfonyl)octahydrocyclopenta[b][1,4]oxazin-3-yl)cyclopropyl)-1-(4-(hydroxymethyl)piperidin-1-yl)ethanone",30.0,uM,=,1.4771212547196624,1,O=C(CC1([C@H]2CO[C@H]3CCC[C@H]3N2S(=O)(=O)c2ccccc2)CC1)N1CCCCC1
5045,715320,10.1021/jm1009082,,,,Inhibition of human CYP3A4,Oc1cccc(-c2ccc3c(-c4cccnc4)c(O)ccc3c2)c1,6-(3-Hydroxyphenyl)-1-(pyridin-3-yl)-2-naphthol,0.22,uM,=,-0.6575773191777937,0,c1ccc(-c2ccc3c(-c4cccnc4)cccc3c2)cc1
5046,699595,10.1016/j.bmcl.2010.11.001,,,,Inhibition of human CYP3A4,CN1CCN(c2cn(S(=O)(=O)c3ccc(F)cc3)c3ccc(Br)cc23)CC1,5-Bromo-1-(4-fluorobenzenesulfonyl)-3-(4-methylpiperazin-1-yl)-1H-indole,4.61,uM,=,0.6637009253896482,1,O=S(=O)(c1ccccc1)n1cc(N2CCNCC2)c2ccccc21
5047,621465,10.1016/j.bmcl.2009.07.118,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,O=C(NC(Cc1ccccc1)CN(CC(Cc1ccccc1)NC(=O)OCc1cncs1)CC(Cc1ccccc1)NC(=O)OCc1nccs1)OCc1cncs1,Tris-N-[2-(thiazol-5-ylmethoxycarbonylamino)-3-phenylpropyl]amine,0.065,uM,=,-1.1870866433571443,0,O=C(NC(Cc1ccccc1)CN(CC(Cc1ccccc1)NC(=O)OCc1cncs1)CC(Cc1ccccc1)NC(=O)OCc1nccs1)OCc1cncs1
5048,510060,10.1016/j.bmcl.2008.07.059,,,,Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay,Cc1c(-c2cccc(OCCCC(=O)O)c2)c(=O)n(C[C@H](N)c2ccccc2)c(=O)n1Cc1c(F)cccc1C(F)(F)F,"(R)-4-(3-(1-(2-fluoro-6-(trifluoromethyl)benzyl)-3-(2-amino-2-phenylethyl)-6-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)phenoxy)butanoic acid",10.0,uM,=,1.0,1,O=c1c(-c2ccccc2)cn(Cc2ccccc2)c(=O)n1CCc1ccccc1
5049,1735372,10.1021/acs.jmedchem.8b00084,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis,Cl.Cl.NCc1ccc(-c2cnccc2-c2ccccc2)s1,(5-(4-Phenylpyridin-3-yl)thiophen-2-yl)methanamine Dihydrochloride,5.3,uM,=,0.724275869600789,1,c1ccc(-c2ccncc2-c2cccs2)cc1
5050,976812,10.1016/j.bmcl.2013.06.100,,,,Inhibition of CYP3A4 (unknown origin),COc1cc(-c2nc3n(n2)CCO[C@H]3c2ccccc2C(F)(F)F)ccc1-n1cnc(C)c1,"(S)-2-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-8-(2-(trifluoromethyl)phenyl)-6,8-dihydro-5H-[1,2,4]triazolo[5,1-c][1,4]oxazine",1.1,uM,=,0.041392685158225,1,c1ccc([C@@H]2OCCn3nc(-c4ccc(-n5ccnc5)cc4)nc32)cc1
5051,1628093,10.1016/j.ejmech.2016.08.024,,,,Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells preincubated for 30 mins using fluorescent substrate,CC(=O)N1CCN(C(=O)CC2([C@H]3COC[C@@H](C4CC4)N3S(=O)(=O)c3ccc(F)cc3)CC2)CC1,"1-(4-acetylpiperazin-1-yl)-2-(1-((3S,5R)-5-cyclopropyl-4-(4-fluorophenylsulfonyl)morpholin-3-yl)cyclopropyl)ethanone",17.0,uM,=,1.230448921378274,1,O=C(CC1([C@H]2COC[C@@H](C3CC3)N2S(=O)(=O)c2ccccc2)CC1)N1CCNCC1
5052,2241391,10.1016/j.ejmech.2021.113981,,,,Inhibition of CYP3A4 in human liver microsomes assessed as reduction in 1'-hydroxy midazolam formation using midazolam as substrate preincubated for 20 mins in presence of NADPH followed by incubation with substrate for 10 mins by LC-MS/MS analysis,COC[C@H](Cc1ccccc1)NC[C@@H](O)c1cc(C(F)(F)F)nc2c(C(F)(F)F)cccc12,"(S)-1-(2,8-Bis(trifluoromethyl)quinolin-4-yl)-2-(((S)-1-methoxy-3-phenylpropan-2-yl)amino)ethan-1-ol",5.9,uM,=,0.7708520116421442,1,c1ccc(CCNCCc2ccnc3ccccc23)cc1
5053,2171279,10.1021/acs.jmedchem.1c01083,,,,Inhibition of human recombinant CYP3A4 expressed in insect microsome using 7-benzyloxy-4-trifluoromethylcoumarin as a substrate incubated for 30 mins followed by addition of NADPH regenerating system measured immediately by fluorescence based analysis,CCCCCCCCCCCCCCCCCCCCOP(=O)(O)CO[C@H](C)Cn1cnc2c(N)ncnc21.N,Ammonium [(1R)-2-(6-Aminopurin-9-yl)-1-methyl-ethoxyl]methyl-icosoxy-phosphinate,50.0,uM,=,1.6989700043360187,1,c1ncc2nc[nH]c2n1
5054,813105,10.1021/jm201346g,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,Nc1ccc2[nH]c(SCc3ccccn3)nc2c1,2-(pyridin-2-ylmethylthio)-1H-benzo[d]imidazol-5-amine,0.52,uM,=,-0.2839966563652008,0,c1ccc(CSc2nc3ccccc3[nH]2)nc1
5055,1735372,10.1021/acs.jmedchem.8b00084,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis,Cl.Cl.Cl.NCc1ccc(-c2cnccc2-c2cccnc2)o1,"(5-([3,4'-Bipyridin]-3'-yl)furan-2-yl)methanamine Trihydrochloride",90.0,uM,=,1.954242509439325,1,c1cncc(-c2ccncc2-c2ccco2)c1
5056,2023309,10.1021/acs.jmedchem.0c01234,,,,Inhibition of CYP3A4 (unknown origin),COc1ccccc1-c1nccc(COc2ccccc2C[C@@H](Oc2ncnc3sc(-c4ccc(F)cc4)c(-c4ccc(OCCN5CCN(C)CC5)c(Cl)c4C)c23)C(=O)O)n1,"(2R)-2-([(5Sa)-5-(3-Chloro-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy)-3-(2-([2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy)phenyl)propanoic acid",1.8,uM,=,0.255272505103306,1,c1ccc(-c2nccc(COc3ccccc3CCOc3ncnc4sc(-c5ccccc5)c(-c5ccc(OCCN6CCNCC6)cc5)c34)n2)cc1
5057,728151,10.1016/j.bmc.2011.01.017,,,,Inhibition of human CYP3A4,CC(C)NC(=O)c1ccc2cc(C(O)(c3c[nH]cn3)C(C)C)ccc2c1,rac-6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-Nisopropyl-2-naphthamide,9.3,uM,=,0.9684829485539352,1,c1ccc2cc(Cc3c[nH]cn3)ccc2c1
5058,674334,10.1016/j.bmcl.2010.09.038,,,,Inhibition of human CYP3A4,Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O,"9-Methyl-3-(2-methyl-imidazol-1-ylmethyl)-1,2,3,9-tetrahydro-carbazol-4-one (GR 38032F)",11.0,uM,=,1.0413926851582251,1,O=C1c2c([nH]c3ccccc23)CCC1Cn1ccnc1
5059,1866289,10.1021/acs.jmedchem.9b00662,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,O[C@H](C[C@H]1c2c(F)cccc2-c2cncn21)[C@H]1CC[C@H](O)CC1,NAVOXIMOD,5.7,uM,=,0.7558748556724915,1,c1ccc2c(c1)-c1cncn1[C@H]2CCC1CCCCC1
5060,2164321,10.1021/acs.jmedchem.1c01784,,,,Inhibition of human recombinant CYP3A4 expressed in baculosomes by fluorescent homogenous assay,Cc1c(C)c2ccc(OCC3CCN(CCCC(F)F)CC3)cc2oc1=O,"7-((1-(4,4-difluorobutyl)piperidin-4-yl)methoxy)-3,4-dimethyl-2H-chromen-2-one",0.8,uM,=,-0.0969100130080563,0,O=c1ccc2ccc(OCC3CCNCC3)cc2o1
5061,718098,10.1016/j.bmcl.2010.12.053,,,,Inhibition of CYP3A4,C[C@H](C1=C(CCN(C)Cc2ccncc2)Cc2ccccc21)c1cnccn1,(R)-N-methyl-2-(3-(1-(pyrazin-2-yl)ethyl)-1H-inden-2-yl)-N-(pyridin-4-ylmethyl)ethanamine,1.281,uM,=,0.1075491297446862,1,c1ccc2c(c1)CC(CCNCc1ccncc1)=C2Cc1cnccn1
5062,776116,10.1016/j.bmcl.2011.09.074,,,,Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy resorufin,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(Cc1ccccc1)C2=O,"3-(aminomethyl)-6-benzyl-4-(2,4-dichlorophenyl)-2-methyl-5H-pyrrolo[3,4-b]pyridin-7(6H)-one",1.4,uM,=,0.1461280356782379,1,O=C1c2nccc(-c3ccccc3)c2CN1Cc1ccccc1
5063,1735372,10.1021/acs.jmedchem.8b00084,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis,Cl.Cl.NCc1ccc(-c2cnccc2-c2ccoc2)o1,(5-(4-(Furan-3-yl)pyridin-3-yl)furan-2-yl)methanamine Dihydrochloride,24.0,uM,=,1.380211241711606,1,c1coc(-c2cnccc2-c2ccoc2)c1
5064,583696,10.1016/j.bmcl.2009.05.066,,,,Inhibition of human recombinant CYP3A4 after 45 mins,Cc1nccn1CC(NC(=O)NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)c1ccccc1,1-(2-(2-methyl-1H-imidazol-1-yl)-1-phenylethyl)-3-(1-((1-(4-(trifluoromethyl)phenyl)-1H-pyrrol-3-yl)methyl)piperidin-4-yl)urea,2.02,uM,=,0.3053513694466238,1,O=C(NC1CCN(Cc2ccn(-c3ccccc3)c2)CC1)NC(Cn1ccnc1)c1ccccc1
5065,1935950,10.1016/j.bmc.2019.02.025,,,,Inhibition of CYP3A4 (unknown origin),COc1cccc(C(O)(CCN(C)C)C(c2cc3cc(Br)ccc3nc2OC)c2cccc3c2OCO3)n1,"rac-1-(benzo[d][1,3]dioxol-4-yl)-1-(6-bromo-2-methoxyquinolin-3-yl)-4-(dimethylamino)-2-(6-methoxypyridin-2-yl)butan-2-ol",7.6,uM,=,0.8808135922807914,1,c1ccc(CC(c2cnc3ccccc3c2)c2cccc3c2OCO3)nc1
5066,1366633,10.1021/jm500535j,,,,Inhibition of CYP3A4 (unknown origin),Nc1nc2ccc(OC3CCOC3)nc2n1CC(O)c1ccc(C(F)(F)F)cc1Cl,"rac-2-(2-Amino-5-((tetrahydrofuran-3-yl)oxy)-3H-imidazo[4,5-b]-pyridin-3-yl)-1-(2-chloro-4-(trifluoromethyl)phenyl)ethanol",2.4,uM,=,0.380211241711606,1,c1ccc(CCn2cnc3ccc(OC4CCOC4)nc32)cc1
5067,652208,10.1016/j.bmcl.2010.07.052,,,,Inhibition of CYP3A4 in human liver microsomes,O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)n(Cc3cccc(Cl)c3)c3ccccc32)CC1,1-(3-chlorobenzyl)-3-(1-(1-(pyridin-4-ylmethyl)piperidine-4-carbonyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one,0.3,uM,=,-0.5228787452803376,0,O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)n(Cc3ccccc3)c3ccccc32)CC1
5068,2157144,10.1021/acsmedchemlett.1c00473,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by TDI- high-throughput based mass spectrometry method,Cc1c(-c2ccc(N)c(C(=O)N(C)C)c2F)cnc2c1C1(CC1)CN2,"6-Amino-2-fluoro-N,N-dimethyl-3-(4'-methyl-1',2'-dihydrospiro[cyclopropane-1,3'-pyrrolo[2,3-b]pyridin]-5'-yl)benzamide",6.5,uM,=,0.8129133566428556,1,c1ccc(-c2cnc3c(c2)C2(CC2)CN3)cc1
5069,1347924,10.1016/j.bmcl.2014.04.024,,,,Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method,CC(C)C(O)(c1ccc2cc(OCC(F)(F)F)c(OCC(F)(F)F)cc2c1)c1c[nH]nn1,"rac-1-(6,7-bis(2,2,2-trifluoroethoxy)naphthalen-2-yl)-2-methyl-1-(1H-1,2,3-triazol-4-yl)propan-1-ol",25.0,uM,=,1.3979400086720375,1,c1ccc2cc(Cc3c[nH]nn3)ccc2c1
5070,830173,10.1016/j.bmcl.2012.05.074,,,,Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay,CC(C)C[C@@H](NC(=O)N1CCC(n2c(=O)[nH]c3ccccc32)CC1)C(=O)N1CCC(N2CCCCC2)CC1,"(R)-N-(1-(1,4'-bipiperidin-1'-yl)-4-methyl-1-oxopentan-2-yl)-4-(2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-1-carboxamide",16.0,uM,=,1.2041199826559248,1,O=C(CNC(=O)N1CCC(n2c(=O)[nH]c3ccccc32)CC1)N1CCC(N2CCCCC2)CC1
5071,1455473,10.1016/j.bmcl.2014.06.026,,,,Inhibition of recombinant human CYP3A4 preincubated for 5 mins before fluorescent substrate addition by fluorescence assay,Fc1ccc(OC(CC2CNC2)c2ccc(Cl)c(F)c2)cc1,3-(2-(4-chloro-3-fluorophenyl)-2-(4-fluorophenoxy)ethyl)azetidine,0.4,uM,=,-0.3979400086720376,0,c1ccc(OC(CC2CNC2)c2ccccc2)cc1
5072,1729574,10.1021/acsmedchemlett.7b00406,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate,NC/C=C\CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21,"(Z)-N1-(((R)-1,2,3,4-Tetrahydroisoquinolin-3-yl)methyl)-N1-((S)-5,6,7,8-tetrahydroquinolin-8-yl)but-2-ene-1,4-diamine",13.0,uM,=,1.1139433523068367,1,c1ccc2c(c1)CN[C@@H](CN[C@H]1CCCc3cccnc31)C2
5073,1468060,10.1016/j.bmcl.2015.03.035,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as marker substrate,COc1cccc(OC)c1[C@@H]1C[C@H](F)C(=O)N1Cc1ccc(OC(F)(F)F)cc1,"rac-(3S*,5S*)-5-(2,6-dimethoxyphenyl)-3-fluoro-1-(4-(trifluoromethoxy)benzyl)pyrrolidin-2-one",10.0,uM,=,1.0,1,O=C1CC[C@@H](c2ccccc2)N1Cc1ccccc1
5074,1544115,10.1016/j.bmcl.2015.11.013,,,,Inhibition of CYP3A4 (unknown origin),Cc1nc(C)c(CNc2nc(OCCCc3ccc4ccccc4n3)nc(Cl)c2C)s1,"6-chloro-N-((2,4-dimethylthiazol-5-yl)methyl)-5-methyl-2-(3-(quinolin-2-yl)propoxy)pyrimidin-4-amine",0.9,uM,=,-0.0457574905606751,0,c1ccc2nc(CCCOc3nccc(NCc4cncs4)n3)ccc2c1
5075,841307,10.1016/j.bmcl.2012.06.029,,,,Inhibition of CYP3A4,CCN1CCC(Nc2ccc3c(c2)C(=C(c2ccccc2)c2nc4cc(OC)ccc4[nH]2)C(=O)N3)CC1,(E/Z)-5-(1-ethylpiperidin-4-ylamino)-3-((5-methoxy-1H-benzo[d]imidazol-2-yl)(phenyl)methylene)indolin-2-one,5.6,uM,=,0.7481880270062004,1,O=C1Nc2ccc(NC3CCNCC3)cc2C1=C(c1ccccc1)c1nc2ccccc2[nH]1
5076,1522957,10.1016/j.bmcl.2015.04.057,,,,Inhibition of CYP3A4 (unknown origin),COc1cc2nc([C@@H](CNC(=O)c3c(Cl)cc(-n4cnc(C)n4)cc3Cl)c3cccc(F)c3)[nH]c2cc1Cl,"(R)-2,6-dichloro-N-(2-(6-chloro-5-methoxy-1H-benzo[d]imidazol-2-yl)-2-(3-fluorophenyl)ethyl)-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzamide",33.26,uM,=,1.5219222448835004,1,O=C(NC[C@@H](c1ccccc1)c1nc2ccccc2[nH]1)c1ccc(-n2cncn2)cc1
5077,1707938,10.1021/acs.jmedchem.7b01420,,,,Inhibition of CYP3A4 (unknown origin),CC1(C)CCC(NC/C=C/CN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)CC1,"(E)-N1-(4,4-Dimethylcyclohexyl)-N4-(((R)-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)-N4-((S)-5,6,7,8-tetrahydroquinolin-8-yl)-but-2-ene-1,4-diamine",0.99,uM,=,-0.00436480540245,0,C(=C/CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21)\CNC1CCCCC1
5078,716988,10.1016/j.bmcl.2010.12.039,,,,Inhibition of CYP3A4,CCOC(=O)c1oc2cnccc2c1Nc1ccc2c(c1)CC/C2=N/O,"ethyl 3-(1-(hydroxyimino)-2,3-dihydro-1H-inden-5-ylamino)furo[2,3-c]pyridine-2-carboxylate",8.3,uM,=,0.919078092376074,1,N=C1CCc2cc(Nc3coc4cnccc34)ccc21
5079,1735372,10.1021/acs.jmedchem.8b00084,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis,Cl.Cl.NCc1ccc(-c2cnccc2-c2ccco2)o1,(5-(4-(Furan-2-yl)pyridin-3-yl)furan-2-yl)methanamine Dihydrochloride,29.0,uM,=,1.462397997898956,1,c1coc(-c2ccncc2-c2ccco2)c1
5080,2130701,10.1021/acsmedchemlett.1c00334,,,,Inhibition of CYP3A4 (unknown origin) by titration method,Cc1nc2c(cnn2-c2csc(C(=O)NC3COC3)c2)cc1Nc1c(F)cccc1Cl,"4-(5-((2-chloro-6-fluorophenyl)amino)-6-methyl-1H-pyrazolo[3,4-b]pyridin-1-yl)-N-(oxetan-3-yl)thiophene-2-carboxamide",1.7,uM,=,0.2304489213782739,1,O=C(NC1COC1)c1cc(-n2ncc3cc(Nc4ccccc4)cnc32)cs1
5081,740562,10.1016/j.bmcl.2011.01.125,,,,Inhibition of CYP3A4,Cn1c(-c2ccc(-c3cnccn3)cc2Cl)nnc1C1(c2ccc(Cl)cc2)CC(F)C1,"2-(3-chloro-4-(5-(1-(4-chlorophenyl)-3-fluorocyclobutyl)-4-methyl-4H-1,2,4-triazol-3-yl)phenyl)pyrazine",36.0,uM,=,1.5563025007672873,1,c1ccc(C2(c3nnc(-c4ccc(-c5cnccn5)cc4)[nH]3)CCC2)cc1
5082,1794581,10.1016/j.bmcl.2018.07.043,,,,Inhibition of CYP3A4 in human liver microsomes in presence of NADPH and Luciferin BE 50,CCOc1nc(Cl)ccc1C1(N2CCN(c3ccnc(C)c3)CC2)C(=O)N(S(=O)(=O)c2ccc(OC)cn2)c2ccc(C#N)cc21,(+/-)-3-(6-chloro-2-ethoxypyridin-3-yl)-1-(5-methoxypyridin-2-ylsulfonyl)-3-(4-(2-methylpyridin-4-yl)piperazin-1-yl)-2-oxoindoline-5-carbonitrile,1.2,uM,=,0.0791812460476248,1,O=C1N(S(=O)(=O)c2ccccn2)c2ccccc2C1(c1cccnc1)N1CCN(c2ccncc2)CC1
5083,701746,10.1021/ml100190t,,,,Inhibition of CYP3A4 uisng midazolam substrate,Cc1ccc(NC(=O)N2CCC(=Cc3cccc(Oc4ccc(C(F)(F)F)cn4)c3)CC2)cn1,N-(6-Methylpyridin-3-yl)-4-(3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}benzylidene)piperidine-1-carboxamide,11.8,uM,=,1.0718820073061257,1,O=C(Nc1cccnc1)N1CCC(=Cc2cccc(Oc3ccccn3)c2)CC1
5084,1794581,10.1016/j.bmcl.2018.07.043,,,,Inhibition of CYP3A4 in human liver microsomes in presence of NADPH and Luciferin BE 50,CCOc1nc(Cl)ccc1C1(N2CCN(c3ccnc(C)c3)CC2)C(=O)N(S(=O)(=O)c2ccc(OC)cn2)c2ccc(C#N)cc21,(+/-)-3-(6-chloro-2-ethoxypyridin-3-yl)-1-(5-methoxypyridin-2-ylsulfonyl)-3-(4-(2-methylpyridin-4-yl)piperazin-1-yl)-2-oxoindoline-5-carbonitrile,2.0,uM,=,0.3010299956639812,1,O=C1N(S(=O)(=O)c2ccccn2)c2ccccc2C1(c1cccnc1)N1CCN(c2ccncc2)CC1
5085,462442,10.1016/j.bmcl.2008.01.047,,,,Inhibition of CYP3A4,CC(C1CC1)n1c(CNC(=O)[C@@H](Cc2ccccc2C(F)(F)F)NC(=O)OC(C)(C)C)nc2cccnc21,"tert-butyl (R)-1-((3-(1-cyclopropylethyl)-3H-imidazo[4,5-b]pyridin-2-yl)methylamino)-1-oxo-3-(2-(trifluoromethyl)phenyl)propan-2-ylcarbamate",0.86,uM,=,-0.0655015487564322,0,O=C(CCc1ccccc1)NCc1nc2cccnc2n1CC1CC1
5086,643969,10.1016/j.bmcl.2010.06.086,,,,Inhibition of human CYP3A4-mediated midazolam oxidation,C[C@@H](c1ccc(Cl)cc1)N1Cc2cncn2C(C[C@@H](O)c2ccccc2)S1(=O)=O,"(R)-2-{6-[(S)-1-(4-Chloro-phenyl)-ethyl]-5,5-dioxo-4,5,6,7-tetrahydro-5lambda*6*-thia-2,3a,6-triaza-inden-4-yl}-1-phenyl-ethanol",0.1,uM,=,-1.0,0,O=S1(=O)C(CCc2ccccc2)n2cncc2CN1Cc1ccccc1
5087,462442,10.1016/j.bmcl.2008.01.047,,,,Inhibition of CYP3A4,CC(C)(C)OC(=O)N[C@H](Cc1cccc(F)c1C(F)(F)F)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1,"(R)-tert-butyl 3-(3-fluoro-2-(trifluoromethyl)phenyl)-1-oxo-1-((3-(1-phenylcyclopropyl)-3H-imidazo[4,5-b]pyridin-2-yl)methylamino)propan-2-ylcarbamate",0.81,uM,=,-0.0915149811213502,0,O=C(CCc1ccccc1)NCc1nc2cccnc2n1C1(c2ccccc2)CC1
5088,1527906,,,,,Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,C[C@@H](c1ccc(Br)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O,"US8575157, 203::US8592410, Comparator 15::US8598163, 73",3.1,uM,=,0.4913616938342727,1,O=C1OC(c2ccccc2)CCN1Cc1ccccc1
5089,841307,10.1016/j.bmcl.2012.06.029,,,,Inhibition of CYP3A4,CCN1CCC(Nc2ccc3c(c2)C(=C(c2nc(C)c[nH]2)c2ccccc2F)C(=O)N3)CC1,(E/Z)-5-(1-ethylpiperidin-4-ylamino)-3-((2-fluorophenyl)(4-methyl-1H-imidazol-2-yl)methylene)indolin-2-one,26.0,uM,=,1.414973347970818,1,O=C1Nc2ccc(NC3CCNCC3)cc2C1=C(c1ccccc1)c1ncc[nH]1
5090,741042,10.1016/j.bmcl.2011.02.067,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCCCNS(C)(=O)=O)c1,"(3R,4S)-N-cyclopropyl-4-(4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)phenyl)-N-(3-(3-methoxypropyl)-5-(3-(methylsulfonamido)propoxy)benzyl)piperidine-3-carboxamide",27.6,uM,=,1.4409090820652175,1,O=C([C@H]1CNCC[C@@H]1c1ccc(OCCOc2ccccc2)cc1)N(Cc1ccccc1)C1CC1
5091,538002,10.1021/jm8006917,,,,Inhibition of human hepatic CYP3A4,Oc1ccc(-c2cc(-c3cccc(O)c3)cs2)cc1,3-[5-(4-Hydroxyphenyl)-3-thienyl]phenol,1.9,uM,=,0.2787536009528289,1,c1ccc(-c2csc(-c3ccccc3)c2)cc1
5092,789986,10.1016/j.bmcl.2011.10.013,,,,Reversible inhibition of CYP3A4,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@]2(O)c2ccccc2)C2CC2)cc(OCCOC)c1,"rac-(3S,4R)-N-cyclopropyl-4-hydroxy-N-(3-(2-methoxyethoxy)-5-(3-methoxypropyl)benzyl)-4-phenylpiperidine-3-carboxamide",2.6,uM,=,0.414973347970818,1,O=C([C@H]1CNCCC1c1ccccc1)N(Cc1ccccc1)C1CC1
5093,1903445,10.1021/acs.jmedchem.9b01713,,,,Inhibition of human liver microsome CYP3A4 using midazolam as substrate incubated for 5 to 20 mins by LC-MS/MS analysis,Nc1nn(-c2ccc3cn[nH]c3c2)c2cc(-c3ccnn3Cc3ccc(Cl)cc3Cl)cnc12,"6-(1-(2,4-Dichlorobenzyl)-1H-pyrazol-5-yl)-1-(1H-indazol-6-yl)-1H-pyrazolo[4,3-b]pyridin-3-amine",4.2,uM,=,0.6232492903979004,1,c1ccc(Cn2nccc2-c2cnc3cnn(-c4ccc5cn[nH]c5c4)c3c2)cc1
5094,789986,10.1016/j.bmcl.2011.10.013,,,,Reversible inhibition of CYP3A4,O=C([C@H]1CNCC[C@@]12OCc1cc(F)c(F)cc12)N(Cc1cccc2cccnc12)C1CC1,"(1R,3'S)-N-cyclopropyl-5,6-difluoro-N-(quinolin-8-ylmethyl)-3H-spiro[isobenzofuran-1,4'-piperidine]-3'-carboxamide",8.9,uM,=,0.9493900066449128,1,O=C([C@H]1CNCC[C@@]12OCc1ccccc12)N(Cc1cccc2cccnc12)C1CC1
5095,51920,10.1016/j.bmcl.2003.08.027,,,,Inhibition of Cytochrome P450 3A4 with testosterone,CCOC(=O)CCCn1c(=O)nc2n(CCCCOC(=O)C[C@@H]3CC4C5CC[C@H](O)C5CCC4[C@@]4(C)CCC(=O)C=C34)c3ccccc3cc-2c1=O,"4-(10-{4-[2-((6S,10R,17S)-17-Hydroxy-10-methyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-6-yl)-acetoxy]-butyl}-2,4-dioxo-4,10-dihydro-2H-pyrimido[4,5-b]quinolin-3-yl)-butyric acid ethyl ester",2.5,uM,=,0.3979400086720376,1,O=C1C=C2C(CC1)C1CCC3CCCC3C1C[C@H]2CC(=O)OCCCCn1c2nc(=O)[nH]c(=O)c-2cc2ccccc21
5096,510060,10.1016/j.bmcl.2008.07.059,,,,Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay,CN[C@@H](Cn1c(=O)c(-c2cccc(OCCCNCC(=O)O)c2F)c(C)n(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1,"(R)-2-(3-(3-(1-(2-fluoro-6-(trifluoromethyl)benzyl)-6-methyl-3-(2-(methylamino)-2-phenylethyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-2-fluorophenoxy)propylamino)acetic acid",33.0,uM,=,1.5185139398778875,1,O=c1c(-c2ccccc2)cn(Cc2ccccc2)c(=O)n1CCc1ccccc1
5097,595637,10.1016/j.bmcl.2009.09.096,,,,Inhibition of human CYP3A4,COc1ccc2c(O[C@@H](C)c3nnc4ccc(-c5ccccc5)nn34)ccnc2c1,"(S)-7-methoxy-4-(1-(6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)ethoxy)quinoline",14.0,uM,=,1.146128035678238,1,c1ccc(-c2ccc3nnc(COc4ccnc5ccccc45)n3n2)cc1
5098,830173,10.1016/j.bmcl.2012.05.074,,,,Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay,O=C(N[C@H](Cc1csc2ccccc12)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1,"(R)-N-(1-(1,4'-bipiperidin-1'-yl)-3-(benzo[b]thiophen-3-yl)-1-oxopropan-2-yl)-4-(2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-1-carboxamide",0.084,uM,=,-1.0757207139381184,0,O=C(N[C@H](Cc1csc2ccccc12)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1
5099,1366633,10.1021/jm500535j,,,,Inhibition of CYP3A4 (unknown origin),CN1CCN(c2ccc3nc(N)n(CC(O)c4ccc(C(F)(F)F)cc4Cl)c3n2)CC1,"rac-2-(2-Amino-5-(4-methylpiperazin-1-yl)-3H-imidazo[4,5-b]-pyridin-3-yl)-1-(2-chloro-4-(trifluoromethyl)phenyl)ethan-1-ol",14.1,uM,=,1.14921911265538,1,c1ccc(CCn2cnc3ccc(N4CCNCC4)nc32)cc1
5100,2193505,10.1016/j.bmcl.2022.128892,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 30 mins,CNC(=O)N(c1ccc(S(=O)(=O)Nc2ccon2)cn1)c1cc(Cl)c(-c2cccc(C(F)(F)F)c2)cc1OC,"6-(1-(2-chloro-5-methoxy-3'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)-3-methylureido)-N-(isoxazol-3-yl)pyridine-3-sulfonamide",5.0,uM,=,0.6989700043360189,1,O=S(=O)(Nc1ccon1)c1ccc(Nc2ccc(-c3ccccc3)cc2)nc1
5101,583696,10.1016/j.bmcl.2009.05.066,,,,Inhibition of human recombinant CYP3A4 after 45 mins,Cc1cc(C)n(CC(NC(=O)NC2CCN(Cc3ccn(-c4ccc(C(F)(F)F)cc4)c3)CC2)c2ccccc2)n1,"1-(2-(3,5-dimethyl-1H-pyrazol-1-yl)-1-phenylethyl)-3-(1-((1-(4-(trifluoromethyl)phenyl)-1H-pyrrol-3-yl)methyl)piperidin-4-yl)urea",0.79,uM,=,-0.1023729087095585,0,O=C(NC1CCN(Cc2ccn(-c3ccccc3)c2)CC1)NC(Cn1cccn1)c1ccccc1
5102,2052438,10.1021/acs.jmedchem.9b00062,,,,Inhibition of human recombinant CYP3A4,CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,SID144204227,0.24,uM,=,-0.619788758288394,0,c1ccc([C@@]2(Cn3ccnc3)OC[C@H](COc3ccc(N4CCNCC4)cc3)O2)cc1
5103,949160,10.1016/j.bmcl.2013.01.011,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate,Cc1cc(C[C@@H](NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2nn[nH]c12,"(R)-N-(1-(1,4'-bipiperidin-1'-yl)-3-(7-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide",7.3,uM,=,0.8633228601204559,1,O=C(N[C@H](Cc1ccc2[nH]nnc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
5104,740562,10.1016/j.bmcl.2011.01.125,,,,Inhibition of CYP3A4,Cn1c(-c2ccc(-c3cnccn3)cc2)nnc1C1(c2ccc(Cl)cc2)CCC1,"2-(4-(5-(1-(4-chlorophenyl)cyclobutyl)-4-methyl-4H-1,2,4-triazol-3-yl)phenyl)pyrazine",10.0,uM,=,1.0,1,c1ccc(C2(c3nnc(-c4ccc(-c5cnccn5)cc4)[nH]3)CCC2)cc1
5105,1512777,10.1016/j.bmcl.2015.07.038,,,,Inhibition of CYP3A4 in human liver microsomes assessed as reduction in testosterone 6beta-hydroxylation by LC-MS/MS method,COc1cccc2nc(CCCN(C)CC[C@]3(OC(=O)C(C)C)C[C@H]4CCC[C@@H]3c3ccccc34)[nH]c12,"Isobutyric acid (1R,8R,12R)-12-(2-{[3-(4-methoxy-1H-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)-tricyclo[6.3.2.02,7]trideca-2,4,6-trien-12-yl ester",5.5,uM,=,0.7403626894942439,1,c1ccc2c(c1)[C@@H]1CCC[C@H]2C(CCNCCCc2nc3ccccc3[nH]2)C1
5106,718343,10.1021/jm101063h,,,,Inhibition of CYP3A4,COC(=O)c1ccc(Oc2ccc(/C=C3\SC(=O)NC3=O)cc2OC)c(C(F)(F)F)c1,"4-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)-2-methoxyphenoxy]-3-trifluoromethylbenzoic Acid Methyl Ester",9.8,uM,=,0.9912260756924948,1,O=C1NC(=O)/C(=C/c2ccc(Oc3ccccc3)cc2)S1
5107,950952,10.1016/j.bmcl.2013.02.023,,,,Inhibition of human CYP3A4,COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1nc(Br)c(-c2ccc(N=[N+]=[N-])cc2)[nH]1)C(C)C,methyl(S)-1-((S)-2-(5-(4-azidophenyl)-4-bromo-1H-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-ylcarbamate,1.5,uM,=,0.1760912590556812,1,c1ccc(-c2cnc([C@@H]3CCCN3)[nH]2)cc1
5108,643712,10.1016/j.bmcl.2010.06.009,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader,CCN1CCN(CCCn2cc(-c3ccc4c(c3)ncn4-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)cn2)CC1,(R)-3-(1-(2-chlorophenyl)ethoxy)-5-(5-(1-(3-(4-ethylpiperazin-1-yl)propyl)-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)thiophene-2-carboxamide,1.0,uM,=,0.0,0,c1ccc(COc2csc(-n3cnc4cc(-c5cnn(CCCN6CCNCC6)c5)ccc43)c2)cc1
5109,802875,10.1016/j.bmcl.2011.12.127,,,,Inhibition of human CYP3A4 using midazolam as substrate by LC-MS/MS analysis,CCCOc1sc(C(=O)N2CCC(c3cccc(CN)c3)CC2)c(C)c1Br,(4-(3-(aminomethyl)phenyl)piperidin-1-yl)(4-bromo-3-methyl-5-propoxythiophen-2-yl)methanone,4.7,uM,=,0.6720978579357175,1,O=C(c1cccs1)N1CCC(c2ccccc2)CC1
5110,2241411,10.1016/j.ejmech.2021.113981,,,,Inhibition of CYP3A4 in human liver microsomes assessed as reduction in 1'-hydroxy midazolam formation using midazolam as substrate preincubated for 20 mins in absence of NADPH followed by incubation with substrate for 10 mins by LC-MS/MS analysis,COC[C@H](Cc1ccccc1)NC[C@@H](O)c1cc(C(F)(F)F)nc2c(C(F)(F)F)cccc12,"(S)-1-(2,8-Bis(trifluoromethyl)quinolin-4-yl)-2-(((S)-1-methoxy-3-phenylpropan-2-yl)amino)ethan-1-ol",2.8,uM,=,0.4471580313422192,1,c1ccc(CCNCCc2ccnc3ccccc23)cc1
5111,1847823,10.1016/j.ejmech.2019.03.037,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins after substrate addition by HPLC analysis,CC[C@H]1OC(=O)[C@H](C)[C@@H](OC(=O)NCCCc2cccnc2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)/C(=N\OC)[C@H](C)[C@H]2OC(=O)O[C@@]21C,"3-O-Descladinosyl-3-O-[N-(3'-(3''-pyridyl)propyl)carbamoyl]-6-O-methylerythromycin A 9-O-methyl oxime-11,12-cyclic carbonate",2.5,uM,=,0.3979400086720376,1,N=C1CCC[C@H](O[C@H]2CCCCO2)C[C@H](OC(=O)NCCCc2cccnc2)CC(=O)OCC2OC(=O)O[C@@H]2C1
5112,2164321,10.1021/acs.jmedchem.1c01784,,,,Inhibition of human recombinant CYP3A4 expressed in baculosomes by fluorescent homogenous assay,CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,SID144204227,0.025,uM,=,-1.6020599913279625,0,c1ccc([C@@]2(Cn3ccnc3)OC[C@H](COc3ccc(N4CCNCC4)cc3)O2)cc1
5113,718343,10.1021/jm101063h,,,,Inhibition of CYP3A4,COC(=O)c1ccc(Oc2ccc(/C=C3\SC(=O)NC3=O)cc2OC)c(Cl)c1,"4-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)-2-methoxyphenoxy]-3-chlorobenzoic Acid Methyl Ester",2.5,uM,=,0.3979400086720376,1,O=C1NC(=O)/C(=C/c2ccc(Oc3ccccc3)cc2)S1
5114,1866289,10.1021/acs.jmedchem.9b00662,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,O=C(N[C@H]1CC[C@H](C(O)CC2c3ccccc3-c3cncn32)CC1)c1ccccc1,"N-((trans)-4-(1-Hydroxy-2-(5H-imidazo[5,1-a]isoindol-5-yl)-ethyl)cyclohexyl)benzamide",1.2,uM,=,0.0791812460476248,1,O=C(N[C@H]1CC[C@H](CCC2c3ccccc3-c3cncn32)CC1)c1ccccc1
5115,1468060,10.1016/j.bmcl.2015.03.035,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as marker substrate,COc1cccc(OC)c1[C@@H]1C[C@H](F)C(=O)N1Cc1ccc2oc3ccccc3c2c1,"rac-(3S*,5S*)-1-(dibenzo[b,d]furan-2-ylmethyl)-5-(2,6-dimethoxyphenyl)-3-fluoropyrrolidin-2-one",8.8,uM,=,0.9444826721501688,1,O=C1CC[C@@H](c2ccccc2)N1Cc1ccc2oc3ccccc3c2c1
5116,1659863,10.1016/j.ejmech.2017.02.016,,,,Inhibition of human liver CYP3A4 expressed in Saccharomyces cerevisiae YY7 microsomal membranes using DBF as substrate after 10 mins by fluorescence assay,COc1ccc(C(=O)/C=C/c2cccnc2)c(OC)c1,"1-(2,4-dimethoxyphenyl)-3-(pyridin-3-yl)prop-2-en-1-one",11.0,uM,=,1.0413926851582251,1,O=C(/C=C/c1cccnc1)c1ccccc1
5117,813105,10.1021/jm201346g,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,COc1ccc2[nH]c(SCc3ccc(C(C)(C)C)cc3)nc2c1,2-(4-tert-butylbenzylthio)-5-methoxy-1H-benzo[d]imidazole,12.3,uM,=,1.089905111439398,1,c1ccc(CSc2nc3ccccc3[nH]2)cc1
5118,880247,10.1021/jm101459g,,,,Inhibition of human recombinant CYP3A4 using resorufin benzyl ether after 30 mins by fluorescence spectrophotometric analysis,Cc1cccc(Sc2ccccc2N2CCNCC2)c1C.Cl,"1-[2-(2,3-Dimethyl-phenylsulfanyl)-phenyl]-piperazine Hydrochloride",8.7,uM,=,0.9395192526186184,1,c1ccc(Sc2ccccc2N2CCNCC2)cc1
5119,2171279,10.1021/acs.jmedchem.1c01083,,,,Inhibition of human recombinant CYP3A4 expressed in insect microsome using 7-benzyloxy-4-trifluoromethylcoumarin as a substrate incubated for 30 mins followed by addition of NADPH regenerating system measured immediately by fluorescence based analysis,C#CCCCCCCCCCCCCCOP(=O)(O)CO[C@H](C)Cn1cnc2c(N)ncnc21.N,Ammonium Pentadec-14-yn-1-yl-(R)-(((1-(6-Amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)phosphonate,54.8,uM,=,1.7387805584843692,1,c1ncc2nc[nH]c2n1
5120,813105,10.1021/jm201346g,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,COc1ccc2nc(SCc3ccc4ccccc4c3)[nH]c2c1,6-methoxy-2-(naphthalen-2-ylmethylthio)-1H-benzo[d]imidazole,3.11,uM,=,0.4927603890268375,1,c1ccc2cc(CSc3nc4ccccc4[nH]3)ccc2c1
5121,2193505,10.1016/j.bmcl.2022.128892,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 30 mins,CNC(=O)N(c1ccc(S(=O)(=O)Nc2ccon2)cn1)c1cc(Cl)c(-c2cccc(OCC(F)(F)F)c2)cc1OC,"6-(1-(2-chloro-5-methoxy-3'-(2,2,2-trifluoroethoxy)-[1,1'-biphenyl]-4-yl)-3-methylureido)-N-(isoxazol-3-yl)pyridine-3-sulfonamide",35.0,uM,=,1.5440680443502757,1,O=S(=O)(Nc1ccon1)c1ccc(Nc2ccc(-c3ccccc3)cc2)nc1
5122,1729574,10.1021/acsmedchemlett.7b00406,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate,NCC1=C(CN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)CCCC1,"(S)-N-((2-(aminomethyl)cyclohex-1-enyl)methyl)-N-(((R)-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)-5,6,7,8-tetrahydroquinolin-8-amine",11.0,uM,=,1.0413926851582251,1,C1=C(CN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)CCCC1
5123,583696,10.1016/j.bmcl.2009.05.066,,,,Inhibition of human recombinant CYP3A4 after 45 mins,O=C(NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)NC(Cc1cnccn1)c1ccccc1,1-(1-phenyl-2-(pyrazin-2-yl)ethyl)-3-(1-((1-(4-(trifluoromethyl)phenyl)-1H-pyrrol-3-yl)methyl)piperidin-4-yl)urea,3.22,uM,=,0.5078558716958309,1,O=C(NC1CCN(Cc2ccn(-c3ccccc3)c2)CC1)NC(Cc1cnccn1)c1ccccc1
5124,595637,10.1016/j.bmcl.2009.09.096,,,,Inhibition of human CYP3A4,COc1ccc2c(OCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1,"7-methoxy-4-((6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy)quinoline",32.0,uM,=,1.505149978319906,1,c1ccc(-c2ccc3nnc(COc4ccnc5ccccc45)n3n2)cc1
5125,1628094,10.1016/j.ejmech.2016.08.024,,,,Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells using fluorescent substrate,CC(=O)N1CCN(C(=O)CC2([C@H]3COC[C@@H](C4CC4)N3S(=O)(=O)c3ccc(F)cc3)CC2)CC1,"1-(4-acetylpiperazin-1-yl)-2-(1-((3S,5R)-5-cyclopropyl-4-(4-fluorophenylsulfonyl)morpholin-3-yl)cyclopropyl)ethanone",30.0,uM,=,1.4771212547196624,1,O=C(CC1([C@H]2COC[C@@H](C3CC3)N2S(=O)(=O)c2ccccc2)CC1)N1CCNCC1
5126,643970,10.1016/j.bmcl.2010.06.086,,,,Inhibition of human CYP3A4-mediated testosterone oxidation,CC(C)CC1n2cncc2CN(Cc2ccc(C(F)(F)F)cc2)S1(=O)=O,"rac-4-Isobutyl-6-(4-trifluoromethyl-benzyl)-6,7-dihydro-5-thia-2,3a,6-triaza-indene 5,5-dioxide",0.28,uM,=,-0.5528419686577808,0,O=S1(=O)Cn2cncc2CN1Cc1ccccc1
5127,52068,10.1021/jm0201924,,,,Inhibition of Cytochrome P450 3A4 as BQ substrate,CC(C)C[C@H](C=O)NC(=O)[C@@H](NS(=O)(=O)c1ccc(F)cc1)C(C)C,2-(4-Fluoro-benzenesulfonylamino)-N-(1-formyl-3-methyl-butyl)-3-methyl-butyramide,531.0,uM,=,2.725094521081469,1,c1ccccc1
5128,2134699,10.1021/acs.jmedchem.1c01121,,,,Inhibition of CYP3A4 (unknown origin),C=CCn1c(=O)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc2n1-c1ccc2c(n1)C(O)(CC)CC2,"Rac-2-allyl-1-(7-ethyl-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-2-yl)-6-(4-(4-methylpiperazin-1-yl)phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one",7.0,uM,=,0.8450980400142568,1,O=c1[nH]n(-c2ccc3c(n2)CCC3)c2nc(Nc3ccc(N4CCNCC4)cc3)ncc12
5129,2241758,10.1016/j.ejmech.2021.113983,,,,Inhibition of CYP3A4 (unknown origin),CNC(=O)[C@@]12C[C@@H]1[C@@H](n1cnc3c(NCCc4ccc(OC)c(OC)c4)nc(C#Cc4ccc(Cl)s4)nc31)[C@H](O)[C@@H]2O,"(1S,2R,3S,4R,5S)-4-[2-[2-(5-chloro-2-thienyl)ethynyl]-6-[2-(3,4-dimethoxyphenyl)ethylamino]purin-9-yl]-2,3-dihydroxy-N-methyl-bicyclo[3.1.0]hexane-1-carboxamide",0.78,uM,=,-0.1079053973095195,0,C(#Cc1cccs1)c1nc(NCCc2ccccc2)c2ncn([C@H]3CCC4C[C@@H]43)c2n1
5130,789986,10.1016/j.bmcl.2011.10.013,,,,Reversible inhibition of CYP3A4,O=C([C@H]1CNCC[C@@]12OCc1cc(F)c(F)cc12)N(Cc1ccnc2ccccc12)C1CC1,"(1R,3'S)-N-cyclopropyl-5,6-difluoro-N-(quinolin-4-ylmethyl)-3H-spiro[isobenzofuran-1,4'-piperidine]-3'-carboxamide",31.0,uM,=,1.4913616938342726,1,O=C([C@H]1CNCC[C@@]12OCc1ccccc12)N(Cc1ccnc2ccccc12)C1CC1
5131,1903445,10.1021/acs.jmedchem.9b01713,,,,Inhibition of human liver microsome CYP3A4 using midazolam as substrate incubated for 5 to 20 mins by LC-MS/MS analysis,Clc1ccc(Cn2nccc2-c2cc(Cl)c3nnn(-c4ccc5cn[nH]c5c4)c3c2)nc1,"4-Chloro-6-(1-((5-chloropyridin-2-yl)methyl)-1H-pyrazol-5-yl)-1-(1H-indazol-6-yl)-1H-benzo[d][1,2,3]triazole",35.5,uM,=,1.5502283530550942,1,c1ccc(Cn2nccc2-c2ccc3nnn(-c4ccc5cn[nH]c5c4)c3c2)nc1
5132,606336,10.1016/j.bmcl.2009.11.061,,,,Inhibition of CYP3A4,Cc1occc1-c1nc(N)c(OC[C@@H](N)Cc2c(C(N)=O)[nH]c3ccccc23)cc1-c1cnc2[nH]nc(C)c2n1,"3-((2S)-2-amino-3-(2-amino-5-(3-methyl-1H-pyrazolo[4,3-b]pyrazin-5-yl)-6-(2-methylfuran-3-yl)pyridin-3-yloxy)propyl)-1H-indole-2-carboxamide",4.0,uM,=,0.6020599913279624,1,c1ccc2c(CCCOc3cnc(-c4ccoc4)c(-c4cnc5[nH]ncc5n4)c3)c[nH]c2c1
5133,462442,10.1016/j.bmcl.2008.01.047,,,,Inhibition of CYP3A4,CC(C)(C)OC(=O)N[C@H](Cc1cccc(Cl)c1)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1,"(R)-tert-butyl 3-(3-chlorophenyl)-1-oxo-1-((3-(1-phenylcyclopropyl)-3H-imidazo[4,5-b]pyridin-2-yl)methylamino)propan-2-ylcarbamate",2.4,uM,=,0.380211241711606,1,O=C(CCc1ccccc1)NCc1nc2cccnc2n1C1(c2ccccc2)CC1
5134,2221810,10.1016/j.bmcl.2022.128625,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as substrate pretreated with NADPH,CCC[C@H]1N(C(=O)c2cnccc2C(F)(F)F)CCC[C@@]1(Oc1csc(C(F)(F)F)c1)C(=O)N1CCN(c2ccccc2OC)CC1,"(4-(2-methoxyphenyl)piperazin-1-yl)((2R,3S)-2-propyl-1-(4-(trifluoromethyl)nicotinoyl)-3-(5-(trifluoromethyl)thiophen-3-yloxy)piperidin-3-yl)methanone",0.3,uM,=,-0.5228787452803376,0,O=C(c1cccnc1)N1CCC[C@@](Oc2ccsc2)(C(=O)N2CCN(c3ccccc3)CC2)C1
5135,813105,10.1021/jm201346g,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,COc1ccc2[nH]c(SCc3ccc(Br)cc3)nc2c1,2-(4-bromobenzylthio)-5-methoxy-1H-benzo[d]imidazole,4.23,uM,=,0.6263403673750424,1,c1ccc(CSc2nc3ccccc3[nH]2)cc1
5136,789986,10.1016/j.bmcl.2011.10.013,,,,Reversible inhibition of CYP3A4,O=C([C@H]1CNCC[C@@]12OCc1cc(F)c(F)cc12)N(Cc1cccc(Cl)c1Cl)C1CC1,"(1R,3'S)-N-cyclopropyl-N-(2,3-dichlorobenzyl)-5,6-difluoro-3H-spiro[isobenzofuran-1,4'-piperidine]-3'-carboxamide",5.6,uM,=,0.7481880270062004,1,O=C([C@H]1CNCC[C@@]12OCc1ccccc12)N(Cc1ccccc1)C1CC1
5137,699595,10.1016/j.bmcl.2010.11.001,,,,Inhibition of human CYP3A4,CN1CCN(c2cn(S(=O)(=O)c3ccc(F)cc3)c3ccccc23)CC1,1-(4-Fluorobenzenesulfonyl)-3-(4-methylpiperazin-1-yl)-1H-indole,4.77,uM,=,0.6785183790401139,1,O=S(=O)(c1ccccc1)n1cc(N2CCNCC2)c2ccccc21
5138,1735372,10.1021/acs.jmedchem.8b00084,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis,Cl.Cl.NCc1ccc(-c2cnccc2-c2ccccc2)o1,(5-(4-Phenylpyridin-3-yl)furan-2-yl)methanamine Dihydrochloride,5.2,uM,=,0.7160033436347992,1,c1ccc(-c2ccncc2-c2ccco2)cc1
5139,830173,10.1016/j.bmcl.2012.05.074,,,,Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay,O=C(N[C@H](Cc1ccc(-c2ccccc2)cc1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1,"(R)-N-(1-(1,4'-bipiperidin-1'-yl)-3-(biphenyl-4-yl)-1-oxopropan-2-yl)-4-(2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-1-carboxamide",1.3,uM,=,0.1139433523068367,1,O=C(N[C@H](Cc1ccc(-c2ccccc2)cc1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1
5140,2171279,10.1021/acs.jmedchem.1c01083,,,,Inhibition of human recombinant CYP3A4 expressed in insect microsome using 7-benzyloxy-4-trifluoromethylcoumarin as a substrate incubated for 30 mins followed by addition of NADPH regenerating system measured immediately by fluorescence based analysis,CCCCCCCCCCCCCCCCCCOP(=O)(O)CO[C@H](C)Cn1cnc2c(N)ncnc21.N,Ammonium [(1R)-2-(6-Aminopurin-9-yl)-1-methyl-ethoxy]methyl-octadecoxy-phosphinate,52.9,uM,=,1.7234556720351857,1,c1ncc2nc[nH]c2n1
5141,1659863,10.1016/j.ejmech.2017.02.016,,,,Inhibition of human liver CYP3A4 expressed in Saccharomyces cerevisiae YY7 microsomal membranes using DBF as substrate after 10 mins by fluorescence assay,COc1ccc(/C=C/C(=O)c2cccnc2)c(OC)c1OC,"1-(pyridin-3-yl)-3-(2,3,4-trimethoxyphenyl)prop-2-en-1-one",11.8,uM,=,1.0718820073061257,1,O=C(/C=C/c1ccccc1)c1cccnc1
5142,1913292,10.1021/acs.jmedchem.9b01032,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH by LC-MS/MS analysis,CN(Cc1cccc(F)c1CNc1cc(F)c(S(=O)(=O)Nc2cscn2)c(F)c1)C(C)(C)C,"4-((2-((tert-Butyl(methyl)amino)methyl)-6-fluorobenzyl)amino)-2,6-difluoro-N-(thiazol-4-yl)benzenesulfonamide",50.0,uM,=,1.6989700043360187,1,O=S(=O)(Nc1cscn1)c1ccc(NCc2ccccc2)cc1
5143,1707938,10.1021/acs.jmedchem.7b01420,,,,Inhibition of CYP3A4 (unknown origin),c1ccc2c(c1)CN[C@@H](CN(Cc1ccc(CNCc3ccncc3)cc1)[C@H]1CCCc3cccnc31)C2,"(S)-N-(4-(((Pyridin-4-ylmethyl)amino)methyl)benzyl)-N-(((R)-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)-5,6,7,8-tetrahydroquinolin-8-amine",0.059,uM,=,-1.2291479883578558,0,c1ccc2c(c1)CN[C@@H](CN(Cc1ccc(CNCc3ccncc3)cc1)[C@H]1CCCc3cccnc31)C2
5144,789986,10.1016/j.bmcl.2011.10.013,,,,Reversible inhibition of CYP3A4,O=C([C@H]1CNCC[C@@]12OCc1cc(F)c(F)cc12)N(Cc1ccc(Cl)cc1Cl)C1CC1,"(1R,3'S)-N-cyclopropyl-N-(2,4-dichlorobenzyl)-5,6-difluoro-3H-spiro[isobenzofuran-1,4'-piperidine]-3'-carboxamide",1.9,uM,=,0.2787536009528289,1,O=C([C@H]1CNCC[C@@]12OCc1ccccc12)N(Cc1ccccc1)C1CC1
5145,51901,10.1016/s0960-894x(02)00026-4,,,,Inhibition of cytochrome P450 3A4 enzyme,Cc1cc(C)cc(-c2[nH]c3ccc(C(C)(C)C(=O)N4C5CCC4CC5)cc3c2[C@H](C)CNCCc2ccc3[nH]c(C)nc3c2)c1,"1-(7-Aza-bicyclo[2.2.1]hept-7-yl)-2-(2-(3,5-dimethyl-phenyl)-3-{(S)-1-methyl-2-[2-(2-methyl-1H-benzoimidazol-5-yl)-ethylamino]-ethyl}-1H-indol-5-yl)-2-methyl-propan-1-one",5.0,uM,=,0.6989700043360189,1,O=C(Cc1ccc2[nH]c(-c3ccccc3)c(CCNCCc3ccc4[nH]cnc4c3)c2c1)N1C2CCC1CC2
5146,1707938,10.1021/acs.jmedchem.7b01420,,,,Inhibition of CYP3A4 (unknown origin),FC1(F)CCC(CNCCCCN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)CC1,"N1-((4,4-Difluorocyclohexyl)methyl)-N4-(((R)-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)-N4-((S)-5,6,7,8-tetrahydroquinolin-8-yl)-butane-1,4-diamine",19.2,uM,=,1.2833012287035497,1,c1ccc2c(c1)CN[C@@H](CN(CCCCNCC1CCCCC1)[C@H]1CCCc3cccnc31)C2
5147,51901,10.1016/s0960-894x(02)00026-4,,,,Inhibition of cytochrome P450 3A4 enzyme,Cc1cc(C)cc(-c2[nH]c3ccc(C(C)(C)C(=O)N4CC5CCC4CC5)cc3c2[C@H](C)CNCCc2ccc3[nH]cnc3c2)c1,"1-(2-Aza-bicyclo[2.2.2]oct-2-yl)-2-[3-{(S)-2-[2-(1H-benzoimidazol-5-yl)-ethylamino]-1-methyl-ethyl}-2-(3,5-dimethyl-phenyl)-1H-indol-5-yl]-2-methyl-propan-1-one",0.1,uM,=,-1.0,0,O=C(Cc1ccc2[nH]c(-c3ccccc3)c(CCNCCc3ccc4[nH]cnc4c3)c2c1)N1CC2CCC1CC2
5148,1813602,10.1021/acs.jmedchem.9b00326,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,COc1ccc2nc3cc(Cl)ccc3c(Nc3ccc(O)c(CN4CCN(C)CC4)c3)c2c1,4-(6-chloro-2-methoxyacridin-9-ylamino)-2-((4-methylpiperazin-1-yl)methyl)phenol,1.0,uM,=,0.0,0,c1cc(CN2CCNCC2)cc(Nc2c3ccccc3nc3ccccc23)c1
5149,1628093,10.1016/j.ejmech.2016.08.024,,,,Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells preincubated for 30 mins using fluorescent substrate,CC(=O)N1C2CCC1CN(C(=O)CC1([C@H]3COC[C@@H](C4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC1)C2,"1-(8-acetyl-3,8-diazabicyclo[3.2.1]octan-3-yl)-2-(1-((3S,5R)-4-(4-chlorophenylsulfonyl)-5-cyclopropylmorpholin-3-yl)cyclopropyl)ethanone",4.3,uM,=,0.6334684555795865,1,O=C(CC1([C@H]2COC[C@@H](C3CC3)N2S(=O)(=O)c2ccccc2)CC1)N1CC2CCC(C1)N2
5150,643712,10.1016/j.bmcl.2010.06.009,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader,C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(N5CCN(C)CC5)c4)ccc32)sc1C(N)=O)c1ccccc1C(F)(F)F,(R)-5-(5-(2-(4-methylpiperazin-1-yl)pyridin-4-yl)-1H-benzo[d]imidazol-1-yl)-3-(1-(2-(trifluoromethyl)phenyl)ethoxy)thiophene-2-carboxamide,0.4,uM,=,-0.3979400086720376,0,c1ccc(COc2csc(-n3cnc4cc(-c5ccnc(N6CCNCC6)c5)ccc43)c2)cc1
5151,621465,10.1016/j.bmcl.2009.07.118,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,CCN(CC(Cc1ccc(O)cc1)NC(=O)OCc1cncs1)CC(Cc1ccc(O)cc1)NC(=O)OCc1nccs1,N-[(S)-2-(thiazol-5-ylmethoxycarbonylamino)-3-(4-phenylmethoxyphenyl)propyl]-N-[2-(thiazol-5-ylmethoxycarbonylamino)-3-(4-phenylmethoxyphenyl)propyl]-ethylamine,0.091,uM,=,-1.0409586076789064,0,O=C(NC(CNCC(Cc1ccccc1)NC(=O)OCc1nccs1)Cc1ccccc1)OCc1cncs1
5152,761291,10.1021/jm101312a,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,CN1C[C@H]2CCCC[C@@]2(c2ccc(Cl)c(Cl)c2)C1,"cis-3a-(3,4-dichlorophenyl)-2-methyloctahydro-1H-isoindole",6.5,uM,=,0.8129133566428556,1,c1ccc([C@@]23CCCC[C@@H]2CNC3)cc1
5153,1703611,10.1016/j.bmcl.2017.05.043,,,,Inhibition of CYP3A4 (unknown origin),COc1ccc(-c2cc3c(N[C@@H]4CC[C@](C)(N)C4(C)C)c(C(N)=O)cnn3c2)cn1,"4-((1R,3S)-3-amino-2,2,3-trimethylcyclopentylamino)-6-(6-methoxypyridin-3-yl)pyrrolo[1,2-b]pyridazine-3-carboxamide",11.0,uM,=,1.0413926851582251,1,c1cncc(-c2cc3c(NC4CCCC4)ccnn3c2)c1
5154,789986,10.1016/j.bmcl.2011.10.013,,,,Reversible inhibition of CYP3A4,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@]23OCc2ccccc23)C2CC2)cc(OCCOC)c1,"(1R,3'S)-N-cyclopropyl-N-(3-(2-methoxyethoxy)-5-(3-methoxypropyl)benzyl)-3H-spiro[isobenzofuran-1,4'-piperidine]-3'-carboxamide",6.0,uM,=,0.7781512503836436,1,O=C([C@H]1CNCC[C@@]12OCc1ccccc12)N(Cc1ccccc1)C1CC1
5155,2069798,10.1021/acsmedchemlett.0c00606,,,,Inhibition of human liver microsome CYP3A4 using sorafenib as substrate incubated for 20 mins by LC-MS/MS with HPLC analysis,Nc1cc(F)c(S(=O)(=O)N2CCC(O)CC2)cc1C(=O)Nc1ccc(F)c(C(F)F)c1,2-amino-N-(3-(difluoromethyl)-4-fluorophenyl)-4-fluoro-5-((4-hydroxypiperidin-1-yl)sulfonyl)benzamide,20.8,uM,=,1.3180633349627615,1,O=C(Nc1ccccc1)c1cccc(S(=O)(=O)N2CCCCC2)c1
5156,2221810,10.1016/j.bmcl.2022.128625,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as substrate pretreated with NADPH,CCC[C@H]1N(C(=O)c2c(C(F)(F)F)ccnc2O)CCC[C@@]1(Oc1csc(C(F)(F)F)c1)C(=O)N1CCN(c2ccccc2OC)CC1,"((2R,3S)-1-(2-hydroxy-4-(trifluoromethyl)nicotinoyl)-2-propyl-3-(5-(trifluoromethyl)thiophen-3-yloxy)piperidin-3-yl)(4-(2-methoxyphenyl)piperazin-1-yl)methanone",9.2,uM,=,0.9637878273455552,1,O=C(c1cccnc1)N1CCC[C@@](Oc2ccsc2)(C(=O)N2CCN(c3ccccc3)CC2)C1
5157,1492957,10.1124/dmd.112.045765,,,,Inhibition of CYP3A4 in human liver microsomes incubated for 3 mins prior to NADPH addition measured after 3 mins by LC-MS analysis,C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@]4(C)CC[C@@H]1[C@]32OO4,"1,5,9-trimethyl-(12S)-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-one",50.0,uM,=,1.6989700043360187,1,O=C1C[C@@H]2CCC[C@@H]3CCC4OO[C@]32[C@H](O1)O4
5158,458143,10.1016/j.bmcl.2007.09.006,,,,Inhibition of CYP3A4 after 30 mins,CC[C@@H]1C[C@H](O)C[C@H](COC(=O)N2CCN(CCO)CC2)N1S(=O)(=O)c1ccc(Cl)cc1,cis-1-(4-chlorophenylsulfonyl)-6-ethyl-4-hydroxypiperidin-2-yl)methyl 4-(2-hydroxyethyl)piperazine-1-carboxylate,15.6,uM,=,1.1931245983544616,1,O=C(OC[C@H]1CCCCN1S(=O)(=O)c1ccccc1)N1CCNCC1
5159,621465,10.1016/j.bmcl.2009.07.118,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,O=C(N[C@@H](Cc1ccccc1)CN(Cc1c[nH]cn1)C[C@H](Cc1ccccc1)NC(=O)OCc1nccs1)OCc1cncs1,Bis-N-[(S)-2-(thiazol-5-ylmethoxycarbonylamino)-3-phenylpropyl]-N-[2-imidazolylmethyl]amine,0.066,uM,=,-1.1804560644581312,0,O=C(N[C@@H](Cc1ccccc1)CN(Cc1c[nH]cn1)C[C@H](Cc1ccccc1)NC(=O)OCc1nccs1)OCc1cncs1
5160,580964,10.1016/j.bmcl.2009.06.085,,,,Inhibition of human CYP3A4,CN([C@@H]1CCc2c(c3ccccn3c2CC(=O)O)C1)S(=O)(=O)c1ccc(F)cc1,"(R)-2-(9-(4-fluoro-N-methylphenylsulfonamido)-7,8,9,10-tetrahydropyrido[2,1-a]isoindol-6-yl)acetic acid",11.0,uM,=,1.0413926851582251,1,O=S(=O)(N[C@@H]1CCc2cn3ccccc3c2C1)c1ccccc1
5161,854796,10.1016/j.bmc.2012.08.056,,,,Inhibition of human CYP3A4 using 7-benzyloxyquinoline as substrate,Cc1ccc(C2(C(=O)N(C)Cc3cccs3)CC2)cc1,N-Methyl-N-(thiophen-2-ylmethyl)-1-p-tolylcyclopropanecarboxamide,1.6,uM,=,0.2041199826559248,1,O=C(NCc1cccs1)C1(c2ccccc2)CC1
5162,621465,10.1016/j.bmcl.2009.07.118,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,CC(C)CN(C[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C[C@H](Cc1ccccc1)NC(=O)OCc1nccs1,Bis-N-[(S)-2-(thiazol-5-ylmethoxycarbonylamino)-3-phenylpropyl]-N-[isobutyl]amine,0.11,uM,=,-0.958607314841775,0,O=C(N[C@H](CNC[C@H](Cc1ccccc1)NC(=O)OCc1nccs1)Cc1ccccc1)OCc1cncs1
5163,718343,10.1021/jm101063h,,,,Inhibition of CYP3A4,COc1cc(/C=C2\SC(=O)NC2=O)ccc1Oc1ccc(C#N)c2ccccc12,"4-[4-(2,4-Dioxothiazolidin-5-ylidenemethyl)-2-methoxyphenoxy]-naphthalene-1-carbonitrile",4.5,uM,=,0.6532125137753437,1,O=C1NC(=O)/C(=C/c2ccc(Oc3cccc4ccccc34)cc2)S1
5164,462442,10.1016/j.bmcl.2008.01.047,,,,Inhibition of CYP3A4,CC(C)(C)OC(=O)N[C@H](Cc1c(F)ccc(F)c1F)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1,"(R)-tert-butyl 1-oxo-1-((3-(1-phenylcyclopropyl)-3H-imidazo[4,5-b]pyridin-2-yl)methylamino)-3-(2,3,6-trifluorophenyl)propan-2-ylcarbamate",3.9,uM,=,0.5910646070264992,1,O=C(CCc1ccccc1)NCc1nc2cccnc2n1C1(c2ccccc2)CC1
5165,971930,10.1016/j.bmcl.2013.05.037,,,,Inhibition of CYP3A4 (unknown origin),COc1ccnc(Oc2ccc3c(c2)c(=O)ncn3Cc2c(F)cc(F)cc2F)c1C(F)(F)F,"6-(4-methoxy-3-(trifluoromethyl)pyridin-2-yloxy)-1-(2,4,6-trifluorobenzyl)quinazolin-4(1H)-one",18.0,uM,=,1.255272505103306,1,O=c1ncn(Cc2ccccc2)c2ccc(Oc3ccccn3)cc12
5166,789986,10.1016/j.bmcl.2011.10.013,,,,Reversible inhibition of CYP3A4,Cc1cccc(CN(C(=O)[C@H]2CNCC[C@@]23OCc2cc(F)c(F)cc23)C2CC2)c1C,"(1R,3'S)-N-cyclopropyl-N-(2,3-dimethylbenzyl)-5,6-difluoro-3H-spiro[isobenzofuran-1,4'-piperidine]-3'-carboxamide",5.0,uM,=,0.6989700043360189,1,O=C([C@H]1CNCC[C@@]12OCc1ccccc12)N(Cc1ccccc1)C1CC1
5167,1780159,10.1021/acs.jmedchem.8b01077,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,Cc1nnc(C(C)C)n1[C@@H]1C[C@H]2CC[C@@H](C1)N2CC[C@H](NC(=O)C1CCCCC1)c1cccs1,"N-((S)-3-(exo-3-(3-Isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-1-(thiophen-2-yl)propyl)cyclohexane Carboxamide",12.3,uM,=,1.089905111439398,1,O=C(N[C@@H](CCN1[C@@H]2CC[C@H]1C[C@H](n1cnnc1)C2)c1cccs1)C1CCCCC1
5168,462442,10.1016/j.bmcl.2008.01.047,,,,Inhibition of CYP3A4,O=C(NCc1nc2cccnc2n1C1(c2ccccc2)CC1)[C@@H](Cc1c(F)ccc(F)c1F)NC(=O)C1(C(F)(F)F)CC1,"(R)-N-(1-oxo-1-((3-(1-phenylcyclopropyl)-3H-imidazo[4,5-b]pyridin-2-yl)methylamino)-3-(2,3,6-trifluorophenyl)propan-2-yl)-1-(trifluoromethyl)cyclopropanecarboxamide",0.98,uM,=,-0.0087739243075051,0,O=C(N[C@H](Cc1ccccc1)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1)C1CC1
5169,1866289,10.1021/acs.jmedchem.9b00662,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,O=C(N[C@H]1CC[C@@H](C(O)CC2c3ccccc3-c3cncn32)CC1)c1ccccc1,"N-((cis)-4-(1-Hydroxy-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethyl)-cyclohexyl)benzamide",1.1,uM,=,0.041392685158225,1,O=C(N[C@H]1CC[C@@H](CCC2c3ccccc3-c3cncn32)CC1)c1ccccc1
5170,583696,10.1016/j.bmcl.2009.05.066,,,,Inhibition of human recombinant CYP3A4 after 45 mins,O=C(NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)NC(Cn1cccn1)c1ccccc1,1-(1-phenyl-2-(1H-pyrazol-1-yl)ethyl)-3-(1-((1-(4-(trifluoromethyl)phenyl)-1H-pyrrol-3-yl)methyl)piperidin-4-yl)urea,4.4,uM,=,0.6434526764861874,1,O=C(NC1CCN(Cc2ccn(-c3ccccc3)c2)CC1)NC(Cn1cccn1)c1ccccc1
5171,767548,10.1016/j.bmcl.2011.06.088,,,,Inhibition of CYP3A4 using DEF substrate,CC[C@@H](NC(=O)c1ccc2c(c1)ncn2Cc1ncc(F)cc1F)c1ccccc1,"(R)-1-((3,5-difluoropyridin-2-yl)methyl)-N-(1-phenylpropyl)-1H-benzo[d]imidazole-5-carboxamide",45.0,uM,=,1.6532125137753435,1,O=C(NCc1ccccc1)c1ccc2c(c1)ncn2Cc1ccccn1
5172,1554473,10.1021/acs.jmedchem.5b01372,,,,Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation,O=C(Cn1cnc2ccccc2c1=O)Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3ccccc3)N2)cc1,"N-(4-(((2S,5R)-5-((R)-Hydroxy(phenyl)methyl)pyrrolidin-2-yl)-methyl)phenyl)-2-(4-oxoquinazolin-3(4H)-yl)acetamide",96.0,uM,=,1.9822712330395684,1,O=C(Cn1cnc2ccccc2c1=O)Nc1ccc(C[C@@H]2CC[C@H](Cc3ccccc3)N2)cc1
5173,948334,10.1021/jm400062r,,,,Inhibition of CYP3A4 (unknown origin)-mediated midazolam hydroxylation to 1'-Hydroxymidazolam,COc1cccc(CN(CCN(C)C)C(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1,3-(4-(1H-Pyrazol-4-yl)phenyl)-1-(2-(dimethylamino)ethyl)-1-(3-methoxybenzyl)urea,80.0,uM,=,1.9030899869919435,1,O=C(NCc1ccccc1)Nc1ccc(-c2cn[nH]c2)cc1
5174,1628093,10.1016/j.ejmech.2016.08.024,,,,Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells preincubated for 30 mins using fluorescent substrate,O=C(CC1([C@H]2COC[C@@H](C3CC3)N2S(=O)(=O)c2ccc(F)cc2)CC1)N1CCC(N2CCCCC2)CC1,"1-(1,4'-bipiperidin-1'-yl)-2-(1-((3S,5R)-5-cyclopropyl-4-(4-fluorophenylsulfonyl)morpholin-3-yl)cyclopropyl)ethanone",1.5,uM,=,0.1760912590556812,1,O=C(CC1([C@H]2COC[C@@H](C3CC3)N2S(=O)(=O)c2ccccc2)CC1)N1CCC(N2CCCCC2)CC1
5175,2241411,10.1016/j.ejmech.2021.113981,,,,Inhibition of CYP3A4 in human liver microsomes assessed as reduction in 1'-hydroxy midazolam formation using midazolam as substrate preincubated for 20 mins in absence of NADPH followed by incubation with substrate for 10 mins by LC-MS/MS analysis,O[C@@H](c1cc(C(F)(F)F)nc2c(C(F)(F)F)cccc12)[C@H]1CCCCN1,"(S)-(2,8-bis(trifluoromethyl)quinolin-4-yl)((R)-piperidin-2-yl)methanol",33.0,uM,=,1.5185139398778875,1,c1ccc2c(C[C@H]3CCCCN3)ccnc2c1
5176,373753,10.1021/jm060073e,,,,Inhibition of CYP450 3A4 transfected in human microsome using PPR fluorogenic substrate,CC(C)C[C@@H]1C(=O)N[C@H](C2Cc3ccccc3C2)C(=O)N1[C@@H](C(=O)NC(C)C)c1ccc2occc2c1,"(2R)-2-(1-benzofuran-5-yl)-2-[(3R,6R)-3-(2,3-dihydro-1H-inden-2-yl)-6-(2-methylpropyl)-2,5-dioxo-1-piperazinyl]-N-(1-methylethyl)ethanamide",4.3,uM,=,0.6334684555795865,1,O=C1CN(Cc2ccc3occc3c2)C(=O)[C@@H](C2Cc3ccccc3C2)N1
5177,1986041,10.1021/acs.jmedchem.0c00564,,,,Inhibition of CYP3A4 (unknown origin) expressed in insect cell microsomes using dibenzylfluorescein substrate by fluorescence based assay,CCOC(=O)C1=C(C)Nc2nc3ccccc3n2C1c1cocn1,"(+/-)-Ethyl 2-Methyl-4-(oxazol-4-yl)-1,4-dihydrobenzo[4,5]imidazo[1,2-a]pyrimidine-3-carboxylate",6.41,uM,=,0.8068580295188175,1,C1=CC(c2cocn2)n2c(nc3ccccc32)N1
5178,1707938,10.1021/acs.jmedchem.7b01420,,,,Inhibition of CYP3A4 (unknown origin),FC1(F)CCC(NCc2ccc(CN(C[C@H]3Cc4ccccc4CN3)[C@H]3CCCc4cccnc43)cc2)CC1,"(S)-N-(4-(((4,4-Difluorocyclohexyl)amino)methyl)benzyl)-N-(((R)-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)-5,6,7,8-tetrahydroquinolin-8-amine",0.2,uM,=,-0.6989700043360187,0,c1ccc2c(c1)CN[C@@H](CN(Cc1ccc(CNC3CCCCC3)cc1)[C@H]1CCCc3cccnc31)C2
5179,826125,10.1021/jm300069y,,,,Inhibition of CYP3A4,CC(C)(CO)c1cccc(CN[C@H]2CS(=O)(=O)C[C@@H](Cc3cc(F)c(N)c(OC(C(F)(F)F)C(F)(F)F)c3)[C@@H]2O)c1,"(3S,4S,5R)-3-(4-Amino-3-fluoro-5-((1,1,1,3,3,3-hexafluoropropan-2-yl)oxy)benzyl)-4-hydroxy-5-((3-(1-hydroxy-2-methylpropan-2-yl)benzyl)amino)tetrahydro-2H-thiopyran 1,1-dioxide",0.8,uM,=,-0.0969100130080563,0,O=S1(=O)C[C@@H](Cc2ccccc2)C[C@@H](NCc2ccccc2)C1
5180,673953,10.1016/j.bmcl.2010.08.086,,,,Inhibition of CYP3A4 using testosterone as substrate,CCNCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1,"(3R,4S)-N-(2-chloro-5-((ethylamino)methyl)benzyl)-N-cyclopropyl-4-(4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)phenyl)piperidine-3-carboxamide",17.0,uM,=,1.230448921378274,1,O=C([C@H]1CNCC[C@@H]1c1ccc(OCCOc2ccccc2)cc1)N(Cc1ccccc1)C1CC1
5181,827667,10.1016/j.bmcl.2012.05.039,,,,Inhibition of CYP3A4,COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1nc(F)c(-c2ccc(-c3ccc(-c4[nH]c([C@@H]5CCCN5C(=O)[C@@H](NC(=O)OC)C(C)C)nc4F)cc3)cc2)[nH]1)C(C)C,"dimethyl-(2S,2'S)-1,1'-((2S,2'S)-2,2'-(5,5'-(biphenyl-4,4'-diyl)bis(4-fluoro-1H-imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl)dicarbamate",3.1,uM,=,0.4913616938342727,1,c1cc(-c2cnc([C@@H]3CCCN3)[nH]2)ccc1-c1ccc(-c2cnc([C@@H]3CCCN3)[nH]2)cc1
5182,1527906,,,,,Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,C[C@@H](c1ccc(-c2ccc(F)cc2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O,"US8575157, 200::US8592410, Comparator 12::US8598163, 70",4.9,uM,=,0.6901960800285137,1,O=C1OC(c2ccccc2)CCN1Cc1ccc(-c2ccccc2)cc1
5183,2157118,10.1021/acsmedchemlett.1c00445,,,,Inhibition of human CYP3A4 using testosterone as substrate by fluorescence plate reader analysis,C[C@@]1(c2cc(NC(=O)c3ccc(C#N)cn3)ccc2F)Cn2c(C#N)cnc2C(N)=N1,"(R)-N-(3-(8-amino-3-cyano-6-methyl-5,6-dihydroimidazo[1,2-a]pyrazin-6-yl)-4-fluorophenyl)-5-cyanopicolinamide",1.5,uM,=,0.1760912590556812,1,O=C(Nc1cccc(C2Cn3ccnc3C=N2)c1)c1ccccn1
5184,1889158,10.1021/acs.jmedchem.8b01719,,,,Inhibition of CYP3A4 in human liver microsomes using nifedipine as substrate preincubated for 7 mins followed by NADPH addition and measured by LC-MS/MS analysis,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(c3ccc(B(O)O)c(Cl)c3)S(C)(=O)=O)c(C3CC3)cc12,(2-Chloro-4-(N-(5-cyclopropyl-2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-6-yl)methylsulfonamido)phenyl)boronic acid,8.1,uM,=,0.9084850188786496,1,c1ccc(Nc2cc3oc(-c4ccccc4)cc3cc2C2CC2)cc1
5185,1869498,10.1021/acs.jmedchem.8b01729,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 3 mins in presence of NADP by LC-MS/MS analysis,Cc1cc(/C=C/C#N)cc(C)c1Oc1ccnc(Nc2ccc(CN3CCN(S(C)(=O)=O)CC3)cc2)n1,"(E)-3-(3,5-dimethyl-4-(2-(4-((4-(methylsulfonyl)piperazin-1-yl)methyl)phenylamino)pyrimidin-4-yloxy)phenyl)acrylonitrile",20.5,uM,=,1.3117538610557542,1,c1ccc(Oc2ccnc(Nc3ccc(CN4CCNCC4)cc3)n2)cc1
5186,643970,10.1016/j.bmcl.2010.06.086,,,,Inhibition of human CYP3A4-mediated testosterone oxidation,C[C@@H](c1ccc(Cl)cc1)N1Cc2cncn2C(C[C@H](O)c2ccccc2)S1(=O)=O,"(S)-2-{6-[(S)-1-(4-Chloro-phenyl)-ethyl]-5,5-dioxo-4,5,6,7-tetrahydro-5lambda*6*-thia-2,3a,6-triaza-inden-4-yl}-1-phenyl-ethanol",1.92,uM,=,0.2833012287035495,1,O=S1(=O)C(CCc2ccccc2)n2cncc2CN1Cc1ccccc1
5187,1707938,10.1021/acs.jmedchem.7b01420,,,,Inhibition of CYP3A4 (unknown origin),c1ccc2c(c1)CN[C@@H](CN(CCCCN(Cc1ccncc1)Cc1ccncc1)[C@H]1CCCc3cccnc31)C2,"N1,N1-Bis(pyridin-4-ylmethyl)-N4-(((R)-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)-N4-((S)-5,6,7,8-tetrahydroquinolin-8-yl)-butane-1,4-diamine",0.622,uM,=,-0.2062096153091813,0,c1ccc2c(c1)CN[C@@H](CN(CCCCN(Cc1ccncc1)Cc1ccncc1)[C@H]1CCCc3cccnc31)C2
5188,789986,10.1016/j.bmcl.2011.10.013,,,,Reversible inhibition of CYP3A4,Cc1c(CN(C(=O)[C@H]2CNCC[C@@]23OCc2cc(F)c(F)cc23)C2CC2)cccc1C(F)(F)F,"(1R,3'S)-N-cyclopropyl-5,6-difluoro-N-(2-methyl-3-(trifluoromethyl)benzyl)-3H-spiro[isobenzofuran-1,4'-piperidine]-3'-carboxamide",2.3,uM,=,0.3617278360175928,1,O=C([C@H]1CNCC[C@@]12OCc1ccccc12)N(Cc1ccccc1)C1CC1
5189,789986,10.1016/j.bmcl.2011.10.013,,,,Reversible inhibition of CYP3A4,CCN(CC)CCCc1cc(CCCOC)cc(CN(C(=O)[C@H]2CNCC[C@@]23OCc2cc(F)c(F)cc23)C2CC2)c1Cl,"(1R,3'S)-N-(2-chloro-3-(3-(diethylamino)propyl)-5-(3-methoxypropyl)benzyl)-N-cyclopropyl-5,6-difluoro-3H-spiro[isobenzofuran-1,4'-piperidine]-3'-carboxamide",5.8,uM,=,0.7634279935629373,1,O=C([C@H]1CNCC[C@@]12OCc1ccccc12)N(Cc1ccccc1)C1CC1
5190,1707938,10.1021/acs.jmedchem.7b01420,,,,Inhibition of CYP3A4 (unknown origin),C(=C/CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21)\CNCc1ccccn1,"(E)-N1-(Pyridin-2-ylmethyl)-N4-(((R)-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)-N4-((S)-5,6,7,8-tetrahydroquinolin-8-yl)-but-2-ene-1,4-diamine",1.56,uM,=,0.1931245983544616,1,C(=C/CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21)\CNCc1ccccn1
5191,462442,10.1016/j.bmcl.2008.01.047,,,,Inhibition of CYP3A4,CC(C)(C)OC(=O)N[C@H](Cc1ccccc1C(F)(F)F)C(=O)NCc1nc2cccnc2n1CC(F)(F)C(F)(F)F,"(R)-tert-butyl 1-oxo-1-((3-(2,2,3,3,3-pentafluoropropyl)-3H-imidazo[4,5-b]pyridin-2-yl)methylamino)-3-(2-(trifluoromethyl)phenyl)propan-2-ylcarbamate",0.98,uM,=,-0.0087739243075051,0,O=C(CCc1ccccc1)NCc1nc2cccnc2[nH]1
5192,2017066,10.1021/acs.jmedchem.0c00223,,,,Inhibition of CYP3A4 in human liver microsome using midazolam as substrate measured after 20 mins in presence of NADPH by LC-MS/MS analysis,CC(Sc1nc2cnccc2n1-c1ccc(C2CC2)c2ccccc12)C(=O)O,"rac-2-((1-(4-Cyclopropylnaphthalen-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl)thio)propanoic Acid",36.5,uM,=,1.5622928644564746,1,c1ccc2c(-n3cnc4cnccc43)ccc(C3CC3)c2c1
5193,977237,10.1016/j.bmc.2013.06.067,,,,Inhibition of CYP3A4 in human liver microsomes assessed as midazolam 1'-hydroxylation after 20 mins by LCMS analysis,CCN(CC)C(c1cccc(Nc2ccnc3cc(Cl)ccc23)c1)c1nnnn1C(C)(C)C,N-{3-[(diethylamino)(1-tert-butyl-1H-tetrazol-5-yl)methyl]phenyl}-7-Chloroquinolin-4-amine,0.006,uM,=,-2.2218487496163566,0,c1cc(Cc2nnn[nH]2)cc(Nc2ccnc3ccccc23)c1
5194,2089574,10.1016/j.ejmech.2020.112465,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins followed by NADPH addition and measured after 20 mins by LC-MS/MS analysis,CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,SID144204227,0.0217,uM,=,-1.6635402661514704,0,c1ccc([C@@]2(Cn3ccnc3)OC[C@H](COc3ccc(N4CCNCC4)cc3)O2)cc1
5195,458143,10.1016/j.bmcl.2007.09.006,,,,Inhibition of CYP3A4 after 30 mins,CC(C)(CO)N1CCN(C(=O)CC2([C@H]3C[C@@H](O)C[C@@H](C4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)CC1,"2-(1-((2R,4S,6S)-1-(4-chlorophenylsulfonyl)-6-cyclopropyl-4-hydroxypiperidin-2-yl)cyclopropyl)-1-(4-(1-hydroxy-2-methylpropan-2-yl)piperazin-1-yl)ethanone",11.0,uM,=,1.0413926851582251,1,O=C(CC1([C@H]2CCC[C@@H](C3CC3)N2S(=O)(=O)c2ccccc2)CC1)N1CCNCC1
5196,728151,10.1016/j.bmc.2011.01.017,,,,Inhibition of human CYP3A4,CC(=O)c1ccc2cc(C(O)(c3c[nH]cn3)C(C)C)ccc2c1,rac-1-{6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthyl}-1-ethanone,1.4,uM,=,0.1461280356782379,1,c1ccc2cc(Cc3c[nH]cn3)ccc2c1
5197,1347924,10.1016/j.bmcl.2014.04.024,,,,Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method,COc1cc2ccc(C(O)(c3ccncn3)C(C)C)cc2cc1OC,"rac-1-(6,7-dimethoxynaphthalen-2-yl)-2-methyl-1-(pyrimidin-4-yl)propan-1-ol",18.0,uM,=,1.255272505103306,1,c1ccc2cc(Cc3ccncn3)ccc2c1
5198,458143,10.1016/j.bmcl.2007.09.006,,,,Inhibition of CYP3A4 after 30 mins,C[C@@H]1CCC[C@H](C2(OC(=O)N3CCN(C(C)(C)CO)CC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1,"1-((2R,6R)-1-(4-chlorophenylsulfonyl)-6-methylpiperidin-2-yl)cyclopropyl 4-(1-hydroxy-2-methylpropan-2-yl)piperazine-1-carboxylate",0.8,uM,=,-0.0969100130080563,0,O=C(OC1([C@H]2CCCCN2S(=O)(=O)c2ccccc2)CC1)N1CCNCC1
5199,1296353,10.1021/jm4015108,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis,Nc1ccc([C@@H]2C[C@H]2C(=O)Nc2ccc(S(=O)(=O)c3ccccc3)cc2)cn1,rac-trans-2-(6-Aminopyridin-3-yl)-N-(4-(phenylsulfonyl)phenyl)-cyclopropanecarboxamide,2.0,uM,=,0.3010299956639812,1,O=C(Nc1ccc(S(=O)(=O)c2ccccc2)cc1)[C@@H]1C[C@H]1c1cccnc1
5200,813105,10.1021/jm201346g,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,COc1ccc2[nH]c(SCc3ccc4ccccc4n3)nc2c1,2-((5-methoxy-1H-benzo[d]imidazol-2-ylthio)methyl)quinoline,2.81,uM,=,0.4487063199050799,1,c1ccc2nc(CSc3nc4ccccc4[nH]3)ccc2c1
5201,583696,10.1016/j.bmcl.2009.05.066,,,,Inhibition of human recombinant CYP3A4 after 45 mins,O=C(NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)NC(Cn1ccnc1)c1ccccc1,1-(2-(1H-imidazol-1-yl)-1-phenylethyl)-3-(1-((1-(4-(trifluoromethyl)phenyl)-1H-pyrrol-3-yl)methyl)piperidin-4-yl)urea,0.04,uM,=,-1.3979400086720375,0,O=C(NC1CCN(Cc2ccn(-c3ccccc3)c2)CC1)NC(Cn1ccnc1)c1ccccc1
5202,465692,10.1021/jm701185v,,,,Inhibition of CYP3A4,Cc1cc(C)n(-c2cc(NC(=O)CN3CCN(C)CC3)nc(-c3nccs3)n2)n1,"N-[6-(3,5-dimethylpyrazol-1-yl)-2-thiazol-2-ylpyrimidin-4-yl]-2-(4-methylpiperazin-1-yl)acetamide",13.0,uM,=,1.1139433523068367,1,O=C(CN1CCNCC1)Nc1cc(-n2cccn2)nc(-c2nccs2)n1
5203,976812,10.1016/j.bmcl.2013.06.100,,,,Inhibition of CYP3A4 (unknown origin),COc1cc(-c2nc3n(n2)CCC[C@H]3c2ccccc2C(F)(F)F)ccc1-n1cnc(C)c1,"(S)-2-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-8-(2-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyridine",0.1,uM,=,-1.0,0,c1ccc([C@@H]2CCCn3nc(-c4ccc(-n5ccnc5)cc4)nc32)cc1
5204,1347924,10.1016/j.bmcl.2014.04.024,,,,Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method,COc1cc2ccc(C(O)(c3cccnc3)C(C)C)cc2cc1OC,"rac-1-(6,7-dimethoxynaphthalen-2-yl)-2-methyl-1-(pyridin-3-yl)propan-1-ol",9.4,uM,=,0.9731278535996988,1,c1cncc(Cc2ccc3ccccc3c2)c1
5205,606336,10.1016/j.bmcl.2009.11.061,,,,Inhibition of CYP3A4,CCNc1nc(-c2ccoc2)c(-c2cnc3[nH]nc(C)c3n2)cc1OC[C@@H](N)Cc1ccccc1,"(S)-3-(2-amino-3-phenylpropoxy)-N-ethyl-6-(furan-3-yl)-5-(3-methyl-1H-pyrazolo[4,3-b]pyrazin-5-yl)pyridin-2-amine",5.0,uM,=,0.6989700043360189,1,c1ccc(CCCOc2cnc(-c3ccoc3)c(-c3cnc4[nH]ncc4n3)c2)cc1
5206,2228092,10.1021/acs.jmedchem.2c00552,,,,Inhibition of CYP3A4 (unknown origin),Cc1ccc(O)c(C)c1-n1c(N)c(C(N)=O)c2nc3c(Br)cccc3nc21,"2-amino-5-bromo-1-(3-hydroxy-2,6-dimethylphenyl)-pyrrolo[2,3-b]quinoxaline-3-carboxamide",9.0,uM,=,0.9542425094393248,1,c1ccc(-n2ccc3nc4ccccc4nc32)cc1
5207,813105,10.1021/jm201346g,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,COc1ccc2[nH]c(SCC(C)(C)C)nc2c1,5-methoxy-2-(neopentylthio)-1H-benzo[d]imidazole,50.0,uM,=,1.6989700043360187,1,c1ccc2[nH]cnc2c1
5208,592053,10.1021/jm900786r,,,,Inhibition of CYP3A4 using 7-benzyloxy-resorufin as substrate,C[C@@]1(C(=O)Nc2ccc(F)nc2)CCCN1c1nc(Nc2cc(C3CC3)n[nH]2)c2cccn2n1,"(S)-1-(4-(5-cyclopropyl-1H-pyrazol-3-ylamino)pyrrolo[1,2-f][1,2,4]triazin-2-yl)-N-(6-fluoropyridin-3-yl)-2-methylpyrrolidine-2-carboxamide",7.0,uM,=,0.8450980400142568,1,O=C(Nc1cccnc1)C1CCCN1c1nc(Nc2cc(C3CC3)n[nH]2)c2cccn2n1
5209,621523,10.1021/np900266m,,,,Inhibition of CYP3A4 after 30 mins by fluorescence microplate reader assay,CCCCCCCC1O[C@H](CC/C(C)=C/COc2c3ccoc3cc3oc(=O)ccc23)C(C)(C)O1,"6',7'-Dihydroxybergamottin Octanal Acetal",0.13,uM,=,-0.8860566476931633,0,O=c1ccc2c(OC/C=C/CC[C@@H]3COCO3)c3ccoc3cc2o1
5210,761291,10.1021/jm101312a,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,c1ccc2cc([C@]34CCC[C@H]3CNC4)ccc2c1,"cis-(3aS,6aR)-3a-(naphthalen-2-yl)octahydrocyclopenta[c]pyrrole",2.65,uM,=,0.4232458739368078,1,c1ccc2cc([C@]34CCC[C@H]3CNC4)ccc2c1
5211,510060,10.1016/j.bmcl.2008.07.059,,,,Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay,Cc1c(-c2cccc(OCCCCC(=O)O)c2F)c(=O)n(C[C@H](N)c2ccccc2)c(=O)n1Cc1c(F)cccc1C(F)(F)F,"(R)-5-(3-(1-(2-fluoro-6-(trifluoromethyl)benzyl)-3-(2-amino-2-phenylethyl)-6-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-2-fluorophenoxy)pentanoic acid",28.0,uM,=,1.4471580313422192,1,O=c1c(-c2ccccc2)cn(Cc2ccccc2)c(=O)n1CCc1ccccc1
5212,789986,10.1016/j.bmcl.2011.10.013,,,,Reversible inhibition of CYP3A4,COCCCc1cc(CCC(=O)N2CCOCC2)c(Cl)c(CN(C(=O)[C@H]2CNCC[C@@]23OCc2cc(F)c(F)cc23)C2CC2)c1,"(1R,3'S)-N-(2-chloro-5-(3-methoxypropyl)-3-(3-morpholino-3-oxopropyl)benzyl)-N-cyclopropyl-5,6-difluoro-3H-spiro[isobenzofuran-1,4'-piperidine]-3'-carboxamide",2.8,uM,=,0.4471580313422192,1,O=C(CCc1cccc(CN(C(=O)[C@H]2CNCC[C@@]23OCc2ccccc23)C2CC2)c1)N1CCOCC1
5213,674156,10.1016/j.bmcl.2010.08.100,,,,Inhibition of CYP3A4 in human liver microsomes by fluorometric assay,Clc1ccc2c(c1Nc1ccnc(Nc3cc(N4CCOCC4)cc(N4CCOCC4)c3)n1)OCO2,"N4-(5-chlorobenzo[d][1,3]dioxol-4-yl)-N2-(3,5-dimorpholinophenyl)pyrimidine-2,4-diamine",0.9,uM,=,-0.0457574905606751,0,c1cc(Nc2ccnc(Nc3cc(N4CCOCC4)cc(N4CCOCC4)c3)n2)c2c(c1)OCO2
5214,1296352,10.1021/jm4015108,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,Nc1ccc([C@@H]2C[C@H]2C(=O)Nc2ccc(S(=O)(=O)c3ccccc3)cc2)cn1,rac-trans-2-(6-Aminopyridin-3-yl)-N-(4-(phenylsulfonyl)phenyl)-cyclopropanecarboxamide,3.5,uM,=,0.5440680443502757,1,O=C(Nc1ccc(S(=O)(=O)c2ccccc2)cc1)[C@@H]1C[C@H]1c1cccnc1
5215,643712,10.1016/j.bmcl.2010.06.009,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader,C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(N)n4)ccc32)sc1C(N)=O)c1ccccc1C(F)(F)F,(R)-5-(5-(2-aminopyrimidin-4-yl)-1H-benzo[d]imidazol-1-yl)-3-(1-(2-(trifluoromethyl)phenyl)ethoxy)thiophene-2-carboxamide,6.8,uM,=,0.8325089127062363,1,c1ccc(COc2csc(-n3cnc4cc(-c5ccncn5)ccc43)c2)cc1
5216,2165881,10.1021/acsmedchemlett.2c00029,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate,Cc1cnc(Nc2ccnn2C)nc1-c1cc2n(c1)C(=O)N([C@H](CO)c1cccc(Cl)c1)C2,"(S)-2-(1-(3-chlorophenyl)-2-hydroxyethyl)-6-(5-methyl-2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)-1,2-dihydro-3H-pyrrolo[1,2-c]imidazol-3-one",11.5,uM,=,1.0606978403536118,1,O=C1N(Cc2ccccc2)Cc2cc(-c3ccnc(Nc4ccn[nH]4)n3)cn21
5217,949160,10.1016/j.bmcl.2013.01.011,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate,Cc1cc(C[C@@H](NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12,"(R)-N-(1-(1,4'-bipiperidin-1'-yl)-3-(7-methyl-1H-indazol-5-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide",6.0,uM,=,0.7781512503836436,1,O=C(N[C@H](Cc1ccc2[nH]ncc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
5218,1296352,10.1021/jm4015108,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,O=C(Nc1ccc(S(=O)(=O)c2ccccc2)cc1)[C@H]1C[C@@H]1c1cccnc1,trans-N-(4-(Phenylsulfonyl)phenyl)-2-(pyridin-3-yl)-cyclopropanecarboxamide,0.68,uM,=,-0.1674910872937636,0,O=C(Nc1ccc(S(=O)(=O)c2ccccc2)cc1)[C@H]1C[C@@H]1c1cccnc1
5219,2157144,10.1021/acsmedchemlett.1c00473,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by TDI- high-throughput based mass spectrometry method,CCc1c(Cl)[nH]c2ncc(-c3ccc(N)c(C(=O)N(C)C)c3)cc12,"2-Amino-5-(2-chloro-3-ethyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-N,N-dimethylbenzamide",0.2,uM,=,-0.6989700043360187,0,c1ccc(-c2cnc3[nH]ccc3c2)cc1
5220,621465,10.1016/j.bmcl.2009.07.118,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,CC(C)(C)CN(CC(Cc1ccccc1)NC(=O)OCc1cncs1)CC(Cc1ccccc1)NC(=O)OCc1nccs1,"Bis-N-[2-(thiazol-5-ylmethoxycarbonylamino)-3-phenylpropyl]-N-[2,2-dimethylpropyl]amine",0.11,uM,=,-0.958607314841775,0,O=C(NC(CNCC(Cc1ccccc1)NC(=O)OCc1nccs1)Cc1ccccc1)OCc1cncs1
5221,1276679,10.1021/jm4012033,,,,Inhibition of CYP3A4 (unknown origin),Cc1csc(C(C)(O)c2nnc(Nc3ncn(Cc4c(F)cccc4F)n3)s2)n1,"rac-1-(5-(1-(2,6-Difluorobenzyl)-1H-1,2,4-triazol-3-ylamino)-1,3,4-thiadiazol-2-yl)-1-(4-methylthiazol-2-yl)ethanol",48.0,uM,=,1.6812412373755872,1,c1ccc(Cn2cnc(Nc3nnc(Cc4nccs4)s3)n2)cc1
5222,936804,10.1021/jm301511h,,,,Inhibition of human recombinant CYP3A4 expressed in Escherichia coli cells,COc1ccc(NC(=O)c2ccc(Cn3ccnn3)c3ccccc23)c(C(=O)NCC2CCOCC2)n1,"6-Methoxy-N-(tetrahydro-2H-pyran-4-ylmethyl)-3-{[4-(1H-1,2,3-triazol-1-ylmethyl)-1-naphthoyl]amino}pyridine-2-carboxamide",0.36,uM,=,-0.4436974992327127,0,O=C(NCC1CCOCC1)c1ncccc1NC(=O)c1ccc(Cn2ccnn2)c2ccccc12
5223,789986,10.1016/j.bmcl.2011.10.013,,,,Reversible inhibition of CYP3A4,O=C([C@H]1CNCC[C@@]12OCc1cc(F)c(F)cc12)N(Cc1cccc2ccccc12)C1CC1,"(1R,3'S)-N-cyclopropyl-5,6-difluoro-N-(naphthalen-1-ylmethyl)-3H-spiro[isobenzofuran-1,4'-piperidine]-3'-carboxamide",6.0,uM,=,0.7781512503836436,1,O=C([C@H]1CNCC[C@@]12OCc1ccccc12)N(Cc1cccc2ccccc12)C1CC1
5224,1735372,10.1021/acs.jmedchem.8b00084,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis,Cl.Cl.Cl.NCc1ccc(-c2cnccc2-c2ccncc2)o1,"(5-([4,4'-Bipyridin]-3'-yl)furan-2-yl)methanamine Trihydrochloride",39.0,uM,=,1.591064607026499,1,c1coc(-c2cnccc2-c2ccncc2)c1
5225,1986041,10.1021/acs.jmedchem.0c00564,,,,Inhibition of CYP3A4 (unknown origin) expressed in insect cell microsomes using dibenzylfluorescein substrate by fluorescence based assay,CC1=C(C(=O)OC(C)C)C(c2ccoc2)n2c(nc3ccccc32)N1,"(+/-)-Isopropyl 4-(Furan-3-yl)-2-methyl-1,4-dihydrobenzo-[4,5]imidazo[1,2-a]pyrimidine-3-carboxylate",2.68,uM,=,0.4281347940287888,1,C1=CC(c2ccoc2)n2c(nc3ccccc32)N1
5226,2165882,10.1021/acsmedchemlett.2c00029,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,Cc1cnc(Nc2ccnn2C)nc1-c1cc2n(c1)C(=O)N([C@H](CO)c1cccc(Cl)c1)C2,"(S)-2-(1-(3-chlorophenyl)-2-hydroxyethyl)-6-(5-methyl-2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)-1,2-dihydro-3H-pyrrolo[1,2-c]imidazol-3-one",5.4,uM,=,0.7323937598229685,1,O=C1N(Cc2ccccc2)Cc2cc(-c3ccnc(Nc4ccn[nH]4)n3)cn21
5227,1628093,10.1016/j.ejmech.2016.08.024,,,,Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells preincubated for 30 mins using fluorescent substrate,O=C(CC1([C@H]2CO[C@H]3CCC[C@H]3N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CCC(N2CCCCC2)CC1,"1-(1,4'-bipiperidin-1'-yl)-2-(1-((3S,4aR,7aS)-4-(4-chlorophenylsulfonyl)octahydrocyclopenta[b][1,4]oxazin-3-yl)cyclopropyl)ethanone",8.0,uM,=,0.9030899869919436,1,O=C(CC1([C@H]2CO[C@H]3CCC[C@H]3N2S(=O)(=O)c2ccccc2)CC1)N1CCC(N2CCCCC2)CC1
5228,1296352,10.1021/jm4015108,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,CCCn1cc(S(=O)(=O)c2ccc(NC(=O)[C@H]3C[C@@H]3c3cccnc3)cc2)cn1,"trans-(S,S)-N-(4-((1-Propyl-1H-pyrazol-4-yl)sulfonyl)phenyl)-2-(pyridin-3-yl)cyclopropanecarboxamide",1.5,uM,=,0.1760912590556812,1,O=C(Nc1ccc(S(=O)(=O)c2cn[nH]c2)cc1)[C@H]1C[C@@H]1c1cccnc1
5229,741042,10.1016/j.bmcl.2011.02.067,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCCOC)c1,"(3R,4S)-N-cyclopropyl-4-(4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)phenyl)-N-(3-(2-methoxyethoxy)-5-(3-methoxypropyl)benzyl)piperidine-3-carboxamide",21.6,uM,=,1.334453751150931,1,O=C([C@H]1CNCC[C@@H]1c1ccc(OCCOc2ccccc2)cc1)N(Cc1ccccc1)C1CC1
5230,1735372,10.1021/acs.jmedchem.8b00084,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis,Cc1ccncc1-c1ccc(CN)s1.Cl.Cl,(5-(4-Methylpyridin-3-yl)thiophene-2-yl)methanamine Dihydrochloride,37.0,uM,=,1.568201724066995,1,c1cncc(-c2cccs2)c1
5231,1534814,,,,,Inhibition Assay: Inhibition assay using P450 CYP enzymes.,CCOC(=O)/C=C/c1c(OC)ccc2cc(-c3cccc(OC)c3)ccc12,"US8546392, 19",1.58,uM,=,0.1986570869544226,1,c1ccc(-c2ccc3ccccc3c2)cc1
5232,609086,10.1016/j.bmc.2010.01.039,,,,Inhibition of CYP3A4-mediated hydroxylation of testosterone in human liver microsomes in NADPH co-factor system by RP-HPLC,Cc1cc2nc(NCCCO)n(CC(=O)c3cc(C(C)(C)C)c(O)c(C(C)(C)C)c3)c2cc1C,"2-(2-(3-Hydroxypropylamino)-5,6-dimethyl-1H-benzo[d]-imidazol-1-yl)-1-(3,5-di-tert-butyl-4-hydroxyphenyl)ethanone",85.0,uM,=,1.9294189257142929,1,O=C(Cn1cnc2ccccc21)c1ccccc1
5233,726744,10.1016/j.bmcl.2011.01.036,,,,Inhibition of CYP3A4,C[C@@H](C[C@@H](CS(=O)(=O)N1CCN(c2ccc(F)cc2)CC1)N(O)C=O)c1ncc(F)cn1,"N-((2S,4S)-1-(4-(4-fluorophenyl)piperazin-1-ylsulfonyl)-4-(5-fluoropyrimidin-2-yl)pentan-2-yl)-N-hydroxyformamide",0.0014,uM,=,-2.853871964321762,0,O=S(=O)(CCCCc1ncccn1)N1CCN(c2ccccc2)CC1
5234,1866289,10.1021/acs.jmedchem.9b00662,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,CC(=O)N1CCC(C(O)CC2c3ccccc3-c3cncn32)CC1,"1-(4-(1-Hydroxy-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethyl)-piperidin-1-yl)ethanone",5.0,uM,=,0.6989700043360189,1,c1ccc2c(c1)-c1cncn1C2CCC1CCNCC1
5235,1642505,,,,,"Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).",CNC(C)C(=O)Nc1ccc(-c2c(-c3ccncc3)nc3cc(C)ccn23)c(C#Cc2ccc3ncccc3c2)n1,"US9481673, 27",3.7,uM,=,0.568201724066995,1,C(#Cc1ncccc1-c1c(-c2ccncc2)nc2ccccn12)c1ccc2ncccc2c1
5236,826125,10.1021/jm300069y,,,,Inhibition of CYP3A4,CC1(C)OCc2ccc(CN[C@H]3CS(=O)(=O)C[C@@H](Cc4cc(F)c(N)c(OC(C(F)(F)F)C(F)(F)F)c4)[C@@H]3O)cc21,"(3S,4S,5R)-3-(4-Amino-3-fluoro-5-((1,1,1,3,3,3-hexafluoropropan-2-yl)oxy)benzyl)-5-(((3,3-dimethyl-1,3-dihydroisobenzofuran-5-yl)methyl)amino)-4-hydroxytetrahydro-2H-thiopyran 1,1-dioxide",0.7,uM,=,-0.1549019599857432,0,O=S1(=O)C[C@@H](Cc2ccccc2)C[C@@H](NCc2ccc3c(c2)COC3)C1
5237,621465,10.1016/j.bmcl.2009.07.118,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,CCN(C[C@H](Cc1ccccc1)NC(=O)OCc1cnc[nH]1)C[C@H](Cc1ccccc1)NC(=O)OCc1ncc[nH]1,Bis-N-[(S)-2-(imidazol-4-ylmethoxycarbonylamino)-3-phenylpropyl]ethylamine,0.348,uM,=,-0.4584207560534191,0,O=C(N[C@H](CNC[C@H](Cc1ccccc1)NC(=O)OCc1ncc[nH]1)Cc1ccccc1)OCc1cnc[nH]1
5238,789986,10.1016/j.bmcl.2011.10.013,,,,Reversible inhibition of CYP3A4,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@]23OC(=O)c2ccccc23)C2CC2)cc(OCCOC)c1,"(1R,3'S)-N-cyclopropyl-N-(3-(2-methoxyethoxy)-5-(3-methoxypropyl)benzyl)-3-oxo-3H-spiro[isobenzofuran-1,4'-piperidine]-3'-carboxamide",7.2,uM,=,0.8573324964312685,1,O=C1O[C@@]2(CCNC[C@@H]2C(=O)N(Cc2ccccc2)C2CC2)c2ccccc21
5239,1659863,10.1016/j.ejmech.2017.02.016,,,,Inhibition of human liver CYP3A4 expressed in Saccharomyces cerevisiae YY7 microsomal membranes using DBF as substrate after 10 mins by fluorescence assay,COc1cccc(/C=C/C(=O)c2cccnc2)c1,(E)-3-(3-Methoxyphenyl)-1-(3-pyridyl)prop-2-en-1-one,1.28,uM,=,0.1072099696478683,1,O=C(/C=C/c1ccccc1)c1cccnc1
5240,1296353,10.1021/jm4015108,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis,CS(=O)(=O)c1cccc(S(=O)(=O)c2ccc(NC(=O)[C@@H]3C[C@H]3c3cccnc3)cc2)c1,rac-trans-N-(4-((3-(Methylsulfonyl)phenyl)sulfonyl)phenyl)-2-(pyridin-3-yl)cyclopropanecarboxamide,0.18,uM,=,-0.744727494896694,0,O=C(Nc1ccc(S(=O)(=O)c2ccccc2)cc1)[C@@H]1C[C@H]1c1cccnc1
5241,1468060,10.1016/j.bmcl.2015.03.035,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as marker substrate,COc1cccc(OC)c1[C@@H]1C[C@H](C)C(=O)N1Cc1ccc(OC(F)(F)F)cc1,"cis-rac-5-(2,6-dimethoxyphenyl)-3-methyl-1-(4-(trifluoromethoxy)benzyl)pyrrolidin-2-one",8.7,uM,=,0.9395192526186184,1,O=C1CC[C@@H](c2ccccc2)N1Cc1ccccc1
5242,51912,10.1016/j.bmcl.2004.04.048,,,,Inhibition of human liver microsome cytochrome P450 3A4,COCCN(C)c1nc(N)c(CN)c(-c2ccc(Cl)cc2Cl)n1,"5-Aminomethyl-6-(2,4-dichloro-phenyl)-N*2*-(2-methoxy-ethyl)-N*2*-methyl-pyrimidine-2,4-diamine",30.0,uM,=,1.4771212547196624,1,c1ccc(-c2ccncn2)cc1
5243,949160,10.1016/j.bmcl.2013.01.011,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate,O=C(N[C@H](Cc1cc(I)c2[nH]c(=O)oc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1,"(R)-N-(1-(1,4'-bipiperidin-1'-yl)-3-(4-iodo-2-oxo-2,3-dihydrobenzo[d]oxazol-6-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide",5.5,uM,=,0.7403626894942439,1,O=C(N[C@H](Cc1ccc2[nH]c(=O)oc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
5244,776116,10.1016/j.bmcl.2011.09.074,,,,Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy resorufin,Cc1nc2cn(Cc3ccccc3)cc2c(-c2ccc(Cl)cc2Cl)c1CN,"(6-benzyl-4-(2,4-dichlorophenyl)-2-methyl-6H-pyrrolo[3,4-b]pyridin-3-yl)methanamine",0.73,uM,=,-0.1366771398795441,0,c1ccc(Cn2cc3nccc(-c4ccccc4)c3c2)cc1
5245,1866289,10.1021/acs.jmedchem.9b00662,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,OC(CC1c2c(F)cccc2-c2cncn21)C1CCCCC1,"1-Cyclohexyl-2-(6-fluoro-5H-imidazo[5,1-a]isoindol-5-yl)ethanol",2.0,uM,=,0.3010299956639812,1,c1ccc2c(c1)-c1cncn1C2CCC1CCCCC1
5246,673953,10.1016/j.bmcl.2010.08.086,,,,Inhibition of CYP3A4 using testosterone as substrate,CC(=O)NCCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1,"(3R,4S)-N-(5-(2-acetamidoethyl)-2-chlorobenzyl)-N-cyclopropyl-4-(4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)phenyl)piperidine-3-carboxamide",6.0,uM,=,0.7781512503836436,1,O=C([C@H]1CNCC[C@@H]1c1ccc(OCCOc2ccccc2)cc1)N(Cc1ccccc1)C1CC1
5247,1729574,10.1021/acsmedchemlett.7b00406,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate,C/C(CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21)=C(\F)CN,"(E)-3-fluoro-2-methyl-N1-(((R)-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)-N1-((S)-5,6,7,8-tetrahydroquinolin-8-yl)but-2-ene-1,4-diamine",13.0,uM,=,1.1139433523068367,1,c1ccc2c(c1)CN[C@@H](CN[C@H]1CCCc3cccnc31)C2
5248,1659863,10.1016/j.ejmech.2017.02.016,,,,Inhibition of human liver CYP3A4 expressed in Saccharomyces cerevisiae YY7 microsomal membranes using DBF as substrate after 10 mins by fluorescence assay,O=C(/C=C/c1ccccc1)c1cccnc1,(E)-3-phenyl-1-(3-pyridyl)prop-2-en-1-one,11.1,uM,=,1.0453229787866574,1,O=C(/C=C/c1ccccc1)c1cccnc1
5249,841307,10.1016/j.bmcl.2012.06.029,,,,Inhibition of CYP3A4,CCN1CCC(Nc2ccc3c(c2)C(=C(c2cc(F)cc(F)c2)c2nc4ccccc4[nH]2)C(=O)N3)CC1,"(E/Z)-3-((1H-benzo[d]imidazol-2-yl)(3,5-difluorophenyl)methylene)-5-(1-ethylpiperidin-4-ylamino)indolin-2-one",6.0,uM,=,0.7781512503836436,1,O=C1Nc2ccc(NC3CCNCC3)cc2C1=C(c1ccccc1)c1nc2ccccc2[nH]1
5250,1659863,10.1016/j.ejmech.2017.02.016,,,,Inhibition of human liver CYP3A4 expressed in Saccharomyces cerevisiae YY7 microsomal membranes using DBF as substrate after 10 mins by fluorescence assay,O=C(/C=C/c1cccnc1)c1ccc2ccccc2c1,(E)-1-(2-Naphthyl)-3-(3-pyridyl)prop-2-en-1-one,28.0,uM,=,1.4471580313422192,1,O=C(/C=C/c1cccnc1)c1ccc2ccccc2c1
5251,2157079,10.1021/acsmedchemlett.1c00445,,,,Inhibition of human CYP3A4 by fluorescence plate reader analysis,C[C@@]1(c2cc(NC(=O)c3ccc(F)cn3)ccc2F)Cn2c(C#N)cnc2C(N)=N1,"(R)-N-(3-(8-amino-3-cyano-6-methyl-5,6-dihydroimidazo[1,2-a]pyrazin-6-yl)-4-fluorophenyl)-5-fluoropicolinamide",4.4,uM,=,0.6434526764861874,1,O=C(Nc1cccc(C2Cn3ccnc3C=N2)c1)c1ccccn1
5252,1488506,10.1124/dmd.112.045708,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis in presence of NADPH,COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1,"Acetic acid (2S,3S)-5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester",12.0,uM,=,1.0791812460476249,1,O=C1C[C@H](c2ccccc2)Sc2ccccc2N1
5253,2171279,10.1021/acs.jmedchem.1c01083,,,,Inhibition of human recombinant CYP3A4 expressed in insect microsome using 7-benzyloxy-4-trifluoromethylcoumarin as a substrate incubated for 30 mins followed by addition of NADPH regenerating system measured immediately by fluorescence based analysis,CCCCCCCCCCCCCCCCSCCCOP(=O)(O)CO[C@H](C)Cn1cnc2c(N)ncnc21.N,Ammonium 3-(Hexadecylthio)propyl-(R)-(((1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)Phosphonate,58.0,uM,=,1.7634279935629371,1,c1ncc2nc[nH]c2n1
5254,1703611,10.1016/j.bmcl.2017.05.043,,,,Inhibition of CYP3A4 (unknown origin),CC1(C)[C@H](Nc2c(C(N)=O)cnn3cc(-c4ccccc4)cc23)CC[C@]1(C)N,"4-((1R,3S)-3-amino-2,2,3-trimethylcyclopentylamino)-6-phenylpyrrolo[1,2-b]pyridazine-3-carboxamide",3.0,uM,=,0.4771212547196624,1,c1ccc(-c2cc3c(NC4CCCC4)ccnn3c2)cc1
5255,673953,10.1016/j.bmcl.2010.08.086,,,,Inhibition of CYP3A4 using testosterone as substrate,COC(=O)NCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1,"methyl 4-chloro-3-(((3R,4S)-N-cyclopropyl-4-(4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)phenyl)piperidine-3-carboxamido)methyl)benzylcarbamate",6.5,uM,=,0.8129133566428556,1,O=C([C@H]1CNCC[C@@H]1c1ccc(OCCOc2ccccc2)cc1)N(Cc1ccccc1)C1CC1
5256,464242,10.1021/jm7013309,,,,Inhibition of human CYP3A4 using 7-benzyl-trifluoromethyl coumarin,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@H](N)CC(C)C)c(C)c34)ccc2[nH]1,"(S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl) 2-amino-4-methylpentanoate",0.095,uM,=,-1.0222763947111522,0,c1cc2c(Oc3ccc4[nH]ccc4c3)ncnn2c1
5257,993294,10.1021/ml400228e,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 to 60 mins by LC-MS/MS analysis,Cn1cc(-c2ccc3c(c2F)CCN3C(=O)Cc2cccc(C(F)(F)F)n2)c2c(N)ncnc21,"5-(4-fluoro-1-{[6-(trifluoromethyl)-2-pyridinyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine",9.09,uM,=,0.9585638832219674,1,O=C(Cc1ccccn1)N1CCc2cc(-c3c[nH]c4ncncc34)ccc21
5258,949160,10.1016/j.bmcl.2013.01.011,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate,O=C(NC(Cc1cc(Cl)c2[nH]ncc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1,"(+/-)-N-(1-(1,4'-bipiperidin-1'-yl)-3-(7-chloro-1H-indazol-5-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide",0.18,uM,=,-0.744727494896694,0,O=C(NC(Cc1ccc2[nH]ncc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
5259,1730868,10.1016/j.ejmech.2017.12.053,,,,Inhibition of CYP3A4 (unknown origin) after 2 hrs by firefly luciferase-luminescence based P450-glo assay,CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,SID144204227,0.1,uM,=,-1.0,0,c1ccc([C@@]2(Cn3ccnc3)OC[C@H](COc3ccc(N4CCNCC4)cc3)O2)cc1
5260,830173,10.1016/j.bmcl.2012.05.074,,,,Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay,O=C(N[C@H](Cc1cc(Br)c(O)c(Br)c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1,"(R)-N-(1-(1,4'-bipiperidin-1'-yl)-3-(3,5-dibromo-4-hydroxyphenyl)-1-oxopropan-2-yl)-4-(2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-1-carboxamide",2.4,uM,=,0.380211241711606,1,O=C(N[C@H](Cc1ccccc1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1
5261,462442,10.1016/j.bmcl.2008.01.047,,,,Inhibition of CYP3A4,CC(C)(C)OC(=O)N[C@H](Cc1c(F)cccc1C(F)(F)F)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1,"(R)-tert-butyl 3-(2-fluoro-6-(trifluoromethyl)phenyl)-1-oxo-1-((3-(1-phenylcyclopropyl)-3H-imidazo[4,5-b]pyridin-2-yl)methylamino)propan-2-ylcarbamate",3.4,uM,=,0.5314789170422551,1,O=C(CCc1ccccc1)NCc1nc2cccnc2n1C1(c2ccccc2)CC1
5262,2221810,10.1016/j.bmcl.2022.128625,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as substrate pretreated with NADPH,CCCC1N(C(=O)c2cnccc2C(F)(F)F)CCCC1(Oc1csc(C(F)(F)F)c1)C(=O)N1CCN(c2ccccc2OCCO)CC1,"(4-(2-(2-hydroxyethoxy)phenyl)piperazin-1-yl)((2R,3S)-2-propyl-1-(4-(trifluoromethyl)nicotinoyl)-3-(5-(trifluoromethyl)thiophen-3-yloxy)piperidin-3-yl)methanone",0.3,uM,=,-0.5228787452803376,0,O=C(c1cccnc1)N1CCCC(Oc2ccsc2)(C(=O)N2CCN(c3ccccc3)CC2)C1
5263,1296352,10.1021/jm4015108,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,CC(C)n1cc(S(=O)(=O)c2ccc(NC(=O)[C@H]3C[C@@H]3c3cccnc3)cc2)cn1,"trans-(S,S)-N-(4-((1-Isopropyl-1H-pyrazol-4-yl)sulfonyl)-phenyl)-2-(pyridin-3-yl)cyclopropanecarboxamide",1.9,uM,=,0.2787536009528289,1,O=C(Nc1ccc(S(=O)(=O)c2cn[nH]c2)cc1)[C@H]1C[C@@H]1c1cccnc1
5264,1846363,10.1016/j.ejmech.2019.02.073,,,,Inhibition of CYP3A4 in human liver microsomes assessed as reduction in metabolite formation using midazolam as substrate incubated for 10 mins in presence of NADPH by HPLC based mass spectrometric method,CC[C@H]1OC(=O)[C@@](C)(F)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)/C(=N\OCC#Cc2ccc3c(c2)c(=O)c(C(N)=O)cn3CC)[C@H](C)[C@H]2OC(=O)O[C@@]21C,"2-Fluoro-3-O-descladinosyl-3-oxo-6-O-methylerythromycin A 9-O-[3-(3'-carbamoyl-1',4'-dihydro-1'-ethyl-4'-oxo-quinol-6'-yl)-2-propargyl]oxime-11,12-cyclic carbonate",7.32,uM,=,0.8645110810583919,1,O=C1CC(=O)OCC2OC(=O)O[C@@H]2C/C(=N/OCC#Cc2ccc3[nH]ccc(=O)c3c2)CCC[C@H](O[C@H]2CCCCO2)C1
5265,813105,10.1021/jm201346g,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,COc1ccc2[nH]c(SCc3ccccn3)nc2c1,5-methoxy-2-(pyridin-2-ylmethylthio)-1H-benzo[d]imidazole,4.01,uM,=,0.6031443726201823,1,c1ccc(CSc2nc3ccccc3[nH]2)nc1
5266,674156,10.1016/j.bmcl.2010.08.100,,,,Inhibition of CYP3A4 in human liver microsomes by fluorometric assay,CN(c1ccnc(Nc2cc(N3CCOCC3)cc(N3CCOCC3)c2)n1)c1cccc2[nH]ncc12,"N2-(3,5-dimorpholinophenyl)-N4-(1H-indazol-4-yl)-N4-methylpyrimidine-2,4-diamine",5.0,uM,=,0.6989700043360189,1,c1cc(Nc2ccnc(Nc3cc(N4CCOCC4)cc(N4CCOCC4)c3)n2)c2cn[nH]c2c1
5267,2016610,10.1021/acs.jmedchem.0c01203,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 to 20 mins in presence of NADPH by LC-MS/MS analysis,Cc1cc(-c2ccn3nc(N)c(-c4cnn(C)c4)c3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2,"5-[2-Amino-3-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]-pyrimidin-5-yl]-2-[(1S)-1-cyclopropylethyl]-7-methyl-2,3-dihydro-1H-isoindol-1-one",0.45,uM,=,-0.3467874862246563,0,O=C1c2ccc(-c3ccn4ncc(-c5cn[nH]c5)c4n3)cc2CN1CC1CC1
5268,1846363,10.1016/j.ejmech.2019.02.073,,,,Inhibition of CYP3A4 in human liver microsomes assessed as reduction in metabolite formation using midazolam as substrate incubated for 10 mins in presence of NADPH by HPLC based mass spectrometric method,CC[C@H]1OC(=O)[C@@](C)(F)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC/C=C/c2ccc3c(c2)c(=O)c(C(N)=O)cn3C2CC2)C[C@@H](C)/C(=N\OC)[C@H](C)[C@H]2OC(=O)O[C@@]21C,"2-Fluoro-3-O-descladinosyl-3-oxo-6-O-[3-(3'-carbamoyl-1'-cyclopropyl-1',4'-dihydro-4'-oxo-quinoline-6'-yl)-E-prop-2-enyl]erythromycin A-9-methyl oxime-11,12-cyclic carbonate",14.9,uM,=,1.173186268412274,1,N=C1CCC(OC/C=C/c2ccc3c(c2)c(=O)ccn3C2CC2)[C@H](O[C@H]2CCCCO2)CC(=O)CC(=O)OCC2OC(=O)O[C@@H]2C1
5269,789986,10.1016/j.bmcl.2011.10.013,,,,Reversible inhibition of CYP3A4,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@]23OCc2cc(F)c(F)cc23)C2CC2)cc(OCCOC)c1,"(1R,3'S)-N-cyclopropyl-5,6-difluoro-N-(3-(2-methoxyethoxy)-5-(3-methoxypropyl)benzyl)-3H-spiro[isobenzofuran-1,4'-piperidine]-3'-carboxamide",13.0,uM,=,1.1139433523068367,1,O=C([C@H]1CNCC[C@@]12OCc1ccccc12)N(Cc1ccccc1)C1CC1
5270,949160,10.1016/j.bmcl.2013.01.011,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate,CCc1cc(CC(NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2c(C)n[nH]c12,"(+/-)-N-(1-(1,4'-bipiperidin-1'-yl)-3-(7-ethyl-3-methyl-1H-indazol-5-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide",6.9,uM,=,0.8388490907372553,1,O=C(NC(Cc1ccc2[nH]ncc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
5271,2204939,10.1016/j.ejmech.2022.114581,,,,Inhibition of CYP3A4T (unknown origin),Cc1cccc(-c2cc(C#N)cc(Oc3c(C(F)(F)F)ccn(Cc4n[nH]c(=O)n4C)c3=O)c2)c1,"3'-methyl-5-((1-((4-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)methyl)-2-oxo-4-(trifluoromethyl)-1,2-dihydropyridin-3-yl)oxy)-[1,1'-biphenyl]-3-carbonitrile",25.3,uM,=,1.403120521175818,1,O=c1[nH]nc(Cn2cccc(Oc3cccc(-c4ccccc4)c3)c2=O)[nH]1
5272,1296353,10.1021/jm4015108,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis,CCCn1cc(S(=O)(=O)c2ccc(NC(=O)[C@H]3C[C@@H]3c3cccnc3)cc2)cn1,"trans-(S,S)-N-(4-((1-Propyl-1H-pyrazol-4-yl)sulfonyl)phenyl)-2-(pyridin-3-yl)cyclopropanecarboxamide",0.14,uM,=,-0.8538719643217619,0,O=C(Nc1ccc(S(=O)(=O)c2cn[nH]c2)cc1)[C@H]1C[C@@H]1c1cccnc1
5273,2171279,10.1021/acs.jmedchem.1c01083,,,,Inhibition of human recombinant CYP3A4 expressed in insect microsome using 7-benzyloxy-4-trifluoromethylcoumarin as a substrate incubated for 30 mins followed by addition of NADPH regenerating system measured immediately by fluorescence based analysis,C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)OCCCOCCCCCCCCCCCCCC#CC(F)(F)F.N,"Ammonium ((1R)-2-(6-Aminopurin-9-yl)-1-methyl-ethoxy]methyl-[3-(16,16,16-trifluorohexadec-14-ynoxy)propoxylphosphinate",12.0,uM,=,1.0791812460476249,1,c1ncc2nc[nH]c2n1
5274,805766,10.1016/j.bmcl.2012.01.060,,,,Inhibition of recombinant CYP3A4,FC(F)(F)c1ccccc1-c1ccc2[nH]c(/C=C/C3CCCCC3)nc2c1,2-(2-cyclohexylvinyl)-5-(2-(trifluoromethyl)phenyl)-1H-benzo[d]imidazole,3.5,uM,=,0.5440680443502757,1,C(=C/C1CCCCC1)\c1nc2cc(-c3ccccc3)ccc2[nH]1
5275,1275554,10.1016/j.bmcl.2013.10.001,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by NADPH and substrate addition measured after 5 mins by LC/MS/MS analysis,Cc1c(Cc2cccc(NS(N)(=O)=O)c2F)c(=O)oc2cc(OC(=O)N(C)C)c(F)cc12,Dimethylcarbamic acid 6-fluoro-3-[2-fluoro-3-(sulfamoylamino)benzyl]-4-methyl-2-oxo-2H-chromen-7-yl ester,14.0,uM,=,1.146128035678238,1,O=c1oc2ccccc2cc1Cc1ccccc1
5276,1986041,10.1021/acs.jmedchem.0c00564,,,,Inhibition of CYP3A4 (unknown origin) expressed in insect cell microsomes using dibenzylfluorescein substrate by fluorescence based assay,CCOC(=O)C1=C(C)Nc2nc3ccccc3n2C1c1cnoc1,"(+/-)-Ethyl 4-(Isoxazol-4-yl)-2-methyl-1,4-dihydrobenzo[4,5]imidazo[1,2-a]pyrimidine-3-carboxylate",4.92,uM,=,0.6919651027673603,1,C1=CC(c2cnoc2)n2c(nc3ccccc32)N1
5277,621465,10.1016/j.bmcl.2009.07.118,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,O=C(N[C@@H](Cc1ccccc1)CN(CC1CC1)C[C@H](Cc1ccccc1)NC(=O)OCc1nccs1)OCc1cncs1,Bis-N-[(S)-2-(thiazol-5-ylmethoxycarbonylamino)-3-phenylpropyl]-N-[cyclopropylmethyl]amine,0.052,uM,=,-1.2839966563652008,0,O=C(N[C@@H](Cc1ccccc1)CN(CC1CC1)C[C@H](Cc1ccccc1)NC(=O)OCc1nccs1)OCc1cncs1
5278,718098,10.1016/j.bmcl.2010.12.053,,,,Inhibition of CYP3A4,C[C@H](C1=C(CCN(C)Cc2ncco2)Cc2ccccc21)c1cnccn1,(R)-N-methyl-N-(oxazol-2-ylmethyl)-2-(3-(1-(pyrazin-2-yl)ethyl)-1H-inden-2-yl)ethanamine,4.84,uM,=,0.6848453616444125,1,c1ccc2c(c1)CC(CCNCc1ncco1)=C2Cc1cnccn1
5279,615765,10.1016/j.bmcl.2010.02.003,,,,Inhibition of CYP3A4,O=C(O)/C=C/c1ccc(NC(=O)C2(NC(=O)c3ccc4c(c3)nc(-c3ccoc3)n4C3CCCCC3)CCCC2)cc1,3-(4-(1-(1-cyclohexyl-2-(furan-3-yl)-1H-benzo[d]imidazole-5-carboxamido)cyclopentanecarboxamido)phenyl)acrylic acid,30.0,uM,=,1.4771212547196624,1,O=C(NC1(C(=O)Nc2ccccc2)CCCC1)c1ccc2c(c1)nc(-c1ccoc1)n2C1CCCCC1
5280,2171279,10.1021/acs.jmedchem.1c01083,,,,Inhibition of human recombinant CYP3A4 expressed in insect microsome using 7-benzyloxy-4-trifluoromethylcoumarin as a substrate incubated for 30 mins followed by addition of NADPH regenerating system measured immediately by fluorescence based analysis,C#CCCCCCCCCCCCCCCCCOP(=O)(O)CO[C@H](C)Cn1cnc2c(N)ncnc21.N,Ammonium Octadec-17-yn-1-yl-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)phosphonate,18.7,uM,=,1.271841606536499,1,c1ncc2nc[nH]c2n1
5281,1872070,10.1021/acs.jmedchem.8b01550,,,,Inhibition of CYP3A4 in human liver microsomes,CC(C)COc1ccc(-c2cn(C)c3cc(C(=O)NS(C)(=O)=O)c(F)cc23)cn1,5-Fluoro-3-(6-isobutoxypyridin-3-yl)-1-methyl-N-(methylsulfonyl)-1H-indole-6-carboxamide,15.0,uM,=,1.1760912590556811,1,c1cncc(-c2c[nH]c3ccccc23)c1
5282,476993,10.1016/j.bmcl.2008.02.076,,,,Inhibition of CYP3A4,O=C1CC(c2cccc(-n3ccnn3)c2)=Nc2ccc(-c3ccccc3F)cc2N1,"4-(3-(1H-1,2,3-triazol-1-yl)phenyl)-8-(2-fluorophenyl)-1H-benzo[b][1,4]diazepin-2(3H)-one",4.3,uM,=,0.6334684555795865,1,O=C1CC(c2cccc(-n3ccnn3)c2)=Nc2ccc(-c3ccccc3)cc2N1
5283,621465,10.1016/j.bmcl.2009.07.118,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,CCN(CC(CC1CCCCC1)NC(=O)OCc1cncs1)CC(CC1CCCCC1)NC(=O)OCc1nccs1,Bis-N-[2-(thiazol-5-ylmethoxycarbonylamino)-3-cyclohexylpropyl]ethylamine,0.066,uM,=,-1.1804560644581312,0,O=C(NC(CNCC(CC1CCCCC1)NC(=O)OCc1nccs1)CC1CCCCC1)OCc1cncs1
5284,813105,10.1021/jm201346g,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,CCSc1nc2cc(OC)ccc2[nH]1,2-(ethylthio)-5-methoxy-1H-benzo[d]imidazole,50.0,uM,=,1.6989700043360187,1,c1ccc2[nH]cnc2c1
5285,1527906,,,,,Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,C[C@@H](c1ccc(Br)cc1)N1CC[C@](CC(C)(C)O)(c2ccc(F)cc2)OC1=O,"US8575157, 201::US8592410, Comparator 13::US8598163, 71",4.4,uM,=,0.6434526764861874,1,O=C1OC(c2ccccc2)CCN1Cc1ccccc1
5286,1347924,10.1016/j.bmcl.2014.04.024,,,,Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method,CC(C)C(O)(c1ccc2cc(-c3cnco3)ccc2c1)c1cnn[nH]1,"rac-2-methyl-1-(6-(oxazol-5-yl)naphthalen-2-yl)-1-(1H-1,2,3-triazol-4-yl)propan-1-ol",102.0,uM,=,2.008600171761917,1,c1ncc(-c2ccc3cc(Cc4cnn[nH]4)ccc3c2)o1
5287,453162,10.1016/j.bmcl.2006.09.056,,,,Inhibition of CYP3A4 in presence of BQ substrate,NCC1CCC(CNc2nc(NCc3ccccc3Cl)ncc2[N+](=O)[O-])CC1,"N2-(2-chlorobenzyl)-N4-((4-(aminomethyl)cyclohexyl)methyl)-5-nitropyrimidine-2,4-diamine",1.4,uM,=,0.1461280356782379,1,c1ccc(CNc2nccc(NCC3CCCCC3)n2)cc1
5288,1296352,10.1021/jm4015108,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,CCCn1cc(S(=O)(=O)c2ccc(NC(=O)[C@@H]3C[C@H]3c3cccnc3)cc2)cn1,rac-trans-N-(4-((1-Propyl-1H-pyrazol-4-yl)sulfonyl)phenyl)-2-(pyridin-3-yl)cyclopropanecarboxamide,3.0,uM,=,0.4771212547196624,1,O=C(Nc1ccc(S(=O)(=O)c2cn[nH]c2)cc1)[C@@H]1C[C@H]1c1cccnc1
5289,1497736,10.1021/jm5020023,,,,Inhibition of human recombinant CYP3A4 using testosterone as substrate after 1 hr by LC-MS/MS analysis,CC1(C)CC[C@]23CC[C@@]4(C)[C@]5(C)CC[C@H]6C(C)(C)C(=O)C(C#N)=C[C@]6(C)C5=CC(=O)[C@@]4([C@@H]2C1)N(C1CCCCC1)C3=O,"(1S,4S,5R,8R,13S,17S,18R)-24-cyclohexyl-4,5,9,9,13,20,20-heptamethyl-10,16,23-trioxo-24-azahexacyclo[15.5.2.0^{1,18}.0^{4,17}.0^{5,14}.0^{8,13}]tetracosa-11,14-diene-11-carbonitrile",2.535,uM,=,0.4039779636693548,1,O=C1C=CC2C3=CC(=O)[C@@]45C(CC[C@]6(CCCC[C@H]64)C(=O)N5C4CCCCC4)C3CC[C@H]2C1
5290,686510,10.1016/j.bmcl.2010.09.039,,,,Inhibition of CYP3A4,O=c1cc(OCc2ccccc2)ccn1-c1ccc2c(cnn2CC2=NCCN2)c1,"4-(benzyloxy)-1-(1-((4,5-dihydro-1H-imidazol-2-yl)methyl)-1H-indazol-5-yl)pyridin-2(1H)-one",38.0,uM,=,1.57978359661681,1,O=c1cc(OCc2ccccc2)ccn1-c1ccc2c(cnn2CC2=NCCN2)c1
5291,1347924,10.1016/j.bmcl.2014.04.024,,,,Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method,CC(C)C(O)(c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1)c1cnn[nH]1,"rac-1-(6,7-bis(difluoromethoxy)naphthalen-2-yl)-2-methyl-1-(1H-1,2,3-triazol-4-yl)propan-1-ol",23.0,uM,=,1.3617278360175928,1,c1ccc2cc(Cc3cnn[nH]3)ccc2c1
5292,1628094,10.1016/j.ejmech.2016.08.024,,,,Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells using fluorescent substrate,CC(=O)N1C2CCC1CN(C(=O)CC1([C@H]3CO[C@H]4CCC[C@H]4N3S(=O)(=O)c3ccc(Cl)cc3)CC1)C2,"1-(8-acetyl-3,8-diazabicyclo[3.2.1]octan-3-yl)-2-(1-((3S,4aR,7aS)-4-(4-chlorophenylsulfonyl)octahydrocyclopenta[b][1,4]oxazin-3-yl)cyclopropyl)ethanone",30.0,uM,=,1.4771212547196624,1,O=C(CC1([C@H]2CO[C@H]3CCC[C@H]3N2S(=O)(=O)c2ccccc2)CC1)N1CC2CCC(C1)N2
5293,1707938,10.1021/acs.jmedchem.7b01420,,,,Inhibition of CYP3A4 (unknown origin),CC1(C)CCC(NCC(C)(C)CCN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)CC1,"N1-(4,4-Dimethylcyclohexyl)-2,2-dimethyl-N4-(((R)-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)-N4-((S)-5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine",7.83,uM,=,0.8937617620579434,1,c1ccc2c(c1)CN[C@@H](CN(CCCCNC1CCCCC1)[C@H]1CCCc3cccnc31)C2
5294,2228092,10.1021/acs.jmedchem.2c00552,,,,Inhibition of CYP3A4 (unknown origin),Cc1ccc(O)c(C)c1-n1c(N)c(C(N)=O)c2nc(C3CC3)cnc21,"6-amino-2-cyclopropyl-5-(3-hydroxy-2,6-dimethylphenyl)-pyrrolo[2,3-b]pyrazine-7-carboxamide",13.0,uM,=,1.1139433523068367,1,c1ccc(-n2ccc3nc(C4CC4)cnc32)cc1
5295,761291,10.1021/jm101312a,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,CN1C[C@@H]2CCC[C@]2(c2ccc(Cl)c(Cl)c2)C1,"cis-rac-(3aS,6aR)-3a-(3,4-dichlorophenyl)-2-methyloctahydrocyclopenta[c]pyrrole",12.7,uM,=,1.1038037209559568,1,c1ccc([C@]23CCC[C@H]2CNC3)cc1
5296,1628094,10.1016/j.ejmech.2016.08.024,,,,Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells using fluorescent substrate,CC(=O)N1C2CCC1CN(C(=O)CC1([C@H]3COC[C@@H](C4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC1)C2,"1-(8-acetyl-3,8-diazabicyclo[3.2.1]octan-3-yl)-2-(1-((3S,5R)-4-(4-chlorophenylsulfonyl)-5-cyclopropylmorpholin-3-yl)cyclopropyl)ethanone",30.0,uM,=,1.4771212547196624,1,O=C(CC1([C@H]2COC[C@@H](C3CC3)N2S(=O)(=O)c2ccccc2)CC1)N1CC2CCC(C1)N2
5297,583696,10.1016/j.bmcl.2009.05.066,,,,Inhibition of human recombinant CYP3A4 after 45 mins,CC(Cn1ccnc1)NC(=O)NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1,1-(1-(1H-imidazol-1-yl)propan-2-yl)-3-(1-((1-(4-(trifluoromethyl)phenyl)-1H-pyrrol-3-yl)methyl)piperidin-4-yl)urea,0.32,uM,=,-0.494850021680094,0,O=C(NCCn1ccnc1)NC1CCN(Cc2ccn(-c3ccccc3)c2)CC1
5298,2221810,10.1016/j.bmcl.2022.128625,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as substrate pretreated with NADPH,C=CCOc1nccc(C(F)(F)F)c1C(=O)N1CCC[C@@](Oc2csc(C(F)(F)F)c2)(C(=O)N2CCN(c3ccccc3OCCO)CC2)[C@H]1CCC,"((2R,3S)-1-(2-(allyloxy)-4-(trifluoromethyl)nicotinoyl)-2-propyl-3-(5-(trifluoromethyl)thiophen-3-yloxy)piperidin-3-yl)(4-(2-(2-hydroxyethoxy)phenyl)piperazin-1-yl)methanone",5.7,uM,=,0.7558748556724915,1,O=C(c1cccnc1)N1CCC[C@@](Oc2ccsc2)(C(=O)N2CCN(c3ccccc3)CC2)C1
5299,789986,10.1016/j.bmcl.2011.10.013,,,,Reversible inhibition of CYP3A4,O=C([C@H]1CNCC[C@@]12OCc1cc(F)c(F)cc12)N(Cc1cccc(C(F)(F)F)c1Cl)C1CC1,"(1R,3'S)-N-(2-chloro-3-(trifluoromethyl)benzyl)-N-cyclopropyl-5,6-difluoro-3H-spiro[isobenzofuran-1,4'-piperidine]-3'-carboxamide",3.6,uM,=,0.5563025007672873,1,O=C([C@H]1CNCC[C@@]12OCc1ccccc12)N(Cc1ccccc1)C1CC1
5300,942020,10.1021/jm301782e,,,,Inhibition of CYP3A4 (unknown origin),Cc1cccc(N2CNC(=O)C23CCN(C[C@H](C)NC(=O)c2ccc(Br)cc2)CC3)c1,"(S)-4-bromo-N-(1-(4-oxo-1-m-tolyl-1,3,8-triazaspiro[4.5]decan-8-yl)propan-2-yl)benzamide",6.8,uM,=,0.8325089127062363,1,O=C(NCCN1CCC2(CC1)C(=O)NCN2c1ccccc1)c1ccccc1
5301,813105,10.1021/jm201346g,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,COc1ccc2[nH]c(SCc3ccc(C(=O)O)cc3)nc2c1,4-((5-methoxy-1H-benzo[d]imidazol-2-ylthio)methyl)benzoic acid,50.0,uM,=,1.6989700043360187,1,c1ccc(CSc2nc3ccccc3[nH]2)cc1
5302,674334,10.1016/j.bmcl.2010.09.038,,,,Inhibition of human CYP3A4,COc1ccccc1-c1nc2c(C(=O)N[C@@H]3C[C@H]4CCC[C@@H](C3)N4C)cccc2o1,"endo-2-(2-methoxyphenyl)-N-((1R,5R)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)benzo[d]oxazole-4-carboxamide",1.1,uM,=,0.041392685158225,1,O=C(N[C@@H]1C[C@H]2CCC[C@@H](C1)N2)c1cccc2oc(-c3ccccc3)nc12
5303,2111417,10.1016/j.ejmech.2020.113109,,,,Inhibition of CYP3A4 (unknown origin) using Luciferin-PPXE as substrate at 10 uM preincubated with enzyme and substrate for 5 mins followed by addition of NADPH regeneration system and measured after 60 mins by luminescence method,COc1ncc2cc1NS(=O)(=O)c1cc(c(F)cc1F)C(=O)NCc1cncc(c1)-c1ccnc3ccc-2nc13,,6.5,uM,=,0.8129133566428556,1,O=C1NCc2cncc(c2)-c2ccnc3ccc(nc23)-c2cncc(c2)NS(=O)(=O)c2cccc1c2
5304,1347924,10.1016/j.bmcl.2014.04.024,,,,Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method,COc1cc2ccc(C(O)(c3c[nH]cn3)C(C)C)cc2cc1OC,"rac-1-(6,7-dimethoxynaphthalen-2-yl)-1-(1H-imidazol-4-yl)-2-methylpropan-1-ol",1.6,uM,=,0.2041199826559248,1,c1ccc2cc(Cc3c[nH]cn3)ccc2c1
5305,458143,10.1016/j.bmcl.2007.09.006,,,,Inhibition of CYP3A4 after 30 mins,O=C(OC1([C@H]2CCC[C@@H](C3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CCN(CCO)CC1,"1-((2R,6S)-1-(4-chlorophenylsulfonyl)-6-cyclopropylpiperidin-2-yl)cyclopropyl 4-(2-hydroxyethyl)piperazine-1-carboxylate",0.4,uM,=,-0.3979400086720376,0,O=C(OC1([C@H]2CCC[C@@H](C3CC3)N2S(=O)(=O)c2ccccc2)CC1)N1CCNCC1
5306,1512778,10.1016/j.bmcl.2015.07.038,,,,Inhibition of CYP3A4 in human liver microsomes assessed as reduction in midazolam 1'-hydroxylation by LC-MS/MS method,COc1cccc2nc(CCCN(C)CC[C@]3(OC(=O)C(C)C)C[C@H]4CCC[C@@H]3c3ccccc34)[nH]c12,"Isobutyric acid (1R,8R,12R)-12-(2-{[3-(4-methoxy-1H-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)-tricyclo[6.3.2.02,7]trideca-2,4,6-trien-12-yl ester",3.0,uM,=,0.4771212547196624,1,c1ccc2c(c1)[C@@H]1CCC[C@H]2C(CCNCCCc2nc3ccccc3[nH]2)C1
5307,1735372,10.1021/acs.jmedchem.8b00084,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis,Cl.Cl.NCC#Cc1cnccc1-c1ccco1,3-(4-Furan-2-yl-pyridin-3-yl)-prop-2-ynylamine Dihydrochloride,11.0,uM,=,1.0413926851582251,1,c1coc(-c2ccncc2)c1
5308,806356,10.1016/j.bmcl.2012.01.081,,,,Inhibition of CYP3A4 after 30 mins by fluorescence assay,C/C(=C\COc1c2ccoc2cc2oc(=O)ccc12)CC[C@@H](O)C(C)(C)O,"6',7'-dihydroxybergamottin",0.81,uM,=,-0.0915149811213502,0,O=c1ccc2cc3ccoc3cc2o1
5309,2282762,10.1021/acs.jmedchem.1c01245,,,,Inhibition of CYP3A4 in human liver microsomes using dextromethorphan as substrate by LC-MS/MS analysis,CC[C@@H](Nc1c(C#N)c(-c2ccc(-c3cccc(Cl)c3F)cc2)nc2cnccc12)C(N)=O,"(2R)-2-((2-(3'-Chloro-2'-fluorobiphenyl-4-yl)-3-cyano-1,7-naphthyridia-4-yl)amino)butanamide",10.0,uM,=,1.0,1,c1ccc(-c2ccc(-c3ccc4ccncc4n3)cc2)cc1
5310,830174,10.1016/j.bmcl.2012.05.074,,,,Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using 7-benzyloxy-4-trifluoromethylcoumarin as substrate after 20 mins by fluorescence detection assay,O=C(N[C@H](Cc1csc2ccccc12)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1,"(R)-N-(1-(1,4'-bipiperidin-1'-yl)-3-(benzo[b]thiophen-3-yl)-1-oxopropan-2-yl)-4-(2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-1-carboxamide",0.87,uM,=,-0.0604807473813814,0,O=C(N[C@H](Cc1csc2ccccc12)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1
5311,2025553,10.1016/j.bmcl.2020.127744,,,,Inhibition of CYP3A4 (unknown origin),C[C@@H](C(=O)Nc1ccc(Cl)cc1)[C@H]1CC[C@@H](c2ccnc3ccc(F)cc32)CC1,"(R)-N-(4-chlorophenyl)-2-((1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide",5.1,uM,=,0.7075701760979364,1,O=C(C[C@H]1CC[C@@H](c2ccnc3ccccc32)CC1)Nc1ccccc1
5312,1707938,10.1021/acs.jmedchem.7b01420,,,,Inhibition of CYP3A4 (unknown origin),c1ccc2c(c1)CN[C@@H](CN(Cc1ccc(CNC3CCOCC3)cc1)[C@H]1CCCc3cccnc31)C2,"(S)-N-(4-(((Tetrahydro-2H-pyran-4-yl)amino)methyl)benzyl)-N-(((R)-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)-5,6,7,8-tetrahydroquinolin-8-amine",0.442,uM,=,-0.3545777306509081,0,c1ccc2c(c1)CN[C@@H](CN(Cc1ccc(CNC3CCOCC3)cc1)[C@H]1CCCc3cccnc31)C2
5313,1659863,10.1016/j.ejmech.2017.02.016,,,,Inhibition of human liver CYP3A4 expressed in Saccharomyces cerevisiae YY7 microsomal membranes using DBF as substrate after 10 mins by fluorescence assay,COc1ccc2cc(C(=O)/C=C/c3cccnc3)ccc2c1,(E)-1-(6-Methoxy-2-naphthyl)-3-(3-pyridyl)prop-2-en-1-one,10.6,uM,=,1.0253058652647702,1,O=C(/C=C/c1cccnc1)c1ccc2ccccc2c1
5314,2121115,10.1016/j.ejmech.2021.113740,,,,Inhibition of CYP3A4 in human liver Microsome using midazolam as substrate preincubated for 10 mins followed by NADPH addition and further incubated for 10 mins as substrate by LC-MS/MS analysis,O=C(NC(Cn1ccnc1)C(=O)c1cccc(F)c1)c1ccc(-c2ccc(Cl)cc2)s1,5-(4-chlorophenyl)-N-(1-(3-fluorophenyl)-3-(1H-imidazol-1-yl)-1-oxopropan-2-yl)thiophene-2-carboxamide,1.17,uM,=,0.0681858617461616,1,O=C(NC(Cn1ccnc1)C(=O)c1ccccc1)c1ccc(-c2ccccc2)s1
5315,1689465,10.1021/acs.jmedchem.7b00662,,,,Inhibition of CYP3A4 (unknown origin),CN1C(=O)C2=C(C1=O)N(CC(=O)Nc1ccc(-c3cccnc3)nn1)CCC2,"2-(6-Methyl-5,7-dioxo-2,3,4,5,6,7-hexahydro-1H-pyrrolo-[3,4-b]pyridin-1-yl)-N-(6-(pyridin-3-yl)pyridazin-3-yl)acetamide",6.2,uM,=,0.7923916894982539,1,O=C(CN1CCCC2=C1C(=O)NC2=O)Nc1ccc(-c2cccnc2)nn1
5316,813105,10.1021/jm201346g,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,CCCCCSc1nc2cc(OC)ccc2[nH]1,5-methoxy-2-(pentylthio)-1H-benzo[d]imidazole,26.3,uM,=,1.4199557484897578,1,c1ccc2[nH]cnc2c1
5317,1534814,,,,,Inhibition Assay: Inhibition assay using P450 CYP enzymes.,CNC(=O)/C=C/c1cc(OC)cc(-c2ccc3cc(OC)ccc3c2)c1,"US8546392, 70",2.25,uM,=,0.3521825181113625,1,c1ccc(-c2ccc3ccccc3c2)cc1
5318,1735372,10.1021/acs.jmedchem.8b00084,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis,Cl.Cl.NCc1ccc(-c2cnccc2-c2ccoc2)s1,(5-(4-(Furan-3-yl)pyridin-3-yl)thiophen-2-yl)methanamine Dihydrochloride,5.2,uM,=,0.7160033436347992,1,c1csc(-c2cnccc2-c2ccoc2)c1
5319,830173,10.1016/j.bmcl.2012.05.074,,,,Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay,O=C(NC(Cc1ccc2[nH]ncc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1,"(+/-)-N-(1-(1,4'-bipiperidin-1'-yl)-3-(1H-indazol-5-yl)-1-oxopropan-2-yl)-4-(2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-1-carboxamide",17.0,uM,=,1.230448921378274,1,O=C(NC(Cc1ccc2[nH]ncc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1
5320,1527906,,,,,Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,C[C@@H](c1ccc(-c2ccc(=O)n(CC(F)(F)F)n2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O,"US8592410, 16",15.6,uM,=,1.1931245983544616,1,O=C1OC(c2ccccc2)CCN1Cc1ccc(-c2ccc(=O)[nH]n2)cc1
5321,1534814,,,,,Inhibition Assay: Inhibition assay using P450 CYP enzymes.,O=C(O)CCC(=O)Nc1ccc(-c2c(O)ccc3cc(-c4cccc(O)c4)ccc23)cc1,"US8546392, 59",0.221,uM,=,-0.6556077263148893,0,c1ccc(-c2ccc3c(-c4ccccc4)cccc3c2)cc1
5322,1859913,10.1021/acsmedchemlett.9b00114,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate measured after 10 mins in presence of NADPH by UHPLC-MS/MS analysis,Cc1cc(N2CCC(C3c4c(F)cccc4-c4cncn43)CC2)ccc1-c1cnn(C)c1,"6-fluoro-5-(1-(3-methyl-4-(1-methyl-1H-pyrazol-4-yl)phenyl)piperidin-4-yl)-5H-imidazo[5,1-a]isoindole",0.44,uM,=,-0.3565473235138126,0,c1ccc2c(c1)-c1cncn1C2C1CCN(c2ccc(-c3cn[nH]c3)cc2)CC1
5323,1468060,10.1016/j.bmcl.2015.03.035,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as marker substrate,COc1cccc(F)c1C1C[C@@H](O)C(=O)N1Cc1ccc2oc3ccccc3c2c1,"rac-(3R*,5S*)-1-(dibenzo[b,d]furan-2-ylmethyl)-5-(2-fluoro-6-methoxyphenyl)-3-hydroxypyrrolidin-2-one",46.0,uM,=,1.662757831681574,1,O=C1CCC(c2ccccc2)N1Cc1ccc2oc3ccccc3c2c1
5324,1347924,10.1016/j.bmcl.2014.04.024,,,,Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method,CC(C)C(O)(c1ccc2cc(-c3cccs3)ccc2c1)c1c[nH]nn1,"rac-2-methyl-1-(6-(thiophen-2-yl)naphthalen-2-yl)-1-(1H-1,2,3-triazol-4-yl)propan-1-ol",81.0,uM,=,1.9084850188786493,1,c1csc(-c2ccc3cc(Cc4c[nH]nn4)ccc3c2)c1
5325,1468060,10.1016/j.bmcl.2015.03.035,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as marker substrate,COc1cccc(OC)c1C1CCC(=O)N1Cc1ccc2oc3ccccc3c2c1,"rac-1-(dibenzo[b,d]furan-2-ylmethyl)-5-(2,6-dimethoxyphenyl)pyrrolidin-2-one",6.9,uM,=,0.8388490907372553,1,O=C1CCC(c2ccccc2)N1Cc1ccc2oc3ccccc3c2c1
5326,424472,10.1016/j.bmcl.2006.08.086,,,,Inhibition of CYP3A4 in human liver microsomes,COC(=O)N(NC(=O)c1c(OC)c(-c2ccccc2)nc2ccccc12)c1ccccc1,N'-(3-methoxy-2-phenyl-quinoline-4-carbonyl)-N-phenyl-hydrazinecarboxylic acid methyl ester,12.0,uM,=,1.0791812460476249,1,O=C(NNc1ccccc1)c1cc(-c2ccccc2)nc2ccccc12
5327,2241411,10.1016/j.ejmech.2021.113981,,,,Inhibition of CYP3A4 in human liver microsomes assessed as reduction in 1'-hydroxy midazolam formation using midazolam as substrate preincubated for 20 mins in absence of NADPH followed by incubation with substrate for 10 mins by LC-MS/MS analysis,O[C@H](c1cc(C(F)(F)F)nc2c(C(F)(F)F)cccc12)[C@@H]1CCCCN1,"(R)-(2,8-bis(trifluoromethyl)quinolin-4-yl)((S)-piperidin-2-yl)methanol",45.0,uM,=,1.6532125137753435,1,c1ccc2c(C[C@@H]3CCCCN3)ccnc2c1
5328,1536230,,,,,"Inhibition Assay: Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v. Pooled human liver microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 5 mg/mL suspension. A solution of NADPH was prepared in phosphate buffer at a concentration of 5 mM. Separate stock solutions of each substrate were prepared in DMSO:MeCN (50:50 v/v), mixed, and diluted in phosphate buffer to obtain a single solution.",OC(Cn1cncn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(OC(F)(F)F)cc2)cn1,"US8754227, 18",3.8,uM,=,0.5797835966168101,1,c1ccc(-c2ccc(CC(Cn3cncn3)c3ccccc3)nc2)cc1
5329,1347924,10.1016/j.bmcl.2014.04.024,,,,Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method,CC(C)C(O)(c1ccc2cc(OC(F)F)ccc2c1)c1c[nH]nn1,"rac-1-(6-(difluoromethoxy)naphthalen-2-yl)-2-methyl-1-(1H-1,2,3-triazol-4-yl)propan-1-ol",14.0,uM,=,1.146128035678238,1,c1ccc2cc(Cc3c[nH]nn3)ccc2c1
5330,538002,10.1021/jm8006917,,,,Inhibition of human hepatic CYP3A4,Oc1cccc(-c2cnc(-c3cccc(O)c3)s2)c1,"3,3-(1,3-Thiazole-2,5-diyl)diphenol",0.8,uM,=,-0.0969100130080563,0,c1ccc(-c2cnc(-c3ccccc3)s2)cc1
5331,1641652,,,,,"Inhibition Assay: Six test compound concentrations (0.1, 0.25, 1, 2.5, 10, 25 μM in DMSO; final DMSO concentration=0.26%) are incubated with human liver microsomes (0.1 mg/mL) and NADPH (1 mM) in the presence of the probe substrate midazolam (2.5 μM) for 5 min at 37° C. The selective CYP3A4 inhibitor, ketoconazole, is screened alongside the test compounds as a positive control.",OCc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,"[8-Chloro-6-(2-fluoro-phenyl)-4H-2,5,10b-triaza-benzo[e]azulen-1-yl]-methanol",2.7,uM,=,0.4313637641589873,1,c1ccc(C2=NCc3cncn3-c3ccccc32)cc1
5332,1485690,10.1124/dmd.111.043018,,,,Inhibition of human CYP3A4 expressed in supersomes assessed inhibition of 1'-OH midazolam formation by LC-MS method,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,FK-506,0.62,uM,=,-0.2076083105017461,0,O=C1CC=CCCCC[C@@H]2CCCC(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H](/C=C/C2CCCCC2)CCC1
5333,621465,10.1016/j.bmcl.2009.07.118,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,O=C(N[C@H](Cc1ccccc1)CN(Cc1cnc2ccccc2c1)C[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)OCc1nccs1,N-[(S)-2-(thiazol-5-ylmethoxycarbonylamino)-3-phenylpropyl][(R)-2-(thiazol-5-ylmethoxycarbonylamino)-3-phenylpropyl][2-quinolylmethyl]amine,0.07,uM,=,-1.154901959985743,0,O=C(N[C@H](Cc1ccccc1)CN(Cc1cnc2ccccc2c1)C[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)OCc1nccs1
5334,1707938,10.1021/acs.jmedchem.7b01420,,,,Inhibition of CYP3A4 (unknown origin),CC(C)(CCN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21)CNC1CCOCC1,"2,2-Dimethyl-N1-(tetrahydro-2H-pyran-4-yl)-N4-(((R)-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)-N4-((S)-5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine",17.7,uM,=,1.2479732663618066,1,c1ccc2c(c1)CN[C@@H](CN(CCCCNC1CCOCC1)[C@H]1CCCc3cccnc31)C2
5335,497350,10.1016/j.ejmech.2007.10.034,,,,Inhibition of human recombinant CYP3A4,COc1cc(/C=C2\CC/C(=C\c3ccc(O)c(OC)c3)C2=O)ccc1O,"2,5-bis(4-hydroxy-3-methoxybenzylidene)cyclopentanone",64.9,uM,=,1.8122446968003687,1,O=C1/C(=C/c2ccccc2)CC/C1=C\c1ccccc1
5336,789986,10.1016/j.bmcl.2011.10.013,,,,Reversible inhibition of CYP3A4,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@]23OC(=O)Cc2ccccc23)C2CC2)cc(OCCOC)c1,"(1R,3'S)-N-cyclopropyl-N-(3-(2-methoxyethoxy)-5-(3-methoxypropyl)benzyl)-3-oxospiro[isochroman-1,4'-piperidine]-3'-carboxamide",5.6,uM,=,0.7481880270062004,1,O=C1Cc2ccccc2[C@]2(CCNC[C@@H]2C(=O)N(Cc2ccccc2)C2CC2)O1
5337,1461971,10.1021/ml500414n,,,,Inhibition of CYP3A4 (unknown origin),COc1ccc(CC(=O)N2CCC3(CC2)CN([C@@H]2CCc4cc(-c5ncccn5)ccc42)C3)cc1,"2-(4-methoxyphenyl)-1-(2-((R)-5-(pyrimidin-2-yl)-2,3-dihydro-1H-inden-1-yl)-2,7-diazaspiro[3.5]nonan-7-yl)ethanone",2.5,uM,=,0.3979400086720376,1,O=C(Cc1ccccc1)N1CCC2(CC1)CN([C@@H]1CCc3cc(-c4ncccn4)ccc31)C2
5338,1983189,10.1021/acs.jmedchem.0c00374,,,,Inhibition of recombinant human CYP3A4 using midazolam as substrate,CS(=O)(=O)n1cc2c(n1)CN([C@@H]1C[C@H](N)[C@@H](c3cc(F)ccc3F)O[C@@H]1C(F)(F)F)C2,"(2R,3S,5R,6S)-2-(2,5-Difluorophenyl)-5-(2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)-6-(trifluoromethyl)-tetrahydro-2H-pyran-3-amine",45.8,uM,=,1.6608654780038692,1,c1ccc([C@@H]2CC[C@@H](N3Cc4c[nH]nc4C3)CO2)cc1
5339,1662545,10.1021/acs.jmedchem.6b01851,,,,Inhibition of CYP3A4 (unknown origin),COc1cc(C(F)(F)F)ccc1-c1nccc2cc(S(=O)(=O)Nc3ccncn3)ccc12,"US9012443, 67",7.2,uM,=,0.8573324964312685,1,O=S(=O)(Nc1ccncn1)c1ccc2c(-c3ccccc3)nccc2c1
5340,2109895,10.1016/j.bmc.2021.116138,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate incubated for 10 mins by LC/MS/MS analysis,CC[C@]1(C)C[C@@H](OC(=O)CSc2nnc(N)[nH]2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O,"(5-amino-4H-[1,2,4]triazol-3-ylsulfanyl)-acetic acid (1S,2R,3S,4R,6R,7R,14R)-4-ethyl-3-hydroxy-2,4,7,14-tetramethyl-9-oxo-tricyclo[5.4.3.0*1,8*]tetradec-6-yl ester",0.24,uM,=,-0.619788758288394,0,O=C(CSc1nnc[nH]1)O[C@@H]1CCCC[C@@]23CCCC1[C@@H]2C(=O)CC3
5341,2157144,10.1021/acsmedchemlett.1c00473,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by TDI- high-throughput based mass spectrometry method,CN(C)C(=O)c1c(N)ccc(-c2cnc3c(c2Cl)C2(CCCC2)CN3)c1F,"6-amino-3-(4'-chloro-1',2'-dihydrospiro[cyclopentane-1,3'-pyrrolo[2,3-b]pyridin]-5'-yl)-2-fluoro-N,N-dimethylbenzamide",0.8,uM,=,-0.0969100130080563,0,c1ccc(-c2cnc3c(c2)C2(CCCC2)CN3)cc1
5342,621523,10.1021/np900266m,,,,Inhibition of CYP3A4 after 30 mins by fluorescence microplate reader assay,C/C(=C\COc1c2ccoc2cc2oc(=O)ccc12)CC[C@@H](O)C(C)(C)O,"6',7'-dihydroxybergamottin",1.58,uM,=,0.1986570869544226,1,O=c1ccc2cc3ccoc3cc2o1
5343,1527906,,,,,Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,C[C@@H](c1ccc(-c2ccc(F)cc2)cc1)N1CC[C@](CCC(N)=O)(c2ccccc2)OC1=O,"US8575157, 199::US8592410, Comparator 11::US8598163, 69",14.1,uM,=,1.14921911265538,1,O=C1OC(c2ccccc2)CCN1Cc1ccc(-c2ccccc2)cc1
5344,1735372,10.1021/acs.jmedchem.8b00084,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis,CCc1ccncc1-c1ccc(CN)s1.Cl.Cl,(5-(4-Ethylpyridin-3-yl)thiophen-2-yl)methanamine Dihydrochloride,13.0,uM,=,1.1139433523068367,1,c1cncc(-c2cccs2)c1
5345,741042,10.1016/j.bmcl.2011.02.067,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH,CCNC(=O)NCCCOc1cc(CCCOC)cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1,"(3R,4S)-N-cyclopropyl-4-(4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)phenyl)-N-(3-(3-(3-ethylureido)propoxy)-5-(3-methoxypropyl)benzyl)piperidine-3-carboxamide",6.3,uM,=,0.7993405494535817,1,O=C([C@H]1CNCC[C@@H]1c1ccc(OCCOc2ccccc2)cc1)N(Cc1ccccc1)C1CC1
5346,1561662,10.1016/j.bmc.2016.02.031,,,,Inhibition of recombinant human CYP3A4 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins by CYPEX assay,Cn1c(SCCCN2CC3CCN(c4ccccc4C(F)(F)F)C3C2)nnc1-c1cnccn1,"rac-2-{4-Methyl-5-[(3-{1-[2-(trifluoromethyl)phenyl]-octahydropyrrolo[3,4-b]pyrrol-5-yl}propyl)sulfanyl]-4H-1,2,4-triazol-3-yl}pyrazine",0.98,uM,=,-0.0087739243075051,0,c1ccc(N2CCC3CN(CCCSc4nnc(-c5cnccn5)[nH]4)CC32)cc1
5347,830173,10.1016/j.bmcl.2012.05.074,,,,Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay,O=C(N[C@H](Cc1ccc2[nH]c(=O)oc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1,"(R)-N-(1-(1,4'-bipiperidin-1'-yl)-1-oxo-3-(2-oxo-2,3-dihydrobenzo[d]oxazol-6-yl)propan-2-yl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide",30.0,uM,=,1.4771212547196624,1,O=C(N[C@H](Cc1ccc2[nH]c(=O)oc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
5348,948334,10.1021/jm400062r,,,,Inhibition of CYP3A4 (unknown origin)-mediated midazolam hydroxylation to 1'-Hydroxymidazolam,COc1cccc(CN(CCO)C(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1,3-(4-(1H-Pyrazol-4-yl)phenyl)-1-(2-hydroxyethyl)-1-(3-methoxybenzyl)urea,35.0,uM,=,1.5440680443502757,1,O=C(NCc1ccccc1)Nc1ccc(-c2cn[nH]c2)cc1
5349,689743,10.1021/jm100714c,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as probe,Cc1ccc2c(N3CCN(CCc4cccc(N5CCNC5=O)c4)CC3)cccc2n1,1-(3-{2-[4-(2-Methyl-5-quinolinyl)-1-piperazinyl]ethyl}phenyl)-2-imidazolidinone,21.0,uM,=,1.3222192947339193,1,O=C1NCCN1c1cccc(CCN2CCN(c3cccc4ncccc34)CC2)c1
5350,453162,10.1016/j.bmcl.2006.09.056,,,,Inhibition of CYP3A4 in presence of BQ substrate,CN(C)CC1CCC(CNc2nc(NCc3ccccc3Cl)ncc2[N+](=O)[O-])CC1,"N2-(2-chlorobenzyl)-N4-((4-((dimethylamino)methyl)cyclohexyl)methyl)-5-nitropyrimidine-2,4-diamine",13.0,uM,=,1.1139433523068367,1,c1ccc(CNc2nccc(NCC3CCCCC3)n2)cc1
5351,2125913,10.1021/acs.jmedchem.0c02008,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,C[C@@H](C[C@@]1(C2CC2)NC(=O)NC1=O)C(=O)N1CCN(c2ccc(F)c(F)c2)[C@@H](C)C1,"(S)-5-cyclopropyl-5-((S)-3-((S)-4-(3,4-difluorophenyl)-3-methylpiperazin-1-yl)-2-methyl3-oxopropyl)imidazolidine-2,4-dione",7.8,uM,=,0.8920946026904804,1,O=C1NC(=O)[C@](CCC(=O)N2CCN(c3ccccc3)CC2)(C2CC2)N1
5352,1707938,10.1021/acs.jmedchem.7b01420,,,,Inhibition of CYP3A4 (unknown origin),CC1(C)CCC(NCc2ccc(CN(C[C@H]3Cc4ccccc4CN3)[C@H]3CCCc4cccnc43)cc2)CC1,"(S)-N-(4-(((4,4-Dimethylcyclohexyl)amino)methyl)benzyl)-N-(((R)-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)-5,6,7,8-tetrahydroquinolin-8-amine",0.334,uM,=,-0.4762535331884355,0,c1ccc2c(c1)CN[C@@H](CN(Cc1ccc(CNC3CCCCC3)cc1)[C@H]1CCCc3cccnc31)C2
5353,464242,10.1021/jm7013309,,,,Inhibition of human CYP3A4 using 7-benzyl-trifluoromethyl coumarin,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@@H](C)N)c(C)c34)ccc2[nH]1,"(S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl) 2-aminopropanoate",0.51,uM,=,-0.2924298239020636,0,c1cc2c(Oc3ccc4[nH]ccc4c3)ncnn2c1
5354,830173,10.1016/j.bmcl.2012.05.074,,,,Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay,O=C(NC(Cc1ccc2[nH]ccc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1,"(+/-)-N-(1-(1,4'-bipiperidin-1'-yl)-3-(1H-indol-5-yl)-1-oxopropan-2-yl)-4-(2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-1-carboxamide",2.5,uM,=,0.3979400086720376,1,O=C(NC(Cc1ccc2[nH]ccc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1
5355,1913292,10.1021/acs.jmedchem.9b01032,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH by LC-MS/MS analysis,CC1(C)CCN1Cc1cccc(F)c1CNc1cc(F)c(S(=O)(=O)Nc2cscn2)c(F)c1,"4-((2-((2,2-Dimethylazetidin-1-yl)methyl)-6-fluorobenzyl)-amino)-2,6-difluoro-N-(thiazol-4-yl)benzenesulfonamide",50.0,uM,=,1.6989700043360187,1,O=S(=O)(Nc1cscn1)c1ccc(NCc2ccccc2CN2CCC2)cc1
5356,874073,10.1021/jm3012239,,,,Inhibition of CYP3A4,O=C(Nc1ccncc1-c1cccc(Cl)c1)c1cnn2cccnc12,"N-(3-(3-chlorophenyl)pyridin-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide",0.2,uM,=,-0.6989700043360187,0,O=C(Nc1ccncc1-c1ccccc1)c1cnn2cccnc12
5357,1805644,10.1021/acs.jmedchem.9b00059,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH-generating system addition and measured after 20 mins by LC-MS/MS analysis,COc1ccccc1N1C(=O)CSC1c1cccc(C(=O)NCCc2ccc(Br)cc2)c1,2-(3-(4-bromophenylethylaminocarbonyl)phenyl)-3-(2-methoxyphenyl)-4-thiazolidinone,19.54,uM,=,1.2909245593827543,1,O=C(NCCc1ccccc1)c1cccc(C2SCC(=O)N2c2ccccc2)c1
5358,715320,10.1021/jm1009082,,,,Inhibition of human CYP3A4,Nc1cccc(-c2c(O)ccc3cc(-c4cccc(O)c4)ccc23)c1,1-(3-Aminophenyl)-6-(3-hydroxyphenyl)-2-naphthol,1.07,uM,=,0.0293837776852096,1,c1ccc(-c2ccc3c(-c4ccccc4)cccc3c2)cc1
5359,830173,10.1016/j.bmcl.2012.05.074,,,,Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay,O=C(N[C@H](Cc1cccc2ccccc12)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1,"(R)-N-(1-(1,4'-bipiperidin-1'-yl)-3-(naphthalen-1-yl)-1-oxopropan-2-yl)-4-(2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-1-carboxamide",0.03,uM,=,-1.5228787452803376,0,O=C(N[C@H](Cc1cccc2ccccc12)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1
5360,826125,10.1021/jm300069y,,,,Inhibition of CYP3A4,CC(C)(C)c1ccnc(CN[C@H]2CS(=O)(=O)C[C@@H](Cc3cc(F)c(N)c(OC(C(F)(F)F)C(F)(F)F)c3)[C@@H]2O)c1,"(3S,4S,5R)-3-(4-Amino-3-fluoro-5-((1,1,1,3,3,3-hexafluoropropan-2-yl)oxy)benzyl)-5-(((4-(tertbutyl)pyridin-2-yl)methyl)amino)-4-hydroxytetrahydro-2H-thiopyran 1,1-dioxide",0.4,uM,=,-0.3979400086720376,0,O=S1(=O)C[C@@H](Cc2ccccc2)C[C@@H](NCc2ccccn2)C1
5361,1544115,10.1016/j.bmcl.2015.11.013,,,,Inhibition of CYP3A4 (unknown origin),Cc1c(Cl)nc(OC[C@H]2C[C@@H]2c2ccccn2)nc1NCc1cnn(C)c1,"US8785467, 1-39",3.8,uM,=,0.5797835966168101,1,c1ccc([C@H]2C[C@@H]2COc2nccc(NCc3cn[nH]c3)n2)nc1
5362,728151,10.1016/j.bmc.2011.01.017,,,,Inhibition of human CYP3A4,CNC(=O)c1cc2ccc(C(O)(c3c[nH]cn3)C(C)C)cc2cc1C,"rac-6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N,3-dimethyl-2-naphthamide",3.6,uM,=,0.5563025007672873,1,c1ccc2cc(Cc3c[nH]cn3)ccc2c1
5363,2221810,10.1016/j.bmcl.2022.128625,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as substrate pretreated with NADPH,CCC[C@H]1N(C(=O)c2c(C(F)(F)F)ccnc2OCCO)CCC[C@@]1(Oc1csc(C(F)(F)F)c1)C(=O)N1CCN(c2ccccc2OCCO)CC1,"((2R,3S)-1-(2-(2-hydroxyethoxy)-4-(trifluoromethyl)nicotinoyl)-2-propyl-3-(5-(trifluoromethyl)thiophen-3-yloxy)piperidin-3-yl)(4-(2-(2-hydroxyethoxy)phenyl)piperazin-1-yl)methanone",1.5,uM,=,0.1760912590556812,1,O=C(c1cccnc1)N1CCC[C@@](Oc2ccsc2)(C(=O)N2CCN(c3ccccc3)CC2)C1
5364,1628093,10.1016/j.ejmech.2016.08.024,,,,Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells preincubated for 30 mins using fluorescent substrate,C[C@H]1CN(C(C)(C)CO)CCN1C(=O)CC1([C@H]2COC[C@@H](C3CC3)N2S(=O)(=O)c2ccc(F)cc2)CC1,"2-(1-((3S,5R)-5-cyclopropyl-4-(4-fluorophenylsulfonyl)morpholin-3-yl)cyclopropyl)-1-((S)-4-(1-hydroxy-2-methylpropan-2-yl)-2-methylpiperazin-1-yl)ethanone",2.2,uM,=,0.3424226808222063,1,O=C(CC1([C@H]2COC[C@@H](C3CC3)N2S(=O)(=O)c2ccccc2)CC1)N1CCNCC1
5365,1523393,10.1021/acs.jmedchem.5b00774,,,,Inhibition of CYP3A4 (unknown origin) preincubated with protein for 30 mins followed by substrate addition,O=S(=O)(NC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12)C(F)(F)F,"N-(((4R,4aS,10bS)-10b-(4-chlorophenylsulfonyl)-7,10-difluoro-1,2,4,4a,5,10b-hexahydropyrano[3,4-c]chromen-4-yl)methyl)-1,1,1-trifluoromethanesulfonamide",21.4,uM,=,1.3304137733491908,1,O=S(=O)(c1ccccc1)[C@@]12CCOC[C@@H]1COc1ccccc12
5366,1986041,10.1021/acs.jmedchem.0c00564,,,,Inhibition of CYP3A4 (unknown origin) expressed in insect cell microsomes using dibenzylfluorescein substrate by fluorescence based assay,CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,SID144204227,0.027,uM,=,-1.5686362358410126,0,c1ccc([C@@]2(Cn3ccnc3)OC[C@H](COc3ccc(N4CCNCC4)cc3)O2)cc1
5367,1527906,,,,,Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,CCn1nc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)ccc1=O,"US8592410, 14",32.7,uM,=,1.5145477526602862,1,O=C1OC(c2ccccc2)CCN1Cc1ccc(-c2ccc(=O)[nH]n2)cc1
5368,1735372,10.1021/acs.jmedchem.8b00084,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis,Cl.Cl.Cl.Cl.NCc1ccc(-c2cnccc2-c2cncnc2)s1,(5-(4-(Pyrimidin-5-yl)pyridin-3-yl)thiophen-2-yl)methanamine tetrahydrochloride,39.0,uM,=,1.591064607026499,1,c1csc(-c2cnccc2-c2cncnc2)c1
5369,2164321,10.1021/acs.jmedchem.1c01784,,,,Inhibition of human recombinant CYP3A4 expressed in baculosomes by fluorescent homogenous assay,Cc1c(C)c2ccc(OCc3cccc(CN(C)CCCC(F)F)c3)cc2oc1=O,"7-((3-(((4,4-difluorobutyl)(methyl)amino)methyl)benzyl)oxy)-3,4-dimethyl-2H-chromen-2-one",0.6,uM,=,-0.2218487496163563,0,O=c1ccc2ccc(OCc3ccccc3)cc2o1
5370,583696,10.1016/j.bmcl.2009.05.066,,,,Inhibition of human recombinant CYP3A4 after 45 mins,O=C(NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)N[C@H](CO)c1ccccc1,(S)-1-(2-hydroxy-1-phenylethyl)-3-(1-((1-(4-(trifluoromethyl)phenyl)-1H-pyrrol-3-yl)methyl)piperidin-4-yl)urea,20.6,uM,=,1.3138672203691537,1,O=C(NCc1ccccc1)NC1CCN(Cc2ccn(-c3ccccc3)c2)CC1
5371,1794581,10.1016/j.bmcl.2018.07.043,,,,Inhibition of CYP3A4 in human liver microsomes in presence of NADPH and Luciferin BE 50,CCOc1nc(Cl)ccc1C1(N2CCN(c3ccncc3)CC2)C(=O)N(S(=O)(=O)c2ccc(OC)cn2)c2ccc(C#N)cc21,3-(6-chloro-2-ethoxypyridin-3-yl)-1-(5-methoxypyridin-2-ylsulfonyl)-2-oxo-3-(4-(pyridin-4-yl)piperazin-1-yl)indoline-5-carbonitrile,0.1,uM,=,-1.0,0,O=C1N(S(=O)(=O)c2ccccn2)c2ccccc2C1(c1cccnc1)N1CCN(c2ccncc2)CC1
5372,1488506,10.1124/dmd.112.045708,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis in presence of NADPH,CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1,"(R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide",5.2,uM,=,0.7160033436347992,1,O=C(Cc1ccccc1)N(Cc1cccnc1)Cc1nc2ncccc2c(=O)n1-c1ccccc1
5373,2204939,10.1016/j.ejmech.2022.114581,,,,Inhibition of CYP3A4T (unknown origin),C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,"17-Hydroxy-10,13-dimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-cyclopenta[a]phenanthren-3-one",0.0451,uM,=,-1.3458234581220394,0,O=C1C=C2CC[C@H]3[C@@H]4CCCC4CC[C@@H]3C2CC1
5374,1659863,10.1016/j.ejmech.2017.02.016,,,,Inhibition of human liver CYP3A4 expressed in Saccharomyces cerevisiae YY7 microsomal membranes using DBF as substrate after 10 mins by fluorescence assay,O=C(/C=C/c1cccnc1)c1ccc2ccc3ccccc3c2c1,(E)-1-(3-Phenanthrenyl)-3-(3-pyridinyl)prop-2-en-1-one,26.0,uM,=,1.414973347970818,1,O=C(/C=C/c1cccnc1)c1ccc2ccc3ccccc3c2c1
5375,1640571,,,,,"In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.",ClC1CC=CC=C1C(c1ccccc1)(c1ccccc1)n1ccnc1,"US9144538, Clotrimazole",0.3,uM,=,-0.5228787452803376,0,C1=CCCC(C(c2ccccc2)(c2ccccc2)n2ccnc2)=C1
5376,1986041,10.1021/acs.jmedchem.0c00564,,,,Inhibition of CYP3A4 (unknown origin) expressed in insect cell microsomes using dibenzylfluorescein substrate by fluorescence based assay,CC1=C(C(=O)OC(C)C)C(c2ccco2)n2c(nc3ccccc32)N1,"(+/-)-Isopropyl 4-(Furan-2-yl)-2-methyl-1,4-dihydrobenzo-[4,5]imidazo[1,2-a]pyrimidine-3-carboxylate",2.9,uM,=,0.4623979978989561,1,C1=CC(c2ccco2)n2c(nc3ccccc32)N1
5377,606336,10.1016/j.bmcl.2009.11.061,,,,Inhibition of CYP3A4,Cc1occc1-c1nc(N)c(OC[C@@H](N)Cc2c[nH]c3ccccc23)cc1-c1cnc2[nH]nc(C)c2c1,"3-((S)-2-amino-3-(1H-indol-3-yl)propoxy)-5-(3-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)-6-(2-methylfuran-3-yl)pyridin-2-amine",1.0,uM,=,0.0,0,c1ccc2c(CCCOc3cnc(-c4ccoc4)c(-c4cnc5[nH]ncc5c4)c3)c[nH]c2c1
5378,728151,10.1016/j.bmc.2011.01.017,,,,Inhibition of human CYP3A4,CC(C)C(O)(c1ccc2c3c(ccc2c1)C(=O)NC3)c1c[nH]cn1,"rac-7-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-1,2-dihydro-3H-benzo[e]isoindol-3-one",6.7,uM,=,0.8260748027008264,1,O=C1NCc2c1ccc1cc(Cc3c[nH]cn3)ccc21
5379,621465,10.1016/j.bmcl.2009.07.118,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,CC(C)(C)CN(C[C@@H](Cc1ccccc1)NC(=O)OCc1nccs1)C[C@H](Cc1ccccc1)NC(=O)OCc1cncs1,"N-[(S)-2-thiazol-5-ylmethoxycarbonylamino)-3-phenylpropyl][(R)-2-thiazol-5-ylmethoxycarbonylamino)-3-phenylpropyl]-N-[2,2-dimethylpropyl]amine",0.1,uM,=,-1.0,0,O=C(N[C@H](CNC[C@@H](Cc1ccccc1)NC(=O)OCc1nccs1)Cc1ccccc1)OCc1cncs1
5380,1689465,10.1021/acs.jmedchem.7b00662,,,,Inhibition of CYP3A4 (unknown origin),O=C(CN1CCCC2=C1C(=O)N(C1CC1)C2=O)Nc1ccc(-c2cccnc2)nn1,"2-(6-Cyclopropyl-5,7-dioxo-2,3,4,5,6,7-hexahydro-1H-pyrrolo[3,4-b]pyridin-1-yl)-N-(6-(pyridin-3-yl)pyridazin-3-yl)-acetamide",2.1,uM,=,0.3222192947339193,1,O=C(CN1CCCC2=C1C(=O)N(C1CC1)C2=O)Nc1ccc(-c2cccnc2)nn1
5381,2121115,10.1016/j.ejmech.2021.113740,,,,Inhibition of CYP3A4 in human liver Microsome using midazolam as substrate preincubated for 10 mins followed by NADPH addition and further incubated for 10 mins as substrate by LC-MS/MS analysis,Cc1ccc(C(=O)C(Cn2ccnc2)NC(=O)c2ccc(-c3ccc(Cl)cc3)s2)cc1,N-(3-(1H-imidazol-1-yl)-1-oxo-1-p-tolylpropan-2-yl)-5-(4-chlorophenyl)thiophene-2-carboxamide,1.24,uM,=,0.093421685162235,1,O=C(NC(Cn1ccnc1)C(=O)c1ccccc1)c1ccc(-c2ccccc2)s1
5382,880247,10.1021/jm101459g,,,,Inhibition of human recombinant CYP3A4 using resorufin benzyl ether after 30 mins by fluorescence spectrophotometric analysis,Cl.Clc1cccc(Sc2ccccc2N2CCNCC2)c1Cl,"1-[2-(2,3-Dichloro-phenylsulfanyl)-phenyl]-piperazine Hydrochloride",6.1,uM,=,0.785329835010767,1,c1ccc(Sc2ccccc2N2CCNCC2)cc1
5383,728151,10.1016/j.bmc.2011.01.017,,,,Inhibition of human CYP3A4,CCNC(=O)c1ccc2cc(C(O)(c3c[nH]cn3)C(C)C)ccc2c1,rac-N-Ethyl-6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide,5.7,uM,=,0.7558748556724915,1,c1ccc2cc(Cc3c[nH]cn3)ccc2c1
5384,789986,10.1016/j.bmcl.2011.10.013,,,,Reversible inhibition of CYP3A4,COCCCc1cc(CCCN2CCOCC2)c(Cl)c(CN(C(=O)[C@H]2CNCC[C@@]23OCc2cc(F)c(F)cc23)C2CC2)c1,"(1R,3'S)-N-(2-chloro-5-(3-methoxypropyl)-3-(3-morpholinopropyl)benzyl)-N-cyclopropyl-5,6-difluoro-3H-spiro[isobenzofuran-1,4'-piperidine]-3'-carboxamide",2.6,uM,=,0.414973347970818,1,O=C([C@H]1CNCC[C@@]12OCc1ccccc12)N(Cc1cccc(CCCN2CCOCC2)c1)C1CC1
5385,560757,10.1016/j.bmcl.2008.11.008,,,,Inhibition of CYP3A4 green,C[C@H]1CN(S(=O)(=O)C[C@]23CC[C@H](C[C@@H]2O)C3(C)C)CCN1c1ncc(C(F)(F)F)cc1F,"(1S,2S,4R)-1-(((S)-4-(3-fluoro-5-(trifluoromethyl)pyridin-2-yl)-3-methylpiperazin-1-ylsulfonyl)methyl)-7,7-dimethylbicyclo[2.2.1]heptan-2-ol",13.6,uM,=,1.1335389083702174,1,O=S(=O)(C[C@]12CC[C@H](CC1)C2)N1CCN(c2ccccn2)CC1
5386,1660008,10.1021/acs.jmedchem.6b01620,,,,Inhibition of CYP3A4 (unknown origin),COc1nc(C2=NOC[C@H](c3cc4ccccc4o3)N2)ccc1-n1cnc(C)c1,"(R)-5-(Benzofuran-2-yl)-3-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)-5,6-dihydro-4H-1,2,4-oxadiazine",25.0,uM,=,1.3979400086720375,1,c1ccc2oc([C@H]3CON=C(c4ccc(-n5ccnc5)cn4)N3)cc2c1
5387,621465,10.1016/j.bmcl.2009.07.118,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,O=C(N[C@H](CNC[C@H](Cc1ccccc1)NC(=O)OCc1nccs1)Cc1ccccc1)OCc1cncs1,Bis-N-[(S)-2-(thiazol-5-ylmethoxycarbonylamino)-3-phenylpropyl]amine,0.148,uM,=,-0.8297382846050426,0,O=C(N[C@H](CNC[C@H](Cc1ccccc1)NC(=O)OCc1nccs1)Cc1ccccc1)OCc1cncs1
5388,2193506,10.1016/j.bmcl.2022.128892,,,,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by substrate addition,CNC(=O)N(c1ccc(S(=O)(=O)Nc2ncccn2)cn1)c1cc(F)c(-c2cccc(C(F)(F)F)c2)cc1OC,"6-(1-(2-fluoro-5-methoxy-3'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)-3-methylureido)-N-(pyrimidin-2-yl)pyridine-3-sulfonamide",9.0,uM,=,0.9542425094393248,1,O=S(=O)(Nc1ncccn1)c1ccc(Nc2ccc(-c3ccccc3)cc2)nc1
5389,1735372,10.1021/acs.jmedchem.8b00084,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis,Cl.Cl.NCC#Cc1cccnc1,3-(pyridin-3-yl)prop-2-yn-1-amine Dihydrochloride,4.0,uM,=,0.6020599913279624,1,c1ccncc1
5390,949160,10.1016/j.bmcl.2013.01.011,,,,Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate,O=C(N[C@H](Cc1cc(Cl)c2[nH]c(=O)oc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1,"(R)-N-(1-(1,4'-bipiperidin-1'-yl)-3-(4-chloro-2-oxo-2,3-dihydrobenzo[d]oxazol-6-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)piperidine-1-carboxamide",17.0,uM,=,1.230448921378274,1,O=C(N[C@H](Cc1ccc2[nH]c(=O)oc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1
5391,1534814,,,,,Inhibition Assay: Inhibition assay using P450 CYP enzymes.,CS(=O)(=O)Nc1cccc(-c2c(O)ccc3cc(-c4cccc(O)c4)ccc23)c1,N-{3-[2-Hydroxy-6-(3-hydroxyphenyl)-1-naphthyl]phenyl}-methanesulfonamide,1.07,uM,=,0.0293837776852096,1,c1ccc(-c2ccc3c(-c4ccccc4)cccc3c2)cc1
5392,1707938,10.1021/acs.jmedchem.7b01420,,,,Inhibition of CYP3A4 (unknown origin),c1ccc(CNCc2ccc(CN(C[C@H]3Cc4ccccc4CN3)[C@H]3CCCc4cccnc43)cc2)nc1,"(S)-N-(4-(((Pyridin-2-ylmethyl)amino)methyl)benzyl)-N-(((R)-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)-5,6,7,8-tetrahydroquinolin-8-amine",0.109,uM,=,-0.9625735020593764,0,c1ccc(CNCc2ccc(CN(C[C@H]3Cc4ccccc4CN3)[C@H]3CCCc4cccnc43)cc2)nc1
5393,1707938,10.1021/acs.jmedchem.7b01420,,,,Inhibition of CYP3A4 (unknown origin),c1ccc(CNCCCCN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)nc1,"N1-(2-pyridylmethyl)-N4-(((R)-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)-N4-((S)-5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine",4.5,uM,=,0.6532125137753437,1,c1ccc(CNCCCCN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)nc1
5394,1445200,10.1021/ml5003376,,,,Inhibition of human CYP3A4 testosterone site in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,Nc1n[nH]c2nc(-c3ccc(NS(=O)(=O)c4cc(Cl)ccc4F)cc3)cnc12,"N-(4-(3-amino-1H-pyrazolo[3,4-b]pyrazin-6-yl)phenyl)-5-chloro-2-fluorobenzenesulfonamide",28.6,uM,=,1.4563660331290431,1,O=S(=O)(Nc1ccc(-c2cnc3cn[nH]c3n2)cc1)c1ccccc1
5395,1925822,10.1021/acs.jmedchem.6b00425,,,,Inhibition of CYP3A4 in human microsomes using midazolam as substrate preincubated with enzyme and NADPH prior to substrate addition by LC-MS/MS analysis,CC(C)COc1ncc(-c2cc(F)c(C(=O)NS(C)(=O)=O)cc2F)cc1Cl,"4-(5-Chloro-6-isobutoxypyridin-3-yl)-2,5-difluoro-N-(methylsulfonyl)benzamide",48.6,uM,=,1.6866362692622934,1,c1ccc(-c2cccnc2)cc1
5396,728151,10.1016/j.bmc.2011.01.017,,,,Inhibition of human CYP3A4,CCCNC(=O)c1ccc2cc(C(O)(c3c[nH]cn3)C(C)C)ccc2c1,rac-6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-Npropyl-2-naphthamide,3.4,uM,=,0.5314789170422551,1,c1ccc2cc(Cc3c[nH]cn3)ccc2c1
5397,774850,10.1016/j.bmcl.2011.09.074,,,,Inhibition of CYP3A4 up to 40 uM,Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(CC(=O)NCc1cccnc1)C2=O,"(+)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-7-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N-(pyridin-3-ylmethyl)acetamide",7.0,uM,=,0.8450980400142568,1,O=C(CN1Cc2c(-c3ccccc3)ccnc2C1=O)NCc1cccnc1
5398,1914413,10.1021/acs.jmedchem.9b01194,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate,O=C(NO)c1ccc(Cn2nnnc2-c2cccs2)cc1,N-Hydroxy-4-(5-thiophen-2-yl-tetrazol-1-ylmethyl)benzamide,47.4,uM,=,1.675778341674085,1,c1ccc(Cn2nnnc2-c2cccs2)cc1
5399,1616390,10.1021/acs.jmedchem.6b00989,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate assessed as reduction in 4-OH-midazolam formation by LC/MS/MS analysis,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,"1-(4-{4-[2-(2,4-Dichloro-phenyl)-2-imidazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-ethanone (ketoconazole)",0.0074,uM,=,-2.130768280269024,0,c1ccc(C2(Cn3ccnc3)OCC(COc3ccc(N4CCNCC4)cc3)O2)cc1
5400,1805644,10.1021/acs.jmedchem.9b00059,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH-generating system addition and measured after 20 mins by LC-MS/MS analysis,COc1ccc(-c2nc(C)nn2-c2cccc(C(=O)NCCCCc3ccccc3)c2)cc1,"3-(5-(4-Methoxyphenyl)-3-methyl-1H-1,2,4-triazolyl)-N-(4-phenylbutyl)benzamide",36.88,uM,=,1.5667909123815915,1,O=C(NCCCCc1ccccc1)c1cccc(-n2ncnc2-c2ccccc2)c1
5401,652208,10.1016/j.bmcl.2010.07.052,,,,Inhibition of CYP3A4 in human liver microsomes,COc1ccc(Cn2c(=O)n(C3CCN(C(=O)C4CCN(Cc5ccncc5)CC4)CC3)c3ccccc32)cc1,1-(4-methoxybenzyl)-3-(1-(1-(pyridin-4-ylmethyl)piperidine-4-carbonyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one,0.4,uM,=,-0.3979400086720376,0,O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)n(Cc3ccccc3)c3ccccc32)CC1
5402,458143,10.1016/j.bmcl.2007.09.006,,,,Inhibition of CYP3A4 after 30 mins,CC(C)[C@@H]1CCC[C@H](COC(=O)N2CCC(N3CCCCC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1,"((2R,6S)-1-(4-chlorophenylsulfonyl)-6-isopropylpiperidin-2-yl)methyl 4-(piperidin-1-yl)piperidine-1-carboxylate",1.3,uM,=,0.1139433523068367,1,O=C(OC[C@H]1CCCCN1S(=O)(=O)c1ccccc1)N1CCC(N2CCCCC2)CC1
5403,789986,10.1016/j.bmcl.2011.10.013,,,,Reversible inhibition of CYP3A4,COCCCc1cc(CCCCNS(C)(=O)=O)c(Cl)c(CN(C(=O)[C@H]2CNCC[C@@]23OCc2cc(F)c(F)cc23)C2CC2)c1,"(1R,3'S)-N-(2-chloro-5-(3-methoxypropyl)-3-(4-(methylsulfonamido)butyl)benzyl)-N-cyclopropyl-5,6-difluoro-3H-spiro[isobenzofuran-1,4'-piperidine]-3'-carboxamide",2.2,uM,=,0.3424226808222063,1,O=C([C@H]1CNCC[C@@]12OCc1ccccc12)N(Cc1ccccc1)C1CC1
5404,1707938,10.1021/acs.jmedchem.7b01420,,,,Inhibition of CYP3A4 (unknown origin),c1ccc(CN(CCCCN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)Cc2ccccc2)cc1,"N1,N1-Dibenzyl-N4-(((R)-1,2,3,4-tetrahydroisoquinolin-3-yl)-methyl)-N4-((S)-5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine",2.24,uM,=,0.3502480183341628,1,c1ccc(CN(CCCCN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)Cc2ccccc2)cc1
5405,462442,10.1016/j.bmcl.2008.01.047,,,,Inhibition of CYP3A4,CC(C)(C)OC(=O)N[C@H](Cc1cccc(F)c1F)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1,"(R)-tert-butyl 3-(2,3-difluorophenyl)-1-oxo-1-((3-(1-phenylcyclopropyl)-3H-imidazo[4,5-b]pyridin-2-yl)methylamino)propan-2-ylcarbamate",4.6,uM,=,0.6627578316815741,1,O=C(CCc1ccccc1)NCc1nc2cccnc2n1C1(c2ccccc2)CC1
5406,621465,10.1016/j.bmcl.2009.07.118,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,O=C(N[C@H](CNC[C@@H](Cc1ccccc1)NC(=O)OCc1nccs1)Cc1ccccc1)OCc1cncs1,N-[(S)-2-(thiazol-5-ylmethoxycarbonylamino)-3-phenylpropyl][(R)-2-(thiazol-5-ylmethoxycarbonylamino)-3-phenylpropyl]amine,0.09,uM,=,-1.0457574905606752,0,O=C(N[C@H](CNC[C@@H](Cc1ccccc1)NC(=O)OCc1nccs1)Cc1ccccc1)OCc1cncs1
5407,621465,10.1016/j.bmcl.2009.07.118,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,O=C(N[C@@H](Cc1ccccc1)CN(Cc1ccccc1)C[C@H](Cc1ccccc1)NC(=O)OCc1nccs1)OCc1cncs1,Bis-N-[(S)-2-(thiazol-5-ylmethoxycarbonylamino)-3-phenylpropyl]-N-benzylamine,0.135,uM,=,-0.8696662315049939,0,O=C(N[C@@H](Cc1ccccc1)CN(Cc1ccccc1)C[C@H](Cc1ccccc1)NC(=O)OCc1nccs1)OCc1cncs1
5408,354698,10.1016/j.bmcl.2006.02.014,,,,Inhibition of CYP450 3A4,O=C(O)c1cccc(-c2ccncc2-c2cc(Cl)ccc2OCc2ccccc2)c1,3-(3-(2-(benzyloxy)-5-chlorophenyl)pyridin-4-yl)benzoic acid,1.4,uM,=,0.1461280356782379,1,c1ccc(COc2ccccc2-c2cnccc2-c2ccccc2)cc1
5409,1534838,,,,,"Inhibition Assay: In the design of clinically safe and effective metalloenzyme inhibitors, use of the most appropriate metal-binding group for the particular target and clinical indication is critical. If a weakly binding metal-binding group is utilized, potency may be suboptimal. On the other hand, if a very tightly binding metal-binding group is utilized, selectivity for the target enzyme versus related metalloenzymes may be suboptimal. The lack of optimal selectivity can be a cause for clinical toxicity due to unintended inhibition of these off-target metalloenzymes. One example of such clinical toxicity is the unintended inhibition of human drug metabolizing enzymes such as CYP2C9, CYP2C19 and CYP3A4 by the currently-available prostate anticancer agent ketoconazole. It is believed that this off-target inhibition is caused primarily by the indiscriminate binding of the currently utilized 1-imidazole to iron in the active site of CYP2C9, CYP2C19 and CYP3A4.",COc1cc2cnc(C(O)(c3cnn[nH]3)C(C)C)cc2cc1OC,"US8623892, 2",23.0,uM,=,1.3617278360175928,1,c1ccc2cc(Cc3cnn[nH]3)ncc2c1
5410,1866289,10.1021/acs.jmedchem.9b00662,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,O=C(Cc1ccccc1)N1CCC(C(O)CC2c3ccccc3-c3cncn32)CC1,"1-(4-(1-Hydroxy-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethyl)-piperidin-1-yl)-2-phenylethan-1-one",0.13,uM,=,-0.8860566476931633,0,O=C(Cc1ccccc1)N1CCC(CCC2c3ccccc3-c3cncn32)CC1
5411,2171279,10.1021/acs.jmedchem.1c01083,,,,Inhibition of human recombinant CYP3A4 expressed in insect microsome using 7-benzyloxy-4-trifluoromethylcoumarin as a substrate incubated for 30 mins followed by addition of NADPH regenerating system measured immediately by fluorescence based analysis,CCCCCCCCCCCCCCCCOCCCOP(=O)(O)CO[C@H](C)Cn1cnc2c(N)ncnc21.N,Ammonium 3-(hexadecyloxy)propyl-(R)-(((1-(6-Amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)phosphonate,53.3,uM,=,1.7267272090265722,1,c1ncc2nc[nH]c2n1
5412,2134699,10.1021/acs.jmedchem.1c01121,,,,Inhibition of CYP3A4 (unknown origin),C=CCn1c(=O)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc2n1-c1cccc(C(C)(C)O)n1,SID103905025,19.0,uM,=,1.2787536009528289,1,O=c1[nH]n(-c2ccccn2)c2nc(Nc3ccc(N4CCNCC4)cc3)ncc12
5413,1628094,10.1016/j.ejmech.2016.08.024,,,,Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells using fluorescent substrate,O=C(CC1([C@H]2COC[C@@H](C3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CC2CCC(C1)N2,"1-(3,8-diazabicyclo[3.2.1]octan-3-yl)-2-(1-((3S,5R)-4-(4-chlorophenylsulfonyl)-5-cyclopropylmorpholin-3-yl)cyclopropyl)ethanone",9.9,uM,=,0.99563519459755,1,O=C(CC1([C@H]2COC[C@@H](C3CC3)N2S(=O)(=O)c2ccccc2)CC1)N1CC2CCC(C1)N2
5414,741042,10.1016/j.bmcl.2011.02.067,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCC2(CC#N)CC2)c1,"(3R,4S)-N-(3-((1-(cyanomethyl)cyclopropyl)methoxy)-5-(3-methoxypropyl)benzyl)-N-cyclopropyl-4-(4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)phenyl)piperidine-3-carboxamide",19.6,uM,=,1.292256071356476,1,O=C([C@H]1CNCC[C@@H]1c1ccc(OCCOc2ccccc2)cc1)N(Cc1cccc(OCC2CC2)c1)C1CC1
5415,1735372,10.1021/acs.jmedchem.8b00084,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis,Cc1ccncc1-c1ccc(CN)o1.Cl.Cl,(5-(4-Methylpyridin-3-yl)furan-2-yl)methanamine Dihydrochloride,29.0,uM,=,1.462397997898956,1,c1cncc(-c2ccco2)c1
5416,462442,10.1016/j.bmcl.2008.01.047,,,,Inhibition of CYP3A4,O=C(NCc1nc2cccnc2n1C1(c2ccccc2)CC1)[C@@H](Cc1ccccc1C(F)(F)F)NC(=O)C1(C(F)(F)F)CC1,"(R)-N-(1-oxo-1-((3-(1-phenylcyclopropyl)-3H-imidazo[4,5-b]pyridin-2-yl)methylamino)-3-(2-(trifluoromethyl)phenyl)propan-2-yl)-1-(trifluoromethyl)cyclopropanecarboxamide",1.9,uM,=,0.2787536009528289,1,O=C(N[C@H](Cc1ccccc1)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1)C1CC1
5417,716988,10.1016/j.bmcl.2010.12.039,,,,Inhibition of CYP3A4,CCOC(=O)c1sc2cnccc2c1Nc1ccc2c(c1)CC/C2=N/O,"ethyl 3-(1-(hydroxyimino)-2,3-dihydro-1H-inden-5-ylamino)thieno[2,3-c]pyridine-2-carboxylate",0.05,uM,=,-1.3010299956639813,0,N=C1CCc2cc(Nc3csc4cnccc34)ccc21
5418,621465,10.1016/j.bmcl.2009.07.118,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,CCN(C[C@H](Cc1ccccc1)NC(=O)OCc1cnco1)C[C@H](Cc1ccccc1)NC(=O)OCc1ncco1,Bis-N-[(S)-2-(oxazol-5-ylmethoxycarbonylamino)-3-phenylpropyl]ethylamine,0.274,uM,=,-0.5622494371796121,0,O=C(N[C@H](CNC[C@H](Cc1ccccc1)NC(=O)OCc1ncco1)Cc1ccccc1)OCc1cnco1
5419,741042,10.1016/j.bmcl.2011.02.067,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCCN(C)C)c1,"(3R,4S)-N-cyclopropyl-4-(4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)phenyl)-N-(3-(2-(dimethylamino)ethoxy)-5-(3-methoxypropyl)benzyl)piperidine-3-carboxamide",22.7,uM,=,1.3560258571931227,1,O=C([C@H]1CNCC[C@@H]1c1ccc(OCCOc2ccccc2)cc1)N(Cc1ccccc1)C1CC1
5420,813105,10.1021/jm201346g,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,COc1ccc2[nH]c(SCc3ccc(C(C)C)cc3)nc2c1,2-(4-isopropylbenzylthio)-5-methoxy-1H-benzo[d]imidazole,8.34,uM,=,0.9211660506377388,1,c1ccc(CSc2nc3ccccc3[nH]2)cc1
5421,652208,10.1016/j.bmcl.2010.07.052,,,,Inhibition of CYP3A4 in human liver microsomes,CCOCCCn1c(=O)n(C2CCN(C(=O)C3CCN(Cc4ccncc4)CC3)CC2)c2ccccc21,1-(3-ethoxypropyl)-3-(1-(1-(pyridin-4-ylmethyl)piperidine-4-carbonyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one,10.6,uM,=,1.0253058652647702,1,O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1
5422,510060,10.1016/j.bmcl.2008.07.059,,,,Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay,Cc1c(-c2cccc(OCCCCCC(=O)O)c2F)c(=O)n(C[C@H](N)c2ccccc2)c(=O)n1Cc1c(F)cccc1C(F)(F)F,"(R)-6-(3-(1-(2-fluoro-6-(trifluoromethyl)benzyl)-3-(2-amino-2-phenylethyl)-6-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-2-fluorophenoxy)hexanoic acid",8.2,uM,=,0.9138138523837168,1,O=c1c(-c2ccccc2)cn(Cc2ccccc2)c(=O)n1CCc1ccccc1
5423,1347924,10.1016/j.bmcl.2014.04.024,,,,Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method,COc1cc2ccc(C(O)(c3cn[nH]c3)C(C)C)cc2cc1OC,"rac-1-(6,7-dimethoxynaphthalen-2-yl)-2-methyl-1-(1H-pyrazol-4-yl)propan-1-ol",27.0,uM,=,1.4313637641589874,1,c1ccc2cc(Cc3cn[nH]c3)ccc2c1
5424,609086,10.1016/j.bmc.2010.01.039,,,,Inhibition of CYP3A4-mediated hydroxylation of testosterone in human liver microsomes in NADPH co-factor system by RP-HPLC,COCCCNc1nc2cc(C)c(C)cc2n1CC(=O)c1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1,"2-(2-(3-Methoxypropylamino)-5,6-dimethyl-1H-benzo-[d]imidazol-1-yl)-1-(3,5-di-tert-butyl-4-hydroxyphenyl)ethanone",97.0,uM,=,1.9867717342662448,1,O=C(Cn1cnc2ccccc21)c1ccccc1
5425,1846363,10.1016/j.ejmech.2019.02.073,,,,Inhibition of CYP3A4 in human liver microsomes assessed as reduction in metabolite formation using midazolam as substrate incubated for 10 mins in presence of NADPH by HPLC based mass spectrometric method,CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,SID144204227,0.06,uM,=,-1.2218487496163564,0,c1ccc([C@@]2(Cn3ccnc3)OC[C@H](COc3ccc(N4CCNCC4)cc3)O2)cc1
5426,841307,10.1016/j.bmcl.2012.06.029,,,,Inhibition of CYP3A4,CCN1CCC(Nc2ccc3c(c2)C(=C(c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1,(E/Z)-5-(1-ethylpiperidin-4-ylamino)-3-((3-fluorophenyl)(4-methyl-1H-imidazol-2-yl)methylene)indolin-2-one,25.0,uM,=,1.3979400086720375,1,O=C1Nc2ccc(NC3CCNCC3)cc2C1=C(c1ccccc1)c1ncc[nH]1
5427,1707938,10.1021/acs.jmedchem.7b01420,,,,Inhibition of CYP3A4 (unknown origin),NCc1ccccc1CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21,"(S)-N-(2-(Aminomethyl)benzyl)-N-(((R)-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)-5,6,7,8-tetrahydroquinolin-8-amine",15.2,uM,=,1.1818435879447726,1,c1ccc(CN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)cc1
5428,826125,10.1021/jm300069y,,,,Inhibition of CYP3A4,CC(C)(C)Cc1cc(CN[C@H]2CS(=O)(=O)C[C@@H](Cc3cc(F)c(N)c(OC(C(F)(F)F)C(F)(F)F)c3)[C@@H]2O)no1,"(3S,4S,5R)-3-(4-amino-3-fluoro-5-((1,1,1,3,3,3-hexafluoropropan-2-yl)oxy)benzyl)-4-hydroxy-5-(((5-neopentylisoxazol-3-yl)methyl)amino)tetrahydro-2H-thiopyran 1,1-dioxide",0.4,uM,=,-0.3979400086720376,0,O=S1(=O)C[C@@H](Cc2ccccc2)C[C@@H](NCc2ccon2)C1
5429,1735372,10.1021/acs.jmedchem.8b00084,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis,Cl.Cl.NCC#Cc1cnccc1-c1ccoc1,3-(4-Furan-3-yl-pyridin-3-yl)-prop-2-ynylamine Dihydrochloride,6.4,uM,=,0.8061799739838872,1,c1cc(-c2ccoc2)ccn1
5430,1707938,10.1021/acs.jmedchem.7b01420,,,,Inhibition of CYP3A4 (unknown origin),c1cncc(CNCc2ccc(CN(C[C@H]3Cc4ccccc4CN3)[C@H]3CCCc4cccnc43)cc2)c1,"(S)-N-(4-(((Pyridin-3-ylmethyl)amino)methyl)benzyl)-N-(((R)-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)-5,6,7,8-tetrahydroquinolin-8-amine",0.058,uM,=,-1.2365720064370629,0,c1cncc(CNCc2ccc(CN(C[C@H]3Cc4ccccc4CN3)[C@H]3CCCc4cccnc43)cc2)c1
5431,1659863,10.1016/j.ejmech.2017.02.016,,,,Inhibition of human liver CYP3A4 expressed in Saccharomyces cerevisiae YY7 microsomal membranes using DBF as substrate after 10 mins by fluorescence assay,O=C(/C=C/c1ccc(Cl)c(Cl)c1)c1cccnc1,"(E)-3-(3, 4-Dichlorophenyl)-1-(3-pyridyl)prop-2-en-1-one",15.0,uM,=,1.1760912590556811,1,O=C(/C=C/c1ccccc1)c1cccnc1
5432,673953,10.1016/j.bmcl.2010.08.086,,,,Inhibition of CYP3A4 using testosterone as substrate,Cc1cc(Cl)c(OCCOc2ccc([C@H]3CCNC[C@@H]3C(=O)N(Cc3cc(CNCCF)ccc3Cl)C3CC3)cc2)c(Cl)c1,"(3R,4S)-N-(2-chloro-5-((2-fluoroethylamino)methyl)benzyl)-N-cyclopropyl-4-(4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)phenyl)piperidine-3-carboxamide",9.9,uM,=,0.99563519459755,1,O=C([C@H]1CNCC[C@@H]1c1ccc(OCCOc2ccccc2)cc1)N(Cc1ccccc1)C1CC1
5433,701746,10.1021/ml100190t,,,,Inhibition of CYP3A4 uisng midazolam substrate,O=C(Nc1cnccn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1,N-Pyrazin-2-yl-4-(3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}benzylidene)piperidine-1-carboxamide,30.0,uM,=,1.4771212547196624,1,O=C(Nc1cnccn1)N1CCC(=Cc2cccc(Oc3ccccn3)c2)CC1
5434,990212,10.1016/j.bmcl.2013.09.048,,,,Inhibition of CYP3A4 (unknown origin) preincubated prior to substrate addition,O=C(Nc1ccc(N2CCN(C(=O)Nc3ccccc3Cl)CC2)nc1)c1oc(N2CCCCC2)nc1C(F)(F)F,N-(6-(4-(2-chlorophenylcarbamoyl)piperazin-1-yl)pyridin-3-yl)-2-(piperidin-1-yl)-4-(trifluoromethyl)oxazole-5-carboxamide,5.0,uM,=,0.6989700043360189,1,O=C(Nc1ccc(N2CCN(C(=O)Nc3ccccc3)CC2)nc1)c1cnc(N2CCCCC2)o1
5435,1468060,10.1016/j.bmcl.2015.03.035,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as marker substrate,COc1cccc(OC)c1C1CC(F)(F)C(=O)N1Cc1ccc(OC(F)(F)F)cc1,"rac-5-(2,6-dimethoxyphenyl)-3,3-difluoro-1-(4-(trifluoromethoxy)benzyl)pyrrolidin-2-one",5.2,uM,=,0.7160033436347992,1,O=C1CCC(c2ccccc2)N1Cc1ccccc1
5436,950952,10.1016/j.bmcl.2013.02.023,,,,Inhibition of human CYP3A4,COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc(-c3ccc(-c4cnc([C@@H]5CCCN5C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]4)cc3)cc2)[nH]1)C(C)C,daclatasvir,7.2,uM,=,0.8573324964312685,1,c1cc(-c2cnc([C@@H]3CCCN3)[nH]2)ccc1-c1ccc(-c2cnc([C@@H]3CCCN3)[nH]2)cc1
5437,2157079,10.1021/acsmedchemlett.1c00445,,,,Inhibition of human CYP3A4 by fluorescence plate reader analysis,COc1cnc(C(=O)Nc2ccc(F)c([C@]3(C)Cn4c(C#N)cnc4C(N)=N3)c2)cn1,"(R)-N-(3-(8-amino-3-cyano-6-methyl-5,6-dihydroimidazo[1,2-a]pyrazin-6-yl)-4-fluorophenyl)-5-methoxypyrazine-2-carboxamide",3.1,uM,=,0.4913616938342727,1,O=C(Nc1cccc(C2Cn3ccnc3C=N2)c1)c1cnccn1
5438,1296353,10.1021/jm4015108,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis,CC(C)n1cc(S(=O)(=O)c2ccc(NC(=O)[C@@H]3C[C@H]3c3cccnc3)cc2)cn1,rac-trans-N-(4-((1-Isopropyl-1H-pyrazol-4-yl)sulfonyl)phenyl)-2-(pyridin-3-yl)cyclopropanecarboxamide,0.3,uM,=,-0.5228787452803376,0,O=C(Nc1ccc(S(=O)(=O)c2cn[nH]c2)cc1)[C@@H]1C[C@H]1c1cccnc1
5439,595637,10.1016/j.bmcl.2009.09.096,,,,Inhibition of human CYP3A4,COc1ccc2c(O[C@H](C)c3nnc4ccc(-c5ccccc5)nn34)ccnc2c1,"(R)-7-methoxy-4-(1-(6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)ethoxy)quinoline",18.0,uM,=,1.255272505103306,1,c1ccc(-c2ccc3nnc(COc4ccnc5ccccc45)n3n2)cc1
5440,993294,10.1021/ml400228e,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 to 60 mins by LC-MS/MS analysis,Cn1cc(-c2ccc3c(c2)CCN3C(=O)Cc2cccc(C(F)(F)F)c2)c2c(N)ncnc21,"7-Methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine",13.0,uM,=,1.1139433523068367,1,O=C(Cc1ccccc1)N1CCc2cc(-c3c[nH]c4ncncc34)ccc21
5441,1866289,10.1021/acs.jmedchem.9b00662,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,O=C(Nc1ccccc1)N1CCC(C(O)CC2c3ccccc3-c3cncn32)CC1,"4-(1-Hydroxy-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethyl)-N-phenylpiperidine-1-carboxamide",0.51,uM,=,-0.2924298239020636,0,O=C(Nc1ccccc1)N1CCC(CCC2c3ccccc3-c3cncn32)CC1
5442,458143,10.1016/j.bmcl.2007.09.006,,,,Inhibition of CYP3A4 after 30 mins,CC[C@@H]1C[C@@H](OC)C[C@H](COC(=O)N2CCN(CCO)CC2)N1S(=O)(=O)c1ccc(Cl)cc1,trans-1-(4-chlorophenylsulfonyl)-6-ethyl-4-methoxypiperidin-2-yl)methyl 4-(2-hydroxyethyl)piperazine-1-carboxylate,10.1,uM,=,1.0043213737826426,1,O=C(OC[C@H]1CCCCN1S(=O)(=O)c1ccccc1)N1CCNCC1
5443,673953,10.1016/j.bmcl.2010.08.086,,,,Inhibition of CYP3A4 using testosterone as substrate,CCNC(=O)Cc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1,"(3R,4S)-N-(2-chloro-5-(2-(ethylamino)-2-oxoethyl)benzyl)-N-cyclopropyl-4-(4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)phenyl)piperidine-3-carboxamide",7.1,uM,=,0.8512583487190752,1,O=C([C@H]1CNCC[C@@H]1c1ccc(OCCOc2ccccc2)cc1)N(Cc1ccccc1)C1CC1
5444,621465,10.1016/j.bmcl.2009.07.118,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,COc1cccc(CN(C[C@@H](Cc2ccccc2)NC(=O)OCc2nccs2)C[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)c1,N-[(S)-2-(thiazol-5-ylmethoxycarbonylamino)-3-phenylpropyl][(R)-2-(thiazol-5-ylmethoxycarbonylamino)-3-phenylpropyl][3-methoxybenzyl]amine,0.05,uM,=,-1.3010299956639813,0,O=C(N[C@H](Cc1ccccc1)CN(Cc1ccccc1)C[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)OCc1nccs1
5445,1729574,10.1021/acsmedchemlett.7b00406,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate,NC[C@H]1CC[C@H](CN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)CC1,"(S)-N-(((1r,4S)-4-(aminomethyl)cyclohexyl)methyl)-N-(((R)-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)-5,6,7,8-tetrahydroquinolin-8-amine",12.0,uM,=,1.0791812460476249,1,c1ccc2c(c1)CN[C@@H](CN(CC1CCCCC1)[C@H]1CCCc3cccnc31)C2
5446,826125,10.1021/jm300069y,,,,Inhibition of CYP3A4,CC(C)(C)c1cccc(CN[C@H]2CS(=O)(=O)C[C@@H](Cc3cc(F)c(N)c(OC(C(F)(F)F)C(F)(F)F)c3)[C@@H]2O)c1,"(3S,4S,5R)-3-(4-Amino-3-fluoro-5-((1,1,1,3,3,3-hexafluoropropan-2-yl)oxy)benzyl)-5-((3-(tertbutyl)benzyl)amino)-4-hydroxytetrahydro-2H-thiopyran 1,1-dioxide",0.3,uM,=,-0.5228787452803376,0,O=S1(=O)C[C@@H](Cc2ccccc2)C[C@@H](NCc2ccccc2)C1
5447,748610,10.1016/j.bmcl.2011.03.115,,,,Inhibition of CYP3A4 preincubated for 30 mins,Cc1ccc(S(=O)(=O)N2CCNC(=O)[C@H]2CC(=O)N[C@@H]2CCCc3cc(CNCC(C)(C)C)ccc32)cc1,"N-((R)-6-((neopentylamino)methyl)-1,2,3,4-tetrahydronaphthalen-1-yl)-2-((R)-3-oxo-1-tosylpiperazin-2-yl)acetamide",2.2,uM,=,0.3424226808222063,1,O=C(C[C@@H]1C(=O)NCCN1S(=O)(=O)c1ccccc1)N[C@@H]1CCCc2ccccc21
5448,813105,10.1021/jm201346g,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,COc1ccc2[nH]c(SCc3cccc(Oc4ccccc4)c3)nc2c1,5-methoxy-2-(3-phenoxybenzylthio)-1H-benzo[d]imidazole,2.49,uM,=,0.3961993470957364,1,c1ccc(Oc2cccc(CSc3nc4ccccc4[nH]3)c2)cc1
5449,643970,10.1016/j.bmcl.2010.06.086,,,,Inhibition of human CYP3A4-mediated testosterone oxidation,CC(C)CC1n2cncc2CN(Cc2cccs2)S1(=O)=O,"4-Isobutyl-6-thiophen-2-ylmethyl-6,7-dihydro-5-thia-2,3a,6-triaza-indene 5,5-dioxide",1.16,uM,=,0.0644579892269184,1,O=S1(=O)Cn2cncc2CN1Cc1cccs1
5450,2296590,10.1021/acs.jmedchem.5b02025,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate assessed as reduction in substrate hydroxylation incubated for 30 mins in presence of beta-NADPH measured by LC-MS/MS analysis,NCCCC[C@H](NC(=O)C(NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCCN)C(c1ccccc1)c1ccccc1)C(N)=O,"(2S)-2,6-diamino-N-((5S,11S,14S,17S,20S,23S,26S)-11,20,23-tris((1H-indol-3-yl)methyl)-1,30-diamino-14,17-bis(4-aminobutyl)-8-benzhydryl-5-carbamoyl-7,10,13,16,19,22,25-heptaoxo-6,9,12,15,18,21,24-heptaazatriacontan-26-yl)hexanamide",63.7,uM,=,1.8041394323353503,1,O=C(CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CCc1c[nH]c2ccccc12)NCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCC(c1ccccc1)c1ccccc1
5451,497350,10.1016/j.ejmech.2007.10.034,,,,Inhibition of human recombinant CYP3A4,COc1cc(/C=C/C(=O)/C=C/c2cc(OC)c(O)c(OC)c2)cc(OC)c1O,"1,5-bis(4-hydroxy-3,5-dimethoxyphenyl)penta-1,4-dien-3-one",13.2,uM,=,1.1205739312058498,1,O=C(/C=C/c1ccccc1)/C=C/c1ccccc1
5452,1859913,10.1021/acsmedchemlett.9b00114,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate measured after 10 mins in presence of NADPH by UHPLC-MS/MS analysis,Cn1cc(-c2ccc(N3CCC(C4c5c(F)cccc5-c5cncn54)CC3)cc2)cn1,"6-fluoro-5-(1-(4-(1-methyl-1H-pyrazol-4-yl)phenyl)piperidin-4-yl)-5H-imidazo[5,1-a]isoindole",6.08,uM,=,0.7839035792727349,1,c1ccc2c(c1)-c1cncn1C2C1CCN(c2ccc(-c3cn[nH]c3)cc2)CC1
5453,1869498,10.1021/acs.jmedchem.8b01729,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 3 mins in presence of NADP by LC-MS/MS analysis,CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,SID144204227,0.0183,uM,=,-1.7375489102695705,0,c1ccc([C@@]2(Cn3ccnc3)OC[C@H](COc3ccc(N4CCNCC4)cc3)O2)cc1
5454,673953,10.1016/j.bmcl.2010.08.086,,,,Inhibition of CYP3A4 using testosterone as substrate,CC(=O)NCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1,"(3R,4S)-N-(5-(acetamidomethyl)-2-chlorobenzyl)-N-cyclopropyl-4-(4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)phenyl)piperidine-3-carboxamide",8.4,uM,=,0.9242792860618816,1,O=C([C@H]1CNCC[C@@H]1c1ccc(OCCOc2ccccc2)cc1)N(Cc1ccccc1)C1CC1
5455,1527906,,,,,Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,C[C@@H](c1ccc(-c2ccc(=O)n(CC3CC3)n2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O,"US8592410, 19",5.7,uM,=,0.7558748556724915,1,O=C1OC(c2ccccc2)CCN1Cc1ccc(-c2ccc(=O)n(CC3CC3)n2)cc1
5456,606336,10.1016/j.bmcl.2009.11.061,,,,Inhibition of CYP3A4,Cc1occc1-c1nc(N)c(OC[C@@H](N)Cc2c[nH]c3ccccc23)cc1-c1cc2c(C)n[nH]c2cn1,"3-((S)-2-amino-3-(1H-indol-3-yl)propoxy)-5-(3-methyl-1H-pyrazolo[3,4-c]pyridin-5-yl)-6-(2-methylfuran-3-yl)pyridin-2-amine",1.3,uM,=,0.1139433523068367,1,c1ccc2c(CCCOc3cnc(-c4ccoc4)c(-c4cc5cn[nH]c5cn4)c3)c[nH]c2c1
5457,643712,10.1016/j.bmcl.2010.06.009,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader,C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(NC5CCN(C)CC5)n4)ccc32)sc1C(N)=O)c1ccccc1Cl,(R)-3-(1-(2-chlorophenyl)ethoxy)-5-(5-(2-(1-methylpiperidin-4-ylamino)pyrimidin-4-yl)-1H-benzo[d]imidazol-1-yl)thiophene-2-carboxamide,1.0,uM,=,0.0,0,c1ccc(COc2csc(-n3cnc4cc(-c5ccnc(NC6CCNCC6)n5)ccc43)c2)cc1
5458,1729574,10.1021/acsmedchemlett.7b00406,,,,Inhibition of CYP3A4 (unknown origin) using BFC as substrate,NC(=O)NC/C=C\CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21,"1-((Z)-4-((((R)-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)((S)-5,6,7,8-tetrahydroquinolin-8-yl)amino)but-2-enyl)urea",19.0,uM,=,1.2787536009528289,1,c1ccc2c(c1)CN[C@@H](CN[C@H]1CCCc3cccnc31)C2
5459,2221810,10.1016/j.bmcl.2022.128625,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as substrate pretreated with NADPH,CCC[C@H]1N(C(=O)c2ncccc2C(F)(F)F)CCC[C@@]1(Oc1csc(C(F)(F)F)c1)C(=O)N1CCN(c2ccccc2OCCO)CC1,"(4-(2-(2-hydroxyethoxy)phenyl)piperazin-1-yl)((2R,3S)-2-propyl-1-(3-(trifluoromethyl)picolinoyl)-3-(5-(trifluoromethyl)thiophen-3-yloxy)piperidin-3-yl)methanone",0.2,uM,=,-0.6989700043360187,0,O=C(c1ccccn1)N1CCC[C@@](Oc2ccsc2)(C(=O)N2CCN(c3ccccc3)CC2)C1
5460,1556413,10.1021/acs.jmedchem.5b01741,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate preincubated for 10 mins followed by NADPH addition by LC/MS/MS analysis,Cc1nc2c([N+](=O)[O-])c(Cl)c(Cl)cc2n1Cc1ccc(B2OC(=O)CN(C)CC(=O)O2)cc1,"2-(4-((5,6-Dichloro-2-methyl-4-nitro-1H-benzo[d]-imidazol-1-yl)methyl)phenyl)-6-methyl-1,3,6,2-dioxazaborocane-4,8-dione",28.12,uM,=,1.4490153163477864,1,O=C1CNCC(=O)OB(c2ccc(Cn3cnc4ccccc43)cc2)O1
5461,462442,10.1016/j.bmcl.2008.01.047,,,,Inhibition of CYP3A4,CC(C)(C)OC(=O)N[C@H](Cc1c(F)cccc1F)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1,"(R)-tert-butyl 3-(2,6-difluorophenyl)-1-oxo-1-((3-(1-phenylcyclopropyl)-3H-imidazo[4,5-b]pyridin-2-yl)methylamino)propan-2-ylcarbamate",6.1,uM,=,0.785329835010767,1,O=C(CCc1ccccc1)NCc1nc2cccnc2n1C1(c2ccccc2)CC1
5462,1913292,10.1021/acs.jmedchem.9b01032,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH by LC-MS/MS analysis,CC(C)N(C)Cc1cccc(F)c1CNc1cc(F)c(S(=O)(=O)Nc2cscn2)c(F)c1,"2,6-Difluoro-4-((2-fluoro-6-((isopropyl(methyl)amino)methyl)-benzyl)amino)-N-(thiazol-4-yl)benzenesulfonamide",38.0,uM,=,1.57978359661681,1,O=S(=O)(Nc1cscn1)c1ccc(NCc2ccccc2)cc1
5463,741042,10.1016/j.bmcl.2011.02.067,,,,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH,CCOC(=O)[C@H]1C[C@@H]1COc1cc(CCCOC)cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1,"(1S,2S)-ethyl 2-((3-(((3R,4S)-N-cyclopropyl-4-(4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)phenyl)piperidine-3-carboxamido)methyl)-5-(3-methoxypropyl)phenoxy)methyl)cyclopropanecarboxylate",19.3,uM,=,1.285557309007774,1,O=C([C@H]1CNCC[C@@H]1c1ccc(OCCOc2ccccc2)cc1)N(Cc1cccc(OCC2CC2)c1)C1CC1
5464,1536230,,,,,"Inhibition Assay: Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v. Pooled human liver microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 5 mg/mL suspension. A solution of NADPH was prepared in phosphate buffer at a concentration of 5 mM. Separate stock solutions of each substrate were prepared in DMSO:MeCN (50:50 v/v), mixed, and diluted in phosphate buffer to obtain a single solution.",OC(Cn1cncn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(OCC(F)(F)F)cc2)cn1,"US8754227, 17",5.8,uM,=,0.7634279935629373,1,c1ccc(-c2ccc(CC(Cn3cncn3)c3ccccc3)nc2)cc1
5465,583696,10.1016/j.bmcl.2009.05.066,,,,Inhibition of human recombinant CYP3A4 after 45 mins,O=C(NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)NC(CN1CCOCC1)c1ccccc1,1-(2-morpholino-1-phenylethyl)-3-(1-((1-(4-(trifluoromethyl)phenyl)-1H-pyrrol-3-yl)methyl)piperidin-4-yl)urea,16.5,uM,=,1.2174839442139065,1,O=C(NC1CCN(Cc2ccn(-c3ccccc3)c2)CC1)NC(CN1CCOCC1)c1ccccc1
5466,605306,10.1016/j.bmcl.2009.11.060,,,,Inhibition of CYP3A4,Cc1n[nH]c2ccc(-c3cc(OC[C@@H](N)Cc4c[nH]c5ccccc45)cnc3-c3ccoc3)nc12,"(S)-1-(6-(furan-3-yl)-5-(3-methyl-1H-pyrazolo[4,3-b]pyridin-5-yl)pyridin-3-yloxy)-3-(1H-indol-3-yl)propan-2-amine",0.1,uM,=,-1.0,0,c1ccc2c(CCCOc3cnc(-c4ccoc4)c(-c4ccc5[nH]ncc5n4)c3)c[nH]c2c1
5467,1859913,10.1021/acsmedchemlett.9b00114,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate measured after 10 mins in presence of NADPH by UHPLC-MS/MS analysis,Cn1cc(-c2ccc(N3CCC(C4c5c(F)cccc5-c5cncn54)CC3)cc2F)cn1,"6-fluoro-5-(1-(3-fluoro-4-(1-methyl-1H-pyrazol-4-yl)phenyl)piperidin-4-yl)-5H-imidazo[5,1-a]isoindole",2.6,uM,=,0.414973347970818,1,c1ccc2c(c1)-c1cncn1C2C1CCN(c2ccc(-c3cn[nH]c3)cc2)CC1
5468,813105,10.1021/jm201346g,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis,FC(F)Oc1ccc2[nH]c(SCc3ccccn3)nc2c1,5-(difluoromethoxy)-2-(pyridin-2-ylmethylthio)-1H-benzo[d]imidazole,10.7,uM,=,1.0293837776852095,1,c1ccc(CSc2nc3ccccc3[nH]2)nc1
5469,606336,10.1016/j.bmcl.2009.11.061,,,,Inhibition of CYP3A4,Cc1occc1-c1nc(N)c(OC[C@@H](N)Cc2c(Cl)[nH]c3ccccc23)cc1-c1cnc2[nH]nc(C)c2n1,"3-((S)-2-amino-3-(2-chloro-1H-indol-3-yl)propoxy)-5-(3-methyl-1H-pyrazolo[4,3-b]pyrazin-5-yl)-6-(2-methylfuran-3-yl)pyridin-2-amine",0.5,uM,=,-0.3010299956639812,0,c1ccc2c(CCCOc3cnc(-c4ccoc4)c(-c4cnc5[nH]ncc5n4)c3)c[nH]c2c1
5470,621465,10.1016/j.bmcl.2009.07.118,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,CCN(CC(Cc1ccc(OCc2ccccc2)cc1)NC(=O)OCc1cncs1)CC(Cc1ccc(OCc2ccccc2)cc1)NC(=O)OCc1nccs1,N-[(S)-2-(thiazol-5-ylmethoxycarbonylamino)-3-(4-hydroxyphenyl)propyl]-N-[2-(thiazol-5-ylmethoxycarbonylamino)-3-(4-hydroxyphenyl)propyl]ethylamine,0.3,uM,=,-0.5228787452803376,0,O=C(NC(CNCC(Cc1ccc(OCc2ccccc2)cc1)NC(=O)OCc1nccs1)Cc1ccc(OCc2ccccc2)cc1)OCc1cncs1
5471,497350,10.1016/j.ejmech.2007.10.034,,,,Inhibition of human recombinant CYP3A4,CC(C)c1cc(/C=C2\CC/C(=C\c3cc(C(C)C)c(O)c(C(C)C)c3)C2=O)cc(C(C)C)c1O,"2,5-bis(4-hydroxy-3,5-diisopropylbenzylidene)cyclopentanone",77.60000000000001,uM,=,1.8898617212581883,1,O=C1/C(=C/c2ccccc2)CC/C1=C\c1ccccc1
5472,643712,10.1016/j.bmcl.2010.06.009,,,,Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader,C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(N5CCOCC5)c4)ccc32)sc1C(N)=O)c1ccccc1C(F)(F)F,(R)-5-(5-(2-morpholinopyridin-4-yl)-1H-benzo[d]imidazol-1-yl)-3-(1-(2-(trifluoromethyl)phenyl)ethoxy)thiophene-2-carboxamide,20.0,uM,=,1.3010299956639813,1,c1ccc(COc2csc(-n3cnc4cc(-c5ccnc(N6CCOCC6)c5)ccc43)c2)cc1
5473,1527906,,,,,Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,C[C@@H](c1ccc(OC(F)F)cc1)N1CC[C@](CCO)(c2ccc(F)cc2)OC1=O,"US8575157, 202::US8592410, Comparator 14::US8598163, 72",19.7,uM,=,1.294466226161593,1,O=C1OC(c2ccccc2)CCN1Cc1ccccc1
5474,2198264,10.1016/j.bmc.2022.116951,,,,Inhibition of CYP3A4 (unknown origin),COc1ccc(CC2CCN(C(=O)c3ccc(C(=O)NC4CCN(Cc5ccc(C#N)cc5)CC4)nc3)CC2)cc1,N-(1-(4-cyanobenzyl)piperidin-4-yl)-5-(4-(4-methoxybenzyl)piperidine-1-carbonyl)picolinamide,2.0,uM,=,0.3010299956639812,1,O=C(NC1CCN(Cc2ccccc2)CC1)c1ccc(C(=O)N2CCC(Cc3ccccc3)CC2)cn1
5475,718098,10.1016/j.bmcl.2010.12.053,,,,Inhibition of CYP3A4,C[C@H](C1=C(CCN(C)Cc2ncc[nH]2)Cc2ccccc21)c1cnccn1,(R)-N-((1H-imidazol-2-yl)methyl)-N-methyl-2-(3-(1-(pyrazin-2-yl)ethyl)-1H-inden-2-yl)ethanamine,4.416,uM,=,0.6450290647211425,1,c1ccc2c(c1)CC(CCNCc1ncc[nH]1)=C2Cc1cnccn1
5476,510060,10.1016/j.bmcl.2008.07.059,,,,Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay,CN[C@@H](Cn1c(=O)c(-c2cccc(OCCCOCC(=O)O)c2F)c(C)n(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1,"(R)-2-(3-(3-(1-(2-fluoro-6-(trifluoromethyl)benzyl)-6-methyl-3-(2-(methylamino)-2-phenylethyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-2-fluorophenoxy)propoxy)acetic acid",22.0,uM,=,1.3424226808222062,1,O=c1c(-c2ccccc2)cn(Cc2ccccc2)c(=O)n1CCc1ccccc1
5477,1296352,10.1021/jm4015108,,,,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,CS(=O)(=O)c1cccc(S(=O)(=O)c2ccc(NC(=O)[C@@H]3C[C@H]3c3cccnc3)cc2)c1,rac-trans-N-(4-((3-(Methylsulfonyl)phenyl)sulfonyl)phenyl)-2-(pyridin-3-yl)cyclopropanecarboxamide,0.89,uM,=,-0.0506099933550872,0,O=C(Nc1ccc(S(=O)(=O)c2ccccc2)cc1)[C@@H]1C[C@H]1c1cccnc1
5478,458143,10.1016/j.bmcl.2007.09.006,,,,Inhibition of CYP3A4 after 30 mins,CC[C@@H]1C[C@@H](OC)C[C@H](COC(=O)N2CCC(N3CCCCC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1,trans-1-(4-chlorophenylsulfonyl)-6-ethyl-4-methoxypiperidin-2-yl)methyl 4-(piperidin-1-yl)piperidine-1-carboxylate,3.4,uM,=,0.5314789170422551,1,O=C(OC[C@H]1CCCCN1S(=O)(=O)c1ccccc1)N1CCC(N2CCCCC2)CC1
5479,1497736,10.1021/jm5020023,,,,Inhibition of human recombinant CYP3A4 using testosterone as substrate after 1 hr by LC-MS/MS analysis,CC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2,"methyl-2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oate",2.74,uM,=,0.437750562820388,1,O=C1C=CC2C3=CC(=O)[C@H]4C(CCC5CCCC[C@H]54)C3CC[C@H]2C1
5480,841307,10.1016/j.bmcl.2012.06.029,,,,Inhibition of CYP3A4,CCN1CCC(Nc2ccc3c(c2)C(=C(c2cccc(F)c2)c2nc4ccccc4[nH]2)C(=O)N3)CC1,(E/Z)-3-((1H-benzo[d]imidazol-2-yl)(3-fluorophenyl)methylene)-5-(1-ethylpiperidin-4-ylamino)indolin-2-one,4.0,uM,=,0.6020599913279624,1,O=C1Nc2ccc(NC3CCNCC3)cc2C1=C(c1ccccc1)c1nc2ccccc2[nH]1
5481,643970,10.1016/j.bmcl.2010.06.086,,,,Inhibition of human CYP3A4-mediated testosterone oxidation,COC(C)(C)CC1n2cncc2CN([C@@H](C)c2ccc(Cl)cc2)S1(=O)=O,"6-[(S)-1-(4-Chloro-phenyl)-ethyl]-4-(2-methoxy-2-methyl-propyl)-6,7-dihydro-5-thia-2,3a,6-triaza-indene 5,5-dioxide",0.53,uM,=,-0.2757241303992109,0,O=S1(=O)Cn2cncc2CN1Cc1ccccc1
5482,761291,10.1021/jm101312a,,,,Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis,Clc1ccc([C@]23CCC[C@H]2CNC3)cc1Cl,"cis-3a-(3,4-dichlorophenyl)octahydrocyclopenta[c]pyrrole",9.17,uM,=,0.9623693356700213,1,c1ccc([C@]23CCC[C@H]2CNC3)cc1
5483,621465,10.1016/j.bmcl.2009.07.118,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,CCN(CC(CC(=O)OC)NC(=O)OCc1cncs1)CC(CC(=O)OC)NC(=O)OCc1nccs1,Bis-N-[2-(thiazol-5-ylmethoxycarbonylamino)-3-methoxycarbonylpropyl]ethylamine,0.088,uM,=,-1.055517327849831,0,O=C(NCCNCCNC(=O)OCc1nccs1)OCc1cncs1
5484,841307,10.1016/j.bmcl.2012.06.029,,,,Inhibition of CYP3A4,CCN1CCC(Nc2ccc3c(c2)C(=C(c2ccccc2)c2ncc[nH]2)C(=O)N3)CC1,(E/Z)-3-((1H-imidazol-2-yl)(phenyl)methylene)-5-(1-ethylpiperidin-4-ylamino)indolin-2-one,25.0,uM,=,1.3979400086720375,1,O=C1Nc2ccc(NC3CCNCC3)cc2C1=C(c1ccccc1)c1ncc[nH]1
5485,1642505,,,,,"Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).",CNC(C)C(=O)Nc1ccc(-c2c(-c3ccncc3)nc3cc(C)ccn23)c(C#Cc2ccc3c(ccc(=O)n3C)c2)n1,"US9481673, 81",4.0,uM,=,0.6020599913279624,1,O=c1ccc2cc(C#Cc3ncccc3-c3c(-c4ccncc4)nc4ccccn34)ccc2[nH]1
5486,718343,10.1021/jm101063h,,,,Inhibition of CYP3A4,COc1cc(/C=C2\SC(=O)NC2=O)ccc1Oc1ccccc1C(F)(F)F,"5-[4-(2-Trifluoromethylphenoxy)-3-methoxybenzylidene]-thiazolidine-2,4-dione",1.9,uM,=,0.2787536009528289,1,O=C1NC(=O)/C(=C/c2ccc(Oc3ccccc3)cc2)S1
5487,1735372,10.1021/acs.jmedchem.8b00084,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis,CCCc1ccncc1-c1ccc(CN)s1.Cl.Cl,(5-(4-Propylpyridin-3-yl)thiophen-2-yl)methanamine Dihydrochloride,4.3,uM,=,0.6334684555795865,1,c1cncc(-c2cccs2)c1
5488,1659863,10.1016/j.ejmech.2017.02.016,,,,Inhibition of human liver CYP3A4 expressed in Saccharomyces cerevisiae YY7 microsomal membranes using DBF as substrate after 10 mins by fluorescence assay,COc1ccc(/C=C/C(=O)c2cccnc2)cc1OC,"(E)-3-(3,4-Dimethoxyphenyl)-1-(3-pyridyl)prop-2-en-1-one",53.0,uM,=,1.7242758696007892,1,O=C(/C=C/c1ccccc1)c1cccnc1
5489,605306,10.1016/j.bmcl.2009.11.060,,,,Inhibition of CYP3A4,Cc1n[nH]c2cnc(-c3cc(OC[C@@H](N)Cc4c[nH]c5ccccc45)cnc3-c3ccoc3)cc12,"(S)-1-(6-(furan-3-yl)-5-(3-methyl-1H-pyrazolo[3,4-c]pyridin-5-yl)pyridin-3-yloxy)-3-(1H-indol-3-yl)propan-2-amine",0.016,uM,=,-1.7958800173440752,0,c1ccc2c(CCCOc3cnc(-c4ccoc4)c(-c4cc5cn[nH]c5cn4)c3)c[nH]c2c1
5490,462442,10.1016/j.bmcl.2008.01.047,,,,Inhibition of CYP3A4,CC(C)(C)OC(=O)N[C@H](Cc1ccccc1OC(F)(F)F)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1,"(R)-tert-butyl 1-oxo-1-((3-(1-phenylcyclopropyl)-3H-imidazo[4,5-b]pyridin-2-yl)methylamino)-3-(2-(trifluoromethoxy)phenyl)propan-2-ylcarbamate",1.3,uM,=,0.1139433523068367,1,O=C(CCc1ccccc1)NCc1nc2cccnc2n1C1(c2ccccc2)CC1
5491,1527906,,,,,Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.,C[C@@H](c1ccc(-c2ccc(F)cc2F)cc1)N1CC[C@](CC(C)(C)O)(c2ccc(F)cc2)OC1=O,"US8575157, 194::US8592410, Comparator 6::US8598163, 64",4.4,uM,=,0.6434526764861874,1,O=C1OC(c2ccccc2)CCN1Cc1ccc(-c2ccccc2)cc1
5492,652208,10.1016/j.bmcl.2010.07.052,,,,Inhibition of CYP3A4 in human liver microsomes,Cn1c(=O)n(C2CCN(C(=O)C3CCN(Cc4ccncc4)CC3)CC2)c2ccccc21,1-methyl-3-(1-(1-(pyridin-4-ylmethyl)piperidine-4-carbonyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one,7.5,uM,=,0.8750612633917001,1,O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1
5493,1628093,10.1016/j.ejmech.2016.08.024,,,,Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells preincubated for 30 mins using fluorescent substrate,O=C(C(O)C1([C@H]2COC[C@@H](C3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CC2CCC(C1)N2,"1-(3,8-diazabicyclo[3.2.1]octan-3-yl)-2-(1-((3S,5R)-4-(4-chlorophenylsulfonyl)-5-cyclopropylmorpholin-3-yl)cyclopropyl)-2-hydroxyethanone",9.0,uM,=,0.9542425094393248,1,O=C(CC1([C@H]2COC[C@@H](C3CC3)N2S(=O)(=O)c2ccccc2)CC1)N1CC2CCC(C1)N2
5494,1866289,10.1021/acs.jmedchem.9b00662,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,OC(CC1c2c(Cl)cccc2-c2cncn21)C1CCCCC1,"2-(6-Chloro-5H-imidazo[5,1-a]isoindol-5-yl)-1-cyclohexylethanol",1.7,uM,=,0.2304489213782739,1,c1ccc2c(c1)-c1cncn1C2CCC1CCCCC1
5495,1986041,10.1021/acs.jmedchem.0c00564,,,,Inhibition of CYP3A4 (unknown origin) expressed in insect cell microsomes using dibenzylfluorescein substrate by fluorescence based assay,CCOC(=O)C1=C(C)Nc2nc3ccccc3n2C1c1ncc[nH]1,"(+/-)-Ethyl 4-(1H-Imidazol-2-yl)-2-methyl-1,4-dihydrobenzo[4,5]imidazo[1,2-a]pyrimidine-3-carboxylate",4.54,uM,=,0.6570558528571039,1,C1=CC(c2ncc[nH]2)n2c(nc3ccccc32)N1
5496,1866289,10.1021/acs.jmedchem.9b00662,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,O=C(Cc1cncnc1)N1CCC(C(O)CC2c3ccccc3-c3cncn32)CC1,"1-(4-(1-Hydroxy-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethyl)-piperidin-1-yl)-2-(pyrimidin-5-yl)ethanone",8.6,uM,=,0.9344984512435676,1,O=C(Cc1cncnc1)N1CCC(CCC2c3ccccc3-c3cncn32)CC1
5497,718098,10.1016/j.bmcl.2010.12.053,,,,Inhibition of CYP3A4,C[C@H](C1=C(CCN(C)Cc2cccs2)Cc2ccccc21)c1cnccn1,(R)-N-methyl-2-(3-(1-(pyrazin-2-yl)ethyl)-1H-inden-2-yl)-N-(thiophen-2-ylmethyl)ethanamine,1.826,uM,=,0.2615007731982801,1,c1csc(CNCCC2=C(Cc3cnccn3)c3ccccc3C2)c1
5498,458143,10.1016/j.bmcl.2007.09.006,,,,Inhibition of CYP3A4 after 30 mins,CC[C@@H]1C[C@H](OC)C[C@H](COC(=O)N2CCC(N3CCCCC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1,cis-1-(4-chlorophenylsulfonyl)-6-ethyl-4-methoxypiperidin-2-yl)methyl 4-(piperidin-1-yl)piperidine-1-carboxylate,5.0,uM,=,0.6989700043360189,1,O=C(OC[C@H]1CCCCN1S(=O)(=O)c1ccccc1)N1CCC(N2CCCCC2)CC1
5499,2157144,10.1021/acsmedchemlett.1c00473,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by TDI- high-throughput based mass spectrometry method,CCc1c[nH]c2ncc(-c3ccc(N)c(C(=O)N(C)C)n3)cc12,"3-Amino-6-(3-ethyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-N,N-dimethylpicolinamide",1.6,uM,=,0.2041199826559248,1,c1ccc(-c2cnc3[nH]ccc3c2)nc1
5500,513545,10.1016/j.bmcl.2008.06.078,,,,Inhibition of CYP3A4,CC(C)C(=O)N(Cc1cccc(Cl)c1Cl)[C@H]1CCNC1,"(S)-N-(2,3-dichlorobenzyl)-N-(pyrrolidin-3-yl)isobutyramide",17.9,uM,=,1.252853030979893,1,c1ccc(CN[C@H]2CCNC2)cc1
5501,1866289,10.1021/acs.jmedchem.9b00662,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,O=C1CCC(C(O)CC2c3c(F)cccc3-c3cncn32)CC1,"4-(2-(6-Fluoro-5H-imidazo[5,1-a]isoindol-5-yl)-1-hydroxyethyl)-cyclohexan-1-one",10.9,uM,=,1.0374264979406236,1,O=C1CCC(CCC2c3ccccc3-c3cncn32)CC1
5502,826125,10.1021/jm300069y,,,,Inhibition of CYP3A4,Nc1c(F)cc(C[C@@H]2CS(=O)(=O)C[C@H](NCc3cccc(OC(F)(F)F)c3)[C@H]2O)cc1OC(C(F)(F)F)C(F)(F)F,"(3S,4S,5R)-3-(4-Amino-3-fluoro-5-((1,1,1,3,3,3-hexafluoropropan-2-yl)oxy)benzyl)-4-hydroxy-5-((3-(trifluoromethoxy)benzyl)amino)tetrahydro-2H-thiopyran 1,1-dioxide",9.2,uM,=,0.9637878273455552,1,O=S1(=O)C[C@@H](Cc2ccccc2)C[C@@H](NCc2ccccc2)C1
5503,643970,10.1016/j.bmcl.2010.06.086,,,,Inhibition of human CYP3A4-mediated testosterone oxidation,CC(C)CC1n2cncc2CN(Cc2ccc(Cl)cc2)S1(=O)=O,"6-(4-Chloro-benzyl)-4-isobutyl-6,7-dihydro-5-thia-2,3a,6-triaza-indene 5,5-dioxide",0.087,uM,=,-1.0604807473813815,0,O=S1(=O)Cn2cncc2CN1Cc1ccccc1
5504,2157144,10.1021/acsmedchemlett.1c00473,,,,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by TDI- high-throughput based mass spectrometry method,CN(C)C(=O)c1cc(-c2cnc3c(c2)C2(CCCC2)CN3)ccc1N,"2-Amino-5-(1',2'-dihydrospiro[cyclopentane-1,3'-pyrrolo[2,3-b]pyridin]-5'-yl)-N,N-dimethylbenzamide",9.8,uM,=,0.9912260756924948,1,c1ccc(-c2cnc3c(c2)C2(CCCC2)CN3)cc1
5505,1296353,10.1021/jm4015108,,,,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis,CC(C)n1cc(S(=O)(=O)c2ccc(NC(=O)[C@H]3C[C@@H]3c3cccnc3)cc2)cn1,"trans-(S,S)-N-(4-((1-Isopropyl-1H-pyrazol-4-yl)sulfonyl)-phenyl)-2-(pyridin-3-yl)cyclopropanecarboxamide",0.2,uM,=,-0.6989700043360187,0,O=C(Nc1ccc(S(=O)(=O)c2cn[nH]c2)cc1)[C@H]1C[C@@H]1c1cccnc1
5506,1445200,10.1021/ml5003376,,,,Inhibition of human CYP3A4 testosterone site in human liver microsomes using midazolam as substrate by LC-MS/MS analysis,COc1ccc(Cl)c(S(=O)(=O)Nc2ccc(-c3cnc4c(C)n[nH]c4n3)cc2)c1,"2-chloro-5-methoxy-N-(4-(3-methyl-1H-pyrazolo[3,4-b]pyrazin-6-yl)phenyl)benzenesulfonamide",18.6,uM,=,1.2695129442179165,1,O=S(=O)(Nc1ccc(-c2cnc3cn[nH]c3n2)cc1)c1ccccc1
5507,1903445,10.1021/acs.jmedchem.9b01713,,,,Inhibition of human liver microsome CYP3A4 using midazolam as substrate incubated for 5 to 20 mins by LC-MS/MS analysis,O=c1[nH]c2ccc(-n3nnc4cnc(-c5ccnn5Cc5ccc(Cl)cc5Cl)cc43)cc2[nH]1,"5-(6-(1-(2,4-Dichlorobenzyl)-1H-pyrazol-5-yl)-1H-[1,2,3]triazolo[4,5-c]pyridin-1-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one",4.2,uM,=,0.6232492903979004,1,O=c1[nH]c2ccc(-n3nnc4cnc(-c5ccnn5Cc5ccccc5)cc43)cc2[nH]1
5508,789986,10.1016/j.bmcl.2011.10.013,,,,Reversible inhibition of CYP3A4,O=C([C@H]1CNCC[C@@]12OCc1cc(F)c(F)cc12)N(Cc1ccccc1Cl)C1CC1,"(1R,3'S)-N-(2-chlorobenzyl)-N-cyclopropyl-5,6-difluoro-3H-spiro[isobenzofuran-1,4'-piperidine]-3'-carboxamide",5.0,uM,=,0.6989700043360189,1,O=C([C@H]1CNCC[C@@]12OCc1ccccc12)N(Cc1ccccc1)C1CC1
5509,497350,10.1016/j.ejmech.2007.10.034,,,,Inhibition of human recombinant CYP3A4,O=C1/C(=C/c2ccc(O)cc2)CC/C1=C\c1ccc(O)cc1,"2,5-bis(4-hydroxybenzylidene)cyclopentanone",5.1000000000000005,uM,=,0.7075701760979364,1,O=C1/C(=C/c2ccccc2)CC/C1=C\c1ccccc1
5510,2046115,10.1021/acsmedchemlett.8b00541,,,,Inhibition of CYP3A4 in human liver microsomes measured after 30 mins,CNc1nc(Nc2ccc(-n3cnc(C)n3)c(OC)c2)nc2c1CC[C@H]2c1ccc(F)cc1,"(S)-7-(4-fluorophenyl)-N2-(3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl)-N4-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine",0.2,uM,=,-0.6989700043360187,0,c1ccc([C@@H]2CCc3cnc(Nc4ccc(-n5cncn5)cc4)nc32)cc1
5511,1866289,10.1021/acs.jmedchem.9b00662,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,OC(CC1c2cc(Cl)ccc2-c2cncn21)C1CCCCC1,"2-(7-Chloro-5H-imidazo[5,1-a]isoindol-5-yl)-1-cyclohexylethanol",0.01,uM,=,-2.0,0,c1ccc2c(c1)-c1cncn1C2CCC1CCCCC1
5512,728151,10.1016/j.bmc.2011.01.017,,,,Inhibition of human CYP3A4,CNC(=O)c1ccc2cc(C(O)(c3c[nH]cn3)C(C)C)ccc2c1,rac-6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-Nmethyl-2-naphthamide,3.6,uM,=,0.5563025007672873,1,c1ccc2cc(Cc3c[nH]cn3)ccc2c1
5513,621523,10.1021/np900266m,,,,Inhibition of CYP3A4 after 30 mins by fluorescence microplate reader assay,CC(C)=CCC/C(C)=C/COc1c2ccoc2cc2oc(=O)ccc12,bergamottin,2.42,uM,=,0.3838153659804312,1,O=c1ccc2cc3ccoc3cc2o1
5514,826125,10.1021/jm300069y,,,,Inhibition of CYP3A4,CC(C)(O)c1cccc(CN[C@H]2CS(=O)(=O)C[C@@H](Cc3cc(F)c(N)c(OC(C(F)(F)F)C(F)(F)F)c3)[C@@H]2O)c1,"(3S,4S,5R)-3-(4-Amino-3-fluoro-5-((1,1,1,3,3,3-hexafluoropropan-2-yl)oxy)benzyl)-4-hydroxy-5-((3-(2-hydroxypropan-2-yl)benzyl)amino)tetrahydro-2H-thiopyran 1,1-dioxide",2.1,uM,=,0.3222192947339193,1,O=S1(=O)C[C@@H](Cc2ccccc2)C[C@@H](NCc2ccccc2)C1
5515,595637,10.1016/j.bmcl.2009.09.096,,,,Inhibition of human CYP3A4,COc1ccc2c(OCc3nnc4ccc(-c5cc(C)ns5)nn34)ccnc2c1,"5-(3-((7-methoxyquinolin-4-yloxy)methyl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-3-methylisothiazole",17.0,uM,=,1.230448921378274,1,c1ccc2c(OCc3nnc4ccc(-c5ccns5)nn34)ccnc2c1
5516,1468060,10.1016/j.bmcl.2015.03.035,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as marker substrate,COc1cccc(F)c1[C@@H]1C[C@H](F)C(=O)N1Cc1ccc2oc3ccccc3c2c1,"rac-(3S*,5S*)-1-(dibenzo[b,d]furan-2-ylmethyl)-3-fluoro-5-(2-fluoro-6-methoxyphenyl)pyrrolidin-2-one",21.0,uM,=,1.3222192947339193,1,O=C1CC[C@@H](c2ccccc2)N1Cc1ccc2oc3ccccc3c2c1
5517,621465,10.1016/j.bmcl.2009.07.118,,,,Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline,CCN(C[C@H](Cc1ccccc1)NC(=O)OCc1cccs1)C[C@H](Cc1ccccc1)NC(=O)OCc1cccs1,Bis-N-[(S)-2-(thien-2-ylmethoxycarbonylamino)-3-phenylpropyl]ethylamine,0.741,uM,=,-0.1301817920206718,0,O=C(N[C@H](CNC[C@H](Cc1ccccc1)NC(=O)OCc1cccs1)Cc1ccccc1)OCc1cccs1
5518,2207469,10.1021/acs.jmedchem.2c01003,,,,Inhibition of CYP3A4 (unknown origin) preincubated for 10 mins followed by NADP addition measured after 50 mins,Cc1cccc2sc(NC(=O)CCN3CCN(c4ccncc4)CC3)nc12,N-(4-Methylbenzo[d]thiazol-2-yl)-3-(4-(pyridin-4-yl)-piperazin-1-yl)propanamide,1.14,uM,=,0.0569048513364725,1,O=C(CCN1CCN(c2ccncc2)CC1)Nc1nc2ccccc2s1
5519,788538,10.1016/j.bmcl.2011.01.024,,,,Inhibition of human CYP3A4,CCN(Cc1cc(C(F)(F)F)ccc1-c1cc(CC(=O)O)ccc1OC)C(=O)OCc1ccccc1,2-(2'-(((benzyloxycarbonyl)(ethyl)amino)methyl)-6-methoxy-4'-(trifluoromethyl)biphenyl-3-yl)acetic acid,18.0,uM,=,1.255272505103306,1,O=C(NCc1ccccc1-c1ccccc1)OCc1ccccc1
5520,1513925,10.1016/j.bmcl.2015.07.091,,,,Inhibition of CYP3A4 (unknown origin) using testosterone as substrate,O=C1c2cc(-c3ccnc(N[C@@H]4C[C@H](O)[C@@H](F)C4)n3)cn2CCCN1[C@H](CO)c1ccccc1,"8-(2-((1R,3S,4S)-3-fluoro-4-hydroxycyclopentylamino)pyrimidin-4-yl)-2-((S)-2-hydroxy-1-phenylethyl)-2,3,4,5-tetrahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one",38.8,uM,=,1.5888317255942073,1,O=C1c2cc(-c3ccnc(NC4CCCC4)n3)cn2CCCN1Cc1ccccc1
5521,1805644,10.1021/acs.jmedchem.9b00059,,,,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH-generating system addition and measured after 20 mins by LC-MS/MS analysis,COc1ccc(-n2nc(C)nc2-c2cccc(C(=O)NCCCCc3ccccc3)c2)cc1,"3-(1-(4-Methoxyphenyl)-3-methyl-1H-1,2,4-triazol-5-yl)-N-(4-phenylbutyl)benzamide",37.69,uM,=,1.576226137449605,1,O=C(NCCCCc1ccccc1)c1cccc(-c2ncnn2-c2ccccc2)c1
5522,1780159,10.1021/acs.jmedchem.8b01077,,,,Inhibition of CYP3A4 (unknown origin) using midazolam as substrate,Cc1ccc([C@H](CCN2[C@@H]3CC[C@H]2C[C@H](n2c(C)nnc2C(C)C)C3)NC(=O)C2CCC(F)(F)CC2)s1,"4,4-Difluoro-N-((S)-3-((1R,3R,5S)-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-1-(5-methylthiophen-2-yl)propyl)cyclohexane-1-carboxamide",10.9,uM,=,1.0374264979406236,1,O=C(N[C@@H](CCN1[C@@H]2CC[C@H]1C[C@H](n1cnnc1)C2)c1cccs1)C1CCCCC1
5523,762993,10.1016/j.bmc.2011.04.014,,,,Inhibition of CYP3A4,CC(C)(C)OC(=O)NC[C@H]1CC[C@H](CNC(=O)c2cc(-c3cccc(CN)c3)nc3ccccc23)CC1,tert-Butyl[(trans-4-{[({2-[3-(aminomethyl)phenyl]-quinolin-4-yl}carbonyl)amino]methyl}cyclohexyl)methyl]-carbamate,2.4,uM,=,0.380211241711606,1,O=C(NCC1CCCCC1)c1cc(-c2ccccc2)nc2ccccc12
5524,652208,10.1016/j.bmcl.2010.07.052,,,,Inhibition of CYP3A4 in human liver microsomes,O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)n(Cc3ccccc3Cl)c3ccccc32)CC1,1-(2-chlorobenzyl)-3-(1-(1-(pyridin-4-ylmethyl)piperidine-4-carbonyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one,0.5,uM,=,-0.3010299956639812,0,O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)n(Cc3ccccc3)c3ccccc32)CC1
5525,789984,10.1016/j.bmcl.2011.10.013,,,,Inhibition of CYP3A4,COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@]2(O)c2ccc(F)c(F)c2)C2CC2)cc(OCCOC)c1,"rac-(3S,4R)-N-cyclopropyl-4-(3,4-difluorophenyl)-4-hydroxy-N-(3-(2-methoxyethoxy)-5-(3-methoxypropyl)benzyl)piperidine-3-carboxamide",0.9,uM,=,-0.0457574905606751,0,O=C([C@H]1CNCCC1c1ccccc1)N(Cc1ccccc1)C1CC1
